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FOCIS Abstract SupplementRegulatory T-Cells in Transplant &
Autoimmunity
10:30 AM–12:30 PM, 5/13/2005
OR-01. Distinct Regulatory Functions Are Defined by
HLA-DR Expression on Human CD4+CD25high Treg
Cells.
C.M. Baecher-Allan, E. Wolf, D. A. Hafler. 1Center for Neurologic
Disease, Harvard Medical School & Brigham and WomenTs
Hospital, Boston, MA, USA.
Although the CD4+CD25high regulatory T cell population
represents only 2–3% of all peripheral blood CD4 Tcells, it contains
over one third of all class II expressing T cells in the peripheral
blood. Highly purified, FACS-sorted DR+ (~30% DR+CD25high)
and DR- (~70%DR-CD25high) CD4+CD62LhighCD25high Treg cells
demonstrate equivalent suppressive activity in an anti-CD3 driven,
in vitro dmicroT co-culture system. Both types of CD25high Treg cells
exhibit cell contact-dependent suppression, anergy, and expression
of Foxp3 mRNA, at only slightly different levels.
Substantial differences in the inhibitory nature of the
DR+CD25high and DR-CD25high populations are uncovered when
the cells are provided with different strength costimulatory signals.
Upon CD2 costimulation, DR+CD25high co-cultures exhibit a
strong, early suppression of both proliferation and Th1/Th2
cytokine production, while DR-CD25high co-cultures exhibit a
much delayed suppression (late) that is accompanied by a
preferential inhibition of Th1 cytokines (IFNg), and often an
induction of IL-10 and IL-4. Importantly, IL-10 has contrasting
effects on regulation by these two different types of Treg cells,
underscoring another major difference between these two types of
CD25high Treg cells. Unlike the usual effect of IL-10 in reducing
the immune response, IL-10 actually inhibits the suppression by
DR+CD25high and thus enhances co-culture responses. In contrast,
IL-10 appears to be a component of the suppressive mechanism of
the DR-CD25high cells. Possibly due to this differential involve-
ment of IL-10, the DR+CD25high and DR-CD25high populations
cross regulate each other in vitro, and may do so in vivo as well.
Importantly, these differences in the kinetics of suppression, Th1/
Th2 skewing, and involvement of IL-10 between the
DR+CD25high and DR-CD25high populations are only seen when
these two populations are studied as distinct populations. Thus it
is apparent that the study of heterogeneous combined Treg
populations would obscure possibly contrasting responses. It is
possible that these different functional features may reflect a1521-6616/$ - see front matter D 2005 Published by Elsevier Inc. for FOCIS.
doi:10.1016/j.clim.2005.03.007temporal order to the utilization of different regulatory subsets in
vivo as the immune response switches from innate to adaptive
immunity.
Dendritic Cells
10:30 AM–12:30 PM, 5/13/2005
OR-02. CNS Dendritic Cells Drive Naive T Cell
Proliferation and Epitope Spreading in Relapsing
Experimental Autoimmune Encephalomyelitis.
S. D. Miller,1 E. J. McMahon,1 S. L. Bailey,1 H. Waldner.2
1Microbiology-Immunology, Northwestern University Medical
School, Chicago, IL, USA; 2Neurology, Harvard University
Medical School, Boston, MA, USA.
Chronic progression of relapsing experimental autoimmune
encephalomyelitis (R-EAE) in the SJL mouse is dependent on the
activation of T cells to endogenous myelin epitopes, i.e. epitope
spreading which plays a major pathologic role in disease
progression. Using transfer of naive CFSE-labeled TCR trans-
genic T cells and mixed bone marrow chimeras, we show that
activation of naive PLP139-151-specific T cells in SJL mice
undergoing PLP178-191-induced R-EAE occurs directly in the
CNS and not in the cervical lymph nodes, spleen or other
peripheral lymphoid organs. Flow cytometric and histologic
examination of the CNS during R-EAE revealed the infiltration
of significant numbers of CD11c+ dendritic cells (DCs) (includ-
ing myeloid, lymphoid and plamacytoid subsets) which are not
seen in the healthy CNS. Functional examination of the antigen
presentation capacity of APC populations purified from the CNS
of mice with established PLP178-191-induced R-EAE shows that
only F4/80-CD11c+CD45hi DCs efficiently present endogenous
antigen resulting in the activation of naive PLP139-151-specific
Tg T cells. In contrast, DCs as well as F4/80+CD45hi macro-
phages and F4/80+CD45lo microglia have the capacity to activate
memory PLP139-151-specific Th1 cells. The current results
indicate that naive T cells can gain access to the inflamed
CNS, bypassing the need for activation in peripheral lymphoid
sites, and that epitope spreading initiates principally within the
CNS target organ. Further, activation of naive T cells is involved
in chronic R-EAE is mediated by CNS DCs, not infiltrating
macrophages or resident microglia. Consequently, blocking the
recruitment or differentiation of DCs may be a viable target for
inhibiting relapse and disease progression in murine MS models
and possibly MS patients themselves.5 (2005) S3–S282
AbstractsS4Antibodies in Disease
Pathogenesis and Therapy
10:30 AM–12:30 PM, 5/13/2005
OR-03. A New Spontaneous Mouse Model for Human
DevicTs Disease.
E. Bettelli,1,5 G. Moorthy,2,5 D. Baeten,1 R. A. Sobel,3,4 A. Holz,2
H. Wekerle,2 V. K. Kuchroo.1 1Center for Neurologic Diseases,
Brigham and WomenTs Hospital and Harvard Medical School,
Boston, MA, USA; 2Max-Planck-Institut fur Neurobiologie,
Martinsried, Germany; 3Laboratory Service, Veterans Affairs
Health Health Care System, Palo Alto, CA, USA; 4Department
of Pathology, Stanford University School of Medicine, Stanford,
CA, USA; 5These Authors Contributed Equally to the Work.
Multiple sclerosis (MS) is an inflammatory disease of the central
nervous system (CNS) characterized by localized areas of inflam-
mation and demyelination. MS can present itself as various clinical
forms: a relapsing-remitting course, progressive course or unusual
progression like in DevicTs disease in which lesions are found only
in the optic nerve and in the spinal cord but not the brain. In addition,
the first clinical presentation in a significant proportion of MS
patient is often isolated optic neuritis (ON). The underlying
immunological basis for different forms of MS and its association
with other diseases like optic neuritis is not well defined.
Experimental autoimmune encephalomyelitis (EAE) is a T cell
mediated disease that shares many clinical and histological
features with MS. However, to date, the development of ON
has always been associated with EAE and there is no spontaneous
animal model of DevicTs disease. Although myelin-specific Th1
cells are able to induce EAE in unimmunized mice, studies in both
MS and EAE suggest that B cells and antibodies may play a role
in demyelination. We have developed a TCR transgenic mouse,
2D2, specific for a minor protein of the CNS myelin called myelin
oligodendrocyte glycoprotein (MOG) and have previously
reported that a large proportion (47%) of these TCR transgenic
mice developed spontaneous isolated ON. We have now crossed
our TCR transgenic 2D2 mice to an IgH knock-in mutant mouse
(Th) in which all the B cells are specific for MOG and produce
MOG-specific antibodies. The knock-in mice do not spontaneously
develop EAE. However, over 60 % of 2D2xTh mice, which express
both MOG-specific T and B cells, developed a very early and severe
form of EAE. Histological examination of the central nervous
system of these animals reveal a selective distribution of the
inflammatory foci and lesions restricted to spinal cord and optic
nerve, a lesion pattern that is typical of DevicTs subform of MS. The
importance of MOG specific T and B cells cooperation, and the role
of antibodies in the development of DevicTs disease will be
discussed.
Antibodies / B Cells
3:30 PM–5:30 PM, 5/13/2005OR-04. Elucidating the Mechanism of Anti-MOG
Antibody-Mediated Demyelination.
C. B. Marta,1 N. H. Ruddle,2 A. R. Oliver,2 R. Bansal,1 S. E.
Pfeiffer.1 1Dept. of Neuroscience, University of Connecticut Health
Center, Farmington, CT, USA; 2Dept. of Epidemiology and Public
Health, Yale University School of Medicine, New Haven, CT, USA.Antibody-induced demyelination is an important component of
the pathology in multiple sclerosis (MS). In particular, antibodies
to myelin oligodendrocyte glycoprotein (MOG) are elevated in MS
patients and have been implicated as mediators of demyelination.
The aim of our studies is to elucidate the mechanism of anti-MOG
mediated demyelination. We show that antibody cross-linking of
MOG in oligodendrocytes results in the repartitioning of MOG
into lipid rafts, leading to changes in the phosphorylation of
specific proteins, and culminating in rapid morphological alter-
ations. Using proteomic analyses, we have identified 10 target
proteins whose phosphorylation state is altered upon anti-MOG
treatment. These proteins fell into functional categories related to
the regulation of signal transduction, leading to cellular stress
response and cytoskeletal instability. These changes were specific
for anti-MOG; although cross-linking myelin associated glyco-
protein (MAG) also instigates signaling modifications, these are
distinct from those observed with MOG and did not result in
oligodendrocyte morphological alterations. We next applied our
findings to EAE models, analyzing antibodies to MOG that
develop after immunization of C57BL/6 mice with MOG from rat
or human origin. Interestingly, although these regimens result in
EAE with similar anti-MOG antibody titers as evaluated by
ELISA, only human MOG requires B cells for disease induction.
Further, IgG to human, but not rat MOG, bound unfixed rodent
oligodendrocytes and induced repartitioning of MOG into lipid
rafts and morphological alterations. These data suggest a novel
mechanism for antibody pathogenicity in B cell mediated EAE,
and provide in vitro tools to determine whether an autoimmune
antibody is pathogenic, and may be useful for evaluating the
pathogenicity of antibodies in MS patients as an adjunct to
diagnosis and treatment. Supported by FG1423A (CM) and RG
2394 (NR) from the National MS Society, and NS10861 and
NS41078 from NIH (SP).
OR-05. Synovial Intracellular Citrullinated Proteins
Colocalizing with Peptidyl Arginine Deiminase Are
Pathophysiologically Relevant Antigenic Determinants
of Rheumatoid Arthritis-Specific Humoral
Autoimmunity.
L. De Rycke,1 A. P. Nicholas,2 T. Cantaert,1 E. Kruithof,1 J. D.
Echols,2 B. Vandekerckhove,3 E. M. Veys,1 F. De Keyser,1 D.
Baeten.1 1Rheumatology, Ghent University Hospital, Ghent,
Belgium; 2Neurology, University of Alabama at Birmingham and
Birmingham Veterans Administration Medical Center, Birmingham,
AL, USA; 3Blood Bank of East-Flanders, Flemish Blood Service,
and Department of Clinical Chemistry, Microbiology and
Immunology, Ghent University Hospital, Ghent, Belgium.
Objectives: Based on previous demonstrations of citrulinated
proteins in the synovial membrane, the present study addresses the
ongoing debate of the specificity of synovial citrullinated proteins
for rheumatoid arthritis (RA) and analyses in vivo their involve-
ment in the induction or perpetuation of the highly RA-specific
anti-citrullinated protein antibodies (ACPA).
Materials and methods: Synovial tissue samples of 19 RA and
19 non-RA controls were analyzed for the presence of citrullinated
proteins by immunohistochemistry with two different anti-citrul-
line antibodies. Double immunofluorescence experiments were
performed with antibodies against fibrinogen, vimentin, and the
citrullinating enzyme peptidyl arginine deiminase type 2. Extend-
ing the RA cohort to 61 patients, ACPA levels were measured by
Abstracts S5ELISA in serum and synovial fluid and related to the anti-citrulline
stainings in synovium and the presence of HLA-DR shared
epitope.
Results: Using different anti-citrulline antibodies, we confirm
the RA-specific presence of synovial intracellular citrullinated
proteins which are different from previously identified, non RA-
specific deiminated proteins such as fibrin and vimentin. The RA-
specificity is related to the distinct presence of the citrullinating
peptidyl arginine deiminase type 2 enzyme in RA synovium.
Additionally, the synovial intracellular citrullinated proteins
detected in RA synovium determine directly the systemic ACPA
levels as well as the local ACPA production in the joint. The
relation between RA-specific intracellular citrullinated proteins and
ACPA is dependent on the presence and load of the HLA-DR
shared epitope.
Conclusion: These data identify the RA-specific synovial
intracellular citrullinated proteins as primary antigenic targets of
ACPA in vivo and provide a pathophysiological rationale for the
specificity of this autoimmune process in human RA.
OR-06. Antibodies to Citrulline-Modified Proteins
Enhance Tissue Injury in Inflammatory Arthritis.
K. A. Kuhn,1 L. Kulik,1 K. J. Braschler,1 W. P. Arend,1 V. M.
Holers.1 1Immunology and Medicine, University of Colorado
Health Sciences Center, Denver, CO, USA.
Antibodies to citrulline-modified proteins have been shown to
be specific and predictive markers of Rheumatoid Arthritis (RA)
although the pathologic relevance of these antibodies has been
unclear. Similar to that which has been observed in RA, in the
murine collagen-induced arthritis (CIA) model of RA we have
identified serum antibody reactivity specific for citrulline-modi-
fied proteins that precedes clinically apparent disease. To under-
stand the role of antibodies to citrulline-modified proteins in
disease, we examined whether tolerance to these antigens could
protect mice from CIA. Mice were tolerized by intravenous
administration of 0.3 mg of a citrulline-modified peptide, a non-
citrullinated control peptide, bovine type II collagen (CII), or
ovalbumin for 3 days. Three and 24 days after the final dose of
tolerogen, mice were challenged with CII in complete FreundTs
adjuvant. Mice tolerized with the citrulline-modified peptide
demonstrated reduced disease severity compared to the control
peptide and ovalbumin (2.4 F 0.8, 6.2 F 1.7, 6.4 F 1.3,
respectively, P b 0.05). These data suggest that immune responses
to citrulline-modified proteins are important in the development of
inflammatory arthritis. As a second demonstration of the
pathogenic potential of antibodies to citrulline-modified proteins,
we determined whether antibodies to these autoantigens could
enhance disease. To accomplish this, we first identified an IgM
monoclonal antibody, designated D513, specific for citrulline-
modified fibrinogen. We then transferred D513 into mice alone
and in combination with a submaximal dose of arthritis-inducing
anti-CII monoclonal antibodies. In combination with anti-CII
antibodies, D513 substantially enhanced disease severity (9.4 F
0.8 with D513 vs. 3.7 F 1.1 without, P b 0.001). Also, we created
two additional monoclonal antibodies of the IgG class specific for
citrullinated fibrinogen which also substantially enhanced disease
severity in combination with anti-CII antibodies (8.3 F 1.2 and
8.3 F 0.7, P b 0.05 compared to anti-CII antibodies alone). These
results demonstrate that antibodies specific to citrulline-modified
proteins are pathogenic and likely play an important role in joint
destruction in human RA.OR-07. T to B Epitope Spreading Is Responsible for the
Diversification of Autoantibody Responses within the
Small Nuclear Ribonucleoprotein Complex.
U. S. Deshmukh,1 H. Bagavant,1 S. M. Fu.1 1Rheumatology and
Immunology, University of Virginia, Charlottesville, VA, USA.
Autoantibodies reactive against different polypeptides within
the small nuclear ribonucleoprotein complex (snRNP) are often
present in patients with systemic lupus erythematosus. Although
the mechanisms for the initiation of anti-snRNP autoantibody
responses are not known, it is well accepted that the complexity
in this response is achieved through intra and intermolecular
epitope spreading. We have established a model for intermo-
lecular epitope spreading within the small nuclear ribonucleo-
protein (snRNP) complex using the recombinant SmD protein.
We have previously demonstrated that the initiating antigen and
the interaction between the MHC and non MHC genes
influences intermolecular epitope spreading. To elucidate the
mechanisms for intermolecular epitope spreading within the
snRNP complex, we immunized mice with synthetic peptides
containing T cell epitopes on SmD. All peptides induced T cells
reactive with the immunogens. In the A/J strain of mice pep-
tides SmD31–45 and SmD52–66 consistently induced intermolec-
ular epitope spreading to A-RNP. Consistent epitope spreading
was not observed in mice immunized with peptide SmD91–110.
Although, all groups of mice had high titer of antibodies
reactive with the peptide immunogens, antibodies capable of
immunoprecipitating SmD antigen were minimally present.
These data are in contrast to those obtained with whole protein
immunization, wherein immunoprecipitating anti-SmD antibodies
were readily generated. These data suggest that in SmD peptide
immunized mice, a T to B cell epitope spreading was
responsible for the generation of anti-A-RNP antibodies. Thus,
if molecular mimicry was responsible for the initiation of anti-
snRNP autoantibodies, our data indicate that a T cell mimic is
sufficient to generate a diversified antibody response within the
snRNP complex.
OR-08. In SjogrenTs Syndrome Serum Autoantibodies
Recognize Tear Lipocalin and alpha-fodrin.
Riccardo Navone,1 Caterina Bason,1 Dimitri Peterlana,2 Roberto
Gerli,3 Claudio Lunardi,2 Antonio Puccetti.1 1Department of
Immunology, Institute G.Gaslini, Genova, Italy; 2Department of
Clinical and Experimental Medicine, University of Verona, Verona,
Italy; 3Department of Clinical and Experimental Medicine,
University of Perugia, Italy.
SjogrenT s syndrome (SS) is a chronic autoimmune disease
characterized by lymphocytic infiltration and tissue damage mainly
confined to the salivary and lacrimal glands, which results in
dryness of the mouth (xerostomia) and eyes (keratoconjunctivitis
sicca). Patients with SS often show a wide spectrum of auto-
immune related disorders, including pancreatitis, sclerosing chol-
angitis, interstitial nephritis, and interstitial pneumonitis. In these
target organs, different epithelial cells in exocrine and non exocrine
tissues are primarily affected. These clinical observations have led
to the assumption that autoimmune reactions against antigens
commonly expressed in epithelial cells may play a pathogenic role
in this disease. Characterization of novel autoantigens associated
with the systemic involvement in SS would provide useful
information to better understand its pathogenesis and to develop
new diagnostic and therapeutic strategies.
AbstractsS6We used pooled IgG immunoglobulins derived from 12
patients with primary SjogrenTs syndrome to screen a random
peptide library to identify disease relevant autoantigen peptides.
Among the identified peptides, one was recognised by 27/38
(72%) patientsT sera in an Elisa assay employing the solid phase
peptide. This peptide was not recognized by sera of normal
donors and of patients affected by other autoimmune diseases
such as systemic lupus erythemathosus, rheumatoid arthritis and
systemic sclerosis. Therefore the reactivity against this peptide
appears to be confined within primary SjogrenTs syndrome
patients.
The identified peptide showed homology with the EBVencoded
early antigen protein D. EBV infection has been associated with
SjogrenTs syndrome. Our findings suggest that EBV infection may
be involved in the disease pathogenesis as putative inciting stimulus.
The same peptide shares similarity with the tear lipocalin, a protein
highly expressed in tears and saliva, and with alpha-fodrin, a
cytoskeleton protein considered an important autoantigen target in
SjogrenTs syndrome.
Anti-peptide antibodies affinity purified from patientsT sera
recognize tear lipocalin in western blot. Moreover the same
antibodies are able to bind alpha-fodrin, which is known to be
cleaved in several fragments and to be exposed on the cell
surface during apoptosis. Our findings suggest that tear lipocalin
may be considered a novel and yet unidentified autoantigen in
SjogrenTs syndrome. We are now investigating the functional
role played by this autoantibody population in the pathogenesis
of the disease.
OR-09. Microarray Profiling of Anti-Lipid Antibodies in
MS.
J. L. Kanter,1 S. Narayana,1 L. Steinman,1 W. H. Robinson.2
1Neurology and Neurological Sciences, Stanford University,
Stanford, CA, USA; 2Medicine, Division of Immunology and
Rheumatology, Stanford University & Palo Alto VA Health Care
System, Palo Alto, CA, USA.
Recent studies suggest that increased T cell and autoantibody
reactivity to lipids may be present in multiple sclerosis (MS)
patients as compared to controls. We have created a 100-feature
lipid ordered array containing duplicate spots of 50 brain,
myelin, and microbial lipids and glycolipids that represent
potential targets of the autoimmune response in MS. Using our
lipid arrays, we tested cerebrospinal fluid from MS patients and
other neurological disease (OND) controls for the presence of
anti-lipid antibodies. Lipid array reactivity was quantified, and
Significance Analysis of Microarrays (SAM) applied to identify
lipids with statistically-significant differences in array reactivity
between MS and control samples. Lipids with significant
differences in array reactivity were ordered using a hierarchical
cluster algorithm and displayed as heat maps using TreeView.
Lipid arrays demonstrated increased autoantibody reactivity to
lipids including sulfatides, 3b-hydroxy-5a-cholestan-15-one (an
oxidized form of cholesterol), two separate forms of oxidized
phosphatidyl-choline, lysophosphatidyl-ethanolamine, and sphin-
gomyelin in MS patient CSF. Based on the array-determined
anti-lipid antibody profiles, the patientsT samples clustered into
groups of MS and OND controls. Our results suggest that lipids
are autoantigen targets in MS and that anti-lipid antibodies could
have diagnostic and predictive value in MS. The arrays
demonstrated increased antibodies against brain polar lipid
extract, oxidized lipids, and sulfatides in mice with acute EAE.We are currently exploring the role of these lipids on
demyelinating disease in vivo in mice.
OR-10. High-Throughput Analysis of Autoantibodies
Recognizing Myelin Antigens in Acute Disseminated
Encephalomyelitis.
K.C.OTConnor,1W.Robinson,3 K.Weichsel,2 T. Chitnis,1 S.Wong,4
L. Steinman,3 H. Fukaura,5 P. De Jager,1 K. Wucherpfennig,2
D. Hafler.1 1Center for Neurologic Diseases, Harvard Medical
School-Brigham & WomenTs Hospital, Boston, MA, USA;
2Cancer, Immunology and AIDS, Dana Farber Cancer Institute,
Boston, MA, USA; 3Department of Neurology and Neurological
Sciences, Stanford University, Palo Alto, CA, USA; 4Diagnostic
Immunology Laboratory, Wadsworth Center, New York State
Department of Health, Albany, NY, USA; 5Department of
Neurology, Iwate Medical University, Morioka, Iwate, Japan.
Acute disseminated encephalitis (ADEM) and multiple scle-
rosis (MS) are inflammatory demyelinating disorders of the CNS
that share clinical and pathological characteristics. The role of
autoantibodies as related to disease pathophysiology and diag-
nosis is unknown. To further characterize myelin autoantibodies
in these diseases, we studied the humoral response to a panel of
candidate autoantigens using protein arrays then confirmed these
data using novel solid and solution phase antibody binding
assays. Serum and CSF samples from patients with ADEM
revealed robust binding to a wide range of autoantigens, but only
a minor subset of samples from MS, encephalitis and normal
controls demonstrated binding distinguishable from background.
To confirm these data, two myelin antigens, myelin basis protein
(MBP) and myelin oligodendrocyte glycoprotein (MOG), were
further evaluated using traditional solid and novel fluid phase
assays. Solid-phase binding to these antigens was observed in a
minor subset of patients with MS and encephalitis, but solution-
phase binding, a characteristic of higher affinity antibodies, was
absent. Matched serum and CSF from patients with ADEM
contained autoantibodies directed toward MBP and MOG. In
contrast to their counterparts found in MS, these autoantibodies
demonstrated robust solution phase binding. These data highlight
a fundamental difference in the humoral response of these
clinically similar diseases and reflects underlying differences in
the pathogenesis of ADEM and MS.
OR-11. Role of CD38 in Human B Cells: Evidence of a
Functional and Physical Association with CD19.
S. Deaglio,1 T. Vaisitti,1 F. Malavasi.1 1Lab of Immunogenetics
and CeRMS, Dept of Genetics, University of Torino, Torino, Italy.
Human CD38 is a 45 kD surface glycoprotein endowed with
ectoenzymatic and receptorial activities. The study of CD38
functions in T and NK cells indicated that the molecule
bypasses its intrinsic structural inability to transduce signals
through physical and functional associations with the TCR and
CD16.
Here we show that membrane localization is critical for
CD38 signaling in human B cells. Membrane fractioning
indicates that a relevant fraction of CD38 molecules (60–85%)
is costitutively present in rafts in normal (tonsil) and neoplastic
(Nalm-6, Raji, Daudi, Namalwa, Ramos, RPMI-8226 and U266)
cells. Upon cross-linking all CD38 molecules translocate into
the rafts, together with a fraction of CD19 but not of CD79a
and b, suggesting that CD38 becomes physically associated with
CD19.
Abstracts S7Lateral associations between the two receptors were confirmed
in live cells using co-capping and biochemically with co-
immunoprecipitation experiments.
CD38-CD19 association also has a functional nature. Indeed,
CD38 ligation transduces signals only in cells where CD19 is
present and active. This is witnessed by the lack of CD38-
mediated Ca2+ fluxes in RPMI-8226 and U266, both CD19-. A
formal proof of a functional interplay between CD38 and CD19
was obtained by the loss of CD38-mediated signals upon CD19
gene silencing.
Lastly, all these events are independent of CD38 enzymatic
activities which are present in all the cell lines analyzed and are
unmodified by CD19 silencing.
Together, these data further stress the notion that i) CD38 is a
unique type of receptor working in synergy with the CD19 in B
cells, and that ii) the enzyme and receptor functions of CD38 are
distinct and independent.
Innate Immune System Regulating Disease
3:30 PM–5:30 PM, 5/13/2005
OR-12. Toll-Like Receptor 2 Regulates Cellular
Responses to Axonal Degeneration in the Central
Nervous System.
A. A. Babcock,1 H. Toft-Hansen,1 R. Landmann,2 S. Rivest,3 T.
Owens.1,4 1Neuroimmunology Unit, Montreal Neurological
Institute, Montreal, QC, Canada; 2Department of Research,
University Hospital, Basel, Switzerland; 3Laboratory of Molecular
Endocrinology, Centre Hospitalier Universite Laval Research
Center, QC, Canada; 4Medical Biotechnology Center, University
of Southern Denmark, Odense, Denmark.
Toll-like receptors (TLRs) are evolutionarily conserved
pattern-recognition receptors that are central to innate immunity.
TLRs initiate innate responses to infection through selective
recognition of conserved pathogen-associated motifs, which
signal for cytokine induction. We have addressed whether
endogenous signaling via TLRs directs the central nervous
system (CNS) response to axonal injury. Stereotactic lesioning
of axons in the entorhinal cortex causes axonal degeneration and
rapid activation of CNS-resident cells (microglia and astrocytes)
in specific regions of the hippocampus. We found that TLR2 was
constitutively expressed in the hippocampus and was specifically
upregulated by microglia in denervated zones prior to leukocyte
recruitment. Detection of MyD88 and InBa mRNA suggested
engagement of downstream signaling pathways. TLR2-deficiency
reduced cytokine (TNFa) and chemokine (CCL3, CCL4, CXCL2
and CXCL10) levels, causing a delay in T cell infiltration.
CCL2-driven macrophage infiltration was TLR2-independent,
suggesting that the pathways which direct macrophage and T
cell entry are differentially regulated by TLR2. Later expansion
of the microglial population required TLR2 signaling, whereas
astrocyte activation was unaffected by TLR2-deficiency. No
responses were altered in TLR4-defective mice, arguing against
endotoxin effects. Our findings suggest that TLR2 signaling
directs the endogenous response to CNS axonal injury through
selective regulation of early cytokine/chemokine expression that
drives later cellular responses implicated in regeneration and
repair.
This work was funded by the Multiple Sclerosis Society of
Canada.OR-13. Linking Innate Immunity to Autoimmunity
through the Role of TLRs and the MyD-88 Signaling
Pathway.
P. P. Ho,1 D. J. Mitchell,2 L. Y. Lee,3 W. H. Robinson,3,4 L.
Steinman.1 1Neurology and Neurological Sciences, Stanford
University School of Medicine, Stanford, CA, USA; 2Microbiology
and Immunology, Stanford University School of Medicine, Stanford,
CA, USA; 3Medicine, Division of Rheumatology & Immunology,
Stanford University School of Medicine, Stanford, CA, USA;
4Medicine, Division of Rheumatology & Immunology, Palo Alto
VA Health Care System, Palo Alto, CA, USA.
There are frequent associations between microbial infections and
autoimmune diseases in humans. An infection often exacerbates an
ongoing autoimmune response leading to chronic inflammation,
tissue destruction and degeneration of the corresponding target organ.
The innate immune system is the first line of defense against
pathogenic insult. Through Toll-like receptors (TLRs), the innate
immune system has the ability to recognize pathogens or pathogen-
derived products and to initiate signaling cascades that trigger
macrophages and dendritic cells to produce proinflammatory
cytokines. This leads to the stimulation of the adaptive immune
response. All known TLR ligands activate through the MyD-88
intracellular signaling pathway leading to the nuclear translocation of
the rel-type transcription factor NF-kB and the activation of MAP
kinases to induce gene expression of proinflammatory cytokines. We
hypothesized that blockade of the innate immune system through
TLRs would be a tangible method of attenuating the inflammatory
cascade due to the inability of signaling through the MyD88-
dependent signaling pathway. In this study, we have investigated the
involvement of TLR4 in the progression of experimental autoimmune
encephalomyelitis (EAE), a prototypic model of multiple sclerosis.
We found that mice deficient in TLR4 expression are resistant to
MOG 35–55 induced EAE disease. To bypass the need for TLR4
binding, we administered CpGs, the ligand for TLR9, to activate the
MyD-88 signaling pathway. We show here that TLR4-deficient mice
receiving a single dose of CpGs at the time of disease induction had
an overall mean disease severity similar to wildtype mice. Therefore,
manipulating the innate immune system through TLRs and theMyD-
88 signaling pathway offers a unique opportunity to suppress
destructive inflammatory responses and may provide a novel
approach for the treatment of Th1-mediated autoimmune diseases.
OR-14. Transcription Factor T-bet Regulates
Inflammatory Arthritis through Linking the Innate and
Adaptive Immunity.
J. Wang,1,2 J. W. Fathman,1 L. H. Glimcher.1,2 1Immunology and
Infectious Diseases, Harvard School of Public Health, Boston, MA,
USA; 2Rheumatology, Brigham and WomenTs Hospital, Boston,
MA, USA.
The transcription factor T-bet (T-box expressed in T cells) plays a
major role in adaptive immunity. T-bet controls the development of
both mouse and human Type 1 (Th1) T helper lymphocytes.
However, the role of T-bet in the innate immune system has been
largely unexplored. Here we demonstrate an essential function for T-
bet in dendritic cells (DCs) in controlling inflammatory arthritis. We
describe that collagen antibody-induced arthritis (CAIA) is a
bipartite disease characterized by an early component, intact in
Rag2/ mice, mediated through the innate immune system and a
later phase influenced by the adaptive immune system. T/ mice
had markedly reduced joint inflammation at both early and late time
points and Rag2/ /T-bet/ double knockout mice were essen-
AbstractsS8tially resistant to disease. Remarkably, adoptive transfer of T-bet
expressing DCs singlehandedly reconstituted inflammation in T-
bet/ mice. Furthermore, we demonstrate that T-bet regulates the
production of novel target genes, cytokine IL-1alpha, and inducible
proinflammatory chemokine MIP-1alpha and TARC by DCs.
Further, DCs from T-bet-/- mice display impaired antigen capture
capability, and hence suboptimal priming of antigen-specific Tcells.
We conclude that T-bet plays a vital function in DCs that links innate
and adaptive immunity. Thus, T-bet provides an attractive new target
for the development of novel therapeutics for inflammatory arthritis.
OR-15. Three Different TLR9 CpG Stimulants Exhibit
Diverse Effects in Murine Graft-Versus Host
Disease (GVHD).
R. A. Puliaev,1 I. A. Puliaeva,1 A. M. Krieg,2 C. S. Via.1
1Pathology Dept., Uniformed Services University of Health
Sciences, Bethesda, MD, USA; 2Coley Pharmaceutical Group,
Wellesley, MA, USA.
The injection of parental strain T cells into unirradiated F1 mice
results in an anti- host response that is either predominately cell
mediated (acute GVHD) or antibody mediated (chronic GVHD).
The lymphocytopenic phenotype of acute GVHD at day 14 is
mediated by anti-host CTL which eliminate host lymphocytes
whereas the lymphoproliferative, lupus-like phenotype of chronic
GVHD is mediated by donor CD4+ driven polyclonal B cell
hyperactivity. The DBA-into-F1 model of chronic GVHD results
from a relative defect in donor CD8+ T cell maturation into effector
CTL and administration of IL-12 in vivo converts the phenotype
from chronic GVHD to an acute GVHD. Thus, the model is useful
for screening agents with immunomodulatory or CTL promoting
potential. In this study, we tested the immunomodulatory activity in
vivo of three different TLR9 stimulants: 1) 2336, an A-Class CpG
which targets APC and promotes Type I interferon; 2) 2006, a B-
Class CpG which promotes B cell activity and is optimized for
human TLR9, and 3) 1826, a B-Class CpG optimized for mouse
TLR9. B6D2F1 mice received 80 million DBA splenocytes and 100
ug of CpG i.p. on days 0 and 2 after parental cell transfer. At 14 days
after cell transfer, mice were assessed by flow cytometry for splenic
lymphocyte subsets. Surprisingly, the results following treatment
with TLR9 ligands varied with the preparation used. The B-Class
CpG, 2006 exhibited significant immunomodulatory potential and
converted chronic GVHD to acute GVHD as measured by
elimination of host B cells, up-regulation of FasL on donor CD4+/
CD8+ Tcells and upregulation of Fas on host B cells. In contrast, the
A-Class CpG 2336 exacerbated chronic GVHD as measured by
increased donor CD4+ Tcells engraftment, host B cells numbers and
anti-ssDNA antibody levels and no increased donor CD8+ T cell
engraftment. The B-class CpG optimized for mouse TLR9 (1826)
exhibited no significant effect either way. These studies demonstrate
that despite targeting of a single TLR in vivo, depending on the
preparation used, there can be opposing effects on disease outcome.
OR-16. HSP60 Inhibits Th1-Mediated Hepatitis Model
Via Innate Regulation of Th1/Th2 Transcription Factors
and Cytokines.
Alexandra Zanin-Zhorov,1 Rafael Bruck,2 Guy Tal,1 Shirly Oren,1
Hussein Aeed,2 Rami Hershkoviz,3 Irun R. Cohen,1 Ofer Lider.1
1The Department of Immunology, The Weizmann Institute,
Rehovot, Israel; 2The Department of Gastroenterology, The E.
Wolfson Medical Center, Holon, Israel; 3The Department of
Internal Medicine D, Assaf Harofe Medical Center, Zerifin, Israel.Extra-cellular heat shock protein (HSP)-60 has been consid-
ered a pro-inflammatory bdanger signalQ. Yet, HSP60 can also
down-regulate experimental immune arthritis and diabetes models
by specific inhibition of Th1-like responses. We now report that
HSP60 in vitro differentially modulates the expression of Th1/
Th2 transcription factors in human T cells: HSP60 down-
regulates T-bet, NF-nB, and NFATp, and up-regulates GATA-3,
leading to decreased secretion of TNFa and IFNg and enhanced
secretion of IL-10. These effects depended on TLR2-signaling,
and could not be attributed to LPS or to other contaminants. In
BALB/c mice, HSP60 in vivo inhibited the clinical, histological,
and serological manifestations of ConA-induced hepatitis, asso-
ciated with up-regulated T-cell expression of SOCS3 and GATA-3
and down-regulated T-bet expression. These results provide a
molecular explanation for the effects of HSP60 treatment on T-
cell inflammation via innate regulation of the inflammatory
response.
OR-17. Toll Receptor Ligands Potently and Broadly
Enhance the Immune Response of Immunodepressed
Cutaneous T-Cell Lymphoma Patients.
M. Wysocka,1 S. Newton,1 B. M. Benoit,1 S. D. Hess,1 A. H.
Rook.1 1Department of Dermatology, University of Pennsylvania,
Philadelphia, PA, USA.
Patients with advanced cutaneous T-cell lymphoma (CTCL)
exhibit profound defects in cell mediated immunity partially
resulting from marked deficiencies in the numbers of
peripheral blood dendritic cells (DCs) and in their capacity
to make DC derived cytokines (IL-12, IL-15 and IFN-a).
Because host immune function appears to play an integral
role in mediating disease-controlling responses in CTCL, we
investigated the effects of synthetic imidazoquinolines which
have been recognized as immune stimulatory by virtue of
activation of DCs following binding to Toll like receptor
(TLR) 7 and 8. TLR 7, 8 and 7/8 binding compounds were
cultured with freshly isolated peripheral blood mononuclear
cells (PBMC) from patients with advanced CTCL (erythro-
derma with circulating malignant T-cells) and normal volun-
teers and a broad panel of immune functions assessed. All
three TLR ligands significantly induced high levels of IFN-a,
while the TLR 8 and 7/8 ligands induced IL-12, IL-15 and
IFN-g. The cytokine inducing effects were associated with
marked activation of NK and CD8 T-cells assessed by CD69
expression and cytolytic activity. Furthermore, striking upre-
gulation of CD80 expression on DCs and monocytes also
occurred. Thus, imidazoquinolines exhibit the ability to
potently and broadly enhance the immune response of
patients with advanced CTCL. Such pre-clinical findings have
typically been associated with significant clinical improvement
when put into clinical practice and therefore have important
implications for the potential enhancement of anti-tumor
immunity among patients with advanced CTCL.
OR-18. Beta-Adrenergic and Toll-Like Receptor 2
Signalling in Epidermal Keratinocytes Drive the Skin
Immune Response to a Soluble Protein.
Georges J.M. Maestroni. 1Experimental Pathology, Istituto
Cantonale di Patologia, Locarno, Switzerland.
Disorders of the skin immune activity are implicated in the
pathogenesis of cutaneous infections, skin malignancies and
acquired inflammatory skin disorders, including psoriasis, atopic
Abstracts S9dermatitis, contact hypersensitivity, lichen planus, alopecia areata
and vitiligo. Here we show that preconditioning of the skin by h-
adrenergic antagonist and the Toll-like receptor 2 (TLR2) agonist
S. Aureus peptidoglycan (PGN) results in increased local
expression of the interleukin (IL)-1a (IL-1a) and IL-12 genes,
which in turn instructs a T-helper 1 (Th1) adaptive response to a
soluble protein antigen. On the contrary, when the TLR4 agonist
E. Coli lipopolysaccharide (LPS) was used, the presence of the h-
adrenergic antagonist was not effective. These effects were
consonant with the pattern of TLRs expression shown by
epidermal keratinocytes but not by skin dendritic cells. As h-
adrenergic signalling defects together with S.Aureus infections
are thought to serve as initiation and/or persistance factors for
numerous Th 1-sustained inflammatory skin diseases, we might
have disclosed at least part of the relevant pathogenetic
mechanism.
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OR-19. Regulatory Function IsDeficient inCD4+CD25+ T
Cells from Patients with Systemic Lupus Erythematosus.
M. I. Vargas-Rojas,1 J. C. Crispin,2 J. Alcocer-Varela.3
1Department of Immunology and Rheumatology, Instituto Nacional
de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City,
Mexico.
During the last decade, the role of active suppression has
gained an important place in the operational models of the
immune response. Regulatory T (Treg) cells are now considered
an essential part of the normal immune response and their
absence or malfunction has been causally linked to disease in
both animal models and clinical scenarios. Recently, our group
and others, have reported that Treg cells are numerically deficient
in patients with Systemic Lupus Erythematosus (SLE), a
systemic autoimmune disease. Treg cells have been found to
be functionally abnormal in other autoimmune diseases, however
their functional competence has not been explored in patients
with SLE. Thus, the aim of this work was to isolate Treg cells
from patients with SLE in order to investigate if their suppressive
capacity is normal. Patients and Methods. Fifteen patients with
SLE (according to ACR criteria) and 15 age- and sex-matched
controls were included. At the moment of the study, patients
were not receiving corticosteroids nor immunosuppressive drugs;
4 patients had active disease. Treg cells (CD4+CD25++) were
quantified by flow cytometry. Results are expressed as the
percentage of cells within total lymphocyte population. Intra-
cellular IL-2 and IL-10 were quantified in CD4+CD25++ and
CD4+CD25- cells. CD4+CD25++ and CD4+CD25- cells were
isolated by magnetic separation. Suppressive capacity was
quantified in 96 hour co-cultures: Treg cells were added to
CD4+CD25+ cell cultures stimulated with plate-bound anti-CD3
and soluble anti-CD28. Cell proliferation was calculated accord-
ing to CFSE dilution. Proliferation results are expressed as an
index that considers the number of cell divisions per cell (the cell
proliferation method is the issue of another abstract). Results.
Treg cells were quantitatively lower in patients than in controls
(active SLE 1.1 F 0.7; inactive SLE 0.71 F 0.8; controls 2.6 F
0.8, Pb0.01). As expected, intracellular IL-2 was exclusively
observed in CD4+CD25- cells. Conversely, intracellular IL-10
was regularly observed in CD4+CD25++ cells. Treg cells obtainedfrom healthy individuals did not proliferate neither in basal nor
in stimulated conditions. Conversely, Treg cells from SLE
patients proliferated when stimulated (Pb0.05). When compared
to cells obtained from normal controls, CD4+CD25- cells from
SLE patients proliferated more spontaneously, but less after
stimulation (Pb0.05). When cocultured, Treg cells from 11 out
of 15 healthy controls inhibited z50% the proliferation of
CD4+CD25- cells; on the other hand, inhibition was only
observed in cells from 3/15 patients with SLE (P=0.003).
Conclusion. Treg suppressive function is deficient in patients
with SLE.
OR-20. IL-2 Mediates Expansion but Not Maintenances
of TGFB Induced Tregs in Inflammation: A Novel Role
of IL-10.
M. C. Fantini,1 C. Becker,1 I. Tubbe,1 H. A. Lehar,2 P. R. Galle,1
M. F. Nerath.1 1Laboratory of Immunology, I.Medical Clinic,
Johannes Gutenberg University, Mainz, Germany; 2Institute of
Pathology, Johannes Gutenberg University, Mainz, Germany.
Regulatory T cells have been implicated in the maintenance of
self tolerance in many animal models and human diseases. These
cells have been subdivided in acquired and natural regulatory cells
on the base of their origin. The first group includes regulatory cells
generated in periphery as the results of antigen specific tolerization
protocols, while the second is represented by naturally occurring
CD4+CD25+ regulatory cells, generating in the thymus during the
first days after birth. This last group of cells are characterized by the
expression of the Winged Helix transcription factor FoxP3, which
has been implicated in the direction of the genetic program
determining the regulatory potential of naturally occurring
CD4+CD25+ regulatory T cells. We have recently shown that
FoxP3 and a regulatory phenotype can also be induced in
CD4+CD25- naRve cells upon TGFh stimulation. While the
suppressive capacity of TGFh induced Tregs (Ti-Tregs) has been
extensively described in vitro, their role in vivo has been poorly
investigated. In order to shed light on the in vivo physiology of Ti-
Tregs we analyzed the expansion and phenotype stability of these
cells in vivo. In brief, Ti-Tregs were adoptively transferred in SCID
mice alone or together with colitogenic CD4+CD62L+ naRve cells in
order to provide an inflammatory environment. Results obtained
from these series of experiments indicate that Ti-Tregs depend for
their survival and expansion on the presence of an ongoing
inflammatory response as indicated by the loss of FoxP3 expression
and regulatory capacity in Ti-Tregs transferred in SCID mice in
absence of colitogenic cells. Further investigations of in vivo Ti-
Treg requirements lead to the identification of exogenous IL-2
provided by the ongoing inflammatory response as the main
responsible for Ti-Treg expansion and suppressive activity limited
at the site of inflammation. Moreover, we have shown that IL-2
alone is not sufficient to maintain FoxP3 expression and the
regulatory phenotype in Ti-Treg cells but that this requires the
presence of IL-10.Therefore we propose TGFh induced regulatory T
cells (Ti-Tregs) as a new class of acquired regulatory cells, highly
inflammation dependent for their expansion and survival. This
makes their action limited to the space where the immune response
occurs and limited to the time this response lasts. The properties
shown by Ti-Treg cells not only offer a new insight on how normally
occurring immune responses can be physiologically controlled, but
also offer the possibility to generate regulatory cells in vitro as a
therapeutical tool circumventing the problem related to a prolonged
and generalized state of immunodepression.
AbstractsS10OR. 21. Identification of Important Functional Domains
of FOXP3 by Analysis of Mutations Present in Patients
with IPEX Syndrome.
T. R. Torgerson,1 E. Gambineri,2 S. Vijay,1 S. Anover,1 H. D.
Ochs.1 1Pediatrics, University of Washington, Seattle, WA, USA;
2Pediatrics, bA. MeyerQ ChildrenTs Hospital, Florence, Italy.
FoxP3 is a member of the forkhead / winged-helix family of
transcriptional regulators that has been shown to play a key role
in the development and function of CD4+CD25+ regulatory T
cells in mice. In humans, defects in the FOXP3 gene lead to a
disease of systemic autoimmunity that is characterized by severe
autoimmune enteropathy, endocrinopathy, and skin disease
known as IPEX (Immune dysregulation, Polyendocrinopathy,
Enteropathy, X-linked). To define regions or domains of FOXP3
that may be functionally important, we have sequenced the
FOXP3 gene in more than 60 patients with a clinical phenotype
suggestive of IPEX syndrome. In this cohort, we have identified
21 unique mutations of FOXP3 in 60% of the patients. The
remaining patients had normal FOXP3 sequences at the
genomic DNA level but half of these had low FOXP3 mRNA
expression. Clinically, patients with mutations in FOXP3 had
more severe disease with a triad of enteropathy, dermatitis, and
endocrinopathy often combined with other autoimmune phe-
nomena whereas patients with normal FOXP3 sequences tended
to have milder disease. There does not appear to be a
geneotype/phenotype correlation between mutations in a partic-
ular region of the gene and a specific complex of symptoms.
The mutations identified thus far, cluster in one of three
regions: the carboxy-terminal forkhead domain, the leucine
zipper, and the amino-terminal proline-rich domain, particularly
near the 3V end of exon 1. Interestingly, no mutations have been
identified in the zinc finger domain. We have introduced the
mutations identified in patients into the FOXP3 cDNA and
expressed them exogenously in cells to assess their effects on
FOXP3 nuclear import, dimerization, DNA-binding and tran-
scriptional control. Using this approach, we have identified
regions in the carboxy-terminal portion of the protein that are
required for nuclear import and DNA binding, regions in the
central portion required for oligomerization, and regions
important for the control of transcription.
OR-22. GRAIL Expression Is Associated with the
Biological Activity of CD25+ T Regulatory Cells.
D. A. MacKenzie,1 C. M. Seroogy.1 1Pediatrics, University of
Wisconsin, Madison, WI, USA.
CD25+ T regulatory cells (CD25+ Treg) are a subset of T cells
with an anergic phenotype that suppress immune responses in an
antigen-specific fashion by a poorly understood mechanism. To date
the only specific gene marker for this subset of T cells is the
transcription factor, Foxp3. We observe a link between CD25+ Treg
cells and GRAIL, an E3 ubiquitin ligase necessary for the develop-
ment of CD4+ T cell anergy in vivo. We hypothesize that GRAIL is
important for the development and function of naturally occurring
and induced CD25+ Treg cells. Several lines of evidence support
this hypothesis: 1) GRAIL is expressed in naturally occurring
CD25+ Treg cells at levels 10-fold greater than CD25- CD4 T cells,
2) a tolerizing immunization in vivo leads to the induction of long-
lived CD25 expressing antigen-specific tolerized T cells. Gene
expression analysis of these cells reveals that GRAIL mRNA is
upregulated (700-fold increase vs. CD25- tolerized cells; 100-fold
increase vs. naturally occurring CD25+ Treg cells). Moreover,GRAIL expression is linked with Foxp3 expression strongly
suggesting a suppressor phenotype in this induced tolerized
population. As an initial step to understanding the role of GRAIL
in CD25+ Treg cell suppressor function, we demonstrate that
enforced expression of GRAIL in an antigen-specific T cell line is
sufficient to convey a suppressor phenotype in vitro. These data link
GRAIL expression to the biological activity of CD25+ Treg cells.
Mechanistic studies are ongoing and will be discussed further.
OR-23. Induction of CD4+CD25+Treg by
Tolerance-Inducing Antigen-Presenting Cells
Derived from Bone Marrow Cultures Initiated
with Anti-CD200R2/3.
R. M. Gorczynski, L. Lee, I. Boudakov. 1Transplant Research
Division, Toronto Hospital, University Health Network, Toronto,
ON, Canada.
Objective: The relatively ubiquitously expressed cell surface
molecule CD200 delivers immunoregulatory signals following
engagement of its receptor, CD200R. A family of CD200Rs has
now been described by several groups, with the isoforms
designated CD200R1-4. Tissue-restricted distribution of these
isoforms has been described, with splenic tissue expressing
predominantly CD200R1, while bone marrow is the tissue showing
the most predominant expression of CD200R2/R3. Little is known
to date concerning the functional activity of CD200Rs expressed
on cells in different tissues. We have used a number of isoform-
specific anti-CD200R agonist mAbs to investigate the effect of
signalling via CD200Rs expressed on splenic cells vs bone marrow
dendritic cell (DC) precursors.
Materials and Methods: We investigated the effect of agonist
anti-CD200R mAbs in three independent functional assays: on the
generation of alloimmunity in primary MLCs; on the generation of
allostimulatory dendritic cells (DCs) from bone marrow cells
cultured in vitro in the presence of (IL-4+GM-CSF); and on
induction of Treg in ConA activated thymocytes in vitro.
Primary MLC cultures were set up with C3H stimulator
spleen cells, and mitomycin-c treated C57BL/6 stimulator cells.
Some cultures contained anti-CD200R mAbs. Cytokines were
assayed in supernatants by ELISA at 40hrs, and CTL were
assayed at day 5. In the second assay, bone marrow cells were
cultured for 8 days with GMCSF and IL-4 with/without anti-
CD200Rs, to generate DCs. DC maturation was induced over-
night by LPS (1Ag/ml), and the mitomycin-c treated DCs were
used to activate fresh splenocytes in MLC, or to induce Treg in
splenocytes cultured for 48hrs with these DCs. T reg were also
induced in ConA activated thymocytes cultured with anti-
CD200R mAbs. Treg were assayed by FACS (for CD4+CD25+
cells), using real-time PCR for FoxP3 expression, and by their
ability to suppress CTL and cytokine production in a fresh
primary MLC culture.
Results: Anti-CD200R1 mAb (but not anti-CD200R2-4) sup-
pressed cytokine production and generation of CTL directly in fresh
MLC cultures. In contrast, addition of anti-CD200R1 caused no
significant perturbation of development of allostimulatory DCs from
bone marrow cultures with (IL-4+GMCSF). However, in the
presence of anti-CD200R2/3 mAbs, no functional allostimulatory
DCs developed from bone marrow cultures. Instead in these cultures
a population of DCs developed which induced CD4+CD25+Treg in
splenocytes. A similar Treg population was induced in thymocytes
activated by ConA in the presence of anti-CD200R2/3. Both
populations of Treg were FoxP3+ and inhibited the antigen-specific
Abstracts S11MLC response of fresh C3H responder cells on stimulation with
C57BL/6 cells. Treg also suppressed skin graft rejection in vivo.
Long-term culture of Treg in IL-2 was achieved (N4months), with
preservation of suppressive function in vitro/in vivo.
Summary: Our data suggest that both CD200R1 and
CD200R2/3 can signal immunosuppressive events, though they
do so by different mechanisms.
OR-24. Induction of TH1-Like Regulatory Cells That
Express Foxp3 and Protect Against Airway
Hyperreactivity.
P. Stock,1 O. Akbari,2 G. J. Freeman,3 R. H. DeKruyff,2
D. T. Umetsu.2 1Pediatric Immunology / Pneumology, University
Hospital Charite, Berlin, Germany; 2Division of Immunology,
ChildrenTs Hospital, Harvard Medical School, Boston, MA, USA;
3Department of Medical Oncology, Dana-Farber Cancer Institute,
Boston, MA, USA.
The range of natural and adaptive regulatory T cell (TReg) types
that control the magnitude and extent of immune responses is
poorly understood. We describe a unique population of regulatory
T cells (TReg) that developed in vivo from naive CD4+CD25- T
cells during a TH1 polarized immune response, distinct from
naturally occuring CD25+ TReg cells. These antigen-specific TReg
cells were induced by CD8a+ DCs, produced both IL-10 and IFN-
c, and potently inhibited the development of allergen-induced
airway hyperreactivity. These TReg cells expressed Foxp3, as well
as T-bet. The expression of IFN-c and T-bet, and their induction by
CD8a+ DCs indicate that these TReg cells are related to TH1 cells.
Thus, adaptive TReg cells are heterogeneous, and include TH1-like
TReg cells (TH1Reg), as well as previously described TH2-like TReg
cells (TH2Reg), which have been shown to suppress airway
hyperreactivity and were induced by CD8a- DCs.
OR-25. Regulatory T Cell Dysfunction and a Unique
Autoreactive T Cell Population May Be Associated with
the Development of Colitis in WASP-Deficient Mice.
V. Cotta-de-Almeida,1,2 F. Takeshima,1,3 M. Maillard,1,4 P.
Michetti,4 S. B. Snapper.1 1Department of Medicine, Massachusetts
General Hospital/Harvard Medical School, Boston, MA, USA;
2Department of Cell Biology, Oswaldo Cruz Foundation, Rio de
Janeiro, RJ, Brazil; 3Nagasaki University School of Medicine,
Nagasaki, Japan; 4Lausanne University Hospital, Lausanne,
Switzerland.
Background: Wiskott-Aldrich syndrome (WAS) is a severe
immunodeficiency associated with autoimmunity, with up to 10%
of patients developing inflammatory bowel disease (IBD). The
majority of WASP-deficient (WKO) mice also manifest severe
colitis. Objective:We aimed to determine whether IBD resulted
from aberrant regulatory T cell function. Methods: Lymphoid
organs obtained from WT and WKO mice were analyzed by flow
cytometry and the number of CD4+CD25+ regulatory T cells
(Tregs) was determined. To directly assess the role of Tregs in
colitis development, we adoptively transferred WT and WKO
CD45RBhi (RBhi) and CD45RBlo (RBlo) CD4+ T cells alone or in
combination into SCID recipients. Clinical scoring and histopatho-
logical analyses were performed. Results: WKO mice had reduced
numbers of Tregs in the peripheral lymphoid organs. This finding
was already evident before the onset of clinical colitis. Interest-
ingly, we also demonstrated decreased numbers of Tregs in the
thymus. As expected, the adoptive transfer approach demonstrated
that WT CD4+RBhi cells induced colitis, which was blocked by theconcomitant transfer of WT CD4+RBlo cells. However, WT
CD4+RBhi cells transfered disease even in the presence of WKO
CD4+RBlo cells. We also found that WKO CD4+RBhi cells are
colitogenic, but they cause disease with late incidence and lower
severity. Surprisingly, the co-transfer of WKO CD4+RBhi and
WKO CD4+RBlo cells resulted in the development of more severe
disease. Furthermore, WKO CD4+RBlo cells alone, but not WT
CD4+RBlo cells, were able to induce colitis. Conclusions: Our data
indicate aberrant development and function of Tregs in WKO
mice. Furthermore, our transfer studies suggest the presence of
unique colitogenic effector cells within the WKO CD4+RBlo
population. Aberrant Treg function and this unique autoreactive
effector cell population may account for autoimmunity and IBD in
WAS patients and WASP-deficient mice.
OR-26. MHC Class II Controls CD4+, CD25+
Regulatory Tolerance to Allogeneic Transplants.
G. Benichou,1 S. K. Germana,2 Y. Akiyama,1 K. Tanaka,1
C. LeGuern.2 1Surgery, MGH/Tranplant Unit, Boston, MA, USA;
2Surgery, MGH/TBRC, Boston, MA, USA.
MHC class II gene function has been closely associated with
regulation of T cell immunity although the mechanism of their
control remains unknown. We have previously demonstrated that
the transfer of donor-type MHC class II genes in the bone marrow
of miniature swine, recipients of subsequent renal allografts,
induced immune tolerance which was not due to deletion of
alloreactive T cells. In order to assess whether such tolerance
mechanism would implicate the regulatory pathway, and notably
CD4+, CD25+ regulatory T cells (T-regs), we examined the effect
of somatic transgenesis of donor class II IAb genes in the bone
marrow of CBA mice (H-2k), on the survival of subsequent
C57BL/6 (H-2b) heart grafts. In this model, donor-specific
tolerance as well as indefinite survival of fully allogeneic grafts
were achieved, without the use of immunosuppression. Class II-
mediated tolerance spread to T cell responses to all graft antigens.
Seventy seven percents of long-term accepted hearts, analyzed 160
days after transplantation, presented no signs of chronic allograft
vasculopathy. In addition, a single injection of 160-day-tolerant T-
regs in naive immunocompetent CBA mice, prolonged the survival
of C57BL/6 grafts. These results indicate that class II-mediated
tolerance affects the regulatory T-reg pathway likely through the
emergence of class II-specific T-regs for suppression of the whole
alloresponse, thereby achieving graft survival. They also provide a
mechanism by which class II expression may control the regulation
of T cell immunity to transplants.
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OR-27. Requirement for the Adipocyte Fatty Acid
Binding Protein aP2 in Allergic Airway Inflammation.
B. Shum,1,2 C. R. Mackay,1,2 C. Z. Gorgun,3 M. J. Frost,1,2 R. K.
Kumar,4 G. S. Hotamisligil,4 M. S. Rolph.1,2 1Arthritis and Asthma
Research Program, Garvan Institute of Medical Research, Sydney,
NSW, Australia; 2CRC for Asthma, Sydney, NSW, Australia;
3Department of Genetics and Complex Diseases, Harvard
University, Cambridge, MA, USA; 4School of Medical Sciences,
University of New South Wales, Sydney, NSW, Australia.
The adipocyte fatty acid binding protein (aP2) is expressed in
adipocytes and macrophages and regulates systemic glucose and
AbstractsS12lipid metabolism, and inflammatory responses. Using Affymetrix
oligonucleotide arrays we demonstrate that aP2 is also expressed in
human bronchial epithelial cells (HBE), and shows a striking
upregulation following stimulation of epithelial cells with the T
helper 2 (TH2) cytokines IL-4 and IL-13. In HBE, aP2 was
significantly down-regulated by the Th1 cytokine IFN-gamma.
Upregulation by Th2-, and downregulation by Th1-cytokines
strongly implicates aP2 as a participant in allergic inflammation.
Consistent with this hypothesis, aP2 expression was markedly
enhanced in bronchial epithelial cells from the lungs of mice
undergoing allergic inflammation. Strong aP2 staining was also
identified in the respiratory epithelium of human inferior turbinate
biopsies. aP2 deficient mice were tested in the model of allergic
airway inflammation and were found to be strongly protected, with
reductions in airway eosinophilia, peribronchovascular inflamma-
tion and pulmonary Th2 cytokine production. Thus, aP2 is a critical
regulator of allergic airway inflammation, and we are currently
investigating its mechanism of action. Finally, our data suggests a
molecular mechanism explaining the relationship between fatty acid
metabolism, diet, obesity and asthma.
OR-28. Transcriptional Regulation of Autoimmune
Diseases by Tumor Suppressor p53.
XiaochunWan, Shi-Jun Zheng, Salah-Eddine Lamhamedi-Cherradi,
Lingyun Xu, Brendan Hilliard, Youhai H. Chen. 1Department of
Pathology and Laboratory Medicine, School of Medicine University
of Pennsylvania, Philadelphia, PA, USA.
The tumor suppressor p53 regulates apoptosis, cell cycle, and
oncogenesis. To explore the roles of p53 in autoimmune diseases,
we studied autoimmune inflammation and innate immune function
using C57BL/6 mice deficient in p53. We found that p53-deficient
mice were more susceptible to experimental autoimmune ence-
phalomyelitis (EAE) and streptozotocin-induced type I diabetes
than control mice, and produced higher levels of IL-1, IL-6 and IL-
12. Upon activation in vitro, p53-/- T cells and macrophages
produced significantly elevated levels of inflammatory cytokines.
The innate immune response of p53-/- macrophages to lip-
opolysaccharides and interferon-y was also significantly enhanced,
which was accompanied with increased levels of total and
phosphorylated signal transducer and activator of transcription
(STAT)-1. These results indicate that p53 inhibits autoimmune
inflammation and innate immunity through downregulating STAT-
1 and pro-inflammatory cytokines.
OR-29. The Sjo¨grenTs Syndrome Associated
Autoantigen Ro52 Is a RING-Dependent E3 Ligase
That Suppresses Cellular Proliferation.
A. Espinosa,1 M. Hedlund,1 S. Brauner,1 V. K. Kuchroo,2
M. Wahren-Herlenius.1 1Rheumatology Unit, Department of
Medicine, Karolinska Institutet, Stockholm, Sweden; 2Center for
Neurologic Diseases, Brigham and WomanTs Hospital, Harvard
Medical School, Boston, MA, USA.
Objective: To determine the function of Ro52. Background: E3
ligases are a group of proteins mediating post-translational
modification with ubiquitin. E3 ligases have been implicated in
many cellular processes, including apoptosis, proliferation and
signaling. Some E3 ligases, e.g. Cbl-b, GRAIL and Itch, are
regulators of important signaling pathways in immune cells. There
is indirect evidence that there are other uncharacterized E3 ligases
involved in regulating immune responses. Ro52 (Ro/SSA, Trim21,
SSA1) is the main autoantigenic target in the autoimmunerheumatic disease SjfgrenTs syndrome. The function of Ro52 is
not known, but based on sequence homology we hypothesized that
this protein is an E3 ligase. Methods and results: To investigate if
Ro52 is an E3 ligase, ubiquitination assays were performed in vivo
and in vitro. FLAG-Ro52, or FLAG-Ro52 lacking the RING
domain (FLAG-Ro52DRING), was co-expressed with 6xHistidine-
tagged ubiquitin in HEK293 cells. Ubiquitinated proteins were
purified with Ni-NTA resin and ubiquitinated Ro52 was visualized
by immunoblotting with anti-FLAG antibody. FLAG-Ro52, but
not FLAG-Ro52DRING, was polyubiquitinated suggesting that
Ro52 is auto-ubiquitinated in a RING dependent manner. In vitro,
Ro52 mediated polyubiquitination together with several ubiquitin
conjugating enzymes, but most notably with UbcH6. Functional
consequences of Ro52-mediated ubiquitination were investigated
in a stably Ro52-transfected A20 B cell lymphoma cell line.
Expression of Ro52-GFP in A20 B lymphoma cells resulted in a
decreased proliferation in five independent clones compared to five
GFP expressing A20 clones and the parental A20 cell line.
Furthermore, when Ro52-GFP expressing A20 cells were activated
with anti-CD40 antibody, there was an increased cell death in the
Ro52 expressing A20 cells compared to the GFP expressing and
parental cells. Conclusion: These data demonstrate that Ro52 is a
novel RING-finger dependent E3 ligase, which inhibits prolifer-
ation and promotes activation induced cell death.
OR-30. Graft-Versus-Leukemia Target Antigens in
Chronic Myelogenous Leukemia (CML) Are Expressed
on Myeloid Progenitor Cells.
C. J.Wu,1,2 M. Biernacki,1 J. L. Kutok,3 S. A. Rogers,1 L. Y. Chen,1
X. F. Yang,1 R. J. Soiffer,1,2 J. Ritz.1,2 1Division of Hematologic
Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA;
2Department of Medicine, Brigham and WomenTs Hospital,
Boston, MA, USA; 3Department of Pathology, Brigham and
WomenTs Hospital, Boston, MA, USA.
Donor lymphocyte infusion (DLI) reliably induces durable
remission in 75–80% of patients with relapsed CML following
allogeneic bone marrow transplantation. To identify immunologic
targets of the graft-versus-leukemia effect of DLI, we used CML
post-DLI responder sera to screen a CML cDNA expression library.
Two of the identified targets were derived from genes encoding
proteins of 66 kD (CML66) and 28 kD (CML28). The development
of high titer specific IgG responses against both antigens in DLI
responders correlated with immune-induced remission. CML66 has
no known homologies, and its coding region contains no known
functional motifs. CML28 is identical to hRrp46p, a component of
the human exosome, which is involved in the 3V processing of RNA.
The human exosome contains known auto-antigens, such as PM/
Scl-100, an autoantibody target of patients with polymyositis or
scleroderma. The present studies were undertaken to characterize the
expression of CML28 and CML66 in primary normal and malignant
hematopoietic tissues. Northern blots showed high-level expression
in a variety of leukemia cell lines, but not in normal tissue, except for
testis. Specific monoclonal antibodies to CML28 and CML66 were
developed and utilized to detect antigen expression in leukemia cell
lines and primary leukemia tissue on western blot and immunohis-
tochemistry. Expression patterns were confirmed by antigen-
specific real-time PCR. Both CML28 and CML66 were highly
expressed in leukemic blasts from patients withAML andCMLblast
crisis, but barely detectable in normal bone marrow, normal
peripheral blood, or leukemic cells from patients with stable phase
CML. In contrast purified CD34+ progenitors from normal
Abstracts S13individuals and patients with stable phase CML expressed high
levels of CML28 and CML66 transcript and protein. Immunohis-
tochemical staining for CML66 confirmed rare staining of myeloid
precursors in normal marrow and diffuse staining of myeloblastic
cells in AML and blast crisis CMLmarrows. The expression patterns
of CML28 and CML66 are similar to some other leukemia
associated antigens, including the Wilms Tumor gene (WT1), and
suggest that abundant expression in the malignant myeloid
progenitor cell may be common to antigens that are targeted by
the humoral immune response following DLI. The striking
similarity between the expression patterns of CML28 and CML66
supports the notion that DLI exerts its curative effect by targeting
antigens present in self-renewing malignant progenitor populations
in CML.
OR-31. BAFF-but Not LT-Dependent B Cell Expansion
Contributes to the Suppression of Lethal Intestinal
Inflamation.
Yasuyo Shimomura,1 Emiko Mizoguchi,2 Atul K. Bhan,1
Atsushi Mizoguchi.1 1Department of Pathology, Massachusetts
General Hospital, Boston, MA, USA; 2Department of Medicine,
Massachusetts General Hospital, Boston, MA, USA.
Expansion and accumulation of B cells are commonly observed
in the inflamed intestine of IBD patients as well as experimental
colitis models. Interestingly, the expanded B cells have been shown
to play a regulatory role in certain intestinal inflammatory conditions
(Immunity 2002,16:219; Gastroenterology 2004,126:115). How-
ever, the molecular events leading to the inflammation-associated
expansion of regulatory B cells have not been elucidated yet.
Therefore, this study was designed to define the molecular
mechanism using an acute colitis model in which colitis is induced
by addition of 4% dextran sodium sulfate (DSS) in drinking water
for 4 days. Interestingly, flow cytometric and immunohistochemical
analyses showed amarked expansion of B cells in the colonic lamina
propria (LP) during the recovery phase (day 8: four days after the
cessation of DSS intake) but not in the acute phase (day 4) of DSS
colitis. The expanded B cells represented a pre-mature phenotype
with similarity to splenic transitional type 1 (T1) or T2 B cell subset.
In addition, analysis of IgHAchain diversities showed that the B cells
are polyclonally expanded. Surprisingly, lymphotoxin (LT) path-
way, that is necessary for the development of GALT formation under
normal conditions, was not required for the inflammation-induced B
cell expansion as indicated by a marked expansion of B cells in the
colon of DSS-treated LTa knockout (KO) mice. Therefore, to
identify the factors involved in the B cell expansion, real-time PCR
of purified B cells using a series of primer sets that can detect broad
ranges of B cell-associated signaling molecules (237molecules) was
performed. Significant upregulations of BAFF-R (B cell-activating
factor belonging to the TNF family-receptor), Btk (BrutonTs tyrosine
kinase), Rac2 and CD40 were observed in colonic B cells at Day 8
compared to Day 0 and Day 4. The functional roles of these
molecules in the inflammation-induced B cell expansion were then
examined using the specific KO mice treated with DSS. During the
recovery phase fromDSS-induced acute colitis, expansion of B cells
in the colonwas not observed in BAFF-R deficient mice and reduced
in Btk and CD40 KO mice. In contrast, absence of Rac2 did not
affect the B cell expansion. BAFF-mediated activation of NFkB p52
has been shown to enhance the survival of B cells. Indeed, Western
blot analysis showed an activation of NFnB p52 from precursor
NFnB p100 in the Day 8 B cells. In addition, a marked increase in
apoptosis of colonic B cells was observed in BAFF-R deficient micecompared to WT mice. Finally, to examine the functional role of B
cells in DSS induced colitis, the colitis was induced in B cell-
deficient mice. Of note, over 60% of B cell-deficient mice died of the
colitis until day 10, whereas over 90% of WT mice survived with a
sign of recovery from the acute colitis. These studies indicate that
intestinal inflammation-induced B cell expansion through BAFF but
not LT pathway contributes to the suppression of acute lethal colitis.
OR-32. Increased Constitutive Activation of NF-KB in
Patients with Multiple Sclerosis.
J. Yan,1 B. Pat,1 C. Winterford,1 H. Inglis,1 M. P. Pender,1
J. M. Greer.1 1School of Medicine, The University of Queensland,
Brisbane, QLD, Australia.
Multiple sclerosis (MS) is characterized by inflammation and
demyelination in the central nervous system (CNS). Current
evidence suggests that MS results from autoimmune responses
mediated by lymphocytes, which are activated in the peripheral
lymphoid organs and migrate into the CNS. Recent studies suggest
that the transcription factor NF-nB, might play an important role in
the development of chronic autoimmune attack in diseases such as
MS. NF-nB is normally found in the cytoplasm of the cell, but
under inflammatory conditions it moves into the nucleus to initiate
gene expression and produce more pro-inflammatory molecules.
The activation of NF-nB is regulated by a group of inhibitor
molecules, known as InB. Several of the InB family members have
polymorphisms that have been associated with susceptibility to MS
in Causasians. In immune cells from people with rheumatoid
arthritis or asthma, NF-nB has been found with aberrant,
constitutively nuclear localization and enhanced transcription of
pro-inflammatory genes. It has been observed that NF-nB and
InBa are co-localized in macrophage nuclei in active MS lesions.
However, it is unknown if NF-nB is constitutively activated in the
immune cells of MS patients. The aim of the current study was to
investigate this question.
Peripheral blood mononuclear cells (PBMC) were collected
from 19 untreated patients with MS and 27 healthy controls. Some
of the cells were fixed, pelleted, embedded in paraffin and
sectioned for immunohistochemistry using antibodies specific for
T cells, B cells or macrophages, and for the NF-nB p65 (RelA)
subunit. The remainder of the cells were lysed, and cytoplasmic
and nuclear fractions were purified from the lysate. These fractions
were then analysed by polyacrylamide gel electrophoresis and
immunoblotting using antibodies specific for the NF-nB p65
subunit and for InBa. The percentage of translocated NF-nB p65,
defined as the relative amount of NF-nB p65 found in the nucleus
divided by the total amount present in the whole cell, was
determined for each sample.
Sixty-eight percent of samples from untreated MS patients had
increased NF-nB p65/RelA translocation to the nucleus, compared
to 22% of PBMC from healthy controls (P b 0.002). Immunohis-
tochemical studies confirmed the translocation of NF-nB p65 to the
nucleus, and showed that, in most patient samples, the increased
NF-nB activity was in T cells and monocytes rather than in B cells.
In addition, the level of InBa protein was reduced in the cytoplasm
of untreated MS patients compare to healthy controls, although not
to a statistically significant degree.
The results indicate that T cells and macrophages from
untreated MS patients show higher levels of constitutively
activated NF-nB than do healthy controls. Such activity may lead
to enhanced transcription of pro-inflammatory genes and relate to
the chronic nature of MS.
AbstractsS14OR-33. Control of Macrophage Activation Via Myeloid
CD200R Signaling during Experimental Autoimmune
Uveoretinitis.
C. J. Calder,1 D. Copland,2 J. Phillips,3 H. Cherwinski,3
M. Jenmalm,3 J. D. Sedgwick,3,4 L. B. Nicholson,1,2 A. D. Dick.2
1Pathology & Microbiology, University of Bristol, Bristol, United
Kingdom; 2Clinical Sciences at South Bristol, University of
Bristol, Bristol, United Kingdom; 3DNAX, Palo Alto, CA, USA;
4Lilly Research Laboratories, Indianapolis, IN, USA.
Myeloid activation is partly controlled by inhibitory signals
through CD200receptor (CD200R) expressed on these cells. We
wished to determine the effects of the absence of CD200R
signaling, or of its induction by DX109, an agonist mAb, in
Experimental Autoimmune Uveoretinitis (EAU) a model of
inflammatory eye disease.
EAU was induced in CD200-/- and WT (C57BL/6) mice by
immunisation with (interphotoreceptor retinoid binding protein)
IRBP1–20, and also in B10.RIII mice which were immunised with
IRBP161–180, and treated at various time points with i.v. injections
of DX109 mAb. Eyes were enucleated and spleens dissected, for
histological disease score and functional assessment, respectively.
For macrophage activation studies, bone-marrow derived-
macrophages (BM-MA) were generated in Teflon bags
containing M-CSF media and these cells were then stimulated
in vitro with TGFh, TNFa and/or IFNg.
As previously reported in CD200-/- mice, disease onset
occurred earlier than in wild type mice, with histologically
increased structural damage, concomitant with increased numbers
of macrophages infiltrating the retina. Whilst microglial-derived
nitrite production was constitutively greater in CD200-/- mice,
TGFh-mediated suppression of nitrite was not seen in CD200-/-
tissue-derived macrophages (taken from both spleen and retina).
CD200R signalling was induced via an agonist binding mAb,
DX109 in vitro. Incubation of macrophages with DX109
abolished IFNg stimulated TNFa and IL-6 production, but not
nitrite secretion. In vivo, the efficacy of systemic treatment of
EAU in B10.RIII mice with DX109 was variable, but suppression
of histological disease was observed compared with mice treated
with an isotype control.
In summary DX109, an agonist antibody targeted at the
CD200R, prevented full expression of classical IFNg induced
macrophage activation. The variable suppression of EAU may be
because local tissue penetration of mAb is required to generate a
significant therapeutic effect.
OR-34. Role of Fgl2 Prothrombinase/Fibroleukin in
Experimental and Human Allograft Rejection.
Qin Ning,1 Yi Sun,1 Meifang Han,1 Li Zhang,1 Chuanglong Zhu,1
Weijie Zhang,2 Hui Guo,2 Jinwen Li,2 Weiming Yan,1 Feili Gong,1
Zhonghua Chen,2 William He,4 Cheryl Koscik,4 Robert Smith,4
Reginald Gorczynski,4 Gary Levy,4 Xiaoping Luo.3 1Department
of Infectious Disease, Tongji Hospital of Tongji Medical College,
Wuhan, Hubei, China; 2Institute of Organ Transplantation, Tongji
Hospital of Tongji Medical College, Wuhan, Hubei, China;
3Department of Pediatrics, Tongji Hospital of Tongji Medical
College, Wuhan, Hubei, China; 4Multi Organ Transplant Program,
University of Toronto, Toronto, Canada.
Objective: Immune coagulation, microthrombus and fibrin
deposition within the microvasculature are major contributors to
the pathogenesis of xenograft rejection, viral induced hepatocel-
lular injury and cytokine induced fetal loss syndrome. Here weinvestigated the contribution of the novel gene product, fibrinogen
like protein 2 (fgl2) prothrombinase, in mediating immune injury
in experimental and human acute allograft rejection.
Method and Result: Using a mouse heterotopic cardiac
transplant model, mouse fg12 (mfgl2)/fibroleukin mRNA tran-
scripts and protein were highly expressed in macrophages, CD4
and CD8 positive T lymphocytes and endothelial cells in rejecting
cardiac allografts in association with deposits of fibrin. While
mfgl2 deficient mice rejected allografts at similar rates to littermate
controls, survival of grafts from mfgl2 deficient mice were
markedly prolonged and largely devoid of intravascular fibrin.
Furthermore, treatment of wild type mice with a neutralizing anti-
fgl2 polyclonal antibody ameliorated histological evidence for
allorejection and intravascular fibrin deposition, and resulted in an
increase in graft survival compared to graft survival from untreated
mice or mice injected with an irrelevant antibody. To address
further the relevance of human fgl2 (hfgl2)/fibroleukin in acute
allograft rejection, we examined kidney biopsies from patients who
had undergone renal transplantation. hfgl2 mRNA transcripts and
protein were markedly expressed mainly in renal tubule cells,
infiltrating lymphoid cells including macrophages, CD8++ T cells,
mature B cells (plasma cells) and endothelial cells. Dual staining
showed fibrin deposition was localized mainly to blood vessels, in
the glomerulus and interstitium and the lumen of tubules, and
occurred in association with hfgl2 expression.
Conclusion: These data collectively suggest that fgl2 accounts
for the fibrin deposition seen in both experimental and human
allograft rejection and provide a rationale for targeting fgl2 as
adjunctive therapy to treat allograft rejection. This work was
supported by the National Science Fund for Distinguished Young
Investigators (No. 30225040 for Dr. Q. Ning, No. 30123019 for Dr.
XP Luo), from the Natural Science Foundation of China (NSFC),
NSFC operating fund 30100171,and 30170846, and the Canadian
Institutes for Health Research (CIHR) Grant #FRN33780.
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OR-35. Glycolipid Mediated Activation of iNKT Cells Is
Sufficient To Induce Airway Hyperreactivity
Independent of Conventional CD4 T Cells.
E. H. Meyer,1,2 O. Akbari,1 G. Berry,3 P. Savage,4 R. H. DeKruyff,1
D. T. Umetsu.1 1Division of Immunology, ChildrenTs Hospital
Boston, Harvard Medical School, Boston, MA, USA; 2Immunology
Program, Stanford University, Stanford, CA, USA; 3Department of
Pathology, Stanford School of Medicine, Stanford, CA, USA;
4Department of Chemistry and Biochemistry, Brigham Young
University, Provo, UT, USA.
We recently showed that the development of allergen-induced
airway hyperreactivity (AHR), a cardinal feature of asthma,
requires the presence of Va14 invariant T cell receptor+, CD1d
restricted natural killer T cells (iNKT). Here we demonstrate that
activation of iNKT cells is not only required, but is sufficient for
the development of AHR, independent of conventional CD4 T
cells, B cells and eosinophils. Respiratory administration of
glycolipids that specifically activate iNKT cells (a-GalactosylCer-
amide [a-GalCer] or sphingomonous glycolipid antigen [PS30])
rapidly induces marked AHR. The induction of AHR with a-
GalCer fails to develop in iNKT cell deficient (CD1d/ and
Ja18/) mice or in IL-4/IL-13 deficient mice, demonstrating the
Abstracts S15dependence of AHR on iNKT cells producing IL-4 and IL-13.
Eosinophils, B cells or IgE are not required for a-GalCer/PS30
induced AHR, since AHR develops in B cell deficient JHD mice
and in mice treated with anti-IL-5 mAb to eliminate eosinophils.
Moreover, MHC class II deficient mice, which lack conventional
CD4 T cells but which have iNKT cells, show exaggerated
glycolipid induced AHR, clearly demonstrating that conventional
CD4 T cells are not required for AHR. Therefore, activation of
pulmonary iNKT is necessary and sufficient to induce AHR in the
complete absence of conventional CD4 T cells. We suggest that
because iNKT cells are central and critical to the pathogenesis of
AHR, therapies that target iNKT cells may be clinically effective in
limiting the development of AHR and asthma.
OR-36. The Involvement of CD1-Restricted NKT Cells
in the Pathogenesis of Collagen-Induced and
Antibody-Induced Arthritis.
S. Kaieda,1 A. Chiba,1 S. Oki,1 T. Yamamura,1 S. Miyake.1
1Immunology, National Institute of Neuroscience, NCNP, Tokyo,
Japan.
Natural killer (NK) T cells are unique subset of T lymphocytes
that express Tcell receptor and a various NK receptors and produce a
large amount of cytokines including IFN-g and IL-4 after
stimulation with a glycolipid ligand such as a_galactosylceramide
(aGC). We have previously shown that administration of OCH,
synthetic analogue of aGC, prevent collagen-induced arthritis (CIA)
by preferentially inducing IL-4 production by NKT cells. However,
the role of NKTcells in the natural course of arthritis models remains
unclear. In the present study, we investigated the role of NKTcells in
collagen-induced and antibody-induced arthritis. To induce colla-
gen-induce arthritis, mice were immunized intradermally at the base
of the tail with 100 Ag of bovine or chiken type II collagen (CII)
emulsified with an equal volume of CFA. Mice were boosted by
intradermal injection with the same antigen preparation on day 21.
Arthritis development was monitored by inspection three times a
week. Starting from day 21, mice were injected intraperioneally
twice per week with anti-CD1 antibody To induce antibody-induced
arthritis, mice were injected either with the mixture of anti-CII
monoclonal antibodies (mAbs) (Arthrogen-CIA mAb [Chondrex.
LLC. Seattle, USA]) followed by LPS injection, or with serum from
KRN T cell receptor transgenic mice crossed with non-obese
diabetic mice (K/BxN). To detect NKT cells, cells were stained
with a-galactosylceramide-loaded CD1 dimer and were analyzed
using flowcytometry. Anti-CII antibodies were measured by
enzyme-linked immunosorbent assay (ELISA). Histopathological
examination was performed to evaluated arthritis. The number of
NKT cells increased in the liver at the peak of the clinical course of
CIA and antibody-induced arthritis. Administration of anti-CD1
mAb inhibited the development of CIA induced in DBA1J mice.
Next we induced in C57BL/6 (B6) mice and NKT cell deficient
(Ja281 knockout) mice. The severity of arthritis was significantly
reduced in NKT deficient mice compared to wild type B6 mice. The
level of anti-collagen antibody was not different between these
groups. The IgG1/IgG2a ratio of anti-CII mAb was elevated and
IFN-g production from draining lymph node cells were reduced in
NKT cell-deficient mice. To elucidate the role of NKT cells in the
effector phase of arthritis, we next examined antibody-induced
arthritis in NKT deficient mice and wild type B6 mice. The clinical
arthritis score and pathological examination revealed that the
severity of arthritis was significantly lower in NKT deficient
(Ja281 knockout or CD1d knockout mice) compared to wild typeB6 mice. CD1-restricted NKT cells play an important role in the
pathogenesis of arthritis, particularly in the effector phase of
arthritis. Considering the fact that Th2 skewing glycolipid ligand
such as OCH inhibited the development of arthritis, NKTcells could
be a new target for the treatment of rheumatoid arthritis.
OR-37. Effects of Natural Killer (NK) Cells on
Allogeneic Bone Marrow Transplantation.
Swati Bhattacharyya,1 Morton J. Cowan.1 1Department of
Pediatrics, UCSF, San Francisco, CA, USA.
Specific objectives of the study: In this stdy, we wanted to
define the role of the NK cells in myeloablation in MHC mismatch
condition. NK cells are capable of receptor mediated lysis of target
cells that lack self class I MHC molecules. Thus it can be used
effectively in an MHC I mismatched allogeneic bone-marrow
transplant to create myeloablation instead of the T lymphocyte. The
advantage of usingNKcells is that it can achieve the creation of space
without developing GVHD. Material, methods and results:
Preliminary experiments were done to assess the myeloablative
propertyofNKcells,whereC57Bl/6(B6)adultNKcellswere injected
i.p. to2daysoldBalb/cnewbornsandbonemarrowwasharvestedand
set up for in-vitro assays. This study showed that allogeneic NK cells
destroys both erythroid and myeloid stem cells. In the next set of
experimentswe injectedNKcellsFbone-marrowfromC57Bl/6 (B6)
into 14D oldBalb/c fetuses. However due to toxicity we had tomove
to restrict the usage of NK cells postnatal only. Seven out of ten
recipients of lin- BM and allogeneic NK cells had multi-lineage
engraftment 8 weeks post transplantation. The engraftment was
inhibited by co-administration of anti NK 1.1 mAb or anti- TGF
beta antibody. This indicate a) transplanted NK cells are playing
important role in the engraftment and b) engraftment is occurring
mostly through secretion of TGF-beta as the result of the addition
of NK cells in transplanted cell mass. We used an immunode-
ficient T-B-NK+ scida -/- model to study the repopulation of the
marrow following transplant with NK cells. We found significant
repopulation of the T cells but significantly lower amount of B
cells in blood. The genotyping PCR with thymocytes showed the
successful reconstitution of thymus and T cells following NK cell +
wt BM transplant in adult animals. The engrafted cells showed
normal TCR rearrangement a feature lacking in the knockout
animals. The bone-marrow analysis showed significant engraftment
of B cells and normal IgG heavy chain rearrangement post-
transplant unlike the scida where the development of B cells are
halted at a very early stage. Conclusion: The NK cells can be used
effectively as an cytotherapeutic myeloablative agent under immu-
nosuppressed conditions.
This work was supported by a grant from the NIH NIAID RO1
HL58842.
OR-38. NK-Mediated Protection in CFA-Injected NOD
Mice Is Dependent on IFN-;.
I.F. Lee,1,3 H.L. Qin,1,3 J. P. Dutz,2,3 A. Aoukaty,1,3 R. Tan.1,3
1Pathology and Laboratory Medicine, University of British
Columbia, Vancouver, BC, Canada; 2Medicine, University of
British Columbia, Vancouver, BC, Canada; 3BC ChildrenTs and
WomenTs Hospital, Vancouver, BC, Canada.
Autoimmune diabetes in non-obese diabetic (NOD) mice may
be prevented by a single injection of complete FreundTs adjuvant
(CFA), but the mechanism of protection needs further elucidation.
We previously showed that NOD mice immunized with CFA have
a markedly reduced incidence of diabetes that is associated with a
AbstractsS16significant decrease in the number of h-cell specific, autoreactive
cytotoxic T lymphocytes (CTL) and that the preventive effect of
CFA is mediated by natural killer (NK) cells. In the present study,
to understand better the mechanism by which NK cells mediate
CFA effect in diabetes, we adoptively co-transferred diabetogenic
NOD spleen cells along with NK cells from either IFN-g deficient
mice or standard NOD mice to NOD/SCID recipients that were
treated with CFA. NOD/SCID recipients that received NK cells
from IFN-g deficient mice developed diabetes rapidly after
adoptive transfer despite CFA treatment; however, recipients that
received NK cells from standard NOD mice either did not develop
diabetes or had delayed onset of disease. In addition, NK cells
derived from CFA-treated mice showed increased cytotoxicity
against autologous dendritic cells. These results indicate that NK
cells mediate the protective effects of CFA through secretion of
IFN-g and raise the possibility that autologous cytotoxicity of
antigen presenting cells may play a role.
OR-39. Microsomal Triglyceride Transfer Protein
Regulation of CD1d-Mediated Glycolipid Antigen
Presentation.
S. K. Dougan,1 A. Salas,1 P. Rava,2 A. Agyemang,3 A. Kaser,1
J. Morrison,1 A. Khurana,4 M. Kronenberg,4 C. Johnson,2
M. Exley,3 M. M. Hussain,2 R. S. Blumberg.1 1Gastroenterology
Division, Department of Medicine, Brigham and WomenTs
Hospital and Harvard Medical School, Boston, MA, USA;
2Anatomy and Cell Biology, SUNY Downstate Medical Center,
Brooklyn, NY, USA; 3Division of Hematology, Beth Isreal
Deaconess Medical Center and Harvard Medical School, Boston,
MA, USA; 4Division of Developmental Immunology, La Jolla
Institute for Allergy and Immunology, San Diego, CA, USA.
Microsomal triglyceride transfer protein (MTP), an ER chaper-
one which loads triglycerides, cholesterol and phospholipids onto
apolipoprotein B, also regulates CD1d presentation of glycolipid
antigens in liver and intestine. We now show that MTP transcripts
and functional protein are present in mouse and human professional
antigen presenting cells. Using a novel lipid transfer assay, we
demonstrate that purified MTP can transfer phospholipid to
recombinant CD1d in vitro. Inhibition of MTP by gene silencing,
chemical inhibition, or gene deletion results in decreased CD1d
surface expression and a decrease in CD1d-restricted presentation of
endogenous and exogenous antigens. By comparison, MHC II
restricted presentation of ovalbumin is unaffected by loss of MTP
indicating that MTP plays a specific role in CD1d presentation.
Recent work has shown that lysosomal saposins edit CD1d-bound
lipids. We propose that MTP acts upstream of the saposins and
functions as a chaperone by loading endogenous lipids into the
nascent CD1d groove. Our studies also suggest that a small molecule
inhibitor could be used to modulate the activity of NKT cells.
OR-40. Exogenous IL-2 Promotes IL-5 Production by
Human CD4+ NKT Cell Clones: The Role of IL-2 in the
Immune Regulation.
K. Sakuishi,1 S. Miyake,1 T. Yamamura.1 1Immunology, National
Institute of Neuroscience, National Center of Neurology and
Psychiatry, Kodaira, Tokyo, Japan.
The ability of CD1d-restricted NKT cells to produce Th1 and
Th2 cytokines has been well described. However, the potential of
human NKT cells to produce cytokines under various immune
responses needs yet to be delineated. We have analyzed the
cytokine production of CD4+ NKT cell clones derived from humanPBMC of healthy subjects and multiple sclerosis patients, and
found that exogenous IL-2 would promote their IL-5 production.
Methods: The NKT cell clones were generated by initially
stimulating fresh PBMC with agalactosylceramide (aGC) or its
analogue OCH. CD4+ NKT cells were then sorted based on the
reactivity to anti-Va24, Vh11, CD4, and CD8 mAbs. To maintain
the clones, Va24+ Vh11+ cells were sorted and then stimulated
with PHA on monthly basis. The NKT cells were stimulated by
aGC or OCH loaded on monocyte-derived immature dendritic
cells, with or without exogenous IL-2. The supernatant was
evaluated 48 hours later by cytomeric beads array (CBA). Results:
Most clones produced IL-5, and the amount was higher than IL-4
in some cases. Exogenous IL-2 enhanced the cytokine production
in response to the glycolipids in all the clones. In the presence of
IL-2, a few clones produced a remarkable amount of IL-5 even in
the absence of aGC or OCH. Conclusion: Our data imply that, in
the presence of IL-2, human CD4+ NKT cells could exhibit the
potential to produce abundance of IL-5 in response to weak
endogenous antigen stimulation, showing the interesting connec-
tion of IL-2 and the NKT cell-mediated immune regulation.
OR-41. Specificity of NKT Cells Against GD3
Ganglioside.
Dianna Y. Wu, Paul B. Chapman. 1Department of Medicine,
Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
We have shown previously that GD3, a ganglioside expressed on
melanoma, can be presented by CD1+ antigen-presenting cells and
that immunization with GD3 induces GD3-specific NKTcells. In the
current study, we evaluated the specificity of the GD3-reactive NKT
cells against other gangliosides that differ in the carbohydrate
components that interact with the NKT cell T-cell receptor (TCR).
By ELISPOT, we have found that a subset of NKT cells from GD3-
immunized mice also recognize GM3 but not GM2, GD2, or
lactosylceramide. We interpret these results to mean that the
presence of N-acetylgalactosamine (GalNc) inhibits interaction with
the TCR since the NKT cells recognize GD3 (Glucose-galactose-
[sialic acid]2) but not GD2 (GalNc-glucose-galactose-[sialic acid]2)
or GM2 (GalNc-glucose-galactose-sialic acid). We also found that
lactosylceramide (glucose-galactose) was not recognized by the
GD3-reactive NKT cells suggesting that at least one sialic acid
molecule is necessary for TCR binding. In conclusion, we have
begun to characterize the epitope recognized by GD3-reactive NKT
cells and find that the TCR of these NKT require glucose-galactose
linked to at least one sialic acid for recognition, but that GalNc
blocks TCR binding. (Supported by NCI RO1 CA97041).
OR-42. CD4+ Invariant T Cell Receptor+ NKT Cells and
the Development of Bronchial Asthma in Humans.
Omid Akbari,1 John L. Faul,2 Gerald J. Berry,2 Jan Wahlstrom,3
Mitchell Kronenberg,4 Rosemarie H. DeKruyff,1 Dale T. Umetsu.1
1Immunology,ChildrensHospital,HarvardMedical School, Boston,
MA, USA; 2Pulmonary and Critical Care Medicine, Stanford
University, Stanford, CA, USA; 3Respiratory Medicine, Karolinska
Institutet, Stockholm, Sweden; 4Developmental Immunology, La
Jolla Institute for Allergy & Immunology, San Diego, CA, USA.
NKT cells comprise a population of T cells that express cell
surface markers characteristic of both NK cells and conventional T
cells that have been shown to exert strong regulatory activity in
autoimmune diseases, such as diabetes mellitus, EAE, oxazalone
induced colitis and in tumor immunity. We previously showed in a
mouse model of asthma that NKTcells producing IL-4 and IL-13 are
Abstracts S17required for the development of airwayhyperreactivity (AHR), a
cardinal feature of asthma. We now show that in human subjects
with asthma, the majority of cells in bronchoalveolar lavage (BAL)
fluid are not conventional CD4+ T cells, but rather CD4+ NKT cells
expressing an invariant Tcell receptor (iNKTcells). In the BAL fluid
of the 11 asthmatic subjects, 55–85% of the CD3+ cells were iNKT
cells, whereas in patients with sarcoidosis, another pulmonary
inflammatory disease, b3% were iNKT cells. Similar results were
obtained using immuno-fluorescence and confocal laser scanning
microscopy of endobronchial biopsy specimens from patients with
asthma and sarcodosis. Like iNKTcells in mouse models of asthma,
the iNKT in the lungs of patients with asthma produced both IL-4
and IL-13, but very little IFN-g. In contrast, iNKT cells in the
peripheral blood of all of our subjects (asthmatic, sarcoidosis and
normal individuals) produced all three cytokines, suggesting the
compartmentalization of Th2 subset of iNKT cells in the lungs of
patients with bronchial asthma.
Taken together, our studies demonstrate that the lungs of patients
with asthma but not sarcoidosis contain predominantly CD4+ iNKT
cells rather than conventional CD4+ Tcells. These pulmonary CD4+
iNKT cells produce a cytokine profile known to amplify the
inflammatory response in asthma strongly suggesting that iNKT
cells play a central role in the pathogenesis of human asthma.
Genetics of Immune-mediated Diseases &
Transplantation
10:30 AM–12:30 PM, 5/14/2005
OR-43. TIM-1 Induces T Cell Activation and Inhibits
the Development of Peripheral Tolerance.
S. E. Umetsu,1 W. L. Lee,2 J. J. McIntire,2 L. Downey,2
B. Sanjanwala,2 O. Akbari,3 G. J. Berry,2 H. Nagumo,4
G. J. Freeman,4 D. T. Umetsu,3 R. H. DeKryuff.3 1Department
of Microbiology and Immunology, Northwestern University
Medical School, Chicago, IL, USA; 2Stanford University School
of Medicine, Stanford, CA, USA; 3Division of Immunology,
Harvard Medical School, Boston, MA, USA; 4Department of
Medical Oncology, Dana-Farber Cancer Institute, Harvard
Medical School, Boston, MA.
Tim1 was initially identified as an atopy susceptibility gene
through positional cloning of a congenic mouse model of asthma. In
the mouse, distinct genetic variants of Tim1 were found to be
associated with development of both Th2-biased immune responses
and allergen-induced airway hyperreactivity. In humans, Tim1 was
also found to be a significant atopy susceptibility gene, with specific
alleles associated with protection against atopy. Here we examined
the immunological function of TIM-1 using a specific monoclonal
antibody (mAb), and demonstrated TIM-1 to be a potent T cell
costimulatory molecule with a critical role in regulation of the
immune system. TIM-1 is expressed on CD4 T cells early after
activation, and expression is sustained preferentially in Th2 but not
in Th1 cells. In vitro stimulation of CD4 T cells with a TIM-1
specific mAb in combination with T cell receptor activation
markedly increased T cell proliferation, indicating that TIM-1
signaling provides a robust positive costimulatory signal to CD4 T
cells. Administration of anti-TIM-1 mAb in vivo in combination
with antigen strikingly enhanced production of cytokines, prevented
the development of respiratory tolerance, and increased pulmonary
inflammation. Our studies indicate that TIM-1 is a novel and
significant costimulatory molecule, and altering TIM-1 functionduring the immune response could provide potent immunomodula-
tory therapies for a variety of immunological disorders.
TLR, NK, Innate Immunity
10:30 AM–12:30 PM, 5/14/2005
OR-44. In Vivo Homeostatic Proliferation of Naive
CD4+ T-Cells Restrains the TCR Repertoire in Healthy
Human Adults.
S. Kohler,1 U. Wagner,2 M. Pierer,2 S. Kimmig,3 B. Oppmann,1
B. Moewes,1 K. Juelke,1 C. Romagnani,1 A. Thiel.1 1Clinical
Immunology, DRFZ, Berlin, Berlin, Germany; 2Medicine IV,
University of Leipzig, Leipzig, Sachsen, Germany; 3Molecular
Biology, MPI for Infection Biology, Berlin, Berlin, Germany.
Objective:HumanCD31- centralnaiveCD4+T-cellshavepreviously
been shown to have post-thymically proliferated and to constitute the
majority of naive CD4+ T-cells in the elderly. By taking advantage of
this new phenotypic marker we wanted to analyse possible con-
sequences of postthymic proliferation for the naive Th-cell pool and
elucidate the driving force of this process in humans.
Methods: The absolute numbers of peripheral blood CD31+ and
CD31- naive CD4+ T-cells were determined in 25 donors of
different age. Additionally, CD31+ and CD31- naive CD4+ T-cells
of 9 healthy donors were highly purified and subjected to a detailed
repertoire analysis by spectratyping. Finally RNAwas isolated from
purified CD31+ and CD31- naive CD4+ T-cells, cDNA prepared
and subsequently Bfl/A1 expression analysed by RT-PCR.
Results:We show here that absolute numbers of CD31- centralnaive
CD4+T-cells remain fairly stable inadult peripheral blood, excluding a
thymus dependent regulation of the CD31- CD4+ centralnaive T-cell
pool.On the contraryCD31+ thymicnaiveCD4+T-cells decreaseduring
ageing, implying a dependence on thymic function. Most importantly
we demonstrate that CD31- centralnaive CD4+ T-cells isolated from
healthy adults are characterisedby ahighly restrictedoligoclonalT-cell
receptor repertoire. In order to elucidate the driving force of this post-
thymicnaiveCD4+T-cell expansion,weevaluated signaturesof recent
TCRengagement inpurifiedCD31+ thymicnaive andCD31- centralnaive
CD4+T-cells.ExvivoRT-PCRanalysis revealedupregulationofBfl1/
A1 among CD31- centralnaive CD4+ T-cells, a gene which has been
shown to be expressed exclusively upon TCR.
Conclusion: Our results demonstrate for the first time that
presumably TCR driven peripheral homeostatic proliferation of
naive CD4+ T-cells in healthy human individuals causes a
significant contraction of the peripheral TCR repertoire. Given the
importance of a highly diverse repertoire for the ability to mount
efficient immune responses, this age-dependent deterioration of
CD4+ T-cell immunity could entail ageing-associated increased
susceptibility to infection or cancer and decreased efficiency of
vaccination. Moreover preferential expansion of self-reactive naive
T cells could contribute to autoimmunity.
Immunodysrcgulation and
Immunoreconstitution
10:30 AM–12:30 PM, 5/14/2005
OR-45. Intragraft Foxp3 Expression Is Associated with
Rejection and Is Suppressed by CsA.
K. G. Haanstra,1 J. A.M. Wubben,1 M. Jonker.1 1Immunobiology,
Biomedical Primate Research Centre, Rijswijk, ZH, Netherlands.
AbstractsS18Foxp3 is a transcription factor and its expression has been
described as a unique marker for regulatory T cells (Treg). TGF-h
seems to play a crucial role in the induction of Foxp3 expression.
We have recently described that intragraft expression of latent TGF-
h is associated with stable kidney allograft function in monkeys no
longer receiving immunosuppression. Thus we were interested if
TGF-h expression and stable graft function correlated with intra-
graft Foxp3 expression. We stained kidney biopsies and kidney
tissue at the time of graft rejection obtained from monkeys treated
with antibodies specific for CD40 and CD86 and from animals
treated with ATG, CsA or with a combination of these drugs for
Foxp3. A polyclonal goat-anti-human Foxp3 antibody was used. In
addition, these tissues were stained for latent and active TGF-h. All
animals with clinical rejection (serum creatinin of 200AMol or
higher) and that showed significant graft infiltrates expressed Foxp3
in the nucleus in 5 to 20% of lymphocytic cells. There was one
exception: one animal that rejected while still on CsA treatment did
not show nuclear Foxp3 expression. In early biopsies (day 21–42
post transplantation) of animals treated with anti-CD40 and anti-
CD40+CD86, only approximately 50% of the animals showed
nuclear Foxp3 expression (5–10% of graft infiltrating cells). Most
of these animals showed significant interstitial infiltrates without
loss of graft function. Five animals were treated with ATG at the
time of transplantation followed by anti-CD40+86 treatment. None
of these animals showed nuclear Foxp3 expression on day 21. Only
later when these animals also showed clinical graft rejection, Foxp3
could be found in the infiltrating cells. Animals (n = 6) that were on
delayed CsA treatment (combined with anti-CD40+86) did not
show expression of Foxp3, while Foxp3 expression was evident
prior to the CsA treatment. Three animals that had stable graft
function for more than 2 years after all immunosuppression was
withdrawn showed low levels of nuclear Foxp3 expression or no
nuclear Foxp3 expression at all. TGF-h was found in almost all
tissue samples examined. There was no direct correlation between
the amount of either latent TGF-h or active TGF-h present in the
grafts and the presence of nuclear Foxp3. We conclude that nuclear
intragraft Foxp3 expression is not unique for tolerated grafts.
Rather, Foxp3 positive cells (Treg) must be considered as part of the
normal immune response during graft rejection. The nuclear
expression of Foxp3 is inhibited by CsA and ATG treatment and
this may indicate that these drugs prevent Treg development.
Disease Regulation: Role of Antigens,
Cytokines, Chemokines
10:30 AM–12:30 PM, 5/14/2005
OR-46. Insulin with Native B:9-23 Sequence Is an
Essential Autoantigen in the NOD Mouse.
M. Nakayama,1 N. Abiru,2 H. Moriyama,3 N. Babaya,1 E. Liu,1
D. Miao,1 L. Yu,1 D. R. Wegmann,1 J. C. Hutton,1 J. F. Elliott,4
G. S. Eisenbarth.1 1Barbara Davis Center for Childhood
Diabetes, University of Colorado Health Sciences Center, Denver,
CO, USA; 2The 1st Department of Internal Medicine,
Graduate School of Biomedical Sciences, Nagasaki University,
Nagasaki, Japan; 3Division of Internal and Geriatric Medicine,
Kobe University Graduate School of Medicine, Kobe,
Japan; 4Department of Medical Microbiology and Immunology,
University of Alberta, Edmonton, AB, Canada.
A fundarmental question is whether there are primary
autoantigens for specific autoimmune disorders. To determineif insulin is essential for development of autoimmune diabetes,
we created NOD mice without native insulin 1 and 2 genes but
with a mutated insulin B:9-23 sequence.
The mutated insulin replaced tyrosine with alanine at B chain
amino acid 16 (B16:Ala insulin). This mutation abrogates the
autoreactivity of multuple insulin B:9-23-reacting T cell clones (e.g.
BDC12.4.1)with preservation of hormonal activity. Four founder
strains of B16:Ala insulin-transgenic mice were established directly
in NOD mice and combined with insulin 1 and 2 knockout NOD
mice.
NOD mice lacking insulin 1 and 2 genes with the mutated
insulin transgene did not develop anti-insulin autoantibodies,
whereas 80% of mice bearing at least one copy of the native
insulin 1 gene without the insulin 2 gene developed insulin
autoantibodies (Pb0.0001). Remarkably, the initial two double
insulin knockout mice sacrificed at 26 (Strain B) and 23 (F)
weeks of age show no inslitis. However sialitis was observed,
suggesting that the protection from autoimmunity by deleting
native insulin is organ-specific. Almost all mice with any native
insulin gene sacrificed after 10 weeks of age had intra-islet
insulitis with or without the B:16Ala transgene (n = 40/41,
Pb0.01). Consistent with lack of insulitis, none of native insulin
null NOD mice developed diabetes. All founder strains of
B16:Ala-transgenic NOD mice developed diabetes and insulitis
when a native insulin gene was also present, suggesting the
preventive effect is dependent on the absence of the native
insulin. Splenocytes from the protected transgenic native insulin
null NOD mice showed delayed transfer of diabetes into
NOD.SCID mice (50% transfer: 13.5 weeks), compared with
standard NOD splenocytes transfer (50% transfer: 6.4 weeks,
Pb0.02). The NOD.SCID mice have native insulin genes.
Splenocytes from the diabetic NOD.SCID recipients showed
immunologic memory and transferred diabetes into a second
NOD.SCID mouse and this mouse developed diabetes at 5
weeks post splenocyte transfer.
Our observation that native insulin null NOD mice with a
mutation of insulin B:9-23 sequence abrogates anti-islet auto-
immunity suggests that insulin is an essential autoantigen for
type 1 diabetes of NOD mice, and insulin peptide B:9-23 is
likely a critical determinant. Ability to transfer disease with
splenocytes from protected mice is likely due to expression of
native insulin B:9-23 sequence of the recipient and indicates
that splenocytes from protected native insulin null mice are
competent to rapidly transfer diabetes into host with appropriate
target.
Genomics and Genetics
3:30 PM–5:30 PM, 5/14/2005
OR-47. Differential Transcript Profiling Identifies
Candidate Genes in the New Zealand Model of
Systemic Lupus Erythematosus, Including the B-Cell
Transcription Factor, Bach2.
R. J. Rigby,1 S. Horswell,2 M. Haywood,1 C. Shoulders,2
B. J. Morley,1 T. J. Vyse.1 1Rheumatology, Imperial College
London, London, United Kingdom; 2Genomic & Molecular
Medicine, MRCClinical Sciences Centre, London,United Kingdom.
Systemic Lupus Erythematosus (SLE) is an autoimmune
disease with multiple target organs, an unknown etiology and a
complex pathogenesis, with genetic, environmental and other, as
Abstracts S19yet undetermined factors. The New Zealand (NZ) mouse model,
comprising the New Zealand Black (NZB) and New Zealand
White (NZW) strains, spontaneously develops a systemic auto-
immunity, and is considered to be an excellent model of SLE.
Numerous SLE-linked loci have been identified throughout the
NZ genome- the challenge now is to determine the genes that
underlie these linkage regions and their role in SLE patho-
genesis. To this end, we have assayed, utilising the Affymetrix
MOE430 GeneChip system, global gene expression in both
splenic CD19+ B-cells and CD4+ T-cells. Samples from lupus-
prone NZB and non-autoimmune BALB/c mice were inves-
tigated, along with two congenic mouse strains that carry NZB-
derived disease-linked regions on the BALB/c genome, namely
distal chromosome 1 (Nba2) and proximal chromosome 4
(Nbwa2).
Differentially expressed genes between NZB and BALB/c were
identified by combining the results of two methods- a fold-change
analysis and a significance analysis of microarrays (SAM). Genes
that were observed as a result of both analyses were considered to
be differentially expressed. Based on thresholds of F 2
(compared to BALB/c) in the fold change analysis and 5% cut-
off values for the SAM analysis, 559 genes and transcripts were
differentially expressed between NZB and BALB/c B-cells and
758 genes and transcripts were differentially expressed between
NZB and BALB/c T-cells.
In an attempt to define disease susceptibility genes within the
congenic intervals, the transcript profiles of genes that mapped
within the congenic intervals were compared with those of BALB/
c. We successfully identified a number of differentially expressed
genes specific to the congenic interval. For example, the interferon-
inducible (Ifi) gene cluster, sited on distal chromosome 1, showed a
considerable degree of differential expression in both NZB and the
Nba2 congenic strain compared to BALB/c. This replicates the
findings seen in an investigation of gene expression in splenic
tissue from NZB and C57BL/6.
In relation to the Nbwa2 locus on proximal chromosome 4,
upregulation of the BTB and CNC homology 2 (Bach2) gene was
present in B-cells from the congenic strain when compared with
BALB/c. Bach2 is a transcription factor that has key roles in B-cell
class switching and the somatic hypermutation evident in the
humoral immune response. We are defining sequence variants
across the Bach2 gene in order to characterise its haplotype
structure in inbred mouse strains.
OR-48. Impact of the Lupus Susceptibility Locus, Sle1
on B Cell Tolerance.
K. Raman,1 L. Li,1 M. Bhaskarabhatla,1 R. Samudrala,1 K. Hsu,1
C. Mohan.1 1Internal Medicine-Rheumatology, UT Southwestern
Medical Center, Dallas, TX, USA.
Purpose: Whereas B6 mice are autoantibody free; B6 mice
rendered congenic for the NZM2410/NZW allele of the Sle1 lupus
susceptibility interval develop high titres of anti-nucleosome
antibodies. Hence Sle1 tips the balance from tolerance towards
autoimmunity. These studies were designed to understand how
Sle1 might breach B cell tolerance.
Methods: B6.Sle1 mice were bred to HEL-Ig.mHEL or HEL-
Ig.sHEL transgenic mice. These mice were then examined for
breach in B cell tolerance using various methods including flow
cytometry, serology, calcium flux analysis and in vitro cultures.
Results: The presence of the HEL-Ig transgene bcured Q the
Sle1 associated autoimmune phenotypes including splenomegaly(B6.Sle1.HEL-Ig 100 F 17 mg vs B6.Sle1 235 F 86 mg pb0.001,
n = 8–22, aged 8–14 months), B (mfi I-Ab B6.Sle1 866.6 F 142.4
units vs B6.Sle1.HEL-Ig 419.1 F 80.38 units, n = 5–11, aged 3–7
months) and T cell activation (number of CD4+CD69+ T cells:
9.187 F 3.736106 vs 4.222 F 1.264 106 n = 4–11), anti-
nuclear antibody production (anti-DNA-histone IgG: B6.Sle1
144.1 F 46.21 U/ml vs B6.Sle1.HEL-Ig 18.62 F 2.820 U/ml,
n = 3–11, aged 4–7 months, P = .0002) and glomerulonephritis.
To study the impact on central deletion, Sle1 was bred to
HEL-Ig.mHEL mice. B6.HEL-Ig.mHEL and B6.Sle1 .HEL-
Ig.mHEL (n = 6, each) mice had comparable diminution of
splenic IgMa HEL+ve transgenic B cells and serum anti-HEL
antibodies, indicating that Sle 1 did not abrogate central deletion
of high avidity anti-self B cells.
To study the impact of Sle1 on clonal anergy, Sle1 was bred
to HEL-Ig.sHEL mice. In this model, although self-reactive B
cells are allowed to escape to the periphery they are functionally
anergised. Importantly, Sle1 breached tolerance in this model
since B6.Sle1.HEL-Ig.sHEL mice had an increased number of B
cells (18.66 F 3.791 106 vs 10.24 F 2.829 106, p b 0.0006,
n = 8–9, aged 3–6 months) and also had significantly higher
levels of anti-HEL antibodies (39.70 F 5.643 U/ml vs 17.33 F
1.691 U/ml, n = 16–19 aged 3–7 months, P = 0.0013).
Interestingly, some of the B6.Sle1.HEL-Ig.sHEL mice (3/10,
aged 8–14 months) also produced anti-ssDNA IgM antibodies. Ex
vivo overnight cultures of whole splenocytes demonstrated
spontaneous activation of B6.Sle1.HEL-Ig.sHEL B cells in the
absence of any stimulus and this activation was further enhanced
in the presence of anti-IgM (n = 4, aged 3.5 months).
Proliferation assays using CFDA-SE dilution revealed increased
response of B6.Sle1.HEL-Ig.sHEL B cells to anti-IgM but not to
sHEL(%undivided B cells: 28.33 B6.Sle1 .HEL-Ig.sHEL vs
50.13% for B6.HEL-Ig.sHEL, n = 2 aged 3–6 months). To
examine if presence of Sle1 rescues deletion of HEL-Ig B cells in
sHEL mice, 25106 B6.HEL-Ig or B6.Sle1.HEL-Ig B cells were
adoptively transferred into sHEL mice. However there was
comparative deletion of either B cells.
Conclusions: These findings support the conclusion that
though Sle1 may not have the capacity to thwart central deletion
of high avidity anti-self B cells, it certainly abrogates effective
danergizationT of low-avidity anti-self B cells. The molecular bases
for these differences are currently being examined.
OR-49. Insulin-VNTR Modulate Functional Phenotypes
of T-Cell Responses to Proinsulin in HLA-DRB1*04
Positive Subjects with and without Type 1 Diabetes.
I. Durinovic-Bello,1 E. Jelinek,1 W. Karges,1 B.O. Boehm,1
C. Polychronakos.2 1Internal Medicine I, University of Ulm,
Ulm, Germany; 2Pediatrics and Human Genetics, McGill
University, Montreal, QC, Canada.
Insulin (pro-insulin, P-Ins) is considered a central beta-cell
autoantigen in young patients of Caucasian ancestry with the high
risk HLA-DRB1*04, DQ8 haplotype (DR4-haplotype). Genetic
predisposition to type 1 diabetes (T1D) is, apart from HLA genes
also determined by complex interactions of a number of other
genetic loci including the INS-VNTR (IDDM2) locus. INS-VNTR
determines diabetes susceptibility by modulating levels of P-Ins
expression in the thymus, higher levels of thymic P-Ins expression
are associated with VNTR class III alleles which facilitate
tolerance induction and protection from T1D, whereas class I
alleles predispose to T1D.
AbstractsS20The aim of this study was to determine whether INS-VNTR
polymorphisms modulate functional phenotype of the T cell
response to P-Ins in subjects with high risk DR4-haplotype, with
(T1D patients and Ab+ subjects) or without (control subjects) beta-
cell autoimmunity. All subjects were typed for INS-VNTR class I
and class III alleles. Peripheral blood lymphocytes and CD4+ T cell
subsets (CD45RA+, naiive and recently primed and CD45RA-,
memory) were stimulated with immunodominant P-Ins73-90
epitope, and cytokine secretion (Th1:IFNg, TNFa, IL-2, and
Th2:IL-4, IL-5, IL-10) was determined. Our analysis reveal the
predominance of CD4+CD45RA+IL-10hi cells in subjects with
protective VNTR class III alleles, but not in subjects with VNTR
class I alleles. CD4+CD45RA+IL-10hi T cell phenotype has been
associated with regulatory function in subjects with T1D, and in
experimental models of autoimmunity.
Our analysis show, for the first time that transcriptional effects
of VNTR genes in subjects with high risk DR4-haplotype affect the
selection of P-Ins specific T lymphocytes in the periphery and
influence predisposition to T1D.
OR-50. A Toll Receptor Pathway Polymorphism Affects
Susceptibility to Inflammatory Bowel Disease.
P. L. De Jager,1,2,3 A. Waliszewska,1,2,3 L. Farwell,1 G. Wild,4
A. Bitton,4 A. Cohen,4 D. Langelier,5 D. Franchimont,4 E. Louis,6
E. S. Lander,1 M. J. Daly,1 D. A. Hafler,1,2,3 J. R. Rioux.1
1Program in Medical and Population Genetics, Broad Institute at
MIT and Harvard, Cambridge, MA, USA; 2Laboratory of
Molecular Immunology, Harvard Medical School, Boston, MA,
USA; 3Center for Neurologic Disease, Department of Neurology,
Brigham and WomenTs Hospital, Boston, MA, USA; 4Department
of Gastroenterology, McGill University Health Center, Montreal,
QC, Canada; 5Department of Gastroenterology, University of
Sherbrooke, Montreal, QC, Canada; 6Department of
Gastroenterology, Inflammatory Diseases Research Group,
CHU, Liege, Liege, Belgium.
Inflammatory bowel disease (IBD) is a complex genetic
disorders caused by a combination of genetic and environmental
factors. Recent evidence has implicated a component of the innate
immune system in the pathogenesis of IBD; mutations in NOD2/
CARD15 in humans have been associated with susceptibility to
IBD. These data prompted us to undertake a thorough investigation
of one innate immunity pathway involved in extracellular
pathogen-associated molecular pattern recognition: the Toll-like
receptor pathway. We selected 18 genes (the TLR gene family as
well as components of downstream signalling pathways) and
performed a haplotype-based association analysis for each gene.
This assessment of the common genetic variations found in the
TLR pathway reveals that there is suggestive evidence for
association of polymorphisms in IRAK2, TIRAP, TLR3, and
TLR4 to IBD in a screening Canadian population of 161 IBD trios
and 114 cases and 68 controls. However, these results were not
replicated in an independent Belgian sample collection of 104 IBD
trios and 610 cases and 383 controls. A second replication effort
consisting of 1000 IBD trios and 400 IBD tetrads will be
concluded shortly and should allow us to make definitive
conclusions regarding the observed associations. Two polymor-
phisms previously associated with IBD (Asp299Gly in TLR4 and
an NF-kB promoter indel) were also assessed using meta-analyses
of the published studies and our study populations. The NF-kB
polymorphism failed to show definitive association in our meta-
analysis; however, we definitively show that the 299Gly allele ofTLR4 is associated with susceptibility to IBD and explore the
phenotypic associations of this allele.
OR-51. Finally Found: Human BAFF-R Deficiency
Causes Hypogammaglobulinemia.
K. Warnatz,1 U. Salzer,1 S. Gutenberger,1 M. Schlesier,1
B. Grimbacher,1 H. H. Peter,1 H. Eibel.1 1Dep. of Rheumatology
and Clinical Immunology, University Clinic, Freiburg, Germany.
Introduction:BAFF-R is amember of theTNF-R superfamily and
is expressedmainlyonmatureBcells.BothBAFF-/- (synonym:Blys)
and BAFF-R-/- mice exhibit a severe defect in peripheral B cell
homeostasis indicating a prominent role of BAFF-R/BAFF inter-
action in the peripheral B cell development of the mouse.
Hypogammaglobulinemia, disturbed germinal center formation
and impaired antibody responses in BAFF-deficient mice rendered
BAFF and its receptor clear candidate genes in the search for the
etiology ofCVID.Herewe report the first patient with a homozygous
mutation of the BAFF-R causing the clinical phenotype of CVID.
Methods: 50 Patients were screened for surface expression of
BAFF-R by flowcytometry. A suspected defect was confirmed by
genomic DNA sequence, RT-PCR and Western blot analysis.
Extensive immunologic phenotyping of peripheral blood cells was
performed. Patient-derived B cells were compared with normal
controls by in vitro activation via BCR F BAFF.
Results: A 60 yr old patient with hypogammaglobulinemia (IgG
0,6g/l, IgA 5,3 g/l, IgM 0,6 g/l) and no family history of
immunodeficiency was identified by FACS analysis to express
no BAFF-R on B cells. This was due to a genomic homozygous
24bp deletion in the transmembrane region of exon 2. The immune
phenotype was distinct and may permit to screen for BAFF/BAFF-
R deficiency. Functional assays are still ongoing. Besides recurrent
pneumonias he suffered from an unusual fungal infection of his
upper respiratory tract.
Conclusion: The first patient with a genomic BAFF-R defect
confirms the role of BAFF as a master regulator of peripheral B
cell homeostasis also in humans. The immune phenotype of this
patient may allow the identification of patients with related defects.
Supported by DFG grants: a) SFB620 TPC1; b) SFB620 TPC2;
c) SFB620 TPA2. d) GR1617/3.
OR-52. Polymorphisms in CTLA4 and CD28 Are
Associated with SLE.
D. S. Cunninghame Graham,1 M. M. Fernando,1 T. J. Vyse.1
1Rheumatology Section, Department of Medicine, Hammersmith
Hospital, Imperial College, London, United Kingdom.
Purpose: CTLA4 (Cytotoxic T Lymphocyte Associated
Protein 4) may have widespread significance in the aetiology of
several autoimmune diseases (AID). It is a good candidate gene
for SLE because it is part of a suggestive linkage interval to
lupus at 2q33, in two genome-wide linkage scans. Linkage to this
region, and associations with different polymorphisms in CTLA4,
have also been reported for type I diabetes (T1D), GravesT
disease and coeliac disease. Functionally, CTLA4 is important in
the inhibition of CD28-mediated T cell activation, through co-
operation with two T cell co-stimulatory molecules, CD28 and
ICOS. These key regulators of T cell activation are encoded in a
300kb region homologous to the Bxs1 lupus linkage interval on
mouse chromosome 1 in BXSB mice. There are reported
associations in several AID with polymorphisms in the 3V UTR,
exon 1 and 3V flanking region of the gene. However, these results
in both SLE and other AID, are inconsistent, largely being small
Abstracts S21scale case-control studies in diverse populations and genotyping
limited polymorphisms. To clarify whether CTLA4 polymorphism
contributes to the genetic predisposition to lupus, we undertook a
family-based association study across the CTLA4 locus in SLE.
Materials: The study cohort consists of 474 SLE European
Caucasian families, from a total collection of 630 SLE families.
All probands conformed to the ACR criteria for SLE. The 20
genotyped variants were selected from a series of haplotype-
tagging SNPs provided by John Todd. Additional polymorphisms
were chosen from the SNP databases and the literature. The SNPs
were typed by MALDI-TOF mass spectrometry. Methods: An
initial haplotype map in our SLE trios was constructed in
Haploview. TDT analysis, on both single SNPs and on
haplotypes, was performed using GENEHUNTER on trios and
using TRANSMIT to include single parent families. Results:
CD28 and ICOS are encompassed within regions of limited
haplotype diversity; two haplotype blocks span CTLA4, with the
first (5V) block including the promoter and the second (3V) block
extending across the 3V flanking region. A single SNP in the
promoter of CD28 ( p = 0.003) was associated with SLE. In
CTLA4 there were 4 associated SNPs in the haplotype covering
the 3V flanking region of CTLA4: SNP 12 ( p = 7  104), SNP
13 ( p = 0.019), SNP 14 ( p = 0.006) and SNP 16 ( p = 0.019).
Furthermore, the same 3V flanking region of CTLA4 is associated
with T1D and GravesT disease, but there are additional
associations in these disorders from SNPs in the 5V haplotype
block. Summary: Our haplotype map delineates discrete hap-
lotype blocks across CD28, CTLA4 and ICOS. The two regions
of association are in the CD28 promoter and the 3V flanking
region of CTLA4. Comparison of the CTLA4 associations in SLE
with those in T1D and GravesT disease, confirm the importance
of the 3V flanking region of the gene in AID, although the SLE-
associated SNPs differ from those identified in TID. Thus, there
may be disease-specific factors in the function and/or expression
of CTLA4 operating in SLE. We are currently fine-mapping the
associated haplotypes in both CD28 and CTLA4.
OR-53. Building an Admixture Map for Disease Gene
Discovery in African Americans.
A. Waliszewska,1,3,4 P. L. De Jager,1,3,4 G. J. McDonald,1,2
D. A. Hafler,1,3,4 D. Reich.1,2 1Program in Medical and
Population Genetics, Broad Institute, Cambridge, MA, USA;
2Department of Genetics, Harvard Medical School, Boston, MA,
USA; 3Laboratory of Molecular Immunology, Harvard Medical
School, Boston, MA, USA; 4Center for Neurologic Diseases,
Brigham and WomenTs Hospital, Boston, MA, USA.
Admixture mapping (also known as MALD, bMapping by
Admixture Linkage DisequilibriumQ) is a promising new tool for
discovering genes that contribute to complex traits in admixed
populations such as African Americans. Gene flow from ancestral
populations into an admixed population generates associations of
the disease with states of ancestry. MALD requires far fewer
markers to search the genome for disease genes than a whole-
genome haplotype mapping study, but has similar statistical power
to find disease genes for markers that differ strikingly in frequency
across populations. We have assembled a genomewide panel of
markers for admixture mapping based on genotyping in African
and European populations. Initially we screened several databases
and identified 450,000 single nucleotide polymorphisms (SNPs)
with known frequencies in Africans and Europeans. We selected
3,583 markers for experimental validation based on large enoughfrequencies between Africans and Europeans to warrant potential
inclusion in our map. Experimental validation involved genotyping
new population samples by the 5V nuclease assay (TaqMan Assays-
on-Demand) or by primer-oligo base extention assay resolved by
MALDI_TOF mass spectrometry on a chip (MassARRAY
Sequenom). Markers were chosen if they were genotyped
successfully in at least 20 West Africans and 20 European
Americans, were in Hardy-Weinberg equilibrium in the parental
populations, had a minimal level of ancestry informativeness
(Shannon Information Content (SIC)N0.035 out of a maximum of
0.709) and were similar in frequency within continents. We are
currently using a subset of the markers in a validated map (1,536)
to screen for risk factors for disease in 742 patients with multiple
sclerosis and 996 with prostate cancer.
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OR-54. Detection of Allergen-Antibody Complexes on
Murine B Cells Using Flow Cytometry.
P. A. Wachholz,1 R. J. Dearman,1 I. Kimber.1 1Immunology,
Syngenta Central Toxicology Laboratory, Macclesfield, Cheshire,
United Kingdom.
The hallmark of atopic allergy is production of allergen-
specific IgE, which in turn requires the cytokines interleukin
(IL)-4 and IL-13, products of allergen-specific Th2 type cells. In
addition to being responsible for activation and release of
inflammatory mediators by mast cells and basophils, allergen-
specific IgE is able to form complexes with the allergen, which can
be efficiently processed and presented by IgE-receptor expressing
antigen presenting cells (APC). Capture and presentation of the
allergen via this mechanism has been shown to result in 100-fold
reduction in the concentration of allergen required to trigger T-cell
activation. Binding of allergen-IgE complexes to the surface of
human B lymphocytes has been demonstrated previously by flow
cytometry using fluorescently labeled anti-IgE antibodies. We have
now investigated the binding of allergen-IgE and allergen-IgG1
complexes to the surface of splenic B-cells isolated from BALB/c
mice.
Methods: CD19+ B-cells were isolated from the spleen of naive
BALB/c mice using magnetic beads (Miltenyi). Serial dilutions of
sera from ovalbumin-sensitized mice (immunized by intraperito-
neal injection), or from naive (untreated) controls, were incubated
alone or in the presence of 3 or 5 Ag of ovalbumin (OVA) for
1 hour at 37 8C. Subsequently, B-cells were added at 5  105/
sample and incubated for 1 hour at 4 8C. Following incubation with
sera/allergen, B-cells were washed twice with PBS containing 1%
bovine serum albumin (BSA) and stained on ice for 45 minutes with
monoclonal fluorescently-labeled anti-IgE and anti-IgG1 antibod-
ies. In additional experiments fluorescently-labeled OVA was used
to reveal binding of OVA/antibody complexes. Cells were analyzed
after washing using a FACScalibur flow cytometer. For each sample
a minimum of 5000 cells was analyzed.
Results: In the absence of serum or allergen, a small percentage
of B-cells was IgE and IgG1 positive. Incubation of B-cells with
allergen (OVA) and sera from OVA sensitized mice at higher
serum concentrations (40–80%) resulted in a marked increase in
IgE+ B-cells (up to 40% increase) and IgG1+ B-cells, which was
already detectable at low serum concentrations (b1%). Binding of
both IgG1 and IgE was dependent upon the presence of both
AbstractsS22allergen and allergen-specific antibodies since incubation with
sera from OVA-sensitized mice and an irrelevant allergen, or from
naive mice and OVA did not result in a similar increase in
antibody positive B-cells. Furthermore, the binding of OVA-IgE,
but not OVA-IgG1, complexes was shown to be inhibited
markedly by treatment with anti-CD23 (FceRII) antibody in vitro.
Conclusion: These data demonstrate that mouse splenic B-cells
bind allergen-specific IgE through the low affinity IgE receptor
(FceRII), with efficient binding only occurring in the presence of
allergen-IgE complexes. This may form the basis of an approach
for the characterization and identification of IgE containing sera.
OR-55. Novel Candidate Markers for Multiple Sclerosis
Using Phage cDNA Display.
V. Somers, C. Govarts, K. Somers, P. Stinissen. 1Biomedisch
Onderzoeksinstituut (BIOMED), Limburgs Universitair Centrum
(LUC)/Transnational University Limburg (tUL), Diepenbeek,
Belgium.
Multiple sclerosis (MS) is a chronic, inflammatory disease of the
central nervous system, characterized by the presence of focal
lesions resulting from myelin breakdown. In the past few years, an
important contribution of B cells and autoreactive antibodies has
been demonstrated in the pathogenesis of MS. To fully explore the
complex information present within the antibody repertoire of
patients, we have developed a novel and powerful molecular
approach dSerological antigen selectionT, which involves the display
of a cDNA expression library on filamentous phage and subsequent
selection on patient IgG. The aim of this study was to apply the SAS
technology to identify antigens that are specifically recognized by
antibodies (IgG) present in the cerebrospinal fluid (CSF) of MS
patients. First, we constructed a cDNA display library by cloning a
normalized cDNA library prepared from active chronic MS plaques,
with varying degrees of demyelination and inflammatory activity
(Soares et al, 1994) for expression as a fusion protein with a
filamentous phage minor coat protein, pVI. Parallel selections were
then performed on 2 pools of CSF (n = 10) from relapsing-remitting
MS patients. Affinity selections revealed a panel of 9 different
clones reactive with the first CSF pool. A detailed serological
analysis of the 9 different antigens on a large panel (n = 100) of
individual patient and control CSF showed exclusive reactivity to
MS patient CSF for seven different antigens. Sequence analysis
revealed that these clones have never been associated with MS.
Antigenic cDNAs from the second pool of CSF are currently
under investigation. In conclusion, our findings demonstrate that
this novel molecular approach is useful to identify novel
candidate antigens in MS that can be used as diagnostic
markers, and can be used to study the humoral immune response
in MS.
OR-56. Phenotypic and Functionnal Ex Vivo Profiling of
Human CMV Specific CD8+ T-Cell Responses after
Allo-HSCT.
V. Bajzik,1 N. Dulphy,1 S. Saada-Duchenoy,1 L. Leca,1 C. Scieux,3
E. Gluckman,2 G. Socie,2 D. Charron,1 A. Toubert,1
H. Moins-Teisserenc.1 1Laboratoire dTImmunologie et UNSERM
U662, IUH, Hopital Saint-Louis, Paris, France; 2Unite de Greffe
de Moelle Osseuse, Hopital Saint-Louis, Paris, France;
3Laboratoie de Bacteriologie-Virologie, Hopital Saint-Louis,
Paris, France.
Recognition of viral antigen by the immune system induces a
coordinate number of changes in lymphocyte subsets. Thisinvolves changes in the expression of cell surface molecules, in
lymphocyte migratory properties and in the ability to proliferate
and exert T-cell mediated cytotoxicity. Primary infection with
human Cytomegalovirus (hCMV) is followed by lifelong persis-
tence with viral latency in cells of the myeloid lineage. CMV
specific CD8-T cells are maintained at a very high frequency in
healthy CMV carriers, reflecting a permanent control of CMV
reactivation at a subclinical level by the hosts immune response.
Because primary CMV infection is usually clinically silent, little is
known about the longitudinal evolution of specific T cells during
the course of antigenic challenge. Due to the latency of the immune
reconstitution, patients with allogeneic haematopoietic stem cell
transplantation (allo-HSCT) are at high risk of CMV reactivation
during the first three months. We have designed a strategy to
follow the CMV reactivation in this context, combining weekly
determination of the viral load with the quantification of CMV
specific immune responses. We took advantage of such monitoring
to explore the complex host-pathogen relation during the course of
infection and latency. We focused on the immune dominant
response against the tegument protein pp65 and characterized the
CD8+ T cell response using a combination of phenotypic (HLA-
class I tetramers) and functional (ELISPOT) assays. Twelve
patients were selected for their ability to mount a CMV response
of more than 2% of total CD8+ T cells. Specific T cells were
detectable at the time of reactivation as early as 34 days after allo-
HSCT and underwent a phase of expansion with stabilization of the
response depending on the intensity of antigenic challenge. In
recipient from a seronegative donor, CD27+CD28+ and
CD27+CD28- early/intermediate phenotypes predominated during
the first wave of reactivation. This was rapidly followed by a
progression though to CD27-CD28- late phenotype. Although the
CD45RA molecule was observed on most late phenotypes,
CD45RA and CD45RO expression did not correlate with the 3
stages defined by CD27 and CD28 expression. In patients who
reactivated twice or more, an enrichment of CD8+T cells with
different phenotypes was observed, consistent with different stages
of differentiation. All CD8+T cells were perforine positive whereas
granzyme expression seemed more restricted in the tetramer
positive T-cell compartment. In conclusion this study showed that
a specific and effective anti-CMV response can be mounted very
early after allo-HSCT, even if the donor was seronegative, and
gave an insight into the evolution of CMV-specific T cell responses
in human, from the onset of reactivation to the stage of chronic
infection.
OR-57. A Compliant Solution for Monitoring Proteins
Using a Lab-on-a-Chip Instrument.
P. Barthmaier,1 T. Wulff,2 C. Buhlmann,2 M. Valer,2 T. Preckel.2
1Liquid Phase Analysis, Agilent Technologies, Palo Alto, CA,
USA; 2Liquid Phase Analysis, Agilent Technologies, Waldbronn,
Germany.
Lab-on-a-Chip (LoaC) technology has had a major impact on
the automatization of protein analysis. Traditionally, SDS-PAGE
gels are run for sizing and quantitation of proteins. Microfluidic
protein analysis is now beginning to replace this traditional method.
In August 2002, the Food and Drug Administration (FDA)
announced a significant new initiative, Pharmaceutical Current
Good Manufacturing Practices (CGMPs) for the 21st Century, to
enhance and modernize the regulation of pharmaceutical manu-
facturing and product quality. With the increasing focus on proteins
as pharmaceutical drugs, there is a strong demand for standardized
Abstracts S23and reproducible protein analysis methods that comply with the
GLP, GMP and 21CFR Part 11 requirements.
Here, LoaC technology can offer a benefit since for protein
analysis it integrates sample handling, separation, staining,
destaining, detection and digital data analysis. In addition, due to
the integration of several individual procedures an increase in
throughput and reproducibility can be achieved.
We have compared chip-based protein analysis with regard to
sensitivity, sizing accuracy and reproducibility to SDS-PAGE. Data
were comparable to that obtained from Coomassie-stained PAGE
gels. The benefits of working on the microfluidic scale include
speed of analysis, sample size and fully automated data evaluation.
Ten samples can be run in thirty minutes. Electropherograms
plotting fluorescence intensity against separation time are gene-
rated for each sample. Data for individual constituents of a
complex mixture are shown along with calculations of concen-
tration and percent total for each protein in the trace.
Analysis of 10 samples takes thirty minutes using only four
microliters of sample. The data analysis is automatically performed
in real-time and is stored and archived in digital format. IQ and
OQ/PV tools and services as well as 21CFR Part 11 compliant
software tailor the instrument for use in regulated environments.
OR-58. Correlation of Clinical Outcome with
Immunophenotype in Islet Transplant Recipients.
N. S. Kenyon,1 X. Xu,1 D. Han,1 C. Healy,2 S. Koester,2
D. Baidal,1 C. Ricordi,1 R. Alejandro.1 1Diabetes Research
Institute, Miller School of Medicine at the University of Miami,
Miami, FL, USA; 2Beckman Coulter, Inc., Miami, FL, USA.
Insulin independence can be achieved via allogeneic islet
transplantation in patients with type 1 diabetes. Our aim was to
determine the immunophenotype in islet transplant recipients and to
determine if alterations in the immune profile (IP) correlated with
graft status. Thirteen islet allograft recipients with long-term (N 5
years) type 1 diabetes treated with steroid free immune suppression
(rapamycin, FK506 and induction therapy with Zenapax) were
monitored serially for changes in IP. Twelve of the 13 patients
received 2 or more islet infusions and all patients received islets
from 2 or more donors. All patients experienced insulin independ-
ence, with 8/13 eventually returning to reduced dosages of
exogenous insulin. Peripheral blood (PB) samples were collected
pre and post transplant for 4 color staining and multiparametric
analysis of lymphocyte subsets (T, B, NK cell) and activation
markers (CD25, CD69, HLA DR). Similar to our observations for
cytotoxic lymphocyte gene (CLG) expression in PB, variable
changes in IP occurred in the early post-transplant period (with each
infusion) which initially did not appear to correlate with graft status.
Differences, however, were subsequently observed for both overall
white blood cell count (WBC) and IP between stable recipients vs.
patients with partial islet allograft loss. Previously, we have shown
that elevated CLG is predictive of islet rejection. In this study, we
compared all IP to both CLG data and to results from anti-donor
mixed lymphocyte reaction (MLR). Data show WBC decreased to
less than 1/2 of baseline in 3/4 stable patients and remained
relatively low, but for 7/8 patients that experienced rejection, WBC
increased subsequent to elevation of CLG and remained higher. In
3/4 stable recipients, CD3/45 T cells dropped to less than 1/2
baseline and remained at or below this level. Similar to WBC, all T
cell counts (including CD3/4 and CD3/8 T cell subsets) dropped
initially and then increased after evidence of rejection (indicated by
CLG elevation, or onset of hyperglycemia, or initiation ofexogenous insulin) in 6/8 patients. Despite anti-IL2R (Zenapax)
therapy, 7/8 patients with partial graft loss showed elevation of
CD4/25 cells after apparent rejection and 7/8 showed elevation of
CD4/69 T cells; 2/4 stable patients showed clear and stable
decreases from baseline and the other 2 experienced gradual
increases over time. Regarding NK and B cell subsets, trends
toward counts that remained below baseline were again seen for
stable patients and increases after evidence of rejection were
observed in patients with partial graft loss. This suggests that
changes in post transplant IP are indicative of alterations in the
recipientTs immune response to transplanted islets, as supported by
CLG, MLR, and clinical data in stable vs. rejecting patients. We are
working to establish flow based methods to assess the functional
status of recipient cell in response to both non-specific and donor
cell stimulation to ultimately tailor patient therapy.
OR-59. Autoimmunity in Children with Atypical Type 1
and Type 2 Diabetes.
L. K. Gilliam,1 J. P. Palmer,1 B. Brooks-Worrell,1 C. J.
Greenbaum,2 C. Pihoker.3 1Medicine, University of Washington,
Seattle, WA, USA; 2Benaroya Research Institute, Seattle, WA,
USA; 3Pediatrics, University of Washington, Seattle, WA, USA.
Aims: The incidence of both type 1 (T1D) and type 2 diabetes
mellitus (T2D) is increasing in children. Although T1D and T2D are
classically thought to have separate pathogeneses and presentations,
often an admixture of T1D and T2D features are present at
diagnosis. Our aim was to examine the relationship between
autoimmune measures, HLA, and clinical course. Methods: 28
subjects with atypical T1D (presenting with features such as
obesity, acanthosis nigricans, absence of DKA and/or absence of
weight loss), and 15 subjects with a clinical diagnosis of T2D were
studied at time of diagnosis. Diabetes-associated autoantibodies
(DAA) including islet cell, GAD65, IA-2, and insulin autoanti-
bodies were measured. 23 subjects underwent HLA genotyping and
were classified as having a high risk (DR4/DQ3; DR3/DQ2),
protective (DR15/DQ6), or low risk (other HLA) haplotypes.
Subjects were 8–18 years of age at diagnosis, and clinical course
was followed in 84% of subjects for a mean period of 47.9 F 18.7
months. Results:Atypical T1D: 25/28 (89%) atypical T1D subjects
were positive for at least one DAA. 14/16 (88%) with HLA typing
had one or more high risk HLA alleles. 24/28 (86%) were
prescribed insulin at diagnosis and remained on insulin throughout
the follow-up period (3 insulin-requiring subjects were lost to
follow-up). All 24 insulin-requiring subjects were DAA positive at
diagnosis. 12/13 HLA-typed insulin-requiring subjects had a high
risk HLA genotype, 1 had a low risk HLA genotype. 2/4 initially
non-insulin-requiring subjects remained on oral agents. Both of
these were DAA negative, and the one typed subject was HLA low
risk. The other 2 subjects initially treated with oral agents
subsequently required insulin for glucose control. Both of these
subjects had high risk HLA, and one was DAA positive. T2D: 5/15
(33%) T2D subjects were DAA positive at diagnosis. 1/7 HLA-
typed subjects had a high risk HLA genotype, 2 had a combination
of high risk and protective alleles, and the remaining 4 had low risk
or protective alleles. At diagnosis, 14 subjects were treated with oral
agents and one with insulin. Follow-up information was obtained
on 11 subjects. The subject initially treated with insulin remained on
insulin. This individual was DAA negative, but was not HLA typed.
7/10 subjects initially treated with oral agents remained on oral
agents during follow-up. Three were DAA positive, and one had
high risk HLA, but no subject in this group was positive for both
AbstractsS24DAA and high risk HLA. Two of the three subjects initially treated
with oral agents who subsequently required insulin for glucose
control were DAA positive, and both had high risk HLA.
Conclusions: Children clinically classified with T2D or with an
atypical presentation for T1D have a high frequency of autoimmune
markers and T1D-associated HLA haplotypes. In addition, these
autoimmune markers in children with clinical features of T2D
appear to be indicators of a more aggressive diabetes disease
process, as has been previously shown in children with typical T1D.
OR-60. Development of a Clinical Assay Evaluating
Toll-Like Receptor Function.
R. P. Deering, J. S. Orange. 1Immunology, The ChildrenTs
Hospital of Philadelphia, Philadelphia, PA, USA.
Toll-like receptors (TLR) are transmembrane pattern recogni-
tion proteins that participate in innate immune responses. A
number of genetic defects influencing the function of these
receptors have been identified and are associated with recurrent
and/or severe infection. Our goal was to develop a reproducible
assay of TLR response for evaluation of TLR function in patients
with recurrent infection. Peripheral blood mononuclear cells
(PBMC) were isolated and incubated with ligands for TLRs 1/2,
2/6, 3, 4, 5, 6, 7 and 9. Tumor necrosis factor (TNF) in cell
supernatant was then evaluated by enzyme-linked immunosorbent
assay (ELISA) as a measure of immune response. Optimal
concentrations of, and mean responses to, individual ligands were
established in healthy adult control donors. A number of variables
were assessed that could affect the assay, including blood
anticoagulant, blood storage time, PBMC cryopreservation, assay
media, and incubation period. The assay was most reproducible in
media containing fetal bovine serum; neither serum-free nor human
serum-containing media could be effectively substituted. Cryopre-
served PBMCs resulted in a considerably higher TNF production
in response to most ligands than freshly isolated cells (31% mean
increase amongst all ligands tested). Using optimized assay
conditions, three patients with a mutation in the IKBKG gene
encoding the NF-kappaB essential modulator (NEMO) protein
were ultimately studied as disease controls. TNF responses in
patients with IKBKG mutations predicting C417Y, L153R, and
exon 9 deletion alterations of NEMO were N= 6.0%, 12.0% and
8.0% of their corresponding controls, respectively. Although a
number of variables influence TNF TLR responses this assay can
be optimized for clinical use in screening for patients affected by
primary immune deficiencies influencing TLR function.
Tolerance
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OR-61. Tolerance to Inhaled Proteins Does Not Develop
in the Presence of Proteinase-Activated Receptor-2
(PAR-2) Activation.
C. Ebeling,1 M. Hollenburg,2 H. Vliagoftis.1 1Department of
Medicine, University of Alberta, Edmonton, AB, Canada;
2Department of Pharmacology and Therapeutics, University of
Calgary, Calgary, AB, Canada.
Aim of Study: Inhalation of innocuous proteins induces the
development of tolerance, an immune response characterized by
the development of Treg cells and absence of airway hyper-
responsiveness (AHR) or airway inflammation. The reason why
some proteins promote allergic sensitization instead of tolerancehas been studied extensively but is still controversial. Many
allergens possess serine proteinase activity. Some of these
allergens/serine proteinases, such as those from house dust mites
and cockroachs, can mediate their effects through the Proteinase-
Activated Receptor-2 (PAR-2). We have previously shown that
exogenous PAR-2 activation during allergen challenge enhances
allergen-mediated AHR and airway inflammation. Our current
hypothesis is that PAR-2 activation at the time of encounter with an
inhaled protein may mediate allergic sensitization by preventing
the development of tolerogenic responses. Methodology: We used
a Balb/c mouse model of tolerance to intranasal (i.n.) administered
ovalbumin (OVA). Balb/c mice were administered OVA (100Ag)
i.n. on 3 consecutive days. Other mice were administered OVA
with the PAR-2 activating peptide (PAR-2AP) SLIGRL-NH2 to
mimic inhaled allergens with PAR-2 activating potential. Control
mice received OVA with the PAR-2CP (control peptide) LSIGRL-
NH2 or were administered saline alone. All mice subsequently
received an interperitoneal (i.p.) immunization with OVA and
Al(OH)3 ten days after the last i.n. administration. Five days
following this immunization, mice were euthanized and T cells
were isolated from the spleen and cultured in vitro with antigen
presenting cells, from a naRve mouse, and OVA for 4 days and
proliferation assessed. Other groups of mice were challenged twice
with OVA on alternate days, 10 days after the i.p. immunization,
and assessed for AHR and eosinophilic inflammation in the lung
the day after the last challenge. Results: T cells isolated from mice
treated initially with OVA alone or with PAR-2CP proliferated
poorly to OVA in vitro, indicating the development of tolerance to
OVAwhile T cells from mice treated with saline alone or OVA and
PAR-2AP proliferated vigorously. Furthermore, mice treated
initially with saline alone or OVA and PAR-2AP developed
AHR and eosinophilic inflammation following OVA challenge
while mice treated with OVA alone or with PAR-2CP showed no
signs of either. Conclusions: PAR-2 activation in the airways
prevents the development of tolerogenic responses towards i.n.
administered OVA. These observations indicate that inhaled
allergens/serine proteinases may induce allergic sensitization
through the activation of PAR-2 in the airways.
OR-62. Nasal Vaccination with a Proteosome-Based
Adjuvant and Glatiramer Acetate Clears AlzheimerTs
B-Amyloid in an Antibody-Independent Fashion.
Dan Frenkel,1 Ruth Maron,1 David S. Burt,2 Howard L. Weiner.1
1Center for Neurologic Diseases, Department of Neurology,
Brigham and WomenTs Hospital, Harvard Medical School, Boston,
MA, USA; 2ID Biomedical Corporation of Quebec, Ville St.
Laurent, QC, Canada.
AlzheimerTs disease (AD) is the most common form of senile
dementia, affecting more than 18 million people worldwide.
Compact senile plaques comprised of h-amyloid (Ah) fibrils are
associated with pathological changes in the surrounding brain
neurons, leading to their death. Immune therapy in mouse models of
AlzheimerTs disease (AD) via Amyloid h (Ah) immunization or
passive administration of Ah antibodies markedly reduces Ah levels
and reverses behavioral impairment. However, a human trial of Ah
immunization led to meningoencephalitis in some patients and was
discontinued. Here we show that nasal vaccination with a
proteosome-based adjuvant (IVX-908) that is well tolerated in
humans mixed with glatiramer acetate (GA), a synthetic copolymer
used to treat multiple sclerosis, potently decreases Ah plaques in an
AD mouse model. Nasal administration of glatiramer acetate with
Abstracts S25IVX-908 resulted in an 84% reduction of thioflavin S -positive
fibrillar amyloid in the hippocampus (pb0.001) and 73% reduction
of total brain Ah levels (pb0.001). vs. the non treated mice. This
effect did not require antibody, as it was observed in B-cell deficient
mice. Vaccinated animals developed activated microglia (CD11b+
cells) that co-localized with Ah fibrils, and the extent of microglial
activation correlated strongly with the decrease in Ah fibrils. We
also noticed a strong correlation between CD11b+ cells and IFN-g
secreting cells and increased numbers of T cells (r= 0.9), which may
play a role in promoting microglial activation. Our results define an
antibody-independent therapeutic approach for the treatment of
AlzheimerTs disease, utilizing compounds that have been safely
tested or are currently in use in humans.
OR-63. Collaboration between Central Tolerance and
Peripheral Regulation To Control Autoimmunity.
Z. Chen,1 C. Benoist,1 D. Mathis.1 1Immunology and
Immunogenetics, Joslin Diabetes Center/Harvard Medical
School, Boston, MA, USA.
A variety of mechanisms have been proposed for immuno-
logical tolerance of self tissue. Prominent roles have been
attributed to central tolerance, illuminated by the role of aire in
thymic deletion of autoreactive T lymphocytes, and peripheral
regulation, exemplified by the function of Foxp3 in generating
CD4+CD25+ regulatory T cells to suppress pathogenic effectors.
Here we report fulminant autoimmunity in very early life and a
gravely shortened life-span in mice deficient in both aire and
Foxp3 vis-a`-vis animals lack either aire or Foxp3. The exacerbated
inflammatory damage in the aire and Foxp3 double-deficient
animals is particularly prominent in the lung and liver, and also
involves several other organs but, despite massive lymphoproli-
feration, little or no inflammatory infiltration occcurs in many other
organs, possibly protected by aire- and Foxp3-indepent mecha-
nism(s). This study highlights the critical importance of both central
tolerance and peripheral regulation in maintaining self -tolerance
and suggests that there is still more to learn.
OR-64. Mechanisms of Retinal Immune Privilege.
C. H. Lau, A. W. Taylor. 1Schepens Eye Research Institute and
Department of Ophthalmology, Harvard Medical School, Boston,
MA, USA.
The eye is an immune privileged tissue that constitutively
produces neuropeptides, cytokines, and factors that actively
suppress inflammation mediated by innate and adaptive immunity.
The neural retina (NR) and retinal pigmented epithelial (RPE) cells
are documented to support immune privilege; however, most of our
understanding of the mechanisms of ocular immunity has been
from analyzing the anterior chamber of the eye. Therefore, to begin
to identify factors important in regulating immunity in the retina,
we investigated the effects of secreted factors from the NR and the
RPE on the activity of resting and activated macrophages. The NR
from healthy C57BL/6J mice was dissected and placed in culture
for 24 hours. Culture media was placed into the resulting posterior
eye cup containing RPE and incubated for 24 hours. These
conditioned media (CM) was used to treat resting or endotoxin-
stimulated macrophages (J774A.1 cell line). After 48 hours, the
macrophage supernatants were assayed by multiplex analysis for
IL-1beta, IL-6, IL-10, TNF-alpha, GM-CSF. In addition, the RPE-
CM and NR-CM were assayed by multiplex analysis. We found
IL-6, GM-CSF in RPE-CM, and IL-6 in the NR-CM. The NR-CM
stimulated GM-CSF production by resting macrophages, but wassuppressed in endotoxin-stimulated macrophages. Both the RPE-
CM and NR-CM suppressed IL-1beta and TNF-alpha production
by the endotoxin-stimulated macrophages, while they induced
significant levels of IL-10 production by the macrophages. While
the NR may support macrophage differentiation through GM-CSF,
both the NR and the RPE suppress the production of inflammatory
cytokines (IL-1beta and TNF-alpha) by endotoxin-stimulated
macrophages, while causing the same macrophages to produce
the anti-inflammatory cytokine, IL-10. Such results suggest that the
mechanisms of immunosuppression by the retina may involve
factors that suppress classical activation while promoting alter-
native activation of macrophages. Therefore, both the neuroretina
and RPE contribute to the mechanisms of retinal immune privilege.
Supported by grants from the USAMRMC.
OR-65. Treatment with a Donor-Specific Transfusion
and Anti-CD154 mAb Induces Non-Responsiveness in a
Population of T Cells That Recognize Alloantigen Via
Indirect Antigen Presentation.
N. E. Phillips,1 D. L. Greiner,1 J. P. Mordes,1 A. A. Rossini.1
1Medicine/Diabetes, University of Massachusetts Medical School,
Worcester, MA, Viet Nam.
Treatment with a donor-specific transfusion (DST) and anti-
CD154 monoclonal antibody (mAb) induces prolonged allograft
survival in mice, in part by deleting host CD8+ Tcells that recognize
alloantigen by direct antigen presentation. The fate of host T cells
that recognize alloantigen via indirect antigen presentation in mice
treated with costimulation blockade is unclear. In this study, we
investigated the fate of Tg361 TCR transgenic CD4+ and CD8+ T
cells that recognize alloantigen via indirect antigen presentation.
Using CFSE-labeling, we first document that both Tg361 transgenic
CD4+ and CD8+ Tcells proliferate in vitro and in vivo in response to
allo-stimulation. Treatment of mice circulating Tg361 T cells with
DST plus anti-CD154 mAb, however, fails to delete these CD4+ and
CD8+ alloreactive T cells, and instead renders them non-responsive
to re-challenge with alloantigen. Mice circulating these non-
responsive alloreactive T cells also fail to reject skin allografts.
The non-responsive state of Tg361 T cells is not reversed by the
addition of IL-2, anti-CD28 mAb, or an agonistic anti-CD134 mAb
in the presence of antigen, protocols that have been successful in
reversing both the clonal and adaptive anergic states of tolerized
CD4+ cells. The non-responsive CD4+ and CD8+ alloreactive Tcells
arecapable of activation, however, as evidenced by their robust in
vitro proliferation in response to anti-CD3 mAb in the presence of
costimulation. These data document a non-deletional mechanism by
which costimulation blockade can block host alloreactive T cell
responses and prolong graft survival.
OR-66. Successful Induction of Mixed Chimerism and
Tolerance with Non-Myeloablative Conditioning in Mice
Presensitized with Fully Mismatched Skin Grafts.
P. D. Bardwell,1 I. Shimizu,1 J. C. Buchli,1 M. Sykes.1
1Transplantation Biology Research Center, Massachusetts General
Hospital / Harvard Medical School, Boston, MA, USA.
Presensitization to donor antigens that may arise from prior
transplants, blood transfusions or pregnancy excludes many
patients from solid organ transplants. Inducing donor-specific
tolerance in presensitized recipients would therefore represent a
significant clinical advance. In presensitized patients, anti-donor
antibodies could potentially be removed by plasmapheresis prior to
transplantation; however this is not practical in mice. Therefore, we
AbstractsS26have used B cell deficient mice to evaluate the ability to tolerize
presensitized T cells via mixed chimerism induction through bone
marrow transplantation (BMT). B cell deficient B6-AMT and wild-
type B6 (H-2b) mice, presensitized with B10.A (H-2a) tail skin,
received non-myeloablative conditioning (anti-CD4, CD8, NK,
CD40L & OX40L monoclonal antibodies and 3 Gy total body
irradiation) before BMT with 80106 B10.A bone marrow cells
(BMC). Twelve weeks after rejection, the presence of anti-donor
IgG in the serum of the presensitized B6 mice was confirmed by
indirect staining and flow cytometry. Multi-lineage chimerism was
monitored at 2, 4, 6, and 12 weeks post-BMT by flow cytometry.
All of the presensitized wild-type B6 mice rejected the donor BMC
by 2 weeks. Thus, anti-donor IgG antibodies present in wild-type
mice after presensitization posed a strong barrier to donor marrow
engraftment. In contrast, 80% of the AMT mice showed engraft-
ment of donor BMC with stable long-term multi-lineage donor
chimerism. Importantly, chimeric AMT mice accepted donor grafts
long-term, while third party grafts were rejected by 2 weeks. Thus
our results show that pre-existing T cell immunity to BMC donor
antigens may be overcome by non-myeloablative mixed chimerism
induction in presensitized mice.
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OR-67. Dendritic Cell Response to Necrosis Is Defective
in Atopy.
H. Kandil,1 F. M. Gotch,2 M. A.A. Ibrahim.1 1Clinical
Immunology, KingTs College Hospital, London, United Kingdom;
2Immunology, Imperial College of Science & Technology, London,
United Kingdom.
We have previously shown that cellular necrosis augments
CD40-mediated interleukin-12 secretion by human monocyte-
derived dendritic cells. In the present study, we compare the
dendritic cell response to cellular necrosis in atopic individuals
with non-atopic control subjects. Using an in vitro culture system,
monocyte-derived dendritic cells were stimulated with either
necrotic K562 cells or a combination of TNF-alpha and IL-1beta.
We demonstrate that dendritic cells from atopic individuals
secreted significantly less interleukin-12p40 in response to necrotic
cell products compared with dendritic cells from non-atopic
subjects. Upon stimulation with necrotic cells and CD40 cross-
linking, dendritic cells from atopic subjects secreted significantly
less interleukin-12p70. Furthermore, CD80, but not CD86, was
upregulated by necrosis significantly less on dendritic cells of
atopic individuals compared with normal subjects. In contrast, the
response of dendritic cells from atopic subjects to TNF-alpha and
IL-1beta was not significantly different from normal individuals.
We conclude that atopy is associated with a defective response of
dendritic cells to necrotic cell death, which may play a role in the
mechanism of atopic sensitisation.
OR-68. CD150 (SLAM) Modulates TLR and CD40
Pathways in Monocyte-Derived Dendritic Cells.
B. Rethi,1,3 P. Gogolak,1 E. Rajnavolgyi,1 C. Terhorst,2 A. Lanyi.1
1Institute of Immunology, University of Debrecen Medical and
Health Science Center, Debrecen, Hungary; 2Division of
Immunology, Beth Israel Deaconess Medical Center, Boston, MA,
USA; 3Microbiology and Tumor Biology Center, Karolinska
Institute, Stockholm, Sweden.SLAM (CD150, Signaling Lymphocyte Activation Molecule) is
a self-ligand receptor on the surface of activated T- and B-
lymphocytes, macrophages and dendritic cells (DC). Its importance
at the interface of adaptive and innate immune responses is
underscored by SLAM being a receptor for Measles virus, which
induces immunosuppression. Moreover, recent reports indicated
that high expression levels of SLAM in T-lymphocytes of patients
infected with M. tuberculosis or M. leprae were associated with
milder pathology.
As the function of SLAM on the surface of human dendritic
cells is poorly understood, we examined the effect of SLAM/
SLAM interactions on activation signals in human peripheral
blood monocyte-derived dendritic cells. The effect of SLAM on
CD40L-induced DC activation was analyzed in co-cultures of
DC with L929 cells expressing CD40L alone or in combination
with SLAM. CD40L-induced IL-12 production was strongly
inhibited by SLAM engagement and resulted in a DC
phenotype that was less potent to induce differentiation of
naive T lymphocytes into IFN-g producing Th1 effector cells.
Interestingly, the ability of these bSLAM-educatedQ DC to
support the proliferation of naive T cells was significantly
increased. To determine the effect of SLAM on different TLR-
induced DC activation, L929 cells or L929 cells expressing
SLAM were co-cultured with immature dendritic cells in the
presence of LPS or poly-IC. Unlike CD40L-induced IL-12
production, TLR induced IL-12 secretion was augmented by
SLAM engagement. In DC activated by CD40L and LPS,
SLAM engagement reduced IL-12 production to the level of
cultures activated by LPS and SLAM, indicating that SLAM
modulates these pathways independently.
Thus, our findings suggest a dual function for SLAM in
monocyte-derived DC that allows SLAM to exert opposing effects
on IL-12-dependent functions, based on the received activation
signals.
OR-69. Activation of Human NK Cells by Plasmacytoid
DC and Its Modulation by CD4+ T Cells and CD25hi T
Regulatory Cells.
C. Romagnani,1,2 M. Della Chiesa,2 S. Kohler,1 L. Moretta,2,3
A. Moretta,2 A. Thiel.1 1Clinical Immunology, German
Rheumatism Research Center, DRFZ, Berlin, Germany;
2Dipartimento di Medicina Sperimentale, Universita di Genova,
Genova, Italy; 3Istituto G. Gaslini, Genova, Italy.
Background: Plasmacytoid dendritic cells (pDC) represent a
specialized cell population that produce type I interferon in
response to virus. However, although pDC-derived type I
interferon is a potent modulator of NK cell functions and NK
cells are essential for antiviral immunity, the role of pDCs in
coordinating NK cell functions has not yet been elucidated in
detail, especially in humans.
Objective of the study: to investigate the interplay between
human pDC and NK cells and to evaluate how CD4+ Th
and CD25hi T regulatory (Treg) cells can modulate these
interactions.
Methods: Highly purified FACS-sorted human pDC, NK cells,
CD4+ CD25hi Treg cells and CD4+ CD25neg T cells were co-
cultured and NK cells were analysed for CD69 expression, for
proliferation after staining with CFSE, for cytokine production
using Bioplex and for cytotoxicity in 4 h-51Cr release assay. pDC
were activated with IL-3 and CpG-A ODN2216 before co-culture
with NK cells.
Abstracts S27Results: pDC, following engagement of TLR9, can activate
autologous NK cells, as indicated by the induction of surface
CD69 expression. Under these conditions, pDC can also
enhance NK cell effector functions, including cytotoxicity and
cytokine production. Moreover, they can induce proliferation of
CD56bright CD16-, but not of CD56dim CD16+ NK cells. This
activity can be highly up-regulated in an IL-2-dependent fashion
by autologous CD4+ CD25- T cells. Strikingly, CD4+ CD25hi
Treg cells can inhibit proliferation of NK cells induced by the
interplay of pDC and T helper cell, while they do not influence
NK cell activation or proliferation induced by pDC alone.
Conclusions: This is the first demonstration in humans that
pDC can activate NK cells, enhance their effector functions and
induce proliferation. In addition, it is the first demonstration that
CD4+ Th and CD25hi Treg cells can modulate NK cell proli-
feration, implying a direct role of adaptive immune response in
amplifying or inhibiting innate immunity.
OR-70. Hepatitis C Virus Core Protein Induced,
Monocyte-Mediated Mechanisms of Reduced IFNA
and Plasmacytoid Dendritic Cells Loss in Patients
with Chronic HCV Infection.
A. Dolganiuc,1 G. Bakis,1 K. Kodys,1 G. Szabo.1 1Medicine,
University of Massachusetts Medical School, Worcester, MA, USA.
Immune responses to acute hepatitis C virus infection are
insufficient in most individuals leading to chronic infection in the
majority of infected individuals. Current successful therapies of
HCV infection are based on use of IFNa. Type I interferons
(IFN), including IFN-alpha (IFNa), inhibit viral replication and
promote antiviral immune responses. Limited and controversial
information is available related to the capacity HCV-infected
patients to produce endogenous IFNa.
The purpose of this study was to investigate the functional
capacity of plasmacytoid dendritic cells (PDCs), the main
producers of IFNa, in patients with chronic HCV infections
compared to controls. We found significantly decreased pro-
duction of IFNa, determined by ELISA, in PBMCs of HCV
patients upon stimulation with PDC-specific TLR9 ligands,
CpG-A DNA (pb0.003) and HSV KOS (pb0.004). This
correlated with a decreased frequency of circulating PDCs
(determined by flow cytometry as lineage-/CD4+ or BDCA2+/
CD123+) in HCV patients compared to controls (HCV 0.11 F
0.09%, control 0.25 F 0.15%; pb0.003). PDCs purified from
HCV patients produced lower levels of IFNa compared to
controls (pb0.009) and were apoptotic, as determined by
staining with Annexin V and DNA laddering. In vitro
stimulation with CpG-A DNA or HSV KOS lead to increased
cell death in PDCs from HCV patients compared to controls
(pb0.01). There was no correlation between the loss of PDCs
and HCV viral count, genotype, or liver functions. Importantly,
there was no reduction in PDC frequency or IFNa production
in patients with sustained virological response after HCV
elimination therapy suggesting a role for viral derived mecha-
nisms for the DC defects. We found that recombinant HCV core
protein did not directly affect PDC functions, but it significantly
reduced TLR9-triggered IFNa production in PBMCs (pb0.001).
We determined that HCV core protein activated monocytes to
produce IL-10 and TNFa. In vitro both IL-10 and TNFa
induced PDC apoptosis and inhibited IFNa production in
normal PDCs. Anti-IL-10 and anti-TNFa neutralizing antibodies
were additive in restoration of IFNa production in TLR9+HCVcore stimulated PBMCs. Depletion of monocytes from PBMCs
abolished IL-10 and TNFa production and prevented HCV
core-induced inhibition of PDC IFNa production.
Our results show that HCV core protein modulates hostTs
ability to produce IFNa by indirectly interfering with PDC
function via monocyte-derived cytokines. We reveal that the
viral-induced mechanisms of PDC loss and IFNa production
defects are likely to contribute to chronic viral persistence and may
provide mechanistic explanation for the therapeutic benefits of
IFNa therapy in HCV infection.
OR-71. Delayed IL-10 Induced Human Tolerogenic DC
Inhibit Naive T Cell Proliferation by Mechanisms Other
Than Their Exaggerated PD-L1/2 Induction.
F. Li,1 K. Laudanski,1 L. Perez,1 C. L. Miller-Graziano.1
1Surgery, University of Rochester Medical Center, Rochester, NY,
USA.
Previous data indicated that IL-10 treated human monocytes
(MO) differentiate to macrophage (Mac) expressing elevated Mac
markers like MRP8/4 while addition of IL-10 to monocytes after
their partial differentiation to dendritic cells (MO IL-4 & GM-CSF
3 days then IL-10 added for additional 2 days) induces a
tolerogenic dendritic cell (tol DC) which can diminish T cell
activation. The mechanisms for tolerogenic DC inhibition of T
cells is still undefined, but is suggested as related to upregulation
of inhibitory costimulation ligand-receptor combinations. Here, tol
DC were generated from 7 control donorsT MO by adding IL-10
after 3 days of culture of MO with IL-4 & GM-CSF and then
inducing for an additional 2 days. Addition of IL-10 to the DC
differentiation cultures did not significantly decrease DC CD1a
levels (68 F 15% positive) versus those of IL-4+GM-CSF classic
DC controls (76 F 14% positive), or their CD209 levels (97 F 1
versus 98 F 1% positive) nor increase Mac characteristics (CD14
5 F 2 versus 3 F 4% positive, or MRP8/14 b1% positive
expression). However, tol DC expression of the inhibitory
costimulatory ligand PD-L1 but not PD-L2 was significantly
(b0.0001) increased from the 13 F 5% of classic DC to 36 F 9%
positive. PD-L1 but not PD-L2 mean fluorescence intensity (MFI)
was also significantly increased on tol DC. We have previously
shown that tol DC are unable to act as adequate antigen presenting
cells (APC). To assess the inhibitory activity of these tol DC, they
were added to autologous T cell cultures in the presence of
immobilized anti CD3 plus CD28 (iCD3+CD28). Since
iCD3+CD28 stimulate T cell proliferation in the absence of any
APC, any diminished proliferation in the presence of tol DC
would indicate a T cell inhibitory rather diminished APC effect.
The addition of 2104 to1 DC significantly (P = 0.035) reduced T
cell proliferation to anti iCD3+CD28 as compared to T cell
cultures with classic or no DC. However, there was no correlation
between the degree of increased tol DC PD-L1 expression and
then mediation of decreased T cells proliferation. Tol DC with the
highest increases in PD-L1 did not exhibit the highest inhibitory
activity. These data suggest that the tol DC function of reducing
autologous naive T cell proliferation to T cell receptor stimulation
resulted from induction of other inhibitory costimulatory receptors
(ILT3/4) rather than the induction of PD-L1 or PD-L2. Never-
theless, the IL-10 induced augmentation of DC PD-L1 expression
may still contribute to T cell inhibition and anergy induction when
tol DC interact with previously activated T cells whose
upregulated PD-1 levels can be triggered by exaggerated tol DC
PD-L1 levels.
AbstractsS28OR-72. Induction of Heme Oxygenase-1 (HO-1) Inhibits
Dendritic Cell Differentiation and Adaptive Immunity.
J. J. Listopad,1 T. Ritter,2 R. Sabat,1 K. Asadullah,1 W.D. Docke.1
1CRBA Dermatology, Schering AG, Berlin, Germany; 2Institute of
Medical Immunology, Charite, Humboldt University, Berlin,
Germany.
The strong immunosuppressive potency of the stress protein
HO-1 has been proven in several models of autoimmunity and
transplantation. The underlying immune mechanisms, however,
are poorly characterized. In our study, the potent HO-1 inducer
Cobalt Protoporphyrine IX (Co-PPIX) strongly suppressed T cell
proliferation in mixed lymphocyte reaction (MLR). As possible
mechanism we demonstrated a selective Co-PPIX induced
increase of HO-1 expression in monocytes associated with
depression of accessory molecule expression and stimulatory
cytokine secretion. The likewise induction of HO-1 in monocyte-
derived dendritic cells (MDDC) by Co-PPPIX was associated with
an almost complete inhibition of the differentiation, maturation, and
function of MDDC. So, a strong decrease of the expression of DC
markers (CD1a, CD83) and accessory molecules (HLA-DR, CD86)
was observed. Whereas IL-12 secretion was inhibited, IL-10
production increased. The antigen-presenting capacity of Co-PPIX
treated MDDC was strongly diminished in lymphocyte trans-
formation assay and MLR. The specificity of these effects was
demonstrated by HO-1 transduction in immature MDDC. Together
these changes indicated a switch of the DCs to an immature, non-
stimulatory phenotype. In vivo, Co-PPIX treatment before chal-
lenge dose-dependently depressed ear inflammation in DNFB
(Type 1) and TMA (Type 2) induced contact dermatitis in mice.
Remarkably, Co-PPIX even more strongly inhibited T-cell-depend-
ent inflammation when applied around sensitization. We hypothe-
size that the inhibition of DC differentiation, maturation, and
function is a crucial mechanism for the suppression of adaptive
immunity by HO-1 induction in vitro and in vivo.
OR-73. Donor-Specific Allograft Tolerance by
Administration of Recipient-Derived Immature
Dendritic Cells and Suboptimal Immunosuppression.
G. Beriou,1 H. Peche,1 C. Guillonneau,1 E. Merieau,1
M. C. Cuturi.1 1U643, INSERM, Nantes, France.
Introduction. The benefits of allogeneic immature bone marrow-
derived dendritic cells (iBMDCs) on allograft survival have been
reported in several studies. However, in contrast to protocols based
on the injection of donor-derived DCs, the administration of
recipient-derived DCs would be much more applicable to cadaveric
organ transplantation. We recently showed that injection of
recipient-type iBMDCs the day before transplantation induced a
significant prolongation of allograft survival. In the present study,
we aimed at improving this protocol to induce allograft tolerance.
Methods. iBMDCs were generated from LEW.1A rat bone
marrow precursors with low-dose GM-CSF and IL-4. After 8 days of
culture, adherent cells displayed immature phenotype, characterized
by low MHCII and CD86 expression. Various amounts of iBMDCs
(3 to 15106 cells) were administered i.v. to syngeneic LEW.1A rats
before and after transplantation of an allogeneic LEW.1W heart,
with or without additional suboptimal immunosuppression, consist-
ing of Rapamycin (0.4mg/kg/day, d0-d14, orally) or LF15-0195, a
new deoxyspergulalin analog (1.5mg/kg/day, d0-d9, i.p.).
Results. Allograft survival was not improved by repeated
injections of syngeneic iBMDCs, or by additional treatment with
low dose Rapamycin. Interestingly, combining injection ofiBMDCs and LF15-0195 had striking synergistic effect, and
induced definitive allograft acceptance in 92% of recipients.
Tolerant iBMDC-LF15-0195 treated recipients accepted donor-
type, but not third party-type skin grafts, demonstrating that
tolerance was donor-specific. We hypothesized that under LF15-
0195 treatment, iBMDCs could maintain their immature phenotype
and function. Indeed, we showed that, in vitro, LF15-0195
decreased MHCII and CD86 expression in rat BMDCs. The
effects of LF15-0195 treatment on the in vivo maturation of the
administered iBMDCs are currently under investigation.
Conclusions. Thus, we demonstrated that donor-specific allog-
raft tolerance can be induced by a single injection of syngeneic
iBMDCs one day prior to transplantation, and a suboptimal
immunosuppressive treatment with LF15-0195. The reported
findings may contribute to the development of new therapeutic
strategies to induce transplantation tolerance in clinical settings.
OR-74. Impact of Plasmacytoid Dendritic Cell (PDC)
Recovery on Outcome after Allogeneic Stem Cell
Transplantation (allo-SCT).
M. Mohty,1 D. Blaise,1 C. Faucher,1 D. Olive,1 B. Gaugler.1
1Unite de Transplantation and Immunologie des Tumeurs, Insitut
Paoli-Calmettes, Marseille, France.
Among DC subsets, the reconstitution of the natural type I-
interferon-producing PDCs has been proposed to play a major role
in establishing immune competence. Therefore, we investigated the
impact of circulating PDCs measured at the 3rd month after reduced
intensity conditioning (RIC, fludarabine-based conditioning) allo-
SCT, in 54 patients with hematological and non-hematological
malignancies who received a RIC-allo-SCT from an HLA-identical
sibling, in order to determine whether this could provide an
indicator for long term outcome. The median absolute count of
PDCs measured at 3 months was 0.725/AL (range, 0–23.2). In a
multiple logistic regression analysis including all relevant param-
eters (demographic and graft characteristics, RIC regimens, CMV
infections, and acute GVHD), only the absence of grade II-IVacute
GVHD was associated with an improved PDC recovery at 3 months
(P = 0.003; OR=6.4; 95%CI, 1.9–22). Being the major type I IFN-
secreting cells, we also investigated whether PDCs recovered after
allo-SCT are functional in response to viral stimulation. Patients
experiencing grade 0-I aGVHD could secrete significantly higher
amounts of IFN-alpha as compared to patients with grade II-IV
aGVHD (mean, 91 vs. 0 pg/ml respectively; P = 0.002), likely
highlighting the deleterious impact of corticosteroids therapy on
PDC function. The CD34+ stem cell dose and other lymphoid
subsets infused with the allograft did not affect PDC recovery.
Though PDC count could not predict death from progression or
relapse, patients with a bhighQ PDC recovery profile had an
improved overall survival (OS; P = 0.03), in contrast to patients
with a blowQ PDC recovery profile who had an increased incidence
of late transplant-related mortality (GVHD, infections) (P = 0.03).
In addition, the overall incidence of late infections (viral, fungal
and bacterial) was significantly higher in the blowQ PDC recovery
group as compared to the bhighQ PDC recovery group (59% vs.
19%; P = 0.002), illustrating the importance of PDCs in anti-
infectious immune responses. In a multivariate analysis, only a
bhighQ PDC count was significantly predictive of a decreased risk
of death (P = 0.04; RR=0.34; 95%CI, 0.12–0.96). The role of
rare immune effector cells would tend to be more evident in truly
RIC and less toxic regimens. In this study, we could show that
monitoring of PDCs may be useful for patientsT management
Abstracts S29(closer surveillance, infection prophylaxis. . .), and may have a
significant impact on the probability of a favorable outcome in
the context of RIC-allo-SCT.
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OR-75. Functional Interaction of Common Gamma
Chain and Growth Hormone Receptor Signaling
Apparatus.
M. Adriani,1 C. Garbi,2 G. Amodio,1 R. Busiello,1 P. Ferri,1
E. Matrecano,1 F. Candotti,3 C. Pignata.1 1Departments of
Pediatrics, bFederico II Q University, Naples, Italy; 2Cellular and
Molecular Biology and Pathology, bFederico II Q University,
Naples, Italy; 3Genetics and Molecular Biology Branch, National
Human Genome Research Institute, National Institutes of Health,
Bethesda, MD, USA.
Severe combined immunodeficiency syndromes (SCIDs) are
characterised by absent T- and B-lymphocytes function. SCIDs are
usually fatal early in infancy without successful immune recon-
stitution. We previously reported on a patient affected with an X-
linked SCID, who received a late Bone Marrow Transplantation at
5,2 years of age. During the follow-up a short stature due to
peripheral Growth Hormone (GH) hyporesponsiveness and abnor-
malities of the protein phosphorylation events following GH
receptor (GHR) stimulation were observed. Mutational screening
and expressional analysis failed to reveal any molecular alteration
of GHR, JAK2 and STAT5a/b genes. Since we hypothesized a role
for the g chain in GHR signaling, in this study we evaluate GHR/g
element functional interaction in EBV transformed lymphocytes
(BCLs) from X-SCID PTs and CTRs. The functional response to
GH, the pattern of GHR induced Ptyr and STAT5 nucleus
translocation were studied. GH enhanced proliferation of CTRs
BCLs in a dose-dependent fashion, with a maximal effect at 200
ng/ml. In contrast, PTs cells did not proliferate at all. Cytofluori-
metric analysis did not reveal any difference in GHR expression. In
PTsT cells, GH stimulation failed to induce phosphorylation of
proteins of 90–92 kDa corresponding to STATs molecules in
contrast to what observed in CTR, in which a peak of STAT5
phosphorylation between 5 and 15 min was observed. In all cell
lines examined, STAT5a and b protein expression was comparable.
In addition, in CTR cells GH induced nuclear translocation of
STAT5 evaluated through confocal microscopy; in contrast, in PTs
cells no efficient translocation occurred after GH stimulation. Here
we report a previously unappreciated functional interaction
between gc and GHR, which eventually leads to the activation
and intranuclear translocation of STAT5 protein.
OR-76. Novel Humoral Immunodeficiency in Humans
Associated with Deleterious Homozygous Mutation in
CD19.
D. Castano,1 P. J. Patino,1 C. Woellner, 2 U. Salzer, 2
B. Grimbacher,2 C. J. Montoya,1 J. C. Orrego,1 C. Rugeles,1
J. L. Franco.1 1Group of Primary Immunodeficiencies,
SIU-University of Antioquia, Medellin, Colombia; 2Clinical
Immunology and Rheumatology, University of Freiburg, Freiburg,
Germany.
In B cells, CD19 is found in a complex with the complement
receptor CD21, the tetraspan membrane protein CD81, and
CD225, and is critical both to balance antigen-induced BCR-mediated signaling thresholds in B cells and to functionally link
CD21 with the BCR following co-recognition of C3d-bearing Ag.
CD19 is a 95 kd transmembrane protein with two extracellular Ig
domains and a cytoplasmic tail containing several tyrosine residues
that become phosphorylated after cross-linking of the BCR,
allowing the interaction with SH2-containing cytoplasmic proteins
and linking CD19 to downstream signaling cascades. In mice,
mutations in CD19 lead to hypogammaglobulinemia, impaired B-
cell memory, low CD5+/B1 B cells and decreased germinal center
formation. In humans, a selective defect in CD19 expression has
not yet been described. Here we present three adult siblings (one
male and two females) affected with recurrent respiratory and
gastrointestinal tract infections since childhood and low serum
IgG, IgA and IgM. Peripheral blood CD20+CD22+ B cells were
within normal ranges by FACS, but showed profoundly reduced
surface expression of CD19 in all three patients. DNA sequencing
of CD19 revealed a homozygous deletion of two nucleotides in
exon 11 (c.1428delAG), leading to a frameshift and a premature
STOP codon in all patients. Six relatives in the family were
heterozygous. B-cell subpopulations in PBL showed significant
decreases in isotype-switched memory cells (CD27+IgD-) and low
CD5+ cells in all patients. Isohemagglutinins where decreased
while soluble CD21 levels were slightly increased in all patients.
TonsilTs morphology and cellularity in one CD19-deficient patient
were normal (CD3, CD79a, CD20, CD5, Bcl-2, and Ki67) with
highly active lymphoid follicles. These results show that mutations
in CD19 lead to a novel humoral immunodeficiency in humans,
affecting immunoglobulin production and leading to a increased
susceptibility to recurrent infections.
Support from Colciencias, CODI, and the Deutsche For-
schungsgemeinschaft (DFG).
OR-77. Mutations in TACI Are Associated with
Immunodeficient Phenotypes in Humans.
U. Salzer,1 H. M. Chapel,2 A. D. B. Webster,3
Q. Pan-Hammarstrom,4 H. H. Peter,1 A. Schmitt-Graff,5
J. K. Rockstroh,6 A. A. Schaffer,7 L. Hammarstrom,4
B. Grimbacher.1 1Rheumatology and Clinical Immunology,
University of Freiburg, Freiburg, Germany; 2Department of
Immunology, Oxford Radcliffe Hospitals, Oxford, United
Kingdom; 3Department of Clinical Immunology, Royal Free
Hospital, London, United Kingdom; 4Division of Clinical
Immunology, Karolinska Institute at Huddinge, Stockholm,
Sweden; 5Institute of Pathology, University of Freiburg, Freiburg,
Germany; 6Medizinische Universitatsklinik I, University of Bonn,
Bonn, Germany; 7National Center for Biotechnology Information,
National Institutes of Health, Bethesda, MD, USA.
Background: Transmembrane activator and CAML interactor
(TACI) is a TNFR superfamily member, functionally related to
BCMA and BAFFR as evidenced by the sharing the ligands BAFF
and APRIL. Mice deficient in TACI exhibit a fatal autoimmune
disease and lymphoproliferation, which contrasts the simultaneous
inability of TACI -/- mice to mount robust T cell independent
antibody responses. This coincidence of autoimmunity, lymphopro-
liferation and signs of immunodeficiency is well recognized in
patients with common variable immunodeficiency (CVID), thus
leading us to investigate TACI as a functional candidate gene in
CVID.
Methods/Results: In a cohort of 16 families displaying
autosomal recessive inherited CVID we found two distinct
homozygous genetic defects in two unrelated families with three
AbstractsS30affected individuals. The mutation in the first family affected a
highly conserved cysteine residue (C104R) in the extracellular
domain of TACI. The mutation observed in the second family was
a nonsense mutation at position 144 (S144X) leading to a putative
truncated TACI protein consisting only of its extracellular domain.
We then extended our screening to patients with sporadic CVID
and found 11 out of 139 patients, who carried a heterozygous
mutation. Two of these affected the conserved cysteine residue
(C104R), seven were located within the transmembrane region
(A181E) and two were in the intracellular part of the protein
(S194X and R202H). FACS staining of patients´ B cells with
heterozygous mutations revealed normal TACI surface staining.
After stimulation with common mitogens (IgM, Il-2, CD40, IL-4)
B cells from patients with mutations in TACI proliferated normally.
A tonsil biopsy in one of the patients revealed prominent enlarged
germinal centers with hypercellularity of B cells. Clinically the
patients presented with hypogammagloblobulinemia, especially
low IgM, and displayed signs of lymphoproliferation and auto-
immunity at a very high frequency.
Conclusions: In our evaluation of TACI as a candidate gene in
patients with CVID we found both homozygous and heterozygous
mutations in familial and sporadic CVID cases. Three mutations
lead to substitution of highly conserved amino acids and two are
nonsense mutations. The human TACI-deficient phenotype con-
sists primarily of a humoral immunodeficiency and thus differs
from the murine model, however, signs of autoimmunity and
lymphoproliferation are also evident.
OR-78. Expansion of Maternally Derived Monoclonal
T Cells with a CD3 + CD8 + TCR;D Phenotype in Two
Children with Severe Combined Immunodeficiency.
E. Hodges,1 A. R. Gennery,2 S. Harris,1 J. L. Smith.1
1Wessex Immunology Service, Southampton University Hospitals
NHS Trust, Southampton, Hampshire, United Kingdom;
2Department of Paediatrics, Newcastle General Hospital,
Newcastle upon Tyne, United Kingdom.
Maternal engrafted T cells occur in patients with SCID to a
variable extent often with absence of clinical signs of GVHD. In
this report we describe maternally engrafted TCRgy cells in two
children (RK & JR) with Artemis and common chain deficiencies
respectively. Both children had no clinical symptoms of GVHD.
The purpose of this study was to characterise these populations in
detail. Peripheral blood from both children was phenotyped and
functionally characterised by response to mitogens. Both children
were delivered at term after a normal pregnancy and were
vaccinated according to protocol; in addition RK received BCG
at birth. Both presented at 5 months with PCP, low serum
immunoglobulins, lymphopenia and failure of lymphocytes to
respond to mitogens. RK presented with a T lymphocyte count of
1.1  10 9/l positive for TCRgy, CD3, CD8 and CD45 R0. No B
cells were found. JR presented with a T lymphocyte count of 1.1 
10 9/l positive for TCRgy, CD3, CD4, CD8, CD45R0 and
CD45RA. B cells numbered 0.6  10 9/l. DNA was isolated from
peripheral blood cells and amplified with Biomed primers to TCRg
and TCRy. In both children clonal TCRg and TCRy rearrange-
ments were found compatible with TCRgy cells utilising TCR Vg-
Jg1.3/2.3 and TCR Vy1-Jy1, TCR Vg-Jg1.2 and TCR Vy genes
respectively. We present evidence in two children with signifi-
cantly raised TCRgy populations of maternal origin in blood.
While neither of the children had clinical evidence for GVHD, RK
who received BCG at birth experienced BCG lymphadenitis, skinand gut biopsies from this child were found to have infiltrates of
TCRgy cells that were shown to be clonally identical to the TCRgy
cells in blood. In this case it is possible that the clone arose in
direct response to BCG vaccination at birth, however, cells were
not investigated from mother for their response to BCG. These data
confirm a previous report where clonal TCRgy cells were found to
cross the placenta but failed to initiate GVHD in the neonate. In
this child with SCID clonal TCRgy cells were also shown to be
present in the mother. In this abstract the origin of these cells was
not resolved.
OR-79. Semi-Nested Degenerate rtPCR Allows Rapid
Identification of TCR-beta Rearrangement on the Single
Cell Level.
Dun Zhou, 1 Rajneesh Srivastava, 1 Verena Grummel, 1
Sabine Cepok,1 Hans-Peter Hartung,1 Bernhard Hemmer.1
1Neurology, Heinrich-Heine University Duesseldorf, Duesseldorf,
NRW, Germany.
T cell receptor variable beta chain (TCRBV) PCR is frequently
used to investigate TCRBV usage in autoimmune diseases,
infection and cancer. Because the TCRBV locus contains more
than 50 variable regions, a large number of forward primers has to
be used to cover all TCRBV segments. Previous studies simplified
the TCRBV analysis by performing a multiplex PCR with 26
primers divided into 5 groups. While this approach has been
worked out for single cell rtPCR, it is very time consuming and
costly and can hardly be applied to large scale screening. To further
simplify TCRBVanalysis, we established a new semi-nested rtPCR
method with two sets of degenerate primers covering 85% and
15% of the TCRBV genes respectively. For single cell analysis, we
extended the rtPCR by designing a nested primers located in the
TCRBV constant region. The specificity of the primes was
confirmed by screening cDNAs from more than 200 T cell clones
which were previously defined for their TCRBV usage by flow
cytometry and conventional TCRBV rtPCR. We retrieved all
TCRBV gene segments comprised in the sample with our primer
sets. High sensitivity was demonstrated by successful amplification
of rearranged TCRBV genes of single T cells sorted from body
fluids or dissected from tissue. This new approach allows fast and
cost-effective high throughput analysis of T cell receptor rearrange-
ment at the single cell level facilitating studies on T cell responses
in human diseases.
In Vivo Immune Responses and Imaging
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OR-80. Expanded T Cells from Human Type 1 Diabetic
Pancreatic Draining Lymph Nodes React with Insulin A
Chain 1–15.
S. C. Kent,1 Y. Chen,1 L. Bregoli,1 S. M. Clemmings,2
N. S. Kenyon,3 C. Ricordi,3 B. J. Hering,2 D. A. Hafler.1 1Center
for Neurologic Diseases, Brigham and WomenTs Hospital and
Harvard Medical School, Boston, MA, USA; 2Diabetes Institute
for Immunology and Transplantation, Department of Surgery,
University of Minnesota, Minneapolis, MN, USA; 3Diabetes
Research Institute, Cell Transplant Center, University of Miami,
Miami, FL, USA.
A central question in Type 1 diabetes is the identification of
autoantigens that trigger pathogenic T lymphocytes associated
with specific destruction of insulin producing beta islet cells.
Abstracts S31Single T cells were directly cloned with mitogen into 96 well
plates from pancreatic draining lymph nodes (PLN) from human
subjects with Type 1 diabetes and control subjects, with the
generation of over 515 independent T cells clones. We sequenced
the T cell receptor alpha and beta chains from these clones:
modest or no expansion of TCR chains was seen in PLN from
non-diseased subjects, including a subject with Type 2 diabetes,
while a high degree of T cell expansion was observed in long-
term diabetics, but not a recent onset diabetic with CD4+ T cells
infiltrating the islets. Using a candidate antigen screening
approach and EBV transformed B cells as antigen presenting
cells, clonally expanded T cell clones from PLN from both long-
term diabetics responded to insulin A chain 1–15 in the context of
DRB1*0401 and not in the context of DRB1*0301 or to other
insulin, GAD65, or MBP85-99 peptides and was specifically
blocked by anti-DR antibody. T cell clones from the PLN of a
DR4+ normal, from the cerebrospinal fluid of a DR4+ multiple
sclerosis patient, a MBP85-99 reactive T cell clone from the
periphery of a multiple sclerosis patient, and non-expanded T cells
from one of the long term diabetic DR4+ PLN did not recognize
the insulin peptide in the context of DRB1*0401. Our results are
the first to establish T cell clonal expansion in human pancreatic
draining lymph nodes from subjects with Type 1 diabetes with the
identification of a cognate autoantigen. These experiments
demonstrate the feasibility of non-biased T cell cloning from the
draining lymph node of an organ targeted in an autoimmune
disease to identify a putative autoantigen. Moreover, these results
confirm in humans results in the NOD mouse model identifying
insulin as a critical autoantigen in diabetes.
Costimulation and Tolerance
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OR-81. Anti-CD28 Antibodies-Induced Transplant
Tolerance Involving TCR- Class II- CD80/86+
Regulatory Cells and Tryptophan Degradation.
F. Haspot,1 C. Seveno,1 F. Coulon,1 K. Renaudin,1 M. Hill,1
I. Anegon,1 C. Usal,1 M. Heslan,1 S. Brouard,1 J.P. Soulillou,1
B. Vanhove.1 1U643, INSERM, Nantes, France.
B7/CTLA-4 interactions negatively regulate Tcell responses and
are necessary for transplant tolerance induction. Tolerance induction
may therefore be facilitated by selectively inhibiting the B7/CD28
pathway without blocking that of B7/CTLA-4. In this study, we
selectively inhibited CD28/B7 interactions using the JJ319 modu-
lating anti-CD28 monoclonal antibody in the LEW.1W to LEW.1A
rat model of acute kidney graft rejection. An induction treatment
(4mg/kg/day from day 0 to 7) abrogated rejection. On the long term
(N100 to 300 days), kidney graft function was normal and stable in
tolerant recipients with an absence of histological lesions of chronic
rejection. Tolerant recipients developed alloantibodies of the Th2-
type against donor MHC class II molecules, unlike untreated
rejecting controls that developed Th1-type antibodies against
MHC class I and II molecules. PBMC and spleen cells from
tolerant animals did not proliferate against donor cells in MLR
but proliferated against third party cells. However, purified T cells
were fully reactive suggesting a regulation of T cells by a non-T
cell population. The depletion from PBMC of either CD80 or
CD86-positive, non-T cells, fully restored this reactivity whereas
the depletion of B cells, CD11b/c+, MHC II+ and CD8+ cells had
no effect. Over represented NK cells expressing CD80/86 werefound partially responsible for this suppressive effect. Anti-donor
reactivity could be restored in vitro by blocking indoleamine 2,3-
dioxygenase (IDO) and iNOS. In vivo, pharmacologic inhibition
of these enzymes led to the rejection of the otherwise tolerated
transplants. This study demonstrates that an initial selective block-
ade of CD28 generates B7+ non-T regulatory cells and a kidney
transplant tolerance sustained by the activity of IDO and iNOS.
Living With the Bugs: Good or Bad
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OR-82. Immature Myeloid Dendritic Cells Induce
Intestinal Granulomas under Certain Environmental
Conditions.
K. Sugimoto,1 A. Ogawa,1 E. Mizoguchi,2 T. Nagaishi,3
R. S. Blumberg,3 A. Mizoguchi,1 A. K. Bhan.1 1Pathology,
Massachusetts General Hospital, Boston, MA, USA; 2Medicine,
Massachusetts General Hospital, Boston, MA, USA; 3Division of
Gastroenterology, Brigham and WomenTs Hospital, Boston, MA,
USA.
Granulomatous inflammation is a characteristic feature of
CrohnTs disease. The factors involved in the development of
intestinal granulomatous inflammation have not been fully defined
yet. T cell receptor a knockout (TCRa KO) mice develop Th2-
mediated colitis resembling human ulcerative colitis. Interestingly,
the absence of both B cells and IL-4 led to the development of a
distinct form of colitis showing transmural granulomatous
inflammation (reminiscent of CrohnTs disease) in TCRa KO
mice (TCRa  B cell  IL-4 triple knockout mice: aAIL4 TKO
mice). In contrast, granulomas were not detectable in IL-4-deficient
TCRa double knockout (aIL4 DKO) and B cell-deficient TCRa
(aA) DKO mice. Colitis in TCRa KO mice is characterized by a
marked increase of IL-4 production, whereas aAIL4 TKO mice
showed significant increase in IL-12p40 and IFN-g production.
Interestingly, the development of granulomatous colitis was
associated with an increase of immature myeloid dendritic cells
(DCs) as indicated by the presence of DCs with CD86-
CD11b+CD11c+ phenotype. The colonic LP DCs produced large
amounts of IL-12 p40 and p19 but not p35. This was associated
with a marked increase in IL-17 expression by CD4+ T cells in
aAIL4 TKO mice, compared to other KO mice. The IL-12p40/p19
production by colonic LP DCs was further upregulated by a toll-like
receptor 9 ligand (CpG) and significantly downregulated by IL-4 as
well as IgG (Fc fraction). In vivo neutralization of IL-12p40 activity
by the administration by specific mAbs suppressed the development
of granulomas in aAIL4 TKO mice. To test the ability of immature
myeloid DCs to induce granulomas, purified immature myeloid
DCs isolated from the granulomas of aAIL4 TKO mice (6
months of age) or bone marrow-derived immature or mature
myeloid DCs from WT mice were directly injected into the
ileocecal valve of recipient young aAIL4 TKO mice (9 weeks of
age) following laparotomy. Importantly, the transfer of colonic
myeloid DCs as well as also bone marrow-derived WT immature
myeloid DCs led to the development of granulomas in the
recipient aAIL4 TKO mice. In contrast, the transfer of mature
myeloid DCs failed to do so. These findings indicate that
immature myeloid DCs have the ability to induce granulomas
under specific intestinal inflammatory conditions characterized by
Th1 dominated immune responses (or absence of Th2 environ-
ment) and impaired B cell functions.
AbstractsS32New Animal Models: Defining Antigens
Recognition by Animal Models
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OR-83. HLA-A11/KboDbo Transgenic Mice Are
Susceptible to PLP41–60 Induced Experimental
Autoimmune Encephalomyelitis (EAE).
A. K. Mangalam,1 M. Khare,1 L. R. Pease,1 M. Rodriguez,1
C. S. David.1 1Immunology, Mayo Clinic, Rochester, MN, USA.
Multiple sclerosis (MS) is a demyelinating disease of central
nervous system (CNS) characterized by plaques of infiltrating
CD4+ and CD8+ T cells. Although EAE, an animal model for
MS, is considered a CD4+ T cell mediated disease, recent
reports have suggested that myelin-specific CD8+ T cells can
also cause EAE in susceptible strains of mice. Among all the
genetic factors linked with MS strongest associations have been
found with HLA class I and class II gene. However role of
HLA class I in pathogenesis of MS is not well defined due to
lack of proper animal model. In this study, we have generated
HLA class I transgenic mice to investigate the function of these
molecules in disease pathogenesis of EAE. Transgene (HLA-
A11) were introduced into class I deficient mice by breeding to
eliminate the effects of endogenous class I molecules. Using a
software program ProPred I, we selected HLA-A11 binding
epitope of myelin proteolipid protein (PLP) 41–60 and immu-
nized transgenic mice expressing HLA-A11 and control mice
with this peptide PLP41–60. T cells from the A11 tg mice
responded to PLP41–60 peptide in a dose dependent manner but
no response was seen in KboDbo mice expressing same mouse
class II. Further, using in vitro antibody blocking experiments,
the T cell response in tg mice was shown to be mediated by
both CD4+ T cells as well as CD8+ T cells and restricted by
the HLA class I transgene molecule. PLP41–60 peptide also
induced pronounced neurological disease in A11 tg mice
characterized by brain ataxia, spinning, spastic reflexes and
head tilt. These mice also showed CNS pathology consisting of
heavy inflammation in menengial and cerebellum region of
brain. This is the first animal model describing a encephalito-
genic role of HLA class I-restricted CD8+ T cells. Further study
is underway to understand role of HLA class I molecule in
predisposition and onset of EAE.
OR-84. Fibrinogen-Induced Arthritis in Mice as a Novel
Model for Rheumatoid Arthritis.
P. P. Ho,1 B. H. Tomooka,2,3 J. P. Higgins,4 L. Y. Lee,2
M. Genovese,2 W. H. Robinson.2,3 1Neurology and Neurological
Sciences, Stanford University School of Medicine, Stanford, CA,
USA; 2Medicine, Division of Immunology and Rheumatology,
Stanford University School of Medicine, Stanford, CA, USA; 3Palo
Alto VA Health Care System, Palo Alto, CA, USA; 4Pathology,
Stanford University School of Medicine, Stanford, CA, USA.
The pathogenesis of rheumatoid arthritis (RA) involves the
deposition and excessive local generation of fibrin in the
inflammed joint. It is belived that the imbalance of fibrinolysis
and coagulation within the rheumatoid joint differentiates RA
from other joint diseases. Recent studies have identified
deiminated fibrin as a candidate autoantigen in human RA.
We have developed a fibrinogen-induced arthritis mouse model
for RA using human fibrinogen as the immunizing antigen. In
this model we demonstrate strong T cell reactivity to fibrinogenwith no cross-reactivity to collagen type II. Using proteome
microarrays containing proteins and peptides representing the
putative autoantigens in RA, we also find strong B cell
reactivity to fibrinogen, and robust autoreactive B cell spreading
to collagen types I, II and V, human cartilage glycoprotein 39,
and citrulline-substituted peptides derived from filaggrin. We
also show that arthritis can be adoptively transferred to naive
mice with either sera or whole splenocytes from diseased mice.
Clinical symptoms from both immunized and adoptively trans-
ferred mice include erythema and mild swelling that encompass
the ankle, foot, and digits. Histopathological analysis of H&E
stained joint sections indicate a mononuclear infiltrate within the
inflamed synovial membrane. This new fibrinogen-induced
arthritis mouse model may provide additional insight into
understanding the disease mechanisms and developing novel
therpeutic interventions for rheumatoid arthritis.
OR-85. Murine Model of Mixed Connective Tissue
Disease in HLA-DR4 Transgenic Mice Induced with
U1-70kD Small Nuclear Ribonucleoprotein Autoantigen.
R. W. Hoffman,1,2 Y. Zang,1 E. L. Greidinger.1,2 1Div.
Rheumatology & Immunology, University of Miami, Miami, FL,
USA; 2Medical & Research Services, Miami VA Medical Center,
Miami, FL, USA.
Objective of study: We sought to develop a murine model of
Mixed Connective Tissue Disease (MCTD) that replicated the
immunologic and clinical features of this human autoimmune
disease.
Materials and methods: Groups of 8–12 week old C57BL/6
mice transgenic for the extracellular domains of HLA-DR4 were
immunized subcutaneously with 50 ug of a maltose binding
fusion protein for U1-70kD ribonucleoprotein (70K-FP) in 50 ul
of either U1-RNA in PBS (at 1 ug/ul) or CFA. Control groups
also included mice injected with 50 ug of maltose binding protein
lacking the 70K-FP with U1-RNA or CFA. Sera from mice were
examined for autoantibodies using immunoblot and ELISA.
Tissues were obtained at necropsy, stained with hemotoxylin
and eosin, and examined in a blinded fashion.
Results: Anti-U1-70kD and other anti-ribonucleoprotein (RNP)
antibodies developed both in mice immunized with 70K-FP +
CFA and 70K-FP + U1-RNA. MCTD-like interstitial and
perivascular lung disease developed in groups of mice immunized
with either 70K-FP + CFA (60%) or 70K-FP + U1 RNA (75%).
Anti-RNP antibodies and lung disease was not observed in
control mice. Injection of a single dose of U1-70kD RNP with its
physiologically associated U1-RNA was adequate to induce
autoimmunity in mice transgenic for the HLA-DR4 allele
associated with susceptibility to MCTD.
Conclusions:A single injection ofHLA-DR4 transgenicmicewith
70K-FP+U1-RNAor70K-FP+CFAinducedanti-RNPautoimmunity
and interstital lung disease. Thus, thismodel replicates both the central
immunologic and clinical features ofMCTD.
OR-86. Proteoglycan-Induced Arthritis: A New and
Unique TCR Transgenic Arthritis Model.
S. E. Berlo,1 P. J. van Kooten,1 T. Guichelaar,1 C. B. ten Brink,1 F.
Hauet-Broere,1 M.A.Oosterwegel,2 T.T.Glant,3 W.vanEden,1 C. P.
Broeren.1 1Department of Infectious Diseases and Immunology,
University of Utrecht, Utrecht, Netherlands; 2Department of
Immunology, UMCU, Utrecht, Netherlands; 3Department of
Orthopedic Surgery, Rush University, Chicago, IL, USA.
Abstracts S33To characterize pathogenic effector T cells in arthritic mice,
and to map T cell recognition sites in human and mouse
cartilage proteoglycan (PG), we have generated PG-specific T
cell hybridomas, which recognize dominant/arthritogenic T cell
epitopes. Among these immortalized T cells, hybridoma 5/4E8
(specific for the consensus sequence of 73GRVRVNSAY in
human cartilage PG) induced arthritis upon adoptive transfer,
which showed high similarities to the histopathology of the
primary form of PG-induced arthritis (PGIA) and those
described in peripheral joints of patients with rheumatoid
arthritis (RA).
To better understand the role of antigen-specific T cells in
the development of this autoimmune model of arthritis, we
have inserted the Va1.1 and Vh4 chains of the T cell receptor
(TCR) of hybridoma 5/4E8 into an in vivo expression vector.
We generated transgenic (Tg) mice constitutively (over)-
expressing both TCR chains. TCR-5/4E8-Tg mice were then
backcrossed to the arthritis susceptible BALB/c strain and
immunized with cartilage PG. Interestingly, a rapid onset of
arthritis with severe clinical symptoms was detected in TCR-5/
4E8-Tg mice after immunization with PG, which has never
occurred in wild-type BALB/c mice. The arthritis was
characterized by a chronic progressive disease course with
intermittent spontaneous exacerbations and remissions remi-
niscent of the clinical appearance of RA. Histological analysis
of inflamed joints showed extensive cartilage and bone erosions
similar to that seen in arthritic joints of human patients. Both
IL-4 and IFN-g cytokine-producing cells, with the predom-
inance of IL-4-secreting cells, were detected during the
prearthritic stage (initiation phase) of arthritis, which then
shifted significantly toward a Th1 bias at the time of onset
of arthritis. We also demonstrated that adoptive transfer of
splenocytes from arthritic or non-arthritic TCR-5/4E8-Tg donor
mice to syngeneic BALB/c-SCID or -RAG-2 knockout recipient
mice could induce arthritis.
In conclusion, the presence of the large number of arthritogenic
epitope-specific T cells with high expression level of epitope-
specific TCR is sufficient to induce arthritis. These arthritogenic
epitope-specific TCR-5/4E8-Tg mice are valuable and powerful
tools, and are now used for further development of T cell directed
immune modulating strategies.
OR-87. BDC 12-4.1 (Anti-Insulin B:9-23) T Cell
Receptor Transgenic Mice Are Lymphopenic but
Entrain Early Insulitis and Can Cause Early Diabetes
Modified by Insulin 2 Gene Expression.
J. M. Jasinski,1 L. Yu,1 M. Nakayama,1 E. Liu,1 M. M. Li,1
D. Miao,1 M. A. Lipes,2 D. Wegmann,1 G. S. Eisenbarth.1
1Barbara Davis Center, University of Colorado Health Sciences
Center, Denver, CO, USA; 2Joslin Diabetes Center, Harvard
University, Boston, MA, USA.
A series of studies suggests that insulin is a key target in the
development of anti-islet autoimmunity in type 1 diabetes of
mouse and man. The majority of the Wegmann CD4 T cell
clones from islets of NOD mice react with insulin and more
than 90% of these react specifically with insulin peptide B:9-23.
Using the prototypic I-Ag7-restricted T cell receptor (TCR) of
the BDC 12-4.1 anti-B:9-23 clone, we have produced separately
and combined a (AV13S3 AJ53) and h (BV2S1 Jh2.1) TCR
transgenics. Expression of the Va chain was verified by RT-
PCR of splenic mRNA and sequencing of the entire a chain.Flow cytometry of peripheral blood mononuclear cells demon-
strates good expression of the h chain transgene in T cells.
Approximately 98% of the peripheral CD4 T cells in tg FVB
mice express the transgenic h-chain compared to 4% in non-
transgenic mice. The transgenic FVB mice were crossed and
back-crossed with NOD RAG1-/- mice. Homozygous RAG-/-
TCR+ mice are lymphopenic compared to heterozygous RAG F
TCR+ mice (mean lymphocyte count 500 lymphocytes/ul versus
4800 lymphocytes/ul; P = 0.02). Heterozygous RAG F TCR+
transgenic mice show insulitis at every age tested (7–62 weeks)
but do not progress to diabetes nor do they develop insulin
autoantibodies. TCR+ RAG-/- tg mice can develop diabetes at
older ages (e.g., 32 weeks). Since the insulin2 gene (Ins2) is
expressed in the thymus (the insulin1 gene is expressed
minimally if at all in the thymus), the TCR transgenic mice
were bred with NOD Ins2 knockout mice to create a TCR+
RAG-/-Ins2-/- mouse. Diabetes developed much earlier in these
mice (10 weeks for first diabetic observed) with partial
restoration of peripheral lymphocytes. We believe the acceler-
ated diabetes and higher peripheral lymphocyte counts of the
Ins2 knock-out transgenic mice are due to lymphocytes escaping
negative thymic selection due to the lack of insulin expressed
as an autoantigen in the thymus. We are currently producing
BDC 12-4.1 TCR congenics on the NOD and B6.NOD-H2g7
backgrounds and will analyze the clonality of the T cell
receptors of the infiltrating cells in insulitic lesions. These
experiments indicate that as a transgenic, the 12-4.1 T cell
receptor confers diabetes susceptibility in immune-compromised
mice and confers insulitis susceptibility in immunocompetent
mice.
OR-88. Implication for the Pathogenesis and
Immunoregulation in a Murine Model of Sarcoidosis.
B. Wei, P. Velazquez, J. Braun. 1Department of Pathology and
Laboratory Medicine, Molecular Biology Institute, UCLA David
Geffen School of Medicine, Los Angeles, CA, USA.
Sarcoidosis is a systemic granulomatous disease with unclear
etiology and limited treatment. Th1 cell activity plays prominent
role in the multi-organ inflammation of sarcoidosis, but
mechanistic study and therapeutic progress is hampered by the
lack of an experimental animal model. We recently reported that
Gai2-/- T cells produced chronic intestinal inflammation when
transferred into RAG2-/- recipients. In this study, we demon-
strate that re-transfer of splenic T cells from these recipients
induce progressive systematic granulomatous disease. The
inflammation involved skin, lungs, pancreas, and intestines.
Environmental microbes are required for disease development.
By flow cytometry, lymphocytes recovered from the mice with
disease were increased in CD4+ T cells with Th1 features.
Surprisingly, co-transfer of wildtype mesenteric node (MLN) B
cells prevented CD4 T cell expansion, inflammation, and disease
activity induced by the immunopathogenic lymphocytes. The
protective function of MLN B cells required genetic sufficiency
for CD1d and IL-10. These results establish a mouse model for
sarcoidosis, and reveal a new setting for protective B cell
immunoregulation via cognate CD1d interaction and IL-10
production. This model provides an experimental system to
delineate immune targeting and immunoregulatory deficits that
may underlay pathogenesis in sarcoidosis. Supported by NIH
DK46763, DK069434, and the CrohnTs and Colitis Foundation
of America.
AbstractsS34OR-89. A New Model of Endogeneous AML Following
Irradiation and Allogeneic Bone Marrow
Transplantation.
B. Van Wijmeersch,1,3 B. Sprangers,1 C. De Wolf-Peeters,2
W. Landuyt,4 M. Waer,1 B. Dubois,3 A. D. Billiau.1 1Laboratory of
Experimental Transplantation, University of Leuven, Leuven,
Belgium; 2Department of Pathology; 3Department of
Neurosciences and Psychiatry, Section Experimental Neurology;
4Laboratory of Experimental Radiotherapy, University of Leuven,
Leuven, Belgium.
Background: It has been shown that SJL/J mice given ionizing
irradiation develop acute myelomonocytic leukemia. The one year-
incidence (10–30%) of this radiation-induced AML (RI-AML)
markedly increased (50 % and 75%), when irradiation was followed
by treatment with corticosteroids or CSF-1 [1, 2]. Leukemogenesis
was shown to be due to a deletion in one copy of chromosome 2,
inducing a pre-leukemic state. A secondary proliferative stimulus
then results in leukemic transformation [3, 4].
Aim: This study was initiated to investigate whether allogeneic
bone marrow transplantation (allo BMT) can be used as a
proliferative stimulus after irradiation of SJL/J mice, thereby
creating a model of endogenous post transplant leukemia relapse.
Materials and Methods: SJL/J mice (H-2Ks) were sublethally
irradiated (8,5 Gy) and transplanted with 107 T-cell depleted
Balb/c BM cells (H-2Kd). Animals were monitored for weight
loss, signs of leukemic disease and survival. At regular time
intervals, peripheral blood was collected for evaluation of donor
chimerism in different cell lineages (flowcytometry). Moribund
animals were sacrificed and lymphoid and other tissues were
prelevated for flowcytometric (CD3, CD4, CD8, CD11b, Gr1,
c-Kit, Vb 8.3, H-2Kd, IAd), histopathological and immunohis-
tochemical studies (HE stains; MPO, B220 and CD3).
Results: BMT led to the development of mixed chimerism of
10 F 4.5, 80 F 17.3 and 97 F 1.5 % in the T-cell, B-cell and
myeloid cell lineage, respectively. From 3 weeks after BMT
onwards, all mice developed weight loss and overt malaise (n =
65), resulting in 60% mortality between day 30 and 60 post BMT.
Autopsy of these mice showed an enlarged spleen with nodules
and a brownish discoloration of the liver with necrosis. Micro-
scopic studies showed destruction of the splenic architecture by a
uniform cell population, which was also found in the liver. The host-
type origin and the immature myeloid nature of this population was
demonstrated using immunohistochemistry (MPO +, B220-, CD3 -)
and flowcytometry (CD11b lo, Gr1 lo, B220 -, CD3 -, CD4 -,
CD8- and H-2Kd -) on spleen, liver and bone marrow. Ex vivo
MLR failed to reveal increased alloreactivity and in vivo
expansion of alloreactive T cell frequency (Vb8.3) was absent,
arguing against graft-versus-host disease.
Conclusion: We describe a new model of endogeneous
leukemia, in which irradiation and allo BMT in SJL/J mice gives
rise to fatal AML. The model most likely involves a radiation-
induced defect, while endogenous growth factors, produced after
allo BMT, play a facilitating role in leukemogenesis. This model
can be of value for the study of leukemogenesis and of
immunotherapy in AML.
References:
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OR-90. Monoclonal Antibody Targeting of TIRC7
Results in Significant Therapeutic Effects on T and B
Cell Response in Collagen-Induced Arthritis in Mice.
N. Utku,1,2 P. Fraser,4 T. Heinemann,2 E. Nieuwenhuis,3
H. D. Volk,1 R. S. Blumberg.3 1Institut of Medical Immunology,
Humboldt-University of Berlin, Berlin, Germany; 2GenPat77
Pharmacogenetics AG, Berlin, Germany; 3Division of
Gastroenterology, Department of Medicine, Brigham and WomenTs
Hospital, Boston, MA, USA; 4Division of Rheumatology,
Department of Medicine, Brigham and WomenTs Hospital, Boston,
MA, USA.
Aim: TIRC7 is an activation induced cell surface molecule on
T and B cells that negatively regulates their function. TIRC7 is
upregulated in vivo in patients with Rheumatoid Arthritis (RA) and
mice with collagen induced arthritis (CIA) suggesting TIRC7
targeting might be a new therapeutic option of RA. Methods: We
analysed the in vitro, ex vivo, and in vivo effects of anti-TIRC7
mAb particularly on memory T cell function under physiological
and pathophysiological (CIA model) conditions. Results: Anti-
body targeting of TIRC7 in vitro significantly inhibited the
memory T cell response to recall antigens in vitro and inhibited
a delayed type hypersensitivity response in vivo (mouse). Most
importantly, DAB mice with established collagen-induced arthritis
(CIA) were treated with TIRC7 mAb alone or in combination with
a TNF-alpha receptor-Ig-fusion protein. Anti-TIRC7 antibody
administration demonstrated significant therapeutic efficacy in
established CIA as monotherapy. Moreover, the combination of
anti-TIRC7 antibody with a TNF alpha receptor-fusion protein
revealed additional therapeutic effects in established arthritis in
mice. Mice treated with anti-TIRC7 mAb also showed a significant
reduction of IgG1 anti-collagen antibody responses together with
reduced B cell numbers. Conclusion: The treatment of auto-
immune diseases such as RA associated with exaggerated T and B
cell response with an anti-TIRC7 mAb might be unique as TIRC7
targeting results in modulation of both T and B cell response.
Moreover, unlike to other therapeutic pathways, anti-TIRC7
antibody therapy exhibits a significant inhibitory effect on memory
T cell activation. TIRC7 targeting could offer a novel therapeutic
strategy for RA patients that synergizes with TNF alpha receptor
therapy and the combination of TIRC7 signaling pathway with
TNF alpha blockade might be important for the clinical use as a
large group of non- responders to anti-TNF alpha targeting therapy
is existing.
OR-91. Transgenic Expression of Program Death
Ligand 1 Protects Islets from Autoimmune Diabetes in
Nonobese Diabetic Mice.
Huey-Kang Sytwu,1 Chia-Jen Wang.2 1Microbiology and
Immunology, National Defense Medical Center, Taipei, Taiwan,
Taiwan; 2Life Sciences, National Defense Medical Center, Taipei,
Taiwan, Taiwan.
PD-L1, also known as B7-H1, is one of the ligands of
programmed death 1 (PD-1) which can negatively regulate
lymphocyte activation. PD-L1 is broadly expressed in mice and
may contribute to the peripheral tolerance by interacting with PD-1.
Based on this PD-1-mediating immune-inhibitory function, we
investigate the preventive and/or therapeutic potential of PD-L1 in
Abstracts S35autoimmune diabetes. In anti-CD3 stimulation experiment, prolif-
erative response of splenocytes from non-obese diabetic (NOD)
mice is down-regulated in a PD-L1.Ig dose-dependent manner. We
further generated the transgenic NOD mice overexpressing PD-L1
in pancreatic cells and characterized the protective potential in these
mice. In these transgenic mice, we observed an islet-specific
transgene expression of PD-L1 both in transcriptional and transla-
tional levels. Strikingly, the severity of insulitis in these transgenic
mice is significantly decreased. Moreover, the disease onset is
delayed as well as the diabetic incidence is decreased in these mice.
To assay whether the protection of diabetes in these mice is
differentially regulated by the Th1 and Th2 development, we
crossed PD-L1 transgenic mice with T1 and T2 doubly transgenic
NOD mice and directly investigated their Th1 and Th2 expression
profiles. In the PD-L1/T1/T2 triply transgenic mice, the higher Th2
marker expression suggests that overexpressed PD-L1 may
indirectly trigger the Th2 development. By enhancing the Th2
function, the original Th1-dominant autoimmune response can be
suppressed in these PD-L1 transgenic mice. Furthermore, the
transgenic islets had a higher transplantation success rate and
survived for longer than wild-type islets. Our results support the
theoretical basis for genetic manipulation in an organ-specific
manner and provide a potential therapeutic approach mediated by
PD-L1 in islet transplantation.
OR-92. PD-L1/PD-L2 Expression Protects Against the
Development of Autoimmune Diabetes.
Mary E. Keir,1,2 Spencer C. Liang,1,2 Arlene H. Sharpe.1,2
1Pathology, Harvard Medical School, Boston, MA, USA;
2Immunology Research Division, Brigham and WomenTs
Hospital, Boston, MA, USA.
PD-1, a member of the B7/CD28 family of costimulatory
molecules, is expressed on activated T and B cells and plays a role
in regulating tolerance and autoimmunity. PD-1 has two ligands,
PD-L1 (B7-H1) and PD-L2 (B7-DC). PD-L1 is widely expressed
on both immune and non-immune cells. PD-L2 has more restricted
expression and is primarily found on macrophages and dendritic
cells. PD-L1 is upregulated on islet cells in diabetic NOD mice. To
investigate the role of PD-L1 and PD-L2 in progression to
autoimmune diabetes, we crossed PD-L1/PD-L2 deficient mice
onto the NOD background. The loss of PD-L1/PD-L2 precipitates
early onset of diabetes in both male and female NOD mice. PD-L1/
PD-L2 deficient mice become diabetic by 4–6 weeks of age, in
comparison to N13 weeks in wild type controls. Both wild type and
PD-L1/PD-L2 deficient T cells are diabetogenic when adoptively
transferred into PD-L1/PD-L2 deficient NOD SCID hosts, while
wild type and PD-L1/PD-L2 deficient T cells do not induce
diabetes when adoptively transferred into wild type NOD SCID
hosts. These data indicates that PD-L1/PD-L2 expression is
required on host tissues (islet cells, endothelium, dendritic cells)
in order to dampen autoreactive T cell responses.
OR-93. ICOS Engagement of CD4 T-Cells Following
Pulmonary Influenza Infection: Evidence for Negative
Regulation of T-Cell Effector Function.
M. E. Dahl,1 A. Coyle,2 D. B. Lewis.1 1Department of Pediatrics
and Immunology Program, Stanford University School of
Medicine, Stanford, CA, USA; 2Millenium Pharmaceuticals,
Cambridge, MA, USA.
Respiratory viruses such as influenza A elicit an immune
response involving the activation, proliferation and recruitment ofCD4 and CD8 T cells to the lung, the major site of viral infection.
A major feature of the anti-viral response is the secretion of IFN-g,
the signature Th1 cytokine, by activated effector CD4 and CD8 T
cells. We have previously observed that these T cells can persist
and spontaneously secrete IFN-g in the lungs for up to 30 days
following viral infection, and have reported that IFN-g induced by
viral infection contributes to major quantitative and qualitative
alterations of pulmonary dendritic cells (Nat. Immunol. 5:337-43,
2004). In the current study, we have determined how the inducible
costimulatory molecule,(ICOS) regulates CD4 and CD8 T cell
responses following influenza A infection. Substantial levels of
ICOS were observed on CD4 and CD8 T cells during the acute
influenza viral infection, which persisted for at least 30 days post-
infection, subsiding gradually in a manner that paralleled the
expression of IFN-g. We neutralized ICOS-ICOS ligand inter-
actions during acute influenza viral infection of BALB/c mice
using either recombinant ICOS-Ig fusion protein or neutralizing
anti-ICOS mAbs. Although there was initially a delayed recruit-
ment of CD4 T cells, this was followed by substantially increased
number of CD4 T cells in the lungs. Moreover, intracellular
staining of these T cells demonstrated an elevated level of
spontaneous production for both IFN-g and the immunoregulatory
cytokine IL-10 for up to 30 days post-influenza infection. Thus,
transient ICOS blockade dramatically alters the normal temporal
expression of IFN-g by CD4 and CD8 T cells. To further
investigate the effects of ICOS-ICOS ligand interactions in vitro,
we activated ovalbumin (OVA)-specific DO11.10 CD4 T cells by
co-culturing them with antigen and dendritic cells in the presence
of blockade of ICOS/ICOS-ligand interactions. This blockade
enhanced antigen-specific proliferation of the CD4 T cells and
secretion of IFN-g. The in vitro primed CD4 T cells that received
ICOS blockade were adoptively transferred in vivo and recipient
mice were then sensitized and challenged with intranasal injections
of OVA. CD4 T cells were purified from the pulmonary lavage of
the mice and the adoptively transferred cells were found to express
higher levels of IFN-g and IL-10 compared to adoptive transferred
CD4 T cells that were not subjected to ICOS/ICOS-ligand
blockade. Together, these results suggest a novel and previously
unappreciated role for ICOS in negatively regulating both Th1 and
regulatory cytokine production by T cells.
OR-94. Tim-4 Is the Ligand for Tim-1, and the Tim-1/
Tim-4 Interaction Regulates T Cell Expansion.
J. Hartt Meyers,1 S. Chakravarti,1 D. Schlesinger,1 Z. Illes,1
H. Waldner,1 S. E. Umetsu,2 J. Kenny,3 X. X. Zheng,3
D. T. Umetsu,2 R. H. DeKruyff,2 T. B. Strom,3 V. K. Kuchroo.1
1Center for Neurologic Diseases, Harvard Medical School &
Brigham and WomenTs Hospital, Boston, MA, USA; 2Division of
Immunology and Allergy, Department of Pediatrics, Stanford
University School of Medicine, Stanford, CA, USA; 3Division of
Immunology, Beth Israel Deaconess Medical Center and Harvard
Medical School, Boston, MA, USA.
The newly identified Tim (T cell, immunoglobulin and mucin
domain-containing molecule) gene family has been associated
with the regulation of TH1 and TH2 immune responses. Tim-1
has been genetically linked to asthma, a TH2-mediated disease;
however, its endogenous ligand has not been identified. We
have found that Tim-4, which is expressed by antigen-presenting
cells, is the ligand for Tim-1. An interaction between Tim-1 and
Tim-4 can be observed between in vivo-derived cells and can be
specifically blocked by anti-Tim-1 antibody. In vivo admin-
AbstractsS36istration of soluble Tim-1 fusion protein (Tim-1Ig) during either
a TH1- or TH2-biased immune response results in hyper-
proliferation and the preferential expansion of TH2 cells.
Furthermore, soluble Tim-4Ig can costimulate T cell expansion
both in vitro and in vivo. Our data suggest that the Tim-4/Tim-1
interaction delivers a signal necessary for the expansion of T
cells.
OR-95. Evidence for Early Anergy Followed by Rapid
Peripheral Deletion of Donor-Specific CD8 T Cells after
Non-Myeloablative BMTwith Anti-CD154: In Search of
a Tolerogenic Donor Cell.
T. Fehr,1 M. Chittenden,1 T. Wekerle,2 M. Sykes.1 1Transplantation
Biology Research Center, Massachusetts General Hospital,
Boston, MA, USA; 2Department of Surgery, Medical University of
Vienna, Vienna, Austria.
Aim: Mixed chimerism and donor-specific tolerance can be
achieved by bone marrow transplantation (BMT) with non-
myeloablative conditioning using 3 Gy total body irradiation
(TBI) and anti-CD154 mAb. CD4 T cells are needed during the
first 2 weeks for CD8 T cell tolerance induction. We now
investigated early CTL activity and the role of various donor cell
populations in this tolerance model.
Methods: Recipient B6 mice were treated with TBI (3 Gy,
day -1), one dose of anti-CD154 mAb (2mg MR1, day 0) and
BMT from a fully allogeneic (B10.A) donor to induce mixed
lymphohematopoietic chimerism. CTL function was assessed by
51Cr release assay on days 4, 7 and 14 after BMT. To assess the
role of specific donor cell populations in tolerance induction,
recipient B10.S mice received the same conditioning followed by
BMT from fully allogeneic B cell- or T cell-deficient mice (AMT
or TCRh-/-, B6 background). In a further experiment, transgenic
mice expressing the diphtheria toxin receptor under a CD11c
promotor were used as donors. In these mice diphtheria toxin
injection leads to rapid depletion of CD11c+ dendritic cells.
Results: In earlier studies we showed that donor-specific CD8
T cells are deleted from the peripheral repertoire within 10–14 days
after BMT with this regimen. We now demonstrate donor-specific
loss of CTL function in 51Cr release assay already by days 4 and 7
after BMT in mice that received the tolerance protocol, but not in
those receiving conditioning without BMT. This finding suggests
an early phase of donor-reactive CD8 T cell anergy before deletion.
In search of a tolerogenic donor cell population, we used either B
cell- or T cell-deficient donor mice and also tested dendritic cell
depletion in a transgenic model system. The absence of any of
these cell populations from the donor marrow did not interfere with
the establishment of lymphohematopoietic chimerism. Tolerance
was further shown by durable mixed chimerism and acceptance of
donor skin, but prompt rejection of third party skin.
Conclusion: Donor-specific alloreactive CD8 T cells are
unresponsive within 4 days and deleted from the periphery within
10 days after BMT with TBI day -1 and anti-CD154 mAb
treatment. Neither B cells, T cells nor dendritic cells of donor
origin are critically required for tolerance induction in this model.
OR-96. TIM-3 Mediated Enhancement of Anti-Tumor
Immune Responses.
Brian K. Helmich,1 Soonpin Yei,1 Vijay K. Kuchroo,2 Dennis J.
Carlo,1 Thomas Moll.1 1Preclinical Research, Telos
Pharmaceuticals LLC, San Diego, CA; 2Department of Neurology,
Harvard Medical School, Boston, MA.Effective immunity against tumors often results from the
development of a vigorous cell-mediated immune response.
Effective anti-tumor immunity is largely predicated on the
contribution of Th1 cytokines (i.e., IFN-g, TNF-a). While differ-
entiation of T cells toward a Th1 or Th2 phenotype involves a
complex chain of events, members of a novel class of molecules
called TIMs (T cell Immunoglobulin andMucin domain-containing
proteins) have recently been shown to exert great influence over
Th1/Th2 immune phenotype balance in vivo. Manipulating the
action of TIM-3, one of the members of this novel protein family,
was previously found to profoundly affect disease severity and
outcome in animal models of autoimmunity and allograft trans-
plantation, and promote hyperproliferation of antigen-activated T
cells and the spontaneous production of Th1 cytokines. These
results strongly suggested that agents targeting TIM-3 pathways
could also enhance effective anti-tumor immune responses in vivo,
presumably through one or more mechanisms favoring Th1 cells
and the promotion of cell-mediated immunity. In the study
described here, an antibody specific to TIM-3 was investigated
for its ability to promote anti-tumor effects in mice. Using the EL4
thymoma tumor model, anti-TIM-3 was delivered as either a stand-
alone therapeutic agent following establishment of tumors under the
skin, or as an adjuvant to irradiated tumor cell vaccination prior to
live tumor challenge. Anti-TIM-3 antibody promoted significant
reductions in challenge tumor growth over time. Furthermore,
including anti-TIM-3 as an adjuvant to tumor vaccination also
allowed treated mice to fully reject subsequent live tumor challenge.
Neither tumor rejection nor limited tumor growth was seen in mice
receiving isotype-matched control antibody under either exper-
imental protocol. By demonstrating a powerful capacity for TIM-3-
specific antibodies to change the course of tumor progression in
treated mice, these experiments further support the prospective role
of TIM-3 to act as a critical regulator of cell-mediated immune
function and Th1 responsiveness.Immunotherapy
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OR-97. Apoptosis Induction as a Therapeutic
Intervention to Eliminate Encephalitogenic T Cells;
Antisense XIAP (AEG35169) in Murine Models of EAE.
S. P. Zehntner,1 L. Bourbonniere,1 S. J. Morris,2 D. Methot,2
G. Doucet,2 J. Durkin,2 J. W. Gillard,2 T. Owens.1,3
1Neuroimmunology Unit, Montreal Neurological Institute,
Montreal, QC, Canada; 2Aegera Therapeutics Inc, Montreal, QC,
Canada; 3Medical Biotechnology Center, University of Southern
Denmark, Odense, Denmark.
MS is an inflammatory disease of the CNS white matter, with
presumed autoimmune etiology. Therapies in current use show
benefit for MS in targeting the T-cell autoimmune response.
Apoptosis of auto-reactive T-cells is a fundamental immunoregu-
latory mechanism. If autoimmune T-cells were predisposed to
death, MS could be alleviated. Increased expression of Inhibitor of
Apoptosis (IAP) proteins protects cells from apoptosis. In
particular, the X-linked IAP (XIAP) interrupts the apoptotic
cascade in T-cells by directly inhibiting effector caspases.
Inhibition of XIAP primes cells for apoptosis induced by multiple
stimuli. We used repeated interperitoneal (IP) injection of XIAP
antisense oligonucleotide (AEG35169) in mice to reduce XIAP
Abstracts S37protein levels in peripheral blood leukocytes. AEG35169 was
similarly administered to treat MOG p35-55 induced EAE in
C57Bl/6 mice. When given daily via IP injection, from time of
symptomatic onset, AEG35169 reduced clinical scores within 5
days and prevented further disease progression in 84% of animals,
compared to control groups receiving random or scrambled
oligonucleotides or saline, 90% of which showed continued
disease or increased severity (n = 16). Anti-XIAP treated animals
showed evidence of considerably increased leukocyte apoptosis,
with high numbers of TUNEL positive cells in the spinal cord. A 5-
day prophylactic treatment with AEG35169, prior to induction of
EAE, followed by daily treatment, reduced the incidence of mild
disease from 85% of animals to 9% (n = 57), and of severe disease
from 84% to 38% (n = 48). Analysis of tissues at 40 days after
immunization indicated no or very limited inflammatory infiltrates
in anti-XIAP protected animals, and correlates of disease such as
chemokine expression in CNS were reduced in treated animals.
Amelioration of disease was not due to immune suppression, and
there was no evidence for a Th1/Th2 shift in treated animals. Our
data establish XIAP as a critical controller of the susceptibility of
CNS-infiltrating T cells to apoptosis, such that experimental
modulation of XIAP prevents or cures EAE. These studies increase
our understanding of regulation of inflammatory pathology in the
CNS and support XIAP as a novel target for therapeutic
intervention in MS.
OR-98. Blockade of TNFA Preferentially Inhibits
Proliferation of Anti-CD3, Recall-Antigen Responsive
and Autoreactive Human VLA-1+CD45RO+CD4+
T Cells.
S. Ben-Horin,1 I. Goldstein,2 A. Koltakov,1 L. Chess,2 I. Bank.1
1Medicine, Chaim Sheba Medical Center and Tel Aviv University,
Ramat Gan, Israel; 2Medicine, Columbia University, New York,
NY, USA.
The very late antigen (VLA)-1 a1h1 integrin, a receptor for
collagen, is induced on the surface membrane of activated T-cells
(TC) and remains preferentially expressed by effector-memory Th1
cells. We recently showed that VLA-1+ T cells at sites of chronic
autoimmune inflammatory arthritis express a restricted and unique
T cell receptor (TCR) Vh repertoire, suggesting they are respond-
ing to a unique set of auto-antigens in tissues. Since VLA-1+
immunocytes are critical in immune mediated Th1 diseases that are
ameliorated by monoclonal antibodies (mAb) to TNFa, we
explored how an anti TNFa mAb affects the VLA-1+CD4+ TC
subset. Anti TNFa mAb (Infliximab, 5–50 Ag/ml) but not control
immunoglobulins, neutralized TNFa during ex vivo mitogen (PHA
or anti-CD3)-triggered activation of VLA-1- peripheral blood (PB)
mononuclear cells (MC) (PBMC) and significantly reduced the
percentage of VLA-1+ TC in 8–12 day cultures (36.9 F -20.3% to
26.9 F 15.7% of the TC, n = 9, pb0.011), but did not affect the
VLA-4+ subset. Furthermore, CFSE-dye intracellular labeling
revealed that the reduction was due to a preferential inhibition of
VLA-1 expression among CD4+ TC that were induced to divide in
the presence of anti CD3. Thus, dividing VLA-1+CD4+ T cells in
the culture, were reduced 66 F 22% while non-dividing VLA-
1+CD4+ TC were slightly increased. In contrast, the anti CD3
VLA-1-CD4+ responsive subset was inhibited to a lesser extent by
TNFa blockade (40–50% inhibition, n = 5). The addition, at a 1:2
cell:cell ratio, of washed MC from 8 day cultures of PBMC
activated by anti CD3 mAb plus anti TNFa, but not, as a control, of
VLA-1- anti CD3 triggered T cells in the absence of anti TNFa,likewise decreased the VLA-1+ subset emerging in autologous de
novo anti-CD3-activated 8 day cultures, suggesting that the
preferential inhibition of VLA-1+ CD4+ TC division by anti
TNFa, may involve MC activated in the presence of anti TNFa
(n = 3 experiments). Importantly, anti TNFa mAb, also preferen-
tially inhibited PB derived VLA-1+CD4+ TC dividing ex vivo in
response to the recall antigen tetanus toxoid, while less potently
inhibiting the VLA-1-CD4+ subset. Finally, non-antigenically or
mitogenically stimulated, spontaneously dividing, (thus presum-
ably autoreactive), synovial fluid (SF) VLA-1+CD4+, but neither
VLA-4+CD4+or CD25+CD4+ TC, from patients with autoim-
mune arthritis, were also dramatically and preferentially reduced
by anti TNFa (85% inhibition, n = 6) in ex vivo cultures. These
data suggest that a critical immuno-modulatory effect of anti TNFa
is mediated by its ability to preferentially target and inhibit
mitogen, antigen or auto-antigen induced expansion of the VLA-
1+ Th1 effector memory subset.
OR-99. An Immunization Strategy for Generation of T
Cell Receptor Mimics.
Vaughan P. Wittman,1,2 David Woodburn,2 Rony Tal,2 Jon A.
Weidanz.1,2 1Pharmaceutical Sciences, Texas Tech University
Health Sciences Center, Amarillo, TX, USA; 2Receptor Logic,
LTD, Amarillo, TX, USA.
Antibodies endowed with specific recognition properties for
HLA-displayed tumor associated antigens have been recently
produced and shown to directly detect expression of HLA-tumor
associated antigens on the surface of cancer cells. The application
of these reagents for validation of T cell epitopes would greatly
facilitate vaccine development. Yet many technical obstacles stand
in the way of developing a consistent approach for making
antibodies with T cell receptor (TCR)-like specificity. Particularly
important would be to develop immunogenic forms of immunogen
that could then be used for rapid and reproducible immunization of
mice for the generation of polyclonal antibody responses reactive
against peptide-A2 epitopes. Development of this technology
might lead to more efficient creation of monoclonal antibodies
(mAbs) specific for HLA-peptide. We hypothesized that HLA-A2-
peptide immunogen presented to the immune system in a
tetravalent form rather than a monovalent form would display
enhanced immunogenicity and promote consistent generation of
high titer IgG polyclonal antibody responses specific for the A2-
peptide immunogen. To test our hypothesis we refolded E. coli
produced insoluble protein and prepared purified forms of
monomer and tetramer HLA-A2 peptide complexes displaying
either human eukaryotic transcription initiation factor 4-gamma
(eIF4G; VLMTEDIKL), a self-protein found to be upregulated in
HIV infected T cells or human tumor suppressor protein p53 (264;
LLGRNSFEV), a self-protein that is widely expressed in many
cancers. We then immunized groups of Balb/c mice (5/group) 3
times with 2-week intervals with either monomer or tetramer forms
of immunogen and assayed mouse sera for polyclonal IgG
antibody response reactive for HLA-peptide by competitive
ELISA. All mice (5/5 from both eIF4G- and 264-peptide-A2
groups) immunized with tetramers of immunogen showed specific
anti-A2-peptide IgG antibody responses. In contrast, no specific
polyclonal antibody response was detected from any of the mice
(0/5) immunized with monomers of eIF4G- and 264-peptide-A2
immunogen. To confirm the specificity of the polyclonal anti-
peptide-A2 response, we evaluated antibody from mice immunized
with tetramer immunogen to stain T2 cells (HLA-A0201 positive)
AbstractsS38pulsed with either eIF4G- or 264- peptide in a competitive binding
assay. Our T2 cell assay results support the ELISA data and
indicate that immunogen formulated as a tetramer is immunogenic
and able to generate anti-peptide-A2 specific antibody responses in
mice. Furthermore, we demonstrated by ELISA and T2 cell
staining that tetramer forms of immunogen efficiently elicit IgG
polyclonal antibody responses reactive against peptide-A2 within 4
weeks after initial immunization. Collectively, our findings support
the hypothesis that tetravalent forms of peptide-A2 immunogen
consistently lead to specific antibody responses against peptide-A2
epitopes. In addition, the ability to generate these probes in a rapid
and reproducible manner will be invaluable for HLA class I
epitope validation.
OR-100. Differential Expression of Phosphorylated
NF-kB/RelA in Normal and Psoriatic Epidermis and
Downregulation of NF-kB in Response to Treatment
with Etanercept.
P. F. Lizzul,1 A. Aphale,1 R. Malaviya,1 Y. Sun,1 S. Masud,1
V. Donbrovskiy,1 A. B. Gottlieb.1 1Clinical Research Center,
UMDNJ-Robert Wood Johnson Medical School, New Brunswick,
NJ, USA.
Etanercept, a recombinant human TNF receptor fusion protein,
is FDA approved for psoriasis and psoriatic arthritis. TNFa
increases the synthesis of proinflammatory cytokines and leads
to the activation of multiple signaling pathways, including NF-kB.
The Rel/NF-kB transcription factors play a central role in
numerous cellular processes, including the stress response and
keratinocyte proliferation and differentiation. Utilizing a phosphor-
ylation specific antibody we examined the expression of active
nuclear NF-kB/RelA via immunohistochemistry in normal skin,
non-lesional psoriatic skin, lesional psoriatic skin and lesional skin
from patients treated with etanercept. There was no expression of
active nuclear NF-kB in normal epidermis, whereas a basal level of
constitutive active phosphorylated NF-kB/RelA was present in
uninvolved epidermis from psoriasis patients. There was also
significant upregulation of active phosphorylated NF-kB/RelA in
epidermis from psoriatic plaques. Serial biopsies from psoriasis
patients treated with etanercept at 1 month, 3 months, and 6 months
demonstrated a significant down regulation of phosphorylated NF-
kB/RelA which correlated with decreases in epidermal thickness,
restoration of normal markers of keratinocyte differentiation, and
clinical outcomes. These data suggest that activation of NF-kB
plays a significant role in the pathogenesis of psoriasis and that a
potential mechanism of action for TNF-targeting agents is down-
regulation of NF-kB transcriptional activity.
OR-101. Anti-IL-2R Therapy: An Alternative Strategy
for Regulating CD40L Expression.
J. Shen,1 J. T. Snyder,1 H. Azmi,1 J. A. Ragheb.1 1Laboratory of
Immunology, NEI, National Institutes of Health, Bethesda, MD,
USA.
Monoclonal antibodies directed against the alpha chain (Tac/
CD25) of the IL-2 receptor (IL-2R) are an emerging therapy in
both transplantation and autoimmune disease. In a cohort of
patients with autoimmune uveitis being treated with multiple
immunosuppressive medications, monotherapy with daclizumab, a
humanized anti-Tac antibody, was sufficient to control their disease
without serious side effects. The basis of this antibodyTs
therapeutic efficacy has not been established. Meanwhile, anti-
bodies against CD40L that were shown to be efficacious in primatetransplant models were withdrawn from clinical use due to serious
side effects associated with their administration. We have reported
that CD40L expression on activated human CD4+ T cells is
biphasic, consisting of an early CD28-independent peak, a
subsequent nadir, and a second, CD28-dependent peak at 48 hr.
The transient expression of CD40L is critical to the physiologic
function of this costimulatory pathway, yet the mechanisms
underlying the biphasic pattern of CD40L expression are largely
unknown. We have also reported that the CD28-dependent second
phase of CD40L expression is severely inhibited in vitro by
daclizumab. We now show in primary PBMC cultures using
blocking antibodies and flow cytometry that IL-2 does not impact
late phase CD40L by acting indirectly through IL-2 regulated Th1
and/or Th2 cytokines as neither IL-12 nor IL-4 had any appreciable
effect on either early or late expression of CD40L. In addition,
CD28 signaling is not necessary for late phase CD40L expression
as recombinant IL-2 or an agonistic anti-CD40 mAb could
substitute for CD28 costimulation. Finally, in contrast to earlier
reports, we observe that down regulation of early CD40L
expression is not dependent upon interactions with CD40. These
findings are in marked contradistinction to what has been reported
in the mouse. Collectively, the data indicate that regulation of late
CD40L expression is likely a direct consequence of IL-2R
signaling. These results suggest that daclizumab, in combination
with agents that can block early CD40L expression, may be a
viable alternative to the use of anti-CD40L antibodies clinically.
OR-102. Prophylactic Administration of Abatacept
(CTLA4-Ig; BMS-188667) Prevents Disease Induction
and Bone Destruction in a Rat Model of
Collagen-Induced Arthritis.
C. Kliwinski,1 D. Kukral,1 J. Postelnek,1 B. Krishnan,1 L. Killar,1
S. Nadler,1 R. Townsend.1 1Discovery Immunology, Bristol-Myers
Squibb Pharmaceutical Research Institute, Princeton, NJ, USA.
Background and Objectives: Rheumatoid arthritis (RA) is an
autoreactive disease in which activated T cells play an important
role orchestrating the autoimmune responses giving rise to the
inflammatory cascade responsible for joint inflammation and bone
destruction. The CD28/B7 costimulatory pathway is critical for full
T cell activation and modulating this pathway has been shown to
inhibit T-cell activation leading to inhibition of these immune
responses. Abatacept modulates T cell activation by interfering
with the engagement of CD80/86 with CD28. Abatacept has been
shown to provide significant improvement in the signs and
symptoms of rheumatoid arthritis in a phase II trial. Here, we
examine the effect abatacept administration has on disease
induction, anti-collagen antibody production and bone destruction
in a rat model of collagen induced arthritis.
Methods: Female DA rats were immunized s.c. on day 0 with
300 ug of bovine type II collagen in incomplete FreundTs adjuvant
at the base of the tail. Immunized rats were administered either 1
mg/kg abatacept or a control human IgG IP on days-1, 0, 2, 4, 6, 8
and 10. Disease progression was monitored by measuring paw
volume in mls. with a plethysmometer. Both hind paws were
measured and the change in volume from base-line measurements
(Day 0) were recorded. At the conclusion of the study (day 27)
serum samples were collected from each animal for measurement
of collagen specific antibodies by ELISA as well as serum cytokine
measurements. Legs from the rats were removed and placed in
formalin and prepared for histological analysis as well as analysis
of bone morphology by micro CT.
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was observed in the IgG treated control animals and continued to
increase throughout the study until reaching a plateau (~ 3–3.5
mls.) on day 21. Administration of abatacept abrogated paw
swelling throughout the course of the study. The IgG treated rats
reached 100% incidence while no incidence was observed in the
abatacept treated group. Serum anti-collagen antibody levels
correlated well with the paw swelling data where abatacept
administration resulted in 90% inhibition of collagen specific
antibodies. We also found that abatacept decreased the expression
of many of the circulating cytokines and chemokines which were
upregulated in diseased animals. The micro-CT data revealed that
abatacept treatment protects the bone from destruction as the knees
and ankles of these rats appear to be normal.
Conclusion: Abatacept, a selective co-stimulation modulator
significantly inhibited the onset and progression of disease in a rat
CIA model. In these studies, paw swelling, collagen specific
antibodies and bone destruction were all inhibited by the treatment.
OR-103. Abatacept (CTLA4Ig) Modulates Human
T-Cell Proliferation and Cytokine Production but Does
Not Affect TNFA Production by Monocytes.
P. M. Davis,1 S. G. Nadler,1 K. A. Rouleau,1 S. J. Suchard.1
1Immunology and Inflammation Drug Discovery, Bristol-Myers
Squibb, Princeton, NJ, USA.
Background and Objectives: Activated T cells play a central
role in the inflammatory cascade leading to joint inflammation and
destruction characteristic of rheumatoid arthritis (RA). The
cytokines secreted by activated T cells can both initiate and
propagate the immunologically driven inflammation associated
with RA.
Abatacept, the first of a new class of agents that selectively
modulate the co-stimulatory signal required for full T-cell
activation, was evaluated in vitro for its ability to regulate human
T-cell proliferation and cytokine production. The effect of
abatacept on immune complex (IC)- or LPS-induced TNFa release
from monocytes was also evaluated to distinguish the impact of
abatacept on innate versus adaptive, antigen-specific responses.
Methods: T cells were isolated from normal healthy volunteers.
The effect of abatacept on antigen-dependent T-cell activation was
evaluated using either an irradiated human B-cell line (PM-LCL)
as the antigen-presenting cells (APCs) for a primary mixed
lymphocyte reaction (MLR), or autologous E-PBMCs as APCs,
for a recall response to tetanus toxin (TT). Cytokines were
measured at various times post activation, with proliferation
determined on day 5. Monocytes were isolated by elutriation,
challenged with LPS or ICs, and TNFa levels measured at 6 h. Chi
L6 was included as a nonspecific Ig fusion protein control.
Summary: Abatacept significantly down modulated T-cell
proliferation, in both primary and recall responses, at concen-
trations between 0.3 and100 Ag/ml, with maximal inhibition (~60–
80%) observed at ~3–10 Ag/ml. These concentrations are below the
abatacept trough plasma levels observed in patients receiving a
clinically effective dose.1 Under conditions of maximal inhibition
of proliferation, and similar to trough plasma levels in patients (30
Ag/ml), abatacept inhibited cytokine production in both primary
and TT-dependent recall responses. However, the extent and rank
order of cytokine inhibition by abatacept was markedly different
between these two responses. Specifically, inhibition of IL-2 N
TNFa N IFNg in a primary response whereas inhibition of IFNg z
IL-2, with a minimal effect on TNFa production in a TT recallresponse. In contrast, abatacept did not inhibit IC- or LPS-induced
TNFa production in human monocytes.
Conclusion: Abatacept, a selective co-stimulation modulator
significantly inhibited the activation (as measured by cytokine
production) and proliferation of human T cells in the context of
a primary MLR or TT-dependent memory response. This
inhibition occurred at concentrations below the serum Cmin
levels observed in patients receiving a clinically effective dose
of abatacept1 (10 mg/kg monthly), consistent with suppression
of T-cell activation in vivo. There was no effect of abatacept on
TNFa production in monocytes challenged with LPS or ICs
indicating that this agent may largely preserve innate immune
responses.
Reference:
1. Kremer JM, et al. NEJM 2003; 349:1907-1915.
OR-104. Essential Role of IL-10 in Restricting Immunity
during a Chronic Viral Infection.
Mette Ejrnaes, Matthias von Herrath. 1Immune Regulation Lab,
La Jolla Institute, San Diego, CA, USA.
Viruses use a variety of strategies to suppress the anti-viral
immune response leading to persistence in the host. Induction of
immune suppression is one of the mechanisms by which viruses
escape clearance and establish a persistent infection. The cytokine
IL-10 has immunomodulatory properties and can down-regulate
cellular immune responses by acting on APCs and T cells. To gain
further insight into the role of IL-10 during viral persistence we
studied lymphocytic choriomeningitis virus (LCMV) infection in
its natural host. The LCMV isolate Clone 13 establishes a
prolonged infection in Balb/c mice, which is associated with a
less effective antiviral immune response and, in some studies,
conditioning of dendritic cells. Results: Here, we report that a
significant amount of IL-10 is being generated by CD4+
lymphocytes and some classes of APCs during persistent LCMV
infection. Treatment with neutralizing IL-10R antibody on days 0,
7, and 14 post Clone 13 infection resulted in accelerated viral
clearance. This was associated with a numeric increase of total
spleen cells in comparison to non-treated mice and decreased
levels of IL-10 were generated by such splenocytes. Lastly, overall
clinical appearance was improved through this intervention as
reflected in an increase in bodyweight, healthy shiny coat, and
increase in physical activity. Conclusion: Our studies indicate that
in persistent viral infections IL-10 plays an essential role in
suppressing the anti-viral response and that systemic blockade can
improve the clinical outcome. A similar strategy might be
beneficial in other chronic infections associated with increased
IL-10 levels, for example hepatitis C virus infection.
This work was supported by an ADA mentor grant and a
program project grant from NIAID for Matthias von Herrath.
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OR-105. Effects of Natalizumab (anti-VLA-4 Antibody)
on Immune Cell Adhesion and Migration in Patients
with MS.
Masaaki Niino,1 Dawn Gano,1 Marie-Lune Simard,1 Alyson
Fournier,1 Manuela Trigueiro,1 Ho Jin Kim,1 Amit Bar-Or.1
1Department of Neurology, Montreal Neurological Institute,
Montreal, QC, Canada.
AbstractsS40Objective: (1) To establish biological dproof of conceptT that in
vivo anti-VLA-4 treatment of patients with multiple sclerosis (MS)
results in decreased functional VLA-4 expression and migratory
capacity of immune cells, and (2) Develop a simple in vitro assay
that could be applied to monitor therapeutic response.
Background: Natalizumab (TysabriR), a humanized mono-
clonal antibody directed against the adhesion molecule VLA-4, has
recently been approved for the treatment of patients with relapsing
remitting MS. It is presumed that beneficial effects in MS would be
based on binding of Natalizumab to VLA-4 on the surface of
circulating immune cells, thereby inhibiting their capacity to
migrate into the CNS. To date, the impact of in vivo therapy with
Natalizumab on the functional expression of VLA-4 on immune
cells of MS patients has not been reported. The development of a
simple assay to measure this effect could prove very useful in
immune monitoring of patients on this emerging therapy.
Design/Methods: Consenting patients participating in the
open-label phase of a clinical trial of Natalizumab in relapsing
remitting MS, provided venous blood immediately prior to (Pre-
infusion), and one hour following (Post-infusion), monthly
Natalizumab infusions (300mg IV). Levels of VLA-4 surface
expression on circulating immune cell subsets were assessed by
flow cytometry. The migratory capacity of immune cells was
evaluated in an established two-compartment Boyden chamber,
known to capture VLA-4 mediated migration of human immune
cells.
Results: We observed that expression of VLA-4 on circulating
immune cells was significantly reduced after in vivo Natalizumab
infusions (P = 0.004; n = 12). The effect was observed on all
immune cell subsets but was greatest on T cells compared to B
cells (P = 0.026) or monocytes (P = 0.032). In the functional assay,
migration of post-infusion immune cells was significantly
decreased compared to the migration of corresponding pre-infusion
cells (P = 0.026). The decrease in observed VLA-4 surface
expression correlated well with the decrease in migratory function
of the corresponding immune cells, following infusions (r =0.71;
p b0.05). We confirmed that the migration assay can be carried out
on frozen mononuclear cells (PBMC), providing a means for
monitoring patientsT responses over time. We plan to present a
batched analysis of prospectively collected samples from these
patients, which should provide insights into the kinetics and
stability of these in vivo effects.
Conclusions: Our study provides the first biological dproof of
conceptT that in vivo Natalizumab therapy results in diminished
VLA-4 functional expression and migratory capacity of circulating
immune cells. The ability to reproducibly capture this effect in a
relatively simple bioassay, and the validation that the assay can be
applied to frozen PBMC, could provide a useful means to monitor
patients on this promising therapy.
OR-106. Molecular Imaging of Adhesion Molecules in
Experimental Autoimmune Encephalomyelitis (EAE).
R. A. Linker,1,4 M. Reinhardt,2 M. Bendszus,3 G. Ladewig,4
P. Hauff,2 M. Maurer.4 1Institute for Multiple Sclerosis Research,
University of Goettingen and Gemeinnuetzige Hertie-Stiftung,
Goettingen, Germany; 2Ultrasound and New Modalities Research,
Schering AG, Berlin, Germany; 3Department of Neuroradiology,
Julius-Maximilians-University Wuerzburg, Wuerzburg, Germany;
4Clinical Research Group for Multiple Sclerosis, Department of
Neurology, Julius Maximilians-University Wuerzburg, Wuerzburg,
Germany.The infiltration of autoreactive T-cells into the central nervous
system (CNS) requires a complex molecular interplay between
immune cells and the blood brain barrier (BBB), especially
involving vascular cell adhesion molecule (VCAM) 1 and
intercellular adhesion molecule (ICAM) 1. We developed a new
ultrasound based approach for the quantification of ultrasound
contrast media in high concentrations, sensitive particle acoustic
quantification (SPAQ). By combination of SPAQ with specific gas-
filled microparticles (MP) targeted against VCAM and ICAM
(VCAM-MP, ICAM-MP), we aimed to monitor the molecular
changes at the blood-brain-barrier during the course of actively
induced or adoptively transferred (AT) myelin basic protein
(MBP)-EAE.
Ex vivo imaging of ICAM-1 expression in AT-EAE at the
disease maximum proved the high sensitivity, specificity and
spatial resolution of the method with the possibility of video-
densitometric quantification. These results could be reproduced in
vivo with a clear periventricular and cerebellar upregulation of
ICAM1 and VCAM1 expression at the maximum of AT-EAE
which could be suppressed by pretreatment of rats with cortico-
steroids (P b 0.008). The imaging results were confirmed by
parallel immunohistochemistry. Subsequent application of ICAM-
MP after ICAM-MP or VCAM-MP injection did not influence
follow-up measurements. Sequential imaging of ICAM-MP in vivo
over the course of active and AT MBP-EAE revealed a significant
upregulation of ICAM before the respective onset of disease (day 2
for AT-EAE, day 10 for active EAE). At that point of time no
signal changes were observed on T2-weighted magnetic resonance
images (MRI). Albumin staining for detection of BBB integrity
and gadolinium enhanced MRI after sonification did not reveal a
disturbance of the BBB thereby proving the safety of the method
in vivo.
Conclusion: Based on these data, molecular imaging of
adhesion molecules with SPAQ is a platform technology for
quantification of changes at the BBB in vivo with a sensitivity
superior to conventional MRI.
OR-107. Immunotherpy of Relapsing Experimental
Autoimmune Encephalomyelitis (EAE) by Neutralization
of CD4+ T Cell Chemoattractant Cytokine IL-16.
D. S. Skundric,1 R. Dai,1 R. P. Skoff,2 W. W. Cruikshank,3 Z.
Kurjakovic.1 1Neurology, Wayne State University School of
Medicine, Detroit, MI; 2Anatomy and Cell Biology, Wayne State
University School of Medicine, Detroit, MI; 3Pulmonary Center,
Boston University School of Medicine, Boston, MA.
Experimental autoimmune encephalomyelitis (EAE) is a CD4+
T cell mediated autoimmune disease. IL-16 is a CD4+ cell
chemoattractant cytokine. Infiltration of the CNS by CD4+ Th1
cells precedes onset and relapses of experimental autoimmune
encephalomyelitis (EAE). We reported that (B6  SJL) F1 (H-2b/s)
mice, with severe relapsing-remitting disease, had extensive
infiltration by CD4+ T cells compared to C57BL/6 (B6) (H-2b)
mice, which developed mild low-relapsing disease in response to
myelin oligodendrocyte peptide 35–55 (MOG35–55). This observa-
tion led us to search for mechanisms that specifically regulate
trafficking of CD4+ T cells in relapsing H-2b/s mice. In this report
we show that the CD4+ cell chemoattractant cytokine IL-16, has
an important role in regulation of relapsing EAE induced by
MOG35–55 in the (B6 SJL) F1, (H-2b/s) mice.We found production
of IL-16 within the CNS of mice with EAE. Levels of IL-16 in the
CNS correlated well with prominent infiltration by CD4+ Tcells and
Abstracts S41B cells during acute and relapsing disease. Infiltrating CD4+ Tcells,
and occassionaly CD8+ T cells and B cells contained IL-16
immunoreactivity. Pro- IL-16 (80 kD) and cleaved IL-16 (55 and
17 kD) were found in spinal cord of mice with active disease. During
remission IL-16 levels were significantly decreased. In relapsing
mice, CNS levels of IL-16 peaked and paralleled with activation of
caspase-3 and CD4+ T cell infiltration. We identified CD4+IL-
16+active-caspase-3+ T cells withn CNS infiltrates. IL-16 (55kD),
which co immuno-precipitated with CD4 coreceptor (CD4R), was
the most abundant form of IL-16 found during relapse. Our data
suggested that IL-16 was produced by infiltrating CD4+T cells
through caspase-3 dependent mechanism. It also indicated func-
tional relationship between IL-16 and CD4R, consistent with CD4R
specific chemoattractant properties of this cytokine. Based on these
observations, we treated EAE mice with IL-16 neutralizing anti-
body. Treatment with neutralizing anti-IL-16 antibody successfully
reversed paralysis and ameliorated relapsing disease. In treated
mice, diminished infiltration by CD4+ T cells, lesser demyelination
and more sparing of axons were observed. Taken together, we show
an important role for IL-16 in regulation of relapsing EAE. We
describe a novel therapeutic approach to specifically impede CD4+
T cell chemoattraction in EAE, based on IL-16 neutralization. Our
findings have high relevance for the development of new therapies
for relapsing EAE and potentially MS.
OR-108. High Resolution Dynamic Visualization of
Immune Cell Function In Vivo in Health and Disease.
R. N. Germain,1 Alex Y. Huang,1 H. Qi,1 M. Chieppa,1 J. Egen,1
F. Castellino,1 I. Ifrim,1 C. Scheinecker,1 K. Eichelberg,1
Z. Wang,1 S. Stoll.1 1Laboratory of Immunology, NIAID. NIH,
Bethesda, MD, USA.
Immune responses involve multiple cell-cell interactions. We
have used explant and intravital confocal or multiphoton micro-
scopy to collect 4D (XYZ and time) data on the interactions of
antigen (Ag)-specific T cells with each other and with Ag-bearing
dendritic cells (DC) in an intact lymph node (LN). Some naRve T
cells move rapidly in the absence of Ag but show prolonged
adherence to Ag-bearing DC, accompanied by immunological
synapse formation. Activation and detachment from the antigen-
bearing DC follows, along with cell division. These data suggest
that T cell activation follows from prolonged lymphocyte
association with individual antigen-bearing DC rather than
summation of signals from brief encounters with such presenting
cells. CD4 and CD8 T cells associate with a single DC when both
antigens are present and direct CD4-CD8 T cell contact is also
seen. Formation of these clusters appears to be non-random in
nature. Rapid movement of DC dendrites is readily visualized, as is
T-DC contact through these processes, followed by movement of
the T cell towards the DC body. Quantitative analysis suggests an
impact of self-MHC recognition on the time of naRve T cell-DC
interaction. Intravital methods have permitted visualization of DC
migration into LN and the egress of lymphocytes from HEV for
initial contact with DC. Fluorescent reporter constructs (e.g., EGFP
under the control of the IL-2 promoter) are revealing the
consequences of T-DC interactions in real time within LN and
fluorescent chimeric proteins are being used to track redistribution
of key proteins during cell movement and interaction. Differential
migratory behavior of lymphocytes and DC in distinct regions of
the lymph node has been observed, as has the failure of rapidly
moving T and B lymphocytes to cross rather strict borders between
the T cell zone and B cell follicle. DC distribution and function arebeing examined in non-lymphoid tissues such as liver (under
steady-state conditions and during inflammation) and kidney. The
behavior of subepithelial DC in the small bowel has been
visualized under steady-state conditions and following infection
with Salmonella, which elicits and active protrusion response from
the DC. These studies are contributing to a more accurate picture of
the molecular, cellular, spatial, and temporal aspects of cell
interaction and signaling events in host immune responses.
OR-109. Migration Matters: Regulatory T Cell
Compartmentalization Determines Suppressive Activity
In Vivo.
K. Siegmund,1 M. Feuerer,1 A. Hamann,1 J. Huehn.1
1Experimental Rheumatology, Charite Universitaetsmedizin
Berlin, Berlin, Germany.
Regulatory T cells (Tregs) have fundamental functions for
suppression of immune responses, however, the compartments at
which they exert their suppressive functions in vivo are not known.
The integrin aEh7 unravels a fundamental dichotomy between
naive-like and effector/memory-like CD4+ Tregs, where only the
latter are capable of suppressing Th1-mediated inflammatory
immune responses. Strikingly, suppressive action of aE
+ Tregs is
completely dependent on their inflammation-seeking capacity:
Tregs from fucosyltransferase-deficient animals, which lack
selectin-ligands and fail to migrate into inflamed sites are unable
to mediate suppression. In contrast, naive-like aE-CD25
+ Tregs,
which show an enhanced recirculation through lymph nodes, are
more efficient in preventing priming of naive CD4+ T cells. These
findings provide first conclusive evidence that appropriate local-
ization is crucial for in vivo activity of Tregs.
OR-110. The Anti-Inflammatory Action of Methotrexate
Is Not Mediated by Lymphocyte Apoptosis, but by the
Suppression of Activation and Adhesion Molecules.
A. Johnston,1 J. E. Gudjonsson,1 H. Sigmundsdottir,1 B. R.
Ludviksson,1 H. Validimarsson.1 1Department of Immunology,
Landspitali University Hospital, Reykjavik, Iceland.
Low-dose methotrexate (MTX) is an established and highly
effective treatment for severe psoriasis and rheumatoid arthritis;
however, its mechanism of action remains unclear. When used for
the treatment of psoriasis, MTX was thought to act directly
against the epidermal hyperproliferation, however, the poor
efficacy of locally administered MTX and the effectiveness of
agents that target T cells strongly suggest that the anti-proliferative
effect of MTX is not responsible for its efficacy in psoriasis.
Therefore, we investigated the effects of low-dose MTX on T cells
and explored through which cellular pathways these effects are
mediated.
Peripheral blood mononuclear cells were isolated and stimu-
lated with streptococcal antigens, superantigens or the mitogen
PHA in the presence of 0–10 mM MTX. T cell expression of
adhesion molecules and activation markers, and the amount of T
cell apoptosis in cultures, were determined flow cytometrically.
The folate- and adenosine-dependent pathways of MTX action
were manipulated using specific agonists and antagonists.
We show that MTX caused a dose-dependent suppression of T
cell activation and adhesion molecule expression, and this was not
due to T cell apoptosis. The suppression of intercellular adhesion
molecule (ICAM)-1 was adenosine and folate-dependent, while
MTX suppression of the skin-homing cutaneous lymphocyte-
associated antigen (CLA) was adenosine-independent. The effect
AbstractsS42of MTX on CLA, but not ICAM-1, required the constant presence
of MTX in cultures.
The suppression of T cell activation and T cell adhesion
molecule expression, rather than apoptosis, mediated in part by
adenosine or polyglutamated MTX, or both, are important
mechanisms in the anti-inflammatory action of MTX.
OR-111. Conditional Deletion of Alpha (v) Integrins
Causes Inflammatory Bowel Disease.
A. Lacy-Hulbert,1,2 J. McCarty,1 J. S. Savill,2 J. T. Roes,3
R. O. Hynes.1 1Center for Cancer Research, Massachusetts
Institute of Technology, Cambridge, MA, USA; 2Centre for
Inflammation Research, University of Edinburgh, Edinburgh,
Scotland, United Kingdom; 3Windeyer Institute, University
College London, London, United Kingdom.
Integrins are heterodimeric transmembrane proteins that regulate
cell-cell and cell-matrix interactions. The alpha (v) containing
integrins represent a major family of RGD-binding integrins, and
have been shown to have important roles in angiogenesis, tumori-
genesis, neural development and wound healing. Alpha (v) beta (3)
is expressed by many immune cells and surface expression is
highest in tissue resident cells such as gy T cells and B1 B cells.
Various alpha (v) integrins are expressed by monocytes, macro-
phages and DCs, and have been shown by antibody blockade to
regulate monocyte transmigration and phagocytosis of apoptotic
cells by macrophages and DCs. However definitive in vivo studies
of the role of alpha (v) in the immune system have been limited by
the lethality of alpha (v) knockout mice. Here we describe the
generation of conditional knockout mice to study the role of these
adhesion molecules as regulators of leukocyte function. Conditional
deletion of alpha (v) using mice expressing CRE from the Tie2
promoter generated mice lacking alpha (v) in endothelial cells and
all hematopoietic cells. Although these mice appeared normal at
birth, they developed signs of chronic disease and weight loss
beginning at 8 weeks, which progressed such that 75% of
experimental animals had died by 40 weeks. Pathological exami-
nations revealed that the mice had developed spontaneous trans-
mural gastro-intestinal (GI) and respiratory tract inflammation,
ulceration and epithelial cell hyperplasia. These histological
findings, in combination with the clinical observations of wasting
and GI obstruction are consistent with chronic progressive
inflammatory bowel disease (IBD). To further define this phenotype
we have selectively deleted alpha (v) in specific leukocyte
compartments and our results suggest that alpha (v) integrins
regulate both cell migration and cell responses to pathogen derived
ligands. In conclusion these data demonstrate that alpha (v) plays an
essential role in regulating immune homeostasis in the GI and
respiratory tracts, and that deletion of alpha(v) generates a new
model of spontaneous, chronic IBD. We therefore propose a novel
function for alpha (v) integrins in the normal regulation of
inflammatory responses and immune homeostasis.
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OR-112. Phenotype of Cytokine Expressing Cells in
Peanut Allergen-Primed Mice.
P. A. Wachholz,1 R. J. Dearman,1 I. Kimber.1 1Immunology,
Syngenta Central Toxicology Laboratory, Macclesfield, United
Kingdom.Food allergy is a significant health problem, particularly in
Western countries. In the UK and the USA, peanuts are a common
cause of food allergy, associated usually with high titer IgE
antibody and consistent with the preferential activation of T helper
(Th) 2 type cells. Using high IgE responder BALB/c strain mice,
we have previously shown that sensitization with peanut lectin (a
minor peanut allergen) is associated with an increase in allergen-
specific IgE and changes in cytokine protein and mRNA
expression indicative of a selective Th2 type response, with
elevated levels of IL-4, but not IFN-g, cytokine expression. Here
we have used flow cytometric analyses of intracellular cytokine
expression patterns to determine the relative contributions of CD4
and CD8 T lymphocytes to the immune phenotype that develops
following exposure to peanut lectin.
Methods: Mice were immunized by intradermal injection of
1mg/ml peanut lectin. Fourteen days following the initiation of
exposure, draining auricular lymph nodes were excised and a
single cell suspension prepared. Draining lymph node cells from
peanut primed or naive mice were labeled with carboxyfluoresein
succinimidyl ester (CFSE) to identify proliferating cells, and
restimulated in vitro with peanut lectin or with the T cell mitogen
concanavalin A (con A) for various periods of time. Cells were
stained with fluorescently-labeled anti-CD8 or -CD4 antibodies
and following saponin permeabilization with fluorescently-labeled
anti-cytokine antibodies.
Results: In vitro stimulation of peanut-primed cells with peanut
lectin or con A induced proliferation of CD4 and CD8 cells from
48–120 hrs. In contrast, cells from naRve mice responded only to
con A. Moreover, allergen-specific CD4 cells expressed a Th2
profile with increased frequencies of IL-4 (6.3%) and IL-10 (5.9%)
and relatively low levels of IFN-g (0.9%) positive cells compare
with unstimulated controls or with cells cultured with con A, after
96 hrs in culture. CD8 cells displayed a Tc1 phenotype with high
levels of IFN-g (6.5%) positive cells but few IL-4 (0.7%) and IL-
10 (1.3%) positive cells regardless of whether restimulation was
with con A or allergen.
Conclusion: These data suggest that CD4, rather than CD8, T
lymphocytes are skewed towards a selective type 2 cytokine
phenotype in a mouse model of peanut allergy.
OR-113. Foxp3+ Regulatory T Cells can be Induced
from CD4+CD25- TGFB Transgenic Cells and are able
to Condition Dendritic Cells to Suppress Naı¨ve T Cells.
Y. Carrier,1 J. Yuan,1 H. L. Weiner.1 1Center for Neurologic
Diseases, Brigham and WomenTs Hospital, Boston, MA, USA.
TGFh is a highly conserved multifunctional cytokine that has
diverse regulatory roles in the immune system. Regulatory T cells
that secrete TGFh and variable amounts of IL-4 and IL-10, termed
Th3, can be induced by oral administration of myelin proteins and
mediate recovery from EAE. Little is known about the differ-
entiation, phenotype and function of these cells. We created an
inducible TGFh-1 transgenic (Tg) mouse model in which TGFh is
linked to the IL-2 promoter and thus allows tissue specific
expression of TGFh upon TCR stimulation. We found that antigen
specific stimulation of naRve peripheral CD4+CD25- T cells from
TGFh Tg mice induces Foxp3-expressing Th3 cells that are
hyporesponsive and that have potent suppressive activities in vitro
and in vivo. TGFh Tg cells do not secrete IL-2, IFN-g, IL-13 or
IL-10. Early expression of TGFh, not IL-4 or IL-10, is critical for
the differentiation of Th3 cells. In a MOG peptide TCR Tg
adoptive transfer model, Th3 cells from TGFh Tg mice not only
Abstracts S43prevented the generation of pathogenic Th1 cells in wild type
animals before the induction of EAE, but also greatly inhibited the
effector functions if transferred at the time of disease onset. Using a
two-step in vitro culture system, we found that antigen-presenting
dendritic cells can act as dtemporal bridgesT to relay the inhibitory
signal from Th3 cells to naive CD4 T cells. Furthermore, Th3 cells
inhibit the T cell induced up-regulation of CD80/CD86 co-
stimulatory signals during activation but not the maturation. Thus,
the suppression by Th3 cells is mediated by mature dendritic cells
with altered antigen-presenting function.
OR-114. Atorvastatin Prevents the Th1 Differentiation
of Myelin-Reactive T Cells during EAE by Interfering
with the Prenylation of Ras and the Activation of ERK.
S. E. Dunn,1 S. Youssef,1 M. J. Goldstein,1 T. PrudThomme,2
M. Weber,2 S. S. Zamvil,2 L. Steinman.1 1Department of Neurology
and Neurological Sciences, Stanford University, Stanford, CA,
USA; 2Department of Neurology, University of California San
Francisco, San Francisco, CA, USA.
Previously, we showed that treatment with the HMG-CoA
reductase inhibitor Atorvastatin (AT) prevented the Th1 differ-
entiation of myelin-reactive T cells and ameliorated clinical
symptoms in mice with experimental autoimmune encephalomye-
litis (EAE) (Youssef et al., Nature 420: 78, 2002). HMG-CoA
reductase is a critical enzyme in the mevalonate biosynthetic
pathway that generates not only cholesterol, but also isoprenoid
derivatives that function to attach certain signaling proteins and
ubiquinone to cell membranes. The aim of the present study was to
distinguish which of these pathway intermediates have a regulatory
function in Th1 differentiation during the development of EAE.
Here, we provide first-time evidence that oral administration of AT
induces a Th2 bias CD4+ cells by compromising the production of
the isoprenoid lipids farnesyl-pyrophosphate (-PP) and geranylger-
anyl-PP. In vivo depletion of these metabolic precursors by AT
caused a transient (i.e., 4–12 h/d) redistribution of farnesylated Ras
and geranylgeranylated RhoA GTPases from the membrane to the
cytosol of T cells. This was accompanied by a reduction in the
phosphorylation of ERK and the DNA binding of c-fos in response
to T cell receptor activation. We also show that selective inhibition
of the ERK pathway with the MEK inhibitor PD98059 shifted the
balance in T cell cytokine production towards Th2. Since ERK
activation has been shown to be required for transactivation of
IFN-g and for repression of the IL-4 promoter (Jorritsma et al., J.
Immunol. 170: 2427, 2003), these results thus explain why CD4+
cells undergo Th2 differentiation when activated by antigen in the
presence of AT.
OR-115. Regulation of T Cell Differentiation by
IL-4RA-Chain Single Nucleotide Polymorphisms.
A. Skapenko,1 I. Prots,1 S. Mattyasovszky,1 C. L. Yone,1
J. R. Kalden,1 H. Schulze-Koops.1 1Nikolaus Fiebiger Center for
Molecular Medicine, University of Erlangen, Erlangen, Germany.
Chronic inflammation in rheumatoid arthritis (RA) is mediated
by repeatedly activated pro-inflammatory Th1 cells. In contrast,
Th2 cells that might down-modulate the chronic autoimmune
response are rarely found in RA. It has been previously
documented that RA T cells are severely impaired in their ability
to differentiate into Th2 effectors while exerting enhanced Th1
differentiation. The mechanisms underlying this functional abnor-
mality, however, have not been delineated. As interleukin-4 (IL-4)
is a most critical determinant in regulating immune responses bypromoting Th2 cell development and inhibiting Th1 cell differ-
entiation, we analyzed the role of single nucleotide polymorphisms
(SNP) in the IL-4 receptor a-chain, which is critical for binding of
IL-4 and for IL-4 signal transduction, in the differentiation of
human T cells. 361 healthy individuals were genotyped by allele
specific PCR for the two IL-4R a-chain SNPs that are located in
functionally important regions of the IL-4R a-chain-the I50V
SNP50 and the Q551R SNP551 in the IL-4-binding and STAT6-
binding domains, respectively. Naive and memory CD4 positive
T cells were isolated from the peripheral blood of individuals
who were homozygous for either allele at SNP50 and SNP551,
and primed for five days with mAbs to CD28 and/or CD3 in the
presence or absence of exogenous IL-4. The phenotype of the
resulting differentiated effector cells was then analyzed by flow
cytometric analysis of cytoplasmic cytokines. The SNP551 alleles
did not affect T cell differentiation. In contrast, the inhibitory
effect of IL-4 on Th1 cell differentiation was significantly
diminished in CD4 T cells that were homozygous for the mutant
allele at SNP50 (50V) as compared to those with the wild type
allele (I50). Likewise, the augmenting effect of IL-4 on Th2 cell
differentiation was enhanced on T cells that were homozygous for
the wild type allele as compared to T cells expressing the mutant
allele. These data indicate that the mutant allele of the IL-4R a-
chain at SNP50 is associated with a decreased T cell response to
IL-4. To delineate a potential mechanism of different responses to
IL-4 in the cells expressing different alleles of the IL-4R, T cells
form individuals who were homozygous for either the wildtype or
the mutant allele at SNP50 were primed with different concen-
trations of IL-4 and analyzed by flow cytometry for STAT6 and
phosphorylated STAT6. Whereas STAT6 concentrations were not
different between T cell expressing I50 or V50, STAT6
phosphorylation in response to IL-4 stimulation was significantly
reduced in T cells expressing the V50 allele compared to T cells
expressing I50. Thus, the V50 SNP50 allele of the IL-4R a-chain
might regulate T cell differentiation by diminishing T cell
responses to IL-4, resulting in reduced STAT-6 phosphorylation
and subsequently in diminished Th2 cell differentiation. The V50
SNP50 allele might thereby contribute to the development of
unbalanced Th subset activation, as characteristic for autoimmune
diseases, such as RA.
OR-116-Diverging Roles for the IL-12 Family in T Cell
Immunity: IL-12 and IL-27-EBI3 Have Similar
Contributions to Pathogen Responses While
IL-23 Is Unique to Certain Autoimmune Pathways.
Jacqueline M. Benson,1 Yevgeniya I. Orlovsky,1 Tayseer
Ghazzouli,1 Mark R. Cunningham,1 Kimberly A. Shamberger,1
Mark A. Schneider,1 Patricia A. Rafferty,1 Peter J. Bugelski,1
Don E. Griswold,1 M. L. Mbow.1 1Discovery Research, Centocor,
Inc, Radnor, PA, USA.
The IL-12 cytokine family (consisting of IL-12, IL-23, and IL-
27) is proposed to mediate Th1 immune responses. Therefore, we
utilized subunit-specific neutralizing monoclonal antibodies or
genetic knockout mice to distinguish the individual contributions
of IL-12, IL-23, and IL-27 in established murine models of Th1
autoimmunity and pathogen responses, namely experimental
autoimmune encephalomyelitis (EAE) and Leishmania major
infection. Specific neutralization of IL-12p35, or mice genetically
deficient in IL-27-EBI3 demonstrated no protection from the
incidence or severity of EAE. However, they each exhibited
transient susceptibility to L. major infection as demonstrated by
AbstractsS44increased lesion size. These data suggest that IL-12 and IL-27-
EBI3 each contribute to L. major immunity, although they are not
required for EAE. In contrast, specific in vivo neutralization of IL-
23 provided significant and long-lasting therapy of EAE when
antibodies were administered prior to disease induction or onset, or
during established EAE. Anti-IL-23 suppressed central nervous
system inflammation and pathology even though antigen-specific
proliferation and cytokine re-stimulation responses were not
influenced by in vivo antibody treatment. FACS analysis demon-
strated that in vivo IL-23 neutralization preserved a more naive
(CD62Lhi, CD45RBhi, CD69lo) CD4+ T cell phenotype. Thus, IL-
23 appears to participate in the in vivo activation and/or trafficking
of encephalitogenic T cells. Mice treated with IL-23 specific
neutralizing antibodies maintained their protective T cell immunity
to L. major infection. Thus, despite its critical role in EAE, IL-23
does not appear to contribute to effective L. major resistance.
Overall, IL-12 and IL-27-EBI3 seem to be more closely related in
function than IL-23. Further investigation will likely continue to
delineate the roles of IL-12, IL-23, and IL-27 in autoimmune
disease and pathogen immunity.
OR-117. IL-4 Can Be a Key Positive Regulator of
Inflammatory Arthritis.
Koichiro Ohmura,1,2 Linh T. Nguyen,1 Richard M. Locksley,3
Christophe Benoist,1 Diane Mathis.1 1Immunology and
Immunogenetics, Joslin Diabetes Center, Harvard Medical
School, Boston, MA, USA; 2Internal Medicine, Dohgo Spa
Hospital, Center for Rheumatic Diseases, Matsuyama, Ehime,
Japan; 3Medicine, UCSF, San Francisco, CA, USA.
Objective: Development of arthritis in the K/BxN mouse model
is dependent on the induction of very high titers of antibodies
(Abs) against the glycolytic enzyme glucose-6-phosphate isomer-
ase, or GPI, promoted by CD4+ T cells expressing a transgene-
encoded T cell receptor (TCR) specific for GPI. Our goal was to
determine whether this unusually strong autoAb response, pre-
sumably reflecting unusually potent help, depends on T cell
differentiation to the T helper (Th)1 or Th2 phenotype. The answer
to this question might generate important insights into human
arthritides, such as rheumatoid arthritis (RA), associated with the
production of autoAbs.
Methods: The roles of cytokines known to control Th
phenotype were investigated by introducing the interleukin
(IL)-4 and IL-12p35 knockout mutations into the K/BxN model,
and evaluating the impact of these deficiencies on clinical
arthritis, autoAb production and T cell activation. The IL-4-
expressing cell-types in KBxN mice were revealed by crossing
in a knock-in alteration resulting in green fluorescence protein
(GFP) expression controlled by endogenous IL-4 gene regula-
tory elements. Transfer experiments permitted the identification
of the IL-4-producing cell-type required for arthritis develop-
ment. Finally, quantitative RT-PCR allowed determination of the
cytokine profile of K/BxN T cells.
Results: While IL-12p35 appeared dispensable for the develop-
ment of arthritis, IL-4 was crucial for full disease development. IL-
4-deficient K/BxN mice had greatly reduced titers of anti-GPI Ab.
The GPI-reactive TCR of standard K/BxN mice induced the
transcriptional activation of the IL-4 locus in CD4+ T cells and in
CD11b+ eosinophils. Yet, K/BxN arthritis is not a pure Th2
disease, as both Th1- and Th2-type cytokines were upregulated in
K/BxN T cells, and the expression pattern of several cytokines in
K/BxN T cells did not match that of conventional Th2 cells.Conclusion: IL-4 is crucial for the development of anti-GPI-Ab-
mediated arthritis in the K/BxN mouse model. However, the
cytokine profile of initiating anti-GPI T cells does not fit that of a
classical Th2 disease. The potential for IL-4 to promote the
development of inflammatory arthritis should raise caution over
proposed therapies for RA aimed at biasing T cells towards IL-4
production.
OR-118. IL-12/23-Deficient Genotype Reveals Two
Distinct Pathways Leading to Arthritis in Mice.
H. Hess.1 1Molecular Pharmacology and Physiology, Biogen Inc.,
Cambridge, MA, USA.
Collagen-induced arthritis (CIA) is an inflammatory joint disease
in rodents. Its etiology involves pathogenic autoimmune responses,
which are provoked by immunization with collagen type II (CII)
together with adjuvant. Mycobacteria, as part of complete FreundTs
adjuvant (CFA), are potent inducers for IL-12 production by
macrophages and DC. IL-12 is a key cytokine that instructs naive
T cells, upon activation, to differentiate along the T helper type 1
(Th1)-pathway. CIA, like RA, claims to be regarded as a
predominantly Th1-type autoimmune disease. However, as disease
progresses, certain Th2-type features become detectable. It appears
that CIA and perhaps RA are mixed type immune responses.
A recently described heterodimeric cytokine, IL-23, shares the
p40 subunit with IL-12. Both cytokines are implicated in either
initiating or sustaining Th1-type responses. Initial studies have
shown that CIA development in IL-12/23p40-ko mice is markedly
reduced. We have extended these studies and found that, provided
that IL-12/23p40-deficient mice had been sensitized with pristane
prior to priming with CII, severe CIA develops at 95% incidence.
When pristane sensitization precedes CII/adjuvant immuniza-
tion, mycobacteria become dispensable for CIA induction. CIA
incidence and severity in wild-type mice immunized with CII is
comparable to the disease observed in pristane-sensitized IL-12/
23p40-K/O mice. Notebly, in wild-type mice, repetitive immuni-
zation with CFA can substitute for the requirement of pristane-
sensitization to maximize CIA severity. IL-12/23-deficient mice do
not respond to this provocation with significant CIA development.
Taken together, the data suggest that pristane triggers an IL-12/23-
independent pathway capable of enhancing the auto-immunogenic
stimulus set by CII. Finally, it appears that both, IL-12 and IL-23
are sufficient, but not necessary to trigger severe arthritis.
OR-119. Systemic Onset Juvenile Idiopathic Arthritis Is
an IL-1 Mediated Disease.
F. Allantaz, E. Arce, M. Punaro, J. Banchereau, V. Pascual.
1Baylor Institute for Immunology Research, Baylor Institute for
Immunology Research, Dallas, TX, USA.
BACKGROUND. Systemic Onset Juvenile Idiopathic Arthritis
(SOJIA) remains an enigmatic pediatric rheumatic disease. Most
patients require systemic corticosteroids for prolonged periods to
control the systemic manifestations, and half the patients develop
chronic arthritis that is difficult to control even with methotrexate
and anti-TNF agents. The IL-1 antagonist Anakinra is partially
effective in the treatment of inflammatory chronic arthritis, but it has
not been evaluated in SOJIA patients with systemic symptoms.
METHODS. Healthy PBMCs were incubated with the serum of
SOJIA patients. Changes in gene transcription were assessed using
oligonucleotide microarrays and real-time PCR. Genes whose
expression was most significantly altered were identified and
analyzed in the PBMCs of 16 SOJIA patients and 12 healthy
Abstracts S45controls. Additionally, we have performed global gene expression
analysis using blood PBMC RNA from 31 SOJIA patients to
hybridize Affymetrix U133 gene arrays. One third of the patients
were in remission, one third had systemic symptoms and the
remaining one third had polyarticular arthritis with no systemic
involvement at the time of analysis. We also compared the gene
expression of these patients to children with systemic infections.
PBMCs from healthy controls and SOJIA patients were exposed in
vitro to PMA/Ionomycin to assess their cytokine secretion capacity.
Twelve SOJIA patients were treated with Anakinra for 2–16months.
RESULTS. SOJIA serum increased the transcription of IL-1a,
IL-1b and other innate immunity genes. Several of these genes were
upregulated in vivo in the PBMCs of SOJIA patients. PMA induced
the release of IL-1b from the PBMCs of SOJIA patients but not
from healthy PBMCs. Treatment of 12 SOJIA patients during the
systemic and/or arthritic phase of the disease with Anakinra for a
period of 2–16 months induced complete disease remission in 9/12
patients and a partial response in the remaining 3 patients.
CONCLUSION. SOJIA patients show a dysregulated IL-1
production and IL-1Ra is an effective treatment for this disease.
Development of Immune Based Therapeutics
10:30 AM–12:30 PM, 5/16/2005
OR-120. A High Affinity, Soluble T Cell Receptor for
Targeting Tumours Expressing NY-ESO and HLA-A2.
R. Ashfield.1 1Research, Avidex Ltd, Abingdon, Oxfordshire,
United Kingdom.
Human tumours over-express a variety of TAAs (Tumour
Associated Antigens), which are either absent or expressed at low
levels in normal tissues. Peptides derived from TAAs are presented
on the surface of tumour cells by Class I HLA molecules, and
represent targets for cytotoxic or immunotherapeutic anti-cancer
agents. NY-ESO is a TAA of unknown function, over-expressed in a
number of tumour types, including melanoma and bladder. We have
generated a soluble TCR (T Cell Receptor) specific for an NY-ESO
peptide presented by HLA-A2. The TCR lacks transmembrane
domains and is stabilised by a novel disulphide bond; it is expressed
in E. coli as separate a and h chains, and refolded from inclusion
bodies. The natural affinity of the TCR is 24AM; in order to generate
a molecule suitable for targeting tumours, the TCR was affinity
matured using phage display technology. The TCR variant used in
subsequent studies is estimated to have an affinity of 20pM by
BIAcore analysis, and a half life on the HLA complex of 19 hours; it
is highly specific for HLA A2-NY-ESO. We show data to
demonstrate that the TCR binds specifically to NY-ESO peptide
pulsed cells (by FACS analysis), and also that it targets tumour cells
expressing NY-ESO, by fluorescence microscopy. Furthermore, the
TCR specifically inhibits activation of a Tcell clone byNY-ESO+ve
tumour cells, measured by INFg ELISPOT. Immune activators,
including cytokines, have been fused to the TCRh chain C terminus;
these fusion proteins are suitable for development as immunother-
apeutic agents, to treat NY-ESO +ve tumours.
Immundiagnostic Disease Predictors
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OR-121. GAD65- and Proinsulin-Specific CD4+ T-Cells
Detected by MHC Class II Tetramers in the PeripheralBlood of Type 1 Diabetic Patients and Prediabetic
Subjects.
V. Oling,1,2 J. Marttila,1,2 J. Ilonen,1,2 M. Knip,1,3 O. Simell,1,2
W. Kwok,4 H. Reijonen.4 1JDRF Center for Prevention of Type 1
Diabetes in Finland, Finland; 2Department of Virology, University
of Turku, Turku, Finland; 3Hospital for Children and Adolescents,
University of Helsinki, Helsinki, Finland; 4Benaroya Research
Institute, Seattle, USA.
In type 1 diabetes the major loss of insulin producing beta cells
is caused by autoreactive T-cells specific for antigens expressed by
the pancreatic islets. Autoantibodies to insulin and glutamate
decarboxylase 65 (GAD65) are strongly associated with type 1
diabetes. In this study we have analyzed the prevalence of
GAD65- and proinsulin-specific CD4+ T-cells in type 1 diabetic
patients, prediabetic subjects (positive for two or more autoanti-
bodies) and in HLA-genotype matched islet-cell autoantibody
(ICA) negative healthy children. Peripheral blood mononuclear
cells, from DRB1*0401, 0404 or 0301 positive children in these
three study groups, were cultured in the presence of two different
GAD65 peptides (557I; aa 555–567 and aa 274–286) or with a
proinsulin (aa 24–36) peptide for 10–11 days. Thereafter the cells
were restimulated with MHC class II monomers for 3 days. The
monomers contained the same peptides as used in the primary
stimulation. Binding of CD4+ T-cells to GAD65 or proinsulin-
containing MHC class II tetramers was analyzed by flow
cytometry. Our results show that 11 of 18 (61%) type 1 diabetic
patients and 7 of the 20 (35%) prediabetic subjects were positive
for one of the GAD65 or proinsulin-containing tetramers, whereas
only 3 of 23 (13%) ICA negative healthy controls had tetramer
binding cells. The difference between type 1 diabetic patients and
healthy controls was statistically significant (P = 0.004, Chi-
square test). The frequency of tetramer positive cells in the
GAD65 or proinsulin activated CD4high/CD25+ cells was higher
in type 1 diabetic patients (0.00–9.19%) and in prediabetic
subjects (0.00–53.60%) than in control subjects (0.00–2.84%)
(P = 0.01 and P = 0.03 for respectively study group, Mann-
Whitney U-test). In conclusion, type 1 diabetic patients and
prediabetic subjects have a higher prevalence of GAD65- and
proinsulin-specific CD4+ T-cells than HLA-genotype matched
healthy controls.
Poster Session 1
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Allergy/Asthma
F1.01. Prevalence of Aeroallergens in Allergic Rhinitis.
Mohammad Amin Kashef,1 Sara Kashef,2 Fardin Eghtedari.3
1Allergy Research Center, Shiraz University of Medical Sciences,
Shiraz, Fars, Islamic Republic of Iran; 2Immunology and Allergy,
Shiraz University of Medical Sciences, Shiraz, Fars, Islamic
Republic of Iran; 3Otolaryngology, Shiraz University of Medical
Sciences, Shiraz, Fars, Islamic Republic of Iran.
Background: Allergic rhinitis is an extremely common disease
world wide. Aeroallergens are very often involved in allergic
rhinitis and their prevalence may vary in different regions. The
causative allergens of allergic rhinitis in our area are uncertain.
Objectives: The purpose of this study was to determine the
aeroallergens which are prevalent in patients with allergic rhinitis
in Shiraz. Methods: A total of 212 patients who were referred to
Motahhari Allergy Clinic with chronic rhinitis were submitted to
AbstractsS46skin prick test (SPT) with a series of common allergenic extracts
including grasses, weeds, trees, house dust mites and moulds.
Results: 132 subjects (62.2%) had positive SPT to at least one
aeroallergen. Male to female ratio was 1.2 and mean age was 18.2
years. The prevalence rates for allergen groups were: pollens
(92.4%), mites (22.7%) and moulds (8.3%). Among 122 patients
reactive to pollens, 92 (75.4%) showed skin reactivity to weeds, 78
(63.9%) to grasses and 68 (55.7%) to trees. Polysensitization was
common, with 75.7% of all sensitized patients positive to more
than one aeroallergen.
F1.02. Modulation of Immunological Functions of Mast
Cells by Heat Shock.
E. Mortaz, F. A. Redegeld, M. W. Heijden, F. P. Nijkamp,
H. R. Wong, F. Engels. 1Dept. Pharmacology & Pathophysiology,
Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht,
Netherlands; 2Dept. Pharmacology & Pathophysiology, Institute
for Pharmaceutical Sciences (UIPS), Utrecht, Netherlands; 3Dept.
Pharmacology & Pathophysiology, Institute for Pharmaceutical
Sciences (UIPS), Utrecht, Netherlands; 4Dept. Pharmacology &
Pathophysiology, Institute for Pharmaceutical Sciences (UIPS),
Utrecht, Netherlands; 5Critical Care, Division of Critical Care
Medicine, ChildrenTs Hospital Medical Center and ChildrenTs
Hospital, Cincinnati, OH, USA; 6Dept. Pharmacology &
Pathophysiology, Institute for Pharmaceutical Sciences (UIPS),
Utrecht, Netherlands.
Mast cells play pivotal roles in immediate-type and inflamma-
tory allergic reactions that can result in asthma. Cross-linking of
the high-affinity receptor for IgE (FcRI) on mast cells activates a
signaling pathway leading to Ca 2+ mobilization and is followed
by degranulation and the release of histamine and other preformed
mediators, as well as de novo synthesis of the arachidonic acid
metabolites i.e leukotrienes, and prostaglandins. To investigate
possible effects of heat shock on immunologic functions of bone
marorow derived mast cells (BMMC), we studied degranulation
and leukotrien production.
We found that heat shock inhibits degranulation of BMMC
without effects on leukotriene production. To further elucidate the
mechanism of suppression of degranulation, we studied the effects of
heat shock on calcium influx and tyrosine phosphorylation. We
found that heat shock inhibits calcium influx and tyrosine
phosphorylation of Syk and SHIP. Since degranulation of mast cells
play a role in allergic and non-allergic reactions our findingmay have
a relevance with respect to protective effects of heat shock response.
F1.03. Naive CD4+ T Cell Activation by
Antigen-Presenting Airway Eosinophils.
H. Wang,1 P. F. Weller.1 1Division of Allergy and Inflammation,
Beth Israel Deaconess Medical Center, Harvard Medical School,
Boston, MA, USA.
In addition to the conventional beffectorQ functions of eosino-
phils, evidence that eosinophils function as antigen-presenting cells
(APCs) has been increasing. A major distinction amongst potential
APC types is between amateur and professional APCs. Amateur
APCs stimulate only previously activated T cells and T cell
hybridomas, whereas professional APCs are capable of initiating
T cell responses. To investigate whether eosinophils are capable of
initiating T cell responses in vivo, eosinophils were isolated from
the spleens of IL-5 transgenic BALB/c mice by Percoll following
MACS, and contamination with other APCs including dendritic
cells was excluded. Co-culture of eosinophils with GM-CSFincreased their expression of costimulatory molecules including
MHC-II. The GM-CSF stimulated eosinophils were allowed to take
up OVA in vitro and then intratracheally injected into wild-type
BALB/c mice that received intravenous injection of Ag-specific
CD4+ Tcells from DO11.10 OVATCR transgenic BALB/c mice 24
h earlier. By alternatively using GFP-labeled eosinophils from IL-5
& GFP double transgenic mice and fluorescently conjugated OVA–
beads, we demonstrated by fluorescence microscopy that the Ag-
loaded eosinophil APCs were physically interacting with naive
OVA TCR CD4+ T cells in the draining paratracheal lymph nodes
(PLNs) 24 h after eosinophil transfer, while Ag-free eosinophils
were randomly distributed across the PLNs with the donor CD4+ T
cells. The physical interaction between Ag-loaded eosinophils and
Ag-specific CD4+ T cells resulted in the activation of the naive
CD4+ T cells, as measured by an early T cell activation marker
CD69 by flow cytometry. However, this eosinophil APC function
was completely impaired if eosinophils were pre-treated with RBC
lysis buffer containing ammonium chloride, which inhibits antigen
processing by eosinophils. Our data suggest that eosinophils may
function as professional APCs to initiate T cell responses to a given
antigen.
F1.04. Transforming Growth Factor Beta-1 May up
Regulate Interferon Gamma Production by Peripheral
Blood Mononuclear Cells from Asthmatics and Normal
Controls.
J. Joseph,1 S. Benedict,1 M. Joseph,2 B. Al-Ramadi.3 1Internal
Medicine, Faculty of Medicine & Health Sciences, Al Ain,
Abudhabi, United Arab Emirates; 2Pediatrics, Al Ain Hospital,
Al Ain, Abudhabi, United Arab Emirates; 3Microbiology &
Immunology, FAculty of Medicine & Health Sciences, Al Ain,
Abudhabi, United Arab Emirates.
Background:
TGF- h-1, a multifunctional cytokine, has been shown to
suppress immunoglobulin production in animal experiments.
Plasma TGF- h 1 has been observed to be higher in some
asthmatics compared to normal controls (Joseph et al, Ann of
asthma Allergy). The effect of TGF h-1 on cytokine production
by human peripheral blood mononuclear cells (PBMC) has not
been investigated.
Methods:
PBMC from asthmatics and normal controls were isolated from
heparinized blood by density-gradient centrifugation on Ficoll-
Paque, washed three times in phosphate buffered saline and re-
suspended at 1  106 cells/ml in serum free medium (AIM-V). For
cytokine measurements, 1 106 PBMC/ml culture medium were
incubated with phorbol-12-myristate 13-acetate (5ng/ml) and Ca2+
ionophore (0.4mg/ml) in the presence of TGF h-1 (100pg/ml)
alone and with antibody to TGF h-1. Following 72 hours of cell
culture, supernatants were collected and stored at -800C until
assayed for cytokines. ELISA kits from Pharmingen, USA were
used to determine IFN-g in the supernatants from PBMC cultures.
Results:
So far results from 4 controls and 6 patients have been
analyzed. The median IFN-g production in unstimulated cells
(5.5 pg/ml) increased significantly following exposure to TGF
h-1 (52 pg/ml) (pb0.01). Upon adding antibody to TGF h-1,
the median IFN-g reduced to 10pg/ml (pb0.01). Following
stimulation with PMA+ ionomycin, the basal median IFN-g
production by PBMC (6144 pg/ml) significantly increased to
9599pg/ml upon exposure to TGF h-1 (pb0.01). Upon adding
Abstracts S47specific antibody to TGF h-1, the median IFN-g level decreased
to 5763 pg/ml (pb0.01). In the resting state, there was trend for
PBMC from asthmatics to produce higher amount of IFN-g
compared to PBMC from controls.
Conclusion:
TGF h-1 may up regulate the production of IFN-g by resting
and stimulated PBMC in normal controls and asthmatics and this
response was abrogated by specific antibody to TGF h-1.
F1.05. Increased Experession in CD30+ and CD57+
Molecules on CD4+ T Cells in Atopic Asthmatic
Children: A Preliminary Report.
N. E. Martinez-Jimenez,1 E. Rojas-Ramos,1 Y. B. Garfias,2 E. G.
Zenteno,2 R. L. Lascurain.2 1Clinical Immunology and Allergy,
ISSSTE, Mexico, Mexico City, Mexico; 2Biochemistry, INER, SSA,
Mexico, Mexico City, Mexico.
Background: The phenotype of CD4+ T cells accumulated in
chronically inflamed tissue, in allergic process, have been found to
be mainly CD4+ memory T cells that express surface markers
associated with IL-4 production. However the process of these
cells and surface markers in peripheral blood have been not clearly
determined. Objective: In this study we performed the frecuency of
surface markers on CD4+ T cells with IL-4 production in
peripheral blood of atopic asthmatic children. Methods: Cross
sectional study trial was carried out in 17 atopic asthmatic children
and 12 healthy children as controls. The proportion of the
peripheral mononuclear cells and surface molecules was studied
by flow cytometry to identify surface molecules in CD4+ T cells
(CD30, CD57, CD154, CD62L, and CD28), and IL-4. The analysis
was performed on PBMC after PMA-Ionomycin stimulation, to
examine IL-4 and INF-g production. Results: CD4+ CD30+
(median; 1.7, percentiles 25–75; 1.3–2.2), and CD4+ CD57+
(median; 3.3, percentiles 25–75; 2.2–4.4) T cells showed an
increased production and correlationship with IL-4 production in
atopic asthmatic children. Conclusion: Although CD4+CD30+ T
cells in peripheral blood have been observed in atopic dermatitis
patients, in this work we identified similar cellular population in
respiratory atopic diseases, and also CD57+ T cells, these cells
seems to corresponds of CD4 T cells which expressing IL-4 under
stimuli. That expressing markers could correspond early activation
in atopic asthma.
Key words: Atopic asthma, children, CD4+ T cells, CD 30,
CD57 and IL-4.
F1.06. CCR3 Expressed on CD4+ T Cells Correlations
with IL-4 Production in Allergic Rhinitis Patients.
Preliminary Report.
E. Rojas-Ramos,1 M. N. Martinez-Jimenez,1 E. G. Zenteno,2 Y. B.
Garfias,2 R. L. Lascurain.2 1Clinical Immunology and Allergy,
ISSSTE, Mexico, Mexico City, Mexico; 2Biochemistry, INER,SSA,
Mexico, Mexico City, Mexico.
In allergic process a number of studies have analysed the
phenotype of CD4+ T cells that express surface markers preferen-
tially associated with IL-4 production. However the repercussions
of nasal challenge over these cells in peripheral blood have been not
clearly determinated. We found that CCR3 on CD4+ T cells
correlated positively with IL-4 production. In conclusion the CD4 T
house dust mite primed cells in allergic rhinitis patients expressing
CCR3 that correlates with IL-4 production, these local challenge
repercussion in peripheral CD4+ T cells could be observed only
when those cells are stimulated with PMA-I.F1.07. Mugwort-Pollen Allergy Represents an Ideal
Candidate for Peptide Immunotherapy.
B. Jahn-Schmid,1 G. F. Fischer,2 B. Bohle,1 F. Ferreira,3 C.
Ebner.1 1Dept. of Pathophysiology, Medical University of Vienna,
Vienna, Austria; 2Dept. of Blood Serology, Medical University of
Vienna, Vienna, Austria; 3Department of Immunology and
Allergology, University of Salzburg, Salzburg, Austria.
Mugwort pollen allergens represent the main cause of pollinosis
in late summer in Europe. Ninety-five percent of mugwort-allergic
patients are sensitized to the major allergen Art v 1. In contrast to
other common pollen allergens which contain multiple T cell
epitopes, Art v 1 contains only one single immunodominant T cell
epitope (Art v 125–36). We characterized the minimal epitope of Art v
125–36 and investigated a possible association of Art v 1-reactivity
with HLA class II-phenotypes.
Art v 1-specific T cell lines and clones were established from 51
patients with clinically defined mugwort pollen allergy and IgE
specific for Art v 1. In 96% of the patients a cellular response to
Art v 125–36 was obtained and a core region of 5–10 amino acids
containing 3–5 amino acids essential for T cell reactivity was
defined by using truncated and single-substitution analog peptides
for T cell stimulation. The frequency of HLA-DRB1*01 in patients
recognizing Art v 125–36 was significantly increased as compared
to healthy controls (69% vs. 21%; odds ratio: 8,45; pb106).
HLA-DRB1*01 was identified as the main restriction element for
the presentation of the immunodominant epitope using monoclonal
anti-HLA antibodies and APC with defined HLA- DRB and
DQB1-alleles.
In conclusion, allergy to Art v 1 is characterized by a uniform T
cell reponse and the disease is associated with the HLA-DRB1*01-
phenotype. Therefore, mugwort pollinosis represents an ideal
candidate for a peptide-based immunotherapy including the
possibility of monitoring antigen-specific T cell responses during
therapy by using HLA-DR-tetramers.
F1.08. Characterization of Human Cord Blood-Derived
In Vitro Generated Mast Cells: Hemopoietic Antigens,
Chemokine Receptors, Activation Markers,
Tetraspanins.
I. Mirkina, T. Schweighoffer. 1RD-ADV, Novartis Institutes for
Biomedical Research, Vienna, Austria.
Mast cells (MC) play pathogenic role in allergic inflammation
via releasing a broad spectrum of inflammatory mediators. We
generated MC from human cord blood CD133+ hemopoietic
precursors by culturing with rhSCF, rhIL-6 and rhIL-3 in Stem
Span medium. To better characterize differentiation process, we
mapped the expression of hemopoietic markers and chemokine
receptors. Adhesion molecule ICAM-1 (CD54), IL-3 receptor
(CD123), aminopeptidase N (CD13) and CD38 were present on
MC and their precursors. Early hemopoietic markers CD133 and
CD34, bright on freshly isolated precursors, disappeared within 2
weeks of differentiation. Development into mature MC was
enhanced when cells underwent freezing/thawing cycle followed
by culturing in the presence of 5% human serum. After 5 to 7
weeks they displayed typical features of mature MC: methachro-
matic staining with Gimsa-May Gruenwald, abundant expression
of granular mast cell tryptase; surface expression of MC antigens
c-kit (CD117) and FceRIa; degranulation after cross-linking
FceRIa by IgE (+Ag). Both MC and precursors markedly
expressed surface CXCR2 and CXCR4 and were negative for
AbstractsS48CCR3. CCR5 was low to undetectable in precursors and absent
in mature MC. Not reported before, MC and precursors
substantially expressed surface CCR6 and some CCR7. Interest-
ingly, we detected chemoattractant receptor homologous molecule
expressed on Th2 cells, CRTH2, on the surface of MC and their
precursors. As CRTH2 is a second receptor for prostaglandin D2
(PGD2), and PGD2 is a major prostanoid released from Ag-
activated MC, our data suggest possible autocrine function of
PGD2 for MC.
To find sensitive marker(s) of MC reactivity to Ag, we
explored the correlation between MC degranulation and
expression of activation markers CD63 (tetraspanin) and
CD203c, both used for testing reactivity of basophils to
allergens. We found both markers to be hardly detectable on
the surface of MC precursors but high on mature MC both at
the surface and intracellularly. This is the first evidence of
CD203c presence on cord blood-derived MC. Expression of
both CD63 and CD203c was further increased after IgE-
dependent and independent stimulation, and this increase mir-
rored degranulation process.
We determined other members of tetraspanin family, CD9 and
CD81, to be high on the surface of MC precursors. Expression of
CD9 and CD81 was further augmented up to 10 fold with
differentiation to mature MC. In contrast to CD63, surface
expression of CD9 and CD81 diminished after stimulation with
PMA/ionomycin but not after triggering with IgE (+Ag). Therefore,
members of btetraspanin webQ could be differentially involved in
MC activation.
These studies define potential targets for anti-allergic inter-
vention and sensitive tools to monitor MC activation.
F1.09. IL-4Ra Single Nucleotide Polymorphisms in
Allergic Bronchopulmonary Aspergillosis.
Alan P. Knutsen,1 Barbara Kariuki,1 Manoj R. Warrier.2 1Allergy/
Immunology, Saint Louis University, St. Louis, MO, USA; 2Allergy/
Immunology, Cincinnati ChildrenTs Hospital, Cincinnati, OH, USA.
Rationale: ABPA is a Th2 hypersensitivity lung disease
resulting from bronchial colonization by Aspergillus fumigatus
in asthmatic and cystic fibrosis patients. Previously, we
reported HLA-DR2/DR5 restriction in ABPA patients. We
propose that single nucleotide polymorphisms (SNPs) of IL-4Ra
also play a role in the development of ABPA in asthmatic and CF
patients.
Methods: DNAwas extracted from cultures of B-cell lines of 26
ABPA and 29 non-ABPA patients and sequenced for IL-4Ra
polymorphisms, including 1 extracellular (ile75val) and 4 cyto-
plasmic (glu400ala, cys431arg, ser503pro, and gln576arg) SNPs.
IL-4 stimulated PBL from ABPA and control subjects were
examined for the expression of CD23 on B cells by flow cytometry.
HLA-DR genotyping was performed using standards techniques.
Results: The frequency of IL-4Ra SNPs was significantly
increased in ABPA patients compared to non-ABPA subjects,
92% vs 55%. The ile75val SNP was identified in 77% of ABPA
patients and was homozygous in 42%. Cytoplasmic SNPs were
identified in 39% of the ABPA patients, and co-existence of
extracellular plus cytoplasmic SNPs were observed in 27% of
ABPA patients. ABPA subjects also had significantly increased
expression of CD23 molecules per B cell of IL-4 stimulated PBL
cultures compared to controls. In two ABPA patients we
identified a previously unreported SNP in the IL-4 binding
region at 468 A Y C, asn98thr. In one ABPA patient, theasn98thr SNP was associated with ile75val and ser503pro SNPs,
and in the other patient the asn98thr SNP was isolated. This was
also associated with up-regulation of CD23 expression on B cells
by IL-4 stimulation.
Conclusions: The presence of IL-4Ra SNPs, particularly
ile75val allele located within the IL-4 binding region may confer
susceptibility to developing ABPA. In addition, a new SNP in the
IL-4 binding region was identified in ABPA.
F1.10. House Dust Mite Allergen (Der p1 and Blo t5)
Levels in AsthmaticsT Home in Hong Kong.
Baoqing Sun, Adrian Wu, Nanshan Zhong. 1Dept of Medicine,
Guangzhou Institute of Respiratory Deseases, Guangzhou,
GuangDong, China; 2Dept of Medicine, The University of
HongKong, HongKong, Hong Kong; 3Dept of Medicine,
Guangzhou Institute of Respiratory Deseases, Guangzhou,
GuangDong, China.
Background: House dust mite(HDM) allergen are involved in
sensitization and development of allergic airway disease, partic-
ularly bronchial asthma and allergic rhinitis. Dermatophagoides
pteronyssinus(Dp) and Blomia tropicalis(Bt) are the predominant
inhalant allergens in most parts of the world.Aim: to measure Derp1
and Blot5 allergen levels in asthmaticsT homes in HongKong.
Methods: Seventy houses were enrolled for a mite indoor environ-
ment study. Dust samples were obtained from two sites of each
subjectsT house: bed and floor. Derp1 and Blot5 levels were
quantified by a two-site monoclonal antibody-based ELISA
techniques. Results: The levels of Derp1 allergens were found in
bed (GM: 3.43 ug/g of dust; 95%CI: 1.89–4.96 ug/g) and on floor
(GM: 1.12 ug/g of dust; 95%CI: 0.71–1.53 ug/g) with significant
differences(P = 0.005). However, the levels of Blot5 allergens were
also found in bed (GM: 19 ug/g of dust; 95%CI: 0.89–38.9 ug/g) and
on floor (GM: 6.14 ug/g of dust; 95%CI: 0.4–11.9 ug/g), with no
statistically significant difference Blot5 allergens found in the
different sites. In addition, Concerning the exposure index for Derp1
and Blot5 allergens found in bed and on floor, 17.6% in bed and
8.6% on floor had levels of Blot5N=10 ug/g of dust, higher than
those obtained for Derp1 (7.2% and 0% in bed and on floor
respectively, pb0.05); On the other hand, higher percentages in bed
and on floor (25% and 35.7%)were observed for the levels of
Blot5=0ug/g of dust as compared with Derp1 in bed and on floor
(4.3% and 14.5% respectively, pb0.05). Conclusions: Der p1 and
Blot 5 are the major sensitizing allergens in this region, Blot 5 is a
more potent one in HongKong, probably reflecting the high level of
exposure to Bt. The unique major Bt and Dp allergens should be
included for precise diagnosis and effective immuno-therapeutic
treatment of mite allergy in HongKong.
F1.11. House Dust Mite Allergen Der f Increase
Bronchial Epithelial Cell Cytokine Expression.
Baoqing Sun, Nanshan Zhong. 1Dept of Medicine, Guangzhou
Institute of Respiratory Diseases, Guangzhou, GuangDong,
China; 2Dept of Medicine, Guangzhou Institute of Respiratory
Diseases, Guangzhou, GuangDong, China.
Background: The house dust mites (Dermatophagoides farinae
(Derf) are a major source of aeroallergens implicated in the
expression of atopic disorders, including asthma, allergic rhinitis,
and atopic dermatitis. In particular, strong circumstantial evidence
suggests that house dust mites antigens are important precipitating
factors of Asthma.Many house dusemite allergens are proteases that
can elicit airway inflammation by stimulating the release of
Abstracts S49cytokines in bronchial epithelial cells. Objectives: we have
investigated whether Der f allergen proteases induced cytokine
production from the epithelial cell line BEAS-2B. Methods: Cells
were exposed to four different concentrations with serial additions of
Der f (0.02, 0.2, 2, 20 ug/ml) were incubated for 24 h to 96 h. and
compare with those without incubation of allergen. Cytokine in the
supernatants were assayed by ELISA, Reverse transcription–PCR
was also performed. Results: Cells treated with Der f allergen
showed serial changes in the cohesiveness of the monolayer. There
was a significant increase in the level of cytokine production
compared with the untreaed sample. Statistically Significantly
increased with addition of Der f caused the release of IL-6 and IL-
8 in time and concentration-dependent manner (pb0.05,respec-
tively). Levels of IL-6 and IL-8 were elevated 24 h and 48 h after
allergen exposure, increasing with time, continued increased levels
to be present of IL-6 and IL-8 in the supernatants at 72 h and 96 h. At
the same time show the concentration dependence of induction of
IL-6 and IL-8 expression as well as an increase in the expression of
IL-6 and IL-8mRNA. Conclusion: HDM-induced airway inflam-
mation may include Der f-mediated release of inflammatory
mediators, and the proteolytic activity of an allergen may stimulate
the release of proinflammatory cytokines from human bronchial
epithelium. Suggesting that IL-6 and IL-8 production by bronchial
epithelial cells may play a role in the pathogenesis of allergic asthma.
F1.12. D. pteronyssinus Extract-Treated Confluent A549
Cells (cA549) Secrete Mediators That Stimulate Human
Pulmonary Fibroblasts To Increase Secretion of Vascu-
lar Endothelial Growth Factor (VEGF).
A. Capetandes,1 M. Frieri.1 1Dept of Pathology, Division of
Allergy Immunology, Nassau University Medical Center, East
Meadow, NY, USA.
Introduction: The pathogenesis of airway remodeling involves
altered interactions between epithelial and mesenchymal cells that
lead to air wall thickening and edema (Davies D. et al., J. Allergy
Clin. Immunol., 2002; Frieri M. Allergy Asthma Proc. 2004).
Airway remodeling is associated with increased VEGF and
increased vascular permeability in the pulmonary submucosa
(Lee KS et al., J. Allergy Clin. Immunol 2004). 300, 600 and
1000 AU/ml dialyzed D. pteronyssinus extract (DpE) stimulated
cA549 to secrete VEGF into serum-free conditioned media (CM)
relative to DpE without cA549 (control media; CTLM) in 24 hours
(Capetandes A. et al., Am. J. Clin. Path., 2004). Rationale:
Determine if mediators secreted into the CM by DpE-treated
cA549 can stimulate NHLF to secrete VEGF relative to CTLM.
Methods: Subconfluent NHLF were cultured for 24 hours with
CM and CTLM generated with and without cA549, respectively,
plus 0, 300, 600 and 1000 AU/ml DpE. The CM and CTLM
were assayed for VEGF by ELISA. Cell number was measured
by MTT incorporation at A550. Data is expressed as mean F
2SD and analyzed by the two-tailed t test (two groups) or
ANOVA (z three groups). Results: NHLF in serum-free media
secreted VEGF relative to control (181 F 23 pg/ml (n = 6)
versus 3.3 F 0.5 pg/ml (n = 4); P b 0.0001, t test); CTLM did
not stimulate NHLF secretion of VEGF over control (n = 6).
Absolute VEGF levels were increased by the following con-
ditions: CM + NHLF (1017 F 97 pg/ml (n = 12)) N CM w/o
NHLF (611 F 44 pg/ml (n = 4)) N CTLM +NHLF (198 F 38
(n = 12); P b 0.0001 ANOVA). 1000 CTLM caused a decrease
in NHLF cell number relative to CM 1000 (0.05 F 0.06 versus
0.15 F 0.014 OD A550; n = 10, P b0.0001, t test. RelativeVEGF pg/ml: MTT with 1000 CM + NHLF was increased
relative to 1000 CTLM + NHLF. Conclusions: cA549 secrete
mediators that stimulate NHLF to increase secretion of VEGF. This
suggests that the inhalation of aerosolized dust mite may stimulate
alveolar epithelial cells to secrete mediators that stimulate
fibroblasts to increase the secretion of VEGF. This may potentially
contribute to the edema found in airway remodeling.
F1.13. Skin Reactivity for Aeroallergens and Peripheral
Eosinophilia in Children with Otitis Media with
Effusion.
Fardin Eghtedari,1 Hossein Mohammadi-Nik,1 Sara Kashef,1
Mohammad Hadi Imanieh,1 Farhad Handjani,1 Eskandar
Kamali-Sarvestani,1 Marzieh Orouj.1 1Allergy Research Center,
Shiraz University of Medical Sciences, Shiraz, Fars, Islamic
Republic of Iran.
This study was performed to evaluate the probable effect of
allergy in children with and without otitis media with effusion
(OME). Is allergy more common in OME patients? Allergic patients
might be helped with allergy treatment. Otitis media with effusion, a
common childhood ear disease, has various predisposing factors that
one of themmay be allergy. Skin prick test (SPT) is able to determine
allergic patients to common aeroallergens. The study was performed
on 30 children with OME in khalili Hospital, a teaching hospital
affiliated to Shiraz University of Medical Sciences in Iran.
Myringotomy with or without ventilation tube insertion plus
adenoidectomy were done for them. A group of 30 pateints in the
same age range (2–9 years) with normalmiddle ear whomunderwent
adenoidectomy was selected as control. Skin prick test for common
aeroallergen (molds, grasses, weeds, trees and mites) was done. The
presence of peripheral eosinophilia was also investigated in both
groups. Peripheral eosinophil counts were significantly higher in the
case group (pb0.01). 3 patients (10%) in OME group had positive
SPT to weeds. SPTwas negative in all children in the control group,
however skin reactivity between two groups was not significantly
different. We were not able to demonstrate a strong correlation
betweenOMEandpositive skin test to common aeroallergens.Wedo
not suggest SPT for evaluation of children with OME.
F1.14. Recurrent Angioedema by Blastocystis Hominis
Successfully Treated with Paromomycin.
D. Micheloud,1 J. Jensen,1 E. Fernandez-Cruz,1 J. Carbone.1
1Clinical Immunology Unit, University Hospital Gregorio
Maranon, Madrid, Spain.
Background: Published reports of urticaria associated para-
sitation by Blastocystis hominis are uncommon. There have been
no reported cases of angioedema by Blastocystis hominis.
Materials: Clinical and immunological data of a patient with
such association. Case report: The subject was a 21-year-old
female with a 5-years history of episodic attacks of swelling of
mouth, face and upper extremities accompanied by recurrent
urticaria. She had been treated with different antihistamines and
oral corticosteroids with only a partial response. Inmunological
tests performed in peripheral blood disclosed normal immunoglo-
bulin levels (IgG 1160 mg/dl, IgA 182 mg/dl, IgM 120 mg/dl),
normal percentages of lymphocyte subsets (CD3 77%, CD4 55%,
CD8 18%, CD19 12%, CD56 7%); normal level of the comple-
ment factors C4 (19 mg/dl), C3 (100 mg/dl), FB (28 mg/dl) and of
C1-inhibitor (15 mg/dl) as well as negative circulating immune
complexes. Functional C1-inhibidor activity was also normal. IgE
specific to ascaris, echinococcus and anisakis were negative.
AbstractsS50Serologies for hepatitis virus B, hepatitis virus C, and HIV were
negative. Complete blood and differential analysis as biochemical
serum parameters were around normal ranges. Urinalysis was
normal. Stool examination revealed Blastocystis hominis at 3
consecutive determinations. Both intestinal parasitation as well as
urticaria-angiedema responded successfully to paromomycin sul-
fate. Remission of urticaria-angioedema have been maintained
after a 24-month of clinical follow-up. Conclusion: Diagnosis of
Blastocystis hominis infection must be suspected in patients with
otherwise frustrating chronic allergic skin disorder. Paromomycin
might be of benefit in chronic persistent urticaria-angioedema
associated with this parasitic infection.
F1.15. Exposure to Monomeric Human Myeloma IgE in
the Absence of Known Specific Antigen Can Enhance
Chemokine Production in In Vitro-Derived Human Mast
Cells.
Adrian M. Piliponsky,1 Kentaro Matsuda,1 Motoyasu Iikura,1
Toshiaki Kawakami,2 Evelyn Wang,1 Mindy Tsai,1 Stephen J.
Galli.1,3 1Pathology, Stanford University School of Medicine,
Stanford, CA, USA; 2Division of Cell Biology, La Jolla Institute for
Allergy and Immunology, San Diego, CA, USA; 3Microbiology and
Immunology, Stanford University School of Medicine, Stanford,
CA, USA.
Two groups recently have reported that various mouse
monoclonal IgE antibodies can induce mouse bone marrow
derived mast cells to secrete mediators in the absence of known
specific antigen. In this study, we investigated whether exposure
to purified human myeloma IgE (catalog number A12162H,
Biodesign International, Kennebunk, ME) in the absence of
known specific antigen had detectable effects on the mediator
secretion of human mast cells that were generated in vitro from
umbilical cord blood cells. Exposure to IgE at 2.5 micrograms/ml,
but not IgG, significantly enhanced the release of chemokines, but
not histamine or cysteinyl leukotrienes, from human mast cells.
These results were obtained both with microcentrifuged prepara-
tions of IgE (which lacked large aggregates of IgE according to
HPLC and mass spectrometry) and with HPLC-purified prepara-
tions of IgE monomers that were devoid of IgE dimers according
to mass spectrometry. However, under all conditions of challenge
tested, chemokine production in response to IgE alone was
significantly less than that induced when aliquots of the same IgE-
sensitized populations of human mast cells were stimulated by
anti-IgE. The production of chemokines in response to exposure
to IgE in the presence or absence of anti-IgE was inhibited by pre-
incubation of the cells with dexamethasone. Overall, these results
indicate that exposure to human myeloma IgE in vitro in the
absence of known specific antigen can induce chemokine
production by human mast cells at the concentrations tested.
While the clinical relevance of these findings remain to be
determined, one might speculate that effects of IgE on mast cells
that are independent of known specific antigen can contribute to
the pathogenesis of mast cell-associated disorders, particularly in
subjects with high levels of IgE.
F1.16. Comparison of the Efficacy of Intranasal
Phototherapy and Fexofenadine Hydrochloride for the
Treatment of Seasonal Allergic Rhinitis.
A. Koreck, Zs Csoma, M. Boros-Gyevi, L. Kemeny. 1Department of
Dermatology and Allergology, University of Szeged, Szeged,
Hungary.We have recently showed that intranasal phototherapy using
mixed low dose UVB, UVA and visible light (mUV/VIS) is
effective in treating seasonal allergic rhinitis.
The aim of the present study was to compare the clinical
efficacy of rhinophototherapy with fexofenadine hydrocloride. We
performed an open study on 18 ragweed-allergic patients, during
the ragweed season in Szeged. 11 patients received intranasal
irradiation with increaseing doses of mUV/VIS light for 2 weeks
and 7 patients received 120 mg fexofenadine HCl once daily for
the same period of time. Individual symptom scores and total nasal
score (TNS) were recorded.
Rhinophototherapy resulted in a significantly better reduction
of individual symptom scores for rhinorrea (P = 0.0007) and
nasal obstruction (P = 0.014) and of TNS (P = 0.004)
compared with fexofenadine HCl. No significant differencies
between the two treatments were observed in reducing symptom
scores for sneezing, nasal itching, palate itching and eye
symptoms. In addition, we have measured the wheal formation
in skin prick test (SPT) by digital planimetry before starting the
study and 10 days after ending the therapy. Interestingly, ten
days after the end of the treatment, in the rhinophototherapy
group the allergen-induced wheal formation was significantly
reduced compared to baseline (P = 0.03), in contrast in the
fexofenadine treated group no differences were observed. No
changes in histamine-induced wheal formation were observed. In
our study, rhinophototherapy was significantly more effective than
fexofenadine in treating allergic rhinitis. The prolonged inhibitory
effect of rhinophototherapy on SPTsuggests a long lasting effect that
was not seen after fexofenadine treatment.
F1.17. Inhibition of the Peptidyl-prolyl Isomerase
(PPIase) Pin1 Induces Caspase-3-Mediated Apoptosis
of Human Peripheral Blood Eosinophils.
Z. J. Shen,1 S. J. Esnault,1 J. S. Malter.1 1Pathology and
Laboratory Medicine, Waisman Center for Developmental
Disabilities, University of Wisconsin, Madison, WI, USA.
Eosinophils (Eos) are prominent cells in asthmatic inflam-
mation. Once in the lung or airways, Eos show significantly
prolonged survival. Anti-apoptotic activity is mediated by
cytokines such as GM-CSF and IL-5, which are markedly
increased in the asthmatic lung. Selective induction of Eos
apoptosis has been proposed as a therapeutic approach for
asthma. Previous studies have shown PPIase (cyclophilin A and
FKBP) inhibitors suppress GM-CSF, IL-3 and TNF-a expres-
sion and function. These data implicate PPIase mediated cis/
trans isomerization of pSer/pThr-Pro bonds in target proteins as
a potential key regulator of cytokine expression. Recently, we
have shown that inhibition of Pin-1, another PPIase, blocked the
pro-survival effect of either GM-CSF or hyaluronic acid (HA).
To identify the mechanisms underlying Eos apoptosis induced
by Pin1 inhibition, we examined caspase-3 (Casp-3) activation.
Eos were treated with the Pin-1 inhibitor juglone at 1.0 AM and
cell lysates examined for full-length Casp-3 proenzyme (p32)
and active Casp-3 (p17) subunits by western blot analysis. As
shown in previously published data, resting Eos underwent
spontaneous (baseline) Casp-3 activation after 24 h in culture
that was completely blocked by rhGM-CSF (100 pg/ml).
Treatment of Eos with HA (100 Ag/ml), which is markedly
increased in the airways of asthmatic lung, prevented sponta-
neous Casp-3 activation as well. However, treatment of Eos
with juglone (1.0 AM) induced Casp-3 activation, even in the
Abstracts S51presence of rhGM-CSF or HA. Furthermore, apoptotic initiation
by Pin1 inhibition was more apparent on Eos pre-activated with
rhGM-CSF. Pre-incubation with high concentrations of rhGM-
CSF or HA also failed to block juglone induced Casp-3
activation and cell death. Kinetic analysis showed that within 10
minutes juglone triggered extremely intense Casp-3 activation.
Casp-3 activation was a very sensitive and early marker for the
ultimate apoptosis of Eos. Trypan blue exclusion indicated that
Eos viability remained high (between 86–97% at 4, 10 and 24
h) despite juglone treatment. These data indicate that Pin1
enzymatic activity is required for preventing Casp-3 activation
and the initiation of apoptosis and does so downstream of the
GM-CSF receptor.
F1.18. Natural CD25+CD4+ Regulatory Cells Inhibit
Proliferation of CD25-CD4+ Cells from Naive or
Immunized BALB/c Mice When Stimulated by Dendritic
Cells Pulsed with Fel d 1 or Major Fel d 1 T Cell
Epitopes.
F. R. Hentges,1 C. A. Leonard,1 C. P. Le Pogam.1 1Laboratory of
Immunogenetics and Allergology, CRP-Sante, Luxembourg,
Luxembourg.
Objectives: Define in a BALB/c mouse in vitro model the
dominant T cell epitopes of the major cat allergen Fel d 1. Test
the effect of natural CD25+CD4+ regulatory cells (T regs) on the
response of CD25-CD4+ cells from naive mice and mice
immunized with Fel d 1. Materials and Methods: For the
analysis of the proliferative immune response of naive mice and
immunized mice, we used an in vitro system where myeloid-
derived antigen-pulsed dendritic cells (DC) induced T cell
proliferation. Immature DCs were harvested from mouse bone-
marrow and matured in vitro for 7 days before being pulsed with
antigen for 2 days. Lymphocytes were obtained from mouse
spleen cells and added to the DC cells for 4 days, before 3H
thymidine addition and harvesting. Cell proliferation was meas-
ured for un-separated spleen lymphocytes and separated T cell
subpopulations. CD25+CD4+ and CD25-CD4+ T cells were
separated by magnetic beads and checked for purity by FACS.
T cell stimulation was measured with whole Fel d 1 and 17
overlapping peptides. Immune BALB/c mice had been injected 3
times with Fel d 1 in Al(OH)3. Results: Un-separated splenic
lymphocytes from naive mice did not give a significant
proliferation when stimulated by Fel d 1 allergen or the 17
synthetic peptides. Un-separated lymphocytes from immunized
mice gave significant stimulation indexes with Fel d 1 and
peptide F 1.4 (aa 20–40 on chain 1). Purified CD25-CD4+
lymphocytes from Fel d 1- immunized mice gave a significant
stimulation with Fel d 1 and peptide F 1.4. When CD25+CD4+ T
regs were added to the CD25-CD4+ cells, proliferation was
inhibited. Purified CD25-CD4+ cells from naive mice gave also a
positive stimulation index when exposed to Fel d 1 or F 1.4
peptide. This proliferation was abolished by the addition of T regs
from naive mice at a ratio of 1 T reg cell to 2 CD25-CD4+ cells.
Conclusions: The major cat allergen Fel d 1 seems to harbour one
major T cell epitope containing region when tested in immunized
BALB/c mice. Natural T regs from immunized mice inhibit
CD25-CD4+ lymphocyte proliferation, when stimulated by Fel d
1- allergen or F 1.4- pulsed DC. Natural T regs from naive mice
inhibit CD25-CD4+ proliferation from naive and immunized
BALB/c mice when tested with Fel d 1- and F 1.4 peptide-
pulsed dendritic cells.F1.19. Omalizumab Improves Asthma Outcomes
Irrespective of Leukotriene Receptor
Antagonist (LTRA) Use.
M. Massanari,1 Y. Deniz,2 R. Maykut,1 C. Reisner,3 G. Geba.1
1US Clinical Development and Medical Affairs, Novartis
Pharmaceuticals Corporation, East Hanover, NJ, USA;
2Clinical Development, Genentech, South San Francisco,
CA, USA; 3Clinical Development, Novartis Pharmaceuticals,
East Hanover, NJ, USA.
Background: Omalizumab (OMA) is a novel humanized
monoclonal anti-IgE antibody for allergic asthma. OMA binds
circulating IgE, leading to a reduction in high affinity IgE receptors
on mast cells (MC), thereby reducing MC degranulation upon
specific allergen exposure. This results in a decrease inMC release of
allergic mediators such as histamine and leukotrienes (LTs). LTRAs
block the effects of cysteinyl LTs responsible for some features of
allergic asthma, however, they do not block other mediators or
categories of LTs released by MC. To examine the effect of OMA in
moderate-severe allergic asthma in patients using LTRAs, we
evaluated asthma exacerbations and need for bursts of systemic
steroids in a pooled analysis of two recently completed clinical trials.
Methods: INNOVATE (a 28 week randomized double-blind
placebo-controlled study) and ETOPA (a 52 week open label trial)
allowed concurrent LTRA use and were used for this analysis. Entry
criteria and clinical outcomes were similar allowing for a pooled
analysis. A total of 731 patients were in the intent-to-treat (ITT)
population in the two studies. All patients received inhaled steroids
(mediandose2000AgBDPequivalent).Longactingbetaagonistswere
used by all patients in INNOVATE and 87% of patients in ETOPA
receiving concurrent LTRAs. Overall, LTRAswere used at baseline in
32.3% of patients (INNOVATE 34.8%, ETOPA 28.9%). Groups were
compared using Poisson regression based on the ITT population,
adjusting for baseline sex, age, use of oral steroids, FEV1 (N=80%, 60-
b80%,b60%),studytreatmentandtreatment-by-LTRAinteraction.
Results: Patients on LTRAs tended to exhibit a greater level of
asthma severity as evidenced by baseline history and trial incidence
of clinical exacerbations, irrespective of treatment. The relative risk
(RR) of asthma exacerbations (primary outcome; OMAvs. control)
of the LTRA subgroup was 0.62 (95% CI: 0.42–0.91), which was
somewhat lower than that observed for the overall study population.
Similarly, the RR for use of systemic steroids (secondary outcome;
OMA vs. control) for the LTRA subgroup was 0.5 (95% CI: 0.35,
0.72), similar to the effect size observed for the overall population.
Conclusions: In patients with moderate to severe asthma, OMA
demonstrated efficacy in the LTRA subgroup that was similar to
improvements shown in the overall population. Asthma morbidity,
as assessed by clinical exacerbations, was improved in conjunction
with significant reductions of systemic steroid bursts.
F1.20. Administration of Chitin Down-Regulate Serum
IgE Levels and Lung Eosinophilia in Ova-Albumin
Allergic Mouse.
C. -L. Kao,1 C.-R. Shen,1,2 C.-J. Lin,1 J.-K. Chen,3 M.-L. Kuo,2
C. -L. Liu.4 1Graduate Institute of Medical Biotechnology, Chang
Gung University, Kweishan, Taoyuan, Taiwan; 2Graduate Institute
of Basic Medical Sciences, Chang Gung University, Kweishan,
Taoyuan, Taiwan; 3Department of Environment and
Biotechnology, Refine and Manufacture Research Center, Chinese
Petroleum Company, Chiayi, Chiayi, Taiwan; 4Graduate Institute
of Engineering and Department of Biochemical Engineering,
Ming-Chi University of Technology, Taishan, Taipei, Taiwan.
AbstractsS52Inflammation in allergic asthma is generated and activated by
endogenous proinflammatory cytokines including IL-4 and IL-5
produced by Th2-type lymphocytes. These allergen-induced Th2
responses enhance airway hyperreactivity in mouse models. In this
study, we have shown that development of Th1/cell-mediated
immune response significantly down-regulated Th2 responses by
eliciting IFN-g production in experimental induced ova albumin
(OVA) allergic BALB/c mice. Inhalation of chitin was made or
mice were given chitin intravenously during the OVA-sensitization.
Allergen-induced immunopathological responses, such as BALF
cytology, anti-OVA humoral responses, and OVA-driven cytokines
production were assessed. The administration of chitin signifi-
cantly suppressed the immunopathological symptoms in OVA-
sensitized mice. To dissect the inhibitory mechanisms of Th2
responses, spleen cells isolated from the chitin-treated or non-
treated OVA-sensitized mice were cultured in the presence of OVA
and/or chitin for 5 days. OVA alone stimulated the production of
Th2 associated cytokines in both groups; in contrast, OVA/chitin
stimulation resulted in the significantly increased production of
IFN-g. Moreover, spleen cells isolated from the chitin-treated mice
showed abundant amounts of IFN-g production with the stim-
ulation of chitin, and less amounts of Th2 cytokine with or without
OVA-stimulation, suggesting that the inhibited Th2 responses
might explain the potential mechanisms, due to the changes in
antibody isotypes and cytokines produced from splenocytes of
mice receiving chitin. In summary, these results indicate that
chitin-induced IFN-g responses successfully down-regulate Th2-
facilitated IgE production and lung eosinophilia in the OVA
allergic animals.
F1.21. Allergic/Toxic Manifestations Associated with
Ingestion of Stir-Fried/Cooked Mushrooms.
M. Ishaq, I. M. Sameera, M. Taj. 1Allergy/Pulmonology, Al-Junaid
Hospital, Nowshera, Pakistan.
Purpose: The idea is to enlighten the series of allergic/ toxic
manifestation with an un-expected onset on ingestion of cooked
mushroom (Cortinarius orellanus), Gyromitra. Gyromitra, poison-
ings have also occurred after ingestion of commercially available
morels contaminated with G. esculenta.
Methods: 10 cases (ages 16–50-years both sex) had been
notified for treatment (1990–2000) to the emergency department of
Al-Junaid hospital, with ingestion of cooked mushroom as
vegetable (toxic species are confused with edible species), followed
by adverse reactions (allergic/toxic) with a variable severity.
Allergic manifestations i.e., Itching burning flushing, tingling
sensations, all over the body, Urticaria with variable severity.
Toxic Manifestations: Were Acute in onset(resulting from
neurotoxins release) i.e., Nausea (15–30 min), vomiting (20–60
min) abdominal cramping, bloated feeling. watery diarrhea (20
min-13 h), prosteration,dehydration, profuse sweating, coma
convulsions hallucinations, excitement, depression, spastic colon,
seizures (20 min-13 h), extreme thirst, and lack of urine
production, Other symptoms included feeling of warmth, clammi-
ness, numbness of the tongue and extreme thirst.
One case in series had concomitant intake of alcoholic beverage
with toxic syndrome. clinical testing procedure i.e, using a 3H-
radioimmunoassay (RIA) test kit had evidenced sub-nanogram
levels of toxin in urine and plasma. 4/10 Patients survived this
early phase& recovered without any complications with meticulous
follow up, 6/10 with much severe manifestations/delayed in
notification for treatment appeared to have recovered for a shorttime, but this period was generally followed by a rapid and severe
loss of strength, prostration, and pain-causing restlessness, sudden
onset of abdominal discomfort (a feeling of fullness). Aggressive
therapy resulted in survival 4/10 (out of 6/10) with variable degree
of liver enlargement. The rest of 2/10 of (6/10) succumbed to death
from irreversible damage to vital organs(hepato-renal insufficiency,
cardiac, and skeletal muscle). The toxin affected primarily the liver,
but there are additional disturbances to blood cells and the central
nervous system.
Results: The degree of reversal of adverse effects depends upon
the urgency of therapeutic notification. In the absence of dietary
history, Allergic/toxic manifestations could be mistaken for
symptoms of hepatic renal impairment as a consequence of other
causes (e.g., viral hepatitis), therefore an urgent distinction be
made, as the delayed onset of symptoms will be mistaken behind
the idea that the organs have previously been damaged. The
importance of rapid diagnosis is evident, victims who are
hospitalized and given aggressive supportive therapy immediately
after ingestion have a mortality rate of only 5–10%, whereas those
admitted 50hours or beyond after ingestion have a 55–85%
mortality rate.
Conclusions: Mushrooms as per its names are alike,but
dissimilar in their nutritional & toxicity nature, its haphazard
selection/consumption could cost life of the consumer.
F1.22. Effects of Tacrolimus upon T-Lymphocyte, NK
Cell, and Eosinophil Activation.
C. N. Huynh,1 E. S. Lee,1 Q. N. Chung,1 M. A. Gibson,1 R. L.
Roberts.1 1Department of Pediatrics, David Geffen School of
Medicine at UCLA, Los Angeles, CA, USA.
Tacrolimus is a macrolide immunosuppressant used to
prevent graft rejection in transplant patients and in the treatment
of atopic dermatitis. The drug inhibits T-lymphocyte activation
by preventing the transcription of IL-2. We wish to investigate
whether tacrolimus also indirectly suppresses natural killer (NK)
cell and eosinophil activation by inhibiting T-cells. Lymphocyte
Assay: Heparinized blood was collected from healthy adult
donors and was layered over a ficol-hypaque density gradient to
isolate lymphocytes. Cells were cultured in-vitro at a concen-
tration of 1.0  106 cells/ml in IL-2 and increasing amounts of
tacrolimus. The drug and cytokines were added bi-weekly to
maintain the appropriate cell concentration. Weekly flow
cytometric analyses were performed to detect tacrolimusT effects
on T- helper cell (CD4+), T- cytotoxic cell (CD8+), and NK
cell (CD16+ and CD 56+) populations. CD 69+ was also
measured to assess lymphocyte activation by double staining for
CD 4+/69+ and CD 8+/16+. Weekly assessments of 51Cr
discharges from K562 cells were performed to detect NK cell
activity. Eosinophil Assay: Tacrolimus effect on eosinophil
viability was investigated by isolating white blood cells from
eosinophilia patients. Whole blood collected from patients was
layered over a 75% percoll gradient. The isolated white blood
cells were kept at a concentration of 1.0  106 cells/ml and
were treated with IL-5. Varying amounts of drug concentration
were added to specific cultures in order to study its differing
effects on cell activation. Cytokine and drug were added bi-
weekly and flow cytometry was performed at 4, 7, and 14 day
increments to monitor eosinophil activation through CD69+
expression and fluorescence. Lymphocyte Activation: Inhibition
was observed in T-lymphocyte and eosinophil populations as
well as NK cell activity. Flow cytometry analysis staining for
Abstracts S53CD4+/69+ expressions indicate that with increasing time and
concentration of tacrolimus, T-lymphocyte activation decreases.
When compared to control (cultures treated with IL-2 alone),
cultures from week 1 treated with tacrolimus at 50ng/ml and
500ng/ml displayed a decrease of 6.1 % and 8.3% respectively.
At week 2, there was an 8.3% and 14.2 % decrease in CD4+/69+
activation levels with tacrolimus 50 ng/ml and 500ng/ml
respectively. CD8+ overall activation level was unaffected with
increasing treatment of drug and time, while 51Cr assay suggested
an overall decrease in NK cell activity. Eosinophil Activation:
Compared to control, flow cytometry results staining for CD 18+/
69+ indicate a 9% and 6% decrease in eosinophil activation at 4
days of incubation. At 14 days, there was a 19% and 23% decrease
in cell activation with tacrolimus 50 ng/ml and 500 ng/ml. With
increasing time and concentration, mean fluorescence for cells
expressing the CD 69+ activation marker decreased. Conclusion:
Although the primary effect of tacrolimus is on T- cells, it also may
affect NK cell and eosinophil activation. The effect on eosinophils
may explain the drugTs beneficial effect in atopic dermatitis
patients.
F1.23. Hemopoietic Cells Accumulate in Murine Lungs
in Response to Ectopic Grafts of Lung Tissue from
Allergic and from IL-5 Transgenic Donors.
M. I. Gaspar-Elsas, E. S. Maximiano, T. Q. Souza-Pinto, D.
Joseph, B. B. Vargaftig, P. Xavier Elsas. 1Pediatrics, Instituto
Fernandes Figueira-FIOCRUZ, Rio de Janeiro, RJ, Brazil;
2Immunology, Inst. Microbiol. Prof. Paulo de Goes-UFRJ, Rio
de Janeiro, RJ, Brazil; 3Pharmacology, Instituto de Ciencias
Biomedicas-USP, Sao Paulo, SP, Brazil; 4Unite Pharmacol.
Cellulaire-U485 INSERM, Institut Pasteur Paris, Paris,
Ile-de-France, France.
Background. Hemopoiesis is an important factor in the
pathogenesis of allergic asthma. Several studies suggest that
extramedullary hemopoietic cells present inside the asthmatic
lungs contribute to chronic airway inflammation. To define the
factors responsible for the emergence of these cells, and their
relationship to allergic inflammation, we isolated intrapulmonary
hemopoietic cells from the lungs of allergic BALB/c mice, and
showed that: a) their presence is strictly dependent on airway
challenge of ovalbumin-sensitized mice (Chest, 2003, 123,
345S); b) they differ from hemopoietic cells in bone-marrow
in their growth properties and sensitivity to steroids (Intl.
Immunopharmacol., 2005, in press). Here we evaluated the
possible contribution to intrapulmonary hemopoietic cell accu-
mulation made by systemically active signals originating in
challenged lungs, and by the local allergic reaction. Objectives.
To define: a) whether allergen-challenged lungs release factors
responsible for intrapulmonary accumulation of hemopoietic
cells; b) whether the production and activity of these factors
can be dissociated from allergen-induced lung injury. Methods.
We developed a transplantation model in which fragments of
allergen-challenged, sensitized lung donors were ectopically
implanted in syngeneic recipients, and hemopoietic cells inside
the recipientsT lungs were quantitated without allergen exposure
of the recipients. The contribution of IL-5 released by the graft
was assessed by ELISA, by neutralization and by IL-5-
transgenic grafts. Results. In BALB/c mice, accumulation of
hemopoietic cells occurred only when: a) donors were sensitized
and challenged in the airways; b) recipients were sensitized
through 2 sc allergen injections, but not airway-challenged.Media conditioned by lung fragments from the appropriate
donors contained biologically active IL-5, as well as immunor-
eactive IL-5 and eotaxin, and induced intrapulmonary accumu-
lation of hemopoietic cells in sensitized recipients. The effect of
the appropriate donor-recipient combination was prevented by
the TRFK-5 anti-IL-5 antibody. Unlike BALB/c, lungs from IL-
5 transgenic CBA/Ca mice contained a large number of
hemopoietic cells, independently of sensitization and challenge.
Lung fragments from naive, IL-5 transgenic donors (or their
conditioned media), induced intrapulmonary accumulation of
hemopoietic cells in nontransgenic, ovalbumin-sensitized recip-
ients. Conclusions. a) intrapulmonary accumulation of hemo-
poietic cells is independent of local immunological injury
induced by the allergen challenge; b) lung grafts systemically
release IL-5, which is required for accumulation of hemopoietic
cells in the recipientsT lungs; c) IL-5 is fully effective only on
sensitized animals.F1.24. Intracellular Stores of Interleukin-4 (IL-4)
Receptor A Participate in the Secretion of IL-4 from
Human Eosinophils.
L. A. Spencer,1 R. C.N. Melo,1,2 S. A.C. Perez,1 A. M. Dvorak,3
P. F. Weller.1 1Department of Medicine, Beth Israel Deaconess
Medical Center, Boston, MA, USA; 2Department of Biology,
Federal University of Juiz de Fora, Juiz de Fora, MG, Brazil;
3Department of Pathology, Beth Israel Deaconess Medical Center,
Boston, MA, USA.
Traditionally considered terminal effector cells, eosinophls are
currently emerging in more subtle roles relating to their influence
on tissue milieu and immunomodulation. This relatively new
appreciation stemmed in part from the realizations that eosinophils
store arsenals of preformed cytokines and chemokines with well-
defined immunomodulatory properties, and are capable of rapid
release of these potent mediators in response to specific stimuli.
Although multiple mediators are stored in close proximity within
eosinophil specific granules, their release appears to be independ-
ently regulated (i.e. eotaxin induces release of IL-4 but not IL-12,
while IFN-g induces secretion of IL-6 and RANTES without
detectable release of IL-4). To date, mechanisms governing this
selectivity have been elusive. Interestingly, eosinophils are
responsive to many of the factors for which they are reservoirs,
indicating that cognate receptors for these ligands are also
expressed. Despite the dual expression of receptor/ligand pairs
by eosinophils, few studies have addressed receptor expression in
relation to the storage and release of cognate ligands. In this study
we utilize flow cytometric analysis to monitor intra- and
extracellular expression of IL-4 and the IL-4 receptor. In an
approach combining electron microscopy, light microscopy and
subcellular fractionation, we further visualize localization of the
IL-4 receptor throughout eotaxin-induced secretion of its ligand,
IL-4. Surprisingly, we discover that in addition to nominal surface
expression, all components of functional types I and II receptor
complexes are pre-formed and stored within freshly isolated
eosinophils. Further, we demonstrate the IL-4 binding component
(IL-4 receptor a chain) is selectively mobilized in concert with IL-
4 and likely participates in the trafficking of IL-4 out of the
granule and through the vesicular compartment. This work
represents the first indication of preformed internal stores of
cytokine receptors within human eosinophils, and proposes a
novel mechanism for the selectivity of mediator release.
AbstractsS54F1.25. Anaphylaxis to Intravenous and Oral
Cyclosporin in a Child and Successful Desensitization.
Sara Kashef,1 Mojhgan Kiani,2 Habib Nourani-Khojasteh,3 Mani
Ramzi.3 1Allergy Research Center, Pediatric Immunology &
Allergy, Shiraz University of Medical Sciences, Shiraz, Fars,
Islamic Republic of Iran; 2Pediatric Immunology & Allergy, Shiraz
University of Medical Sciences, Shiraz, Fars, Islamic Republic of
Iran; 3Department of Hematology & Oncology, Shiraz University
of Medical Sciences, Shiraz, Fars, Islamic Republic of Iran.
Hypersensitivity reactions to cylosporin are rare. Cyclosporin
formulations for parental and oral use are vital drugs after bone
marrow transplantation (BMT), thus recognition of hypersensi-
tivity reactions and guidelines for subsequent use are important in
transplant surveillance. The purpose of this paper is to report a case
of anaphylaxis to intravenous and oral cyclosporin successfully
managed by oral desensitization also to present a review of
different formulations of cyclosporin with the least drug reaction.
Case report: This 9- year-old girl with thalassemia major was
admitted post BMT, when developed an anaphylactic reaction
(respiratory distress, hypotension and generalized urticaria) after
second exposure with intravenous then oral cyclosporin. Fortu-
nately she had a good response to immediate rescue treatment.
There is not any immunosuppressive drug as effective as cyclo-
sporin for the engraftment. Two available formulations of cyclo-
sporin in Iran do contain Cremophor-EL (polyoxyethylated caster
oil) in IV or poly-5-oleate (a chemically similar compound to
cremophor-EL) in oral compounds. The previous reported cases of
cyclosporin hypersensitivity were confirmed to be due to this
solubilizing agent rather than the cyclosporin itself. The safest
suggested formulation, corn-oil-based soft gelatin capsule, was not
available for us, thus oral desensitization was started according to
the classic penicillin desensitization protocol and tolerated appro-
priately by the patient. There are a few reports of cyclosporin
desensitization in the literature. Cyclosporine anaphylaxis is rare
but possible, and in the face with unavailability of the suitable
formulation, desensitization should be considered.
F1.26. Skin Reactivity to Aeroallergens Is Not Related to
the Nasal Polyp Tissue Eosinophil Inflammation.
Fardin Eghtedari,1 Seyed Reza Cheraghzadeh,2 Sara Kashef,3
Ahmad Monabati,4 Elham Shoraka.5 1Allergy Research Center,
Department of Otolaryngology, Shiraz University of Medical
Sciences, Shiraz, Fars, Islamic Republic of Iran; 2Department of
Otolaryngology, Shiraz University of Medical Sciences, Shiraz,
Fars, Islamic Republic of Iran; 3Allergy Research Center,
Pediatric Immunology & Allergy, Shiraz University of Medical
Sciences, Shiraz, Fars, Islamic Republic of Iran; 4Department of
Pathology, Shiraz University of Medical Sciences, Shiraz,
Fars, Islamic Republic of Iran; 5Department of Obstetrics &
Gynecology, Shahid Beheshti Hospital, Shiraz, Fars, Islamic
Republic of Iran.
The role of allergy in the pathogenesis of nasal polyposis is not
clear. In this study we investigated the possible correlation of skin
reactivity to aeroallergens, with the polyp tissue eosinophil
inflammation. Twenty-five patients with nasal polyposis who were
candidate for polypectomy under general anesthesia were enrolled.
Polyp tissues were stained with hematoxilin-eosin for eosinophil
count. Skin prick test (SPT) with at least 11 common aeroallergens
(Allergopharma, Germany) including pollens, mites and molds
were done for all patients. The positive SPT was defined as a
reaction at least 3mm larger than the negative control (Glycerol).12 of 25 patients had at least one positive SPT. In 18 patients
eosinophil count in the polyp tissue was more than 50 percent of
cells counted in the field. We did not find a significant correlation
between the polyp eosinophil count comparing to the skin
reactivity. It seems that polyp eosinophil inflammation is not a
consequence of allergy to the aeroallergens in the nasal polyposis.
F1.27. Superior Safety of Polymerized Allergen
Vaccines: Zero Systemic Reactions during 55,000
Injections of Polymerized Ragweed and Grass
Vaccines in 500 Allergy Patients.
S. Kagen, J. Zondlo, R. Muthiah, M. Kagen. 1Allergy-Immunology,
Kagen Allergy Clinic, Appleton, WI, USA.
Allergen immunotherapy is the only treatment for allergic rhinitis
and asthma that can reverse the immune imbalance in patients with
these IgE-mediated disorders. This form of therapy involves gradual
administration of increasing doses of allergens to patients who have
been found to possess allergen-specific IgE reactivity. The treatment
is 90% effective in reducing both allergy symptoms and medication
use, while improving the quality of life for the allergy sufferer.
Allergen immunotherapy with aqueous allergens, however, carries
the risk of systemic reactions. Using a questionnaire of its member-
ship, the Immunotherapy Committee of the American Academy of
Allergy, Asthma and Immunology verified the potential risks of both
death and near death reactions immediately following administra-
tion of aqueous allergens. Their findings confirmed that there had
been 273 near death reactions and 20 deaths associated with aqueous
immunotherapy from 1990 to 2001.
To reduce life-threatening reactions to allergen immunotherapy,
Patterson developed the technique of glutaraldehyde polymeri-
zation of ragweed and grass allergens. In multiple studies,
polymerized vaccines were found to be as effective as aqueous
allergen extracts, and devoid of systemic responses. Here we extend
PattersonTs findings and demonstrate that polymerized ragweed and
grass vaccines are superior in safety to aqueous materials. 500
allergy patients were given over 55,000 injections of polymerized
ragweed and grass allergens, with zero systemic responses.
To eliminate the risk of death associated with aqueous allergen
immunotherapy, while retaining its effectiveness, we strongly
recommend that allergy patients receive polymerized ragweed and
grass vaccines. Given that the use of aqueous allergen immuno-
therapy by untrained physicians and nurse practitioners is increas-
ing nationwide, it may be safer for patients to have the FDA either
eliminate the availability of aqueous ragweed and grass allergens
altogether, or restrict their use to physicians board certified in
Allergy-Immunology.
F1.28. Trans Fatty Acid and Atopic Eczema/Dermatitis
Syndrome: The Relationship with a Free Radical
cis-trans Isomerization of Membrane Lipids Trans
LIPIDS in Atopic Dermatitis.
L. Chini,1 F. Angelini,1 C. Chatgilialoglu,2 S. Dellonte,2
V. Moschese,1 S. Corrente,1 R. Iannini,1 M. Chianca,1 P. Rossi,1
C. Ferreri.2 1Pediatrics, Policlinico Tor Vergata, University of
Rome Tor Vergata, Rome, Italy; 2ISOF, Consiglio Nazionale delle
Ricerche, Bologna, Italy.
The formation of trans fatty acid residues in membrane lipids
can be due to the radical-catalysed isomerization process of
naturally occurring cis fatty acid moieties. Radical stress is well
documented in atopic diseases but no data are still available on a
Abstracts S55possible association with high levels of trans fatty acids in these
patients. We investigated the presence of trans lipid isomers in
erythrocyte and T-lymphocyte membranes of 24 children affected
by atopic eczema/dermatitis syndrome (AEDS) taking advantage
of the trans lipid library available from radical processes modelled
in vitro. We found trans fatty acids both in erythrocyte and
lymphocyte membranes and their total content reached the highest
value of 3.0% of the main fatty acid residues. The high trans fatty
acid levels correlated significantly with the increasing amount of
palmitic acid and with the decrease of stearic acid. This fatty acid
also correlated with the decrease of arachidonic level, and this
scenario can fit with an imhibition of elongase enzymatic activity.
Moreover, the highest trans fatty acid levels were detected in 12
out of 24 children which have atopic dermatitis not mediated by
IgE (prick/RAST negative). A new significance of lipid impair-
ment in AEDS can be proposed, which generally involves the role
of trans isomers in human pathologies. This study aims to
contributing to lipidomic researches regarding the double bond
structure and the influence of a geometrical change of membrane
lipids in physiology and diseases.
F1.29. Proinflammatory Cytokines and Nitric Oxide
in Exhaled Breth Condensate in Monitoring of
Exacerbation Asthma in Children.
Boleslaw Kalicki,1 Anna Jung,1 Wanda Stankiewicz,2
Marek Dabrowski,2 Janusz Zuber.1 1Paediatric, Military Medical
Institute, Warsaw, Poland; 2Immunology, Institute of Hygiene and
Epidemiology, Warsaw, Poland.
Proinflammatory cytokines and nitrici oxiden play important
role in exacerbation of asthma. The aim of the study was to
determine NO, IL-4, IL-6 level in exhaled breath condesate of
asthmatic children.
Material and methods. The samples of exhaled breath con-
densate were collected in 31 children with asthma (16 females and
15 males, aged 8–18y, mean 13,3y) during 15min. breathing and
then were frozen to (-) 70 8C. The examination of the exhaled
breath condensate were done by EcoScreen equipment (Jaeger
Comp.). Results were compared in 3 group of asthmatic children (I
group- 7 children with asthma exacerbation, II group- 9 children
without exacerbation of asthma, well controlled by steroids and
h2mimetic drugs, III group- 15 children with asthma improvement
without drugs longer than 3 months) and control (IV-th group- 15
healthy children aged 11–17y, mean 14,5y).
Results. The highest value of NO, IL-6, IL-4 were found in I
group of children. All parameters have shown significant differ-
ences between examination groups.
Conclusions. 1. Mean concentrations of NO and cytokines IL-6,
IL-4 had strong correlation with exacerbation asthma in children.
2. The examinations of NO in exhaled breath condensate
especially but also IL-6, IL-4 cytokines are useful, non-invasive
method in monitoring exacerbation asthma in children.
F1.30. Combined Skin Prick, Immediate Patch and
Specific-IgE Testing in the Diagnosis of Peanut Allergy
in Children.
B. K. Wainstein,1 A. Yee,1 M. Ziegler,1 D. Jelley,1 J. B. Ziegler.1
1Immunology and Infectious Diseases, Sydney ChildrenTs Hospital,
Sydney, New South Wales, Australia.
Introduction: In children with probable peanut allergy, an 8-mm
skin prick test (SPT) has been reported to be 100% specific. We
aimed to determine the sensitivity and specificity, for peanut allergy,of skin tests, peanut specific-IgE, and combinations of these, in
children with a lower pre-existing probability of peanut allergy.
Methods: Children attending the allergy clinic with a positive
peanut SPT (n = 84; age range 0.9–17.3 years; mean 4.5 years) were
included in the study. Immediate skin application food tests (I-
SAFT) using 1 gram of peanut butter (positive if any wheals were
detected at 15 minutes), peanut specific-IgE levels and open-label
peanut food challenges were performed. Results: Fifty-two of 85
peanut challenges were positive. SPT specificity was 67% at 8 mm
and 100% at 15-mm. I-SAFT alone was 82% specific. A peanut
specific-IgE level of 0.35 kU/L alone was 98% sensitive but 33%
specific. A level of 10 kU/L was 100% specific. Combinations of an
8-mm SPTwith a positive I-SAFT and a peanut specific-IgE N 0.35
kU/L were 88% specific. Conclusion: An 8-mm SPT cannot predict
peanut allergy in children without a high pre-existing probability of
peanut allergy. If a child without a recent history of a peanut
reaction has a SPTof b 15-mm diameter, peanut specific-IgE should
be measured. Challenge is not necessary if the level is b 0.35 or N 10
kU/L. Allergy test results should be interpreted in the context of a
history or suspicion of food allergy.
F1.31. CowTs Milk Allergy in Infantile Colic.
Mohammad Hadi Imanieh,1 Hosein Moravej,1 Sara Kashef,1
Farhad Handjani,1 Eskandar Kamali-Sarvestani,1 Fardin
Eghtedari,1 Marzieh Orouj.1 1Allergy Research Center, Shiraz
University of Medical Sciences, Shiraz, Fars, Islamic Republic
of Iran.
CowTs milk allergy has been considered as a cause of infantile
colic. Clinicians frequently change the diet of these infants to a
cowTs milk free diet. In this study, we evaluated the role of cowTs
milk allergy in infantile colic in a group of exclusively breast fed
infants. 114 exclusively breast fed infants between three weeks and
three months of age, who were referred with infantile colic,
enrolled in this study. Skin prick test with cowTs milk extract
(Allergopharma) and a stool exam for occult blood were done for
all babies. Then, they were randomly selected as two groups of
case and control. In case group (including two babies with positive
skin prick test), we advised mothers not to consume cowTs milk
and other dairy products for two weeks. In control group, we did
not change the diet of mothers. 77 babies came back for follow up,
35 babies in the case and 42 babies in the control group. Infants
with colic whose mothers did not take dairy products, did not
improve significantly in comparison with control group. Preva-
lence of positive skin prick test in colicky infants was 2.6 %, which
is nearly similar to prevalence of cowTs milk allergy in the
population of infants below one year of age (2.2–2.6% on the basis
of previous studies). Occult bleeding in stool was significantly
higher in colicky infants in comparison with non-colicky infants.
CowTs milk allergy does not seem to be a common cause of
infantile colic. It is not advised to eliminate the dairy products from
the diet of nursing mother.
F1.32. 5-Lipoxygenase Locolization to Cytosolic Lipid
Bodies in Rat Basophil Leukemia Cells.
Z. Jin,1 D. Wan,1 H. B. Wang,1 I. Ghiran,1 R. J. Soberman,2
P. F. Weller.1 1Division of Allergy and Inflammation, Beth-Israel
Deaconess Medical Center, Harvard Medical School, Boston, MA,
USA; 2Massachusetts General Hospital, Harverd Medical School,
Boston, MA, USA.
The metabolism of arachidonic acid via the 5-lipoxygenase (5-
LO) pathway generates leukotrienes, eicosanoids with varied
AbstractsS56paracrine and intracrine roles in inflammation. 5-LO in different
cells may variably be present in the cytosol and/or the nucleus
and may undergo activation-dependent translocation to sites,
including the nuclear envelope. Lipid bodies are organelles that in
leukocytes and other cells have roles in the local formation of
both 5-LO- and cyclooxygenase pathway-derived eicosanoids. We
have evaluated the expression of 5-LO in rat basophil leukemia
cells (RBL-2H3). Resting RBL cells contained numerous lipid
bodies, as identified by staining with Oil Red O and the
incorporation of a fluorescent fatty acid analog. By immunocy-
tochemistry, 5-LO was present in the cytosol and nucleus of
resting RBL cells, as well as at punctate cytosolic sites, that co-
stained as lipid bodies. Resting RBL cells were disrupted by
nitrogen cavitation and subjected to subcellular fractionation with
a protocol designed to isolate buoyant lipid bodies. By Western
blotting of subcellular fractions, 5-LO was present in lipid body
as well as cytosolic and nuclear fractions. To investigate the
localization of 5-LO within RBL cells, cells were transfected a
plasmid encoding an EGFP-5-LO fusion protein. Examination of
cells as soon as 1 hr after transfection with EGFP-5-LO
demonstrated very prominent focal green fluorescence at punctate
cytosolic sites that stained as lipid bodies with Oil Red O. EGFP-
5-LO fluorescence remained largely lipid body associated at 4 hrs
post-transfection, when a lesser number of cells also began to
exhibit diffuse cytosolic fluorescence. To ascertain whether cell
activation altered the EGFP-5-LO distribution, cells were
sensitized with anti-DNP IgE and activated with DNP. At both
1 and 4 hrs after IgE-mediated activation, lipid body numbers per
cell increased ~50%. At 1 and 4 hrs after activation, EGFP-5-LO
fluorescence exhibited almost exclusively punctate cytosolic
localization with lipid bodies. Thus, lipid bodies in RBL cells
constitute a discrete pool of 5-LO that is especially enriched in
newly synthesized 5-LO. These findings provide additional
evidence for the functions of lipid body organelles in the
formation of eicosanoids pertinent to inflammation.
Category: allergy/asthma
Theme: immunoregulation
F1.33. Approaches to Immunogenicity of Human Protein
Products.
H. S. Ko.1 1Division of Hematology, Office of Blood Research and
Review, Center for Biologics Evaluation and Research, Food and
Drug Administration, Rockville, MD, USA.
Potentially serious immune reactions or loss of treatment
effect may result from repeated exposure of patients to
therapeutic proteins or peptides even when they are from human
sources or based on human sequences. Objective: The objective
of this investigation is to study the approaches taken in the
development of human protein/peptide products available in the
United States with respect to their immunogenicity potential.
Materials and Methods: The package inserts of twenty ther-
apeutic human protein/peptide products were examined for the
following information: alterations to peptide sequence or poly-
saccharide attachment, manufacturing process, choice of exci-
pients, viral validation, assay of antibody development, in vitro or
in vivo correlates of cell mediated immunity, precautions and
contraindications in specific patient populations, therapeutic
effect, and adverse reactions. The products included hormones,
cytokines, coagulation factors, immune globulins, as well as other
blood components. Results: (1) Information on changes poten-
tially affecting immunogenicity, such as differences in conforma-tion of the therapeutic agent molecule and the possible adjuvant
effect of certain excipients, is rarely presented except for some
recombinant products. (2) Immunogenicity is most often studied
for the development of serum antibodies to the therapeutic agent,
but rarely in terms of cell-mediated immune responses or skin-
sensitizing antibodies, unless the route of administration is dermal
application. (3) Instructions on testing for antibodies to the
therapeutic agent are often dictated by changes in treatment
effect, and only occasionally by manifestations of adverse
reactions, such as anaphylaxis. (4) Special populations, which
are susceptible to the development of immune responses to the
therapeutic agent, are generally addressed in the precautions,
warnings and contraindications sections of labeling. However,
systematic studies to explore immunogenicity in specific pop-
ulations are often lacking. Conclusions: Information regarding
immune reactions to human proteins/peptides remains inad-
equately pursued or presented for many available therapeutic
products. Greater attention needs to be focused on this important
issue, which has bearing on both safety and effectiveness of the
products.F1.34. Plasma Concentration of Soluble IL-4 Receptor in
Asthma Patients during Specific Bronchial Challenge
with Dermatophagoides Pteronyssinus(Dp) Allergen.
K. Kowal,1 A. Pampuch,1 L. M. DuBuske,2
A. Bodzenta-Lukaszyk.1 1Department of Allergology and Internal
Medicine, University Medical School of Bialystok, Bialystok,
Poland; 2Immunology Research Institute of New England,
Gardner, MA, USA.
Soluble IL-4 receptor (sIL-4r), functioning as a decoy receptor,
inhibits action of IL-4. The aim of this study was to evaluate serum
concentration of sIL-4r in asthma patients during bronchial
challenge with Dp allergen.
The study was performed on 51 asthma patients with a positive
history of dust allergy symptoms, positive skin prick test results
with Dp extract and with a significant bronchoconstrictive response
to bronchial Dp challenge. Ten healthy persons with negative skin
prick tests to common aeroallergens were used as controls.
Bronchial provocation challenge with Dp extract was performed
only in asthma patients. Blood samples were collected before, 1
hour (TEAR) after, 8 hours (TLAR) after and 24 hours (T24) after
allergen challenge. Plasma concentration of sIL-4r was evaluated by
ELISA (R&D Systems).
The mean plasma concentration of sIL-4r was greater in
asthma patients (46.6 F 18.6 pg/ml) than in healthy controls
(29.1 F 14.5 pg/ml). There was no difference in the mean
plasma concentration of sIL-4r between patients who responded
to allergen challenge with isolated early asthmatic response
(single responders-SR) and those who responded with both
early and late asthmatic responses (dual responders-DR). During
the TEAR, a significant fall in plasma sIL-4r concentration was
found in DR (to 33.7 F 12.6 pg/ml; P b 0.001), but not in SR
(45.8 F 23.6 pg/ml). At T24 the mean plasma concentration of
sIL-4r was significantly greater in SR (57.9 F 27.9 pg/ml) than
in DR (41.1 F 13.4 pg/ml), but was not significantly different
from the baseline levels.
The fall in sIL-4r plasma concentration in DR seen at TEAR
may result in increased activity of IL-4 which in turn may
participate in the development of sustained allergic inflammation
in these patients.
Abstracts S57F1.35. Interleukin-4 and Its Alternatively Spliced
Variant (IL-4D2) in Healthy Donors and Patients with
Atopic Asthma.
A. A. Babakhin,1 E. I. Bateneva,1 S. M. Andreev,1 M. R. Khaitov,1
D. Y. Trofimov,1 L. P. Alekseev,1 L. M. DuBuske.2 1National
Research Center, Institute of Immunology, Moscow, Russian
Federation; 2Immunology Research Institute of New England,
Gardner, MA, USA.
Background. The interleukin-4 (IL-4) splice variant (IL-4y2) is
known to antagonize many biological activities of IL-4. The aim of
the study was to compare the IL-4 and IL-4y2 expression ratio in
patients with asthma versus healthy subjects.
Materials and methods. Eight healthy subjects and eight
patients with atopic asthma confirmed by case history, skin tests
and RAST were involved in the study. Informed consent from
patients and healthy subjects to participate in the study was
obtained. RNA was extracted from PBMC obtained by Ficoll-
Urographin gradient centrifugation. cDNA was used for quanti-
tative PCR with specific form-discriminating primers and SYBR
Green I performed using iCycler iQ (BioRad, Hercules, USA).
Results. The IL-4:IL-4y2 expression ratio was 6.8 F 2.5 and
7.1 F 3.3 for patients with atopic asthma and healthy subjects
respectively. The IL-4:IL-4y2 ratio did not correlate with age, sex,
total serum IgE levels, or the presence of eczema, rhinitis or
anaphylaxis in the patients with asthma.
Conclusion. There was no difference in relative expression of
splice variant of IL-4 in healthy subjects versus atopic asthma
patients.
F1.36. B Epitope Assay of hIL-4D2, an Alternative
Splicing Variant of hIL-4.
S. M. Andreev,1 I. V. Dubinkin,1 A. O. Petrukhina,1 A. M.
Vasiliev,2 I. V. Kosarev,2 N. V. Tokhtamysheva,2 G. Y. Puchkova,2
A. A. Babakhin,1 L. M. DuBuske.3 1NRC Institute of Immunology,
Moscow, Russian Federation; 2Institute of Immunological
Engineering, Lyubuchany, Moscow Region, Russian Federation;
3Immunology Research Institute of New England, Gardner, MA,
USA.
HIL-4y2 is a natural alternative splicing form of human IL-
4, derived from hIL-4 mRNA by the elimination of second
exone encoding for the amino acid residues 22–37. The
structural and biological properties of IL-4y2 are poorly
understood, and its direct (non-mRNA) quantitative measure-
ment is currently not possible. The major purpose of this study
was: a) to compare the 3D structures of hIL-4y2 to the parent
cytokine hIL-4; b) to attempt to reveal the dominant B epitope
sequences in loop regions of hIL-4y2 using synthetic peptides
and computer-assistant 3D modeling; c) to prepare monoclonal
antibodies (MAbs) specific for each cytokine form; and d) to
evaluate the binding affinities of the antibodies. The hIL-4/hIL-
4y2 peptides were synthesized by solid-phase methods, charac-
terized by analytical HPLC and mass-spectrometry. To increase
immunogenicity, the peptides were conjugated to keyhole limpet
hemocyanine (KLH) and used as immunogens. Polyclonal and
monoclonal antibodies to both hIL-4 and hIL-4y2 peptides in
addition to whole recombinant proteins were produced in
BALB/c mice. Analysis of reactivity of mouse antisera
produced against hIL-4 and hIL-4y2 showed very low reactivity
to all synthetic peptides, while anti-peptide antisera obtained
demonstrated noticeable reactivity to IL-4, especially the anti-serum to the peptide mimicked splicing fragment consisting of
sequence 22–37 of IL-4. ImmunoDot and ELISA demonstrated
that anti-IL-4 MAbs produced were able to recognize only
peptide 22–37. Reactivity of anti-IL-4 peptide antisera to hIL-
4y2 was completely absent. A 3D model of IL-4y2 which was
used as a template to design the peptide mimicked the unique B
epitope which emerged in the splicing site. Assay of antibody
binding of MAbs to I125 labeled cytokines showed that K50
values varied from 1010 to 106 M. These techniques may
allow for identification and further characterization of differ-
ences between hIL-4y2 and IL-4, including both quantitative
and qualitative functional aspects.
F1.37. LPS Differentially Modulates Th2 Cell Responses
to Antigen during Acute and Relapse Allergic Asthma in
Mice.
M. Zerbs,1 R. Bankoti,1 G. Dekan,2 G. Stingl,1 M. M. Epstein.1
1Dermatology, Medical University of Vienna, Vienna, Austria;
2Clinical Pathology, Medical University of Vienna, Vienna,
Austria.
Endotoxin has been shown to have a powerful effect on
adaptive immunity. Although endotoxin, in particular, LPS is an
important adjuvant during the priming of allergic immune
responses, it has been shown to suppress recall Th2 immune
responses. We tested the effect of LPS on in vivo priming and
memory responses in a model of allergic asthma induced
without adjuvants. Mice were immunized twice on days 0 and
21 with 10 mcg of ovalbumin (OVA) intraperitoneally. One
week later, mice were challenged with a series of 4 aerosoliza-
tions with 1% OVA on 2 consecutive days. Groups of mice
were either evaluated for acute disease or recuperated for at
least 2 months before being rechallenged for relapse disease.
We found that mice sensitized intraperitoneally with OVA with
very low LPS content (removed with detoxigel; contained 50
pg/ml endotoxin) and rechallenged with OVA (Sigma, grade V;
contained 190 ng/ml endotoxin), developed minimal allergic
lung inflammation, mucus secretion, and OVA-specific IgE and
IgG1, compared with animals immunized with high LPS
containing OVA. In support of previous data, these results
demonstrate that LPS has an influence during OVA priming.
However, when mice were immunized using the same protocol
with low-fat milk powder (containing endotoxin 1.3 ng/ml) and
aerosolized with a 1% milk solution, responses were signifi-
cantly higher than low endotoxin containing OVA primed mice.
These data indicate that LPS may be critical for inducing Th2
responses to OVA but is not necessary for priming to milk
proteins. To test the effect of LPS on in vivo memory responses
that lead to disease relapse, we challenged recuperated mice
with OVA and titrated doses of LPS (1.0, 100.0, 1000.0 ng/ml)
in the aerosol OVA solution. We found that there was inhibition
of allergic inflammation, mucus production, and immunoglobu-
lin at 1.0 and 1000.0 ng/ml added LPS but not at 100.0 ng/ml.
To determine whether the LPS suppression on memory
responses with low and high LPS doses involved B cells, we
did the same experiment in B cell deficient mice. Interestingly,
in the absence of B cells, we found suppression with
intermediate LPS doses but no effect with high and low doses
suggesting that B cells play a role in the LPS effect on recall
memory responses. In summary, our results show that LPS is
necessary during priming with certain proteins, such as OVA,
but not with others, such as with milk. Additionally, LPS has
AbstractsS58an inhibitory effect on memory responses that appears to
involve B cells.
F1.38. Differential Th2 Immune Responses in C57BL/6
and BALB/c Mice in a Novel Model of Milk-Induced
Allergic Asthma.
M. Zerbs,1 G. Dekan,2 G. Stingl,1 M. M. Epstein.1 1Dermatology,
Medical University of Vienna, Vienna, Austria; 2Clinical
Pathology, Medical University of Vienna, Vienna, Austria.
CowTs milk allergy is a significant health problem during
infancy and childhood. Patients are usually allergic to all the major
milk proteins in cowTs milk or formulas, including caseins, beta-
lactoglobulin, and alpha-lactalbumin and as a result develop
dermatitis, asthma, or anaphylaxis. Currently, there are no animal
models of milk-induced allergic asthma. The advantages of milk as
an allergen in experimental models is that it is natural and clinically
relevant, broadens the scope and general applicability of mouse
models of allergic asthma, induces an allergic response to a
combination of proteins, and is cost effective (3 kg of milk powder
in Vienna is 15.00 EUR; 50 g ovalbumin 900.00 EUR). To establish
models of acute and relapse milk-induced allergic asthma in mice,
we injected either BALB/c or C57BL/6 mice with 10 mcg of low-fat
milk powder dissolved in PBS intraperitoneally three weeks apart.
One week later we exposed mice to a series of 4 milk-aerosol
challenges with a 2% solution of milk powder in PBS, on two
consecutive days. Mice were either evaluated for disease during
acute onset of disease or recuperated in the following 2 months and
were then re-exposed to milk with a similar series of aerosol
challenges to generate disease relapse. We observed increased lung
inflammation, mucus secretion, and milk-specific IgE and IgG1 at
acute onset disease (day 31) and during relapses (day 90) in both
C57BL/6 and BALB/c mice. However, milk sensitization and
aerosolization induced 10-fold higher infiltrating inflammatory
cells in bronchoalveolar lavage fluid in C57BL/6 compared with
BALB/c mice. The percent eosinophils in the airways were 70 F
0.7 % for C57BL/6 and 31 F 3.5% for BALB/c mice, compared to
no eosinophils in naive and recovered mice. Furthermore, the
number of perivascular and peribronchial infiltrates and eosinophils
within the lungs in tissue sections reflected these differences.
Similarly, mucus hypersecretion and milk-specific IgE and IgG1
levels were higher in C57BL/6 compared to BALB/c mice and all
observed differences between strains were apparent in acute and
relapse disease. Recuperated C57BL/6 and BALB/c mice had
lymphocytic infiltrates in the lungs, as previously demonstrated in
ovalbumin-induced models. In contrast to ovalbumin-induced
allergic asthma, milk sensitization and aerosolization resulted in a
large difference between mouse strains, which is not yet fully
understood. Here, we present a useful, inexpensive, and clinically
relevant mouse model of milk allergy in C57BL/6 mice and
demonstrate significant genetic differences in immune responses of
C57BL/6 and BALB/c to cowTs milk.
F1.39. Response of Older Patients with Asthma to
Omalizumab: A Pooled Analysis across 5 Clinical Trials.
R. J. Maykut,1 Y. Deniz,2 M. Massanari,1 C. Reisner,3 F.
Kianifard,1 G. P. Geba.1 1US CD&MA, Novartis Pharmaceuticals
Corporation, East Hanover, NJ, USA; 2Clinical Development,
Genentech, Inc., South San Francisco, CA, USA; 3CRD, Novartis
Pharmaceuticals Corporation, East Hanover, NJ, USA.
Background: Asthma in older adults is under-recognized and
is often associated with allergic triggers. Anti-immunoglobulin E(IgE) therapy with omalizumab (OMA) is indicated in patients (z
12 years) with moderate to severe allergic asthma who continue to
be inadequately controlled despite treatment with inhaled cortico-
steroids. Previous analyses have not focused specifically on
efficacy in older adults. We examined treatment response to
OMA on asthma exacerbations as well as patient-reported and
investigator-reported global treatment effectiveness in patients 50
years and older.
Methods: Data were combined from 5 randomized double
blind placebo-controlled (PBO) trials of patients with moderate to
severe allergic asthma (confirmed by skin test or RAST testing); 4
were of 28 weeks and 1 was 32 weeks in duration. The pooled
study population involved a total of 2236 patients (1136 treated
with OMA, 1100 treated with PBO) who met entry criteria that
included, at baseline, need for treatment with moderate to high
dose inhaled corticosteroids. 601 subjects were z50 years of age.
The relative risk (RR) of clinically significant asthma exacerba-
tions (OMA vs. PBO; primary endpoint) was determined using
Poisson regression, controlling for age category, study, sex,
baseline IgE, and prior history of asthma exacerbations for the
overall population and for patients z50 years. A similar approach
was taken for evaluation of patient- and investigator-reported
global treatment effectiveness (excellent, good, moderate, poor,
worsening) using cumulative logistic regression for the two groups
comparing OMA to PBO.
Results: The mean age of the older subgroup was 58 years;
61% were female; the mean IgE level was 184 IU/dl (range 19–
743). For the overall study population the mean age was 40
years (range 12–79); 58% female; the mean IgE level was 211
IU/dl (range 19–1055). OMA was associated with a reduced risk
of clinically significant asthma exacerbations in all 5 trials
reviewed. Pooled analysis in the overall study population
revealed a RR (OMA vs. PBO) of 0.79 (95% CI 0.62-0.97). In
the subgroup of patients 50 or older, the RR was 0.72 (95% CI
0.48-1.09). The improvement shown with OMA was in agree-
ment with patient- and investigator-reported global effectiveness
which demonstrated significantly greater response (P b 0.0001)
on both measures in patients assigned to OMA relative to PBO
irrespective of age.
Conclusions: In patients z50 years of age, omalizumab was
associated with a RR reduction in clinically significant asthma
exacerbations and significantly better patient-and investigator-
reported global effectiveness ratings compared to placebo, suggest-
ing that omalizumab is effective in older patients with moderate to
severe allergic asthma. Treatments were generally well tolerated.
F1.40. Development of a CD154-Dependent Model of
IL-13 Producing B Cells.
O. Hajoui,1 J. Guay,1 S. Al-Tamemi,1,2 B. D. Mazer.1,2 1Meakins
Christie Laboratories, McGill University, Montreal, QC, Canada;
2Division of Allergy and Immunology, Montreal ChildrenTs
Hospital, Montreal, QC, Canada.
Our laboratory has demonstrated that human B lymphocytes
synthesize IL-13, and that autocrine production of this cytokine
appears to be essential for maintaining IgE production by these
cells. To initiate IgE synthesis, contact between CD40 on B cells
and CD40 ligand (CD40L or CD154) on Th2 cells is necessary. A
culture system, using murine CD154-transfected fibroblasts (LTK)
has been established for the propagation of human B cells in vitro.
Our objective is to develop a model of IL-13-producing B cell
using this co-culture system.
Abstracts S59Methods: Human B lymphocytes were isolated from tonsils
and purified by sheep red blood cell rosetting. LTK cells were
stably transfected with a cDNA encoding for the wild-type form of
the human CD154 protein. In the co-culture system, 5 105 B cells
were co-incubated with 1.3  105 untransfected LTK (CD154-)
cells or transfected LTK-4A1 (CD154+) cells and seeded in 24-
well plates. Isolated B cells were also stimulated with soluble anti-
CD40 antibody (1Ag/ml). Recombinant IL-4 (200U/ml) was added
to cultures and incubated up to 14 days to induce IgE production.
After 5 days of co-culture, detection of intracellular IL-13 in B
cells was assessed by flow cytometry. We also measured levels of
phosphorylated STAT6 by flow cytometry.
Resultats: Using BrdU staining, we demonstrated that LTK-
4A1 most efficiently supported survival of B lymphocytes with an
increase in proliferation (41.36% versus to 9.59%) compared to
soluble anti-CD40 antibodies. LTK-4A1 blocked apoptosis of B
lymphocytes more efficiently than soluble anti-CD40 (39.7% vs.
13.77%). Most importantly, after 5 days in culture with LTK-4A1,
the number of CD19+/IL-13+ B cells was significantly higher
(47.9% versus 17.1%) compared to the soluble anti-CD40 Ab. The
production of IgE by human B lymphocytes cultured with LTK-
4A1, as assessed by ELISA, also increased significantly (13.4 ng/
ml versus to 1.8 ng/ml) when compared to B cells stimulated with
soluble anti-CD40 antibodies. In contrast, IL-13 receptor signaling
was equally influenced by both culture systems. STAT6 phosphor-
ylation in response to exogenous IL-13 was nearly equal 24 hours
after co-culture with LTK-4A1 or with soluble anti-CD40
compared to the untransfected LTK control (75% of phospho-
STAT6 positive cells in co-culture with LTK-4A1 or with soluble
anti-CD40 versus 10% with LTK).
Conclusion: LTK-4A1 induces more efficient cross linking of
CD40 than soluble CD40 antibodies. This leads, in turn to high
levels of IL-13 positive B cells, not previously demonstrated. This
likely suggests that IL-13 production by B cells is important in
vivo. Th2 cytokine production by human B lymphocytes may be
underreported due to incomplete stimulation via CD40.
F1.41. Daclizumab Does Not Alter the Function of
Healthy Human CD4+CD25+ Regulatory T Cell In Vitro.
T. Sornasse,1 Y. Zhang,1 W. Hong,1 D. Polakoff,1 V. V. Vexler.1
1Research, Translational Medicine, Protein Design Labs, Inc.,
Fremont, CA, USA.
Rationale
Daclizumab (ZenapaxR), a humanized monoclonal antibody
directed against the IL-2 receptor a chain (CD25), is approved for
the prevention of renal allograft rejection and is under evaluation
for treatment of asthma, multiple sclerosis and other autoimmune
diseases. Daclizumab inhibits activation of human T lymphocytes
by blocking IL2-induced T cell proliferation, and by reducing
production of Th2- and Th1-associated cytokines.
Naturally occurring regulatory T cells (T Regs) are thought to
play an important role in the prevention of autoimmune diseases in
man and mouse (Sakaguchi, S. Annu Rev Immunol 22, 531-562
(2004)). Since T Regs are characterized by the constitutive
expression of high levels of CD25, we evaluated the in vitro
effect of daclizumab on the function of these cells.
Methods
CD4+ T cells were enriched from whole blood obtained from
healthy human donors using StemCell Technologies RosetteSepk
system. T Regs were flow sorted as CD4+CD25bright (top 1.5% of
CD25 staining intensity) and effector T cells (T Eff) were sorted asCD4+CD25- (bottom 5%of CD25 staining intensity). The inhibitory
activity of T Regs was assessed in a standard co-culture system.
Briefly, 2104 T Eff alone, T Reg alone, and T Eff + T Reg were
stimulated for 3 days in the presence of immobilized anti-CD3 in the
presence of irradiated autologous APCs. Proliferation was measured
by 3H-thymidine incorporation during the last 16 hours of culture.
Results
T Regs stimulated for 3 days in the presence of daclizumab (10
Ag/mL) showed no or little proliferation, similar to T Regs
stimulated in the absence of DAC. T Effs stimulated alone
demonstrated substantial proliferation that was inhibited by
daclizumab, on average by 40%. As expected, T Regs suppressed
the proliferation of T Effs in the co-culture system. In this system,
preincubation of T Regs with daclizumab did not affect the
suppressive activity of these cells.
Conclusions
In these co-culture experiments, daclizumab had no effect on
the function of T Reg cells but did inhibit T Eff cells from healthy
human volunteers.
F1.42. Respiratory Exposure to OVA Induce Functional
Effector CD4 T Cells.
B. Chiu,1 V. R. Stolberg,2 S. W. Chensue.1,2 1Pathologh,
University of Michigan Medical School, Ann Arbor, MI, USA;
2Pathology and Laboratory Medicine, VA Ann Arbor Healthcare
System, Ann Arbor, MI, USA.
Respiratory exposure to environmental antigens such as OVA
induces rapid expansion of antigen specific T helper cell
population in mice. Primary intranasal challenge with OVA
also induces differentiation of activated OVA specific effector
Th cells from naRve precursors. Effector function has been
demonstrated in short-term culture with antigen re-stimulation.
The effector Th cells are found both in draining lymph node
and in circulation. However, secondary intranasal challenge with
OVA fails to induce inflammation in the lung, even when the
size of the Th cell population is at its peak. Based on these
observations, Th cells primed in the respiratory system by
environmental antigens in the absence of adjuvant are viewed as
defective or anergic. In this study, we demonstrated the
expression of effector function of intranasal primed Th cells
in the lung following a challenge with antigen-bead emboli in
C57BL6 mice. Importantly, secondary intranasal challenge with
soluble antigen did not induce Th cell mediated inflammation in
the lung. These results suggest that Th cells primed via
respiratory route by environmental antigens are not anergic.
More importantly, it is clear that the expression of Th cell
effector function is tightly controlled by innate response in the
lung. Bead emboli, but not soluble OVA, induced rapid increase
of chemokine expression and rapid increase of the number of
activated dendritic cells in the lung. However, it is not clear
which innate events are critical for the expression of Th cell
effector function in the lung. We propose that loss of innate
regulation of Th cell effector function in a peripheral organ is
necessary for T cell mediated organ specific disorders.
F1.43. A-317491 Inhibits the Activation of Guinea-Pig
Pulmonary Vagal Sensory Nerve Terminals by
A,B-methylene-ATP.
A. Pelleg,1 B. J. Undem.2 1R&D, Duska Therapeutics, Inc., Bala
Cynwyd, PA, USA; 2Asthma Center, Johns Hopkins University,
Baltimore, MD, USA.
AbstractsS60Extracellular adenosine 5V-triphosphate (ATP) is a local
physiologic regulator. We have previously shown that ATP
stimulates bronchopulmonary vagal sensory terminals of nocicep-
tive C and stretch-sensitive A fibers, and that this action is
mediated by P2X receptors (R) (J Physiol (Lond) 490:265-75,
1996, ditto 551:869-79, 2003). The stimulatory action of ATP on C
and A fibers could be involved in ATP-induced bronchoconstric-
tion and cough. Vagal sensory neurons in the nodose ganglion
express homomeric P2X2R and P2X3R as well as heteromeric
P2X2/3R. To further explore the P2XR subtype that mediates ATP-
induced action potentials (AP) in nodose C and A fiber terminals in
the lungs, the effects of A-317491, a potent and selective
antagonist at P2X3R and P2X2/3R sites (Proc Natl Acad Sci
USA 99:17179-84; 2002), on the activation of guinea-pig intra-
pulmonary vagal sensory nerve terminals by a,h-methylene-ATP
(a,h mATP), a potent selective agonist at P2X3R and P2X2/3R
sites, were studied in a perfused isolated lung preparation. The AP
in C (n = 4) and A fibers (n = 7) induced by a,h mATP (10 AM,
1ml, bolus) in the absence and presence of A-317491 (1 and 10
uM, 30 min) were quantified as discharge/sec; data are mean + SD.
a,h mATP induced AP in a non-desensitizing manner in both C
and A fibers, the frequency was 146 F 29 and 1543 F 285,
respectively. A-317491 (10 AM) reduced this response by 62F 5%
and 88 F 5%, respectively (P b .05). At 1 uM, A-317491
significantly inhibited the action of a,h mATP in A fibers by 59 F
12%, but had no inhibitory effect on C fibers. Conclusion: a,h
mATP stimulates both nociceptive C and stretch-sensitive A fibers
by acting on P2X2/3R. The present data could also indicate some
difference in the nature of the P2XR subtype expressed on the two
fiber phenotypes. In addition, since aerosolized ATP induces
bronchoconstriction and cough in human subjects and more so in
patients with asthma and COPD, A-31749 could constitute a novel
therapeutic modality in the management of patients with chronic
obstructive airway diseases.
Support: Duska Therapeutics, Inc., Bala Cynwyd, Pennsylvania.
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F1.45. Sodium Sulfite Activates Mast Cells and
Basophils through Induction of Oxidative Stress.
C. R. Collaco,1 D. J. Hochman,1 R. M. Goldblum,1 E. G. Brooks.1
1Pediatrics, The University of Texas Medical Branch, Galveston,
TX, USA.
Sulfur dioxide is known to induce bronchoconstriction, and
asthmatics are particularly sensitive. The cell physiological basis
for this is unknown. We have investigated the biological basis for
sulfite sensitivity in a mast cell line (RBL-2H3), human peripheral
blood basophils, and airway epithelial cells. RBL-2H3 cells were
exposed to varying concentrations of sodium sulfite in the presence
and absence of anti-oxidants and inhibitors of redox pathways.
Sodium sulfite induced mast cell and basophil degranulation to a
level equivalent to that induced by IgE cross-linking and
ionomycin. The response was independent of extracellular calcium
influx. Using a redox sensitive fluorescent dye, 2V7V-dichlorofluor-
escein diacetate, sulfite was shown to increase the generation of
intracellular reactive oxygen species (ROS). Upregulation of
sulfite-induced ROS generation was also demonstrated in the
airway epithelial cell line, A549. Both ROS and degranulation
induced by sulfite was inhibited by the free radical scavenger
tetramethylthiourea and the flavoenzyme inhibitor diphenyleneio-
dinium. Overall, the data suggest that one potential mechanism ofsulfite-induced asthmatic symptoms may be due to activation of
airway mast cells and epithelial cells through the generation of
ROS via activation of the NADPH oxidase complex with increased
generation of superoxide anion.
F1.46. Structural Basis for Epitopes Sharing between
Group 1 Allergens of Cedar Pollen.
T. Midoro-Horiuti,1 C. H. Schein,2 V. Mathura,2 W. Braun,2
E. W. Czerwinski,2 A. Togawa,1 Y. Kondo,1 T. Oka,3 M.
Watanabe,4 R. M. Goldblum.1 1Pediatrics, University of Texas
Medical Branch, Galveston, TX, USA; 2Human Biological
Chemistry and Genetics, University of Texas Medical Branch,
Galveston, TX, USA; 3Oka Pharmacy, Tamano, Okayama, Japan;
4Tokyo Research Laboratories, Kowa Co., Ltd., Noguchi, Tokyo,
Japan.
Cedar pollen hypersensitivity is a major cause of seasonal
airway symptoms in several regions of the Northern Hemisphere.
Group 1 allergens have been isolated, cloned and sequenced from
the pollens of at least six cedar species. We recently resolved the
crystal structure and mapped the known IgE epitopes of Jun a 1
from mountain cedar (MC). Given the high degree of amino acid
sequence identity and evidence for immunologic cross-reactivity
between cedar allergens, we investigated the structural basis for
sharing of IgE epitopes between two group 1 allergens. Cross-
reactivity between Jun a 1 and Cry j 1 from Japanese cedar (JC)
was probed with sera from JC-allergic patients by ImmunoCAP
inhibition. Linear IgE epitopes were identified for Cry j 1 with an
array of overlapping Jun a 1 peptides, using sera from patients
allergic to JC. The binding of mouse monoclonal anti-Cry j 1
antibodies to these peptides were also tested. A 3-D model of the
Cry j 1 protein was prepared with the MPACK suite, using the
crystal structure of Jun a 1 as the template. ImmunoCAP inhibition
indicated that about 1/3 of the IgE anti-JC pollen antibodies in the
sera of JC-allergic patients reacted with Jun a 1. Peptides
representing 3 of the 4 Jun a 1 epitopes bound human IgE anti-
Cry j 1 antibodies. These epitopes mapped to regions of the Cry j 1
model that had similar surface exposure to homologous regions of
the Jun a 1 crystal structure. One epitope, which maps to the beta-
helical core of Jun a 1 was not recognized by the sera of JC
patients, despite complete sequence identity and apparent similarity
of surface exposure. Monoclonal antibodies to Cry j 1 identified
another shared epitope that is probably conformational and one
unique Cry j 1 epitope, which may be a glycopeptide structure.
These findings indicate that the IgE antibodies to several linear and
conformational IgE epitopes of group 1 cedar allergens cross-react
with homologous allergens. The shared responses may recognize
structural elements common to many plant allergens. These
findings suggest that patients from genetically diverse population
respond to similar linear and conformational epitopes of homol-
ogous allergens. Understanding the similarity and difference in the
immune responses to groups of allergens will aid in the develop-
ment of more effective allergy vaccines.
F1.47. Food Allergy Related Hospitalizations New York
State Hospitals from 1994-2003.
L. R. Forbes,1 R. Y. Lin.2 1Pediatrics, St. VincentTs Medical Center
Manhattan, New York, NY, USA; 2Medicine, St. VincentTs Medical
Center Manhattan, New York, NY, USA.
Objective: To profile hospital admissions for food allergy in
New York state with respect to demographic characteristics
including age, gender, race, and year. Also to compare food
Abstracts S61allergy admissions with admissions related to other acute allergic
diseases.
Methods: A database of all acute hospitalizations in New York
state was examined from 1994-2003. The Statewide Planning and
Cooperative Research System (SPARCS) database compiles
mandatory reporting from acute care hospitals with an information
input regarding diagnoses, disposition, procedures, insurance,
demographics, and charges. Patient admissions with diagnosis
(principal or otherwise) for food allergy (using ICD-9 codes V15.0,
995.6) or other allergic diseases including anaphylaxis, urticaria
and allergy unspecified (ICD-9 codes of 995.0, 995.1, 999.4, and
708) were extracted. Demographic characteristics were tabulated
for the hospitalizations and patterns were examined. Admissions
for food allergy were compared to admissions for other acute
allergic diseases.
Results: Over the decade examined, admissions for New York
state hospitals which coded for allergic disease exclusive of food
related codes increased only by less than 5%. However, the
number of admissions for allergic conditions involving food
allergy tripled. The median age for allergic disease related
admissions increased over the years studied; however, the median
age for food allergy admissions actually decreased. The increase
in age for non-food related allergic disease admissions appeared
to be primarily due to an increase in angioedema admissions
where the age was greater. Food allergy related admissions
increased more in non-African American patients than in African
American patients over the decade study. In contrast, allergy
related admissions exclusive of food related codes increased in
African Americans, especially angioedema. Age related differ-
ences were observed with respect to specific foods causing
anaphylaxis.
Conclusions: Food allergy related hospitalizations are being
increasingly reported in New York State. Whether an increase in
food allergy related hospitalizations relate to and increase in food
allergy or a greater awareness of these conditions cannot be
determined, but further research on patterns of food allergy related
hospitalization is clearly warranted.
F1.48. Vitamin E Supplementation Augments the Levels
of Endogenous Antioxidants and Improves Lung
Function in Asthmatic Patients.
Ahmed Nadeem, Sunil K. Chhabra, Hanumanthrao G. Raj.
1Department of Biochemistry, Vallabhbhai Patel Chest Institute,
University of Delhi, Delhi, India; 2Department of
Cardiorespiratory Physiology, Vallabhbhai Patel Chest
Institute,University of Delhi, Delhi, India.
Asthma is a chronic inflammatory disease with established
oxidant-antioxidant imbalance. Antioxidant therapy might be a
better strategy to augment endogenous antioxidants for better
management of asthma. Vitamin E is a strong lipophilic
antioxidant with multiple actions both at biochemical and cellular
level. Effects of its supplementation with standard therapy have
not been explored in asthmatics. We conducted a double blind
standard therapy-controlled study to assess the role of exogenous
supplementation of vitamin E on endogenous oxidant-antioxidant
balance in asthmatics. Fifty six patients were divided into two
groups: 1) placebo group, patients on standard therapy and 2)
vitamin E-supplemented group, patients on standard therapy plus
400 I.U. of vitamin E capsules twice daily. Venous blood was
collected on day 1 as baseline, then again after 8 weeks of
respective treatments. The present study showed that standardtherapy as well vitamin E-supplemented group had lower levels of
superoxide anion generation as compared to the baseline. Plasma
glutathione peroxidase (GSH-Px) was increased in standard
therapy group whereas no difference was found in plasma GSH-
Px from baseline in vitamin E-supplemented group. Plasma lipid
peroxides were increased and total antioxidant capacity was
decreased in standard therapy group whereas vitamin E-supple-
mented group had significantly lower levels of lipid peroxides and
higher total antioxidant capacity. Total blood glutathione was also
decreased in standard therapy group whereas no significant
difference was found in vitamin E-supplemented group. Plasma
nitrates and nitrites (NOx) were decreased in standard therapy
group whereas they were increased in vitamin E-supplemented
group. Plasma protein sulfhydryls and red cell superoxide
dismutase (SOD) levels were increased in standard therapy group,
while there was no change from baseline in red cell SOD activity
in vitamin E-supplemented group, the levels of the former
remained increased in this group also. No significant difference
was found in plasma protein carbonyls and red cell catalase in
either standard therapy group or vitamin E-supplemented group.
Plasma vitamin E levels increased more than two fold after
vitamin E supplementation but no change was observed in
standard therapy group. There was significant improvement in
FEV1% predicted in both the groups after 8 weeks of respective
treatments but vitamin E-supplemented group had greater degree
of improvement in terms of % increase from baseline. Our study
provides biochemical and clinical evidence for the first time that
vitamin E augments endogenous antioxidant screen and improves
lung function. So, it may be used as an adjunct therapy in the
treatment of asthmatics.
Bone Marrow or Stem Cell Transplantation
F1.49. Recovery of CD4 and CD8 Lymphocyte Subsets
and Their Impact on Acute Graft-vs. Host Disease
(GVHD) after Reduced Intensity Conditioning (RIC)
Allogeneic Stem Cell Transplantation (allo-SCT).
M. Mohty,1 D. Blaise,1 C. Faucher,1 D. Olive,1 B. Gaugler.1
1Immunologie des Tumeurs, Insitut Paoli-Calmettes, Marseille,
France.
RIC regimens (including highly immunosuppressive non-
myeloablative therapy in replacement of high dose chemotherapy
or radiotherapy) for allo-SCT, are being explored with good
results concerning feasibility and engraftment. However, little is
known about the immune recovery pattern in these patients,
especially the different CD4 and CD8 lymphoid T cell subsets.
Here, we assessed at different time points after allo-SCT, the
kinetic of recovery of naRve (CD45RA+/CD27+), central memory
(CD45RA-/CD27+), and terminally differentiated (CD45RA+/
CD27-) CD4+ and CD8+ T lymphocytes in 64 patients from a
single center, receiving HLA-identical RIC allo-SCT. Patients and
graft characteristics are: age 48 y (27–63), diagnoses: 22 myeloid
malignancies (34%), 22 lymphoid malignancies (34%) and 20
metastatic solid tumors (31%). 51 pts (80%) were considered as
high risk. 49 pts (77%) received a fludarabine, busulfan and
antithymocyte globulin-based RIC, while 15 pts (23%) received a
low dose irradiation-based RIC. 91% of patients received a
peripheral blood stem cell graft, with 42 (66%) receiving cyclo-
sporine (CSA) alone for GVHD prophylaxis and 22 (34%)
receiving CSA and MMF. 24 pts (38%) developed grade 2–4 acute
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CD4+ T cell subsets, CD8+ T cell subsets had a progressive and
sustained recovery in the first 3 months after allo-SCT, with
acquisition of functional markers such as 2B4 and perforin. Among
the different subsets analyzed, the recovery of naRve CD4+ T cells,
and central memory CD4+ and CD8+ T cells, measured at day 28
after allo-SCTand before onset of grade 2-4 acute GVHD, showed a
significant correlation with the risk of grade 2–4 acute GVHD (P =
0.001; P = 0.002 and P = 0.05 respectively). Patients developing
grade 2–4 acute GVHD recovered a median of 47 naRve CD4+ T
cells/AL prior to onset of GVHD as compared to 11 cells/AL in
patients with grade 0–1 acute GVHD. NaRve CD4+ T cell levels
significantly decreased after appropriate acute GVHD treatment. In
a Cox multivariate analysis taking into account all relevant risk
factors for acute GVHD, early recovery of naRve CD4+/CD45RA+/
CD27+ T cells in the first month after allo-SCT was the strongest
parameter significantly predictive of grade 2–4 acute GVHD
development (P = 0.006; Rr = 4.0; 95%CI, 1.5–11.0). Interestingly,
there was a significant correlation between the total number of
CD4+ T cells infused with the allogeneic graft and the early
recovery of naRve CD4+ T cells (P = 0.001), suggesting that graft
manipulation might represent an attractive tool towards harnessing
alloreactivity after RIC-allo-SCT.
F1.50. Cross-Presentation of Minor Histocompatibility
Antigens Requires Dendritic Cells and
Immunoproteasomes.
T. M. Hill,1 L. Van Kaer,1 J. W. Yewdell,2 D. C. Roopenian,3
S. Joyce.1 1Microbiology and Immunology, Vanderbilt University
School of Medicine, Nashville, TN, USA; 2Laboratory of Viral
Diseases, National Institute of Allergy and Infectious Diseases,
National Institutes of Health, Bethesda, MD, USA; 3The Jackson
Laboratory, Bar Harbor, ME, USA.
CD8 T lymphocytes (CTL) play a major role in mediating
allograft rejection in MHC-identical solid and bone marrow trans-
plant settings. In such instances, alloreactivity is directed towards
either donor- (solid organ) or recipient- (bone marrow) derived
antigens that often represent only minor variations of self. Such
alloantigens are called minor histocompatibility (minor H) antigens.
These variant minor H antigens elicit robust CTL responses that in
the most severe cases lead to graft versus host disease (GVHD) or
graft rejection, and may result in death. The molecular mechanisms
by which minor H antigens are processed and presented to donor or
recipient CTL remain poorly understood. In this study, we have
exploited mice deficient in various aspects of antigen presentation to
demonstrate the roles of both donor- and recipient-derived dendritic
cells and proteasomes in the aquisition, processing, and cross-
presentation of minor H antigens. Our findings reveal an important
role for recipient dendritic cells and donor proteasomes in the
generation of an effective minor H antigen response. These findings
have important implications not only for the understanding of
GVHD, but for viral and tumor vaccine design as well.
F1.51. Permanent Mixed Chimerism in Mice by Short,
Low Toxicity, Radiation Free Treatment Allows
Myoblast Allograft Tolerance across Fully
MHC-Mismatched Barriers.
L. Stephan,1 J. P. Tremblay.2 1Human Genetic, CRCHUL, Quebec,
QC, Canada; 2Human Genetic, CRCHUL, Quebec, QC, Canada.
Duchenne muscular dystrophy (DMD) a fatal neuromuscular
recessive disease is characterized by widespread muscle damagethroughout the body. No cure is currently available for DMD. Our
research group is pursuing a research program to develop a
treatment based on healthy donor myoblast transplantation (MT).
A sustained FK506 immunosuppression is currently required to
prevent rejection of allogeneic human MT. However, the major
draw back of MT is that long-term use of immunosuppressive
treatments is associated with adverse effects: nephrotoxicity,
increased cancer risk etc. . .
During last years, transplantation tolerance has been obtained
by development of stable donor-specific chimerism resulted by
bone marrow transplantation (BMT). Induction of stable multi-
lineage chimerism (SMLC) across fully MHC-mismatched
barriers have been established by a busulfan myelosuppressive
treatment in mice primed with an allogenic spleen cells trans-
fusion followed by a single cyclophosphamide (Cyp) dose, an
immunosuppressive drug. We have developed a protocol to obtain
same SMLC with donor BMT following by a conditioning
regimen involving a treatment with single Cyp(200mg/kg) dose
and low treosulfan (Treo) dose (3*500mg/kg), a less toxic
busulfan analog. We tried to obtain similar chimeris level in
mdx mice, a dystrophic mouse model, with Cyp/Treo based
protocol in order to prevent rejection of allogeneic healthy Balb/c
myoblasts and of the muscle fibers that they formed in grafted
tibialis anterior (TA).
All mice (9) treated, have variable mixed chimerism levels
(0.5–55%) for leukocyte cells population (CD90) 230 days after
the BMT. Most (5/9) treated mice have CD90 chimerism
between 10 and 20%. All treated mice have variable chimerism
level in (CD4+ or CD8+) T-cell population in same proportion
as CD90 population. Consequently, mice have developed
SMLC. Dystrophin positive fibers were present in chimeric
TA mice 100 and 200 days after MT. Hybrid fibers number
was equivalent to the one observed in TA sections of mdx
mice treated with FK506 immunosuppression. No infiltration
with CD4, CD8 T-cells was observed around dystrophin
positive fibers at 100 or 200 days after MT. To test tolerance
ddresistanceTT capacity, we have done a challenge by initially
grafting donor myoblasts in mice left (6) TA using Cyp/Treo
protocol developed above. One hundred days later, a second
MT from the same donor strain was performed in the right TA
without any additional therapy. Mice were sacrificed 100 days
after the second MT. In both TA grafted, we observed
dystrophin positive fibers and no CD4 or CD8 T-cells
infiltration. Thus, we conclude that first grafts can survive
after challenge with donor antigen/MT without additional
treatment.
Taken together, we show that Treo low toxicity associated with
a protocol which does not require any irradiation and using only
clinical use approved drugs, would permit to obtain safe sustained
immunological tolerance of the DMD patients for donor MT.
Accordingly, it could be applied as a conditioning regimen for
several other organ or tissue transplantations.
F1.52. Neonatal CD4+ CD25+ T Cells—Age Restricted
Development of Immune Tolerance.
R. Reibke,1 B. Arnold,2 G. J. Hammerling.2 1Dept. of Internal
Medicine III, University of Munich, Klinikum Grosshadern,
Munich, Germany; 2Molecular Immunology, German Cancer
Research Center, Heidelberg, Germany.
The regulation of immune responses is an intrinsic capacity of
the developed immune system and is believed to be mediated by
Abstracts S63specialised T cells. The CD4+ CD25+ T cell is the best defined
subset with regulatory function. Being essential in maintaining
immune balance in mice and having shown regulatory capacity in
man, the prerequisites for their development are still controversial.
However, understanding the developmentally needs for immune
tolerance might facilitate its manipulation.
Having shown that the neonatal phase is pivotal to induce
dominant tolerance to peripheral antigens, we built up a syngeneic
bone marrow transplantation model to determine whether develop-
ment of regulatory T cells is restricted to a certain developmentally
window.
For that reason, rag-/- mice were transplanted with T cell
depleted rag F bone marrow. After reconstitution, non-irradiated
recipients showed immune dysregulation and died of wasting
disease. Disease was driven by host derived T cells. Bone marrow
derived T cells abolished disease, whereas TCR transgenic or
neonatal recipients were not protected. Depletion of CD4+/
CD25+ cells alone resembled whole T cell depletion, whereas
addition of bone marrow derived CD4 cells prevented, or even
cured, disease up to 30days after BMT. Strikingly, T cells
developed in bone marrow chimeras were ineffective. Taken
together, these results demonstrate, that regulatory T cells might
be helpful tools treating immune dysregulation. However, their
development is restricted to a certain developmentally window in
early live while its largely diminished in adults or after BMT.
Understanding development and role of regulatory T cells in
immune reconstitution will allow us to improve GvT reactions
while avoiding GvHD.
F1.53. In Vivo Neutralization of Both Interferon Gamma
(IFN-g) and Interleukin-2 (IL-2) Accelerates Anti-Host
Cytotoxic T Lymphocyte (CTL) Development and Acute
Graft-Versus-Host Disease (GVHD) in the
Parent-Into-F1 Model.
I. A. Puliaeva,1 R. A. Puliaev,1 F. D. Finkelman,2 C. S. Via.1
1Pathology, Uniformed Services University of Health Sciences,
Bethesda, MD, USA; 2Medicine, University of Cincinnati College
of Medicine, Cincinnati, OH, USA.
The parent-into-F1 model of acute GVHD is a useful model of
in vivo CTL development. We have previously demonstrated that
anti-host CTLs characteristic of acute GVHD in the B6-into-F1
model are impaired with selective blockade of either IL-2 or IFN-
g. Surprisingly, preliminary experiments indicated that at 14 days
after donor transfer, mice receiving combined IL-2 and IFN-g
blockade exhibited more severe lymphopenia than untreated acute
GVHD suggesting a paradoxical worsening of disease when
compared to selective blockade of either IL-2 or IFN-g alone. To
address the mechanism involved, acute GVHD was induced in
B6D2F1 mice by the injection of 50 million B6 wild type (WT)
parental spleen cells or 50 million B6 IFN-g -/- donors plus
neutralizing anti-IFN-g mAb (XMG-6, 1 mg i.v. weekly).
Neutralization of IL-2 was achieved with 2 mg anti-IL-2 mAb
(S4B6) weekly i.v. Controls consisted of normal F1 mice or
GVHD mice receiving IFN-g blockade alone, or control mAb
alone (GL117). At 7, 10 and 14 days after parental cell transfer,
mice were assessed for splenic lymphocyte subpopulations by
flow cytometry and for ex vivo anti-host CTL activity. Our
results indicate that peak donor CD8+ T cell expansion (day 10)
is 2-fold greater for GVHD mice receiving combined IFN-g and
IL-2 blockade compared to untreated or control mAb treated WTGVHD mice. Importantly, combined IFN-g and IL-2 blockade
accelerated GVHD phenotype with peak anti-host CTL activity
seen at day 7 (vs. day 10 for WT GVHD) and complete host B
cell elimination and CTL downregulation seen at day 10 (vs. day
14 for WT GVHD). Of note, at day 7, GVHD mice receiving
combined IFN-g and IL-2 blockade did not differ from IFN-g
only blockade GVHD mice with respect to donor T cell
engraftment or host B cell elimination. These results support
the hypothesis that the early absence of IFN-g accelerates CTL
development regardless of the presence of IL-2. In contrast, the
absence of IL-2 after day 7 permits greater CD8+ T cell
expansion, consistent with the loss of an IL-2 dependent
regulatory mechanism.
F1.54. Role of Apoptotic Cells in the Induction of
Regulatory T Cells.
Kim A. Campbell,1 Amy Krutsick,1 Janine Huber,1 David Peritt.1
1Research & Clinical Development, Therakos, Inc., Exton, PA,
USA.
Extracorporeal photopheresis (ECP) is an immunomodulatory
cell therapy being investigated as a treatment for various
immune-mediated inflammatory disorders. Clinically, ECP
involves the intravenous reinfusion of autologous, apoptotic
peripheral blood leukocytes. In animal models, delivery of
apoptotic cells has been shown to regulate immune responses
through the modulation of cytokines, generation of regulatory T
cells, and downregulation of antigen-presenting cell (APC)
function. We and others have shown that activation of naRve T
cells in the presence of APCs that have engulfed ECP-treated
apoptotic cells leads to the generation of a T cell population with
suppressive activity. In the present study, we demonstrate that the
direct interaction of ECP-treated peripheral blood mononuclear
cells (PBMCs) with naRve human CD4+ T cells in vitro promotes
a T cell phenotype with regulatory activity. The generation of
human regulatory T cells by ECP is dependent on APCs and can
be reversed by the addition of IL-2. CD25 expression is
upregulated on these regulatory T cells and they proliferate in
response to concanavalin-A. However, these regulatory T cells do
not express increased levels of Foxp3 or IL-10, nor do they
secrete significant levels of the pro-inflammatory cytokines IL-2,
IFNg, IL-4, and TNFa. Transfer of ECP-derived regulatory T
cells to a secondary mixed lymphocyte reaction results in a
greater than 50% inhibition of syngeneic responder T cell
proliferation and IFNg production at a Treg:responder ratio of
1:20. In addition, transwell assays demonstrate that inhibition of
responder T cells by ECP-derived regulatory T cells is contact-
dependent. Additional studies are underway to further character-
ize the phenotype of these regulatory cells and to determine their
suppressive capacity in vivo.
F1.55. Distribution of CD4+25+ Cells in Fetal Sheep
Early in Gestation.
Alireza Torabi,1 John S. Pixley,2 Jessica Chase, Esmail D.
Zanjani.1 1Department of Animal Biotechnology and Department
of Medicine, University of Nevada, Reno, Reno, NV, USA; 2VA
Medical Center, University of Nevada, Reno, Reno, NV, USA.
Our laboratory has shown that transplantation of hemato-
poietic stem cells (HSCs) into fetal sheep results in long-term
multi-lineage hematopoietic chimerism. This observation demon-
strates that tolerance can be induced during prenatal period by
early injection of HSCs (optimal age for transplantation = 55–65
AbstractsS64days of gestation, term = 145 days). However, the relationship
between hematopoietic chimerism and tolerance has remained
obscure. In order to understand the ontogeny of immune system
in fetal sheep, we analyzed various cell populations in the
thymus, spleen, bone marrow (BM), small intestine (site of
PeyerTs patch formation), liver, and peripheral blood (PB) of fetal
sheep, between days 39 to 82 gestation, by flowcytometery.
These observations demonstrated that at day 39 the thymus
contains up to 9% CD4+25+ cells. This population is minimally
detectable at days 45 and 52 (0–1%); however increases to 11%
at day 58 and then diminishes to 1–2% by day 65 and 2.5% at
day 82. At day 58 of gestation, there is a peak CD4+25+ cells
population in PB, BM, and liver as well. CD4+25+ cells are seen
in BM, small intestine, and spleen at day 39 of gestation but not
liver and PB. CD4+25+ expression in the small intestine
increased from 8% at day 39 to 40% at day 82. However, in
BM and spleen, CD4+25+ expression diminishes to 2% at day 82
of gestation.
The CD4+25+ cell population in peripheral lymphoid organs, at
early gestational ages, express CD45R, likely a memory phenotype
of T cells (as described before by Cooper et al. Journal of
immunology, 1994, 152: 3098). Immunohistochemistry studies at
day 58 show CD45R cells abruptly increase in the medulla of the
thymus, but decrease at day 65 and gradually increase at day 82.
These data suggest that there is a population of CD4+25+45R+
cells (phenotypically consistence with T regulatory cells) in the
primary and secondary lymphoid organs early in gestation. These
data support the establishment of peripheral tolerance early in
gestation that may have a role in tolerance induction following in
utero HSCs transplantation.
F1.56. Clinical Relevance of Recipient Leukocyte
Infusion (RLI) Therapy.
T. I. Saito,1 M. Sykes.1 1TBRC/BMT Section, Massachusetts
General Hospital, Boston, MA, USA.
BACKGROUND
Surprisingly, anti-tumor responses can occur in patients who
reject donor grafts following nonmyeloablative hematopoietic cell
transplantation (Dey et al., Biol Blood Marrow Transplant 7:604).
In murine mixed chimeras prepared with nonmyeloablative
conditioning, we previously showed that recipient leukocyte
infusions (RLI) induced anti-tumor responses against host-type
tumors (Rubio et al. Blood 102:2300).
To further investigate the clinical relevance of this RLI model,
we:
1. Evaluated the effect of RLI from tumor-bearing mice
2. Compared RLI with allogeneic lymphocyte infusion in
untreated mice.
METHODS
Mixed chimerism was achieved in BALB/c (H-2d) mice
conditioned with depleting anti-CD4 and CD8 mAbs on Day-5,
cyclophosphamide 200 mg/kg on Day -1 and 7 Gy thymic
irradiation on Day 0 prior to transplantation of 25  106 B10.BR
(H-2k) bone marrow cells. Some groups received RLI (3107
BALB/c spleen cells) seven weeks post-BMT. Some RLI donor
mice received BALB/c A20 B cell lymphoma cells (1  105) two
weeks before RLI. Some groups received RLI depleted of B cells by
MACS column for purging tumor cells. A20 cells (5  105) were
given i.v. one week after RLI in chimeras or after allogeneic
lymphocyte infusion (3  107 B10.BR spleen cells) to untreated
BALB/c mice.RESULTS
In the clinical setting, RLI would be obtained from tumor-
bearing hosts. We therefore examined whether RLI is still
effective when the lymphocytes are obtained from tumor-bearing
mice. Recipients of RLI from tumor-bearing mice showed similar
tumor survival compared to recipients of RLI from naive donors.
Thus, with a purging procedure, the same anti-tumor effect was
achieved with RLI from tumor-bearing hosts as from non-tumor-
bearing hosts.
Allogeneic lymphocyte injection is a potentially feasible anti-
tumor therapy. We therefore compared anti-tumor effects of
allogeneic lymphocyte infusion into naive mice with that of RLI
given to mixed chimeras. RLI recipients had longer survival than
naive mice receiving allogeneic lymphocytes. This result suggests
not only that the anti-tumor effect of RLI therapy is stronger than
allogeneic lymphocyte infusion therapy but also suggests that
rejection of allogeneic cells is insufficient and mixed chimerism is
required prior to the induced rejection to achieve maximum anti-
tumor effects.
CONCLUSION
Together, these data reinforce the potential of RLI therapy to be a
newHSCTstrategy which does not have the risk of graft-versus-host
disease.
F1.57. Anti-Mouse Thymocyte Globulin Administration
Prevents Acute Graft-versus-Host Disease in a Murine
Model.
M. C. Ruzek,1 J. S. Waire,1 A. Vitsky,2 J. Williams,3 S. M.
Richards,1 R. D. Garman.1 1Immunology and Clinical Laboratory
Sciences, Genzyme Corporation, Framingham, MA, USA;
2Pathology, Genzyme Corporation, Framingham, MA, USA;
3Immune Mediated Diseases, Genzyme Corporation, Framingham,
MA, USA.
ThymoglobulinR, a rabbit anti-human thymocyte globulin, is
FDA approved for use in acute transplant rejection. Positive
results in this setting suggest that ThymoglobulinR would likely
be effective against graft-versus-host disease. To test this
hyothesis preclinically, we generated an anti-mouse thymocyte
antiserum (mATG) by immunizing rabbits with mouse thymo-
cytes and purifying IgG from the resulting immuneserum. These
methods were performed identically to those used to generate
ThymoglobulinR, the human counterpart ATG. In addition, a
model of acute graft-versus-host disease (GVHD) was devel-
oped. GVHD was induced by transfer of spleen cells from
C57BL/6 mice into non-irradiated BALB/c RAG-2 deficient
mice that lack mature T and B cells. Following transfer of the
allogeneic cells, the C57BL/6 hosts displayed progressive weight
loss which was accompanied by increased production of a
variety of proinflammatory cytokines detected in the serum,
hepatic necrosis and inflammation in several organs. In the
absence of therapeutic intervention, control mice display
significant disease within 3 weeks. We then applied mATG at
various time points following cell transfer in the GVHD model
to evaluate its effectiveness in disease prevention/reversal.
Administration of mATG at days 0–3 post allogeneic cell
transfer depletes most T cells from the circulation (FACS
analysis) and completely prevents all evidence of acute GVHD.
GVH mice treated with mATG showed no evidence of weight
loss, elevated cytokine levels or target organ pathology. This
protective effect of mATG on acute GVHD persisted for at least
12 weeks. We also tested the effectiveness of mouse ATG
Abstracts S65treatment given after acute GVHD was well established. In
contrast to mATG administration at the initiation of disease,
treatment 10–13 days following allogeneic cell transfer showed
no evidence of GVHD amelioration. Thus, we show that dependent
upon timing of dosing, mATG treatment can be quite effective at
preventing acute GVH in a murine model of disease. These results
suggest that exploration of ThymoglobulinR dosing in relation to
bone marrow transplant in human patients as prophylaxis for
GVHD is warranted.
This work is supported by Genzyme Corporation.
F1.58. IFN-Gamma Promotes Lymphohematopoietic
GVH Reactions while Attenuating GVHD in Murine
Allogeneic Hematopoietic Cell Transplantation Models.
Hui Wang,1 Shumei Wang,1 Megan Sykes,1 Yong-Guang Yang.1
1Bone Marrow Transplantation Section, Transplantation Biology
Research Center, Boston, MA, USA.
The role of IFN-g in the induction of graft-versus-host disease
(GVHD) after allogeneic hematopoietic cell transplantation (allo-
HCT) has been elusive. IFN-g is protective in lethally irradiated
mice receiving allogeneic T cells plus marrow cells, but
deleterious in non-conditioned or sublethally irradiated recipients
of allogeneic T cells alone (i.e., without marrow cells). We have
recently observed that T cells from IFN-g KO donors induce
more severe damage in parenchymal GVHD target tissues, but
have reduced ability to eliminate recipient hematopoietic cells in
lethally irradiated murine allo-HCT models. These results suggest
that the deleterious effect of IFN-g in allo-HCT recipients of
donor T cells alone might be due to facilitation of anti-host
lymphohematopoietic GVH reactions, which result in destruction
of host type hematopoietic cells and hematopoietic failure of the
recipients. To test this hypothesis, we compared the development
of GVHD in sublethally irradiated (6 Gy) B6D2F1 mice that
received splenocytes alone or along with bone marrow cells
(BMC) from IFN-g KO or wild-type (WT) B6 donors. B6D2F1
mice that received sublethal irradiation alone were used as non-
GVHD controls and all survived long-term. Consistent with
published studies, the recipients of WT B6 splenocytes alone
(without BMC, so that the inoculum contained minimal numbers
of hematopoietic stem cells) developed more severe GVHD
compared to mice receiving a similar number of splenocytes from
KO B6 donors (P b 0.05). In contrast, when mice received donor
spleen cells along with BMC, the recipients of KO allo-HCT
developed severe acute GVHD and succumbed to death by 5
weeks, while most of the recipients of WT allo-HCT survived
long-term (P b 0.01). Unlike the recipients of WT allo-HCT, the
addition of BMC to splenocytes did not significantly delay
GVHD death in the recipients of GKO allo-HCT. In order to
quantitatively evaluate the ability of WT vs. IFN-g KO donor T
cells to induce lethal GVHD, we compared the survival of
lethally irradiated B6D2F1 mice that received a fixed number of
BMC along with titrated numbers of splenocytes from WT or
IFN-g KO B6 mice. The minimal number of splenocytes needed
to induce lethal GVHD was approximately 10 fold less for KO
than WT donor cells. Taken together, our results indicate that WT
allo-HCT mediates stronger lymphohematopoietic GVH reactions
than GKO allo-HCT, but the latter cause more severe damage in
parenchymal tissues. Since lymphohematopoietic GVH reactions
may selectively eliminate host lymphohematopoietic cells, includ-
ing lymphoma cells, a better understanding of the mechanisms by
which IFN-g separates the two types of GVH reactions could leadto novel approaches to separating GVHD and graft-vs.-leukemic
effects.
F1.59. Distinct Effects of Early and Delayed
CTLA4-Blockade after Murine miHC-Disparate
Allogeneic Bone Marrow Transplantation:
Graft-Versus-Host Disease Versus Auto-Immunity.
S. Fevery,1 P. Vandenberghe,2 B. Sprangers,1 O. Rutgeerts,1
C. Lenaerts,1 J. Goebels,1 C. Segers,1 W. Landuyt,3 L. Boon,6 A.
Kasran,4 C. De Wolf-Peeters,5 M. Waer,1 A. D. Billiau.1 1Lab.
Experimental Transplantation, University of Leuven, Leuven,
Belgium; 2Center of Human Genetics; 3Lab. Experimental
Radiotherapy; 4Lab. Experimental Immunology; 5Dep. Pathology,
University of Leuven, Leuven, Belgium; 6Bioceros NV, Amsterdam,
Netherlands.
Background: It has been shown that CTLA-4 blockade early
after murine MHC-disparate allogeneic bone marrow transplanta-
tion (BMT) results in augmentation of donor or host alloreactivity
(graft-vs-host disease (GVHD), resp. rejection). Later after BMT,
CTLA-4 blockade in combination with DLI induced a graft-vs-
leukemia (GVL) effect with a slightly increased risk for GVHD.
Aim: To explore, in a model of MHC-compatible, miHC-
disparate allo BMT, how CTLA-4 blockade can be used to
modulate GVHD and to induce GVL effects. Materials &
Methods: C3H  AKR 7,5 Gy radiation BM chimeras were
treated with blocking anti-CTLA-4 MoAb (UC10-4F10) or
irrelevant Hamster IgG, early (d-1 to 12) or late (d21 to 34).
Mice were monitored for weight changes, clinical signs of GVHD
and survival. Moribund animals were sacrificed for histopathol-
ogy. FACS was used to study T cell chimerism and host/donor-
reactive T cell-frequency, MLR to study ex vivo alloreactivity,
ELISA to determine circulating antiDNA Ab. Results: CTLA-4-
blockade early after non-T cell depleted (TCD) allo BMT induced
acute and (N90%) lethal GVHD (increased donor T cell
chimerism and alloreactive TCR-Vb6+ cells), histopathologically
confirmed. Late after non-TCD allo BMT, however, CTLA-4-
blockade induced weight loss, alopecia, splenomegaly, lympha-
denopathy and cachexia with 60% mortality. Treated and non-
treated animals did not show any difference in chimerism or
alloreactive T cell-frequency. Histopathology showed lymphopro-
liferation in spleen, lymph nodes but also in stomach, intestine,
salivary glands and liver. In the liver, periportal infiltrates showed
numerous plasmacells. AntiDNA Abs and liver-enzyme abnor-
malities were detected in the treated group. Ex vivo, splenocytes
of diseased animals showed strikingly strong spontaneous
proliferation but MLR reactivity towards host- or donor-type
antigens was equal to that of tolerant non-treated chimeras.
Conclusions: In a miHC-disparate context, CTLA-4-blockade,
early after non-TCD BMT induces vigorous acute GVHD,
consistent with activation of alloreactive T cells from the BM
inoculum. In contrast, CTLA-4 blockade from day 21 onwards
does not give rise to the breaking of transplantation tolerance,
however, induces a lymphoproliferative syndrome with auto-
immune manifestations.Our data suggest that after non-TCD allo
miHC-disparate BMT, donor-host tolerance relies on clonal
deletion which is insensitive to aCTLA-4 Ab. In contrast,
tolerance to self is maintained by peripheral tolerance mecha-
nisms, in which CTLA-4 signaling appears to play a major
role.We are currently investigating if CTLA-4 blockade can elicit
antileukemic reactivity and how the balance between auto-
immunity and antitumor immunity can be modulated.
AbstractsS66F1.60. Successful Bone Marrow Transplantation in a
Patient with WHIM Syndrome.
Y. Kamachi,1 Y. Nakamura,1 A. Hama,1 K. Kudo,1 A. Yoshimi,1
N. Watanabe,1 I. Tsuge,2 S. Kojima.1 1Pediatrics, Nagoya
University Graduate School of Medicine, Nagoya, Aichi, Japan;
2Pediatrics, Fujita Health University, Toyoake, Aichi, Japan.
WHIM syndrome is a rare primary immunodeficiency disease
characterized by Warts, Hypogammaglobulinemia, Infections and
Myelokathexis. Until now, there is no report on a patient with
WHIM syndrome treated by allogeneic bone marrow transplanta-
tion (BMT). We performed nonmyeloablative BMT for an 18-year-
old female patient who has a nonsense mutation (S338X) in the
chemokine receptor CXCR4 which was identified as causative
gene of WHIM syndrome, from her healthy HLA-matched sister
who has no mutation of the gene. The patient had experienced
recurrent middle ear, sinopulmonary, and urinary tract infections
since 2 years of age. She was recognized as leukopenic (white
blood cell counts of 1.4  109/L), neutropenic (0.7  109/L) and
hypogammaglobulinemic (IgG428mg/dl, IgA4mg/dl, IgM21mg/
dl), when she was admitted to a local hospital at 7 years of age with
the aim of operation for chronic otitis media. She was referred to
our hospital for investigation of leukopenia. Examination of bone
marrow aspirate revealed a marked granulocytic hyperplasia and
bone marrow neutrophils contained extremely pyknotic nuclei and
vacuolated cytoplasms. Her disease was diagnosed as WHIM
syndrome. Treatment with daily subcutaneous injection of
recombinant human G-CSF increased mildly her blood neutrophils
and decreased frequency of her febrile episodes. Four months later,
therapy was discontinued because of the development of spleno-
megaly and myelofibrosis. She has worn a hearing aid due to
intractable otitis media since 11 years of age. Because her deafness
was gradually aggravated, she was considered for allogeneic BMT
at 18 years of age. This treatment plan was approved by the
Institutional Review Board at Nagoya University Graduate School
of Medicine and written informed consent was obtained from the
patient, her parents and her sister. The conditioning regimen
consisted of fludarabine (30mg/m2/d on days -5 to -2) and TBI (2
Gy  1 on day -1). Because of the incompatibility between red-cell
groups, a total of 30  107/kg erythrocytes-depleted bone marrow
mononuclear cells were infused to the patient from her sister on
January 16, 2002. GVHD prophylaxis consisted of tacrolimus and
short-term methotrexate. The absolute granulocyte count in the
peripheral blood was more than 500/Al on day 27. Although there
was no evidence of infection or no sign of acute GVHD, mild
eczematous lesions were observed on the body on day 70. The
diagnosis of chronic GVHD was confirmed by a skin biopsy. These
skin lesions improved for 70 to 80 days by continuing only oral
administration of tacrolimus. She had N99% donor cells in
peripheral blood as determined by microsatellite typing on
day 30. Thirty six months after BMT, she is doing well,
with normal blood cell counts and no need for therapy.
Because allogeneic BMT has the potential to cure primary
immunodeficiency diseases affecting marrow-derived cells, we
consider that nonmyeloablative BMT is the treatment of choice
for patients with WHIM syndrome who have an HLA-matched
sibling donor.
F1.61. Characterization and Depletion of Human
PBMNC Reactive with Murine Stimulator Cells.
L. D. Fast,1 G. DiLeone,1 M. Chuck.1 1Department of Medicine,
Rhode Island Hospital/Brown University, Providence, RI, USA.Human leukocytes respond vigorously when they encounter
murine cells. One outcome of this response is the development of
xenogeneic GVHD when human PBMNC are used to reconstitute
immunodeficient recipient mice. It was hypothesized that prevent-
ing xenogeneic GVHD would permit the long term reconstitution
of immunodeficient mice with functioning human cells. Two
proposed approaches to prevent xenogeneic GVHD were depleting
the xenoreactive cells prior to injection of PBMNC into the
recipient mice or by generating recipient mice that lack the
antigens that stimulate the xenogeneic GVHD responses by the
human leukocytes. To characterize the human anti-murine
response, the ability of unfractionated human PBMNC to
proliferate in response to murine C57BL/6 stimulator cells lacking
expression of murine H-2 class I, II or both was tested. The
absence of H-2 antigen expression on the murine stimulator cells
did not interfere with the proliferative responses of human
PBMNC to these stimulator cells. These findings suggested that
a number of human leukocyte subpopulations were able to
proliferate in response to antigens other than H-2 antigens on
xenogeneic murine cells. To characterize this response further, the
cell surface markers expressed by activated CD69+ human
leukocytes after incubation with murine stimulator cells were
analyzed. These results indicated that the activated population of
cells included T, B, NK, and NKT cells. Depletion of these
activated CD69+ cells resulted in the inhibition of proliferative
responses to the original C57BL/6 stimulating cells upon
restimulation of the cells remaining after depletion. However the
depleted cells were still able to proliferate to xenogeneic stimulator
cells from other mouse strains and to allogeneic PBMNC.
Additional studies will characterize the antigens responsible for
inducing each of the responding lymphoid populations and test if
administration of depleted populations prevents the development of
xenogeneic GVHD.
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F2.01. Cytokines in the Placenta of Pakistani Newborns
with and without Intrauterine Growth Retardation.
M. Hahn-Zoric,1 S. Amu,1,2 A. Malik,2 R. Asraf,3 S. Zaman,4
I. Kjellmer,5 H. Hagberg,6 L. Padyukov,1 L. A. Hanson.1
1Department of Clinical Immunology, Gothenburg University/
Sahlgrenska University Hospital, Gothenburg, Sweden;
2Department of Obstetrics and Gynecology, King Edward Medical
College, Lahore, Pakistan; 3Department of Social and Preventive
Pediatrics, King Edward Medical College, Lahore, Pakistan;
4Department of Social and Preventive Pediatrics, Fatima Jinnah
Medical College/Sir Ganga Ran Hospital, Lahore, Pakistan;
5Perinatal Center, Department of Pediatrics, Gothenburg
University, Gothenburg, Sweden; 6Department of Obstetrics
and Gynecology, Gothenburg University, Gothenburg, Sweden.
Objective: Intrauterine growth retardation (IUGR) is a major
risk factor for increased neonatal mortality and morbidity. The
prevalence of IUGR in newborns of Lahore, Pakistan was reported
to be up to 24%, while in a Swedish population in about 1–4% of
pregnancies. Despite the recognized problem with IUGR pregnan-
cies, the mechanisms behind this condition remain unclear.
It has been shown that cytokines play a major role in normal
pregnancy, but are also involved in IUGR and other pregnancy
Abstracts S67dysfunctions. During normal pregnancy, a predominance of Th2
type cytokines prevails and is considered to protects the foetus,
while an increase of Th1 type cytokines may have deleterious
effects. In this study we wanted to evaluate the possible role of
certain Th1 and Th2 cytokines in the development of IUGR. We
analyzed the gene expression, gene polymorphisms and protein
levels of these cytokines from IUGR and non-IUGR pregnancies in
a Pakistani population, where IUGR is very common.
Material and methods: 45 IUGR and 55 control mother/infant
pairs were studied. mRNA expression levels for IL-10, IL-8, TNF-
a, TGF-h, IL-6, IL-4, IL-1h, IL-12 and INF-g from the maternal
(decidua) and the foetal (trophoblast) side of the placenta were
quantified with RT-PCR. Cytokine and cytokine receptor gene
polymorphisms for -1087IL10, -308TNFA, -174IL6, TGFB1,
IL1RA, TNFR1, IL4RA 150V and -159CD14 were determined
from genomic DNA by the combination of PCR and restriction
enzyme cleavage. Serum levels of IL-1h, IL-6, IL-8, IL-10, IL-12,
TNF-a and TGF-h were quantified in maternal and umbilical cord
blood by ELISA and Luminex.
Results: There was a significant decrease of IL-10 (P b 0.0001)
and IL-12 (P b 0.008), but an increase of TGF-h (P b 0.009) in the
decidua and similarly a decrease of IL-10 (P b 0.03), but an
increase of TGF-h (P b 0.009) in the trophoblasts of the IUGR
placentas compared to the non-IUGR placentas.
We found significantly lower levels of IL-1h in serum from the
mothers of the IUGR infants (P b 0.008) and of TGF-h in serum of
the infants with IUGR (P b 0.05) compared to the non-IUGR
infants.
Conclusion: We note that the IL-10 mRNA expression in the
decidua was down-regulated, but the TGF-h mRNA up-regulated
in IUGR placentas of mothers from a population with multiple risk
factors for IUGR. We propose that the low IL-10 in the placenta
may be involved in the pathogenesis of IUGR and might possibly
be treatable.
F2.02. Setup of IgG MAR Methods and Determination
of the Prevalence of Antisperm Antibodies in Semen of
Immunoinfertile.
Abdolreza Esmaeilzadeh, Mehri Ghasemi, Sudabeh Esmaeilzadeh.
1Immunology, Zanjan Medicall Collage, Zanjan, Zanjan, Islamic
Republic of Iran; 2Zanjan University of Medical Scienc, Zanjan,
Zanjan, Islamic Republic of Iran; 3Azad University of Bonab,
Bonab, Azerbaijan e Shargi, Islamic Republic of Iran.
Background: Infertility affects 10% to 15% of couples desiring
children. Immunologic factors have been proposed to be Involved
in as many as 20%of otherwise unexplained cases of infertility.
Due to Importance of antisperm antibodies diagnosis in Immu-
noinfertility, our main aim in this study is setup of IgG MAR and
determination of the prevalence of ASA in zanjan province-Iran.
Methods: out of 312 Semen Samples collected for this study.
Setup IgG MAR with use of IgG -sensitized Erythrocytes were
prepared. (From RBC O RH+ and incomplete IgG anti Rh D) and
antihuman IgG serum. Coordinate time all samples were tested for
ASA by means of the direct MAR test. Greater than 10% of motile
sperm-bound to RBC was considered a positive.
Results: our finding showed that specificity and sensitivity of
IgG MAR Versus commercial sperm MAR kits(Gold standard) are
100%and 94.7% respectively In our study 18 cases from 312
samples(5.7%)were positive for ASA.
Conclusion: Our findings showed that ASA as an important
causative factor in immunoinfertility field and Direct Mixedantiglobulin reaction is a cheap, quick and sensitive screening test
for detection of sperm-bound antibodies.
Keywords: Prevalence-Mixed antiglobulin reaction -Anti
sperm antibody
F2.03. Sildenafil Does Not Influence Natural Killer
Cell Activity in Women with a History of Recurrent
Spontaneous Abortion.
M. Jerzak,1 M. Kniotek,2 N. Stachowicz,3 A. Gorski,2
W. Baranowski.1 1Department of Gynecology, Military Institute of
Medicine, Warsaw, Poland; 2Department of Clinical Immunology,
Transplantation Institute, University School of Medicine, Warsaw,
Poland; 31st Department of Gynecology, University Medical
School, Lublin, Poland.
Introduction: Endometrial growth seems to be dependent on
uterine artery blood flow and the importance of endometrial
development on pregnancy outcome has been previously reported.
NK cytotoxicity has been reported to be predictive of subsequent
pregnancy loss in women who had recurrent spontaneous abortions
(RSA). Sildenafil citrate (VIAGRA), a type 5-specific phospho-
diesterase inhibitor, augments the vasodilatory effects of NO by
preventing the degradation of cGMP. Vaginal sildenafil improves
uterine artery blood flow and sonographic endometrial thickness in
patients with prior failed assisted reproductive cycles due to poor
endometrial response. While improving uterine blood flow in the
proliferative phase, NO may have detrimental effects at the level of
the endometrium during the implantation window. The NO-
mediated release of cytokines such as tumour necrosis factor-from
activated natural killer cells has been implicated as a cause of
implantation failure. Therefore, the purpose of the study was to
establish the effect of sildenafil on NK cell activity in women with a
history of RSA, including women with multiple in-vitro fertilization
failures. Materials and Methods: Fifteen nonpregnant women with
the history of RSA and ten normal healthy women with the previous
successful pregnancy outcome were studied. Measurement of
uterine artery blood flow (pulsatility index, PI) was recorded using
Doppler ultrasound by intravaginal probe in the study women.
Natural killer cell activity was measured using flow cytometry. The
following peripheral blood NK cellsT surface antigens: CD16, CD56
were also studied using flow cytometry. NK cell activity before and
after sildenafil therapy in RSA women were studied. In addition,
influence of 10mg or 400 ng sildenafil on NK cell activity after in
vitro culture were performed. Results: We determined that there is a
positive correlation between increased natural killer cell activity and
PI in women with the history RSA compared to normal healthy
women (r N 0.5, P b 0.05). Our preliminary data suggest that
sildenafil has no significant influence on NK cell activity.
Conclusions: Our data suggest that increased natural killer cell
activity can be associated with diminished uterine artery blood flow.
Sildenafil might be interesting therapeutic option for women with
reproductive failure. However, further studies are needed to
determine the role of this therapy in human reproduction. This
work was supported by grant nr 2 P05E 07926.
F2.04. IgE Is Distributed on Macrophages Both in
Human and Murine Term Placentae.
J. Wang,1 X. Cui.2 1Department of Immunology and Cell Biology,
School of Animal Health Science, Hebei Agricultural University,
Baoding, Hebei, China; 2Department of Medicine, Hospital
Affiliated to Xuanhua Iron and Steel Company Ltd, Xuanhua,
Hebei, China.
AbstractsS68Objective: High level serum IgE is the hallmark of immune
response in allergic patients. Epidemiological studies indicate that
the prenatal environment plays an important and decisive role in
the development of allergy later in life. To test whether the impact
of maternal atopy could be transmitted through the maternal-fetal
interface, this experiment was conducted. Methods: Animal
model was developed by administration of allergens before
mating for the study of the impact of maternal allergy on the
development of an allergic immune response in early life. Healthy
pregnant women who have approved to have their placenta
collected for medical investigation are invited to give birth at the
university hospital. Twenty-five pregnant women who were
demonstrated to be atopics, based on clinical symptoms of atopic
disease together with a positive Phadiatop and/or skin prick test
gave their birth at the same hospital. Placentas were collected
both from mouse and human groups and kept at 70C until the
preparation of slides was carried out. All slides were double-
stained for the analysis with immunohistochemistry. To detect
macrophages both in murine and human placentas, monoclonal
antibodies, F4/80 and anti-CD14 Abs, were employed in
immunohistochemical procedures. Results: CD14+ placental
macrophages show an intensive positive reaction to anti-IgE
monoclonal antibody. Surprisingly, there was no remarkable
difference between healthy mouse and the atopic model mouse
as well as the human counterparts on the distribution pattern of
IgE in placentas. Conclusion: IgE is distributed on macrophages
both in murine and human term placentas. The atopic mothers
could not pathologically impose their babies by their high level
serum IgE during the pregnancy.
F2.05. Complement Activation as a Mediator of
Recurrent Immunologically-Triggered Miscarriages.
G. Girardi,1 E. Chan,1 P. Redecha,1 J. M. Thurman,2
V. M. Holers,2 J. Salmon.1 1Department of Medicine, Hospital for
Special Surgery-Weill Medical College, Cornell University, New
York, NY, USA; 2Departments of Medicine and Immunology,
University of Colorado HSC, Denver, CO, USA.
Between 1% and 3% of women in the United States suffer
recurrent miscarriages; 50% to 70% of conceptions fail. We
have recently identified a novel role for complement activation
in antiphospholipid antibody-induced pregnancy loss (J Clin
Invest 112:1644, 2003). We now test the hypothesis that
complement activation is a necessary intermediate in the
pathogenesis of recurrent spontaneous miscarriage. DBA/2-
mated female CBA/J mice are a well-studied model of
immunologically-mediated peri-implantation pregnancy loss that
shares many features with human recurrent miscarriage.
Embryos from mating CBA/J females with DBA/2 males show
an increased rate of resorption (30–40%), compared to rates of
b10% observed in the control groups (CBA/J  BALB/c) (P b
0.01). Histological studies showed extensive C3 deposition,
inflammatory infiltrates, and fetal debris in deciduas as early as
day 6 of gestation. In contrast, there was no evidence of
complement in decidua from CBA/J  BALB/c. To provide
direct evidence that complement is, in fact, a critical mediator in
this model of spontaneous pregnancy loss, we attempted to
rescue fetuses from DBA/2-mated CBA/J mice with complement
inhibitors. To block C3 activation by alternative and classical
pathways, we treated mice with a recombinant C3 convertase
inhibitor Crry-Ig (3 mg ip day 2, 4 and 6). Crry-Ig completely
rescued pregnancies in DBA/2-mated CBA/J mice (Crry-Ig vsuntreated 8.5 F 6.3% resorptions vs 28.0 F 7.2%, P b 0.01).
Inadequate expression of complement regulatory proteins is a
possible cause of increased complement deposition and embry-
onic death, but Western blotting of embryos and deciduas did
not show such deficiency.
To examine the importance of complement activation at the
level of C5, we treated DBA/2-mated CBA/J pregnant mice
with anti-C5 mAb. Administration of anti-C5 mAb (1 mg ip on
day 2 and 4) prevented pregnancy loss (8.6F 4.4% resorptions, P b
0.01). To distinguish the role of C5a and C5a receptor (C5aR) from
that of MAC seeded by C5b, we treated pregnant mice with a highly
specific peptide antagonist of C5a receptor (C5aR-AP) AcPhe[L-
ornithine-Pro-D-cyclohexylalanine-Trp-Arg]. C5aR-AP (100 Ag ip
on day 2) significantly improved pregnancy outcomes (8.0 F 5.9%
fetal resorptions, P b 0.01) suggesting that C5a-C5aR interactions
play a critical role in fetal loss. Given the importance of alternative
pathway in ischemic and antibody-trigged injury, we considered the
role of factor B in our model. Treatment of pregnant DBA/2-mated
CBA/J mice with a blocking anti-fB mAb improved outcomes to
those of controls (8.4F 6.6% fetal resorptions,P b 0.01). Our results
show that complement activation plays an essential and causative
role in damaging the fetal-placental unit: Factor B, C3, C5 and C5aR
are required for miscarrriage. These studies identify key innate
immune effectors that mediate poor pregnancy outcomes and
provide novel and important targets for prevention of recurrent
pregnancy loss in patients.
F2.06. Prolonged Preterm Rupture of Fetal Membranes
(PPROM), Is Associated with an Increased Maternal
Anti-Fetal T-Cell Responsiveness.
A. Steinborn,1 C. Seidl,2 E. Schmitt,3 Y. Stein,1 A. Klee,4
M. Gonser,4 E. Seifried,2 C. Sohn.5 1Depart. Obstet. Gynecol.,
University of Frankfurt, Frankfurt/Main, Germany; 2Institute of
Transfusion Medicine and Immunohaematology, Blood
Transfusion Center of German Red Cross, Frankfurt/Main,
Germany; 3Institute of Immunology, University of Mainz, Mainz,
Germany; 4Depart. Obstet. Gynecol., Dr. Horst-Schmidt Hospital,
Wiesbaden, Germany; 5Depart. Obstet. Gynecol., University of
Heidelberg, Heidelberg, Germany.
A fetus, although semi-allogeneic, is usually accepted by the
maternal immune system. However, complications including allo-
responsive mechanisms are thought to be potentially detrimental
for a successful pregnancy. Therefore, we used the mixed
lymphocyte culture (MLC) reaction to compare the allogeneic
T-cell response of non-pregnant women (n = 96) with the
response of healthy pregnant (n = 68) and pregnant women
affected by different gestation-associated diseases such as
prolonged preterm rupture of fetal membranes (PPROM) (n =
20), uncontrollable preterm labor (PL) (n = 15), preeclampsia
(n = 22) and intrauterine growth retardation (IUGR) (n = 12).
Peripheral blood mononuclear cells (PBMCs) of all three groups
were stimulated with PBMCs from unrelated volunteers. Pregnant
women had significantly reduced stimulation indices (SIs)
(median value 21.8, range 1.3–167.0) compared to non-pregnant
women (median value 62.5, range 8.4–379.5). Exposing PBMCs
from pregnant women to PBMCs of their own fetus led to a
further significant decrease of SIs (median value 2.2, range 0.6–
51.5). Among the two groups of pregnant individuals, SIs of
women with prolonged preterm rupture of fetal membranes
(PPROM) were significantly higher (median value 6.3, range
1.3–56.8) in comparison to women with uncontrollable PL
Abstracts S69(median value 1.4, range 0.9–8.5), women with preeclampsia
(median value 1.8, range 1.1–14.9), women with IUGR (median
value 1.9, range 0.7–38.1) and women with normal term delivery
(median value 2.2, range 0.6–51.5) when the maternal PBMCs
were stimulated with PBMCs of their own fetus. This phenom-
enon could not be observed after stimulation with PBMCs from
unrelated volunteers. In addition, an increased humoral immune
response was assessed for women with PPROM (40.5 % women
anti-HLA-antibody positive) in comparison to women with
uncontrollable PL (15.2 % women anti-HLA-antibody positive).
Our results revealed a strongly reduced allogeneic T cell response
of PBMCs from pregnant women that was further downregulated
when PBMCs from their own fetus were used as stimulators. The
same finding could be observed in pregnant women who suffer
from different gestation-associated diseases. An exception were
women with PPROM who exhibited a comparatively high
alloresponse implying an increased anti-fetal reaction under these
conditions.
F2.07. STAT3 Knock Down Reduces the Invasion of
Choriocarcinoma Cells.
Tobias G. Poehlmann,1 Anja Meissner,2 Tobias Wengenmayer,1
Karlheinz Friedrich,2 Ekkehard Schleussner,1 Udo R. Markert.1
1Obstetrics, Friedrich Schiller University, Jena, Germany;
2Biochemistry, Friedrich Schiller University, Jena, Germany.
Objectives: The Signal Transducer and Activator of Tran-
scription 3 (STAT3) is involved in the invasiveness of carcinoma
cells. In an earlier study, we found that invasiveness correlates
with STAT3-DNA binding activity in trophoblast and choriocarci-
noma cells. Aim of this investigation was to verify the role of
STAT3 in these observations by RNA interference induced STAT3
knock down. Methods: By using short interference RNA (siRNA),
STAT3 was knocked down in the Jeg-3 choriocarcinoma cell line.
Oligonucleotides were designed to interfere exclusively with
STAT3 mRNA. For control scrambled oligonucleotides were
designed to not interfere with any known human protein. The
successful knock down was analyzed by polyacrylamid gel
electrophoresis and western blot. Matrigel was used for an in
vitro invasion assay. Invasion of cells was measured by counting
cells on the filter beyond the matrigel as well as in the medium
beyond the filter. Results: By applying a concentration of 66nM of
siRNA oligonucleotides the invasion of Jeg3 choriocarcinoma
cells was reduced by 57%. Invasion of non-transfected cells was
increased by stimulation with Leukemia Inhibitory Factor (LIF;
64%) and Interleukin-6 (IL-6; 12%). In STAT3-knock down cells
these effects were completely blocked for IL-6 and significantly
reduced for LIF (16% invasion). Conclusion: STAT3 plays a key
role in the invasion of choriocarcinoma cells. The slight remaining
invasive capacity of Stat3 knocked down cells may be due to a not
complete elimination of Stat3 or to further invasion triggering
pathways.
F2.08. Evaluation of Four Different Methods of Sperm
Surface Antigens Extraction Using Biotinilated Sperm
Due to Finding a Better Method for ELISA Technique.
Asghar Talebian, Mohammad Reza Sadeghi. 1Reproductive
Endocrinology, Avesina Research Center, Tehran, Tehran, Islamic
Republic of Iran; 2Reproductive Endocrinology, Avesina Research
Center, Tehran, Tehran, Islamic Republic of Iran.
Introduction: One of the most important problems in
detection of antisperm antibody (ASA) is to design an internatinalcorrect method with at least false answers. It seems that Enzyme-
Linked Immunosorbent Assay (ELISA) will be more sensitive,
specific and with more diagnostic value for detection of ASA, if
it is used sperm surface antigens without contamination with
sperm inside antigens and nonspermic antigens as coated antigens
in ELISA technique. In this way, some techniques such as using
different specific detergents are recommended. This study has
focused on different methods of sperm surface antigens extraction
to determine a better method of antigens extraction for ELISA
technique. Materials and Methods: We extracted sperm surface
antigens by four different method: Sonication method, using
NaCl salt, SDS detergent and using LIS detergent on sperm prior
treated by biotin and then we evaluated all four extraction method
by blotting and ELISA technique to assess the better exposing
surface antigens. Results and Conclusion: Our results have
demonstrated that extraction method by LIS detergent expose
sperm surface antigens better than other three methods and we
concluded that this method is superior for using in ELISA
technique.
Other
F2.09. The Changes of T Lymphocyte CD Markers in
Patients Exposed to Mustard Gas.
Minoo K. Adib,1 Fariborz Mokarian,2 Mohammad R. Azizy.1
1Immunology, Medical School.Isfahan University of Medical
Sciences, Isfahan, Isfahan, Islamic Republic of Iran; 2Oncology,
Omid Hospital.Isfahan University of Medical Sciences, Isfahan,
Isfahan, Islamic Republic of Iran; 3Immunology, Medical
School.Isfahan University of Medical Sciences, Isfahan, Isfahan,
Islamic Republic of Iran.
INTRODUCTION: The immunodepressive effects of mustard
gas was detected in previous studies.The present study was
performed on 31 Iranian chemical casualities, after 10 years of
exposure to mustard gas, to determine the changes of absolute
lymphocyte count and T cell CD markers compared to normal
control group.
METHODS: CBC and absolute lymphocyte count was
determind by H 1 automatic system.T cell CD markers (CD2,
CD3,CD5,CD7) was analyzed by Flow cytometric method.using
conjugated monoclonal antibodies.
RESULTS: Absolute lymphocyte count were increased but
lymphocyte CD2.CD3 and CD5 markers were decreased signifi-
cantly (P b 0.05) compared to normal control group (The decrease
in CD4 and CD8 markers were reported by other investigators
previously).
CONCLUSION: The increase suseptibility to respiratory and
other infections in these patients, could be due to decrease in T
lymphocyte subsets.Increase in absolute lymphocyte count could
be due to lymphoproliferative changes in B or NK lymphocyte
lineage,and requires another investigation.
F2.10. Binding of Phage Displaying Multimeric CD147
on U937 Cell Conducts Apoptotic Signal.
Nutjeera Intasai,1 Watchara Kasinrerk,1 Sabine Mai,2 Chatchai
Tayapiwatana.1 1Clinical Immunology, Fac of Associated Medical
Sciences, Chiang Mai, Thailand; 2The Genomic Centre for Cancer
Research & Diagnosis, Manitoba Institute of Cell Biology,
Manitoba, Winnipeg, Canada.
Molecular effect of CD147, leukocyte surface molecule, on the
neighbor cells is largely unclear, currently. Herein, multivalent
AbstractsS70CD147 displaying on VCSM13 phage was generated to enhance
the functional affinity of CD147 for its partner (s) and to study the
ligand-receptor signaling in U937 monocytic cell line. Cellular
morphological change of U937 incubated with multivalent CD147
phages had been observed since 24 h of cultivation and cell
propagation was ceased after 48 h. This phenomenon was
presumably related to the anchoring of multivalent CD147 phage
to U937 surface molecule (s) proven by either ELISA or
immunocytochemistry. Interestingly, the apoptotic nucleus was
found to coordinate with U937-bound phage. Cytotoxic activity of
CD147 phage on U937 was further analyzed by EthD-1/calcein
AM double stains. In contrast to wild-type phage, dual-colour
fluorescent in U937 induced with recombinant phage, which
associated with the apoptotic characteristic, was indicated. The
level of cleaved caspase-3 in U937 incubated with multivalent
CD147 phage was not as high as in U937 stimulated with cisplatin
when determined by flow cytometry. Nevertheless, the signal was
apparently stronger than uninduced U937 and VCSM13-incubated
U937. Quantified by immunocytochemistry, only 12.8% of multi-
valent CD147-activated U937 with apoptotic nucleus harbored
substantial amount of cleaved caspase-3, whereas 41% was
resulted from cisplatin-induced U937. Accordingly, the caspase
dependent pathway supposed to partially involve in CD147-
provoked cell death program. A novel function of CD147 in
triggering apoptosis implied the existence of CD147 counter-
receptor (s) on U937 membrane.
F2.11. Sensitivity of Soil Bacteria towards Cadmium
Metal and Its Effect on Moung Bean Plant.
Rafia Azmat, Aliya Hayat, Tanveer Khanum. 1Chemistry, Jinnah
University for Women, Karachi, Sindh, Pakistan; 2Microbiology,
Jinnah University for Women, Karachi, Sindh, Pakistan;
3Microbiology, Jinnah University for Women, Karachi, Sindh,
Pakistan.
Introduction
Pollution is now a days a termendous threat to the universe,
progress in different scientific fields helps at one side to the world
but on technologist hand it causes great dangerous effects on
human and plants. Heavy metal pollution (hanaeklaus., 1999) in
aquatic system has become a serious threat today. Heavy metals are
wide spread pollutants of great environmental concern as they are
non degradeable and thus persistant (Trueby.P., 1990) Many
bacteria are facultative anaerobes. Nitrogenfixing facultative
bacteria are generally only capable of fixing nitrogen when they
are growing in anaerobic environments. Examples of such bacteria
include some of the Enterobacteriaceae, such as Enterobacter
species (Camb. Univ. press).Chemical treatment of water resources
are very expensive, in this endeavour,microbial biomass has
emerged as an option for developing economic and ecofriendly
waste water treatment process but presence of heavy metal can
damage microbial life.The present study was carried out to check
the toxicity of Cd (cadmium) metal on bean plant and their
physiological process in relation with nitrifying bacteria in soil and
roots and shoots of the plant.
Methodology
Plants were analysed after 15 days of germination, the contents of
chlorophyll a, b carbohyderates, proteins and amino acids were
determiend by standeredmethod(Chapman.S.B.,1976).Mineral ions
were analysed by flame photometry and atomic absorption techni-
qe.The toxicity of different concentrations of Cd metal on nitrifying
bacteria was determined by SPC (standard plate count) method.Results and discussion
Cd was found to be highly toxic to the seedling as well as for
the microbial life present in the rhizopsphere of bean plant at all
concentrations used.Morphology of plant was effected while
colour of plant turns yellow. The growth of the plant was inhibited
and the length of root and shoot was found to be decreased,
cmpared with controll plants.Reduction in the proceses of the
photosynthesis was observed as yellow coloured leaves appeared
instead of green coloured because of the decline in the chlorophyll
a and b contents.
Nutritive values of plants decreases with the increase in the
concentration of Cd metal which may be due to the absence of
nitrifying bacteria which are normally found in symbiotic
association with these plants where they fixes atmosphereic
nitrogen in the roots of leguminous plants (Dakora and Donald,
2002) but in the presence of Cd metal nodule formation was
inhibited results in the decrease in the protiens contents and
absence of amino acids at high concentrations of Cd. Potassium
and sodium (Hsiao.T.C.,1986)were investigated and low percen-
tages showed that accumalation of Cd was higher in the roots as
compare to the other mineral ions due to which plants were not
able to stand in the errect position.Iron Magnesium Magnese which
were responsible for metabolic activity, transpiration and trans-
location were also effected and their percentages were also found
to be decreased at higher concentration of Cd.
F2.12. Surgical Trauma and the Mannan-Binding Lectin
(MBL) Pathway of Innate Immunity.
H. Ytting,1 I. J. Christensen,1 S. Thiel,2 J. C. Jensenius,2 H. J.
Nielsen.1 1Dept. of Surgical Gastroenterology, Hvidovre University
Hospital, Hvidovre, Denmark; 2Institute of Medical Microbiology
and Immunology, University of Aarhus, Aarhus, Denmark.
Introduction: The mannan-binding lectin (MBL) pathway of
innate immunity is important in host defense against pathogens.
Major surgical trauma is known to influence various immune
functions and in the present study we investigate the effect of major
surgery on two central components of the MBL pathway; MBL
and the associated protease MASP-2, compared with the effect on
IL-6 and CRP levels.
Methods: Sixty patients were randomized to open or laparo-
scopic colectomy for benign or malignant disease. Serum levels of
MBL, MASP-2, IL-6 and CRP were determined preoperatively,
and 1, 2 and 6 hours following incision, and at postoperative day 1,
2, 8, and 30.
Results: All four parameters showed a slight decrease in serum
levels within the first two hours after incision. For MBL andMASP-
2 a minor, but significant (P = 0.01 and P = 0.04 respectively) peak
was found on postoperative day 8. Compared to the preoperative
level a significant, 10-fold increase of IL-6 was found 6 hours after
incision (P = 0.0001), and with levels significantly lower on day 30
(P = 0.0005). For CRP a significant increase was seen on
postoperative day 2 (P = 0.0001), whereas the levels on day 30
were not statistically different from preoperative levels (P = 0.08).
The levels of IL-6 and CRP were significantly correlated (r = 0.71,
P b 0.0001), whereas no other significant correlations were detected
between the parameters. No significant differences between the
responses to the two surgical techniques were revealed.
Conclusion: In contrast to the marked effects on the levels of
IL-6 and CRP major surgery only marginally influenced the MBL
pathway. There was no difference in the response to the two
different surgical techniques.
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Map.
Guo Feng. 1Department of Blood Transfusion, Chang Hai
Hospital Second Military Medical University, Shanghai, China.
Objective: To study the theory of hemaimmune reaction.
Methods: Cancer cells or yeast cells (or NS) were added into
human fresh anticoagulant whole blood (or blood cells and plasma)
treated by citric acid, and incubated for 30 minutes at 378. Main
Outcome Indexes: adhering rate. IL-8, CD35, DARC (Fy6),
CXCR4 et al.
Results: It was found that cancer cells (dead cells) and yeast cells
can activate a war of hemaimmune reaction (HIR). In time of war
against cancer cells and yeast cells, the level of indexes (adhering
rate, IL-8,CXCR4)was significantly higher than that in time of peace
(NS control group). In time ofwar against cancer cells and yeast cells,
level (IL-8) of HIR in white blood cell group with plasma added was
significantly higher than that (IL-8) in white blood cells group
without plasma. Level (IL-8, CXCR4) of HIR in white cells group
with red blood cells added was significantly higher than that (IL-8,
CXCR4) in white blood cells group without red blood cells added.
Conclusion: human hemaimmune reaction looks like a modern
war in the body. The results suggest that the complement and red
blood cell play a vital role in blood immune reaction, and there is a
road map of hemaimmune reaction: Antigens (cancer cells or yeast
cells) can activate complement in plasma, then the antigens which
were opsonized by complement C3b are mainly adhering to red
blood cells, and then they are adhering to white blood cells to
activate hemaimmune reaction system (see Figure l). Furthermore,
it can provide useful information for studying innate and adaptive
immune and for establishing experimental (or war type) system of
hemaimmune reaction road map.
F2.14. A Novel CD70+ APC Imprints a Unique Pattern
of NK Receptors on Gut Mucosal CD8 T Cells.
A. Laouar,1 V. Haridas,1 R. A.W. van Lier,2 H. Yagita,3
N. Manjunath.1 1Dept. of Pediatrics, Harvard Medical School,
CBR Institute for Biomedical Research, Boston, MA, USA; 2Dept.
of Pediatrics, Harvard Medical School, CBR Institute for
Biomedical Research, Boston, MA, USA; 3Dept. of Laboratory
Immunology, Academic Medical Center, Amsterdam, Amsterdam,
Netherlands; 4Dept. of Medicine, Juntendo University, Tokyo,
Tokyo, Japan; 5Dept. of Pediatrics, Harvard Medical School, CBR
Institute for Biomedical Research, Boston, MA, USA.
We have identified a novel antigen presenting cell population in
the intestinal lamina propria that constitutively expresses the
costimulatory molecule CD70. Here we show that stimulation via
this APC induces a unique pattern of NK receptors on the mucosal
CD8 T cells. Resident CD8 T cells in the gut mucosa in naRve mice
exhibited an activated phenotype and expressed the Ig family NK
receptors 2B4 and gp49B1 but did not express the lectin-like CD94-
NKG2 heterodimeric receptor. In contrast, activated CD8 T cells in
the peritoneal exudate lymphocytes and spleen following Vaccinia
or Listeria infection expressed gp49B1 and CD94-NKG2 and but
did not express 2B4. Similar differences in NKR expression were
also found on antigen-specific CD8 T cells generated at different
sites during the same infection. The NKR expression profile in the
gut mucosa was dependent on stimulation via CD70+ APC since
2B4 expression could be dramatically reduced by administration of
blocking CD70 antibody. CD70 antibody treatment however, had
no effect on NKR expression by activated CD8 T cells at peripheral
sites, where CD70+ APC do not occur. However, when mice wereintraperitoneally immunized with CD70 expressing allogenic P815
cells, 2B4 was induced on CD8 T cells accumulating in the
peritoneal cavity. Thus, CD70 costimulation via CD70+ APC
imprints unique NK receptors on mucosal T cells.
F2.15. CAUSAL Protein Signaling Networks Derived
from Multiparameter Single-Cell Data.
O. D. Perez,1 K. Sachs,2 D. PeTer,3 D. Lauffenburger,2
G. P. Nolan.1 1Department of Microbiology and Immunology,
Stanford University School of Medicine, Stanford, CA, USA;
2Biological Engineering Division, Massachusetts Institute of
Technology, Cambridge, MA, USA; 3Department of Genetics,
Harvard Medical School, Boston, MA, USA.
We demonstrate the application of Bayesian networks for
computational elucidation of causal intermolecular influences in
signaling networks, using simultaneous multivariate measurements
of phosphorylated proteins and phospholipids in populations of
single human primary CD4+ T cells. Selective perturbations, both
activating and inhibiting, were important to inferring the direction
of influence between signaling components. We identified most
classically reported signaling relationships and predicted novel
influence connections, including inter-pathway crosstalk from the
kinase Erk1 to the kinase Akt (confirmed experimentally). These
results manifest the feasibility of data-driven construction of causal
signaling network models from primary cell data at the single cell
level and may have utility in understanding patient specific
signaling alterations in disease states.
F2.16. DonTt Judge a Cell by Its Surface Only:
Combination with Functional Assays.
D. T. Montag,1 M. T. Lotze.1,2,3 1Bioengineering, University of
Pittsburgh, Pittsburgh, PA, USA; 2Surgery, University of
Pittsburgh, Pittsburgh, PA, USA; 3Molecular Genetics and
Biochemistry, University of Pittsburgh, Pittsburgh, PA, USA.
Immunophenotyping of peripheral blood mononuclear cells
(PBMCs) is of limited value for assessment of most clinical states.
As a more informative alternative, immunophenotyping may be
combined with functional assays as a correlate of clinical status.
Most functional assays, however, are tedious or require prolonged
culture periods. One simple, highly informative, and rapid
approach is to examine cell signaling within individual cells
following brief stimulation. Abnormalities within the signaling
pathways of specific cell types could provide important insights
concerning pathological conditions. This study focuses on the
JAK/STAT pathway as it is central to host defense, cell growth, and
apoptosis. Dysfunction of this pathway has been observed within
cancer cells of various types. We have developed conditions
allowing dual labeling of cell surface markers and intracellular
phosphorylated STAT members within individual, normal PBMCs,
which have undergone rapid cytokine stimulation in vitro.
The PBMCs are first incubated with a primary antibody against
cell surface CD4, CD8, CD14, or CD56. Cytokine [IFNg, IL-2, IL-
4, or IL-13] treatment is then applied to induce STAT phosphor-
ylation. The cells are immediately fixed with 2% PFA and then
permeablized with a cocktail of saponin, methanol, ethanol,
isopropanol, or acetone at varying concentrations. The cells are
labeled with primary antibody against several pSTAT proteins.
Analysis of the efficacy of extracellular and intracellular labeling is
completed using a BD FACSArray flow cytometer.
With all of the reagents tested, it appears that there is a trade-off
between intracellular and extracellular labeling of cells. 90%
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others, gives a good signal for phospho-STATs, but does not allow
identification of many cell surface molecules. Other permeabiliza-
tion methods, such as saponin, and lower alcohol concentrations,
allow for better cell surface labeling, but simultaneously cause a
decrease in the pSTAT signal. Of the reagents tested, 70% methanol
allows for the best dual labeling of both intracellular and
extracellular proteins. These methods will permit rapid analysis
of complex cell populations, including PBMCs. Interrogation of
signaling pathways in individual cell types will allow more
profound evaluation to gain additional insight into abnormalities
causing or arising from the presence of immune dysfunction.
F2.17. Cigarette Smoke Extract Impairs CD40
Ligand-Induced Maturation of Human Dendritic Cells.
T. W. Barnes,1 P. R. Kroening,1 H. Kita,2 R. Vassallo.1
1Pulmonary and Critical Care Medicine, Mayo Clinic College of
Medicine, Rochester, MN, USA; 2Division of Allergic Diseases,
Mayo Clinic College of Medicine, Rochester, MN, USA.
Dendritic cells (DC) are key regulators of innate and acquired
immunity. DC maturation is a critical event in the DC life cycle,
conferring to it the capacity to both simulate T cell proliferation and
polarization. DCs may be matured by Toll receptor ligands (like
LPS), as well as by T cell dependent mechanisms via CD40 ligand-
mediated (CD40L) activation. We have previously demonstrated
that cigarette smoke extract (CSE) inhibits several maturation events
induced by lipopolysaccharide (LPS), including the upregulation of
co-stimulatory molecules, and production of the key Th-1 polarizing
cytokine IL-12p70. In the current study, we hypothesized that CSE
also impairs DC maturation mediated by T cell dependent pathways
through CD40L stimulation. CSE was generated by bubbling the
smoke from one cigarette (1R3F University of Kentucky) through
10 ml PBS. Immature DCs were generated from human monocytes
cultured with IL-4 (5ng/ml) and GM-CSF (800U/ml). During the
final 48 hours of culture, DCs were incubated with CSE at
concentrations that do not diminish cellular viability (as measured
by Annexin V and Propridium iodide staining). During the final 24
hours, DCs were matured with interferon-gamma (50ng/ml) and
CD40L (500ng/ml). The expression of costimulatory molecules was
determined by flow cytometry and IL-12p70 concentration was
determined by ELISA. PGE2 levels were also analyzed by ELISA.
CSE-conditioned DCs matured with CD40L, expressed lower levels
of CD-86 and CMRF-56 compared to control DCs. In addition, IL-
12p70 production by CD40L matured DCs was inhibited in a dose-
dependent fashion by CSE conditioning. CSE-conditioned DCs
produced more PGE2 than controls, suggesting a mechanism by
which CSE alters DC maturation. Our data illustrate that CSE alters
DC maturation induced by both LPS and CD40L. The inhibition of
IL-12 production by CSE illustrates an important mechanism by
which smoking inhibits essential adaptive immune responses
relevant to the pathogenesis of cancer and certain infections.
F2.18. Isolation of Lactobacilli, Bacillus and
Psuedomonas from Yogurt and To Determine Their
Bacteriocin Activity Against Various Clinical Isolates.
Tanveer Khanum, Nadia Noor, Nasra Jalil, Sadaf Hedayat.
1Microbiology, Jinnah University for Women, Karachi, Sindh,
Pakistan; 2Microbiology, Jinnah University for Women, Karachi,
Sindh, Pakistan.
Bacteriocin are low molecular weight single polypeptide or
polypeptide complexes having an antibacterial activity, synthesizedin ribosomes and secreted by bacterial cells or bthe group of
heterogenous substances ranging from low molecular weight
compounds to high molecular particles resembling bacteriophage
protein components (Rasool & Khan, 1991).Q
In 1967 (Bradly) classified bacteriocins into two broad types:
a) A group of low molecular weight, trypsin sensitive, thermo-
stable bateriocin.
b) A group of high molecular weight, trypsin resistant,
thermostable beteriocin.
Microorganisms in yogurt and the subsequent creation of
organic acids and bio-active proteins inhibit the growth the growth
of many pathogenic microorganisms.
Methodology
Different yogurt samples were used for isolation of bacterial
strains After making the dilution of yougurt samples, the diluted
samples were spreaded on nutrient agar and incubated at 37 8C.
Isolated colonies were identified by using different conventional
methods. Ten reference strains were used to check bacteriocinogenic
activity. The isolates includes E. coli, Staph.aureus, Klebsiella,
Salmonella, Enterococcus, Micrococcus, Bacillus, Staph. epidermi-
dis, Pseudomonas. After this bacteriocin production was detected
againt reference strains by using agar well and cross streak methods.
The titres of bacteriocin produced were quantified by two fold serial
dilutions of bacteriocin.
Results and disscussion
The average colony forming unit per ml calculated as 8.4106
Cfu/ml. The bacteria isolated were identified by using different
conventional methods. Bacteriocin of Lactobacilli was active
against Shigella, Bacillus and Micrococcus.
The bacteriocin of bacillus was active against S. aureus, St.
epidermidis, Enterococcus and E. coli.
Bacteriocin of Pseudomonus was active against Shigella, S.
aureus, St. epidermidis, Entercoccus, Micrococcus, Bacillus and
S. typhi.
The arbitrary unit of bacteriocin of Lactobacilli against Shigella
is 1:4, against S. aureus is 1:2 against St. epidermidis is 1:8 against
Entercoccus is 1:8, against Bacillus is 1:2.
The arbitrary unit of bacteriocin of Pseudomonas against
Shigella is 1:6, against S. aureus is 1:2, against St. epidermidis is 1:4.
The arbitrary unit of bacteriocin of Bacillus was not found.
It was found that yougurt contain high number of bacteria
which include both Gram negative and positive species of bacteria.
The bacteriocin of lactobacilli are broad spectrum as active against
both Gram negative and positive bacteria and best inhibitory
activity was observed against St. epidermidis.
Pseudomonas produce powerful bacteriocin which inhibit the
growth of majority of clinical isolates where bacteriocin of Bacillus
and Lactobacilli were not as effective.
We also observed those bacteria which produce bacteriocin line
of diffusion after removal of growth and also bacteriocin activity
was best observed when the plates were first refrigerated and then
cross streaked which indicate that refrigeration temperature
facilitated the diffusion of bacteriocin in medium.
F2.19. Dendritic Cells Overexpressing FasL Induce
Anti-Tumoral T-Cell Response In Vivo.
Sofia Buonocore, Najate Ouled Haddou, Fabrice Moore, Marianne
Laporte, Frederic Paulart, Francoise Flemal, Kris Thielemans,
Michel Goldman, Veronique Flamand. 1Laboratory of
Experimental Immunology, Institut dTImmunologie Medicale (IMI),
Brussels, Belgium; 2Dermatology Department, Erasme Hospital,
Abstracts S73Brussels, Belgium; 3Laboraory of Physiology, Vrije Universiteit
Brussel, Brussels, Belgium.
We previously showed that FasL retrovirally transduced bone
marrow-derived DC increase allospecific cytotoxic activities and
Th1 cytokines production in vivo thanks to a FasL dependent
neutrophils recruitment. The aim of our study is to test if the
expression of FasL by DC can promote a stronger cytotoxic
activity and a better anti-tumoral immunity compared with DC
expressing a control Ag. We used the tymoma EL4 isolated from
C57BL/6 mice and transfected with the cDNA encoding ovalbu-
min (EG7-OVA), the predominant Ag expressed by the tumor. We
first evaluated a therapeutic approach which consisted in subcuta-
neous injection of EG7-OVA tumor cells and FasL or control-DC
in C57BL/6 mice. We studied the consequences of the treatment on
the tumor growth. We realised histological analysis on tumor sites
and we measured the anti-tumoral T cell response. We observed
that co-injection of FasL-DC and EG7-OVA cells inhibit tumor
growth. Histology of tumors sites harvested from mice co-injected
with control-DC and EG7-OVA cells showed only a moderate
inflammatory infiltrate composed essentially of mononuclear cells.
In contrast, tumor sites coming from mice co-injected with FasL-
DC and EG7-OVA cells reveal a massive destruction of the tumor
associated with apoptosis and neutrophils recruitment. We dem-
onstrated that in vivo EG7-OVA apoptosis could not be explained
only by the tumoricid activity of FasL-DC since we observed that
only 6 to 7% of tumor cells were lysed by FasL-DC in vitro. We
demonstrated that neutrophils contribute to the tumor eradication in
FasL-DC and EG7-OVA co-injected mice as anti-Gr1 monoclonal
antibodies treatment restore tumor growth. Finally, mice co-
inoculated with FasL-DC and EG7-OVA tumor cells displayed a
higher Th1 cytokines production and were protected against tumor
challenge. Indeed, we observed that the antitumoral protective
response was mediated by OVA-specific CD8+ T cells. We now
evaluate the role of neutrophils recruited by FasL-DC in the
induction of the OVA-specific T cell response.
F2.20. CD8aa + T-Cells Represent a Long-Lived
Memory T-Cell Subset in Patients with Melanoma
Undergoing Epitope-Based Tumor Vaccination.
I. Magalhaes,1 N. K. Vudattu,1 K. Freitag,1 J. Karbach,2
A. Kumar,3 Z. Zhu,3 K. Kuus-Reichel,3 M. Juelch,4 C. Castelli,5
E. Jaeger,2 M. Maeurer.1 1Dept. of Medical Microbiology,
University of Mainz, Mainz, Germany; 2Dept. of Hematology/
Oncology, Krankenhaus Nordwest, Frankfurt, Germany;
3Immunomics Operation, Beckman Coulter Inc., San Diego, CA,
USA; 4Thymed GmbH, Mainz, Germany; 5Dept. of
Immunotherapy of Human Tumors, Istituto Tumori, Milano, Italy;
6Microbiology and Tumor Biology Center, Karolinska Institute,
Solna, Sweden.
Tumor vaccines are targeting CD8+ T-cells capable of differ-
entiating into activated effector cells which mediate tumor-
destruction, and memory cells crucial for long-term tumor-immune
surveillance. The CD8ab heterodimer represents the predominant
CD8 form in the peripheral blood circulation, although some CD8+
T-cells express the homodimeric CD8aa. Recent data suggest that
CD8aa cells may represent a biologically important subset of
memory T-cells. We tested longitudinally sampled peripheral blood
mononuclear cells (PBMCs) from patients with melanoma, vacci-
nated with the differentiation antigen Melan/MART-1, for i) the
presence of CD8aa expressing T-cells, ii) for T-cell differentiation
and homing markers (CD45RA/CCR7) and iii) antigen-specificT-cells using AAGIGILTV (naturally processed peptide) and
ELAGIGILTV (superagonist) peptides loaded into HLA-A2 tet-
ramers. MART-1/Melan-A reactive T-cells were present in CD8ab
and CD8aa expressing T-cells. Although CD8ab and CD8aa cells
show a different composition based on CD45RA and CCR7
expression, the examination of tetramer Melan/MART-1 specific
T-cells in the two CD8 subsets shows a terminally differentiated
phenotype (CD45RA+/CCR7-) which is maintained over time.
These data suggest that CD8aa cells represents a memory T-cell
pool, contributing to a long-lived immune protection. We could
consolidate this hypothesis using transfected recipient surrogate
(TCR-/CD8-) cells which express either the MART-1/Melan-A
specific TCR and CD8aa or CD8ab as a transgenes: TCR
interaction with HLA-A2/peptide complexes shows different
requirements in TCR+/CD8ab cells as compared to TCR+/CD8aa
cells. In vitro culture of PBLs from vaccinated patients with
melanoma, using different cytokines and peptide stimulation,
showed that IL7 or IL2 lead to a differential expansion of the
CD8aa and CD8ab Melan/MART-1 specific T-cell population,
respectively. This represents the first ex vivo report of anti-tumor
directed CD8aa T-cells in patients with melanoma undergoing
peptide vaccination. The assesment of this memory T-cell pop-
ulation will be relevant for immunomonitoring of patients with
tumors and aid to design improved tumor vaccines capable of
stimulating long-lived cellular immune responses.
F2.21. Human Adipocyte and Its Participation in Innate
Immunity.
Laurence Hoareau,1 Marie-Paule Gonthier,1 Regis Roche,1
Franck Festy,1 Christian Lefebvre D Hellencourt,1 Maya Cesari,1
Jean-Pierre Riviere,2 Marie-Amedee Dijoux,2 Sandrine
Bes-Houtmann.1 1University of Reunion, LBGM, Saint Denis,
Reunion, France; 2Laboratoire dTanapathologie, CHD Felix
Guyon, Saint Denis, Reunion, France.
Introduction: In addition to the well know role of adipocyte in
energy homeostasis, some recent studies suggest that this cell is
also involved in immunity. To further investigate the immune
capacities of adipocyte, we studied the expression of Toll Like
Receptors (TLR), which are important players in innate immunity.
In addition, the functionality of TLR2 and TLR4 was tested, by
using one of the TLR ligand in adipocytes culture.
Methods: Human subcutaneous primary preadipocytes and
mature adipocyte were used as cellular model. The presence of
different TLRs was determined at RNA level by reverse tran-
scriptase polymerase chain reaction (RT-PCR) and at protein level
by Western Blotting and immunocytochemistry. Furthermore, cells
were stimulated with lipopolysaccharide (LPS), and cytokines gene
expression were quantified at different times by real time PCR, in
order to assess adipocytes response to one of the TLR ligand.
Results: We demonstrated that human subcutaneous adipose
cells and tissue expressed TLR 2 and 4 mRNA. These results were
confirmed by the presence of the corresponding proteins. The same
results were observed in mature adipocytes and in the tissue. After
stimulation with LPS, an increase in mRNA level for Cyclo-
oxygenase-2 (Cox-2) and interleukine 6 (IL-6) was observed in
culture.
Conclusion: Our results showed for the first time the presence
in adipocytes of TLR 2 and TLR4, two important receptors
involved in innate immunity. These receptors are present not only
on preadipocytes but also in mature adipocyte and on the adipose
tissue. Furthermore, we demonstrate that these receptors on
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production. These results suggest that adipose cells could respond
to bacterial infection via the interaction between bacterial
component and TLR and participate in innate immunity. Finally,
to better understand the mechanisms of adipocyte response to
infection, analysis of TLR signalling pathways from subcutaneous
adipocyte are in progress.
F2.22. HDL-Reverse Cholesterol Transport and Signal
Transduction in T-Cells.
T. Fulop,1 A. Larbi,1 A. Khalil,1 N. Douziech,1 C. Fortin,1 G.
Dupuis.2 1Research Center on Aging, Universite de Sherbrooke,
Sherbrooke, QC, Canada; 2Deapartment of Biochemistry,
Universite de Sherbrooke, Sherbrooke, QC, Canada.
HDL-mediated Reverse Cholesterol Transport (RCT) serves to
regulate plasma cholesterol levels as well as cholesterol exchange
with circulating cells. We have previously shown that membrane
cholesterol in increased by 2-folds in T-cells from elderly donors.
This was accompanied by defects in cellular activation leading to
immune senescence. RCT is well-known in the case of athero-
sclerosis but its role in T-cells cholesterol metabolism as well as
T-cells signalling is still unknown. RCT is a lipid rafts-dependent
mechanism that involves a fast and a slow pool of membrane
cholesterol. In this study we sought to determine the role of HDL
in cholesterol metabolism of T-cells. We separated T-cells from
young (b25 years) and elderly (N65 years) healthy SENIEUR
subjects. We studied cholesterol uptake by the tritiated cholesterol
and for extrusion by HDL-driven reverse cholesterol transport.
The cholesterol uptake was decreased in T-cells of elderly. The
fast cholesterol pool is extracted from lipid rafts microdomains,
but separated lipid rafts from elderly donors still contain a high
amount of cholesterol. The incubation of T-cells with HDL
induced a signalisation that involved Jak-2 after 90 min that
corroborates with the fast pool cholesterol (lipid rafts) while a long
lasting activation of ERK is observed after 24h that corroborates
with the slow pool cholesterol (non-rafts). In the case of elderly
donors, the activation of these pathways is differentially altered.
These data are the first to show that HDL-mediated RCT is impaired
in aging explaining the changes in lipid rafts properties. Moreover, it
has been suggested recently that lipid rafts play an important role in
the cholesterol exchange mediated by HDL. Thus, lipid rafts may
auto-regulate their cholesterol content and changes in lipid rafts
properties with aging may explain defects in T-cell activation.
F2.23. The Effect of Treatment Recurrent Herpes
Simplex with Larifan.
Evita Niedrite,1 Ingmars Mikazans,1 Guna Feldmane,2
Arija Volrate.2 1Dept. of Dermatovenereology, Riga StradinTs
University, Riga, Latvia; 2Institute of Microbiology and Virology,
Riga, Latvia.
Introduction. Viral infection of herpes has captured a growing
attention during the last decade that shall be explained with the
ever- increase of herpes viruses throughout the world, frequent
relapses and unsatisfactory results of the usually prescribed therapy
of Herpes simplex viruses.
Various researches deal with the immunology of herpes virus
attempting to more accurately define the impact of immune
regulation factors.
The therapy of Herpes simplex infection more excessively
suggest immune modeling remedies that directly or indirectly
affect the response of immune competent cells.Aims of the research. To evaluate the efficiency and safety of
Larifan rectal suppositories for the treatment of frequently
relapsing infections of simple Herpes as well to detect the
concentration of circulating interferon during therapy.
Methods. The research compromises the analysis of a variety
of Larifan- suppositories, a general and local antiviral medicine
synthesized in Latvia. Larifan is a medicine of natural origin of
doubly spiraled ribonuclein acid that forms up in Escherichia coli
cells that are infected with bacteriofages. Larifan is wide scope
antiviral medicine. In vitro proves its capability to slow down the
reproduction of encephalomyelitis in Venezuela horses and other
viruses, reducing the output of viruses for 100 000 times. The
animals involved in experiments proved to have both preventive
and therapeutic affects in case of tick encephalitis, mice
encephalomyocarditis, rabies, influenza and other viral infections.
Out of the total number of 36 patients involved in the research,
all of them had frequently relapsing simple herpes (6 times and
more per year), 19% (n = 7) had genital herpes, 81% (n = 29) had
labial herpes. The involved patients ranged from 18- 70 years of
age. All of them had 1 rectal suppository consisting of 4 mg active
substance before sleep on the 1st, 2nd, 6th, 10th and 14th days. All of
patients had 5 such courses, between each of them was 4 weeks
without treatment. Circulating interferon was detected in sera of 23
patients before therapy and on the 7th day during the 1st course.
Circulating interferon was detected by the biological standart
micromethod.
Results. 30 of 36 patients ended the therapy completely. 6
discontinued therapy of various reasons. None of them discon-
tinued therapy because of side effects of Larifan. 66% (n = 20)
patients had no relapses during therapy, 17% (n = 5) patients had 1
relapse, 3% (n = 1) had 2 relapses, 7% (n = 2) had 3 relapses, 7%
(n = 2) had 5 relapses.
The increase of circulating interferon was detected in 87%
(n = 16) patients, only 13% (n = 7) of patients it remained low.
Conclusion. The results prove that a suppository variety of
Larifan combines both the local and systemic immune modeling
properties. Larifan would be an efficient medicine to treat
frequently recurring herpes infections during their aggravations.
To evaluate the significance of Larifan suppositories in the
treatment of frequently recurring herpes infections further long
term researches are needed and are carried out.
F2.24. Multidimensional Liquid Phase Separations of
Intact Proteins as an Alternative to 2D Gel
Electrophoresis for Proteomics.
A. Apffel,1 A. Adler,1 T. Sana,1 J. Garcia,1 R. Kincaid,1
S. Udiavar.1 1Molecular Technologies Laboratory, Agilent
Laboratories, Palo Alto, CA, USA.
In the field of expression proteomics, the dominant separation
technology has been Two Dimensional Gel Electrophoresis
(2DGE) frequently coupled with Mass Spectrometric identification
methods. Although an extremely powerful separation technique,
2DGE suffers from a number of drawbacks including lack of speed
and automation, poor reproducibility and quantitation and funda-
mental limitations in linearity resulting in a bias towards highly
expressed proteins. Alternative approaches based on Multidimen-
sional HPLC separation of proteolytic digest of complex samples
have emerged combining nanoscale reversed phase separations of
strong cation exchange fractions. Although these approaches have
demonstrated utility, the complexity of the resulting mixture
represents a considerable chromatographic challenge. Furthermore,
Abstracts S75pooling the proteolytic fragments from a large number of proteins
eliminates any association of a given peptide with its parent
proteins and thus configurations of multiple Post Translational
Modifications.
In an effort to overcome the limitations of existing techniques,
we have been evaluating the use of multidimensional liquid phase
separation of intact proteins as an alternative. In this approach, 96
fractions from a first dimension are collected and re-fractionated by
a second, orthogonal separation mechanism collecting 16 fractions
resulting in a total of 1536 fraction per sample. As 1st dimension
modes, we have coupled strong anion exchange chromatography
with a 2nd dimension based on high speed separations using a 5mm
3002 Macroporous Reversed Phase material at high temperatures
(608C) for very high resolution and recovery. This material allows
rapid diffusion of large molecular proteins resulting reversed phase
cycle times of 5–10 minutes/fraction. The combinations of these
chromatographic modes are largely orthogonal, utilize compatible
mobile phases and yield resolution of several hundred proteins in a
single analysis.
Following the 2D Fractionation of intact proteins, all of the
collected fractions are reduced, alkylated and proteolytically
digested for subsequent analysis by Nanoscale electrospray LC/
MS based on a microfluidic ChipMS System for Ion Trap Mass
Spectrometry. Although each fraction generally contains multiple
proteins, it is feasible to identify the components using rapid
Nanospray LC-MS/MS information. In this workflow, the LC-MS/
MS is the most time consuming, so a key feature of this approach
has been the development of tools to visualize and compare the 2D
separations of intact proteins to identify and prioritize fractions for
subsequent analysis by LC-MS/MS. Following collection of the
MS/MS data, the pooled spectra are processed and compared to
protein library data bases using SpectrumMill software to identify
proteins present in the samples.
This method is demonstrated with the analysis of a protein
extract of Murine Immunodepleted Sera from NOD and NOD.B10
Mice. Discussion is made of optimization and current limitations of
the method as well as future potential.
F2.25. Screening of Immunostimulatory
Oligosaccharides by Using a New HPLC-Chip/MS
Technology.
R. Grimm,1 H. Yin,1 M. Ninonuevo,2 K. Killeen,1 C. Lebrilla.2
1Integrated Biology Solutions, Agilent Technologies, Palo Alto,
CA, USA; 2Department of Biomedicine, UC Davis, Davis, CA,
USA.
Oligosaccharides are involved in a host of cell-cell processes
and play a key role in the immune system. Changes in
glycosylation or the formation of aberrant oligosaccharides
accompany a host of diseases from infection to cancer (eg. ovarian
cancer, diabetes, cystic fibrosis, arthritis, autoimmunity, respiratory
capacity diseases). In this presentation, we introduce a new fully
automated and integrated analytical platform for oligosaccharide
profiling consisting of a chip-based chromatography system in
conjunction with time-of-flight mass spectrometry. The micro-
fluidic HPLC chips are made of laser ablated and laminated
biocompatible polyimide films. Sample enrichment, separation and
nanoelectrospray tips are fully integrated in the chip device. High
resolution separations of oligosaccharides are achieved with porous
graphitized carbon (PGC) column material packed in the chip
device. Oligosaccharide isomers are readily separated and
resolved. Specific oligosaccharide structures are identified byaccurate mass measurements and highly reproducible retention
times. In this way, over 100 different oligosaccharides are
simultaneously identified and monitored. Those known to have
immunostimulatory effects were unambiguously identified. This
new advanced chip-based analytical platform is also capable to
analyze other aspects related to diseases like changes in the
phosphorylation pattern or changes at the metabolomics level.
F2.26. The Role of Mannose-Binding Lectin in Natural
IgM Mediated Ischemia/Reperfusion Injury.
M. Zhang,1 K. Takahashi,4 E. M. Alicot,6 T. Vorup-Jensen,1
B. Kessler,2 J. Christian Jensenius,5 R. A. B. Ezekowitz,4 F. D.
Moore,3 M. C. Carroll.1 1CBR Institute of Biomedical Research,
Harvard Medical School, Boston, MA, USA; 2Dept. of Pathology,
Harvard Medical School, Boston, MA, USA; 3Surgery, Brigham
and WomenTs Hospital, Boston, MA, USA; 4Dept. of Pediatrics,
Massachusetts General Hospital, Boston, MA, USA; 5Dept. of
Medical Microbiology and Immunology, University of Aarhus,
Aarhus C, Denmark; 6DecImmune Therapeutics, Boston, MA,
USA.
Ischemia/reperfusion (I/R) injury consists of an acute inflam-
matory response involving complement which is activated upon
the recognition of natural IgM to self-antigen exposed by ischemia.
This study dissected the role of lectin versus classical complement
pathways in an intestinal I/R model. When RAG-1-/- mice were
reconstituted with I/R-specific clonal IgM, mannose-binding lectin
(MBL) co-localized with IgM in the injured tissue. Further,
MBL-/- mice were protected from I/R injury (40min ischemia,
3hour reperfusion) with the absence of IgM and C3 deposition. In
contrast, C1q-/- mice were injured similarly as WT animals with
deposition of MBL and IgM in the damaged tissue. Reperfusion in
MBL-/- mice for 15min showed IgM deposition in intestinal villi,
and subsequent proteomic analysis identified specific self-antigen
bound to IgM. Preliminary results from in vitro study show that
murine MBL binds to IgM. This study reveals that I/R patho-
genesis is initiated by IgM response to ischemic antigen followed
by direct activation of downstream lectin pathway of complement.
F2.27. Effect of Plaferon LB on the Damaged Peripheral
Nerve Regeneration.
T. Chikovani,1,2 M. Kvezereli,2 G. Burkadze,1 T. Giorgadze,2
V. Bakhutashvili.2 1Microbilogy, Virology & Immunology, Tbilisi
State Medical University, Tbilisi, Georgia; 2Biomedicine, Institute
of Medical Biotechnology, Tbilisi, Georgia.
Axonal repair of mature neurons involves complex molecular
changes. Critical role is played by Schwann cells as well as
macrophages and inflammatory cells. One of the most important
molecules, which determine degeneration/regeneration processes
in damaged nerve, is nitric oxide (NO). NO influences on many
aspects of nervous system physiology, being either detrimental or
beneficial. As it is already revealed, the possible NO targets are
neurofilaments and myelin sheaths of interrupted axon, newly
formed neuromuscular endplates and Schwann cells in the distal
nerve stump.
Manipulation of NO supply may offer interesting therapeutic
options for peripheral nerve lesions recovery. The possibility of
regeneration of transected sciatic nerve axon under the influence of
Plaferon LB (PLB), inhibiting inducible nitric oxide synthase
activity in vitro was investigated.
Experiment was conducted on twenty white rats. Animals were
daily treated by PLB or saline. Treatment was begun three days
AbstractsS76before transection. Ten animals were treated with PLB, others were
undergone a course of saline treatment. Operation was carried out
by microsurgeon; sciatic nerve was transected and than sewed up.
Animals were sacrificed seven and thirty days after operation.
The nerve was removed for nitric oxide (NO) measurement (after 7
days) and morphological examination (after month). NO was
measured by electron spin resonance method using NO trap.
For morphological investigation, preparations were stained by
hematoxylin-eosin methods, neurohistological method-Nils and
immunocytochemical method by using monoclonal antibody S100.
Our findings suggest that PLB may play an important role in
the regeneration of the injured peripheral nerve. In the injured
nerve intense increase of NO production as well as the quantity of
Shwann and mast cells was observed. According to our results
PLB prevents the induction of NO production in axotomized
sciatic nerve. Quantitative analysis showed that under the influence
of PLB increase of Shwann and mast cells was statistically high
reliable.
F2.28. Activation of the Lectin Pathway of Complement
in IgA Nephropathy.
M. R. Daha,1 M. P. Rastaldi,2 M. A. Seelen,1 J. W. Eijgenraam,1
B. D. Oortwijn,1 D. J. Van Gijlswijk-Janssen,1 M. C. Faber-Krol,1
N. Calvaresi,2 M. Matsushita,3 T. Fujita,4 C. Van Kooten,1
A. Roos.1 1Department of Nephrology, Leiden University Medical
Center, Leiden, Netherlands; 2Renal Immunopathology Center,
Milan, Italy; 3Institute of Glycothechnology and Department of
Applied Biochemistry, Tokai University, Hiratsuka, Japan;
4Department of Biochemistry, Fukushima Medical University,
Fukushima, Japan.
IgA nephropathy (IgAN) is characterized by glomerular co-
deposition of IgA and complement components. The complement
system can be activated via three activation pathways, the classical
pathway, the alternative pathway, and the more recently identified
lectin pathway. Complement activation leads to tissue deposition of
activated complement components and release of pro-inflammatory
factors. IgA can activate the complement system via the alternative
pathway but not the classical pathway. Furthermore, recent data
indicate involvement of the lectin pathway of complement in
IgAN. The LP can be activated by binding of mannose-binding
lectin (MBL), L-ficolin and H-ficolin to carbohydrate ligands,
followed by activation of MBL-associated serine proteases
(MASPs) and C4. We studied the potential role of the lectin
pathway in IgAN and the interaction between MBL and human
IgA as a possible explanation for lectin pathway activation in
IgAN.
Renal biopsies of IgAN patients (n = 60) were stained for IgA1,
IgA2, MBL, L-ficolin and complement. Polymeric and monomeric
serum IgA of IgAN patients (n = 14) and healthy controls (n = 8)
was purified by affinity chromatography and gel filtration. Binding
of MBL to IgA was studied by ELISA.
All IgAN cases showed mesangial deposition of IgA1 but not
IgA2. Glomerular deposition of MBL was observed in 15 out of 41
cases with IgAN (25 %) and showed a mesangial pattern. All
MBL-positive cases, but none of the MBL-negative cases, also
showed glomerular deposition of L-ficolin, MASP-1/3, C4-binding
protein and C4d. Glomerular deposition of MBL and L-ficolin was
associated with significantly more mesangial proliferation, inter-
stitial damage, and proteinuria.
In vitro studies demonstrated binding of MBL to IgA from
healthy controls and from IgAN patients, with a strong inter-individual variation. MBL binding was observed to polymeric but
not to monomeric IgA. The interaction between MBL and IgAwas
dose-dependent and could be inhibited by EDTA and D-mannose
but not L-mannose, indicating involvement of the lectin domain of
MBL.
Together, these findings strongly point to a role of the lectin
pathway of complement in glomerular activation of C4 in IgAN,
and suggest a contribution for both MBL and L-ficolin in the
progression of the disease. Furthermore, the findings support the
hypothesis that glomerular MBL binding and complement activa-
tion in IgAN is based on an interaction of MBL with IgA.
F2.29. Characterisation of Antibody Titres in an
Intravenous Immunoglobulin Concentrate
(FlebogammaR).
M. Lopez,1 J. I. Jorquera.1 1R&D Area, Instituto Grifols, S.A.,
Parets del Valles, Barcelona, Spain.
To evaluate the IgG antibody levels in an intravenous
immunoglobulin concentrate (FlebogammaR) against several
pathogens.
From 3 to 217 lots of FlebogammaR, product at 5% IgG
concentration containing 5% sorbitol as excipient, were studied.
The titres against Cytomegalovirus (CMV), hepatitis A and B,
measles, varicella (VZV), parvovirus B19, poliovirus type I, II
and III, rubella, Epstein Barr (EBV), herpes simplex type 1 and 2,
influenza A and B, parainfluenza type 1 and 2, adenovirus,
mumps, coxsackie, echovirus, tetanus, diphtheria, streptococcus
pneumoniae, candida albicans, bordetella pertussis, helicobacter
pylori, campylobacter jejuni, chlamydia, borrelia burgdorferi and
toxoplasma gondii, were studied. ELISA tests were used except
for antibodies to poliovirus type I, II and III, diphtheria and
measles, which were performed by neutralization tests. The
results are shown as IU/ml or Elisa Units (U/ml) when no
international reference is available. For determination against
poliovirus, measles and diphtheria, the CBER lot 176 and US
Diphtheria antitoxin standard F4505 reference preparations were
used.
The most relevant results obtained are as follows: hepatitis A
and B (35F 4 and 1.1F 0.5 IU/ml respectively), VZV (12F 1 IU/
ml), tetanus (22 F 4 IU/ml), parvovirus B19 (141 F 21 IU/ml),
CMV (31 F 6 IU/ml). For all these agents, the titres in the final
product are 6- to 9-fold the value observed in the starting plasma.
The results obtained for neutralizing antibodies against poliovirus
type I, II and III and measles were 0.34F 0.11, 0.71F 0.13, 0.59F
0.10 and 0.30 F 0.08 sample/reference ratio, respectively, and
against diphtheria 4.4 F 0.5 U/ml. The presence of neutralizing
antibodies is demonstrated and the results meet FDATs requirements
for these preparations. With regard to the other antibodies studied,
since no international reference is available, the quantitation is
performed in relation to the cut-off or positivity limit of the ELISA
method used. Thus, the activity against EBV (644 F 50 U/ml),
herpes (9290 F 735 U/ml), mumps (1890 F 169 U/ml),
helycobacter (436 F 41 U/ml), adenovirus (62 F 9 U/ml), rubella
(323F 37 U/ml), St. pneumoniae (449F 57 mg/L), influenza, etc.,
is 5-fold the cut-off limit. Finally, antibodies are also detected, even
though to a lower extent, against Candida (50 F 5 U/ml),
Bordetella (28 F 2 U/ml), Campylobacter (90 U/ml), Coxiella
(42 F 21 U/ml) and Coxsackie (220 F 11 U/ml).
FlebogammaR contains IgG antibodies against a wide panel of
pathogens, between 6- and 9-fold the normal plasma values for a
high number of agents.
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Evaluation of Neutralizing Antibodies to Vaccinia Virus.
H. Biescas,1 R. Gajardo,1 A. Vandermeeren,2 M. Esteban,2
J. I. Jorquera.1 1Research and Development Area, Instituto
Grifols, Barcelona, Spain; 2Centro Nacional de Biotecnologia,
CSIC, Campus Universidad Autonoma, Madrid, Spain.
Immunocompromised individuals may be at risk for Vaccinia
infection if widespread smallpox-immunization programs are
needed. The aim of this study was to determine the level of
neutralizing antibodies to Vaccinia virus in Human Intravenous
Immunoglobulin (IVIG) manufactured by Instituto Grifols.
Thirteen batches of FlebogammaR were evaluated for the
presence of anti-Vaccinia antibodies by a Vaccinia Plaque
reduction neutralization assay. The Vaccinia virus working stock
(Western Reserve-WR strain) was mixed with IVIG preparations,
and after incubation at 378C for 1h were inoculated onto monkey
cells (BSC-40) for detection. An international standard from
NIBSC (63/024) (potency of 1000 IU/ml) was used as the
Antibody-positive Control preparation. Sera from non-smallpox
vaccinated donors was the negative control preparation used.
There is a linear correlation between the rate of virus neutraliza-
tion and the antibody concentration. The neutralizing titer for a
specific sample was expressed as the sample dilution that reduced
the number of virus plaques to 50% (determined in triplicate) as
compared with the number seen in the virus positive control
(without IVIG added).
The results of the experiments provided a neutralizing potency
of 35 (range 18 to 68) anti-Vaccinia IU/ml IVIG. Anti-Vaccinia
antibodies in the product were also determined by ELISA and WB
techniques revealing that the product was able to react against
several Vaccinia virus proteins. There were no relevant differences
among batches in the anti-Vaccinia titers.
The results of this study are consistent with the work of
Goldsmith et al. (Vox Sang. 2004, 86:125-9). The titers of anti-
Vaccinia antibodies found in this preparation have biological
relevance since they provided protection against Vaccinia infection
to immunocompromised mice.
F2.31. Compatibility Study of Two Intravenous
Immunoglobulin Preparations with Plastic Containers.
M. Lopez,1 M. Costa,1 J. I. Jorquera.1 1R&D Area, Instituto
Grifols, S.A., Parets del Valles, Barcelona, Spain.
The customization of intravenous immunoglobulins (IVIG)
therapeutical doses to each patientTs needs, by unifying the content
of several bottles in a single container, is more and more frequent.
This study deals with the compatibility of two IVIG preparations
sharing formulation (5% sorbitol) with two types of plastic
container.
Nine lots of two preparations manufactured by Grifols,
FlebogammaR (licensed) and 5% IGIV3I (under clinical trial),
both containing 5% sorbitol as excipient, were filled in Griflex-
polypropylene (PP) or Gribag-PVC sterile bags, at a rate of 40 ml
solution/100 ml bag, what implies worst case conditions as refers to
product-plastic contact ratio. The GrifillR system, which ensures
sterile filling, was used. The product, filled in the plastic containers,
was stored at 5 8C, 30 8C and 40 8C for a period between 10 and 15
days. For each temperature, tests before and after transfer from the
original container (glass bottle) to the plastic container (PVC or PP),
as well as at different storage time points, were scheduled. The
following parameters were evaluated: appearance, pH, turbidity,
osmolality, total protein (Bio-Rad), molecular distribution (HPLC),anticomplementary activity (ACA), prekallikrein activator (PKA),
antibodies titration against tetanus and hepatitis B (ELISA),
antibodies against poliovirus type I (neutralization), DEHP (gas
chromatography, mass spectrometry) and other polypropylene
plastic additives: BHT, Irganox 1010 and 1073 and Ethanox 330
(HPLC), sorbitol (HPLC), pyrogens (injection into rabbits), toxicity
(intraperitoneal injection into guinea pigs and mice), sterility
(Steritest system, from Millipore) and bags weight control.
The results of the tests performed do not show significant
variations in the productsT characteristics after transferring them to
the plastic containers. The results at temperatures of 5 8C and 30 8C
do not show any sign of incompatibility with the plastic material,
the antibody titres studied remaining perfectly stable. The markers
used to assess the possible migration of plastic components to the
product (DEHP for PVC) and PP additives are undetectable or very
low (the DEHP content shows values below 5 Ag/ml in all instances
and the PP markers are undetectable). The mean weight loss is
between 0.1% and 0.2% after 10–15 days of storage at 5 8C and
between 0.6% and 1.3% at 30 8C. In the accelerated temperature
studies (40 8C) a higher weight loss is noticed (between 1.2% and
2.9%), but no significant variations are detected in the other
parameters studied.
5% sorbitol-formulated IVIG shows compatibility with PVC
and PP during short time periods, between 2 8C and 30 8C.
F2.32. Peripheral Blood Lymphocyte Immunological
Profile of Patients with Autoimmune Hepatitis in
Different Stages of Immunosuppressive Therapy.
K. Gutkowski, M. Hartleb, A. Pluta, D. Gutkowska.
1Physiotherapy Institute, RzeszowTs University, Rzeszow, Poland;
2Gastroenetology Department, Medical University of Silesia,
Katowice, Poland; 3Physiotherapy Institute, RzeszowTs University,
Rzeszow, Poland; 4Epidemiology Department, Center for Disease
Control and Prevention, Rzeszow, Poland.
Introduction: Autoimmune hepatitis (AIH) is a rare disease
characterized by progressive necro-inflammatory hepatocyte injury
caused by breakdown of immune tolerance to self-antigens
however pathogenic mechanisms underlying the development of
AIH are still unclear.The aim of our study was a complex analysis
of autoimmune phenomena involving activation and apoptosis as
well as transfer of co-stimulatory signals of particular lymphocytic
subpopulations in peripheral blood of patients with AIH in
different stages of immunosuppressive therapy.
Material and methods: Examinations were carried out in 26
AIH patients divided into two groups. The first group consisted of 13
patients with de-novo diagnosed AIH in which immunophenotyping
of peripheral blood lymphocytes was done twice i.e., before and
after five months of immunosuppressive therapy. The second group
consisted of 13 patients showing clinical and laboratory features of
AIH remission (single immunophenotyping).
The functional state of lymphocytes was examined using three-
color flow cytometry technique with 17 monoclonal antibodies
repertoire. The reference ranges for activation and apoptosis markers
were obtained from immunophenotyping of 30 healthy volunteers.
Results: The percentage of T cells, Tc with surface marker
CD95 was significantly lower in AIH de-novo diagnosed patients
than in healthy subjects. The percentage of activated Th, as well as
B cells were significantly higher in AIH de-novo diagnosed than in
healthy subjects.
After five months of immunosuppressive therapy following
changes with comparison to initial data were found: a) increase of
AbstractsS78percentages of T, Th and Tc cells, b) increase of percentage of Th
cells with surface CD95, c) decrease of percentage of NK cells, d)
decrease of percentage of activated B and B1a cells.
After 2 to 4 years of immunosuppressive therapy no significant
differences in percentages of T, Th, Tc and NK cells were found
between AIH patients and healthy subjects.
Conclusions:
1. The activated T lymphocytes appear during clinical exacer-
bation of AIH.
2. The percentage of peripheral blood NK cells decreases after 5
months of immunosuppressive treatment and normalizes after
2–4 years of treatment.
3. The percentage of activated B cells was increased in active
phase of disease and significantly decreased following 5
months and 2–4 years of immunosuppressive therapy.
4. Exacerbation of AIH is associated with a decrease number of
activated Tc lymphocytes which probably results from accu-
mulation of these cells in the liver.
5. Activation of lymphocytes T via CD69 antigen seems to be a
principal immune event in pathogenesis of AIH exacerbation.
6. Immunosuppressive therapy lasting 2–4 years leads to
normalization of amount of basic T lymphocyte populations
in peripheral blood. No such effect was observed after 5
months of immunosuppressive therapy.
F2.33. Identifying Common bInnate SignatureQ from
Gene Expression Profile in Innate vs. Adaptive
Lymphocytes.
T. Yamagata,1 C. Benoist,1 D. Mathis.1 1Section on Immunology
and Immunogenetics, Joslin Diabetes Center, Boston, MA, USA.
Innate and adaptive immune responses are two radically different
strategies the host immune system takes against pathogen assaults.
This dichotomous view of the immune response has now been
widely accepted. However, it is not clear what the definition, or
hallmark, of innate immunity is, and what really distinguishes it
from adaptive immunity. In order to address this question, we took a
broad approach and compared gene-expression profiles in innate vs.
adaptive immune cell populations. The players in innate immune
responses include neutrophils, macrophages, natural killer (NK)
cells, and dendritic cells (DCs), whereas those in adaptive responses
include the classical Tand B cells. However, comparing two extreme
cell-types (e.g. neutrophils vs. T cells) could end up highlighting
superficial differences such as TCR and downstream genes. There-
fore, we have explored differences in gene expression by comparing
close, but distinct, paired innate vs. adaptive populations;
CD3+CD4+NK1.1+ T cells (NKT) vs. CD3+CD4+NK1.1- T cells
(CD4T); IgMhiIgDintCD11b+B cells (B1) vs. IgMintIgDhiCD11b- B
cells (B2); TCRb+CD8a+CD8b-cells (CD8aa) vs. TCRb+
CD8a+CD8b+ cells (CD8ab). These six populations were sorted
from wild-type C57BL/6 mice or TCR transgenic mice, and mRNA
was hybridized to Affymetrix U74Av2 chips. The genomic analyses
were done in two ways: a mathematical/geometrical analysis of the
cell population coordinates based on their gene expressions
(Reference Population Plot; RPP), and a bioinformatic analysis of
the over-expressed genes based on their molecular functions. The
RPPs indicate that innate lymphocytes have active-, memory-, NK-,
and regulatory-like characters. We found 22 genes over-expressed
N1.5 fold in the intersection of three innate vs. adaptive
comparisons, a number which is significantly higher than the
background level (1 gene) in randomized datasets. We also defined
33 genes that are under-expressed in innate cells. These two sets ofgenes successfully sort multiple lymphocyte populations into innate
and adaptive subgroups in the RPP, indicating that expression levels
of the 22 genes can be designated as an bunbiasedQ innate signature.
The molecular characterization of the genes induced in innate
populations pointed to multiple molecular pathways being acti-
vated. We have found a limited set of functional entities to be
enhanced across the populations of innate lymphocytes: essentially
the intracellular vacuole trafficking and interferon-inducible
GTPase systems. This finding prompts one to speculate that the
innate immune system might deploy a unique intracellular
recognition system to detect subtle changes in the tissue environ-
ment. Our analyses have revealed shared genes and pathways
induced in innate lymphocytes, and thus a common binnate
signatureQ that distinguishes innate lymphocytes from adaptive
ones. These findings are not only instrumental for genomic
definition and classification of binnatenessQ in various immune
cell-types, but also have implications for our understanding of the
origin and evolution of innate immunity.
F2.34. Different O-glycosylated Structures Are
Expressed in T Cell Activation.
Marisela Linares,1 Ma.Carmen Jimenez-Martinez,1 Blanca
Ortiz,2 Edgar Zenteno,2 Ricardo Lascurain.3 1Research Unit,
Institute of Ophthalmology, Fundacion Conde de Valenciana,
Mexico, D.F., Mexico, D.F., Mexico; 2Biochemistry, Instituto
Nacional Enfermedades Respiratorias, Mexico, D.F., Mexico,
D.F., Mexico; 3Biochemistry, Universidad Nacional Autonoma de
Mexico, Mexico, D.F., Mexico, D.F.
Previously, we reported that the saccharidic structure (Gal,
GalNAc) recognized by Amaranthus leucocarpus lectin (ALL) is
expressed on activated T cells. Gal, GalNAc structure is also
recognized by Peneaut agglutinin (PNA). The objective of this
work is to determine if the structure recognized by ALL is similar
to the structure recognized by PNA.
PBMC were obtained form healthy donors and cultured in
presence of 1 mg/ml of Concanavalin A (Con A). Then, the cells
were recovered every 24 h during 4 days. After that, the cells were
labeled with the FITC conjugated-lectins Amaranthus leucocarpus
(ALL) or Peneaut agglutinin (PNA) and against different mAb
such as CD3-Cychrome, CD69-PE or CD25-PE. In some cases the
cells were treated by neuraminidase to eliminate the sialic acid
camouflage. The results were analyzed by flow cytometry.
Results: After stimulation with Con A, the percentage of ALL+
T cells increases from 3% to 69% at 48 h, diminishing gradually,
whereas the percentage of cells PNA+ T cells increases from 1% to
90% at 72 h and maintaining this percentage until 96 h. The
expression of CD69 and CD25 and we observed that the CD69 and
CD25 expression was 3 times more on ALL+ T cells. However on
the neuraminidase treated cells the expression of CD69 and CD25
was disminished in both, ALL+ and PNA+ T cells.
Conclusions: Our results suggest that saccharidic structure
recongnized by ALL is different to the saccharidic structure
recognized by PNA.
F2.35. Short-Term Atorvastatin Treatment Enhances
Specific Antibody Production Following Tetanus Toxoid
Vaccination in Healthy Volunteers.
P. Y. Lee,1 P. O. Scumpia,1 J. A. Byars,1 K. M. Kelly,1 H. Zhuang,1
D. Theriaque,1 J. Shuster,1 P. W. Stacpoole,1 M. S. Segal,1 W. H.
Reeves,1 M. L. Brantly.1 1General Clinical Research Center,
University of Florida, Gainesville, FL, USA.
Abstracts S79Statins are a class of HMG CoA reductase inhibitors used by
millions of Americans with high cholesterol. Several lines of
evidence suggest that these drugs possess anti-inflammatory and
immunomodulatory properties beyond their cholesterol-lowering
effects. Recent reports have shown that statins affect immune
responsiveness by skewing the TH1/ TH2 balance and interfering
with MHC class II expression. While inhibition of inflammatory
processes can be protective, suppression of immune responses such
as antigen presentation may weaken host defense. To determine
whether HMG CoA reductase inhibitor treatment has an effect on
in vivo acute phase response and antibody production following
tetanus vaccination in normal healthy volunteers in a double blind,
parallel, placebo controlled study. Twenty healthy volunteers were
randomized to receive atorvastatin 40 mg (AT) or calcium placebo
(PL) for 10 days and all volunteers received tetanus toxoid (TT)
vaccine on day 5 of the study. The acute phase response was
evaluated by determining changes in ESR, CBC with differentials,
and serum concentrations of acute phase proteins (a1-antitrypsin,
C-reactive protein, and a1-acid glycoprotein) and cytokines (IFN g,
IL-4, IL-6, and IL-10). The humoral response to vaccination was
assessed by measuring total immunoglobulins and specific anti-TT
antibodies. Baseline measurements of all variables were similar in
both groups. Following the ten-days of study drug or placebo,
subjects in the atorvastatin group had a significant reduction in
total cholesterol (AT: 44.4 F 9 mg/dL; PL: 22.7 F 8 mg/dL;
P b 0.0001) and LDL cholesterol (AT: 46.2 F 9 mg/dl; PL:
13.2 F 7 mg/dl; P = 0.0001) compared to the control group,
demonstrating the effectiveness of atorvastatin. The baseline anti-
TT antibody concentrations and the number of years elapsed since
last vaccination were similar in both groups. Unexpectedly, the
production of specific antibody against TT (predominately IgG1)
was more than 3 fold higher in volunteers treated with atorvastatin
15 days post-vaccination (AT: 2306F 468 units; PL: 713F 21 units,
P = 0.0085). Atorvastatin suppressed the post-vaccination rise in
platelet counts (AT:5.2F 3.1%; PL: 9.63F 4.4%;P = 0.0132) and
lymphocytecounts (AT:7.4F9.1%;PL:33.4F10.5%;P=0.0089)
consistent with its anti-inflammatory properties. There were no
significant changes in ESR, serum levels of acute phase reactants or
cytokines in the treatment and control groups. This study demon-
strates that statins augment specific immune responses following
vaccination in healthy volunteers rather than suppress them. Beyond
their applications in reducing cholesterol and suppressing inflamma-
tion, it is possible that statinsmay benefit groupswho respond poorly
to vaccinations, such as the elderly or immunocompromised patients.
Further clinical studies are needed to determine if these groups
demonstrate a similar response to atorvastatin as well as to determine
the mechanism(s) that mediated this effect.
F2.36. An Immunology Syllabus to StudentTs Medicine.
Osmel Gaspar Guerra Segura. 1Immunology Lab, Teach. and Gen.
Hosp. Dr. A. Neto, Guantanamo, Guantanamo, Cuba.
We did a pedagogical diagnostic of the knowledges of
Immunology to the students of second year of Medicine before
and after the teaching the topics in Microbiology and Pathology,
then the diagnostic was done to the six year students and Internal
Medicine residents. To accomplish the objetives were designed
some pedagogical instruments (interview, questions, TestTs know-
ledges) to students and proffesors wich taught and recieved the
subject. The 93 % of the knowledges were adquired by the second
year students, and the Internal Medicine residents obtained the
lowest marks. The highest integration of contents of Immunologywith other subjects is only about 40 %. ThatTs right we propose an
Immunology syllabus in agreement with social and professional
needs of cuban doctors and from other countries.
F2.37. Use of C1 Inhibitor Concentrate for Treatment of
Angioedema Attacks in Patients with C1 Inhibitor
Deficiency. Survey of 1102 Infusions in 503 Patients.
A. Zanichelli,1 L. C. Zingale,1 B. Cicardi,1 L. Maggioni,1
E. Pappalardo,1 M. Cicardi.1 1Internal Medicine, University of
Milan, Hospital S. Giuseppe, Milan, Milan, Italy.
C1 inhibitor deficiency is a rare condition that can be either
inherited (hereditary angioedema, HAE) or acquired (acquired
angioedema, AAE) and is clinically characterized by recurrent, self-
limiting skin and intestinal edema and life-threatening upper airway
obstruction. Replacement therapy with C1-INH concentrate is the
treatment of choice for severe acute attacks of angioedema inEurope.
We report the need and efficacy of C1-INH concentrate in 477
patients with HAE and 25 with AAE observed for: 30–25 years 50
patients, 24-20 in 44, 19-15 in 48, 14-10 in 96, 9-5 105, b5 in 159.
Efficacy was evaluated as the time to beginning of resolution of
symptoms. Side effects were recorded. C1-INH concentrate was
used in 149 of 477 HAE patients (31%) for a total of 1013
infusions (mean infusion/patient 6.8, range 1–84) and by 8 of 25
AAE patients (32%) with a total of 89 infusions (mean infusion/
patient 11.1, range 1–27). The dose ranged from 500U to 2000U
for HAE, 1000U-12000U for AAE.
In 431 laryngeal attacks time to beginning of resolution was
between 30 and 60 minutes in 424 episodes (98%) and between 1
and 2 hours in 6 episodes. One HAE patient underwent trache-
ostomy for laryngeal edema despite treatment with C1-INH
concentrate. In 475 abdominal attacks time to beginning of
resolution was within one hour in 469 episodes (99 %), between
1 hour and 12 hours in 6 episodes. Among 21 episodes of edema of
the oral mucosa time to beginning of resolution was within one
hour in 20 (90 %) and between 1 and 48 hours in 2. In 39 facial
attacks the time to beginning of resolution was within 60 min in 26
(67%), between 1 and 2 hours in 7 and between 2 and 12 hours in
5. In 45 peripheral attacks the time to resolution was within one
hour in 23 episodes (51 %), between 1 and 2 hours in 8 episodes
and between 2 and 48 hours in 14 episodes. In 5 patients with AAE
(54 infusions) beginning of resolution was always within one hour;
in the remaining 3 patients (35 infusions) the response became
progressively slow 3 (3 hours or more) requiring higher doses of
C1-INH concentrate. Two anaphylactoid reactions were reported in
2 HAE patients. Prevalence of HCV in treated patients dropped
from 71% to 3% with the introduction of virucidal methods. No
HIV infection was ever detected. Our data indicate that treatment
with C1-INH concentrate is highly effective in angioedema of the
laryngeal or abdominal mucosa; its effectiveness is reduced when
the skin is involved and particularly in peripheral attacks. Patients
with AAE may become resistant to the treatment. Safety is
generally good and transmission of blood borne infection has
drastically reduced since viral inactivation procedures have been
introduced.
F2.38. Immunonutritional Assessment of Special
PlasmaTs Donors.
Osmel Gaspar Guerra Segura, Nerys Noa Rdguez. 1Immunology
Lab, Teach. and Gen. Hosp. Dr. A.Neto, Guantanamo,
Guantanamo, Cuba; 2Quality Control, Provincial
Blood Bank, Guantanamo, Guantanamo, Cuba.
AbstractsS80We did a prospective study of special plasmaTs donors with
more than a year in the plasmapheresis program of hiperimmune
anti TT (tetanic toxoid) plasma in the provincial Blood Bank of
Guantanamo. We have evaluated the donors nutritionaly with the
CERES program from Hygene of Foods Institute from Hanvana
wich have an special form for the collection of data in the relation
to high, weight and race. From the immunohematologic and
biochemist point of view, we value each fractions of Protein
Electrophoresis, Eritro, Hemoglobin and in particular the specific
antibodies (anti TT) and positiveness to antigens of Hepatitis B and
C and HIV test. From the nutritional point of view the lipids supply
is the only deficiency in those donators where antropometric and
hematologic parameters are agree with literature. Specific anti-
bodies titles (anti TT) vary in the 98 % of donors.
F2.39. Presentation of the Human Hepatitis B Surface
Antigen- Loop by the Cpn10 Scaffold Induces a Specific
Antibody Response in Mice by Genetic Immunization.
S. Neckermann,1 J. Lohrmann,2 W. Zimmermann.1 1Tumor
Immunology Laboratory, Department of Urology, University Clinic
Grosshadern, Ludwig-Maximilians-University, Munich, Germany;
2GENOVAC GmbH, Freiburg, Germany.
Introduction:
Cpn10 proteins belong to a widely distributed protein family
found from mammals to bacteria. Because of their conservation
between species they exhibit low immunogenicity. This property is
advantageous when fusion proteins are used in genetic immuniza-
tions: antibodies against the fusion partner and not against Cpn10
are generated. Cpn10 spontaneously forms a heptafold scaffold and
each subunit of this scaffold displays an exposed polypeptide loop.
This native loop can be replaced by a foreign loop sequence.
An important application of this bloop replacementQ strategy
lies in presenting extracellular loops of transmembrane proteins
like G-protein coupled receptors (GPCR) for which it has been
proved difficult to generate antisera against their short extracellular
loops. The broad interest on the GPCR family is based upon the
fact that 50–60% of approved drugs elicit their therapeutic effect
by selectively addressing GPCRs.
As a proof of principle for the applicability of the Cpn10
scaffold we have replaced the Cpn10 loop by the baQ determinant
of the Hepatitis B surface antigen (HBsAg). The baQ determinant is
a small loop of nine amino acids, which is highly immunogenic
when presented in the context of the full length HBsAg. In this
study, we wanted to analyze whether presentation of this HBsAg
loop in the Cpn10 scaffold can elicit a specific immune response
upon genetic immunization and whether the scaffold is able to
mimic the native conformation. Therefore we immunized mice
with a plasmid coding for the Cpn10-HbsAg scaffold and analyzed
the antisera for specific anti-HBsAg antibodies.
Methods:
The murine Cpn10 cDNA and the nucleotides coding for the baQ
determinant were cloned into an optimized immunization vector.
BALB/c mice were immunized once in a two week interval over a
period of 12 weeks using a HeliosR gene gun. Blood samples were
taken from each animal every two weeks and analysed for the
presence of specific antibodies using a cell-based ELISA assay.
Results:
Screening the antisera in the cell-based ELISA showed that all
mice elicited specific antibodies against the plasmid-encoded
Cpn10-HBsAg antigen. It could also be demonstrated that this
immune response was not directed against the scaffold itselfproving the low immunogenicity of the scaffold in the murine
system. Therefore the detected antibody response seems to be
specific for the baQ determinant of the HBsAg.
Discussion/Conclusion:
We could show for the first time that the murine Cpn10
scaffold can be used in genetic immunization experiments for
presenting a foreign peptide loop and for eliciting an immune
response against this encoded antigen-loop. Whether this scaffold
allows formation of the native loop conformation needs to be
further investigated in an ELISA, where the recombinant HBsAg
protein should be detectable by the sera. Futher experiments have to
be performed to establish whether this approach can be extended
and used e.g. for the directed generation of antibodies against
GPCR loops.
F2.40. Angioedema without Urticaria in 929 Italian
Patients: Proposal for a Diagnostic and Therapeutic
Approach.
L. C. Zingale,1 L. Beltrami,2 A. Zanichelli,1 M. Cicardi.1 1Dpt of
Internal Medicine, University of Milan, Milan, Italy; 2Dpt of
Cardiology, University of Milan, Milan, Italy.
Angioedema without major urticaria flares is poorly charac-
terized, it is caused by different conditions and few data exist on
the underlying etiopathogenetic mechanisms. Here we report our
experience on patients with this symptoms and propose a
diagnostic-therapeutic approach.
Methods
929 consecutive patients were examined at our outpatient clinic
for recurrent angioedema without urticaria between 1993 and 2002.
Known causes of angioedema were identified by clinical history
with detailed information about personal and familial allergies;
relationship of angioedema to potential causative agents were
search (food, drugs, insect stings); complete physical examination,
routine laboratory tests (blood cell count, protein electrophoresis,
erythrosedimentation rate, stool for ova and parasites, pharyngeal
and urine cultures, sinus and dental film, anti-tissue autoantibodies,
rheumatoid factor), complement parameters (C1 inhibitor, C4,
C1q) were performed. Further testing was done when pertinent
based on clinical finding. When all was negative, response to H1-
antihistamine was considered.
Results
According to our testing angioedema were classified as follow:
related to external agents (drugs, insect stings, food) 209 (22.5%)
(in particular 85 of them were related to treatment with an ACE-
inhibitor); associated to autoimmune diseases or infections 77
(8.2%); hereditary C1 inhibitor deficiency 183 (19.6%); acquired
C1 inhibitor deficiency 14 (1.5%); idiopathic histaminergic 253
(27.2%), idiopathic non histaminergic 40 (4%). 153 patients (16.4)
dropped out from the study and could not be classified.
Conclusion
Based on the frequency of the different diagnosis we propose
the following progression of testing: 1. anamnestic identification of
causative agents, 2. testing for complement abnormalities, 3. H1
antagonist treatment, 4. complete diagnostic workup.
F2.41. Dynamic Control of T Cell Homing by Gut and
Peripheral Dendritic Cells.
J. R. Mora,1 G. Cheng,1 D. Picarella,2 M. Briskin,2
N. Buchanan,2 U. H. von Andrian.1 1CBRI, Harvard Medical
School, Boston, MA, USA; 2Millennium Pharmaceuticals,
Cambridge, MA, USA.
Abstracts S81T cell activation by intestinal dendritic cells (DC) induces gut-
tropism. We show that, reciprocally, DC from peripheral lymph
nodes (PLN-DC) induce homing receptors promoting CD8 T cell
accumulation in inflamed skin, particularly ligands for P- and E-
selectin. Differential imprinting of tissue-tropism was independ-
ent of Th1/Th2 cytokines and not restricted to particular DC
subsets. Fixed PLN-DC retained the capacity to induce selectin
ligands on T cells, which was suppressed by addition of live
intestinal DC. By contrast, fixed intestinal DC failed to promote
gut-tropism and instead induced skin-homing receptors. More-
over, the induction of selectin ligands driven by antigen-pulsed
PLN-DC could be suppressed din transT by adding live intestinal
DC, but PLN-DC did not suppress gut homing receptors
induced by intestinal DC. Reactivation of tissue-committed
memory cells modified their tissue-tropism according to the last
activating DCTs origin. Thus, CD8 T cells activated by DC
acquire selectin ligands by default unless they encounter
fixation-sensitive signal(s) for gut-tropism from intestinal DC.
Memory T cells remain responsive to these signals allowing for
dynamic migratory reprogramming by skin- and gut-associated
DC.
(Pew Fellowship to J.R.M. & NIH grants HL62524, HL54936,
HL56949, AI-061663 to U.H.vA.).
F2.42. Isoation and Characterization of Water Isolates
for Bacteriocinogenic Activity.
Hina Waheed, Nazish Aziz, Tanveer Khanum, Kishwar Jabeen,
Saba Ali Imama, Hina Rahat, Aliya Hayat. 1Microbiology, Jinnah
University for Women, Karachi, Sindh, Pakistan; 2Microbiology,
Same, Karachi, Sindh, Pakistan; 3Microbiology, Same, Karachi,
Sindh, Pakistan; 4Microbiology, Same, Karachi, Sindh, Pakistan;
5Microbiology, Same, Karachi, Sindh, Pakistan.
A Prospective study has been carried out to study the
bacteriocin producing abilility of water isolates a total of 27
isolates were screened for their bacteriocinogenic potential against
intragenic and intergenic microorganisms 20% of the isolates were
found to exert broad range bacteriocinogenesis (bioactivity).
However none of the producers was antagonistic against the
related streptococcal strains.
Bacteriocinogenesis was demonstrated by 1) stab over lay 2)
cross streak 3) patch test4) Agar well.Titration of bacteriocine was
done by arbitary unit(AU) method.In First method test strains were
stabbed into Luria agar plate and incubated at 378C for 24 hrs,
chloroform was used to kill the bacteria, plates were than overlaid
by soft agar (0.6%) containing 5–10 micro liter of 2-3 hours grown
indicator strainsand incubated at 378C for 24 hrs and examined for
zone of inhibition In second Test strains were streaked across the
surface of a Luria agar plate and incubated at 378C over night the
growth of test strain was removed and plate was exposed to
chloroform as described earlier, indicator strain was then cross
streaked.Plate was incubated at 378C over night,and examined for
inhibition of growth.In 3rdA luria agar plate was overlaid with 3 ml
soft agar containing 5–10 micro liter of indicator strain. Plate was
kept at 378C for 2 hrs for drying. A fresh colony of strain was
stabbed into indicator lawn.Plate was incubated at 378C for 24 hrs in
4th Test strain was grown in Luria broth,culture was centrifuged at
3000 rpm for 20 min, supernatant was collected. Luria agar plate
was overlaid with 3 ml soft agar containing 5–10 micro liter
indicator strain. Wells were made and 100–200 micro liter
supernate was added in the well. Plate was incubated at 378C for
24 hrs, zone of inhibition of indicator strain around the well wasmeasured. For titration, Inoculate the nutrient broth by different
producers strains and incubated at 378C, next day centrifuge those
tubes for 20 minutes then make 2 fold dilutions (1:2-1:4,so on)on
nutrient agar make 5 wells and marked according to dilution tubes
(1:2-1:32).Take 50 micro liter from 1:2 dilution tube and transfer in
1:2 marked well and this processwas repeated with all dilutions.
Next day check the zone of inhibition.Among many results most
appropriate results obtained about Listeria monicylogenes and
Strepptococcus Pyogenes Bacteriocinogenic organisms gave this
activity against some Gram negative stains such as E.coli, S.typhi,
Klebsiella, Pseudomanas and some G+ve stains such as S.aureus,
S.fecalis, M.leutus, Bsubtilus. Streptococcin titer was estimated to
be 1:64 A.U. The lacuna percentage (which determine the number
of Streptococcin producing clones in a population) was found to be
14.6 elevated temperature 408C mediated curing of the producing
isolates revealed the chromosomal location of bacteriocinogenic
determinantsas reported in the past studies.
F2.43. Inhibition of Pericardic Adhesions by the
Amoebian Anti-Inflammatory Pentapeptide (MLIF).
Preliminary Results.
J. A. Gimenez-Scherer,1 C. Riera-Kinkel,2 R. Silva-Garcia,1 M. G.
Rico Rosillo,1 J. Garcia,3 E. Foyo,3 E. Tena,3 R. Arguero,2 R. R.
Kretschmer.1 1Unidad de Investigacion Medica en Inmunologia,
H. Pediatria, Centro Medico Nacional Siglo XXI, IMSS, Mexico,
DF, Mexico; 2Hospital de Cardiologia, Centro Medico Nacional
Siglo XXI, IMSS, Mexico, DF, Mexico; 3Bioterio, Centro Medico
Nacional Siglo XXI, IMSS, Mexico, DF, Mexico.
Cardiac surgery is usually followed by adhesions, which still
represents an incompletely solved problem. Different treatments
have been proposed, the fibrin seal probably been the best so far,
reducing adhesions by about 50%. Entamoeba histolytica produces
an anti-inflammatory peptide (Met-Gln-Cys-Asn-Ser) termed
Monocyte Locomotion Inhibitory Factor (MLIF) for its first
described effect. Monocytes are key cells of the late inflammation
and also modulates the cicatrization stage of the wound-healing
process. Thus, MLIF could regulate wound-healing. The purpose
of this study is to prevent the formation of experimentally induced
pericardic adhesions in rats (a model originally developed to
induce cardiac colateral circulation). Epicardiectomy and 3x soft
sandpaper scratches over 0.5 cm2 apical area of the heart were
performed in four groups of eight male Wistar rats each under
anesthesia and sterile conditions. Groups received either; MLIF
100 Ag in 0,05 ml of pyrogen free saline solution, fibrin seal
solution (0.1 ml), both, or none, the final volume adjusted to 0.1 ml
with saline solution. All the animals recovered and were humanly
sacrificed at day ten with an anesthetic overdose. Systematized
necropsies and photographic registers were done, and were blindly
evaluated by three independent participants. Control animals
(without MILF and or fibrin seal) developed strong, nodular and
extensive adhesions. The fibrin seal allowed only focal,-yet strong-
adhesions (++++ to +, pb0.05). MLIF inhibits the strong adhesions
(++++ to +, P b 0.05) but allowed the development of soft,-and
extensive-adhesions (++++ to +++, P = n. sig.). MLIF together
with fibrin seal completely inhibits the pericardic adhesions in this
model (++++ to 0, pb0.05). That combined MLIF and fibrin seal
inhibited adhesions but either substance alone induced only a
partial-and qualitatively different-reduction of adhesions suggests
that these factors have different target mechanisms and act
synergically, namely MLIF reducing activation signals from
monocytes to fibroblasts, while fibrin seal modulating the
AbstractsS82cicatrization stage of wound-healing. (supported by CONACYT
28363-M and IMSS- FOFOI 2004-432 grants).
F2.44. Attenuation of the GAA-Specific Immune
Response in 6neo/6neo GAA Knockout Mice, a Model of
Pompe Disease.
K. J. Munroe,1 S. M. Richards,1 R. D. Garman,1 A. M. Joseph.1
1Immunology Laboratory, Cell & Protein Therapeutics R&D,
Genzyme Corporation, Framingham, MA, USA.
Pompe disease is an autosomal recessive lysosomal storage
disorder characterized by the deficiency of acid alpha-glucosidase
(GAA). The absence or decreased expression of GAA results in
the accumulation of glycogen in muscle tissue. Infantile Pompe
patients experience life-threatening manifestations such as cardi-
omegaly and late-onset patients experience progressive myopathy
with or without respiratory insufficiency. The use of recombinant
human alpha-glucosidase (rhGAA) is being investigated as a
therapeutic agent for Pompe disease. In our clinical studies, it has
been observed that patients treated with rhGAA can seroconvert in
response to the therapeutic protein. The role of these rhGAA-
specific antibodies is unclear, but they could potentially inhibit the
activity of the therapeutic protein or alter the biodistribution,
thereby decreasing enzyme efficacy. We have previously demon-
strated that weekly intraperitoneal administration of rhGAA in
6neo/6neo GAA knockout (GAA KO) mice results in high rhGAA-
specific IgG titers. We have shown that high doses of methotrex-
ate (MTX) were able to suppress these titers ten-fold when
administered 24 and 48 hours following the first eight weekly
rhGAA treatments. Further studies were conducted in GAA KO
mice to both model intravenous administration of rhGAA which is
the clinical route of therapeutic administration and to identify a
lower efficacious dose of methotrexate. We have observed that
intravenous delivery of rhGAA in GAA KO mice significantly
reduces rhGAA-specific IgG titers from those observed upon
intraperitoneal administration of rhGAA. In addition, we have
demonstrated that MTX is most effective at reducing this immune
response when administered 0, 24 and 48 hours following the first
eight weekly rhGAA treatments. Moreover, lower weekly doses of
MTX are as effective as the higher dose at inhibiting the rhGAA-
specific immune response when given 0, 24 and 48 following
rhGAA treatment. These studies suggest that the timing of MTX
treatment influences its ability to inhibit the rhGAA-specific
immune response. This approach may be effective in minimizing
drug-specific antibody responses in patients receiving protein
therapeutics.
F2.45. The Effect of Electro Active Dental Metal Fillings
Replacement on Lymphocyte Activity in Patients with
Oral Discomfort.
J. Prochazkova,1 S. Podzimek,1 M. Miksovsky,1 J. Bartova,1 K.
Hana.2 1Clinical Department, The Institute of Dental Research,
1st Medical Faculty and GUH, Charles University, Prague, Czech
Republic; 2Research Department, The Institute of Biomedical
Engineering, Czech Technical University, Prague, Czech Republic.
The release of metal ions from dental metal fillings is being
supported by presence of galvanic cell in the oral cavity and such a
way can cause local or general pathological problems in sensitive
and genetically susceptible individuals.
Aim of the study: To investigate the in vitro lymphocyte
responses to metals before and after replacement of electro active
dental metal fillings in patients with oral discomfort.Methods: Sixty-eight patients with oral discomfort and dental
metal fillings were investigated. They were divided into two
groups. Group A (38 persons)-patients with pathological levels of
galvanic currents and group B (30 persons)-patients with physio-
logical levels of galvanic currents and voltage. The galvanism
measurement was performed by the equipment Odontologic 2000
(Embitron CZ). The lymphocyte activity was tested by the
lymphocyte proliferation method modified for metals (MELISA)
in 33 patients from Group A and 24 patients from group B. The
electro active metal fillings replacement was performed in 18
patients from group A. Follow up MELISA at least half a year after
fillings replacement was performed.
Results: The higher lymphocyte activity to metals was
discovered in both examined groups. The highest levels of
proliferation activity were found to Ni, Hg and Mo in Group A
and to Hg, Ni and Au in Group B. In general, lymphocytes of
patients in group B were sensitized more than the ones in group
A. The follow up results after electro active fillings removal
show that lymphocyte reactivity to at least all metals tested
decreased. The highest decrease was found in reaction to
inorganic mercury.
Conclusion: The long-time influence of galvanism can, only in
sensitive and genetically susceptible individuals, influence the
lymphocytes proliferation. The beneficial effect of dental metal
fillings replacement was confirmed by decrease of lymphocyte
reactivity to metals. Our findings support the hypothesis that
suffering from the oral discomfort is not only a subjective feeling
of the patient but that it can be based on a real cell discomfort due
to release of metal ions from dental metal fillings and due to
galvanism. But the activity of lymphocytes to metals can be
influenced by a couple of other factors as well.
Acknowledgment: The study is supported by the grant of
Czech Ministry of Health nr. NR 8324-3.
F2.46. A Review of the Allergic /Toxic Adverse Reactions
to Anti-Tuberculous Drugs(ATD), A 10 Years
Therapeutic Survey.
M. Ishaq, Taj M. , I. M. Sameera. 1Allergy/Pulmonology, Al-Junaid
Hospital, Nowshera, Pakistan.
Introduction:Various un-towards reactions (Allergic/Toxic) had
been observed during the course of treatment for patients with
pulmonary/extra pulmonary tuberculosis.
Methods: The old theme about tuberculosis as duntreatableT has
been replaced by the dcurableT with introduction of the effective
anti-tuberculosis drugs, but still their effectiveness is with in the
limit of careful assessment of patients for ATD.Allergic & toxic
manifestations are as under.
Rifampicin:1 (Urticaria,red skin with orange discoloration).
2(Febrile reactions), 3(Hepato),1(Neuro&Nephrotoxicity, blood
dyscrasia haemolysis and shock, blurring of the vision, confusion,
ataxia/peripheral neuritis,Pseudomembranous colitis).
Ethambutol:
R(Skin rashes, itching/burning sensations, anaphylactoid reac-
tions). 1(Nausea vomiting, abdominal pain, anorexia), 1(head ache
peripheral neuropathy, hallucination dis-orienattion, mental con-
fusion) 2(Visual disturbance),1(transient impairment of liver
function) 1(gouty arthritis).
Isoniazide:R(Itching/Skin rashes, Slurred speech, hallucination,-
coma,generalized convulsion, status epilepticus, peripheral neu-
ropathy, hypotension respiratory failure, severe metabolic
acidosis),1(fever, nausea, vomiting, Hepatitis). R(hemolytic anemia).
Abstracts S83Pyrazinamide: R(skin rashes) 2(Hepatoxicity,gouty arthritis),
Streptomycin: 1(Wide spread Skin rashes, hives, nausea
vomiting, headache), 2(hypotension), 1(ear & kidney damage). In
some rare with paralysis by interfering with calcium transport in
the central nervus system.
Ethionamide:2(Severe skin rashes, acne, alopecia, photosensi-
tivity),1(nausea vomiting anorexia,diarrhea, excessive salivation,
metallic taste), 2(hepatotoxicity). 1(Mental depression, anxiety/
psychosis, Systemic encephalopathy with pellagra-like symptoms),
1(dizziness, drowsiness, headache, convulsion, peripheral neuro-
pathy, tremors, paresthesias). 1(Optic neuritis, optic atrophy,
diplopia,1Olefactory disturbances), 1(Deafness), R(Hypothyroid-
ism), 1(impotence,menorrhagia,gynaecomastia), R(hypoglycemia,
hypotension),R(Thrombocytopenia, Rheumatic pains).
Thiacetazone: 1(Skin rashes, nausea, vomiting, Jaundice),
1(giddiness, bone marrow suppression,agranulocytosis).
% incidence of adverse reactions as observed R=0-1%,1=5-
10%,2=N10-30%,3=N30%-80%.
Results: Careful selection with Appropriate diagnosis of the
infectious patients are less likely associated with adverse
effects.
Conclusions: Incidence of adverse effects had been relatively
less frequent with first line than second line ATDs treatment.
F2.47. Defective Intrathymic T Cell Development and
Early Onset of IBD in Mice Devoid of WASP and
N-WASP.
V. Cotta-de-Almeida,1,3 D. Onaldi,1 M. Maillard,1,4 F. W. Alt,2 S.
B. Snapper.1 1Dept of Medicine, Massachusetts General Hospital/
Harvard Medical School, Boston, MA, USA; 2Dept of Genetics,
ChildrenTs Hospital/Harvard Medical School, Boston, MA, USA;
3Dept of Cell Biology, Oswaldo Cruz Foundation, Rio de Janeiro,
RJ, Brazil; 4Lausanne University Hospital, Lausanne, Switzerland.
BACKGROUND: Wiskott-Aldrich syndrome protein (WASP)
family members (WASP, N-WASP, WAVEs) are key molecules
that regulate cytoskeletal changes in response to cell surface
signals. These events are critical for various biological processes
including cell migration and immune synapse formation. We
recently generated chimeric mice deficient for N-WASP (NWKO)
and mice double-deficient for WASP and N-WASP (DKO)
employing Rag-2-deficient blastocyst complementation. NWKO
chimeric mice, like WASP KO (WKO) mice, did not demonstrate
any change in T cell development. In contrast, WASP/N-WASP
DKO mice have a marked defect in T cell maturation associated
with a block in the CD4/CD8 double-negative stage, and a
consequent decrease of T cell numbers in the peripheral lymphoid
organs.
AIM: To elucidate the mechanism underlying the aberrant T cell
development in WASP/N-WASP double-deficient mice.
METHODS: We deleted N-WASP selectively in T-cells from
WKO mice by using the Cre-loxP system. In this approach we
mated conditional N-WASP-KO with WKO and lck-Cre trans-
genic mice (creDKO). Lymphoid organs were processed for
phenotypical analysis employing standard developmental and
activation markers. We also assessed thymocyte migratory
function driven by CXCL12 and CCL19 by transwell migration
assays and thymocte apoptosis by Annexin V staining. Colonic
samples were obtained for histological analyses and cytokine
measurements.
RESULTS: The lck-driven N-WASP deletion in WKO mice
(creDKO) during T cell development resulted in a significantdecrease in thymic cellularity. We also found increased apoptotic
cell death in the creDKO animals compared to WT and WKO mice.
CD69+ cells were substantially decreased in both CD4 and CD8
single-positive thymocytes from creDKO mice- which may
correlate directly with the increase in apoptosis. In addition,
creDKO thymocytes have a significant migration defect when
compared with WKO thymocytes, which are also defective in
migration compared with WT thymocytes. Consequently, we found
significantly decreased numbers of T cells in the spleen of creDKO
mice. However, we observed that the majority of these T cells
present an effector phenotype (CD44hiCD62Llo). Interestingly,
creDKO mice present with colitis at an earlier onset which may be
associated with increased severity.
CONCLUSIONS: These studies demonstrate redundant func-
tions for WASP and N-WASP with a critical combined role for
both proteins in T cell development and function. Together the
functional analyses of creDKO thymocytes suggest that the
decreased migratory activity of these cells might be related to
decreased signaling resulting in increased cell death and conse-
quent reduced thymocyte numbers. Furthermore, the finding of
significant increased proportion of effector T cells in the periphery
of cre-DKO may be associated to the early onset of inflammatory
bowel disease.
F2.48. FAS Induced Apoptosis- A Model System for
BiFARTM Implementation.
H. Kalinski, A. Chajut, A. Khan, R. Skaliter. 1Research and
Development, Quark Biotech, Inc., Fremont, CA, USA.
FAS induced apoptosis, a key signaling pathway in many
diseases, was studied using a functional genomic approach in
joint study by Quark Biotech and Agilent Technologies. QuarkTs
proprietary BiFARTM platform is based on the discovery of
essential functional genes using Gene Inhibitory Elements (GIEs;
antisense, shRNAs or dominant negative peptides). Abundance of
GIEs is expected to change based on their ability to inhibit
certain genes. GIEs that are protective to a certain treatment will
be enriched and GIEs sensitizing to a certain treatment will be
depleted.
In this study, PC3 cells were tranduced with a GIE library,
propagated and then exposed to high or sub-lethal doses of anti-
Fas antibody. Using a custom oligonucleotide Agilent microarray,
designed to match the specific GIE library, the relative abundance
of GIEs before and after anti-FAS treatment was measured.
Analysis of functional GIEs identified GIEs that were protective
to FAS and others that were sensitized to the treatment. Protective
GIEs inhibiting genes involved in the interferon response,
phosphoinositol metabolism, vesicle transport and chaperons
were found. Sensitizing GIEs included those inhibiting anti-
apoptotic genes.
The BIFAR platform, implemented on AgilentTs microarrays,
allowed functional dissection of FAS induced apoptosis, a process
known to participate in the killing of virally infected cells,
transformed cells and peripheral auto-reactive T-cells, as well as
other physiological processes. The discovery of the inhibition of
genes leading to accelerated FAS induced apoptosis can be
implemented in therapeutics that are aimed at the enhancement
of tumor suppression or tolerance.
This basic approach can be applied to a variety of other
functional systems using a variety of GIE types in proliferating
cells as well as fully differentiated cells, to elucidate signal
transduction pathways and identify novel drug targets.
AbstractsS84F2.49. Protective Effect of Thalidomide in Rats with
Granuloma in the Cerebral Amygdala and
Pentylenetetrazole-Induced Epilepsy.
L. Aguirre-Cruz,1 M. Martinez-Moreno,1 G. Palencia,1 N.
Mendez-Mar,1 J. Manjarrez,2 R. Alvarado,2 E. Flores,3 M.
Pacheco,3 P. Salgado,3 L. Rodriguez-Fragoso,4 J. Sotelo.1
1Neuroimmunology Department, National Institute of Neurology
and Neurosurgery (INNN), Mexico City, Mexico; 2Reticular
Formation Physiology Laboratory, INNN, Mexico City, Mexico;
3Magnetic Resonance Unity, INNN, Mexico City, Mexico;
4Pharmacy Faculty, Autonomous University of Morelos,
Cuernavaca, Morelos, Mexico.
Chronic brain inflammation by persistent infections, trauma-
tisms or extensive surgeries (e.g. tumoral resection) is a main
cause of secondary epilepsy. To evaluate the preservation of
functional neural tissue by chronically administered antifibrotic
and immunomodulating drugs in damaged brain, we induced a
granuloma in the cerebral amygdala of 130 Wistar rats, by
stereotaxic injection of aluminum silicate (interaural 6.2 mm,
lateral 5.0 mm, height 8.5 mm, according to PaxinoTs Atlas),
which were randomly distributed in 9 groups (n = 13), treated
with: vehicle (water, 5% alcoholic-water or maize oil); methyl-
prednisolone acetate (4 mg/kg/week, IM); colchicine (300 Ag/kg/
day, orally); thalidomide (160 mg/kg/day, orally); cyclosporine
(10 mg/kg/day, orally); mixture of colchicine-methylprednisolone
(300 Ag/kg/day-4 mg/kg/week); thalidomide-methylprednisolone
(160 mg/kg/day-4 mg/kg/week); cyclosporine-methylprednisolone
(10 mg/kg/day-4 mg/kg/week) during forty five days. Two weeks
after the end of the treatment, experimental epilepsy was induced
by PTZ subthreshold increasing doses (20–70 mg/kg), adminis-
tered according 48 hours intervals, until the development of
generalized seizures. Cortical electrodes were implanted in three
animals from each group. Electrical activity was registered during
20 minutes. Time elapsed since the application of the drug until
the first myoclonic and tonic-clonic seizure (latency), as well as
the number and duration of afterdischarges were measured and
compared between groups.
Histological and imaging analyses and collagen quantification
of granulomatous lesion were also made. Evident contrast of all
measures was found in rats that received thalidomide. Dose
required to develop tonic-clonic seizures in this group was higher
(P b 0.05) than that required in the rest of groups. The latency
for generalized tonic-clonic seizures was also longer in thalido-
mide treated rats than in controls. Afterdischarges in the control
group were more frequent than those in the thalidomide group, in
which we also found sleep-like high voltage slow waves and
isolated spikes that didnTt burst in a real afterdischarge.
Thalidomide seems to preserve functional brain tissue surround-
ing a granulomatous lesion and would be a promissory alternative
to prevent secondary epilepsy.
F2.50. Self-Limitation of Th1-Mediated Inflammation by
IFN-;.
M. Feuerer, K. Eulenburg, A. Hamann, J. Huehn. 1Exp.
Rheumatology, Charite Universitaetsmedizin Berlin, Berlin,
Germany.
Objective of the study: IFN-g is a pro-inflammatory effector
cytokine of cell-mediated immunity that plays an essential role in
both innate and adaptive phases of an immune response.
Interestingly, in several Th1 dependent autoimmune models lack
of IFN-g is associated with an acceleration of disease. The aim ofthe study was to investigate how IFN-g could be involved in the
regulation of a Th1 dependent inflammation.
Materials and methods: To study the influence of IFN-g on
effector T cells we used an adoptive transfer model of differentiated
antigen-specific Th1 cells. To differentiate the impact of IFN-g we
analyzed the antigen specific delayed type hypersensitivity (DTH)
reaction in different KO strains.
Results: IFN-g displayed a dual function in a Th1-dependent
immune reaction. In the early phase, IFN-g accelerated the
inflammation, whereas in the late phase it mediated the process
of self-limitation. IFN-g negatively regulates Th1 homeostasis
after antigen challenge. Studies in IFN-g R KO and iNOS KO mice
revealed that IFN-g could act via the receptor of host cells and that
NO is involved downstream. Transfer experiments into IFN-g KO
mice showed that Th1 cells control both themselves and the
corresponding inflammation.
Conclusion: Our results show that IFN-g is an important player
in the regulation of a Th1 dependent inflammation. The proin-
flammatory cytokine can act as a negative feedback regulator and
control the self-limitation of a Th1 dependent inflammation.
F2.51. Origin and Generation of Distinct CD4+
Regulatory T Cell Subsets.
C. Siewert,1 K. Siegmund,1 M. Feuerer,1 L. Klein,2 A. Hamann,1
J. Huehn.1 1Experimental Rheumatology, Charite
Universitaetsmedizin Berlin, Berlin, Germany;
2IMP/IMBA, Vienna, Austria.
Objective of the study: CD4+ regulatory T cells (Tregs) are
increasingly recognised to play an important role in the main-
tenance of T cell homeostasis and self-tolerance. We recently
reported a phenotypic and functional dichotomy among naturally
occurring murine Treg subsets characterised by the expression of
the integrin aE and CD25. aE-expression on Tregs correlates with an
effector/memory-like phenotype, in contrast to naive-like aE-CD25
+
Tregs. These phenotypic characteristics have a crucial impact on the
migratory properties of Tregs in vivo and ultimately result in a
differential potency to suppress immune responses within distinct
anatomical compartments. In the current study we intend to
elucidate the relationship between aE
+ and aE- Treg subsets. We
want to clarify whether aE
+ Tregs originate from the thymus as a
distinct lineage or whether they are generated in the periphery under
certain conditions.
Materials and methods: We performed BrdU-labelling experi-
ments to follow in vivo proliferation of different Treg subsets under
normal and athymic conditions. In transfer experiments we
investigated the stability of their phenotype and conditions of
their generation.
Results: The effector/memory-like phenotype of aE-expressing
Tregs suggests antigen-specific differentiation or expansion in the
periphery. Indeed, BrdU-labelling experiments in both normal and
thymectomised mice revealed a high frequency of proliferating
cells within this subset. Interestingly, aE-expressing Tregs were
comparatively enriched in adult-thymectomised mice, as they
sustained stable cell numbers even in the absence of thymic
output, while mild lymphopenia was observed in the remaining T
cell compartment.
We transferred distinct Treg subsets into non-lymphopenic
recipients and observed that under such conditions aE-expressing
Tregs represent a stable subset or differentiation stage of Tregs
rather than a transient population. By transferring TCR transgenic
cells and subsequently applying antigen, we want to identify the
Abstracts S85cellular precursor of aE-expressing Tregs and the conditions of their
generation in vivo. Initial experiments indicate that aE-expression is
indeed induced on a fraction of transferred cells under tolerogenic
conditions. Interestingly, this induction appears to be confined to
certain compartments.
Conclusion: aE-expressing effector/memory-like Tregs repre-
sent a stable population in the normal immune system. They
contain cells, which are constantly cycling, presumably in response
to self-antigen and/or environmental antigen. These effector/
memory-like Tregs have the potential to maintain a stable
population size in the periphery even in the absence of thymic
output. Preliminary results suggest, that this phenotype is induced
in the periphery after antigen-specific differentiation under distinct
conditions. A better understanding of the fundamental physiology
of the generation of Treg subsets may aid in the design of future
therapeutic strategies for the treatment of ongoing autoimmune
diseases.
F2.52. Correlation between Histamine and Mast Cells
and Presence of IgE.
Mandana Sattari,1 Shidehmehr Mofakham,1 Saeed Khalili.1
1Immunology, Shaheed Beheshti University, Medical School,
Tehran, Islamic Republic of Iran.
Aim: According to presence of immune system factors in
chronic periapical lesions, hypersensitivity reactions may have
some role in pathogenesis of these lesions. Up to now, among the
factors participating in type I hypersensitivity reaction, only one of
them has been studied. So the aim of this study was to evaluate the
relationship between presence of IgE & number of mast cell and
presence of IgE and histamine in human dental chronic periapical
lesions.
Materials and Methods: 40 specimens were collected from 39
patients. After extraction of the lesions, they were divided into
two sections. Half of the sections were used for explant culture
and were maintained for 3 days. Then sandwich enzyme linked
immunosorbent assay (ELISA) was used to determine the
presence and concentration of IgE and histamine. Based on the
presence of IgE, the samples were divided into case (with IgE)
and control (without IgE) groups.The other sections were used for
estimating the number of mast cells by histopathological
technique.
Results: The average percent of mast cells in case and control
groups was respectively, 10.25 F 7.02 and 6.9 F 4.09. Statistical
analysis (Mann Whitney-U test and Spearman correlation coef-
ficient) showed that there is no difference between the case and
control groups regarding the number of mast cells and histamine
concentration. Also there was not any correlation between IgE and
mast cells or IgE and histamine.
Conclusion: It is concluded that hypersensitivity reaction type I
possibly does not have any role in pathogenesis of chronic
periapical lesions.
F2.53. Neutrophil Chemotaxis and Dental Caries.
Mandana Sattari,1 Saeed Khalili,1 Maryam Basirat.1
1Immunology, Shaheed Beheshti University Medical Science,
Tehran, Islamic Republic of Iran.
Aim: In addition to microorganisms, several other factors such
as host immune responses are also involved in pathogenesis of
dental caries. Among the factors of immune system, the role of
neutrophil in prevention or pathogenesis of dental caries is not wellstudied. So the aim of this study was to investigate the neutrophil
chemotaxis in patients with dental caries.
Materials and Methods: For this purpose, fifty of dental
students with dental caries were selected. 10 ml of heparinized
blood were collected from subjects for neutrophil chemotaxis test
by modified Boyden chamber method.
Results: The amount of neutrophil chemotaxis in the above
subjects was 94.38 F 12.08 micrometer. Statistical analysis did
not show any significant difference regarding to neutrophil
chemotaxis in defferent degrees of DMF. But by comparing of
neutrophil chemotaxis with the degree of active caries, significant
differences were shown between 0 and 5 degrees; and 1 and 5
degrees of active caries regarding to the mean of neutrophil
chemotaxis.
Conclusion: It is suggested that not only deficiency in
neutrophil chemotaxis is not assumed in pathogenesis of dental
caries, but also there is a direct correlation between neutrophil
chemotaxis and the degree of active caries. Of course more studies
are needed in order to prove this hypothesis.F2.54. Correlation between Neuropeptides
Concentration and Different Parts of Human Gingiva
and the Effects of Neuropeptides on Neutrophil Death.
Mandana Sattari,1 Saeed Khalili.1 1Immunology Dept, Shaeed
Beheshti University of Medical Science, Tehren, Islamic Republic
of Iran.
Objective: It is not well defined up to now that why some parts
of gingiva is more susceptible to periodontal diseases. Since these
regions are adjacent to the foramen of some nerves and paths and
regarding to the important role of neuropeptides in inflammation
and specially gingival and periodontal inflammation. On the other
hand it was shown that substance P (SP) and calcitonine gene
related peptide (CGRP) have some role in periodontal diseases.
Since it was established that neutrophil is one of the most
important defense line against periodontal diseases. So the aim
of this study was to determine the correlation between concen-
tration of neuropeptides and different region of human healthy
gingival and their effects on neutrophil death.
Materials & Method: In the first section twenty gingival
samples from first maxillary incisor and molar regions and
twenty gingival samples from other regions were collected
during periodontal surgery. Tissue samples were immediately
transported to sterile tubes filled with tissue culture media. After
culturing for 72 hrs the supernatant fluid were extracted and
after diving them in microtubes, were frozen at 70 degree of
centigrade. EIA was used for detection of neuropeptides and in
the second section we collected heparinate blood from a healthy
individual neutrophil were collected from it. For this purpose,
5ml heparinate blood mixed with five ml dextran was
maintained at laboratory temperature for 45 minutes and the
high concentration and low concentration extract of neuro-
peptides (regarding to the concentration of SP and CGRP in first
section) were collected with neutrophils Annexin V flous
stanning kit was used for detecting the death of neutrophils
under flourecence microscope.
Finding: we find significant difference between different
gingival regions regarding to CGRP concentration and it was also
a significant reverse correlation between CGRP and different of
Gingiva We could not find any significant correlation between SP
and different regions of gingiva. Both SP and CGRP were present
AbstractsS86in the all of the samples. In the second part we find that SP and
CGRP significantly induce apoptosis in neutrophils.
Conclusion: It is concluded these neuropeptide probably
participate in the regulation and maintance of gingival health and
based on the low level of CGRP in the gingival of upper and lower
6 dental region prevalence of local aggressive priodontitis
distributed to low level CGRP and SP in this region we could
suggested a possible role for the susceptibility of these regions to
localized priodontitis and in the second part of this study we can
concluded that both of SP and CGRP induces apoptosis instead of
necrosis in the neutrophil, this is also may be parallel with
regulatory role of these neuropeptides.
F2.55. Human MyD88s Is the Result of MyD88 Splicing
like That Reported in the Mouse.
A. Dominguez,1 J. L. Ventura,2 A. Zentella,2 R. Kretschmer,1 J. R.
Velazquez.1 1Investigation in Medical Immunology, Instituto
Mexicano del Seguro Social CMNSXXI, Mexico City, DF, Mexico;
2Biochemestry, Instituto Nacional de Nutricion Salvador Zubiran,
Mexico City, DF, Mexico.
MyD88, the first adaptor protein that was discovered, possess
a TIR-domain that interacts with a Toll-like receptor and with IL-
1R, leading to activation of the NF-kB and JNKsignaling
systems. MyD88 is highly conserved in nature. Mouse and
human MyD88 genes reveal a 82% homology at protein level.
Human and murine genes are organized into five exons and four
introns. A splicing variant of MyD88 lacking exon 2 the so
called MyD88s, has been reported. In the mouse MyD88s is a
protein isoform that regulates IL-1 and LPS signaling pathways
trough its inability to bind or to activate downstream signaling
molecules. The murine MyD88 splicing has been established as
the generator of MyD88s, there is not information yet on such
human MyD88s processing. By nucleotide sequencing analysis of
U937 and human peripheral blood mononuclear cells we noticed
that human MyD88 splicing is comparable to that reported in the
mouse. Human MyD88s is the result of exon 2 excision. It
therefore lacks the ID domain (aa 110-154). In the human
mononuclear cells tested, MyD88s was constitutively expressed
as a transcript and as a protein. Murine and human MyD88s are
similar and are processed in comparable ways. However, the
regulatory mechanisms in which they are involved could be
exquisitely different.
F2.56. Relationship of School Attendance with Quality of
Life, Physical Function, Disease Activity and Damage in
Pediatric Systemic Lupus Erythematosus.
L. N. Moorthy,1 M. G. Peterson,2 M. J. Harrison,2 K. B. Onel,3 M.
J. Baratelli,1 D. R. Mohan,1 Thomas Lehman.2 1Robert Wood
Johnson University, New Brunswick, NJ; 2Hospital for Special
Surgery, New York, NY; 3La Rabida Children’s Hospital, Chicago,
IL.
Background: Pediatric systemic lupus erythematosus (SLE) is
a multisystem disease that significantly impacts quality of life
(QOL) of children. SLE’s impact on school attendance, an
important outcome and potential predictor of other outcomes, has
received little attention.
Objective: Examine the relationship of school attendance with
QOL, physical function, SLE activity and damage in children with
SLE.
Design/Methods: In this cross-sectional study, children with
SLE (6–18 years) and parents completed child/parent versions of:Childhood Health Assessment Questionnaire (CHAQ), Pediatric
QOL Inventory (PedsQL Generic 4.0 and Rheumatology 3.0
modules). Physician completed: SLE Disease Activity Index
(SLEDAI) and Systemic Lupus International Collaborating Clin-
ics/ACR Damage Index (SLICC). Number of days over the prior
30 the child missed school due to physical/mental health reasons
was recorded using PedsQL family information form. Spearman
correlations were determined between number of missed school
days and other variables.
Results: 24 children (23 girls) with SLE (mean age 15 F 3
years, mean education 9th grade, mean SLE duration 46 F 30
months, SLEDAI 0-24, SLICC 0-6, median CHAQ 0.3, mean
PedsQL-Generic 67F 20), and 19 parents (median CHAQ 0, mean
PedsQL-Generic 69 F 18) participated. 4 children were excluded
because school attendance was inapplicable. In 30 days prior to
participation, 10 children (50%) missed school with a mean of 3 F
7 days. Mean number of days too ill to play = 3 F 7 and mean
number of days needed someone = 3 F 6 days. The number of
missed school days moderately correlated with decreased QOL as
reported by parents and as measured by the PedsQL-Generic
module (r 0.56, p 0.02), but did not correlate significantly with
Rheumatology module, CHAQ, SLEDAI, SLICC, or any of the
child reported scores.
Conclusions: Number of missed school days is correlated with
decreased general QOL in children with SLE as perceived by their
parents. However, parallel correlation between missed school days
and overall QOL as perceived by children was not identified.
Discrepant perception between parents and children warrant further
investigation in a larger cohort. Lack of correlation of school
attendance with other scales suggests that generic scale captures a
less tangible element of SLE.
F2.57. Improvement of Antimycobacterial Therapy Due
to IL-10 Activity Blockage Is Strain Dependent.
S. Roque,1,2 C. No´brega, R. Appelberg,1 M. Correia-Neves.1,3
1Laboratory of Microbiology and Immunology of Infection,
Institute for Molecular and Cell Biology (IBMC), Porto;
2Mestrado de Imunologia Clinica, Universidade da Beira Interior;
3Instituto Superior de Saude do Alto Ave (ISAVE), Fontarcada,
Portugal.
Mycobacterium avium infection is a common opportunistic
infection in immunocompromised patients. Treatment against
these infections is complex and not always effective. Antimyco-
bacterial treatment implies a combination of two or more drugs
administered for long periods. Furthermore, this chemotherapy
repeatedly fails to induce sterile cure, and the occurrence of
antibiotic-resistant bacteria is not a rare event. IL-10 is a cytokine
with pleiotropic activities. IL-10 major effects are associated with
its anti-inflammatory and immunosuppressive properties. Partic-
ular interest on IL-10 results from its ability to increase
susceptibility to infection in several mouse models. In fact,
previous studies from our group have shown that abrogation of
IL-10 activity improves the efficacy of antimycobacterial drugs in
BALB/c mice.
Surprisingly, in the present study we show that this IL-10
effect seems to be strain specific. Combination of anti-IL-10
receptor mAb administration and antimycobacterial therapy
(clarithromycin, rifampicin and ethambutol) in BALB/c and
C57BL/6 chronically infected with M. avium (strain 2447) only
increased response to treatment in the BALB/c strain. Whether
this represents strain differences in the immune response to M.
Abstracts S87avium during antimycobacterial treatment is currently being
investigating.
F2.58. Quality Control of DNA with the Agilent 2100
Bioanalyzer for Oligonucleotide Array CGH (aCGH).
Samar Lightfoot,1 Hans Brunnert,2 Carsten Buhlmann,2 Paige
Anderson.1 1Agilent Technologies, Palo Alto, USA; 2Agilent
Technologies, Waldbronn, Germany.
Comparative genomic hybridization (CGH) measures copy
number variations at multiple loci simultaneously, providing an
important tool for studying cancer and developmental disorders,
and for developing diagnostic and therapeutic targets. We have
recently developed an oligonucleotide array platform for array
based comparative genomic hybridization (aCGH) analyses that
can detect and map copy number alterations in the human genome,
including single copy losses and gene specific homozygous
deletions, as well as amplicons of varying sizes.
The application of this technology to the study of human
disease requires adequate quality control of DNA sample
preparation prior to hybridization. The Agilent 2100 bioanalyzer
and associated RNA assays are now established industry standards
for checking the integrity of RNA samples. However, in addition to
RNA sample analyses, the bioanalyzer has on-chip electrophoresis
capabilities for DNA analysis. Here we investigated the use of the
bioanalyzer for monitoring critical steps in the workflow of an
aCGH experiment including DNA amplification, digestion of
template and labeling. Our results demonstrates that the bioana-
lyzer can robustly monitor the quality and quantity of DNA
templates used in aCGH experiments.
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Sa1.01. Receptor-Modified T Cells as Novel Therapeutic
Approach for Multiple Sclerosis.
I. Moisini, T. L. Geiger. 1Pathology, St. Jude ChildrenTs Research
Hospital, Memphis, TN, USA; 2Pathology, University of Tennessee
Health Science Center, Memphis, TN, USA.
Multiple sclerosis is a chronic autoimmune disease mediated
by T cells reactive to different antigenic peptides of the myelin
sheath. Experimental autoimmune encephalomyelitis induced with
peptides such as MBP, MOG, PLP emulsified in CFA recapit-
ulates the human disease in mice. T cells re-directed against the
antigen-specific T-lymphocytes that mediate immunopathology
have been previously shown to be selective and effective as a
targeted therapy of experimental autoimmune encephalomyelitis
(Mekala et al. Nature Biotechnology 2002). To develop human-
ized receptors capable of re-directing therapeutic T lymphocytes
against potentially disease-causing cells, we linked the immuno-
dominant epitope, 84-102, of the human myelin basic protein
MBP to the extracellular and transmembrane domains of the
HLA-DR2 beta chain (DRB1*1501) and the TCR-zeta cytoplas-
mic domain. We similarly linked the DR2 alpha chain
(DRA*0101) to the TCR-zeta. The alpha and beta chain
constructs (denoted as HC2) were linked using the TMV 2A
sequence and subcloned into the MSCV-I-GFP retroviral vector.
GFP positive, retrovirally transduced 4G4 hybridomas andC57Bl/6J CD8+ T cells cells were isolated by flow cytometry.
Western and flow cytometric analysis showed the expression of
the construct. In order to assay the specificity of effector HC2
cells we used two different types of target cells: Ob hybridoma
specific for human peptide MBP84102 /MHC II DR2 (courtesy of
Dr. Lars Fugger, Skejby Hospital, 2rhus) and hMBP84102-
specific T cell line derived from humanized DR2xTCR double-
transgenic mice. Recognition of the chimeric receptor by hMBP-
specific cells was shown by the production of specific cytokines
(interleukin-2 and interferon-gamma) by the HC2-transduced T
cells. Recognition of target cells by HC2-transduced T cells also
induced proliferation of the transduced therapeutic cells. We have
also shown that cytotoxic HC2 cells could specifically recognize the
cognate TCR of MBP84102-reactive target cells and kill the target
cells in vitro. In vivo studies in a humanized murine model system,
validating the use of these modified T cells as a cellular
immunotherapeutic agent capable of selecting targeting pathologic
antigen-specific T cells, are ongoing.
Sa1.02. The Role of Leukemia Inhibitory Factor (LIF) in
Experimental Autoimmune Encephalomyelitis (EAE).
R. A. Linker,1 A. Wieczarkowiecz,1 S. Weikard,2 N. Kruse,1 C.
Kleinschnitz,2 B. Holtmann,3 M. Sendtner,3 R. Gold.1 1Insitute for
Multiple Sclerosis Research, University of Goettingen and
Gemeinnuetzige Hertie-Stiftung, Goettingen, Germany; 2Dept. of
Neurology, Clinical Research Group for Multiple Sclerosis,
University of Wurzburg, Wuerzburg, Germany; 3Institute for
Neurobiology, University of Wurzburg, Wuerzburg, Germany.
LIF is a neurotrophic cytokine, belonging to the IL-6 family of
cytokines. It plays a role in oligodendrocyte survival, but also in
stem cell biology. Here we searched for possible immune functions
of LIF.
RT-PCR analysis proved the presence of LIF receptor beta on
murine macrophages, dendritic cells and T-cells and its upregu-
lation by activation. We studied myelin-oligodendrocyte glyco-
protein peptide aa 35-55 (MOG 35-55) induced EAE in LIF
knockout mice (LIF -/- mice). LIF -/- mice suffered from a less
severe course of EAE in comparison to wild-type mice until day
70 p.i.(n = 10/10). In primary lymph node proliferation assays,
lymphocytes from LIF -/- mice responded less to MOG 35-55
than those from wild-type mice, but exhibited a similar mitogen
response. The defect in antigen-specific proliferation could not be
restored by addition of LIF or IL-6 to cell culture. Supernatants
from primary lymph node cultures were used to investigate
cytokine production after immunization with MOG 35-55. LIF -/-
mice displayed decreased levels of MCP-1 and IFN-g whereas no
difference in the production of IL-12, IL-6 or IL-5 was observed.
Finally, a histological analysis was performed to investigate the
inflammatory reaction in situ after immunization with MOG 35-
55. The blinded quantification of CD3 and Mac-3 positive cells
revealed significantly lower numbers of T-cells and macrophages
in the spinal cord of LIF -/- mice on day 60 p.i. These results
were paralleled by a decrease of MCP-1 and GM-CSF mRNA
levels in the spinal cord of LIF -/- mice on day 40 p.i.
In summary, our results are in line with a defective antigen-spe-
cific T-cell priming and a selective defect in cytokine/chemokine
production in LIF -/-mice. This may result from impaired recruit-
ment of antigen presenting cells (APC) and disturbed APC-T-cell
interaction overall leading to a less severe course of MOG 35-55
EAE. The direct effects of LIF on T-cells are currently under
investigation.
AbstractsS88Sa1.03. Novel Immunotoxin: A Fusion Protein
Consisting of Gelonin and an Acetylcholine Receptor
Fragment as a Potential Immunotherapeutic Agent for
the Treatment of Myasthenia gravis.
M. Hossann,1 Z. Li,2 Y. Shi,2 U. Kreilinger,1 J. Buettner,1 P. D.
Vogel,1 Y. Jingming,2 J. G. Wise,1 W. E. Trommer.1 1Chemistry,
TU Kaiserslautern, Kaiserslautern, Germany; 2Biotechnology,
Shanxi University, Taiyuan, China.
In continuation of our attempts for antigen-specific suppression
of the immune system (Urbatsch, I.L., Sterz, R.K.M., Peper, K.,
and Trommer, W.E. (1993) Eur. J. Immunol. 23, 774-779) a fusion
protein composed of amino acids 4-181 of the extracellular domain
of the a-subunit of the human muscle acetylcholine receptor and
the plant toxin gelonin was expressed in E.coli.
The fusion protein formed inclusion bodies but could be
solubilized in the presence of guanidinium chloride. It exhibited a
rather native structure as shown by antibodies recognizing a
conformational epitope. Half maximal inhibition of translation was
achieved at 46 ng/mL as compared to 4.6 ng/mL for native and 2.4
for recombinant gelonin.
Its use as therapeutic agent for the treatment of Myasthenia
gravis was investigated in an animal model. Female Lewis rats were
immunized with complete acetylcholine receptor from the electric
ray Torpedo californica and developed thereafter experimental
autommune Myasthenia gravis. Quantitative assessment of the di-
sease was achieved by repetitive stimulation of the sciatic nerve.
Rats showed no more symptoms of Myasthenia gravis, neither vi-
sually nor electrophysiologically after treatment with the fusion
protein as determined one and seven weeks after the second
application.
Sa1.04. Fumarate Therapy Ameloriates Chronic
Experimental Autoimmune Encephalomyelitis (EAE).
S. Schilling,1 S. Goelz,2 R. A. Linker,1 F. Luhder,1 R. Gold.1
1Institute for Multiple Sclerosis Research, University of Goettingen
and Gemeinnuetzige Hertie-Stiftung, Goettingen, Germany;
2Biogen Idec, Cambridge, USA.
Background: Treatment with fumaric acid derivates is well
established as an effective therapy in severe psoriasis, a Th1
mediated skin disease. It has been proposed that one of the
underlying ways that fumaric acid works is by inducing a Th1 to
Th2 shift. In this study we investigated the clinical and molecular
effects of Dimethyl fumarate (DMF) and Monomethyl fumarate
(MMF) in chronic EAE, a model for multiple sclerosis.
Methods: C57BL/6 mice were immunized with myelin-oligo-
dendrocyte glycoprotein peptide aa 35-55 (MOG 33-35)/ CFA and
received pertussis toxin. 3 groups of 8 mice/group were treated
from day 3 to day 30 twice a day with 5 mg/kg body weight
Dimethyl fumarate (DMF), Monomethyl fumarate (MMF) or the
vehicle alone. Medication was administered by oral gavage.
Animals were weighed and scored for clinical signs of disease
on a daily basis over 30 days. Mice reaching paraplegia had to be
sacrificed due to animal experimentation laws. Blood samples were
taken from all mice before immunization, at the peak of the disease
(day 11) and in partial remission (day 21), plasma protein
concentration of 60 cytokines, chemokines and other markers
was measured by Multi-Analyte Profile (MAP) testing.
Results: In the control group and MMF treated group, 5/8 mice
suffered from paraplegia, whereas in the DMF group only 2/8 mice
reached this clinical endpoint. Onset of disease was earlier in theMMF treated group (mean: day 11,8) compared to DMF (mean: day
13,6) and control group (mean: day 12,3), this was not significant.
DMF treated mice had a significantly less severe clinical course in
this preventive treatment approach, pb0,001. Blood samples are
currently analyzed using a Multi-Analyte Profile including 60
cytokines and chemokines, and histological studies are ongoing.
Conclusion: Our data suggest that DMF has a beneficial effect
in chronic EAE. We will present cytokine and histological results
pending further analyses.
Sa1.05. Beneficial Autoimmunity Restrains Destructive
Immunity in a Regulatory Manner.
Nathan Karin,1 Yaniv Zohar,1 Uri Weinberg,1 Rachel Anunu,1
Gizi Wildbaum.1 1Immunology, Rappaport Faculty of Medicine,
Technion, Haifa, Israel.
In previous studies we have shown that targeted DNA vaccines
encoding selected proinflammatory mediators, particularly chemo-
kines and cytokines, could effectively suppress experimentally
induced autoimmune diseases in a selective manner. For example:
targeted DNA vaccine encoding the CC chemokine RANTES
(CCL5) could selectively suppress experimentally induced rheu-
matoid arthritis, but had no beneficial effect on experimental
autoimmune encephalomyelitis (EAE), whereas DNA vaccines
encoding MCP-1 (CCL2) effectively suppressed both diseases. The
beneficial effect of each vaccine could be transferred by chemo-
kine-specific autoantibodies developed in protected donors.
Throughout these studies we have repeatedly observed an
unexpected phenomena. The elicitation of beneficial autoantibody
production, during ongoing autoimmunity, is very rapid. In the
current presentation we shall show that this rapid response results
from an amplification of a regulatory response induced by the
disease itself. We shall show the high relevance of this regulatory
mechanism to human disease and its therapeutic implications for
autoimmunity and cancer.
Key reference:
Wildbaum, G., Nahir, M. & Karin, N. Beneficial autoimmunity
to proinflammatory mediators restrains the consequences of self-
destructive immunity. Immunity, 19, 679-688 (2003).
Sa1.06. CD4+CD25+FoxP3+ Regulatory T Cells Are a
Highly Apoptosis Sensitive T Cell Population with an
Impaired Suppressive Function in Multiple Sclerosis.
B. Fritzsching,1,2 N. Oberle,1 N. Eberhardt,1 J. Haas,2
M. Korporal,2 B. Wildemann,2 P. H. Krammer,1 E. Suri-Payer.1
1Department of Immunogenetics, German Cancer Research
Center, Heidelberg, Germany; 2Section of Molecular
Neuroimmunology, Department of Neurology, University of
Heidelberg, Heidelberg, Germany.
CD4+CD25+FoxP3+ regulatory T-cells suppress human and
murine T-cell function. The role of regulatory T cells in human
disease and its modulation are of major interest. Enhanced survival
and expansion of regulatory T cells would be beneficial in
autoimmune disease. In contrast, increased depletion by apoptosis
would be advantageous in cancer. In addition to their described
sensitivity to IL-2 deprivation, we show that freshly isolated FACS-
sorted human regulatory T cells are highly sensitive towards CD95-
dependent apoptosis in contrast to their CD4+CD25- T cell
counterparts. However, restimulation of expanded regulatory T
cells revealed a reduced sensitivity towards activation induced cell
death (AICD) in contrast to AICD-sensitive CD4+CD25- T cells.
Simultaneously, expanded regulatory T cells remained highly
Abstracts S89sensitive towards CD95L-triggered apoptosis. Murine CD4+CD25+
regulatory T cells displayed a similar sensitivity. Our data suggest a
model in which CD4+CD25- effector T cells could modulate the
number of regulatory T cells via the CD95L/ CD95 system in the
contraction phase of an immune response. Furthermore, we found a
defective suppressive function of regulatory T cells in Multiple
Sclerosis (MS) patients. Given known alterations of the CD95
system in MS we are investigating whether an altered sensitivity of
regulatory T cells towards CD95-dependent apoptosis could be
critical for the modulation of defective regulatory response in
Multiple Sclerosis.
Sa1.07. Accumulation of CD4+CD25+ Regulatory
T Cells in the CNS during Recovery from EAE.
M. J. McGeachy,1 L. A. Stephens,1 S. M. Anderton.1 1Institute of
Immunology and Infection Research, University of Edinburgh,
Edinburgh, United Kingdom.
Many studies focus on the role of CD4+CD25+ regulatory Tcells
(Tregs) in preventing the onset of autoimmunity. Here we have
investigated the regulation of activated pathogenic T cells in a
spontaneously remitting model of autoimmune disease- experimen-
tal autoimmune encephalomyelitis (EAE). EAE was induced by
immunization of C57BL/6 mice with the central nervous system
(CNS) autoantigenic peptide MOG(35-55). In our hands this leads
to the development of EAE from 7 days post-immunization, with
peak of disease in the second week, followed by a recovery phase
with most mice free of clinical signs by 30 days post-immunization.
The mice are subsequently resistant to a second round of disease
when re-immunized with MOG(35-55). Spinal cord and draining
lymph node (LN) cells were purified from mice at different time-
points during disease. Cells were phenotypically examined by
FACS analysis, and functionally tested for their ability to proliferate
or suppress proliferation and cytokine production of naRve or primed
cells in vitro. We found that the proportion of CD4+ cells expressing
CD25 in the CNS increased during the course of disease, correlating
with recovery. These CD4+CD25+ cells preferentially produced IL-
10, while IFNg-secreting CD4+ cells were CD25-. In vitro,
CD4+CD25+ CNS cells were anergic, but proliferated in response
to anti-CD3 in the presence of IL-2. These CD25+ cells could also
suppress proliferation of responder CD25- cells in vitro. Anti-CD25
(PC61) antibody was used to deplete CD25+ cells in vivo 3 days
prior to EAE induction. This depletion led to exacerbated disease
with greatly delayed recovery, supporting a functional role for Tregs
in remission. Interestingly, CD25-depletion after recovery rendered
mice fully susceptible to reinduction. Moreover, transfer of CNS-
derived CD25+ cells led to accelerated recovery from subsequent
EAE. In conclusion, accumulation of CD4+CD25+ Tregs (produc-
ing IL-10) in the CNS during the recovery phase of EAE suggests a
role in the control of myelin-reactive pathogenic T cells. Our
hypothesis is that autoantigen-reactive regulatory T cells are
expanded or induced in draining lymph nodes, then recruited to
the effector site to aid in the resolution of this autoimmune disease.
Sa1.08. The Pathology of Progressive Multiple Sclerosis.
A. E. Kutzelnigg,1 C. Lucchinetti,2 W. Brueck,3 M. Schmidbauer,4
H. Lassmann.1 1Department of Neuroimmunology, Brain Research
Center, Medical University Vienna, Vienna, Austria; 2Department
of Neurology, Mayo Clinic, Rochester, MN, USA; 3Institute of
Neuropathology, University of Goettingen, Goettingen, Germany;
4Department of Neurology, Municipal Hospital Lainz, Vienna,
Austria.Multiple sclerosis is defined as inflammatory demyelinating
disease of the white matter of the central nervous system. While
the functional neurological deficit of patients with acute or
relapsing-remitting MS can be explained by the focal white
matter lesions in the CNS, this is not the case for patients with
primary or secondary progressive MS who experience a gradual
accumulation of their clinical deficit. So far no pathological
feature of the disease has been described which clearly distin-
guishes relapsing-remitting from progressive disease in MS
patients.
In the present study, we systematically analyzed cortical and
white matter pathology in a large sample of multiple sclerosis
brains with different disease courses (11 cases with acute MS, 6
with RRMS, 20 with SPMS and 14 with PPMS). Hemispheric and
double hemisperic tissue sections were examined for cortical
demyelination and pathological changes in the white matter which
offered the unique opportunity to evaluate disease involvement of
large tissue areas.
Cortical demyelinated plaques were abundant in patients with
primary or secondary progressive MS, but were virtually absent in
patients with acute or RRMS (percentage of demyelinated cortical
area: acuteMS: 0,36; RRMS: 4,54; PPMS: 14,89; SPMS: 21,22; P =
0,0014). Focal load of demyelinated lesions in the white matter was
almost the same in the four groups.
Similar results were obtained from our analysis of the cerebellar
cortex (percentage of demyelinated cortical area: acute MS: 0,85;
RRMS: 1,89; PPMS: 33,28; SPMS: 38,2; P = 0,042).
Especially in primary, but also in secondary progressive MS
cases, myelin pallor was observed in the normal appearing white
matter, which was associated with significant inflammation as
well as microglia and macrophage activation. These pathological
changes were sparse in acute and RRMS brains (inflammatory
infiltrates per mm2: acMS: 0,05; RRMS: 0,07; PPMS: 0,20;
SPMS: 0,30; P = 0,019). No correlation between size and
location of white matter plaques and cortical demyelination or
diffuse white matter damage was observed.
In conclusion, we suggest that in MS brains three different
pathological processes occur, which are are stage-specific and
occur at least in part independently from each other: focal white
matter plaques, cortical demyelination and diffuse damage of the
white matter.
All pathologies occur on the background of inflammation
although the type of inflammation is different. Focal white matter
lesions seem to be due to new waves of inflammation entering
the brain with BBB damage. With chronicity of the disease,
inflammatory cells accumulate gradually throughout the whole
CNS, leading to diffuse damage in the bnormalQ white matter and
the cortex.
Sa1.09. Endoneural CD34+ Fibroblasts: Putative
Regulators of Macrophage Activation in the Peripheral
Nerve?
A. Kroner,1 B. D. Kohl,1 I. Kobsar,1 R. Martini,1 M. Maeurer.1
1Experimental Developmental Neurobiology, Julius Maximilians
University, Wuerzburg, Bavaria, Germany.
Using mouse models of distinct hereditary demyelinating
neuropathies (heterocygous P0-deficiency, P0+- and homocy-
gous CX32-deficiency, CX32–) we could recently demonstrate
that T-cells and macrophages are involved in the pathogenesis
of hereditary demyelinating disorders. Beyond these immune
cells we have also found blood-derived CD34+ fibroblast-like
AbstractsS90cells in the endoneurium of P0+- mice. We supposed that
these fibroblast-like cells might be identical to the recently
described population of CD34+ peripheral blood fibrocytes and
might therefore comprise another cell type of potential
importance for immune regulation in hereditary demyelinating
neuropathies.
In this study we further characterized this novel cell
population in the endoneurium of P0+- mice. We observed
that these fibroblast-like cells show close contacts with
endoneurial macrophages. Contact sites between these two
cell populations were found regularly under normal and
demyelinating conditions. The interaction between these two
cell populations seems to play a role for immune regulation
within the peripheral nerves since immunodeficient P0+-/RAG–
mice lack an age-related increase of CD34+ cells that parallels
the occurrence of pathological changes within the peripheral
nerves of P0+- mice. We suppose that this lack of CD34+
fibroblast-like cells might result in altered macrophage
activation.
In conclusion we could show that macrophages and fibroblast-
like cells have close contacts within the endoneurium. According
to our morphological observations we hypothesize that CD34+
fibroblast-like cells are involved in regulation of macrophage
function under demyelinating conditions.
Sa1.10. Decreased T-Cell Immunity to Epstein-Barr
Virus in Multiple Sclerosis.
M. P. Pender, A. Lenarczyk, J. M. Burrows, J. Harness, S. R.
Burrows. 1Medicine, The University of Queensland, Brisbane,
QLD, Australia; 2Queensland Institute of Medical Research,
Brisbane, QLD, Australia.
Introduction: Increasing evidence indicates that infection with
the Epstein-Barr virus (EBV) has a role in the pathogenesis of
many human chronic autoimmune diseases, including multiple
sclerosis (MS). We have proposed a new hypothesis that chronic
autoimmune diseases occur in individuals genetically susceptible
to the effects of B-cell infection by EBV, and that the EBV-infected
B cells not only produce autoantibodies but also inhibit activation-
induced apoptosis of autoreactive T cells in the target organ
(Trends Immunol 24 (2003) 584-588; http://eprint.uq.edu.au/
archive/00001146).
Aims: This study aims to determine whether patients with MS
have an increased frequency of EBV-infected immortalized B cells
and defective immunity against latent EBV infection, which may
lead to the development of MS.
Methods: Sera from patients with MS (not on immunomo-
dulatory therapy) and healthy controls are tested for the
presence of anti-EBV viral capsid antigen (VCA) IgG or anti-
EBV nuclear antigen (EBNA) IgG using ELISA. We are using
real-time PCR to quantify the EBV DNA load in the
cerebrospinal fluid (CSF) and peripheral blood mononuclear
cells (PBMC) of patients with MS. We are also performing IFN-
gamma ELISPOT assays to measure peripheral blood T-cell
reactivity against major histocompatibility complex (MHC)
class-I-restricted latent and lytic EBV peptides, MHC class-II-
restricted EBV peptides and human cytomegalovirus (HCMV)
peptides.
Results: Our preliminary results show detectable levels of
EBV DNA in the CSF in 3 of 8 patients with MS.
Furthermore, our results from the IFN-gamma ELISPOT assays
indicate a reduction in the T-cell response to MHC class-I-restricted latent EBV peptides in MS patients compared to
healthy controls.
Conclusions: Our findings of the presence of EBV in the CSF
of MS patients and of reduced T-cell immunity against latent EBV
antigens may shed light on the role of EBV infection in the
pathogenesis of MS.
Sa1.11. HLA-DR2 Is Associated with Chronic
Inflammatory Demyelinating Polyradiculoneuropathy
(CIDP) in Females, but Not Males.
P. A. McCombe,1 P. A. Csurhes,1 M. A. Alizart,1 J. M. Greer.1
1School of Medicine, University of Queensland, Brisbane,
Queensland, Australia.
CIDP is an inflammatory and demyelinating disease affecting
the peripheral nervous system. It is related to the Guillain-Barre´
syndrome (GBS), but is a chronic condition and is distinguished
from GBS by its temporal pattern and potential for clinical relapse.
CIDP occurs more commonly in males than in females, and is
thought to be autoimmune in nature, although this still remains
unproven. Because it is thought that CIDP might have an
autoimmune component, several studies have investigated HLA
molecules carried by patients with CIDP. These studies have
shown a trend towards increased carriage of HLA DR2 and DR3;
however, since CIDP is relatively uncommon, the number of
individuals studied has been small and the majority of patients
have been male. Because studies in other autoimmune diseases
have shown that sex-related factors appear to influence the risk
associated with carriage of different HLA molecules, we set out to
test a larger cohort of patients to determine if there are HLA
associations with CIDP, and whether these differ depending on the
gender of the patients.
We have investigated carriage of class II HLA molecules in a
cohort of 100 CIDP patients (60 male), and compared this to
carriage of these molecules in 90 healthy controls and 71 patients
with GBS. DNA was extracted from 5 ml whole blood, which
was collected after written informed consent had been obtained.
Dynal low-resolution SSP kits were used to type for HLA-DR,
DQA and DQB molecules, to a resolution equivalent to that of
serotyped subgroups.
In comparison to female healthy controls, there was an
increased carriage of DR2 by female patients with CIDP (P b
0.05), but not by female patients with GBS. Upon further
subtyping of DR2+ individuals, the majority of individuals in all
3 groups were found to carry DRB1*1501. There were no
differences in the frequency of carriage of DR2 between males in
any of the 3 groups. There was a trend in male CIDP patients
towards increased carriage of DR6 compared to male controls,
whereas there was a trend towards decreased carriage of DR6 in
female CIDP patients compared to controls. Our results did not
confirm any association between carriage of DR3 and develop-
ment of CIDP.
There were no significant differences for frequency of carriage
of DQA or DQB molecules between healthy controls, CIDP
patients, or GBS patients when groups were considered as a whole,
or subdivided based on gender.
These results show that gender-specific HLA-DR associations
occur in CIDP. They reflect similar findings in studies of other
autoimmune diseases and provide additional evidence for an
autoimmune disease mechanism in CIDP. The HLA typing in this
study was only done to a low resolution, and further associations
between CIDP (particularly in males) and carriage of particular
Abstracts S91HLA molecules may become apparent if the typing were done to
the molecular level.
Sa1.12. Antibodies Specific for Myelin Proteolipid
Protein Are of Potential Pathogenic Relevance in Myelin
Opsonization in Multiple Sclerosis.
J. M. Greer,1 M. P. Pender.1 1School of Medicine, University of
Queensland, Brisbane, Queensland, Australia.
Myelin proteolipid protein (PLP) is the most abundant
protein of central nervous system myelin and is a putative
target antigen in multiple sclerosis (MS). Increased levels of T
cell reactivity directed against PLP have been well-documented
in MS. We have found that there are also increased levels of
antibodies specific for PLP, particularly for the extracellular loop
consisting of amino acids 180-230, in patients with MS
compared to healthy controls and patients with other neuro-
logical diseases (OND). The aim of the current study was to
determine whether these antibodies could have any pathogenic
relevance in MS.
Sera from 70 patients with MS (12 with primary progressive
MS, 14 with secondary progressive MS and 44 with established
relapsing-remitting MS or a first attack of MS), 25 patients with
OND and 25 healthy controls were screened for their ability to
opsonize DiI-labelled purified human myelin and thereby
increase the uptake of the myelin into macrophages. The
percentages of individuals in each group whose sera induced
levels of myelin uptake greater than 2 standard deviations
higher than the mean of the healthy control group were 69% for
MS, 0% for healthy controls and 16% for OND patients. Over
70% of the sera from secondary or primary progressive MS
patients induced increased levels of myelin uptake by macro-
phages. The percentage of patients with established relapsing-
remitting MS or a first attack whose sera induced increased
levels of myelin uptake by macrophages was slightly lower
(59%).
Of those sera that induced increased myelin uptake, 60%
contained antibodies specific for the PLP180-230 region, as
assessed by ELISA. Preadsorption of sera with peptides from this
region of the PLP molecule was found to be able to inhibit partly or
wholely the opsonizing potential of those sera that showed PLP
reactivity in ELISA. Thus, approximately 40% of patients with MS
contain PLP-specific antibodies in their sera that can opsonize
myelin for phagocytosis.
Antibodies could have functional pathogenic effects in MS via
a variety of mechanisms such as causing demyelination by
antibody-dependent cell-mediated cytotoxicity or complement-
dependent lysis, or via opsonization of myelin resulting in
phagocytosis. In addition, they may induce upregulation of MHC
and costimulatory molecules in the CNS, inhibit remyelination, or
cause axonal damage and modulation of synaptic transmission. An
antibody that could bind to extracellular epitopes of intact myelin
(such as PLP180-230) would be more likely to be directly
pathogenic than one that recognizes only disrupted myelin,
although the later could be involved in escalating inflammation
by activating the complement cascade. Our results show that PLP-
specific antibodies can exhibit at least one of these potential
pathogenic effects.
Identification of MS patients exhibiting elevated pathogenic
antibody responses may be an important step in selecting patients
for treatment with intravenous immunoglobulin or plasmapheresis
to decrease this activity.Sa1.13. Autoantigen Specific T Cells Inhibit Glutamate
Uptake in Astrocytes by Decreasing Expression of
Astrocytic Glutamate Transporter GLAST- A
Mechanism Mediated by Tumor Necrosis Factor-a.
T. Korn,1 T. Magnus,2 S. Jung.1 1Department of Neurology,
Universitaet des Saarlandes, Homburg, Germany; 2Stem Cell
Section, Laboratory of Neurosciences, National Institute on Aging,
National Institutes of Health, Baltimore, MD, USA.
Glutamate excitotoxicity is increasingly being recognized as
pathogenic mechanism in autoimmune inflammatory disorders of
the central nervous system (CNS). Astrocytes are the predom-
inant players in clearing the extracellular space from glutamate
and normally have extensive spare capacities in terms of
glutamate uptake. We asked what might be the basis of
glutamate accumulation in T cell-triggered autoimmune inflam-
mation. In vitro, exposure of primary rat astrocytes to antigen-
activated myelin basic protein (MBP)-specific T cells resulted in
the decrease of astrocytic glutamate uptake rates as far as vmax
was concerned. In parallel, the amount of the astrocytic Na+-
dependent glutamate transporter GLAST was reduced in a time
range of 48 to 60 h. Similar decreases of GLAST protein were
observed in astrocytes re-isolated after co-culture with T cells
activated by MBP and astrocytes as antigen presenting cells
(APCs) or after co-culture with T cell blasts pre-activated in the
presence of splenocytes beforehand. Since incubation of astro-
cytes with cell-free supernatant from MBP-activated T cells also
resulted in a reduced expression of GLAST, a humoral factor
appeared to be the driving agent. In blocking experiments using
neutralizing antibodies and by exposure of astrocytes to
recombinant cytokines, tumor necrosis factor-a (TNF-a) was
identified to be responsible for the down-modulation of GLAST.
GLAST was also down-regulated in the CNS of autoimmune
encephalitic rats, but not in animals suffering from systemic
inflammation. Since the loss of GLAST was not confined to
inflammatory infiltrates, here too, a humoral factor seemed to be
causative. In conclusion, T cell-derived TNF-a impaires gluta-
mate clearance capacity of astrocytes in vitro and probably also
in vivo in autoimmune inflammatory disorders providing a
pathogenic link to glutamate excitotoxicity that may be
responsible for early axonal dysfunction remote from active
inflammatory demyelination.
Sa1.14. The MHC Is the Major Determinant for the
Requirement of B7.1/7.2-Costimulation in the Induction
of Experimental Autoimmune Encephalomyelitis (EAE).
B. Greve,1 C. Jabs Mansell,1 R. A. Sobel,2,3 A. H. Sharpe,4 V. K.
Kuchroo.1 1Center for Neurologic Diseases, Harvard Institutes of
Medicine, Brigham and WomenTs Hospital, Boston, MA, USA;
2Laboratory Service, Veterans Affairs Medical Center, Palo Alto,
CA, USA; 3Department of Pathology, Stanford University School
of Medicine, Stanford, CA, USA; 4Department of Pathology,
Harvard Medical School, Boston, MA, USA.
Full activation of T-cells requires costimulatory signals such
as B7.1/B7.2-CD28/CTLA-4 interaction besides MHC-peptide-
TCR signalling. We have previously shown in B7.1/B7.2-
deficient (DKO) mice that the genetic background (SJL/J versus
C57BL/6J) determines the requirement for B7 costimulation in
induction of EAE. Whereas, DKO on the B6 background were
highly resistant to the development of EAE following immuniza-
tion with the encephalitogenic MOG 35-55 peptide, DKO mice
AbstractsS92on the SJL mice remained susceptible to EAE when immunized
with the PLP 139-151 peptide. Since the two strains differ in
their MHC molecules, thus differ in peptide binding and the
selection and expansion of the encephalitogenic T cell repertoire,
we examined the role of the MHC as a determinant for the
requirement of B7 costimulation inEAE. In 88 [SJLx(SJLxB6
F1)] DKO back-cross 1 (BC1) mice we found that homozygosity
of the s haplotype is a strong susceptibility factor for clinical and
histological PLP139-151-induced EAE in these mice. In order to
detect further susceptibility regions we studied MOG 35-55-
induced EAE in 204 (SJLxB6) F2 DKO mice which were
selected for at least one b allele at the MHC locus. No additional
susceptibility regions were identified. Our results indicate that the
expression of class II molecules (homozygosity of the s allele at
the H2-A locus) is the major susceptibility factor which
determines the requirement and dependence for B7-costimulation
for the induction of EAE.
Sa1.15. Anti-CTLA4 scFv, a Single-Chain Antibody,
Attenuated Host Humoral Immune Responses during
Repeated DNA Vaccination in Immune Competent
Animals.
An-Bang Liu,1 Steve R. Roffler.2 1Neuromuscular Research, Tzu
Chi Neuro-Medical Scientific Center, Tzu Chi Medical Center,
Hualien, Taiwan; 2Institute of Biomedical Science, Academia
Sinica, Taipei, Taiwan.
Objectives: To induce tolerance in immune-competent ani-
mals with a plasmid (p4F10-eB7) expressing a membrane-bound
single-chain antibody against CTLA4. Materials and Methods:
Thirty 9-week old immune-competent C57B/L6 mice were
divided into three groups. Ten mice received an intramuscular
injection of endotoxin-free plasmid, pCBLacZ, at the left anterior
tibialis. The plasmid encodes a potent immunogen, Escherichia
coli beta-galactosidase. Ten mice received a co-injection of
p4F10-eB7 and pCBLacZ. Another ten mice received five
consecutive intramuscular injections of the plasmid. Five of
them received injection of pCBLacZ alone. The other five
received coinjection of two plasmids. Results: For single
injection, we examined the expression of beta-galactosidase in
muscle fibers on the 6th and 12th days after injection. Significant
difference of transduced muscle fibers was only found 6 days
after single injection. However, serum IgG against beta-galacto-
sidase was much lower in the animals received consecutive
injections of two plasmids as compared with those in the control
group. Conclusions: Expression of anti-CTLA4 antibody in
muscle cells protected the expression of beta-galactosidase in
immune-competent mice. This membrane bound single-chain
antibody attenuated host humoral immune responses during
repeated immunization. The probable mechanism is peripheral
tolerance induced by anergy of activated T cells after interaction
with the single-chain antibody. This novel strategy targeting on
activated T cells may be used for treatment of acquired
autoimmune diseases.
Sa1.16. Memory CD4+ T Cells and EAE.
W. Elyaman,1 T. Chitnis,1 J. Imitola,1 M. H. Sayegh,2 S. J.
Khoury.1 1Center for Neurologic Diseases, Brigham and WomenTs
Hospital, Boston, MA, USA; 2Transplantation Center, Brigham
and WomenTs Hospital and ChildrenTs Hospital, Boston, MA, USA.
The memory T cell pool functions as a dynamic repository of
antigen-experienced T lymphocytes that accumulate over thelifetime of the individual. Previous studies indicate that T cells
which are reactive to myelin antigens are mainly memory cells in
MS patients. We hypothesize that there are specific mechanisms of
disease mediated by memory T cells. Here, we developed an
animal model of memory CD4+ T cell-inducing EAE. Wild-type
(WT) or MOG TCR transgenic memory CD4+ T cells were
generated from WT B6 or 2D2 transgenic mice respectively,
immunized with MOG/CFA for more than 100 days. CD4+CD44hi
cells were sorted and immediately transferred into TCR ab -/- mice
followed by immunization with MOG/CFA. A control group of
mice immunized with MOG peptide were used to generate
CD4+CD44hi effector cells. Our data indicate that disease induced
by memory cells is more severe when compared to that induced by
effector cells. Confocal double-labeling images showed CNS
infiltration of CD4+ memory cells associated with astrocytic
activation and dramatic demyelination as shown by GFAP-positive
cells and SMI32 staining, respectively. Furthermore, sorting of
memory CD4+CD44hi according to the expression of either
CD62L or CCR7 providing central (TCM) or effector (TEM)
memory T cells demonstrated more severe EAE induced by TEM
than TCM associated with increase proliferation and high
production of IFNg in response to MOG peptide in vitro. Co-
stimulatory signal blockade of T cells in this model, demonstrated
that while CTLA4Ig suppressed effector CD4+CD44hi-induced
EAE, it did not significantly inhibit disease induced by memory
CD4+CD44hi cells. By contrast, anti-ICOS-L treatment worsened
effector cell-induced EAE, but inhibited memory cell-induced
disease. Our data suggest the presence of specific mechanisms of
disease mediated by memory CD4+ cells and has relevance to the
treatment of human autoimmune disease by costimulatory signal
blocking agents.
Sa1.17. Therapeutic Effects of Glycosylated B Interferon
(BIFN) on Childhood Adrenoleukodystrophy (ALD
CCER).
G. A. Moviglia,1 A. E. Pereyra,1 G. S. Shuster,2 C. Ruggilo.2
1Immunotherapy, Regina Mater Foundation, Buenos Aires,
Argentina; 2MRI, Medical Image, Buenos Aires, Argentina.
Childhood Cerebral Adrenoleukodystrophy (ALD CCER) is a
genetic disease. Based on some bibliographic research and our own
experience we conjecture that the lesions it causes in the central
nervous system (CNS) are the result of an autoimmune demyeli-
nating reaction resembling the Multiple Sclerosis (MS) inflamma-
tory reaction. bIFN has shown a positive therapeutic action on MS;
for that reason, we developed a clinical trial to test its effect on
ALD CCER. Thirteen boys affected by the disease were divided
into three groups: Group A, 5 patients with a Behavior Perform-
ance Index (BPI) of over 80 points, received bIFN; Group B, 5
patients with a BPI of under 80 points, received bIFN; and Group
C, 3 patients with a BPI of under 80 points, did not receive
medication. The bIFN was supplied by Ares-Serono International.
The dosage schedule was 3 to 6.106 IU of bIFN by intramuscular
injection, at 8 p.m. on three consecutive days every week. The
patients were followed for 24 months via monthly neurological,
psychological and immunological evaluation and by telephone
follow-up thereafter to assess survival and general clinical and
neuropsychological performance. The results of our small clinical
trial strongly suggest that bIFN can change the natural history of
ALD CCER. bIFN improved the clinical conditions of 4 out of 5
patients from the first group for almost three years, and has
maintained these conditions for two of these patients up to the
Abstracts S93present (six years after stopping the bIFN treatment). The treatment
also slowed the evolution of the disease in the second group. MRI,
immunological and psychometric data confirmed these findings,
which support the theory that the interaction of immune cells with
nervous tissue cells plays a crucial role in the CNS repair, as well
as that bIFN may be a therapeutic agent for it.
Sa1.18. Anti-Myelin Antibodies as an
Immune-Modulatory Marker for IVIG Treatment in
Patients with Progressive Multiple Sclerosis.
Sarah B. Kelley, Isaac Melamed, David Barr-Or. 1Immunology, 1st
Immunology and Infusion Center, Englewood, CO, USA;
2Immunology, 1st Immunology and Infusion Center, Englewood,
CO, USA; 3Trauma Research Department, Swedish Medical
Center, Englewood, CO, USA.
Multiple Sclerosis (MS) is the most common Neurological
Autoimmune Disorder diagnosed in young adults and is charac-
terized by the repeated occurrence of demyelinating lesions within
the central nervous system (Pohlau, et al., 1998).
Part of the mechanism of MS is an abnormal production of
auto-antibodies, specifically producing cross-reactive epitopes,
which leads to an auto-immune reaction against myelin.
It is our belief that IVIG can act as a neuro-immune modulator
for patients diagnosed with MS. Current research has demonstrated
that, in relapsing MS, an association exists between high dose
IVIG and reductions in relapse rates, exacerbations and the number
and size of brain lesions, as well as increases in functional
improvements.
A recent study from researchers at the University of California
found that the anti-myelin antibody is found in virtually all patients
with progressive multiple sclerosis (Brown, 2002). We theorize
that the anti-myelin antibody may be used as a marker for the
treatment of patients diagnosed with progressive MS on high dose
IVIG treatment.
In our study, we report on a 43-year-old patient with a
diagnosis of progressive multiple sclerosis; the disease that has
resulted in rapid regression over the past 5 years. The subject
presented to our clinic with a history of countless treatmentTs and
therapies that failed to improve his condition or stall his
regression. An extensive immune work-up revealed extremely
low CD3 and CD8 numbers along with low lymphocyte
stimulation function, an IgG3 subclass deficiency and positive
anti-myelin antibodies; past records indicated the presence of
positive anti-myelin antibodies for over 5 years. Upon completion
of a thorough physical examination and work-up, the patient was
started on high dose IVIG: 2g/kg divided over three consecutive
days. Subsequent testing, conducted after a short period of time,
revealed negative anti-myelin. This patient has now been on IVIG
for three months. As a result of this treatment, he is beginning to
display increased energy, decreased muscle spasticity and improve-
ment in his ability to walk.
Based upon the preliminary data, we suggest that: 1) IVIG may
have an immuno-modulatory effect in MS and 2) anti-myelin AB
may serve as a marker for the immuno-modulation effect.
Sa1.19. T Cell Tolerance Induced by Cross-Reactive
TCR Ligands Can Be Broken by Superagonist Ligand
Resulting in Anti-Inflammatory Cytokine Production.
Z. Illes,1,2 H. Waldner,1 J. Reddy,1 E. Bettelli,1 L. B. Nicholson,1,3
V. K. Kuchroo.1 1Center for Neurologic Diseases, Harvard
Medical School, Brigham and WomenTs Hospital, Boston, MA,USA; 2Department of Neurology, University of Pecs, Pecs,
Hungary; 3School of Medical Sciences, Bristol, United Kingdom.
Cross-reactive activation by high affinity non-self ligands, of
T cells with the potential to recognize self, may be important in
breaking self-tolerance. In a TCR transgenic mouse that shows a
broad cross-reactivity to a number of ligands, we have
previously shown that a hyperstimulating superagonist ligand,
L144 induced unresponsiveness to a self-ligand, proteolipid
protein (PLP) 139-151 peptide. In a further examination of the
role of cross-reactive superagonists in an autoimmune response,
we demonstrate here that a superagonist ligand can break
tolerance induced by the lower affinity cognate antigen. In our
proposed balteredQ hierarchical anergy model, T cells tolerant to
cognate ligand, Q144, responded to superagonist, L144 by
proliferation and the production of mainly IL-4 and IL-10 in
vitro. In contrast, T cells that were tolerized to the superagonist,
were unable to respond to any peptide that cross-reacted with
the transgenic TCR. In vivo, low-dose immunization with
superagonist was able to break tolerance to the cognate ligand,
and resulted in a blunted proliferative response and Th2
cytokine production following a re-challenge in vitro. A
combination of different T cell responses may thus provide a
multilevel defense against autoimmunity during a T cell response
against cross-reactive high-affinity foreign antigens, and may
serve as an important regulatory mechanism to prevent auto-
immune disease.
Sa1.20. Agonistic Anti-CTLA4 Antibody Inhibits T Cells
Expansion, Cytokine Production and Development of
Autoimmunity.
K. Miyamoto,1,3 L. Vijayakrishnan,1 E. Greenfield,1 B. Carreno,1
A. Sharpe,2 V. Kuchroo.1 1Center for Neurolosic Diseases, BWH,
Harvard Medical School, Boston, MA, USA; 2Pathology, BWH,
Harvard Medical School, Boston, MA, USA; 3Neurology, Kinki
University, Osaka-Sayama, Osaka, Japan.
We generated a novel agonistic anti-CTLA4 monoclonal
antibody, by immunizing Lou/M rats with the CTLA4Ig fusion
protein and screened the hybriboma supernatants for binding to
CTLA4 in ELISA and CHO expressing CTLA4 on their surface.
Of the three antibodies thus generated, one antibody 3C1.B5 was
agonistic in that inhibited T cell expansion and IFNg secretion in
vitro and in vivo. This contrasts with the previously described
anti-CTLA4 antibody 4F10, which promotes T cell clonal
expansion and IFNg secretion presumably by blocking the
inhibitory signal delivered by CTLA4. We compared the effects
of both anti-CTLA4 antibodies in murine relapsing remitting
autoimmune disease experimental autoimmune encephalomyelitis
(EAE), a demyelinating disease mediated by PLP139-151 specific
CD4+ T cells in SJL /J mice. Whereas, administration of the 4F10
antibody in vivo exacerbated EAE, the agonsitic anti-CTLA4
antibody 3C1.B5 ameliorated disease. To understand the molecular
basis for the difference in the functional effects of the two antibodies,
we undertook epitope mapping and binding studies. We demonstate
that the Tyrosine residue in the MYPPPY domain of the CTLA4
utilized for binding by the B7 molecules, is also crucial for binding
of the blocking anti-CTLA4 (4F10) antibody but not for the
agonistic anti-CTLA4 antibody (3C1.B5). Cross-blocking studies
show that the agonistic anti-CTLA4 antibody recognizes a closely
related but distinct epitope on the CTLA4molecule. Thus binding of
the two anti-CTLA4 antibodies to a closely related but distinct
epitopes gives distinct functional T cell responses.
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in Iranian Patients with Multiple Sclerosis.
M. Izad,1 A. A. Amirzargar,1 D. Fathi,2 M. H. Niknam,1 M.
Vodjgani.1 1Dep.of Immunology, Faculty of Medicine, Tehran
University of Medical Sciences, Tehran, Islamic Republic of Iran;
2Dep. of Neurology, Shariati Hospital, Tehran University of
Medical Sciences, Tehran, Islamic Republic of Iran.
Tumor necrosis factor-a (TNF- a) as an important immune
regulator and inflammatory cytokine is implicated in the patho-
genesis of multiple sclerosis (MS). A single nucleotide poly-
morphism, G to A, at position 308 in the promoter has been
previously shown. This polymorphism is associated with TNF- a
production level. To study the effect of this polymorphism on
susceptibility to multiple sclerosis, we screened genomic DNA
samples from 98 definite MS patients and 97 unaffected ethnically
matched individuals as healthy controls, using sequence-specific
primers (PCR-SSP). The results indicated that the frequency of GG
genotype (related to low production of TNF- a) was significantly
increased in MS patients compared to controls while the frequency
of GA and AA genotypes (related to high production of TNF- a)
decreased (df = 2, P = 0.04). Our findings suggest that
polymorphism at position 308 and production levels of TNF- a
could influence susceptibility to MS.
Sa1.22. Corticotropin-Releasing Hormone Contributes
to the Peripheral Inflammatory Response in
Experimental Autoimmune Encephalomyelitis.
Y. Wang,1 C. Benou,1 J. Imitola,1 L. VanVlerken,2 C. Chandras,2
K. P. Karalis,2 S. J. Khoury.1 1Center for Neurologic Diseases,
Brigham and WomenTs Hospital and Harvard Medical School,
Boston, MA, USA; 2Division of Endocrinology, ChildrenTs
Hospital and Harvard Medical School, Boston, MA, USA.
Corticotropin-releasing hormone (CRH), a hypothalamic neuro-
peptide, is thought to have peripheral pro-inflammatory effects
outside the central nervous system. Studies have shown that T
lymphocyte can produce CRH, and CRH binding site presents on
macrophages and lymphocytes. Upregulation of CRH peptide
production has been shown in peripheral sites with acute or chronic
inflammation. Our objective was to study the peripheral role of
CRH on T lymphocyte and antigen-presenting cell (APC)
activation in an immune mediated disease model of experimental
autoimmune encephalomyelitis (EAE). Material and Method:
Crh-/- mice on a C57BL/6  129 genetic background were
immunized with MOG 35-55 peptide together with complete
FreundTs adjuvant and pertussis toxin. The severity of EAE was
scored on the scale of 0-5 as described previously. To eliminate the
anti-inflammatory effect of corticosterone, astressin, a peripheral
CRH antagonist with no glucocorticoid inhibition effect was given
to wild-type mice on day 11-16 post immunization. In comparison
between crh-/- and crh+/+ T cells, T cell proliferation assay and the
ELISA assay of cytokine production were conducted on either
naRve CD4+ T cells with anti-CD3/anti-CD28 TCR stimulation or
MOG-specific CD4+ T cells from immunized mice in response to
g-irradiated MOG-loaded APC stimulation. The antigen presenta-
tion function was examined by MOG-specific wild-type T cell
proliferation in response to MOG-loaded crh-/- or crh+/+ APCs.
Anti-CD3/anti-CD28 stimulated InBa phosphorylation in crh-/-
splenocytes was tested by western blot analysis. Result: We found
that crh-/- mice as well as astressin treated wild-type mice are
resistant to EAE with decrease in clinical score as well as
decreased cellular infiltration in the central nervous system.Furthermore, antigen-specific responses of primed T cells as well
as anti-CD3/anti-CD28 TCR costimulation response of naRve T
cells were decreased in crh-/- mice with decreased production of
Th1 cytokines, IFN-g and IL-2 and increased production of Th2
cytokine IL-5. Wild-type mice treated in vivo with a CRH
antagonist astressin showed a decrease in IFN-g production by
primed T cells in vitro. This effect of CRH is independent of its
ability to increase corticosterone production, since adrenalectom-
ized wild-type mice had similar disease course and severity as
control mice. Furthermore, a decreased antigen-specific T cell
response was observed in wild-type MOG-specific T cells when
incubated with MOG-loaded crh-/- APCs compared with MOG-
loaded crh+/+ APCs. We found that InBa phosphorylation induced
by TCR cross-linking was delayed and compromised in crh-/-
T cells. Conclusions: Peripheral CRH exerts a pro-inflammatory
effect in EAE with selective increase in Th1-type responses. This
effect CRH is likely the result of optimal activation of T cells
through activation of NF-nB pathway.
Sa1.23. Individual Statins Differ in Immunomodulatory
Potential and Capability To Treat Th1-Mediated CNS
Autoimmune Disease.
M. J. Goldstein,1 M. S. Weber,2 S. E. Dunn,1 T. ProdThomme,2 L.
Steinman,1 S. S. Zamvil,2 S. Youssef.1 1Neurology, Stanford
University, Stanford, CA, USA; 2Neurology, University of
California, San Francisco, CA, USA.
Rationale: Oral HMG-CoA reductase inhibitors differ in their
ability to treat hypercholesterolemia. Recent studies have shown
that certain statins can promote a Th2 bias and prevent or reverse
relapsing and chronic paralysis in experimental autoimmune
encephalomyelitis (EAE). However, it is not clear whether some
statins are more effective than others in treating this autoimmune
disease. Furthermore, some studies have shown purified statin
administered either orally or parenterally (i.p.) can also have
immunomodulatory effects. In this study we examined whether
statins differ in their ability to modulate autoimmunity in EAE. We
further investigated whether differences in formulation (prescrip-
tion vs. purified) and route of administration (oral vs. parenteral)
effect treatment and the development of Th2 bias.
Methods: Relapsing-remitting EAE was induced in (PL/J 
SJL/J) F1 mice by immunization with MBP Ac1-11. Prescription
formulation of atorvastatin, rosuvastatin, lovastatin, simvastatin,
pravastatin, and placebo was administered orally in PBS vehicle
one time daily. Prescription form was administered at one and ten
times the equivalent of the highest-approved, human dose. Purified
atorvastatin was administered orally or parenterally. Th1 and Th2
cytokine profiles of T cells isolated from treated mice were
evaluated by ELISA. Phosphorylation of STAT signaling mole-
cules was measured by Western blot.
Results: Control and placebo-treated mice developed EAE with
similar incidence and severity. While all statins tested ameliorated
EAE, atorvastatin and rosuvastatin were the most effective when
administered orally in prescription formulation. All statins
inhibited antigen-specific proliferation, secretion of Th1 cytokines
and IL-12-dependent STAT4 phosphorylation. Atorvastatin and
rosuvastatin induced Th2 cytokines, which was associated with
increased phosphorylation of STAT6. Immunodulatory effects were
reversed by treatment with L-mevalonate. The route of admin-
istration was tested using prescription and purified atorvastatin.
Orally administered prescription atorvastatin was superior to
purified atorvastatin administered either parenterally or orally.
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EAE progression, although individual statins appear to vary in the
strength of their immunomodulatory effects and only some statins
induce a Th2 bias. Atorvastatin and rosuvastatin, the most potent of
the statins in lowering cholesterol, are the most robust in both
amelioration of EAE as well as induction of a Th2 T cell
phenotype, which likely reflects differences in enzymatic binding
efficiency, half-life, and lipophobicity. Drug formulation and route
of administration are important factors in determining in vivo
immunomodulation by atorvastatin. This study highlights the
importance of selecting the type of statin for testing in treatment
of multiple sclerosis and other autoimmune diseases.
Sa1.24. FMRI Correlates of Strategic Planning in
Multiple Sclerosis.
J. J. Randolph,1 H. A. Wishart,1 R. M. Roth,1 B. C. McDonald,1 J.
W. MacDonald,1 J. D. West,1 N. S. Koven,1 A. C. Mamourian,2 L.
H. Kasper,3 A. J. Saykin.1 1Department of Psychiatry, Dartmouth
Medical School, Lebanon, NH, USA; 2Department of Radiology,
Dartmouth Medical School, Lebanon, NH, USA; 3Section of
Neurology, Dartmouth Medical School, Lebanon, NH, USA.
Recent work using functional magnetic resonance imaging
(fMRI) indicates that patients with multiple sclerosis (MS) show
altered brain activation on motor and cognitive tasks relative to
controls. However, few studies have examined MS patientsT brain
activation patterns on fMRI probes of executive cognitive
functioning. The present study used a modified version of the
Tower of London task to examine potential alterations in the neural
circuitry of strategic planning in MS. Six MS patients and four
healthy controls were administered an fMRI Tower of London task,
which included easy (2–3 move solution), hard (4–5 move
solution), and control conditions. The hard greater than easy
contrast was of particular interest in our analyses. fMRI data were
obtained on a 1.5T GE scanner. Data were analyzed using a
random effects model in SPM99. While both MS participants and
controls activated predicted regions during task performance,
including right dorsolateral prefrontal cortex, MS patients showed
increased anterior right hemispheric activity relative to controls
(P b .01, k=3). In contrast, controls tended to show more posterior
right hemispheric activation than patients (P b .01, k=3).
Behaviorally, controls tended to perform better than patients across
task conditions. These preliminary findings support previous
reports of altered brain activation patterns associated with cognition
in MS. Our group and others are engaged in longitudinal research to
determine the relationship between changes in neural activity and
cognitive task performance, and to examine the potential utility of
fMRI for tracking progression of brain changes associated with
cognitive decline in MS.
Sa1.25. A New Clinically Relevant Approach To Expand
Myelin Specific T Cells.
Nathalie Arbour,1 Rejean Lapointe,2 Philippe Saikali,1 Jack P.
Antel.1 1Neuroimmunology Unit, Montreal Neurological Institute
McGill University, Montreal, QC, Canada; 2Department of
Medicine, Faculty of Medicine, University of Montreal (Hospital
Centre Notre-Dame), Montreal, QC, Canada.
Intro: Human self-reactive T cells are postulated to play an
important role in many autoimmune diseases. Although detection
of self-reactive T cells directly ex-vivo has been achieved, in-depth
functional characterization of these cells is impeded by their low
precursor frequency. Hence, researchers have expanded self-reactive T cells in vitro in order to characterize and compare these
cells from autoimmune patients and controls. Antigen specific T
cells need to be re-stimulated on a regular basis with new antigen
presenting cells (APCs) and antigen (Ag). This has been usually
achieved by using autologous fresh or frozen irradiated peripheral
blood mononuclear cells (PBMCs) or EBV-immortalized B cells or
dendritic cells in the presence of Ag. This approach requires either
one large blood sample from which cells are frozen for later use or
repetitive blood draws. Evaluation of self-reactive T cells from
many donors is thus hindered by the large volume of blood
necessary. We explored a method successfully applied for tumor
antigens to present myelin antigen to T cells using in vitro
expanded autologous B cells (Lapointe et al. 2003).
Our goal is to assess the feasibility of expanding human myelin
specific T cells from one small blood draw.
Methods: Myelin specific Tcells were expanded from 50–75 ml
of blood. PBMCs were put in culture with myelin basic protein
(MBP) or myelin oligodendrocyte glycoprotein (MOG) peptide. A
week after the first round of stimulation T cells were separated into
CD8+ and CD4+ using beads (Miltenyi) prior to be re-stimulated. In
parallel, a fraction of donorTs PBMCs was stimulated with irradiated
CD40L-expressing fibroblasts in the presence of IL-4; B cells
proliferated and after few rounds of stimulation were the only cell
type in the culture and expressed high levels of MHCmolecules and
co-stimulatory molecules, essential hallmarks of efficient APCs.
Expanded B cells were loaded with Ag, irradiated and then used as
APC to stimulate T cells for multiple subsequent rounds of
stimulation. CD4+ T cell lines were re-stimulated every 10–14 days
and CD8+ Tcell lines every 7–9 days. Proliferation was measured by
thymidine incorporation and cytokine release by ELISA.
Results: At the second or third round of stimulation T cells
were tested for their specificity by comparing their proliferation
and IFN-g secretion in the supernatant when put in cultured with
Ag-loaded B cells vs. unloaded B cells. T cell lines exhibiting Ag-
specific proliferation and/or IFNg secretion at least two times
higher than in the absence of Ag were considered Ag-specific and
were expanded further. MBP and MOG specific CD4+ and CD8+ T
cell lines were obtained from multiple donors in comparable
number than those obtained with a traditional approach (fresh
PBMCs) and kept in culture for many weeks.
Conclusion: Human myelin specific T cell lines both CD4+ and
CD8+ can be expanded in vitro from a relatively small blood
sample facilitating immunological studies of such cells in multiple
donors.
Sa1.26. IL-15 and IL-2 Fusion Proteins Attenuate
Experimental Autoimmune Encephalomyelitis.
C. Gutierrez,1 T. Chitnis,1 M. H. Sayegh,2 X. X. Zheng,3 S. J.
Khoury. 1Center for Neurologic Diseases, Brigham and WomenTs
Hospital, Boston, MA, USA; 2Transplantation Center, Brigham
and WomenTs Hospital and ChildrenTs Hospital, Boston, MA, USA;
3Immunology, Beth Israel Deaconess Medical Center, Boston, MA,
USA.
Objective:To investigate the effect of therapy with IL-15Fc and
IL-2Fc fusion proteins on experimental autoimmune encephalo-
myelitis(EAE). Background: Peripheral T cell activation and their
migration into the central nervous system(CNS) are involved in the
pathogenesis of EAE.Targeting the IL-2 receptor, which shares the
gand h portions with the IL-15R, suppresses immune respon-
ses.The IL-15Ra chain is specific for IL-15, and is expressed on
CD8+, natural killers, macrophages,endothelial cells and tissues
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induce protection in EAE: IL-2Fc that binds to activated T cells and
induces cytolysis, and IL-15Fc that binds to the IL-15Ra.
Methods: C57BL/6 mice were immunized with MOGp35-55 in
CFA to induce EAE. Daily i.p injections of either IL-2Fc (5ug/
dose), IL-15Fc (5ug/dose), IL-2Fc+IL-15Fc or control IgG2 were
given for 10 days, starting either on day 0 or on day 10
postimmunization, to target the priming or effector stages of
disease, respectively. Outcomes measured included clinical disease,
cell proliferation measured by thymidine incorporation, cytokine
profiles measured by ELISPOT assays, and immunohistological
staining of the CNS at day 15, 30 and 40 post immunization.
Results: Early treatment with the combination fusion proteins
decreased disease severity(MMG 0.6; pb0.0001) and incidence(P =
0.01)significantly compared to the control Ig group (MMG=2.4).
Injection of IL-15Fc alone also attenuated disease(MMG 1.0;
Pb0.0001) while IL-2Fc(MMG = 2.1) showed no disease attenu-
ation. Treatment with any of the infusion proteins induced a high
background proliferation of splenocytes; but MOG peptide-specific
proliferation was suppressed in splenocytes from IL-15Fc(P =
0.002) as well as combination therapy (Pb0.0001) treated mice.
Protected mice showed an increase in MOG-specific IL-4 produc-
tion when compared to the control group (Pb 0.03). Staining for
inflammatory cells in the CNS showed a decrease in CD4+ and
macrophage infiltrates in the protected groups, particularly in those
receiving combination therapy. These scarce infiltrates were
positive for IL-4 and IL-10. In contrast, IFNg was highly expressed
in the CNS of control mice as well as those treated with IL-2Fc
alone. Injection of any of these fusion proteins during the effector
stage of the disease (d10-20) did not show any protection.
Conclusions: These results suggest that blocking the specific IL-
15Ra is protective in EAE and is more effective when combined
with the cytolytic effect of IL-2Fc fusion protein. Protection is
associated with an increase in Th2 cytokines both in the periphery
and the CNS. The additive effect of combination therapy may be
due to the cytolytic effect of IL-2Fc on MOG-specific T cells, and
decreased cell migration into the CNS mediated by IL-15 blockade.
Further studies need to be done in order to fully understand the
mechanisms by which these molecules protect in EAE.
Sa1.27. Dendritic Cells from the Mesenteric Lymph
Nodes of OVA Fed Animals Stimulate NaRve T Cells In
Vitro To Express Latency-Associated Peptide.
Kaiyong Yang,1 Ana Faria,2 Howard L. Weiner.1 1Center for
Neurologic Diseases, Brigham and WomenTs Hospital, Boston,
MA, USA; 2Departamento de Bioquimica e Imunologia,
Universidade Federal de Minas Gerais, Brazil.
Oral exposure of soluble antigens leads to the induction of
systemic hyporesponses, a phenomenon known as oral tolerance.
In this study, we isolated dentritic cells (DCs) from the PeyerTs
Patches (PPs), mesenteric lymph nodes (MLNs) and spleens of fed
mice and measured their ability to support CD4+ T cell
proliferation, cytokine production and differentiation. We found
that the ability of DCs to support T cell proliferation appeared in
PPs first, followed by MLNs and spleen. Moreover, PP DCs
promoted significant increases of Th1 cytokines (IL-2, IFNg and
TNFa) but no increases of Th2 cytokines (IL-4 and IL-5).
However, MLN DCs promoted significant increases of both Th1
and Th2 cytokines. Although DCs from all these lymphoid tissues
were able to induce naRve T cells to express surface TGFb, as
determined by the up-regulation of latency-associated peptide(LAP+), MLN DCs were the most efficient. At their peak time
(~12hrs after last feeding), MLN DCs induced a ~5-fold increase of
CD4+LAP+ cells. These studies demonstrate that MLN DCs
acquire fed antigens and induce the expansion of CD4+LAP+ T
cells in situ which then may participate in specific tolerance to fed
antigens and regulation of autoimmune processes associated with
oral tolerance to autoantigens.
Sa1.28. Immature Dendritic Cells Can Reduce
Experimental Autoimmune Encephalomyelitis in the
Mouse.
M. I. Iruretagoyena,1 S. E. Sepulveda,1 A. M. Kalergis.1
1Departamento de Genetica Molecular y Microbiologia, Pontificia
Universidad Catolica de Chile, Santiago, Chile.
Multiple Sclerosis (MS) is a chronic autoimmune disorder that
affects the central nervous system. Although the aetiology of the
progressive neurological loss has not yet been fully elucidated, it is
believed that genetically determined susceptibility and environ-
mental triggers are both implicated in the detrimental immune
response against components of the myelin sheath, where myelin-
specific T cells are thought to play a central role. As an animal
model for this disease, Experimental Autoimmune Encephalomye-
litis (EAE) can be induced in C57BL/6 mice. EAE is an
inflammatory demyelinating disease that is primarily mediated by
CD4+ T cells and shares most of the clinical and histopathological
aspects of MS. Due that dendritic cells (DCs) are professional
antigen presenting cells important for the activation of self-reactive
T cells, we are interested in evaluating their therapeutic potential in
the regulation of autoimmune responses. DCs have a central role in
maintaining peripheral tolerance to self and alterations in their
physiology are likely to be responsible for defective immune
regulatory mechanisms. We first observed that immature DCs are
able to promote tolerance in the EAE model. To further enhance
the tolerogenic capacity of these cells, we used drugs that interfere
with NFkB activity, such as andrographolide, a bicyclic diterpe-
noid lactone and Rosiglitazone, a PPARg agonist. In vitro, these
molecules were able to interfere with DCs maturation and with
their ability to present antigens to T cells. T cell activation by DCs
was completely abolished by exposing DCs to andrographolide
and Rosiglitazone during antigen pulse. Injections of immature
DCs treated with either andrographolide or Rosiglitazone showed
an enhanced capacity to reduce EAE symptoms. Our results
indicate that injection of immature DCs can prevent myelin-
specific T cells activation in EAE. These data suggest that
pharmacological approaches that promote a tolerogenic phenotype
in DCs could be useful as a potential strategy in the design of new
therapies to prevent or treat detrimental immune responses.
Sa1.29. CD4+CD25+ Regulatory T Cells Mediate
Recovery from Experimental Autoimmune
Encephalomyelitis in Association with LAP+
TGF-B Secreting Cells.
H. Ochi,1,2 X. Zhang,1,2 J. Reddy,1 D. Frenkel,1 V. K. Kuchroo,1
H. L. Weiner.1 1Center for Neurologic Diseases, Department of
Neurology, Brigham and WomenTs Hospital, Harvard Medical
School, Boston, MA, USA; 2Contributed Equally.
In SJL/J mice, PLP139-151 is the immunodominant ence-
phalitogenic epitope and induces a relapsing-remitting form of
EAE. It has been reported that CD4+CD25+ regulatory cells
play a role in affecting the onset and progression of EAE, as
transfer of CD4+CD25+ cells at these stages ameliorate disease.
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recovery from disease has not been well defined. Here we show
that EAE-recovered SJL/J mice have an increase number of
Forkhead box P3 (Foxp3)-expressing CD4+CD25+ T cells.
These cells were anergic and inhibited the proliferative response
of CD4+CD25- T cells against PLP139-151 or anti-CD3
stimulation. Depletion of CD4+CD25+ T cells prior to the
recovery phase exacerbated disease, resulted in the expansion of
IAs/PLP139-151-tetramer-positive cells and enhanced IFN-g
production. In addition, transforming growth factor (TGF-h)
was shown to be involved in the recovery from EAE as the
percentage of CD4+CD25+ cells expressing TGF-h latency
associated peptide (LAP) on the cell surface increased
significantly in blood and spleen of EAE-recovered mice as
compared to the naRve mice (P b 0.001 and P b 0.01,
respectively) and in vivo neutralization of TGF-h abolished
recovery from disease. Our results demonstrate that
CD4+CD25+ regulatory cells mediate recovery from PLP139-
151-induced EAE in SJL/J mice in which TGF-h plays an
important role.
Sa1.30. Genetic Markers of Disease Risk, Prognosis and
Treatment Response in Multiple Sclerosis.
A. Foti,1 D. Lichter,1 J. Parekh,1 J. Bryce,3 G. Ginsburg,1
J. Lekstrom-Himes,1 D. Hafler,2 P. DeJaeger,2 R. Roubenoff,1
S. Khoury,2 H. Weiner,2 A. Parker.1 1Department of Molecular
Medicine, Millennium Pharmaceuticals, Inc., Cambridge, MA,
USA; 2Department of Neurology, Harvard Medical School,
Boston, MA, USA; 3Department of Clinical Operations,
Millennium Pharmaceuticals, Inc., Cambridge, MA, USA.
Multiple Sclerosis (MS) is a multifactorial, polygenic disease
that manifests itself as a chronic inflammation of the CNS. In
addition to influencing the presence or absence of disease, genetics
may also play a significant role in individual variations in
prognosis and differential response to therapy among patients.
In order to better understand the genetic variation involved in
these heterogeneous aspects of the disease we selected 43 SNPs
from 22 genes that were associated with risk or severity of MS in at
least one published study. These loci were genotyped using DNA
from a large MS patient registry which was established as a
longitudinal study aimed at finding biomarkers of disease risk,
prognosis and response to therapy.
Our case-control association analysis utilized 190 patients
enrolled to date and an ethnically-matched cohort of healthy
controls (n = 363). The DR15 allele of the HLA-DRB1 locus
associated very strongly with presence of disease (P = 0.000004,
OR=2.439, CI95=1.671-3.561), as did VDR (P = 0.001, OR=1.845,
CI95=1.271-2.680), PTPRC (P = 0.009, OR=1.594, CI95=1.099-
2.311), TNFRSF6 (P = 0.002, OR=1.778, CI95=1.236-2.557),
SH2D2A (P = 0.00005, OR=15.937, CI95=2.719-93.099) and
CNTF (P = 0.007, OR=1.728, CI95=1.141-2.616).
When we compared patients with benign vs. malignant disease
course (n = 37 vs. 27) we observed an association of MBP with
disease prognosis (p=0.003, OR=5.319, CI95=1.727-16.393). Para-
doxically, the DR15 allele also associated with the presence of
benign disease (P = 0.004, OR=5.447, CI95=1.628-17.945); it is
therefore a risk factor, while at the same time providing a better
prognosis.
A comparison of responders vs. non-responders to beta-
interferon or glatiramer acetate therapy (n = 38 vs. 28) showed a
significant association of IL1B with response (Pb0.1, OR=5.182,CI95=1.821-14.747). Linear regression analysis of genotypic
association with age of onset revealed a potential involvement of
TNFSF6 (P = 0.002).
All analyses were controlled for gender. Among several
markers that exhibited significant sex-specific associations, TNF
was associated with malignant disease only in female patients
(P = 0.01), and TNFSF10 was significantly associated with risk of
disease in males (P = 0.0016).
These results illustrate the complex genetic etiology of MS,
which involves a variety of sometimes gender-specific factors
combining to influence not only the presence but the progression of
the disease. These markers may eventually improve our under-
standing of the disease and provide better clinical and diagnostic
indicators of disease risk and prognosis.
Sa1.31. Investigating Anti Human MOG Antibodies in
Multiple Sclerosis Using Stably MOG Transduced Cell
Lines.
Rajneesh Srivastava,1 Dun Zhou,1 Stefan Nessler,1 Sabine
Cepok,1 Hans-Peter Hartung,1 Bernhard Hemmer.1 1Department
of Neurology, Heinrich-Heine-University Dusseldorf, Dusseldorf,
NRW, Germany.
Multiple Sclerosis (MS) is a chronic inflammatory disease of
the central nervous system (CNS). Although the cause of MS is
still uncertain, an ongoing autoimmune response against myelin
antigens seems most likely. Myelin Oligodendrocyte Glycoprotein
(MOG) is considered the most promising candidate autoantigen in
MS. MOG induces experimental autoimmune encephalomyelitis in
several rat and mouse strains. Recent findings in MS suggest that
the development of antibodies against MOG is associated with
progression of disease during early MS. However, studies in
humans and animal models are based on a fragment of the MOG
protein expressed in E. coli. To achieve physiological MOG
expression with proper glycosylation, we cloned the human MOG
isoform 2 gene in a lentiviral expression vector. We transduced
primary cells and several human and murine tumor cell lines.
Transduced cell lines expressed high levels of MOG on the surface.
Stable expression was achieved in murine lymphoma and several
human glioma cell lines. These transgenic lines allowed fast and
reliable detection of anti-MOG antibodies at lower nanogram
concentration comparable with the sensitivity of ELISA assays.
Further studies are ongoing to determine anti-MOG antibodies in
MS patients and controls to obtain further insights into the role of
anti-MOG antibodies in multiple sclerosis.
Sa1.32. Role of CD46 in Multiple Sclerosis.
A. L. Astier,1 D. A. Hafler.1 1Center for Neurologic Diseases,
Brigham and WomenTs Hospital, Boston, MA, USA.
CD46 acts as a costimulatory molecule for human T cells and
coligation with CD3 promotes T cell proliferation. Furthermore,
addition of IL-2 induces a Tr1 phenotype, characterized by a large
production of the regulatory cytokine IL-10. However, in a murine
transgenic model, the two intracytoplasmic isoforms of CD46
(Cyt1 and Cyt2) that are produced by alternative splicing, have
antagonist roles in an in vivo T cell-mediated inflammation. While
Cyt1 decreases the inflammation, Cyt2 increases it. This difference
has been linked to their differential effects on CD4+ T cell
proliferation, CD8+ CTL cytotoxicity, as well as IL-2 and IL-10
production. Hence, CD46 is a crucial regulator of T cell activation,
and depending on the ratio of the intracytoplasmic isoforms
present, a different outcome in T cell activation might result in
AbstractsS98humans. As multiple sclerosis (MS) is an autoimmune disease with
a direct involvement of T cells, we investigated the role of CD46 in
MS. While as previously described, IL-10 could be induced upon
CD46 stimulation in healthy donors (5/5), T cells from most
patients with MS did not produce IL-10 or to a much lesser extend
(8/11). We then investigated the ratio of the two intracytoplasmic
isoforms of CD46 in T cells of patients with MS as compared to
healthy donors. Interestingly, we found that upon CD46 costimu-
lation the Cyt1/Cyt2 ratio is altered in MS patients when compared
to healthy individuals, which might correlate with the lack of IL-10
secretion observed upon CD46 stimulation. These preliminary data
suggest that a dysregulation of CD46 activation in human T cells
may be involved in MS etiology.
Sa1.33. Myelin-Specific Cytokine Responses Show a
Dramatic Gender Bias in Multiple Sclerosis (MS).
I. M. Moldovan,1 A. C. Cotleur,1 N. Zamor,1 J.-C. Lee,3 R. A.
Rudick,2 C. M. Pelfrey.1 1Neurosciences, NC30, Cleveland Clinic
Foundation, Cleveland, OH, USA; 2Mellen Center for MS
Treatment and Research, Cleveland Clinic Foundation, Cleveland,
OH, USA; 3Biostatistics, Cleveland Clinic Foundation, Cleveland,
OH, USA.
Most autoimmune diseases disproportionately affect women.
Unfortunately, most animal models and in vitro studies show that
steroid hormones (estrogens and androgens) are suppressive for
autoreactive responses. This raises the question: what is the
evidence for a heightened autoimmune response in women that
would help explain their increased susceptibility to autoimmune
disease? To address this question, we examined sex differences in
antigen-induced cytokine-secreting cells between untreated relaps-
ing-remitting multiple sclerosis (RRMS) patients and controls. We
studied Th1 (IFNg and TNFa) and Th2 (IL-5 and IL-10) cytokine
responses to MS-relevant epitopes of myelin (MBP, PLP, MOG) as
well as irrelevant epitopes. We observed significant female
skewing (P V 0.005) in the IFNg response to 3 PLP peptides:
PLP 40-60, 103-120, 195-206. PLP 40-60 and 195-206 showed a
simultaneous male skewing (PV0.007) in IL-5 responses. For PLP
40-60, this resulted in a IFNg/IL-5 ratio of 174.4 in MS females,
whereas the MS male IFNg/IL-5 ratio was only 0.3. Similarly, for
PLP 195-206, the MS female IFNg/IL-5 ratio was 26.8, and the
MS male ratio was 1.7. MBP responses also showed strong gender
interactions: MS females had very strong MBP-IFNg responses
and virtually no MBP IL-5 response (P = 0.004) while the reverse
was true for MS males: high IL-5 and extremely low IFNg
responses (P = 0.0023). For MBP, this gave an IFNg/IL-5 ratio of
77.4 in MS females compared to a ratio of 0.8 in MS males. For
MOG 64-96, MS females gave an IFNg/IL-5 ratio of 82.9, whereas
MS males gave a ratio of 1.0. In contrast, mitogen-stimulation gave
IFNg/IL-5 ratios with less than a 2 fold difference between MS
females and MS males. Control females showed slightly elevated
IFNg responses compared to control males, however, IFNg/IL-5
ratios were b9. These results show that MS-relevant myelin
proteins can induce female MS patientsT lymphocytes to secrete
inflammatory cytokines, whereas the very same myelin epitopes
induce males to secrete anti-inflammatory cytokines. These
interactions suggest that disease and gender are not independent
factors in the immune response, but rather they interact to promote
gender bias in cytokine responses that may explain why women are
more susceptible to MS. A gender bias in cytokine responses could
have implications for designing clinical trials involving antigen-
specific therapies in MS.Supported by the National MS Society grants FA 1459-A-1 and
RG 3263-A-3, and NIH grant RO1 NS 41972.
Sa1.34. Intrathymic Expression of Torpedo
Acetylcholine Receptor Alpha Subunit.
D. Song,1 Y. Zheng,1 A. I. Levinson.1 1Allergy/Immunology
Section, University of Pennsylvania School of Medicine,
Philadelphia, PA, USA.
We have developed an approach to test a new hypothesis of
the intrathymic pathogenesis of myasthenia gravis. The hypoth-
esis posits that acetylcholine receptor alpha subunit (AChRa)-
specific CD4+ T cells, which escape central deletion, migrate to
the thymus where, during the course of a nonspecific inflamma-
tory reaction, they are activated by intrathymically expressed
autoantigen. This approach entails expressing Torpedo AChRa
(T-AChRa) as a neo-self-antigen in the thymus of adult C57Bl/6
(B6) mice. B6 AChRa CD4+ T cells see an immunodominant T-
AChRa peptide that does not cross-react with mouse AChRa.
Thus, this epitope can only be encountered in the B6 mouse
thymus if we express T-AChRa there. However, it is widely
regarded that 1) membrane expression of AChRs requires the
proper assembly and folding of constituent subunits and 2) T-
AChR subunits are assembled and expressed only at below 268C.
We reasoned that even though T-AChRa would not assemble
with mouse subunits at 37 C, it was possible that a small amount
of T-AChRa could be expressed on the surface of mammalian
cells in vivo at murine body temperature. We transiently
transfected the tsA201cell line with Ta/pRBG4, a mammalian
vector that expresses T-AChRa cDNA. In additional experiments,
tsA201 cells were transfected with either 1) mouse AChRa
alone, 2) T-AChRa + mouse AChRh, AChRy, and AChRe, or 3)
mouse AChR a + mouse AChRh, AChRy, and AChRe (positive
control). Expression of AChRa protein was investigated by flow
cytometry using mAB 210, a rat IgG mAB that sees an epitope
on the extracellular domain of Torpedo as well as mammalian
AChRa, followed by FITC-goat anti-rat IgG antibody to detect
expression of the of the transfected protein. We also used FITC-
a-bungarotoxin as an independent marker for detecting the alpha
subunit. Mock-transfected cells served as negative controls. We
observed 1) a low, albeit statistically significant, number of viable
cells that had surface staining of mAB 210 after transfection with
only mouse AChRa relative to mock transfected cells, 2) a
similar magnitude of T-AChRa expression on cells transfected
only with T-AChRa, 3) no augmentation of T-AChRa expression
when the mouse AChRh, AChRy, and AChRe subunits were co-
transfected and 4) many of the positive control cells (transfected
with murine AChR a, h, y, and e subunits) expressing mouse
AChRa. Transfected cells that were permeabilized by treatment
with saponin/paraformaldehyde expressed considerable amounts
of T-AChRa intracellularly. Thus, despite the temperature
requirements unique to the assembly of T-AChR subunits and
their membrane expression, a small amount of T-AChRa, like
mouse AChRa, can be transported to the cell membrane where it
is expressed as a single entity. A greater amount of the
unassembled T-AChRa or mouse AChRa subunits was detected
intracyoplasmically. These results indicate that unassembled T-
AChRa can indeed be expressed on/in mammalian cells in vivo.
They lay the groundwork for determining whether T-AChRa-
specific B6 CD4+ T cells can be activated when they encounter
their cognate autoantigen in the thymus in a context that
promotes activation.
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Reactive CD8+ T Cell Lines Derived from MS Patients
and Healthy Volunteers.
A. Dressel,1 A. Vogelgesang,1 S. Peters,1 F. Weber.2 1Department
of Neurology, University Greifswald, Greifswald, Germany;
2Section of Neurology, Max-Planck-Institute of Psychiatry,
Munich, Germany.
Background: Multiple Sclerosis (MS) is the most frequent
disabling neurological disease in young adults. Glatiramer Acetate
(GA) is a synthetic amino acid copolymer that has been shown to
reduce the relapse rate in patients with relapsing-remitting MS. The
proposed mechanism of action of GA is functional suppression of
autoreactive T cells specific for myelin antigens. GA reactive
CD4+ T-cells have been generated from MS- patients and controls
by us and others. As CD8+ T cells may be involved in the
pathogenesis of MS, we established an experimental system to
generate human, GA reactive CD8+ T- cell lines and clones, which
demonstrated an antigen specific, dose dependent proliferation und
IFN gamma production. The aim of our current study was to
investigate the cytokine profile of GA-reactive CD8+ T cell lines
derived from MS patients and controls. Results: So far 88 CD8+ T
cell lines from healthy volunteers, 61 lines from GA treated MS
patients and 47 lines from untreated MS patients were generated.
GA reactive CD8+ T cells of untreated MS patients produced more
IFN gamma (P b 0.05) and IL- 4 (P b 0.001), but less IL-5 (P b
0,01) than CD8+ T cells derived from healthy volunteers. Cells
derived from GA treated MS patients showed less TNF alpha (P b
0.001), lower levels of IL- 10 (P b 0.001), less IL- 4 (P b 0.001),
but more IL- 5 (P b 0.05) production than T cell lines
generated from untreated MS patients. Conclusions: The data
presented here demonstrate that the cytokine spectrum secreted
by GA reactive CD8+ T cells differs in untreated MS patients
and healthy controls and that this cytokine shift may be partly
corrected by initiation of GA treatment in patients suffering from
RRMS.
Acknowledgments: This work was in part supported by TEVA
Pharma Deutschland GmbH to FW and AD and from the
Gesellschaft fqr Nervenheilkunde Mecklenburg- Vorpommern to
AV and AD
Sa1.36. An Exploration of the Role of TLR2 and TLR4
in CD14+ Cells in Multiple Sclerosis.
P. L. De Jager, C. S. Wolfish, V. Viglietta, J. Flores, H. L. Weiner, D.
A. Hafler, S. J. Khoury. 1Neurology, Brigham and WomenTs
Hospital, Center for Neurologic Diseases, Harvard Medical
School, Boston, MA, USA; 2Neurology, Brigham and WomenTs
Hospital, Center for Neurologic Diseases, Harvard Medical
School, Boston, MA, USA; 3Neurology, Brigham and WomenTs
Hospital, Center for Neurologic Diseases, Harvard Medical
School, Boston, MA, USA; 4Neurology, Brigham and WomenTs
Hospital, Center for Neurologic Diseases, Harvard Medical
School, Boston, MA, USA; 5Neurology, Brigham and WomenTs
Hospital, Center for Neurologic Diseases, Harvard Medical
School, Boston, MA, USA; 6Neurology, Brigham and WomenTs
Hospital, Center for Neurologic Diseases, Harvard Medical
School, Boston, MA, USA; 7Neurology, Brigham and WomenTs
Hospital, Center for Neurologic Diseases, Harvard Medical
School, Boston, MA, USA.
Multiple sclerosis (MS) is a chronic disease of the central
nervous system characterized by inflammation and areas ofdemyelination. The role of the innate immune system in this
disease is emerging. One critical family of molecules in innate
immunity is the Toll-like receptor (TLR) family which plays a
fundamental role in pathogen recognition and activation of the
innate immune response. The TLRs have been implicated in
several autoimmune diseases, but their role in MS remains
unclear. We present an initial exploration of the role of two of
these molecules, TLR2 and TLR4, using a retrospective study
of immunophenotypes captured by the MS Natural History
Database at the Partners MS Center in Boston. We analyzed
data from forty-four (44) patients with MS by McDonald
criteria; each subject had data from three different visits to the
MS Center over the course of one year. At each visit,
peripheral blood mononuclear cells (PBMCs) were collected
and stained using monoclonal antibodies against CD14, TLR2
and TLR4. The expression of these molecules on PBMCs was
measured both ex vivo and after stimulation with lipopolysac-
charide (LPS) and ionomycin. These data were then correlated
with the associated clinical phenotypes that are available in the
database, including disease subtype, course, and activity as well
as MRI volumetric data. Large interindividual and intraindivid-
ual variability in TLR2 and TLR4 expression on CD14+ cells
was observed despite the precision of such measurements in
our clinical laboratory. This variability could not be explained
solely by disease activity in subjects as reported in the
database. The role of TLR2 and TLR4 on CD14+ cells in
MS remains unclear. However, these data demonstrate that
TLR2 and TLR4 expression on CD14+ cells may undergo
large intraindividual fluctuation over time, a fact that needs to
be taken into account in any future association of these
molecules with human disease.
Sa1.37. Regulation of Expression of Matrix
Metalloproteinases in CNS Inflammation Versus CNS
Injury.
H. Toft-Hansen,1 A. A. Babcock,1 R. K. Nuttall,2 D. R. Edwards,2
T. Owens.1,3 1Neuroimmunology, Montreal Neurological Institute,
McGill University, Montreal, QC, Canada; 2School of Biological
Sciences, University of East Anglia, Norwich, Norfolk, United
Kingdom; 3Medical Biotechnology Center, University of Southern
Denmark, Odense, Denmark.
Matrix metalloproteinases (MMPs) are a family of 22
proteases, including 6 membrane-bound MMPs (MT-MMPs).
Their physiological inhibitors are tissue inhibitor of metal-
loproteinases (TIMPs). MMPs are thought to mediate cellular
infiltration in CNS inflammation, which is an integral part of
the pathogenesis of Multiple Sclerosis (MS) and its animal
model experimental autoimmune encephalomyelitis (EAE).
MMPs may also mediate infiltration, and possibly repair, after
CNS injury. We have investigated the differential expression of
selected MMPs in spinal cord from mice with adoptively
transferred EAE, and in a model of CNS axonal injury in
the hippocampus, using real-time RT-PCR to profile changes
in expression. MMP-12 is a secreted MMP, which is virtually
absent in the uninflamed CNS. It is highly up-regulated in
EAE, where it is expressed almost exclusively by infiltrating
macrophages. After axonal transection, MMP-12 expression
correlated with kinetics of macrophage infiltration measured
by flow cytometry in the lesion-reactive hippocampus. In CC
chemokine receptor-2 (CCR-2) deficient mice, macrophage
infiltration is absent. Consistently, there was no up-regulation
AbstractsS100of MMP-12 in the lesion-reactive hippocampus of CCR-2
deficient mice.
After axonal transection, TIMP-1 was up-regulated prior to
leukocyte infiltration of the lesion-reactive hippocampus, impli-
cating an endogenous source. TIMP-1 may be expressed to
counteract potential damaging effects of MMPs. Whereas the
majority of secreted MMPs were up-regulated in EAE, 4 of 6
MT-MMPs were down-regulated. Conversely, none of the 3
MT-MMPs investigated so far were affected in the lesion-
reactive hippocampus. We sorted CD45dim CD11b+ microglia
from CNS of mice with EAE and found expression of 4 out of
6 MT-MMPs down-regulated. This suggests that activation of
microglia in the course of neuroinflammation is correlated with
reduced expression of some MT-MMPs. Activated microglia in
the lesion-reactive hippocampus may differentially regulate
MMP expression, possibly because axonal transection leads to
activation of microglia in the absence of inflammation.
This work was funded by the MS Society of Canada and a
CIHR-IHRT grant.
Sa1.38. Searching for Biomarkers in Multiple Sclerosis:
The Need for Natural History Studies.
Vissia Viglietta,1 Bonnie Glanz,1 Guy Buckle,1 Howard L.
Weiner,1 Samia J. Khoury.1 1Neurology, Brigham and WomenTs
Hospital, Boston, MA, USA.
Multiple sclerosis (MS) is a chronic autoimmune disease
whose main pathophysiological features are lymphocyte infiltra-
tion and inflammation, demyelination, and axonal damage of the
central nervous system. This disease is heterogeneous in its
clinical manifestation, prognosis, and response to different treat-
ments. Although several therapies are available to treat patients
with MS, tools to predict the course of the disease or the success
of a particular treatment are still missing. The combination of
different therapeutic strategies directed at the different pathophy-
siologic processes of the disease might be necessary. In order to
achieve this goal we need to develop reliable biomarkers of
disease activity and response to treatment. In this study we
examined immunological biomarkers by analyzing relevant
molecules on peripheral blood mononuclear cells (PBMC)
from patients with MS, both ex vivo and after in vitro
stimulation using flow cytometry-based assays. We measured a
battery of cytokines, chemokines and their receptors, activation
markers, and costimulatory molecules longitudinally in more
than one hundred patients with MS enrolled in the Multiple
Sclerosis Natural History Study at the Partners MS Center in
Boston. The patients in different categories of disease and in
different treatment subgroups were recruited and followed
prospectively for up to three years with consecutive measure-
ments of immunological markers, clinical assessment and MRI
measures. Changes in biomarkers were correlated with clinical
and MRI measures and with response to treatment. Our
preliminary analysis shows a differential effect of various
therapies on different immunological targets, some increasing
anti-inflammatory response while others dramatically reducing
pro-inflammatory responses at different time points after initiating
therapy.
This prospective multi-parameter analysis of immune
markers with clinical responses and MRI support represents
a systematic approach for the identification of surrogate
markers of disease activity and treatment response in patients with
MS.Sa1.39. Protection in a Rodent Model of Multiple
Sclerosis by Carbon Monoxide Release.
M. V. George,1 S. Iyer,2 L. Gao,3 T. Fong,4 R. Buelow,5 D. J.
Matthes.1 1Biological Sciences, San Jose State University, San
Jose, CA, USA; 2Development Sciences, Genentech, South San
Francisco, CA, USA; 3Research, Genzyme Corporation,
Framingham, MA, USA; 4Research, Cellerant Therapeutics, Palo
Alto, CA, USA; 5Research, Therapeutic Human Polyclonals,
Mountain View, CA, USA.
PURPOSE: Iodoform is metabolized by the cytochrome P-450
oxidative system to CO and CO2. In vivo, the anti-inflammatory
effects of CO have been previously demonstrated in LPS-induced
shock, graft rejection, and lung injury models. In EAE, increased
CO has a variety of potentially beneficial effects including the
protection from 1) nitric oxide synthase, 2) cellular infiltration, 3)
macrophage activation, and 4) inflammatory processes including
TNF-a production. Experimental autoimmune encephalomyelitis
(EAE), an animal model of multiple sclerosis (MS), was chosen to
study the effect of this compound in acute inflammatory auto-
immune encephalomyelitis.
METHODS: EAE was induced in Lewis rats after immuniza-
tion on day 0 with myelin basic protein (MBP) from guinea pig.
On day 10, the rats developed an inflammatory encephalomyelitis
with lymphocyte infiltration and subsequent progressive paralysis.
Rats injected with MBP were randomized to receive by vehicle or
iodoform (250 mg/kg/day) by oral gavage. Daily clinical scores
were determined on a 0–5 scale. Brain and spinal cord samples
were obtained at early and peak clinical signs from the vehicle
control group and corresponding treated group for cytokine and
histological analysis. In addition, pharmacokinetics and blood
chemistries were also determined.
RESULTS: Iodoform reduced the severity of EAE in a dose
dependant fashion. Significant reduction in severity was evident
after 5 days of therapy (P = 0.001). Iodoform ameliorated
pathological damage as determined by image analysis. Carbox-
yhemoglobin levels peaked within a few hours of administration but
normalized within 24 hours without cumulative pharmacokinetic
consequences. Analysis of brain cytokine levels indicated that
iodoform increased IL-10 in EAE animals with no effect on TNF-a
or IFN-g.
CONCLUSIONS: These results demonstrate a powerful CO-
mediated amelioration of EAE and suggest that further study of
halothanes would be warranted to define their potential benefits in
the treatment of human autoimmune diseases such as MS.
Sa1.40. IFN;-Dependent Regulation of the
Neutrophil-Activating Cytokines IL-17 and IL-18
in EAE.
R. D. Wheeler,1 L. M. Kelly,1 S. L. Carter,1 T. Owens.1,2
1Neuroimmunology Unit, Montreal Neurological Institute,
Montreal, QC, Canada; 2Medical Biotechnology Center,
University of Southern Denmark, Odense, Denmark.
Inflammation is an important aspect of autoimmune disease that
contributes to the pathology of conditions such as multiple sclerosis
and its animal model, experimental autoimmune encephalomyelitis
(EAE). The processes that underlie inflammation in the CNS,
including migration of cells and release of their effector molecules,
are co-ordinated by a network of cytokines and chemokines released
by resident brain cells as well as infiltrating immune cells. Following
induction of EAE, mice that lack IFNg or its receptor develop a very
severe disease that progresses rapidly to paralysis and death,
Abstracts S101compared to a milder relapsing-remitting phenotype in wild-type
littermates. The severe disease observed in IFNg-deficient mice is
characterized by lesions in the spinal cord and brainstem that are
larger and more diffuse than in wild-type mice. Furthermore,
inflammatory CNS infiltrates consisted primarily of macrophages/
microglia and T cells in wild-type mice, but included large numbers
of polymorphonuclear cells (mainly neutrophils) in IFNg-deficient
mice. It is not clear why IFNg deficiency results in more neutrophils
infiltrating the CNS. We hypothesized that this is due to a change in
the cytokine networks. Two possible candidate molecules are IL-17
and IL-18, both of which promote neutrophil migration and
activation. We induced EAE in wild-type and IFNg-deficient mice
by active immunization with PLP139-151 peptide in CFA, and
investigated expression of these two cytokines by real-time PCR. IL-
17 mRNA was not detectable in the spinal cord of unimmunized
animals, but was induced with onset of EAE. IL-17 mRNA was
expressed at significantly higher levels in the spinal cords of IFNg-
deficient mice compared to wild-type mice. IL-18 mRNA and
protein was expressed constitutively in the spinal cord of unimmu-
nized mice and did not change with onset of EAE. We also
investigated expression of IL-18 binding protein (IL-18BP), an
endogenous, potent inhibitor of IL-18 that is regulated by
IFNgamma. IL-18BP mRNA was dramatically up-regulated after
onset of EAE in the spinal cord of wild-type but not IFNg-deficient
mice. This study demonstrates that IFNgamma deficiency could
result in aberrant IL-18 actions due to a failure to up-regulate IL-
18BP. Thus, the enhanced neutrophil infiltration could be due to
enhanced IL-17 expression or a lack of inhibition of IL-18.
Elucidation of these pathways will help understand how perturba-
tions of the cytokine network can impact on cellular infiltration and
CNS pathology.
Sa1.41. Differential Reactivity Against Solid-Phase and
Liquid-Phase Myelin/Oligodendrocyte Glycoprotein in
Multiple Sclerosis and Experimental Allergic
Encephalomyelitis.
T. Menge,1 H.C. von Budingen,2 P. H. Lalive,1 S. L. Hauser,1 C. P.
Genain.1 1Department of Neurology, University of California San
Francisco, San Francisco, CA, USA; 2Neurologische Klinik,
Universitat Zurich, Zurich, Switzerland.
Background: Myelin/oligodendrocyte glycoprotein (MOG) is a
potent encephalitogenic antigen in experimental allergic encepha-
lomyelitis (EAE), the animal model of multiple sclerosis (MS); it
is a known target for pathogenic demyelinating antibody
responses in EAE. In humans, anti-MOG antibodies have been
described as prognostic markers in early MS. However, anti-
MOG antibodies are not specific and can be found in a high
proportion of healthy individuals, when analyzed by different
methods.
Objective: To validate a novel, easy to perform liquid-phase
based immune assay for the detection of serum anti-MOG
antibodies and to assess the different immunological properties
of MOG in solution- and in solid-phase immune assays.
Design/Methods: Sera of 37 MS patients with different disease
stages, and 13 healthy control subjects (HC), chosen according to
their reactivity against recombinant extracellular human MOG
(rhMOG125) determined by solid-phase ELISA, were tested for the
presence of anti-rhMOG125 IgG by incubation with the biotinylated
rhMOG125 in solution. Immunecomplexes were captured by plate-
bound Protein G and detected by peroxidase-labeled streptavidin.
Biotinylated tetanus toxoid (TT) was used as a positive control. Apanel of monoclonal fab fragments (Fabs) and sera of 15 non-
human primates C. jacchus marmoset immunized with either
human whole white matter (HWM), recombinant ratMOG or linear
20-mer MOG peptides (n = 5 per group) were used to validate the
assay.
Results: No reactivity against solution-phase rhMOG125 was
detected in humans, in contrast to high anti-TT reactivity. In
ELISA sera reacted equally against rhMOG125 and TT. For anti-TT
reactivity the correlation between LP and ELISA was highly
significant (P b 0.001, PearsonTs correlation), validating the assay
technically.
In the marmoset EAE model, sera of MOG peptide immune
animals reacted significantly weaker to solution-phase rhMOG125
as compared to sera of ratMOG- or HWM-immune marmosets
(mean binding ratio 1.9 vs. 33.9 (ratMOG-immune) and 14.3
(HWM-immune), respectively; P b 0.001, SNK T-test). The
binding ratios of ratMOG- and HWM-immune sera were indis-
tinguishable from each other in solution- or solid-phase assays. By
means of monoclonal antibodies and fab fragments, we were able to
detect a 7-32 fold lower antibody affinity against soluble rhMOG125
compared to solid-phase rhMOG125.
Conclusions: We conclude that (1) immunodominant epitopes
are less well presented on soluble rhMOG125, (2) antibodies
against linear epitopes of MOG do not bind to MOG in solution,
and (3) antibody assays employing solution phase rhMOG125 are
hence not suitable for serum antibody studies in MS most likely
because of the biological nature of this membrane-bound, water
insoluble antigen.
Sa1.42. Characterization of B Cell Immunoglobulin
Variable Region Genes Derived from Muscle Tissue of
Subjects with Inclusion Body Myositis.
E. M. Bradshaw,1 L. Bregoli,1 A. A. Amato,2 D. A. Hafler,1 S. A.
Greenberg,2 K. C. OTConnor.1 1Department of Neurology, Center
for Neurologic Diseases, Brigham and WomenTs Hospital, Boston,
MA, USA; 2Department of Neurology, Division of Neuromuscular
Disease, Brigham and WomenTs Hospital, Boston, MA, USA.
The inflammatory myopathies are putative autoimmune dis-
orders characterized by muscle weakness and the presence of
inflammatory infiltrates in skeletal muscle. In inclusion body
myositis (IBM), the inflammatory cells that are infiltrating muscle
have been characterized as predominately CD8+ cytotoxic T
lymphocytes. While there does not appear to be significant B cell
infiltrates as indicated by CD20 immunohistochemistry, we
recently demonstrated the presence of significant muscle infiltrates
of CD138+ plasma cells. Here, we examined the immunoglobulin
variable region sequences of these cells. B cell immunoglobulin
variable region gene libraries of IBM muscle were created by
reverse transcriptase-polymerase chain reaction followed by
sequencing of the whole immunoglobulin cDNA variable region,
allowing identification of somatic mutations. There was significant
oligoclonal expansion found in IBM muscle, in contrast to libraries
from peripheral blood mononuclear cells that showed no oligo-
clonal expansion. Moreover, a pattern of B cell affinity maturation
was evident in that clones sharing the same CDR3 had
accumulated varying numbers of common and unique somatic
mutations within the CDR regions and this clonal variation was
also observed within groups comprised of CD19+ and CD138+ B
cells. These data suggest that a local inflammatory response occurs
within the muscle tissue of patients with IBM that may indicate the
presence of a humoral antigen-specific response present in muscle.
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Cells Using Multiple Displacement Amplification:
Application to B- and T-Cell Receptor Variable
Region Genes.
L. Bregoli, K. OTConnor, D. A. Hafler. 1Center for Neurologic
Diseases, Brigham and WomenTs Hospital, Harvard Medical
School, Boston, MA, USA.
Interest in examining the genetic nature of single cells has been
shared by investigators in different fields. The limited amount of
genetic material from a single cell specimen presents a technical
challenge even for the most efficient and specific PCR protocols.
In the present report we show the application of a recently
developed method for whole genome amplification (WGA), the
multiple displacement amplification (MDA) (Dean, Gen Res
2001), to single cells FACS-sorted from human blood. This
procedure allows the interrogation of a single cellTs genetic
information through the production of several copies of the single
cells genome followed by specific PCR experiments on a small
fraction of the MDA product. We also compare MDA to whole
genome amplification of single cells using the primer extension
pre-amplification (PEP) method.
This technique can be applied to the analysis of the clonality
and antigen-specificity of T-cells and B-cells which infiltrate
tissues in autoimmune diseases. In fact, it allows the sequencing of
both chains of immunoglobulin and T-cell receptor V-(D)-J
rearranged genes from single cells isolated from frozen human
tissue. Single cells are dissected from the stained tissue with the
use of a laser capture microdissection device, their DNA is
amplified with MDA, then a small fraction of the amplification
product is used as template for the specific PCRs. Furthermore, the
combination of laser capture microdissection and MDA allows to
study single cells/cell types from paraffin-embedded tissues, where
the RNA is mostly degraded but the DNA remains intact.
Sa1.44. Characterization of B Cell Immunoglobulin
Variable Region Genes Derived from Lesions of Patients
with MS.
K. C. OTConnor,1 N. H. Moore,1 L. Bregoli,1 E. Bradshaw,1 K.
Wucherpfennig,2 D. A. Hafler.1 1Department of Neurology,
Harvard Medical School, Brigham and WomenTs Hospital, Boston,
MA, USA; 2Department of Cancer Immunology and AIDS, Dana
Farber Cancer Institute, Harvard Medical School, Boston, MA,
USA.
The notion that the process of B cell affinity maturation with
ensuing production of potentially pathogenic autoantibodies may
occur inside the CNS of patients with multiple sclerosis (MS) is
supported by the presence, within lesions, of oligoclonal B cells
and cell surface markers capable of supporting such a local
immune response. Although B cells carrying somatic mutations of
Ig variable (V) region genes have been detected in the CSF and
CNS tissue of patients with MS, more direct evidence for the
process of B cell affinity maturation confined within this compart-
ment is needed. Here, we have characterized the B cell Ig variable
(V) region genes derived from multiple lesions within the white
matter of patients with MS. Analysis of variable region gene
libraries revealed evidence of significant oligoclonal expansion of
local B and plasma cells. Control tissue and PBMCs revealed no
such oligoclonal expansion. Moreover, a pattern of B cell affinity
maturation was evident in that clones sharing the same CDR3 had
accumulated varying numbers of common and unique somaticmutations within the CDR regions and this clonal variation was
also observed within groups comprised of CD19+ and CD138+ B
cells. These data suggest that a local inflammatory response occurs
within the CNS tissue of patients with MS which includes
differentiation and affinity maturation. Auto- or exogenous
antigens resident in the CNS need to be considered as driving
such a response.
Sa1.45. Genetic Resistance to Autoimmunity Is Mediated
by Autoantigen-Specific CD4+CD25+ Regulatory Cells.
J. Reddy, Z. Illes, X. Zhang, J. Encinas, J. Pyrdol, L. Nicholson, R.
Sobel, K. Wucherpfennig, V. Kuchroo. 1Center for Neurologic
Diseases, Brigham and WomenTs Hosp/Harvard Medical School,
Boston, MA, USA; 2Cancer Immunology and AIDS, Dana-Farber
Cancer Institute, Boston, MA, USA; 3Pathology, Stanford
University School of Medicine, Stanford, CA, USA.
SJL mice are highly susceptible to the induction of experimental
autoimmune encephalomyelitis (EAE) with myelin proteolipid
protein (PLP) peptide 139–151, whereas H-2 congenic B10.S mice
are resistant. Immunodominance and susceptibility to PLP 139-151-
induced EAE was found to be associated with a high precursor
frequency of PLP 139-151-specific T cells in the naive repertoire of
SJL mice. To understand the mechanism for disease resistance in
B10.S mice, we determined the precursor frequency of PLP 139-
151-reactive T cells in both strains of mice using IAs / PLP 139-151
tetramers. Both SJL and B10.S mice had similar frequencies of
tetramer-reactive Tcells in the naRve peripheral repertoire. However,
in SJL mice the majority of PLP 139-151 tetramer-positive cells
were in the CD4+CD25- population whereas there were more
tetramer-positive cells in the CD4+CD25+ population of B10.S
mice, suggesting that there were more PLP 139-151-specific T cells
in regulatory population. Depletion of CD4+CD25+ cells in vivo
facilitated expansion of PLP 139-151-reactive cells with production
of TH1 cytokines in EAE-resistant B10.S mice. Furthermore,
depletion of CD25+ T cells with anti-CD25 antibody treatment
prior to immunization with the encephalitogenic peptide resulted in
induction of EAE in these otherwise resistant mice. These data
indicate a role for autoantigen-specific CD4+CD25+ cells in genetic
resistance to autoimmunity.
Autoimmune Rheumatologic Diseases
Sa1.46. A 20 Year Old with Knee Arthritis Develops
Multiple Organ Dysfunction: Think Zebras, Not Horses.
P. B. Pinho,1 M. Rodriguez,1 D. Menasha,1 B. Suri,1 M. Youseff-
Bessler,1 B. Suri,1 R. K. Messo,2 L. Bielory.1 1Internal Medicine,
UMDNJ-NJMS, Newark, NJ, USA; 2Internal Medicine, Staten
Island University Hospital, Staten Island, NY, USA.
A 20 year-old female with Systemic Onset Juvenile Idiopathic
Arthritis (SoJIA)presents to University Hospital with right knee
arthritis and pharyngitis previously treated with naproxen and
penicillin with no response. She denied flares for the past 7 years.
Vancomycin and Ceftriaxone were started after bilateral arthro-
centeses (each appearing inflammatory) were performed. Follow-
ing the second arthrocentesis she experienced right shoulder and
pleuritic chest pain. Naproxen and prednisone were started. Labs
showed: CRP 196 mg/dL; normal liver and renal functions. WBC
was normal but bands increased from 15%-56% and hemoglobin
fell 3 grams since admission. HIV, ANA, double stranded DNA,
RPR and RF were negative. By hospital day (HD #) 8 she
reported fatigue, malaise, nausea and vomiting. New cervical and
Abstracts S103inguinal adenopathy, splenomegaly, abdominal distention and
right upper quadrant pain were noted. A light erythematous, non-
pruritic, macular rash covered her anterior neck and shoulders.
Over three days acute renal failure and liver function abnormal-
ities developed; non-steroidals were discontinued. Bilateral
infiltrates evolved on her chest radiograph. On HD #11 she had
a generalized tonic-clonic seizure, was intubated and transferred
to the intensive care unit (ICU). The next few days were marked
by hypotension, tachycardia and persistent fevers (N101oF). She
developed clonus, asymmetric plantar reflexes and obtundation.
Laboratory data revealed pancytopenia with bands of 88%, and
marked coagulopathy. All cultures and viral studies returned
negative. Despite her condition, ESR was only 5, but CRP was
24 and ferritin was 152,197. Macrophage Activation Syndrome
(MAS), a complication of SoJIA was considered and high dose
solumedrol and cyclosporin were started. Blood product support,
hemodialysis and pressor management were instituted. By HD
#14 she was extubated and by HD #20 she was downgraded from
ICU. She was discharged home on HD #31 on a prednisone taper
and cyclosporin. Bone marrow biopsy during her ICU course
showed prominent hemophagocytosis. TNFa, IL2 and IL6 levels
were markedly elevated during her critical illness, but normalized
by the time of discharge. MAS is a secondary hemophagocytic
syndrome most commonly associated with SoJIA. Its symptoms
are attributed to activation and proliferation of well-differentiated
macrophages precipitated by a change in medication or infectious
cause. Presenting symptoms include pyrexia, changes in menta-
tion, organomegaly, lymphadenopathy, bleeding, bruising and
purpura; paradoxically arthritis and serositis can improve.
Laboratory abnormalities can include pancytopenia, transaminase
elevation, coagulopathy, decreased ESR (hypofibrinogenemia),
hypertriglyceridemia, hyponatremia, hypoalbuminemia and hyper-
ferritenemia. Histological evaluation of bone marrow shows
macrophage hemophagocytosis. Mortality exceeds 20%, but with
rapid diagnosis and the institution of high dose steroids, cyclo-
sporin and other immunomodulators, good outcomes can be
achieved.
Sa1.47. Differential Expression of Co-Stimulatory
Molecules on PBMCs from Patients with Active
Systemic Lupus Erythematosus and Rheumatoid
Arthritis.
E. Rojas-Ramos,1 N. E. Martinez-Jimenez,1 Y. B. Garfias,2 E. G.
Zenteno,2 R. L. Lascurain.2 1Clinical Immunology and Allergy,
ISSSTE, Mexico, Mexico City, Mexico; 2Biochemistry, INER, SSA,
Mexico, Mexico City, Mexico.
Background: Following activation of antigen-presenting cells
(APCs), co-stimulatory pathways including B7-1 and B7-2
recognizing CD28 and CTLA-4 play a key role in the activation
of autorreactive lymphocytes, also CD40 ligand is expressed by
activated T cells and is considered to be a critically T-cell marker,
and their increased expression might further contribute to cognate
T-B cell interactions and autoantibody production. To succeed an
appropriate interaction between T and B cells is required an
appropriate signaling of co-stimulatory molecules, being the
broadly studied; B7-CD28 and B7-CTL4 who are crucial in both
pathways IL-2 production and tolerance induction. Objective: The
aim of this study was to explode, which preferably co-stimulatory
via in APCs interacting with CD4+ T cells, and which are the
correlation with activity disease in Systemic Lupus Erythematosus
and Rheumatoid Arthritis patients. Methods: Cross sectional studywas carried out in SLE and RA patients with activity disease. The
proportion of peripheral mononuclear cells was studied using flow
cytometry in order to measure the percentage of surface molecules
in CD4+ T cells, and antigen presenting cells such CD14+ and
CD19+. Results: CD4+ CD152+ T cells showed a high expression
only in Lupus patients, CD80+ and CD86+ in both type of cells
CD14+ and CD19+ showed increased levels of those molecules
predominantly in Lupus patients.
Conclusion: Costimulatory molecules play an essential role in
the activation and regulation of T cell immune responses in lupus
and arthritis patients trough CD28, CD30, CD152, CD154, CD80
and CD86, they could be used to monitoring the activity disease
and also could be a target for therapeutic manipulation of the
costimulatory system in order to beneficial effects in clinical
autoimmune disease
Keywords: PBMCs, CD4+, CD28+, CD14+, CD19+, CD152,
CD154, co-stimulatory molecules, CD80, CD86, disease activity,
Systemic Lupus Erythematosus and Rheumatoid Arthritis.
Sa1.48. Effects of Taxus Yunnanensis for the Pain on
Patients with Rheumatoid Arthritis.
Testuroh Okano,1 Koya Kubo,1 Yutaka Tajima,2 Osamu
Nakajima,3 Takahiro Nobukawa.4 1Immunology/AHS, Kitasato
Univ, Sagamihara, Kanagawa, Japan; 2Infectiom Control
Sciences, Juntendo Univ, Bunkyo, Tokyo, Japan; 3Rheumatology,
Institute of Chem. Therapy, Chiba, Chiba, Japan; 4Med. Res.
Institute, Kanazawa Med. Univ., Kanazawa, Isikawa, Japan.
The extract from Taxus yunnanensis (TY) had many beneficial
effects in certain clinical settings, in which physicians can easily
use on patients without interrupting therapy. We will show the
long-term effect of TY on patients with severe pain due to
rheumatoid arthritis (RA). After prescribing the TY extract, the
extent of morning stiffness, joint swelling and pain were reduced,
and the lowered patientsT quality of life (due to severe pain caused
by RA) was significantly improved with increasing daily life
activities. However, the beneficial effects of TY did not appear
shortly, although TY had an immediate relieving effect on allergic
diseases. Plasma cytokine levels were not decreased promptly.
Although walking ability of the patients got better after 3 days, it
took around 8–20 days and 1 month to improve morning stiffness
and joint pain, respectively. Therefore, a longer prescribing period
seems to be necessary to demonstrate the beneficial effect of TY.
The following two patients were good responders to TY; they were
prescribed TY extract in addition to the usual therapeutics for RA.
It is noteworthy that their plasma IL-6 levels reduced to the normal
level after taking TY.
Case 1 (Class 4 disability): Plasma IL-6 level dramatically
reduced from 165pg/ml to the normal level 32 weeks after
prescribing TY. CRP became negative simultaneously. RF also
became negative at 20 weeks.
Case 2 (Class 3 disability): Plasma IL-6 decreased from 6.8pg/
ml to the normal level 16 weeks after prescribing TY. CRP level
also decreased from 4.4 to 0.6mg/ml within 8 weeks. RF activity in
the serum improved from 220 to 78U/ml.
Sa1.49. Protection from Collagen-Induced Arthritis by
Complement Receptor CR2/CR1 Deficiency.
K. A. Kuhn,1 V. M. Holers.1 1Immunology and Medicine,
University of Colorado Health Sciences Center, Denver, CO, USA.
In mice, complement receptors CR2 and CR1 are expressed on
B cells, T cells, and follicular dendritic cells, linking innate
AbstractsS104complement and adaptive T cell and B cell immune responses.
Upon binding of its ligand C3d, CR2 lowers the threshold for B
cell activation; however, the function of CR2 on T cells is
unknown. Mice deficient in CR2 and CR1 (Cr2-/-) demonstrate
altered humoral immunity in response to foreign and self antigens
as well as an altered natural antibody repertoire. Collagen-induced
arthritis (CIA), a model of autoimmune arthritis, depends upon
complement activation, effective collagen presentation by antigen
presenting cells, autoantibody production by B cells, and cytokine
production by T cells. Therefore, CIA provides a model in which
the roles of lineage-specific expression of CR2 and CR1 in
autoimmune disease may be dissected. DBA/1j mice were immu-
nized with bovine type II collagen (CII) emulsified in complete
FreundTs adjuvant (CFA) on days 0 and 21 to establish CIA. On
day 35, draining lymph nodes from mice with CIA demonstrated a
greater percentage of CD4+ cells expressing CR2 compared to
naRve mice (3.59% vs. 1.29%, P = 0.005, respectively), suggesting
a role for CR2 expression on T cells during autoimmune disease.
To determine the importance of CR2/CR1 for the development of
CIA, Cr2-/- and Cr2 F mice backcrossed 5 generations onto the
DBA/1j strain were generated. Mice were immunized with CII in
CFA on days 0 and 21 and evaluated in a blinded fashion for the
development of arthritis. Cr2-/- mice (n = 20) had significantly
reduced severity (2.5 F 0.9 vs. 5.5 F 1.2, P = 0.05) and incidence
(45% vs. 64%) of arthritis compared to Cr2 F mice (n = 25).
However, anti-bovine and anti-murine CII antibodies did not differ
significantly between the two groups of mice, nor did cellular
proliferation and cytokine production in response to CII restim-
ulation ex vivo differ between the two groups. C3 deposition within
the joints of Cr2-/- mice was significantly reduced, suggesting that
activation of complement in these mice was altered. These results
demonstrate that CR2 and CR1 are required for robust develop-
ment of CIA, likely because of altered T cell activation and
trafficking to the joint or because of defects within the anti-CII
antibody repertoire.
Sa1.50. Leptin Modulates Autoimmune Reactivity in
(NZB  NZW)F1 Lupus Mice.
A. La Cava, F. M. Ebling, B. H. Hahn. 1Medicine/Rheumatology,
University of California Los Angeles, Los Angeles, CA, USA.
Leptin is an adipocytokine that links the metabolic status to
several important immune functions. We and others have recently
shown that leptin, similarly to other pro-inflammatory cytokines,
can promote the differentiation of T helper (Th1) cells and can
contribute to the onset and progression of organ-specific auto-
immunity in several animal models of autoimmune disease.
Nonetheless, the role of leptin in systemic autoimmunity, and in
particular in systemic lupus erythematosus (SLE), remains elusive.
We studied here whether leptin exerted some influence on the
development and progression of systemic autoimmunity in lupus-
prone (NZB  NZW)F1 (BWF1) mice. We found by ELISA that
that the circulating levels of serum leptin increased progressively
with age in untreated female mice (P b 0.0002 at 13 and 20 weeks
vs 1 week of age). This increase correlated with development of
autoantibodies and kidney disease. Importantly, treatment of
BWF1 mice with recombinant leptin promoted Th1 autoreactivity
(as indicated by predominant IgG2a rather than IgG1 anti-double
stranded (ds)DNA antibody responses). Histological studies
indicated that leptin accelerated production of autoantibodies and
favored deposition of immune complexes and kidney glomerular
damage in the mice treated with leptin, as compared to saline-treated control mice. Interestingly, intraperitoneal injection of a
single dose of 100 Ag of anti-leptin antibodies to severely nephritic
mice (proteinuria z 300 mg/dl) delayed progression of renal
disease and significantly prolonged survival of the treated mice
(P b 0.001 by the Mann-Whitney U test at six weeks post-
treatment). Taken together, these studies point to an important role
of leptin in the development and progression of lupus in BWF1
mice and raise the possibility to consider leptin antagonists as
novel therapeutic tools for immune intervention in systemic
autoimmunity.
Sa1.51. Hyperhomocysteinemia in Hughes Syndrome.
J. Carbone,1 A. Rodriguez-Huertas,2 E. Dulin,3 M. Rabadan,2 E.
Sarmiento,1 D. Micheloud,1 R. Mora,1 E. Fernandez-Cruz.1
1Clinical Immunology Unit, University Hospital Gregorio
Maranon, Madrid, Spain; 2Hematology Department, University
Hospital Gregorio Maranon, Madrid, Spain; 3Biochemistry
Department, University Hospital Gregorio Maranon, Madrid,
Spain.
Background. Hyperhomocysteinemia is a risk factor for
trombosis and recurrent pregnancy loss. Similar mechanisms
appear to mediate thrombosis and pregnancy loss associated with
hyperhomocysteinemia and with antiphospholipid antibodies.
Objective. To report on the case of a patient with the association
of hyperhomocysteinemia and antiphospholipid or Hughes syn-
drome; and to assess the prevalence of increased levels of
homocysteine in a group of patients with Hughes syndrome.
Materials and Results. A 41-year old woman with a previous
history of migraine, placental abruption, arterial hipertension,
unstable angina and multinodular goitre was admitted because of
two consecutive transitory ischemic attacks. Laboratory inves-
tigations revealed the presence of elevated titres of anticardiolipin
antibodies (66 GPL-units/ml) and significant hyperhomocysteine-
mia [homocysteine concentration, 36 umol/L (normal values: 1.6-
11 umol/L)]. The genotype of the termolabile C677T allele of 5,10
methylene tetrahydrofolate reductase was studied by polimerase
chain reaction. The patient was found to be a carrier of the C677T
homozygous genotype. She was treated with anticoagulants and
showed radiological and clinical improvement. The patient started
treatment with folic acid and vitamin B6. Hyperhomocysteinemia
was normalized. We performed a retrospective study on 23 patients
with clinical and laboratory features of the Hughes syndrome in
comparison with 42 patients with unexplained fetal loss (without
antiphospholipid antibodies) and with 51 patients with thrombotic
events (without antiphospholipid antibodies). Rates of hyper-
homocysteinemia were statistically similar in patients with
Hughes syndrome and in disease control groups (17.4%, 9.5%
and 23.5%, respectively). Using a cut-off point of 11 umol/l, four
patients with Hughes syndrome had hyperhomocysteinemia.
Three patients had thrombotic events (including the presented
case) and the other patient had 9 consecutive unexplained
abortions. Homocysteine levels were similar in patients with
Hughes Syndrome and disease controls (10 F 0.6, 6.9 F 0.5 and
9.98 F 0.8 umol/l, respectively). Patients with thrombosis (without
antiphospholipid antibodies) had significantly higher levels of
plasma homocysteine than women with abortions (P = 0.018).
Conclusion. The results presented in this study suggest that
hyperhomocysteinemia is not significantly increased in patients
with Hughes syndrome. However, antiphospholipid antibodies may
coexist with high levels of plasma homocysteine in individual cases
of Hughes Syndrome.
Abstracts S105Sa1.52. Atherosclerosis in Murine SLE.
Zhongjie Ma,1 Marc Monestier,2 Robert Eisenberg.1 1Department
of Medicine, University of Pennsylvania, Philadelphia, PA;
2Department of Microbiology and Immunology, Temple University,
Philadelphia, PA.
Introduction: The accelerated development of atherosclerosis
and increased risk of cardiovascular disease in young women with
systemic lupus erythematosus (SLE) is a disturbing feature of the
disease that is not well understood. We have combined mouse
models of SLE and atherosclerosis to begin to elucidate the
mechanisms of this disease synergy.
Methods: Chronic graft-versus-host (cGVH) disease was
induced in young apoEKO C57BL/6 mice by injection of 10E8
coisogenic bm12 spleen cells. Mice were maintained on normal
chow diet. Mice were sacrificed, and the hearts and aorta were
collected at 16 weeks after induction of cGVH for histology. The
cholesterol levels were measured with an enzymatic colorimetric
method. The frozen heart tissues were stained with Oil red O and
hematoxylin, and the aortas were stained with Sudan IV. En face
lesion areas were calculated with image-pro 5.0 software system.
Serum IgG, anti-dsDNA, anti-chromatin, anti-oxLDL, and anti-
cardiolipin levels were measured by ELISA. Proteinuria was
detected with Uristix reagent strips at sixteen weeks after induction
of GVH. Spleen cells were stained with immunofluorescence and
detected with FACS.
Results: The plasma cholesterol levels in the apoEKOmice were
greatly increased, and this was not significantly changed by cGVH.
cGVH induced increased levels of IgG, anti-chromatin, anti-DNA,
anti-oxLDL, and anti-cardiolipin, as well as proteinuria, in both
C57BL/6 and in apoEKO mice. ApoEKO mice with and without
cGVH had substantial lesions in the aortic root and aorta tree, as
well as some lesions in the coronary arteries, which were slightly
increased by cGVH. ApoEKO mice had increased numbers of
splenic marginal zone B cells, which were depleted by cGVH.
Conclusion: These results indicate that we can induce cGVH
and lupus-like autoimmunity in apoEKOmice, and alter some of
the manifestations associated with Atherosclerotic cardiovascular
disease (ASCVD). We have extended this approach to other mouse
lupus models, such as C57BL/6-lpr/lpr.
Sa1.53. Association of a Single Nucleotide Polymorphism
of PTPN22 (1858C/T) with Rheumatoid Factor
Positivity in a Healthy Population.
K. D. Deane,1 L. A. Parrish,1 D. S. Majka,1 J. H. Buckner,2 V.
Gersuk,2 P. Concannon,2 J. M. Norris,3 V. M. Holers.1 1Division
of Rheumatology, University of Colorado Health Sciences Center,
Denver, CO, USA; 2Benaroya Research Institute at Virginia
Mason, Seattle, WA, USA; 3Deparment of Preventive Medicine
and Biometrics, University of Colorado Health Sciences Center,
Denver, CO, USA.
Objective: It has been demonstrated previously that a single
nucleotide polymorphism C1858T in the protein tyrosine phos-
phatase gene PTPN22 is associated with a rheumatoid factor (RF)
positive subset of patients with known rheumatoid arthritis. Our
study was performed to investigate the association between this
polymorphism and the presence of RF in a healthy population.
Methods: Healthy subjects were recruited in Denver, Colorado
as part of the ongoing Studies of the Etiologies of Rheumatoid
Arthritis (SERA) project. At the time of this interim analysis, 334
subjects were available [mean age of 38 (range 29–56), 88% non-
Hispanic white, and 69% female]. Each of these subjects providedepidemiologic information and underwent an interview and
physical examination to ensure that no subjects included in the
analysis had evidence of RA. Serum samples were drawn and the
presence of RF was determined using nephelometry. The PTPN22
polymorphism (1858C -N T) was identified using MGB-Eclipsek
Probe System (Epoch Biosciences, Inc), performed at the Benaroya
Research Institute, Seattle, Washington. Statistical analysis was
performed using logistic regression (SAS version 8).
Results: In this healthy population, 45 out of 334 (13%)
subjects had a positive RF. 64 out of 334 (18.9%) had at least one
PTPN22 variant allele. After adjusting for age, gender, race,
smoking status, and shared epitope status, the PTPN22 poly-
morphism was marginally associated with the presence RF (OR
2.02, Confidence Limits[CL] 0.92-4.45), P = 0.08).
Conclusions: In this preliminary analysis of healthy subjects,
the 1858C -N T missense single nucleotide polymorphism in
PTPN22 is marginally associated with the presence of RF. The size
of the odds ratio is similar to that reported previously for this
polymorphismTs association with RF positive RA patients and will
likely become statistically significant once we complete patient
accrual (estimated 450 subjects by Spring 2006). This gene may
contribute to pre-clinical immune dysregulation and the initial
development of RA-specific autoimmunity.
Sa1.54. Anti C1q, Anti Histone Antibodies and C1q
Deposits in Silent Lupus Nephritis.
M. E. Zabaleta-Lanz,1 L. E. Munoz,1 R. E. Vargas-Arenas,1 F. J.
Tapanes,1 N. E. Bianco.1 1Institute of Immunology, Central
University School of Medicine, Caracas, DF, Venezuela.
Specific Objective: To investigate the presence of Anti C1q,
Anti-Histone antibodies and C1q deposits in Silent Lupus
Nephritis (SLN).
Materials and Methods: 29 SLN (LUPUS 12:26-30, 2003)
and 11 SLE patients with Overt Lupus Nephritis (OLN) were
included. Urinary and renal function tests were assesed by standard
techniques. Renal Biopsies were performed in all the studied SLE
patients. Anti C1q (Siegert et.al), Anti Histone(Aesku.diagnostics),
Anti ds DNA (Wampole) were detected by ELISA. Immunoglo-
bulins, C1q, C3 and C4 deposits were searched in renal tissues by
Immunofluorescence (IF).
Results: 18/27 (66.6%) SLN individuals had elevated Anti C1q
antibodies (mean titers:127.3 F 52.5 EU) while in OLN 4/9
(44.4%) were positive (mean titers: 134 F 94.8 EU). Anti Histone
antibodies were positive in 8 out of 19 (mean titers: 98.5 F 61.9
U/ml)) available SLN sera (42%) while 6 out of 7 (85.7%) OLN
showed augmented serum levels (mean titers: 84.5 F 62.8). Anti
dsDNA were elevated in 28/29 (96.5%) SLN patients(mean titers:
98.7 F 88.3 U/ml) and in 10/11 (91%) of OLN individuals (mean
titers: 54.2 F 30.7 U/ml). Prevalence and mean titers of these three
autoantibodies were significantly different than those encountered
in 25 control sera (P b 0.01). In addition in SLN patients, serum
levels of Anti C1q and Anti Histone antibodies significantly
correlated with Anti dsDNA levels and with increased activity
index in renal tissue (P b 0.05). As previuosly reported, 18/29(62%)
SLN showed WHO Class II kidney lesions. In those SLN with
detectable Anti C1q antibodies, IgG (66%), C1q (44%), C3 (77%)
and C4 (55%) deposits were found.
Conclusions: This is the first report of detectable Anti C1q
and Anti Histone autoantibodies in SLN. Furthermore, their
significant correlation with Anti dsDNA antibodies and with
increased activity index in renal tissue suggest an early and
AbstractsS106simultaneous participation of these complexes in Lupus
Nephritis.
Sa1.55. Modulation of Inflammation in Refractory
Rheumathoid Arthritis by Granulocyte Apheresis: First
European Prospective Multicenter Open Pilot Study.
R. Sanmarti,1 R. Lafuente,2 J. Gratacos,3 J. Valverde,4 S.
Marsal,5 E. Casado,3 D. Reina,4 J. Rodriguez,1 A. Erra.5
1Rheumatology, Hospital Clinic i Provincial, Barcelona, Spain;
2Intensive Care Unit, Hospital De L VHospitalet, Barcelona, Spain;
3Rheumathology, Hospital Parc Tauli, Sabadell, Barcelona, Spain;
4Rheumathology, Hospital de Bellvitge, Hospitalet de Llobregat,
Barcelona, Spain; 5Rheumathology, Hospital Vall d VHebron,
Barcelona, Spain.
Introduction: Granulocyte apheresis (GCAP) is a novel
hemoadsorption treatment that is currently being used for the
treatment of some autoimmune diseases. Inmunomodulatory
properties of GCAP have been reported associated to emerging
evidence of clinical improvement in patients.
Objective: To assess the efficacy and safety of AdacolumnR
GCAP in patients with refractory rheumatoid arthritis (RA).
Methods: Patients with active RAwho had failed to respond to
at least one DMARDs or biologics (TNF-alpha antagonists) were
treated with weekly GCAP for five weeks. Clinical assessments
and response to therapy were analyzed at weeks 5,7,12 and 20 in
an open multicenter pilot trial. The primary outcome measure of
therapeutic response was the 20% improvement in the American
College of Rheumatology criteria at week 20. EULAR response
criteria based in the disease activity score for 28 joints (DAS-28)
and disability by the Healt Assessment Questionnaire (HAQ) were
also analyzed.
Results: Twenty seven patients were enrolled: 81.5% were
women with mean disease duration of 14.4 years. The mean number
of previous DMARDs was 3.7 and 48.1% of them have failed to
biologics. On an intent to treat basis analysis 40.7% of patients
achieved an ACR20 improvement and 44.4% patients a therapeutic
EULAR response at week 20. These percentages were of 50% and
54.5% in the 22 patients who completed the trial. In four out of the 10
patients who completed the trial and previously failed to biologics,
an ACR20 response was achieved at week 20. A significant decrease
was noted in the different ACR response components, including the
tender joint count, swollen joint count, pain score and the patientTs
and physicianTs global assessment and also the DAS28 index; most
of them improve since week 5. ESR and CRP, but not HAQ,
significantly decrease at week 20. The treatment was well tolerated
and only one serious adverse event related to study therapy was
documented (sepsis due to catheter infection).
Conclusions: Treatment with GCAP led to significant clinical
improvement in a subset of patients with RAwho previously failed
to DMARDs or biologics. The therapy was safe and well tolerated.
Further large, placebo controlled studies are required to assess the
exact role of this therapy in refractory RA.
Sa1.56. Interferon-alpha Pathway Activation Identifies a
Subgroup of Systemic Lupus Erythematosus Patients
with Antibodies against RNA-Binding Proteins, Renal
Disease, and Low Complement.
K. A. Kirou,1 C. Lee,1 S. George,1 K. Louca,1 M. G. E. Peterson,1
M. K. Crow.1 1Mary Kirkland Center for Lupus Research and
Department of Medicine, Hospital for Special Surgery and Weill
Medical College of Cornell University, New York, NY, USA.Gene expression studies have demonstrated increased interferon
(IFN)-inducible gene (IFIG) expression in peripheral blood
mononuclear cells (PBMC) of many patients with systemic lupus
erythematosus (SLE). Our recent data have implicated a predom-
inant type I IFN effect in the IFIG expression observed in SLE. The
objective of this study was to examine the hypothesis that
increased disease severity and activity as well distinct autoantibody
specificities characterize SLE patients with type I IFN pathway
activation. In order to do that, freshly isolated PBMC from 77 SLE
patients, 22 disease controls (DC), and 28 healthy donors (HD)
were subjected to real-time PCR for 3 IFIG that are preferentially
induced by IFNa, and the data were used to derive IFNa scores for
all individuals. Expression of IFIG was significantly higher in SLE
patients compared to DC or HD. SLE patients with high (H) and
low (L) IFNa scores were compared for clinical manifestations of
disease, disease severity, disease activity, serologic features and
potential confounders by bivariate and multivariate analysis. We
found that SLE patients with a H IFNa score had significantly
higher prevalence of renal disease, a greater number of ACR
criteria for SLE, and a higher SLICC damage index (DI) score than
SLE patients with L IFNa scores. Patients with H scores showed
increased disease activity, as measured by lower C3, hemoglobin,
absolute lymphocyte count, and albumin, and higher anti-dsDNA
titer, ESR, and SLEDAI-2K score. The presence of antibodies
specific for RNA-binding proteins (RBP: Ro, U1-RNP, Sm), and
dsDNA, but not phospholipids, was significantly associated with a
H IFNa score. Logistic regression analysis confirmed that renal
disease, higher SLICC DI scores, low complement levels, and
presence of anti-RNA binding protein (RBP) autoantibodies were
independently associated with a H IFNa score, and suggested that
the same might be true for the absence of treatment with
hydroxychloroquine (HCQ). In conclusion, activation of the IFNa
pathway defines a subgroup of SLE patients characterized by
increased disease severity, including renal disease, increased
serologic disease activity, and autoreactivity to RBP. These data
provide support for the further examination of the role of IFNa
score as a potential biomarker for lupus disease activity and
suggest a pathogenic link between RBP and IFNa production.
Sa1.57. The Rheumatic Joint Contains Hyperreactive
CD28null CD4+ T Cells.
A. E. R. Fasth,1 A. -K. Ulfgren,1 L. Klareskog,1 C. Trollmo,1 V.
Malmstrom.1 1Rheumatology Unit, Department of Medicine,
Karolinska Institutet, Stockholm, Sweden.
Background. A subpopulation of unusual CD4+ T cells lacking
the costimulatory molecule CD28 can be found in a subpopulation
of patients with chronic inflammation and to a lesser extent in
healthy individuals. These CD28nullCD4+ T cells are potent
secretors of TNF and IFN-g, and proliferate vigorously upon
stimulation. We, and others, have previously demonstrated that
circulating CD28nullCD4+ T cells can constitute of up to 50% of
CD4+ T cells in peripheral blood (PB) from patients with chronic
rheumatic diseases.
Aim. Are CD28nullCD4+ T cells present also in the inflamed
joint of rheumatic patients? And if so, are their functional profile
proinflammatory?
Methods. Mononuclear cells were isolated from PB and
synovial fluid (SF), from inflamed knee joints, of patients with
different rheumatic diseases. The cells were sorted into CD28null
and conventional CD28+ CD4+ T cells and stimulated in vitro by
anti-CD3 without the presence of antigen presenting cells.
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from patients, but only in individuals displaying this population
also in their peripheral blood. These CD28-negative cells from the
inflamed joints were confirmed to be CD28null cells since they had
the same restricted TCRVbeta repertoire as the corresponding cells
in the circulation. The joint derived CD28null cells were as
proliferative and prone to secrete proinflammatory cytokines as
the CD28null cells in PB.
Conclusion. When present in the joint CD28null cells is likely
to contribute to the inflammation as they easily expand and secrete
proinflammatory cytokines. Ongoing efforts include investigations
of synovial tissue for CD28null cells and linking the presence of
these hyperreactive T cells in the joint to a clinical feature.
Sa1.58. Absence of B Cells Decreases Both Proliferation
and Cytokine Secretion.
T. Wallerskog,1 L. Klareskog,1 V. Malmstrom,1 C. Trollmo.1
1Rheumatology Unit, Department of Medicine, Karolinska
Institutet, Stockholm, Sweden.
The aim is to analyze if the reduced proliferation and cytokine
secretion of mononuclear cells in systemic lupus erytematosus
(SLE) patients treated with the B cell depleting therapy Rituximab
can be explained by the absence of B cells.
Background and methods: Rituximab, an anti CD20 antibody
therapy, was originally developed against lymphomas, but is now
increasingly used in autoimmune diseases. Our earlier studies of
Rituximab treated SLE patients have shown that shortly after
treatment both proliferation and cytokine secretion decreased in in
vitro cultures, and increased with the return of B cells in the
circulation. To investigate if it is the lack of B cells or the
immunosupressive treatment given together with Rituximab that
accounts for this dramatic effect, we established an in vitro system.
B cells were depleted by anti CD20 magnetic beads from
peripheral blood mononuclear cells (PBMC) from three healthy
subjects. Cells were stimulated with PHA or anti-CD3 antibodies,
with or without anti-CD28 co-stimulation. Cytokine secretion and
proliferation were measured with cytometric bead array and 3H-
Thymidine incorporation.
Results: Similar to our ex vivo patient data, both proliferation
and cytokine secretion were reduced in B cell depleted PBMC
cultures as compared to intact PBMC cultures. This was true for
both PHA and anti-CD3 stimulated cells.
Mainly TNFa, IL-10 and IL-6, but also IL-4 and IL-2, were
secreted to a lesser extent.
Discussion: Our in vitro experiments indicate that it is not the
immunosuppressive treatment that accounts for the decreased
immune response seen in Rituximab treated SLE patients, but a
per se effect of the lacking B cells. Future experiments will
delineate if it is their potential to co-stimulate, to present antigens,
or to secrete cytokines that is most important for the activation of T
cells.
Sa1.59. Synovial Fluid NKT Cells Display Different
Properties Compared to Peripheral Blood NKT Cells in
Rheumatoid Arthritis.
L. Linsen, V. Somers, M. Thewissen, P. Geusens, J. Raus, P.
Stinissen. 1Biomedisch Onderzoeksinstituut (BIOMED), Limburgs
Universitair Centrum (LUC)/Transnational University Limburg
(tUL), Diepenbeek, Belgium.
Natural killer T cells (NKT) are a population of regulatory T
cells that co-express an invariant T cell receptor as well as NK cellmarkers. Several studies have shown that NKT cells are decreased
or dysfunctional in autoimmune conditions such as insulin-
dependent diabetes mellitus, systemic sclerosis, systemic lupus
erythematosus and multiple sclerosis. Significant therapeutic
effects of a-GalactosylCeramide (a-GalCer), a synthetic antigen
of NKT cells, have been demonstrated in animal models of
autoimmunity. NKT cells have therefore been implicated to
participate in the regulatory immune mechanisms controlling
autoimmunity. However, their role in the pathogenesis of
rheumatoid arthritis (RA) remains unclear. To this end, we studied
the frequency, cytokine profile and heterogeneity of NKT cells in
peripheral blood mononuclear cells (PBMC) of 23 RA patients and
22 healthy controls, which included paired PBMC-synovial fluid
(SF) samples of 7 and paired PBMC-synovial tissue (ST) samples
of 4 RA patients, respectively. Using flow cytometry, a decreased
NKT cell frequency was observed in blood of RA patients
compared to healthy controls. In addition, direct ex vivo ELISPOT
analysis revealed a reduced IL-4/IFN-g ratio in NKT cells of RA
patients. The invariant T cell receptor sequence was detected in
paired SF and ST samples. NKT cells of all healthy controls, but
only of 53.8% of the RA patients (responders) expanded upon in
vitro stimulation. However, reactivity towards a-GalCer was
observed in NKT cells isolated from SF of both responder and
non-responder RA patients. Intracellular FACS analysis of the
cytokine profile of CD4+ and CD4- PBMC derived NKT cell lines
of RA patients revealed that both produced significantly less IL-4
compared to those of healthy controls. In contrast, SF derived NKT
cell lines displayed a Th0 phenotype comparable to that of healthy
controls. These findings suggest that SF NKT cells are functional,
even in patients with non-responding NKT cells in the blood.
In conclusion, our data demonstrate that NKT cells are
decreased and biased towards a Th1 phenotype in blood, but are
not impaired in SF of RA patients. This indicates NKT cells that
might be functionally related to resistance or progression of
rheumatoid arthritis.
Sa1.60. Regulation of Myeloid Cell Function and MHC
Class II Expression by TNF.
R. B. Mueller,1 A. Skapenko,1 M. Grunke,1 J. Wendler,1 B.
Stuhlmuller,2 J. R. Kalden,1 H. Schulze-Koops.1 1Department of
Internal Medicine III, University of Erlangen, Erlangen, Germany;
2Department of Rheumatology, Charite University Hospital,
Berlin, Germany.
Neutralizing agents to TNF are the most successful means to
ameliorate systemic autoimmune inflammation. Neutralization of
TNF, however, is often associated with the development of
autoantibodies, in particular to nuclear antigens, the mechanisms
of which are unknown. Here, we analyzed the effect of TNF and its
neutralization on MHC class II expression and function of antigen
presenting myeloid cells in rheumatoid arthritis (RA). Monocytes
were isolated from the peripheral blood of RA patients before and
after anti-TNF-mAb treatment and from controls by negative
selection, differentiated in vitro into macrophages and analyzed by
flowcytometry for HLA-DR expression. T cell responses to
activation by myeloid cells were assessed in proliferation assays,
and mRNA levels of the class II transactivator (CIITA) were
determined by semiquantitative RT-PCR. HLA-DR expression was
significantly reduced on myeloid cells from RA patients with
active disease, but was increased to normal levels after TNF mAb
treatment. Concordantly, in vitro application of TNF to monocytes
from healthy individuals reduced their ability to upregulate HLA-
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inhibited their ability to stimulate T cells in mixed lymphocyte
reactions. Molecular analysis revealed that the effect of TNF on
HLA-DR expression was mediated via suppression of the tran-
scription factor CIITA. The data indicate that TNF decreases HLA-
DR expression by reducing CIITA mRNA levels in myeloid cells,
functionally resulting in a decreased stimulatory capacity of
myeloid cells for T cells. Concordantly, ameliorating disease
activity in chronic inflammatory diseases by neutralizing TNF
restores HLA-DR expression of myeloid cells and their ability to
stimulate T cells. Thus, anti-TNF treatment might lead to
augmented T cell activation by myeloid cells, thereby promoting
immune responses to (auto)antigens and the development of anti-
nuclear antibodies that are frequently associated with anti-TNF
therapy.
Sa1.61. Isolated Type 5 Antimitochondrial
Autoantibodies Associated with History of
Thrombocytopaenia and Foetal Loss.
Alvarez Silvia, Sanchez-Ramon Silvia, Rodriguez-Mahou
Margarita, Carbone Javier, Gil Juana, Micheloud Dariela,
Fernandez-Cruz Eduardo. 1Immunology, University General
Hospital Gregorio Maranon, Madrid, Spain.
Anti-mitochondrial (AMA) of M5 type antibodies were initially
described in patients with autoimmune diseases, and then have
been identified in sera of patients with antiphospholipid antibodies
and recurrent foetal loss, haemolytic anaemia and thrombocyto-
paenia, and have controversial association with thrombosis. Up to
date, very scarce literature exists regarding M5 type AMA. AMA
of M5 type are directed towards an unknown antigen located in the
inner membranes of mitochondria (50 kDa). Indeed, M5 type
AMA have been always reported in the context of antiphospholipid
syndrome strictly linked to antiphospholipid antibodies.
We report here on a 65-years-old Caucasian woman diagnosed
as autoimmune polyglandular syndrome (APS) IIIC type, namely
autoimmune thyroiditis, pernicious anaemia and recurrent idio-
pathic thrombocytopaenic purpura. Clinical history was also
relevant for two foetal losses at 2 and 4 gestational months,
respectively, associated to persistent M5 type AMA at high titre
(1/640). Antinuclear, anti-DNA and antiphospholipid antibodies
(anticardiolipin, anti-beta-2-glicoprotein-I) were all of them persis-
tently negative through a 10-years follow-up period. Coagulation
studies were repeatedly normal.Conclusion: In our patient, type 5
AMA was the only marker of thrombocytopenia and recurrent
miscarriages without antiphospholipid antibodies. In isolated cases,
M5 Abs appear to be a diagnostic marker for clinical manifestations
of antiphospholipid syndrome.
Sa1.62. FOXP3+ Regulatory T Cells in the Rheumatic
Joint: Contribution of Both CD25+ and CD25- T Cells.
D. Cao,1 A. -K. Ulfgren,1 C. Trollmo,1 V. Malmstrom.1 1Dept of
Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm,
Sweden.
Background
Natural regulatory T cells are usually identified in two ways; by
mRNA expression of the transcription factor FOXP3 or by the
level of surface expression of CD25. Humans are never immuno-
logically naRve, resulting in T cells expressing CD25 also due to
activation. Thus, frequency determinations based on CD25
expressing regulatory T cells can never be more than rough
estimates.Objective
In this study we investigate the presence of regulatory T cells in
different compartments of patients with rheumatic joint disease. We
compare CD25 and FOXP3 in peripheral blood and the site of
inflammation, by analyzing both synovial fluid and synovial tissue.
Materials and methods
FOXP3 mRNA levels were investigated from sorted peripheral
blood and synovial fluid CD4 T cells populations. The sorted
populations expressed different densities of CD25. RNA was also
prepared from synovial tissue biopsies. Additionally, CD25- T cells
were activated in vitro to investigate possible induction of FOXP3.
Results and discussion
We could find FOXP3 message in all compartments inves-
tigated, even in biopsies from synovial tissue. In synovial fluid, the
CD25bright cells were markedly enriched for FOXP3 compared to
the CD25int, while the difference between the two CD25
populations were less apparent in blood. Interestingly, also cells
negative for CD25 could be FOXP3+, and this was more common
in synovial fluid than in blood.
Thus, our study shows that FOXP3+ regulatory T cells are not
restricted solely to CD25+ T cells. Especially in an inflammatory
environment like synovial fluid FOXP3+ CD25- T cells were
found. An induction of FOXP3 in CD25- cells could not be
mimicked in vitro perhaps suggesting that these regulatory T cells
originate from CD25+ cells that have downregulated or shed their
CD25 expression. Such a scenario is supported by studies showing
the presence of soluble CD25 in both sera and synovial fluid from
rheumatic patients.
Sa1.63. Increased Systemic and Local Expression of
Toll-Like Receptor 2 and 4 in Spondyloarthropathy Is
Downmodulated by Tumour Necrosis Factor alpha
Blockade.
L. De Rycke,1 B. Vandooren,1 E. Kruithof,1 F. De Keyser,1 E. M.
Veys,1 D. Baeten.1 1Rheumatology, Ghent University Hospital,
Ghent, Belgium.
Objective: An abnormal host defense against pathogens is
implicated in the pathogenesis of spondyloarthropathy (SpA), a
disease characterized by abundant synovial infiltration with innate
immune cells. Considering the role of Toll-like receptors (TLRs) in
activation of innate inflammation and occurence of TLR-dependent
infections after TNFalpha blockade, we analyzed TLRs in SpA and
their modulation by TNFalpha blockade.
Methods: Peripheral blood monocytes were obtained in SpA
and rheumatoid arthritis (RA) during infliximab therapy and in
healthy controls (HC). Expression of TLR2 and TLR4 and
TNFalpha production upon LPS stimulation were analyzed by
flowcytometry on different monocyte subsets. Synovial biopsies
from 23 SpA before and after infliximab or etanercept treatment
and from 15 RA were analyzed by immunohistochemistry.
Results: TLR4, but not TLR2, expression was increased on
monocytes in SpA, whereas both TLRs were increased in RA. The
CD163+ macrophage subset, which is increased at the inflamma-
tory sites in SpA, has a particularly increased TLR expression.
Accordingly, expression of both TLRs was significantly higher in
SpA than in RA synovium. Infliximab decreased TLR2 and TLR4
expression on monocytes in SpA and RA, leading to lower levels
than in HC and to an impaired TNFalpha production upon LPS
stimulation. Paralleling the systemic effect, synovial TLRs were
downregulated following infliximab as well as etanercept, indicat-
ing a class-effect of TNFalpha blockers.
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TLR2 and TLR4 expression which are sharply reduced by
TNFalpha blockade. These data emphasize a central role for innate
immune-mediated inflammation in SpA and provide an additional
clue for the efficacy as well as the potential side-effects of
TNFalpha blockade.
Sa1.64. IgM Anti-dsDNA Antibodies Are the Main
Anti-Nuclear Reactivity Induced by Infliximab but
Not Etanercept Treatment: Biological and
Clinical Implications.
L. De Rycke,1 D. Baeten,1 E. Kruithof,1 E. M. Veys,1 F. De
Keyser.1 1Rheumatology, Ghent University Hospital, Ghent,
Belgium.
Background: Previously, we demonstrated anti-nuclear anti-
body (ANA) and anti-dsDNA antibody induction after 30/34
weeks of infliximab therapy in rheumatoid arthritis (RA) and
spondyloarthropathy (SpA).
Aim: To further assess in detail the clinical and biological
correlates of autoantibody induction during longer-term TNFalpha
blockade with either the monoclonal antibody infliximab or the
soluble receptor etanercept.
Methods: 34 SpA and 59 RA patients were treated with
infliximab for two years. Additionally, 20 SpA patients were
treated with etanercept for one year, providing a unique head-to-
head comparison of autoantibody induction during TNFalpha
blockade in a human disease model with low baseline auto-
immunity. Sera were blindly analysed for ANA, anti-dsDNA, anti-
ENA, anti-histone and anti-cardiolipin antibodies. The anti-dsDNA
antibodies were further isotyped with gamma-, mu- and alpha-
chain specific conjugates.
Results: In the infliximab-treated SpA and RA cohorts, we
observed high numbers of newly induced ANA (61.8% and 40.7%)
and anti-dsDNA antibodies (70.6% and 49.2%) after one year, but
no further increase between year 1 and year 2. In contrast,
induction of ANA (10%) or anti-dsDNA antibodies (10%) was
only occasionally found in the etanercept-treated SpA cohort.
Neither during infliximab nor etanercept, anti-ENA, anti-histone
antibodies or clinically relevant lupus-like symptoms were
described. Isotyping revealed predominantly IgM and/or IgA
anti-dsDNA antibodies. Similarly, infliximab but not etanercept
selectively increased the IgM but not the IgG anti-cardiolipin
titers.
Conclusion: This study indicates that the prominent ANA and
anti-dsDNA autoantibody response is not a pure class effect of
TNFalpha blockers, is independent of the disease background and
is not associated with clinically relevant lupus-symptoms.
Sa1.65. High Serum Levels of Chemokines but Low
Expression of Chemokine Receptors of Peripheral Blood
Mononuclear Cells in Juvenile Systemic Lupus
Erythematosus.
J. -L. Huang,1 C. -J. Lin,2,3 C. -L. Liu,4 T. -C. Yao,1 H. -Y. Chang,2
G.-W. Chen,2 C.-R. Shen.2 1Division of Rheumatology, Chang
Gung Children Hospital, Kweishan, Taoyuan, Taiwan; 2Graduate
Institute of Medical Biotechnology, Chang Gung University,
Kweishan, Taoyuan, Taiwan; 3Department of Loaboratory
Medicine, Mackay Memorial Hospital, Taipei, Taipei, Taiwan;
4Graduate Institute of Engineering and Department of
Biochemical Engineering, Ming-Chi University of Technology,
Taishan, Taipei, Taiwan.Systemic lupus erythematosus (SLE) is a chronic autoimmune
disease and immune function in SLE is paradoxically charac-
terized by active T cell help for autoantibody production, along
with impaired T cell proliferative and cytokine responses in vitro.
Recently, evidence reveals that chemokines as well as chemokine
receptors are closely involved in initiating the hyperreactivity.
This study was designed to investigate the expression levels of
various chemokines and their receptors in relation to the disease
activity of juvenile SLE, and to compare the pattern of
chemokine elevations with that in normal individuals. Serum
levels of chemokines including CCL-2, CCL-5, CXCL-8, -9 and-
10 were analyzed by chemokine cytomeric beads arrays (CBA),
whereas the expression of chemokine receptors such as CCR-2,
-3, -4, and-5 on peripheral blood mononuclear cells (PBMC)
were assessed by real-time RT-PCR and/or Western blot. Here
we demonstrate the difference of chemokines and their receptors
expression in juvenile SLE patients compared with normal
individuals. Significantly higher serum levels of CCL-2 (MCP-
1), CXCL-8 (IL-8), -9 (MIG) and-10 (IP-10) were found in most
SLE patients analyzed, while their chemokine receptors such as
CCR-2, -3, -4, and-5 were expressed relatively low in patientsT
PBMC. Analysis between clinical manifestations such as
SLEDAI (Systemic Lupus Erythematosus Disease Activity
Index) and levels of the above chemokines expression levels
revealed a strong correlation. However, decreased serum levels
of CCL-2, CXCL-9 and CXCL-10 appeared in patients with high
levels of anti-dsDNA if compared with those in patients with
low anti-dsDNA. Overall, four chemokines that were elevated in
SLE were proinflammatory, characteristic of activation of the
monocyte and macrophage lineage, and in the case of IL-8, also
of neutrophils. These data suggest a major role for a cell-
mediated immune response occurring in the pathophysiology of
SLE.
Sa1.66. Modulation of Murine Lupus by an Inhibitory
GpG Oligonucleotide.
K. L. Graham,1 L. Y. Lee,2 P. Teo,1 L. Steinman,2 P. J. Utz,1
P. P. Ho.2 1Department of Medicine, Division of Immunology and
Rheumatology, Stanford University School of Medicine, Stanford,
CA, USA; 2Department of Neurology, Stanford University School
of Medicine, Stanford, CA, USA.
Activation of the innate immune system by DNA containing
hypomethylated CpG motifs has been implicated in the patho-
genesis of systemic lupus erythematosus (SLE). We have
previously described an immunomodulatory oligodeoxynucleo-
tide (ODN), containing a single base switch from CpG to GpG,
which ameliorated murine experimental autoimmune encephalo-
myelitis (EAE), a T helper 1-mediated model of human multiple
sclerosis. Here, we examined the consequences of immunosti-
mulatory CpG-ODN and inhibitory GpG-ODN treatment in the
NZBNZW F1 (NZB/W) murine model of SLE. Beginning at 5
months of age, we administered CpG or GpG ODNs at regular
intervals to female NZB/W animals, over a period of 20 weeks.
While CpG-ODN treatment did not appear to impact overall
disease severity, GpG-ODN treatment significantly delayed the
onset of proteinuria, and improved 40-week survival in NZB/W
mice. We also determined the effects of ODN administration on
NZB/W T lymphocyte cytokine profiles and splenocyte surface
marker expression. Interestingly, GpG-ODN treatment enhanced
production of TNF-a by NZB/W T cells, and inhibited T cell
production of IL-4. Consistent with observations made in the
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treated NZB/W mice also displayed reduced surface expression
of CD80 and CD86. Taken together, the data indicate that GpG-
ODN treatment can modulate immune cell function and
ameliorate disease in the NZB/W model of lupus nephritis.
The protective mechanism of the GpG-ODN in murine SLE may
involve general inhibitory effects on costimulatory molecule
expression by antigen presenting cells, as well as alteration of T
cell cytokine profiles.
Sa1.67. The Phosphodiesterase Inhibitor Rolipram
Facilitates the Suppression of Antigen-Induced Arthritis
in Mice by Oral Administration of the Inducing Antigen.
Shin Yoshino,1 Kouya Yamaki,1 Yoshiki Harada.1 1Department of
Pharmacology, Kobe Pharmaceutical University, Kobe, Hyogo,
Japan.
Clinical trials of the oral treatment of patients with auto-
immune diseases including rheumatoid arthritis and multiple
sclerosis with type II collagen and myelin, respectively, showed
disappointing results. This may be in part due to the insufficient
induction of oral tolerance to the respective autoantigen in
humans. Therefore, we have looked for agents that can facilitate
induction of oral tolerance. In the present study, we tested the
hypothesis that the phosphodiesterase IV inhibitor rolipram, that
was previously reported to produce suppressive cytokines
including TGF-beta and IL-10, can facilitate the suppression of
antigen-induced arthritis (AIA) in mice by oral administration of
the inducing antigen. Such suppressive cytokines have been
shown to play a role in oral tolerance, especially induced by low
doses of oral antigen. To prove the hypothesis, DBA/1J mice
were immunized with ovalbumin (OVA) emulsified with CFA
(day 0). AIA was induced by intraarticular injection of OVA in
PBS on day 21. Oral tolerance was induced by oral admin-
istration of either 0.1 or 10 mg of OVA daily over a period of 5
consecutive days commencing on day -5. Rolipram (1 and 3 mg/
kg) was orally given immediately before each administration of
OVA. The results showed that oral administration of 0.1 and 10
mg of OVA alone was followed by suppression of AIA, although
the extent of suppression of AIA was greater in mice fed 10 than
0.1 mg of the oral antigen. When 0.1 mg of OVA was given
together with rolipram, significantly facilitated suppression of
AIA was observed. Co-administration of 10 mg of OVA and
rolipram failed to modulate the suppression of AIA caused by the
oral antigen alone. Secretion of IFN-gamma from spleen cells
was suppressed by 0.1mg of oral OVA alone and this suppression
was significantly enhanced in mice given both the antigen and
rolipram. In contrast, the suppression of IFN-gamma secretion by
administration of 20 mg of OVA alone was blocked by the
combination of the same dose of the antigen and rolipram. There
was no difference in the secretion of IL-10 between either 0.1 or
10 mg of OVA alone- and OVA plus rolipram-treated groups.
These results suggest that rolipram appears to facilitate the
suppression of AIA by oral administration of low (0.1 mg) but
not high (10 mg) doses of OVA. This may be in part explained
by significantly accelerated decreases in IFN-gamma in mice
treated with the lose dose of OVA plus rolipram. In our studies,
the facilitated suppression of AIA by the administration of the
oral antigen together with the phosphodiesterase IV inhibitor does
not appear to be mediated by the modulation of IL-10 secretion.
Agents such as rolipram that facilitate induction of oral tolerance
might be useful in the treatment of autoimmune diseases inhumans including rheumatoid arthritis with oral pathogenic
autoantigens.
Sa1.68. Therapeutic Response of Rituximab in a Patient
with Amyopathic Dermatomyositis Refractory to
Methotrexate and Cyclosporin.
S. M. Fung, R. Herzog, Y. Padeh, A. Rubenstein. 1Division of
Allergy and Immunology, Albert Einstein College of Medicine,
Bronx, NY, USA.
Objective: Rituximab, an anti-CD20 monoclonal antibody, has
become a target for immunotherapy of B cell lymphomas and,
more recently, B cell-mediated autoimmune diseases. We report a
case involving a 45 year old female patient with severe auto-
immune disease and B cell immunodeficiency who was treated
with rituximab.
Findings: The patient initially presented at 42 years of age with
RaynaudTs phenomenon, positive anti-nuclear antibody (ANA),
and positive thyroid peroxidase antibodies. Fever, oral and vaginal
ulcers, polyarthritis, digital vasculitis, elevated erythrocyte sed-
imentation rate, and elevated rheumatoid factor (RF) also
developed. The mixed connective tissue disease was treated with
azathioprine, hydroxychloroquine, and methylprednisolone. Mean-
while digital infarcts, polychondritis, and a malar facial rash
occurred. A classic dermatomyositis rash was confirmed by skin
biopsy. Subsequently, her amyopathic dermatomyositis was treated
with intravenous immunoglobulin (IVIG) 25 grams in addition to
methotrexate 25 mg weekly and cyclosporin resulting in limited
improvement. Painful, debilitating digital infarcts, Coombs pos-
itive hemolytic anemia, and pulmonary vasculitis evolved. Upon
our immune evaluation, lymphocyte studies showed a low B cell
percentage of 4%, a low absolute B cell count of 53 cells/ml,
increased CD4+CD45RA+ naRve T cells at 51%, and low
CD4CD45RO+ memory T cells at 27%. Additionally, lymphocytic
mitogenic responses were markedly decreased to StaphA, a B cell
mitogen. Also, there was an increase in C3D immune complexes.
RF was elevated at 58 IU/ml and Epstein Barr Virus (EBV)
serology showed a high titer viral capsid antigen IgG and high titer
early antigen antibody suggestive of reactivated EBV disease.
Treatment of dermatomyositis with an underlying B cell immuno-
deficiency was started with high dose IVIG at 1 gram/kg of
Gammunex combined with cyclophosphamide and steroids. There-
after, all in vitro markers of autoimmunity including C-reactive
protein, ANA, direct Coombs, and RF normalized. However, her
pulmonary and upper extremity vasculitis progressed. Rituximab
therapy was considered because our immune evaluation revealed
a preponderance of CD20+ cells. Five weekly doses of rituximab
at 375 mg/m2 were added to the high-dose IVIG, cyclo-
phosphamide, and steroid therapy. The pulmonary vasculitis
improved, digital infarcts and ulcers slowly healed, and all
autoimmune markers including RF became normal. Immune
studies repeatedly showed b1% CD19+ and CD20+ cells at 24
weeks. The patient was weaned off cyclophosphamide and
remains on IVIG and low dose prednisone with no further
exacerbations of her autoimmune disease at 24 weeks.
Conclusion: Our patient with a severe, refractory autoimmune
disease and underlying B cell defect responded successfully to
addition of rituximab, specifically targeting a B-cell mediated
autoimmune process. The favorable response of rituximab in our
patient is supported by recent published reports showing B cell
depletion with rituximab led to a sustained clinical response in
methotrexate-resistant rheumatoid arthritis.
Abstracts S111Sa1.69. Azathioprine Use but Not Hydroxycholorquine
or Prednisone Use Is Associated with Lower Coronary
Artery Calcification Determined by Electron Beam
Computed Tomography (EBCT) in SLE Patients.
E. R. Gehrie,1 A. J. Cucchiara,1 E. Nackos,1 J. M. Von Feldt.1
1Department of Rheumatology, University of Pennsylvania,
Philadelphia, PA, USA.
Purpose: To determine if several of the DMARDs, B-blockers,
ACE-I, or aspirin are associated with the presence of coronary
calcification by Electron Beam Computed Tomography (EBCT) in
SLE patients.
Methods: One hundred and thirty seven patients with SLE over
the age of 18 who fulfilled at least 4 of the American College of
Rheumatology criteria for the classification of SLE were recruited
for the study. A history, physical exam, EKG and EBCT measuring
coronary calcium were performed. Results from the EBCT were
used as an independent measure of current cardiovascular disease.
The information regarding current, past and number of years on a
medication was recorded. Analysis inculding standard studentTs t-
test was performed on the data.
Results: A t-test analysis of the data showed that when
comparing patients with SLE who were currently on azathioprine
to patients with SLE who were not currently taking the drug, those
on the drug had a lower EBCT calcium score, (P = 0.03). Results
were unchanged when beverQ users were added to the analysis.
Comparison of SLE patients taking hydroxycholoroquine to those
who were never on hydroxycholoroquine showed no difference in
EBCT calcium score, (P = 0.59). Comparison of SLE patients on
prednisone to those SLE patients never on prednisone showed no
difference in EBCT score, (P = 0.35). SLE patients having received
intravenous cyclophosphamide also showed no difference in EBCT
score compared to those who were never exposed to the drug, (P =
0.48). SLE patients taking mycophenolate mofetil and methotrexate
similarly showed no difference in EBCT score for those exposed
versus not exposed, (P = 0.15 and P = 0.24 respectively). SLE
patients on statins had a higher EBCT calcium score than those not
on the drugs, (P = 0.02) and SLE patients on B-blockers also had a
higher EBCT score than those not on the drug, (P = .008). Patients
on ACE-I and aspirin show no difference in EBCT score compared
to those not on these drugs, (P = 0.24 and P = 0.22, respectively).
Discussion: Ever or current azathioprine use is associated with
lower EBCT calcium score in SLE patients. Azathioprine is
associated with decrease in inflammation in the endothelium and
may affect the extent of coronary calcification (Weigel et al,
Thrombosis Research. 94(2):87-94, 1999 Apr 15. Gao et al,
Circulation. 80(5 Pt 2):III100-5, 1989 Nov). The other DMARDs
studied were not associated with lower coronary calcification. The
higher EBCT score associated with B-blocker and statin use is
likely associated with previously identified cardiovascular risk
factors in these patients.
Sa1.70. Proteomic Analysis of Secreted Proteins Defines
Subtypes of Rheumatoid Arthritis.
W. Hueber,1,2 B. H. Tomooka,1,2 W. J. van Venrooij,3 P. J. Utz,1
M. C. Genovese,1 W. H. Robinson.1,2 1Division of Immunology
and Rheumatology, Stanford University School of Medicine,
Stanford, CA, USA; 2GRECC, VA Palo Alto Heath Care System,
Palo Alto, CA, USA; 3Department of Biocehmistry, Radboud
University Nijmegen, Nijmegen, Netherlands.
Rheumatoid arthritis (RA) is an autoimmune synovitis charac-
terized by heterogeneity between patients in disease manifesta-tions, clinical outcomes and therapeutic responses. We applied
synovial antigen microarrays and a bead-based multiplex cytokine
assay to profile autoantibody and cytokine responses in RA, with
the objective of identifying profiles of secreted proteins in blood
that provide diagnostic information and delineate disease subtypes.
We demonstrate that autoreactive B cell responses targeting
deiminated epitopes and elevated serum concentrations of proin-
flammatory cytokines (TNFa, IL-1a, IL-1b, IL-6, and IL-15) were
present in a subset of early RA patients with features predictive for
development of severe RA. In contrast, autoimmune targeting of
the native epitopes contained on synovial arrays, including human
glycoprotein 39 and collagen types II and V, and low concen-
trations of serum cytokines were associated with predictors of less-
severe RA. Proteomic analysis of secreted proteins enables
molecular stratification of patients with early RA into clinically-
relevant disease subsets.
Sa1.71. Death Receptor 5 as a Therapeutic Target:
Increased Expression in B and T Cell Subsets in SLE.
R. H. Carter,1 S. Pandey,1 T. Zhou.1 1Dept. of Medicine, University
of Alabama at Birmingham, Birmingham, AL, USA.
Ligation of Death Receptor 5 (DR5) induces cell death in
activated B and T cells. TRAIL, a DR5 ligand, can reduce disease
manifestations in animal models. Thus, DR5 is an attractive target
for therapeutic elimination of pathogenic lymphocytes in auto-
immune diseases. To determine which lymphocytes express DR5,
subsets of B and T cells from human blood, tonsil and spleen were
identified by surface markers and analyzed for binding of anti-DR5
mAb. Germinal center B cells in the tonsil and spleen expressed
DR5, as did plasmablasts in these tissues and in blood. CD38-
intermediate cells in the blood did not, consistent with the
phenotypic characterization of these as transitional cells. The
increase in plasmablasts in the circulation in SLE subjects resulted
in an increase in the percentage of blood B cells expressing DR5. A
small but reproducible increase in DR5 expression on post-naive
subsets was observed in both CD4 and CD8 T cells in healthy
subjects. However, DR5 expression was significantly greater in
these same subsets of T cells from lupus subjects, compared to the
same subsets in healthy controls. Thus, DR5 expression appears to
be modulated by both differentiation and by other factors, possibly
including disease-associated factors such as type 1 IFN. Therapeu-
tic targeting of DR5-expressing cells would spare resting B cells
and naive T cells but has the potential to eliminate activated cells to
a degree that would be determined by disease-specific mechanisms.
Sa1.72. Immune Response to a Citrullinated Peptide of
Fibrinogen in DR4 tg Mice Following Intra-Articular
Injection of Streptococcal Cell Wall Antigen.
W. Brintnell,1 J. A. Hill,1 C. Nadasdy,1 D. A. Bell,1 E. Cairns.1
1Department of Medicine, Division of Rheumatology and
Department of Microbiology and Immunology, London Health
Sciences Centre, University of Western Ontario, London, ON,
Canada.
Background/Purpose:
Anti-citrulline antibodies are highly specific serologic markers
for RA and the immune response to citrulline is linked to the
expression of the RA shared epitope. We have previously
demonstrated that DR4 tg mice immunized with citrulline develop
arthritis. While citrullination of polypeptides under the influence of
peptidyl arginine deiminase (PAD) has been shown to be
unregulated in normal mice following the induction of inflamma-
AbstractsS112tion (Streptococcal cell wall (SCW) induced), these mice do not
develop an immune response to citrulline or chronic arthritis. We
sought to investigate the arthritogenic properties of and immune
response to citrullinated proteins following acute SCW arthritis
induction in DR4-tg mice.
Methods:
25 Ag of streptococcal cell wall antigen (Streptococcus
pyogenes Group A PGPS 10S, Lee Laboratories Grayson, Georgia,
USA) in 5.0 Al of PBS was injected into one knee joint of DR4 tg
and wt mice. The other knee joint of these mice received 5.0 Al of
PBS. Mice were sacrificed at various time points to investigate
pathological changes, and T and B-cell immune responses.
Results:
Pathology of the injected joint from day 2 demonstrated a
massive influx of leukocytes and the start of synovial proliferation.
Approximately 75% of the leukocyte infiltration had dissipated by
day 7. At day 7, synovial hyperplasia, the first signs of erosion at
the bone cartilage surface by the proliferating synoviocytes, and
depletion of approximately 50% of the proteoglycan normally
present in the articular cartilage was observed. Splenic T-cell
proliferation was observed in the DR4 tg mice at various time
points with a citrullinated peptide of the a chain of fibrinogen
(QDF TNCit INK LKN S) but this was not evident in the wt mice.
No T-cell proliferation was detected in either group of mice when
stimulated with the unmodified version of this peptide.
Conclusion:
SCW as expected induced an acute inflammatory arthritis in
both normal wt and DR4 tg mice. This was followed by a strong
citrulline specific T-cell response only in the DR4 tg mice,
presumably by the inflammatory induced expression of PAD and
citrullinated fibrinogen. These observations are consistent with our
previous studies indicating that the T-cell response to citrulline is
restricted by MHC class II molecules expressing the shared epitope.
This SCW induced arthritis in DR4 tg mice represents a good model
to evaluate the immunogenetic effects of citrulline in-vivo,
including the development of citrulline induced arthritis.
Sa1.73. Homozygous Type I C2 Deficiency and
Immunoglobulin Deficiencies in a HLA-B27 Positive
Young Girl Presenting with an Antinuclear
Antibody-Positive Juvenile Rheumatoid Arthritis.
G. Hauptmann,1 A. Meyer,2 B. Uring-Lambert,1 J. Goetz,2 I.
Jahn,2 S. Finck,3 B. Cribier,4 D. Lipsker.4 1Centre de Recherche
dTImmunologie, Faculte de Medecine, Strasbourg, France;
2Laboratoire dTImmunologie, Hopitaux Universitaires, Strasbourg,
France; 3Service de Pediatrie, Centre Hospitalier, Haguenau,
France; 4Service de Dermatologie, Hopitaux Universitaires,
Strasbourg, France.
A homozygous type I C2 deficiency was evidenced in a 11-
year old girl which was found to be also HLA-B27 positive. This
young girl, with antecedents of recurrent otitis media, was
admitted to the hospital for a polyarticular arthritis with fever,
significant inflammatory syndrome (increased ESR, C-reactive
protein and fibrinogen), mild normocytic anaemia, abnormal liver
function tests but no eye inflammation. She was found to have
antinuclear antibodies at 1:640 on Hep2 cells with a speckled
pattern and nuclear dots. Antibodies against extractable nuclear
antigens and nDNA were not found. Complement analyses
showed the absence of serum hemolytic activity, normal C4,
elevated C3 levels and undetectable C2. Homozygous type I C2
deficiency was confirmed by PCR analysis of the C2 gene (28-bpdeletion). Factor B and C4 allotyping showed that the patient was
typically homozygous for C2*Q0, BF*S, C4A*4 and C4B*2
(bS042Q complotype). This complotype was linked on one
chromosome to the typical HLA-A*25, B*18, DRB1*15(2),
DQB1*06(1) bancestralQ haplotype but on the other chromosome
to HLA-A*2, B*27, DRB1*13(6), DQB1*06(1) which represents
a very unusual association with the S042 complotype. Upon
serum immunoglobulin determinations, IgD and IgG4 immuno-
globulins could not be detected, IgA and IgM levels were close to
the lower normal range. Altogether, the clinical syndrome in this
patient was related both to homozygous C2 deficiency and
positivity for HLA-B27.
Sa1.74. The Combination of Complement Deficiency and
Cigarette Smoking as Risk Factor for Cutaneous Lupus
Erythematosus (CLE) in Men; a Focus on Combined C2/
C4 Deficiency.
G. Hauptmann,1 P. Boeckler,2 M. Milea,2 A. Meyer,3 B.
Uring-Lambert,1 J. Goetz,3 B. Cribier,2 D. Lipsker.2 1Centre de
Recherche dTImmunologie, Faculte de Medecine, Strasbourg,
France; 2Service de Dermatologie, Hopitaux Universitaires,
Strasbourg, France; 3Laboratoire dTImmunologie, Hopitaux
Universitaires, Strasbourg, France.
Although deficiencies in the components of the classical path-
way of complement activation were among the first identified risk
factors for systemic lupus erythematosus (SLE), only a few studies
addressed their significance in patients with cutaneous lupus
erythematosus (CLE). Among environmental factors, it was
postulated that cigarette smoking might intervene in the patho-
genesis of LE.
In a retrospective study of 85 patients with CLE, 32 individuals
were screened for C4 and/or C2 deficiency. Among them 17 had a
C4A deficiency (1 homozygous- 16 heterozygous), five a C4B
deficiency (2 homozygous- 3 heterozygous), and two a combined
heterozygous C2 and C4A deficiency. The serum level of C4 was
decreased in 40 % of patients with C4B deficiency and in only 5 %
of patients with C4A deficiency. The C3 level was normal in all
patients. A high proportion (58 %) of these complement-deficient
patients were male (F/M ratio = 0.70); the mean age at diagnosis
was 36 years. Of particular interest was the detection of a
combined heterozygous C2 (type I) and heterozygous C4A
deficiency in two male patients. This combined deficiency was
only rarely reported up to now but its expected frequency in the
caucasion population of European descent should approximate 0.1
% and its frequency in patients with LE is unknown. In this series,
82 % of the patients were smokers and 94 % of male patients with
CLE were smokers. By comparison, the frequency of smoking in
the normal French men and women is about 33 % and 36 %,
respectively. It has been recently suggested that smoking behaviour
could be related to specific major histocompatibility complex
haplotype(s) on chromosome 6 characterized by the presence of a
C4A null allele. Our findings seem to corroborate this hypothesis
which needs to be confirmed by large prospective studies.
Sa1.75. Pregnancy Outcomes in Ten Japanese Women
with Mixed Connective Tissue Disease.
K. Abe, R. Matudaira, Y. Takasaki, H. Hashimoto. 1Internal
Medicine and Rheumatology, Juntendo University School of
Medicine, Tokyo, Japan.
Objective: Only a few studies on pregnancy outcome in
patients with mixed connective tissue disease(MCTD) are available
Abstracts S113and their results are contradictory. The purpose of this study is to
examine pregnancy and fetal outcomes in MCTD patients.
Methods: A retrospective study we have followed ten mothers
with MCTD, during their pregnancies since 1999 to 2003 at
Juntendo University Hospital.
Result: 1. Of the 10 pregnancies, we observed 5(50%) live
birth at term, 2(20%) premature birth, 2(20%) spontaneous
abortion, 1(10%) artificial abortion.
2. One case had interstitial pneumonia and high titer of sialyl
carbohydrate antigen KL-6 following no therapy, KL-6 level was
decreased during pregnancy. At 37 weeks of gestation, the
laboratory findings were suggestive of early HELLP syndrome,
and the pregnancy was terminated.
3. Two of 10 pregnancies with renal involvement resulted in
spontaneous abortion. Serum anti-phospholipid antibodies were not
determined either. And active nephritis was recognized at the
pregnancy.
Conclusions: Since MCTD has a relatively good prognosis, no
therapy changes are required during pregnancy. But premature
delivery and spontaneous abortion were high rate in this study. It
considered that organic involvement and flare are possibility of risk
for pregnancy with MCTD women.
Sa1.76. Characteristics of Patients with Clinical
Manifestations of APS with Anti-beta2-Glycoprotein-I
but Not Anticardiolipin Antibodies or Any Other
Autoimmune Condition.
D. Micheloud,1 J. Carbone,1 S. Sanchez-Ramon,1 J.
Lopez-Longo,2 A. Velastegui,1 J. Ruiz-Tiscar,1 E. Sarmiento,1
E. Fernandez-Cruz,1 M. Rodriguez-Mahou.1 1Autoimmunity
Section, Immunology Department, University Hospital Gregorio
Maranon, Madrid, Spain; 2Rheumatology Department, University
Hospital Gregorio Maranon, Madrid, Spain.
Background: Clinical and immunological abnormalities of
patients with clinical manifestations of the antiphospholipid
syndrome (APS), with anti-beta2-glycoprotein-I antibodies (anti-
b2-GP-I) but without serum anticardiolipin antibodies (aCL) or
any other autoimmune condition are not well documented.
Materials. From July 2002 through July 2003, 1179 serum
samples obtained in our hospital in the Community of Madrid,
were tested for anti-b2-GP-I and aCL antibodies by enzyme–
linked immunosorbent assay. A total of 56 patients with
discordant anti-b2-GP-I and aCL antibodies were identified.
Fifteen out of 56 patients (26.8%) had positive anti-b2-GP-I and
negative aCL. The patients had repeated determinations of aCL
and lupus anticoagulant, all of which have been negative.
Results: A logistic regression analysis, adjusting for the
variables age, sex and risk factors of thrombosis showed that
the risk for developing APS criteria associated with anti-b2-GP-I
antibodies was significant [odds ratio 3,88; 95% confidence
interval: 1.05-14.27; P = 0.04). Five out of 15 anti-b2-GP-I-positive
patients (4 female, 1 male) had clinical APS, without serological nor
clinical evidence of any autoimmune disease during a mean follow-
up of 31.2 months [deep vein thrombosis (DVTs) n = 2; DVTs +
pulmonary thromboembolism n = 2 and retinal thrombosis n = 1].
The only abnormal immunological test observed in those five anti-
b2-GP-I-positive-patients was the findings of IgM hypergamma-
globulinemia in one patient. Use of oral anticoagulants were given
to only one anti-b2-GP-I-patient. Conclusion: Not rarely clinicians
might be in front of patients that accomplish clinical criteria of APS
but they do not have the autoantibodies listed in the classificationcriteria set of APS. Determination of anti-b2-GP-I should be taken
into account in the evaluation of individual cases with clinical
characteristics of the APS and repeated negative results on
conventional antiphospholipid antibody tests.
Sa1.77. Transcriptional Regulation of Fli1 and Lupus.
J. D. Fulton,1 G. Gilkeson,1 T. Nowling.1 1Medicine,
Rheumatology Div., Medical University of South Carolina,
Charleston, SC, USA.
The Ets transcription factor Fli1 functions as a regulator of
hematopoiesis and hemostasis and is required for early develop-
ment. Fli1 also has been implicated in the regulation of the
immune system and autoimmunity. Fli1 is expressed in the
thymus and spleen and its overexpression in mice results in the
development of immunological renal disease similar to that
observed in systemic lupus erythematosus. Elevated expression
of Fli1 has been observed in the spleen of lupus mouse models
NZB/NZW f1 and MRL/lpr. Furthermore, elevated levels of Fli1
in peripheral blood monocytes from lupus patients correlates
with disease activity. Interestingly, MRL/lpr mice that have a
heterozygous knockout of Fli1, and a subsequent 50% reduction
in Fli1 expression, have significantly reduced renal disease and
prolonged survival. These studies strongly indicate that Fli1
plays an important role in the pathogenesis of lupus. To further
understand the role of Fli1 in the immune system we are
examining the regulation of Fli1 in normal and lupus mice. Our
preliminary results show that Fli1 expression is higher in CD19+
and CD8+ cells from predisease NZM2410 and MRL/lpr lupus
prone mice and in CD8+ cells from late disease MRL/lpr mice
compared to BALB/c mice. Transient transfections of Fli1
promoter/reporter constructs into a B cell line indicate that the
highest level of expression is driven by a 400 bp region
encompassing most of exon 1 and that most of the positive
regulatory elements necessary for this expression are localized
within a 200 bp region. Furthermore, we have examined the
promoter and upstream regulatory regions of Fli1 from BALB/c,
NZM2410 and MRL/lpr spleen and identified a polymorphism
in exon 1. Transient transfection analyses indicate this poly-
morphic region contributes to the positive regulation of Fli1
promoter/reporter constructs. Interestingly, this region is highly
homologous to the human Fli1 sequence and is located adjacent
to a regulatory element found to be necessary for Fli1
expression in a leukemia cell line. Further analyses of the
regulatory region, including the polymorphism, will allow
further insight into what elements and binding factors are
necessary for normal expression, as well as aberrant expression
in lupus prone mice.
Sa1.78. Chronic GVH-Like Disease in a Man Exposed to
Organic Solvents: Evidence for a Role of Microchimeric
Cells of Maternal Origin.
A. de Lavareille,1 O. Michel,2 P. Heimann,3 E. Cogan,4 M.
Goldman,1 F. Roufosse.1,4 1Clinical Immunology Unit, Institute
for Medical Immunology, Erasme Hospital, Brussels, Belgium;
2Department of Internal Medicine, Saint Pierre Hospital, Brussels,
Belgium; 3Department of Medical Genetics, Erasme Hospital,
Brussels, Belgium; 4Department of Internal Medicine, Erasme
Hospital, Brussels, Belgium.
Chronic GVHD (cGVHD) shares features with systemic
sclerosis (SSc), including T cell activation and excess collagen
deposition in tissues. Increased foeto-maternal microchimerism has
AbstractsS114been shown in SSc, suggesting that allo-immunity could contribute
to its pathogenesis. Exposure of breeder mice to vinyl chloride has
been shown to result in proliferation of microchimeric cells and
parallel development of skin fibrosis. Herein, we describe
immunological findings in a male patient with lymphocytic
infiltrates and fibrosis involving skin, lungs and the digestive tract
highly reminiscent of cGVHD, following exposure to organic
solvents. We provide evidence that maternal microchimerism could
be involved in the disease process.
The patient was lymphopenic with a CD4/CD8 ratio of 0.33.
Lymphocyte phenotyping revealed a high proportion of circulat-
ing T cells bearing activation markers, among both CD4 (81%
CD25+, including 42% CD25high cells) and CD8 (23% CD25+)
populations. Oligoclonal expansion of T cells was demonstrated
by flow cytometry and immunoscope analysis, involving CD8+
cells belonging to Vh7 (32% of CD8 cells) and Vh17 (24% of
CD8 cells) families. Both Vh7+CD8+ and Vh7+CD8+ cell
populations stained negatively for CD27, CD28 and perforin.
High resolution HLA typing of the patient and his mother
demonstrated that they were nearly identical for MHC class II
(both were DRB1*1104 DRB1*1302 and DQB1*0301
DQB1*0604, patient DPB1*0301 DPB1*0401, mother
DPB1*0301 DPB1*0402), but not for MHC class I molecules.
Search for microchimeric cells of maternal origin by FISH in
peripheral blood revealed the presence of 7 XX cells among a
total of 40600 analysed cells (0.017%) from the patient.
Bidirectional mixed lymphocyte cultures (MLCs) were per-
formed using T cells from the patient and irradiated non-T cells
from his mother, and vice versa, to explore the potential functional
consequences of maternal microchimerism in this patient. In
presence of patient non-T cells, maternal CD8+ cells showed an
increase of HLA-DR expression (24% vs 8.4% when cultured
alone) but neither proliferation nor IFN-gamma production,
whereas CD4 cells remained quiescent. In contrast, both CD4+
and CD8+ T cells derived from the patient were activated in
presence of maternal non-T cells, as shown by increased HLA-DR
expression (41.6% vs 16.4% in absence of maternal non-T cells for
CD4+ cells, and 32% vs 11% for CD8+ cells) and secretion of
IFN-gamma. Removal of patient CD4+CD25high cells from
cultures resulted in decreased overall activation of patient T cells
in response to maternal non-T cells, indicating that they were
effector and not regulatory T cells.
This observation suggests that chronic activation of T lympho-
cytes related to long term persistence of maternal cells and
exposure to organic solvents might lead to a GVH-like disease
reminiscent of SSc.
Sa1.79. IgG Fc Receptor Polymorphisms Influence
Susceptibility to Collagen-Induced Arthritis.
M. Andren,1 B. Johanneson,2 M. Alarcon-Riquelme,2 S. Kleinau.1
1Department of Cell and Molecular Biology, Uppsala University,
Uppsala, Sweden; 2Department of Genetics and Pathology,
Uppsala University, Uppsala, Sweden.
SWR mice are resistant to collagen-induced arthritis (CIA)
despite carrying the arthritis susceptible haplotype H-2q and being
able to produce of anti-collagen type II (CII) antibodies following
CII-immunization. These IgG anti-CII antibodies are generally
pathogenic, as they can trigger joint inflammation via interactions
with IgG Fc receptors (FcgR), notably FcgRIII. However, SWR
mice are resistant to the arthritogenic properties of these antibodies.
Considering this, we have in the present study investigated ifpossible FcgR polymorphisms are involved in the susceptibility to
CIA. This was studied by generating mice carrying the FcgRIII
gene from the arthritis susceptible DBA/1 mouse (F4.D +/+) or from
the SWR mouse (F4.S +/+). After CII-immunization, F4.D +/+
mice, but not F4.S +/+ mice, developed a progressively severe
arthritis. In addition, the direct effect of IgG anti-CII antibodies on
arthritis development was studied by passive transfer of a cocktail
of monoclonal anti-CII antibodies to F4.D +/+ and F4.S +/+ mice.
Like in actively induced arthritis, F4.D +/+ mice developed a severe
arthritis in contrast to F4.S +/+ mice, which were almost protected
from disease. Consequently the gene for FcgRIII was sequenced in
DBA/1 and SWR mice, as well as in 9 additional mouse strains;
C57BL/6, C57BL/10, BALB/c, CBA, NZW, NZB, BXSB, NOD
and MRL. We found that FcgRIII exhibits three different
haplotypes in mice, FcgRIII:V, FcgRIII:H and FcgRIII:T, and that
SWR (FcgRIII:V) and DBA/1 mice (FcgRIII:H) indeed differ in the
FcgRIII gene. Interestingly, the DBA/1 mouse shared the
FcgRIII:H haplotype with the autoimmune-prone strains, NZW,
NZB, BXSB, NOD and MRL. We also demonstrate that SWR and
DBA/1 mice differ at the level of FcgRIIB, displaying the Ly-17.1
or the Ly-17.2 haplotype respectively. These results suggest that
polymorphisms in FcgRs may form the basis of one aspect of
susceptibility to autoimmune arthritis.
Sa1.80. Outcome of a National Israeli Cohort of
Pediatric Systemic Lupus Erythematosus.
Natalia Gorodnitsky,1 Pinhas Hashkes,2 Masza Mukamel,3 Shai
Padeh,4 Riva Brik,5 Judith Barash,6 Dror Mevorach,7 Yakov
Berkun,7 Tzvia Tauber,8 Joseph Press,9 Liora Harel,3 Pnina
Navon,10 Yakov Naparstek,7 Yosef Uziel.1 1Pediatric Medical
Center, Meir Hospital, Kfar-Saba, Israel; 2Rheumatology, Cleve-
land Clinik, Cleveland, USA; 3Pediatric Medical Center,
Schneider, Petach-Tikva, Israel; 4Pediatric Medical Center,
Tel-Ha Shomer Hospital, Ramat-Gan, Israel; 5Pediatric Medical
Center, Rambam Hospital, Haifa, Israel; 6Pediatric, Kaplan
Hospital, Rechovot, Israel; 7Rheumatology Center, Hadasa Hos-
pital, Jerusalem, Israel; 8Pediatric Medical Center, Asaf-Ha-Rofe
Hospital, Lood, Israel; 9Pediatric Medical Center, Soroca
Hospital, Beer-Sheva, Israel; 10Pediatric, Hadasa, Mt Scopus,
Jerusalem, Israel.
INTRODUCTION: About 10–20% of systemic lupus eryth-
ematosus SLE develops during childhood. Its clinical manifes-
tations range from mild constitutional symptoms to progressive
involvement of all target organs. The aim of this study was to
describe the clinical manifestations and outcomes of a national
cohort of pediatric patients with SLE.
PATIENTS / METHODS: We have collected retrospective
data on all cases meeting the ACR diagnostic criteria of childhood
onset SLE, registered in the Israeli national registry of children
with rheumatic diseases, who were diagnosed and followed
between 1987–2003. We examined disease activity and damage
by using SLE disease activity index (SLEDAI), and SLE
collaborating clinics/ACR (SLICC/ACR) disease damage.
RESULTS: 102 patients were identified. 81% were females.
The mean age at diagnosis was 13.3 F 2.6 years (range 6.9–17.7)
Initial clinical manifestations included renal involvement in 41%,
CNS in 7%, hematological in 94%, malar rash in 49%, oral or nasal
ulcerations in 21%, musculoskeletal in 45%, and serositis in 16%.
The mean SLEDAI was 17.2 F 9.0 (range 2–60). 80 children
(80%) started therapy with corticosteroids, and 19 (19) with
immunosuppressive drug.
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8.2 F 8.0 (range 0–46). 55 (66%) were still on corticosteroids and
27 (32%) were on immunosuppressive drugs. 60 children had 3
years of follow up with a mean SLEDAI of 9.5F 7.3 (range 0–36).
44 (73%) were on corticosteroids and 23 (38%) were on
immunosuppressive drugs. Their mean SLICC/ACR damage index
was 0.4 F 1.1 (0–7). 44 children had 5 years of follow up with a
mean SLEDAI of 6.7 F 5.2 (0–21). 28 (64%) of them were on
steroids, 22 (50%) on immunosuppressive drugs. Their mean
SLICC/ACR damage index was 0.5 F 1.2 (0–7). Five patients
developed chronic renal failure, one died.
CONCLUSIONS: In our national cohort the 5-year outcome of
pediatric SLE was good; the damage index was very low with
relatively low activity in most patients. It is possible that relatively
early and prolonged use of immunosuppressive medications in
many patients led to the good outcome.
Sa1.81. Dyslipoproteinemia in the Active Course of SLE:
A Contributory Role for Anti-Double Stranded DNA
Antibodies.
Sara Kashef,1 Mohammad Mehdi Ghaedian,2 Akbar Rajaee,3
Abbas Ghaderi.4 1Allergy Research Center, Pediatric Immunology
& Allergy, Shiraz University of Medical Sciences, Shiraz, Fars,
Islamic Republic of Iran; 2Shiraz Medical School, Shiraz
University of Medical Sciences, Shiraz, Fars, Islamic Republic of
Iran; 3Department of Rheumatology, Shiraz University of Medical
Sciences, Shiraz, Fars, Islamic Republic of Iran; 4Department of
Immunology, Shiraz University of Medical Sciences, Shiraz, Fars,
Islamic Republic of Iran.
Dyslipoproteinemia is common in lupus patients. In this study,
we investigated dyslipoproteinemia in the course of active SLE
with focus on the role of anti-dsDNA antibodies as a possible
contributory factor. Forty- six lupus patients under 45 years old
who fulfilled the American College of Rheumatology revised
criteria for the classification of SLE were selected. The exclusion
criteria consisted of: renal failure, nephrotic syndrome, thyroid and
liver disease, diabetes mellitus, obesity, pregnancy, taking drugs
that induce dyslipidemia. Disease activity was measured by
systemic lupus erythematosus disease activity index criteria. The
controls were forty-one healthy indivisuals matched for age ( F 3
years) and sex. According to the lipid profiles, in active, inactive
and control groups, we found the high level of serum triglycerides
and VLDL and low level of serum HDL in active group compared
with inactive group (P b 0.05). This pattern of dyslipoproteinemia
was observed in patients with positive anti-dsDNA antibodies
when compared with patients with negative anti-dsDNA antibodies
(P b 0.05). This pattern of dyslipoproteinemia in active SLE is
attributable to autoimmune mechanisms especially in relation to
the presence of anti-dsDNA antibodies.
Sa1.82. Mutations in Gene Transcripts of Systemic
Lupus Erythematosus (SLE) T Lymphocytes.
Dama Laxminarayana.1 1Section on Rheumatology and Clinical
Immunology, Department of Internal Medicine, Wake Forest
University School of Medicine, Winston Salem, NC, USA.
RNA editing is the co- or post-transcriptional modification of
RNA which results in the insertion, deletion or substitution of
nucleotides. RNA editing correct, extend or diversify the informa-
tion encoded within the corresponding genomic sequence, and
frequently alter the function of the affected RNAs. Therefore, RNA
editing plays an important role in the regulation of gene expressionand in the induction of phenotypic variability. The occurrence of
high circulating levels of type I interferons (IFNs) in SLE has been
well documented. Our previous experiments demonstrated up-
regulation of type I IFN inducible RNA editing gene, 150-kDa
ADAR1 expression in SLE T cells. Goal of these experiments is to
identify the role of type I IFN inducible ADAR1 in editing of
protein kinase A (PKA) and ADAR2 gene transcripts of normal and
SLE patients. cDNAs synthesized from T cells of SLE and normal
control groups were amplified using PKA and ADAR specific
primers. The amplified products of the PKA and ADAR2 tran-
scripts were cloned into pCR2.1-TOPO vectors. Sequence analysis
of the PKA and ADAR2 transcripts demonstrated 3 to 5-fold
increase of A Y G transcript mutations in SLE compared to
controls. Novel AY G editing sites were identified in the PKA and
ADAR2 gene transcripts of SLE T lymphocytes. The ADAR1 gene
up-regulation suggests a possible cause for PKA and ADAR2
gene transcript editing in SLE T cells. In addition to AY G,
novel T (U) Y C editing was also observed in PKA and ADAR2
gene transcripts of normal and SLE Tcells. The enzyme responsible
for such editing and the mechanisms underlying such editing are
unknown. Sequence analysis of the PKA and ADAR2 transcripts
demonstrated 2.5 to 5.4-fold increase of T (U) Y C transcript
mutations in SLE compared to controls. Taken together, these results
clearly indicate the increased occurrence of mRNA editing in the
PKA and ADAR2 gene transcripts of SLE T lymphocytes. Mutant
gene transcripts are pathophysiologically significant, for they can
encode diverse, aberrant forms, including truncated, dominant-
negatives, resulting in abnormal gene function. Therefore, it is
proposed that deficient and/or abnormal activity of genes such as
PKA and ADAR2 will contribute to the pathogenesis of SLE by
impairing T cell functions.
Sa1.83. The Mechanism of Nasal Tolerance in Lupus
Prone Mice Is T Cell Anergy Induced by Immature B
Cells That Lack B7 Expression.
Henry Yim Wu, Alon Monsonego, Howard L. Weiner. 1Center for
Neurologic Diseases, Brigham and WomenTs Hospital & Harvard
Medical School, Boston, MA, USA.
To determine if B cells of lupus prone NZB mice possess
intrinsic defects that directly lead or contribute to T cell
hyperresponsiveness, we injected age, sex and MHC II matched
NZB and Balb/c mice with histone peptide H471 representing a
dominant Th cell epitope in histone H4 of the nucleosome. We
cocultured purified CD4+ T and B220+ B cells of naRve or
peptide primed NZB and Balb/c mice in the presence of the
peptide. We found that B220+ B cells of NZB mice express
high levels of surface CD86 following antigen priming. Antigen
presentation exclusively by autoimmune B cells of NZB mice
induced hyperresponsiveness from normal CD4+ T cells of Balb/
c mice. T cell hyperresponsiveness is a result of CD86
costimulation by B cells of NZB mice. Induction of nasal
tolerance to H471 in NZB mice suppressed CD86 surface
expression and led to downregulation of T cell proliferative
response and cytokine production. More interestingly, B220+ B
cells purified from nasally tolerized NZB mice induced T cell
anergy to anti-CD3 and anti-CD28 antibody stimulation in vitro.
The anergic T cells do not possess suppressive function in
coculture with naRve T cells nor produce suppressive cytokines
interleukin 10 (IL-10) and transforming growth factor-beta
(TGF-b) upon anti-CD3 and anti-CD28 antibody stimulation in
vitro.
AbstractsS116Sa1.84. Synovial Fluid and Inflammatory Response in
Rheumatoid Arthritis.
Lj D. Petrovic-Rackov. 1Clinic for Rheumatology and Clinical
Immunology, Military Medical Academy, Belgrade, Belgrade,
Serbia, Yugoslavia.
The TH1 immunologic reaction is the major amplification
factor in pathogeneses of the rheumatoid arthritis (RA). Rheu-
matoid arthritis is destructive synovitis of autoimmune nature.
Cytokines TH1 lymphocytes with products of synoviocyte disrupt
natural balance in cytokine network inside synovial tissue, which
leads to inflammatory reaction and joint damage. Experimental
researches in vitro and in vivo on mice model have proved that
cytokines of interleukine-12 (IL-12), interleukin-15 (IL-15) and
interleukin-18 (IL-18) participate in pathogenesis of erosive
inflammatory arthritis. The research has the aim to find out
relation between concentrations of TNF-alpha, IL-18, IL-15 and
IL-12 in serum samples (S) and synovial fluid (SF) in patients
with active RA. Concentrations of cytokines in serum samples
and SF are measured in 64 patients with high (HiA), modest
(MoA) and mild active (MiA) disease, according to the Disease
Activity Score 28 (DAS 28). The comparison of concentrations
between S and SF showed that patients with active RA have
considerably increased (P b 0,01) concentrations of TNF-alpha,
IL-18 and IL-15 in SF samples, while values of IL12 were higher
in S without significant difference in accordance with SF.
Significant increase of TNF-alpha, IL-15 and IL-18 in SF
compared to S existed in HiA group. In groups MoA and MiA
there was significant increase of TNF-alpha, IL-15 in SF, while
concentrations of IL-18 and IL-12 were not different between
samples (p N 0,01). The conclusion is that patients with active
RA have higher concentrations of TNF-alpha, IL-18 and IL-15 in
SF than in S, which proves the proposition that those cytokines
are produced in joint and could be good indicators of local
disease activity. Concentration of IL-18 in SF reflects local
activity in patients with the most severe form of the disease.
Sa1.85. Glycopeptides from Type II Collagen
Incorporating Galactosylated Hydroxylysine Mimetics
To Study the Fine Specificity of Arthritogenic T Cells.
J. Marin,1 M.-A. Blaton,2 J.-P. Briand,1 G. Chiocchia,2 C.
Fournier,2 G. Guichard.1 1Immunologie et Chimie Therapeutiques
(ICT), UPR 9021 CNRS, Institut de Biologie Moleculaire et
Cellulaire (IBMC), Strasbourg, France; 2Departement
dTImmunologie, Institut Cochin, INSERM U567, CNRS
UMR8104, Universite Paris 5, Paris, France.
Five analogues of the bovine type II collagen (bCII)
immunodominant glycopeptide [h-D-Gal-(5R)-5-Hyl264]CII(256-
270) (1), carrying diverse modifications at the hydroxylysine
(Hyl) side chain were designed and synthesized to explore the
fine specificity of bCII-reactive T cells involved in the initiation
and/or regulation of collagen-induced arthritis (CIA), a mouse
model for rheumatoid arthritis (RA). The required h-D-Galacto-
syl-(5R)-5-Hydroxy-L-lysine and corresponding mimetics con-
veniently protected for solid phase synthesis were all obtained by
a divergent route featuring enantiopure 5-hydroxylated 6-oxo-1,2-
piperidinedicarboxylates as key intermediates. All three bCII-
specific T hybridomas used in this study as well as a recurrent
pathogenic CD4+ T cell clone isolated from bCII-immunized
DBA/1 mice recognized the galactosylated form 1 of the
immunodominant bCII (256-270) epitope. These cells were
extremely sensitive to changes at the q-amino group but differin their pattern of recognition of analogues with Hyl side chain
modified at C-5 (i.e. inversion of stereochemistry, methylation).
These data further document the importance of collagen
posttranslational modifications in autoimmunity and in the CIA
model in particular and provide new insight on the molecular
interaction between glycopeptide 1 and the TCR of pathogenic T
cells.
Sa1.86. CD8A on Monocytes May Aggravate
Immune-Complex Mediated Disease by Binding MHC
Class I and Enhancing TNF Production.
D. J. Gibbings,1 A. D. Befus.1 1Medicine, University of Alberta,
Edmonton, AB, Canada.
CD8a is expressed by monocytes and macrophages (Mo and
M) in rats, but according to available evidence not in mice. While a
few previous studies, most dating from the 1980Ts, suggested
human Mo or M express CD8a this was not convincingly
demonstrated. CD8+ Mo and M are present in several rat models
of diseases involving immune complexes, such as glomeruloneph-
ritis, arthritis, and ischaemia. Depletion of CD8+ cells mitigates
pathology in these disease models. If Mo and M express CD8, they
may be partially responsible for pathology in some of these
diseases in rats and humans previously ascribed to CD8+ T cells.
TNF is therapeutically targeted in many of these diseases, and
released in large quantity by Mo. We hypothesized CD8 on
human Mo may be involved in TNF-mediated pathology in
immune complex diseases. Six anti-CD8a mAb recognized
human monocytes (CD14hi) by flow cytometry. Ten to 25 percent
of monocytes expressed high amounts of CD8a, while the
remaining 75–90% of monocytes expressed low amounts of
CD8a. A proportion of Mo and lymphocytes can be difficult to
distinguish by some methods including cell morphology, flow
cytometry (FSC-SSC gating), and potentially anti-CD3 mAb
labelling. Moreover, because many of the anti-CD8a mAb used
here are sold for clinical evaluation (e.g. OKT8, B9.11, LT8,
51.1), to avoid confusion between CD8hi Mo with CD8hi
lymphocytes in clinical and research settings, careful definition
of T cells (e.g. anti-TCR mAb) may be necessary. CD8a protein
was found on the surface of a Mo cell line (THP-1) in continuous
culture that also expressed CD8a mRNA. In the absence of
another source of CD8a, THP-1 and likely other Mo transcribe
and translate CD8a. Functionally, Mo may use both CD8a and
FcgR to bind tissues containing immune complexes. We
established that Mo can bind tetramers of MHC class I (HLA-
A2), independent of bound peptide. CD8a accounted for some
MHC class I tetramer binding to Mo, as this was partially
inhibited by some anti-CD8a mAb. In agreement with literature,
not all CD8a mAb blocked binding of MHC class I, demonstrat-
ing that mAb binding to the surface of Mo does not
indiscriminately block binding of MHC class I tetramers. Select
anti-CD8a mAb but not non-specific mAb imbedded in immune
complexes enhanced Mo TNF production. Similar studies with
other anti-CD8a mAb did not induce TNF production, suggesting
that particular epitopes of CD8a activate Mo, and mAb specific
for surface proteins of Mo do not indiscriminately enhance TNF
production. The ability of Mo to bind MHC class I and release
TNF through CD8a shows that Mo CD8a could be involved in
initiating and aggravating pathology induced by immune-com-
plexes. It is possible that some effects attributed to CD8+ T cells,
where T cells have been inadequately characterized, are due in part
to CD8+ Mo.
Abstracts S117Sa1.87. Anti-Cyclic Citrullinated Peptide and Anti-Sa
Antibodies for the Diagnosis of Rheumatoid Arthritis in
an Out-Patient Clinic of Chronic Inflammatory
Connective Tissue Diseases (CICTD).
J.L. Ruiz-Tiscar,1 S. Sanchez-Ramon,1 D. Micheloud,1 A. Garcia-
Segovia,1 B. Santamaria,1 R. Urrea,1 M. Escalona,2 A. Estecha,2
J. L. Lopez-Longo,2 E. Fernandez-Cruz,1 M. Rodriguez-Mahou.1
1Immunology, Gregorio Maranon Hospital, Madrid, Madrid,
Spain; 2Rheumatology, Gregorio Maranon Hospital, Madrid,
Madrid, Spain.
Introduction: Several studies have shown the diagnostic
usefulness of anti-cyclic citrullinated peptide (CCP) and anti-Sa
antibodies in rheumatoid arthritis (RA), but up to now there is no
study that has assessed both autoantibodies simultaneously in a
cohort of patients.
Objective: To determine the sensitivity, the specificity, the
positive (PPV) and negative (NPV) predictive values of anti-CCP
and anti-Sa in a monographic out-patient clinic of CICTD.
Methods: Cross-sectional study. We studied 250 patients: 87
RA, 90 CICTD, 50 espondyloarthritides, 19 polymyalgia rheu-
matic (PMR) and 4 juvenile idiopathic arthritis. Anti-CCP and anti-
Sa antibodies were identified by ELISA and immunoblotting
techniques, respectively.
Results: Anti-CCP antibodies were detected in 63/87 RA
(sensitivity: 72,4% specifity: 94,4%, PPV: 87,5%, NPV: 81,9%),
3/19 PMR, 2 palindromic rheumatism (PR), 1 systemic lupus
eritematosus, 1 undifferentiated connective tissue disease (UCTD),
1 ankylosing spondylitis (AS) and 1 undifferentiated espondyloar-
thritides (sensitivity 72.4%, specificity 94.4%, positive predictive
value 87.5% and negative predictive value 86.5%). Anti-Sa
antibodies were detected in 38/87 patients with RA (Sensitivity:
43,6%, specifity: 96,3%, PPV: 86,3%, NPV: 76,2%), 2 UCTD, 1
SjfgrenTs syndrome, 1 PR, 1 AS and 1 juvenile idiopathic arthritis.
Conclusions: The specificity and the predictive values of anti-
CCP and anti-Sa antibodies for the diagnosis of RA are
comparable. However, the sensitivity of anti-CCP antibodies is
higher, given the higher sensitivity of the ELISA technique when
compared with immunoblotting.
Sa1.88. Evaluation of the Effect of Different Modified
Extracellular Matrix Proteins in the Inflammation and
Extracellular Matrix Turnover in Cartilage and
Synovial Tissue Co-Cultures from Patients with
Osteoarthritis (OA) and Rheumatoid Arthritis (RA).
O. Munoz-Chable,1 J. Alcocer-Varela,1 E. Diaz-Borjon,2
J. Barrios,3 R. Hernandez-Pando,3 J. Furuzawa-Carballeda.1
1Inmunologia y Reumatologia, Instituto Nacional de Ciencias
Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico;
2Ortopedia; 3Patologia Experimental, Instituto Nacional de
Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City,
DF, Mexico.
Introduction: Modified extracellular matrix (ECM) proteins
such as hydrolyzed (elastin, collagen fibronectin, thrombospondin,
etc.) or polymerized proteins (collagen-PVP), has been shown to
regulate inflammatory processes. Due to, the evaluation of the
effect in osteoarthritis (OA) and rheumatoid arthritis (RA), diseases
related to chronic inflammation, results of a special interest.
Objectives: To evaluate the effect of the hydrolyzed collagen and
elastin, (b) collagen-PVP, and (c) the mixture of the hydrolyzed
collagen and elastin plus collagen-PVP in co-cultures fromcartilage and synovial tissue from RA or OA knee or hip.Material
and Methods: Cartilage and synovial tissue co-cultures from 5
patients with RA (ACR) or 5 patients with OA (ACR) were
performed. All of them were prescribed for total knee or hip
replacement surgery. Each tissue was fragmented into 96 segments
of approximately 5mm3. Tissues were cultured with RPMI-1640,
10% SFB, antibiotics and antimicotics during 7 days under the
following conditions: a) RPMI (control), b) 1% collagen-PVP, c)
1% hydrolyzed collagen and elastin and d) 1% hydrolyzed collagen
and elastin + 1% collagen-PVP. In order to determine the effect of
the different culture conditions on the ECM turnover (elastin,
collagen and sulfate proteoglycans and hyaluronic acid) tissues
were stained with Hematoxilin and Eosin, Verhoeff and Alcian
Blue staining techniques. Proinflammatory cytokines (IL-1b, IL-8,
IL-10, IL-12, TNF-a, and IFN-g) in supernatants were quantified
by ELISA. Data were normalized by total protein concentration
evaluated by the Folin-Lowry micro-method. IL-1b, TNF-a and Ki-
67 expression was determined by histochemistry. The statistical
analysis was made by t-Student test and U Mann-Whitney.
Results: The histological analysis showed a remodeling tissue,
related to an increase of highly sulphated proteoglycans, sialomu-
cin and hyaluronic acid. A scarce increment of elastin fibers in
tissues treaded with the mixture of hydrolyzed and collagen-PVP
vs. control cultures were observed. A 2-3-fold increment of Ki-67
was determined in the tissues treated vs. control cultures. IL-1b and
TNF-a were determined 1.5-2-fold lower levels in treated cultures
vs. controls. IL-8 levels were decreased in all supernatants from
treated co-cultures from RA patients. However, only in super-
natants from OA tissue treated with hydrolyzed proteins statisti-
cally decreased vs. the controls was determined. Conclusions:
Modified proteins induce a tissue remodeling, promoting the
recovery of cartilage proteoglycans, down-regulating the expres-
sion from some proinflammatory cytokines and promoting the
chondroid cells proliferation.
Sa1.89. Anti-alpha-Fodrin Antibodies of IgA Isotype in
Patients with SjfgrenTs Syndrome (SS).
J. L. Ruiz-Tiscar,1 S. Sanchez-Ramon,1 D. Micheloud,1 B.
Santamaria,1 R. Urrea,1 M. Escalona,1 A. Estecha,2 F. J.
Lopez-Longo,2 E. Fernandez-Cruz,1 M. Rodriguez-Mahou.1
1Immunology, Gregorio Maranon Hospital, Madrid, Madrid,
Spain; 2Rheumatology, Gregorio Maranon Hospital, Madrid,
Madrid, Spain.
Introduction: The afodrine is localised in the plasma membrane
of most mammalsT cells. After the cell break-down during
apoptosis by the action of the caspase-3, a cleavage-product of
the alpha-fodrin of 120 kD acts as a neoantigen, being recognised
by sera of patients with SS. 90–60% of patients with SS presented
positive IgA anti-afodrin antibodies.
Objective: To assess the frequency and the clinical associations
of IgA anti-alpha-fodrin antibodies in patients with primary and
secondary SS in our environment.
Materials and Methods: We studied 491 patients diagnosed of
SS, 209 primary SS and 282 secondary SS: 190 rheumatoid arthritis
(RA), 59 systemic lupus eritematosus (LES), 13 scleroderma and 19
polymyositis. IgA anti-afodrin antibodies were tested by ELISA.
Results: Anti-afodrin antibodies were detected in 29 patients
(5.9%): 6/209 primary SS (2,7%) and 23/282 secondary SS (8,2%),
13/190 RA (6.8%), 6/60 SLE (10%) and 2/19 Polymyositis
(10,5%). No significant differences were observed when we
compared patients with and without anti-afodrin antibodies,
AbstractsS118neither in epidemiological data, in time of disease evolution, nor in
clinical manifestations.
Conclusions: In our environment, IgA anti-alpha-fodrin anti-
bodies are not common in patients with SS (5.9% vs 90–60% of the
literature), and are not associated with any specific clinical
manifestation. Sensitivity of IgA anti-alpha-fodrin antibodies is
higher in secondary SS.
Sa1.90. Tumor Necrosis Factor Genetic Polymorphism
as Part of Rheumatoid Arthritis Evolution.
A. Cruzat,1 I. Schiattino,2 M. Cuchacovich,3 J. C. Aguillon.1
1Disciplinary Program of Immunology, Faculty of Medicine.
University of Chile, Santiago, Regio´n Metropolitana, Chile;
2Health Public School, Faculty of Medicine. University of Chile,
Santiago, Regio´n Metropolitana, Chile; 3Rheumatology Section,
University of Chile Clinical Hospital. University of Chile,
Santiago, Regio´n Metropolitana, Chile.
RATIONALE: Rheumatoid arthritis (RA) is a systemic auto-
immune disease characterized by chronic synovial joint inflamma-
tion leading to cartilage and bone destruction. The etiology and
pathogenesis of the disease is still unsolved, although evidences
reveal that TNF plays a central role. The pathogenic role of TNF
can be evidenced by: It has been observed that in plasma, synovial
fluid and tissue of patients with RA high concentrations of TNF are
found; transgenic mice that over-express the human TNF gene
develop a polyarthritis similar to RA, while the administration of
human TNF monoclonal antibodies from their birth, prevent the
articular lesions and diminish the incidence of murine arthritis and,
probably the most notable piece of evidence, comes from studies in
which it has been demonstrated the clinical benefit of patients with
RA treated with anti-TNF monoclonal antibodies or with soluble
receptors of TNF. OBJECTIVE: The purpose of this work is to
study the historic evolution of RA, which it would be considered
an increasing disease, relatively new, favored by a specific
mutation at position-308 in the promoter region of the TNF gene.
METHODS: 308 single nucleotide polymorphism (SNP) was
determined by polimerase-chain reaction (PCR)-restriction frag-
ment length polymorphism. RESULTS: The-308 SNP determines a
higher expression of this cytokine. The frequence of this poly-
morphism is 43.5% in Caucasic population. In studies of
association of de SNP-308 and RA, the positive findings have
been: in Caucasic population the allele TNF2 is 3 times higher in
patients with RA, than in healthy controls; a relation between the
SNP-308 and the presence of extra-articular manifestations with
rheumatic nodules; in Swedish patients it has been demonstrated
that individuals bearing the heterozygous form, develop a more
severe disease and at an earlier age, and a significant association
with bad prognosis was found in Turkish patients with RA.
CONCLUSION: 308 SNP seems to participate in the evolution of
RA. Financed by Fondecyt-Chile 1040860 and Fondef-Chile
D03I1055.
Sa1.91. Mannan Binding Lectin and Complement C4A
in Icelandic Multicase Families with Systemic Lupus
Erythematosus.
S. Saevarsdottir,1 H. Kristjansdottir,2 G. Grondal,2 T.
Vikingsdottir,1 K. Steinsson,2 H. Valdimarsson.1 1Department of
Immunology, Landspitali University Hospital, Reykjavik, Iceland;
2Center for Rheumatology Research, Landspitali University
Hospital, Reykjavik, Iceland.Objective: Low mannan binding lectin (MBL) and C4AQ0 has
been associated with systemic lupus erythematosus (SLE). We
asked whether low MBL might predispose to SLE in members of
multicase SLE families, where there is an overall increased
frequency of C4AQ0. Methods: Low MBL was detected by
measuring serum levels (ELISA) and genotyping for mutant
structural (O) and promoter (LX) alleles (RT-PCR). C4AQ0 was
detected by protein electrophoresis. Twenty-four SLE patients from
nine Icelandic families were compared to 83 first-degree and 23
second-degree non-SLE relatives, and 24 unrelated family mem-
bers served as controls. Results: MBL-low (wild-type/O) and
MBL-deficiency (O/O, LX/O) genotypes were associated with
MBL levels below 1000 Ag/L, and low MBL was observed in five
of the nine families (n = 86). In these five families, 64% of SLE
patients, 38% of their first-degree and no second-degree relatives
carried MBL-low/deficiency genotypes (P b 0.001) compared to
29% of the controls (P = 0.007). All patients carried a MBL-low
allele (O, LX) and/or C4AQ0 (P b 0.001). The SLE patients also
had C4AQ0 combined with MBL-low/deficiency genotypes more
often than their non-SLE relatives (P = 0.01) and controls (P =
0.015). In accordance with MBL genotypes, patients from these
families also had lower MBL levels than their relatives (P b 0.001)
and controls (P = 0.02). Low MBL predisposed to SLE
independently of C4A status. There was no evidence of MBL
consumption. Conclusion: MBL-low/deficiency genotypes and
low MBL serum levels predispose to SLE independently of
C4AQ0. Low MBL was absent in four of the nine families,
highlighting the heterogeneity of SLE.
Sa1.92. Abnormal Dendritic Cell Activation in SLE.
H. Zhuang,1 D. C. Nacionales,1 S. Narain,1,2 E. Sobel,1,2
P. Y. Lee,1 Jason B. Weinstein,1 K. M. Kelly,1 H. B. Richard,1,2
M. Satoh,1,2 W. H. Reeves.1,2 1Division of Rheumatology &
Clinical Immunology, University of Florida, Gainesville, FL, USA;
2Center for Autoimmune Disease, University of Florida,
Gainesville, FL, USA.
Circulating peripheral blood mononuclear cells (PBMCs)
from SLE patients express high levels of Type I interferon
(IFN-I) inducible genes. IFN-I is produced by plasmacytoid
dendritic cells (PDCs) and promotes the maturation of myeloid
dendritic cells (MDCs), which play a key role in antigen
presentation. We investigated the interrelationships between IFN-
I production and circulating PDCs and MDCs in subjects with
SLE (n = 88), other autoimmune diseases (n = 82), and healthy
controls (n = 57). Expression of the IFN-inducible genes Mx1
and OAS (real-time PCR) was increased in SLE PBMCs vs. the
other groups (P b 0.0001, ANOVA). High Mx1 expression was
seen in ~20% of lupus patients (compared to the mean + 2 S.D.
of controls). In contrast, circulating PDC and MDC counts (flow
cytometry) were decreased in ~50% of SLE patients compared
with controls (P b 0.0001, ANOVA). Production of autoanti-
bodies against dsDNA and snRNPs (Sm/nRNP, Ro, and La) was
positively associated with high IFN-I production and negatively
with the numbers of circulating PDCs and MDCs, whereas anti-
phospholipid antibody production was negatively associated with
IFN-I production. Patients with low PDC/MDC counts fulfilled a
greater number of ACR criteria and had a higher prevalence of
renal disease. To better understand the basis for the low numbers
of circulating dendritic cell precursors in SLE, we asked whether
the PDC/MDC counts were persistently or intermittently low.
Longitudinal studies showed that in individual SLE patients
Abstracts S119IFN-I inducible gene expression can fluctuate as much as 100-
fold. These differences were independent of respiratory infec-
tions, SLEDAI, and medication use. However, PDC and MDC
counts tended to remain low in SLE regardless of the IFN-I
levels. Healthy subjects exhibited a different pattern: IFN-I
expression was generally much lower at baseline, increased
dramatically within 1–2 days in response to viral upper
respiratory infections, and returned to baseline within 10 days;
interestingly, the numbers of circulating PDCs/MDCs did not
decrease during viral infections. Studies in a mouse model
suggested that the low circulating PDC/MDC counts in lupus are
due to enhanced dendritic cell maturation (increased CD86
expression) and migration from the circulating pool to sites of
inflammation. We propose that IFN-I produced by abnormally
activated PDCs stimulates MDC maturation and the presentation
of self-antigens, culminating in autoimmunity. The abnormal
dendritic activation in SLE could reflect either an intrinsic
dendritic cell defect or an exaggerated response to extrinsic
(microbial?) activators.
Sa1.93. Marginal Zone Lymphoma with Autoantibodies
to RO52 in SjogrenTs Syndrome.
R. Lyons,1 M. Rodriguez,1 E. K. L. Chan,1 L. Yang,1 C. Stewart,1
M. Satoh,1 W. H. Reeves.1 1Division of Rheumatology & Clinical
Immunology, University of Florida, Gainesville, FL, USA.
Marginal zone (MALT) lymphomas arising in the stomach
sometimes bear immunoglobulin receptors specific for Helico-
bacter pylori antigens and eradication of the infection may lead
to tumor regression. Marginal zone lymphomas also arise in the
salivary glands of patients with SjogrenTs syndrome (SS). It is
not known if these SS-associated tumors also have antigen
specificity. We studied two SS patients with B cell neoplasms
consistent with marginal zone lymphomas originating within the
parotid gland. Both patients were positive for anti-Ro52
autoantibodies using a recombinant human Ro52 based ELISA.
The first patientTs lymphoma exhibited typical lymphoepithelial
lesions on H&E staining and was k L-chain+, CD5-, CD10-, and
CD23- by flow cytometry. The solitary tumor was excised
surgically after which her anti-Ro52 IgG autoantibody level fell
from 735 units to 414 units. In contrast to the total IgG, which
exhibited a k/l ratio of 1.5:1, the k/l ratio of her anti-Ro52
antibodies was ~60:1. The k L-chain+ anti-Ro52 antibody level
decreased by more than 40% after surgery whereas the l L-
chain+ anti-Ro52 remained unchanged indicating that excision of
the tumor specifically decreased the k L-chain+ anti-Ro52
antibodies. The second patientTs lymphoma was l L-chain+ with
surface markers compatible with a marginal zone lymphoma.
The neoplasm was too widespread at the time of diagnosis to
permit local excision. The ratio of k/l L-chains in total
immunoglobulin from Patient 2 was 8:1, whereas the k/l ratio
of her anti-Ro52 autoantibodies was 0.5:1. Thus, both the tumor
and most of her anti-Ro52 antibodies were l L-chain+. These
data suggest that the production of anti-Ro52 antibodies was
dependent on the presence of tumor cells (Patient 1) and that the
anti-Ro52 antibodies exhibited non-random usage of L-chains
(Patients 1 and 2), consistent with the possibility that the
neoplastic B cells produced autoantibodies against Ro52. By
analogy with marginal zone lymphomas arising in the stomach
that are specific for H. pylori antigens, we speculate that some
marginal zone lymphomas originating in the salivary glands may
be stimulated by the self-antigen Ro52. These cases raise thepossibility that anti-Ro52 autoantibodies, a specificity character-
istic of SjogrenTs syndrome, can be produced by marginal zone
B cells and that these cells may on occasion undergo neoplastic
transformation.
Sa1.94. IL-1 Receptor Expression in Muscle Fibre
Membrane and Muscle Cell Nuclei in Patients with
Polymyositis or Dermatomyositis.
I. E. Lundberg,1 C. Grundtman,1 C. Dorph,1 J. Burton,2 U.
Andersson,3 S. Salomonsson.1,2 1Rheumatology Unit, Department
of Medicine, Karolinska University Hosptial, Solna, Karolinska
Institutet, Stockholm, Sweden; 2Department fo Physiology and
Pharmacology, Karolinska Institutet, Stockholm, Sweden;
3Department of Woman and Child Health, Karolinska University
Hosptial, Solna, Karolinska Institutet, Stockholm, Sweden.
Background: Interleukin-1 (IL-1) is a prototype of a pro-
inflammatory cytokine in that it induces expression of a variety
of genes and synthesis of several proteins that, in turn, induce
acute and chronic inflammatory changes. Polymyositis and
dermatomyositis are chronic inflammatory muscle disorders,
characterized by proximal muscle weakness and by inflamma-
tory cell infiltrates in skeletal muscle. Increased expression of
IL-1alpha in endothelial cells of capillaries and IL-1beta in
mononuclear inflammatory cells, is a consistent finding in
muscle tissue from myositis patients. The pathophysiologic role
of these cytokines in myositis has not yet been clarified. Our
hypothesis is that IL-1 could have a negative effect on muscle
fibre metabolism and regeneration and contribute to the
persisting muscle weakness and muscle fatigue often seen in
these patients.
Aim: To investigate if muscle fibres express IL-1 receptors (IL-
1R) in healthy or inflamed muscle tissue and if so, if there was any
difference of IL-1 receptor expression between symptomatic and
non-symptomatic muscle tissue.
Method: Muscle biopsies from 8 polymyositis patients, 3
dermatomyositis patients, and 6 healthy controls were included in
this study. The muscle biopsies from the patients were taken from
two different sites, one from a symptomatic muscle and the other
from a non-symptomatic muscle. IL-1alpha, IL-1RI, and IL-1RII
expression was investigated by immunohistochemistry. Local-
ization of IL-1RI and IL-1RII expression was also investigated
by double staining and confocal microscopy with laminin to
identify muscle fibre membrane and a the marker BOBO3 to
identify nuclei.
Results: IL-1RI and IL-1RII were expressed, in the membrane
and in the nuclei of muscle fibres as well as in inflammatory cells
and endothelial cells in muscle biopsies from myositis patients.
Healthy controls only had a scattered pattern of IL-1RI and IL-1RII
expression in a few endothelial cells and in a few nuclei of the
muscle fibres. There was no difference between symptomatic and
asymptomatic muscles. The membrane and nuclear expression of
IL-1RI and II was confirmed with double staining and confocal
microscopy. IL-1a was expressed in endothelial cells and inflam-
matory cells in the patients.
Conclusion: This is the first time that IL-1RI and IL-1RII have
been described in the membrane of human muscle fibers.
Furthermore, IL-1Rs were localized to cell nuclei. The implication
of this is not known, but IL-1alpha is known to have an intracrine
pathway and this could possibly be mediated through nuclear
receptors. The observed expression of IL-1RI and IL-1RII in
muscle fiber membranes supports our hypothesis that IL-1 could
AbstractsS120have a direct effect on muscle fibres and thereby affect muscle
function.
Sa1.95. Increased Expression and Production of Tumor
Necrosis Factor-Related Apoptosis Inducing Ligand
(TRAIL) by T Cells from Lupus Patients Is a Feature
of Active Disease.
V. Rus,1 V. Zernetkina,1 R. Puliaev,3 S. Mathai,1 C. Cudrici,2 C. S.
Via.3 1Medicine, University of Maryland School of Medicine,
Baltimore, MD, USA; 2Neurology, University of Maryland School
of Medicine, Baltimore, MD, USA; 3Pathology, Uniformed
Services of the University Health Sciences, Bethesda, MD, USA.
TRAIL is a member of the TNF family with proapototic
activity. Increased T cell associated and soluble TRAIL (sTRAIL)
levels in serum from patients with systemic lupus erythematosus
(SLE) have been previously reported. In this study we set to
characterize the upregulation of both T cell associated and sTRAIL
in vivo and the modulation of TRAIL expression and soluble
protein release following T cell activation and IFNa exposure in
vitro. Lastly, the functional ability of the two forms of TRAIL to
mediate apoptosis was compared. Using flow cytometry the ex
vivo expression of membrane bound TRAIL was higher on CD4+
and CD8+ T cells from ten lupus patients compared to ten healthy
controls, particularly on activated CD69+CD8+ T cells. sTRAIL
levels determined by ELISA in sera from 34 lupus patients and 26
controls were significantly elevated in patients with active SLE and
correlated with disease activity and with levels of IFN a but not
with any particular clinical feature. In vitro, both T cell associated
and sTRAIL were maximally induced by T cell activation plus IFN
a in patients and controls. Western blot analysis of immunopre-
cipitated sera demonstrated the presence of the 21 kD monomeric
forms but not of multimeric forms of sTRAIL. Although both T-
cell associated and sTRAIL were functional in vitro in inducing
apoptosis of TRAIL sensitive Jurkat cells as determined by
Annexin V staining and 51Cr release assay, the apoptotic activity
of membrane TRAIL was 2.5 fold higher compared to that of
sTRAIL. In conclusion, increased T cell associated and sTRAIL is
a feature of active disease in lupus patients and likely reflects the in
vivo T cell activation and IFN a production. IFN a induced
enhancement of TRAIL expression and of TRAIL mediated
apoptosis may amplify the abnormal apoptotic process in SLE.
Sa1.96. Intramuscular Administration of Polymerized
Type I Collagen for the Treatment of Patients with
Rheumatoid Arthritis. A Double Blind
Placebo-Controlled Clinical Trial.
J. Furuzawa-Carballeda,1 J. Alcocer-Varela.1 1Immunology and
Rheumatology, Instituto Nacional de Ciencias Medicas y Nutricion
Salvador Zubiran, Mexico City, DF, Mexico.
RATIONALE: Collagen-polyvinylpyrrolidone (Collagen-PVP)
has been shown to down-modulate some proinflammatory medi-
ators expression on synovial tissue from rheumatoid arthritis (RA)
patients. Collagen-PVP subcutaneous administration to RA
patients was safe and well-tolerated drug for the short term-
treatment.
AIM: To determine the efficacy, tolerance and safety of
intramuscular injections of porcine type I collagen-PVP in patients
with RA in a long term-therapy.
METHODS: The protocol was approved by the Committee of
Medical Ethics of the National Institute of Medical Sciences and
Nutrition. Only patients who gave informed consent to participatewere recruited. The study was double blind placebo-controlled and
included 30 patients who fulfilled the 1987 American Rheumatism
Association (ACR) criteria for active RA. Patients on stable
therapy with methotrexate and/or non-steroidal antiinflammatory
drugs (NSAIDs) were enrolled in a 1 year prospective, comparative
and longitudinal study. Patients were treated in accordance to
Freyberg scheme with intramuscular injections of 2 ml of collagen-
PVP (3.4 mg of collagen) or 2 ml of placebo during 6 months. The
primary endpoints were done according to Ritchie index (RI, 72-
joint count), 72-swollen joint count, disease activity score (DAS),
erythrocyte sedimentation rate (ESR), and C-reactive protein
(CRP). The secondary endpoints included morning stiffness, pain
intensity on a visual analog scale (VAS), and spanish-health
assessment questionnaire (HAQ-DI). The improvement was
determined using American College of Rheumatology response
criteria (ACR20, 50 and 70). Statistical analysis was performed by
the non-parametric double tailed Mann-Whitney U test. Data were
expressed as the mean F SD. The p values smaller than or equal to
0.05 were considered as significant.
RESULTS: Collagen-PVP was safe and well tolerated. There
were no adverse events. Patients had a statistically significant
improvement (P b 0.05) in collagen-PVP-treated vs. placebo at 6
months of treatment in: swollen joint count (8.2 F 0.8 vs. 14.9 F
1.6; D-14, 55% vs. D-10, 41%), RI (10.6 F 0.8 vs. 15.2 F
1.5; D-19.1, 60% vs. D-13.6, 45%), morning stiffness (9.6 F
3.1 vs. 27.1 F 5.9 min; D-84, 67% vs. D-84, 57%), HAQ-DI
(47.0 F 10.8 vs. 25.2 F 10.3; D-0.7, 47% vs. D-0.3, 25%),
DAS (3.5 F 0.2 vs. 4.3 F 0.3; D-2.4, 36%, D-1.4, 25%),
ACR20 (78.6 vs. 71.4%), ACR50 (57.1 vs. 0%) and ACR70 (7.14
vs. 0%), CRP (1.1 F 0.4 vs. 2.5 F 0.7; D-0.8, 20% vs. D0.6,
126%) and rheumatoid factor (243.9 F 57.3 vs. 490.4 F 74.9; D-
128, 20% vs. D-80, 0.9%). Patients treated with collagen-PVP
required lower doses of methotrexate vs. placebo (12.6 F 0.6 vs.
14.2 F 0.7 at 6 months and 12.3 F 0.8 vs. 15.4 F 0.6 at 12
months; pb0.05). Serological or hematological parameters
remained unchanged.
CONCLUSION: Collagen-PVP has been shown to be a safe and
well-tolerated drug for the long-term treatment of RA. Combina-
tion of collagen-PVP plus methotrexate was more efficacious than
methotrexate alone. This drug could be useful in the treatment of
RA.
Sa1.97. Clinical Characteristics of 88 Patients with
Juvenile or Adult Dermatomyositis.
Tamas Constantin,1 Andrea Ponyi,1,2 Katalin Molnar,3 Judit
Muller,1 Zsuzsanna Szalai,3 Gyorgy Fekete,1 Katalin Danko.2
12nd Department of Pediatrics Hungary, Semmelweis University,
Budapest, Hungary; 23rd Department of Internal Medicine,
Division of Clinical Immunology, University of Debrecen,
Debrecen, Hungary; 3Department of Dermatology, Heim Pal
ChildrenTs Hospital, Budapest, Hungary.
Introduction
Dermatomyositis (DM), belonging to the group of the
idiopathic inflammatory myopathies, is characterized by a bimodal
pattern of age-specific incidence of rates, with peaks in the age
group from 5 to 16 years (juvenile DM) and in the age group from
45 to 65 years (adult DM). The aim of this study is to evaluate the
clinical characteristics of 22 patients with juvenile DM.
Methods
A national registry of patients with juvenile dermatomyositis
(JDM) was elaborated by the authors in Hungary. We summarize
Abstracts S121data of the register according signs and symptoms, disease course,
frequency of relapses and survival of patients with JDM. Analysis
was performed using data for 22 patients diagnosed between 1976
and 2003 according to Bohan and PeterTs criteria. Survival
probability was calculated by Kaplan-Meier method. Data of
juvenile patients were compared with data of 66 patients with adult
DM.
Results
All children had symmetrical weakness of the proximal
muscles. The most frequent cutaneous features were facial
erythema and GottronTs papules (19/22). Extramuscular and
extraskeletal manifestations of the disease were more frequent in
adult patients. The most common extramuscular feature was
arthralgia (7/22). Only one patient with juvenile DM had interstitial
lung disease (ILD). Cardiac manifestation of the disease or
respiratory muscle involvement was not observed in juvenile
patients. Respiratory muscle involvement (12/66) and ILD (11/39)
were more frequent among adult DM patients than the cardiac
manifestation of the myositis (6/55). In view of the disease course,
the authors found that frequency of polycyclic and monophasic
subtypes of the disease were similar. The hazard of the relapse was
found higher during the first year after the remission. None of the
juvenile patients died. Among adult patients 4 disease-specific
deaths occurred.
Conclusion
Patients with JDM are usually admitted to Dermatology
departments, therefore paediatric dermatologists should be
familiar with the clinical presentation of JDM. We report the
first study on clinical characteristics and disease course of
patients with juvenile DM who were diagnosed, treated and
followed-up in Hungary. To our best knowledge, this is one of
the largest studies on comparing clinical data of juvenile and adult
patients.
Sa1.98. Pre-B Cell Colony Enhancing Factor Stimulates
Production of Proinflammatory Mediators by Human
Monocytes and Is Overexpressed in Systemic
Autoimmune Disease.
S. Liu,1 C. Lee,1 K. A. Kirou,1 M. K. Crow.1 1Mary Kirkland
Center for Lupus Research, Hospital for Special Surgery, New
York, NY, USA.
Studies of early vertebrates have provided clues to the
development of the adaptive immune system, and even more
primitive animal phyla, the Porifera, express molecules that are
precursors of mammalian innate immunity. To gain new insight
into potential mechanisms of autoimmunity in humans, we have
studied a cytokine-like molecule, pre-B cell colony enhancing
factor (PBEF), a protein produced by sponges in response to
xenogeneic cells and with nicotinamide (Nam) phosphoribosyl
transferase activity in both bacteria and mammals. PBEF was
induced in B lymphocytes by activation of surface immunoglobu-
lin receptors and IL-4 and stimulated production of IL-8 and other
proinflammatory mediators by monocytes through an NF-kB
dependent pathway. Consistent with its homology to Nam
phosphoribosyl transferase, PBEF induction of IL-8 was inhibited
by Nam. To determine whether PBEF might be overexpressed in
patients with autoimmune disease, PBEF mRNAwas measured by
quantitative real-time PCR in PBMC from 89 patients with
systemic lupus erythematosus (SLE), 22 patients with rheumatoid
arthritis (RA), and 28 healthy donors (HD). The mean PBEF
expression was significantly increased in SLE (relative expressioncompared with housekeeping control = 3.95 F 5.61) and RA
(3.31 F 3.8) compared with HD (0.87 F 0.48), with p for both
comparisons b0.001. Consistent with the in vitro induction of IL-8
by PBEF, expression of PBEF was positively correlated with
expression of IL-8 in SLE PBMC (r2 = 0.589, P b 0.0001). In
summary, our data demonstrate that PBEF is a cytokine-like inducer
of proinflammatory mediators that utilizes the nicotinamide adenine
dinucleotide and NF-kB pathways to stimulate innate immune
system activation. Increased production of PBEF in autoimmune
diseases may represent a mechanism that promotes inflammation
and tissue damage and may be a rational target for therapeutic
inhibition.
Sa1.99. Mannose-Binding Lectin Polymorphisms in
Rheumatoid Arthritis and the Associations with
Radiological Progression Rate and Serological Markers.
L. De Rycke,1 I. Peene,1 E. Kruithof,1 T. Van De Casteele,2
L. Nuytinck,2 E. M. Veys,1 F. De Keyser.1 1Rheumatology, Ghent
University Hospital, Ghent, Belgium; 2Innogenetics, Ghent,
Belgium.
Background: Mannose-binding lectin (MBL) is a pattern
recognition molecule encoded by the MBL2 gene. A role for
MBL in susceptibility or severity of disease has been found in a
variety of pathologies, such as infectious, autoimmune, and
cardiovascular diseases. Previously, the role of MBL in patients
with rheumatoid arthritis (RA) has been reported, however, without
concordant results. Several DNA polymorphisms have been
characterized in the MBL2 gene, resulting in considerable
variations in quantity and/or functionality of the soluble MBL
protein. Due to a strong linkage disequilibrium, only 7 common
haplotypes are detected in humans. These are the following,
arranged according to decreasing expression levels and/or func-
tionality of soluble MBL: HYPA, LYPA, LYQA, LXPA, HYPD,
LYPB, and LYQC. The genotypes, taking into account only one
promotor polymorphism and expressed as a two-letter code, are
YA/YA, YA/YO, YA/XA, YO/YO, YO/XA, and XA/XA.
Objectives: 1) to compare the MBL2 genotypes in RA versus
healthy controls, and 2) to investigate the associations with
radiological progression rate and serological markers.
Patients and methods: MBL2 genotyping (INNO-LiPA
MBL2, Innogenetics, Ghent, Belgium) was performed in 166 RA
patients and 172 healthy controls. The radiological progression rate
in RAwas assessed as the modified Larsen score divided by disease
duration. All RA patients were tested for anti-cyclic citrullinated
peptide antibodies (anti-CCP2 antibodies, Eurodiagnostica, Arn-
hem, The Netherlands), rheumatoid factor (RF, Latex Fixation assay,
DifcoLaboratories, Detroit, MI) and shared epitope (INNO-LiPA
HLA-DRB1 or-DRB decoder amplification kits, Innogenetics,
Ghent, Belgium). TheMann-WhitneyU test was used for comparing
the different combined haplotypes. P-values b0.05 were considered
significant.
Results: No differences were detected in MBL2 genotype
frequencies between RA patients (YA/YA: 31%; YA/YO: 30%;
YA/XA: 25%; YO/YO: 6%; YO/XA: 5%; XA/XA: 3%) and
healthy controls (YA/YA: 35%; YA/YO: 22%; YA/XA: 25%; YO/
YO: 6%; YO/XA: 7%; XA/XA: 5%). The median radiological
progression rate in RA was similar for the different MBL2
genotypes: YA/YA: 3.5; YA/YO: 3.4; YA/XA: 3.3; YO/YO: 2.4;
YO/XA: 3.2; XA/XA: 2.6. Bad radiological prognosis (z 5.45,
defined as the 25% highest radiological progression rate) was not
linked with a specific MBL2 genotype. There were no differ-
AbstractsS122ences in median anti-CCP2 concentrations between the MBL2
genotypes: YA/YA: 140 U/ml; YA/YO: 233 U/ml; YA/XA: 149
U/ml; YO/YO: 153 U/ml; YO/XA: 170 U/ml; XA/XA: 176 U/
ml. The median RF titers were 50 U/ml for all MBL2 genotypes.
Also the percentage of shared epitope positive patients was
comparable in the different MBL2 genotypes: YA/YA: 78%; YA/
YO: 73%; YA/XA: 70%; YO/YO: 78%; YO/XA: 83%; XA/XA:
75%.
Conclusions: In our study, neither RA susceptibility nor
radiological prognosis was associated with a specific MBL2
genotype. Furthermore, RA-associated serological markers were
equally found in the different MBL2 genotypes.
Sa1.100. Interferon Inducible Proteins Are Novel
Autoantigens in Systemic Lupus Erythematosus.
D. L. Thibault,1 W. Hueber,1 T. Sylvester,1 D. Zeng,1 S. Strober,1
P. J. Utz.1 1Department of Medicine, Division of Rheumatology
and Immunology, Stanford University, Stanford, CA, USA.
Many studies have indicated a role for the type I interferon
system in both human and murine systemic lupus erythematosus
(SLE). In the anti-CD1 T cell receptor transgenic lupus mouse
model (CD1 SLE model), single positive (CD4+ or CD8+) T cells
from transgenic BALB/c donors induce a lupus-like syndrome
when transferred to irradiated BALB/c nu/nu recipients. Disease in
these mice is characterized by the presence of anti-dsDNA
antibodies, proteinuria, and immune complex glomerulonephritis.
Immunoprecipitation studies have revealed that a prominent target
of serum autoantibodies in CD1 SLE mice is an interferon-
inducible antigen that has been identified as a member of the
interferon-inducible 200 (Ifi200) family. We therefore hypothe-
sized that IFN-inducible proteins are also targeted by serum
autoantibodies derived from human lupus patients. We screened a
panel of monoclonal and polyclonal antibodies directed against
well-characterized lupus autoantigens by Western blot and found
that the expression of Ifi16 and Ro52 proteins is inducible in
HT1080 cells upon treatment with IFN-a and that the expression of
both proteins peaks at 24 hours following treatment. Ifi16 is the
human homolog of mouse Ifi202 and has previously been shown to
be an IFN-g-inducible target of antinuclear antibodies in 29% of
SLE patients. The expression of both Ifi16 and Ro52 is also
induced following treatment with IFN-h, another type I IFN.
HT1080 cells were treated with IFN-a for 24 hours, lysed, and
probed by Western blot with sera derived from 15 SLE patients.
Serum from a single patient uniquely targeted an unidentified 32
kD-interferon inducible protein. Finally, the expression of Stat1, an
inducible protein involved in both type I and type II IFN signaling,
was elevated in PBMCs derived from SLE patients as compared to
normal controls. Taken together, the data suggest that IFN-
inducible proteins represent a novel class of autoantigens and
reveal a potential link between the type I IFN system and
autoimmunity.
Sa1.101. Estrogen Receptor Effects on the
Anti-Inflammatory Action of PPARs in Lupus Mice.
J. L. Svenson,1 G. S. Gilkeson.1 1Rheumatology, Medical Univ. of
South Carolina, Charleston, SC, USA.
Nuclear receptors are recognized as regulators of inflamma-
tion. PPARg is a nuclear receptor that was previously considered
an orphan receptor but is now studied for its role in many
biological processes. PPARg agonists are inhibitors of inflamma-
tory mediators including nitric oxide (NO), TNF-alpha, andinterleukin 6. Because of these early reports, the thiazoledine-
diones (TZDs) and other synthetic PPARg agonists are being
studied in both animal models and human patients for their
effects on inflammatory diseases such as systemic lupus
erythematosus (SLE) and multiple sclerosis. We recently reported
that PPARg is not necessary for the reduction of the inflamma-
tory mediator iNOS or NO by synthetic PPARg agonists.
However, intrinsic PPARg function in the absence of synthetic
agonists appears to play an endogenous role in inflammatory
modulation. It is thought that PPARg competes with other nuclear
factors, like NFkB for common cofactors and activator molecules
by a mechanism called transrepression. Our interest is in
determining if such transrepression occurs between nuclear
hormone receptors, specifically estrogen receptors (ER) and
PPARs in inflammatory conditions. Such competition between
the estrogen receptors and PPARs may partially account for
gender differences in inflammatory diseases. Our current studies
demonstrate that like activation of PPARg, activation of PPARy
with GW610742X at 10–20AM is effective at significantly
reducing NO production by 50% in LPS stimulated RAW246.7
macrophages. Since RAW246.7 macrophages are reported not to
express PPARg, this suggests that PPARy may be an effective
regulator of inflammation. We elected to use a murine model of
lupus for our studies due to 10 fold higher incidence of lupus in
females compared to males. We bred the ERh -/- genotype onto
the MRL/lpr lupus mouse background for 8 generations. We
collected peritoneal macrophages and stimulated them with LPS
to induce NO production. After treatment with the PPARy agonist
GW610742X, we measured effects on NO production.
GW610742X reduced NO production by macrophages at 10–
20AM concentrations. NO reduction was most effective in
macrophages from ERh -/- mice at 55% and least effective in
ERh +/+ mice at 30%. Our results suggest that nuclear receptors
like ERh may interfere with the anti-inflammatory properties
exhibited by some of the PPARs. In addition these results
demonstrate the anti-inflammatory properties of PPARy. Com-
petitive nuclear receptors may be useful pharmacological targets
for the treatment of inflammatory diseases like SLE.
Supported by VA Medical Research Service and NIH grant
AR047451.
Sa1.102. Pathogenetic Value of the Disbalance Trace
Elements under Systemic Sclerosis.
Andriy I. Mazepa,1 Mariya A. Mazepa,1 Ivan V. Mazepa.1
1Biochemistry, Medical Academy, Ivano-Frankivsk,
Ivano-Frankivsk, Ukraine.
Heavy metals can induce autoimmune reactions by direct
linkage with MHC molecules, by modifying membrane proteins,
presentation of cryptopeptides, bcrushingQ autoantigen by toxic
radicals of oxygene, increase activity of enzymes of nucleinic
exchange. These statements have formed the basis for studying
concentration of Fe, Cu, Zn, Co, Mn, Cr, Sr, Pb, Ba in blood serum
of 116 patients with systemic sclerosis by inductive coupled
plasma(ICP) method.
It was established, that in patients with systemic sclerosis
deficiency of Zn, Fe and Mn is observed, increased value of Cu,
Co and Cr, indicates clear correlations between the desease
duration, level of activity, character of clinical sympthomes and
some immunological parameters. Copper concentration is mostly
expressed (increase in 5 times in comparison with norm) and zinc
(decrease in 3 times). Methods of treatment used in systemic
Abstracts S123sclerosis cases(in particular, penicylamine) promotes further zinc
exhaustion on blood serum and cellular levels.
The received results point to trace elements disbalance as
pathogenetic basis of this desease.
Sa1.103. Increased Granulopoiesis in Active SLE Blood:
New Insights into SLE Pathogenesis.
B. Vega, J. Borvak, A. Caldwell, V. Cantrell, J. Banchereau,
V. Pascual. 1Baylor Institute for Immunology Research, Baylor
Institute for Immunology Research, Dallas, TX, USA.
Gene expression profiling of active Systemic Lupus Eryth-
ematosus (SLE) mononuclear cells show a significant granulopoi-
esis signature that can be traced down to the presence of immature
blood neutrophil precursors. Indeed, using antibodies against
CD16 and CD11b, neutrophils can be separated into three stages:
immature neutrophil (IN) stage I (CD16-/CD11b-); IN stage II
(CD16-/CD11b+), and stage III or mature neutrophil (CD16+/
CD11b+). While in healthy individuals cells negative for either
CD16 or CD11b are not found in the blood, blood neutrophils in
SLE patients contain cells belonging to all three stages. We have
successfully obtained RNA from highly pure populations of
immature (stage I) and mature (stage III) SLE as well as mature
healthy blood neutrophils. After RNA amplification, labeling and
hybridization to Affymetrix U133 gene chip arrays, we have
detected i) genes that are specifically transcribed in immature
versus mature neutrophils, ii) neutrophil genes that contribute to
the SLE-specific gene signatures. Furthermore, we have found that
the presence of immature neutrophils correlates with SLE disease
activity and with the development of renal disease, suggesting that
they are relevant to disease pathogenesis and severity.
The presence of immature neutrophils in the SLE blood could
be a reactive process due to the apoptosis of mature cells. Indeed,
we have found that the number of immature neutrophils in the
SLE blood mononuclear fraction correlates with the ability of the
patientsTs serum to induce apoptosis of healthy mature neutro-
phils. Whether anti-neutrophil antibodies and/or death-inducing
molecules like TRAIL are responsible for the pro-apoptotic effect
of SLE serum on healthy neutrophils is currently under
investigation.
We have also found that mature SLE neutrophils display
accelerated spontaneous apoptosis when compared with healthy
mature neutrophils in culture. Despite an increased apoptosis rate,
mature SLE neutrophils promptly release as much IL-8 and MIP1-
alpha as healthy cells when stimulated with the TLR2 agonist
lipopeptide and TLR7/8 agonist R848, implying that these cells are
functional. The release of cytokines by pro-apoptotic SLE
neutrophils could be contributing to an inflammatory environment
which would facilitate the maturation of antigen-presenting cells
and the processing of apoptotic material in an immunogenic
manner, explaining some of the key pathogenic events in SLE.
Sa1.104. Rheumatoid Factor Seropositivity in a Normal
Population Is Associated with the Use of Oral
Contraceptives and Cigarette Smoking.
D. S. Majka,1 S. Pande,2 K. D. Deane,3 L. A. Parrish,3
W. P. Arend,3 V. M. Holers,3 J. M. Norris.2 1Division of
Rheumatology, Northwestern University, Feinberg School of
Medicine, Chicago, IL, USA; 2Department of Preventive Medicine
and Biometrics, University of Colorado Health Sciences Center,
Denver, CO, USA; 3Division of Rheumatology, University of
Colorado Health Sciences Center, Denver, CO, USA.Objective: To determine whether oral contraceptive (OCP) use
and cigarette smoking are associated with the presence of
rheumatoid factor (RF) in a cohort of reproductive age women
without rheumatoid arthritis (RA).
Materials/Methods: Subjects were 297 women who were
the parents of children enrolled in a cohort originally
established for the prospective study of the development of
type I diabetes mellitus-related autoimmunity. This parental
population was selected because it is enriched with HLA-DR4,
a susceptibility marker for both type I diabetes mellitus and
RA. Subjects were interviewed and examined to rule out a
current diagnosis of RA. When exam or history was consistent
with a possible diagnosis of RA, the subjectTs medical record
was reviewed. Subjects who met 1987 American College of
Rheumatology criteria for RA were excluded from the analyses.
A questionnaire was administered to obtain data on current and
past history of tobacco and OCP use. Serum samples obtained
from the adults at the time of the interview were tested for RF
by nephelometry. Logistic regression models were performed to
determine the association between RF and pack years of
smoking as well as OCP use. Adjusted odds ratios (OR) and
95% confidence intervals (CI) were used as the measures of
association.
Results: Subject age range was 23.1-53.7 years (mean: 38.1,
median: 38.3). 89.6% of women reported ever using OCPTs, and
the mean duration of OCP use was 7.3 years. Categories of
smoking were Never (n = 204), 1-19 pack-years (n = 88), and z20
pack-years (n = 5). 10.4% of the subjects had a positive RF. After
adjusting for age, ethnicity, presence of the shared epitope, and
OCP use, smoking z 20 pack-years was associated with a positive
RF, OR: 18.94 (95% CI: 2.74, 130.85), P = 0.0017, compared with
Never smoking. Smoking 1-19 pack-years [OR:0.72 (95% CI:
0.27, 1.90)] was not associated with a positive RF compared with
Never Smoking. Ever use of OCPTs was negatively associated with
the presence of RF, OR: 0.20 (95% CI: 0.08, 0.50), P = 0.0006,
independent of age, ethnicity, presence of the shared epitope, and
smoking status.
Conclusions: These data suggest that OCP use may protect
against the development of RF in individuals without RA.
Additionally, heavy cigarette smoking may be a risk factor for
RF seropositivity in individuals without RA. Previous studies
have proposed that smoking is a risk factor for RA develop-
ment, and OCP use is inversely associated with RA develop-
ment. Our results suggest that both of these environmental
exposures may act very early in the development of clinically
apparent disease.
Sa1.105. Efficacy of Apratastat, a Novel Dual Inhibitor
of TNF-A Converting Enzyme/Metalloproteinase, in
Murine Collagen-Induced Arthritis Models.
M. Hegen,1 Y. Zhang,1 J. Levin,2 J. Xu,3 T. Cummons,3
K. Harding,4 B. J. Sheppard,5 M. W. Leach,5 L. L. Lin,1
J. Gibbons,3 J. Skotnicki,2 C. L. Nickerson-Nutter.1 1Inflam-
mation, Wyeth Research, Cambridge, MA, USA; 2Medicinal
Chemistry, Wyeth Research, Pearl River, NY, USA; 3Oncology,
Wyeth Research, Pearl River, NY, USA; 4Bioresources, Wyeth
Research, Cambridge, MA, USA; 5Exploratory Drug Safety, Wyeth
Research, Andover, MA, USA.
Background: Tumor necrosis factor (TNF)-a is an established
target for the treatment of rheumatoid arthritis (RA). Pro-TNF-a is
proteolytically processed to a soluble form by TNF-a converting
AbstractsS124enzyme (TACE). Orally bioavailable, small molecule inhibitors
that block release of TNF-a present a highly desirable strategy for
treating RA.
Objectives: 1) To determine the effects of Apratastat, a novel
dual TACE/metalloproteinase inhibitor in two CIA models. 2) To
compare Apratastat in one CIA model with a broad-spectrum
metalloproteinase inhibitor, having no significant TACE activity
(1).
Methods: Collagen-induced arthritis (CIA) was induced in
DBA/1 mice by immunizing at the base of the tail with bovine
type II collagen (CII) emulsified in complete FreundTs
adjuvant, and boosting with either lipopolysaccharide (LPS)
or CII emulsified in incomplete FreundTs adjuvant 21 days
later.
Results: Apratastat was evaluated in CIA mouse models with
either an LPS boost or a collagen boost. In a prophylactic regimen
with an LPS boost, Apratastat was administered orally at doses of 5,
10, or 20 mg/kg BID from days 18 through 35 post inoculation. The
minimum efficacious dose was 10 mg/kg BID. In a second CIA
model with a collagen boost, therapeutic treatment was initiated in
each mouse when the disease severity score was at least 1.
Apratastat (10, 25, 50, or 100 mg/kg BID, and 200 mg/kg QD,
PO), or MPI-369 (100 mg/kg BID, PO), a broad-spectrum metal-
loproteinase inhibitor having no significant TACE activity, were
evaluated in the therapeutic regimen. Apratastat at 100 mg/kg BID
or 200 mg/kg QD produced a significant reduction in clinical and
microscopic disease severity scores. In contrast, MPI-369 did not
show activity. The lower doses of Apratastat were similar to the
vehicle control.
Conclusion: These data show that a potent TACE/metal-
loproteinase inhibitor, Apratastat, reduces the clinical and histo-
logical manifestations of joint destruction in 2 murine CIA models
of immune-mediated arthritis.
Reference:
1. J. Med. Chem. 2003, 46, 2361-75.
Sa1.106. Marginal Zone (MZ) B Cells Are Most
Susceptible to Loss of Tolerance in the Chronic GVH
Model of SLE.
A. Choudhury, P. L. Cohen, R. A. Eisenberg. 1Medicine, Division
of Rheumatology, University of Pennsylvania, Philadelphia, PA,
USA.
Systemic lupus erythematosus (SLE) is characterized by the
production of autoantibodies and glomerulonephritis. The
chronic GVH (cGVH) model of SLE is induced by allo-
recognition of foreign major histocompatibility complex (MHC)
Class II determinants. Our studies using CD4KO mice showed
that endogenous CD4 T cells are required for emergence of
autoreactive B cells during cGVH. In new studies we have
attempted to characterize which subsets of B cells are prone to
losing tolerance in cGVH. We have used the 3H9 bknockinQ tg
model, in which the chromosomal JH locus has been replaced
with the rearranged V(D)J-3H9tg. B cell subsets were
characterized phenotypically by expression of specific cell
surface proteins. Thus, immature B cells were sorted as
HSAhiIgMhiAA4.1+IgD- while mature B cells were sorted as
HSAloIgMloAA4.1-IgD+. These different B cell subsets were
adoptively transferred into irradiated (300 rads) JHT recipients,
which lack endogenous B cells because of a targeted deletion
in their JH segment. cGVH was induced by challenging the
recipients with bm12 spleen cells. Our data showed that matureB cells lose tolerance and produce anti-dsDNA autoantibodies
sooner than immature B cells. To determine which subset of
the transferred mature B cell population was susceptible to loss
of peripheral tolerance during GVH, we utilized additional cell
surface markers. IgMintIgDhiCD21intCD23hiCD1-CD9lo were
sorted as follicular (FO) recirculating B cells, while IgMhiIg-
DloCD21+CD23-CD1hiCD9hi were considered as MZ B cells,
which are normally located at the junction of white and red
pulps. In similar adoptive transfer experiments followed by
induction of GVH, our data indicated that MZ B cells lost
tolerance and secreted autoantibodies sooner than FO B cells.
MZ B cells have recently been proposed to play a critical role
in host defense against T-independent blood-borne pathogens
and in spontaneous development of autoantibodies, and
expanded MZ B cell populations have been characterized in
several lupus-prone strains of mice. Our data now show that
MZ B cells are particularly vulnerable to loss of tolerance in
the cGVH model of SLE and thus, may be an attractive target
for therapeutic interventions.
Sa1.107. Elevated Levels of Anti-Oxidized Low Density
Lipoprotein Autoantibodies Is Correlated with Disease
Activity of Systemic Lupus Erythematosus.
Ruihua Wu, Guoqiu Shen, Robert Morris, Galina Lummer, John
Sama, Allan Metzger. 1R & D, RDL Reference Laboratory, Los
Angeles, CA, USA.
Systemic lupus erythematosus (SLE) is a multi-systemic
autoimmune disease characterized by a great diversity of
clinical manifestations accompanied by a large number of
autoantibodies. In the present study we investigated the change
of anti-dsDNA autoantibodies and anti-oxLDL autoantibodies in
the progression of SLE. Twenty-seven patients with SLE were
defined according to the American College of Rheumatology
criteria and were monitored over 2 years for disease activity.
The anti-dsDNA autoantibody was measured by Farr assay and
the anti-oxLDL autoantibody was determined by a standardized
EIA. Both the antibodies were measured twice a year over the
time. The results showed that 18 subjects were positive (N 5
IU/mL), 8 subjects were negative and 1subject varied in the
borderline for levels of anti-dsDNA autoantibody; and 11
subjects were positive (N 100 unit/mL), 10 subjects were
negative and 6 subjects varied between positive and negative
for levels of anti-oxLDL autoantibody in the all detection
during the monitored period. Six out of 27 patients were all-
negative levels of both the autoantibodies. The levels of both
autoantibodies substantially decreased in one patient and
markedly increased in 4 patients over the time. The levels of
anti-oxLDL autoantibody were significantly higher (P b 0.001)
in the anti-dsDNA autoantibody positive group (119.4 F 49.2
unit/mL) compared to the anti-dsDNA autoantibodies negative
group (82.9 F 37.7 unit/mL). There was a very significant
correlation between the levels of anti-dsDNA autoantibody and
the levels of anti-oxLDL autoantibody in the anti-dsDNA
antibody positive group (R = 0.5856; P b 0.0001). There was
no any correlation between both the autoantibodies in the anti-
dsDNA antibody negative group (R = 0.0619). This study further
suggests that oxidative damage is involved in the pathogenesis of
SLE. The anti-oxLDL autoantibodies are as similar as anti-
dsDNA autoantibodies to be relevant to SLE progression. It could
be used as an associating marker in the monitoring of disease
activity in SLE. The mechanism of elevated the levels of anti-
Abstracts S125oxLDL autoantibodies in active SLE subjects should be further
study.
Sa1.108. Pediatric Systemic Lupus Erythematosus
(SLE)-Loss of Tolerance to Maternal Microchimerism?
A. M. Stevens,1 N. C. Lambert,2 H. M. Hermes,1 T. E. Erickson,2
J. L. Nelson.2,3 1Pediatrics, University of Washington, Seattle, WA,
USA; 2Immunogenetics, Fred Hutchinson Cancer Research
Institute, Seattle, WA, USA; 3Medicine, University of Washington,
Seattle, WA, USA.
Objective: Pregnancy-derived microchimerism has been
implicated in the pathogenesis of autoimmune diseases that
resemble graft-versus-host disease (GVHD). Evidence for fetal
microchimerism (FMc) has been found in the blood and organs
of women with systemic sclerosis and SLE. The mouse model
for GVHD in which parental lymphocytes induce SLE-like
glomerulonephritis and autoantibodies suggests that maternal
microchimerism (MMc) may also be involved in SLE. We
found maternal cells in the tissues of patients with autoimmune
diseases and controls in the form of T lymphocytes, renal
tubular cells, hepatocytes, and cardiac myocytes. Thus, persis-
tence of MMc implies normal immune tolerance to maternal
antigens, and loss of tolerance could lead to inflammation
directed at MMc within tissues. Alternatively, clonal prolifer-
ation of maternal T lymphocytes reactive to host antigens could
lead to elevated MMc in the peripheral blood. This study
investigated MMc levels as well as tolerance to maternal
antigens in childhood onset SLE.
Methods: Pediatric subjects were studied to avoid the
potentially confounding factor of FMc. We used Real-Time
Quantitative PCR specific for non-shared maternal HLA alleles
to quantify maternal DNA in peripheral blood from 38 subjects: 14
with SLE and 24 age-matched, healthy controls. Lymphocyte
reactivity was evaluated by intracellular cytokine assay and flow
cytometry after stimulation of the probandTs peripheral blood
mononuclear cells with CD14+ macrophages from the mother or
an unrelated donor (URD).
Results: Maternal DNA was detected in 21% of SLE
patients and 38% of controls (OR 0.45, P = 0.17). The mean
level of MMC in SLE was 1.7 genome equivalents (gEq)/
million, (range 0–12) compared to 20.5 gEq/million, (range 0–
319) in controls. After stimulation by URD macrophages 14%
of CD4+ T lymphocytes from a healthy child produced
interferon-g, whereas only 2% responded to maternal; 25%
produced IL-4 in response to URD and 2% to maternal. In
contrast, tolerance to maternal cells was not observed in a
pediatric SLE patient: 10% of CD4+ lymphocytes produced
IFN-g in response to URD macrophages compared to 20% to
maternal, and 16% produced IL-4 to URD compared to 31% to
maternal.
Conclusions: MMc was common in the healthy subjects
tested. In contrast to previous studies in which FMc and MMc
was increased in autoimmune disease, there was a trend toward
decreased MMc in pediatric SLE patients. In one SLE patient
increased reactivity to maternal antigen presenting cells was
observed, suggesting that MMc could be cleared from the
circulation by host T cells. These preliminary results suggest
the hypothesis that immunological tolerance to MMc is intrinsic
to normal biology but may be lost in chronic inflammatory
disease, leading to tissue-specific inflammation. Additional
studies are needed to investigate MMc in tissues for frequency,morphology and phenotype and to extend initial observations
suggesting a loss of tolerance to MMc in SLE.
Sa1.109. Hypogammaglobulinemia in a Pediatric Patient
with Idiopathic Retroperitoneal Fibrosis Treated with
Tamoxifen.
R. Tachdjian,1 R. L. Roberts,1 D. K. McCurdy.1 1Allergy,
Immunology and Rheumatology, UCLA School of Medicine, Los
Angeles, CA, USA.
We present a 16 year old male with a history of
retroperitoneal and mediastinal fibrosis. His case was compli-
cated by renal and ureteral obstruction, and superior and
inferior venae cavae obstruction with significant collateral flow.
This childTs symptoms began at the age of 10, when he
noticed increased fatigue with activity. At that time renal
function tests were abnormal, with ultrasound showing right
hydronephrosis and CT scan showing stenosis of the inferior
vena cava (IVC) between the infrarenal portion of the IVC
and the hepatic portion, with extensive collaterals circulation.
Ureteral stents were placed, and pulse doses of solumedrol
were administered but the obstruction persisted. Previous
reports have shown that the drug tamoxifen promotes
activation-independent shedding of L-selectin (CD62-L) from
neutrophils and lymphocytes, and it has been used in adults to
treat this disease. It was decided to add this medication to his
treatment regimen along with prednisone. The tamoxifen did
result in resolution of his ureteral obstruction and removal of
the stents. His course was complicated by a large deep venous
thrombosis of the lower extremity and thrombosis of the SVC
for which he continues to take warfarin prophylactically. Our
patient has not had evidence of recurrence in the second
month since discontinuation of tamoxifen, but he continues to
be hypoxemic and oxygen dependent with physical activity.
Pulmonary function testing is indicative of severe restrictive
disease. What makes this case unique is hypogammaglobuli-
nemia (with an IgG in the range 244–473 mg/dL) both before
and during the treatment course. Although his absolute B cell
count is low, the percentage from the total counts is normal.
Additionally, he has no identifiable source of protein loss from his
body. The lack of immunoglobulin production in this patient points
towards a possible early diagnosis of combined variable immuno-
deficiency (CVI). We will be treating him with intravenous
immunoglobulin (IVIG) in order to replace the deficiency and
prevent infection. This is the first report of CVI in retroperitoneal
fibrosis.
Sa1.110. Dendritic Cells Pulsed with Type II Bovine
Collagen Modulate the Murine Collagen Induced
Arthritis.
L. E. Salazar,1 O. A. Aravena,1 P. Abello,2 A. Aguirre,1
D. Catalan,1 C. Llanos,3 F. Sabugo,3 F. Gonzalez,1 C. Gonzalez,2
M. Cuchacovich,3 J. C. Aguillon.1 1Disciplinary Program of
Immunology, University of Chile; 2Program of Anatopatologic in
Veterinaria, University of Chile; 3Department of Rheumatologic,
Hospital Clinic of University of Chile, Santiago, Chile.
Dendritic cells (DCs) are antigen presenting cells that play
an important role in the immunopathogenesis of rheumatoid
arthritis. DCs genetically modified have shown to reduce the
severity of arthritis in the murine model of collagen induced
arthritis (CIA). In addition, DCs expressing differential levels of
MCH class II and co-stimulator molecules have demonstrated
AbstractsS126to interfere with the induction of CIA by a deficient
presentation of antigen to T cells. Aim: To assess the capacity
of DCs pulsed with peptides derived from type II bovine
collagen (CII) to modulate the antigen-specific immune
response in mice with active arthritis. Methods: After five
days of culture with GM-CSF, bone marrow-derived DCs were
incubated with LPS and then pulsed for 4 h with CII. DBA1/
lacj mice with active arthritis were subcutaneously inoculated
either with CII-pulsed DCs or DCs alone. Both clinical and
histopathological parameters were followed up for 70 days after
the first CII administration. Results: Previous the immunization
procedure, DCs were phenotipically and functionally charac-
terized by MHC class II and co-stimulator markers and by a
phagocytosis assay, respectively. In both analyses DCs dis-
played a semi-mature pattern. We observed that the group of
mice with CIA and immunized with DCs alone showed a higher
score of clinical signs than the control group of CIA (P b 0.05).
However, the group of CIA mice immunized with CII-pulsed
DCs showed a significant lower clinical score than CIA controls
(P b 0.005). Conclusion: The immunization with semi-mature
DCs pulsed with type II bovine collagen interferes with the
immunological course of murine arthritis in an antigen-specific
manner.
Financed by Fondecyt-Chile 1040860, Fondef-Chile D03I1055
and Mecesup UCH0115.
Sa1.111. IL-12 Regulates Collagen-Induced Arthritis in
DQ8 Mice through STAT4-Dependent Mechanisms.
V. Taneja, M. Behrens, H. S. Luthra, M. M. Griffiths, C. S. David.
1Immunology, Mayo Clinic, Rochester, MN, USA; 2Immunology,
Mayo Clinic, Rochester, MN, USA; 3Rheumatology, Mayo Clinic,
Rochester, MN, USA; 4Medicine, University of Utah, Salt Lake
City, UT, USA; 5Immunology, Mayo Clinic, Rochester, MN,
USA.
IL-12 signaling through STAT-dependent pathway is essen-
tial for induction of IFNg and differentiation of Th1 cells.
Mice expressing HLA-DQ8 in the absence of endogenous
class II molecules develop severe collagen-induced arthritis
(CIA), an animal model for rheumatoid arthritis. The develop-
ment of arthritis in DQ8 mice is T cell dependent with a Th1
profile. To understand the role of IL-12 in collagen-induced
arthritis, we have generated Abo.DQ8 transgenic mice lacking
STAT4. Both STAT4/ and STAT4+/+ mice could mount
response to collagen in vitro. Immunization of both strains of
mice with type II collagen led to development of arthritis.
However incidence of CIA was significantly higher in
DQ8.STAT4+/+ mice compared to DQ8.STAT4/ mice.
The development of arthritis was dependent on Th1 cytokines
as both transgenic mice produced IL-18 and TNF-a.
DQ8.STAT4/ mice produced very low levels of IFNg
suggesting IL-12 controls the production of IFNg through a
STAT4-dependent pathway. STAT4-/- mice developed milder
arthritis with delayed onset than that observed in DQ8.STAT4+/+
mice. CIA in the absence of IFNg and IL-12, suggests that these
cytokines might regulate the severity of disease. Mice carrying
non-susceptible HLA-DQ6 transgene produce lower amounts of
Th1 cytokines and develop milder CIA with lower incidence
compared to DQ8 mice. This suggests that while MHC is the
major predisposing factor, cytokines produced in response to
antigen presented by the MHC molecule may determine severity
of disease.Sa1.112. Identification of Genes Participating in
Suppression of Murine SLE by CD8+ Ti Cells.
R. P. Singh, F. M. Ebling, D. Elashoff, D. V. Sven, C. Zamber,
D. Patel, A. L. Cava, B. H. Hahn. 1Division of Rheumatology/
Medicine, David Geffen School of Medicine at UCLA, Los Angeles,
CA, USA; 2Dept. of Biosatstics, Haematology/Onccology, David
Geffen School of Medicine at UCLA, Los Angeles, CA, USA;
3Research Department, Genome Explorations Inc., Memphis, TN,
USA.
Systemic lupus erythematosus (SLE) is caused by autoanti-
bodies (e.g. anti DNA), and immune complexes causing organ
damage. NZB/NZW Fl female (BWF1) mice tolerized with an
artificial peptide (pCONSENSUS, pCONS) based on anti-DNA
IgG sequences containing MHC Class I and Class II T cell
determinants, develop regulatory CD4+CD25+ T cells and
inhibitory CD8+ T cells, both of which suppress autoAb
production. In the present study, using the Affymetrix Gene
Chip array 430, 2.0, we analyzed 45,000 murine genes. One to
one comparison of white blood cells (WBC), CD4, and CD8
cell subsets from tolerated vs. non-tolerized mice showed 448,
174 and 60 genes that are differentially expressed by at least
two-fold, respectively. From the CD8+ T cell arrays, we
confirmed upregulation of several genes using real- time
PCR. Increased expression pattern (more than two fold) with
real -time PCR of 6 genes in CD8+T cells from tolerized mice
was repeatedly found (IFI202B, Trp-53, Foxp3, CCR7, bcl2,
and IFNar1). Immunophenotyping and cell sorting revealed
significant expansion of CD3+CD8+, after pCONS treatment in
BWF1 mice. Significant increased mRNA expression of TGFb
and Foxp3 was found in CD8+CD28+Ti stimulated with anti-
CD3/CD28 after pCONS treatment, suggesting a role of TGFb
and Foxp3 in the suppressor function of these CD8+ T cells.
Anti-TGFb abrogated suppression of anti-DNA production in
vitro by CD8+ T cells cocultured with syngeneic CD4+ T
helpers and B cells. Intracellular staining revealed increased
expression of IFN-g and Foxp3 in splenic CD8 T cells from
tolerized mice compared to those from untreated mice.
Furthermore, Annexin V and 7AAD staining showed signifi-
cantly less apoptosis in tolerized CD8+Ti cells than in naive.
CD8+ Ti from tolerized mice exposed to si RNA of Foxp3
lost their ability to suppress anti-DNA production in vitro. This
confirms the role of Foxp3 in the suppression associated with
this model of immune tolerance. The role of other upregulated
molecules are being studied in a similar fashion. We conclude
that the suppressive function of tolerized CD8+ T cells relates
to increased survival and secretion of TGFb, and to upregu-
lation of Foxp3. Other gene products upregulated in these cells
may also relate to their ability to survive and suppress
autoimmunity. These studies on the molecular mechanisms of
suppression of lupus in BWF1 mice may have potential
therapeutic value in human SLE.
Sa1.113. Impact of Gender on Immune Nephritis.
T. Henry, Y. Fu, J. Zhou, C. Mohan. 1Internal
Medicine-Rheumatology, University of Texas Southwestern
Medical Center, Dallas, TX, USA.
Background: We have recently reported that the co-admin-
istration of anti-glomerular sera with LPS leads to severe nephritis,
as gauged by proteinuria, azotemia, glomerular crescent formation,
and proliferative lesions. The focus of this work is to ascertain how
gender might impact nephritis in this model.
Abstracts S127Methods:Male and female C57BL/6 mice (some of which were
deficient in estrogen receptors) were challenged with anti-glomer-
ular serum plus LPS, and monitored for evidence of renal disease. In
addition, some mice were subcutaneously implanted with 40-day
release estradiol pellets (0.5mg), and then subjected to the
nephrotoxic insult.
Results: LPS and anti-glomerular antibody challenged female
C57BL/6 mice exhibited significantly worse proteinuria (10.9 vs.
4.9 mg/24h at peak of disease, P b 0.007) and blood urea nitrogen
(120.3 vs. 55.8 mg/dL at peak of disease, P b 0.029, N = 5 mice
per group), compared to age-matched C57BL/6 male mice.
Moreover estradiol-treated C57BL/6 males exhibited significantly
worse proteinuria as early as D8 (16.7 vs. 11.8 mg/24h, P b 0.0005,
N = 5–6 mice per group), compared to placebo-treated C57BL/6
males. Importantly, estradiol-treated C57BL/6 males that were
deficient in ESR1 estrogen receptors exhibited significantly lower
proteinuria (5.7 mg/24h), compared to estradiol treated C57BL/6
males (13.3 mg/24h, P b 0.004, N = 3–12 per group).
Conclusion: It is clear that gender can profoundly influence
immune-mediated nephritis, through the action of estrogens.
Studies are in progress to determine the cellular and molecular
bases for the differences.
Sa1.114. Use of Gene-Expression Profiling in Labial
Salivary Glands Using cDNA Microarrays To Identify
New Pathogenic Pathways in Primary SjfgrenTs
Syndrome.
Jacques-Eric Gotttenberg,1 Carlo Lucchesi,2 Nicolas Cagnard,2
Franck Letourneur,2 Sylvie Mistou,2 Jean Sibilia,3 Gilles
Chiocchia,2 Xavier Mariette.1 1Rheumatology, INSERM E 109,
Bicetre Hospital, Le Kremlin Bicetre, France; 2Immunology,
Institut Cochin, Paris, France; 3Rheumatology, Strasbourg
Hospital, Strasbourg, France.
Objective. The pathogeny of primary SjfgrenTs syndrome (pSS)
is still poorly understood. Since pSS is a multifactorial disease, an
approach focused on a single gene or gene product could be too
restrictive. No comprehensive, systematic study of genes expressed
or repressed in salivary gland, one of the main target-organ of
patients with pSS, has ever been reported. We aimed to compare the
gene-expression profiling in salivary glands of patients with pSS
with that of subjects without any auto-immune features.
Patients and Methods. Patients with pSS according to Euro-
pean-American consensus group criteria were included in the study,
as well as patients withSS and rheumatoid arthritis and subjects
without any feature of autoimmunity (no autoantibody, focus
score b 1). Total RNAwas isolated from labial salivary glands and
RNA levels, quality and purity were assessed with the use of the
RNA 6000 Nano assay on the Agilent 2100 Bioanalyzer. RNAwas
amplified (one-round amplification, Ampliamp, Ambion, UK),
controlled on the BioAnalyzer, and c-DNA fluorescent probes were
prepared from 250 ng of amplified RNA. CDNA fluorescent probes
were hybridized to custom chips, containing 11000 cDNA spots
(manufactured by the Commissariat a` lTEnergie Atomique, CEA,
France). RNA from a pool of 4 normal parotid samples was
amplified and used as a common reference. Each sample was
hybridized twice, with a dye-swap. All intensity values were
normalized using LOWESS. The whole procedure of gene-
expression profiling fulfilled the MIAME standards for microarray
data. P values were corrected for multiple comparisons according to
Benjamini-Hochberg False Discovery Rate procedure.Results. Thirty-two microarrays were hybridized, using salivary
glands of 7 patients with pSS, 7 subjects without any feature of
autoimmunity and 2 patients with SS and rheumatoid arthritis.
Taking into account features present in all microarrays, 169 genes
(93 genes up-regulated, 76 genes downregulated) were differentially
expressed between patients with pSS and subjects without any
feature of autoimmunity. 612 genes were differentially expressed
between these 2 groups after algorithmic evaluation of missing
values. Hierarchical clustering showed that 6/7 patients with pSS
clustered tightly together, as well as 6/7 subjects without any feature
of autoimmunity. The 169 genes mainly belonged to the cell-cycle,
oxidative burst, apoptosis, protein metabolism and chemokine
families. Validation of these results using quantitative RT-PCR and
immunohistochemistry are currently under way.
Conclusion. This gene-expression profiling study in the target
organ of pSS, which fulfilled the best standards for microarray data,
demonstrates that the transcriptomic approach could be very helpful
to unravel new pathogenic pathways in autoimmunity.
Sa1.115. Four Systemic Lupus Erythematosus
Autoantigens Identified by HEp-2 Library Screening.
A. D. Chang,1 L. Q. Tai,1 J. Nguyen,2 R. A. Gatti,2 D. K.
McCurdy.1 1Pediatric Allergy, Immunology, Rheumatology,
University of California, Los Angeles, Los Angeles, CA, USA;
2Pathology, University of California, Los Angeles, Los Angeles,
CA, USA.
Objective: To determine and characterize autoantigens that
stimulate autoantibody production in systemic lupus erythematosus
(SLE) by screening human epithelioma-2 (HEp-2) expression
library with patient sera.
Materials and Methods: Forty pediatric SLE patients with
nephritis were screened for high titer anti-nuclear antibodies (ANA)
by immunofluorescence and Western blot using HEp-2, leukemia
(acute lymphocytic and myelocytic leukemia), and normal cells.
Two sera yielded extremely high-titer ANA. Column-purified
immunoglobulin G (IgG) samples from these two pediatric patients
(both with diffuse proliferative glomerulonephritis) were used to
screen a HEp-2 cell line expression library made with a Zap II
cDNA synthesis kit by Stratagene. After immunoscreening,
phagemids from the lambda ZAP-II vector were excised, amplified
by PCR, characterized by agarose gel electrophoresis, and
sequenced. Sequenced samples were identified by the National
Center for Biotechnology Information (NCBI) BLAST program.
Results: Out of the seventeen clones that were isolated, seven
were identified by both sera. After screening out vector and repeat
sequences, four unique antigens were identified: melanoma antigen
gene Xp-2 (MAGE Xp-2), ribosomal protein P0, ribosomal protein
P1, and ribosomal protein S6.
Conclusion: Four autoantigens in systemic lupus erythemato-
sus were identified by HEp-2 expression library screen. Screening
different tissue expression libraries with patient sera may further
characterize SLE autoantibody antigen specificities, improve our
understanding of the pathogenesis of autoantibody production and
end-organ damage in SLE, and may lead to the development of
novel therapeutic interventions.
Sa1.116. Exploration of a Burn Medication for Potential
Anti-Inflammatory Agent through External Application.
Yuching Wu,1 Rany Ly,1 Wenhsiou Wu,1 Abdulrahman Ibrahim.2
1Immunology, MYC, Inc., Irvine, CA, USA; 2Center for Virus
Research, The University of California at Irvine, Irvine, CA, USA.
AbstractsS128Objective: External application of the extract of two herbs
from two genera, Axonopus and Ludwigia, abbreviated as A/L
extract, has been used to treat patients with second to third
degree of burn injuries with high efficacy for decades. How A/
L extract works to enhance the healing of burn injuries was
unknown. The main symptoms after severe burn are redness,
pain, blister, and swelling due to inflammation; therefore, anti-
inflammatory medication is a basic and critical treatment.
Hence, the aim of our studies is to determine whether A/L
extract has anti-inflammatory activities.
Methods: Non-adherent peripheral blood leukocytes (NA-PBL)
and monocytes were isolated from human whole blood collected
from three healthy donors. Human NA-PBL and monocytes were
then stimulated with PHA with or without the presence of filter-
sterilized A/L extract. Supernatant was collected at 48hr and 72 hr
for the measurement of TNF-alpha and IL-2 by ELISA. The cells
were also stained with MTT at 72hr for proliferation assay.
Three groups of mice after 2nd or 3rd degree of burn by boiled
water were treated with placebo, 0.1% A/L extract, or 0.5% A/L
extract daily.
Results: In vitro studies from human NA-PBL and monocytes
stimulated with PHA show that the incubation of the cells with A/L
extract reduced the production of IL-2 (30% for NA-PBL, 48% for
monocytes at 48 hrs) and TNF-alpha (~15% for both NA-PBL and
monocytes at 48 hours and 35% for NA-PBL and 20% for
monocytes at 72 hours). The proliferation assay shows that the cell
prolifereation stimulated by PHA was inhibited by 25% with the
presence of A/L extract. The results from the mice with burn
injuries show a dose response: it took the mice (n = 7) treated with
placebo about a month to heal, 3 weeks for the group (n = 6)
treated with 0.1% A/L extract and 15 days for the group (n = 7)
with 0.5% A/L extract. In independent experiments, the treatment
of A/L extract on the mice with severe inflammation on whole
back and whole limb also reduced the symptoms of inflammation,
such as redness and swelling, within an hour; so did the results
from the volunteers with pain on joint.
Conclusion: The results from both in vitro and in vivo
studies suggest that external application of A/L extract is able
to reduce both superficial and sub-dermal inflammation. The
external application to treat sub-dermal inflammation, such as
Rheumatoid arthritis, will greatly reduce any risk of side
effects. Further efforts will be made to study the effect of A/L
extract on synoviocytes and the safety of oral usage to treat
systemic inflammation.
Sa1.117. Regulation of Autoimmune Arthritis by the
Homologous Dominant Self and Cryptic Mycobacterial
Hsp65 Epitopes.
M. Durai,1 H. R. Kim,1 Y. Mia,1 E. Kim,1 K. D. Moudgil.1
1Microbiology and Immunology, University of Maryland School of
Medicine, Baltimore, MD, USA.
Identification of the disease-regulating T cell determinants
within an antigen targeted in an autoimmune disease would be
of significance both in better understanding of the mechanism
of natural remission/recovery from acute phase of the disease
and in developing antigen-specific immunotherapeutic
approaches for that disease. Although pathogenic epitopes have
been identified in several self and foreign antigens, there is
barely any information regarding bona fide regulatory T cell
epitopes. Using the Lewis rat adjuvant-induced arthritis (AA)
model of human rheumatoid arthritis (RA), we have defineddisease-regulating T cell epitopes within the AA-related antigen,
mycobacterial heat-shock protein 65 (Bhsp65), and in its self
homolog, rat hsp65 (Rhsp65). These epitopes reside within the
C-terminal region of hsp65. Interestingly, despite sequence
differences between the corresponding homologous C-terminal
epitopes of the foreign (mycobacterial) and self hsp65, these
epitopes are not only immunogenic and crossreactive with each
other, but they also possess comparable AA-regulating proper-
ties. Intriguingly, the C-terminal epitopes of the self hsp65 are
well processed and presented (dominant) from the native
antigen, whereas those of the foreign hsp65 are poorly
processed and presented (cryptic or hidden). However, like
Bhsp65, Rhsp65 is also a good immunogen, showing that
Lewis rats are not tolerant to either hsp65. Our results support
a model for immunoregulation of autoimmune arthritis in which
arthritic Lewis rats having inflammatory acute AA upregulate
the expression as well as presentation of endogenous self hsp65
leading to priming of ambient C-terminal epitope-reactive T
cells. These T cells then contribute to the downregulation of
acute AA. Concurrently, the cryptic epitopes of Bhsp65 are
efficiently processed under the inflammatory milieu of acute
AA, and thereby, activate subsets of T cells directed against C-
terminal epitopes of Bhsp65. These T cells are then activated
and expanded by C-terminal epitopes of Rhsp65, and vice
versa, resulting in a reinforcement of the regulatory T cell
activity against AA. These results describe a novel disease-
regulating feature of cryptic antigenic determinants contrary to
their well-known pathogenic attribute observed in other anti-
gens. Thus, cryptic epitopes of autoimmune diseases-related
antigens can be exploited for immunotherapeutic purposes in
RA and other autoimmune diseases. (Supported by grants from
the NIH, Arthritis Foundation- National Office and Maryland
Chapter, and the Maryland Arthritis Research Center.)
Sa1.118. Both Chlordecone and Estrogen Enhance the
Germinal Center B Cell Reaction and Reduce the Splenic
B Cell Apoptosis in Ovariectomized (NZB  NZW) F1
Mice.
F. Wang,1,2 S. M. Roberts,1,3 E. S. Sobel.2 1Department of
Pharmacology and Therapeutics, University of Florida College
of Medicine, Gainesville, FL, USA; 2Department of Medicine,
University of Florida College of Medicine, Gainesville, FL, USA;
3Department of Physiological Sciences, University of Florida
College of Veterinary Medicine, Gainesville, FL, USA.
Systemic lupus erythematosus (SLE) is a debilitating auto-
immune disease that affects women nearly nine times as often as
men. Estrogen has been implicated as an important risk factor.
The weakly estrogenic organochlorine pesticide chlordecone can
accelerate the onset and severity of immune complex glomer-
ulonephritis in female (NZB  NZW) F1 (NZB/WF1) mouse
model. Moreover, chlordecone exposure caused the earlier onset
of serum IgG anti-dsDNA and anti-chromatin in ovariectomized
NZB/WF1 mice, similar to the effects caused by exogenous
exposure to 17-beta estradiol. This murine model of SLE is
characterized by the spontaneous development of germinal
centers (GCs), which play a key role in the maturation of the
humoral immune response. Chemokine receptors CXCR4 and
CXCR5 are important for GC dark and light zone organization,
and cell adhesion molecules ICAM and VCAM-1 may play an
important role in reducing GC B cell apoptosis. We therefore
examined the effects of chlordecone and 17-beta estradiol on
Abstracts S129germinal center B cells using two-month old ovariectomized
NZB/WF1 mice. Mice were subcutaneously implanted with
sustained-release pellets containing 17-beta estradiol (0.025mg/
kg/day) or chlordecone (0.5 and 2.5mg/kg/day). Control mice
received pellets with matrix only. Mice were sacrificed six weeks
after implantation, and spleen cells were studied by flow
cytometric analysis. Splenic B cells were also purified for
proliferation assays using 3H-thymidine and apoptosis tests with
annexin-V and 7-AAD. Both estradiol and chlordecone caused a
significant increase in spleen size/weight (P b0.01 by estradiol
and P b 0.05 by chlordecone, ANOVA). We also found that both
chlordecone and estradiol increased the percentage of B cells
expressing the GC marker GL7 (P b 0.01 by ANOVA), the B
cell co-stimulatory molecule B7-2 (P b 0.01), and the activation
marker CD44 (P b 0.01 by estradiol and P b 0.05 by
chlordecone). The expression of CXCR4 (P b 0.01), CXCR5
(P b 0.01 by estradiol and P b 0.05 by chlordecone), ICAM (P b
0.01), and VCAM-1 (P b 0.01 by estradiol and P b 0.05 by
chlordecone) on splenic B cells was upregulated as well. On the
other hand, neither chlordecone nor estradiol produced a significant
increase in B cell proliferation, but they both significantly reduced
splenic B cell apoptosis. These findings suggest that both
chlordecone and estradiol may enhance autoimmunity through
effects on the germinal center response.
Sa1.119. IL10 Promoter Polymorphisms in Mexican
Patients with Spondyloarthropathies.
G. Vargas-Alarcon,1 J.M. Rodriguez-Perez,1 G. Hernandez-
Pacheco,1 J. Londono,2 C. Pacheco-Tena,3 J. Granados,2 R.
Burgos-Vargas.3 1Physiology, Instituto Nacional de Cardiologia
Ignacio Chavez, Mexico City, Mexico; 2Immunology and Rheu-
matology, Instituto Nacional de Ciencias Medicas y Nutricion
Salvador Zubiran, Mexico City, Mexico; 3Rheumatology, Hospital
General de Mexico, Mexico City, Mexico.
The spondyloarthropathies (SpA) are a heterogeneous group of
diseases characterized by axial as well as peripheral enthesitis and
arthritis and less frequently by a range of extra-articular manifes-
tations. The strong association between HLA-B27 and the SpA,
particularly ankylosing spondylitis (AS) in the general population
and in first degree relatives of affected individuals confers this allele
a significant role in disease susceptibility. Yet, the fact that only
approximately 2% of HLA-B27 individuals develop AS and that a
small proportion of patients with AS does not carry the B27 allele
suggests other genes participate in the disease susceptibility. Of
special interest is the IL-10 gene that codified a potent immune
modulator. Thus, the aim of the present study was to investigate the
allele distribution of IL10 promoter polymorphisms in SpA
Mexican patients. One hundred and twenty-six patients with SpA
(55 with undifferentiated SpA (U-SpA), 55 with AS, and 16 with
reactive arthritis (ReA)) and 91 healthy controls were studied. The
IL-10 promoter polymorphisms (positions-592, 819 and-1082)
were determined by polymerase chain reaction-restriction fragment
length polymorphism. Statistical methods included the Mantel-
Haenzel, X2, FisherTs exact test, and Woolf method for odds ratio
(OR). The allele and genotype frequencies of the three polymorphic
sites were similar in the whole group of SpA patients and healthy
controls. When clinical subgroups (U-SpA, AS and ReA) were
compared to healthy controls, the results did not reveal significant
differences in allele or genotype frequencies. These data suggest
that IL10 promoter polymorphisms are not involved in the genetic
susceptibility to SpA in Mexican patients.Sa1.120. Genetic Dissection of Congenital Heart Block in
a Rat Model.
L. S. Horvath,1 S. Salomonsson,1 M. Jagodic,2 K. Becanovic,2
S.-E. Sonesson,3 T. Olsson,2 M. Wahren-Herlenius.1 1Department
of Medicine, Karolinska Institutet, Stockholm, Sweden; 2
Department of Neuroimmunology, Karolinska Institutet,
Stockholm, Sweden; 3Department of Women and Child Health,
Karolinska Institutet, Stockholm, Sweden.
Congenital heart block is a passively transferred autoimmune
disease where Ro52 antibodies are transported from the mother to
the fetus in Ro/SSA positive women. The diagnosis of the mother
may be SLE or SjfgrenTs syndrome. The fetus can be affected with
mild symptoms or they may develop a life-threatening heart block.
It has been shown that the Ro52 antibodies are necessary for
disease development, and immunization of rat mothers with Ro52
derived peptides results in heart block in the pups. However, the
fact that mothers of affected children can later give birth to healthy
children despite persisting Ro52 autoantibodies indicates that
another factor such as genes are involved in the penetrance of the
disease. The aim of this study was to investigate this by
ascertaining the MHC and non-MHC genetic influence in heart
block development in an immunization-induced rat model of
congenital heart block.
Four rat strains, 3 sharing the same MHC region (RT1)
haplotype (DA, PVG.AV1, LEW.AV1), and 2 with similar
background genes but different MHC genes (LEW.L and
LEW.AV1) were studied. Female rats were immunized with
Ro52 or control protein and mated. The resulting pups (208 from
Ro52 immunized mothers, and 105 from the control immunized
mothers) were analysed for congenital heart block with extremity-
lead electrocardiography of conscious pups. Serum samples were
taken throughout the study from both mothers and pups and
epitope mapping of the antibody specificities using recombinant
Ro52 and a panel of overlapping and mutated Ro52 peptides was
performed.
Analysis of the ECGs of the 313 born pups from the four
strains showed that in the 3 strains sharing the same MHC region
haplotype (DA, PVG.AV1, LEW.AV1) AV block I developed in
45%, 35% and 44% of the pups, respectively. In the Lew.L strain
only 14% of pups were affected by AV block I. These results
indicate that genes in the MHC region are important for
penetrance of the disease (P b 0.001). There was no significant
difference in generated Ro52 antibody epitope specificity between
the rat strains. The hearts of all 44 rat mothers and 24 of the pup
hearts were collected for immunohistochemical investigation of
inflammatory markers.
Our study is the first to explore genetic influence in development
of congenital heart block in animal models, and results show that
genes found in the rat MHC region are of significant importance for
the penetrance of congenital heart block, while non-MHC genes
appear to have little or no influence on the disease.
Sa1.121. Identification of Disease Profiles for
Rheumatoid Arthritis Using Antibody and Antigen
Arrays.
David L. Hirschberg,1 Anya Tsalenko,1 Mark Westall,1 Bill
Fisher,1 Bo Curry,1 Wolfgang Hueber, Orr Sharpe,2 Beren
Toomoka,2 Dorothy Yang,1 Artie Schleifer,1 Willy McAllister,1
WilliamH. Robinson,2 Viorica Lopez-Avila.1 1Agilent Technologies
Inc., Palo Alto, USA; 2Stanford University School of Medicine,
Division of Immunology & Rheumatology, Stanford, CA, USA.
AbstractsS130Autoimmune maladies, such as, rheumatoid arthritis are
difficult to diagnose and most likely represent a collection of
pathologies that give rise to the symptoms of each disease.
Furthermore, there is no definitive set of markers for these
diseases that can be monitored in real time to predict or assess
the effect of any treatment. Simultaneous and serial measure-
ments of hundreds of proteins in the blood and synovial fluid
will be needed to make a differential diagnosis and to discover
novel patterns that would stratify the diseases. Protein micro-
arrays are well suited for this type of proteomic approach
despite the fact that they are limited by the specificity of the
affinity reagents (i.e., antibodies), and the measurement
accuracy is dependent on the array performance, sample
preparation, and assay reproducibility. We demonstrate an
improved method for fabrication of antibody and antigen
microarrays using a thermal inkjet printer and functionalized
glass slides, and have addressed quality issues such as
checking purity and integrity of proteins prior to deposition,
printed array quality, cross-reactivity of the affinity reagents,
and need for removal of the high abundant proteins. Using our
optimized array platform we developed antibody arrays for
detection of over 60 markers of inflammation, including
autoantibodies, cytokines, chemokines, soluble receptors and
enzymes. Forty samples of synovial fluid and serum from RA
patients and controls were run on the arrays. The arrays
demonstrated increased levels of known inflammatory markers
in RA samples among them matrix metalloproteases and
cytokines.
Sa1.123. Identification of disease profiles for rheumatoid
arthritis using antibody and antigen arrays.
David L. Hirschberg,1 Anya Tsalenko,1 Mark Westall,1 Bill
Fisher,1 Bo Curry,1 Wolfgang Hueber, Orr Sharpe,2 Beren
Toomoka,2 Dorothy Yang,1 Artie Schleifer,1 Willy McAllister,1
William H. Robinson,2 Viorica Lopez-Avila.1 1Agilent
Technologies Inc., Palo Alto, USA; 2Stanford University School of
Medicine, Division of Immunology and & Rheumatology, Stanford,
CA, USA.
Autoimmune maladies, such as, rheumatoid arthritis are
difficult to diagnose and most likely represent a collection of
pathologies that give rise to the symptoms of each disease.
Furthermore, there is no definitive set of markers for these
diseases that can be monitored in real time to predict or assess
the effect of any treatment. Simultaneous and serial measure-
ments of hundreds of proteins in the blood and synovial fluid
will be needed to make a differential diagnosis and to discover
novel patterns that would stratify the diseases. Protein
micoarrays are well suited for this type of proteomic approach
despite the fact that they are limited by the specificity of the
affinity reagents (i.e., antibodies), and the measurement
accuracy is dependent on the array performance, sample
preparation, and assay reproducibility. We demonstrate an
improved method for fabrication of antibody and antigen
micoarrays using a thermal inkjet printer and functionalized
glass slides, and have addressed quality issues such as
checking purity and integrity of proteins prior to deposition,
printed array quality, cross-reativity of the affinity reagents, and
need for removal of the high abundant proteins. Using our
optimized array platform we developed antibody arrays for
detection of over 60 markers of inflammation, including
autoantibodies, cytokines, chemokines, soluble receptors andenzymes. Forty samples of synovial fluid and serum from RA
patients and controls were run on the arrays. The arrays
demonstrated increased levels of known inflammatory markers
in RA samples among them matrix metallaproteases and
cytokines.
Sa1.124. Relationship of school attendance with quality
of life, physical function, disease activity and damage in
pediatric systemic lupus erythematosus.
L N Moorthy,1 M G Peterson,2 M J Harrison,2 K B Onel,3 D R
Mohan,1 Thomas Lehman.2 1Robert Wood Johnson University,
New Brunswick, NJ, USA; 2Hospital for Special Surgery, New
York, NY, USA; 3La Rabida Children’s Hospital, Chicago, IL,
USA.
Background: Pediatric systemic lupus erythematosus (SLE) is
a multisystem disease that significantly impacts quality of life
(QOL) of children. SLETs impact on school attendance, an
important outcome and potential predictor of other outcomes, has
received little attention.
Objective: Examine the relationship of school attendance with
QOL, physical function, SLE activity and damage in children with
SLE.
Design/Methods: In this cross–sectional study, children with
SLE (6–18 years) and parents completed child/parent versions
of: Childhood Health Assessment Questionnaire (CHAQ),
Pediatric QOL Inventory (PedsQL Generic 4.0 and Rheuma-
tology 3.0 modules). Physician completed: SLE Disease
Activity Index (SLEDAI) and Systemic Lupus International
Collaboration Clinics/ACR Damage Index (SLICC). Number of
days over the prior 30 the child missed school due to
physical/mental health reasons was recorded using PedsQL
family information form. Spearman correlations were deter-
mined between number of missed school days and other
variables.
Results: 24 children (23 girls) with SLE (mean age 15 F
3 years, mean education 9th grade, mean SLE duration 46 F
30 months, SLEDAI 0–24, SLICC 0–6, median CHAQ 0.3,
mean PedsQL–Generic 67 F 20), and 19 parents (median
CHAQ 0, mean PedsQL–Generic 69 F 18) participated. 4
children were excluded because school attendance was
inapplicable. In 30 days prior to participation, 10 children
(50%) missed school with a mean of 3 F 7 days. Mean number
of days too ill to play = 3 F 7 and mean number of days
needed someone = 3 F 6 days. The number of missed school
days moderately correlated with decreased QOL as reported by
parents and as measured by the PedsQL–Generic module (r
0.56, p 0.02), but did not correlate significantly with Rheuma-
tology module, CHAQ, SLEDAI, SLICC, or any of the child
reported scores.
Conclusions: Number of missed school days is correlated
with decreased general QOL in children with SLE as
perceived by their parents. However, parallel correlation
between missed school days and overall QOL as perceived
by children was not identified. Discrepant perception between
parents and children warrant further investigation in a larger
cohort. Lack of correlation of school attendance with other
scales suggests that generic scale captures a less tangible
element of SLE.
Category: Autoimmune Rheumatologic Diseases
Keywords: quality of life; systemic lupus erythematosus
(SLE); childhood diseases
Abstracts S131Theme: Other; Related to quality of life of autoimmune
diseases
Sa1.122. Development and Validation of the Simple
Measures of Impact of Lupus Erythematosus in
Youngsters (SMILEYn) Questionnaire.
L N Moorthy,1 M G Peterson,2 M J Harrison,2 K B Onel,3 M J
Baratelli,1 D R Mohan,1 T Lehman.2 1Robert Wood Johnson
University, New Brunswick, NJ, USA; 2Hospital for Special
Surgery, New York, NY, USA; 3La Rabida Children’s Hospital,
Chicago, IL, USA.
Background: Pediatric systemic lupus erythematosus (SLE)
is a chronic fluctuating disease significantly impaction quality
of life (QOL). There is no pediatric SLE–specific health–related
QOL tool. SLE heterogeneity, childrenTs evolving needs and
expectations, and parent–proxy respondents complicate QOL
measurement.
Objective: Develop a brief, valid and easily understood SLE–
specific pediatric QOL tool.
Design/Methods: We developed Simple Measure of Impact
of Lupus Erythematosus in Youngsters (SMILEYn) based on
qualitative research on pediatric SLE- a 31 item tool, with
parallel child/parent versions and 5–faces scale items. Children
2–18 years and parents completed child–parent versions of the
SMILEYn, Pediatric Quality of Life Inventory (PedsQL)
Generic 4.0 scale, and Childhood Health Assessment Ques-
tionnaire (CHAQ). Children also completed the Piers–Harris
Self–Concept Scale. Correlations of child/parent SMILEYn
versions with the corresponding versions of the above scales
were determined by Spearman rank test.
Results: 15 children (12 girls) with SLE (mean age 14 F 2
years, mean SLE duration 44 F 37 months, SLE disease
activity index 0–20, mean self–concept 50 F 9) participated
with mean SMILEYn score of 106 F 20. 14 parents had a
mean SMILEYn score of 98 F 24. Significant correlations are
indicated by asterisks (table). Subjects completed SMILEYn in
b10 minutes. Correlation of child/parent SMILEYn (n = 14)
was not significant (r = 0.4, P = 0.1).Table 1
Correlation of child/parent SMILEY with corresponding child/parent
version of the scales
SMILEY CHAQ PedsQL Generic
SMILEY child (n 15) 0.8** 0.7**
SMILEY parent (n 13) 0.5 0.5
**Pb/=0.01; *Pb/=0.05.Conclusions: Our results demonstrate that SMILEYn is a
brief, easily understood and valid pediatric SLE–specific QOL
scale. Lack of significant correlation between child/parent
reports suggests that we may be measuring different informa-
tion from children/parents; childrenTs perception of their QOL
may be different from their parentTs perceptions. Accrual of
additional subjects is necessary to confirm results. [Table 1].
Category: Autoimmune Rheumatologic Diseases.
Keywords: Quality of life; systemic lupus erythematosus
(SLE); children
Theme: Other; Related to quality of life of autoimmune
diseasesDiabetes & Other Autoimmune
Endocrine Diseases
Sa1.125. A Fractal Analysis of Binding and Dissociation
Kinetics of Connective Tissue Interstitial Glucose,
Adipose Tissue Interstitial Glucose and Related Analytes
on Biosensor Surfaces.
A. M. Doke, A. Sadana. 1Chemical Enginnering, University of
Mississippi, University, MS, USA; 2Chemical Enginnering,
University of Mississippi, University, MS, USA.
A fractal analysis is used to model the binding and dissociation
kinetics of biomedical analytes like connective tissue interstitial
glucose, adipose tissue interstitial glucose, insulin and other related
analytes. The analysis provides insights into diffusion-limited analyte-
receptor reactions occurring on heterogeneous biosensor surfaces.
The fractal analysis is applied to the binding of glucose and
other related analytes in solution to glucose derivatives immobi-
lized on a biosensor chip. The fractal analysis provides a useful
lumped parameter(s) analysis for the diffusion-limited reaction
occurring on a heterogeneous surface via the fractal dimension and
the rate coefficient. To demonstrate fractality a log-log plot is made
with a large amount of available data. It is a convenient means to
make the degree of heterogeneity that exists on the surface more
quantitative. The fractal approach provides additional information
about interactions that may not be obtained by a conventional
analysis of biosensor data.
Results and Conclusions:
Numerical values obtained for the binding and the dissociation
rate coefficients are linked to the degree of heterogeneity or
roughness (fractal dimension, Df) present on the biosensor chip
surface. The binding and the dissociation rate coefficients are
sensitive to the degree of heterogeneity on the surface. For
example, for the binding of adipose tissue interstitial glucose, as
the fractal dimension value increases by a factor of 3.31 from Df1
equal to 0.5720 to Df2 equal to 1.891, the binding rate coefficient
increases by factor of 8.88 from k1 equal to 0.0545 to k2 equal to
0.4841. An increase in the degree of heterogeneity on the probe
surface leads to an increase in the binding rate coefficient. A dual
fractal analysis gives a better fit in most cases for the binding
kinetics. A single fractal analysis is adequate to describe the
dissociation kinetics. Affinity (ratio of the binding to the
dissociation rate coefficient) values are also presented.
The values of binding rate coefficient, k, linked with the degree
of heterogeneity existing on the biosensor surface provide a
complete picture of the reaction kinetics occurring on the sensor
chip surface. Dual fractal analysis is used only when the single
fractal analysis did not provide an adequate fit. This was done by
regression analysis provided by Quattro Pro 8.0.
It is suggested that roughness on surface leads to turbulence
which enhances mixing of glucose and decreases diffusional
limitations leading to an increase in the binding rate coefficients
for glucose.
Sa1.126. Serum Levels of Interleukin-16 in Patients with
Newly Diagnosed Type 1 Diabetes Mellitus.
V. V. Popova,1 S. V. Melnichenko,1 T. N. Malinovskaya,1 K. P.
Zak,1 B. N. Mankovsky.1 1Diabetes, Institute of Endocrinology,
Kiev, Ukraine.
Type 1 diabetes mellitus is considered to be the typical
autoimmune disorder resulting in the loss of pancreatic beta-cells
AbstractsS132with the consequent development of absolute insulin deficiency.
However, the exact changes of the components of the immune
system including impairments of different cytokines levels preced-
ing the development of clinically overt type 1 diabetes mellitus
remain not fully understood. Therefore, the aim of this study was to
investigate the serum levels of interleukin-16 in patients with newly
diagnosed type 1 diabetes mellitus. We studied 10 patients with
clinically overt type 1 diabetes mellitus aged 8–15 years old before
initiating of insulin therapy and 10 aged-matched healthy control
subjects. Serum interleukin-16 levels were measured by specific
immunoenzyme assay. We found that serum levels of interleukins-
16 were significantly decreased in patients with type 1 diabetes
mellitus compared to control subjects-94F 9.99 pg/ml vs. 270 F
34.78 pg/ml (mean F SEM), respectively, P b 0.001. These
data could explain the decrease of the number CD4+ T-lymphocytes
in subjects with newly diagnosed type 1 diabetes mellitus which
was revealed in our earlier studies as these lymphocytes represent
the target cells for interleukin-16. We may hypothesize that revealed
significant decrease of the interleukin-16 production could play a
role in the pathogenesis of autoimmune insulitis and consequent
clinical manifestation of type 1 gdiabetes mellitus.
Sa1.127. Antigen-Based Therapies Utilizing Ignored
Determinants of B-Cell Antigens Can More Effectively
Slow Late-Stage Autoimmune Disease in Diabetes-Prone
Mice.
Angelica P. Olcott,1 Jide Tian,1 Valerie Walker,1 Hoa Dang,1
Blake Middleton,1 Luciano Adorini,2 Lorraine Washburn,1 Daniel
L. Kaufman.1 1Molecular and Medical Pharmacology, David
Geffen School of Medicine, UCLA, Los Angeles, CA, USA;
2BioXell, Milano, Italy.
As organ-specific autoimmune diseases do not become manifest
until well-advanced, interventive therapies must inhibit late-stage
disease processes. Using a panel of immunogenic peptides from
various g-cell antigens, we evaluated the factors influencing the
efficacy of antigen-based therapies in diabetes-prone NOD mice
with advanced disease. The ability of the major g-cell autoantigen
target determinants (TDs) to prime Th2 responses declined by a80%
between 6 to 12 weeks of age, while the ability of immunogenic
ignored determinants (IDs) of g-cell antigens to prime Th2 responses
was unaffected by the disease process. The different patterns of TD
and ID immunogenicity (even from the same g-cell antigen) may be
due to the exhaustion of uncommitted TD, but not ID -reactive, Tcell
pools by recruitment into the autoimmune cascade. Therapeutic
efficacy was associated with a peptideTs immunogenicity and ability
to promote Th2 spreading late in the disease process, but not its
affinity for I-Ag7 or its expression pattern (g-cell specific/non-
specific, or rare/abundant). Characterization of some IDs revealed
them to be babsoluteQ cryptic determinants. Such determinants have
little impact on T cell selection, leaving large precursor T cell pools
available for priming by synthetic peptides. Traditional antigen-
based therapeutics using whole autoantigens or their TDs cannot
prime responses to such determinants. These findings suggest a new
strategy for designing more efficacious antigen-based therapeutics
for late-stage autoimmune diseases.
Sa1.128. NKT Cells May Contribute to the
Immunopathogenesis of Non-Alcoholic Steatohepatis.
Kazuto Tajiri,1 Yukihiro Shimizu,1 Yoshiharu Tokimitsu,1 Yasuhiro
Nakayama,1 Katsuharu Hirano,1 Masami Minemura,1 Kazumi
Ebata,1 Toshiro Sugiyama,1 Koichi Tsuneyama.2 1ThirdDepartment of Internal Medicine, Toyama Medical and
Pharmaceutical University, Toyama, Japan; 2First Department of
Pathology, Toyama Medical and Pharmaceutical University,
Toyama, Japan.
Objectives: Non-alcoholic steatohepatitis (NASH) is a com-
mon chronic liver disease, leading to cirrhosis and hepatocellular
carcinoma. It has been considered tumor necrosis factor a or
adipocytokine is important in the pathogenesis of NASH, which
has a feature of metabolic syndrome. Although NASH is
characterized by necro-inflammatory changes, an essential role of
the inflammatory cells has not yet been identified. To clarify the
role of inflammatory reactions in the pathogenesis of NASH, we
analyzed the composition of liver-infiltrating cells isolated from
liver biopsy specimens of NASH. Methods: 26 patients with
NASH and 23 with fatty liver (FL) were analyzed. We performed
immunohistochemical staining using antibodies against CD3, CD4,
CD8, CD56, CD68, and CD15. Oxidative stress was assessed by
the expression of 4-hydroxy-2-nonenal (HNE). We counted the
numbers of each population of liver-infiltrating cells (/mm3). We
diagnosed the liver histology using scoring system proposed by
Brunt et al., and examined the correlations between the histological
scores and the number of each population of liver-infiltrating cells.
Moreover, we analyzed the surface markers of isolated liver-
infiltrating cells by flow cytometry with antibodies against CD3,
CD56, CD11b, lineage markers, HLA-DR, and CD1d in 5 cases. In
addition, localization of CD1d expression was also examined, and
analyzed the association with that of CD56+ cells by an
immunohistochemical method. Results: Among various popula-
tions, only the numbers of CD56+ cells were significantly higher in
NASH than those in FL (NASH: FL = 57.8 F 48.5: 15.4 F
15.2, P = 0.02). In NASH, the numbers of CD56+ cells tended to be
decreased as fibrosis progresses (r = -0.55, P = 0.039), and the
expression of HNE or the number of CD68+ cells showed a positive
correlation with that of CD56+ cells (HNE; r = 0.56, P = 0.036,
CD68; r = 0.55, P = 0.041). Moreover, flow cytometric analysis
showed that NKT cells (CD3+CD56+), rather than NK cells (CD3-
CD56+), are increased in the livers with NASH. Furthermore, flow
cytometric analysis showed that CD1d molecules are found to be
expressed on antigen presenting cells such as macrophages
(CD11b+) and dendritic cells (lineage- DR+). In addition, CD1d
expression was significantly increased in the liver with NASH
compared with FL or normal livers. Importantly, a part of CD1d
expression was recognized around CD56+ cells. Conclusion: We
showed that NKT cells are proliferated and activated in an early
stage of NASH. In the liver with NASH, hepatocytes contain a lot of
fat with the lipid being peroxidated, which generates oxidative
stress. Antigen presenting cells might uptake peroxidated lipid
derived from degenerated hepatocytes, and present processed lipid
antigen on CD1d. NKT cells would recognize those lipid antigens
through CD1d, leading to the release of various cytokines. These
processes could contribute to the pathogenesis of NASH.
Sa1.129. Pro-Apoptotic DNA Vaccination as a Therapy
for Type 1 Diabetes.
A. Li, O. Ojogho, E. Franco, P. Baron, W. Concepcion, A. Escher.
1Transplantation Institute for Molecular and Translational
Medicine, Loma Linda University, Loma Linda, CA, USA.
Type 1 diabetes is in most cases the result of cell-mediated
autodestruction of pancreatic h-cells. We have shown previously
that DNA coding for the pro-apoptotic BAX protein promotes
diabetes prevention in pre-diabetic NOD mice when co-delivered
Abstracts S133intramuscularly with DNA coding for a secreted form of the h-cell
antigen glutamic acid decarboxylase (GAD). Furthermore, co-
delivery of BAX recruits dendritic cells containing plasmid-encoded
protein in peripheral lymphoid organs. Here, we report that the same
DNA vaccine reverses new onset diabetes when delivered intra-
dermally and induces immunosuppressive CD4+CD25+ regulatory
T cells (Treg). Female NODmice received the vaccine at the time of
diabetes onset and a second time in case of relapse. A variety of
responses to the treatment were observed. Mice responded either to
both the initial and relapse treatment, to the initial treatment only, or
not at all. Fifty percent of the treated mice were overtly diabetic
(fasting blood glucose N 300 mg/dL) by the age of 40 weeks. By
contrast, more than 90% of untreated mice and of mice treated with
plasmid vector alone were overtly diabetic by that age. Immuno-
logical analysis revealed that draining lymph nodes of mice treated
with the pro-apoptotic DNA vaccine contained higher numbers of
Treg with enhanced immunosuppressive function compared to
control animals. Our results indicate that delivery of a DNAvaccine
alone can reverse the symptoms of an autoimmune disease, and
suggest a real clinical potential for pro-apoptotic DNA vaccines in
the treatment of immune-mediated inflammatory disorders.
Sa1.130. Increased B Cell Replication with Onset of
Diabetes and after Induction of Immune Tolerance in the
NOD Mouse.
N. A. Sherry,1 M. Glandt,2 Y. Liu,1 A. M. Brillantes,2 K. Herold.2
1Pediatrics, Columbia University, New York, NY, USA; 2Medicine,
Columbia University, New York, NY, USA.
Recent studies concerning h cell turnover suggest that there
is a continual process of h cell death and renewal. The effects
of autoimmunity on this process have not been well studied but
the regenerative potential of islet cells has been suggested by
recent studies in animal models. We have examined changes in
h cell mass and replication in the presence of islet inflamma-
tion, and during tolerance induction with CD4+CD25+ regu-
latory T cells.
The mean percentage of replicating h cells was higher in female
pre-diabetic NODmice (age = 9–14wks) compared to agedmatched
NOD/Scid mice (1.62F 0.9, n = 6 vs. 0.19F 0.1%, n = 5; P b 0.01).
There was no significant difference in h cell mass between the two
groups (0.07F 0.04mg, n = 4 vs. 0.09F 0.05, n = 4; P =NS). Upon
diabetes onset in female NOD mice, the percentage of replicating h
cells increased to 3.56F 0.9%, n = 3. These data are consistent with
a compensatory response to inflammation.
To further demonstrate that the increase in h cell replication was
in response to the anti-islet autoimmune process, h cell replication
was measured in NOD/Scid mice 2 and 4–5 weeks post-transfer of
diabetogenic splenocytes. Our data show an increase in the mean
percentage of replicating h cells with time (0.90F 0.1%, n = 2, and
1.93 F 0.4%, n = 3; P b 0.05 at 2 and 4–5 weeks post transfer,
respectively). In contrast, no change in h cell replication was seen in
non-treated age-matched NOD/Scid mice (0.26 F 0.1%, n = 2 and
0.15 F 0.1%, n = 3; P = NS).
Cotransfer of CD4+CD25+ regulatory T cells (Tregs), harvested
from NOD mice treated with anti-CD3 mAb, prevented the
development of diabetes in NOD/Scid mice by adoptive transfer
of diabetogenic splenocytes. Four weeks after adoptive transfer of
diabetogenic cells and Tregs, only 1 out of 5 NOD/Scid mice
developed diabetes. In contrast, 5 out of 5 NOD/Scid mice that
received CD4+CD25- T cells and diabetogenic cells developed
diabetes (P = 0.05). In mice protected by Tregs, h cell mass wassignificantly greater than in those that received CD4+CD25- cells
(0.02 F 0.02 mg, n = 5 vs. 0.00011 F 0.00001 mg, n = 5,
respectively; P = 0.03). The percent of replicating h cells in mice
that received Tregs was 1.97 F 0.6%; n = 5, whereas h cell mass
was too small to determine replication rates in recipients of
CD4+CD25- cells.
These findings suggest that in NOD mice, islet inflammatory
lesions can play a role in stimulating h cell replication. Never-
theless, heightened h cell replication, initially in response to
autoimmunity, is insufficient to overcome the rate of autoim-
mune-mediated beta cell destruction. Treatment with Tregs leads to
improved preservation of h cell mass with maintenance of
heightened h cell replication and prevents the development of
diabetes in NOD mice.
Sa1.131. A Subset of Insulin and Glucagon Positive Cells
Survives Destruction in bOlderQ Female NOD Mice.
M. Nakayama,1 N. Babaya,1 T. Still,1 E. Liu,1 R. Gianani.1
1Barbara Davis Center for Childhood Diabetes, University of
Colorado Health Science Center, Denver, CO, USA.
The NOD mouse is a key animal model of Type 1A diabetes.
The majority of female NOD mouse develops immune mediated
diabetes between 15 and 35 weeks of age but a subset remain
non- diabetic after 40 weeks of age. Lack of diabetes develop-
ment in these mice could be due to a failure of the immune
system to completely target and destroy beta cells or to the
presence of insulin producing cells resistant to destruction or
both. In order to distinguish between these two hypotheses, we
studied the pancreatic histology of 11 non-diabetic female NOD
mice that remained non- diabetic after 40 weeks of age. These
mice range in age between 42 and 96 weeks. From each pancreas
we obtained H&E sections as well double immunofluorescence
staining with antibodies to insulin and glucagon. Each of the
eleven mice had severe islet lymphocytic infiltrates, which
affected the majority of the islets. In 5/11 mice there was no
insulin staining while in 5 mice there were islet cells that
exhibited double positivity for insulin and glucagon. In one
mouse, we could detect both single insulin positive cells
(negative for glucagon) and cells with double positivity. In all
mice studied, glucagon positive cells were preserved and in mice
with insulin positivity only a subset of the glucagon positive cells
expressed positivity for insulin. Transfer of diabetes was analyzed
for six of these NOD mice by injecting 3  107 splenocytes in 8–
10 week old SCID- NOD recipients. These splenocytes rapidly
induced diabetes (b 5 weeks).
These data show that older non-diabetic NOD females show
insulitis with loss of beta cells and that their splenocytes are
capable of transferring diabetes. Furthermore, the surviving insulin
positive cells show an unusual phenotype characterized by
positivity for glucagon. Further studies will elucidate the origin
of these cells and we hypothesized that double positive cells resist
immune mediated beta cell destruction though alternatively they
may represent unusual recently developed insulin expressing cells.
Sa1.132. PDL1 Regulates Autoimmunity by Limiting
Expansion of Autoreactive Th1 Cells and Mediates
Resistance to Diabetes in NOD Mice.
I. Guleria,1 S. Eckenrode,2 M. J. Ansari,1 M. Azuma,3 M.
Atkinson,4 J. She,2 M. H. Sayegh.1 1Transplantation Research
Center, Brigham and WomenTs Hospital and ChildrenTs Hospital
Boston, Harvard Medical School, Boston, MA, USA; 2Medical
AbstractsS134College of Georgia, Augusta, GA, USA; 3Tokyo Medical and
Dental University, Tokyo, Japan; 4University of Florida, College
of Medicine, Gainesville, FL.
We have previously demonstrated that the Programmed Death-1
(PD1) pathway plays a critical role in regulating the development
of diabetes in NOD mice. In the present study, we explored the
mechanisms involved in this regulation utilizing various knockout,
transgenic and NOD congenic strains of mice. We observed that B
cell deficient NOD mice, which are normally resistant to diabetes,
develop the disease following PDL1 blockade whereas CD4
deficient NOD mice were resistant to PDL1 blockade; thereby
suggesting CD4+ T cells play an important role in anti-PDL1
mediated acceleration of diabetes. We then utilized BDC2.5 TCR
Tg mice to more clearly dissect the role of PDL1 in regulating
autoreactive CD4+ T cells. PDL1 blockade precipitated early onset
diabetes, an expansion of BDC2.5 TCR Tg cells, and decreased
apoptosis. NOD congenic mice that have a variable degree of
resistance to autoimmune diabetes (NOD.Idd5, NOD.Idd3,
NOD.Idd3/10/18, and NOD.Idd9 usually develop diabetes with a
incidence of 40%, 20%, 8% and 3%, respectively) were then
utilized to study the role of PDL1 in diabetes resistance. Anti-
PDL1 mAb treatment accelerated diabetes in all the congenic
strains albeit with different acceleration patterns. Interestingly, in
NOD.Idd9 congenic mice, PDL1 blockade both accelerated the
time of onset as well as increased the incidence of diabetes to 50%.
Utilizing Idd9 mice, we have shown that blockade of PDL1 results
in precipitation of diabetes by changing the local cytokine milieu
from Th2 to Th1 cells, with upregulation of IFN-gamma and TNF-
alpha. We conclude that PDL1 regulates autoimmune diabetes by
limiting the expansion of autoreactive Th1 cells and thus plays a
critical role in mediating disease resistance. These results provide
the rationale for developing novel therapies to re-establish
tolerance in autoimmune diabetes.
Sa1.133. Human HLA-A2 MHC Class 1 Molecule Is
Permissive for the Development of Diabetes in
Experimental Autoimmune Diabetes.
A. Ide,1 E. Melanitou,1,2 E. Liu,1 H. Moriyama,1 D. Miao,1 G. S.
Eisenbarth.1 1Barbara Davis Center for Childhood Diabetes,
University of Colorado Health Sciences Center, Denver, CO, USA;
2Institut Pasteur, Paris, France.
Type 1 diabetes is an immune-mediated disease characterized
by the autoimmune destruction of pancreatic h-cells. A variety of
environmental and genetic factors are involved in the development
of the disease. We have previously developed an experimental
autoimmune diabetes (EAD) model with insulin peptide B:9-23
immunization and/or polyinosinic-polycytidylic acid (PolyI:C), as
a viral RNA mimic Toll-like receptor (TLR) activator, in transgenic
mice expressing the costimulatory molecule B7.1 in their islets
(drivenly the Rat Insulin Promotor, RIP). B:9-23 peptide immu-
nization induces diabetes and insulin autoantibodies (IAA) in I-Ad
mice expressing B7.1. A major goal is the development of
bhumanizedQ mice that can develop immune mediated diabetes
with known native autoantigen stimulus. As reported by Marron et
al., human leukocyte antigen (HLA)-A2.1 transgenic NOD mice
progress to diabetes more rapidly than A2 negative mice. We have
combined transgenes for human A2.1 with B7.1 transgenic
(BALB/c B7.1x C57Bl/6 A2.1 mice, original C57Bl/6 B7.1 mice
were a gift from Dr L. Wen and C57Bl/6 A2.1 mice were provided
from Dr B.L. Kotzin). Mice were immunized with B:9-23 with or
without PolyI:C. Overall 29% of the mice by 41 weeks (n = 7,range diabetes onset 22–43 weeks) developed diabetes following
Poly:IC injection alone. Forty-three percent developed diabetes by
26 weeks (n = 7; range 21–26 weeks, P b 0.54) with B:9-23
immunization and PolyI:C injection. Our studies indicate that
human A2 is permissive for the development of diabetes in EAD
but does not accelerate disease in the model following either TLR3
activation or peptide B:9-23 immunization. Studies are underway
to define potential islet peptide A2 restricted antigen presentation
using ELISPOT analysis in this model of immune mediated h-cells
destruction.
Sa1.134. Similarities and Differences in Autoimmune
Responses between Type 1 and Type 1.5 Diabetes
Patients.
B. Brooks-Worrell,1,2 H. Chiu,1,2 A. Goel,1,2 J. P. Palmer.1,2
1Department of Medicine, University of Washington, Seattle, WA,
USA; 2Metabolism and Endocrinology, Puget Sound Health Care
System, Seattle, WA, USA.
Type 1.5 diabetes or LADA comprises approximately 10% of
Caucasian adult phenotypic type 2 diabetes patients. The islet
reactive autoantibodies and T cells found in type 1.5 diabetes
patients suggest an autoimmune pathogenesis. In this study, we
asked how T cell reactivity and phenotype compared in type 1.5
versus type 1 diabetes. We identified type 1.5 diabetes patients
(n = 12) through autoantibody and T cell responses to islet
proteins. T cell reactivity to islet proteins was measured by
cellular immunoblotting and peripheral T cell populations were
measured by FACS and compared between type 1.5 patients
versus type 1, type 2, and normal controls. T cells from both
type 1 and type 1.5 diabetes patients respond similarly to islet
proteins in the molecular weight regions of 116kDa, 97kDa,
60kD. In contrast, islet proteins in the molecular weight regions
of 65-90kDa and 21-38kDa were significantly (P b 0.05) less
stimulatory to T cell responses from type 1.5 diabetes patients
versus type 1 patients. The number of CD4+CD25+ cells was
significantly lower (P b 0.05) in the peripheral blood of type 1
patients compared to type 1.5 patients, type 2 patients and
normal controls. CD4+CD38+ cells were significantly lower in
the peripheral blood of type 1.5 patients compared to the other
subject groups and T cell receptor positive gd cells were
significantly (P b 0.05) decreased in the peripheral blood of
type 1 and type 1.5 patients. These results suggest that type 1
and type 1.5 diabetes are immunologically similar in some
respects but in other ways are different. These differences may
be important in the slower disease progression of the type 1.5
diabetes disease process.
Sa1.135. The Role of Cytomegalovirus Infection in the
Development of Type 1 Diabetes-Associated
Autoimmunity in HLA-Susceptible Children.
J. Aarnisalo,1,2 O. Simell,1,3 M. Knip,1,4 J. Ilonen.1,2 1JDRF
Center for Prevention of Type 1 Diabetes in Finland, Finland;
2Department of Virology, University of Turku, Turku, Finland;
3Department of Pediatrics, University of Turku, Turku, Finland;
4Hospital for Children and Adolescents, University of Helsinki,
Helsinki, Finland.
Type 1 diabetes is an autoimmune disease resulting from the
destruction of pancreatic beta cells. The HLA genotype influences
the disease susceptibility. However, only a small proportion of
genetically susceptible subjects progress to type 1 diabetes, which
suggests that also environmental factors play a major role in the
Abstracts S135disease process. Several viral infections including cytomegalovirus
(CMV) infections have been implicated to be associated with the
development of type 1 diabetes-related autoimmunity.The aim of
this study was to explore whether there is any correlation between
CMV infections and type 1 diabetes-associated autoimmunity in
young children with HLA-conferred disease susceptibility. The
cases with diabetes-associated autoantibodies and their HLA, age
and sex-matched controls were participants in the Diabetes
Prediction and Prevention (DIPP) Study running at the Universities
of Turku, Tampere and Oulu in Finland. According to the study
protocol, newborn infants carrying susceptible HLA genotypes are
observed at 3 to 6 months intervals and regularly tested primarily
for ICA and if positive also for GADA, IA-2A and IAA. Forty-one
prospectively followed antoantibody positive subjects (21 girls, 20
boys, age 3 to 48 months, median 18 months) and 190 sex, age and
HLA-matched controls were analyzed for CMV IgG class anti-
bodies by EIA at the time of seroconversion to autoantibody
positivity or within the next 6 months. No significant difference
was seen in the prevalence of CMV antibodies. At the time of
seroconversion 10 (24%) of the autoantibody positive subjects and
60 (32%) of their controls were positive for CMV IgG class
antibodies (P = 0.47, Chi-square test). No differences were either
found between ICA, GADA, IAA or IA-2 positive subjects and
control subjects when each autoantibody was analyzed separately.
In conclusion, these data suggest that early cytomegalovirus
infections do not increase the probability to develop type 1
diabetes-associated autoimmunity.
Sa1.136. Rotavirus-Specific T-Cell Responses and Type 1
Diabetes (T1D): No Evidence for Interrelationship.
M. Makela,1,2 J. Marttila,1,2 M. Knip,1,3,4 O. Simell,1,5 J.
Ilonen.1,2 1JDRF Center for Prevention of Type 1 Diabetes in
Finland, Finland; 2Department of Virology, University of Turku,
Turku, Finland; 3Hospital for Children and Adolescents, Univer-
sity of Helsinki, Helsinki, Finland; 4Department of Pediatrics,
Tampere University Hospital, Tampere, Finland; 5Department of
Pediatrics, University of Turku, Turku, Finland.
Rotavirus infections have been implicated as a possible trigger
of T1D. We elucidated this connection by comparing peripheral
blood T-cell responses to rotavirus between children with newly
diagnosed T1D (n = 37), children with T1D-related autoantibodies
(n = 34) and control children carrying HLA-conferred suscepti-
bility to T1D but without T1D-related autoantibodies (n = 104).
Lymphocyte proliferation assays based on stimulation with an
antigen were performed using freshly isolated peripheral blood
mononuclear cells. We measured also childrenTs IgG and IgA
class rotavirus antibodies in plasma samples drawn at the same
time as the T-cell samples. No differences were observed in the
strength of T-cell responses to rotavirus between the children with
overt T1D or multiple autoantibodies, or the control children.
Furthermore, also the frequencies of positive T-cell responses to
rotavirus were closely similar in all three groups. The result
remained similar, when only the children with serological
evidence of earlier rotavirus infections were studied. Further, no
differences were observed in the responses to the control antigens
PPD and tetanus toxoid, but T-cell responses to purified coxsackie
B4 virus were stronger in the children with autoantibodies than in
the control children. In conclusion, our cellular immunity studies
provided no evidence supporting association of rotavirus infec-
tions with T1D or presence of T1D-related autoantibodies in
young children.Sa1.137. The Possible Biochemical Targets of Altered
Opioid Mediated Nocicpetion at Diabetes Conditions.
Gayane S. Vardanyan,1 Aghadjanov I. Michael,1 Aghadjanova M.
Elena,1 Alla L. Shaljyan.1 1Biochemistry, Yerevan State Medical
University, Yerevan, Yerevan, Armenia.
Diabetes is associated with infringment in endogenous opioid
system and opposite alterations in various type opioid receptor
sensitivity. However, it is not clear whether membrane lipid
modification processes take part in development of such disorder
as well, as their possible role in etiology of neurological
complications in these patients. In order to evaluate processes
mentioned involvement we suppose to investigate effects of
selective delta-opioid receptor agonist Deltorphine II, delta-1-
receptor antagonist 7-Benzylidennaltrexone and delta-2 receptor
antagonist Naltriben on some aspects of phosphoinositide cycle
functioning in lymphocytes. The regulator role of processes
mentioned at the initial membrane-bound step of studied opioid
agonist and antagonists information translocation has been
demonstrated in both diabetic and non-diabetic cells. The evidence
exists that alterations in lipid-mediated signal transduction path-
ways and receptors lipid microenvironment may be responsible for
altered nociception at diabetes conditions. The amplification of free
radical processes is known to be one of pathogenic mechanisms to
form a basis for neuropathological complications at diabetes
conditions. However, it is not clear whether membrane lipid free
radical oxidation processes and enzymes of antiradical defense
system take part in such disorders. In order to evaluate the
involvement of above mentioned processes in altered nociception
at diabetes conditions the intensity of lipid peroxidation processes
have investigated as well, as activity of enzymes of cell antiradical
protection, superoxid glutathione reductase dismutase in diabetic
patients erythrocyte membranes at the conditions of opioid
receptors blockade and sensitization. Some correlation between
intensity of enzymatic lipid peroxidation and opposite changes of
receptor sensitivity as well. as possible participation of cell
antiradical protection enzymes have been demonstrated. The
evidence exists, that studied lipid mediated transduction pathway
together with receptor microenvironment modifications appear to
be possible biochemical targets of altered nociception at diabetes
conditions.
Sa1.138. Combinatorial treatment of recent-onset type 1
diabetes by induction of islet-antigen specific Tregs and
anti-CD3.
Damien Bresson,1 Lisa Togher,1 Kevan Herold,2 Matthias von
Herrath.1 1La Jolla Institute for Allergy and Immunology, San
Diego, CA, USA; 2Columbia University, New York, NY, USA.
Rationale: A central issue when using immune-suppressive
therapy in transplantation and autoimmunity is to balance benefits
with systemic side effects. Administration of non Fc-binding anti-
CD3 has shown good efficacy in temporarily maintaining C-
peptide levels in recent-onset diabetes over a 1–2 year timeframe,
but immunosuppressive side effects limit higher-dose regimens or
continuous administration. One novel attractive avenue in type 1
diabetes (T1D) is the islet autoantigen-specific induction of
adaptive regulatory T cells (Tregs) that can act in vivo as bystander
suppressors of autoaggressive responses selectively within the
pancreatic draining lymph node (PDLN). In our hands, such cells
can be induced via oral or intranasal administration of insulin, pro-
insulin peptides and DNA vaccines expressing islet antigens and
efficacy is associated with IL-4 and IL-10 production. Their site
AbstractsS136specificity is a strong clinical advantage and can be attributed to the
fact that autoantigens leading to their expansion and activation are
only presented in the PDLN. Since anti-CD3 is known to increase
numbers of intrinsic CD25+ Tregs as well as TGF-h and IL-10
production, we reasoned that it would create a favorable systemic
milieu for islet-antigen specific induction of autoreactive, adaptive
Tregs and synergy could be expected.
Approach: Combinatorial therapy of recent-onset diabetes in
NOD and RIP-LCMV mouse models using anti-CD3 FabT2 and
intranasal proinsulin.
Results: At least 50% increased reversion of recent-onset
diabetes was observed in NOD and RIP-NP mice treated with a
combination of anti-CD3 and proinsulin compared to each
intervention given alone. In particular, mice with more rapid beta
cell loss benefited from this synergistic effect. Mechanistically, we
observed increased numbers of proinsulin specific antigen-induced
Tregs producing IL-4 and IL-10 in mice that received combina-
torial therapy compared to those receiving anti-CD3 alone.
Furthermore, we found much higher numbers of TGF-beta
producing CD25+ Tregs in mice treated with both, compared to
mice that received anti-CD3 alone.
Conclusion: Antigen-specific induction of Tregs can synergize
with systemic immune modulatory approaches to revert recent-
onset T1D. Synergy was evidenced by enhanced clinical efficacy
and increased numbers of intrinsic TGF-beta producing
CD4+CD25+ as well as adaptive autoantigen-specific IL-4/IL-10
producing Treg populations. This strategy should be considered for
the clinic and maybe also for transplantation.
D.B. is supported by a JDRF postdoctoral fellowship and
MGVH is supported by DK51091, AI44451 and a U-19 prevention
center grant.
Sa1.139. De Novo Generation of Antigen-Specific
CD4+CD25+ Regulatory T Cells from Human
CD4+CD25- Cells.
M. R. Walker,1,3 B. D. Carson,2,3 S. F. Ziegler,2,3 G. T. Nepom,1,3
J. H. Buckner.1 1Diabetes, Benaroya Research Institute at Virginia
Mason, Seattle, WA, USA; 2Immunology, Benaroya Research
Institute at Virginia Mason, Seattle, WA, USA; 3Immunology,
University of Washington, Seattle, WA, USA.
CD4+CD25+FoxP3+ T cells are thought to be essential in
maintaining tolerance to self antigens. These cells, known as
regulatory T cells (TR), have been classified in two main
categories: natural TR, which are derived from the thymus, and
adaptive TR, which arise in the periphery. The importance of
these cells in controlling responses to foreign antigens has just
begun to be described. Previously, we have reported that
activation of human CD4+CD25- T cells led to expression of
FoxP3 in CD25+ cells and acquisition of cell contact-dependent,
cytokine-independent regulatory activity. Results in our labora-
tory reveal that these in-vitro derived TR could be generated
from both memory and naive cells and by activation of
CD4+CD25- T cells with alloantigen or a foreign antigen, HA
(307-319). In the HA system, MHC class II tetramers were used
to identify antigen-specific T cells. Antigen activation of
CD4+CD25- led to two populations of CD4+CD25+ cells,
Tetramer+ and Tetramer- cells, with antigen specific suppression
occurring only in the Tetramer+ cells. HA generated TR required
cognate antigen for activation, but once activated subsequently
suppressed noncognate bystander T cell responses as well. For
this reason, we have started testing the ability of a diabetesautoantigen, GAD65, to generate antigen-specific TR. GAD-
specific TR can be generated from both normal and diabetic
subjects, and once activated these TR also suppress bystander T
cell responses. This raises the possibility that antigen-specific TR
may be useful therapeutically in autoimmune diseases by
localizing generalized suppressive activity to tissues expressing
select target antigens.
Sa1.140. TGF-B Enhances Autoimmune Diabetes by
Increasing Survival of Memory Effector CD8
Lymphocytes.
Amy E. Juedes,1 Chrystelle Asseman,1 Lisa Togher,1 Yufeng
Peng,2 Allison Green,2 Richard A. Flavell,2 Matthias G. von
Herrath.1 1Developmental Immunology, La Jolla Institute for
Allergy and Immunology, San Diego, CA, USA; 2Immunobiology,
Yale University, New Haven, CT, USA.
TGF-h is produced by a variety of cell types and can exhibit
strong immune dampening functions. Surprisingly, in a model of
virally-induced autoimmune diabetes, local expression of TGF-h
in h-cells under the control of a doxycycline-dependent promoter
resulted in increased islet infiltration and disease incidence. This
was attributed to a selective anti-apoptotic effect of TGF-h on
differentiated memory-effector CTL. Conversely, mice lacking
functional TGFh-receptors on T cells exhibited enhanced apoptosis
and fewer memory CD8 lymphocytes. The effects of TGF-h were
clearly dependent on the T cell differentiation status, as it
effectively suppressed activation of naRve anti-viral CTL. Our
results highlight a novel aspect of the pleiotropic nature of TGF-h,
and have implications for the design of immuno-therapies
involving this cytokine.
Sa1.141. Protection from Type 1 Diabetes by iNKT Cells
May Require Interactions with CD4+CD25+ Regulatory
T Cells.
D. Ly,1,2 Q. S. Mi,3 T. L. Delovitch.1,2 1Autoimmune/Diabetes
Group, Robarts Research Institute, London, ON, Canada;
2Department of Microbiology and Immunology, University of
Western Ontario, London, ON, Canada; 3Center for
Biotechnology and Genomic Medicine, Medical College of
Georgia, Dept of Pathology-Section of Dermatology, Augusta,
GA, USA.
Invariant natural killer T (iNKT) cells comprise a subset of
regulatory T cells characterized by their co-expression of NK
cell markers and an invariant TCR that recognizes a lipid
antigen in a CD1d-restricted manner. Previously, we reported
that activation of iNKT cells by the sphingoglycolipid alpha-
galactosylceramide (a-GalCer) protects against type 1 diabetes
(T1D) in NOD mice. This protection involves the polarization
towards a Th2-like immune response accompanied by increased
IL-4. As potent activation of iNKT cells also trans-activates
other immune cells, we further analyzed whether iNKT cells
influence the function of CD4+CD25+ regulatory T cells. We
found that CD4+CD25+ T cells from NOD.CD1d-/- mice
deficient in iNKT cells functioned similarly in vitro to
CD4+CD25+ T cells from wild-type NOD mice and suppressed
the proliferation of NOD T responder cells upon stimulation with
a-GalCer. Adoptive transfer of NOD diabetogenic T cells and
NOD CD4+CD25+ T cells pretreated in vivo with multiple low
doses of a-GalCer further indicated that activation of iNKT cells
do not influence the regulatory capacity of CD4+CD25+ T cells
to inhibit the transfer of T1D. In contrast, protection from T1D
Abstracts S137mediated by adoptive transfer of activated iNKT cells requires
the presence of CD4+CD25+ T cells, as splenocytes pretreated
with a-GalCer and depleted of CD25+ cells were unable to
confer protection from T1D. These data suggest that even
though iNKT cells may not influence CD4+CD25+ T cell activity,
iNKT cell-mediated protection appears to require the presence of
CD4+CD25+ T cells. (Supported by CIHR grant MOP 64386 to
TLD).
Sa1.142. Immunomodulation in Type 1 Diabetes by
NBI-6024, An Altered Peptide Ligand of the Insulin
B(9–23) Epitope.
D. G. Alleva,1 R. A. Maki,1 A. L. Putnam,2 M. S. Kipnes,3 P.
Dandona,4 J. B. Marks,5 D. L. Simmons,6 C. J. Greenbaum,7 R. J.
Jimenez,1 P. J. Conlon,1 P. A. Gottlieb.2 1Molecular Medicine,
Neurocrine Biosciences, Inc., San Diego, CA, USA; 2Barbara
Davis Center for Childhood Diabetes, University of Colorado
Health Sciences Center, Denver, CO, USA; 3Diabetes and
Glandular Disease Clinic, San Antonia, TX, USA; 4Diabetes-
Endocrinology Center of WNY Kaleida Health, Buffalo, NY, USA;
5Department of Diabetes, Endocrinology, and Metabolism, Uni-
versity of Miami, Miami, FL, USA; 6Division of Endocrinology
and Metabolism, University of Arkansas for Med Sciences, Little
Rock, AR, USA; 7Diabetes Clinical Research Unit,, Virginia
Mason Research Center, Seattle, WA, USA.
NBI-6024 is an altered peptide ligand (APL) corresponding to
the 9–23 amino acid region of the insulin B chain (B(9–23)), which
is an epitope recognized by interferon (IFN)-g-producing T
lymphocytes in type 1 diabetic patients. Immunomodulatory
effects of NBI-6024 in recent-onset type 1 diabetic patients in a
phase I clinical trial (NBI-6024-0003) were measured using the
ELISPOT assay in peripheral blood mononuclear cells. IFN-g
responses to B(9–23) were observed in 62.5% (5 of 8) of patients
receiving placebo and in only 8% (1 of 13) of non-diabetic
untreated control subjects. NBI-6024 administration (five biweekly
or biweekly-monthly s.c. injections) led to a dose-dependent
reduction in the percentage of patients with IFN-g responses to
B(9–23) and a concomitant increase in the percentage with IL-5
responses to B(9–23). Similar trends were observed with NBI-6024-
specific ELISPOT responses. This Phase I clinical study demon-
strated that NBI-6024 treatment did not enhance, but rather
suppressed, the pathogenic IFN-g response of recent-onset type 1
diabetic patients in a dose-dependent fashion. Enhanced IL-5
responsiveness after NBI-6024 treatment is consistent with
induction of a T helper (Th) 2-like immunological phenotype.
The significance of these findings on the clinical outcome of
disease is under investigation in a Phase II multi-dose study.
Sa1.143. A Single Explanation for Three Puzzles in Type
1 Diabetes (T1D).
Zuheir L. Awdeh,1 Edmond J. Yunis,1,2,3 Mark J. Audeh,4 Dolores
A. Fici,1 Alberto Pugliese,5 Charles E. Larsen,1,3 Chester A.
Alper.1,3 1Immunogenetics Division, The CBR Institute for
Biomedical Research, Boston, MA, USA; 2Department of Cancer
Immunology and AIDS, The Dana-Farber Cancer Institute,
Boston, MA, USA; 3Departments of Pathology, Medicine and
Pediatrics, Harvard Medical School, Boston, MA, USA; 4Boston
College, Chestnut Hill, MA, USA; 5Diabetes Research Institute,
University of Miami School of Medicine, Miami, FL, USA.
There is an excess of HLA-DR3/DR4 heterozygous individuals
among Caucasian patients with T1D. The incidence of T1D isrising in many countries and the MHC haplotype composition of
T1D patients has also changed over the past several decades.
Earlier, we proposed that, for any polygenic disease, if there is
mixing of two populations with reciprocally different frequencies
of susceptibility genes at different loci, the incidence in the mixed
offspring will be much higher than in the original populations
because of susceptibility gene complementation at those different
loci. We propose that the apparent increased risk for HLA-DR3/
DR4 heterozygotes as compared with homozygotes for either
HLA-DR3 or DR4 and the heterozygote overrepresentation among
patients is because their parents appear to come from different,
previously isolated populations. Thus, HLA-DR3 and DR4 are
both disease and population markers. Our evidence is that (a)
HLA-DR parental genotype distribution deviated from the Hardy-
Weinberg equilibrium in a way opposite to the patients: the parents
had a paucity of HLA-DR3/DR4 heterozygotes, (b) DR3-trans-
mitting parents had different HLA-A2 frequencies on their
untransmitted HLA haplotypes than those who transmitted DR4,
(c) DR3-positive parents had different INS allele frequencies than
DR4-positive parents, and (d) parents of T1D patients had greater
self-reported ethnic mixing than control parents. Thus, a specific
kind of intrafamilial population admixture explains all three
phenomena.
Sa1.144. The (Relatively) Simple Genetics of a Polygenic
Disease: Type 1 Diabetes (TID).
Chester A. Alper,1,2 Charles E. Larsen,1,2 Edmond J. Yunis,2,3
Zaheed Husain,1,2 Zuheir L. Awdeh.1 1Immunogenetics Division,
The CBR Institute for Biomedical Research, Boston, MA, USA;
2Departments of Pediatrics, Medicine and Pathology, Harvard
Medical School, Boston, MA, USA; 3Department of Cancer
Immunology and AIDS, The Dana-Farber Cancer Institute,
Boston, MA, USA.
Concordance for T1D is approximately 40% for monozygotic
twins, approximately 12% for MHC-identical sibs, and approx-
imately 6% for sibs in general. Thus, there is an MHC T1D
susceptibility gene, but non-MHC genes are also required for
susceptibility. From the population distribution of certain MHC
markers and from analysis of affected sib pairs, the MHC
susceptibility gene(s)must be expressed recessively and have a
frequency in the general population of approximately 0.53. Because
all of the MHC markers for T1D are embedded within conserved
extended haplotypes with fixed DNA over at least the HLA-B to
HLA-DRB1/-DQB1 interval (around 1 megabase in length),
identification of the true T1D susceptibility locus has been difficult.
The presence at low frequency of so-called protective HLA-DR/DQ
haplotypes in patients strongly suggests that HLA-DRB1*0301,
DQB1*0201 (DR3) and HLA-DRB1*04, DQB1*0302 (DR4) are
markers for susceptibility but not themselves the true MHC
susceptibility gene(s), which remain(s) to be discovered. Intrinsic
penetrance is the concordance rate in monozygotic twins and is the
rate at which all completely susceptible persons in the population
(who have all necessary susceptibility genes) have T1D. Penetrance
of susceptibility genes is not likely due to differential environmental
effects since the concordance rate in dizygotic twins is the same as
the rate in all sibs. From the fact that homozygotes for MHC-
determined dominantly expressed IgD deficiency have about twice
the frequency of the deficiency as heterozygotes, we concluded that
penetrance in that situation is stochastic and a property of the MHC
susceptibility gene. It seems likely that a similar mechanism is
operative in T1D.
AbstractsS138Sa1.145. An Atypical Case of IPEX Syndrome with
Multiple FOXP3 Mutations.
E. Gambineri,1 C. Azzari,1 M. Moriondo,1 L. Bianchi,1 A. M.G.
Gelli,1 A. Vierucci,1 M. de Martino.1 1Department of Pediatrics,
bAnna MeyerQ ChildrensT Hospital, University of Florence,
Florence, Italy.
The rare X-linked syndrome known as IPEX (Immune
dysregulation, Polyendocrinopathy, Enteropathy and X-linked
inheritance) is characterized by early-onset IDDM (type 1
diabetes), severe enteropathy, eczema, and variable autoimmune
phenomena. The IPEX gene has been mapped to chromosome
Xp11.23-Xq13.3 and encodes a putative DNA-binding protein,
FOXP3, which has a significant homology to forkhead/winged-
helix transcription factor family. We have observed the IPEX
phenotype in one patient, at the age of one month, with intractable
diarrhea, dermatitis and elevated IgE. Autoantibodies against
pancreas, thyroid and gut were negative. The mutation analysis
of the FOXP3 gene has revealed three distinct nucleotide
substitutions. The mutations consist of a known splice-site
mutation (exon 4 and 5 boundary), and two other aberrations
(within intron 8 and the second within exon 9), previously not
described. Interestingly, expression studies of FOXP3 mRNA
detected a product of about 100bp smaller compared to the normal
control. The sequence analysis of this product revealed the absence
of exon 2. Molecular analysis extended to other members of the
family showed the same FOXP3 mutations in one of the two
healthy brothers of the patient; in addition the mother was
identified as a carrier for the same mutations. At present, the
patient is 17 months old and his diarrhea is under remission
without treatment, as he is routinely monitored in order to control
the disease progression. IPEX is a syndrome usually associated
with overwhelming autoimmunity and severe phenotype. Here we
present an atypical case of IPEX manifesting in unusually mild
clinical features corresponding to a novel set of FOXP3 mutations.
Further studies will be important to clarify the link between the
phenotype of this patient and the specific molecular aberrations in
the FOXP3 gene. Moreover, whether the gene product without
FOXP3 exon 2 is a normal splicing variant of FOXP3 mRNA, or
is the result of multiple mutations found in the patient is under
investigation.
Immunology of the Eye
Sa1.146. Increase of Serum KL-6 Levels In Sera of
Uveitis Patients with Sarcoidosis.
N. Kitaichi,1 S. Ohno.1 1Ophthalmology & Visual Sciences,
Hokkaido University Graduate School of Medicine, Sapporo,
Hokkaido, Japan.
Purpose: KL-6 is a human glycoprotein secreted by type II
alveolar cells in lung, and its serum levels increase in pneumonia of
various causes. KL-6 is a member of the MUC-1 family, which is
expressed in cornea and conjunctiva as well as lung. The purpose
of the present study is to investigate the clinical usefulness of
quantifying serum KL-6 levels for diagnosing and following up
sarcoidosis in patients with uveitis.
Patients & Methods: Sera were obtained from 24 uveitis
patients diagnosed as sarcoidosis, 37 uveitis patients with other
etiologies, and 138 healthy control subjects. Patients were
considered to have indication for sarcoidosis when their KL-6
concentrations exceeded 370 U/ml. Within this criterion, 137 of
138 (N99%) of healthy subjects were negative for sarcoidosis.Serum KL-6 concentration was determined by a human KL-6
electrochemiluminescence immunoassay (ECLIA).
Results: The average level of KL-6 in sera of uveitis patients
with sarcoidosis, other etiologies, and healthy controls were 387 F
52 (Mean F SD) U/ml, 266 F 23, and 183 F 6, respectively. The
level of KL-6 in uveitis patients with sarcoidosis was significantly
higher than in patients with other etiologies of uveitis. The KL-6
measurement identified 45.8 % of sarcoidosis-positive patients.
When the KL-6 results were combined with serum angiotensin-
converting enzyme (ACE) concentrations, 87.5 % of sarcoidosis
patients were identified, compared to 66.7 % using ACE results
alone. The combined measurement identified 10.8 % of non-
sarcoid patients and 0.72 % of healthy subjects as positive (false
positive). And there were significant correlations between serum
KL-6 and ACE levels in the patients with sarcoidosis. Moreover,
serum KL-6 concentrations were less affected by systemic
corticosteroid administration than ACE, and never affected by
ACE inhibitory drugs for systemic hypertension.
Conclusions: Combined measurements of serum KL-6 and
ACE may be useful as a screening for sarcoidosis in uveitic
patients. And also, it may be valuable to follow up the diagnosed
sarcoidosis, because the concentration of serum KL-6 less
fluctuates than that of ACE in patients treated with systemic
corticosteroids and/or anti-hypertensive drugs.
Supported by JSPS Research Fellowship for Young Scientists,
Japan Society for the Promotion of Science, Tokyo.
Sa1.147. Cytotoxic CD8brightCD56+ T Cells are
Immunopathogenic Effectors in Patients with Active
BehcetTs Uveitis.
Jae Kyoun Ahn,1 Hyeong Gon Yu,1 Hum Chung,1 Sung-pyo
Park,1 Young Joo Kim.1 1Ophthalmology, Seoul National
University College of Medicine, Seoul, Seoul, Republic of Korea.
Recent our report demonstrated that the intraocular infiltration
of CD8brightCD56+ T cells was a distinct feature in active BehcetTs
uveitis (BD) from other etiologies of endogenous uveitis. However,
the phenotypic natures and effector functions of CD8brightCD56+ T
cells in active BD have remained elusive. This study was
conducted to determine the phenotypic and functional character-
istics of CD8brightCD56+ T cells and to investigate the cytotoxic
mechanisms of theses subsets. Forty five patients with BD (active:
24, inactive: 21) and 20 healthy controls were recruited in this
study. Phenotypic analysis of fresh PBMCs were performed using
anti-CD8 mAb and anti-CD56 mAb in conjunction with a three- or
four-color immunofluorescence tests for the expression levels of
the following molecules: CD11b, CD27, CD45RA, CD45RO,
CD62L, CD94, NKG2D, HLA-DR. Flow cytometric measure-
ments of intracellular cytokines (IFN-g and IL-4) and cytotoxic
molecules (intracellular perforin and surface FasL) were performed
by in vitro PMA and ionomycin (PI) stimulation. Ex vivo cytolytic
capacities of purified CD8brightCD56+ T cells against K562, Raji,
and human umbilical vein endothelial cell line (HUVEC) were
measured by standard 51Cr release assay. Modulation of cytotox-
icity was done using the treatment of HUVEC by rhIFN-g and the
treatment of effector cells by concanamycin A (CMA) or brefeldin
A (BFA). CD27 and CD62L were down-regulated on peripheral
CD8brightCD56+ T cells in patients with active BD in contrast to
the up-regulation of CD11b and HLA-DR. Interestingly, CD94/
NKG2Awas up-regulated on peripheral CD8brightCD56+ T cells in
BD in contrast to the down-regulation of NKG2D. Furthermore, in
patients with active uveitis, these subsets were polarized to produce
Abstracts S139IFN-g, contained high amounts of preformed intracellular perforin,
and exclusively expressed surface FasL upon stimulation by PI.
Moreover, in vitro cytolytic functions of CD8brightCD56+ T cells in
active BD were up-regulated against both K562 and Raji, which
were effectively inhibited by CMA. Interestingly, in vitro cytolytic
activity of these subsets against HUVEC was also up-regulated,
which was effectively suppressed by BFA rather than by CMA.
Cytolytic functions of PI-stimulated CD8brightCD56+ T cells were
greatly enhanced against HUVEC, which was augmented by
pretreatment of IFN-g on HUVEC. CD8brightCD56+ T cells,
characterized by cytotoxic effector memory Tc1 phenotypes with
functional NK receptors, play immunopathogenic roles in BD and
exhibit strong cytolytic functions against vascular endothelial cells
through FasL-dependent pathway.
Sa1.148. Flt3L-Elicited, In Vitro-Matured Splenic
Dendritic Cells (DC) Induce Autoimmune Disease in the
Retina.
J. Tang,1 W. Zhu,1 P. B. Sliver,1 S.B. Shu,1 C.C. Chan,2 R. R.
Caspi.1 1Section of Immunoregulation, Lab of Immunology,
National Eye Institute, NIH, Bethesda, MD, USA; 2Section of
Immunopathology, Lab of Immunology, National Eye Institute,
NIH, Bethesda, MD, USA.
Experimental autoimmune uveitis (EAU), a model for human
uveitis, is induced in mice by immunization with a retinal antigen
in complete FreundTs adjuvant and pertussis toxin. Here we
describe a new EAU model induced with in vitro-matured, retinal
antigen-pulsed DC. DC were expanded in vivo by hydrodynamic
injection of 50 Ag of Flt-3 ligand DNA. On day 5, the size of the
spleen was doubled and the CD11c+ population tripled from an
average of 4.9% to 15.0%, for a total increase of 6-fold over
background. Combined stimulation of CD11c+ DC with LPS and
anti-CD40 enhanced expression of costimulatory molecules and
secretion of IL-1, IL-6, IL-10, IL-12, IFN-g and TNF-a. When
pulsed with a uveitogenic peptide, these cells induced vigorous
immune responses in vivo. Furthermore, 2 injections of DC 4 days
apart plus pertussis toxin elicited a typical EAU-like inflammation
in eyes of susceptible B10RIII mice, with an incidence of up to
87%. Sorted CD8a+ and CD8a- DC subpopulations exhibited
differential cytokine production when stimulated as above, with the
CD8a- population releasing more IL-1h, IL-2, IL-6, IL-10 and
TNF-a than the CD8a+ population, whereas CD8a+ DC produced
more IL-12 and IFN-g. Expression of CD80 and CD86 was
similar. Current work is aimed at examining differences in the
ability of these splenic DC subpopulations to induce EAU. This
alternative EAU model, which allows direct manipulation of DC in
vitro, will permit better characterization of the role of these cells in
autoimmunity to the retina and may help to devise new approaches
to therapy.
Sa1.149. Thrombospondin 1 Mediates a Contact
Dependent Mechanism by Which Retinal Pigment
Epithelial (RPE) Cells Regulate T Cell Function.
J. L. Vega,1,2 S. Masli,2 A. W. Taylor,2 H. L. Weiner,1 J. W.
Streilein.2 1Neurology, Brigham and WomenTs Hospital, Harvard
Medical School, Boston, MA, USA; 2Ophthalmology, Schepens
Eye Research Institute, Harvard Medical School, Boston, MA,
USA.
Soluble factors released by cultured RPE cells were previously
shown to suppress T cell proliferation, and to confer T cells with
regulatory properties. This study was performed to investigate thepossibility that molecules on the surface of RPE cells can exert
similar effects on T cell function. T cells activated via soluble a-
CD3 were cultured in the presence or absence of fixed RPE cells
for 72h in serum free medium, and their proliferation, as well as
their ability to suppress the proliferation of bystander T cells, was
assessed via 3H thymidine incorporation. For the latter, T cells
were irradiated at the end of the 72h co-culture period with RPE
cells, and were then washed and re-plated with freshly isolated T
cells activated with a-CD3 antibodies. T cell viability was
quantified using the alamar blue bioassay. In order to investigate
whether surface TSP-1 played a role in mediating the contact-
dependent effect of RPE cells on T cell function, the above
experiments were repeated using fixed RPE cells recovered from
the eyes of TSP-1 knockout mice. These studies were comple-
mented with immunohistochemistry and western blotting in order
to confirm the expression of TSP-1 by cultured RPE cells. Finally,
to begin to address the potential TSP-1 receptors on T cells
involved in mediating this effect, we examined the importance of
the integrin a4h1 (VLA-4), used by naive and activated T cells for
attachment to the TSP-1 molecule. This was done by preventing
the binding of TSP-1, on RPE cells, to VLA-4 on T cells, with
blocking antibodies, and by blocking the function of its associated
potassium channel, Kv1.3, with margatoxin (MgTx). Our results
show that fixed RPE cells suppress the proliferation of activated T
cells, and in turn confer them with a similar ability to suppress
bystander proliferation. Further, cultured RPE cells expressed TSP-
1 homogeneously throughout their cell surface, and fixed RPE
cells lacking the TSP-1 gene, failed to suppress T cell proliferation.
Similarly, inhibiting TSP-1 binding to its receptor VLA-4 on T
cells, or blocking the function VLA-4Vs associated potassium
channel, Kv1.3, prevented T cells from becoming regulatory. We
conclude that aside from soluble factors, RPE cells also exhibit a
contact-dependent mechanism, mediated by TSP-1/VLA-4 inter-
actions, by which they suppress the proliferation of activated T
cells, and confer them with regulatory properties.
Sa1.150. Altered Peptide Ligands of a Retinal Antigen
Protect from Anti-Retinal Autoimmunity by Eliciting
Active Regulatory Mechanisms.
L. M. Cortes,1 D. Avichezer,1 P. B. Silver,1 C. C. Chan,1 R. R.
Caspi.1 1Laboratory of Immunology. National Eye Institute,
National Institutes of Health, Bethesda, MD, USA.
We identified altered peptide ligands (APL), capable of
immunomodulating experimental autoimmune uveitis (EAU), a
Th1-driven disease induced in B10.RIII mice by immunization
with the retinal antigen IRBP in complete FreundTs adjuvant.
Alanine-substituted peptides of the major pathogenic epitope,
residues 161–180, were synthesized. They were tested for
immunogenicity, crossreactivity with the native 161–180 epitope,
pathogenicity, and ability to prevent EAU when given in
incomplete FreundTs adjuvant (IFA) 2 weeks before EAU
challenge with native p161-180. Two peptides, 169A and 171A,
were unable to elicit disease and crossreacted with p161-180 by
lymphocyte proliferation. Mice pre-treated with either of the
putative APL failed to develop EAU and had reduced cellular
responses to p161-180 by lymphocyte proliferation and by delayed
hypersensitivity. Their cytokine response profile to p161-180
showed reduced IFN-g and enhanced IL-4, and serum antibody
titers to p161-180 revealed reduced IgG2a and elevated IgG1
isotypes, suggesting a Th2 shift in the response. Protection was
transferable with lymphoid cells from protected donors to naRve
AbstractsS140recipients who were subsequently immunized for EAU. Thus, APL
pretreatment appears to prevent induction of EAU by skewing the
subsequent response towards a non-pathogenic effector phenotype,
as well as by eliciting regulatory cells.
Sa1.151. Modulation of Innate Immune Response with
Granulocyteapheresis in Behc¸etTs Disease: 1 Year
Experience.
O. Garcia, R. Lafuente, J. Munoz, A. Vidaller, J. Arruga.
1Ophthalmology, Hospital Universitari de Bellvitge, Hospitalet,
Barcelona, Spain; 2Intensive Care Unit, Hospital General,
Hospitalet, Barcelona, Spain; 3Blood Bank, Hospital Universitari
de Bellvitge, Hospitalet, Barcelona, Spain; 4Internal Medicine,
Hospital Universitari de Bellvitge, Hospitalet, Barcelona, Spain;
5Ophthalmology, Hospital Universitari de Bellvitge, Hospitalet,
Barcelona, Spain.
Introduction: Granulocyteapheresis (GCAP) is a novel treat-
ment that has the capability of modulating innate immune response
in some autoimmune diseases such as Ulcerative Colitis, Crohn’s
Disease, Rheumathoid Arthritis, and Behcet’s Disease. We present
our results with this treatment in a period of 1 year in 3 cases of
ocular Behcet’s Disease.
Objective: to evaluate GCAP efficacy to control uveitis
activity, number of relapses and steroid sparing effect in a 1 year
period.
Material and Methods: 3 patients with ocular Behcet disease
resistant to conventional medical treatment were selected for
GCAP treatment. One patient presented active uveı´tis and the
others were clinically inactive. Patients demographics were: age
25,7 F 3,1;2 female/1 male; time from diagnose 66,7 F 45,7
months; average of uveı´tis relapses/year 5,38 F 3.6; all patients
were steroid dependant and needed cyclosporine A (2/3),
azathioprine (2/3) and/or micophenolate mofetil (1/3) to control
the disease. Informed consent was obtained from all patients.
GCAP treatment was approved by Spanish Ministry of Health for
Compassionate Use. We performed an induction treatment of 1
GCAP session/week during 10 consecutive weeks. Patients were
maintained with 1 GCAP session each month during 1 year. The
GCAP procedure consists in an extracorporeal blood circulation
through a column filled with cellulose diacetate beads. Each
procedure lasts 1 hour and 1.8 liters of blood are processed at 30
ml/h. Visual acuity, intraocular inflammation degree, and predni-
sone requirements were assessed during the study period. No
adverse event were reported.
Results: During induction treatment uveitis was controlled in all
patients and none of them presented any relapse. Visual acuity was
stabilized in 3 eyes and improved in the other 3. Prednisone dose was
tapered down from 35,8F 13.7 to 15F 5 mg/day. After completion
of 1 year maintenance treatment, mean number of uveitis relapses
were 1 F 1, and daily prednisone dose was reduced to 21.6 F 7.6.
Visual acuity was stable during maintenance treatment.
Conclusion: GCAP treatment is a safe and effective treat-
ment for ocular Behcet´s Disease refractory to conventional
medical treatment. A one year maintenance regimen can reduce
uveitis relapses, preserve visual acuity and reduce prednisone
requirements.
Sa1.152. Systemic Autoimmune Disease in Patients with
Uveitis.
J. Carbone,1 E. Sarmiento,1 D. Micheloud,1 R. Mora,1 M.
Rodriguez-Mahou,1 R. Cobo,2 J.L. Vicario,3 J.J.Rodriguez-Molina,1 E. Fernandez-Cruz.1 1Clinical Immunology
Unit, Immunology Department, University Hospital Gregorio
Maranon, Madrid, Spain; 2Ophthalmology Department,
University Hospital Gregorio Maranon, Madrid, Spain;
3Transfusion Center, Community of Madrid.
Background. The eye (and especially the highly vascular
tissues such as the uvea and the conjunctiva) is considered a
special btargetQ for immunopathologic reactions. Uveitis refers to
inflammation of the uveal tract, which includes the iris, ciliary
body, and choroid. Uveitis is a potentially blinding condition
predominantly occurring in the working age group. Although the
aetiology is unknown in most cases, many patients have an
associated underlying systemic disease. Uveitis can be the initial
manifestation of an autoimmune systemic disease, and may
appear years before the diagnosis of the primary disease. A
retrospective study was conducted of patients with uveitis to
determine the frequency of associated autoimmune systemic
diseases and to assess the value of limited laboratory screening
of these patients. Materials. 64 patients (33 male, 31 female)
with uveitis (38 anterior, 14 posterior, 4 intermedia, 8 panuveitis)
were studied. All patients underwent a standard diagnostic
protocol including the following immunological tests: serum
immunoglobulins, complement components, circulating immune
complexes (CIC), antinuclear antibodies (ANA), antineutrophil
cytoplasmic antibodies (ANCA), anticardiolipin antibodies (ACA)
and major histocompatibilty complex antigens. Results: Overall
87.5% of patients had at least one detectable immunological
abnormality. 14/64 patients had detectable levels of ANA (titer 1/
40-1/320) (21.9%), 8/64 IgM ACA (12.5%), 7/64 IgG ACA
(10.9%), 5/64 rised ANCA (7.8%) and 4/64 positive rheumatoid
factor (6.3%). A relationship with a subclinical autoimmune
systemic disorder could be presumed in 11/64 cases (17.2%)
defined as the presence of autoantibodies (ANA, ANCA or ACA)
in the presence of complement comsumption, hypergammaglo-
bulinemia o increased CIC. HLA-B27-associated anterior uveitis
was observed in 8/64 patients (12.5%), HLA-DR52-associated
posterior uveitis in 2/64 (3.1%), HLA-DR53-associated Vogt-
Koyanagui-Harada syndrome in 1/64 (1.6%) and HLA-A29-
associated birdshot retinochoroidopathy in 1/64 (1.6%). A
definite association with a systemic autoimmune disease was
determined for 8/64 patients (12.5%) most of them with lupus
like disease (LLD) (4), LLD plus antiphospholipid syndrome (1),
Sjfgren syndrome (2) and systemic vasculitis (1). The presence
of the systemic autoimmune disease was not suspected prior to
eye involvement and was only recognised after the subsequent
diagnostic procedures. Conclusion. In a proportion of patients
with uveitis an autoimmune systemic disorder may be present.
The systemic autoimmune diseases were frequently undiagnosed
before the onset of the ocular disease and before the uveitis
consultation. Studies of the immunological profile can therefore
help in further assessment of patients with uveitis.
Sa1.153. In Silico Prediciton of Binding of
Auto-Antigenic Peptides to HLA-DRB1 in
Vogt-Koyanagi-Harada Disease.
P. S. Prasad,1 R. D. Levinson.1 1Ophthalmology, David Geffen
School of Medicine, UCLA, LA, CA, USA.
Purpose: To evaluate the ability of computer-based algorithms
(in silico) to identify putative auto-antigenic peptides and to
evaluate predicted binding of putative auto-antigenic peptides in
different populations with the same disease. Methods: Three
Abstracts S141internet-accessible computer-based algorithms were used to predict
binding of tyrosinase (TYR) and tyrosinase-related protein-1
(TRP-1)-derived peptides to HLA-DRB1*0405. These results were
compared to published studies of in vitro immunogenic responses
to TYR and TRP-1-derived peptides by HLA-DRB1*0405-
restricted T cells from patients with Vogt-Koyanagi-Harada
(VKH) disease. Three websites (SYFPEITHI, MHC-Thread, and
Propred) were used to determine relative likelihood of binding
scores for the immunogenic TYR and TRP-1 peptides determined
in vitro to HLA molecules that confer risk for VKH disease in
different populations, HLA-DRB1*0101, DRB1*0404, and
DRB1*0405. Results: We found that using all three websites
together, at least one in silico fragment overlapped with each of
the in vitro peptides by at least nine amino acids with the
exception of TRP-1 p243-254, which overlapped with a frag-
ment predicted by Propred by seven amino acids. The peptide
that was immunogenic in vitro in the most patients (TYR p426-
437) was identified by all three websites. TYR p134-146, TYR
p423-434 and TYR p426-437 were found by Propred to have a
high likelihood of binding to HLA-DRB1*0101, DRB1*0404,
and DRB1*0405, while TYR p193-203 and TYR p429-440
were predicted by Propred to have a high likelihood of binding
only to HLA-DRB1*0405. Conclusions: In silico-predicted
binding of putative immunogenic peptides to specific HLA-DR
alleles holds promise for high throughput evaluation of putative
auto-antigens and suggests a correlation between HLA binding
and immunogenicity. Predicted binding of immunogenic peptides
to HLA-DRB1*0101 and DRB1*0404 is consistent with clinical
studies that have found that these alleles confer risk for VKH
disease in Mestizo individuals. Conversely, differences between
likelihood of binding of immunogenic peptides to relevant HLA
molecules suggest that there may be differences as well
between peptides that induce disease in Mestizo and Asian
populations.
Sa1.154. Increased Ratio of Activating:Inhibitory Killer
Immunoglobulin-Like Receptor Genes in Uveitis.
R. D. Levinson,1 Z. Du,2 G. N. Holland,1 E. F. Reed,2 R.
Rajalingam.1 1Ophthalmology, David Geffen School of Medicine,
UCLA, LA, CA, USA; 2Immunogenetics, UCLA, LA, CA, USA.
Purpose: To evaluate Killer Immunoglobulin-like receptor
(KIR) genes in patients with uveitis. Methods: Individuals
diagnosed with birdshot chorioretinopathy (BCR) (n = 19) and
Vogt-Koyanagi-Harada (VKH) disease (n = 25) were evaluated for
both activating and inhibitory KIR genes as well as Class I human
leukocyte antigen (HLA) specificities using polymerase chain
reaction protocols. The presence or absence of the appropriate
HLA ligands for inhibitory genes was established. The individual
genotypes, the patterns of gene inheritance, and the ratio of
activating:inhibitory genes with their HLA ligands were compared
to local and published Caucasian (BCR) or Mestizo (VKH)
controls. Results: The ratio of activating:inhibitory KIR genes
with their HLA ligands was elevated compared to controls both
forms of uveitis. In addition, patterns of activating genotype
not found in any controls were found. Conclusion: The ratio
of activating:inhibitory KIR genes is increased in individuals
with BCR and VKH disease. The fact that a similar pattern
was found in two different forms of uveitis with distinct
clinical syndromes and known HLA associations implies that
increased activating:inhibitory KIR genes may be a marker of risk
for uveitis.Poster Session 2
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Sa2.01. Quality Assurance Survey (QAS) in the
Detection of Infectious Diseases with Outbreak Potential.
M. B. Dela Cruz. 1Office of the Secretary-Department of Health
Philippines (on Leave), Department of Health, Manila, Manila,
Philippines.
Objectives: 1. That a system in monitoring 14 infectious
diseases with outbreak potential is essential for its containment,
thus control if not eradication.
2. That the National Reference Laboratory (NRL)-Philippines
shall establish partnership with National Epidemic Sentinel
Surveillance System (NESSS)- National Epidemiology Center-
Department of Health, Philippines.
Materials and Methods: A network of hospital sentinel are to
the Regional Epidemiology and Surveillance Units. Sentinel sites
are hospitals which have at least 250 bed capacity. The hospital
have a laboratory capacity to do malarial smears, blood and stool
cultures and hepatitis serology, participating authorities, surveil-
lance personnel and availability of communication means between
sentinel sites and regional epidemiology and surveillance units.
Hospital admission are the basis in monitoring occurences of
diseases, thus, a rapid, timely, accurate information and early
warning on the disease outbreak.
Quality Assurance procedures are ensured in each sample
collection and during transport to NRLs. laboratory results are the
sole basis to confirm clinical diagnosis.
laboratory management includes Quality Control sampling to
monitor accuracy and precision of existing procedures.
Results: Sixteen (16) RESU were involved nationwide and all
the Five (5) designated NRLs-Philippines conducted the screening
and specific/confirmatory tests.
All data from these surveillance and quality evaluation were
extensively used utilized by the Department of Health for policy
formulation and program evaluation, thus were able to contain the
infectious disease identified.
CONCLUSION: A quality assurance survey which is essential
in the containment of infectious disease with outbreak potential has
been established by the National Reference Laboratory-Philip-
pines. This system will enable monitoring of precise and accurate
screening and confirmatory tests of the disease and therefore a
ready detection and containment if not eradication.
Sa2.02. Lack of Association between Interferon-Gamma
Receptor-1 Polymorphism and Pulmonary Tuberculosis
in Iranian Population Sample.
Mehdi Mirsaeidi,1 Masoud Houshmand,2 Payam Tabarsi,1
Mohammad Mehdi Banoei,2 Sonia Zargari,1 Majid Amiri,1
Davood Seyed Mansouri,1 Mohammad Sanati,2 Mohammad Reza
Masjedi,1 Ali Akbar Velayati.1 1Tuberculosis & Respiratory
Infections, National Research Institute of Tuberculosis and Lung
Disease, Tehran, Tehran, Islamic Republic of Iran; 2Molecular
Genetics, The National Research Center for Genetic Engineering
and Biotechnology, Tehran, Tehran, Islamic Republic of Iran.
Background: Tuberculosis is one of the most common
infectious diseases in the world. In recent years, genetically
approach has been developed. One of the interesting gene for
investigator is IFN-gR1.
AbstractsS142Aim: Determination of susceptibility to tuberculosis with
polymorphism of IFN-gR1 gene.
Material and Method: Study was prospective case-control.
Fifthy patients with smear & Culture positive tuberculosis have
been chosen randomly. They were matched with 54 healthy
controls with no history of TB.Polymorphism at 395 codon of IFN-
gR1 gene was detected with Newport method. Data were analyzed
with SPSS version 11.
Results:Mean age of patients and control were 55F 20 and 53F
13.5 years respectively. Demographic characteristic had no dif-
ference within two groups. (P-value N.05) one patient in case group
had heterozygote mutation at IFN-gR1 gene. In control group there
were no mutations.
Conclusion: Genetically susceptibility to TB is not in 395
codon of IFN-gR1 in Iranian TB sample and polymorphism of this
loci has occured in 2% of TB patients and 0.96% of total study
population.
Sa2.03. The Functional Activity of Specific Antibodies in
Progression of HIV-Infection.
Irina I. Andreeva.1 1Clinical of Immunology, Rostov State Medical
University, Rostov-on Don, Russian Federation.
Background. Polyclonal activation of B-lymphocytes is one of
the basic mechanisms of the HIV pathogenesis, however, the
resulting anti-HIV antibodies show no protective effects. In this
connection, it is expedient to study the functional properties of
antibodies, in particular, their affinity.
Methods. We observed 88 patients aged 25–45 and infected
with HIV-1, of which 42 patients were at the stage of generalized
lymphoadenopathy (LAP), 34 persons at the stage of pre-AIDS,
12- at the stage of AIDS. ELISA was used to determine the anti-
HIV antibodies titer, the degree of their affinity (AK).
Results. It was found that at the LAP stage the content of
immunoglobulins at this stage of disease was IgA-1,59 F 0,42g/l;
IgM-1, 02 F 0,20g/l; IgG-10, 90 F 1,26g/l, but the anti-HIV
antibody titer was lg 4,30 F 0,14, and the degree of their affinity
(AK) was 30F 6 units. As the HIV infection progressed at the pre-
AIDS stage the content of immunoglobulins was IgA-1.85 F
0.54g/l; IgM-1.11 F 0.12g/l; IgG-13.28 F 1.28g/l, as well as
increase of the degree of the anti-HIV specific antibodies lg.
4.94 F 0.11 accompanied by reduction of the degree of their
affinity AK was 50 F 9 units. As the HIV infection progressed at
the AIDS stage the content of immunoglobulins was IgA-1.05 F
0.34g/l; IgM-1.51 F 0.14g/l; IgG-10.15 F 1.16g/l, the anti-HIV
specific antibodies was lg. 4.00 F 0.05, accompanied by reduction
of the degree of their affinity- AK was 60 F 8 units.
Conclusions. Thus, the development of the infection process is
characterized by aggravation of the insufficiency of the functional
activity of the anti-HIV specific antibodies, confirmed by the
marked reduction of their affinity.
Sa2.04. Impairment of Recent Thymic Emigrants in
HCV Infection.
R. Cianci,1 M. Nasi,2 M. Pinti,2 S. Starnino,1 A. Florio,1 G.
Cammarota,1 A. De Luca,3 R. Cauda,3 A. Grieco,1 G. Rapaccini,1
G. Gasbarrini,1 A. Cossarizza,2 F. Pandolfi.1 1Internal Medicine,
Catholic University, Rome, Italy; 2Biochemical Sciences,
University of Modena, Italy; 3Infectious Diseases, Catholic
University, Rome, Italy.
Object: Virus C hepatitis (HCV) often has a more favorable
course in younger patients. Considering the involution of thethymic function with age, we investigated the output of recent
thymic emigrants in HCV patients.
Matherials and methods: To evaluate recent thymic emigrants,
we used a competitive quantitative PCR in order to determine the
percentages of cells with Cj-T cell receptor excission circles
(TREC). This study was performed in 13 HCV patients at diagnosis
and before any anti-HCV treatment. The results obtained in this
group were compared to those obtained in a gruop of 17 age-
matched controls.
Results: We found that in the 13 HCV patients naive for anti-
HCV treatment percentage of TREC was 3%. We could not detect
a correlation between the percentages of TREC and the patientsT
viremia. In contrast, in the 17 age-matched controls the percentage
of TREC detected by us was 6% (P = 0.02).
Conclusions: Our study describes a novel immune defect in
HCV patients. Additional studies are needed to get further insight
in the possible role of TREC defect in the pathogenesis and
prognosis of the disease.
Sa2.05. The Persistence of Allergen-Specific IgE and
Long-Lived Plasma Cells.
Elke O. Luger,1 Verena Fokuhl,1 Michael Wegmann,2 Harald
Renz,2 Andreas Radbruch.1 1DRFZ, German Rheumatism
Research Center, Berlin, Germany; 2Department of Clinical
Chemistry and Molecular Diagnostics, Philipps-University
Marburg, Marburg, Germany.
Background: IgE antibodies play a major role in the
pathogenesis of typ I allergies. As the half life of serum IgE
is short, plasma cells continuously have to secrete large amounts
of IgE to maintain the serum titers over long periods of time. It
is currently debated, whether IgE-secreting plasma cells are
short-lived end products of a chronic activation of B cells, or
long-lived, if maintained in supportive niches of the bone
marrow or in inflamed tissue. Method: We have analyzed
proliferation and lifetime of IgE-secreting plasma cells in an
ovalbumin (OVA)-specific, murine allergy model. The time point
of origin and the plasma cell turnover in the spleens, lungs,
lymph nodes and the bone marrow of OVA allergic mice were
determined according to incorporation of BrdU into DNA of
proliferating cells. Organs and sera were analysed using
ELISPOT, ELISA, fluorescence microscopy and flow cytometry.
Results: 4–6 weeks old mice were sensitized with OVA and then
continuously fed BrdU for 2 weeks, supplied via their drinking
water. 25% of IgE-secreting plasma cells in spleens of the OVA
allergic mice were BrdU-positive, indicating that they had
proliferated within the time of BrdU-feeding. 75% of the IgE-
secreting splenic plasma cells had been generated before that time
period and thus had a lifetime of more than 2 weeks. Anti-
proliferative, immunosuppressive therapy (cyclophosphamid) did
not eliminate the cells producing OVA-specific IgE antibodies,
indicating that the respective plasma cells are not dividing and
long-lived. Conclusion: IgE-secreting plasma cells can be long-
lived. These long-lived, IgE-secreting plasma cells provide
allergen-specific IgE independent of the presence of allergen and
are resistant to immunosuppression.
Sa2.06. Transmission Hepatic Electron Microscopic
Findings in Chronic Experimental Schistosomiasis
Mansoni after Praziquantel and an Antifibrotic.
A. M. Ahour,1 M. A. El khafif,2 S. I. Hassan,3 N. G. Nessim,3 N. M.
Amer,3 I. M. Ali.3 1Biochemistry Department, Ein Shams
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This study aims to evaluate the effect of a drug combination:
praziquantel (CAS 55268-74-1 EMBAY 8440, Biltricide), and an
antifibrotic agent (B_Amino Propionitrile Mono fumarate salt
(2079-89-2), upon the transmission hepatic Electron microscopic
findings in chronic experimental murine schistosomiasis mansoni.
In this study, a group of 40 Swiss albino mice was used. This group
was further subdivided into four small subgroups. Subgroup I:
constituted infected untreated challenged contol mice. Sacrifice was
done 13 weeks later, a time needed for the infection to develop into
a chronic one. Subgroup II: infected mice treated with praziquantel
500mg/Kg body weight, orally for two successive days, 13 weeks
post primary infection. Sacrifice was done 5 weeks later. Subgroup
III: infected mice given B-Amino Propionitrile daily as 5mg powder
in 0.5ml saline for 14 successive days. Sacrifice was done 18 weeks
post primary infection. Subgroup IV: mice given both PZQ +
BAPN. Sacrifice was done 18 weeks post primary infection.
Mice given Beta Aminopropionitrile (BAPN) alone, compared
to those given praziquantel solely, or in combination, revealed
amelioration in the mitochondrial changes, reappearance of the
cristae and absence of already deposited collagen. The nucleus
regained its regular nuclear membrane and condensed chromatin.
These changes were less evident in the other previously men-
tionned groups.
Key words: Chronic Schistosomiasis mansoni, Primary infec-
tion, challenge or secondary infection, Beta amino propionitrile,
Praziquantel., Transmission Electron Microscopy.
Sa2.07. Transmission Hepatic Electron Microscopic
Findings in Acute Experimental Schistosomiasis
Mansoni after Praziquantel and an Antifibrotic.
S. I. Hassan,1 I. M. Ali,1 N. G. Nessim,1 N. M. Amer,1 M. A. El
Khafif,2 Amin M. Ahour,3 M. M. Mohandes.4 1Parasitology
Department, Theodore Bilharz Research Institute, Guiza, Cairo,
Egypt; 2Biochemistry Department, Ein Shams University, Cairo,
Egypt; 3Parasitology Department, Ein Shams University, Cairo,
Egypt.
This study aims to explore the repercussions of a drug
combination: praziquantel (CAS 55268-74-1 EMBAY 8440,
Biltricide), and an antifibrotic agent (B_Amino Propionitrile Mono
fumarate salt (2079-89-2), upon the transmission hepatic Electron
microscopic findings in acute experimental murine schistosomiasis
mansoni.
In this study, a group of 100 Swiss albino mice was used. This
group was further subdivided into four small subgroups. Subgroup
I: infected untreated challenged contol mice Subgroup II: infected
mice treated with praziquantel 500mg/Kg b. weight, orally for two
successive days. Subgroup III: infected mice given B-Amino
Propionitrile daily as 5mg powder in 0.5ml saline for 14 successive
days. Subgroup IV: mice given both PZQ + BAPN. Sacrifice was
done twelve weeks post primary infection.
Mice given the combination regimen Praziquantel + Beta
Aminopropionitrile (PZQ + BAPN), compared to those given each
drug solely, revealed amelioration in some of the previously
swollen mitochondria with roughening of the endoplasmic retic-
ulum. Agaim, there was resorption of the previously deposited
collagen fibres in the intercellular matrix. These findings are the
main stigmata of hepatic cellular regeneration.These data were less
salient in mice given Praziquantel or Beta aminopropionitrile alone.Key words: Acute Schistosomiasis mansoni, Primary infection,
challenge or secondary infection, Beta amino propionitrile,
Praziquantel., Transmission Electron Microscopy
Sa2.08. Serum Transaminase Levels in Murine
Schistosomiasis Mansoni after Giving Praziquantel and
an Antifibrotic Agent.
A. M. Ashour,1 M. A. El Khafif,2 Soad I. Hassan,3 N. G. Nessim,3
I. M. Ali,3 N. M. Amer.3 1Parasitology Department, Ein Shams
University, Cairo, Egypt; 2Biochemistry Departemnt, Ein Shams
University, Cairo, Egypt; 3Parasitology Department, Theodore
Bilharz Research Institute, Cairo, Egypt.
This study is a trial to evaluate the effect of a combination
between an anthelmintic drug praziquantel (CAS 55268-74-1
EMBAY 8440, Biltricide), and an antifibrotic agent (B_Amino
Propionitrile Mono fumarate salt (2079-89-2). It is also a trial to
elucidate the repercussions of this drug combination upon worm
load and percent resistance to reinfection. Moreover, it aims to
study liver enzymes level (Alanine aminotransferase and Aspartate
amino transferase AlT & AST) in experimental murine schistoso-
miasis mansoni.
In this study, a group of 100 Swiss albino mice was used.
This group was further subdivided into six small subgroups.
Subgroup I: constituted infected untreated control mice. Subgroup
II: infected untreated challenged contol mice. Subgroup III:
challenged control mice. Subgroup IV: infected mice treated with
praziquantel 500mg/Kg b. weight, orally for two successive days.
Subgroup V: infected mice given B-Amino Propionitrile daily as
5mg powder in 0.5ml saline for 14 successive days. Subgroup
VI: mice given both PZQ + BAPN. Sacrifice was done 112–124
days post primary infection.
Mice given the combination regimen Praziquantel + Beta
Aminopropionitrile (PZQ + BAPN), compared to those given each
drug solely, revealed absence of worm recovery at perfusion, the
highest score of percent resistance to reinfection, and a 19.6+0.9 &
18.3+0.9 IU/L serum alanine aminotransferase & aspartate amino-
transferase levels respectively. These data were less salient in mice
given Praziquantel or Beta aminopropionitrile alone.
Key words: Chronic Schistosomiasis mansoni, primary infec-
tion, challenge or secondary infection, Beta amino propionitrile,
Praziquantel. Serum transaminase levels (ALT &AST).
Sa2.09. Effect of a Novel Muramyl Dipeptide Derivative
Together with Praziquantel in Experimental
Schistosoma Mansoni Infection.
S. S. Boutros,1 F. A. Ebeid,1 H. A. Ismail,2 N. G. Nessim.3
1Parmacology Department, Theodore Bilharz Research Institute,
Guiza, Cairo, Egypt; 2Immunology Department, Theodore Bilharz
Research Institute, Guiza, Cairo, Egypt; 3Parasitology
Department, Theodore Bilharz Research Institute, Guiza, Cairo,
Egypt.
The goal of this study, is to evaluate the effect of a
combination between an anthelmintic drug praziquantel (CAS
55268-74-1 EMBAY 8440, Biltricide), and a muramyl dipeptide
derivative Adamantylamide Dipeptide (AdDP) {CAS 768-94-5
(Amantadine)} in potentially tolerized Schistosoma mansoni
infected, egg-injected C57BL/6 mice. It is also a trial to elucidate
the repercussions of this drug combination upon worm and tissue
egg loads and oogram pattern. A group of 120 C57BL/6 mice
was used in the experiment. This group was further subdivided
into five small subgroups. Subgroup I constituted infected control
AbstractsS144mice. Subgroup II: received four intravenous doses (10ug each
via the tail vein) of soluble egg antigen (SEA) on days-7, -5, -3
and-2 before infection. Subgroup III: included infected mice
given AdDP 12 mg subcutaneously in 0.2 ml saline. Subgroup
IV: infected mice given Antigen (SEA) + AdDP. Subgroup V:
included mice given Antigen (SEA) + AdDP + PZQ(500 mg/Kg
for two successive days). Sacrifice was done 10 weeks post
infection.
Egg-injected mice given the combination regimen
Praziquantel + Adamantylamide Dipeptide (PZQ + AdDP),
compared to infected untreated control, revealed absence of worm
recovery at perfusion and 100 % dead ova in the oogram. Again an
evident reduction in the hepatic and intestinal tissue egg loads was
recorded in this group compared to infected untreated (wether egg
injected or not) control mice.
Key words: Schistosomiasis mansoni infection, Soluble Egg
Antigen, Adamantylamide Dipeptide, Praziquantel.
Sa2.10. Discovery of Neutralizing CpG ODN from
Serotype 2 and 5 Adenoviruse Based on the Relationship
between Free Energy and Bioactivity.
Zhou Hong,1 Wang Liangxi,1 Zheng Jiang,2 Ding Guofu,1 Liu
Wei.1 1Department of Pharmacology, Department of
Pharmacology, Chongqing, China; 2Medical Research Center,
Southwestern Hospital, Chongqing, China.
Large amount of CpG-S ODN as well as bacterial DNA could
trigger over inflammatory response, even sepsis. Therefore, it is
important to balance the activity of CpG-S ODN and reduce the
release of cytokines induced by CpG-S ODN. Despite compa-
rable levels of unmethylated CpG dinucleotides, DNA from
serotype 12 adenovirus (Adv12 DNA) is immunestimulatory, but
DNA from serotype 2 and 5 (Adv2 DNA, Adv5 DNA) are
nonstimulatory and can even inhibit activation by bacterial DNA.
Based on the above difference, Krieg found some neutralizing
CpG ODN (CpG-N ODNs). However, Zhao found above CpG-N
ODN had no inhibitory effects even when the concentration
ration reached to 10:1. Therefore, it seems the CpG-N ODNTs
sequences should be investigated further. In the present experi-
ments, we searched for CpG-N ODN in Adv2 and Adv5 DNA,
DNA after comparing the sequence differences between Adv2
DNA, Adv5 DNA and Adv12 DNA, Escherichia coli DNA (EC
DNA). Nineteen specific CpG motifs and 12-nucleotide sequen-
ces in Adv2, 5 DNA were ascertained after numbers and
frequencies of 256 kinds of CpG motifs in Adv2, Adv5,
Adv12 or EC DNA were calculated. However, none had been
found to have the properties of CpG-N ODN after their assays
on TNF-a release induced by CpG-S ODN. Accidentally, we
found there existed a relationship between free energy and
bioactivity. Therefore, putative CpG-N ODN were re-discovered
and investigated. We got six CpG-N ODNs with activity to
inhibit TNF-a release induced by CpG-S ODN. Among them,
CpG-N ODN208 was the strongest one. In our in vitro
experiments, CpG ODN208, without cellular toxicity, inhibited
TNF-a release from hPBMC or RAW264.7 induced by CpG-S
ODN in a dose- and time-dependent manner. In our in vivo
experiments, CpG-N ODN208 could markedly protect mice from
lethal challenge by CpG-S ODN and significantly decreased
TNF-a release in mice. Above results suggested that there
existed a relationship between free energy and bioactivity of
CpG-N ODN, and strong inhibitory CpG-N ODN could be
screened based on this kind of relationship.Sa2.11. Evaluation of IL-10 Serum Level in Visceral
Leishmaniasis.
Abdolvahab Alborzi, Manoochehr Rasouli, Abolfazl Khoshdel,
Simin Kiany. 1Clinical Microbiology Research Center, Shiraz
University of Medical Sciences, Shiraz, Fars, Islamic Republic of
Iran; 2Clinical Microbiology Research Center, Shiraz University of
Medical Sciences, Shiraz, Fars, Islamic Republic of Iran; 3Clinical
Microbiology Research Center, Shiraz University of Medical
Sciences, Shiraz, Fars, Islamic Republic of Iran; 4Clinical
Microbiology Research Center, Shiraz University of Medical
Sciences, Shiraz, Fars, Islamic Republic of Iran.
Background: Visceral leishmaniasis is a fatal disease, which is
caused by Leishmnia spp. After inoculation of promastigotes by
sand fly, some individuals can develop type-1 immune response
and control the infection, while others may be involved with acute
form of the disease. It seems that IL-10 can inhibit type-1 immune
response and cause more severe form of the disease. The aim of the
this study was to evaluate the IL-10 serum levels in the different
courses of the disease.
Methods: Thirty two patients with visceral leishmaniasis were
included in this study. Blood samples were collected from the
patients in three phases: at the time of diagnosis, after medical
therapy (when the patients became afebrile), and at the time of
discharge. Sera were separated and stored at -708C until cytokine
assay. IL-10 level was determined using ELISA method.
Results: The mean IL-10 serum levels were significantly
different in three phases of sampling (P = 0.002). The mean F SE
of IL-10 serum levels in three phases were 77.4 F 15.6 pg/ml,
55.8 F 18.6 pg/ml and 17.7 F 4.9 pg/ml, respectively.
Conclusion: According to our results higher levels of IL-10 at
the time of diagnosis may act as an inhibitory factor for cellular
immunity and have a role in the development of visceral
leishmaniasis. It seems that after medical therapy, IL-10 serum
level decreases significantly, which may be associated with
recovery.
Sa2.12. IL-10 Gene Polymorphisms and Susceptibility to
Brucellosis.
Simin Kiany, Manoochehr Rasouli, Mohammad Ali Dehyadegari,
Noredin Rafatpour, Abdolvahab Alborzi. 1Immunology of
Infectious Diseases Department- Clinical Microbiology Research
Center, Shiraz University of Medical Sciences, Shiraz, Fars,
Islamic Republic of Iran; 2Immunology of Infectious Diseases
Department- Clinical Microbiology Research Center, Shiraz
University of Medical Sciences, Shiraz, Fars, Islamic Republic of
Iran; 3Clinical Microbiology Research Center, Shiraz University of
Medical Sciences, Shiraz, Fars, Islamic Republic of Iran; 4Clinical
Microbiology Research Center, Shiraz University of Medical
Sciences, Shiraz, Fars, Islamic Republic of Iran; 5Clinical
Microbiology Research Center, Shiraz University of Medical
Sciences, Shiraz, Fars, Islamic Republic of Iran.
Background: Brucella spp. Is a gram-negative facultative intra-
cellular bacterium and causative agent of brucellosis. It is clarified
that type-1 immunity is important to control Brucella infection. In
this regard, macrophages have critical role. IL-10 is a Th2-type
cytokine that inhibit macrophage activation. It is known that
production of IL-10 is affected by its gene promoter polymorphisms.
In this study we investigated the relationship between IL-10 gene
promoter polymorphisms and susceptibility to brucellosis.
Methods: One hundred and ninety patients with brucellosis, 186
healthy individuals who were members of patientsT family and 82
Abstracts S145healthy animal husbandmenwho had infected animals withBrucella
were included in this study. All individuals were genotyped for three
bi-allelic IL-10 gene promoter polymorphisms at positions -1082(G/
A), -819(T/C), and -592(A/C) using PCR-RFLP.
Results: Genotype and allele frequencies of -592(A/C) and
-819(T/C) were significantly different between patients and
animal husbandmen groups (P b 0.05).
Conclusion: There are some reports showed that A allele at
position -592 of IL-10 gene is associated with lower IL-10
production in-vitro or in-vivo. According to the results, higher
frequency of A allele at position -592 in animal husbandmen may
cause these individuals more resistant to disease.
Sa2.13. Investigation of IFN-; Gene Polymorphism in
Visceral Leishmaniasis.
Simin Kiany, Manoochehr Rasouli, Abolfazl Khoshdel,
Abdolvahab Alborzi. 1Immunology of Infectious Diseases
Department- Clinical Microbiology Research Center, Shiraz
University of Medical Sciences, Shiraz, Fars, Islamic Republic of
Iran; 2Immunology of Infectious Diseases Department- Clinical
Microbiology Research Center, Shiraz University of Medical
Sciences, Shiraz, Fars, Islamic Republic of Iran; 3Pediatric
Infectious Diseases Department, Shiraz University of Medical
Sciences, Shiraz, Fars, Islamic Republic of Iran; 4Clinical
Microbiology Research Center, Shiraz University of Medical
Sciences, Shiraz, Fars, Islamic Republic of Iran.
Background: Although correlation between kala-azar disease
and several factors have been determined, some unknown factors
also exist that need to be recognized. Protective immunologic
response against leishmaniasis are characterized by a strong cell-
mediated immune response. IFN-g is an important component of
type-1 immunity. Since cytokine gene polymorphisms may
associated with different ability for cytokine production, the aim
of this study was to investigate the relationship between IFN-g
gene polymorphism and kala-azar.
Methods: We genotyped 122 patients with kala-azar, 63
patientsT siblings who were healthy, and 103 healthy individuals
who were resident in endemic area and had positive Leishmanin
skin test. Genomic DNA was extracted from blood samples and
IFN-g gene polymorphism at position +874 (T/A) was determined
by allele specific polymerase chain reaction (ASPCR) method.
Results: The frequency of TT genotype in patients was
significantly less than their siblings (22.1% and 30% respectively)
[P = 0.021], while no significant difference was detected between
patients and healthy individuals resident in endemic area (P = 0.35).
Discussion: Cell-mediated immune response is an effective
immunity against Leishmania and IFN-g play a fundamental role
in cellular immunity induction. The results showed that TT
genotype was increased in patients compared to their siblings.
Some researchers reported the association of IFN-g +874 TT
genotype with higher IFN-g production. Therefore, it seems that
higher production of IFN-g in patientsT siblings may help them to
be more resistant to infection.
Sa2.14. Polymorphisms of IL-10 Gene Promoter in
Patients with Kala-azar.
Manoochehr Rasouli, Simin Kiany, Abdolvahab Alborzi, Abolfazl
Khoshdel. 1Immunology of Infectious Diseases Department-
Clinical Microbiology Research Center, Shiraz University of
Medical Sciences, Shiraz, Fars, Islamic Republic of Iran;
2Immunology of Infectious Diseases Department-ClinicalMicrobiology Research Center, Shiraz University of Medical
Sciences, Shiraz, Fars, Islamic Republic of Iran; 3Clinical
Microbiology Research Center, Shiraz University of Medical
Sciences, Shiraz, Fars, Islamic Republic of Iran; 4Pediatric
Infectious Diseases, Shiraz University of Medical Sciences, Shiraz,
Fars, Islamic Republic of Iran.
Background: Visceral leishmaniasis is caused mostly by
Leishmania infantum in south of Iran. Manifestations range from
asymptomatic infection to fatal disseminated visceral disease.
Protective immune response against Leishmania is cell-mediated
immunity and it is known that IL-10 can down-regulate this kind of
response. Researchers showed that polymorphisms in IL-10 gene
promoter can regulate IL-10 production. The aim of this study was
to determine the relationship between IL-10 gene polymorphisms
and outcome of the disease.
Methods: One hundred and twenty pediatric patients involved
with kala-azar, 57 healthy individuals who were patientsT siblings
and 102 healthy individual who lived in endemic area without any
history of kala-azar or cutaneous leishmaniasis and with positive
Leishmanin skin test were included in this study. Polymorphisms
of IL-10 gene promoter (-1082G/A, -819T/C, -592A/C) were
determined using PCR-RFLP.
Results: There were no significant differences in genotype and
allele frequencies of investigated IL-10 gene polymorphisms
between the groups.
Conclusion: It is documented that protective immunity against
leishmaniasis is cell-mediated immunity. Therefore the presence of
Th2-type cytokines during the disease can worsen the condition of
the patients. Since the results showed no significant differences in
genotype and allele distributions between the groups, study of the
cytokine profiles and other cytokine gene polymorphisms are
recommended.
Sa2.15. Role of Regulatory CD25+CD4+ Cells during
Infection with Trypanosoma cruzi.
D. Golgher, R. Vasconcelos, R. Arantes, R. T. Gazzinelli.
1Departament of Biochemistry and Immunology, Universidade
Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil;
2Departament of Biochemistry and Immunology, Universidade
Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil;
3Departament of Pathology, Universidade Federal de Minas
Gerais, Belo Horizonte, Minas Gerais, Brazil; 4Departament of
Biochemistry and Immunology, Universidade Federal de Minas
Gerais, Belo Horizonte, Minas Gerais, Brazil.
During infection by Trypanosoma cruzi, the etiological agent of
Chagas disease, both cellular and humoral immune responses are
essential in controlling the parasitemia. While this immune
response is necessary for protection it is also responsible for the
morbidity caused by the infection. CD25+CD4+ regulatory cells
(Tregs) represent a unique lineage of T cells that have an important
role in controlling immune responses against self and foreign
antigens. We wanted to investigate if Tregs played any role in
controlling immune responses during T.cruzi infection. C57BL/6
mice were depleted of CD25+ cells (injected with monoclonal
antibody PC61) or were injected with an isotype matched control
(GL113) and infected with parasites of the strain Colombiana
(strain that elicits an intense myocarditis). Both groups were
evaluated for the amount of circulating parasites, mortality rate,
immunological parameters and histological analysis of the heart
throughout the course of the infection. Our results show that Tregs
have a role during infection by T.cruzi. Animals depleted of
AbstractsS146CD25+ cells had decreased levels of parasites in the bloodstream
and decreased mortality rate. This is associated with an augmenta-
tion of activated T cells and better production of pro-inflammatory
cytokines. CD25+ depleted animals also display a more severe
inflammation of the cardiac tissue when compared to control
animals.
Sa2.16. Dendritic Cell Mediated Immune Response
Is Impaired by the Mycobacterium tuberculosis
Mannosylated-LipoArabinoMannan.
N. Dulphy,1 J.-L. Herrmann,2 J. Nigoux,3 G. Puzo,3 D. Charron,1
P. H. Lagrange,2 A. Toubert.1 1INSERM U662, Institut
Universitaire dTHematologie; Hopital Saint Louis, Paris, France;
2Equipe dTAccueil EA3510, Faculte Lariboisiere-Saint Louis;
Universite Paris VII, Paris, France; 3Departement bMecanismes
Moleculaires des Infections MycobacteriennesQ, Institut de
Pharmacologie et de Biologie Structurale, Toulouse, France.
Both dendritic cells (DC) and natural killer (NK) cells have a
role in innate immunity against tuberculosis. Interactions between
M. tuberculosis and DCs have demonstrated either a constrained
survival or slight growth of the intracellular bacteria. Data of DC
maturation during M. tuberculosis infection are discordant. Similar
discrepancies were observed when studying NK interactions with
M. tuberculosis infected DCs, with either a killing of M. tuber-
culosis H37Ra (Brill et al. Infect. Immun. 2001) or an absence of
cytolysis of the infected DCs mainly due to a fully mature
phenotype (Ferlazzo et al. Eur. J. Immunol. 2003). One of the main
component playing a key role in DC-M. tuberculosis interaction is
the mannosylated-lipoarabinomannan (ManLAM), present at the
surface of the bacteria (Tailleux et al. J. Immunol. 2003). ManLAM
is one of the candidate ligand to DC-SIGN, a DC specific lectin
binding receptor, allowing M. tuberculosis entry inside DCs.
ManLAM may have a counteractive effect on DCs towards a fully
protective inflammatory response. Here, we investigated the
impact of ManLAM or PiLAM (LAM from M. smegmatis capped
with phosphoinositide residues) on DC maturation and function
using combined approaches of phenotyping, cytokines release, NK
cell activity and T-cell priming. In contact with ManLAM, DCs
displayed a pattern of partial maturation including the intermediate
expression of MHC class I and class II molecules and a low
expression of the costimulatory molecules CD80 and CD86
compared to fully LPS-matured DCs. They cannot be considered
as immature DCs because they lost their FITC-dextran phagocytic
activity. At the opposite, they do not present a fully matured
phenotype. Indeed, ManLAM-incubated DCs are still sensitive to
autologous NK lysis and are not able to prime naive T-cell
responses. Absence of NK lysis was noticed when ManLAM-DCs
were incubated with CD40 antigen, confirming a partial maturation
of DCs with ManLAM only and the need of a second signal to
complete maturation. Altogether, the overall effect could be an
impaired innate immune response towards M. tuberculosis.
Sa2.17. Inflammatory Response and Apoptosis of
Polymorphonuclear Neutrophils by Prevalent Strains of
Mycobacterium tuberculosis.
Pokkali Supriya,1 Rajavelu Priya,1 Das Sulochana.1 1Department
of Immunology, Tuberculosis Research Centre, Chennai, Tamil
Nadu, India.
Background: Macrophages and Polymorphonuclear Neutro-
phils (PMN) are the professional phagocytes involved in anti-
bacterial defense. The PMN influx, the first line of defense, occursas the early response to curtail the mycobacterial infection.
Chemokines stimulate the migration of PMN from circulation to
the site of infection. Mycobacterium tuberculosis (M.tb) induced
activation leads to proinflammatory response and apoptosis of
PMN. Objective: We characterised two prevalent strains of
Mycobacteria (S7 and S10) showing differential immune response
in PPD positive population. Here, we aimed to study the efficacy of
these strains to induce apoptosis and modulate the expression of
surface molecules and cytokine secretion in PMN of TB patients.
Methods: PMN were isolated from RBC pellet obtained from
Ficol-Hypaque gradient centrifugation and further subjected to
sedimentation in 3% Dextran. PMN were infected with various
mycobacterial strains (S7, S10, and H37Rv) at Multiplicity Of
Infection (MOI) of 3:1 and incubated for 3 and 18hrs. The
Phagocytic index, percentage of apoptotic Neutrophils (Annexin
V-FITC positive by FACS), cell phenotypes (CD16 and CD69 by
FACS) and cytokines (TNF-a and IL-1b by ELISA) were assessed.
Results: A significant increase in Annexin V positive cells with
corresponding decrease in CD16 and CD69 expression was
observed with S7 and S10 strains when compared to uninfected
control after 3hrs of infection. Further decrease in CD16
expression was observed at 18hrs but no significant change in
Annexin V positivity. When compared to H37Rv, S7 showed high
CD16 expression at both the time points but high CD69 expression
only at 3hrs. Conclusions: Clinical strains down-regulated CD16
expression and inhibited de novo synthesis of an early activation
marker, CD69 on TB-PMN. These strains also showed a
significant increase in apoptosis after infection thereby reducing
the number of phagocytes and escaping from the intracellular lytic
microenvironment. Thus clinical isolates were able to inhibit the
early activation of Neutrophils and thin out the killing mechanisms
for their own survival.
Sa2.18. Comparison of Regional and Systemic Humoral
Immune Response to a Parasitic Infection.
C. H. Wang,1 S. D. Wagner,1 H. Montalvo, Jr.,1 C. L. Hauschild,1
A. M. Vanhoose.1 1Biology, California State University Channel
Islands, Camarillo, CA, USA.
The kinetics of humoral immune response against Trichinella
spiralis (TS) were characterized with immunofluorescence assay.
The mesenteric lymph nodes (MLN) and the spleen of infected rats
were examined for concurrent expression of multiple antibody
(Ab) isotypes from day 1 to day 15 after infection. The tissues were
processed and stained with either a pan-B cell marker (OX33)
conjugated with rhodamine (XRITC) or combinations of dual
monoclonal Ab probes plus secondary Ab conjugated with XRITC
or fluorescein (FITC). As compared to the uninfected controls, the
MLN and the spleen showed significant proliferation of dual-Ab
expressing B cells (Debc) on days 7 and 10 respectively, with the
regional immune response proceeding ahead of the systemic
response. During the immune response, only minimal numbers
of B cells expressed single Ab isotype while most B cells
expressed more than one isotypes of Ab. When combining all
the numbers of Debc within each tissue for each of the respective
days, and comparing those numbers with the total numbers of B
cells that were OX33+ in the serial sections of the same tissue
specimens, the combined Debc in the spleen were N6 times higher
than OX33 labeled B cells on day 10, and the Debc in MLN were
N 3 times higher than OX33+ B cells on day 10. Our results thus
indicate that the Debc were most likely expressing more than two
isotypes on the surface during the peak days of the humoral
Abstracts S147immune response to the pathogen and such phenomenon occurred
in both immunologic tissues.
Sa2.19. Co-Administration of Corticosteroids (CS) with
Anti-Tuberculous Drugs (ATD) in Tuberculous
Menangitis Had Not Only Reduced the Intra- Cranial
Pressure Symptoms, Also Had Increased PatientTs
Compliance.
M. Ishaq, I. M. Sameera. 1Allergy/Pulmonology, Al-Junaid
Hospital, Nowshera, Pakistan.
Purpose: Patients with tuberculous meningitis, under ATD
regimen alone though had been associated with an improvement in
the clinical manifestations, but still there been sporadic incidences
of residual manifestations on completion of ATD, concerning
cerebral edema from chronic inflammatory changes of tuber-
culoisis.Cncomitant administration of (CS) had significantly
improved the clinical outlook.
Methods: Patients with tuberculous meningitis, complaining of
evening rise of temperature & manifestations from raised intra-
cranial pressure i.e, confusion,anorexia,diffuse head ache, irrita-
bility lethargy, on ophthalmoscope there had edema of the optic
disc, then one group of(n = 8) patients had been medicated with
(ATD) alone(ATD-) another group of (n = 10) patients with (ATD)
& (CS)(ATD+). For adultTs prednisolone 40mg/day in divided dose
for 7–10days followed by 20mg/day in divided dose, then tapering
the dose according to the therapeutic response by 5 mg weekly for
8–9weeks.For children prednisolone 1–2mg/kg body weight for 7–
9weeks. In another trials Dexamethasone in dose of 0.15mg/kg
body weight four times/day for 1–2weeks, then discontinued in a
tapering fashion over 4weeks had been also found beneficial. On
completion of the treatment, Patients with (ATD+) had a uniform
therapeutic response with almost insignificant incidence of residual
symptoms, where as Patients with (ATD-) alone comparatively
been associated with occasional head ache, altered sensorium etc.
Results: (CS) in the therapeutic trials had the beneficial role of
resolving portentous CSF resulting from inflammatory changes.
also had improved patients compliance concerning intake of
(ATD).
Conclusions: From the later on follow up of patients, there was
no incidence of relapse in either group, but (n = 2) patients treated
with (ATD-) still had been medication for head ache & convulsion
etc.
Clinical Implications: Patients with (ATD+) had been pro-
vided with steroid medication card on completion of treatment.
Sa2.20. Relationship Study between the Status of Innate
Immunology and the Infection of SARS.
Wang Haibin.1 1Dept. of Clinic Immunology, 302 Hospital,
Beijing, Beijing, China.
Objectives: To investigate the rrelationship between the status
of innate immunology and the infection of SARS. Methods The
persons including of following six groups have been studyed.
Group A, 4 cases of the doctors or nurses who contacted closely
with SARS patients without careful prevention but not infected.
Group B, 3 cases of the doctors or nurses who were infected by
SARS in the working despite with careful prevention. Group C,8
cases of pneumonia who was treated in hospital with SARS
patients but no SARS; Group D, 22 intensive SARS patients;
Group E, 36 mild SARS patients and Group F, 21 cases of
healthy children who have no antibody responses with HBsAg
injection. The machine of Array 360 has been used to detect thegross of IgM, IgG and IgA in plasma. The lymphocytes subtype
of CD3, CD4, CD8 and CD56 have been assayed by flow
cytometer. The number of CR1 on erythrocyte was detected by
cell-ELISA. PCR and RFLP have been used to analysis the
genomic density polymorphism of ECR1. The immune reactivity
of lymphocyte to foreign antigen will be observed by dynamic
microscope. Results: The gross of IgM, IgA and IgG Group A,
C and F are all in lower level than that of normal individuals,
especially in IgM (P = 0.0014), and the reactivity of their
lymphocyte to antigen is also in lower levels. The percent of NK
cells is significantly higher than that of normal. By contrary, the
levels of IgM in group B, D and E are significantly higher than
normal individuals, and their lymphocytes are easily destroyed by
antigen stimuli. The numbers of CD3/CD4/CD8 are all in low
levels. The number of ECR1 in intensive SARS patients are
significantly lower than that in mild SARS patients but the former
CR1 are most in HH genotypes. Conclusion: There is significant
relationship between the higher immune responses and the SARS
infection. The immune destroy may be the main pathogenesis of
SARS.
Sa2.21. A Safe Nanoemulsion Adjuvant Produces a
Killed-Virus Nasal Vaccine for Smallpox.
A. U. Bielinska, K. W. Janczak, J. J. Landers, J. R. Baker, Jr.
1Internal Medicine and Center for Biologic Nanotechnology,
University of Michigan, Ann Arbor, MI, USA.
Rationale: Current, live virus vaccines for smallpox have
unacceptable side effects. We use nanoemulsions (NEs), a soy-oil
based antimicrobial with virucidal activity toward Vaccinia Virus
(VV), as an adjuvant for a killed virus nasal vaccine. The
nanoemuslion works by first removing viral envelope proteins
then triggering phagocytosis of the proteins into antigen presenting
cells in the mucosa.
Methods: A NE approved for human use was mixed with VV
(Western Reserve serotype). Mixtures of NE and VV were applied
to the nares of mice. Systemic and mucosal antibody and cellular
immune responses were then evaluated, and animal sera were
tested for the ability to neutralize virus.
Results: A brief incubation with 10% nanoemulsion led to
greater than a six-log reduction of virus titer. EM analysis
suggested the NE disrupted the viral lipid membrane. Anti-VV
mucosal IgA and serum IgG were detected three weeks after a
single intranasal administration of NE/vaccinia mixture, and the
immune response was optimized in animals vaccinated 2–3
times. High titers of VV neutralizing antibodies were detected
in mice immunized with NE-killed virus. Virus-specific Th1
immunity (INFg production) was observed in splenocytes from
immunized animals. No evidence of protective immunity was
observed in control animals immunized with formalin-killed
virus. No animal had evidence of viral replication after
vaccination, documenting the complete inactivation of the virus
by NE.
Conclusions: VV inactivated by NE is immunogenic and can
serve as a killed virus mucosal vaccine for small pox. The presence
of NE is necessary for the development of robust protective
mucosal and systemic immunity.
Sa2.22. Novel Pan-DR Binding T-Cell Epitopes of
Adenovirus Induce a Mixed Profile in Healthy Donors.
L. M. Haveman,1,2 M. Bierings,1 M. R. Klein,1,2 S. Albani,2,3 B. J.
Prakken.1,2 1Department of Pediatric Immunology, Wilhelmina
AbstractsS148ChildrenTs Hospital / University Medical Center, Utrecht,
Netherlands; 2IACOPO Institute, University of California, San
Diego, USA; 3Department of Pediatrics, University of California,
San Diego, USA.
Background
In the immunocompromised host adenovirus can cause fatal
infections, especially after stem cell transplantation. No specific
antiviral therapy of proven value currently exists for severe
adenoviral infection. A potential form of treatment is adoptive
therapy infusing adenovirus specific T-cells from the donor. The
aim of the study was to identify target epitopes of adenovirus and
to capture and characterize adenovirus specific T-cells.
Methods
Eleven proteins of adenovirus type 5 were selected. By using a
computer algorithm designed to predict HLA pan-DR binding T-
cell epitopes, we selected 19 peptides based on predicted high
affinity to multiple HLA-DR alleles and a high degree of
homology with other adenovirus serotypes. Peripheral blood
mononuclear cells (PBMCs) from 26 healthy adults were isolated
and incubated with these peptides. Proliferation expressed as
Stimulation Index (SI) was determined. Six peptides with highest
SI were selected. In ten subjects the cytokine and chemokine
profile induced by these epitopes was determined with Multiplex
Immuno-assay (MIA). In addition PBMCs were cultured with
complete inactivated adenovirus and restimulated with the different
peptides. Subsequently, with MIA cytokine production was
measured. Moreover, with the use of T-cell capture method1 and
FACS-sorting it was possible to induce and capture adenovirus
specific T-cells. With polymerase chain reaction (PCR) character-
ization of adenovirus specific T-cells was performed.
Results
Six pan-DR binding epitopes of adenovirus were selected based
on a positive proliferation response in a large percentage of donors,
namely E1B protein (65% of donors), 2 peptides of hexon protein
(58% and 73%), DNA-polymerase (57%), E3A-glycoprotein (46%)
and fiber protein (34%). These epitopes induced a predominant pro-
inflammatory cytokine and chemokine profile. Also after culturing
with complete inactivated adenovirus and restimulation with the
adenoviral peptides, cytokine profile showed a pro-inflammatory
pattern, suggesting that peptides are naturally processed. By using
T-cell capture method adenoviral peptide specific CD4+ T-cells
were identified and sorted. Preliminary data show that such
adenovirus specific T-cells display a high expression of TGF-1
beta, IFN gamma and Tbet (Th1 response), but remarkably also
expression of GATA3 and IL10 (Th2 response).
Conclusion
With a pan-DR binding computer algorithm it was possible to
identify HLA-class II restricted T-cell epitopes of adenovirus type
5. These peptides induce a predominant pro-inflammatory cytokine
profile and also seem to be naturally processed. With T-cell capture
method it was possible to capture and characterize the adenovirus
specific T-cells. This is an important step towards adoptive
immunotherapy by infusion of adenovirus specific T-cells.
1 Prakken, B.et al. Artificial antigen-presenting cells as a tool to
exploit the immune dsynapseT. 2000 Nat.Med 6.12:1406-10.
Sa2.23. Naturally Occurring Breakdown Products of
Inflammation, Generated in Inflammatory Sites,
Functioned as Down-Regulator of Inflammation.
Liora Cahalon,1 Zvi Landau,2 Raanan Margalit,1 Arie Admon,3
Tamar Ziv,3 Alexandra Zanin-Zhorov,1 Ofer Lider.1 1Immunology,Weizmann, Rehovot, Israel; 2Internal Medicine bDQ, Kaplan
Medical Center, Rehovot, Israel; 3Biology, the Smoler Proteomic
Center, Technion, Haifa, Israel.
Inflammation usually occurs in extravascular tissues following
the invasion of micro-organisms, such as bacteria, to the body.
These sites also contain immuno-modulators (e.g., chemokines,
cytokines, acute phase proteins), and leukocyte-derived extracel-
lular matrix-specific enzymes, such as heparanase and elastase,
which can modify the composition of the tissue, and probably also
degrade certain inflammatory mediators, thus yielding putative
bioactive products. We postulate that these new small molecular
weight mediators can exert effector functions needed to evoke or
terminate inflammation.
Herein, we identified novel immunoregulatory compounds in
the degraded products of human body fluids, especially in wound
fluids of chronic leg ulcers of diabetic patients. Thus far we were
able to isolate and identify several amino acid sequences and
synthesized, and examined them in vitro and in vivo. Among these
peptides, two are derived from apolipoprotein A-1 and two from
fibrinogen. Treatment of purified human T cells with these peptides
down-regulated nuclear factor-nB activity and reduced the
secretion of TNF-a and interferon-g. In vivo, these peptides
markedly inhibited DTH reaction and ConA-induced hepatitis in
mice. We suggested that these peptides may terminate inflamma-
tory reactions by transmitting negative signals to the inflammation-
inducing leukocytes.
Our results indicate that by using this approach we may have
found a first set of such novel anti-inflammatory peptides. We hope
that such peptides can be used to down-regulate inflammatory
reactions in vivo in human patients suffering from chronic
inflammatory diseases.
Sa2.24. The Inflammatory & Immunological Complex
Clinical Presentation of Mycoplasmal Infection in School
Children.
M. Ishaq, I. M. Sameera. 1Allergy/Pulmonology, Al-Junaid
Hospital, Nowshera, Pakistan.
Purpose: Outbreaks of mycoplasma infection had been
associated in school children/camps at early and late winter
seasons, sometimes with a considerable number of hospital
admissions & loss of school days amongst children & adolescents.
Methods: In an under developed community with bunch of
schools, children& adolescents age 5–16 years mean age10 F .5
years. Presenting features i.e,raised temperature 95% cases,
malaise 85–90%, cough 80–85, headache 80%, medium to fine
rales 60–65%. On Laboratory investigation were leucocytosis
(10,000–20,000/m3) 20–30% cases, raised ESR, variable Pulmo-
nary segmental/lobar consolidations seen, cold agglutinin level
1:4-1:256 titer appears in blood of 50% of children, most of the
cases had raised indirect of fluorescent antibody in the range of
1:10–1:320. Also isolation of organisms i.e. M. Pneumoniae.
Results: Ignored/late treated cases from the distant locations,
almost 0.1–0.9% had transverse myelitis, encephalitis menango-
encephalitis proved by CSF, PCR, culture studies. Hematological
complications, 0.5–1% had thrombocytopenia, hemolytic anemia,
and renal failure. Cardiac complications i.e. myopericarditis,
haemopericardium heart block, 0.02–0.1% etc; 2–4% with
mucocutaneous manifestations,i.e, erythematous maculopappuler
erruptions, steven jhonsonTs syndrome, 4–5% with joint manifes-
tation i.e. mimicking rheumatic arthritis. 10–20% of complicated
cases had nausea, vomiting, altered bowel habits, etc;
Abstracts S149Conclusions: Mycoplasma infection is a contagious disorder
resulting from substandard hygienic living, poor school health
(failure of provision of well ventilated classrooms/Isolation of
infected cases) etc;
Clinical Implications: Mycoplasma pneumonia is held respon-
sible for 20% cases of community acquired pneumonia.
Sa2.25. Yeast Cells Activation Method of Hemaimmune
Reaction Road Map Experimental System.
Guo Feng. 1Department of Blood Tansfusion, Changhai Hospital
Second Military Medical University, Shanghai, China.
Objective: To establish a experimental system of war against
yeast cells in hemaimmune reaction road map.
Methods: 0.2ml suspension of yeast cells (5I´108/ml) (or 0.2ml
NS as control) were added into 0.2ml fresh anticoagulant (citric
acid) whole blood or 0.2ml white blood cells, added 0.3ml plasma
(or 0.3ml NS as control), and incubated for 1h at 378. Further
more, we added 0.2 ml red blood cellls into the tube above-
mentioned respectively, and incubated for 1h at 378. The
hemaimmune reactionary activity was assessed by checking blood
cell adhering rate to yeast cells, CD35, DARC (Fy6), CXCR4, IL-
8, IL-6, CD25, gene activation (Fy6 gene) et al.
Results: Yeast cells can activate hemammune reaction road
map experimental system showing change of various indexes.
Yeast cell activation method will be a useful method to study the
relationship between whole blood cells and plasma and the
relationship between red blood cells and white blood cells in
hemaimmune reaction.
Conclusion: It can provide a useful method for innate and
adaptive immunity study and for immune regulation study and for
the theory study of hemaimmune reaction road map in clinic.
Sa2.26. Phage Display Epitope Study of Two
Toxins Produced by Enteroaggregative Esherichia coli
That Cause Pediatric Diarrhea: Identification and
Characterization of Antigenic and
Immunogenic Mimotopes.
T. G. Gazarian,1 U. Hernandez,1 J. Villaseca,1 K. G. Gazarian,2
C. Eslava.1 1Department of Public Health, Faculty of
Medicine,UNAM, Mexico City, DF, Mexico; 2Department of
Molecular Biology and Biotechnology, Institute of Biomedical
Research, Mexican National University, Mexico City, DF, Mexico.
In earlier publications from this laboratory, two toxins a of
104kDa (Pet) and other of 114 kDa (Pic), members of the SPATES
(serine-protease autotransporters from enterobacteriaceae) family
were described as molecular agents associated with pediatric
diarrhea caused by Enteroaggregative E.coli, especially in devel-
oping countries. Despite different location of their genes, in the
chromosome (Pic) and in a plasmid (Pet), the proteins showed a
high level of sequence identity. Both proteins have been identified
in the same patient and are immunogenic, however, neither their
epitopes nor immunological relationships with each other and with
the disease are known. Collections of peptides with properties of
immunodominant epitopes that elicit the immune responses in
patients, would be very beneficial for the research advancing into
the immunology of the proteins and their relationships with the
disease. To the identification of such peptides we screened gp3
random phage-display linear and constrained libraries with sera of
patients and with rabbit antisera obtained against Pet and Pic
proteins. The screening of two highly complex phage libraries
resulted in collections of peptides sharing well-defined consensusmotifs. Although the motifs did not show similarity to the proteins,
the carrying those peptides phage were reactive with sera and
induced in mice and rabbits antibodies reactive against Pet and Pic
in ELISA and in denaturing Western blot. The results indicate that
they mimic epitopes containing immunogenic determinants that do
not loss their antigenic activity upon denaturation. In addition, the
anti-sera against Pet-related peptides showed a cross-reaction with
the Pic, and vice versa, i.e. both toxins are not only structurally but
also immunologically similar. We conclude that the peptides from
phage libraries specific to epitopes of these enterotoxins allow
further elucidation of their roles in the pathogenesis of diarrhea and
are useful in laboratory diagnosis of patient sera. In the ongoing
experiments the peptides with best immunogenic and antigenic
potentials are used in serological studies of patients and for their
ability of inducing neutralization-effective responses in animal
models.
Sa2.27. The Combined Modulation of Nicotine and
Chlamydia Heat Shock Protein on Cell Proliferation
and Apoptosis in HEp-2 Cells.
A. I. Hakki, A. Radwan, H. Friedman, S. H. Pross. 1Medical
Microbiology & Immunology, MDC-10, Colloge of
Medicine-University of South Florida, Tampa, FL, USA.
Nicotine, the major active component of tobacco, has been
reported to modulate the process of inflammation and apoptosis.
Chlamydia pneumoniae (Cpn), an obligate intracellular pathogen,
is a common cause of respiratory tract infections worldwide and
has been considered among other risk factors involved in coronary
artery disease. Cpn- infected cells have been reported to be
resistant to apoptosis, but it is not clear what component of Cpn is
responsible for this action. The present study investigated the role
of both nicotine and Chlamydia heat shock protein 60 (cHsp-60)
individually and in combination on viability, proliferation and
apoptosis in human epithelial cell line (HEp-2). The results of these
studies showed that treatment of HEp-2 cells with nicotine
significantly increased cell count and viability compared to the
untreated controls. Treatment of HEp-2 cells with cHsp-60 did not
result in significant changes in cell count and viability. Interest-
ingly, when apoptosis was induced in HEp-2 cells with TNF-alpha,
cHsp-60 did in fact significantly increase cell count and viability.
In order to ascertain whether this increase reflected a protection
against apoptosis, caspase activity was assessed. Results showed
that active caspases were down-regulated in cells treated with
either nicotine or with cHsp-60. Combined treatment with both
nicotine and cHsp-60 resulted in even further down-regulation of
active caspases. The anti-apoptotic action of nicotine was blocked
by D-tubocurarine chloride, a nicotinic receptor antagonist. The
high prevalence of Cpn infection and the ready availability of
nicotine in the population lead to concerns about possible
combined exposure to both agents. The impact of the combined
exposure to nicotine and cHsp-60 on parameters of immune status,
in both normal and immunocompromised hosts, warrants further
investigation.
Key Words: Nicotine, cHsp-60, HEp-2 cells, apoptosis
Sa2.28. Circulating VD1 and VD2 T Cells in
HIV-1-Infected Patients: Response to CXCR3 and
CXCR4 Ligands and to HIV-1 Tat.
A. Poggi,1 D. Fenoglio,2 G. Murdaca,2 M. Setti,2 F. Indiveri,2 M.
R. Zocchi.3 1Oncogenesis, Laboratory of Immunology, National
Institute for Cancer Research, Genoa, Italy; 2Department of
AbstractsS150Internal Medicine, Laboratory of Clinical Immunology, University
of Genoa, Genoa, Italy; 3Department of Internal Medicine,
Laboratory of Tumor Immunology, San Raffaele Scientific Institute,
Milan, Italy.
Twentyeight HIV-1-infected patients, in the stage A of the
disease, according to the CDC (Center for Disease Control,
Atlanta) criteria, have been studied. We found in 18 out of
28 patients an increase in the number of circulating Vy1 T cells
(3–9%) of T lymphocytes (healthy donors: 1–3%). Three of these
patients also displayed an increased number of peripheral Vy2 T
cells (4–6% vs 2–3% in healthy donors). Moreover, Vy2 T cells
were CXCR3bright and CXCR4dull, while among the Vy1 subset
50% of the cells were CXCR3- and CXCR4+. Vy1 and Vy2 T cell
clones transmigrate across endothelial monolayers in response to
interferon-g inducing protein-10 (IP-10/CXCL10) and stromal-
derived factor-1 (SDF-1/CXCL12) according to the expression of
the specific receptors CXCR3 and CXCR4. In a fraction (10%) of
Vy1 T cell clones coexpressing CXCR3 and CXCR4, the
homeostatic chemokine 6Ckine/SLC (CCL21) was more effective
than IP-10/CXCL10 in driving transendothelial migration of Vy1
CXCR3+ cells, while Vy2 CXCR3+ cells were driven more
efficiently by IP-10/CXCL10.
IP-10/CXCL10 or 6Ckine/SLC/CCL21 and SDF-1/CXCL12-
induced transmigration were inhibited by the phosphoinositide-3
kinase (PI-3K) blockers wortmannin and LY294002, supporting
that CXCR3 and CXCR4 are coupled to PI-3K. This was further
confirmed by the activation of the PI-3K-dependent serine kinase
Akt/PKB obtained upon ligation of CXCR3 and CXCR4. In
addition, occupancy of CXCR3, but not of CXCR4, led to
CAMKII activation; accordingly, the CAMKII inhibitors KN62
and KN93 could decrease IP-10/CXCL10 and 6Ckine/SLC/
CCL21-driven transmigration. Finally, we show that HIV-1
protein Tat, which can be found in the sera of these patients,
interferes with the chemotactic activity of IP-10/CXCL10,
6Ckine/SLC/CCL21 and SDF-1/CXCL12 and that the inhibition
is due to the cystein-rich domain of the protein, which contains
CXC and CXC chemokine-like sequences. This mechanism may
contribute to the redistribution of the two gy T cells subset, the
resident increasing in peripheral blood in early AIDS and
removed from intestine in the advanced disease, supporting the
importance of gy T cells in the first defence against HIV-1
infection.
Sa2.29. Adenovirus Capsid Hexon Is the Main Target
Protein of Adenovirus-Specific CD4+ T-Cells That
Display a Th1 like Cytokine Profile in Healthy Adults.
O. Arbach,1 M. Frentsch,1 B. Chmielewicz,2 M. Kaiser,3 H.
Ellerbrok,2 R. Lauster,4 A. Radbruch,1 A. Scheffold,5 A. Thiel.1
1Clinical Immunology Group, German Rheumatism Research
Center, Berlin, Germany; 2Robert-Koch-Institute, Berlin,
Germany; 3GenExpress, Berlin, Germany; 4Molecular Biology,
German Rheumatism Research Center, Berlin, Germany;
5Immunomodulation Group, German Rheumatism Research
Center, Berlin, Germany.
Adenovirus infections are usually harmless in healthy children
and adults but are serious and potentially fatal in immunocompro-
mised individuals. Like for CMV and EBV-infections, adoptive
transfer of specific T-cells is also discussed for adenoviral
infections. However, the main adenovirus derived antigenic target
of adenovirus-specific T-cell responses has yet to be defined. We
here identified the main immunodominant protein of the adenovi-rus-specific CD4+ T-cell response and functionally characterized
adenovirus-specific CD4+ T-cell with respect to their cytokine
profile. Three major adenoviral proteins including two structural
capsid proteins (hexon, penton, polymerase) were recombinantly
expressed. CD4+ T-cell-lines specific for the entire set of
adenovirus-derived proteins were generated after stimulation of
PBMC from healthy adults with adenovirus-lysate 3 (Ad-Lys3)
according to antigen-induced CD154 surface expression. Specific-
ity of adenovirus-specific CD4+ T-cell-lines was evaluated after
restimulation with Ad-hexon, Ad-penton, Ad-polymerase accord-
ing to intracellular expression of CD154. Direct qualitative cytokine
profile of Ad-specific CD4+ T-cells was assessed after short-term
stimulation of whole blood of healthy adults with Ad-hexon and co-
expression analysis of CD154 with IL-2, IL-4, IL-10, TNFa and
IFNg. Ad-Lys3-specific CD4+ T-cell-lines can easily be generated
according to CD154-expression and showed high specificity for the
adenovirus derived hexon capsid protein. Only a few Ad-Lys3
specific CD4+ T-cells responded to Ad-penton and none to Ad-
polymerase. Qualitative assessment of the cytokine profile of Ad-
hexon specific Th-cells proved a Th1-like profile with no IL-4
expressed and dominant expression of TNFa and IFNg. Hexon
capsid protein is the main target protein of the adenovirus-specific
CD4+ T-cell response in adults that is characterized by a Th1-like
cytokine profile. Our results envisage that Adenovirus-derived
hexon protein is a candidate antigen for ex vivo generation of
adenovirus-specific T-cells in cellular therapies.
Sa2.30. Identification of SARS T Cell Epitopes Using the
iTopiak Epitope Discovery System.
C. A. Johnson,1 J. Chang,1 C. M. Cameron,2 D. J. Kelvin,2 L. R.
Lofaro,1 K. R. Bray.1 1Clinical Research and Development,
Beckman Coulter, San Diego, CA, USA; 2Division of Experimental
Therapeutics, University Health Network, Toronto, Canada.
Objective: SARS is a severe infectious disease caused by a
virus identified through gene sequencing and serological analysis
as a new strain of human coronavirus. SARS coronovirus (SARS-
CoV) causes severe acute respiratory symptoms in patients and
results in a high mortality rate. Antigenic peptides recognized by
SARS virus specific CTLTs are useful tools for studying the CTL
responses during infection enabling researchers to better monitor
disease and develop T-cell mediated vaccines. In order to identify
potential immunogenic epitopes from the SARS N-protein, we
used Beckman CoulterTs iTopia Epitope Discovery System* to
analyze the protein across 8 MHC Class I alleles.
Materials and Methods: The iTopia Epitope Discovery System
was used to screen the SARS N protein by analyzing all overlapping
nonamers (414 peptides) across 8 different HLA-A/B alleles:
HLA*A0101, HLA*A0201, HLA*A0301, HLA*A1101,
HLA*A2402, HLA*B0702, HLA*B0801, HLA*B1501. The pep-
tide binding assay is the first assay in the system and is a rapid
screening of all test peptides across all 8 alleles. All identified
binders are further characterized with the ED50 Affinity and Off
Rate dissociation assays. The previously identified binders are
serially diluted and analyzed in the Affinity assay. An ED 50 value
is determined and represents the concentration of peptide needed to
achieve 50% binding. These same binders are also analyzed in the
Off Rate assay. Peptides are incubated for up to 8 hrs and time
points are taken at specified intervals. Results are analyzed using a
one phase exponential decay curve and are expressed as t 1/2 value
in hrs representing the amount of time needed to achieve 50%
dissociation of the peptide from the MHC complex. The Off Rate
Abstracts S151and Affinity values for each test peptide are evaluated using a multi-
parametric calculation to generate an iScore. This iScore allows
peptides to be systematically ranked for subsequent functional
studies. These newly identified peptides can be used to manufacture
HLA Class I iTAg MHC tetramers which are an important tool to
visualize and quantify the precise in vivo SARS CTL response.
Results: Identification of SARS candidate epitopes are as
follows: 6 epitopes for HLA*A0101, 30 epitopes for HLA*A0201,
18 epitopes for HLA*A0301, 28 epitopes for HLA*A1101, 37
epitopes for HLA*A2402, 18 epitopes for HLA*B0702, 7 epitopes
for HLA*B0801 and 27 epitopes for HLA*B1501. Based on
iTopia rankings of candidate epitopes, SARS iTAgk MHC
Tetramers were manufactured and used to stain cryopreserved
PBMCTs from SARS infected donors.
Conclusion: Using the iTopia Epitope Discovery System, the
SARS N protein (422 amino acids) was screened and potential
immunogenic epitopes were identified based on experimental
binding, affinity and off rate determinations. SARS results
demonstrate the capacity of the iTopia system to screen large
number of MHC Class I restricted peptides and prioritize the
epitopes with greatest potential for producing an immune
response.
* For Research Use only; not for use in diagnostic procedures
Sa2.31. Leishmania Infection in Two Twins, Association
to Perforin Defect.
M.E. Seoane,1 M.S. Lovillo,2 J.L. Jimenez,1 J.A. Leon,2 M.A.
Munoz.1 1Division of Molecular Immuno-Biology, University
General Hospital Gregorio Maranon, Madrid, Madrid, Spain;
2Department of Paediatrics, University General Hospital Virgen
del Rocio, Sevilla, Sevilla, Spain.
Introduction: The underlying pathology of haemophagocytic
lymphohistiocytosis (HLH) relates to inherited defects on natural
killer cell and cytotoxic T-cell activity. Mutations on perforin gene
in familial-HLH forms and infections in acquired-HLH forms have
been published.
Objective: To study a family with two twins with suspect
symptom and bone marrow aspiration signs of HLH and; negative
serology for bacteria, virus or parasites in both twins. These twins
presented a different degree of clinical severity (Twin 1 had more
severity than Twin 2).
Methods: Family study perforin expression was analysed by
four-color multiparametric flow cytometry COULTERO` EPICSO`
XLTM Flow Cytometer of Beckman-Coulter (Coulter Corporation).
Perforin expression was studied in CD56+CD3- cells,
CD56+CD3+ cells, CD8+ CD3+ cells. Genetic analyses were
carried out to identify the putative perforin mutation. Genomic
DNA was prepared from PBMC using standard protocols, after
informed consent was obtained. Exons 2 and 3 of the perforin gene
(prf1) were amplified using polymerase chain reaction in the
family and in several controls. Quantification of plasma sIL-2R
levels was performed in triplicate using commercially-available
ELISA kits (Bender MedSystems, Viena, Austria).
Results: The family study showed decreased perforin
expression in CD 56+CD3- NK cells, CD8+CD3+ cytotoxic
T cells in the father and Twin 1, and a normal expression in
the mother and Twin 2 when we compared it with healthy
controls of similar age. Sequencing of prf1 disclosed one
mutation, previously described (Clementi, Blood 2002; 100
(6):2266-7.), in Twin 1 and father in the codon 91 of the exon
2 (GCG-GTG that changes Ala91 to Val). Both were hetero-zygous for this mutation. In all others samples, including Twin
2, no mutations were detected. Although, we did not sequence
the entire prf1 gene, it is unlikely that the Twin 2 have another
perforin mutation since their expression was normal by flow
cytometry.
Both twins had higher levels of sIL-2R than healthy controls of
similar age; Twin 1 showing a higher level (18.55 ng/ml) than
Twin 2 (14.38 ng/ml). In contrast, sIL-2R levels of both
progenitors were normal.
While, Leishmania parasites were visualized by electron
microscope examination on the liver tissue of both twins. Finally
Treatment began with antimonials and both patients recovered
completely but more quickly Twin 2.
Conclusion: Visceral Leishmaniasis associated to HLH syn-
drome can cause additional and considerable etiologic diagnosis
difficulties. However, our results indicate that could be conven-
ience of analysis of perforin defects and concomitant infections in
all types of HLH. Leishmania infection is not only able to trigger
haemophagocytic syndrome but perforin defects may worsen
eradication of leishmania infection.
Sa2.32. The Calcium-Promoted Ras Inactivator
(CAPRI) Links Fcg Receptor to Cdc42 and Rac1 and Is
Essential for Host Innate Defense.
J. Zhang, I. Dzhagalov, J. Guo, W. Y. He. 1Immunology, Duke
University, Durham, NC, USA.
Fc receptor (FcR)-mediated phagocytosis requires the activa-
tion of the Rho GTPases Cdc42 and Rac1. However, how
Cdc42 and Rac1 are recruited to the FcR is unknown. Here we
show that the Ca2+-promoted Ras inactivator (CAPRI), a Ras
GTPase-activating protein, functions as an adaptor for Cdc42
and Rac1 during FcR-mediated phagocytosis. CAPRI-deficient
macrophages exhibit impaired FcgR-mediated phagocytosis and
oxidative burst, as well as a defective activation of Cdc42 and
Rac1. CAPRI interacts constitutively with both Cdc42 and
Rac1, and translocates to phagocytic cups during FcgR-mediated
phagocytosis. Importantly, CAPRI-deficient mice have impaired
innate immune response to bacterial infection. These results
suggest that CAPRI provides a link between FcgR and Cdc42
and Rac1 and is essential for host innate defense.
Sa2.33. An 8 Year Old Girl with Recurrent Dermatomal
Herpes Outbreaks.
Cecilia P. Mikita,1 Steven M. Holland,2 Michael R. Nelson.1
1Department of Allergy-Immunology, Walter Reed Army Medical
Center, Washington, DC, USA; 2Laboratory of Clinical Infectious
Diseases, National Institute of Allergy and Infectious Diseases,
Bethesda, MD, USA.
Case Report: An 8 year old Caucasian girl presented with a
five year history of recurrent dermatomal vesicular lesions
affecting her face and back. At 2 1/2 years of age, the patient
developed primary gingivostomatitis with painful, vesicular
lesions over her entire oral mucosal surface. She continued to
have mucosal outbreaks every other month until 3 1/2 years of
age when she complained of facial irritation, soreness, and
fevers with subsequent vesicular lesions originating at the corner
of her mouth and following the V3 dermatome. Her lesions
never cross the midline and occur several times a year triggered
by respiratory infections or stress. She continues to have acute
outbreaks despite prophylactic acyclovir dosed at 45 mg/kg/day.
The patient also has a history of recurrent respiratory tract
AbstractsS152infections since six weeks of life. These infections resolve after
standard courses of oral antibiotics. She has no history of lower
respiratory tract, bone, joint, deep tissue, or fungal infections.
The family history is remarkable for recurrent viral infections in
her father and two siblings. Her physical examination was
unremarkable with no evidence of lymphadenopathy, hepatos-
plenomegaly, or chronic rash. A direct fluorescent antibody test
performed during a subsequent outbreak was positive for herpes
simplex virus and negative for varicella virus in perilesional
skin. Multiple viral cultures of lesions at different times were
positive for herpes simplex virus. An evaluation for a possible
defect in the innate and cell-mediated immune system revealed
decreased natural killer cell lysis, an intracellular cytokine assay
(ICC) for interferon-gamma production was negative for
varicella, cytomegalovirus, Epstein Barr virus, and influenza, a
delayed type hypersensitivity (DTH) skin test was reactive to
tetanus and mumps, and a lymphoproliferation assay (LPA) for
mitogens and tetanus was normal. DTH skin test reactivity and
LPA to candida were nonreactive. An HIV test was negative.
Evaluation for STAT 1 deficiency was negative. Flow cytometry
revealed an elevated CD4/CD8 ratio. Humoral immune function
was evaluated and immunoglobulin levels of IgG, IgA, IgM,
and IgE were normal and IgG2 was mildly decreased.
Diphtheria, Tetanus,and Haemophilus antibody titers were
protective. Zero of twelve Pneumococcal antibody levels were
N1.0 ug/ml before and after vaccination. HSV IgG titers were
positive while varicella virus IgG titers were equivocal. Flow
cytometry revealed an elevated number of CD 19+ cells.
Discussion: The patient presented with recurrent dermatomal
vesicular lesions which were caused by herpes simplex virus.
Health care providers who typically associate recurrent dermatomal
outbreaks with herpes zoster should consider culturing for HSV or
other viral etiologies. Although rare, recurrent dermatomal HSV
lesions may be a hallmark of an as yet undefined immunodefi-
ciency that may be elucidated as the field of clinical immunology
matures.
Sa2.34. Reconstitution of Genetically Determined
Deficiency of the Innate Immune Defence with
Recombinant Mannan-Binding Lectin (MBL).
J. C. Jensenius,1 M. Axelsen,2 L. Kongerslev,2 S. Thiel.1
1Department of Medical Microbiology and Immunology,
University of Aarhus, Aarhus, Denmark; 2NatImmune A/S,
Copenhagen, Denmark.
The innate immune defence encompasses a number of cellular
and humoral components. Among the latter the complement
system plays important roles, and is also involved in establishing
an adequate specific clonal immune response. The recently
established mannan-binding lectin (MBL, or mannose-binding
lectin) complement pathway relies on the recognition of the
microorganisms by their pathogen-associated molecular patterns
(PAMPs). The oligomeric structure of MBL provides for 12 or
more clustered C-type lectin domains, which allows for high
avidity binding to suitably spaced sugar residues. This binding
triggers the activation of the MBL-associated serine protease,
MASP-2, which in turn activates C4 and C2 to generate the C3
convertase, C4bC2b. The level of MBL in plasma varies from less
than 10 ng to 5 Ag/ml and is determined by polymorphisms in exon
one and in the promoter region. Numerous studies have found
association between MBL deficiency and increased susceptibility
to infections. It appears that alone MBL deficiency does notpredispose to infections, but only when also other elements of the
immune system are suboptimal. Thus, e.g., leukaemia patients in
chemotherapy are at high risk of serious infections when MBL
deficient (Peterslund et al. Lancet,358, 637-8, 2001), MBL
deficient colorectal cancer patients have increased risk of post-
operative infections (Ytting H et al. Cancer Immunol Immuno-
therapy, online pub, 2004). MBL deficiency has also been reported
to be associated with autoimmune manifestations, and surprisingly,
with increased risk of atherosclerotic diseases. Recombinant MBL
is now being produced in a human cell line by NatImmune A/S,
Copenhagen by methodologies modified from Vorup-Jensen et al.
(Int. Immunopharmacology, 1, 677-87, 2001; Jensenius et al.
Biochem Soc Trans. 2003 31, 763-7, 2003) and purified to yield a
preparation certified for clinical trials. The rMBL shows physical
and biological characteristics similar to those of plasma-derived
MBL. Preclinical and phase I trials have been conducted and are
currently being evaluated. No safety concerns were observed.
Sa2.35. An Active Role for Complement Regulator CD46
in Signal Transduction upon Infection.
P. S. Tsang, S. H. Sacks, N. S. Sheerin. 1Department of Nephrology
and Transplantation, KingTs College London, London, United
Kingdom.
The renal epithelium is the initial site of contact between
pathogens and their hosts. Through this interaction epithelial cells
may have the opportunity to detect and respond to pathogens, which
leads to activation of inflammatory responses and recruitment of
leukocytes. This initial phase of inflammatory response to infection
often involves activation of innate immune system in particular the
complement. A series of fluid phase and cell surface inhibitors,
including Membrane Cofactor Protein (CD46), exist to prevent
excessive complement activation. CD46 is also known to be the
receptor for various types of pathogens. Here we have investigated
the potential of CD46 to mediate signal transduction and
subsequent internalisation in human renal epithelial cells. CD46
was found on both apical and basolateral surfaces of cells by
staining with anti-CD46 antibody and a fluorochrome. Introduction
of a secondary antibody brought clustering of receptors. Incubating
at 37 8C led to internalisation of antibody, which was not seen when
incubating at 4 8C. Extracellular antibody was detected by a green-
labelled fluorochrome. Cells were then fixed and permeablised, and
a red-labelled fluorochrome was used to detect intracellular and
extracellular antibody. We have previously shown that src kinases
are activated on CD46 cross-linking. However, internalisation was
independent of src kinase activity. Here we present data demon-
strating that antibody can be internalised specifically through its
binding to CD46 receptor, which suggests that CD46 may play an
active role in mediating signalling events. It is our interest to
investigate whether CD46 can serve as a receptor for mediating
internalisation of opsonised pathogens upon infection.
Sa2.36. Access to the Entire Human Antigen-Specific
CD4+ T-Cell Response According to Antigen-Reactive
CD154 Expression.
Marco Frentsch,1 Olga Arbach,1 Dennis Kirchhoff,2 Thomas
Schneider,3 Alexander Scheffold,2 Andreas Thiel.1 1Clinical
Immunology, German Arthritis Research Centre, Berlin, Berlin,
Germany; 2Immunmodulation, German Arthritis Research Centre,
Berlin, Berlin, Germany; 3Gastroenterology and Infectious
Diseases, Charite-Campus Benjamin Franklin, Berlin, Berlin,
Germany.
Abstracts S153Current techniques to assess antigen-specific T-cells suffer from
various limitations: Either the access is restricted to activated cells
that reacted with the expression and secretion of cytokines or could
only be performed with a so far rare selection of specific peptide
MHC-II multimers. We report here on a new method to assess the
entire fraction of CD4+ T-cells specific for a particular antigen
independent of their cytokine memory.
For this we have employed here the intracellular and
extracellular detection of antigen-induced CD154 expression after
in vitro stimulation with various antigens such as CMV, TT,
Adenovirus, birch allergen, SEB and Mycobacterium tuberculosis
ESAT-6. In the course of antigen-driven in vitro activation of
CD4+ T-cells CD154 is specifically expressed by antigen-specific
CD4+ T-cells. Antigen-specific CD154 expression is detectable
intracellularly in fixed CD4+ T-cells when stimulations are
performed in the presence of Brefeldin A facilitating co-expression
analysis of cytokines. Moreover, we developed a strategy to
circumvent the rapid internalisation of reactive surface CD154
expression after interaction with its counterpart CD40. This
enabled us to isolate a live antigen-specific CD4+ T-cells with a
simple single cell surface staining after in vitro stimulation for the
fast generation of highly specific CD4+ T-cell lines.
Our approach offers the striking option to assess the entire pool
of CD4+ T-cells with a defined specificity allowing for combined
quantitative and qualitative analysis of Th-cell immunity and for
isolation of specific Th-cells for targeted cellular immunotherapies.
Sa2.37. Excessive Innate Immune Responses Could
Prime Massive Hepatocyte Apoptosis Induced by
Lipopolysaccharide.
Katsuharu Hirano,1 Yukihiro Shimizu,1 Yasuhiro Nakayama,1
Masami Minemura,1 Yoshinari Atarashi,1 Satoshi Yasumura,1
Toshiro Sugiyama.1 1The Third Department of Internal Medicine,
Toyama Medical and Pharmaceutical University, Toyama, Japan.
Background/Aims: Although liver diseases are known to be
exacerbated by bacterial infections, the mechanism is still unclear.
In a mice model, P. acnes -primed mice show granuloma formation
in response to the bacteria, and massive hemorrhagic liver injury is
observed after lipopolysaccharide (LPS) injection. However,
whether antigen-specific response or granuloma formation is
requisite for the injury is unknown. We, therefore, examined
whether antigen-nonspecific accumulation of DCs and macro-
phages in the liver by the overexpression of GM-CSF could prime
severe liver injury after LPS injection.
Methods: We injected a recombinant adenovirus encoding
GM-CSF (AdGM) containing 1108plaque-forming units, and
one mg per mouse of LPS was administered seven days later
into C57BL/6 (B6) mice via a tail vein. The composition of
hepatic mononuclear cells were analyzed by flow cytometry.
The concentrations of GM-CSF, TNF-a and IFN-g in the serum
of mice were measured by ELISA. Liver histology, serum
alanine aminotransferase (ALT) levels and apoptosis of hep-
atocytes were also examined. To further examine the role of Fas
pathway and TNF-a in the apoptosis of hepatocytes, we used
FasL-deficient mice B6-gld/gld. In both B6-wild type and B6-
gld/gld mice 100Ag per mouse of a neutralizing anti-TNF-a
antibody was intravenously injected 30 minutes before LPS
injection.
Results: Liver histology of the AdGM-primed mice showed
marked infiltrates of mononuclear cells (CD11b+macrophages
and CD11c+I-Ab+CD11b+myeloid DCs) without granulomaformation on day 7. Expression of toll-like receptor-4 on
intrahepatic mononuclear cells isolated from AdGM-primed
mice was up-regulated. Although serum ALT levels were within
normal range before LPS injection, the levels were elevated as
early as 6 hours after LPS injection only in AdGM-primed
mice. The peak levels were 5922 F 3678 IU/L reached at 12
hours after LPS injection, and all those mice died within 24
hours. Serum TNF-a concentrations were elevated after LPS
injection, and peaked at 2–6 hours after LPS injection.
Hemorrhagic liver injury was histologically recognized, In
AdGM-primed mice, TUNEL-positive hepatocyte nuclei were
already observed one hour after LPS injection when liver injury
was not histologically apparent, and the rates of TUNEL-
positive apoptotic hepatocytes were increased to about 80%
three hours after LPS injection. When AdGM and LPS were
injected in FasL-deficient B6-gld/gld mice, serum ALT levels
were not elevated by the pretreatment with a neutralizing anti-
TNF-a antibody.
Conclusions; Our present study provides a new model of severe
liver injury, in which massive accumulation of innate immune cells
such as DCs and macrophages in the liver by overexpressing GM-
CSF enhances the susceptibility to LPS, leading to hemorrhagic
liver injury with massive hepatocyte apoptosis after LPS injection.
Both TNF-a and Fas-mediated signaling were thought to be
important for the hepatocyte apoptosis.
Sa2.38. Evalution CD64 Marker in Neonatal Spesis for
Rapid Diagnosis.
Mino Adib, Farzad Oreizi, Fereshteh Sahebfosul, Vajiheh Ostadi.
1Immunology, Medical School of Science, Isfahan, Isfahan, Islamic
Republic of Iran; 2Immunology, Medical School of Science,
Isfahan, Isfahan, Islamic Republic of Iran; 3Immunology, Medical
School of Science, Isfahan, Isfahan, Islamic Republic of Iran;
4Immunology, Medical School of Science, Isfahan, Isfahan, Islamic
Republic of Iran.
Introduction: Neonatal sepsis is a life- threatening disease with
an incidence of 1 to 10 per 1000 live births and a mortality rate of
15% to 50%. The clinical signs are nonspecific and indistinguish-
able from those caused by a variety of neonatal no infective
disorders. The aim of this study was to determine sensitivity,
specificity, positcive and negative predictive value of neutrophil
markers, in early diagnosis of neonatal sepsis.
Methods: In this study were comprised 65 neonates with a
gestational age of 27 to 38 weeks who suspected for sepsis within
28 days of life. 1 ml of whole blood was obtained from neonates to
determine CD64 expression of peripheral blood neutrophils by
flow cytometry. Neonates were classified into two groups.
Classification was based on positive blood culture. In the sepsis
group (n = 8) all of neonates were positive blood culture and had
clinical symptoms. In the suspected group (n = 57), each neonate
had at least 1 clinical sign but negative blood culture. 12 healthy
term neonates with physiologic hyperbilirubinemia classifed in
control group.
Results: CD64 was elevated in sepsis group and this increase
was significant(pb0.001).specificity and sensitivity of CD64 were
100% and 92% respectively. The negative and positive predictive
value of CD64 for identifying sepis were 100% and 88%
respectively.
Discussion: High sensitivity of CD64 (100%) and specificity of
92.3% indicates that evaluation of CD64 as neutrophil marker can
help clinicians for early diagnosis of neonatal sepsis.
AbstractsS154Sa2.39. T. Whipplei Specific Immune Reactions Are
Significantly Reduced in Patients with WhippleTs
Disease.
V. Moos,1 D. Kunkel,1 T. Marth,2 B. LaScola,3 M. Zeitz,1
T. Schneider.1 1Medical Clinic I, Charite, Campus Benjamin
Franklin, Berlin, Germany; 2Internal Medicine, St Josef Hospital,
Zell/ Mosel, Germany; 3Unite de Rickettsies, Faculty of Medicine,
Marseille, France.
Objective: WhippleTs Disease (WD) is a rare systemic
infectious disease prefaced by replication of the actinomycete
Tropheryma (T.) whipplei in macrophages of the intestinal mucosa.
The possibility of a predisposing immune deficiency is discussed
for WD and a reduced TH1 reactivity that could explain the rarity
of the disease despite the ubiquitous existence of the pathogen, was
already shown for WD patients. However, due to a lack of bacterial
preparations T. whipplei-specific intestinal or peripheral immune
reactions of WD patients were not analysed till now.
Methods: T. whipplei-specific stimulations were performed in
peripheral blood and lamina propria lymphocytes (LPL) with
sonicated T. whipplei cultures, followed by FACS-analysis of
expression of cytokines (IFNg, IL-4, IL12) and activation markers
(CD69, CD154) of CD4+ T-cells. Several common bacterial and
viral antigens (Tetanus Toxoid, Cytomegalovirus and Tuberculin)
were used to control general antigen-specific reactivity.
Results: We established specific stimulations with recently
evolved laboratory strains of T. whipplei and compared for the first
time immune reactions of WD patients, healthy controls (age-
matched and young), and patients with Tuberculosis as a myco-
bacterial model infection. In every control and patient with Tuber-
culosis analysed so far, we were able to detect T. whipplei-specific
CD4+ T-cells in the blood as well as in the duodenal mucosa.
However, WD patients showed a significantly reduced reactivity
against the pathogen. The reactivity against SEB ofWDpatients was
slightly reduced compared to controls, whereas the reactivity to
common antigens was comparable. Additionally, we used a system
with in vitro generated autologeous dendritic cells loaded with T.
whipplei antigens that were able to enhance reactivity in healthy
controls but still could not induce antigen-specific reactions in WD
patients.
Conclusion: Hence we can conclude that T. whipplei-specific
reactivity occurs in healthy controls and that frequent exposure to
the bacteria seems to activate immune reactions, whereas our
results hint at a significantly reduced antigen-specific reaction of
WD patients resulting in insufficient protection against the
pathogen and onset of WD.
Sa2.40. Adoptive Transfer of CFSE-Labeled Autologous
PBMC for the Visualization of T Cell Migration in a
Non-Human Primate Model.
D. Kunkel,1 V. Moos,1 C. Stahl-Hennig,2 F. J. Kaup,2 M. Zeitz,1
T. Schneider.1 1Medical Clinic I, Charite-Campus Benjamin
Franklin, Berlin, Germany; 2German Primate Center, Gottingen,
Germany.
Background: Several inflammatory pathological conditions at
mucosal surfaces are thought to be the consequence of altered T
cell homing. Our aim was to to study the migration of Tcells under
such conditions in the non-human primate system. The transfer of
allo- or congenic fluorescently labeled cells has provided a useful
technique for the visualization of T cell activation, proliferation and
migration in vivo and is a well established application in the mouse
model. However, until now there is no equivalent technique in thenon-human primate system, which for several diseases is the only
available animal model where the pathologic development is
similar to that in humans.
Methods: Here we describe the establishment of an autologous
transfer system in the rhesus macaque model. Mononuclear cells
were isolated from peripheral blood, labeled with carboxyfluor-
escein diacetat, succinimidyl ester (CFSE) and tracked after re-
injection.
Results: Flowcytometric analysis after transfer revealed a
distinct population of labeled lymphocytes in peripheral blood
and lymph nodes as well as in the intestinal mucosa of all animals.
The percentage of labeled T cells in peripheral blood remained
almost stable for up to 4 weeks, whereas the fluorescence intensity
of the whole population decreased slightly, probably due to
physiological turnover of intracellular proteins. Preliminary results
indicate an increased frequency of CD4+ T cells migrating to the
mucosa after transfer of in vitro activated cells compared to the
migration of non-activated cells.
Conclusions: The well established transfer of CFSE labeled
cells in the mouse system has been successfully adapted to the
rhesus macaque system and allows us to analyse the migratory
behaviour of T cells in diseases where the only available animal
model is the non-human primate system, e.g. HIV/SIV infection.
Sa2.41. The Effect of Post-Traumatic Stress Syndrome
on the Outcome of Influenza Vaccination.
E. Kosor,1 A. Gagro,1 V. Folnegovic-Smalc,4 M. Vilibic,4
D. Kozaric-Kovacic,5 M. Grubisic-Ilic,5 V. Drazenovic,2
K. Gotovac,1 A. Sabioncello,1 E. Cecuk,3 V. Kerhin-Brkljacic,3 I.
Gjenero-Margan,2 B. Kaic,2 S. Rabatic,1 G. Mlinaric-Galinovic,2
D. Dekaris.1 1Research and Development, Institute of Immunology,
Zagreb, Croatia; 2Virology, Croatian Institute of Public Health,
Zagreb, Croatia; 3National Referal Organ Transplant and Tissue
Centre, University Hospital Centre Zagreb, Zagreb, Croatia;
4University Department of Psychiatry, Psychiatric Hospital
Vrapce, Zagreb, Croatia; 5Department of Psychiatry, National
Center for Psychotrauma Dubrava, Zagreb, Croatia.
Psychological stress is known to affect immune function and to
influence on infectious disease susceptibility. Previous studies have
demonstrated that chronic stress can impair humoral immune
response to influenza vaccination but no data is available on post-
traumatic stress disorder (PTSD). PTSD, according to Diagnostic
and Statistical Manual of Mental Disorders (DSM-IV), is a
condition (or anxiety disorder) that can occur after exposure to
extreme traumatic experience and is accompanied by intense fear,
helplessness or horror. Exposure to trauma can result in immune
deregulation, and increasing number of evidence suggests that
there are immune alterations associated with PTSD.
The aim of this studywas to determine the effect of psychological
stress on the immune response to influenza vaccination in war
related PTSD patients (n = 32). Peripheral blood mononuclear cells
(PBMC) and sera were obtained before and 14 days after vaccination
(Agrippal, Chiron, Italy) from patients and control subjects during
2003/2004 winter season. Detection of specific antiviral antibody
titre in sera for all viral strains contained in the vaccine was
performed with inhibition of hemagglutination (IH) assay. Ex vivo
tetramer staining of recently activated CD8+ T lymphocytes was
used for monitoring of T cell response specific for HLA-A*0201-
restricted influenza A matrix antigen (M158–66) and haemaglutinin
antigens (A/New Caledonia/H1N1, HA345–354, HA542–550) before
and after influenza vaccination. Sixteen patients showed 4-fold
Abstracts S155increase of H1N1 antibody titre 14 days after vaccination. In four of
total ten HLA-A*0201+ patients 2- to 4-fold increase of frequency
of recently activated influenza-specific T cells was observed after
vaccination. However, PTSP patients showed diminished frequen-
cies of influenza-specific CD8+ T cells after vaccination compared
to healthy controls. Generated humoral response in our patients
argues against the hypothesis that post-traumatic stress might
influence the protection following vaccination. Diminished cellular
response in PTSD patients could indicate that immune dysregulation
observed earlier in these patients selectively affects cellular immune
response.
Sa2.42. Cholesterol Loading of T Cells as a Model of T
Cell Aging.
A. Larbi,1,2 G. Dupuis,2 C. Fortin,1,2 H. Berrougui,1 A. Khalil,1
T. Fulop.1,2 1Laboratory of Immunology, Research Center on
Aging, Sherbrooke, QC, Canada; 2Immunology Program, Faculty
of Medicine, Clinical Research Center, Sherbrooke, QC, Canada.
Lymphocytes functions are impaired in human aging explain-
ing the increased susceptibility to diseases. It was observed that
defects in T-cell receptor signal transduction could explain this
age-related immune senescence. Lipid rafts are critical compo-
nents of the membranes that serve for signal transduction
enhancement. Our hypothesis is that changes in lipid rafts
properties could explain defects in signal transduction. Choles-
terol is a major component of the cell membrane and especially
of lipid rafts. In this connection, we found an elevation by two
folds of lipid rafts associated-cholesterol in T-cells with aging.
This increase was associated to defects in lipid rafts coalescence,
impairments in Lck and LAT association to lipid rafts. We sought
to determine the role of cholesterol in immune senescence. We
modulated cholesterol content in peripheral T-cells from normo-
lipemic young donors using a mixture of cyclodextrin and
cholesterol. Cholesterol content in whole cell extracts as well
as in lipid rafts was measured by HPLC. We were able to
increase cellular cholesterol content by 1.5 fold to up to 7 folds.
We observed changes in cell shape and size (microscopy, flow
cytometry) as well as a dramatic loss of membrane fluidity. We
analyzed T-cell proliferation and protein phosphorylation (west-
ern-blotting) following CD3 and CD28 stimulation. We found
that an in vitro increase in membrane cholesterol by 2-folds have
similar consequence on signal transduction as observed in human
aging. We could here establish a T-cell model of aging by
cholesterol modulation. Altogether, these data suggested that
signal transduction critically depends on membrane cholesterol
content and that changes in lipid rafts properties may be taken
into account to explain immune senescence as well as in other
pathological diseases.
Sa2.43. The Role of Programmed Death-1 Pathway in a
Neutrophil Mediated Shock Syndrome.
B. Zhu,1 K. Raddassi,1 M. H. Sayegh,2 S. J. Khoury.1 1Center for
Neurologic Diseases, Brigham and WomenTs Hospital, Boston,
MA, USA; 2Transplantation Research Center, Brigham and
WomenTs Hospital and ChildrenTs Hospital Boston, Boston, MA,
USA.
Programmed death-1 (PD-1) and its ligands PD-L1 and PD-L2
are members of B7/CD28 superfamily, and play important roles in
modulating the adaptive immunity in experimental autoimmune
encephalomyelitis (EAE), type-1 diabetes, asthma and trans-
plantation. In the study of PD-1 pathway in EAE, we found thatmultiple injections of either PD-1 or its ligand blocking antibody
after standard EAE induction caused a shock syndrome in multiple
mouse strains, which included 129X1/SvJ, C57BL/6, and SJL/j
mice. Animals showed piloerection, cyanosis, drop in body
temperature and were eventually dead within 2 hours of antibody
injection. Interestingly, BALB/c mice, a strain known to be TH2
prone, are relatively resistant to the development of shock
syndrome. In addition, the blockade of PD-1 pathway did not
enhance OVA peptide induced anaphylaxis in BALB/c mice.
Pathological study in shock mice found massive neutrophil
infiltration in the lung, liver and skin, suggesting PD-1 pathway
blockade directly or indirectly activated neutrophils in this model.
Consistently, freshly isolated neutrophils from normal mice were
found to express PD-1 and PD-L1, and neutrophils isolated from
anti-PD-L1 treated mice showed enhanced and accelerated super-
oxide production upon PMA stimulation. We are currently further
studying the role of PD-1 pathway in animal models known to
involve neutrophils in pathogenesis, such as sepsis and ischemia-
reperfusion injury.
Sa2.44. Immune Response Balance on Human
Cutaneous Leishmaniasis.
L. Castellano,1 D. Correia Filho,1 L. Argiro,2 H. Dessein,2
A. Prata,1 A. Dessein,2 V. Rodrigues.1 1Lab of Immunology,
Faculdade de Medicina do Triangulo Mineiro, Uberaba, Minas
Gerais, Brazil; 2Fac Medecine, INSERM U399, Marseille, France.
T helper lymphocytes play a major role on infectious diseases
and these cells can be driven into at least two different
subpopulations according to their cytokine production pattern.
Th1 lymphocytes are implicated on the resolution of infections
caused by intracellular pathogens such as Leishmania species,
while Th2 cells are thought to be important to the establishment
of these infections. This Th1/Th2 balance was previously showed
to be able to drive antibody isotype switching. Based on this
knowledge ELISA tests were performed to measure the plasma
levels of anti-Leishmania specific IgG1, IgG3, IgG4 and IgE
antibody isotypes. Production of Interleukine-4 and IFN-g by
peripheral blood mononuclear cells (PBMC) from subjects living
in an endemic area of American Cutaneous Leishmaniasis (Bahia
State, Brazil) was analysed. Patients were grouped on active
lesions (n = 20), cured lesions (scars) (n = 40) and asymptomatic
(n = 34). PBMC were cultured for 24 and 96 hours stimulated
with Leishmania braziliensis antigens. The analysis of IgG
isotypes response showed that both IgG1 and IgG3 were able
to differentiate the group of patients presenting active lesions
from the others (Kruskal Wallis; P = 0.0004 and P = 0.0004,
respectively). Moreover, the analysis of cytokine production
revealed that IFN-g level was significantly higher on patients
with active or cured leishmaniasis than on the asymptomatic
group (Kruskal Wallis; pb0,0001). There was a correlation
between the production of IFN-g by PBMC stimulated with L.
braziliensis antigens and the plasma levels of IgG1 and IgG3
antibody isotypes in patients presenting active lesions (Spearman
Correlation; P = 0.0065 and P = 0,0107, respectively). The level
of IL-4 was significantly higher on patients presenting active
lesions than on the others (Kruskal Wallis; P b 0.0001). The
results confirm that IFN-g is produced during human Cutaneous
Leishmaniasis and that, during active lesions, a concomitant high
production of IL-4 is observed. Our results also point out that
IgG1 and IgG3 are useful antibodies to differentiate patients with
active lesions.
AbstractsS156Sa2.45. Investigatin of IL-4 Gene Polymorphism in
Patients with Brucellosis.
Manoochehr Rasouli, Amin Abbasian, Simin Kiany. 1Immunology
of Infectious Diseae Departrment, Clinical Microbiology Research
Center- Shiraz University of Medical Sciences, Shiraz, Fars,
Islamic Republic of Iran; 2Immunology of Infectious Diseae
Departrment, Clinical Microbiology Research Center- Shiraz
University of Medical Sciences, Shiraz, Fars, Islamic Republic of
Iran; 3Immunology of Infectious Diseae Departrment, Clinical
Microbiology Research Center- Shiraz University of Medical
Sciences, Shiraz, Fars, Islamic Republic of Iran.
Brucellosis is endemic in many Middle East countries
including Iran, where it undermines animals and human health.
The Immune response against Brucella involves both humoral
(Th2) and cell-mediated (Th1) immunity. The Th1/Th2 cytokine
ratio seems to be involved in the susceptibility or resistance to
Brucella infection. Th1 cytokines confer resistance were as Th2
cytokines predispose to brucellosis. IL-4 is a Th2 cytokine which
its production can be affected by its gene polymorphism at
position -590(C/T). The aim of this study was to investigate the
association between IL-4 gene promoter polymorphism and
susceptibility to brucellosis.
One hundred and ninety seven patients with brucellosis, 186
healthy individuals who were members of patients family and 82
healthy animal husbandmen who had animals involved with
brucellosis, were included in this study. All individuals were
genotyped for IL-4 gene promoter polymorphism at position -
590(C/T) using PCR-RFLP.
The results showed the distribution of CC genotype is
significantly more in animal husbandmen than the patient group
(P = 0.034). No statistical significant differences in genotypes
distribution were shown between patients and their healthy family,
but there was a trend toward increased frequency of CC genotype
in family group (P = 0.063).
As data shown, the distribution of CT and TT genotype which
were associated with more production of IL-4 were increased in
patients (29.3%) compare to animal husbandmen (17.4%, P =
0.034)) and patientsT family members (21%, P = 0.063). We
suggest that individuals who carry T allele can produce more IL-4
and this cytokine induce Th2-type immune response which could
be important to develop a full-pictured brucellosis. While,
individuals with CC genotype can probably induce a Th1-type
immune response more effectively and control the Brucella before
developing the disease.
Sa2.46. Immunophenotype Characterization of
Peripheral Blood T Lymphocytes before and after
Treatment in Tuberculosis Patients.
Fereshteh Sahebfosul, Farzad Oreizi, Zohre Pessaran, Ahmad
Ghavaminejad. 1Immunology, Medical School, Isfahan, Isfahan/
Isfahn, Islamic Republic of Iran; 2Immunology, Medical School,
Isfahan, Isfahan/Isfahan, Islamic Republic of Iran; 3Immunology,
Medical School, Isfahan, Isfahan/Isfahan, Islamic Republic of
Iran; 4Immunology, Medical School, Isfahan, Isfahan/Isfahan,
Islamic Republic of Iran.
Intoduction: Tuberculosis is a chronic mycobacterial infection.
The main effecter cells against mycobacterium tuberculosis are
CD4+ T lymphocytes.
Objective: Our objective in this research was to evaluate
the quantity of T lymphocytes and their subpopulation before
and after treatment with combination of 4 drugs recommendedby WHO (DOTS Protocol) in sputum-positive tuberculosis
patients.
Materials and Methods: 20 patients as cases and 20 healthy
people were selected as controls. Flow cytometry was done for
TCD3+, TCD4+ and TCD8+ lymhocytes by use of monoclonal
antibodies.
Result: Our results showed that there was a defect in cell
mediated immunity during tuberculosis showing itself as
decrease in TCD3+ and TCD4+ lymphocytes and increase in
TCD8+ lymphocytes. The changes in TCD3+ and TCD4+ but
not in TCD8+ were reversible after 2 months of treatment.
Conclusion: The result of our study and other studies confirm
defect in cell mediated immunity during infection with mycobacte-
rium tuberculosis. Although decrease in CD4+ lymphocytes that are
main cells in defense against tuberculosis, has been established,
there is no consensus about decreasing or increasing of CD8+
lymphocytes in tuberculosis.
Sa2.47. Class I Restricted Epitopes Highly Represented
in the Trypanosoma cruzi Genome Are Recognized by
CD8+ T Cells from Individuals with Chronic T. cruzi
Infection.
S. A. Laucella,1 B. Weatherly,2 D. Martin,2 M. C. Albareda,1 M.
G. Alvarez,3 G. Bertochi,3 A. H. Armenti,3 J. Sidney,4 A. Sette,4
M. Postan,1 R. L. Tarleton.2 1Research Department, Instituto
Nacional de Parasitologia, Buenos Aires, Argentina; 2Center for
Tropical and Emerging Global Diseases, UGA, Athens, GA, USA;
3Hospital Interzonal Eva Peron, Buenos Aires, Argentina; 4La
Jolla Institute for Allergy and Immunology, San Diego, CA, USA.
Immunity to T. cruzi is complex, minimally involving a
substantial antibody response and the activation of CD4+ and
CD8+ T cell responses.
We have recently shown that chronic chagasic patients with
mild clinical disease have a significantly higher frequency of
IFN-g producing T cells specific for a parasite lysate than do
individuals with severe disease. However, it has been difficult to
identify the specific epitopes recognized by T. cruzi-specific T
cells, and thus to quantify the response of CD8+ T cells from
infected individuals. In T. cruzi-infected mice, peptides from trans-
sialidase family proteins (ts), are dominant targets of the CD8+ T
cell response. In the present study, we have investigated the
response of CD8+ T cells from HLA-A2.1+, T. cruzi-infected
individuals to ts family, HLA-A2.1-binding epitopes.
The 1294 genes annotated as encoding ts family proteins were
screened for homologues of two ts-derived, HLA-A2.1-binding
peptides that we had previously found to be recognized by a low
frequency of CD8+ T cells in HLA-A2.1+ infected subjects. This
screening yielded a total of 845 homologues, 71 of which were
encoded by N50 ts. Thirty-two of the 71 peptides elicited IFN-g
production by CD8+ T cells from HLA-A2.1 transgenic mice
chronically infected with T. cruzi, with peptides with the highest
frequency of occurrence and the highest predicted HLA-A2.1-
binding affinity stimulating the greatest response. Antigenicity of ts
peptides was fairly associated with the capacity to bind multiple
molecules from the A2 supertype. To ascertain whether these
epitopes were recognized by CD8+ T lymphocytes from T. cruzi-
infected subjects. IFN-g ELISPOT responses were evaluated with
PBMC from chronic chagasic patients.
IFN-g secretion was demonstrated in 10 out of 17 patients
(59%) with mild disease, with 24 out of the 28 peptides assayed
recognized by at least one patient. For each responder, the
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responses varied between 11% (3 of 28 tested) and 100% (5 of 5
tested); peptides ts3, ts37, ts38, ts44 and ts66 being the most
frequently recognized. By contrast only 2 out of 10 patients with
severe clinical stages showed positive responses. These data
demonstrate that the frequency of IFN-g producing T cells in
chronic chagasic patients is determined in part by the clinical status
of the patient and also by the frequency of occurrence of the
epitopes in the T. cruzi genome. We have identified a very specific
set of class I MHC restricted peptides target of immune responses in
patients capable of controlling T. cruzi infection. The identification
of CD8+ T cell targets in the natural infection with T. cruzi may be
applicable to the development of vaccines against T. cruzi.
Sa2.48. Sustained Expansion, Activation and
Maturation of Virus-Specific CD8+ T Cells after Acute
Parvovirus B19 Infection.
V. O. Kasprowicz,1 A. Isa,2 O. Norbeck,2 T. Tolfvenstam,2 P.
Klenerman,3 P. Bowness.1 1Human Immunology Unit, Weatherall
Institute of Molecular Medicine, University of Oxford, Oxford,
United Kingdom; 2Department of Virology, Karolinska Institute,
Stockholm, Sweden; 3Peter Medawar Building for Pathogen
Research, University of Oxford, Oxford, United Kingdom.
Human Parvovirus B19 (dB19T) is a ubiquitous DNA virus
that causes erythema infectiosum, polyarthropathy, transient
aplastic crisis and fetal death. IFN-gamma elispots, intracellular
cytokine staining, and HLA-peptide tetrameric complex
(dtetramerT) staining were used to identify CD8+ T lymphocyte
responses to the non-structural protein NS1. To understand the
origins of such responses and their potential role in disease we
prospectively analysed the evolution of virus-specific CD8+ T
cell responses, in five individuals, during and after acute
infection. Individuals responded to B19 tetramers at frequencies
up to 2% CD8+ T cells. Surprisingly their responses increased
over the first year post infection despite resolution of clinical
symptoms and control of viremia. Parvovirus-specific CD8+ T
cells rapidly developed and maintained an activated CD38+
phenotype, with strong expression of perforin and CD57 and
downregulation of CD28 and CD27. These cells possessed strong
effector function and intact proliferative capacity (demonstrated
by IFN-gamma elispots, Chromium-51 release assays and
tetramer staining of B19-specific CD8+ T cell lines). In remotely
infected individuals lower frequencies of cells specific for
individual epitopes were observed, typically b0.5% of CD8+ T
cells, which were CD38 low although also CCR7 low. The likely
explanation for the striking persistent expansion of such activated
mature effector cells after acute resolution of infection- analogous
to CMV infection- is through low level antigen exposure. Such
cells may contribute to the long term control of this significant
pathogen.
Sa2.49. Defining Putative T Cell Epitopes from PE and
PPE Families of Proteins of Mycobacterium tuberculosis
with Vaccine Potential.
G. M. Chaitra,1 Sridhar Hariharaputran,2 Nagasuma R. Chan-
dra,2 S. M. Shaila,1 Rabindranath Nayak.1 1Department of
Microbiology & Cell Biology, Indian Institute of Science,
Bangalore, Karnataka, India; 2Bioinformatics Center, Indian
Institute of Science, Bangalore, Karnataka, India.
There is substantial evidence that BCG provides partial
protection against pulmonary tuberculosis. But this evidence doesnot convincingly demonstrate that BCG prevents tuberculosis (TB)
development. The availability of Mycobacterium tuberculosis
H37Rv genome sequence has thrown open new opportunities for
designing a rational vaccine for TB. The identification of T cell
epitopes from immune relevant antigens remains a critical step in
the development of vaccines. The discovery of two multigene
families, PE and PPE, which make up to 8% of Mycobacterium
tuberculosis H37Rv genome has kindled an interest in using these
proteins as potential vaccine candidates. All possible nonameric
peptide sequences from PE and PPE proteins were analysed
computationally, for their ability to bind to 33 alleles of class I
HLA. Of all PE and PPE proteins, a significant number of these
peptides are predicted to be high affinity HLA binders, irrespective
of the length of the protein. Structural basis for peptide binding to
HLAwas carried out by molecularmodeling studies. The structural
studies correlated well with the binding prediction. Two proteins
from PE and PPE family of Mycobacterium tuberculosis genome
have been selected for further study as these proteins show high
percentage of binding peptides. The recombinant proteins were
tested for their ability to elicit immune response in mouse model.
The recombinant Rv1818c is good inducer of antibody response
but very poor inducer of T cell response, where as Rv3812 is
shown to induce good T cell response in terms of invitro T cell
proliferation, IFNg secretion and DTH response. The predicted
epitopes are experimentally verified by identification of T cells,
which specifically recognize the naturally processed epitope in an
HLA-restricted fashion. These peptides may be used in a vaccine
cocktail keeping in mind the HLA haplotype profile of the
population.
Sa2.50. The Study between the Changes of CD35
Expressed on Erythrocyte in Patients with
Hepatocirrhosis and the Severity of Liver Function
Destroying.
Ma Chi,1 Wang Haibin.2 1Dept. Immunology, Peking Union
Medical College, Beijing, China; 2Dept. Lab of Clinical
Immunology, Beijing 302 Hospital, Beijing, China.
[Objective] To study the relationship between the changes of
CD35 expressed on erythrocyte (ECD35) in patients with
hepatocirrhosis and the severity of liver function destroying.
[Methods] One-step detection method of ECD35 has been used
108 cases in hepatocirrhosis as followed, 2 percent of Glutaralde-
hyde-fixed red blood cells (RBC) are analyzed in V well microstate
plates. To the cell buttons in each well, the compound of b-
CR1Ab+SA*AP was added and mixed thoroughly. The microtitre
was incubated at 378C for 45min, followed by three washes in 1%
S/BSA. Substrate was added and incubated at 378C for 20min. The
supernatant was transferred to a clean U microtitre plate to
facilitate reading in a plate reader at 405nm (A405). The number
of CD35 was calculated by the standard of red cell. Another
detection of ALT, CHE, ALB, GLO, TBIL, and GAM were
assayed with the machine of AU 5400. [Results] The number of
ECD35 in patients with Hepatocirrhosis was significantly lower
than that in healthy individuals. The patients were divided in to
two groups according to the levels of ECD35 by 200/cell. The
results showed that the patients with low activity of CHE and
decreased ALB were almost in low CD35 number groups, the
levels of GLO, TBIL and GAM are increased accordingly. There is
no obviously relationship between the changes of ALT and ECD35.
[Conclusions] The results suggest that the quantity of CD35 on
erythrocytes may be involved in pathogeny, development and
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ECD35 maybe used as an important assay in liver functions
Sa2.51. Deficient IgM to IgG Antibody Switch in
Patients Unresponsive To Conjugate Pneumococcal
Polysaccharides.
L. E. Leiva, E. J. Saturno, H. Monjure, E. Barr, K. Mason, R. U.
Sorensen. 1Pediatrics, LSU Health Sciences Center and ChildrenTs
Hospital, New Orleans, LA, USA.
Introduction: We have identified a group of patients with
recurrent respiratory infections who have normal total immuno-
globulins and normal response to protein antigens but who failed to
develop IgG antibodies to the Pneumococcal 7-valent conjugate
vaccine (PCV7) serotypes. Rationale: To investigate if the
mechanism of unresponsiveness to the PCV7 vaccine could be
due to a defect in isotype switching. Methods: This is a
retrospective study of 60 patients referred to our clinic for
evaluation of recurrent respiratory infections who received
complete immunization with the PCV7 vaccine for age, according
to ACIP guidelines. All patients were evaluated with total
immunoglobulin and IgG subclass concentrations and their
immunization history was documented. We measured IgG and
IgM anti-pneumococcal polysaccharide (PP) antibody titers against
serotypes 1, 4, 6B, 9V, 14, 18C, 19F and 23F by a standardized
ELISA test. The data were analyzed using Epi Info and SPSS.
Samples were obtained from patients who were already immunized
by their primary care physicians. The patients were assembled into
3 groups, an unimmunized group with laboratory data prior to the
vaccine and two immunized groups of responders and non-
responders according to their IgG anti-PP antibody titers. Non-
responder patients were defined as those with IgG anti-PP antibody
titers to all 7 serotypes included in the PCV7 vaccine not
statistically different from unimmunized controls. Results: Despite
differences in IgG anti-PP antibody titers, both responder and non-
responder patients had IgM antibody titers to all 7 serotypes
significantly higher than those of unimmunized controls. Con-
clusions: These results suggest that a deficient IgM to IgG
antibody switch may be the explanation for the failure of patients
to respond to conjugate pneumococcal polysaccharides. The
cellular and molecular mechanisms underlying this defect are
under investigation.
Sa2.52. A Delayed Diagnosis of Cystic Fibrosis in a
Patient with Asthma and Allergic Bronchopulmonary
Aspergillosis.
K. R. Lowe,1 C. P. Mikita.1 1Allergy/Immunology, Walter Reed
Army Medical Center, Washington, DC, USA.
INTRODUCTION:
Allergic Bronchopulmonary Aspergillosis (ABPA) is a complex
hypersensitivity reaction including both IgE- and IgG-mediated
immune responses following Aspergillus colonization of an
asthmatic airway. Cystic Fibrosis (CF) is a multisystem disease
characterized by disordered exocrine gland function. Disease
manifestations include respiratory, gastrointestinal, hepatobiliary,
pancreatic, and reproductive dysfunction. ABPA is extremely
difficult to recognize in the context of CF, as clinical, radiographic,
and immunologic features frequently overlap.
CASE REPORT:
A 49 year old Caucasian female with a past medical history of
steroid-dependent asthma, allergic rhinitis, ABPA, and frequent
pneumonias presented with acute maxillary sinusitis. Pediatricmedical history was unremarkable. Asthma was first diagnosed in
the patientTs third decade of life. Past medical history was
additionally remarkable for infertility and intermittent episodes of
hemoptysis. At 26 years of age Mycobacterium intracellulare
pneumonia was diagnosed with symptoms of respiratory distress
and hemoptysis. Two years later, APBA was diagnosed. In the
subsequent 23 years, the patient had multiple hospitalizations for
basthmaQ exacerbations, hemoptysis, and pneumonia. Daily oral
steroids and intermittent courses of antibiotics were given to
control asthma symptoms and infections. At 43 years of age, the
patient was hospitalized for Pseudomonas pneumonia with
symptoms of respiratory distress and hemoptysis. At 49 years of
age, while presenting with acute sinusitis, a chest and sinus CT
were performed. Sinus CT was remarkable for chronic sinusitis
changes, and chest CT demonstrated multifocal bilateral cylindrical
bronchiectasis, with multiple mucous-inspissated dilated bronchi.
Sweat chloride testing and genetic testing were consistent with the
diagnosis of CF with the DF508 and L206W mutations.
CONCLUSIONS:
This case illustrates a delayed diagnosis of CF, in the setting of
an adult patient with recurrent infections, atypical pneumonias,
asthma, and ABPA. It further demonstrates the importance of
clinical suspicion for CF in patients of all ages who present with a
history of asthma and frequent sinopulmonary infections. Sweat
chloride testing is a non-invasive testing modality that may
dramatically alter both management and prognosis for patients
with CF.
Sa2.53. Determination of Borrelia burgdorferi
Outer-Surface Protein A161–175 Peptide Binding to HLA-
DR Molecules Associated with Antibiotic-Refractory or
Antibiotic-Responsive Lyme Arthritis.
E. E. Drouin,1 B. Falk,2 L. J. Glickstein,1 W. Klitz,3 W. W. Kwok,2
G. T. Nepom,2 L.A. Baxter-Lowe,4 A. C. Steere.1 1CIID/
Rheumatology Division, Massachusetts General Hospital /
Harvard Medical School, Boston, MA; 2Benaroya Res Inst, Seattle,
WA; 3UC Berkeley, Oakland, CA; 4Immunogenetics and
Transplantation Lab, UCSF, San Francisco, CA.
Objective: Clinical correlations have linked antibiotic-refrac-
tory Lyme arthritis with certain HLA-DR molecules and the B.
burgdorferi T cell epitope, outer surface protein A161–175
(OspA161–175). Previously, HLA-DRB1*0401, 0101, and 0404
molecules, which are associated with antibiotic-refractory arthritis
were shown to bind this peptide, whereas the DRB1*0801 and
1101 molecules, which are associated with antibiotic-responsive
patients, did not. To further these studies, we determined the
relative binding affinity of OspA161–175 to 14 HLA-DR molecules,
and correlated peptide binding with MHC frequency in antibiotic-
refractory or antibiotic-responsive arthritis patients.
Methods: The cDNAs of the extracellular domains of DRa and
DRh attached to the leucine zipper sequences were cotransfected
and purified in Drosophila cells. DR molecules were purified by
affinity chromatography. MHC-peptide binding was detected by
the capture of HLA-DR/Eu-OspA161–175 complexes on DR anti-
body coated plates. Dilutions of the peptide (0.0001-50 AM) were
tested, and the half maximal binding concentration (1/2 max) was
determined. Binding affinity was correlated with the frequency of
each MHC molecule in 71 antibiotic-refractory and 50 antibiotic-
responsive patients.
Results: Of the 14 MHC molecules tested, 7 bound the
OspA161–175 peptide. The DRB1*0401 molecule bound the peptide
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molecule bound it moderately well (1/2 max = 0.2–0.4 AM), and the
DRB1*0402 or 0102 molecule bound it weakly (1/2 max = 4–6
AM). In addition, testing of the linked and equally expressed
DRB1*1501/DRB5*0101 molecules showed that this DRB5
molecule, but not the DRB1 molecule, bound the peptide
moderately well. Altogether, 79% of patients with antibiotic-
refractory arthritis had at least one of these 7 OspA peptide-binding
HLA-DR molecules compared with 46% with antibiotic-responsive
arthritis (odds ratio = 4.4, Pb0.001). In contrast, the DRB1*0301,
0801, 1101, 1104, 0701 and DRB4*0101 molecules showed no
binding of the OspA peptide. Only 21% of the antibiotic-refractory
patients had one of these alleles compared with 54% of the
antibiotic-responsive patients (odds ratio = 0.2, P b 0.001).
Moreover, patients with two OspA161–175-binding alleles were 9.6
times more likely (CI 1.9-46.9) to have an antibiotic-refractory
course than patients with two non-OspA161–175 binding alleles.
Conclusion: The highly significant correlations of OspA161–175
peptide binding to implicated HLA-DR molecules further supports
the hypothesis that T cell recognition of this bacterial epitope is
important in the autoimmune pathogenesis of antibiotic-refractory
Lyme arthritis. This is the only form of chronic inflammatory
arthritis in which the identity of each component of the disease-
associated tri-molecular, MHC-peptide-TCR complex has been
deciphered.
Sa2.54. Mycobacteria Directly Induces Cytoskeletal
Rearrangements for Macrophage Motility through
TLR2-Dependent PI3. K Signaling.
E. B. Lasunskaia,1 M. N. Campos,1 R. da Matta,2 T. L. Kipnis,1 W.
D. da Silva.1 1Laboratory of Biology of Recognition, Universidade
Estadual do Norte Fluminense, Campos, Rio de Janeiro, Brazil;
2Laboratory of Cell and Tissue Biology, Universidade Estadual do
Norte Fluminense, Campos, Rio de Janeiro, Brazil.
Cell migration and adhesion are both important for controlling
mycobacterial infection and are critically dependent on the
reorganization of the cytoskeleton. Mycobacteria elicits rapid
morphological changes such as cell spreading the process relevant
to in vivo changes of macrophage shape during extravasation and
migration. In this study we investigated the BCG mycobacteria-
induced signaling events leading to macrophage cytoskeletal
rearrangements employing specific pharmacological inhibitors to
suppress distinct kinase pathways known to be elicited by
infection. Viable or lysed mycobacteria, as well as purified cell
wall lipoprotein p19, TLR2 agonist, induced RAW264.7 cells to
extend actin-rich pseudopods which imparts circular spreading
within 30 min that was substituted by persistent cell polarization
24h post-treatment. BCG induced rapid phosphatidylinositol
3- kinase, PI3-K, activation which become recruited to the
activated TLR2 receptor. Suppression of PI3-K with LY294002
inhibitor abrogated generation of cell protrusions and polarity
demonstrating the involvement of PI3-kinase pathway in actin
reorganization essential for cell motility. Inhibition of MEK1/ERK
kinases with PD98059 reduced the number of polarized cells but
did not prevent filopodia or lamillopodia formation suggesting the
role of this pathway in stabilization of leading lamillopodia. Nor
NF-nB nor p38MAPK activation by BCG were important for
cytoskeletal rearrangements observed although their suppression
inhibited chemokine and growth factors secretion by activated
macrophages that could promote the cell motility in an autocrine
manner. h1-integrins blockade with a corresponding antibodyinhibited macrophage spreading and polarization but had no effect
on pseudopod protrusions or PI3-K activation demonstrating the
down-stream position of integrin-mediated adhesion in signaling
pathway leading to motility phenotype.The data obtained demon-
strate that direct effect of mycobacteria on macrophage shape at
least in part is mediated through TLR2-dependent PI3-K activation.
Financial support: CNPq, FAPERJ, CAPES.
Sa2.55. Chlamydia pneumoniae Infection of Human
Immune Cells Modulates Cytokine Production.
Y. Mamata,1 C. Newton,1 T. W. Klein,1 Y. Yamamoto,1,2 H.
Friedman.1 1Medical Microbiology and Immunology, University of
South Florida College of Medicine, Tampa, FL, USA; 2Basic
Labolatory Science, Osaka University, Suita, Osaka, Japan.
Chlamydia pneumoniae (Cpn) is an obligate intracellular
bacterium known to cause acute upper respiratory tract infections,
but recent studies show Cpn is also involved in a variety of chronic
inflammatory diseases, including atherosclerosis and possibly
autoimmune diseases like multiple sclerosis as well as arthritis
and asthma. In fact, we have reported that this organism can be
detected by PCR for Cpn specific 16s r RNA in human peripheral
blood mononuclear cells associated with subclinical chronic
bacterial infection. Even though this organism grows preferentially
in epithelium cells in the respiratory tract, in the present study we
show that these bacteria can infect and replicate in the human
monocytic cell line (THP-1) and the human T cell line (Molt-4) and
also human peripheral blood mononuclear cells in vitro as detected
by FITC-conjugated anti-Chlamydia monoclonal antibody (spe-
cific to Chlamydia LPS) staining or PCR for Cpn 16s rRNA. The
Cpn mRNA level was upregulated at 48h as compared to 24h after
infection assessed by real-time PCR for Cpn 16s rRNA ( p b 0.05).
We also found that Cpn infected cells evinced marked alteration of
cytokine production important in immune responses to microbial
infection. Cpn infection of human immune cells modulated
a variety of cytokines. In particular, Cpn infected MOLT-4 and
THP-1 cells suppressed TGF h1 production as compared to
uninfected cell assessed by ELISA ( p b 0.05). In contrast, Cpn
infection of the human cell lines in vitro markedly stimulated
production of proinflammatory cytokines, including TNF a and IL
10. Interestingly Cpn infected PBMCs enhanced production of TNF
a, IFN g, IL 4 (PHA induced), IL 10 and IL 12 as compared to
lower TGF h1. Infection with viable Cpn stimulated more IL 12 and
IFN g(Th1 cytokines) and less IL 4 (Th2 cytokines) as well as TGF
h1 (Th3 cytokines) compared to stimulation with heat killed Cpn in
PBMCs. This may be related to antibacterial immunity by this
common opportunistic bacterium. Further studies are warranted to
assess the role of Chlamydia on immune responsiveness, since Cpn
are considered important in induction and progression of athero-
sclerosis, neurologic or autoimmune diseases. The cytokine profile
differences observed appeared related to antibacterial immunity and
perhaps autoimmunity. Thus, infection of human immune cells with
Cpn may result in significant immune deregulation.
Sa2.56. Homeostatic Chemokines: Organizers of
Cellular Interactions Required for T Cell Priming in the
Pulmonary Environment during the Influenza Infection.
J. Rangel-Moreno,1 J. E. Moyron-Quiroz,1 K. Kusser,1 S.
Goodrich,1 L. Hartson,1 M. Tighe,1 T. D. Randall.1 1Immunology,
Trudeau Institute, Saranac Lake, NY, USA.
Background: Homeostatic chemokines (HCs) play an impor-
tant role in the compartmentalization of B- and T cell environments
AbstractsS160in secondary lymphoid organs (SLOs). Additionally, at early
embrionary steps of the development of these tissues, they organize
the recruitment of inducer cells (CD3-CD4+CD45+), facilitating
their interaction with organizer populations (VCAM+ICAM+).
This cellular event promotes a second wave of chemokine
production, responsible for the latter recruitment of immune cells
to their future homes in B- and T cell zones. Additionally, HCs
have been also detected at sites of inflammation, where they
contribute to the formation of ectopic tertiary lymphoid structures.
Rationale: in our murine model of influenza infection, we detected
HC local production by Northern blot, Taqman-PCR and immu-
nohistochemistry. This finding encourages us to explore the
participation of these molecules during the pulmonary immune
response against influenza viruses.Methods: C57BL/6-, cxcl13 -/-,
plt/plt -/- and lt alpha -/- mice were infected with PR8 influenza
virus and sacrificed at different time points, collecting spleens and
lungs for the analysis of the immune response and the course of the
infection. Cellular interactions and distribution of immune cells was
evaluated by immunohistochemistry and immunofluorescence.
Taqman PCR was a useful tool for measuring chemokine
production. Finally, by using flow cytometry, we determined the
phenotype of immune cells, the functionality of CD8 T cells and the
migration of T and B-lymphocytes to the spleen of uninfected mice.
Results: we found that the absence of homeostatic chemokines is
highly associated to the generation of altered cellular interactions in
the local environment, which modified the course of the infection. It
appears that their production is playing an important role in the
organization of the B- and Tcell microenvironments in the lung, in a
similar way than they do in SLOs. Interestingly, it was appreciated
that in the absence of the draining lymph node (cxcl13 -/-) or
adequate APC-T cell interactions (plt/plt -/-), influenza-infected
mice were still able to mount an adequate primary T cell response,
killing the vast majority of viruses. Even though, the viral clearance
was a little bit delayed in Knockout mice, compared with the fast
killing of virus found in wild type mice. Conclusions: Our findings
reinforce the idea that the lung can work as an alternative place for T
cell priming and that local cellular interactions could be enough for
the initiation of the T cell response against Influenza viruses.
Sa2.57. Human dMemoryT CD4+ T Cells Are Distributed
between Five Phenotypically and Functionally Distinct
Subsets.
E. Amyes, A. J. McMichael, M. F. C. Callan. 1Division of
Medicine, Chelsea and Westminster Hospital Campus, Imperial
College, London, United Kingdom; 2MRC Human Immunology
Unit, Weatherall Institute of Molecular Medicine, Oxford,
Oxfordshire, United Kingdom.
T cells are heterogeneous, varying in terms of their phenotype,
functional capabilities and history of antigen-encounter. The
derivation of a functionally relevant model for classifying
CD4+ T cells has been hampered by limitations on the numbers
of parameters that may be measured using classical 4-colour flow
cytometry. The purpose of this study was to develop a detailed,
functionally meaningful scheme for classifying human CD4+ T
cells. To achieve this we have taken advantage of the introduction
of reagents for 5-colour flow cytometry and have performed
multi-colour FACS analysis on resting, polyclonally-activated and
antigen-stimulated preparations of peripheral blood mononuclear
cells taken from healthy individuals. We show that CD4+ T cells
are predominantly distributed between six of eight possible
subsets identified by expression of CCR7, CD45RA and CD28.One subset corresponds to the previously described naive
compartment and one has the phenotypic properties of the
described central memory compartment. Two of the remaining
four subsets include antigen-experienced CD4+ T cells that
express CD45RA. We find clear differences between CD4+ T
cells within the different subsets in terms of their expression of
cytolytic mediators, their capacity to secrete cytokines and their
ability to proliferate. Furthermore, we find that T cells specific for
different virus infections accumulate within different subsets,
implying that protective immunity against different pathogens
involves CD4+ T cells with different phenotypic and functional
properties. On the basis of these results we propose a cross-
sectional model for classification of peripheral CD4+ T cells.
Knowledge of where T cells lie on this model informs about their
functional capacity and can reflect their history of antigen-
exposure.
Sa2.58. Characterization of the Th Cellular Immune
Response Induced by the Diphtheria Toxin Cry1A
Mutants in Spleen Cells from Intranasally Primed
BALB/c Mice.
Fernando T. Hernandez,1 Gloria G. Guerrero.1 1Escuela de
Ciencias Biologicas. Unidad Torreon, Universidad Autonoma de
Coahuila, Torreon, Coahuila, Mexico.
The objective of this work was to characterize directly the Th1
(IL12p70, IFN-g), Th2 (IL4, IL10) cytokine patterns induced by
spleen cells from BALB/c mice presensibilized by intranasal route
and restimulated with diphtheria toxin Cry1A mutants. Differential
cytokines induced by spleen cells were measured and quantified by
ELISA. We found that each set of toxins are priming different
effectors T cells, measured by. Wild type Cry1A toxins are priming
mostly Th1 cytokine producers whereas DTB quimeric toxins are
priming both Th1-Th2 cytokine producers cells, suggesting that
eight B fragment diphtheria toxin motif exchanged in domain I
from Cry1A toxins are influencing the capacity of these toxins to
modulate the Th cellular immune response. In addition the data
support the assumption that helical topology from domain I
contribute to the cellular properties of the Cry proteins by acting
like epitopes for T cells subsets and this in agreement with
theorethical predictions,using ANTHEPROT program. By other
hand it was observed that Cry1A toxins have the ability to induce
regulatory T cells. In this aspect Cry1A toxins represent a good
model to study several aspects of immunoregulation at the
molecular and cellular level in mice.
Sa2.59. Intranasal Vaccination with Chlamydial
Protease-Like Activity Factor and Interleukin-12
Promotes the Clearance of Pulmonary
C. trachomatis Infection.
Ashlesh K. Murthy,1 Yu Cong,1 Guangming Zhong,2 Bernard P.
Arulanandam.1 1Biology, University of Texas at San Antonio, San
Antonio, TX, USA; 2Microbiology and Immunology, University of
Texas Health Science Center, San Antonio, TX, USA.
Chlamydia trachomatis is a gram-negative bacterium that infects
the human conjunctiva, respiratory and genital tract, and is a cause of
significant morbidity worldwide. Chlamydia has evolved various
immune evasion mechanisms that have posed complex problems in
the development of an efficacious anti-chlamydial vaccine. HeLa
cells infected with C. trachomatis display a progressive reduction in
immunostaining for h2-microglobulin (MHC class I), which
parallels the accumulation of intracellular Chlamydial protease-like
Abstracts S161activity factor (CPAF). Therefore, neutralization of CPAF activity in
vivo may be a viable vaccine approach against C. trachomatis
infection. To this end, we have shown the efficacy of interleukin-12
(IL-12) as a potent mucosal adjuvant. BALB/c mice were immu-
nized intranasally (i.n.) with CPAF + IL-12 and challenged i.n. with
C. trachomatis . CPAF + IL-12 immunized animals displayed
significantly greater reduction (N95%) in lung bacterial load on day
10 after C. trachomatis challenge as compared to mice immunized
with CPAF, IL-12 or PBS alone. CPAF + IL-12 immunization
induced significantly higher titers of serum anti-CPAF total Ab,
IgG2a and IgG2b antibodies as compared to animals immunized
with CPAF, IL-12 or PBS alone. Furthermore, pulmonary anti-CPAF
total Ab, IgG2a and IgA were induced to higher levels in animals
receiving CPAF + IL-12 as compared to other immunization groups.
In addition, CPAF + IL-12 immunized MHC class I deficient mice
displayed reduced bacterial clearance after pulmonary C. tracho-
matis challenge as compared to vaccinated wild type animals.
Together, these results demonstrate that i.n. CPAF + IL-12
immunization induces robust systemic and mucosal antibody
responses and may enhance the clearance of C. trachomatis from
the lungs via a CD8+ T cell mediated mechanism. (Supported
by National Institutes of Health grants AR048973-02 and
SO6GM008194-24)
Sa2.60. Identification of ssRNA Sequences That
Stimulate Innate Immunity through TLRs.
Alexandra Forsbach,1 Carmen Montino,1 Christian Muller,1 Jorg
Vollmer,1 Stefan Bauer,3 Grayson B. Lipford.2 1R&D, Coley
Pharmaceutical GmbH, Langenfeld, Germany; 2R&D, Coley
Pharmaceutical Group, Wellesley, MA, USA; 3Inst. for Medical
Microbiology & Immunology, Technical University of Munich,
Munich, Germany.
Viral infection of the mammalian host triggers the immune
system to innate and adaptive immune responses. Recognition of
these conserved pathogen-associated molecular patterns (PAMP) is
directed mostly by Toll-like receptors (TLR). Ten TLR family
members have been reported in human where TLR9, 8, 7 and 3
respond to nucleic acid derivatives and are intra-endosomal in
location, potentially allowing for viral PAMP recognition.
Recently, we have discovered that single-stranded RNA
(ssRNA) stimulates both human and mouse immune cells to
secrete cytokines and chemokines. In response to ssRNA human
PBMC release IFN-alpha, IFN-gamma, TNF-alpha, IL-6, IL-8,
IL-10, IL-12p40, IP-10 and MCP-1 while Th2 cytokines and
chemokines were not detected. Monocytes were the main source
for TNF production, pDC the main source for IFN-alpha and NK-,
NK/T-cells the main source for IFN-gamma production upon
stimulation with viral derived ssRNA sequences. We have identified
genomic regions and sequences from ssRNA viruses that are
stimulatory and can show that these responses are sequence specific.
ssRNA sequences are currently under pre-clinical investigation and
may serve as potential vaccine adjuvants and immune modulators.
Sa2.61. Mechanism of In Vivo Cytotoxicity Mediated by
CFP10-Specific CD8+ T Cells.
S. M. Behar,1 J. Woodworth,1 A. B. Kamath.1 1Division of
Rheumatology, Immunology, and Allergy, Brigham and WomenTs
Hospital, Boston, MA, USA.
The human pathogen M. tuberculosis is responsible for more
deaths than any other infectious disease. The public health
problems posed by tuberculosis have grown more serious as aconsequence of the global AIDS epidemic and the emergence of
multidrug resistant strains of M. tuberculosis. To combat this
ongoing worldwide scourge, vaccine development for tuberculosis
continues to be a global priority. Most infected individuals develop
long-lived protective immunity, which is able to control and
contain M. tuberculosis in a manner that is T cell-dependent. Thus,
there has been considerable interest in understanding how different
T cell subsets contribute to the primary immune response following
infection, and whether those T cells can be elicited by vaccination
and can mediate protection against M. tuberculosis. This informa-
tion will be required rationally design the best vaccine to advance
into human trials. There is excellent experimental evidence that
CD8+ T cells participate in the immune response to tuberculosis,
which has generated interest in vaccine strategies that elicit M.
tuberculosis-specific CD8+ T cells. To activate CD8+ T cells,
mycobacterial antigens need to enter and be processed by the MHC
class I pathway, which can be targeted by using DNA vaccines or
on live attenuated vaccines strains. Unfortunately, evaluating the
role of CD8+ T cells in host resistance and determining whether
vaccines elicit protective CD8+ T cells has been hampered because
few mycobacterial antigens have been identified that are recog-
nized by CD8+ T cells. Thus, even basic questions concerning the
function of CD8+ T cells during M. tuberculosis infection remain
unanswered.
We have identified an epitope of the CFP10 protein that is
recognized by up to 30% of the CD8+ T cells in the lungs of
mice following M. tuberculosis infection. Interestingly, deletion
of the region of the mycobacterial genome that encodes CFP10
was the original event that resulted in the attenuation of M. bovis
BCG and also attenuates M. tuberculosis. Furthermore, most M.
tuberculosis infected people have evidence of immunity to the
CFP10 antigen. As predicted, CFP10-specific CD8+ T cells were
detected in mice infected with the Erdman and H37Rv M.
tuberculosis strains, but not in mice infected with H37Ra or
BCG. Importantly, CFP10-specific CD8+ T cells recognized M.
tuberculosis infected macrophages. We have previously shown
that in vivo cytolytic activity of CD8+ T cells specific for
mycobacterial antigens could be detected in the spleen, pulmo-
nary LN and lungs of infected mice. We now present our studies
on the how the cytolytic activity is mediated including the finding
that it is independent of the CD95/95L pathway. We now in the
process of determining whether perforin and Rab27a are required
for in vivo cytotoxicity following infection. These studies
highlight the cytolytic function of antigen-specific CD8+ T cells
elicited by M. tuberculosis infection and enable us to determine
whether the cytotoxic function of CD8+ T cells is required
for optimum pulmonary immunity to M. tuberculosis
infection.
Sa2.62. Characterization of an Lck-Independent
Pathway of T-Cell Activation Used by Bacterial
Superantigens: Mechanistic and Therapeutic
Implications on Autoimmunity.
C. Bueno,1,2 G. Criado,1,2 M. L. Baroja,1,2 S. S. Ferguson,2,3 C.
Tsoukas,5 J. Madrenas.1,2,4 1Immunology, FOCIS Centre for
Clinical Immunology and Immunotherapeutics; 2Immunology,
Robarts Research Institute; 3Department of Physiology and
Pharmacology; 4Department of Microbiology and Immunology,
The University of Western Ontario, London, ON, Canada;
5Department of Biology, San Diego State University, San Diego,
CA, USA.
AbstractsS162The current paradigm to explain activation of mature T cells
following engagement of their T-cell antigen receptor (TCR) with
peptide:MHC molecules relies on early activation of the src family
kinase Lck. Lck phosphorylates tyrosine-based activation motifs
on the subunits of the TCR complex, providing sites for recruit-
ment and activation of the syk family kinase ZAP-70. ZAP-70
phosphorylates the transmembrane adapter LAT providing docking
sites for the assembly of multimolecular complexes. These
signalosomes trigger several signaling cascades that cause trans-
location / activation of transcription factors leading to changes in
gene expression. Despite the requirement for Lck under most
conditions, T cell activation can proceed in the absence of Lck
under some circumstances. One of these involves the activation of
T cells by superantigens (SAg), a type of stimuli implicated in the
development of autoimmunity. Also, we and others have shown
that TCR partial agonists with the capacity to induce T cell
tolerance also use an Lck-independent TCR signaling pathway. We
have dissected Lck-independent TCR signaling on human T cells
upon stimulation with SAg. In contrast to Lck-dependent TCR
signaling, early TCR signaling in the absence of Lck was
characterized by lack of phosphorylation of ZAP-70, LAT and
phospholipase (PLC) Cg-1. We found that SAg induced significant
activation of the mitogen-activated protein kinases (MAPK) ERK-
1/-2, Ca2+ influx, and translocation of NF-AT and NF-nB
transcription factors in the lck-deficient T cells, leading to
production of interleukin-2 (IL-2). The Lck-independent T cell
response was blocked with protein kinase C (PKC) and MAPK
inhibitors, but not by inhibitors of PI-3 kinase. In addition, we
observed that IL-2 production by Lck-deficient T cells was
enhanced by lithium chloride (LiCl) and minimally inhibited by
pertussis toxin. Since LiCl stabilizes IP3 generation, which is
involved in Ca2+ influx, we explored the involvement of
alternative PLCs, in particular PLC-h. We found that inhibition
of PLC- h blocked Lck-independent activation of ERK-1/-2
suggesting that this enzyme is involved in TCR signaling. In
conclusion, our data provide initial characterization of the Lck-
independent TCR signaling induced by SAg. This pathway is
dependent on activation of PLC- h and PKC. Since the activity of
PLC- h is regulated by heterotrimeric G-proteins, our data suggest
that SAg-induced T cell activation involves a G protein-dependent
pathway. These findings have implications to design inhibitors of T
cell activation in the context of SAg-induced diseases.
Sa2.63. HLA Phenotype and the Production of IFN-;
and Interleukin-10 in Patients with Chronic Urogenital
Chlamydiosis.
G. N. Drannik,1 V. E. Driyanskaya,1 S. N. Vashchenko,1 A. G.
Drannik,2 L. M. DuBuske.3 1Institute of Urology, Academy of
Medical Sciences, Kiev, Ukraine; 2McMaster University,
Hamilton, ON, Canada; 3Immunology Research Institute of New
England, Gardner, MA, USA.
INTRODUCTION: The intensity of immune response as well
as the predisposition to many diseases, including infectious illness,
has been associated with specific HLA phenotypes.
OBJECTIVE: To investigate the relationship between specific
HLA phenotypes of patients and the predisposition to a chronic
course of urogenital chlamydiosis in addition to in vitro production
of IFN-g and interleukin (IL)-10 by peripheral blood mononuclear
cells (PBMC).
STUDY DESIGN: Seventy-eight patients with urogenital
chlamydiosis were included in this study. HLA phenotype wasdetermined by the standard Terasaki microlymphocytotoxic test
utilizing a panel of anti-HLA-A and -B sera. Cytokine expression
was assessed by commercial ELISA (Immunotec, France) of
supernatants following in vitro culturing of PBMC with or without
mitogen.
RESULTS: Patients with chronic urogenital chlamydiosis were
found to have significantly greater prevalence of the HLA antigens
A10, B27, and B51. Individual analysis of HLA phenotypes
demonstrated that IFN-g production was independent of the
presence of these HLA risk-associated antigens. Conversely,
significantly greater in vitro levels of IL-10 were observed in
83% of patients with the HLA risk-associated antigens for chronic
urogenital chlamydiosis when compared to the study control
subjects.
CONCLUSIONS: HLA antigens A10, B27, and B51 can be
considered as risk antigens associated with development of a
chronic course of urogenital chlamydiosis. In vitro production of
IL-10 by PBMC from patients with chronic urogenital chlamy-
diosis and these HLA risk-associated antigens is significantly
greater than in control subjects. In contrast, IFN-g production is
not dependent upon HLA phenotype. The chronic course of
urogenital chlamydiosis in some patients may be associated with
an immunosuppressive effect induced by interleukin-10.
Sa2.64. Are Probiotics Essential Adjunctive Therapies
for C difficile Enteritis?
K. D. Karpa,1 N. Trenev,1 M. L. McCann.1 1College of Medicine,
PSU, Hershey, PA, USA.
Recurrent C difficile gastroenteritis is increasing in both
incidence and severity, especially in the young and elderly.
Although the antibiotics flagyl and vancomycin are effective in
ameliorating acute symptoms, both are often followed by
recurrences after they are discontinued. Other antibiotics, which
also kill normal flora in addition to the intended pathogen, also
exacerbate or induce relapses in C difficile carriers who are
otherwise asymptomatic. The following cases demonstrate the
need to replace normal flora with a suitable probiotic, not only to
hasten remission but to prevent recurrences and to eliminate the
carrier state.
Case 1) MG, age 85, was admitted for the third time from
assisted care to Intensive Care for intravenous fluids and parenteral
antibiotics. In 10 months she suffered 8 relapses, 6 requiring
extended hospitalization and rehabilitation. Confined to isolation,
she had severe abdominal pain, suicidal depression, thrush, and
persistent diarrhea, only temporarily relieved by flagyl or
vancomycin therapy. Stools were persistently positive for C
difficile. As an alternative to long-term antibiotic therapy, the
family investigated probiotics and asked her doctors to start it.
They declined.
After obtaining legal control of the patient, we discontinued
both vancomycin and flagyl and started probiotics. Four enteric
coated capsules (T Trio, Natren Co) containing 3 live organisms,
L acidophilus, DDS-1 strain, B bifidum, Myeloff strain, and L
bulgaricus were given q.i.d. The stools gradually became formed
and the patientTs symptoms disappeared. Unexpected was the
remmission of arthritis, allowing both prednisone and methotrex-
ate to be discontinued. The dose was gradually reduced to 1
capsule b.i.d. Diarrhea recurred once when probiotics were
inadvertently discontinued. C difficile was eliminated from the
feces after 3 months and remains so with monthly testing for the
past year.
Abstracts S163Case 2) BP, age 74, was admitted to a nursing home for a
diabetic leg ulcer. He soon developed recurrent C difficile diarrhea
treated with flagyl or vancomycin, which recurred whenever
therapy was discontinued. For the next year, long after his leg
ulcer had healed, he was in and out of the nursing home for
retreatment of C diff. Finally probiotics were added, symptoms
abated, and he was able to be discharged home. He also continues
to take prophylactic probiotics, 1 or 2 caps/day and has remained
well for the past year. Other similar cases, one a child, will be
presented.
We suggest that C difficile is an increasing problem not only
because of immune deficiencies, but also because of the increase in
use of antibiotics which kill the normal bowel commensal bacteria.
These normal gut bacteria perform vital immunoregulatory
functions and also close the tight junctions between endothelial
cells which C difficile toxins open, thus allowing unregulated
absorption of both toxins and allergens. The remarkable improve-
ment of arthritis in case 1 fits the theory that certain antigen
epitopes on gut bacteria may cross-react with synovial cells as the
gut becomes more permeable. Probiotics should be considered
essential for recurrent C difficile, either used alone or as adjunctive
therapy.
Sa2.65. Alterations in Th1 Subpopulations Correspond
to Clinical Pathology in Severe Trauma Patients.
A. K. De,1 K. Laudanski,1 R. V. Maier,2 P. E. Bankey,1 J. P.
Minei,3 C. Elson,4 D. Hayden,4 D. A. Schoenfeld,4 L. L.
Moldawer,5 R. G. Tompkins,4 C. L. Miller-Graziano.1 1Surgery,
University of Rochester Medical Center, Rochester, NY, USA;
2Surgery, University of Washington, Seattle, WA, USA; 3Surgery,
University of Texas Southwestern, Dallas, TX, USA; 4Surgery and
Biostatistics, Massachusetts General Hospital, Harvard, Boston,
MA, USA; 5Surgery, University of Florida, Gainsville, FL, USA.
Post-trauma alterations in T-cell surface markers and functions
are suggested to correlate with increased time to recovery and
development of multiple organ dysfunction syndrome (MODS).
Recently, dysfunctional co-stimulation, shifts in T-cell subset ratios
and emergence of regulatory T-cells have all been suggested as
contributors to immunological dysfunction. However, a definitive
link between trauma patientsT T-cell immune alterations and
clinical outcome is still undefined. Here, 31 trauma patients were
divided into two groups based on the severity of their clinical
course (average of the injury score and time to recovery from
MODS; b30 versus N30). We assessed the surface expression of
the co-stimulatory ligand-CD28 and the subset markers-CXCR3
(Th0/Th1), CCR5 (Th1) and CCR4 (Th2) to reflect shifts in T-cell
populations or decreased activation. Regulatory T cell receptor
levels-dual CD4CD25 and CTLA4, were also assessed to indicate
any evidence of immunosuppression. These parameters were
correlated to severity of clinical outcome b30 versus N30.
Additionally, T cell intracellular cytokine (IL-2, IFNg, IL-4, GM-
CSF and IL-10) levels in response to ex vivo PMA/Ionomycin
stimulation were assessed. Patients (n = 31) from three different
clinical centers were followed over 28 days post-injury (sampled at
b12hrs and days 1,4,7,14,21 and 28). Samples from normal
subjects (n = 22) were simultaneously processed. Surface
expression of CCR5 and CXCR3 were significantly decreased
while CCR4 and dual CD4CD25 expression were significantly
increased in T-cells from all trauma patients as compared to normal
subjects. CTLA4 was unchanged. Similarly, stimulated intra-
cellular cytokine (IL-2 and IFNg) levels were significantly reducedin T-cells from all trauma patients as compared to normal subjects.
Some adaptive T cell post-injury alterations may occur in all
patients while other selective aberrant alterations may be contri-
buting to clinical pathology. Consequently, we compared alter-
ations in these immune parameters between the patientsT groups
with the most severe (N30) versus less severely (b30) clinical
courses. Only IFNg and CXCR3 (pb0.05 at 14 days post-injury)
expression were significantly reduced in patients with a poor
clinical course, when compared to the less severely injured
subjects. However, there was no significant difference in CCR5
or IL-2 between the two patient groups. These data suggest a
selective defect in the Th1 populations from the severely injured
patients, rather than a simple expansion of their Th2 cells. Such
selective Th1 defects in severely injured patients could contribute
to their increased clinical pathology.
Sa2.66. The Effect of Immunotherapies on In Vivo
Antiviral Responses to HIV.
S. Andjelic,1 Z. Popmihajlov,1 L. Kelly-Rossini,1 P. Bellman,1
B. Boyle,1 M. Lesser,1 J. Ruitenberg,2 C. Waters,2 R. El Habib,3
K. A. Smith.1 1Medicine, Weill Medical College of Cornell
University, New York, NY, USA; 2Becton Dickinson, San Jose,
CA, USA; 3Aventis Pasteur, Marcy lTEtoile, France.
To determine the capacity of immune-based therapies (IBT) to
boost HIV-specific immunity, a randomized, controlled, phase II
trial tested IM ALVAC (vCP1452) F daily, low-dose SQ
interleukin-2 (IL2) (1.2 mU/M2 BSA). Subjects enrolled had
[HIV] b 50 & [CD4+T] N 400. There were 3-steps of 12–wks each:
Step 1, IBT, ALVAC/IL2; Step 2, bDiagnostic (HAART) Treatment
InterruptionQ (DTI); Step 3, extension of DTI; if [HIV] b 30,000
(b 4.48 log10) and [CD4+T] N 50% of baseline. Endpoints = mean
trough plasma [HIV] wks 21–25 of Step 2, and % of subjects to
enter Step 3=Responders (R). 28/42 subjects completed the trial; 14
were Rs and entered Step 3. The meanF SEM trough [HIV] of r =
3.73 F 0.15 log10 and is significantly lower ( p b 10
4) than
Nonresponders (NR) = 4.88 F 0.08. In Step 2, [CD8+T] increased
2-fold in Rs compared to NRs. R [CD4+T] remained at 100% of
baseline through steps 2 & 3, while NRs lost 20% of [CD4+T].
Analyzed according to IBT regimens, the highest proportion of Rs
was observed in the vaccine groups: placebo = 33%; vaccine =
78%; placebo + IL2 = 33%; vaccine + IL2 = 50%. These data
indicate that a DTI is a valid clinical trial design to test IBTs, &
support the notion that therapeutic immunization may improve the
in vivo antiviral host response.
Sa2.67. An Automated Methodology for Evaluation of
Dendritic Cells in Whole Blood.
C. Smith,1 E. Rabellino,1 J. Wilkinson,1 S. DTCosta.1 1Biomedical
Research Division, Beckman Coulter Inc., Miami, FL, USA.
Dendritic cells (DCs) are potent antigen presenting cells that
play important roles in the induction of immune responses against
microorganisms and tumors and are also vital players in the
induction of tolerance and autoimmunity. Due to these unique
features, DCs are very promising therapeutic tools being used to
manipulate the immune system and form the basis of a number of
ongoing clinical trials as biological adjuvants and modulators in
cancer, infectious disease and autoimmunity. In order to further
study the biology of these relatively rare DCs, as well as evaluate
their efficacy in the various clinical trials, the easy identification
and enumeration of these cells in whole blood, preferably in an
automated and standardized format is pivotal.
AbstractsS164The current study was designed to develop an automated and
standardized methodology for the phenotypic identification and
enumeration of DCs in whole blood. The Beckman Coulter, Inc. 3-
color DC phenotyping reagents were used in conjunction with the
COULTERR PrepPlus 2 automated pipetting instrument, the TQ-
Prep automated lysing and fixing instrument, the CellPrep auto-
mated non-centrifugal washing instrument, and the Cytomics FC500
flow cytometer with totally automated instrument setup, data
acquisition, and data analysis. Normal and abnormal whole blood
samples were evaluated for identification and enumeration of DCs
and results compared to the recommended validated manual
techniques.
The automated methodology enabled a more precise, and
standardized bhands offQ identification and enumeration of DCs in
whole blood. Signal to noise ratios were improved while
maintaining similar cell recoveries compared to the manual
methods in both normal and abnormal blood specimens. Therefore,
the use of validated reagents, precise pipetting, automated
preparation, automated cytometer setup, defined gating strategies,
and automated data analysis and data reduction techniques enables
a standardized phenotypic evaluation and enumeration of rare
dendritic cell events in whole blood.
Sa2.68. Ozonetherapy and Quality of Life in HIV
Positive Patients.
Osmel Gaspar Guerra Segura, Barbara Elias-Calles Fernadez.
1Immunology Lab., Teach.and Gen Hosp. Dr. A. Neto, Guanta-
namo, Guantanamo, Cuba; 2Ozonetherapy Dept., Teach. and Gen
Hosp. Dr.A. Neto, Guantanamo, Guantanamo, Cuba.
We have been done a prospective longitudinal study of positive
HIV patients admited at the sanatory living in Guantanamo
province in a period of two years. The sample includes 17 patients
wich were divided into three aleatory groups. Th e first one was
treated with Ozone, the second with a conventional treatment and
the third with Ozone therapy-conventional treatment. Then we did
an evaluation of some immunohematological and biochemist
parameters and clinical success. At the begining, in 32 % of the
patients the Eritro was high, lymphocytes subsets were within the
normal limits and 69,2 % had an oxidative stress from moderate to
severe and with a good evolution without opportunistic infections.
Sa2.69. Characteristics of Fas Ligand Expression by
Human Cytomegalovirus Infection.
Eung-Soo Hwnag,1 Jung Heon Kim,1 Ye Jin Kwon,1 Hye Jin
Jung,1 Su-Yeon Kim,1 Chung-Gyu Park,1 Chang-Yong Cha.1
1Department of Microbiology and Immunology, Seoul National
University College of Medicine, Seoul, Republic of Korea.
The immune response is regulated not only by cell proliferation
and differentiation, but also by apoptosis. Malfunctions of
apoptosis have been implicated in many forms of human diseases.
Many viral infection disturb the normal regulation of apoptosis in
the various cells. Although Fas-mediated apoptosis is one of the
immune effector pathways leading to the elimination of virus-
infected cells, viruses may escape immune surveillance by
expressing Fas ligand (FasL) on the infected cells. Human
cytomegalovirus (HCMV) infection was reported to induce FasL
on retinal epithelial cells. This study was performed to find out the
induction of FasL in various cell lines and to elucidate the
characteristics of FasL expression in human fibroblasts upon
HCMV infection. The constitutive FasL expression was found on T
cell lines (Jurkat, H9 and CEM), but not on B cell line (Nalm6),osteogenic sarcoma cell lines (Saos-2, G292, HOS and MG63),
astrocytoma cell ine (U373MG), lung cancer cell line (A549),
human fetal lung fibroblasts (FLF), Epstein Barr virus-transformed
lymphoid cell line (LCL) and human kidney cell line (293) by flow
cytometry analysis. Upon HCMV infection with 2 multiplicity of
infection, FasL expression was found only in Saos-2, FLF and
LCL although some cell lines such as G292 and MG63 could be
infected with HCMV. Time-course analysis of FasL expression
with flow cytometry showed that FasL expression was found on
the fibroblast surface immediately after HCMV infection. FasL
expression was down-regulated at 12 hr and then up-regulated at
24 hr and thereafter, but down-regulated after 96 hr. FasL
expression rate in FLF was increased dependent on the increasing
titer of HCMV. Apoptotic death of Jurkat cells were measured by
propidium iodide staining and flow cytometry for the detection of
FasL expression on the cell surface of FLF after Jurkat cells were
co-cultured with FLF infected by HCMV with various infectious
doses. It was found that the apoptotic death rate of Jurkat cells on
the HCMV-infected FLF was proportional to the infectious doses
of HCMV to FLF. Relative changes of mRNA expression of FasL
and HCMV immediate early (IE) and early proteins were measured
by real time polymerase chain reaction in FLF after HCMV
infection at sequential time points. HCMV infection up-regulated
FasL mRNA in less than 6 hr but down-regulated to the basal level
from 12 hr to 24 hr and then up-regulate FasL mRNA thereafter,
but down-regulated after 96 hr. It was similar to the changes of
FasL expression. It was reported that only HCMV IE2 activated the
promoter of FasL, but in this experiment HCMV IE1 and IE2
mRNA were increased and persisted continuously except in 72 hr,
and HCMV UL44 mRNA were increased and persistent. These
results mean that other factors than HCMV IE2 involve in the
regulation of FasL expression. Conclusively the functionally active
FasL could be induced in the restricted cell types by HCMV
infection and would be regulated with many cellular and viral
factors in addition to the earlier reported HCMV IE2.
Sa2.70. Characterization of a Th1/Tc1 Type Immune
Response to the Novel Therapeutic Hepatitis C Peptide
Vaccine IC41 in Humans.
S. Jelovcan,1 H. Wedemeyer,2 V. Buerger,1 E. Tauber,1 C. Klade.1
1Intercell AG, Campus Vienna, Vienna, Austria; 2Medizinische
Hochschule Hannover, Abt. Gastroenterologie, Hepatologie und
Endokrinologie, Hannover, Germany.
IC41 is a vaccine consisting of five synthetic peptides harboring
relevant CD4+ and CD8+ T-cell epitopes of Hepatitis C Virus
(HCV) and the synthetic Th1/Tc1 adjuvant Poly-L-Arginine. In
recent multicenter studies this novel vaccine was investigated in
more than 200 subjects. To monitor immunogenicity, PBMC were
cryo-preserved and T-cell responses were assessed by interferon-
gamma ELIspot and lympho-proliferation. In addition, a highly
sensitive five-color HLA class I tetramer-binding assay was
developed to quantitate and phenotype HCV–specific CD8+
cytotoxic T cells. A HLA-A*0201-transgenic mouse reference
standard was established as long-term quality control of the custom-
made HCV tetramers used in these clinical longitudinal studies.
Here we present the detailed analysis of a well known HCV NS3-
derived HLA-A2 epitope part of IC41. This included staining for a
panel of different surface markers (CD45RA, CCR7, CD27, CD28,
CD38, and HLA-DR), intracellular interferon gamma and perforin.
The evolution of the HCV-specific T-cell response was compared to
recall responses against CMV. Moreover, CD8+ T cell responses
Abstracts S165against the NS3 epitope seen in tetramer or ELIspot analyses were
correlated with proliferative CD4+ T cell responses. Most impor-
tantly, several chronic HCV patients with T cell responses against
this epitope showed a concomitant yet transient decline in HCV
RNA. In summary, these data indicate that therapeutic vaccination
with IC41 can induce cellular immunity against HCV, and results
from these studies provide first insights in the mode of action of
IC41 on human T lymphocytes.
Sa2.71. Hepatitis B Virus X and C Protein Induce
Transcription of hfgl2 Prothrombinase Gene.
Meifang Han,1 Dong Xi,1 Gary Levy,2 Xiaoping Luo,1 Qin Ning.1
1Department of Infectious Disease, Tongji Hospital of Tongji
Medical University, Huazhong University of Science and
Technology, Wuhan, Hubei, China; 2Department of Medicine and
Surgery and Multiorgan Transplant Program, The Toronto
Hospital of the University of Toronto, Toronto, Canada.
Objectives: Fibrinogen–like protein 2/fibroleukin (fgl2) plays a
pivotal role in the pathogenesis of both experimental and human
fulminant viral hepatiits. We have previously reported that the
nucleocapsid protein of murine hepatitis virus 3 which causes
massive hepatocellular necrosis in Balb/cJ mice induces tran-
scription of mfgl2. The aim of this study was to investigate the key
factor(s) of hepatitis B virus (HBV) that induces transcription of
human fgl2 (hfgl2) and the cis-acting elements involved.
Methods: three eukaryotic expressing plasmids of HBV
structure genes encoding C, X and S proteins respectively were
constructed. Expression of these plasmids in eukaryotic cells were
detected by immunohistochemistry and Western blot. A series of 5V
truncated promoter of hfgl2 gene were subcloned into the
luciferase report vector pGL2-basic to form the promoter- report
constructs. Chinese hamster ovary cells and HepG2 cells were
cotransfected with constructs expressing HBV X, C and S protein
respectively and a hfgl2 promoter construct upstream of the
luciferase report gene.
Results: HBV X protein and C protein but not S protein
activates the transcription of hfgl2 gene, showing a an average of
6-fold and 5.4-fold increasing in relative luciferase activity. Further
more, series deletion array of hfgl2 gene promoter show that a
strong regulatory domain from-816 to -468 (relative to the
transcription start site) is responsible for the regulation of hfgl2
gene transcription in response to HBV proteins.
Conclusion: These results indicate that HBx and HBc proteins
are the viral factors that involved in the hfgl2 expression, and the
promoter region of-816 to-468 may contain the cis-elements in
response to viral proteins C and X. This study provides new
insights in understanding the interaction between virus and host
gene expression and its contribution to the pathogenesis of viral
fulminant hepatitis. This work was supported by the National
Science Fund for Distinguished Young Investigators (No.
30225040 for Dr. Q. Ning, No. 30123019 for Dr. XP Luo).
Sa2.72. BCG Vaccination of the Human Newborn
Induces Specific Regulatory CD4+ T Cells.
J. Riley,1 A. Keyser,1 A. Soares,1 H. Fletcher,3 W. Hanekom.1
1Institute of Infectious Diseases, University of Cape Town, Cape
Town, South Africa; 2University of Oxford, Oxford, United
Kingdom.
Regulatory CD4+ T cells (Tregs) are critical for control of
protective immune responses to foreign organisms. We hypothe-
sized that BCG vaccination of the newborn induces specific Tregs,and that a dynamic equilibrium between specific regulatory and
conventional immunity exists.
We incubated whole blood from 36 10-week old South African
infants, routinely vaccinated with BCG at birth, with BCG and
determined mRNA expression of the Treg-specific marker Foxp3
(real time RT-PCR). A median 19% (range of 0–650%) upregu-
lation of Foxp3 strongly suggested presence of specific Tregs.
Tregs may suppress conventional immunity through either
TGF-h, or IL-10, or CTLA-4. We therefore incubated whole blood
of vaccinated infants with BCG in the presence of neutralizing
antibodies against these molecules, and showed a median 11% to
25% increase in soluble IFN-g production (ELISA), suggesting
that these Treg effector molecules do indeed control conventional
BCG-induced immunity.
Because these effector molecules may be made by cells other
than Tregs, we correlated BCG-induced mRNA expression of these
molecules with that of FoxP3. FoxP3 expression correlated with
TGF-h expression (r2 = 0.9, P b 0.001), but not with IL-10 or
CTLA-4 expression. This suggested that TGF-h may be the
effector molecule of mycobacteria-specific Tregs.
To determine whether IL-10-producing Tregs (Tr1 cells) were
present, we measured BCG-induced CD4+ T cell-specific expres-
sion of this cytokine (flow cytometry). Low frequencies of CD4+ T
cells made IL-10 (median 0.01%). However, individual cells were
either IL-10+ or IFN-g+, but not double+, suggesting presence of
both specific Tr1 and specific conventional CD4+ T cell subsets.
(TGF-h could not be measured with this assay.)
Finally, we found that BCG-induced IFN-g mRNA expression
correlated with Foxp3 expression (r2=, P b 0.001), suggesting a
dynamic equilibrium between specific regulatory and conventional
immunity.
We conclude that newborn vaccination with BCG does induce
specific Tregs, which may control conventional effector/memory T
cell immunity.
Sa2.73. Effect of an Anti-Inflammatory Pentapeptide
Produced by Entamoeba histolytica upon Gene
Expression Related to Inflammation/Woundhealing.
R. Silva,1 G. Rico,1 I. Estrada,2 R. Ramos,2 D. Arenas,3
J. Gimenez,1 A. Torres,4 M. Morales,1 R. Kretschmer.1 1UIM
Inmunologia, IMSS, Mexico, DF, Mexico; 2Inmunologia
Molecular, IPN, Mexico, DF, Mexico; 3UIM en Genetica, IMSS,
Mexico, DF, Mexico; 4Genetica de Poblaciones, IMSS, Mexico,
DF, Mexico.
INTRODUCTION
The monocyte locomotion inhibitory factor (MLIF), an anti-
inflammatory pentapeptide (Met-Gln-Cys-Asn-Ser) produced by
Entamoeba histolytica, inhibits the in vitro and the in vivo
locomotion of human monocytes (PBMN), without affecting that
of neutrophils or eosinophils. MLIF also virtually cancels the
production of reactive oxygen and nitrogen intermediates (ROI,
RNI) in PBMN and nPMN, and again spares eosinophils from
this effect. MLIF also inhibits delayed hypersensitivity skin
reactions to 1-chloro-2-4dinitrobenzene in guinea pigs and
gerbils. All this may contribute to the regeneration without
scarring of the affected organs (i.e. liver, skin) found on
recovery after treatment.
OBJETIVE
To determine the effect of MLIF on the profile of inflammation/
woundhealing gene expression in the human cell line MRC-5,
using a microarray device.
AbstractsS166MATERIAL AND METHODS
A 96% pure construct of MLIF and the human cell line MRC-5
were employed. The cell line MRC-5 was expanded in MEM
containing 10% bovine fetal serum until reaching the adequate cell
count. Cells were adjusted at 5106 cells/5 ml and were placed in
6-well plates, incubating them for 24h at 378C with 5% CO2 in:
PMA-Ionomicine (10ng/106cells/ml, 0.5Ag/106cells/ml), or PMA-
Ionomicine+MLIF (10ng/106cells/ml, 0.5Ag/106cells/ml, 50Ag/
106cells/ml). Controls consisted of cells incubated without any
stimulus or cells exposed to 50Ag/106cells/ml MLIF alone. Cells
were treated and lysed in 1ml of TRIZOLR. Total RNAwas isolated
following the manufacturer´s instructions and DNA was removed
with DNAase I. RNA integrity was confirmed by agarose gel
electrophoresis.
The synthesis of labelled cDNAwith 33P was started from total
RNA (Human Cytokine Labelling PrimersR) and purified in
Sephadex G-25R columns. The cDNA was hybridized in gene
microarray membranes (Panorama Human Cytokine Gene
ArraysR) Membrane were exposed using BioMax MR X-ray
filmR. Spots were quantified by digital analysis. Average values of
housekeeping genes and negative controls were used to adjust
values of the genes in the membrane. We used 0.999 % confiability
and a Z value of 3.090.
RESULTS
MLIF modifies the gene expression of cultured MRC-5 cells
(65 genes are over-expressed, 46 genes diminish their expression).
The over-expressed genes included: MCP-1, a2 integrin and C-Kit.
Under-expressed genes include: IGF-BP6, INFg, and MIP 1h.
DISCUSSION AND CONCLUSIONS
The MLIF effect on this panel of 375 inflammation/woundheal-
ing genes using MRC-5 cells are multiple and complex. Possible
pro, anti-inflammatory and woundhealing. Profiles may correlate
with the known biological effects of MLIF (Supported by IMSS-
FOFOI grant 2003-011).
Sa2.74. Spectrum of CD1d-Restricted T Cells: Control of
Anti-Viral and Anti-Tumor Responses.
R. Wang,1 S. C. Yue,1 P. Ilyinskii,1 J. J. Van der Vliet,1 Kazuhiko
Yanagisawa,1 A. Shaulov,1 Q. He,2 M. J. Koziel,2 S. P. Balk,1 M.
A. Exley.1 1Cancer Biology, Hematology / Oncology, Beth Israel
Deaconess Medical Center, Boston, MA, USA; 2Infectious
Diseases, Beth Israel Deaconess Medical Center, Boston, MA,
USA.
bInvariantQ TCR-a+, non-invariant diverse ah+, and gy+
CD1d-restricted T cells are subsets of dNKTT cells with distinct
locations and functions. CD1d-restricted T cells can rapidly
produce large amounts of anti- &/or pro-inflammatory cytokines
and chemokines depending on microenvironment and stimulus.
Systemic stimulation of invariant NKT cells leads to transient
protection against numerous diseases through indirect activation of
various antigen presenting cells (APC), B and T cells, all of which
can express CD1d, as well as NK cells. CD1d-restricted T cell
activation can rapidly stimulate APC pro-inflammatory IL-12
production. This was modeled by direct ligation of human APC
CD1d in vitro. In vivo, both invariant NKT cell activation and
CD1d ligation could protect against acute picornavirus infection,
suggesting re-examination of results involving CD1d bblocking.Q
CD1d-restricted T cells are also essential for optimal physiological
response against picornavirus through augmentation of IL-12
production and NK cell activation. A case report further supports
an antiviral role for human invariant NKT cells. However,excessive activation of local CD1d-restricted T cells can lead
(directly and indirectly) to tissue damage. High levels of IFN-g
producing Th1 resident hepatic CD1d-restricted T cells may protect
against acute infection, yet contribute to pathology during chronic
infections such as hepatitis C through amplified and modified Th1/
Th2 responses to tissue CD1d. Analogous results were found in
model viral myocarditis. Invariant NKT cells are also essential for
optimal model anti-tumor responses against spontaneous cancer,
metastases, and tumor vaccines. Cancer progression correlates with
failure of patient invariant NKT cells to activate protective anti-
tumor responses. This defective response can be corrected in vitro
and a phase 1 trial has been designed. Finally, the presence of NK
cell markers is not essential for function. Therefore, CD1d-
restricted T cells are diverse multi-functional cells at the innate-
adaptive immune response interface. Therapeutic approaches
exploiting distinct CD1d-restricted T cell populations are being
explored, for example in graft-versus-tumor responses and graft-
versus-host disease suppression.
Sa2.75. Establishment of a Substitutive SARS Murine
Model and Its Application in SARS Study.
Weiming Yan,1 Chuanglong Zhu,1 Xiaoping Luo,1 Qin Ning.1
1Department of Infectious Disease, Tongji Hospital of Tongji
Medical College, Wuhan, Hubei, China.
Objectives: To establish a substitutive murine model of severe
acute respiratory syndrome (SARS) with murine hepatitis virus
type 3 (MHV-3) and to investigate the interaction between SARS
virus and host immune response, mfgl2 prothrombinase gene as a
representative of host genes.
Methods: The Balb/cJ mice were infected with 100PFU of
MHV-3 via trachea and Balb/cJ mice injected with sterilized saline
were served as control. Survival rate and pathological features in
organs were observed. Virus titers in different organs were
determined on monolayer of L2 cells by a standard plaque assay.
Virus distribution and cellular localization were studied by in situ
hybridization. As a proinflammatory gene, mfgl2 expressions were
measured in the lung by in situ hybridization and immunohisto-
chemistry to investigate the role of mfgl2 in the pathogenesis of the
disease.
Results: Mice infected with MHV-3 via trachea developed
typical interstitial pneumonia with pathological characteristics of
leukocyte infiltration, hyaline membranes formation, exudation of
fibrin fluid within the lung, presence of vascular thrombosis in the
pulmonary vessels and died within 5 days, while all mice in control
group survived with no inflammation in lung. Moderate histo-
logical changes were also found in liver and spleen but mild in
other organs examined. MHV-3 particles were identified in the
cytoplasm of alveolar epithelia, infiltrating cells in the lung, serous
gland epithelium of the trachea/bronchus, cells (lymphocytes and
others) in the periphery of the germinal centers in the spleen,
hepatocytes, brain neurons, epithelia of the distal renal tubules,
epithelium of small intestine, myocardium cells. mfgl2 expression
was evidenced in lymphocytes and mononuclear inflammatory
infiltrates within stroma and in terminal and respiratory bronchioles
associated with fibrin deposition and micro-vascular thrombosis.
Conclusions: The pathological changes in this substitutive
SARS murine model mimic the characteristics of SARS in human.
In addition to the physical damage of virus replication in lung and
immune organs including spleen, liver, the up-regulation of novel
gene mfgl2 in lung in association with fibrin deposition and micro-
vascular thrombosis may play a vital role in the development of
Abstracts S167SARS. This work was supported by national SARS 973 project of
China (fund No. 2003CB514100) and National Science Fund for
Distinguished Young Investigators (No. 30225040 for Dr. Q. Ning,
No. 30123019 for Dr. XP Luo).
Sa2.76. Direct Innate Immune Activation by Human
Naive B Cells Via Combined TLR9 and RP105.
Kazuko Yamazaki,1 Takashi Yamazaki,2 Takuma Hayashi,1 Kazuo
Sugane,1 Kazunaga Agematsu.1 1Department of Infectious
Immunology, Graduate School of Medicine,Shinshu University,
Matsumoto, Nagano, Japan; 2Department of Pediatrics, Shinshu
University, Matumoto, Nagano, Japan.
Recognition of microbial infection and initiation of host
defense responses is controlled by multiple mechanisms. B cells
provide an important link between the innate and adaptive
branches of the immune system. However, direct involvement of
B cells in imparting potentially protective responses is unclear.
We here focused the relevance of naive B cells via TLR9/RP105
to innate immunity by secreting essentially germline encoded
polyreactive antibodies. The proliferation of CD27+ memory B
cells was higher than that of CD27¯naive B cells by CpG DNA
stimulation as reported. The proliferation of naive B cells was
extremely higher than that of memory B cells by CpG DNA and
anti-RP105 mAb stimulation. The expansion and cell size were
dramatically increased by combined CpG DNA and RP105
signaling. The signaling through RP105 increased the expression
of CD69 and CD86. The life span of naive B cells was prolonged
by anti-RP105 MAb and CpG DNA plus anti-RP105 MAb. Total
immunoglobulin and Staphylococcus Pneumoniae specific IgG/
IgM production by adult naive and cord blood B cells ware
recognized in the presence of CpG DNA/anti-RP105 mAb.
Interestingly, IL-21 enhanced the production of Staphylococcus
Pneumoniae specific IgG/IgM. However, the differentiation of B
cell to plasma cells was not affected by anti-Rp105 mAb
stimulation. Both TLR9 and RP105 signalings activated NF-kB
pathway. Naive B cell activation via TlR9/RP105 pathway may
play a beneficial role through profound their expansion and
generation of antigen specific low affinity antibodies. This innate
immune system by naive B cells may detect infections and trigger
antimicrobial host defense responses.
Sa2.77. Evaluacion del Numero de Linfocitos T
Reguladores en Pacientes Con Tuberculosis.
L. R. Gamez,1,2 M. Rocha,1 R. Gonzalez,2 S. Romano,1 D. P.
Portales.1,2 1Inmunologia, Facultad de Ciencias Quimicas de la
Universidad Autonoma de San Luis Potosi, San Luis Potosi, San
Luis Potosi, Mexico; 2Inmunologia, Facultad de Medicina de la
Universidad Autonoma de San Luis Potosi, San Luis Potosi, San
Luis Potosi, Mexico.
RESUMEN
Introduccio´n: Las ce´lulas con funcio´n inmuno-reguladora ma´s
ampliamente caracterizadas son los Linfocitos T CD4+ CD25bright
cuyo papel en la regulacio´n de enfermedades inflamatorias y
autoinmunes es preponderante. Por otro lado la tuberculosis es una
enfermedad causada por el bacilo Micobacterum tuberculosis y se
caracteriza por cursar con dan˜o tisular severo, en el pulmo´n, debido
principalmente a la propia respuesta inmune del enfermo por lo que
posiblemente los mecanismos de regulacio´n de esta respuesta
inmune quiza´s este´n alterados. En este estudio analizamos el
numero de ce´lulas inmuno-reguladoras en sangre perife´rica de
pacientes con tuberculosis en comparacio´n con sujetos sanos, ası´como la expresio´n del gen GITR el cual se ha reportado que esta
presente en estas ce´lulas y que abate su funcio´n supresora.
Objetivo: En ratones las ce´lulas T reguladoras CD4+ CD25+
tienen un papel preponderante en la prevencio´n de feno´menos de
autoinmunidad. Estas ce´lulas reguladoras tambie´n se han descrito
en humanos. En este trabajo investigamos la presencia y el fenotipo
de estas ce´lulas en la sangre perife´rica de individuos con
tuberculosis pulmonar activa y en sujetos sanos.
Me´todos: Se estudiaron doce pacientes con tuberculosis y doce
sujetos sanos. Se analizo´ el numero de las diferentes subpobla-
ciones de linfocitos T CD4+ en sangre perife´rica por citometria de
flujo, ası´ como la expresio´n de GITR por RT-PCR en ce´lulas
mononucleares de sangre perife´rica.
Resultados: Los niveles de los diferentes tipos celulares tanto en
pacientes como en los sujetos control en la sangre perife´rica tienen
un rango de valores muy amplio, no observa´ndose diferencia
significativa entre ambos grupos a excepcio´n de las ce´lulas pro-
ductoras de IL-10 que en los pacientes es mas grande comparado con
los controles.Conclusiones: Para las ce´lulas Treg., las que producen
TGFb y las CTLA-4+ nuestros resultadosmuestran valores similares
tanto en pacientes como en sujetos sanos que nos indica que estas
ce´lulas no se ven afectadas con la presencia de la enfermedad solo las
que son IL-10+ muestran valores mas elevados en el grupo de los
pacientes aunque este estudio se llevo a cabo en sangre perife´rica en
donde el numero de estas ce´lulas es muy pequen˜o con lo que
pensamos que seria de gran importancia el desarrollar el mismo
estudio pero directamente en el sitio de la lesio´n.
Sa2.78. Direct Epitope Discovery for Yellow Fever Virus
Asibi-17D.
A. Collymore-Slovak,1 A. Gilb,1 C. Roberts,1 M. Jones,1 W. H.
Hildebrand.1 1Microbiology and Immunology, University of
Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
Major histocompatibility complex (MHC) class I molecules
bind intracellular peptides for presentation to cytotoxic T
lymphocytes (CTL). CTL respond to foreign peptides presented
by the class I of virus-infected and cancerous cells. Identification of
peptides presented by class I molecules during a yellow fever virus
(YFV) infection is important for understanding in vivo immume
responses to infection and for comparing these responses to those
arising from vaccination with Yellow Fever-Asibi [17D]. YFV
belongs to the family Flaviviridae and is a positive-sense, single-
stranded, encapsulated RNA virus. The virus enters cells by
receptor-mediated endocytosis, viral RNA synthesis occurs in the
cell cytoplasm, and viral protein synthesis proceeds in the
endoplasmic reticulum. Virions mature in the endoplasmic
reticulum and are released through the cellTs plasma membrane
by exocytic fusion. YFV is spread to a human host when the saliva
of an infected female mosquito mixes with capillary blood during a
meal. The virus then infects vascular endothelial cells and is able to
spread to the reticuloendothelial system where it replicates and
secondary viremia may occur causing the immune system to be
overwhelmed. To understand which peptide epitopes distinguish
the class I MHC of YFV-infected cells, we selected the U937
human macrophage cell line for characterization. We transfected
HLA-A*0201 and B*0702 into the U937 cell line and then
infected the cell line with YFV strain 17D. U937 cells secreting
either A*0201 or B*0702 are cultured in a hollow fiber bioreator
unit, the class I HLA is harvested from both infected and
uninfected cells, and the peptide epitopes unique to YFV infected
cells identified by comparative mass spectrometric mapping and
AbstractsS168MSMS sequencing of peptides unique to YFV infected cells.
Identification of MHC class I epitopes unique to YFV infected
cells will be useful for understanding to which of the epitopes
available on infected cells does the YFV vaccine elicit, or fail to
elicit an immune response.
Sa2.79. Clonal Organization of T Cell Memory:
Paradigm of bFocused DiversityQ Contributes to
Repertoire Flexibility.
Yuri N. Naumov,1 Shalyn C. Clute,1 Elena N. Naumova,2 Jack
Gorski,3 Liisa K. Selin.1 1Department of Pathology, University of
Massachusetts Medical School, Worcester, MA, USA; 2Department
of Family Medicine and Community Health, Tufts University
School of Medicine, Boston, MA, USA; 3Blood Research Institute,
The Blood Center of S.-E. Wisconsin, Milwaukee, WI, USA.
The human memory CD8 T cell receptor (TCR) repertoire
specific to the influenza A virus, HLA-A2.1-restricted M158–66
epitope was analyzed. b-TCR clonotypic sequences of tetramer-
selected cells or cells from the bulk cultures revealed a clonally
diverse population of responding T cells. These cells used BV17
almost exclusively and focused on a similar CDR3b structure, a
paradigm we refer to as bfocused diversityQ. This was observed in
four different HLA-A2.1 individuals. We determined a strong
clonal selection based on a-TCR usage as all expressed a-TCRs
originated from AJ42 and multiple AV (AV27, AV8.1, AV 8.6 and
others) families. Furthermore, there was a CDR3a motif identified
utilizing AGA(Gn)GG or similar amino acid sequences. Some of
these CDR3a only differed by the length of the run of Gly residues.
Thus, the pattern of TCR repertoire in the context of bfocused
diversityQ extends to both of the TCR chains. This complex
repertoire structure was highly resistant:-not only was it stable over
time, but persisted under condition of highly variable antigen
stimulations in vitro. These results suggest that the ab-TCR
repertoire flexibility in the context of bfocused diversityQ might
allow antigen-specific immune responses to accommodate
extremes of antigen challenges. (NIH Grant: AI-49320).
Sa2.80. Capture and Specific Delivery of Exogenous
Lipid Antigens by Apolipoprotein E.
P. van den Elzen,1 S. Garg,2 M. Brigl,2 J. E. Gumperz,2 F. M.
Sacks,3 G. S. Besra,4 D. B. Moody,2 M. B. Brenner.2 1Pathology,
Brigham and WomenTs Hospital, Harvard Medical School, Boston,
MA, United Kingdom; 2Medicine, Division of Rheumatology,
Immunology and Allergy, Brigham and WomenTs Hospital,
Harvard Medical School, Boston, MA, USA; 3Nutrition, Harvard
School of Public Health, Boston, MA, USA; 4School of
Biosciences, University of Birmingham, Edgbaston, Birmingham,
United Kingdom.
T lymphocytes recognize antigens presented by antigen
presenting cells (APC). Peptides are presented by the MHC
system, with endogenous peptides presented by MHC class I and
exogenous peptides presented by MHC class II. In contrast to the
MHC system, CD1 molecules survey different intracellular
compartments for lipid antigens which are presented at the APC
surface to lipid-reactive T cells. Recently, saposins were shown to
mediate an important step in presentation by transferring lipid
antigens from lysosomal lipid bilayers to CD1 molecules.
However, the mechanisms of exogenous lipid antigen delivery to
CD1 antigen loading compartments are not known. Serum
lipoproteins are the primary mediators of extracellular lipid
transport for metabolic needs, however their role in lipid antigenpresentation has not been investigated. Here, we define the
pathway mediating exogenous lipid antigen delivery by apolipo-
protein E (apoE) to achieve antigen presentation by CD1. In human
serum, lipid antigens sequester in the very low density lipoprotein
(VLDL) fraction with antigenicity being dependent upon apoE-
mediated uptake into dendritic cells. In addition, we have found
that dendritic cells themselves secrete apoE, which can then
efficiently capture lipid antigens. ApoE-lipid antigen complexes
are internalized by receptor mediated uptake resulting in rapid and
efficient antigen delivery to endosomal lipid antigen loading
compartments enabling CD1 restricted T cell activation. The
immune system has thus co-opted an important component of
lipid metabolism for the presentation of lipid antigens.
Sa2.81. Supertype Analysis: Definition of Overlapping
Peptide-Binding Capacities for MHC Class I Molecules.
R. Buchli,1 R. S. VanGundy,1 C. F. Giberson,1 W. H. Hildebrand.2
1Research Department, Pure Protein L.L.C., Oklahoma City, OK,
USA; 2Department of Microbiology and Immunology, University
of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
Major histocompatibility complex (MHC) proteins are encoded
by highly polymorphic genes and play a crucial role in immunity.
The polymorphisms that distinguish MHC molecules are predom-
inantly positioned to modify peptide binding. However, recent
studies seem to indicate that not all genetically diverse MHC
molecules are functionally different. As such, classification of
MHC molecules into functional supertypes on the basis of
overlapping peptide-binding specificities has become an important
issue, with direct implications for the development of epitope-
based vaccines with wide population coverage. Unfortunately,
direct experimental validation of multiple members of these
supertypes has been tremendously difficult because of lack of
high quality human leukocyte antigen (HLA) molecules. In this
study, we describe a direct biochemical approach for classifying
HLA molecules into supertypes using recombinant soluble HLA
(sHLA) proteins. A set of 53 single-specificity sHLA receptors was
screened for their binding capacity towards a series of unrelated
fluorescent-labeled peptide ligands. During the process, each
peptide candidate was incubated with activated sHLA, and the
peptide/HLA interaction was monitored over time. Data analysis
showed various degrees of overlapping peptide binding capacities
among the alleles tested, reflecting the ability of MHC class I
alleles with genetically more or less distinct peptide binding sites to
share the binding of identical peptides. As a result of this study, we
were not only able to better define supertype classification but also
to include additional alleles not currently characterized. Taken
together, this novel HLA screening procedure represents a versatile
tool for supertype-binding analysis and will have profound use in
the understanding of antigenic peptide selection, degeneration and
discrimination during T-cell mediated immune responses. A
complete knowledge of this phenomenon finds utility in epitope
design for the development of HLA based vaccines and immuno-
therapeutics.
Sa2.82. Development and Validation of Fluorescence
Polarization-Based Competitive Peptide Binding
Assays-New Screening Tools for Epitope Discovery.
R. S. VanGundy,1 R. Buchli,1 C. F. Giberson,1 W. H. Hildebrand.2
1Research Department, Pure Protein L.L.C., Oklahoma City, OK,
USA; 2Department of Microbiology and Immunology, University
of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
Abstracts S169Various approaches are currently proposed to successfully
develop therapies for the prevention and treatment of infectious
diseases and cancer. One of the most promising approaches is the
development of vaccines that elicit cytotoxic T lymphocyte (CTL)
responses. In order to facilitate CTL-specific epitope discovery and
validation, we have developed a state-of-the-art biochemical HLA
class I peptide-binding assay including A*0101, A*0201, A*0301,
A*1102, A*2401, A*2902, A*6801, A*6901, B*0702, B*0801,
B*1501, B*2705, B*3505, B*4001, B*4402, and Cw*0801. The
technique is based on competition and uses FITC-labeled class I
binding reference peptides in combination with highly purified,
recombinant soluble HLA class I molecules to quantitatively
measure the binding capacity of non-labeled peptide candidates.
Fluorescence polarization allows direct, real-time measurements in
solution without separation steps. The assay shows excellent
reproducibility and sensitivity with dynamic ranges between 170 to
240 mP. Optimal loading of synthetic peptides into fully assembled
soluble HLA-A*0201 complexes is enabled by thermal destabili-
zation at 538C for 15 minutes demonstrating that efficient peptide
exchange does not require the removal of endogenous peptides
from the reaction environment. Multiple assay-specific parameters
have been determined showing that the binding of the selected
fluorescent peptides to soluble HLA is effective with many of the
molecules (21–37%) binding exogenously added peptides. To
further explore the specificity of binding and to demonstrate the
immunologic relevance of the FP-based competition assay, a panel
of HLA A*0201-restricted and naturally processed peptides have
been tested for binding to sHLA-A*0201. In this validation
approach, a panel of 15 peptides was selected to represent binders
that reflect several orders of magnitude of A*0201 binding affinity.
Obtained IC50 values were directly compared to the values
published from direct cell-free I125-radioligand assays and cellular
based fluorescence assay systems. Results proved to be in excellent
agreement with each other also allowing the formulation of an FP-
based category system, where peptides with an FP-based IC50
value of 5 AM and lower were considered high affinity binding, 5–
50 AM IC50 values were considered medium-affinity binding, and
50 -1,000 AM IC50 values were judged as low-affinity binding.
With the ability to exactly determine molecular affinity parameters,
our FP-based HLA competition assays are of prime importance for
the development of immunomodulating compounds. Built into a
high-throughput screening platform, this new assay approach will
bridge current screening gaps and considerably shorten the route to
clinical development considering the myriad of possible peptide
sequences, coupled with the genetic variability of MHC molecules
among individuals.
Sa2.83. Anthrax Toxins Impair Pulmonary Dendritic
Cell Functions: Implications in Pathogenesis.
A. Cleret,1 A. Quesnel-Hellmann,1 J. Mathieu,1 D. Vidal,1 J. -N.
Tournier.1 1Immunology Unit, CRSSA, La Tronche, France.
Anthrax is a life-threatening disease of present and future
concern, especially since it was used as a bioterrorist weapon in
2001. Bacillus anthracis, the agent of anthrax, secretes two critical
virulence factors, the lethal toxin (LT) and the edema toxin (ET).
To investigate the role of toxins in the physiopathology of
inhalational anthrax, we evaluated the functions of murine lung
dendritic cells (LDC) upon infection with B. anthracis strains
secreting LT, ET, both toxins, or with a non toxinogenic strain.
Briefly, isolation of LDC from BALB/c mice was performed after
digestion by collagenase and DNase followed by positive selectionwith CD11c microbeads. We purified three cell populations gated
on CD11c/CD11b expression: (i) a CD11chigh/CD11blow; (ii) a
CD11cint/CD11bint and a (iii) CD11clow/CD11bhigh population.
Upon infection with LT expressing strains, we observed a
down-regulation of CD86 and MHC class II expression on
CD11cint cells. LDC infected with a non toxinogenic strain
induced the secretion of TNF-alpha, IL-10, IL-6 but a low level
IL-12p70. LT producing strains selectively inhibited the production
of TNF-alpha, IL-10 and IL-6, whereas ET producing strains
inhibited TNF-alpha, did not affect IL-10 and increased signifi-
cantly IL-6 production, as compared to a non toxinogenic strain.
These results suggest that anthrax toxins produced during infection
impairs LDC functions and suppress the innate immune response.
This may represent a new strategy developed by B. anthracis to
escape the host response and spread through the alveolar wall.
Sa2.84. Rheumatic Fever: Development of an Animal
Model Using Streptococcal M1 Recombinant Protein.
F. F. Alcantara,1,2,3 E. Postol,1,3 E.R. Alencar,1,3 V. R. Assis,1 L.
Demarchi,1 J. Kalil,1,2,3 L. Guilherme.1,3 1Immunology Laboratory,
Heart Institute (InCor), Sao Paulo, Sao Paulo, Brazil; 2Allergy
and Clinical Immunology, University of Sao Paulo, Sao Paulo,
Sao Paulo, Brazil; 3Institute for Immunological Investigations,
University of Sao Paulo, Sao Paulo, Sao Paulo, Brazil.
Rheumatic fever is an inflammatory autoimmune condition
following 3% of non treated group A streptococci pharyngitis of
certain M serotype strains. Heart valves are permanently damaged
by inflammation leading to heart valve replacement surgery. In
addition to a cellular heart valve attack, anti-basal ganglia
autoantibodies arising later in the autoimmune process target
caudate and subthalamic nuclei antigens, being responsible for the
neurologic symptoms of SydenhamTs chorea. Antibodies targeting
both heart antigens and M proteins were found in blood of affected
patients. M protein and cardiac valve derived proteins were shown
to be recognized by T cell clones obtained from lymphocytes
infiltrated in rheumatic patient cardiac valves (Guilherme et. al,
1995, Circulation 92:415-20). Therefore, antigenic mimicry
between streptococcal M protein epitopes and heart components
has been proposed as the triggering factor leading to the heart
autoimmune attack. The understanding of the disease process and
therapeutic advances has been hampered by the lack of an
adequate animal model for the disease. We have injected Lewis
rats with streptococcus recombinant M1 protein 500ug on day 0
followed by 500ug boost on day 7 and sacrifice on day 21, in
order to reproduce a recently described animal model of
rheumatic fever (Quinn, A. et al, 2001, Infect.Immun.
69(6):4072-78). Rat hearts were subjected to histopathological
analyzes. Spleen and lymph node lymphocyte cells, as well as
sera, were harvested and probed against ABC domains of the M1
complete extracellular protein, AB domains (N-terminus), or C
domain (C-terminus) and myosin or control proteins. Rat-immu-
nized cells were used for FACS analysis to study their phenotypic
profile and cytokine production. We have obtained specific
lymphoproliferative and humoral immune responses against M1
ABC, AB and C domains of the S.pyogenes M1 protein. The
proliferation index reached above 10, and the antibody titers were
significantly higher than in controls, up to the 12.800 fold
dilution, but we could not detect any proliferative nor humoral
response against myosin. The anathomopathological evaluation of
rat hearts displayed presence of lymphomononuclear infiltration
and signs of lesions suggestive of of Rheumatic Fever in some of
AbstractsS170the immunized animals. We are currently analyzing different
immunization protocols in order to reproduce the disease in Lewis
rats. We believe that the definition of the M protein minimal
epitope(s) responsible for RF will certainly contribute to better
understanding of the disease process.
Sa2.85. Effect of the Zinc in the Viability and
Differentiation in Human and Murine Cells.
G. B. Vega,1 A. Polo,1 M. E. Morales,2 G. Rico.2 1Coordinacion
de Educacion Medica Continua Facultad de Medicina, UNAM,
Mexico, DF, Mexico; 2UIM en Inmunologia. Hospital de Pediatria
CMN-SXXI, IMSS, Mexico, DF, Mexico.
The majority of the studies done mainly in murines show the
resulting alterations from Zinc deficients and the stimulus or the
protection induced by the metal in some cell cultures, however,
there are evidences that demonstrate that Zinc supplementation in
vitro or in vivo can cause disturbs in the immune system.
Our study has as objective to establish which is the influence of
Zinc in the maturity and viability of different cellular lines (U937,
human monocytes and mice bone marrow macrophages), as well as
the effect that and identical stimulus (proportioned by Zinc) can
generate in the same cellular line but from different origin.
The monocytes were obtained from vein blood from healthy
individuals through the Boyqm method. The bone marrow cells
were obtained from the femur of BALB/c mice, 6 to 8 weeks old,
and the U-937 cells from aliquots maintained in culture.
5106 cell/well were added in sterile plastic micro plates, then
it was added the medium required for each cellular line with or
without the stimulante factor required for its differentiation
(supernatant of L 929 cells with the granulocyte macrophage
colony stimulated factor for the bone marrow cells of mouse and
PMA for the human monocyte and U-937 cells) without Zinc or
with different dose of metal (0.05–1.0 mM). They were in culture
for 11 days at 378C with 5% of CO2. Microscopic observation were
done at 3,9 and 11 days, for the morphologic analysis and cellular
differentiation; the viability and total recount of cells were
determinated on days 6 and 11.
The viability of cells of bone marrow of mouse, mononuclear
phagocytes and U-937 cells incubated with 0.05 and 0.1 mM of
Zinc was similar to the controls without Zinc (90%). With 1.0 mM
of metal, viability decreased considerably (P b 0.0006), 50% of the
mouse bone marrow cells and human MP, 80% in U-937 cells. The
number of cells increased and there was no cellular differentiation
for the morphologic characteristics observed at the beginning of the
culture (small and round cells) were not modified during the stated
lapse of time (11 days). Deleterious effect induced with this dose of
Zinc was observed in the three cellular lines.
Variations in number, size, morphology and viability of the
cells observed with the different concentrations of the metal, and/or
with the same doses at different times suggest that the effect
exerted by Zinc depends not only of the used dose but also of the
period of its interaction with cells.
Sa2.86. IL-27/WSX-1 Signalling: An Important Role in
the Pathogenesis of Experimental Septic Peritonitis.
Stefan Wirtz,1 Ingrid Tubbe,1 Mark Birkenbach,2 Richard S.
Blumberg,3 Neurath F. Neurath.1 1I. Medical Department,
Univesity of Mainz, Mainz, Germany; 2Department of Pathology
and Anatomy, Eastern Virginia Medical School, Norfolk, VA, USA;
3Gastroenterology Division, Brigham and WomenTs Hospital,
Harvard Medical, Boston, MA, USA.Sepsis represents a significant health problem worldwide. At
present, there are only a few effective therapeutic approaches for
the treatment of septic patients and mortality rates still remain high.
In the present study we elucidated the potential role of the recently
discovered heterodimeric cytokine Interleukin-27 (IL-27) in the
pathogenesis of septic shock or acute polymicrobial sepsis.
In a first series of experiments, we injected mice deficient for
the EBI3 subunit of IL-27 or WT controls intraperitoneally with 40
mg/kg E. coli LPS. As a result, EBI3 deficient mice survived
significantly longer than WT mice following endotoxin admin-
istration. Furthermore, in the cecal ligation and puncture model
(CLP) of polymicrobial sepsis EBI3 deficient mice displayed
improved long-term survival (45 %) compared to control mice,
which almost all died within 72 h post CLP.
After systemic administration of recombinant IL-27 into EBI3
KO mice immediately after CLP these mice died within 2 days sug-
gesting a pathogenic role of IL-27 in the immune pathology of the
disease. Mini-laparoscopic analysis demonstrated that IL-27-EBI3
deficient mice had a significantly reduced inflammatory response in
the peritoneal cavity compared to wildtype controls after CLP.
We next investigated cytokine levels in serum and peritoneal
lavage at different time-points after induction of septic peritonitis.
As a result IL-27-EBI3 KO mice showed a markedly attenuated
proinflammatory cytokine response as indicated by decreased
expression of IL-6 in both blood and peritoneal lavage, whereas
bacterial concentrations in blood were similar to those in control
mice. Subsequently, we analyzed the kinetics of IL-27 expression
after CLP by quantitative Realtime-PCR. The expression of both
IL-27 subunits was strongly induced in liver, spleen, lung and
peritoneum 4, 6 and 8 h post CLP. Interestingly, peritoneal
macrophages were the major source for IL-27 expression. To
determine the cells/tissues that are targets for the biological
functions of IL-27 during sepsis, we analyzed the expression of
the IL-27 receptor chains WSX-1 and gp130 in cells, which have
been implicated in the pathogenesis of the disease. We found out,
that Mast cells and neutrophil granulocytes co-expressed both
receptor chains suggesting that IL-27 can induce the release of
proinflammatory mediators in these cells. CONCLUSION: Our
data implicate that IL-27 has a critical role in the early patho-
genesis of septic peritonitis and may be a potential new therapeutic
target for this disease.
Sa2.87. Morphine Facilitates Transendothelial
Migration of HIV-1 Infected Monocytes across the Blood
Brain Barrier by Modulating P-Glycoprotein Expression
in Brain Microvascular Endothelial Cells.
S. D. Mahajan,1 S. A. Schwartz,1 R. C. Chawda,1 N. McCulloch,1
M. P. Nair.1 1Medicine, Division of Allergy,Immunology and
Rheumatology, State University of New York at Buffalo, Buffalo,
NY, USA.
The structural and functional integrity of the BBB is altered by
various diseases of the CNS such as HIVAIDS Dementia (HAD).
HIV-1 enters the CNS via the transmigration of infected monocytes
across the BBB. Drug abuse in HAD patients leads to greater
fluidity of cellular membranes which, increases the permeability of
the BBB to immunocompetent cells. The efflux transporter P-
glycoprotein (P-gp) is an important component of the BBB and an
HIV-1 induced increase in P-glycoprotein expression could be one
of the mechanisms for reduced intracellular accumulation and
resistance to anti-retroviral agents resulting in the progression of
HAD. Morphine is transported by P-gp therefore the BBB
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expression in the endothelial cells of the BBB. We hypothesize that
one of the mechanism by which morphine increases the trans-
migration of HIV-1 infected monocytes across the BBB is via the
modulation of P-gp expression by the brain microvascular
endothelial cells (BMVEC) that constitute the BBB. Using an in-
vitro BBB model, we studied the effect of morphine (107to
1011M) on transmigration of HIV-1 infected monocytes and on P-
gp gene and protein expression by BMVEC. The monocytes were
infected with HIV-1 IIIB strain and were used in transmigration
assays. P-gp gene expression was quantitated using real time,
quantitative PCR while protein levels were measured using western
blot analysis. Our results show that morphine significantly
increased the transendothelial migration of uninfected monocytes
by 39% (P b 0.01) as compared to control and it further enhanced
transmigration of HIV-1 infected monocytes by an additional 23%.
Morphine at 107 and 109 M concentration alone and in
combination with HIV-1 tat (10–100ng/ml) significantly increased
P-gp gene and protein expression in BMVEC. Increased P-gp
expression in BMVEC results in enhanced BBB permeability to
HIV-1 infected monocytes contributing to the neuropathogenesis of
HIV-1 in drug abusers.
Sa2.88. Intralesional T Cell Lines Obtained from
Rheumatic Heart Disease Lesions Can Be Used as a
Tool for Searching for Non-Autoimmune M Protein
Epitopes for Developing a Safe Vaccine Against Group A
Streptococci.
L. Guilherme,1,3 S. E. Oshiro,1,3 C. Puschel,1,3 W. R. Silva,1,3 F.
Higa,1,3 L. Chaves,1,3 A. C. Tanaka,1 G. Spina,1 P. M. A.
Pomerantzeff,1 J. Kalil.1,2,3 1Heart Institute, University of Sao
Paulo, Sao Paulo, Sa˜o Paulo, Brazil; 2Clinical Immunology and
Allergy, School of Medicine, University of Sao Paulo, Sao Paulo,
Sa˜o Paulo, Brazil; 3Institute for Immunology Investigation,
University of Sao Paulo, Sao Paulo, Sa˜o Paulo, Brazil.
Rheumatic fever (RF) is a post-infectious autoimmune disease
prevalent in over 20 million children, mostly in developing
countries. It is triggered by Streptococcus pyogenes and affects
susceptible individuals following a non-treated throat infection.
Thirty to 45% of patients develop carditis, the most serious disease
manifestation leading to severe and permanent valvular lesions and
to the development of chronic rheumatic heart disease (RHD). We
have been studying the mechanisms leading to pathological auto-
immunity in rheumatic fever and RHD for the last 15 years. Our
studies have contributed to a better understanding the cellular and
molecular basis of RHD, opening a gateway for the development of a
vaccine for a post-infectious autoimmune disease. We studied the C-
terminal region of the M protein, in which we have identified some
potentially protective epitopes, recognized by both T and B
lymphocytes from more than 500 healthy individuals and RF/
RHDpatients. In order to verify potentially autoimmune epitopes we
analyzed 21 overlapping C-terminal peptides (20 mers each differ-
ing by only two amino acid residues) and 9 N-terminal peptides
previously described as heart-tissue cross-reactive by proliferation
and cytokines secretion assays using 09 heart-infiltrating Tcell lines
(HIL) obtained from rheumatic heart disease (RHD) patients. Our
results showed that 5 out of 9 HIL were able to recognize 7 C-
terminal peptides. Among these peptides, four {M(254-273),
M(292-311) M(293-312) and M(295-314)} recognized by 02 HIL
induced interferon gamma production. Two peptides M(258-277)
andM(259-278) were recognized by oneHIL and induced TNFa andIL-5 production. Only one HIL simultaneously recognized the C-
terminal M(269-288) and the cross reactive M5(1-20) peptides.
Our results indicate that peptides differing by only a few amino
acids are capable of generating divergent immune responses, which
could be the key issue in defining vaccine epitopes.
Sa2.89. Is There Any Relation between Lymphocyte
Subsets, NK Activity and Infection in Beta Thalassemia
Patients.
Arezoo Jamali,1 Hossein Hadi nadoushan,2 Mina Izadyar,3
Farhad Vaezzadeh,1 Mahroo Mirahmadian,2 Bita Ansaripour.2
1Medical Laboratory Scienses, Allied Medical School,Tehran
University of Medical Scienses, Tehran, Tehran, Islamic Republic
of Iran; 2Immunology, Tehran University of Medical Scienses,
Tehran, Tehran, Islamic Republic of Iran; 3Medical Center of
Peditrics, Tehran University of Medical Scienses, Tehran, Tehran,
Islamic Republic of Iran.
In h-Thalassemia is multiple transfusion therapy is used to
maintain nearly normal hemoglobin levels, and partially suppresses
the increased, but ineffective erythropoiesis. Unfortunately, trans-
fusion is associated with alloimmunization, risk of exposure to
infectious pathogens and accumulation of iron. A major cause of
morbidity and mortality in thalassemia is infections, assumed to be
result of immunological changes. There is some contaversy in
relation between immunological status, transfusion therapy regi-
men and frequencuy of infection and to date it is not quite clear
why these patients are suseptible to infectin.
In this study lymphocyte immunophenotyping for CD3+ (T-
cells), CD3+/CD4+ (T-helper cells), CD3+/CD8+ (T-cytolytic),
CD3+,CD19+ (B-cells) and CD3-/CD16+,CD56+ (Natural killer
cells) was detected in the whole blood of 30 beta thalassemic
patients using a three -color flow cytometric technique, Nnatural
Killer cell activity was a also determined, with flow cytometric
assay for NK cytotoxicity using PKH2-labled K562 target cells.
Serum ferritin was measured by RIA as the iron status. We
recruited 30 healthy children of comparable age that had never
gone under blood transfusion. Information about the first date of
transfusion, history of infection and age of adminestring chalation
therapy were obtained by interview, archive files and related
physician.
Results showed an increased CD19+ lymphocytes (P b 0.05)
without alteration in T lymphocytes Or CD4+/CD8+ ratio and
number of CD3-/CD16+, CD56+ cells but decreased NK
activity(P b0.05). The results do not correlate with the tendency
to infection. The study of other factors is neede to detect those who
are more suseptible to infections.
Immuno-Oncology.
Sa2.90. Dysregulation of Histone Modification and DNA
Methylation in Acute Myeloid Leukemia.
M. Ogawa, K. Sakashita, K. Koike. 1Pediatrics, Shinshu University
School of Medicine, Matsumoto, Nagano, Japan.
Objectives: Like p16, p15 is a gene which inhibits CDK4 and
CDK6 and negatively regulates the cell cycle. Because DNA
methylation of p15 is frequently observed in patients with acute
myelogenous leukemia (AML), the silencing of p15 is thought to
be closely related to the onset and progression of tumors. Recently,
the relationship between DNA methylation and histone modifica-
tion (acetylation and methylation) has been highlighted, and
treatment targeted at these changes has been devised. The present
study was undertaken to examine the relationship between DNA
AbstractsS172methylation of p15 gene and histone modification in AML.
Methods: Tumor cells were isolated from the bone marrow or
peripheral blood of 6 patients with AML (4 cases of primary AML
and 2 cases of recurrent AML; 4 boys and 2 girls with ages ranging
from 1 to 14 years). More than 90% of the isolated cells were
confirmed to be leukemic cells. Bone marrow and peripheral blood
mononuclear cells from healthy individuals were used as control.
Leukemic blood cell line, HL60, which expressed p15 gene, and
MOLT4 whose p15 was silenced by methylation were also
examined. Acetylation of histones H3 and H4 and the methylation
of histone H3 at lysine 9 (H3 Lys 9) were analyzed by chromatin
immunoprecipitation. The methylation status of p15 gene of
immunoprecipitated DNA was evaluated by PCR using methyl-
ation specific primer. To know the possible role of DNMTs in
AML, we examined their expression levels by competitive PCR.
Results: Bone marrow and peripheral blood mononuclear cells and
HL60 cells showed acetylated histone H3 and H4, but not
methylation of H3 Lys 9. On the other hand, MOLT4 cells had
not only methylation of histone H3 Lys 9 but also histone H3 and
H4 acetylation. All 6 AML cases showed histone H3 and H4
acetylation as well as methylation of H3 Lys 9. Interestingly the
p15 promoter DNA immunoprecipitated with antibody specific for
acetylated histone H3 or H4 was unmethylated in some alleles and
methylated in other alleles. Coexistence of methylated alleles and
unmethylated alleles were observed by methylation-specific PCR
and sequencing in the case of methylated H3 Lys 9. DNMTs
expression levels were not overexpressed in AML, compared with
their levels in normal bone marrow and peripheral blood.
Conclusion: These results suggest unbalance between histone
modification and DNA methylation of p15 gene in patients with
AML.
Sa2.91. Immunological and Comparitive Study of Ras
Family Oncogene Product in Various Human Tissues.
V. Mehrotra, V. L. Lahiri. 1Biochemistry, Himalayan Institute of
Medical Sciences, Dehradun, Uttranchal, India; 2Pathology, S N
Medical College, Agra, Uttar Pradesh, India.
Biology in recent years has focused on identifying specific
genes termed as Proto-Oncogenes, ex-pression of which appears to
underlie the process of carcinogenesis. These Proto-Oncogenes
become activated as Oncogenes by a variety of mechanism: viral
transduction, promoter insertion, amplification, point mutations
and chromosomal translocations. The Oncogenes are classified
according to sequence homology, functional similarity and site of
action of their gene products. Out of which ras-gene belongs to G-
protein related to 21 KD, located on the inner face of plasma
membrane (P21) is playing a very important role in detecting a
wide variety of normal and tumour tissues. This proteins bind
guanine nucleotides with high affinity.
The present work was aimed at study of the distribution of ras-
oncogene in human epithelial cancers and precancerous lesions,
with confirmed histological examination. Lesions were of oral
cavity, respiratory tract, gastrointestinal tract and liver, breast,
kidney and urinary bladder, ovary and skin. Cryostat sections of
tissues were prepared. Primary antibody Ras (Ki/Ha) P21
(lyophilized) was obtained commercially and Peroxidase-Anti-
Peroxidase method was used to localize the antigens.
The staining was predominantly in the cytoplasm; appearance
was fined granular/ diffused. Squamous cell carcinomas of various
sites showed 95.6% positivity and 94.4% in cases of adenocarci-
noma. Anaplastic carcinomas showed 71% positivity whereascases of verruca, transitional cell, PagetTs disease showed 60%
positivity. In the premalignant lesions: oral leukoplakia, submu-
cous fibrosis showed 75% positivity. All the cases of benign
lesions showed 65% positivity while normal tissues of oral cavity,
respiratory tract and skin showed only 25% positivity.This study
helps to compair the normal and abnormal tissues
and also provides an excellent class of tumor markers for
targeting and therapy, using immunological, pharmacological or
radiolabelled agents to inhibit their functioning in cancers.
Sa2.92. Defects in TCR Associated Proteins in Relation
to Immune Impairment in Oral Cancer Patients.
V. T. Cheriyan,1 S. C. Dutt,2 S. M. Krishna,1 P. Balaram.1
1Division of Cancer Research, Regional Cancer Centre,
Trivandrum, Kerala, India; 2Division of Radiotherapy, Regional
Cacner Centre, Trivandrum, Kerala, India.
Cancer of the oral cavity is easily detectable and curable in the
early stages. However, recurrence and nodal metastasis are
frequent often due to late diagnosis of the disease and limited
understanding of the biology of the tumour. Immunosuppression is
reported in cancer patients even though the mechanism remains ill-
defined. Recent reports suggest T-lymphocytes to be the principal
effector cells in this process and modification of signal transducing
molecules to be responsible for the impairment. TCR-zeta protein
is an essential component of TCR complex that binds zap 70
protein and transduces signals following TCR activation. T-cell
activation also leads to translocation of NFkB components like
Rel-B and c-Rel to the nucleus activating the transcription of
variety of genes including IL2. This study addresses the expression
status of the signal transducing proteins and its role in the immune
impairment in patients with cancers of the oral cavity. 70 oral
cancer patients were collected for the study, after obtaining
informed consent. Healthy normal individuals were selected as
controls. Percentage population of CD3 +, CD4+ and CD8+ cells
were enumerated by surface phenotyping using FACS Calibur and
capacity to respond to mitogens and anti-CD3 was assessed by the
Thymidine incorporation assay. T-cell function was assessed by
quantitation of levels of IL-2 production after stimulation with
PHA/anti-CD3. The expression status of the signalling molecules
TCR-~ , CD3- e, zap-70, p56lck, PKC, rel-B and c-rel was evaluated
by western blotting following stimulation of lymphocytes with
anti-CD3 in presence and absence of r-IL2. Surface phenotyping of
CD3 +, CD4+ and CD8+ cells showed significant decrease in CD3
and CD4 positive cells and the CD4/CD8 ratio with significant
increase in the CD8+ cells. Cell proliferation assay clearly
demonstrated defects in cell proliferation to T cell specific mitogen
and majority of the oral cancer patients showed decreased response
to PHA and anti-CD3. Production of IL-2 by the lymphocytes was
also found to be reduced. Exogenous Interleukin-2 could increase
the transformation response in all the controls and in 20% of the
patients to different degrees varying from 10% to 90%. Low levels
of the signaling molecules (TCR-~ , CD3- e, zap-70, p56lck, PKC,
rel-B and c-rel) and an impairment in the transduction of rel-B to
the nucleus were observed in these lymphocytes. Decreased CD4+/
CD8+ ratio with an increase in suppressor cells, reduced
lymphocyte proliferation and production of IL-2 suggest a
defective immune regulation in cancers of the oral cavity. Impair-
ment in the translocation of rel-B to the nucleus and the reduced
levels of signal transducing proteins might be the reason for the
decreased production of interleukin-2 and immune impairment in
oral cancer patients.
Abstracts S173Sa2.93. Is the Oncogenesis Epigenetic Induced
Alternative Way for Cell Survival?
I. Bubanovic, S. Najman. 1Ob/Gyn, Medica Centre, Nis, Serbia,
Yugoslavia; 2Department for Byology, Medical University School,
Nis, Serbia, Yugoslavia.
Microevolution of tumors is accompanied by all, or almost all,
elements that characterize evolution in the Darwinian sense. The
evolution of tumors progress on a time scale of months and years
within a limited population of altered cells, involve all the
phenomena observed in the long-term evolution of species. These
phenomena include random changes in the genome of tumor cells,
various forms of selection pressure and selection of tumor cells.
Mutations of key genes endow tumor cells with a selective growth
advantage and, in the presence of an unstable genome, these cells
further mutate and undergo progressive dclonal evolutionT. Albeit
this model of tumor survival is widely accepted, there is possibility
that emergence of dfirstT altered cell generation follow same axioms
as mentioned phenomena of tumor growth and escape. To that
effect, shifting of a normal cell to the tumor cells might bi
explained as activation of adaptive mechanisms for cell survival.
Thanks to large genetic potential and searching for dbetter
solutionT, the dendangered cellT or cell under abnormal
dconditions/selection pressureT may wend to malignant alteration
as an alternative way for survival. For example, epigenetic factors
such as dchemical distressesT or virus-infection may activate the
silenced genes that are responsible for malignant alteration. In
vertebrates, evolutionary accumulation of genetic potentials is
associated with phenomena of epigenetic induced adaptation and
ability of species for survival in different conditions. In the same
way, shifting of the cell from normal to altered might be conceived
as an epigenetic induced adaptation for cell survival, as well as
mechanism of tumor escape.
Sa2.94. Anti-Interleukin-10 Strategies in Treatment of
Malignant Diseases.
I. Bubanovic, S. Najman. 1Ob/Gyn, Medica Centre, Nis, Serbia,
Yugoslavia; 2Institute for Biology, Medical University School, Nis,
Serbia, Yugoslavia.
Interleukin-10 (IL-10) is important cytokine for phenomena of
tumor growth, escape and even carcinogenesis. This cytokine is
essential for tumor cell proliferation because its neutralization
decreases clonogenicity of malignant cells, whereas addition of
recombinant IL-10 increases cell proliferation. IL-10 autocrine/
paracrine loop plays an important role in the resistance of certain
tumors to chemotherapeutic drugs. In addition, immunomodula-
tory/suppressive nature of IL-10 plays significant role in mecha-
nisms of tumor escape from immune monitoring. Nevertheless,
there is no clear anti-IL-10 strategy in treatment of malignant
disease. In fact, there are a few hypotheses, and small number of
experimental/clinical studies, that propose anti-IL-10 strategy in
treatment of malignant diseases. For example, Ammonium
Trichloro(dioxoethylene-o,oT)tellurate (AS101) inhibits synthesis
of tumor IL-10 on the transcriptional level. Therefore, AS101
treatment combined with chemotherapy may be effective in the
treatment of certain malignancies. Another possibility is treatment
of malignant patients by anti-IL-10 antibodies with unpredictable
consequences and complications in relation to autoimmunity and
immune complexes disease. The strategy that we suggest is based
on extracorporeal blood filtration/purification method with a view
to removing IL-10 molecules from patientTs blood by anti-IL-10
antibodies attached on the filter walls. The present strategyprovides a method for enhancing an immune response in tumor
sufferers to facilitate the elimination of IL-10 and/or other
immunosuppressive cytokines and other molecules. The method
involves the removal of immune system inhibitors from the
circulation of the tumor sufferers, thus, enabling a more vigorous
immune response to the tumor. Particularly useful in the strategy is
an absorbent matrix composed of an inert, biocompatible substrate
joined covalently to a binding partner, such as antibody, capable of
specifically binding to the IL-10.
Sa2.95. Modulation of TNF alpha Effects on Apoptosis
Induction in PC Cell Line.
V. Jurisic,1 G. Bogdanovic,2 T. Srdic,2 V. Kojic,2 J. Dimitar,2 N.
Kraguljac.3 1Pathophysiology, University of Kragujevac, School
of Medicine, Kragujevac, Serbia, Yugoslavia; 2Experimental
Oncology, Institute of Oncology, Novi Sad, Serbia, Yugoslavia;
3Institute of Hematology, Belgrade, Serbia, Yugoslavia.
TNF-alpa is a pleiotropic cytokine which can induce apoptosis
is sensitive cells, but also regulated cell proliferation, cellular
activation and differentiation. To be better estimated role of TNF
on PC cell line, originally developed from patients with myelodis-
plastic syndrome at Institute of Oncology Sremska Kamenice,
Novi Sad, we monitored the kinetics of changes after in vitro
treatment with or without TNF-alpha in presence anti-CD45 and
CD95 MoAb, IL-3, FLT3 and GM-CSF. We analyzed cell viability
by cell enumeration; intracellular metabolic activity by determi-
nation of total LDH activity after cell sonication, cell proliferation,
cell membrane molecule expression, apoptosis and necrosis using
flow cytometry (Becton Dickinson, San Jose, USA). Analyses
were performed 2, 6, 8 and 24h after treatment under some
experimental conditions. Our results showed that in comparison
with untreated cells, TNF-alpha induced significantly increase in
apoptosis and necrosis, in PC cells, which expressed high level of
CD95 and TNF alpha receptors. Immunophenotype of this cells
also excluded B cell or T cell charactristics, but presence of early
hematologycal markers was found. Pretreatment of PC cell with
anti-CD45 and anti CD95 monoclonal antibodies modulated cell
death induced by TNF. In addition, presence of TNF in cell culture
medium induced significantly decrease in cell proliferation,
stimulated by IL-3, GM-CSF or FLT-3. However, no changes in
CD13 and CD33 antigen expression following cell proliferation,
determined after 7 days cultures and stimulation in comparison to
percentage of antigen expression before treatment. No changes in
intracellular LDH activity before and after cell proliferation
induced with TNf or different cytokine kombinations. We conclude
that sensitivity to apoptosis and evidence for their increase limited
cell proliferation estimated on this cell line.
Sa2.96. Priming of T Cells to Intracranial Tumor
Antigens Does Not Confer a Survival Advantage.
S. Velicu,1 Y. Han,1 I. Ulasov,1 T. Gajewski,1 M. S. Lesniak.1
1Neurosurgery, The University of Chicago, Chicago, IL, USA.
Introduction: The ability of T cells to recognize a tumor
antigen is the most important step in immune activation. The
degree to which this event occurs in the CNS remains a matter
of open debate. In the present study we sought to (1) determine
whether peripheral T cell priming occurred in response to
intracranial tumors, (2) to evaluate whether the degree of
priming offered a survival advantage, and (3) to design ways of
improving the specificity and delivery of T cells to intracranial
tumors.
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transduced with the H-2Kb restricted SIY peptide. 1103 or 106
B16-SIY cells were the implanted in the flanks or brains of H-2Kb
restricted C57BL/6 and 129S6 mice. ELISPOT assays were
performed on spleens isolated 7 or 13 after tumor implantation
to assess endogenous T lymphocyte responses. In a separate set of
experiments, naRve 2C CD8+ cells, which recognize the SIY
peptide, were isolated from 2C/RAG2-/- mice by negative
selection and stimulated on Days 0 and 4 through co-incubation
with replication-incompetent, H-2Ld- and B7-co-expressing P815
mastocytoma cells in a 1:5 ratio. The cells were then injected into
B6/129 mice harboring B16-SIY intracranial tumors with or
without local intracranial delivery of IL-2 at varying time points.
Results: While the B16-SIY tumor grew in the flanks of
C57BL/6 mice and was associated with poor T cell priming to the
SIY antigen, it did not grow in 129 mice where the T cell response
was prominent. In contrast, intracranial delivery of B16-SIY was
uniformly fatal in both animal models, in spite of peripheral T cell
priming to the SIYantigen. Mice treated with tumor-specific T cells
either before or after intracranial tumor implantation exhibited a
statistically significant increase in survival, from 16 days (controls)
to 21 days (T cells), P b 0.01. Co-therapy with T cells and IL-2
exhibited strong synergism: 16 days for controls, 39 days with T
cell delivery prior to tumor establishment (P b 0.001), and 58 days
with T cells after tumor establishment (P b 0.00001). Twenty-
percent of mice treated with T cells and IL-2 were long term
survivors of greater than 120 days. Immunohistochemical analysis
of animal brains revealed local CD4+ and CD8+ infiltration in
intracranial tumor-bearing mice that had been treated with either T
cells alone or T cells and IL-2.
Conclusions: Our results confirm that T cell priming does
indeed occur in response to CNS tumors, however, the strength of
the response does not correlate with survival. While the use of
tumor specific T cells offers a survival advantage, local delivery of
IL-2 to the site of the tumor further augments the immunother-
apeutic response. This study represents the first report in which T
cells directed against intracranial antigens along with IL-2 exhibit a
synergy which significantly prolongs the survival of animals with
intracranial tumors.
Sa2.97. An In Vivo Role for Trypanosoma cruzi
Calreticulin in Antiangiogenesis.
M. C. Molina,1 V. Ferreira,1 W. Schwaeble,2 D. Lemus,3 A.
Ferreira.1 1Immunology Disciplinary Program, ICBM, Faculty of
Medicine, University of Chile, Santiago, Santiago, Chile;
2Morphology Disciplinary Program, ICBM, Faculty of Medicine,
University of Chile, Santiago, Santiago, Chile; 3Department of
Microbiology and Immunology, University of Leicester, Leicester,
United Kingdom.
Angiogenesis leads to neovascularization from existing blood
vessels. It is associated with tumor growth and metastasis and is
regulated by pro and antiangiogenic molecules. Most well
characterized anti-angiogenic molecules are currently under
clinical trials for cancer treatment. During the last few years we
have cloned, sequenced and expressed a Trypanosoma cruzi (T.
cruzi) calreticulin gene (TcCRT). Its product, TcCRT, a 45kDa
protein, is more than 50% identical to human CRT (HuCRT). Most
vertebrate CRTs are known by their chaperone properties. We have
recently demonstrated that TcCRT, present on the surface of
trypomastigotes, binds to the collagenous portions of both C1q and
mannan binding lectin and inhibits the classical activation pathwayof human complement (J. Immunology 172: 3042-3050. 2004).
Since TcCRT is highly homologous to a functional antiangiogenic
fragment from HuCRT (aa 120-180), recombinant (r) and native
(n) TcCRT were tested in their antiangiogenic effects, in the chick
embryonic chorioallantoid membrane (CAM) assay. Both proteins
mediated highly significant antiangiogenic effects in the in vivo
CAM assay. This effect was further substantiated in experiments
showing that the genetic plasmid construct pSecTag/TcCRT also
displayed significant antiangiogenic properties, as compared to the
empty vector, thus indicating that the parasite gene was transfected
to the vertebrate host. Most likely, the fact that antiangiogenic
substances act preferentially on growing neoplasic tissues but not
on already established tumors, is due to their effects on emerging
blood vessels. Thus, by virtue of its capacity to specifically bind to
laminin, CRT may interfere with the assembly of endothelial cells
and, as a consequence, in the generation of new blood vessels. In
synthesis, our results indicate that TcCRT, like its human
counterpart, has antiangiogenic properties. These properties may
explain, at least partly, the reported antineoplasic effects of
experimental T. cruzi infection. (Supported by: FONDECYT-
Chile Grants N8 1010930 and 7010930, and MECESUP- Chile
UCH0115).
Sa2.98. Post-Transcriptional Control of MICA
Expression by BCR/ABL Oncogene through
PI3K/mTOR Pathway.
N. Boissel,1 D. Rea,3 V. Tieng,1 N. Dulphy,1 M. Brun,1 J. M.
Cayuela,4 P. Rousselot,5 R. Tamouza,1 P. Le Bouteiller,6 F. X.
Mahon,7 A. Steinle,8 D. Charron,1 H. Dombret,2 A. Toubert.1
1Unite INSERM U396, Laboratoire dTImmunologie et
dTHistocompatibilite, Institut Universitaire dTHematologie, Paris,
France; 2Service dTHematologie Adulte, Hopital Saint-Louis,
Paris, France; 3Unite de Therapie Cellulaire et Clinique Trans-
fusionnelle, Hopital Saint-Louis, Paris, France; 4Laboratoire
Central dTHematologie, Hopital Saint-Louis, Paris, France;
5Service dTOnco-Hematologie, Centre Hospitalier de Versailles,
Le Chesnay, France; 6Unite INSERM U563, Hopital Purpan,
Toulouse, France; 7Laboratoire dTHematologie, CHU de Bor-
deaux, Bordeaux, France; 8Institute for Cell Biology, Eberhard-
Karls-University, Tuebingen, Germany.
MHC class I chain-related molecules (MIC) are NKG2D
ligands that participate in immune surveillance of cancer. Engage-
ment of NKG2D by cell surface MIC triggers NK cell activation
and antigen-specific CTL immunity. However, the release of
soluble forms of MIC (sMIC) by the tumor may impair this
response by decreasing NKG2D surface expression. The molec-
ular basis for MIC expression in tumors is unknown. We
demonstrated the first direct relationship between an oncogene
and MIC expression in chronic myeloid leukemia, a malignancy
caused by the BCR/ABL fusion oncoprotein. At diagnosis,
around one third of patients showed increased serum levels of
sMICA that correlated with white blood cell count and that
decreased upon therapy with imatinib mesylate (IM), a specific
BCR/ABL inhibitor. In K562 cell line, IM decreased both surface
MICA/B expression and NKG2D-mediated lysis by NK cells.
Up-regulation of MICA/B-expression by BCR/ABL was con-
firmed by silencing BCR/ABL gene expression. IM did not affect
MICA mRNA levels but decreased MICA protein expression and
sMICA release. Likewise, MICA expression was reduced upon
treatment with inhibitors of PI3K and mTOR, that are both
activated by BCR/ABL. These results suggest a post-transcrip-
Abstracts S175tional regulation of MICA by the BCR/ABL oncogene via a
PI3K/mTOR mediated pathway.
Sa2.99. Innate Immune Adherence Activity to Tumor
Cells Properties of Methotrexate-Loaded Adult and
Cord Blood Erythrocytes.
Wang Xuan. 1Department of Transfusion, Changhai Hospital
Second Military Medical University, Shanghai, China.
Objective: To study the effect of MTX-loaded process on
innate immune adherence activity to tumor cells of adult and cord
blood erythrocytes.
Methods: MTX was loaded in erythrocytes using the modified
hypotonic preswelling technique. We used the erythrocytes after
undergoing washing, swelling and drug-loading treatment from
adult and cord blood erythrocytes, and measured the rate of rosette
formation.
Results: We observed that the innate immune adherence
activity of erythrocytes from adult and cord blood after hypotonic
swelling treatment significantly increased as compared with other
groups (P b 0.05), which the rate of rosette formation was up to
(61.45 F 8.51)%, (17.00 F 2.16)%, respectively. However, MTX-
loaded treatment was no significant change than un-treated carrier
erythrocytes.
Conclusion: MTX-loaded treatment did not affect the innate
immune adherence activity to tumor cells of erythrocytes
significantly.
Sa2.100. Erythrocytes Promote the Expression of
CXCR4 on Leucocyte Membrane Actived by Tumor
Cell.
Cha Zhanshan. 1Department of Blood Transfusion, Changhai
Hospital Second Military Medical University, Shanghai, China.
Objective: To research the potential role of erythrocytes in
leucocytes reactivity against with neoplasms.
Methods: 0.2ml suspension of inactivated cancer cells (S180,
5I´106/ml) (or 0.2ml NS as control) were added into 0.2ml fresh
anticoagulant whole blood (or 0.2ml white blood cells) treated by
citric acid, and incubated for 1 h at 378. Using monoclonal
antibody of CXCR4, we compare the difference of expression level
of CXCR4 in leucocytes, and compute the activation index (treated
group-control group/control group).
Results: It was found that cancer cells could activate
hematogenic immunity. In 8 normal blood donors and cancer
patients, the activation index of CXCR4 in whole blood cells was
significantly higher than that in white blood cells (t = 2.598,
P b 0.05).And in the cancer groups, the modulus of CXCR4
(57.64 F 10.30) in whole blood cells treated group was
significantly higher than that (35.26 F 4.92) in whole blood
cells control group (t = 3.397, P b 0.01).
Conclusion: These results indicate that there is a road map of
blood immune reaction and erythrocytes is requisite. The
erythrocytes can promote the expression of CXCR4 of granulocyte.
Erythrocytes plays a vital role in leucocytes reactivity against with
neoplasms.
Sa2.101. Cancer Cell Activation Study of Hemaimmune
Reaction Road Map Experimental System.
Guo Feng. 1Department of Blood Tansfusion, Changhai Hospital
Second Military Medical University, Shanghai, China.
Objective: To establish a detection method of IL-8, IL-6
and DARC (Fy6), Which has application in the study ofcancer cell activized to hemeimmune reaction line map
theory.
Methods: Using ELISA method of IL-8. IL-6 and Flow
cytometry of Fy6. We detected Experimental system of hemaim-
mune reaction road map. Cancer cells (S180,5106/ml) or NS
were added in fresh anticoagniant whole blood (treated by citric
acid), or in red blood cell and white blood cells and plasma (or
NS),and incubated for in at 378 to see results.
Results: Cancer cells (deathly cells) can activate hemaimmune
reaction road map experimental system. In cancer cells added to
whole blood group, level (531.6pg/ml) IL-8 higher than that
(b0.5pg/ml) In NS added to whole blood group and in cancer cells
added to whole blood group, Level (28.85) of Fy6 on red cell
Lower than that (45.80) of Fy6 on NS added to whole blood group.
In cancer cells added to whole blood cells group, Level (2.86 or 1)
of activation index (IL-8 or IL-6) higher than that (0.36 or 0.25) in
cancer cells added to white blood cells group. In cancer cells added
to white blood cells group, Level (138–126.3pg/ml) of IL-8 higher
than that (55.99–3.90pg/ml) in NS added to white blood cells
group.
Conclusion: The results suggested that the red blood cells and
complement plays a vital role in regulation (IL-8, IL-6) of hema
immune reaction. And there is road map of hemaimmune reaction.
Antigen (cancer cells) can activate complement, Adhere to
complement (C3b), than be adhereing to red blood cells, Then
adhereing to white blood cells to activate hemaimmune reaction.
Furthermore, it can provide useful experimental system of
hemaimmune reaction road map theory study.
Sa2.102. Apoptosis-Based Therapies for Hematological
Malignancies.
F. Q. B. Alenzi.1 1Department of Medical Laboratory Sciences,
King Faisal University, Dammam, Saudi Arabia.
Apoptosis is an intrinsic cell death program that plays critical
roles in tissue homeostasis, especially in organs where high rates of
daily cell production are offset by rapid cell turnover. The
hemopoietic system provides numerous examples attesting to the
importance of cell death mechanisms for achieving homestatic
control. Much has been learned about the mechanisms of apoptosis
of lymphoid and hematopoietic cells since the seminal observation
in 1980 that glucocorticoids induce DNA fragmentation and
apoptosis of thymocyte and the demonstration in 1990 that
depriving Colony Stimulating Factors (CSFs) from factor-depend-
ent hematopoietic cells causes programmed cell death. From an
understanding of the core components of the apoptosis machinery
at the molecular and structural levels, many potential new therapies
for leukemia and lymphoma are emerging. In my presentation, I
will introduce some of the drug discovery targets thus far identified
within the core apoptotic machinery, and describe some of the
progress to date towards translating our growing knowledge about
these targets into new therapies for cancer and leukemia.
Sa2.103. The Role of CD4+CD25+ T Cells in Leukemia
Relapse after BMT.
F. Q. B. Alenzi.1 1Department of Medical Laboratory Sciences,
King Faisal University, Dammam, Saudi Arabia.
CD4+CD25+ T cells may play an important role in mediating
immune tolerance by regulating T cells which cause autoimmune
disease. Evidence from murine systems suggests hese cells inhibit
immune responses against tumours. In order to investigate this
hypothesis, we have decided to assess their role in leukemia relapse
AbstractsS176after either bone marrow transplantation and/or chemotherapeutic
treatment. Leukemias and patients were selected for this project.
Immunophenotypic analysis indicates that patients with CML who
relapsed after allogenic BMT have a higher proportion of
CD4+CD25+ T cells compared to those who are disease free. Our
findings suggest that a proportion of CD4+CD25+ T cells in CML
patients at relapse are inhibitory. Therefore, these results may reveal
that a relapse after chemotherapeutic treatment may be caused by an
increase in the regulatory population which may lead to the
enhanced inhibition of a graft versus leukemia effect.
Sa2.104. The Immunoreactivity of Serum IgA with
Gliadin in Patients with Myeloma Multiplex.
Zorica D. Juranic,1 Aleksandra I. Konic-Ristic,2 Svetislav Jelic,1
Nenad Milanovic,1 Milica Marinkovic,1 Dusanka Milosevic,1
Jelena Radic,1 Nevenka Stanojevic-Bakic.1 1Experimental
Oncology, Institute of Oncology and Radiology of Serbia,
Belgrade, Serbia, Yugoslavia; 2Institute of Bromatology, Faculty
of Pharmacy, Belgrade, Serbia, Yugoslavia.
Gluten intolerance is system immunological disorder which is
characterized in part by the presence of antigliadin antibodies,
which sometimes are also directed to calreticulin. The aim of this
work was to determine is there any immunoreactivity of serum IgA
with gladin, or with tissue transglutaminase, in small group of
patients with myeloma multiplex.
Three patients with IgA and 4 patients with IgG myeloma
multiplex, 1 patient with both IgG and IgA, M components in the
serum, 1 patient with non-Hodgkin lymphoma- lymphoplasmocy-
ticum, and 7 healthy people were included in the study. For
determination of the level of the immunoreactivity of antigliadin
IgA antibodies a home made ELISA test was used, with 5
micrograms of crude gliadin (SIGMA) as the antigen, while 1%
bovine serum albumin was used as blocker. Immunoreactivity of
IgA anti-gliadin antibodies was determined in prediluted serum to
1:250, and 1:500. Blanks were wells coated with blocker 1%BSA
(without gliadin), incubated with corresponding serum dilutions,
treated with secondary, HRP labeled, goat anti-human IgA anti-
body, and additionally, wells coated with only gliadin treated with
secondary, goat anti-human IgA antibody. Immunoreactivity of IgA
anti-transglutaminase antibodies was determined in prediluted
human serum to 1:100, using commercial. ELISA test (Binding
Site), with recombinant tissue transglutaminase, as the antigen.
Results from this work showed high intensity of the interaction
of serum IgA with gliadin in two patients with IgA plasmocytoma
(only in patients with IgA, M component in the serum). The
OD492 at 1:250 serum dilution were 0.523 and 0.206, while there
was no interaction of serum IgAwith gliadin in all healthy persons
sera, i.e., at 1:250 serum dilution it was in the limits of the
experimental error (OD492 b 0.050). The level of this reaction was
of less pronounced intensity, in one patient with IgA plasmocy-
toma (in his serum there was no M component), OD492 was 0.107.
Antigliadin IgA immunoreacivity was also found in 1out of 4
patients with IgG myeloma multiplex, OD 492 was 0.529. In one
patient with non-Hodgkin lymphoma- lymphoplasmocyticum,
antigliadin IgA immuno-reactivity was high, OD492 was 0.750.
Surprisingly, patient with two M components, showed IgA immune
reactivity with the blocker, bovine albumin, but not with gliadin.
There was no intensive reaction of serum IgA with tissue
transglutaminase for all examined patients, indicating that all
immune disturbances characteristic for celiac disease are not
developed in these patients.In conclusion, these preliminary results are the first showing
antigliadin IgA immunoreactivity in some patients with myeloma
multiplex; they set up a question on the importance of gluten
intolerance, (or of some parasitic/or bacterial infection which could
induce anticalreticulin/antigliadin immunity ?) in the emergence
and development of myeloma multiplex.
Sa2.105. Transcription Factors Abnormalities
Associated with Lymphoid Malignancies.
R. Beluzic,1 A. Tomljenovic,1 S. Dzebro,2 M. Dominis,2 M.
Antica.1 1Molecular Medicine, Rudjer Boskovic Institute, Zagreb,
Croatia; 2Merkur Clinical Hospital, Department of Pathology,
Zagreb, Croatia.
Ikaros gene family encodes for a group of Kruppel-like zinc-
finger proteins which act as lymphoid-specific transcription
factors. Apart from Ikaros, this group includes Aiolos, Helios,
Eos and Pegasus. Knock-out studies on mice have shown that
Ikaros, Aiolos and Helios function as transcription regulators
playing an important role in differentiation of particular subsets of
lymphocytes.
All members of Ikaros gene family share the similarity in
their overall structure. The four N-terminal zinc-finger motifs are
responsible for sequence-specific DNA-binding, while C-terminal
zinc-finger pair acts as a dimerization domain: homo- and
heterodimers of Ikaros, Helios and Aiolos bind DNA with high
affinity in a sequence-specific manner. These complexes can then
activate or repress transcription from certain promoters if the
DNA-binding domains of both members of the complex are
intact. However, by the mechanism of alternative splicing
different isoforms can be created that lack one or more N-
terminal zinc-fingers. These non-DNA binding isoforms act as
dominant-negative because complexes contain at least one such
molecule cannot bind DNA efficiently. There is a possibility that
up regulated production of shorter isoforms could result in
phenotypes seen in knock-out mice which include complete or
partial arrests in different stages of lymphocyte development,
leading to development of leukemia and lymphomas. Therefore
we decided to correlate the expression of long and short isoforms
of these proteins in bone marrow, peripheral blood lymphocytes
and lymph nodes of patients with different lymphoproliferative
disorders. Using reverse-transcription-polymerase chain reaction
(RT-PCR) we analyzed lymph nodes from patients with different
types of leukemia. Eight human hematological cell lines were
also screened for the expression of Aiolos and Helios.
Preliminary results show a heterogenous pattern of expression
of Aiolos and Helios among these samples. Shorter isoforms,
which are probably generated in smaller amounts than fully
functional molecules, will be detected by more sensitive real-time
PCR and different subpopulations of cells will be analyzed using
flow cytometry. The results could improve our understanding of
the mechanisms of normal lymphocyte differentiation and
possible pathways in development of human lymphoproliferative
disorders.
Sa2.106. Generation of Linear and Cyclic Peptides
Revealed a Unique Fine Specificity of Rituximab and
Its Possible Cross-Reactivity with an Acid
Sphingomyelinase-Like Phosphodiesterase 3B
Precursor.
Federico Perosa,1 Elvira Favoino,1 Maria Antonietta
Caragnano,1 Marcella Prete,1 Franco Dammacco.1 1Department
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Bari Medical School, Bari, Italy.
The heterogeneity of effector functions displayed by Rituximab
and other anti-CD20 mAb which apparently recognize the same
CD20-epitope suggests that additional mechanisms, probably
related to mAb fine specificity, can be responsible for B cell
depletion. To improve our understanding of Rituximab function,
we investigated its fine specificity. The biopanning with Rituximab
of an eptapeptide cystein-constrained (c7c) phage display peptide
library (c7c PDPL), of an eptapeptide linear (7-mer) PDPL, and of
a dodecapeptide linear (12-mer) PDPL resulted in the isolation of
13, 9 and 10 clones respectively, which specifically reacted with
Rituximab in ELISA and Western blot. The c7c PDPL-derived
clone insert sequences expressed the motif A(S)NPS, which
matched the CD20 amino acid stretch 170ANPS173. Two cyclic
peptides bearing ANPS- (Rp15-C) and SNPS- (Rp3-C) motif
specifically recognized Rituximab paratope, while no reactivity
was observed with Rp3-C-derived peptide mRp3-C (bearing the
mouse CD20 170SNSS173). The 7- and 12-mer PDPL-derived clone
insert sequences expressed the motif WPXWLE, which could be
aligned only to the reverse-oriented amino acids 161WPKWLE156
of acid sphingomyelinase-like phosphodiesterase 3b precursor
(ASMLPD3b), though linear peptide Rp1-L, Rp5-L and Rp10-L
bearing the motif competed with cyclic peptide for Rituximab-
paratope binding. Testing the reactivity of anti-CD20 mAb 1F5,
2H7, AT80, B1 and CAT13.6 with linear and cyclic peptides
showed that only 1F5 displayed a reactivity profile similar, though
not identical, to that of Rituximab. Furthermore, Rituximab reacted
with ASMLPD3b-derived peptide, suggesting a possible interac-
tion with this enzyme precursor. Our results indicate a unique fine
specificity of Rituximab and suggest a possible mechanism to
explain the recently reported ability of Rituximab to increase acid
sphingomyelinase activity in raft microdomain.
Sa2.107. Functional Analysis of Peripheral Blood
Lymphocytes Subsets in Patients with
Cancer-Associated Dermatomyositis.
A. Ponyi,1,2 M. Aleksza,1 L. Gergely,1 M. Garami,2 T.
Constantin,2 K. Danko.1 1Division of Clinical Immunology, 3rd
Department of Internal Medicine, Medical and Health Science
Center, University of Debrecen, Debrecen, Hungary; 22nd
Department of Pediatrics, Faculty of Medicine, Semmelweis
University, Budapest, Hungary.
Objectives
Dermatomyositis is characterized by immune-mediated muscle
inflammation leading to progressive weakness of the skeletal
muscles and the presence of cutaneous symptoms. Patients with
dermatomyositis have a higher risk of malignant disease than the
normal population. The exact pathomechanism of the association is
obscure and less is known about how autoimmunity meets with
tumor immunity in these patients.
Patients and Methods
Our aim was to characterize different lymphocyte subsets in
cancer-associated dermatomyositis patients compared with healthy
controls and patients who had primary dermatomyositis. Fifteen
patients with cancer-associated dermatomyositis and 44 primary
dermatomyositis patients were included in this study. Different
lymphocyte subpopulations were measured by phenotypical cha-
racterization with monoclonal antibodies. Intracellular cytokine
expression of peripheral T lymphocytes was assessed after an in
vitro incubation with an activating cocktail. The cells were labeledwith anti-CD4 or anti-CD8 antibodies and intracellular accumu-
lation of IL-4 or IFN-g was detected. The frequency of different T-
cell subsets was measured within the T lymphocyte population by
flow cytometry.
Results
Concerning on the phenotypic characterization, there were no
detectable differences in the percentages of CD4+, CD8+ and
CD19+ cells. Compared to controls, CD3+ cells were decreased
(70.9% vs. 56.6%), while CD56+ cells were elevated (8.4% vs.
15.1%) in cancer-associated dermatomyositis patients, but not in
primary dermatomyositis patients. The ratio of activated CD3+/
HLA-DR+ and CD3+/CD69+ cells was elevated both in cancer-
associated and primary dermatomyositis cases. There was no
significant difference in the ratio of Th1 cells compared to
controls both in untreated and treated cancer-associated derma-
tomyositis patients (21.0% vs. 24.4% and 21.9%). On the other
hand, significantly decreased Th1 ratio was found in active
primary dermatomyositis patients (21.0% vs. 9.8%). The
percentage of Th2 cells were normal in cancer-associated and
in primary dermatomyositis patients as well, but it was
decreased in inactive primary dermatomyositis patients com-
pared to healthy controls.
Conclusion
T lymphocytes of primary dermatomyositis were less polarized
towards Th1 cells, while this was not observed in cancer-associated
dermatomyositis patients. Cancer-associated dermatomyositis dif-
fers from primary myositis in many aspects of clinical and
immunological features. Better understanding of the precise
interaction of the host immune system with the malignant disease
can shed light on the association between an autoimmune disease
and malignancy.
Sa2.108. Bacteriophage HAP1: Molecular Basis of Its
Antitumour Activity.
K. Dabrowska,1 M. Zembala,2 J. Boratynski,1 M. Kujawa,3
K. Switala-Jelen,1 J. Wietrzyk,1 A. Opolski,1 A. Gorski.1,4
1Institute of Immunology and Experimental Therapy, Polish
Academy of Sciences, Wroclaw, Poland; 2Institute of Catalysis
and Surface Chemistry, Polish Academy of Sciences, Cracow,
Poland; 3Center for Biostructure, Medical University of Warsaw,
Warsaw, Poland; 4Transplantation Institute, Medical University of
Warsaw, Warsaw, Poland.
Previously we investigated interactions of bacteriophage T4
with mammalian cells: unexpected binding of phage T4 to cancer
cells and its antitumour activity. We selected in vitro the mutant
HAP1 that was able to bind the cells much stronger (than parental
T4), it was also more effective against B16 melanoma tumour and
metastases in vivo (Dabrowska et al. Acta Virol. 48, 2004,
Dabrowska et al. Anticancer Res. 24, 2004). We proposed a
possible molecular basis of these interactions: reactions of beta3
integrins on target cells and T4 capsid proteins: probably gp24,
which contain KGD-aminoacid motifs, i.e. RGD homologues able
to bind beta3 receptors (Gorski et al., Medical Immunol. 2, 2003).
Here we present further results that may highlight non-antibacterial
properties of phages.
In direct sequencing of phage-head genes we found a non-sense
mutation in the hoc gene of HAP1. Phage particle size and
morphology was observed in the electron micrographs and
determined by dynamic light scattering (PCS). T4 and HAP1 do
not differ in their general morphology, but the head of HAP1 is
smaller than the head of T4. This is in line with the well-described
AbstractsS178morphogenesis of the T4 capsid: after incorporation of Hoc protein
T4 phage head becomes visibly larger. These indicate that HAP1
lacks gp Hoc. The normal Hoc protein is balloon-shaped and it
extends to about 5 nm away from the capsid surface, 160 regularly
arranged units per one capsid. Because of its special localisation gp
Hoc impedes access of external factors to the head surface. Without
gp Hoc, there are no important spatial disturbers that can diminish
the interactions of other head components with any external targets.
This also applies to gp 24, which was proposed as the active protein.
Differences in T4 and HAP1 interactions with platelets were also
observed (Kniotek et al., Immunology 2004). This may suggest that
Hoc could be involved.Hoc protein is not necessary for T4 viability
nor for its structure, and its exact function is unknown. However, a
very interesting report reveals its relatedness to eukaryotic immu-
noglobulin-like domains. This similarity results rather from diver-
gence from a common ancestor, not just from convergent evolution
(Bateman et al., Virus Genes. 14, 1997). The immunoglobulin
superfamily is engaged in adhesion processes, MHC functions, T-
cell receptors, and others. On the other hand, we know that higher
organisms are strongly exposed to bacteriophages. They have
become ban environmentQ for phage life cycles (Dabrowska et al.,
J. Appl. Microbiol. 98, 2005) and, one can expect, phages adapt to
them. All these considerations suggest that some bacteriophage
molecules are predicted to interact with eukaryotic organisms,
influencing important immunological processing and/or to modulate
these interactions. Hoc protein seems to be one of these molecules.
Sa2.109. Thy-1+ Immature Natural Killer Cells Suppress
Dendritic Cell Functions during the Development of
Leukemia in a Mouse Model.
Kazumi Ebata,1 Yukihiro Shimizu,1 Yasuhiro Nakayama,1 Masami
Minemura,1 Jun Murakami,1 Tsutomu Kato,1 Toshiro Sugiyama,1
Shigeru Saito.2 1Third Department of Internal Medicine, Toyama
Medical and Pharmaceutical University, Toyama, Toyama, Japan;
2Department of Obstetrics and Gynecology, Toyama Medical and
Pharmaceutical University, Toyama, Toyama, Japan.
Objective: Although immune response is thought to regulate
the progression of various cancers, cancers often progress by
escaping from hostsT immune surveillance. In the present study, we
investigated the changes in the immune status during the
progression of mouse leukemia.
Materials and Methods: We established a leukemia model by
injecting in BALB/c mice with WEHI-3b cells intraperitoneally.
Mononuclear cells were isolated from peripheral blood (PB) and
bone marrow (BM) every 10 days, and analyzed the cell
composition by flow cytometry. Cells were separated by using
magnetic microbeads-conjugated antibodies.
Results and discussion: The numbers of peripheral white blood
cells (most of themwere leukemic cells) were dramatically increased
after day 24 following injection of WEHI-3b cells, and reached
1.8105/ml on day 30. During progression of leukemia, both
dendritic cells (DCs, I-Ad CD11c+) and DX5+CD3- cells showed
marked increases in PB, although most cell types were increased.
We, therefore, focused on the kinetics and functions of those two cell
populations. Increased DCs expressed lower levels of I-Ad than that
of DCs from normal mice and had low allo T-cell stimulatory
activity. In the BM of leukemic mice, only DX5+CD3- cells were
continuously increased despite the progression of leukemia, and
those cells were rapidly increased in PB. The increase in DX5+ cells
in BM was thought to be induced by soluble factors from leukemic
cells, because co-culture of WEHI-3b cells with normal bonemarrow cells in trans-wells showed a selective increase in DX5+ and
CD25+ cells. The morphology of most of the circulating DX5+ cells
from leukemicmice was large granular lymphocytes, and the surface
markers of the cells were shown to be lineage-CD94-
CD122+CD25+Ly-49-Thy-1brightc-kitdim. These data suggest that
those DX5+ cells were immature NK cells. Isolated circulating NK
cells from leukemic mice were able to down-regulate the expression
of I-Ad on normal BM-derived DCs, which was possibly mediated
by TGF-h produced by those cells. Moreover, these NK cells
significantly suppressed the allo T-cell stimulatory activity of DCs,
which required cell-to-cell contact between NK cells and DCs, and
CD25 was thought to be involved. Because direct interaction
between NK cells and DCs induced IL-2 production, IL-2 might be
associated with the inhibitory effect. In the d90s, Thy-1+ bone
marrow cells were reported to have immunoregulatory functions in
bone marrow transplantation without further analyses. Immature
Thy-1+NK cells with immunosuppressive activities identified in the
present study might be a population of such cells.
Conclusion: We have identified circulating immature NK cells
with immunosuppressive activities during the development of
leukemia, which is important not only for understanding the
development of the disease, but also for effective immunotherapy.
Sa2.110. The Application of an In Vitro Viability Assay
Followed by Subtractive Hybridization for Identification
of Prognostic Markers in Acute Myeloid Leukemia.
A. Maha,1 H. F. Seow,1 S. K. Cheong,2 C. F. Leong.2 1Clinical
Laboratory Sciences, Universiti Putra Malaysia, Serdang,
Selangor, Malaysia; 2Clinical Haematology & Stem Cell
Transplantation Services, Hospital University Kebangsaan
Malaysia, Bandar Tun Razak, Kuala Lumpur, Malaysia.
A high percentage of acute leukaemia patients relapse after an
initial response to treatment. Currently, risk-adapted therapy is
useful for only a fraction of patients. Novel markers need to be
identified to provide therapeutic direction to reduce over-treatment
or under-treatment of patients. Furthermore, the mechanisms that
regulate early relapse have not been identified. We studied in vitro
viability using the MTT assay of blasts from 13 de novo Acute
Myeloid Leukemia patients (FAB: 4 M2, 7 M4 and 2 M5a) and
compared it with the duration of survival (in months) of these
patients. A significant correlation (r = .721, P = 0.005) between
viability and duration of survival was observed. We then selected a
sample with low in vitro viability and a longer survival period and
another sample with high viability and short survival period.
Subtractive hybridization was performed to enrich and amplify for
differentially expressed genes in these two samples. Nucleotide
sequencing of four preliminary clones showed one differentially
expressed gene was a mitochondrial gene, cytochrome c oxidase.
This gene was upregulated in a sample that showed high in vitro
viability and shorter survival period. Mitochondrial genes have
been indicated in leukaemia patients refractory to conventional
chemotherapy and may play a role in early relapse. Thus, we
conclude that in vitro cell viablity may be useful as a prognostic
marker and the study of this biological difference in acute leukemia
patients may lead to a further understanding of the mechanisms
that control cell survival and relapse.
Sa2.111. Expression of Granzyme B and CD86 Is
Associated with Persistence of Cervical Cancer.
Valeska B. Guzman,1 Andrey Morgun,1 Ismael D.C.G. Silva,2
Sylvia M.F. Brenna,2 Carmen R.N. Carvalho,2 Julisa C.L.
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1Immunogenetics Division-Pediatrics Department, Federal
University of Sao Paulo, Sao Paulo, SP, Brazil; 2Gynecology
Department, Federal University of Sao Paulo, Sao Paulo, SP,
Brazil.
Background: Cervical carcinoma is a human papilloma virus
(HPV)-related malignancy, in which escape of the tumor from the
hostsT immune response is thought to play an important role in
carcinogenesis and may involve alterations in the expression of
immune-regulatory molecule genes. The purpose of the present
study was to evaluate the relationship between the expression levels
of CD28, cytotoxic T-lymphocyte-associated-4 (CTLA4), inducible
costimulator (ICOS), ICOSL, CD80 (B7-1), CD86 (B7-2) and
Granzyme B (GrB) genes and response to treatment in cervical
cancer.Materials &Methods: The mRNA levels were determined,
by quantitative real-time RT-PCR in cervical cancer specimens from
75 patients collected prior to radiotherapy or radiotherapy plus
chemotherapy. After 6 months, the patients were divided into two
groups, according to disease persistence (n = 25) or not persistence
(n = 50). Target mRNA levels were normalized by the mRNA level
of reference gene (DHPS) and expressed in relative units (RU).
Results: GrB and CD86 mRNA levels were significantly higher in
biopsies from patients with persistence than in those without
persistence, with median values of 2.12 and 0.84 RU for GrB (P =
0.008), 0.53 and 0.27 RU for CD86 (P = 0.001), respectively. No
difference was observed regarding the other molecules.Conclusion:
Besides prognostic potential concerning response to treatment, this
finding also suggests association of more aggressive tumor process
with a particular immune activation profile.
Supported by: FAPESP.
Sa2.112. Potent Tumoricidal Capacity of Macrophages
Activated by GcMAF and Therapeutic Use of GcMAF
for a Variety of Cancers.
N. Yamamoto,1 M. Urade,2 Y. Koga,1 M. Ueda.1 1Molecular
Immunology, Socrates Institute for Therapeutic Immunology,
Philadelphia, PA, USA; 2Oral Surgery, Hyogo College of
Medicine, Hyogo, Japan.
Intratumor BCG administration can eradicate local as well as
metastasized cancerous cells, suggesting development of immunity
against the tumors. Administration of BCG into noncancerous
normal tissues, however, results in no significant effect on the
tumors. A potent inflammatory agent, BCG, in normal tissues
activates membranous phospholipase A2 to release lysophospholi-
pids that efficiently activate macrophages. Because cancerous
tissues contain alkylphospholipids, BCG-induced inflammation
produces alkyl-lysophospholipids and alkylglycerols that activate
macrophages with approximately 400 times more efficiently than
lysophospholipids (Yamamoto et al. 1988. Cancer Res 48: 6044-9).
These results imply that highly activated macrophages can kill
cancerous cells. Inflammation-primed macrophage activation proc-
ess is the principal macrophage activation cascade that requires
serum vitamin D3-binding protein (known as Gc protein) and
participation of B and T lymphocytes. Stepwise hydrolysis of Gc
protein with h-galactosidase of inflammation-primed B cells and
sialidase of T cells yields a potent macrophage activating factor
(MAF), the protein with N-acetylgalactosamine as the remaining
sugar. Stepwise treatment of highly purified Gc protein with
immobilized h-galactosidase and sialidase generated the most
potent MAF (terminated GcMAF) ever discovered which produces
no side effect in human. Administrating 10 pg GcMAF per mouseand 100 ng GcMAF per human results in the maximal activation of
macrophages, which develop enormous variation of receptors.
When human macrophages were treated in vitro with 100 pg
GcMAF/ml for 3 hrs, the macrophages were highly activated. These
macrophages can bind a variety of cancerous cells. Because cancer
cells are too big to be phagocytized, macrophage membrane spreads
over the cancer cell. These attached macrophage membrane surface
is the same as phagosome membrane, which secretes superoxide
and other lytic enzymes. Trypan blue begins to penetrate through
the attached site and eventually stains the entire cells. Time course
study of the cell death was performed with effector/target ratio of 3.
In 4 hrs, 51% of prostate cancer cells LNCaP and 60% of breast
cancer cells MDA-MB-231 were killed. In 18 hrs, 82% of LNCaP
and 86% of MDA were killed. When prostate, breast, colon and
lung cancer patients were treated with less than 25 weekly
administrations of 100 ng GcMAF, the majority of cancer patients,
excluding very advanced, exhibited healthy control levels of the
serum prognostic index, indicating eradication of tumors. When in
vitro cancer cell-killing study with macrophages activated by
GcMAF was performed in the presence of serum or IgG fraction of
GcMAF-treated prostate and breast cancer patients, greatly accel-
erated cell-killings (more than 80% of cells in 4 hrs) were observed.
These results suggest that the macrophages activated with GcMAF
kill cancerous cells via Fc-receptor mediation preferentially and that
GcMAF-therapy develops IgG antibodies against the tumors.
Sa2.113. Clonal B Cells in Blood and Bone Marrow of
Patients with a Plasma Cell Dyscrasia- Light Chain
Amyloidosis.
Michelle K. Manske,1 Stephanie Maiden,2 Roshini S. Abraham.1
1Hematology / Internal Medicine, Mayo Clinic College of
Medicine, Rochester, MN, USA; 2Department of Biochemistry,
University of Missouri at Rolla, Rolla, MO, USA.
Light chain amyloidosis (AL) is a plasma cell neoplasia, where
there is a clonal expansion of terminally differentiated B cells
(plasma cells) within the bone marrow (BM) and the monoclonal
immunoglobulin light chain forms insoluble amyloid fibrils that
deposit systemically. We have previously shown that there is a bias
in light chain variable (VL) gene usage in clonal plasma cells, with
3 rarely used E light chain genes (6a, 3r and 2b2) accounting for
60% of the AL light chain V gene repertoire. We now show that
peripheral blood and bone marrow of these patients contain
clonally related B cells, that have a mature B cell, non-plasma
cell phenotype, in the absence of plasma cells. We evaluated the
light chain V gene repertoire in the clonal isotype compartment (n
or E) of 5 AL patients (3E + 2n for PBL and 4E + 1n for BM) and 2
healthy controls. The BM mononuclear cells were enriched
separately for CD19+ B cells and CD138+ plasma cells. The
peripheral clonal isotype repertoire had between one-third to one-
half of the B cells using the same V and J genes as the clonal
population in the BM. By sequence alignment of the blood B cells
and BM plasma cells using the same VJ genes, there was evidence
of intraclonal variations in the blood B cells compared to the BM
cells. Also, there was a restriction in diversity in the VL gene
repertoire with AL patients using 6–8 different genes compared to
12–16 VL genes in the healthy controls. Though there is a clonal
expansion within the specific isotype compartment, there is no
change in the global numbers of n and E B cells in blood. In the
CD19+ BM population, 3 of the 5 patients tested had between 0.8-
1.4% of plasma cells in the B cell population. Three of the 5
patients had between one-third to greater than two-thirds of the
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CD138+ (plasma cell) population. These patients, by sequence
alignment, showed clonal homology in the CDR3 and VJ
junctions. In the remaining 2 patients, one had no evidence of
any clonally related CD19+ B cells while the other showed 3
populations of B cells using the same V gene but different J genes.
In this latter patient, we were unable to identify a dominant clonal
plasma cell population. Interestingly, the greater the number of
clonal B cells in the CD19+ BM population, the more restricted the
VL gene diversity. The CD138 and CD19 sorted populations in the
BM from the healthy controls showed a typical polyclonal
repertoire with 22–25 VE and 15–17 Vn genes represented in the
CD138+ plasma cells and 7–15 VE and 15–23 Vn genes in the
CD19+ B cells. The presence of clonal B cells in the BM and blood
of AL patients is relevant for understanding the pathobiology of
disease and also has significant implications for therapy. These
data, while preliminary, suggests the need for a paradigm shift in
AL pathogenesis.
Sa2.114. Immunomodulation by Different Forms of a
Chimeric Costimulatory Molecule That Selectively
Binds to CD28.
M. Neighbors,1 J. C.-C. Chang,1 S. Leong,1 R. Ong,1 I. Sipos,1
D. Apt,1 J. Punnonen.1 1Human Therapeutics, Maxygen, Redwood
City, CA, USA.
The efficacy of several immunotherapeutics and adjuvants is
limited by their specific activity and/or undesired ligand binding
properties. We have used DNA shuffling to generate large libraries
of chimeric adjuvant proteins and costimulatory molecules, and
have selected the improved variants based on ligand binding and
functional properties. This presentation describes one such
chimera: CD28 binding protein (CD28BP), which is a DNA
shuffled version of B7.1 that preferentially binds to CD28.
Interestingly, CD28BP demonstrates adjuvanticity in a mem-
brane-bound form yet inhibitory activity when soluble. We have
combined DNA encoding CD28BP with DNA encoding an in
silico shuffled cancer antigen that induces immune responses
cross-reactive with Epithelial Cell Adhesion Molecule (EpCAM)
to form the basis of a cancer vaccine candidate. In non-human
primate studies we show that this approach achieves the goal of
augmenting EpCAM-specific immunity with an excellent safety
profile. Importantly, we demonstrate that the presence of CD28BP
in the vaccine construct is required for the detection of EpCAM-
specific CD8 T cell IFN-gamma production. Based on these
findings, we believe this novel vaccine approach has the potential
to break the immunological tolerance against EpCAM that limits
current colorectal carcinoma vaccine approaches. Moreover,
CD28BP has broader applications as a general DNA vaccine
adjuvant. In contrast, soluble CD28BP protein has the capacity to
inhibit mixed lymphocyte reactions and antigen-specific T cell
responses in vitro making it a suitable candidate for autoimmune
therapeutic applications.
Sa2.115. Enhanced Melanoma Tumor Growth in CD28
Deficient Mice.
F. Luhder,1 H. Voigt,2 D. Schrama,2 A. O. Eggert,2 J. C. Becker.2
1Institute for Multiple Sclerosis Research, Georg-August
University, Gottingen, Germany; 2Department of Dermatology,
Julius-Maximilians-University, Wurzburg, Germany.
For the activation of naRve T cells two signals are necessary.
Besides the cognate recognition of antigen in the context of MHCmolecules, co-stimulatory signals are essential for effective T cell
responses and here the CD28/B7 receptor ligand system is best
characterized. The role of CD28/B7 for anti-tumor immune
responses is still controversial. We induced anti-Trp-2180–188/K
b
melanoma specific CD8+ T cell responses by DC vaccination and
compared their efficacy to control either subcutaneous or pulmo-
nary metastases of B16 melanoma in CD28-deficient and wildtype
mice. In both models, the tumors developed faster in CD28-
deficient mice. For subcutaneous metastases, the difference was
only prominent during a certain time window after tumor challenge,
whereas the areal tumor burden of pulmonary metastases was
significantly enhanced in CD28 k.o. mice. Furthermore, the
influence of CD28 signalling on priming, homing or effector
function of Trp-2180–188/K
b-reactive circulating or tumor infiltrating
T cells was phenotypically investigated. Trp-2180–188/K
b-reactive
CD8+ T cells could be detected after DC vaccination in a
comparable frequency in the circulation as well as among the
cellular infiltrate in subcutaneous tumors in both geneotypes.
Clonotype mapping of tumor infiltrating lymphocytes showed that
subcutaneous tumors in animals of either genotype harbored an
oligoclonal infiltrate. Functional analysis of Trp-2180–188/K
b-reac-
tive cells, however, revealed that the number of IFNg-producing
cells was substantially lower in CD28 k.o. mice. Hence, in our
model priming or homing of Trp-2180–188/K
b-reactive CD8+ T cells
does not seem to be affected in CD28 k.o. mice, but CD28 seems to
be essential for effector functions of tumor specific CD8+ T cells.
Sa2.116. ALL and CLL Cells Express Elevated
TNF-alpha upon Stimulation When Compared with
Normal B Cells.
T. Selvaggi,1 S. Liau,1 M. Michelis,1 G. Mantile-Selvaggi.1
1Special Diagnostic Immunology Laboratory, Hackensack
University Medical Center, Hackensack, NJ, USA.
Rationale: We hypothesized that the malignant B cell has
significant autocrine function inducing its own replication and
sought to establish its role in its own survival by evaluation of its
cytokine profile compared with B cells from phenotypically normal
(NL) peripheral blood (PB) and bone marrow aspirates (BM). We
further hypothesized that the immunologic profiles differ by the
type of B cell malignancy.
Methods: Discarded BM or PB specimens from patients
diagnosed morphologically and immunophenotypically as ALL
(n = 16) or CLL (n = 18) were evaluated for induced expression of
tumor necrosis factor alpha (TNF), IL2 and IL4 and compared with
NL BM or PB specimens (n = 13). Specimens were washed,
resuspend at 1–1010E6/ml in RPMI+10% a FCS and incubated
with PMA (25 ng/ml), ionomycin (1.0 mcg/ml) and brefeldin A
(10mcg/ml) for 4–6 hours at 378 in 5% CO2. The cells were then
washed, resuspended in PBS, incubated with monoclonal anti-
bodies (MAb) to CD19; CD2; CD38 and CD45 (Beckman Coulter,
Hialeah FL) for 15 minutes, then fixed and permeabilized with
Intraprep kit (Beckman Coulter) and incubated with MAb to TNF,
IL2 and IL4. (Becton Dickinson, San Jose CA) for 15 minutes. The
cells were washed, resuspended in PBS and analyzed by a Coulter
XL flow cytometer using standard CD45 by right angle side scatter
employing logical gating strategies using PE and FITC conjugated
isotypic controls antibodies to establish the histogram region
negative for fluorescence. The percentage of CD19+ cells express-
ing TNF was recorded for each specimen. The mean for each of the
ALL and CLL groups was compared with the NL group using a
standard t test with unequal variance.
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increase in the percentage of cells expressing TNF (7.25%)
compared with NL stimulated B cells (0.3%) (P = 0.012).
Similarly, stimulated CLL cells showed a statistically significant
increased expression of TNF (4.06%) compared with NL
stimulated B cells (P = 0.015).The difference in TNF expression
between stimulated ALL cells and CLL cells did not reach
statistical significance (P = 0.17). Within the CLL group, for
specimens with B cell CD38 expression less than 15% (n = 9) the
mean TNF expression was 0.68% and for specimens with CD38
expression greater than 15% (n = 6) the mean TNF expression was
10.6%. There was a significant difference in the percentage of TNF
expression in those CLL cells with CD38 expression greater than
15% compared with those with CD38 expression less than
15% (P = 0.04). There was no difference between NL cells and
ALL or CLL cells and induced IL2 and IL4 expression.
Conclusion: Stimulated ALL and CLL B cells express TNF
suggesting a possible role for this cytokine in the pathogenesis of
these malignancies. For CLL, the degree of TNF expression may
have prognostic significance given its correlation with CD38
expression. These findings support the initiation of an investigation
into the possible role for available anti-TNF therapies in clinical
studies of both ALL and CLL.
This work is support by a grant from the National Leukemia
Research Association.
Sa2.117. Role of the MAP Kinase Signaling Pathway in
the Regulation of Antigen Expression by Human
Melanomas.
M. Kono,1 I. S. Dunn,1,2 L. B. Rose,1,2 P. J. Durda,2 J. T.
Kurnick.1,2 1Pathology, Massachusetts General Hospital, Boston,
MA, USA; 2CytoCure, LLC, Beverly, MA, USA.
Efforts to enhance anti-tumor immunity have led to identi-
fication of numerous tumor-associated antigens, but vaccination
with such antigens have shown limited efficacy. Our studies have
focused on the ability of melanomas to escape immune destruction
by selective down-regulation of the very antigens that are being
targeted with tumor vaccines, because even if a vaccine is able to
raise highly specific cellular and humoral immunity, immune-
mediated destruction requires continued expression of target
antigens. With melanoma vaccines, the melanocyte-specific
antigens such as Melan-A/MART-1, gp100 and tyrosinase show
extensive heterogeneity with respect to their expression levels in
tumor cells. During our search for agents that can retain or
enhance melanoma antigen expression, we showed that the MAP
kinase pathway (MEK1/2) inhibitors PD98059 and U0126 were
capable of enhancing expression of both mRNA and proteins for
several antigens in melanoma cell lines. While treatment of
melanomas with these agents induces dramatic morphological
changes, and over time induces some apoptosis (approximately
25% at 4 days), there is a dose and time-dependent enhancement
of antigen expression in viable cells. In melanomas a specific B-
raf V599E mutation has been detected at high frequency, which
results in constitutively active B-raf and activation of the MAP
kinase signaling pathway. Data obtained with the MAP kinase
inhibitors therefore suggested a possible link between B-raf
function and antigen expression. However, we observed no simple
relationship between B-raf mutational status and antigen expres-
sion levels in 23 melanoma cell lines. Furthermore, Western
blotting showed no clear correlation between phospho-ERK
levels, melanoma antigen expression, and B-raf mutational status.These data, together with MEK inhibitor enhancement of antigen
expression, indicate that there are multiple influences on MAP-
kinase signaling that influence levels of antigen expression.
Transient over-expression of B-raf offered a direct means of
modulating MAP kinase signaling in a series of melanomas.
Accordingly, we found that in four antigen-positive cell lines of
variable V599E B-raf mutational status (two heterozygous wild-
type /mutant, one homozygous wild type, and one homozygous
mutant), transient over-expression of mutant B-raf resulted in
increased ERK activation and reduction of Melan-A/MART-1 and
gp100 antigen levels. We conclude that inhibition of ERK
activation by MAP kinase pathway inhibitors promotes antigen
expression in melanoma cell lines, irrespective of original antigen
expression status (high, low or absent expression of Melan-A/
MART-1 and gp100). Conversely, when ERK activation is
induced by transient constitutively active mutant B-raf trans-
fection, antigen expression declines. These data indicate that while
several factors may influence levels of antigen expression in
melanomas, blocking MAP kinase activation enhances expression
of several melanocyte-associated antigens, indicating that MAP
kinase inhibition may prove helpful in targeting of melanomas in
immunotherapy trials.
Sa2.118. Optimization of a Manufacturing Process of
Dendritic Cell Vaccine To Treat Colorectal Cancer.
O. Faure,1 R. Guillermo,1 M. Loudovaris,1 S. M. Lee,1 F. Aono,1
T. Vo,1 L. Ho,1 M. Schilling,1 J. Bender.1 1Product Development /
Manufacturing Departments, IDM, Irvine, CA.
Patients with advanced colorectal cancer have limited options for
treatment. Immunotherapy, and especially dendritic cell (DC)-based
vaccines, appears to be one of the most promising therapies. We
identified peptides from CEA, MAGE and HER2/neu that stimu-
lated CTL in vitro for further development. Previously, using normal
healthy donors, we developed a large scale manufacturing process to
produce adequate number of autologous DC loaded with the
immunogenic peptides for use in a clinical trial. This process
cultures mononuclear cells (MNC) in serum-free VacCellR media
containing GM-CSF and IL-13. On day 7, DC enriched by
elutriation were first pulsed with KLH, then matured with a bacterial
membrane fraction from Klebsiella pneumoniae (FMKp) and IFN-
g, and pulsed with peptides. These matured DC were finally
cryopreserved. This manufacturing process is capable of generating
10–21 vaccine doses per batch from a qualification study with
normal healthy donors (n = 5). This process was further simplified
by using the Gambro ELUTRAk Cell Separation System to
perform the elutriation step with a single-use closed system sterile
disposable set. Here, we present the qualification of this modified
manufacturing procedure in three full scale Collidemk process
runs. Three apheresis products from three normal healthy donors,
after overnight shipping, contained 1.2 F 0.1  1010 MNC with
monocytes ranging from 13 to 18%. MNC were cultured for 7 days
in VacCell media containing GM-CSF and IL-13. Enrichment by
elutriation generated 1.1F 0.3 109 DC, with a mean viability and
purity of 96F 2% and 93F 4%, respectively. Upon maturation and
peptide pulsing these DC showed typical patterns of phenotypic
maturation, up regulation of CD25, CD80, CD86 and CD83 and
down regulation of CD14with secretion of IL-12p70 and TNFa. The
process generated 7.9 F 3.0  108 viable DC that is equivalent to
23F 8 vaccine doses per process. Based on these data, the process to
manufacture the Collidem vaccine was amended to use this closed
system elutriation method, and a Phase I / II clinical trial is underway
AbstractsS182to evaluate the Collidem peptide pulsed DC vaccine for treatment of
colorectal cancer patients.
Sa2.119. Hfgl2 Prothrombinase/Fibroleukin Expression
in Cancer and Its Potential Clinical Significance.
Qin Ning,1 Fang Chen,1 Hanying Sun,1 Weiming Yan,1 Wenli
Liu.1 1Department of Infectious Disease, Tongji Hospital of Tongji
Medical College, Wuhan, Hubei, China.
Objectives: Immune coagulation, microthrombus and fibrin
deposition within the microvasculature are major contributors to
the pathogenesis of xenograft rejection, viral induced hepatocel-
lular injury and cytokine induced fetal loss syndrome. Here we
investigated the contribution of the novel gene fibrinogen like
protein 2 (fgl2) prothrombinase mediated immune coagulation in
cancer and its potential clinical significance.
Methods: Malignant tumor tissues were obtained from 11
patients with colon cancer, 15 patients with cervical cancer, 10
patients with breast cancer, 9 patients with esophageal cancer, 12
patients with lung cancer, 16 patients with gastric carcinoma.
Immunohistochemistry and in situ hybridization were used to
detect the hfgl2 prothrombinase and hfgl2 mRNA in tumor tissues.
Antibodies for CD8, CD57, CD68 and vWF were also used in
series histological sections to determine the cellular types in which
the hfgl2 was expressed.
Results: hfgl2 prothrombinase and hfgl2 mRNAwas expressed
in almost all the above cancers. Further more, it was evidenced that
hfgl2 was highly expressed not just in cancer cells, but also in
interstitial infiltrated cells include macrophages, NK cells, CD8+T
lymphocytes and vascular endothelial cells.
Conclusion: The expression of hfgl2 in cancer cells and
activated interstitial infiltrated cells may contribute to the
characteristic statue of hypercoagulability, which in turn induces
tumor angiogenesis and metastasis. The molecule of hfgl2 may
serve as a potential therapeutic target for the management of tumor
development. This work was supported by the National Science
Fund for Distinguished Young Investigators (No. 30225040 for Dr.
Q. Ning, No. 30123019 for Dr. XP Luo).
Sa2.120. Expression of Stromal Cell-Derived Factor-1 in
Brain Biopsies from Patients with Primary Central
Nervous System Lymphoma.
J. R. Smith,1 K. M. Falkenhagen,1 R. M. Braziel,2 S. E.
Coupland,3 J. T. Rosenbaum.1 1Casey Eye Institute, Oregon
Health & Science University, Portland, OR, USA; 2Department of
Surgical Pathology, Oregon Health & Science University,
Portland, OR, USA; 3Department of Pathology, University
Hospital Benjamin Franklin, Berlin, Germany.
Objective: Although the pathogenesis of primary central
nervous system lymphoma (PCNSL) remains unclear, it is
hypothesized that specific chemokine-chemokine receptor inter-
actions contribute to localization of malignant B lymphocytes to
the brain and eye. One candidate mediator is the lymphoid
chemokine, stromal cell-derived factor-1 (SDF-1, CXCL12).
Although initial work focused on its critical role in hematopoiesis,
more recently the participation of SDF-1 in neural development has
been recognized; SDF-1 is constitutively expressed by brain
neurons and endothelium, neuroglia and meningeal cells. Con-
sequently we studied the expression of this chemokine in PCNSL.
Methods: Formalin-fixed, paraffin-embedded specimens from
10 patients with PCNSL were cut 3 microns in thickness and
stained by standard indirect immunohistochemical methods, usinga goat polyclonal anti-human anti-SDF-1 antibody (Santa Cruz
Biotechnology) at a concentration of 5 Ag/mL. Following
deparaffinization of the tissue, antigen retrieval was performed
by boiling the sections for 10 minutes in 10 mM citrate buffer at
pH 6.0. Normal tonsil, and astrocytoma and meningioma biopsies
were also immunostained. Negative controls were prepared by
substituting goat IgG (Sigma) for the specific antibody.
Results: Positive staining for SDF-1 was identified in all 10
of the PCNSL biopsy specimens. This expression was localized
to neurons, endothelial cells and meningeal cells. Weaker staining
was also observed in lymphoma cells that were either diffusely
distributed throughout the brain tissue or present as perivascular
infiltrates. Neuronal and meningeal expression of SDF-1 was
noted in the astrocytoma and meningioma biopsies; tonsil stained
positively for SDF-1 in the crypt and outer epithelium, and
within the tonsil proper. Negative controls showed no positive
staining. Interestingly, a mouse monoclonal anti-human SDF-1
antibody (R&D Systems) that recognized SDF-1 in tonsil showed
no reactivity in either normal brain or PCNSL biopsy
specimens.
Conclusions: Expression of SDF-1 occurs within PCNSL
lesions in the brain, as well as normal brain tissue. Studies
examining the functional relevance of this expression are indicated
to assess possible involvement of SDF-1 in the pathogenesis of
PCNSL.
Sa2.121. Phase 1–2 Evaluation of Different
Immunotherapy Protocols for GBM.
G. A. Moviglia,1 A. Carrizo,1 G. Varela,1 A. Kreutel,1 C. A.
Gaeta,1 R. Moya,1 P. Farina,1 H. Costanzo,1 S. Merino,1 M. J.
Veloso,1 A. Paes de Lima,1 H. Molina.1 1Immunotherapy, Regina
Mater Foundation, Buenos Aires, Argentina.
Glioblastoma Multiform (GBM) cells escape immune recog-
nition by two major mechanisms. These cells produce strong
anti-inflammatory substances in the local tumor micro environ-
ment and fail to express MHC II proteins as well as co-
stimulatory and adhesion molecules on their surface. Mixed
Leukocyte Culture Cytoimplant (MLC) has been previously
shown to function as a powerful intratumor pro-inflammatory
cytokine pump, which can reverse the anti-inflammatory activity
of the tumor microenvironment (Cancer, 2000, 88: 1325–1335).
Tumor-B cell hybridoma vaccines (TBH) have been shown to
function as antigen presenting cells, which can facilitate CD4 T
cell recognition of the tumor antigen (Transfus Sci 1996, 17:
643–649). The use of each of these therapies as single agents or
combined have been tested successfully in clinical trials for
others tumors (for pancreatic adenocarcinoma, ASCO Proceeding
2001, 20: 264a, and for breast cancer ASCO Proceeding 2003,
22: 182.). In this phase one study we have evaluated toxicity and
possible antitumoral effect of each treatment and the combination
of both. As a preliminary study 11 consecutive patients with GBM
according to standard selection criteria were divided in three
treatment groups. Group 1: (4 patients) Debulking Surgery (DS) +
Radiotherapy (Rx), second DS + MLC; Group 2: (4 patients) DS +
Rx, second DS + TBH; Group 3: (3 patients) TQ + Rx, second TQ +
MLC + TBH.
Results and Conclusions
Group I: 4 patients; 4.5 months of survival after second surgery;
CR 1/4, PR 2/4, PD 1/4; 2/4 Severe Inflammation.
Group II: 4 patients; 10.75 months of survival after second
surgery; CR 2/4, PR 1/4, PD 1/4; 0/4 Severe Inflammation.
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surgery; CR 2/3, PR 1/3, PD 0/3 2/3 Severe Inflammation.
50 % of the patients from group 2 are alive up to now, with non
signs of relapsings. However, at the moment the Kaplan Meyer
analysis does not show significant difference in the survival
between the three groups. Treatment with MLC has a strong and
rapid therapeutic effect, but it is limited in duration. It can generate
sever encephalitis. Treatment with TBH has a slow and lasting
therapeutic effect. It does not generate encephalitis. Treatment with
MLC + TBH acts synergically, provoking a rapid, strong and
lasting therapeutic response. In 50% of patients, it generated
encephalitis. The three immunotherapy regimens seems to have
strong antitumoral effect but they differ on velocity and the risk to
develop secondary severe brain inflammation which is a compli-
cation that seems to be related with the MLC procedure and start
around 15 days after the it was done. No other major toxic effect
was observed.
Sa2.122. Suppression of Lck Sensitizes Acute
Lymphoblastic T Cells to the Antiproliferative Action of
Interferon Alpha.
S. M. Chan,1 P. J. Utz.1 1Medicine, Stanford University, Stanford,
CA, USA.
We studied the effects of Lck suppression on the sensitivity of
acute lymphoblastic T cells to the antiproliferative action of
interferon alpha. Short interfering RNA (siRNA)-mediated Lck
ablation reduced the activity of downstream signaling pathways
indicating that Lck is constitutively active in lymphoblastic T cells
despite the absence of T cell receptor stimulation. Lck-deficient and
Lck siRNA-treated Jurkat cells were drastically more sensitive to the
antiproliferative effect of interferon alpha than wildtype or untreated
cells through a reduction in the rate of S-phase progression.
Interestingly, Lck deficient cells were not more sensitive to the
proapoptotic action of interferon alpha. Exposure of a panel of acute
lymphoblastic T cells to an Lck-specific inhibitor similarly
sensitized the cells to the antiproliferative effect of interferon alpha.
This work provides a rational basis for the combined use of Lck-
specific inhibitors and interferon alpha for the treatment of T cell
acute lymphoblastic leukemia. We are currently employing reverse
phase protein microarray technology to explore the mechanism by
which Lck inhibition sensitizes interferon alpha activity.
Sa2.123. Regulatory Cells and Human Malignant
Gliomas.
A. Waziri,1 A. T. Ogden,1 R. C.E. Anderson,1 J. N. Bruce,1 D. E.
Anderson.2 1Department of Neurological Surgery, Columbia
University College of Physicians & Surgeons, the Gabriele Bartoli
Brain Tumor Research Laboratory, the Neurological Institute, New
York, NY, USA; 2Center for Neurologic Diseases, Harvard Medical
School, Boston, MA, USA.
We have isolated and analyzed both tumor cells and tumor
infiltrating lymphocytes (TILs) present in ex vivo central nervous
system (CNS) tumor specimens. We used flow cytometry to
examine immunologically important cell surface molecules on
glioblastoma multiformae (GBM) tumor cells prior to any culturing
in vitro, and screened supernatants from ex vivo GBMs for
secreted cytokines. Tumor cells expressed moderate to high levels
of both HLA class I and class II molecules, suggesting that tumor
cells could directly interact with and influence TILs. In addition, a
majority of the GBMs examined (n = 10) secreted high amounts of
the immunosuppressive cytokine IL-10. Based on these observa-tions, we hypothesize that GBM tumor cells promote the differ-
entiation and/or expansion of IL-10-secreting type 1 T regulatory
(Tr1) cells, which in turn suppress tumor immunity in situ.
Consistent with this hypothesis, additional preliminary observa-
tions suggest that a CD25+ population of CD4+ TILs, which
appear to represent effector cells activated in situ, infiltrates GBMs
and that these cells are notable for their secretion of IL-10. In
contrast, CD4+ TILs lacking CD25 expression are notable for their
secretion of IFN-g and the absence of IL-10. These data suggest a
novel mechanism by which the tumor microenvironment of GBMs
influences the function of TILs and hinders their ability to mount
an effective tumor response.
Sa2.124. Transfection of Breast and Lung Cancer Cell
Lines with sHLA-A*0201 and sHLA-B*0702.
M. L. Gonzalez,1 C. M. Roberts,1 A. R. Gilb,1 W. H. Hildebrand.1
1Microbiology and Immunology, University of Oklahoma Health
Sciences Center, Oklahoma City, OK, USA.
Introduction. Cancer is a disease that affects more than a
million individuals every year. The pathogenesis of cancer is not yet
completely understood and is considered to be multifactorial.
Although there is a wide range of behavior between different
cancers, all cancer cells present atypical morphology, bizarre
mitotic cycles and uncontrolled growth rate, ultimately leading to
invasion and killing of the host. The human immune system
represents a powerful mechanism for detecting and destroying
cancer cells. Immune recognition is mediated by the major
histocompatibility complex class I (MHC I) molecules, which scan
the cellTs proteome and carry small peptides of intracellular origin
to the cell surface. Effector T-lymphocytes (CTL) survey MHC-
peptide complexes and target cells displaying cancer-specific
peptides. What epitopes differentiate the cancer cells from normal
cells? Recognizing the MHC-peptide phenotype of cancer cells is a
critical step in the development of CTL-activating vaccines and/or
the design of new therapies. Objective. The process of epitope
discovery from cancer cells requires large amounts of HLA to
extract and identify the peptides presented by the MHC I.
Therefore, our immediate goal is to transfect and express the
soluble human MHC I molecules (sHLA)-A*0201 and -B*0702 in
two or more cancer cell lines that will allow the production of large
quantities of sHLA and facilitate the elucidation of MHC-epitopes
presented on cancer cells. Materials and Methods. Breast cancer
cell lines MCF-7 and MDA-MB-231 as well as lung cancer cell
lines A549 and NCI-H292 were transfected with sHLA-A*0201 and
sHLA-B*0702. sHLA constructs lack the intracellular and trans-
membrane domains of the a-chain, and were modified at the 5V end
by adding the last 10 carboxi-terminal amino acids of the rat VLDL
receptor (VLDLr). sHLA-VLDLr were cloned into the mammalian
expression vector pcDNA3.1(-) Geneticin or Zeocin (Invitrogen)
using FuGene 6 Transfection Reagent (Roche). Transfected cell
lines were selected with the specific antibiotic, and assayed for
production of the transfected A*0201 and B*0702 molecules using
an in-house ELISA. Several positive clones were obtained form each
cell line and high producers were selected by sequential subcloning
and ELISA testing for sHLA protein production. Results. Two
breast cancer and two lung cancer cell lines were successfully
transfected with sHLA-A*0201 and sHLA-B*0702. Stable clones
producing sHLAz50 ng/ml are now available for the production of
high quantities of sHLA and the future detection of unique peptide
epitopes that distinguish cancer cells from normal cells. Conclu-
sions. Stable and high sHLA-producer cancer cell lines are an
AbstractsS184important preliminary step in the cancer epitope discovery process.
Fulfillment of our immediate goal enables us with the tool to proceed
in the discovery of unique epitopes that characterize the MHC-
peptide phenotype of cancer cells.
Sa2.125. Serologic Study Using a GST-Capture ELISA
for Determination of Anti-HPV16 Antibodies in
Tunisian Women.
M. Achour, P. Sehr, D. Zeghal, L. Kochbati, F. Zouari, M. Pawlita,
R. Oueslati. 1Biology, Faculty of Sciences, Bizerte, Zarzouna,
Tunisia; 2DKFZ, Heidelberg, Germany; 3Hospital la Rabta, Tunis,
Tunisia; 4Institute Salah Azaiz, Tunis, Tunisia; 5Hospital la Rabta,
Tunis, Tunisia; 6DKFZ, Heidelberg, Germany; 7Biology, Faculty
of Sciences, Bizerte, Zarzouna, Tunisia.
Cervical cancer is the second most tumor in tunisian women
just after breast cancer.
Human papillomavirus (HPV) infection is considered the main
cause of invasive cervical cancer espacially HPV16 and HPV18;
Moreover, antibodies against the E6 and E7 proteins of HPV types
16 and 18 have been found to be strongly associated with cervical
cancer. Many assays can be used to define presence of these
antibodies but the majority of them have low sensitivity.
The present work is the first one in Tunisia in which we have
used a GST-capture ELISA in order to estimate the antibody
response against HPV16 E6 and HPV16 E7. These antigens were
overexpressed in E.coli as GST fusion proteins as described by the
research group of Pawlita.
Using this system, we have analysed 205 sera; 71 cases of
cervical cancers, 64 cases of inflammation of the cervix and 70
controls. Results showed that among cancers, positivity is 37% and
42% for 16 E6 and 16 E7 respectively and it is 0% and 2% for
inflammations, 3% in controls for both 16 E6 and 16 E7.
Immunology of the Eye
Sa2.126. The Involvement of Autoimmunity Against
Retinal Antigens in Determining Disease Severity in
Toxoplasmosis.
A. L. Vallochi,1 C. Silveira,2 R. Belfort, Jr.,2 L. V. Rizzo.1
1Immunology, University of Sao Paulo, Sao Paulo, Sa˜o Paulo,
Brazil; 2Ophthalmology, Federal University of Sao Paulo, Sao
Paulo, Sa˜o Paulo, Brazil.
PURPOSE. Ocular lesions are frequent in various individuals
infected with Toxoplasma gondii. Disease intensity in ocular
toxoplasmosis varies greatly between patients. Autoimmunity has
been suggested as a possible component to retinal destruction.
METHODS. Immunologic parameters in the response to retina
antigens were evaluated in infected persons with and without
ocular lesions and in no infected controls. Subjects were divided
into groups on the basis of titers of serum antibodies to T. gondii,
presence and severity of ocular lesions, and clinical history.
RESULTS. Peripheral blood mononuclear cells from patients
with mild disease responded to one or more retinal antigens with a
significantly higher frequency than patients without disease or with
severe disease. Interestingly, the cytokines produced by the
proliferating mononuclear cells did not follow any specific patters,
except for the fact that IL-4 and IL-5 were seldom detected.
CONCLUSIONS. Our results suggest that although the presence
of an immune response towards autoantigens is not protective
against the development of ocular lesions by the Toxoplasma gondii,
it may protect against the development of severe disease.Sa2.127. Ipsilateral Lymphadenectomy To Inhibit
Corneal Allograft Rejection in Rats.
Ling Shiqi, Hu Yanhua. 1Ocular Surface Center, Sun Yat-sen
University, Guangzhou, Guangdong, China; 2Ophthalmology of
Tongji Medical College, Huazhong University of Science and
Technology.
Objective: To investigate use of ipsilateral lymphadenectomy
therapy for inhibiting immune rejections in rat corneal trans-
plantation. Methods: Corneal allogenic transplantation models
were established in rats. 18 female Wister rats were used as
donors,and 36 female sprague dawley (SD) rats were used as
recipients. After corneal penetrating transplantation, recipients
were randomly divided into 3 groups: Group A was the control
group; Group B, the bilateral lymphadenectomy group; Group C,
the ipsilateral lymphadenectomy group. Among of 12 rats in each
group, the corneas of 2 rats in each group were used for
pathological study at day 14 after the transplantation, the other
10 rats were used for studying corneal immune rejection with a slit
lamp. The point in time when allograft rejection occurred was
recorded and mean survival time (MST) were compared. In
addition, the rejection index, clarity, edema and vascularization
of the grafts were examined and compared 14 days after
transplantation. Results: MST of the grafts in group B and C were
(46.30 F 9.464)days, (44.43 F 7.604)days, respectively, and were
increased significantly (P b 0.01) in comparison with the group A,
which had MST of (10.71 F 1.567) days. The difference in the
MSTs between group B and C was not significantly (P N 0.05).
Pathological study showed that at 14 days after transplantation, the
corneas in group A were in a state of edema and showed disturbed
collagen fibers and very significant neovascularity.However, for
corneas in group B and C, no significant changes were detected
compared with nomal corneas except for a reduced density of
endothelial cell. 14 days after corneal transplantation.The rejection
index for group B and C,was much lower than that for group C.
Conclusions: Both bilateral and ipsilateral lymphadenectomy
therapies have a significant effect in preventing corneal allograft
rejection. Ipsilateral lymphadenectomy is a less complex surgical
procedure and is just as effective in preventing rejection.
Key Words: inhibit; corneal transplantation; allograft rejection
Sa2.128. Different Circulating Levels of Endothelin-1 in
Plasma from Glaucoma Patients.
Aida Jimenez-Martinez,1 MaCarmen Jimenez-Martinez,1 Vincent
Korder.1 1Research Unit, Institute of Opthalmology, Conde de
Valenciana, Mexico, D.F., Mexico, D.F., Mexico.
Introduction: The glaucomatous optic neuropathy is one of the
first causes of blindness around the world. The exact cause of
glaucoma is not known, however in the recent years it has been
suggested that endothelin-1 (ET-1) on aqueous humor (AH) is
related with the generation of glaucoma in humans and animals
models.
In order to understand the participation of ET-1 in the
maintenance of the different types of glaucoma, we determined
the ET-1 concentration in AH and plasma from glaucoma patients.
Materials and Methods: After informed consent, blood and AH
samples were taken from patients with glaucoma treated with
trabeculectomy (Primary open-angle glaucoma-POAG-, Acute
closed-angle glaucoma-ACAG-, Pseudoexfoliative glaucoma-PG-)
and from patients with senile cataract treated with phacoemulsifi-
cation and without antecedent of glaucoma (Control group, CG).
ET-1 determination was made by a chemiluminescent immunoassay
Abstracts S185and the results were analyzed with the Mann-Whitney Rank
Sum Test considering a difference statistically significant with a
P b 0.05.
Results: ET-1 concentration in AH from glaucoma patients was
3.9 F 0.9 pg/100ml, while in CG group was 5.2 F 1.5pg/100ml;
ET-1 plasma concentration from glaucoma patients was 0.8 F 0.1
pg/100ml, while in CG group was 0.4F 0.1 pg/100ml (P = 0.008).
We do not find statistical differences in the concentration of ET-1
in AH between the different groups of glaucoma patients: POAG
3.2 F 0.8 pg/100ml, ACAG 7.9 F 3.1 pg/100ml, PG 3.2 F 2 pg/
100ml, and we do not find statistical differences when we
compared each group with CG group. Also, we do not find
statistical differences in the concentration of ET-1 in plasma
samples between the different groups of glaucoma patients: POAG
0.9 F 0.2 pg/100ml, ACAG 0.6F 0.2 pg/100ml, PG 0.7 F 0.2 pg/
100ml. However, when we compared ET-1 concentration in plasma
from each group of glaucoma patients with the CG group, we
found that only in the POAG patients a difference statistically
significant (P = 0.014).
Conclusions: Our results suggest that only in the groups of
patients with POAG could be and association with the ET-1 plasma
concentration and glaucoma. We consider that the diverse clinical
presentations of glaucoma studied here are a consequence of a
different molecular process, in which of them, the ET-1 could play
a minimum role. At the present time, there are developing drugs
against endothelin to treat glaucoma, however the differences
observed in our study should be considerer in order to guarantee
the success of new therapies for glaucoma.
Sa2.129. LPS Stimulation Induce an up Regulation of
TLR-4 on Limbal Epithelial Cells without Secretion of
TNF-Alpha.
Yonathan Garfias,1 Marisela Linares,1 Raul Suarez,1 Alejandra
Sanchez-Navarro,1 MaCarmen Jimenez-Martinez.1 1Research
Unit, Institute of Ophthalmology, Conde de Valenciana, Mexico,
D.F., Mexico, D.F., Mexico.
Introduction: Little is known about the expression of natural
immune receptors as toll like receptors in corneal epithelium, and
their function in ocular immune response is controversial.
Objective: We sought to determine the extracellular expres-
sion of TLR-4 on human limbal epithelial cells cultivated in
vitro and if so, to determine its cellular function after LPS
stimulation.
Matherials and Methods: From sclera-corneal rims, limbal
epithelial cells were isolated and grown in the presence of
supplemented hormonal epithelial medium at 378C and 5% CO2
until confluence. At passages one or two, the cells were exposed to
different doses of LPS from E. coli for 24 h. After stimulation, the
cells were recovered and stained with PE-conjugated monoclonal
antibodies against human TLR-4 and analyzed by flow citometry;
mRNA was obtained and RT-PCR was performed for the
identification of TLR-4, GADPH was used as an internal control.
Secretion of TNF-alpha by these cells was evaluated by ELISA on
the supernatant. PBMC were used as LPS activation controls.
Results: Limbal epithelial cells expanded in vitro expressed con-
stitutively low density TLR-4; after stimulation with LPS the ex-
pression of TLR4 was augmented taking into account the medium
fluorescence intensity.A similar behaviorwas observed at themRNA
level, the expression was augmented after stimulus. When TNF-
alpha was evaluated, interestingly, this cytokine was not
detectable at any concentration of LPS and even at 48 h ofstimulus. PBMC secreted optimal concentrations of TNF-alpha
after LPS stimulation.
Conclusions: Although the extra cellular expression of TLR4
on limbal epithelium stimulated in vitro up-regulates TLR4, its
function seems not to be associated with the secretion of TNF-
alpha on limbal epithelium.
Sa2.130. CD80 and CD86 Expression on Corneal
Epithelial Cells Infected with Adenovirus.
MaCarmen Jimenez,1 Herlinda Mejia,1 Marisela Linares,1
Alejandra Sanchez-Navarro,1 Raul Suarez,1 Yonathan Garfias.1
1Research Unit, Institute of Ophthalmology, Fundacion Conde de
Valenciana, Mexico, D.F., Mexico, D.F., Mexico.
Introduction: CD80 and CD86 belongs a family of proteins
named B7. B7 molecules costimulate T cell during immune
activation. Normally, the corneal epithelial cells do not have any
expression of those molecules on their surface. The objective of this
study is to determine if the corneal epithelial cells induce B7-
molecules after a viral infection.
Materials and Methods: Corneal epithelial cells were isolated
from human corneas treated with dispase-II, and grown in the
presence of supplemented hormonal epithelial medium at 378C
and 5% CO2 until confluence. At passages one or two, the cells
were exposed to different doses of adenovirus 5 (Ad5) for 2 h.
After infection the cells were washed three times and then
cultured at different times. Then, the cells were recovered and
stained with PE-conjugated monoclonal antibodies (mAbs)against
human CD80 and CD86 and with FITC-conjugated mAbs against
human cytokeratin and the results were analyzed by flow
citometry.
Results: Non infected corneal epithelial cells did not express
at any time CD80 or CD86; however Ad5 infected epithelial
cells were positive to CD80 since 24h (40%) raising its
maximum level at 72 h (~90%), CD86 expression on epithelial
corneal cells was detected also at 24h (20%) raising its
maximum level at 72h (~70%). Conclusions: Our results suggest
that corneal epithelial cells express CD80 and CD86 after virus
infection.
Sa2.131. Adamantiades-BehcetTs Disease: A Trend in
Time.
L. I. Kump,1 K. L. Moeller,1 S. Kurup,1 G. F. Reed,1 R. B.
Nussenblatt.1 1Laboratory of Immunology, National Eye Institute,
NIH, Bethesda, MD, USA.
Purpose: To analyze differences in response to treatment of
ocular Adamantiades-BehcetTs disease (ABD) in the 1970Ts,
1980Ts and 1990Ts.
Methods:Medical records of thirty six patients with uveitis due
to Adamantiades-BehcetTs disease followed at the National Eye
Institute (NEI) were reviewed.
Results: All the patients were divided in 3 groups according to
the time of follow-up: first group was followed from 1962 untill
1972, second group from 1983 untill 1992 and the third group from
1992 through 2004. Visual acuities and degrees of inflammation in
each group were recorded at each visit. There were 12 patients (24
affected eyes) in the 1970Ts group, 7 patients (14 eyes) in the 1980Ts
group and 17 patients (34 eyes) in the most recent group. Mean
follow-up in the 1970Ts group was 3.06 years, in the 1980Ts-4.68
years and in the most recent group- 4.03 years. Mean time between
the diagnosis of ABD and presentation to NEI was 3.8 years in the
1970Ts group, 3 years in the 1980Ts group and 4.4 years in the most
AbstractsS186recent group. Therapeutic agents used in the 1970Ts group included
systemic steroids, methotrexate, 6-mercaptopurine, azathioprine,
cyclophosphamide and chlorambucil. Agents used in the 1980Ts
group included systemic steroids, cyclosporine, chlorambucil and
colchicine. Medications used in the most recent group included
systemic steroids, cyclosporine, azathioprine, daclizumab, myco-
phenolate mofetil, methotrexate and infliximab. Statistical analysis
showed that average logMAR change per year was 0.6479 in the
1970Ts group, –0.0225 in 1980Ts group and –0.0272 in the most
recent group.
Conclusion: Adamantiades-BehcetTs disease is a severe blind-
ing disorder. Though the trend for clinical improvement from
1970Ts to 1990Ts was noticed, the changes in visual outcomes did
not reach statistical significance. Larger studies may be more
empowered to demonstrate the trend for improvement due to
introduction of newer agents and directed therapy.
Sa2.132. Visual Outcomes in Children with Juvenile
Idiopathic Arthritis-Associated Uveitis.
L. I. Kump,1,2 R. A. Cervantes Castaneda,1 S. N. Androudi,1 G. F.
Reed,2 C. S. Foster.1 1Ocular Immunology and Uveitis Service,
Massachusetts Eye and Ear Infirmary, Boston, MA, USA;
2Laboratory of Immunology, National Eye Institute, NIH,
Bethesda, MD, USA.
Purpose: To analyse visual outcomes in children with juvenile
idiopathic arthritis-associated uveitis.
Methods: Charts of 89 children with JIA-associated uveitis
were reviewed.
Results: Among 269 children with uveitic syndromes referred to
a tertiary eye center 89 children (33%) had juvenile idiopathic
arthritis associated uveitis. The process was bilateral in 76 children.
Seventy three patients were females, 84% of patients were
Caucasian. Mean age of onset of uveitis was 5.7 years. Mean
follow-up was 2.96 years. ANA positivity was detected in 51
patients, 42 of them females. The patients with JIA-associated
uveitis developed numerous complications in the course of their
disease: among 165 affected eyes 105(64%) developed cataracts, 33
(20%) developed increased intraocular pressure, 76 (46%) eyes
developed band keratopathy, posterior synechiae were present in 96
(58%) eyes. Among 89 children 73% were on immunomodulators,
and 40% were treated with non-steroidal anti-inflammtory agents
alone or in combinaion with immunomodulators, and 21% were
treated with topical and or/systemic steroids. Among 65 children
who required immunomodulation, only one chemotherapeutic agent
was used in 30 children, two agents in 21 children, and three or more
in 14 children. Visual acuities of the patients were documented and
compared at standard intervals. By mixed models linear regression,
visual acuity improved an average of 0.0113 logMAR units at each
two-month visit (P = 0.032).
Conclusion: In spite of the severity of JIA-associated uveitis,
much of the childrenTs vision can be preserved if the patients are
treated appropriately.
Sa2.133. Increased Expression of IKBA Permits
Tolerance Induction by TGFB-Treated Antigen
Presenting Cells.
A. P. Ghafoori,1 B. Turpie,2 J. W. Streilein,2 S. Masli.2 1HMS,
Harvard Medical School, Boston, MA, USA; 2Department of
Ophthalmology, Schepen Eye Research Institute, Harvard Medical
School, Boston, MA, USA.Antigens introduced in the anterior chamber of the eye are
processed and presented by resident antigen presenting cells (APCs)
in a manner that results into antigen-specific peripheral tolerance
that is characterized by suppression of Th1-mediated immune
response such as delayed type hypersensitivity (DTH). Similarly,
conventional APCs such as peritoneal exudates cells (PECs) or a
macrophage hybridoma clone (#59) that are treated with TGFh in
vitro can induce comparable peripheral tolerance. Such TGFh-
treated APCs are known to express a unique set of genes that are
essential for their tolerance inducing ability. Suppression of two
genes regulated by NFnB, IL-12 and CD40, is critical for their
tolerizing property. The InB proteins that prevent nuclear trans-
location of NFnB dimers therefore, can also support suppressed
expression of IL-12 and CD40. Antigen presenting cells treated with
TGFh, were found to up-regulate their expression of InBa. In this
series of experiments we have assessed contribution of InBa to
tolerance promoting properties of APCs. Macrophage hybridoma
stably expressing anti-InBa siRNA or ectopically overexpressing
InBa were examined for their ability to express InBa protein (using
western blot), suppress OVA-specific DTH and secrete IL-12 in
culture supernatants. These APCs were pulsed with ovalbumin
(OVA) and cultured overnight in the presence or absence of TGFh2
(5 ng/ml). NFnB activity of these APCs was assessed by measuring
nuclear levels of p50 and p65 using TransAm chemiluminescence
assay (Active Motif, CA). Increased levels of InBa protein were
detectable in TGFh-treated #59 and InBa overexpressing #59,
however APCs expressing anti-InBa siRNA failed to do so.
Inhibtion of IL-12 secretion by TGFh treatment was found reversed
in APCs expressing anti-InBa siRNA. While both TGFh-treated
#59 and #59 overexpressing InBa suppressed OVA-specific DTH,
such suppression was not induced by TGFh-treated #59 expressing
anti-InBa siRNA. Nuclear p50 levels were significantly decreased
in TGFh-treated #59 and InBa overexpressing APCs, while such a
decrease was prevented in TGFh-treated anti-InBa siRNA express-
ing #59. These results demonstrate that TGFh-treatment of APCs
increases their expression of InBa which prevents expression of
proinflammatory molecules such as IL-12 by preventing nuclear
translocation of NFnB. Such increased expression of InBa permits
tolerance induction by these APCs.
Sa2.134. CD36 and Thrombospondin Interaction Is
Essential for the Tolerance Inducing Properties of
TGFB-Treated Antigen Presenting Cells.
S. Masli,1 B. Turpie,1 J. W. Streilein.1 1Department of
Ophthalmology, Schepens Eye Research Institute, Harvard
Medical School, Boston, MA, USA.
Antigen presenting cells (APCs) in the anterior chamber of the
eye are known to induce antigen-specific systemic tolerance in
which Th1-mediated immune response such as delayed type
hypersensitivity (DTH) is suppressed. Active TGFh, abundantly
available in the ocular environment, confers such tolerance-
inducing property on these resident APCs. Similarly, in vitro
treatment of conventional APCs with TGFh converts their func-
tional phenotype to that of tolerizing APCs. Investigation of
molecular mechanisms underlying this conversion has revealed
significant involvement of various molecules such as TNFa, MIP-
2, TGFh2, CD40 and IL-12. Products of these genes, via various
pathways contribute to systemic tolerance induced by TGFh-
treated APCs. More recently, we detected increased expression of
extracelluar matrix protein, thrombospondin (TSP), in TGFh-
treated APCs. In this report we have assessed molecular
Abstracts S187interactions of TSP that lead to tolerogenic phenotype of these
APCs. Conventional APCs (either hybridoma cell line #59) or
thioglycollate-elicited peritoneal exudates cells (PECs) can express
TSP receptors such as CD47 as well as CD36. Macrophage
hybridoma #59 or peritoneal exudates cells collected from wild
type(WT) or TSP-1 null or CD36 KO mice were used as APCs.
These APCs, pulsed with ovalbumin (OVA) and treated with
TGFh2 (5 ng/ml), were examined for their ability (1) to suppress
OVA-specific DTH response, (2) to inhibit IL-12 secretion by
ELISA and RT-PCR and (3) to enhance TSP or TNFa expression
by RT-PCR. While WT APCs treated with TGFh or #59 treated
with TSP suppressed OVA-specific DTH, both TSP-1 and CD36
deficient APCs failed to do so in response to TGFh treatment. In
case of TSP-1 deficient APCs, exogenously added TSP restored
their ability to acquire tolerogenic properties upon TGFh exposure.
Unlike WTAPCs, both TSP and CD36 deficient APCs treated with
TGFh secreted increased levels of IL-12. Exogenously added TSP
mimicked TGFh in inhibiting IL-12 secretion by WT PECs and
enhancing TNFa expression by #59. Absence of CD36 on PECs
also prevented their ability to increase expression of TSP. These
results support the possibility that TSP expressed by TGFh-treated
APCs contributes significantly to tolerance inducing property by
facilitating inhibition of IL-12 secretion and expression of TNFa.
Interaction of TSP with its receptor CD36 is essential for the
tolerizing phenotype of TGFh-treated APCs.
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Su1.01. STAT-1 Mediates the Stimulatory Effect of IL-10
on CD14 Expression in Human Monocytic Cells.
A. A. Rahim Rahimi,1 K. Gee,3 S. Mishra,1 W. Lim,1
A. Kumar.1,2,3 1Departments of Biochemistry, Microbiology and
Immunology, University of Ottawa; 2Pathology and Laboratory
Medicine, University of Ottawa; 3Division of Virology and
Molecular Immunology, Research Institute, ChildrenTs Hospital of
Eastern Ontario, Ottawa, ON, Canada.
IL-10, an anti-inflammatory cytokine, has been shown to exhibit
stimulatory functions including CD14 upregulation on human
monocytic cells. CD14-mediated signaling following LPS stimula-
tion of monocytic cells results in the synthesis of proinflammatory
cytokines. Our flow cytometry results show that LPS-induced CD14
expression on monocytic cells may be mediated by endogenously
produced IL-10. To investigate the molecular mechanism by which
IL-10 enhances CD14 expression, both human monocytes and the
promyelocytic HL-60 cells were used as model systems. IL-10
induced the phosphorylation of phosphatidylinositol 3-kinase
(PI3K) and p42/44 extracellular signal-regulated kinase (ERK)
mitogen-activated protein kinases (MAPK) as determined by west-
ern blotting with phospho-specific anitbodies. By employing speci-
fic inhibitors for PI3K (LY294002) and ERK MAPKs (PD98059),
we demonstrate that LY294002 either alone or in conjunction with
PD98059 inhibited IL-10-induced phosphorylation of signal trans-
ducer and activator of transcription-1 (STAT-1) and consequently
CD14expression.However, IL-10-inducedSTAT-3phosphorylation
remained unaffected under these conditions. Furthermore,
LY294002 and PD98059 inhibited the binding of the STAT-1
transcription factor to its binding site in the CD14 promoter. Finally,
transfection of HL-60 cells with STAT-1 interfering RNA vectorsinhibited IL-10-induced CD14 expression. Taken together, these
results suggest that IL-10-induced CD14 upregulation in human
monocytic cells may be mediated by STAT-1 activation through the
activation of PI3K either alone or in concert with the ERK MAPK.
Su1.02. Altered Cytokine Production and Reduced
Membrane Signaling through the Antigen Receptor in
CD4+ T Cells Overexpressing Ly-6A.2 Molecule.
Anil Bamezai, Jennifer Reed, Abraham Chacko. 1Biology
Department, Villanova University, Villanova, PA, USA.
Mouse Ly-6 molecules serve as excellent differentiation markers
on immune cells of hematopoietic origin, but their influence on
cellular differentiation is unknown. CD4+ cells over-expressing Ly-
6A.2 resist polarization to either Th1 or Th2 phenotype. To
understand the mechanism underlying the polarization tolerance
in Ly-6A.2 over-expressing CD4+ T cells, we examined their
cytokine profile in response to varied antigenic stimulation under
primary culture conditions. Ly-6A.2 over-expressing cells gener-
ated higher levels of both Th1 and Th2 signature cytokines in a dose
dependent manner. In addition, the CD4+ T cells over-expressing
Ly-6A.2 showed reduced phosphorylation of LAT than the controls.
Our results suggest that Ly-6A.2 expression on CD4+ T cells
diminishes their membrane proximal signaling in response to the
antigen receptor and therefore might contribute to their altered
cytokine profile. These results also suggest that CD4+ T cells
capable of producing high levels of Th1 and Th2 signature
cytokines in response to antigen stimulation are resistant to
polarization to either Th1 or Th2 phenotype.
Su1.03. Lymphocytes Demonstrate Different
Functioning Changes Induced by Exogenous PDGF-AB
and TGF-b In Vitro at Cerebral and Coronary
Atherosclerosis: What Is Established?
Andrei I. Teplyakov.1 1Resrarch Institute for Ecopathology and
Occupational Diseases, Mogilev, Belarus.
We hypothesized that proatherogenic T cells are controlled by
cytokines network balance. Among them, TGF-b has been implied
in atherogenesis, but its mechanism of action remains unclear.
Taken together, abrogation of TGF-b signaling in T cells able to
accelerate the atherosclerosis and permit to suggest that TGF-b
reduces atherosclerosis by dampening T cell activation. Inhibition
of T cell activation may therefore represent a strategy for
antiatherosclerotic therapy. Goal: to analyze the possible evidence
for TGF-b action on lymphocytes functions (Go chromatin
topography changes) in vitro at cerebral and coronary atheroscle-
rosis. Object: 29 patients. The original research technique has been
used: adding TGF-b to achievements the final concentration: 0.05,
0.5 and 5.0 ng/ml in whole blood sampled PDGF-AB for
achievement final concentration in whole blood sample: 0.5, 5.0
and 10.0 ng/ml with following incubation in plastic tube for each
sample. The lymphocytes chromatin nuclei behavior was estimated
after 30, 60 and 360 min for each samples. The chromatin of
lymhocytes nuclei was studied using Computer TV Morphodensi-
tometry System bDiaMorphQ (Russia) in the smears dyed especially
for DNA. Results are contraindicated to habitual opinions about
common atherogenic mechanisms without evaluation of organ-
target influence. At first sight, it seem to be possible that
mechanisms of sensitivity to PDGF have switched on (i.e. PDGF
at cerebral atheroslerosis acted in other manner or in assembly to
other factor, which are could be known). However, more complex
manner of chromatin changes of lymphocytes, implicated in
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involved components of cytokines network factors, which are
reversed timely. The main detected features at cerebral in
comparison to coronary atherosclerosis have consist of initial
hetero- and euchromatin rebuilding. Obtained results have con-
flicted to becoming fixed opinion that cerebral and coronary
atherosclerosis are common process, unified any atherosclerosis
without locations evaluation. So it is possible, that the detected
changes have resulted more disseminated vascular implication in
cerebral atherosclerosis in comparison to coronary ones. Con-
clusion. Obtained results are controversial to described the
dampening lymphocytes activation, induced by TGF-b. We have
no satisfied results, evidenced the TGF-b suppressive manner on
lymphocytes functioning at atherosclerosis. Received results, in
our opinion, reflects the more complicated interaction between
TGF-b and lymphocytes functioning changes. It has been
confirmed by the facts, that G0 lymphocytes chromatin (dependent
from concentration and exposition time) have changed its portrays
on biphasic manner after PDGF-AB adding: initially at short
period of time we detected the same nuclear activation (and gene
expression activation, correspondingly) with following stable
chromatin topography changes, reflected the stable lymphocytes
functioning changes on pathologic manner, which is needed to
more detail investigation.
Su1.04. Live Measurement of Chemokine Triggered
Integrin Activation on a Single-Molecule Level.
R. H. Eibl.1 1Institute of Pathology, Technical University of
Munich, Munich, Germany.
Atomic force microscopy (AFM) based force spectroscopy can
be used for direct measurement and quantification of cell adhesion
forces on living cells down to single-molecule interactions. This
technique is used here to study the physiologic activation of
alpha(4) integrins by the chemokine CXCL12 on living cells
expressing the chemokine receptor CXCR4. At low physiologic
concentration of CXCL12 the rupture force of a single pair of
adhesion receptors increases from 40pN to 60-80pN, whereas at
higher concentrations of CXCL12 it lowers the rupture forces back
to 40pN. This study confirms that arrest chemokines such as
CXCL12 can rapidly modulate the affinity of an integrin receptor.
To date, this is the first direct measurement of chemokine induced
affinity modulation of a single (adhesion) receptor as well as of the
desensitization of a chemokine receptor, both measured on a
molecular level on a living cell. AFM based force spectroscopy has
evolved into a completely new pharmacological test for single-
molecule interactions on living cells. This technique will be used to
elucidate the mechanisms involved in both physiologic leukocyte
homing as well as organ-specific tumor cell metastasis.
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Su1.05. Sp1 Binding Site of TGF-beta1 Promoter Is the
Target for Trans-Activation by HPV-16 E6 and E7
Oncoproteins.
O. Peralta-Zaragoza,1 V. Bermudez-Morales,1 M. Bahena-
Roman,1 J. Alcocer-Gonzalez,2 F. Recillas-Targa,3 V. Madrid-
Marina.1 1Division of Pathogens Molecular Biology, National
Institute of Public Health from Mexico, Cuernavaca, Morelos,
Mexico; 2School of Biological Sciences, Autonomous University of
Nuevo Leon, Monterrey, Nuevo Leon, Mexico; 3Department of
Molecular Genetics, Institute of Cellular Physiology, National
Autonomous University of Mexico, Mexico, DF, Mexico.
TGF-beta1 is a multifunctional cytokine involved in several
immunoregulatory processes and plays a critical role in the escape of
some cancer from host immunity. HPV is the main etiologic agent in
cervical cancer, and E6 and E7 oncoproteins have properties of
transforming cell and transregulation of cellular genes. We have
identified a correlation between TGF-beta1 gene expression and the
advance of the malignancy, which suggest that HPV induces TGF-
beta1 gene expression. However, the mechanisms by which HPV
induce TGF-beta1 in cervical cancer remain unclear. In this study we
analyzed whether HPV-16 E6 and E7 oncoproteins are involved in
the molecular mechanisms of TGF-beta1 gene expression. For that
end, we amplified the human 5V-TGF-beta1 promoter by PCR from
peripheral blood lymphocyte DNA, which was cloned in pBlue-
script and sequenced. This DNA fragment was subcloned in
pBLCAT3 and several constructs generated by deletion of TGF-
beta1 promoter. C33A cells were transfected with this constructs and
evaluated the effect of HPV-16 E6 and E7 oncoproteins by
cotransfection with pSV2E6 and pSV2E7. We observed that E6
and E7 oncoproteins induced two-fold promoter activity inside
TGF-beta1 core promoter, while had not significant effect in other
TGF-beta1 regulatory regions.We also observed several interactions
DNA-protein between HPV-16 E6 and E7 oncoproteins with Sp1
regulatory elements of TGF-beta-1 core promoter by Footprinting
and EMSA. In addition, we identified a super shift DNA-protein
complex specific associated to Sp1 binding site of TGF-beta-1 core
promoter when the anti-E6 or anti-E7 antibodies were used. The
results suggest specific interactions between viral transcriptional
factors inside of TGF-beta1 core promoter. These results may
explain the molecular mechanisms of TGF-beta1 gene regulation in
cervical cancer as well as tumor escape mechanisms from host anti-
tumoral immune response.
Su1.06. Orexin-A Has Delayed Reponse to Intestinal
Ischemia-Reperfusion Injury.
Ji Lin,1 Guang-Tao Yan,1 Xiu-Hua Hao,1 Lu-Huan Wang,1 Kai
Zhang.1 1Research Laboratory of Biochemistry, Basic Medical
Institute, General Hospital of P.L.A, Beijing, Beijing, China.
BACKGROUND: Orexin-A, also named hypocretin-1, is a
novel neuropeptide secreted by specific neurons in lateral
hypothalamus. Recent findings suggest that orexin-A provides a
critical link between the peripheral energy balance and central
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motivated behaviors, mainly promoting food intake and suppress-
ing energy expenditure. As orexin-A is an active mediator closely
related with energy metabolism, we hypothesize that orexin-A may
undergo a fluctuation during the severe metabolic impediment of
acute inflammation, such as intestinal I/R injury.
MATERIALS AND METHODS: An intestinal ischemia-
reperfusion (I/R) injury model of rats was established, and rats
were divided randomly into six groups: sham-operation group,
60 min ischemia/30 min reperfusion group (I60VR30V), I60VR90V,
I60VR150V, I60VR240V and I60VR360V, 9 rats each group. A highly
sensitive orexin-A radioimmunoassay was used to check the
change of orexin-A concentrations in plasma and hypothalamus
tissue, and RT-PCR was used to detect the change of orexin-A
mRNA expression in hypothalamus tissue. Therefore, the change
of orexin-A levels both in peripheral blood and central secretory
tissues before and after intestinal I/R injury could be inves-
tigated.
RESULTS: Compared with before injury, plasma orexin-A
levels of each group showed no significant difference. Compared
with sham group after injury, both plasma and hypothalamus
orexin-A levels of every other group showed no significant
difference. Compared with sham group after injury, orexin-A
mRNA expression of I60VR30V and I60VR90V decreased step by step,
that of I60VR150V reached the lowest, and that of I60VR240V and
I60VR360V recovered gradually to the level of sham group.
CONCLUSION: Orexin-A has a delayed response to acute
inflammatory stimuli such as intestinal I/R injury, and it may
participate in metabolic disorders in the injury as inflammatory
cytokines.
Keywords: Ischemia-reperfusion, intestinal; Orexin-A; Radio-
immunoassay; PCR; Inflammation, acute; Cytokine
Su1.07. Increased Interleukin-6 Serum Levels in
Subjects with Metabolic Syndrome.
I. N. Kondratska,1 B. N. Mankovsky.1 1Diabetes, Institute of
Endocrinology, Kiev, Ukraine.
An activation of generalized non-specific inflammation could
play a role in the pathogenesis of metabolic syndrome and its
components. However, the data regarding the changes of pro-
inflammatory interleukins in subjects with metabolic syndrome
remain controversial. Therefore, the aim of this study was to
investigate the levels of interleukin-6 in the serum in subjects with
metabolic syndrome compared to those without this syndrome. We
studied 55 patients with metabolic syndrome (age- 55.8 F 1.37
years, BMI–32.4F 0.6 kg/m2, data are presented as meanF SEM)
and 50 subjects with no metabolic syndrome (age- 52.7 F 1.40
years, BMI–27.6 F 0.6 kg/m2). The diagnosis of metabolic
syndrome was made based on ATP-III criteria (2001). In the
group of patients with metabolic syndrome there were 18 subjects
with type 2 diabetes mellitus, 16 persons with impaired glucose
tolerance, arterial hypertension was diagnosed in 45 subjects. In
those persons without metabolic syndrome type 2 diabetes mellitus
was registered in 3 subjects, impaired glucose tolerance was found
in 7 persons, arterial hypertension was diagnosed in 8 subjects. All
persons studied did not receive any medications for the treatment
of diabetes mellitus or arterial hypertension at the time of the
examination. There were no clinical signs of any concomitant
disease in patients studied. The levels of interleukin-6 were
measured by specific assay. We found that the levels of
interleukin-6 were significantly increased in patients with meta-bolic syndrome compared to those without this syndrome- 1.44 F
0.3 and 0.625 F 0.16 pg/ml, respectively, P b 0.05. We can
conclude that elevated serum interleukin-6 levels could reflect an
activation of generalized inflammation in patients with metabolic
syndrome, which could contribute to the development and
progression of atherosclerosis and high risk of cardiovascular
disease in these patients.
Su1.08. LIGHT Regulates CD86 Expression on
Dendritic Cells through NF-kB, but Neither p44/42
MAPK nor JNK/AP-1 Signal Transduction Pathway.
G. M. Zou,1 W. Y. Hu.2 1Bone Marrow Transplantation, Rush
University Medical Center, Chicago, IL, USA; 2Physiology and
Biophysics, University of Illinois at Chicago, Chicago, IL, USA.
The members of the tumor necrosis factor (TNF) family play
pivotal roles in the regulation of the immune system. LIGHT is a type
II transmembrane protein belonging to the TNF family that was
originally identified as a weak inducer of apoptosis. This cytokine
has been extensively studied on its role in Tcell regulation. Recently,
we identified its role in inducingmaturation of dendritic cells, such as
LIGHT upregulated CD86 expression on dendritic cells in our
previous report. However, the signal transduction pathway on this
regulation remain unknown. In this study, we found that LIGHT
activated NF-kB, p44/42 MAPK, but not JNK. LIGHT upregulates
CD86 expression on DCs through activation of NF-kB, but not p44/
42 signal pathway, because inhibition of NF-kB activity by its
inhibitor could blunt the effect of LIGHT in up-regulation of CD86
expression, but neither inhibitor of p44/42 nor JNK inhibitor has this
effect. Thus we demonstrate that LIGHT regulates CD86 expression
through NF-kB signal transduction pathway but neither p44/42
MPAK nor JNK/AP-1 signaling pathway. We conclude that NF-kB
signal plays a key role in LIGHT-mediated upregulation of CD86
expression.
Su1.09. An Important Role of Inducible Histamine in
P.acnes-Primed and LPS-Induced Hepatitis in Mice.
M. Nishibori,1 H. K. Takahashi,1 M. Yokoyama,1 A. Yokoyama,1 T.
Yoshino,2 T. Watanabe,3 T. Watanabe,4 H. Ohtsu,5 H. Wake,1 S.
Mori.1 1Department of Pharmacology, Okayama Univ Grad Schl
of Med & Dent, Okayama, Okayama, Japan; 2Department of
Pathology, Okayama Univ Grad Schl of Med & Dent, Okayama,
Okayama, Japan; 3Department of Mol Immunology, Kyushu Univ,
Fukuoka, Fukuoka, Japan; 4Department of Pharmacology, Tohoku
Univ Gad Schl Med, Sendai, Miyagi, Japan; 5Department of Appl
Quant Med Eng, Tohoku Univ Grad Schl Eng, Sendai, Miyagi,
Japan.
Histamine is a well known mediator of allergic inflammation,
synthesized by one step enzymic reaction with histidine
decarboxylase (HDC). The increase in vascular permeability,
vasodilatation and the stimulation of nerve terminals of primary
sensory neurons through the stimulationof H1-receptors con-
ntribite to the facilitation of the inflammatory response. In
addition to H1-receptor-mediated effects, histamine has been
demonstrated to be involved in the regulation of innate and
aquired immune responses through H2-receptors. In the previous
study, we demonstrated that histamine inhibited the IL-18-
induced expression of ICAM-1 on monocytes and the susequent
production of IL-12 and IFN-g in human PBMC. Histamine also
inhibited the ICAM-1 expression on monocytes in a human
mixed lymphocyte reaction in the presence of IL-18. These
effects of histamine were all mediated by H-2-receptors.
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diffuse intrahepatic infiltration by inflammatory cells with
massive multilobular necrosis. Heat-killed Propionibacterium
acnes (P.acnes) followed by challenge with a low dose of
lipopolysaccharide (LPS) induces acute and massive liver injury,
mimicking fulminant hepatic failure. In the present study, we
examined a functional role of inducible histamine in the
protection against hepatic injury and lethality in P.acnes-primed
and LPS-induced hepatitis, using HDC knockout and H2-
receptor knockout mice. Moreover, we investigated the effects
of the inhibitor of histamine N-methyltransferase(HMT) on
hepatitis. LPS challenge after P.acnes-priming increased HDC
activity in the liver of wild-type mice, associated with a marked
elevation of histamine and tele-methylhistamine levels. Western
blotting showed the increase in 74 KDa HDC band in the liver.
These results strongly indicated that HDC protein was induced
by LPS in the liver and that the histamine produced had high
turnover rate. HDC-like immunoreactivity was observed in
CD68-positive Kupffer cells/macrophages. Treatment of wild-
type mice with famotidine and ranitidine but not chlorphenir-
amine augmented hepatic injury and inhibited the survival rate.
The same dose of P.acnes and LPS induced severe hepatitis and
high lethality in HDC and H2-receptor knockout mice, the former
were rescued by the subcutaneous injection of histamine. Hista-
mine suppressed the expression of IL-18 and TNF-a in the liver,
leading to the reduced plasma levels of inflammatory cytokines.
HMT inhibitor had similar effects to histamine. These findings
indicated that endogenously produced histamine plays a very
important role in preventing excessive innate immune response in
endotoxin-induced fulminant hepatitis through the stimulation of
H2-receptors.
Su1.10. Receptors for Vascular Endothelial Growth
Factor (VEGF) on Murine Lymphocytes and
Macrophages.
Ekaterina P. Kisseleva,1 Andrei V. Krylov,1 Victoria I. Lioudyno.1
1Immunology, Institute for Experimental Medicine, St. Petersburg,
Russian Federation.
VEGF is considered to be one of the most important angiogenic
factors. It is known to be chemoattractive for human monocytes
and to possess some immunoregulatory influence on T-cells. The
aim of the study was to evaluate the mRNA expression of VEGF
receptors: VEGFR1 (Flt-1) and VEGFR2 (KDR/Flk-1) in murine
immunocompetent cells. Isolated thymocytes, lymph node cells,
whole thymus and peritoneal macrophages from intact C3HA mice
were used for investigation. Peritoneal cells were allowed to adhere
for 2 hours and then washed from non-adherent cells. The level of
mRNA expression was studied by reverse transcription-polymerase
chain reaction (RT-PCR). Total RNA was isolated with the help
of guanidine thiocyanate method. Synthesis of cDNA templates
was carried out using 2 Ag of total RNA, oligo d(T)15 primers
and M-MLV reverse transcriptase (Promega) according to the
manufacturerTs instructions. Specific primers used for PCR
amplifications were: VEGFR1 forward primer-5V-GAAGCGGTT-
CACCTGGACTGAGACC-3V; VEGFR1 reverse primer-5V-GGCQ
TTTGCTGGGGGGATTTCTCTAA-3V; PCR product size 432 bp;
VEGFR2 forward primer-5V-ACAGACAGTGGGATGGTC-
CTTGCAT-3V; VEGFR2 reverse primer-5V-AAACAGGAGGT-
GAGCTGCAGTGTGG-3V; PCR product size 272 bp. Primer
pairs were designed from nucleotide sequences available in public
database. As a control for housekeeping gene an RT-PCRprocedure for h-actin was also delivered. Whole thymus expressed
mRNA for both VEGFR1 and VEGFR2, while isolated thymo-
cytes expressed only VEGFR2 mRNA. Peritoneal macrophages as
well as isolated lymph node cells expressed mRNA for both
receptors. Incubation of peritoneal macrophages in the presence of
50 ng/ml of VEGF during 24 h resulted in the enhancement of
VEGFR1 mRNA expression. The expression of VEGFR2 gene in
murine thymocytes was shown for the first time. This suggests that
VEGF may directly influence thymic cells and have some specific
influence on the development of T-cells. As it was previously
shown VEGF can modulate thymocyte mitogen-induced prolifer-
ation and spontaneous apoptosis in vitro and evokes thymic
involution while administered in vivo (Ohm et al., 2003). The
expression of VEGFR2 mRNA in murine peritoneal macrophages
is also a novel finding. These data indicate that tissue macrophages
possess both receptors unlike blood monocytes that are known to
express only VEGFR1. Supported by grants: RFBR N.03-04-
49186 and Scientific Schools N.540.2003.4.
Su1.11. Modulation of Suppressor of Cytokine Signalling
3 (SOCS3) Expression and Stability in Human
Neutrophils and in Differentiated PLB-985 Cells by
G-CSF, GM-CSF and IL-4.
C. Ratthe,1 D. Girard.1 1INRS, Institut Armand-Frappier,
Pointe-Claire, QC, Canada.
Rationale: Polymorphonuclear neutrophils (PMN) are major
players in inflammation. They are the first cells to arrive at an
inflammatory site and are involved in the inflammatory response.
Inflammation is largely resolved when PMN undergo apoptosis
and are then ingested by phagocytes such as macrophages. Many
cytokines can modulate PMN functions including apoptotic rate
and the ability to exert phagocytosis. This is the case with G-
CSF, GM-CSF and IL-4. IL-4 is particularly known to enhance
PMN phagocytosis and to delay apoptosis. After binding to their
specific receptor, many cytokines activate the intracellular Jak/
STAT pathway. It was recently discovered that the Jak/STAT
pathway can be regulated by a family of proteins named SOCS
(suppressor of cytokine signalling), that inhibit the pathway via a
feedback loop mechanism. CIS, SOCS2 and SOCS3 have been
reported to be expressed in PMN. The aim of the present study
was to evaluate the expression of SOCS and their modulation in
PMN and in the PLB-985 cell line following cytokine stimula-
tion. PLB-985 are immature promyelocytic cells that acquire a
neutrophil-like phenotype when dimethylsulfoxide (DMSO) is
added to the culture medium. Methods: PMN were freshly
isolated from the venous blood of healthy volunteers. Differ-
entiated PLB-985 (PLB-985D) were obtained after incubation of
PLB-985 cells with 1,25% DMSO for 6 days. Cells were
incubated with either G-CSF, GM-CSF, IL-2, IL-4 or IL-6 for
1 to 8h. RT-PCR was used to detect SOCS mRNA and protein
expression was studied by immunoblotting using specific anti-
bodies. The proteasome inhibitor MG132 was used to investigate
the SOCS protein pool that is rapidly degraded in the cell.
Cycloheximide (CHX) was used to inhibit protein synthesis and
to answer whether or not SOCS proteins are de novo synthesized.
Results: G-CSF, GM-CSF and IL-4 were found to induce the
mRNA expression of SOCS3 in PMN after 1h of stimulation.
PMN, but not PLB-985D cells, were found to express a basal
level of the SOCS3 protein. After pre-incubation with MG132,
treatment of cells with G-CSF, GM-CSF or IL-4 enhanced the
level of SOCS3 in PMN and induced its expression in PLB-985D
Abstracts S191at the protein level. Stimulation with IL-6 also induced SOCS3
expression in PLB-985D but not in PMN. CHX reversed the
increase of SOCS3 in PMN following stimulation with cytokines.
CIS and SOCS2 mRNA expressions varied in PMN and PLB-
985D, but this was not observed at the protein level. Conclusions:
SOCS3 mRNA and protein expression increased in PMN and
PLB-985D after stimulation with G-CSF, GM-CSF or IL-4.
SOCS3 is rapidly degraded in PMN and PLB-985D, since the
increased expression of protein was better observed when cells
were pre-incubated with the proteasome inhibitor MG132. The
elevated level of SOCS3 protein expression in PMN and PLB-
985D is probably the result of de novo protein synthesis, since
this was inhibited by CHX. CIS and SOCS2 mRNA levels varied
in cells following stimulation with the cytokines we used, but their
protein expression remained stable suggesting the existence of
another mechanism governing their expression.
Su1.12. Quantification of mRNA Expression of TNF-A
and TGF-B, Fas, TNFR1 and 2 Using Real-Time
Quantitative RT-PCR.
F. Q.B. Alenzi. 1Department of Medical Laboratory Sciences, King
Faisal University, Dammam, Saudi Arabia.
Measurement of the expression level of cytokines is important
for the study of in vivo and in vitro effects of cytokines. However,
sensitive and quantitative measurements of mRNA are difficult to
perform because the established techniques (e.g. northern blotting)
are laborious and prone to contamination. We have applied and
validated a real-time quantitative PCR for cytokine mRNA
quantification. This method is easy to optimize and offers sensitive,
reliable and quantitative results with significantly reduced labour,
allowing analysis for cytokine expression for large number of
samples. We applied this method for comparing expression levels
of several cytokines (TNF-a and TGF-h) and their receptors (Fas,
TNFR1 and 2) between eosinophils and neutrophils isolated from
peripheral blood. The results showed significance difference
comparing to the volunteer samples.
Su1.13. Role of TWEAK, a Member of the TNFa Family
of Cytokines, in Arthritis.
S. Perper,1 B. Browning,2 C. Gao,1 K. Giza,1 L. Rajman,3
L. Runkel,3 M. Scott,3 L. C. Burkly,2 T. Zheng,2 H. Hess.1
1Immunopharmacology, Biogen Idec, Cambridge, MA, USA;
2Exploratory Science, Biogen Idec, Inc, Cambridge, MA, USA;
3Validation Genetics, Biogen Idec, Inc, Cambridge, MA, USA.
TWEAK is a macrophage-derived cytokine and member of the
TNFa family of ligands originally identified as a weak inducer of
death in certain tumor cell lines (TNF-like weak inducer of
apoptosis). TWEAK exerts pleoitropic effects on a variety of cell
types in vitro, including proangiogenic and proinflammatory
activities. These cells express a known receptor for TWEAK,
FGF-inducible molecule 14 (Fn14), which is restricted to epithelial
and mesenchymal cell types, including synoviocytes and chon-
drocytes, and is highly upregulated in contexts of injury and
inflammatory disease. It was reported that TWEAK induces human
synoviocyte production of proinflammatory cytokines, chemokines
and MMPs, and osteoclastogenesis of a murine macrophage cell
line. Thus, TWEAK may promote joint inflammation and damage.
Here we report that neutralizing TWEAK mAbs markedly reduce
clinical paw severity in mouse and rat collagen-induced arthritis
models. Inhibition by anti-TWEAK mAbs occurs at the challenge
phase and does not appear to alter T cell priming or elicitation ofanti-collagen antibodies. Decreased clinical paw severity correlates
with reduced inflammation and protection from cartilage and bone
loss at the histological level. Further studies are in progress to
dissect the mechanism of action whereby TWEAK promotes joint
inflammation, cartilage and bone loss and to investigate the
potential interplay between TWEAK and TNF in this context.
Su1.14. The Anti-Proliferative Effect of Infliximab on
T-Cells Is Prevented by CD28 Induced Co-Stimulation.
B. Gunnlaugsdottir,1,2 S. M. Maggadottir,1,2,3
B. R. Ludviksson.1,2,3 1Center for Rheumatology Research,
Landspitali-University Hospital, Reykjavik, Iceland; 2Institute of
Laboratory Medicine, Department of Immunology,
Landspitali-University Hospital, Reykjavik, Iceland; 3Department
of Medicine, University of Iceland, Reykjavik, Iceland.
Introduction: The systemic neutralization of the proinflamma-
tory cytokine TNFa has been shown to be beneficial for patients
with RA. Since CD28+ T-cells have been implicated in the patho-
genesis of RA, we evaluated if the anti-proliferative effect of Infli-
ximab could be prevented by anti-CD28 induced co-stimulation.
Aim: The aim of this study was to dissect the effect of TNFa
neutralization on a well-defined cell population under highly
standardized stimulatory conditions. The effect of anti-TNFa
neutralization was thus examined on highly purified naRve human
cord blood T-cells under different stimulatory conditions.
Methods: Highly purified (N90% CD3+CD45RO-) naRve
human T-cells were negatively selected from cord blood. The
cells were cultured in a serum free medium (AimV) with or
without anti-human TNFa chimeric monoclonal antibody (Inflix-
imab (100Ag/mL)), with or without TGF-h1 (10ng/mL) and with
or without anti-IL-10 (10Ag/mL). The cells were stimulated for
four days with anti-CD3 (10 Ag/mL) with or without anti-CD28
(1Ag/mL). For analysis of cell division, T-cells were labeled with
CFSE.
Results: The effect of TNFa neutralization resided both on the
presence of CD28 induced co-stimulation and TGF-h1. The anti-
proliferative effect was completely lost in the presence of anti-
CD28 induced co-stimulation and strongly reduced in the presence
of TGF-h1. Interestingly, the anti-proliferative potential of Inflix-
imab exceeded that of TGF-h1 under suboptimal stimulatory
conditions (without co-stimulation). Infliximab acted similarly
upon both CD4+ and CD8+ T-cells whereas our earlier work has
shown that TGF-h1 generally affects CD8+ T-cells more strongly
than CD4+ T-cells. Finally, Anti-IL-10 did not affect proliferation
except when TGF-h1 was present, independently of co-stimulation.
Conclusion: The primary T-cell responses towards anti-TNFa
treatment is affected by CD28 induced co-stimulation and TGF-h1.
This may affect the effectiveness of Infliximab in the RA synovium
where elevated levels of CD28+ T-cells and TGF-h1 have been
reported.
Su1.15. Lack of Linkage between DNA Methylation and
Interleukine-10 Gene Expression.
Jun Dong,1 Claudia Ivascu,2 Florian Eckhardt,2
Hyun-Dong Chang,3 Carolina Haefliger,2 Lars Tykocinski,3
Martin Rudwaleit,4 Jochiem Sieper,4 Andreas Radbruch,3 Andreas
Thiel.1 1Clinical Immunology, German Rheumatism Research
Center, Berlin, Germany; 2Epigenomics, Berlin, Germany; 3Cell
Biology, German Rheumatism Research Center, Berlin, Germany;
4Rheumatology, Charite Campus Benjamin Franklin, Berlin,
Germany.
AbstractsS192Objective: Epigenetic regulation including DNA methylation
profoundly influences effector cytokine gene expression such as
IFN-g and IL-4 in differentiated T helper (Th) cells. However,
until now the DNA methylation status of IL-10, a cinderella
immunoregulator of the immune system, remains unrevealled.
Methods: A double cytokine secretion assay allowing simulta-
neuous isolation of cytokine-secreting cell subset of interest was
used to highly purify human IL-10+ IFN-g-, IL-10+ IFN-g+, IL-
10- IFN-g+ and IL-10- IFN-g- human Th cell subsets after short-
term ex vivo polyclonal stimulation. Subsequently a global
quantitative DNA methylation analysis of IL-10 and other Th
cell differentiation related genes was perfomed. Results: Strik-
ingly, no methylation differences were detected between these
Th-cell subsets in 15,5 kb of IL-10 genomic locus spanning 9,1
kb upstream and the complete gene encompassing 99 CpGs. This
included both promoter as well as other conserved noncoding
regions. In contrast, hypomethylation and hypermethylation of the
IFN-g gene promoter and exon I and intron I regions were
noticeable in IFN-g-producers versus nonproducers, respectively.
In addition, antigen-specific IL-10+ Th-cell subsets showed faded
fidelity upon in vitro restimulation already after 2 weeks of in
vitro expansion. Conclusion: Our results point out a lack of
epigenetic memory for IL-10 expression in human Th cells. Thus,
clinical applications of IL-10+ regulatory Th cells should be
evaluated carefully with respect of a stable IL-10 expression in
the transferred T-cell population.
Su1.16. Epigenetic Regulation of TNF alpha in
Monocytes/Macrophages.
K. E. Sullivan,1 K. Dietzmann,1 A. R. Suriano,1 A. N. Sanford,1 M.
A. Petri, M. Bhatia,2 B. Aramati.1 1Allergy Immunology,
ChildrenTs Hospital of Philadelphia, Philadelphia, PA, USA;
2Stem Cell Biology, Robarts Research Institute, London, ON,
Canada; 3Rheumatology, Johns Hopkins University School of
Medicine, Baltimore, MD, USA.
TNF alpha is regulated at the level of transcription, message
turnover, translation and protein turnover. We have also
demonstrated a strong role for epigenetic regulation of expres-
sion. This has implications for chronic inflammatory diseases
where the epigenetic bprintQ may be altered and contribute to
disease persistence. We examined histone acetylation, histone
methylation, DNA methylation and nuclear localization of the
TNF alpha gene in cell lines and primary cells before and after
stimulation to understand the role of epigenetics in the regulation
of gene expression. Histone acetylation was not altered in our
model systems by acute stimulation but was increased reprodu-
cibly by increasing maturation of monocytes. Artificially
increasing histone acetylation in some settings increased TNF
alpha expression but not in others suggesting histone acetylation
was not sufficient for transcriptional competence. In contrast,
histone K4 methylation was increased in competent cells and
inhibition clearly impaired production of TNF alpha suggesting
that this epigenetic mark was critical for transcription. DNA
methylation correlated with competence to produce TNF alpha
and was also found to be developmentally regulated and critical
for production of TNF alpha. Lastly, we have used FISH to
define the location of the TNF alpha locus within the nucleus. A
human centromere probe was used to define heterochromatin.
The TNF alpha locus was generally found in euchromatin in
terminally differentiated cells, however, human stem cells which
are not competent to produce TNF alpha had their TNF alphalocus in heterochromatin. From these data, we conclude there is
a temporal sequence of events culminating in transcriptional
competence. Early in development, the TNF alpha gene exits
heterochromatin and the DNA becomes demethylated. Monocyte
lineage cells further undergo modification of the H3 and H4
histones with acetylation according to their maturational state.
Histone H3 lysine 4 methylation appears to be the final event
leading to transcriptional competence of the TNF alpha gene. To
determine whether these epigenetic marks could be altered in
inflammatory disease states, we investigated patients with
systemic lupus erythematosus (SLE) for evidence of altered
chromatin structure. Patients with SLE had increased histone
acetylation at their TNF alpha locus in monocytes compared to
controls suggesting that epigenetic changes may participate in
disease perpetuation. In conclusion, these data support a very
strong role for TNF alpha epigenetic regulation in the control of
expression of this powerful cytokine.
Su1.17. A Fast and Robust Multiplexed Immunoassay
Panel for Simultaneously Quantifying 24
Cytokines/Chemokines in Rat Serum or Plasma Using
Luminex xMAP Technology.
S. Ji,1 T. Whitehead,1 H. Hwang,1 R. Rick,1 J. Mistry.1 1R&D,
LINCO Research, St. Charles, MO, USA.
Rat is an animal model used extensively in many areas of
biomedical research, where quantification of multiple cytokines
and chemokines is critical for understanding physiological and
pathological processes such as inflammation. However, limited
sample availability, high cost, extra time and labor associated
with using multiple conventional ELISA products make it
impractical to measure multiple cytokines and chemokines in rat
models. We previously reported a 14-plex immunoassay panel
for rat cytokines, which is currently available as a commercial
product. Here we report the expansion of this multiplexed
immunoassay system for simultaneous quantification of 24
different rat cytokines and chemokines (Eotaxin, G-CSF,
GMCSF, GRO/KC, IFNg, IL-1a, IL-1h, IL-2, IL-4, IL-5, IL-
6, IL-9, IL-10, IL-12p70, IL-13, IL-17, IL-18, IP-10, leptin,
MCP-1, MIP-1a, RANTES, TNFa and VEGF) in a single
serum/plasma sample of 5 AL volume. The methodology
includes typical sandwich immunoassays on the surface of
polystyrene beads using specific immobilized capture antibodies,
biotinylated detection antibodies and streptavidin-phycoerythrin
as the reporter molecule. A Luminex100 reader is used to
quantify the fluorescent signal on the beads. Each antibody pair
used for individual analyte is highly specific, with no or
negligible cross-reactivities to other cytokines or chemokines
within the panel. The standard curves for all analytes range
from 6.4 to 20,000 pg/mL. The overall sensitivities are between
b1 to 20 pg/mL in serum matrix. The assay robustness is
demonstrated by acceptable precisions (V14% for inter-assay
CV%, V8.5% for intra-assay CV%), an average recovery of
93.6 F 23% for linearity of sample dilutions, and an accuracy
of 97 F 18% in serum matrix. Total assay time is 3.5 hour for
serum-free samples or overnight for serum or plasma samples.
The assay panel may also be used for samples such as cell
culture supernatant, cell/tissue extract or other biological fluids.
This simple, sensitive, accurate, and reproducible assay panel
offers an economic and convenient tool for accurate and
simultaneous quantification of multiple rat cytokines and
chemokines in biological samples.
Abstracts S193Su1.18. Markers of Inflammation, Vitamin E and
Peripheral Nervous System Function. The InCHIANTI
Study.
R. Paganelli,1 A. Di Iorio,1 L. Ferrucci,2 E. Sparvieri,1 A.
Michetti,1 C. Franceschi,4 A. Cherubini,3 U. Senin,3 G. Abate.1
1Department of Medicine and Sciences of Aging, University G.
dTAnnunzio, Chieti, Italy; 2Longitudinal Studies Section, Clinical
Research Branch, NIH, Baltimore, MD, USA; 3Institute of
Gerontology and Geriatrics, University of Perugia, Perugia, Italy;
4Department of Biomedical Sciences, University of Bologna,
Bologna, Italy.
Aging is characterized by a decline in function of multiple
physiological systems. The causes of this decline are still unclear but
increased oxidative stress, disturbances in energy metabolism and a
primary dysregulation of the immune system might play an
important role. Aging of the peripheral nervous system is associated
with several morphologic and functional changes, including a
decrease of the nerve conduction velocity. These changes contribute
to age-related-decline in muscle strength, sensory discrimination,
and autonomic responses, thereby increasing the risk of falls and
disability. The aims of this study were to investigate how nerve
conduction velocity in the peripheral nervous system correlates with
immunological and inflammatory markers and age-associated
diseases. We measured motor nerve conduction velocity of the right
superficial peroneal nerve using a standard neurophysiologic
technique in a population based sample of subjects aged between
20 and 103 years old taking part in the InCHIANTI study; blood
count and standard biochemistry were assayed and a sample
obtained for cytokines and vitamin E measurements. The
InCHIANTI study examined persons living in the municipalities
of Greve in Chianti and Bagno a Ripoli, two small towns located in
the surroundings of Florence (Italy), randomly selected from the
local population registry. Of the 1292 subjects enrolled in the study,
573 (44.3%) were males and 719 (55.7%) females. Average NCV
declined with age both in men and in women. However, in each age-
group NCV was higher in women than in men. The age-associated
decline in NCV was linear. A history of diabetes (P b 0.001), stroke
(P = 0.009) and peripheral arterial disease (P = 0.05) as well as the
presence of cognitive impairment (0.004) were associated with a
lower NCV, even after sex and age adjustment. Among the cytokines
considered, no significant association with peripheral conduction
could be found for Il-1h, IL-1 Ra, IL-10 and TNF-a. A significantly
lower NCVwasmeasured in subjects whose serum levels of the IL-6
(P b 0.001) as well as those of its soluble receptor (s IL-6R) (P b
0.001) were in the lower tertile. When IL-6 was adjusted for age and
sex the differences among groups disappeared (P = 0.32), while for s
IL-6R (P = 0.03), the adjustment changed only the strength of the
association. At multivariate analysis, besides age and height,
independent predictors of nerve conduction velocity included:
diabetes (b0.001), cognitive impairment (0.001), sIL-6R (0.03); a-
tocopherol (0.04), uric acid (0.01), number of lymphocytes (0.01)
and neutrophils (0.004). Our results support the hypothesis that
inflammation and oxidative damage are involved in the aging of the
peripheral nervous system, independently from age-associated
diseases.
Su1.19. Protective Effect of Galectins Against the
Generalized Shwartzman Reaction of Mice.
Ryusuke Nakagawa,1 Hiroko Abe,1 Mitsuomi Hirashima,2 Akira
Yamauchi.1 1Cell Regulation, Kagawa University, School ofMedicine, Kita-gun, Miki-cho, Kagawa, Japan; 2Immunology
and Immunopathplogy, Kagawa University, School of Medicine,
Kita-gun, Miki-cho, Kita-gun, Miki-cho, Japan.
Galectins are animal lectins that exhibit affinity for h-galacto-
sides and share certain conserved sequence elements. To date, 14
galectins have been cloned in mammals and shown to play
modulatory roles in diverse biological processes such as cell
adhesion and proliferation, T cell apoptosis, and immune
responses.
Structurally, both galectin (Gal)-8 and Gal-9 belong to the
tandem-repeat subfamily that is characterized by the presence of
two distinct carbohydrate recognition domains (CRDs) joined by a
linker peptide. It has shown that Gal-8 induces adhesion activity
and superoxide production in neutrophils, and that Gal-9 possesses
eosinophil chemoattractant activity as well as induces superoxide
production and prolongs cell survival in eosinophils.
In this study, we showed that intraperitoneal administration of
recombinant Gal-8 and Gal-9 strongly induced neutrophil accu-
mulation in peritoneal cavity of mice and Gal-8 and Gal-9
exhibited neutrophil chemoattractant activity in vitro. Neutrophil
play a critical role in innate immune response and complications of
bacterial infection such as septic shock and septic multiple organ
dysfunction syndrome. Therefore, to determine whether galectin-
induced neutrophil contribute to enhance septic shock, we
examined the functions of Gal-8 or Gal-9 in LPS-induced lethal
shock syndrome, known as the generalized Shwartzman reaction
that can be elicited by two consecutive injections of LPS.
Unexpectedly, Gal-8 or Gal-9 treatment with first LPS challenge
increased mouse survival and suppressed the elevation of IL-12,
IFN-g and TNF-a levels. This protective effect of Gal-8 or Gal-9
against the Shwartzman reaction and suppression of these cytokine
productions were diminished by depletion of neutrophils using
anti-Gr-1 monoclonal antibody. Furthermore, treatment of mutant
Gal-8 that lacks h-galactoside binding activity, with LPS could
not suppress the elevation of IL-12, IFN-g and TNF-a levels,
whereas neutrophil accumluation in peritoneal cavity of mice was
observed.
Thus, these results indicated that galectins modified various
cytokine production induced with LPS and improved mouse
mortality of the Shwartzman reaction via neutrophil accumulation.
Taken together, h-galactoside binding activity of galectins was
required to modify LPS induced cytokine production.
Su1.20. Analysis of Cytokine Network for Initiation of
Immune Responses in the Hyperplastic Thymus
Associated with Myasthenia Gravis.
I. Kamo,1 A. Kikuchi,2 H. Tomoyasu,3 N. Sakuragawa.1
1Regenerative Medicine, School of Medicine, Toho University,
Sagamihara, Kanagawa, Japan; 2Ultrastracuture, National
Institute of Neuroscience, Kodaira, Tokyo, Japan; 3Respiratoy,
Japan Red Cross, Ohmori, Tokyo, Japan.
Myasthenia gravis (MG) is closely associated with thymic
abnormality such as hyperplasia and thymoma. Unlike exper-
imental MG, thymectomy is effective in relieving the symptom.
In particular, the hyperplastic thymus contains many IL-2R
expressing B-cells, including anti-AChR antibody producing B-
cells, suggesting that they are developed under the influence of
hyperplastic circumstances rather than simply accumulated here
from the periphery as a reservoir. In the present study we aimed
to analyze thymic environment for induction of B-cell responses.
AbstractsS194MG thymi were used to examine a potential for production of T-
cell cytokines regulatory for B-cell responses. For analysis of a
B-cell stimulatory mechanism, nude mouse splenocytes and
various cytokines detected in the MG thymus were used. In the
hyperplastic thymi associated with MG, IL-2 producing cells, but
not IL-4 or IFN-g producing cells, were exclusively detected,
suggesting that conventional mature Th-1 cells that exclusively
produce both IL-2 and IFN-g are involved at less extent in
thymic IL-2 production. We found that the myoid cell condi-
tioned medium provided a circumstance for thymic and splenic
lymphocytes to produce IL-2. We also found many precursor
myoid cells that produce 80-kDa and 100-kDa haemopoietic
biglycan and AChR (+) cells only in their subset. These two
factors and other cytokines produced by myoid cells significantly
stimulated B-cell responses in a synergistic fashion with IL-2. All
these results suggest that hyperplastic MG thymus contains an
alternative immuno-stimulatory environment that may play an
important role in breakage of anergic state against AChR.
Su1.21. Age-Related Changes in Cytokine Production in
Chernobyl Clean-up Workers from Latvia.
Natalja Kurjane,1 Natalija Gabrusheva,2 Ruta Bruvere,2 Elvira
Hagina,3 Tija Zvagule,1 Arija Volrate,4 Guna Feldmane.4 1Centre
of Occupational and Radiological Medicine, P.Stradins University
Hospital, Riga, Latvia; 2Biomedical Research and Study Centre,
University of Latvia, Riga, Latvia; 3Institute of Immunology, Riga,
Latvia; 4Institute of Virology and Microbiology, Riga, Latvia.
The statement that exposure to ionizing radiation accelerates the
aging process is disputable. The latest investigations confirm aging
to be associated with increased inflammatory activity reflected by
increased levels of circulating proinflammatory cytokines. Chronic
low-grade inflammation with following impairment of immune
system functions in aging promotes the development of age-related
diseases, such as cancers, degenerative and infection diseases. In
the same way, increased inflammatory activities have been
observed after radiation exposure. Other cytokines but proinflam-
matory also are known to participate in the aging process.
Approximately 6000 LatviaTs men were affected by ionizing
radiation during they have been working in Chernobyl to clean up
the after-effects of the Chernobyl power plant accident. The
morbidity increases progressively among them year by year
significantly exceeding that in population.
Aim of the present work was to evaluate the production of
several cytokines by peripheral blood cells of individuals who
participated in 1986 in the clean-up work of the Chernobyl nuclear
power plant explosion aftereffects depending on age.
Materials and methods. ELISA measured plasma concen-
trations of sIL-1h and sIL-6 as well as level of IL-2 and IL-4
spontaneous and after stimulation by LPS and PHA mitogens after
24h and 96h in peripheral blood mononuclear cell culture
supernatants were determined in 40 Chernobyl clean-up workers
12–17 years after their work in Chernobyl and in 40 blood-donors
without a history of occupational radiation exposure. The ability of
peripheral blood leukocytes (PBL) to produce IFNs was deter-
mined in 74 Chernobyl clean-up workers 12–14 years after the
work in Chernobyl and in age matched 25 blood-donors. IFNs
were tested in whole blood cultures by the standard virus
cytopathic inhibition micromethod after their in vitro induction
by Newcastle disease virus, phytohemagglutinin or double-
stranded RNA. Individuals were divided in 2 age groups: the
first-age 35–45 and the second-age 46–65.Results. The ability of PBL to produce IFN were significantly
decreased in both Chernobyl clean-up workers age groups in
comparison with blood-donors (control groups) and the incidence
of inability to produce IFN in the 2nd Chernobyl clean-up workers
group two times exceeds that in the 1st (P b 0.01). The
concentration of sIL-6 was significantly higher in the 2nd age
group. The production of IL-2 as well as IL-4 by peripheral blood
mononuclear cells showed no significant differences nor between
both age groups or between Chernobyl clean-up workers and
donors.
Conclusion. The increased concentration of pro-inflammation
cytokine sIL-6 together with significantly impaired anti-viral
defense by decreased ability of PBL to produce IFNs in Chernobyl
clean-up workers from Latvia are age dependent.
Su1.22. Phosphodiesterase Regulation of TNF-A
Expression after Spinal Cord Injury.
S. M. Schaal, M. Perez, A. E. Marcillo, W. D. Dietrich, D. D.
Pearse. 1Miami Project To Cure Paralysis, Departments of
Neurological Surgery, Neurology, and Cell Biology and Anatomy,
Miller School of Medicine, Miami, FL, USA.
Spinal cord injury (SCI) consists of two phases, instantaneous
cellular destruction and axonal damage caused by the initial
mechanical trauma, followed by progressive injury termed
bsecondary injury,Q resulting from exposure of surrounding tissue
to excitatory amino acids, cytokines, and oxidative metabolites
from cellular debris or invading immune cells. It is known that
increasing cyclic adenosine monophosphate (cAMP) has potent
suppressive effects on the pro-inflammatory actions of the immune
response, a critical component of secondary injury. Tumor necrosis
factor- a (TNF-a), a central pro-inflammatory cytokine known to
be activated after SCI, is important in triggering cell death and is
negatively regulated by cAMP elevation. The cAMP modulation of
TNF-a expression is further investigated in this study.
Previous work performed in the lab has shown that the
administration of rolipram, a phosphodiesterase inhibitor and a
pharmacological agent capable of elevating intracellular levels of
cAMP, increases the number of spared oligodendrocyte-myelinated
axons after SCI. The overall goal of the current study was to
elucidate putative mechanisms by which rolipram can affect TNF-
a initiated signaling events that mediate axo-pathology and cell
death following spinal cord injury. Female Fischer rats underwent a
C5 moderate contusion injury and subsequent rolipram or vehicle
treatment. Animals were then sacrificed at different intervals after
injury according to known TNF-a peak expression points. ELISA
testing of control untreated tissue in comparison to rolipram treated
demonstrated that rolipram reduces TNF-a production after SCI
compared to vehicle controls. The expression of tnf-a is largely
controlled through an autoregulatory loop via the transcription
factor, nuclear factor kappa B (NFKB), hetero- or homo-dimeric
complexes of 5 different subunits. It has been previously
demonstrated that a potential shift in the balance of NFKB dimers,
with an increase in p50 homodimers causes transcriptional
repression culminating in reduced expression of tnf-a (Bohuslav
et al., J Clin Invest. 1998). In the current study, the role of this
transcriptional control mechanism in rolipram-mediated tnf-a
inhibition was explored. Western Blots of injured spinal cord from
rolipram or vehicle treated animals were taken an hour after injury
and probed for the p50 subunit of NFKB. Results showed that p50
production was greatly increased in the injured spinal cords of
rolipram treated animals. Furthermore, in rolipram treated animals,
Abstracts S195we also found increased translocation of the catalytic protein
kinase A (PKA) subunit to the nucleus. We propose that elevated
levels of cAMP and downstream activation of PKA after rolipram
treatment, leads to an interaction of PKA at the transcriptional
control level of tnf-a that alters the balance of NFKB subunit-
mediated activation and repression of the tnf-a promoter. Further
investigation of this interaction may lead to novel neuroprotective
therapies for spinal cord injury repair.
Su1.23. Analysis of IL-27 (EBI3/p28) Expression in
EBV- and HTLV-1-Associated Lymphomas:
Heterogeneous Expression of EBI3 Subunit by Tumoral
Cells.
F. Larousserie,1,2 E. Bardel,1 S. Pflanz,3 B. Arnulf,4
C. Lome-Maldonado,5 O. Hermine,1 L. Bregeaud,2 M. Perennec,2
N. Brousse,2 R. Kastelein,3 O. Devergne.1 1CNRS UMR 8147,
Universite Paris V, IFR Necker, Paris, France; 2UPRES EA 219,
Hopital Necker, Paris, France; 3DNAX Research Institute, Palo
Alto, CA, USA; 4Service dTImmuno-Hematologie, Hopital
Saint-Louis, Paris, France; 5Department of Pathology, Instituto
Salvador Zubiran, Mexico City, Mexico.
IL-27 is a novel heterodimeric cytokine of the IL-12 family
composed of two subunits, Epstein-Barr virus (EBV)-induced gene
3 (EBI3) and p28. EBI3 is expressed at high levels in EBV-
transformed B cell lines, and is induced in vitro by the EBV
oncogene LMP1 in an NF-kappaB dependent manner. We now
show that EBI3 expression is upregulated in HTLV-1-infected cell
lines and IL-2 dependent leukemic cells from Adult-T cell
leukemia/lymphoma (ATL) patients, compared to normal activated
T cells. EBI3 expression is decreased in HTLV-1-transformed cells
by treatment with BAY11-7082, an inhibitor of NF-kappaB, and is
induced in Jurkat cells by expression of HTLV-1 wild-type Tax
oncoprotein, but not by a Tax mutant, M22, that is defective for
NF-kappaB activation. In situ analysis of EBI3 and p28 expression
in HodgkinTs lymphomas (HL), in various EBV-associated
lymphoproliferative disorders (LPDs) (including post-transplant
LPDs and nasal-type NK/T-cell lymphomas), and in ATL showed
that EBI3 is expressed by neoplastic cells in all cases of HL and of
LMP1-positive EBV-associated LPD, and at variable levels in ATL
cases, but rarely in control T-cell lymphomas. In contrast, in all
lymphomas tested, no or few tumoral cells expressed p28.
Consistent with these data, no significant p28 and IL-27 expression
was detected in HL-derived cell lines and EBV- or HTLV-1-
transformed cell lines. This selective overexpression of EBI3 by
transformed cells suggests that EBI3 may play a role, independ-
ently from its association to p28, to regulate anti-viral or anti-
tumoral immune responses.
Su1.24. Pin1 Regulates Cytokine Expression in Human
Peripheral Blood Mononuclear Cells.
S. J. Esnault,1 Z. J. Shen,1 J. S. Malter.1 1Pathology and
Laboratory Medicine, Waisman Center, University of Wisconsin,
Madison, WI, USA.
Inappropriate cytokine production can trigger a variety of
allo- or autoimmune diseases. This is particularly true in organ
transplant where immuno-suppressors like FK506 or cyclosporin
A have revolutionized the field. As part of their action, these 2
drugs function as peptidyl-propyl isomerase (PPIase) inhibitors.
A third member of the PPIase family, Pin1 has been implicated
in cell-cycle progression but its function on cytokine expression
has not been investigated. In this study, we analyzed the role ofPin1 on cytokine expression in human peripheral blood
mononuclear cells (PBMC). PBMC from normal donors were
activated with PHA plus PMA or anti-CD3 plus anti-CD28.
Pin1 was inhibited with varying concentrations of juglone, an
irreversible active site inhibitor of Pin1. At 1 AM, juglone strongly
inhibited (60 to 80 % inhibition) GM-CSF, TNF-a, IL-8 and IL-4
mRNA levels by activated PBMC. At concentrations as low as
0.1 AM, juglone still reduced GM-CSF, TNF-a and IL-8 mRNAs
by 65, 35 and 34 %, respectively but had little effect on IL-4. In
order to further demonstrate Pin1Vs role in cytokine mRNA
regulation, we transduced the WW domain of Pin1 (TAT-
WWPin1) into PBMC. The WW domain affects Pin1-protein
interactions and prevents Pin1 functions as a dominant negative.
At 20nM, TAT-WWPin1 decreased GM-CSF mRNA accumu-
lation by 50% but IL-4 mRNA level remained unchanged. These
data suggest Pin1 is critical for the mitogen-induced elabo-
ration of cytokines and its inhibition maybe a powerful
immuno-suppressant.
Su1.25. Cytokine and Enzyme Spectrum in
Tracheobronchial Aspirate of Newborns with
Pneumonia Treated with Recombinant IL2.
Dilbar Kajumova,1 Leonid Nikulin,1 Oleg Borovikov.2 1Pediatric
Department, Kuban State Medical Academy, Krasnodar, Russian
Federation; 2Clinical Immunology and Allergy, Kuban State
Medical Academy, Krasnodar, Russian Federation.
In tracheobronchial aspirate (TBA) of newborns, suffering from
intrauterine pneumonia high levels of IL-1h, IL-8 and TNFa (P b
0,001) were determined. The high levels of the proinflammatory
cytokines accompanied by the elevation up to 23 times of
neutrophil elastase (NE) and in 21 times of neutrophil myeloper-
oxydase (MPO). The levels of studied enzymes in control were 70F
21 ng/ml and 250 F 75 mg/ml, respectively. Group A of patients
were treated with including into traditional therapy endotracheal
and intravenous infusions of recombinant IL2 (bRoncoleukinQ-
Biotech, Russia). The duration of lung mechanical ventilation
period of newborns of group A decreased in 2.5 times (P b 0,001),
in comparison to traditionally treated patients (group B); the
duration of antibacterial therapy reduced in 1.5 times (P b 0.05);
hospitalization period-in 1.4 times and death rate-in 5 times. On the
7th day of therapy a significant decrease in IL-8 and TNFa levels
have been noticed in patients of group A. The concentration of IL1h
was 3 times higher than in traditionally treated group. NE levels
have been decreased up to 347 F 109 ng/ml (1041 F 303 ng/ml-in
group B). MPO also decreased more than in control group (2978F
1032 mg/l and 6686 F 1371 mg/l, accordingly). On the 21 day of
monitoring the cytokineTs and enzymeTs spectrum in TBA of rIL2
treated newborns dose not differ from healthy babies, while the
levels in the control group were remain high.
Su1.26. Cytokines and Anticytokines Therapy in Severe
Acute Pancreatitis.
S. Chooklin,1 A. Perejaslov.1 1Department of Surgery, Medical
University, Lviv, Ukraine.
Recent studies show an important role of cytokines in the
pathophysiology of acute pancreatitis. The increased levels of pro-
inflammatory cytokines determine progression of disease and
development of its systemic complications. Imbalance between
pro- and anti-inflammatory cytokines may play the pivotal role in
the development of the septic complications in severe course of
acute pancreatitis.
AbstractsS196The serum levels of interleukins (IL) 1-beta, 6, 8, 10, IL-1-
receptor antagonist (IL-1Ra), tumor necrosis factor (TNF-alpha),
CD8, and CD4 lymphocytes were studied in 83 patients with acute
pancreatitis.
The increased levels of all pro-inflammatory cytokines at the
time of admission were noted in all patients. By that, the highest
levels of these cytokines were in patients with severe course of the
disease. The initial levels of anti-inflammatory cytokines were
higher in patients with mild pancreatitis in compared with severe
once. Development of septic complications accompanies by the
rapid overexpression of IL-10. Such changes in IL-10 expression
in patients with septic complications may be explained by the
inhibition of IL-10 the bactericidal function of neutrophils. At
development of purulent-septic complications increase others anti-
inflammatory cytokines was observed. It was combined with is
persistent imbalance of immunoregulatory T-lymphocytes with
suppression predominance. Good results are received at application
anticytokines therapies (pentoxifylline, dexamethasone) in initial
stage of disease. In remote period there are indications to
application immunoregulatory cytokines, such as interleukin 2.
Thus, the therapy directed on correction of cytokines status is
perspective in acute pancreatitis.
Su1.27. Cytokine Production by Dendritic Cells
Stimulated with Microbial Products Modulated by
Epigallocatechin Gallate (EGCG).
J. Rogers,1 I. Perkins,1 A. van Olphen,1 N. Burdash,1 T. W.
Klein,1 H. Friedman.1 1Medical Microbiology and Immunology,
University of South Florida College of Medicine, Tampa, FL, USA.
Dendritic cells (DCs) are important monocytic phagocytes
essential for innate immunity, especially to opportunistic intra-
cellular microorganisms like Legionella pneumophila. In this study
DCs were stimulated in vitro by either infection with Legionella or
the microbial stimulant LPS from E. coli or MDP from Gram
positive bacteria. Production of the Th1 helper cell activating
cytokine IL-12 and the proinflammatory cytokine TNFa was
rapidly induced. These cytokines are important for antimicrobial
immunity and were assessed in the DC cultures by ELISA assay.
Treatment of the stimulated DCs with EGCG, the primary
polyphenol catechin in plant products, inhibited in a dose depend-
ent manner production of IL-12 important for activating immune
cells against intracellular bacteria like Legionella. In contrast,
treatment of the DCs with EGCG enhanced production of TNFa in
a dose dependent manner. TNFa is important in inflammation and
considered crucial for the inflammatory response. Thus the results
of this study show that EGCG, the major catechin widely present in
plant products such as green tea, has marked effects on production
of immunoregulatory cytokines by stimulated DCs known to be
involved in antimicrobial immunity, especially innate immunity.
Further studies are warranted to determine the mechanisms of the
effects of this and other catechins on cytokine production by
immune cells, such as DCs.
Su1.28. TSG-6 Protein Up-Regulates Cyclooxygenase-2
Expression and Prostaglandin Biosynthesis in
Macrophage Cell Line.
C. Mindrescu,1 J. Le,1 H.-G. Wisniewski,1 J. Vilcek.1 1Department
of Microbiology, New York University, School of Medicine, New
York, NY, USA.
TSG-6 protein, the secreted product of TNF-stimulated gene 6
(TSG-6), is an important endogenous mediator of inflammationand female fertility. Previous studies have shown that TSG-6 has a
protective effect in murine models of experimentally induced
arthritis, but the mechanism responsible for this effect has
remained elusive. To gain insights into the role of TSG-6 we
investigated whether TSG-6 protein affects the expression of
inducible cyclooxygenase-2 (COX-2), a key enzyme in inflamma-
tion and immune responses. We found that TSG-6 protein up-
regulates the COX-2 protein expression in the RAW 264.7 murine
macrophage cell line. The effect of TSG-6 was abolished by heat
denaturation, trypsin digestion, or anti-TSG-6 specific antibodies.
TSG-6 treatment of cells also resulted in a rapid increase in COX-2
mRNA levels, suggesting that TSG-6 up-regulates COX-2 gene
expression. Up-regulation of COX-2 was accompanied by an
increase in the biosynthesis of prostaglandins, with a predominance
of PGD2. The PGD2 metabolite, 15-deoxy-D
12,14-PGJ2, can act as
negative regulator of inflammation through the activation of the
nuclear peroxisome proliferator activator receptor-g, and inhibition
of multiple steps in the nuclear factor-nB signaling pathway. Thus,
induction of COX-2 expression in macrophages and preferential
PGD2 synthesis may underlie the protective effect of TSG-6
observed in experimental models of arthritis. Hyaluronan, a
molecule with which TSG-6 interacts, modulates the COX-2-
inducing activity of TSG-6 protein. This work provides the first
demonstration that TSG-6 can influence the expression of a gene
regulating inflammation in a cell culture system, which may help to
gain a better understanding of the physiological and pathophysio-
logical functions of TSG-6.
Su1.29. The Experimental Study on the Antitumor
Effect of 4-1BBL In Vivo.
Li Qiaoxia, Shan Baoen. 1Research Center, The Fourth Hospital of
Hebei Medical University, Shijiazhuang, Hebei, China; 2Research
Center, The Fourth Hospital of Hebei Medical University,
Shijiazhuang, Hebei, China.
Objectives: To observe the oncogenicity in vivo of mouse
gastric carcinoma cell lines MFC, transfected with 4-1BBL gene
and itTs effect on mouse immune function.
Methods: 1. Mouse gastric tumor cell lines (MFCs) was
transfected with pMKITneo/4-1BBL,pMKITneo through Lip-
ofectaminek2000 mediation. 2.The MFC cells high-expressing 4-
1BBL were choosen by slot-blotting. 3.The MFC/4-1BBL
cells,MFC/pMKITneo cells and wild-type MFC cells were injected
subcutaneouly into 615 mice to observe their oncogenicity. 4. The
numeral changes of NK cells, CD4+ and CD8+ T cells in peripheral
blood of bearing-tumor mice were measured by FACS. 5. The
apoptosis ratio and the cycle distribution of tumor node cells in
tumor-bearing mice was detected by FACS.
Results: The 4-1BBL gene had been introduced successfully
into mouse gastric carcinoma cell lines MFCs. The oncogenicity of
MFC/4-1BBL cells was obviously lower than that of MFC/
pMKITneo cells and wild-type MFC cells. The peripheral blood
NK cells and CD4+ T cells in mice inoculated with MFC/4-1BBL
cells were notably more than that in mice inoculated with MFC/
pMKITneo cells and MFC cells, but to CD8+ T cells had no
difference as compared with before injection of MFC/4-1BBL cells.
Conclusions: The oncogenicity of MFC/4-1BBL cell distinctly
declines, and it can induce the proliferation of NK cells and CD4+
T cells in tumor-bearing mice. This study provides experimental
basis for the further developing of the gene-modified tumor
vaccine. [Key words] 4-1BBL gene, gene transfection, tumor
immune.
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Modified Tumor Vaccine.
Shan Banen, H.A.O. Jingsheng. 1Research Center, The Fourth
Hospital of Hebei Medical University, Shijiazhuang, Hebei, China;
2Research Center, The Fourth Hospital of Hebei Medical
University, Shijiazhuang, Hebei, China.
Objectives: To evaluate the effects of mIL-23 gene modified
murine colon carcinoma cell (Colon26/IL-23) vaccine on macro-
phages and T cells.
Materials and Methods: Colon26/IL-23, Colon26/
LXSN(transfected with vector) and Colon26 cells were treated
with mitomycin C to prepare tumor cell vaccines. BALB/c mice
were immunized with those vaccines by i.p. injection. Griess assay
was used to detect the level of NO in peritoneal macrophages. The
proliferation of macrophages and splenic cells was determined
using ([3H]-TdR) incorporation method. Macrophage mediated
tumor cytotoxicity and CTL activity were assessed by radioactive
([3H]-TdR) release assay and LDH assay respectively. The survival
of the mice i.p. immunized with the vaccines were also observed.
Results: Cytotoxicity of macrophage and CTL activity to
tumor were enhanced in the mice i.p. immunized with Colon26/IL-
23 vaccine and the level of NO secreted by the macrophages from
the mice injected with Colon26/IL-23 vaccine was higher than
those in controls. The Colon26/IL-23 vaccine also promoted the
proliferation of macrophages and splenic cells and increased
survival time of mice which were challenged with wild Colon26
cells.
Conclusions: mIL-23 gene modified tumor vaccine can
activized macrophages and T cells and also has anti-tumor effect.
Su1.31. Expressions of mIL-23 Gene in Murine Colon
Carcinoma Cells Induces Production of NO and TNF-A
in Murine Macrophages.
H.A.O. Jingsheng, Shan Baoen. 1Research Center, The Fourth
Hospital of Hebei Medical University, China, Hebei, China;
2Research Center, The Fourth Hospital of Hebei Medical
University, Shijiazhuang, Hebei, China.
Objectives: To examine whether expression of mIL-23 in
murine colon carcinoma cells (Colon26/IL-23) could induce
murine macrophage to secrete NO and TNF-a.
Materials and Methods: Normal BALB/c mice were injected
by i.p. with Colon26/IL-23, Colon26/LXSN (transfected with
vectors), and Colon26 cells respectively. On days 5 and 10 after
the cell implantation, peritoneal macrophages were prepared by
lavage with HBSS and collecting the adherent cells. NMA (NG-
monomethyl-L-arginine) and LPS were inhibiter and inducer of
NO production respectively. The production of NO was deter-
mined by Griess assay. The levels of TNF-a and IL-12 were
detected by ELISA. Some mice were used for observation of
survival.
Results: The levels of NO and TNF-a produced by the
macrophages from the mice injected Colon26/IL-23 cells were
higher than those from control mice at both time-points. NWA
inhibited the production of NO in all groups. The production of NO
and TNF-a of the LPS stimulated macrophages from the mice
injected Colon26/IL-23 cells was more than those in control
groups. The level of IL-12 of the macrophages from the mice
injected Colon26/IL-23 cells is similar to controls. The average
survival time of the mice injected Colon26/IL-23 cells is longer
than that of control groups.Conclusions: Expressions of mIL-23 in murine colon carci-
noma cells can induce murine macrophages to secrete higher levels
of NO and TNF-a and has anti-tumor effect.
Su1.32. Control of Apoptosis of Primary Human
Peripheral CD4+ T Cells.
M. Pajusto, J. Tarkkanen, P. S. Mattila. 1Department of
Otorhinolaryngology, Helsinki University Central Hospital,
Helsinki, Finland; 2Department of Pathology, Helsinki University
Central Hospital, Helsinki, Finland; 3Department of
Otorhinolaryngology, Helsinki University Central Hospital,
Helsinki, Finland.
Objective of the study: Peripheral T cell homeostasis is
accomplished by balancing between proliferation and apoptosis.
This is essential in establishing prompt immune responses but at
the same time to avoid hypersensitivity reactions, immune-
mediated diseases, and lymphoproliferative disorders. Apoptosis
is controlled via two different pathways. Antigen stimulation can
induce Fas-dependent cell death, called activation-induced cell
death (AICD), whereas absence of survival signals leads to
activated T cell autonomous death (ACAD). Human adenotonsillar
CD4+ T cells are critically located at the point of entry of foreign
inhaled and digested antigens in the pharynx. This population
includes cells that show expression of activation antigens. We used
these in vivo activated adenotonsillar CD4+ T cells as a model to
study homeostasis of peripheral CD4+ T cells. Materials and
methods: Adenotonsillar tissue samples were obtained from
children aged 1 to 4 years who underwent surgery because of
adenotonsillar hyperplasia or infections. Naive phenotype CD4+
CD45RA+ and memory phenotype CD4+ CD45R0+ T cells were
purified from homogenized tissues after ficoll centrifugation using
antibodies conjugated with magnetic beads. To stimulate cells
through TCR, cells were incubated with different concentrations of
CD3 antibody. The involvement of the Fas-FasL interactions was
determined using FasL antibody and recombinant Fas protein. To
inhibit apoptosis, cells were treated with cytokines. Apoptosis was
detected by analyzing phosphatidyl-serine translocation, DNA
degradation, and caspase-3 activity. Results: Some adenotonsillar
naive phenotype CD4+ CD45RA+ and most memory phenotype
CD4+ CD45R0+ T cells expressed high levels of activation
antigens, such as CD69. CD4+ CD45RA+ T cells, but not CD4+
CD45R0+ T cells, were sensitive to Fas-dependent apoptosis upon
stimulation with a high concentration of anti-CD3 antibody. CD4+
CD45R0+ T cells were susceptible to rapid and spontaneous
apoptosis in vitro that could be partially inhibited by cytokines IL-2,
IL-15, and IL-7 that bind to the cytokine receptor common gamma
chain, the chemokine CXCL12, and by IL-6, but not by interfering
Fas-FasL engagement or TCR signaling, or by elimination of
reactive oxygen species by a synthetic superoxide dismutase
mimetic. Conclusions: Apoptosis of adenoidal naive phenotype
CD4+ CD45RA+ T cells could be induced with a high concen-
tration on anti-TCR antibody and was Fas-dependent, thus
resembling AICD-type cell death. Apoptosis of CD4+ CD45R0+
T cells was reminiscent to ACAD-type cell death as it could be
inhibited by various cytokines and it was not Fas or TCR
dependent. Thereby, homeostasis of peripheral human CD4+ T
cells is first achieved by deletion of naive CD45RA+ Tcells by high
concentrations of antigens, such as auto-antigens or nutrients. The
magnitude of the immune response is then fine-tuned by various
cytokines that can inhibit the death of activated memory phenotype
CD45R0+ T cells.
AbstractsS198Su1.33. Regulation of Inducible Heparanase Gene
Expression in Human T-Cells by Soluble and
Immobilized TNFA.
Ilya Sotnikov, Liora Cahalon, Oded Vainas, Rinat Eshel, Ben-Zion
Katz, Neta Ilan, Israel Vlodavsky, Irun Cohen, Ofer Lider.
1Immunology, The Weizmann Institute of Science, Rehovot, Israel;
2Bone Marrow Transplantation, The Hematology Institute,
Sourasky Medical Center, Tel-Aviv, Israel; 3Oncology,
Hadassah-Hebrew University Hospital, Jerusalem, Israel.
In the course of an inflammatory response immune cells need to
acquire directional migrating phenotype. This is done by means of
degrading extracellular mesh with enzymes, and by promoting
adhesion and migration of the cells by active molecules, such as
cytokines. One of the enzymes is heparanase, a heparan sulfate specific
endoglycosidase, secreted by immune cells, which combines cytokine-
like properties with conventional enzymatic activity. Upon acid-
ification of cellular environment heparanase degrades sugar chains,
whereas at basic pH it increases adhesion of the cells to extracellular
matrix and promotes their movement along chemokine gradients.
Given the versatile functions of this molecule, finding the
prerequisites for its gene expression regulation is important. Our
major goal was to investigate inducible heparanase gene tran-
scription in primary human T-cells in response to exogenous signals.
In our work we utilized 95% pure CD3+ T-cells, derived from
healthy human donors. As an activator we used TNFa, a major pro-
inflammatory cytokine, which delivers a stress signal to cells,
bearing TNF receptors, and influences their transcriptional
programs. T-cells were exposed to soluble TNFa, or the cytokine
was first pre-complexed with fibronectin, and then the cells were
placed on this immobilized TNFa.
We measured the heparanase mRNA levels and protein content
in cell lysates using real-time quantitative PCR, and heparanase
enzymatic assay, respectively.
The cytokine in its soluble and fibronectin-immobilized form
promotes the accumulation of heparanase mRNA and protein in a
strictly defined time- and concentration-dependent manner. To assess
the intracellular signaling pathways, involved in TNFa-induced
signal transduction, necessary for the heparanase gene transcription,
we used chemical components, known to inhibit key players of
signal transduction cascades, initiated by TNF receptor ligation. We
show, that the heparanase mRNA accumulation depends on PKC,
p38, JNK, PI3k signaling cascades, whereas it is not influenced by
NFkB and ERK. To further strengthen the notion of specificity of
TNFa signaling, we also demonstrate, for the first time, a strong
correlation between the effects of active TNFa concentrations on the
upregulation of relevant transcription factors, such as GATA-3, Ets-1,
Egr-1, but not Ets-2, measured by immunoblotting, and heparanase
mRNA accumulation. Finally, we show, that these effects are
reproduced, although to a limited degree, by other members of
TNF superfamily, FasL and TRAIL, suggesting the involvement of
intracellular signaling components, shared by these ligands.
In conclusion, we claim that heparanase, an important agent in
the autoregulatory loops of inflammatory lesion, is responsive to the
signals, delivered by the common stress signals, such as TNFa.
Su1.34. Serum Free PBMC Freezing and Testing
Conditions Afford Enhanced Detection of
Antigen-Specific T Cells and Standardization of Immune
Monitoring.
W.J. Zhang,1 S. Gregory,2 M. Ewell,2 W. Lopaczynski,2 T. Watts,2
C. Shive,1 N. Sigmund,1 S. Berry,1 O. Targoni,1 J. Lathey,2 P. V.Lehmann.1 1R&D, Cellular Technology Ltd., Cleveland, OH, USA;
2BBI Biotech Research Laboratories, A Division of SeraCare Life
Sciences, Gaithersburg, MD, USA.
Serum has been essential for both freezing and testing of human
PBMC. Serum contains a plethora of bioactive molecules whose
variable concentrations makes every serum batch unique, with
unique affects on T cell performance in vitro. We developed a
serum free protocol for freezing PBMC. The thawed PBMC
displayed N 80% viability regardless whether they were frozen
with serum, or serum free. Moreover, the thawed PBMC
maintained full functionality compared to the fresh cells when
tested in ELISPOT assays against a panel of 23 individual peptides
and 5 protein recall antigens recognized by CD8 and CD4 cells,
respectively. Strikingly, the PBMC performed frequently better
under serum free conditions: increased numbers of cytokine
producing cells were elicited by the recall antigens without an
increase of activity in the medium control. The magnitude of signal
enhancement under serum free conditions was considerably larger
than with inclusion of costimulatory antibodies, such as anti-CD28.
Apparently, serum contains suppressive factors (such as IL-10 and
TGF-beta) that can interfere with T cell activation. Thus, serum
free freezing and testing media are not only a convenient
alternative to bypass the need for screening for boptimialQ serum
batches, but also such media enhance and standardize T cell
monitoring.
Su1.35. Serum High Mobility Group B1 [HMGB1] Is a
Damage Associated Molecular Pattern [DAMP]
Cytokine Elevated in Chronic Hepatitis C Patients and
Diminishing Following Orthotopic Liver
Transplantation.
M. T. Lotze,1 R. Day,2 M. E. DeVera,3 A. J. Demetris,3 R. A.
DeMarco,1 O. Shakil.3 1Surgery, Bioengineering, and Molecular
Genetics and Biochemistry, University of Pittsburgh Molecular
Medicine Institute, Pittsburgh, PA, USA; 2Department of
Biostatistics, University of Pittsburgh, Pittsburgh, PA, USA;
3Surgery, Medicine, and Pathology, Starzl Transplant Institute,
Pittsburgh, PA, USA.
Introduction. Hepatitis C virus (HCV) infection is the leading
cause of chronic liver disease in the U.S., affecting approximately
4 million people. The impact in healthcare-related costs is
enormous, with over $600 million being spent annually in loss
of work and medical costs. The immune mechanisms that lead to
chronic liver damage and cirrhosis in hepatitis C have not been
elucidated but are increasingly being attributed to nonapoptotic,
unscheduled cell death and release of a variety of DAMPs
including uric acid, S100 proteins, heat shock proteins, and
HMGB1, each acting in a cytokine like role with specialized
immunoglobulin type receptors including RAGE and TLR2 and
TLR4. HMGB1 is a highly conserved nuclear protein that has a
surprising extracellular role. It binds DNA, increasing access to
transcription factors, and also recruits cells across endothelial
barriers, promoting local production of TNF, IL-6, and IFNg. It is
released from necrotic cells, activated macrophages, NK cells and
mature DCs, but not neutrophils. Following DNA damage as a
result of apoptotic death, ultraviolet irradiation, or platination, it is
sequestered in the nucleus. Detectable in serum and tissue it
serves as a leaderless cytokine, prototypic of the DAMPs that
drive repair and a previously underappreciated role in inflamma-
tion. Results. HMGB1 was measured in a highly sensitive
sandwich ELISA developed in our laboratory and did not
Abstracts S199correlate with other serum analytes including ALT, AST, total
bilirubin, or albumin. Pretransplant HMGB1 was detectable in the
serum of all 17 patients evaluated, ranging from 9.9–487.1 ng/ml
including three pts with hepatoma (62.6, 74.1, and 485.9). We
evaluated whether HMGB1 correlated with disease activity at
baseline or at 3, 6, 9 or 12 months of follow-up with the presence
of hepatoma, histologic activity index [HAI], rejection activity
index or stage (degree of fibrosis). The highest 12-month
HMGB1 (161), was associated with the largest HAI (6). This
was the only significant (P = 0.02, Pearson correlation)
association. Following orthotopic liver transplantation, HMGB1
levels diminished at 3mo. [n = 16] by a median ratio of .41
compared to baseline [P b .05] and at 12mo. [n = 14] by a
median ratio of .13 [P b .001]. One pt with a baseline level of
74.1ng/ml with hepatoma increased post transplant to 581.3ng/ml
and is being reevaluated for recurrence. Conclusion. We conclude
that HMGB1 represents an independent measure of tissue damage
and injury, as well as cancer that may be useful in the assessment
of patients with HCV infection. Controlling HMGB1 activity and
release is an approach being developed as an experimental
therapy for patients with sepsis, arthritis, cancer, and other
inflammatory disorders.
Su1.36. Ex Vivo Pro-Inflammatory Cytokines
Expression in Patients with Aggressive Periodontitis.
F. E. Gonzalez,1,2 D. Catalan,1 J. C. Aguillon.1 1Disciplinary
Program of Immunology, Faculty of Medicine, University of Chile,
Santiago, Regio´n Metropolitana, Chile; 2Dentomaxilofacial
Service, University of Chile Clinical Hospital. University of Chile,
Santiago, Regio´n Metropolitana, Chile.
RATIONALE: Periodontitis includes a broad spectrum of
immuno-inflammatory responses to periodontal pathogens from
oral biofilm that destroy the supporting tissue of the teeth. In this
pathology the balance between pro and anti-inflammation is tipped
to pro-inflammatory activity mediated by cytokines that include
TNFa and IL-1h. OBJECTIVE: We explored the relationship of
TNFa and IL-1h expression and the aggressive periodontitis (AP)
condition in Chilean patients. METHODS: Until now we recruited
42 individuals with AP and 40 control subjects. For cytokine
expression blood culture were stimulated with LPS from E. coli or
P. gingivalis extracts. TNFa and IL-1h were measured by an ultra-
sensitive ELISA kit.
RESULTS: The LPS-induced TNFa levels in AP patients were
higher than controls (P = 0.0414) while means of serum TNFa
concentrations in patient group were 3 times higher than those
found in controls (P = 0.000). Although no significant the highest
mean for LPS-induced IL-1h level was obtained by the AP
group.
CONCLUSION: The mononuclear cells from AP patients
express higher induced TNFa and IL-1h levels than healthy
individuals in an ex vivo culture system.
Financed by Fondecyt-Chile 1040860, Fondef-Chile D03I1055
and University of Chile Clinical Hospital 016/03.
Su1.37. IL-22 Increases the Innate Immunity of the Skin.
K. Wolk, S. Kunz, E. Witte, M. Friedrich, K. Asadullah, R. Sabat.
1Interdisciplinary Group Molecular Immunopathology,
Dermatology/Medical Immunology, University Hospital Charite,
Berlin, Germany; 2Interdisciplinary Group Molecular
Immunopathology, Dermatology/Medical Immunology, University
Hospital Charite, Berlin, Germany; 3Interdisciplinary GroupMolecular Immunopathology, Dermatology/Medical Immunology,
University Hospital Charite, Berlin, Germany; 4Interdisciplinary
Group Molecular Immunopathology, Dermatology/Medical
Immunology, University Hospital Charite, Berlin, Germany;
5CRBA Dermatology, Schering Inc., Berlin, Germany;
6Interdisciplinary Group Molecular Immunopathology,
Dermatology/Medical Immunology, University Hospital Charite,
Berlin, Germany.
Interleukin(IL)-22 was discovered in 2000. It belongs to the IL-
10 family of cytokines whose members (additionally IL-10, IL-19,
IL-20, IL-24, and IL-26) are structurally related molecules. We
have previously shown that IL-22 is mainly produced by activated
T cells, particularly the Th1 subset. The data presented here
surprisingly show that IL-22, unlike IL-10, does not act on immune
cells. This conclusion is based on a systematic study at all possible
levels of analysis: on receptor expression, signal transduction,
effects in vitro, and effects in vivo. In contrast, the quantitative
analyses of a wide range of tissues and corresponding primary cells
and cell lines showed that many non-immune tissue cells are target
of IL-22 as they express both chains of the IL-22 receptor complex.
Very high levels of IL-22 receptor chains were found in skin and
keratinocytes. In primary human keratinocytes these levels were
further upregulated by IFN-g suggesting an increased sensitivity of
these cells towards the IL-22 action under T1 conditions. The
receptor complex on these cells was functional and induced STAT3
tyrosine phosphorylation. For the first time, this study also
identified effects of IL-22 on keratinocytes, namely the upregula-
tion of the antimicrobial agents b-defensin 2 and b-defensin 3. This
effect was transcriptionally regulated, and independent on protein
de novo synthesis and alternative protein secretion indicating a
direct effect of IL-22. Additionally, this induction was time- and
dose-dependent, and enhanced upon cellular differentiation. The
extent of induction was comparable to that by other known
inducers of b-defensins. In skin from patients with psoriasis, high
levels of IL-22 were highly significantly associated with strongly
upregulated expression of b-defensin-2 and b-defensin-3 suggest-
ing a protective effect of IL-22 in this disorder. Taken together, IL-
22 does not serve the communication between immune cells but is
a T cell mediator that directly promotes the innate, non-specific
immunity of the skin.The observation that activated T1 cells
directly regulate the non-specific immune defense in tissues
demonstrates a so far unknown but very important side of the
immune system.
Su1.38. IL-7 in Human B Cell Development.
Y. K. Parrish,1 E. Sahakian,1 G. M. Crooks,1 E. Zielinska,1 L. W.
Barsky,1 K. J. Payne.1 1Research Immunolgy/BMT, Childrens
Hospital Los Angeles, Los Angeles, CA, USA.
Human B cell production has been thought to differ from that in
mouse with respect to the requirement for IL7. In mice, IL7
increases the in vitro production of B cells from adult murine bone
marrow by 20–30 fold. In contrast, human studies have focused on
B lymphopoiesis from fetal precursors and show little increase in
B cell production with IL7 (~2 fold). A re-examination of IL7
knockout mice has shown that IL7 is required to generate adult-
derived B2 cells (CD5–), but not for the production of fetally-
derived CD5+ B1 cells. Here we examine the role of IL7 in human
B cell development from hematopoietic stem cells (HSCs) isolated
from human umbilical cord blood (CB), a source likely to contain
both HSCs that give rise to B1 cells, as well as those capable of
generating B2 cells. FACs analysis of human CB shows mutually
AbstractsS200exclusive expression of IL7Ra and CD5 on CD34+CD19+ pro-B
cells. When FACS-sorted Lin- CD34+ CB HSCs were placed in
stromal cell co-cultures, the addition of IL7 increased the in vitro
production of human B lineage cells up to 60-fold as compared to
cultures with anti-IL7 neutralizing antibody. IL7-induced increases
observed on human stroma were ~10-fold more than those with the
murine S17, MS-5, or OP9 stromal cell lines. A titration of IL7 into
co-cultures showed that the threshold for IL7-induced increases in
human B cell production was 10 to 100 fold lower in co-cultures
with human stroma as compared to those with murine stroma.
Surprisingly, murine stromal cells provided better support for
human B cell production in the absence of murine or human IL7
activity. Our data show that IL7, in the presence of human stroma,
can dramatically impact B cell production from at least a subset of
progenitors in human CB. On the other hand, murine stroma
support IL7-independent B cell production from human CB
progenitors. Using Ki-67 and Annex V/7AAD staining we are
examining the extent to which proliferation and/or anti-apoptotic
effects, at the pro-B and pre-B stages, contribute to IL7 effects seen
in vitro. Our studies suggest that the roles of IL7 in human and
murine B cell development may be more similar than previously
believed.
Su1.39. An Important Role for CX3CR1 in Vascular
Remodeling.
P. Liu,1 S. Patil,2 M. Rojas,3 A. Fong,1 S.S. Smyth,3 D.D. Patel.1
1Thurston Arthritis Research Center and Department of Medicine,
University of North Carolina at Chapel Hill, Chapel Hill, NC;
2School of Medicine, Duke University, Durham, NC; 3Division of
Cardiology and Carolina Cardiovascular Biology Center, Univer-
sity of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Objectives: A functional polymorphism in the chemokine
receptor CX3CR1 has recently been associated with protection
from coronary artery disease (CAD) and internal carotid artery
(ICA) occlusive disease in man. CX3CR1 is functionally expressed
on monocytes and vascular smooth muscle cells (VSMC), both of
which cell types are critical for the vascular remodeling found in
atherosclerosis, angioplastic restenosis, and ICA occlusive disease.
Our objectives in this study were to investigate whether CX3CR1
was involved in the inflammatory process of vascular remodeling,
and the mechanisms by which it may play a role.Methods: Femoral
arteries of CX3CR1-deficient and wild type mice were subjected to
injury by the passage of an angioplasty guidewire or sham
operation. After 5, 14, and 28 days, mice were euthanized, perfused
with 4% paraformaldehyde, and tissues harvested for immunohis-
tochemistry. In some cases, mice were injected with bromo-
deoxyuridine (BrdU) for 24 hours prior to tissue harvest for cell
proliferation studies. Results: CX3CR1 deficiency resulted in
protection from vascular remodeling following guidewire-induced
injury. The incidence of vascular inflammation or remodeling was
decreased in CX3CR1
-/- mice (38.1% vs. 86.4% for WT, P = 0.001).
At d5, the injured arteries of WT mice had a marked monocyte
infiltration into the intima compared to non-injured arteries on the
control side of each animal (13.6 F 11.5 vs. 0.0 F 0.0, P = 0.006).
At d14, WT injured arteries had neointimal hyperplasia with a
mixture of monocytes and VSMC. By d28, the intimal hyperplasia
comprised primarily of VSMC with an average intima to media
ratio (I/M) of 0.78 F 1.04 compared to 0.0 in non-injured arteries
(P = 0.02). In CX3CR1
-/- mice, there was no detectable monocyte
invasion to the intima at d5 (100% decrease compared to WT, P =
0.006), and there was an 86.8% decrease in the numbers ofmonocytes in the intima at d14. At d28, the intima area was
decreased in CX3CR1
-/- mice by 62% compared to WT mice (P =
0.11), with a concomitant decrease in the numbers of VSMC in the
intima (87.1%, P = 0.055). As expected, the number of VSMC in
the media declined during the injury response in WT animals
(33.4% decline, P = 0.025) while it remained unchanged in the
media of CX3CR1
-/- mice (9.9% decline, P = 0.22). The percentage
of actively proliferating cells in injured vessels was also decreased
in CX3CR1
-/- mice (12% vs. 27% in WT, P = 0.027). Conclusions:
CX3CR1 plays a critical role in vascular remodeling following
femoral artery injury. One of the primary mechanisms involves
monocyte recruitment to and/or retention within the injured vessel
intima. Although the VSMC defects seen at d28 were downstream
of the monocyte defects observed at d5, we can not rule out a
possible contribution of CX3CR1 to the proliferation and media-to-
intima migration of VSMC in the course of vascular remodeling.
Su1.40. Chromatin Regulation of Interleukin 10 Gene
Expression at the Allele Level.
D. Calado,1 D. Holmberg,2 H. Matthias.1 1Cellular
Differentiation, Gulbenkian Institute for Science, Oeiras, Portugal;
2Umea Center for Genome Research, Umea University, Umea,
Sweden.
It is generally assumed that most mammalian genes are
transcribed from both alleles in most situations. But it is now
clear that several genes do not have this transcriptional behavior. In
general these genes are grouped in 3 different classes, a) imprinted
genes, b) most genes in the X chromosome of female cells and c)
autosomal genes that are stochastically monoallelic transcribed.
Interleukin 10 (IL-10) is a multifunctional cytokine, its activities
array from the classical inhibition of effector functions of T
lymphocytes, monocytes and macrophages, to regulation of growth
and differentiation of B lymphocytes and dendritic cells, and its
recent key role in differentiation and function of the T regulatory
cell. In the 15 years since IL-10 was first described, most studies
aimed the biological function but few addressed its genetic
regulation. Making use of IL-10eYFPkimice, in which transcription
from different alleles is easily distinguishable, we observed that IL-
10 shows a pseudo-monoallelic transcription pattern in CD4+ T
cells. Most CD4+ T cells express stochastically only from one
allele while only few transcribe it from both. Allelic exclusion in
this case does not seem to take place and a bias towards bi-allelic
expression is obtained with increased TCR signaling. We propose
that this pseudo-monoallelic expression is the reflection of a tightly
controlled low frequency expression of the IL-10 gene. We also
show that chromatin appears to play a major role regulating this
process. Thus at least two levels of regulation seem to be
implicated in the bona fide regulation of IL-10 expression. TCR
signaling through activation of transcription factors and regulation
of chromatin opening seem to act together to provide efficient
control of IL-10 expression. We think that this two-layer regulation
might reveal an extremely important mechanism in controlling
genetic expression in biological situations of low frequency
expression of genes and as such might apply to many more genes
than the few ones studied so far.
Su1.41. Local Interleukin-1 Immunotherapy
Effectiveness Depends on Cytokine Genetic Background.
A. S. Simbirtsev,1 A. J. Gromova,1 L. E. Timchuk,1
E. A. Variouchina.1 1Immunopharmacology, Institute of Highly
Pure Biopreparations, St.Petersburg, Russian Federation.
Abstracts S201Interleukin-1 (IL-1) is one of the main mediators involved in
the control of inflammation and acute phase response. IL-1 family
molecules regulate tissue repair, inflammatory and immune
reactions. Important question of IL-1 biology today is how to
use this pleiotropic highly biologically active molecule in the
therapy of various human diseases. Systemic IL-1 administration
induces adverse effects limiting IL-1 therapeutic use. Very
promising is IL-1 local application just to the lesion or
inflammatory site. Human recombinant IL-1 beta has been used
for local therapy in patients with chronic bacterial purulent
rhinosinusitis after failure of routine antibiotic therapy. IL-1 beta
solution application (10 ng/ml) directly to the inflammatory site
daily for 3–5 days led to a clinical improvement in most of treated
patients. Endogenous IL-1 beta and IL-1 receptor antagonist (IL-
1RA) ex vivo production and gene polymorphism studies for the
distribution of IL-1b and IL-1RA alleles were performed in all
patients. Patients with more rare IL-1b (+3953)+ allele had elevated
IL-1 beta production and patients with IL-1RA 2*(VNTR)+ allele
had higher antagonist production compared with patients bearing
normal alleles. These abnormal alleles were found in 30% and 90%
of patients respectively that was much more frequently compared
to healthy subjects suggesting for genetic predisposition to chronic
rhinosinusitis probably due to the disregulation in the IL-1 family
cytokines production. We have found that recombinant IL-1
therapy was highly effective in patients carrying IL-1RA
2*(VNTR)+ allele with increased endogenous IL-1RA levels. In
these patients IL-1 beta local application significantly increased
functional activity of leukocytes isolated from the inflammatory
sites tested in the assays of neutrophil migration to fMLP,
superoxide production, adhesion and phagocytosis. Cytological
analysis showed that the reduction in inflammatory manifestations
was accompanied with the decrease in the proportion of
neutrophils and increase in the numbers of monocytes/macro-
phages. Negative results of IL-1 beta therapy was obtained in
patient who had very rare combination of homozygous IL-1b
(+3953)+ and normal IL-1RA 2*(VNTR)- allelic variant that led to
elevated IL-1 beta production and normal IL-1RA levels. Accord-
ing to obtained results IL-1 family cytokines gene polymorphisms
are linked to chronic rhinosinusitis and may influence results of
cytokine immunotherapy.
Su1.42. Local T-Lymphocytes from Subacute and
Chronic Hypersensitivity Pneumonitis Show Phenotypic
and Functional Differences.
Felipe Mendoza,1 Lourdes Barrera,1 Emma Melendro,2 Annie
Pardo,3 Moises Selman.1 1Inmunoquimica, National Institute of
Respiratory Diseases, Mexico City, Mexico; 2Medicina
Experimental, Universidad Nacional Autonoma de Mexico, Mexico
City, Mexico; 3Facultad de Ciencias, Universidad Nacional
Autonoma de Mexico, Mexico City, Mexico.
Background:
Hypersensitivity pneumonitis (HP) is a complex lung
syndrome of varying intensity and clinical presentation that
result of an immunologically-induced inflammation in response
to a large variety of inhaled antigens. HP may present as acute,
subacute, or chronic form. HP is characterized by a remarkable
T-cell alveolitis. However, the evaluation of lymphocyte pheno-
types, primarily CD4+/CD8+ T cell subsets has given incon-
sistent results. Likewise, studies of other T-cell phenotypes in
human HP like T-helper 1 (Th1) versus Th2 are scanty. We
hypothesized that some divergence in T-cell subsets may play arole. We analyzed a variety of T-lymphocyte phenotypes in cells
obtained by bronchoalveolar lavage of subacute and chronic
patients.
Methods:
Forty one patients with HP induced by avian antigens and
classified as subacute (21 patients), or chronic (20 patients), 5
healthy subjects.HP BAL cells were stained with mAbs to CD3,
CD4, CD8, CXCR3, CCR4 for surface staining and intracellular
IFN-g, IL-2, IL-4, IL-10. The antigen specific secretion of IFN-g,
IL-2, IL-4, IL-10 following pigeon serum stimulation was
determined by CBA, and this was used to identify specific CD4
Th1 and Th2 subpopulations. In order to precise the best cut point of
CD4+/CD8+ ratio, an analysis of their sensitivity versus 1-
specificity (ROC curves) was used. The test with higher sensitivity
and the lower 1-specificity was considered to be the most useful.
Results:
BAL CD4+/CD8+ ratio was highly heterogeneous, and although
higher levels were revealed in patients exhibiting chronic HP,
results did not reach statistical significance (3.5F 3.7 versus 1.7 F
1.5 and 1.2 F 0.4 from subacute patients and controls respec-
tively). However, 14 chronic patients showed values over 2.0
compared with 7 subacute patients. ROC curve showed that a
CD4+/CD8+ ratio 1.5 was the best cut point to separate chronic
from subacute cases displaying sensitivity (S) of 67%, a specificity
of 80%, a positive predictive value of 78%, and a negative
predictive value of 70%. A significant difference in the receptor
chemokine expression was noticed. Thus, subacute patients
exhibited significantly higher numbers of T-cells expressing
CXCR3 (40.6 F 10.7 % versus 25.6 F 7.3% in chronic cases).
By contrast, CCR4 was higher expressed in chronic patients 6.0 F
1.3% versus subacute 2.1 F 1.3%.
Intracellular IFN-g/IL-4 ratio was significantly higher in
subacute patients 1.6 F 0.9% versus chronic 0.7 F 0.45% after
antigen specific stimulation. Also IFN-g /IL-10 ratio measured in
supernatant cultures was significantly higher in subacute patients
152 F 24.2 versus chronic 0.6 F 0.7.
Conclusions:
Our results revealed several differences in chronic patients
when compared with subacute patients, including an increase in
CD4+/CD8+ ratio and an increase in Th2-like response.
Su1.43. Phenotypic and Functional Analysis of Memory
CD4 and CD8 T Lymphocytes in Subacute and Chronic
Hypersensitivity Pneumonitis.
L. Barrera,1 F. Mendoza,2 M. Selman.1 1Immunochemistry,
National Institute of Respiratory Diseases, Mexico City,
Mexico City, Mexico; 2Sistemas Biologicos, Universidad
Autonoma Metropolitana, Mexico, D.F., Mexico.
Background: The chemokine receptor CCR7 has been used in
previous studies in combination with the CD45RA antigen as a
tool to define different populations of memory CD4 and CD8 T
lymphocytes with different homing and function capacities and at
different stages of differentiation. Using this approach four
populations of memory CD4 and CD8 T lymphocytes have been
defined in patients with subacute and chronic hypersensitivity
pneumonitis (HP) in bronchoalveolar lavage and blood. The
following pattern of differentiation of CD4 and CD8 T cells has
been demonstrated: CD45RA+CCR7+YCD45RA-CCR7+ Y
CD45RACCR7 Y CD45RA+CCR7.
Methods: Peripheral blood mononuclear cells (PBMC) and
bronchoalveolar lavage cells (BALc) obtained from 5 subacute and
AbstractsS2025 chronic HP patients were stained with mAbs to CD4, CD8,
CCR7, CD45RA, CD62L. The secretion of IFN-g following
specific stimulation was determined on antigen-specific CD4 and
CD8 lymphocytes and this was used to identify specific CD4 and
CD8 effector cells.
Results: The CD8 memory blood T lymphocytes was equally
composed pre-terminally differentiated CD45RACCR7 (CD8
subacute: 30 F 12%; CD8 chronic 30 F 2.1 vs controls 10.5 F
2.3% P b 0.05) and terminally differentiated CD45RA+CCR7-
(CD8 subacute: 20 F 7%; CD8 chronic: 30 F 14% vs controls
15.2 F 3.7) in subacute and chronic patients. In contrast CD4
blood T cells was composed pre-terminally differentiated (CD4
subacute: 34 F 15%; CD4 chronic: 38 F 27% vs controls 10.3 F
3.8 P b 0.05) and a higher proportion of terminally diferentiated
memory CD4 T lymphocytes (CD4 subacute: 66 F 16%; CD4
chronic: 62 F 28% vs controls 16.1 F 3.5 pb0.01). In BAL the
CD4 and CD8 memory T cells was predominantly composed pre-
terminally differentiated T memory cells in both CD4 and CD8
cells (CD4 subacute: 83 F 8.2%; CD4 chronic: 94 F 4% vs
controls 85.6F 9.3; CD8 subacute: 88F 5.4%; CD8 chronic 95F
0.7% vs controls 36.4 F 4.7 P b 0.05).
Conclusions: A number of studies suggest that effector and
memory cells with differing functional and migratory capabilities
arise as an inevitable consequence of antigen encounter. The
present results demonstrate that selective impairment of the
differentiation of antigen specific subacute and crhonic HP
memory cells in blood and BAL indicate a different distribution
of CD4 and CD8 memory lymphocytes.
Su1.44. Pro-Inflammatory and Anti-Inflammatory
Cytokines Track with KIR Haplotypes A and B in
Octo/Nonagenarian Subjects.
I. M. Rea,1 L. D. Maxwell,2 O. A. Ross,2 C. A. Rea-Lyon,1
H. D. Alexander,3 D. Middleton.2 1Geriatric Medicine,
Queens University Belfast, Belfast, Northern Ireland,
United Kingdom; 2NI Regional Histocompatability and
Immunogenetics Laboratory, Belfast City Hospital, Belfast,
Northern Ireland, United Kingdom; 3Haematology Laboratory,
Belfast City Hospital, Belfast, Northern Ireland,
United Kingdom.
Background: Natural Killer cells (NK) play a pivotal role in
the innate immune response, controlling tumour and infection-
related responses. The cytolytic activity of NK cells is controlled
by an array of activating and inhibitory cell surface receptors,
including the killer immunoglobulin-like receptors (KIRs), which
can be grouped into the most common haplotype groups called A
and B. Cytokine changes occur in ageing and we wondered
whether changes in serum cytokines were related to group A and B
KIR haplotypes.
Methods: KIR haplotyping available from 300 subjects from the
Belfast Elderly Longitudinal Free-living Aging Study (BELFAST)
was matched with a subset of corresponding serum cytokines.
Results: Subjects categorized into the KIR haplotype associated
with activation, showed increased serum cytokine values for both
pro-inflammatory cytokines IL-2, IL-6, sIL-6, TNFa and IL-12 as
well as increased values for the anti-inflammatory cytokines IL-10
and TNFb. There was no apparent sex-related difference.
Conclusions: KIR haplotypes A and B in octo/nonagenarians
do track with their activation status in relation to cytokines and
could be effectors of tumour and infection-related responses and
the immune-related changes in ageing.Su1.45. Evaluation of TH1/TH2 Cytokine Modulations in
Chronically HIV-Infected Adults Who Received
Therapeutic Vaccination and Intermittent HAART
Following an Initial HAART Intensification (CTN-140
Pilot Trial).
Sardar Sindhu,1,2,3 Maude Loignon,1 Jose Menezes,2,3 Emil
Toma.1,3 1Microbiology & Infectious Diseases, CHUM-Hotel Dieu
Hospital, Montreal, QC, Canada; 2Immunovirology Lab and Viral
& Immune Diseases Program, CHUM-Ste Justine Hospital,
Montreal, QC, Canada; 3Microbiology & Immunology, University
of Montreal, Montreal, QC, Canada.
Evaluation of TH1/TH2 cytokine modulations is important to
determine the immune competence and/or restoration in chronic
HIV patients undergoing initial highly active antiretroviral therapy
(HAART) intensification (GM-CSF, Hydroxyurea, and ddI),
therapeutic vaccination (RemuneTM) and structured treatment
interruption (STI). We evaluated serum levels of interferon
(IFN)-gamma, interleukin (IL)-2, tumor necrosis factor (TNF)-
alpha, IL-15, IL-4, and IL-10 in 10 patients enrolled in the
Canadian HIV Trials-140 pilot study. All patients were in viremic
control, i.e., virus load (VL) was b 50 copies mL1 at the time of
baseline samplings. Nine sampling points were at baseline,
HAART-intensification, therapeutic vaccination, 1st peak VL
(rebound during STI), 1st b 50 VL, 2nd peak VL, 2nd b 50 VL,
3rd peak VL, and 3rd b 50 VL, respectively. All cytokines were
measured by competitive enzyme-linked immunosorbent assays
(ELISA). The difference between group means at a given time-
point and at baseline was determined by t-test. We found that IFN-
gamma levels were comparable to baseline value of 58.88 pg mL1
at all time points except at 2nd peak VL and at 2nd b 50 VL
samplings when the levels were significantly reduced. IL-2 levels
were elevated significantly (P b 0.05) at 1st time as VL was below
50 copies mL1 compared with baseline value of 58.43 pg mL1
and high levels (higher than in age-matched HIV-seronegative
controls) were sustained thereafter. Conversely, IL-10 levels were
reduced significantly at 1st time as VL was b 50 copies mL1 than
baseline concentration of 109.90 pg mL1 and low levels were
maintained at all subsequent time points. Regarding both TNF-
alpha and IL-4, all modulations were found to be statistically non-
significant (p N 0.05) as compared with baseline mean concen-
trations of 124.0 pg mL1 and 75.35 pg mL,1 respectively.
However, IL-15 levels were comparable to baseline concentration
of 241.10 pg mL1 (which was higher than those in controls) until
1st time as VL was b 50 copies mL1 and the levels were
significantly reduced thereafter. Therefore, it was concluded that
these immunomodulatory therapeutic interventions were able to
induce/maintain a TH1-dominant cytokine profile in these patients
whereas suppressed IL-15 levels at 2nd peak VL and thereafter
might be due to a deregulated innate immune response.
Su1.46. Cytokine Expression in CD4+ Cells Exposed to
the Monocyte Locomotion Inhibitory Factor Produced by
E. histolytica.
S. Rojas,1 G. Rico,1 J. Perez,2 J. Velazquez,1 R. Kretschmer.1
1UIM en Inmunologia, Hospital de Pediatria CMN S-XXI, IMSS,
Mexico, DF, Mexico; 2Division de Ciencias Biologicas y de la
Salud, Universidad Autonoma Metropolitana, Mexico, DF,
Mexico.
The Monocyte Locomotion Inhibitory Factor (MLIF), could so
contribute to the sparse delayed inflammation observed in amebic
Abstracts S203abscess of the liver, either directly through its effects upon MP (i.e
depression of chemotaxis and respiratory burst), or indirectly
through the modulation of the production and/or secretion of
cytokines involved in the recruitment of MP in the late stages of
inflammation. We evaluated the effect of MLIF on the production
of pro/anti-inflammatory cytokines in CD4+ cells.
Materials and Methods
T CD4+ lymphocytes were purified by negative selection using
a commercial kit (MACS- ReagenTs isolation of human CD4+ T
cells. One  107 PBMC cells were placed in propylene tubes with
80ml PBS-albumin-EDTA and 20 Al antibody cocktail to eliminate
cells other than CD4+ (10 min at 4 8C). The CD4+ lymphocyte
purified fraction was found to be 95% pure. MLIF (96% pure) was
commercially obtained (American Peptide Co, Sunnyvale, CA,
USA). Five  105 T CD4+ cells were placed in RPMI-1640 with
10% fetal calf serum (FCS) and were stimulated for 24 h in the
presence of PMA (50 ng/ml), MLIF(50 Ag/ml) or PMA+MLIF.
The supernatant fluids were analyzed by ELISA.
Results
Pro-inflammatory cytokines. Cells activated with MLIF
expressed an increased production of constitutive pro-inflamma-
tory cytokines IL-1h, IL-2 and IFN-g (262, 245, 46 pg/ml
respectively) when compared with the production of constitutive
basal RPMI cell controls (26, 18, 10 pg/ml respectively). PMA
enhanced the induced production of the same pro-inflammatory
cytokines (192, 384, 84 pg/ml respectively). The expression of
IL-1h and IFN-g induced by PMA was significantly inhibited by
MLIF (25% and 20% respectively), which did not occur with
IL- 2.
Anti-inflammatory cytokines. MLIF, increases the production
of constitutive anti-inflammatory cytokines when compared to
basal IL-5, IL-6 and IL-10 (188, 114, 134 pg/ml respectively)
when compared to the basal production in control cells RPMI (15,
16 and 13 pg/ml respectively). With PMA, an increase of
production of induced IL-5, IL-6 and IL-10 (575, 250, 326 pg/
ml respectively), while the mixture of PMA+MLIF was found to
decrease the production of constitutive PMA of IL-5 and IL-6, but
not of IL-10, that significantly increased its expression.
Conclusions
Pro/anti-inflammatory cytokines were produced by MLIF, in
amounts similar to those induced by PMA. With the PMA+MLIF
mixture the IL-1h, IFN-g, IL5 and IL-6 (all with pro-inflammatory
potential) production was inhibited, but not that of IL-10 (the
prototype of an anti-inflammatory cytokine), which disclosed a
significantly increase of its expression. Thus MLIF can orchestrate
an anti-inflammation pattern of cytokines that contribute to the
exiguous inflammation found in advanced lesions of invasive
amebiasis (CONACYT GRANT 38104-M).
Su1.47. Interleukin 21 Modulates Cytokine Pathways
That Contribute to the Pathology of Arthritis.
L. Lowe,1 M. Senices,1 M. Hegen,1 J. C. Keith, Jr.,1 J. Lamothe,1
P. Wu,1 M. Whitters,1 C. Nickerson-Nutter,1 D. Young,1 M.
Collins.1 1Inflammation, Wyeth Research, Cambridge, MA, USA.
Interleukin 21 (IL-21) is secreted by activated T cells and
modulates immune cell functions with both pro- and anti-
inflammatory effects. Interleukin 21 receptor, (IL-21R) homolo-
gous to IL-2R beta and IL-4R alpha, associates with gamma
common chain upon ligand binding. IL-21R is constitutively
expressed on many cell types in the immune system, and is
upregulated by IL-21. Rationale: Since blockade of the IL-21pathway with soluble IL-21RFc resulted in a reduction of clinical
signs of arthritis in rodent models, we examined the effect of this
pathway on rat and murine responses in vitro to understand the
potential mechanisms of IL-21 regulation in arthritis. Methods:
Arthritis was induced in DBA/1 male mice with bovine type II
collagen, and in the Lewis Rat with FreundTs Complete Adjuvant.
Animals were treated with soluble mIL-21RFc, which neutralizes
both murine and rat IL-21 bioactivity. Draining lymph node cells
from collagen-immunized mice were cultured in vitro with collagen
and either IL-21 or IL-21RFc and assayed for proliferation and
cytokine secretion. Cytokines and anti-collagen specific IgG levels
were also measured in the serum by ELISA analysis. In the rat, Con
A stimulated spleen cells or anti-CD3 activated splenic T cells were
assayed for proliferation and cytokine secretion in response to IL-21
and IL-21RFc. Results: When compared with control animals, 3x
weekly treatment with IL-21RFc resulted in less severe signs of
disease in both rat and murine prophylactic and therapeutic models
of CIA. Addition of murine IL-21 to collagen restimulated LN cells
resulted in a dose dependent inhibition of proliferation, and a
decrease in IFN-gamma, GMCSF, and IL-6 and increase in IL-10 in
the culture supernatant. Conversely, addition of IL-21RFc enhanced
the collagen proliferation response and resulted in increased IFN-
gamma, GMCSF and IL-6 and decreased IL-10 production
suggesting that IL-21RFc modulated endogenous IL-21, as well
other antigen-induced cytokines. Conclusion: These results suggest
that Interleukin 21 plays a role in modulation of antigen-specific T
cell responses and this may contribute to the pathology of arthritis.
Su1.48. Critical Role of STAT1 on Self-Renewal
Capacity of CNS Stem Cells by an Inducible
Interferon-;Genetic Program.
J. Imitola, R. Fryer, Y. Wang, S. Rasmussen, R. V. Jensen, S. J.
Khoury. 1Neurology, Brigham and WomenTs Hospital, Boston, MA,
USA.
Objective: To investigate the molecular mechanisms of neural
stem cells (NSCs) responses to the proinflammatory cytokine
interferon-g.
Background: Self-renewal capacity is a fundamental property
of NSCs, in which stem cells proliferate forming multipotent
neurospheres in the presence of FGF-2. NSCs respond to
inflammation, however it is not known what molecules account
for their response during disease. Our hypothesis is that NSCs
express functional immune related genes that interact with stem-
ness genes, and control NSC intrinsic properties.
Materials and Methods: We analyzed multiple microarray
datasets for inflammatory genes expressed by NSCs then
performed gene clustering by Gene Ontology, and data mining
using several bioinformatics databases. For testing self-renewal
capacity, NSCs were isolated from different regions of mouse
brain, and cultured in DMEM/F12 with N2 supplement and bFGF
(20 ng/ml). For gene expression analysis mRNA from duplicate
NSC cultures exposed to interferon-g for 24 h, were processed on
Affimetrix microarrays. Genes showing a change in expression
of N2-fold with a p-value of P b 0.001, were confirmed using a
different microarray platform, confocal microscopy and western
blot.
Results: We found that NSCs express several interferon
related genes, we confirmed their expression in vivo on E14.5
germinal zone by confocal microscopy. IFN-g at doses of 50 to
500 U/ml added to NSC cultures from E14.5, newborn, or adult
brain, decreases the frequency of FGF-2 induced neurosphere
AbstractsS204formation (39.6 F 9.2% vs. 4.6 F 3.5%, P b 0.002) and
neurosphere diameter (131 F 33.2 vs. 42.2 F 14, P b 0.0001).
To determine the genes affected by IFN-g, primary NSCs were
treated with IFN-g and subjected to microarrays. We identify N100
affected genes, clustered in 3 groups by a Terrain Gene Map: a)
IFN-g highly inducible genes (absent in untreated NSCs with 20–
2000 fold increase) b) MHC genes and proteosome genes
increased 2–10 fold c) Decreased genes, 50% of which are
related to stemness including cell cycle, histone and lifespan
genes. We confirmed the expression of selected genes by confocal
microscopy and western blot. To elucidate the molecular path-
ways affected by IFN-g, we analyzed downstream pathways of
IFN-g, and we found a 20-fold increase in stat-1 gene expression.
Interferon-g induced rapid phosphorylation of STAT1 Tyr-701
and nuclear translocation of STAT 1 in NSCs 15 min after
treatment. Using NSCs isolated from stat-1-/- mice, we found that
the reduction of self-renewal capacity by IFN-g in wild type mice
was absent in stat-1-/- NSCs. Instead, stat1-/- brains contain more
NSCs and IFN-g in vitro increased their neurosphere formation
by 3-fold (self-renewal capacity). Experiments of differential gene
expression and behavior in vivo of stat1-/- vs wildtype mice after
IFN-g treatment are under way to further evaluate the importance
of stat1 in NSCs.
Conclusion: NSCs have a functional interferon genetic
program. Interferon-g induces this program and leads to the
activation of multiple genes including stat-1, which appear to form
a central checkpoint for NSCs self-renewal capacity.
Su1.49. Role of CXCL1/CXCR2 in Promotion of Glial
Survival during Experimental Demyelination.
L. T. Remington,1 S. P. Zehntner,1 C. A. Hollmann,1 T. Owens.1
1Neuroimmunology, Montreal Neurological Institute, Montreal,
QC, Canada.
Inadequate repair is thought to underlie chronic demyelination in
Multiple Sclerosis (MS). Oligodendrocyte precursor cells (OPCs),
which are present in the adult central nervous system (CNS), have
the ability to migrate into lesions and differentiate into mature
oligodendrocytes. OPC proliferation and differentiation is driven by
growth factors such as the chemokine CXCL1. Administration of
CXCL1 may enhance OPC function and remyelination. We have
examined the role of CXCL1 and its receptor (CXCR2) in the corpus
callosum of female C57BL/6 mice during cuprizone-induced
demyelination. Response to the demyelination causes astrocytes,
microglia and OPCs to accumulate in the corpus callosum. Removal
of the toxin cuprizone allows remyelination to occur. We found a
transient increase in CXCL1 mRNA in the forebrain prior to OPC
accumulation, as early as 1 week after the initiation of cuprizone
treatment. The level of CXCL1 mRNA peaked at two weeks and
then declined to normal levels. CXCR2 positive cells also increased
in the corpus callosum during demyelination. PDGF receptor alpha
positive OPCswere shown to express CXCR2, suggesting a possible
mechanism for migration of these cells into the corpus callosum. To
test this, we injected a replication-defective adenovirus encoding
CXCL1 via the cisterna magna which introduced the virus into the
cerebrospinal fluid without inflammation. Virus was injected at 0
weeks or 3 weeks after initiation of cuprizone treatment and mice
were sacrificed at either 3 weeks or 6 weeks. Virally encoded
CXCL1 mRNAwas detected in the cerebellum up to 6 weeks after
virus injection. Immunohistochemical detection of NG2 positive
OPCs showed no effect of the CXCL1 encoding adenovirus on the
number of OPCs in the corpus callosum. These data suggest thatendogenous CXCL1 is sufficient for OPC mobilization and
remyelination. Deletion strategies are currently underway.
Su1.50. Standardizing Multiparameter Flow Cytometry
for Evaluation of Cytokine-Secreting Activity in T Cells
Via Automation of Sample Preparation and Analysis.
J. Wilkinson,1 C. Smith,1 S. DTCosta,1 E. Rabellino.1 1Biomedical
Research Division, Beckman Coulter Inc., Miami, FL, USA.
The utility of evaluating T cell functional assays is well
recognized in the context of determining an efficacious vaccine
strategy for infectious diseases/cancer, a tolerance profile in
autoimmunity and transplantation, as well as for understanding
the basic mechanisms of T cell immune responses in disease
pathogenesis. However, the variability associated with T cell
functional assays continues to be problematic, especially in studies
involving multi-center clinical trials as well as in longitudinal
studies. The variable natures of these assays are associated with a
variety of factors ranging from source of the T cells, the processing
methodology (isolation, freezing, thawing, and culturing), the
sample preparation for staining and finally, data analysis, and data
reduction. With a view to reducing variability and standardizing
targeted steps of the assays involving T cell function, an automated
methodology for staining and analysis of intracellular cytokines via
flow cytometry was developed.
A modification to available sample preparation instruments
was performed that enabled the automated pipetting, incubation,
and staining of intracellular and surface molecules of human
stimulated whole blood or PBMC for flow cytometric analysis. A
5-color flow cytometry assay (2–3 surface markers; 2–3 intra-
cellular cytokines) was developed to characterize the brestricted
polyclonalQ Th1 versus Th2 cytokine profile response in T cells
stimulated by SEB/CD28. The automated sample staining and
analysis greatly reduced variability between specimens while
reducing the hands-on sample preparation and analysis time. The
complex nature of the cytokine profile and inter- and intra-
subject variability was revealed on evaluation of several
cytokines in the context of multiparametric evaluation of the T
cell responses. The use of automation thus provides a greater
degree of standardization in these functional assays, allowing for
a correlation of variability and complex immune response
profiles, to vaccine efficacy or disease progression without as
significant an interference due to the variable nature of the
manual assay.
Su1.51. LTBR Is Expressed, Functional, and Regulated
on Endothelial Cells during Contact Sensitization.
S. Liao,1 N. H. Ruddle.1 1Epidemiology and Public Health, Yale
University School of Medicine, New Haven, CT, USA.
High endothelial venules (HEVs) are specialized lymph node
blood vessels that allow entrance of lymphocytes into lymph
nodes. Through our analysis of genetically deficient and trans-
genic mice, we have previously determined that the LTah
complex is critical for expression of several HEV genes during
development and that the LThR is expressed on HEV. The
specific objectives of this study were to determine: 1) whether
LThR signaling is crucial for HEV gene expression in adult wild
type mice and 2) whether this is a direct effect on endothelial cells
in induction of HEV gene expression. These questions were
investigated in vivo in C57BL/6 mouse peripheral lymph node
(PLN) and in vitro in the bEnd.3 cell line. The regulation of HEV
genes (GlyCAM-1, MAdCAM-1, SLC, an HEV specific GlcNAc-
Abstracts S2056-sulfotransferase [HEC-6ST], and LThR itself) was evaluated by
immunohistochemistry and real time PCR, using an LThR
activator, an LThR inhibitor and contact sensitization. LThR
was expressed constitutively on HEV in PLNs and was inhibited
by one injection of an LThR-Fc fusion protein. HEV genes were
regulated by contact sensitization with oxazolone in C57BL/6
mice. LThR was regulated in parallel with HEC-6ST after contact
sensitization with oxazolone. An interesting kinetic pattern was
detected for these and several other HEV genes: there was an
initial decrease in gene expression and a rebound by 7 days in
most of the genes with the exception of MAdCAM-1, where there
was an exactly opposite effect. The initial phase of gene regulation
after contact sensitization was independent of TNFRI, though the
optimal rebound of gene expression was partially dependent on
that receptor. LThR signaling was essential for the optimal
rebound of gene expression after sensitization. bEnd.3, a mouse
endothelial cell line, prominently expressed the LThR and upon
stimulation with a hamster anti-LThR antibody showed a dramatic
up-regulation of MAdCAM-1. These in vitro and in vivo data
taken together indicate that the LThR is expressed on endothelial
cells, can signal direcly, is crucial for constitutive HEV gene
expression and is regulated during an immune response. These
data also provide information regarding plasticity of HEV gene
expression during an immune response, suggesting an initial
reversion to an immature phenotype and recovery through a
developmental program to an adult phenotype.
Supported by NIH CA 16885 to NHR and the Anna Fuller
Fund (SL).
Su1.52. Interferon-A Inducing TLR9 Agonists.
E. R. Kandimalla, D. Yu, T. Sullivan, S. Agrawal. 1Discovery,
Hybridon, Inc., Cambridge, MA, USA.
Bacterial and synthetic DNA containing CpG dinucleotides
(CpG DNA) have been shown to be the natural ligands for
TLR9, a molecular pattern recognition receptor. CpG DNA
activation of TLR9 has been shown to produce Th1 type
immune responses, including IFN-a induction. Through exten-
sive DNA structure-activity relationship studies, we have
identified novel synthetic dinucleotides and DNA structures
(immunomers) that are recognized by TLR9. The combination of
novel DNA structures with synthetic stimulatory dinucleotides
provided us a portfolio of immunomodulatory oligonucleotides
(IMOs). In general, IMOs produce distinct TLR9-mediated
immune responses with high IL-12 and low IL-6 cytokine
secretion profiles compared with natural CpG dinucleotide motif.
Based on human cell culture assays and in vivo non-human
primate studies, we have identified novel IMOs consisting of
synthetic stimulatory motifs, which induce high levels of IFN-a.
The induction of IFN-a by IMOs is dependent on the presence
of specific nucleotide sequences and the activation of plasma-
cytoid dendritic cells. These novel IMOs also induced human B
cell proliferation and activated B cells to express surface markers
and secrete cytokines. IMOs induced expression of a number of
cytokine and chemokine genes, including IFN-a gene and a
number of interferon inducible genes such as 2V5V-adenylate
synthetase in human PBMCs. In non-human primates, IMOs
administered s.c. at 1 mg/kg dose induced high levels of IFN-a
secretion up to 72 hr. These results suggest that IMOs that
induce high levels of IFN-a may be suitable candidates for the
treatment of hepatitis C and cancer, where recombinant IFN-a
therapy is commonly used.Su1.53. TGF-Beta in Foxp3 Expression and
Development of Peripheral CD4+CD25+ Treg.
W. J. Chen, Y. Liu. 1Mucosal Immunology Unit, OIIB, NIDCR,
NIH, Bethesda, MD, USA.
Although CD4+CD25+ regulatory T cells (Treg) are instrumen-
tal in the maintenance of immunological tolerance, one critical
question is whether CD4+CD25+ regulatory T cells (Treg) can only
be generated in the thymus or can differentiate from peripheral
CD4+CD25- naRve T cells. We have shown that conversion of naRve
peripheral CD4+CD25- T cells into CD4+CD25+ regulatory cells
can be achieved through co-stimulation with TCR and TGF-beta.
These converted regulatory cells are not only unresponsive to TCR
stimulation, but also inhibit normal T cell proliferation in vitro.
Importantly, TGF-beta-converted transgenic CD4+CD25+ suppres-
sor cells proliferate in response to immunization, but inhibit
antigen-specific naRve CD4+ T cell expansion in vivo in an OVA
peptide TCR transgenic adoptive transfer model. In a murine
asthma model, co-administration of TGF-beta-induced suppressor
T cells prevents house dust mite (HDM)-induced allergic patho-
genesis in lungs. Significantly, TGF-beta induces Foxp3 gene
expression in TCR-challenged CD4+CD25- Tcells, which mediates
their transition toward a regulatory T cell phenotype. The TGF-beta
induction of Foxp3 is attributed to the CD4+CD25- naRve T cells,
but not selective expansion of a small number of pre-existing
regulatory T cells. Accordingly, TGF-beta induced-Foxp3 expres-
sion in naRve CD4+CD25- T cells can be detected as early as 16
hours after stimulation. TGF-beta induces Foxp3 expression in
CD4+CD25- T cells in the 5C.C7 TCR transgenic mouse on a
Rag2-/- and IL-2-/- background. TGF-beta 1-/- mice exhibit
reduced number of peripheral CD4+CD25+CD62L+ T cells.
Finally, CD28 signaling is involved in TGF-beta induction of
Foxp3 in CD4+CD25- T cells. The data provide new evidence in
understanding the mechanisms for generation and development of
CD4+CD25+ regulatory T cells, and open a unique opportunity to
intentionally manipulate this pivotal population of cells for immune
tolerance and T cell-based immunotherapy.
Su1.54. Osteoprotegerin Synthesis by Circulating T Cells
Is Related to Osteoporosis in HIV-Infected Patients.
A. Chakravarti,1 L. Flamand,1 R. Lalonde,2 P. E. Poubelle.1
1Department of Medicine, Centre de Recherche en Rhumatologie
et Immunologie,Universite Laval, Quebec, QC, Canada; 2Division
of Infectious Diseases, Royal Victoria Hospital, McGill University,
Montreal, QC, Canada.
Osteoprotegerin (OPG), a cytokine of the TNFR superfamily, is
the decoy receptor for Receptor Activator of NF-nB ligand
(RANKL). OPG counteracts bone resorption induced by inter-
action of the receptor-ligand pair RANK-RANKL. OPG, present in
blood, is also implicated in diverse aspects of vascular function and
in immune regulation. The aims of this study are to better
understand the different functions of circulating OPG through an
elucidation of the role of immune cells in its regulation and to
explore new aspects of interactions between the immune and
skeletal systems. Our objectives, formulated in this broad frame-
work, would be:
1. To delineate the subpopulation(s) of peripheral blood
mononuclear cells responsible for the synthesis of osteoprotegerin
and to identify the factors of regulation.
2. To study the functional impact of OPG regulation by immune
cells in an appropriate physiopathological context i.e in HIV in-
fected individuals.
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combined with immunoblots to examine the synthesis and the
regulation of OPG by subpopulations of normal human peripheral
blood mononuclear leucocytes (PBMCs), enriched by immuno-
magnetic separation, under different conditions of incubation. RNA
synthesis profiles were studied using RT-PCR and Northern blot
analyses. We provide evidence that, amongst PBMCs, OPG is
constitutively secreted only by CD4+ T lymphocytes, and that T cell
production of OPG is up-regulated by an anti-CD3 antibody, IL-1h,
TNF-a, GM-CSF, vitamin D3, but not TGF-h. The T cell synthesis
of OPG is strongly increased by IL-4, unlike IL-10 which inhibits
the constitutive and IL-4-induced production of OPG. To verify the
pathophysiological importance of T cell-derived OPG, we chose to
study circulating concentrations of OPG of patients infected with
HIV-1 knowing that disease induced by HIV-1 is specifically
associated with both compromised CD4+T cell number & function,
and an increased incidence of osteoporosis. Given that OPG is
presently considered one of the final components that decides
outcome of bone resorption, we compared circulating concentra-
tions of OPG in HIV-infected individuals to agematched normal
subjects and remarked a significant decrease of OPG concentrations
in plasma from HIV-infected patients. Additionally, normal T
lymphocytes in the presence of recombinant HIV-1 gp120 had an
unequivocal reduction of their constitutive OPG production.
Moreover, nelfinavir, a protease inhibitor used in highly active
antiretroviral therapy, significantly inhibited the constitutive OPG
synthesis by normal T cells. These results are the first to suggest a
causal link between HIV-induced T cell malfunction, i.e a
dysregulation of its capacity to produce OPG, and secondary
osteoporosis. We highlight a new role for T lymphocytes in the
regulation of circulating OPG, and suggest the therapeutic potential
of OPG or OPG mimetics in the decreased bone mineral density
associated with HIV infections.
Su1.55. Detection of Cytokines in Patients with
Hypersensitivity to Metals.
Z. Venclikova,1 J. Bartova,1 L. Mrklas.1 1Clinical Department,
The Institute of Dental Research, 1st Medical Faculty and GUH,
Charles University, Prague 2, Prague, Czech Republic.
Introduction: In the dental praxis, dentist are often confronted
with suspect delayed hypersensitivity reaction to various metals
used in prosthetic and restorative dentistry. Cytokines have been
involved in most disease processes including hypersensitivity. In
this study a new method of detection of cytokines so called
bHuman Cytokine ArrayQ was used in ten patients with suspect
delayed hypersensitivity to metal components of dental alloys.
Methods: The clinical part of study involves examination of the
oral cavity with respect to the presence of dental alloys including
dental radiograph. Special questionaire focused in general health
status was also used. In the immunological examination mono-
nuclear cells separated from peripheral blood were used to study the
production of cytokines. By using Ray Bio TM Human Inflammation
Antibody Array III it was possible to identify the expression profiles
of 40 cytokines. The detection of cytokines was performed after 3
days cultivation with mercury and nickel chlorides.
Results: Nickel chloride stimulated production of IL-6, IL-10,
IFN-gamma, IL-1 alfa, TNF alfa and TNF beta. Mercury chloride
stimulated production IL-4, IL-6, IL-10, IL-1 alfa and sTNF RII.
Conclusion: Mercury chloride activated rather clones of TH2
lymphocytes, while nickel chloride TH1 lymphocytes. Both metal
salts activated regulatory clones Tr.Acknowledgment: This project was supported by grant of
Czech Ministry of Health No. NK 7437-3.
Su1.56. SCYA4L Polymorphism Genotyping by
Fluorescent Resonance Emission (FRET) Probes in
Real-Time PCR.
Roger Colobran,1 Rosa Faner,1 Carles Llop,1 Ricardo Pujol,1
Manel Juan.1 1LIRAD (Laboratori dTImmunobiologia per a la
Recerca i Aplicacions Diagnostiques) / IICSGTIP (Institut
dTInvestigacio en Ciencies de la Salut Germans Trias i Pujol),
CTBT (Centre de Transfusio i Banc de Teixits) / UAB (Universitat
Aut.
Human CCL4/MIP-1beta and CCL3/MIP-1alpha are two
highly related molecules that belong to a cluster of inflammatory
CC chemokines located in chromosome 17. CCL4 and CCL3 were
formed by duplication of a common ancestral gene, generating the
SCYA4 and SCYA3 genes, which, in turn, present a variable
number of additional non-allelic copies (SCYA4L and SCYA3L1).
Moreover, our group found that SCYA4L locus is polymorphic and
displays a second allelic variant (SCYA4L2) highly represented in
HIV+ patients compared to the one described originally
(SCYA4L1).
Recent evidences have pointed out that variation in SCYA3L1
gene copy number play a key role in susceptibility to HIV infection.
Probably SCYA4L will be also related with this phenomenon.
Similarly this gene dosage variation could be involved in other
diseases where these chemokines play important roles.
We developed a FRET probes Real-time PCR based method to
determine easily, fast and reliably the genotype for the poly-
morphic SCYA4L locus. This polymorphism consists in a single
nucleotide change situated in the second intron acceptor splice site
(+590ANG). Our approach uses specific primers for SCYA4L
locus and a pair of FRET hybridization probes. We have tested the
use of the sensor probe complementary to each one of the allelic
variants, obtaining a better melting resolution with the SCYA4L2
specific probe, while SCYA4L1 sensor probe is more useful for
total SCYA4L copy number determination. Based on this approach
we are setting up a protocol to determine the copy number of the
SCYA4L gene whereas it informs about copy number belonging to
SCYA4L1 or to SCYA4L2 allelic variants.
Su1.57. Correlation of Interleukin-4 and Chronic
Periodontitis.
Mandana Sattari,1 Saeed Khalili,1 Leili Mehrdad.1 1Immunology,
Shaheed Beheshti University Medical School, Tehran, Islamic
Republic of Iran.
Aim: Regarding to the presence of numerous B cells in chronic
periodontitis and since TH2 cells have important role in inducing
the humoral responses, so the aim of this study was to determine
the correlation between IL-4 (as a most important cytokine for
differentiation of TH2 cells from TH0 cells and IL-12 (as a most
important cytokine for differentiation of TH1 cells from TH0 cells)
and chronic periodontitis.
Materials and Methods: For this purpose, 20 gingival samples
from healthy patients and 20 gingival samples from patients with
chronic periodontitis were collected during periodontal surgery.
Tissue samples were cultured for 72 hours, then ELISA was used
for determining the concentration of IL-4 and IL-12 in supernatant
fluids.
Results: IL-4 and IL-12 were found in all of samples. There was
no significant difference between case and control groups
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difference between two groups regarding the ratio of IL-4 to IL-12
(IL-4/IL-12). Also there was correlation between IL-4/IL-12 and
attachment loss (P~0.028).
Conclusion: It is concluded that in chronic periodontitis,
probably the number of TH2 cells is more than TH1 cells but in
active phases of inflammation and tissue damage, the number of
TH2 cells could be decreased by the reduction in IL-4 production.
Su1.58. Interleukin-21 Maintains T Cells in a Naive
Phenotype.
S. Ferrari-Lacraz,1 D. C. Foster,2 R. Chicheportiche.1
1Immunology and Allergy, University Hospital, Geneva, Geneva,
Switzerland; 2Cytokine Biology, Zymogenetics, Seattle, WA, USA.
Of the large number of cytokines released during the develop-
ment of the immune response, T cell growth factors (TCGFs) such
as interleukin-2 (IL-2), IL-15 and IL-21 play major and distinct
parts in T-cell activation. These TCGFs determine whether
activated T cells undergo apoptosis or persist as regulatory/memory
cells after robust immune activation, the key to peripheral T-cell
homeostasis.
IL-21 is a major TCGF and part of the innate and adaptive
immune response. IL-21 co-stimulates naive, but not memory T
cells, contrary to IL-15 that is a major stimulus of memory CD4+
and particularly CD8+ T cells. Unlike IL-2 and IL-15, IL-21 has no
significant effect on the proliferation of T cells in the absence of
anti-CD3 or other stimuli. Here we demonstrate that IL-21 plays a
potent role in maintaining the naive phenotype of human CD4+ T
lymphocytes, with the persistence of specific cell-surface markers.
PBMC were isolated from healthy young donors, CD45RO-
(naive) and CD45RO+ (memory) CD4+ T cells were subsequently
isolated on a FACSvantageW sorter. The selected CD4+ cells were
cultured for up to 3 weeks with IL-2 or IL-21. The phenotype of
naive and memory CD4+ T cells was assessed by immunofluor-
escence. Markers such as CD45RA, CD27, CD62L and partic-
ularly CCR7 were clearly upregulated in CD4+ T cells cultured
with IL-21 as compared to IL-2. Less than 1% of CD4+ T cells
cultured with IL-2, but 43% of CD4+ T cells cultured with IL-21
express CD45RA at day 21. This means that the majority of naive
CD4+ T cells cultured with IL-2 switched to a CD45RO+ memory
cell phenotype by day 21. The expression of CCR7 on CD4+ T
lymphocytes cultured with IL-21 induces the migration of these
cells through the chemoattraction of CCL21. Moreover, IL-21
reduces the frequency of proliferating naive T cells compared to
IL-2, but proliferation markers, such as Ki-67 (B56) and
proliferating cell nuclear antigen (PCNA) were expressed equally
in both cell-culture conditions.
Therefore, IL-21 is a unique TCGF able to maintain CD4+ T
lymphocytes under a naive phenotype, and to increase their cell-
surface expression of CCR7 and their migration through chemo-
attraction to CCL21. These findings suggest that IL-21 may play a
unique role in innate and adaptive immune response due to the
persistence of naRve T lymphocytes.
Su1.59. Osteopontin, a Th1 Cytokine, Promotes Cell
Survival and Inhibits Programmed Cell Death of
Activated T Cells.
E. M. Hur,1 L. Steinman.2 1Program in Immunology, Stanford
University, School of Medicine, Stanford, CA, USA; 2Neurology
and Neurological Sciences, Stanford University, Medical School,
Stanford, CA, USA.Osteopontin (OPN), previously regarded as an adhesive bone
matrix protein, has recently been shown to be a pleiotropic
cytokine regulating early cell-mediated immunity. Our previous
studies have shown OPN to play a critical role in autoimmune
demyelinating diseases. In multiple sclerosis and experimental
autoimmune encephalomyelitis (EAE) OPN expression is signifi-
cantly increased in the affected tissues. Here we show that OPN
inhibits TCR-mediated apoptosis in vitro without affecting cell-
cycle progression as measured by BrdU incorporation and CFSE
labeling. To investigate the effect of OPN on activation-induced T
cell death in vivo, we activated Vh8(+) T cells by injecting
Staphylococcal enterotoxin B (SEB) into OPN-/- mice and
monitored the deletion of Vh8(+) T cells. We found that the death
of these stimulated T cells in vivo is accelerated in OPN-/- mice.
Adoptive transfer of T cells from OPN-/- mice to Rag-1-/- recipients
revealed that OPN secreted from T cells prolongs survival of
activated T cells in vivo. We also found in OPN-/- mice that
expression of the pro-apoptotic Bcl-2 family protein, Bim, was
increased in both CD4+ and CD8+ T cells. Furthermore, compared
to wild type mice, OPN-/- mice display a remarkably reduced
number of certain T cell subsets. In OPN-/- mice, in comparison to
the T cell subpopulations CD62L(lo)CD44(hi) and CD62L(lo)C-
D44(int), CD62L(hi)CD44(hi) express higher levels of pro-
survival protein Bcl-2. Despite of increased cell death in OPN-/-,
after T cell activation the level of active caspase-3 was lower in
OPN-/- cells than wild type cells. Furthermore, treatment of OPN-/-
and wild type lymphocytes with a cell-permeable caspase inhibitor
reduced the death of activated wild type but not OPN-/- T cells,
which suggests that activation-induced cell death in OPN-/- T cells
is mediated by an alternative, caspase-independent pathway. In this
study, we suggest that OPN plays a role in regulating programmed
cell death of activated T cells and that OPN signaling promotes T
cell survival.
Su1.60. Comparison of RNA Preparation Methods and
Their Effect on Cytokine/Chemokine Gene Expression.
A. L. Asare,1 S. A. Kolchinsky,1 P. Wood,2 V. L. Seyfert-Margolis.1
1Immune Tolerance Network, University of California, San
Francisco, San Francisco, CA, USA; 2Center for Human Genetics
and Integrated Biology, University of Pittsburgh, Pittsburgh, PA,
USA.
Objective: Commercially available blood collection tubes for
gene expression studies lyse red blood cells and stabilize RNA to
ensure detected transcript profiles reflect the physiological state of
the subject. We assessed two such systems for their ability to
detect and quantify differential expression of cytokine and
chemokine genes. Method: Peripheral blood samples from 8
healthy volunteers were collected in both Tempus Tubek blood
collection tubes (Applied Biosystems (ABI), Foster City, CA) and
PAXgenekBlood RNA Tubes (PreAnalytiX, Valencia, CA). All
samples were isolated according to the manufacturersT instruc-
tions. RNA purity and yield were assessed prior to analysis.
Samples were preprocessed as follows: 1) Blood was drawn
directly into Tempusk and PAXgenek tubes or 2) Samples were
drawn in LI Heparin tubes, stimulated with PHA, and then
transferred into the two RNA collection tube types. We analyzed
both: 1) Transcript detection at single time-points and 2) Differ-
ential expression between baseline samples and samples stimu-
lated with 25 Ag/ml PHA after 3 hrs. Affymetrix HG-U133 2.0
GeneChipn with 47K transcripts and quantitative RT-PCR for 184
cytokine and chemokine transcripts (probe primers from ABI)
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generated a GeneChipn analysis set of 1,245 reliably detected
transcripts. Clustering using standard correlation generated the
following differential expression profiles: Set A (370 transcripts)
showing up regulation using both tubes; Set B (336 transcripts)
showing down regulation using both tubes; Set C (180 transcripts)
showing no change, but having elevated baseline values in
Tempusk but not PAXgenek; Set D (249 transcripts) showing
no change, but having elevated baseline values in PAXgenek but
not in Tempusk. Transcripts in Set C and D were not cytokine/
chemokine related. Transcripts in Set A with greater than 10 log
scale expression include chemokine (c motif) ligand 1, class 1
MHC-restricted T cell associated molecule, chemokine (C-X-C
motif). Quantifying differential expression by RT-PCR showed
high similarity between the tubes for all cytokine/chemokine
transcripts. Some allergy relevant cytokines, such as IL-5, were
not detectable at high levels in the GeneChipn assay, but were
detected at high levels using RT-PCR. Conclusion: Different
kinetics for each tube during the lysing process may account for
detection level differences at single time-points for non-cytokine/
chemokine related transcripts found using GeneChipsn. These
time-point differences could not be confirmed using RT-PCR since
cytokine/chemokine RT-PCR probes were used. This demonstrates
that the selection of a particular tube for RNA studies may depend
heavily upon the transcripts of interest. For cytokine/chemokine
transcripts, both tube types provide essentially equivalent expres-
sion profiles.
Su1.61. Regulation of Interferon Gamma Expression by
Tumor Necrosis Factor Receptor Type 1 Signaling.
L. M. Kelly,1 R. D. Wheeler,1 T. Owens.1,2 1Neuroimmunology
Unit, Montreal Neurological Institute, Montreal, QC, Canada;
2Medical Biotechnology Center, University of Southern Denmark,
Odense, Denmark.
Cytokine networks play a crucial role in the disease pro-
gression of both multiple sclerosis (MS) and its animal model,
experimental autoimmune encephalomyelitis (EAE). The study of
these networks is necessary for understanding the disease and for
developing treatments. However, cytokines are multifaceted and
may fulfill contradictory roles depending upon a variety of factors,
e.g. stage of disease. Tumor necrosis factor (TNF) is an important
cytokine in both EAE and MS. Mice that lack TNF receptor type 1
(TNFR1 KO) develop mild EAE but express high levels of
interferon gamma (IFN-gamma) in the spinal cord. IFN-gamma is
a pro-inflammatory cytokine traditionally considered detrimental
in MS, but which has been shown to be protective in EAE. The
present study examines the mechanism by which lack of TNFR1
results in increased IFN-gamma production using an in vitro co-
culture approach. Wild type (WT) or TNFR1 KO mice were
immunized with MOG35-55 peptide in complete FreundTs
adjuvant. Seven to ten days later, lymph node T cells were
isolated by MACS using negative selection. Splenic antigen
presenting cells (APCs) from unimmunized mice were also
obtained by MACS using negative selection. WT or TNFR1 KO
T cells were co-cultured with WT or TNFR1 KO APCs in the
presence of MOG35-55 peptide, and cytokine expression was
analyzed at various time points by ELISA or real-time PCR. Both
WT and TNFR1 KO T cells produced significantly more IFN-
gamma when co-cultured with TNFR1 KO APCs compared with
WT APCs. This observation was not altered by the addition of
neutralizing anti-TNF antibody, demonstrating that the enhancedIFN-gamma secretion was not due to TNF actions through
TNFR2. Furthermore, these data demonstrated that TNFR1
signaling on the APC is critical in regulating IFN-gamma
production. APCs can regulate T cell IFN-gamma production by
secretion of IFN-gamma-inducing factors, such as IL-12. Prelimi-
nary results show that mRNA expression of the p40 subunit of IL-
12 was higher in co-cultures containing TNFR1 KO APCs
compared to WT APCs. This suggests that the absence of TNFR1
on APCs leads to higher levels of IL-12, which results in higher
IFN-gamma secretion by T cells. The p40 subunit is a component
of IL-23 as well as IL-12. IL-12 promotes IFN-gamma-secreting T
cells, whereas IL-23 promotes IL-17-secreting T cells that have
recently been shown to be critical for EAE pathology. Protein
array analysis revealed high levels of IL-17 in our co-cultures, and
future work will further investigate the role of IL-17 in our co-
culture system. In conclusion, this study shows that lack of
TNFR1 on APCs leads to greater IFN-gamma production by T
cells, potentially due to a change in p40 expression. These data
further extend our understanding of the cytokine networks
underlying CNS inflammation. This study was funded by the
Canadian Institutes of Health Research and the Multiple Sclerosis
Society of Canada.
General Autoimmunity
Su1.62. Bacterial HSP70 Immunization Inhibits
Proteoglycan-Induced Arthritis.
S. E. Berlo,1 C. B. ten Brink,1 P. J. van Kooten,1 R. van der Zee,1
M. Singh,2 B. J. Prakken,3 T. T. Glant,4 W. van Eden,1 C. P.
Broeren.1 1Department of Infectious Diseases and Immunology,
University of Utrecht, Utrecht, Netherlands; 2German National
Research Institute for Biotechnology, Braunscheig, Germany;
3Department of Pediatric Immunology, UMCU, Utrecht,
Netherlands; 4Department of Orthopedic Surgery, Rush
University, Chicago, Netherlands.
Immune responses to heat-shock protein 70 (HSP70) are seen in
inflammatory diseases, such as rheumatoid arthritis (RA), diabetes
and atherosclerosis. Although HSPs have well described roles as
chaperones for intracellular proteins, the significance of immune
responses to HSP is only now becoming clear and indicate that
HSPs are targets for disease suppressive immune regulation. In
experimental disease models HSP can be used as therapeutic
agents to prevent or arrest inflammatory damage and first clinical
trials using HSP peptides have shown a shift in pro-inflammatory
cytokine profiles of peptide specific T cells to production of anti-
inflammatory cytokines. In order to analyze the mechanisms
leading to HSP induced immune regulation we set out to test the
possible protective effects of HSP70 in a novel mouse (BALB/c)
arthritis model. This proteoglycan-induced arthritis (PGIA) model
can be induced by immunization with cartilage PG emulsified
with the adjuvant dimethyl dioctadecyl ammonium bromide
(DDA).
A single i.p. injection of 100 Ag mycobacterial HSP70 given
10 days prior to the first PG injection (both given in DDA)
resulted in a two-week delay of the arthritis onset. Furthermore,
HSP70 preimmunization induced a significantly milder arthritis,
as assessed by clinical score (mean maximum arthritis score
0.7 F SEM 0.4; compared with 3.5 F SEM 1.3 in the control
mice; P b 0.001). The protective effect of HSP70 was accompanied
with HSP70-specific T cell proliferation, IFN-g and IL-10
production, in mice pretreated with HSP70. Interestingly, in
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arthritis inducing proteoglycan, which was not present in
control mice. In addition, joint sections of HSP70-pretreated
mice showed less leukocyte infiltration, reactive synovial cell
proliferation and cartilage destruction compared to the control
group.
In conclusion, HSP70-initiated modulation, could dramati-
cally suppress the development of inflammation and subsequent
tissue damage in PGIA. In addition, we demonstrated that
HSP70 preimmunization, indeed, activated T cells, altered the
cytokine profile and modulated the immune regulatory
response.
Su1.63. Characterization of Functionally Important
Regions of CD200:CD200R for Immunoregulation Using
Blocking Synthetic Peptides and/or mAbs.
R. M. Gorczynski, D. X. Chen. 1Transplant Research Division,
University Health Network (UHN), Toronto, ON, Canada.
Objective: We have previously defined the immunoregulation
which occurs, allowing prolongation of allograft survival and
suppressing collagen-induced arthritis in mice, following interaction
of the cell surface molecules, CD200 and CD200R. The CD200R1
isoform is most important in delivering direct immunosuppressive
signals. Other groups have used a biophysical approach to
investigate the structurally important regions for these interactions,
and have suggested the N-terminal (extracellular domains) of the
molecules are crucial. We report on our investigations of the
important interactions using an approach investigating purturbation
of various biological functions which follow CD200:CD200R
interactions.
Materials and Methods: A series of 15-mer peptides were
synthesized which defined continuous sequences of the extrac-
ellular region of the murine and human CD200 molecule. In
addition, peptides mapping to the presumptive CDR1, CDR2
and CDR3 of the human and mouse CD200R1 molecules were
synthesized. We assessed the ability of these different mole-
cules to block the interaction of CD200 with CD200R1 in a
competitive ELISA using plate-bound CD200R1Fc and bio-
tinylated CD200Fc, as well as by FACS using FITC-conjugated
CD200Fc binding to 24hr-LPS-activated adherent cells. Peptides
were also used to modulate the suppression of MLC reactivity
in vitro which follows from inclusion of CD200Fc in MLC
cultures, measuring development of CTL after 5 days of
culture.
In addition, using a newly prepared panel of mAbs to mouse
and human CD200Fc, we compared the rank activities of
antibodies for binding (FACS or ELISA) to CD200 with their
abilities to augment immune reactivity in MLCs.
Results: Peptides defining discrete regions in the N-terminal
regions of CD200 and CD200R1 were functionally active in the
different assays, including the assay which investigated blockade of
CD200Fc-mediated suppression. Moreover, infused in vivo, the
same mouse-specific peptides suppressed protection from graft
rejection afforded by injection of soluble immunosuppressive
CD200Fc.
Using the panel of mAbs, we observed again that only mAbs
defining epitopes in the N-terminal domain could augment MLC
reactivity (or block immunosuppression by soluble CD200Fc),
while mAbs targeting C-domain epitopes, although reactive in
ELISA or FACS (targeting cell surface CD200) were inactive in
MLCs. In a final assay we compared by rank these different anti-CD200s for FACS staining of CD200 expressed on various cell
types, including fresh dendritic cells and lymphoid tumor cells.
These data suggested there exists a significant heterogeneity in
expressed CD200.
Summary: Our data confirm that the N-terminal regions of
CD200 and CD200R1 are crucial to mediate immunoregulation,
and suggest that it will prove possible to generate smaller molecular
weight antagonists of this interaction which may have clinical
utility.
Su1.64. Gene Identification of Single Chain Format
Variable(scFv) Anti-B2-Glycoprotein-I (aB2GP-I) and
Anti-Prothrombin (aPt) Antibodies Obtained from a
Primary Anti-Phospholipid Syndrome (PAPS) Patient by
Phage Display.
J. Cabiedes,1 M. Languren,1 B. Becerril,2 L. E. Fernandez-
Altuna,2 D. F. Hernandez-Ramirez,1 V. Pascual,1 A. R. Cabral.1
1Immunology and Rheumatology, Instituto Nacional de Ciencias
Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico;
2Biotecnologia y Bioprocesos, Instituto de Biotecnologia. UNAM.,
Cuernavaca, Morelos, Mexico, Malta.
Introduction: Anti-phospholipid syndrome (APS) is an auto-
immune disease characterized by thrombotic and hemocytopenic
manifestations in patients with high titers of autoantibodies
directed against phospholipids and phospholipids cofactor pro-
teins. Molecular studies of anti-phospholipids (aPL) had been
performed on monoclonal autoantibodies obtained from EBV
transformed B cells, which do not represent the repertoire of the
autoimmune aPLs. Using phage display technology is possible the
study of a wide repertoire of VH(D)JH and VLJL rearrangements
that recognize specific antigens. Objective: To study by phage
display the VH(D)JH and VLJL rearrangements of anti-g2GP-I and
anti-Pt from a patient with PAPS with high titers of these
autoantibodies.
Methods: cDNA was synthesized from RNA obtained from
peripheral blood mononuclear cells. The VHDJH and VLJL (n and
E) rearrangements were amplified. Heavy and light chains
fragments were linked to obtain scFv fragments. The scFv were
ligated to a pSyn2 vector. E. coli XL1-Blue were transformed with
the products of the ligation. Cultures were co-infected with the
M13/KO7 phage to rescue the antibodies in the format phage-scFv
antibody. Four rounds of selection were done against g2GP-I and
Pt. Positive clones were sequenced and analyzed.
Results: Two clones that recognize g2GP-I (beta 1 and 2)
and one that recognize Pt (Prot-1) were obtained. VH genes
from the Beta1 and 2 belong to the VH4 family. Beta1
rearrangement shows 96.7 % of homology with the VHSP/
VH4.22 gene, no D gene was identified and the JH gene used
was the product of the JH5 gene with 98.03 % of homology.
Light chain is composed by the product of the 1b.366F5/DPL5
gene that belongs to the VE1 family, it shows 99.4 % of
homology, no JL gene was identified. Beta2 clone shows 98.97
% of homology with the VIV-4/4.35+ gene, no D gene was
identified and it was rearranged with the product of the JH4b
gene with 81.25 % homology, light chain used the product of
the gene V2-14+ which belong to the VE3 family with 88.88 %
of homology and it is rearranged with the product of the JL3b
gene. The third clone, Prot1 carries the product of the DP-47/
V3-23 gene that belongs to the VH3 family with 98.6 % of
homology, no D gene was identified and the JH gene identified
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chain is the product of the 1b.366F5/DPL5 gene, which belongs
to the VE1 family with 93.6 % of homology, it was re-arranged
with the product of the JL3b gene, and it shows 89.47 % of
homology.
Conclusions: We confirm the bias through the use of VH3 and
VH4 gene families. The number of somatic mutations suggests that
the rearrangements are the product of antigen driven clones. The
antibodies in format scFv represent well those autoantibodies
found in patients with PAPS.
Su1.65. A Novel Network of Human B Cell Effector
Cytokines Is Implicated in Autoimmunity:
Dysregulation in Patients with Multiple Sclerosis and
Potential as Therapeutic Target.
A. Bar-Or,1 M. Niino,1 M. Duddy,1 F. Adatia,1 S. Hebert,1
H. J. Kim.1 1Neuroimmunology Unit, Montreal Neurological
Institute, McGill University, Montreal, QC, Canada.
Background: Beyond their roles as potential antibody produc-
ing cells, there is growing interest in the fundamental roles that B
cells may play in regulating immune responses. Emerging animal
studies point to an important contribution of B cell effector
cytokines to autoimmunity. We set out to study the potential
involvement of human B cells and their cytokines in immune
regulation and autoimmunity.
Results: We report that the profile of human B cell cytokine
production is context dependent, being critically influenced by the
balance of signals through the B cell receptor and CD40. B cells
appropriately stimulated by sequential B cell receptor and CD40
stimulation proliferate and secrete tumour necrosis factor (TNF)-a
and lymphotoxin (LT) which contribute to germinal center reaction
and thereby amplify the ongoing immune response. In contrast,
CD40 stimulation alone-a mimic of a B cell receiving bystander T
cell help in the absence of specific antigen recognition-induces
significantly less pro-inflammatory cytokines (n = 24; P b 0.0002)
but significantly enhanced production of IL-10 (P b 0.004) that
serves to suppress inappropriate immune responses. We further
observed that this novel network of reciprocal regulation of B cell
effector cytokines, is abnormal in a subgroup of patients with
relapsing remitting multiple sclerosis where B cells maintain their
capacity to proliferate and produce the proinflammatory cytokines
TNF-a and LT (n = 18; P = 0.46 compared to normals), but have a
significantly diminished capacity to produce IL-10 (n = 18; P b
0.02). This B cell cytokine network can be targeted therapeutically,
as evidenced in patients treated with mitoxantrone (NovantroneR),
a recently approved immune suppressant in MS. Compared to B
cells from untreated patients, B cells from mitoxantrone treated MS
patients produce significantly less of the pro-inflammatory
cytokines TNF-a (n = 8; P b 0.02) and LT (P b 0.05), but
significantly more of the anti-inflammatory cytokine IL-10 (P b
0.05). We further observed that treatment was associated with a
decrease in the proportion of circulating memory B cells,
suggesting that the apparent reciprocal regulation of B cell
cytokines mediated by mitoxantrone, related to differential effects
on distinct B cell subsets. This guided further studies of the
fundamental B cell cytokine network and enabled us to ascribe
unique effector cytokine profiles to normal memory and naive
human B cell subsets.
Summary: We ascribe active roles for memory and naive
human B cell subsets in appropriately promoting or suppressinglocal immune responses in the normal state through production of
distinct effector cytokines. We further suggest that dysregulation of
this B cell cytokine network occurs in some patients with the
human autoimmune disease multiple sclerosis, and that this
network represents a potential therapeutic target.
Su1.66. Class Switch Recombination in
B-Lymphopoiesis Is a Novel Pathway for Development
of Autoimmune B Cells.
Doron Melamed.1 1Immunology, Technion, Faculty of Medicine,
Haifa, Israel.
Activation of autoreactive B cells is pivotal for the initiation
and propagation of many autoimmune diseases. It is generally
thought that this activation reflects a breakdown in peripheral
tolerance, although the nature of the development of these cells is
not completely understood. Many studies in B lymphopoiesis have
shown that IgM receptors drive development and construction of
naive B cell repertoire, whereas IgG receptors promote formation
of the memory B cell compartment. This isotypic change results
from a gene rearrangement process called class switch recombi-
nation (CSR), and is thought to occur in mature peripheral B cells
upon activation and providing of appropriate T cell help. In the
absence of T cell help, activated B cells undergo Fas-mediated
apoptosis, a process thought as a peripheral mechanism for self-
tolerance. We have recently shown that CSR spontaneously occur
during normal B lymphopoiesis in vivo and in vitro, and that these
cells acquire a memory phenotype. We found that CSR in B
lymphopoiesis is T cell-independent, but further expansion of the
cells is regulated by T cells. To further study these cells we have
used the Igm-deficient mouse model (mMT), where B cell
development is limited by the ability of the cells to undergo
CSR. We found that isotype switched B cell precursors can mature
to the periphery and differentiate to antibody-producing plasma
cells. These B cells generate a gH-driven repertoire that is oligo-
monoclonal and bearing self-tissue reactivity. Further studies
revealed that isotype-switched B cell precursors are negatively
selected by Fas signaling, as blocking the Fas/FasL interaction
rescues the development of isotype-switched B cells in vivo and in
vitro. Our studies propose a novel developmental pathway driven
by gH-isotypic receptor that effectively circumvents peripheral
tolerance requirements. This pathway, however, is strictly con-
trolled by the Fas signaling to prevent B cell autoimmunity.
Su1.67. The Role of VCAM-1 in Self-Reactive T Cell
Fate.
Jonathan A. Abbas,1 Pandelakis A. Koni.1 1Program in Molecular
Immunology, Institute of Molecular Medicine and Genetics,
Medical College of Georgia, Augusta, GA, USA.
Vascular Cell Adhesion Molecule 1 (VCAM-1) plays a role in
leukocyte migration and adhesion, and is found on a variety of cells
including endothelial cells, thymic epithelium, and dendritic cells.
VCAM-1 binds to its principal ligand, Very Late Antigen-4 (VLA-
4) found on B cells and T cells. Disruption of VCAM-1/VLA-4
signaling is associated with prolonged allograft acceptance and
impaired T cell responses. Therefore a role has been established for
VCAM-1 as a positive factor for T cell activation and proliferation.
It is our hypothesis that in the absence of VCAM-1 expression on
dendritic cells, antigen specific, self-reactive CD4+ T cells will fail
to proliferate as effectively as when VCAM-1 is present. It is also
hypothesized that some self-reactive T cells activated in the
absence of VCAM-1 will survive and acquire a regulatory T cell
Abstracts S211phenotype. To test this hypothesis we will use 3A9 antigen
specific T cells that recognize Hen Egg Lysozyme (HEL) protein
presented as peptide by antigen presenting cells. Transgenic mice
expressing membrane-bound or soluble HEL have been crossed
onto conditional VCAM-1 knockout mice lacking functional
expression of VCAM-1 on all subsets of splenic dendritic cells.
By adoptive transfer of labeled 3A9 T cells into either HEL or
VCAM-/- HEL recipient mice, the fate of these antigen specific T
cells can be followed over time.
Su1.68. The Autoimmune Response to Modified Human
Low-Density Lipoprotein.
G. Virella,1 M. B. Derrick,1 C. Chassereau,1 S. R. Thorpe,3 M. F.
Lopes-Virella.1,2 1Depts. of Microbiology & Immunology and
Medicine, Medical University of South Carolina, Charleston, SC;
2Ralph H. Johnson VAMC, Charleston, Charleston, SC;
3Department of Chemistry and Biochemistry, University of South
Carolina, Columbia, SC.
Human LDL modified in vitro has been used to develop
antibodies that allow the detection of spontaneously modified LDL
in circulation. Most modified lipoproteins circulate as antigen-
antibody complexes (immune complexes, IC) that can be charac-
terized after precipitation with 4% PEG. Chemical and immuno-
logical analysis of IgG and LDL isolated from IC demonstrated that
the human immune system recognizes malondialdehyde lysine,
carboxymethyl lysine and other yet uncharacterized epitopes. The
IgG fraction isolated from precipitated IC contains antibodies
reactive with copper-oxidized LDL (oxLDL) and AGE-modified
LDL (AGE-LDL) predominantly of the pro-inflammatory sub-
classes 1 and 3. Comparison of the IgG subclass and dissociation
constants of antibodies contained in precipitated IC and remaining
in the supernatant after PEG precipitation showed that antibodies
included in IC have statistically significant higher avidity and
relatively higher IgG1 concentrations. Affinity chromatography
isolation of circulating antibodies to oxLDL and AGE LDL showed
that IgG antibodies predominated over IgM antibodies, and that IgG
subclasses 1 and 3 predominated over subclasses 2 and 4, for both
antigens. Because IgG1 and IgG3 antibodies can activate comple-
ment and deliver activating signals to phagocytic cells as a
consequence of their interaction with Fcg receptors, the pathogenic
potential of modified LDL-IC is unquestionable. Furthermore,
clinical studies carried out in patients with type 1 diabetes have
clearly demonstrated that high levels of modified LDL-IC predict
cardiovascular events. Our observations have also additional
clinical implications. On one hand, we have demonstrated that the
assay of modified LDL and corresponding antibodies in serum is
extremely inaccurate, due to the interference of IC. On the other
hand, our studies suggest that measurements of modified LDL in
IC, rather than serum, are required for the evaluation of the
pathogenic potential of modified LDL. In conclusion, the auto-
immune response triggered by spontaneously modified LDL seems
to be a significant factor in the pathogenesis of atherosclerosis.
Su1.69. Studies on Signal Transduction Pathways
Downstream of CD28/IL-2 That Regulate the E3 Ligase,
GRAIL.
L. X. Wu,1 L. Soares,1 C. G. Fathman.1 1Department of Medicine,
Division of Immunology and Rheumatology, Stanford University,
Stanford, CA, USA.
Anergy can be induced in CD4+ T cell clones by a strong TCR
signal in the absence of costimulatory signals. CD28/B7 costimu-lation has been shown to play a critical role in preventing anergy
induction. Two models have been proposed to explain these
results: one predicts that CD28 costimulation has a direct inhibitory
effort on factors involved in anergy induction. The other suggests
that CD28 costimulation results in the production of growth
factors, such as IL-2, which in turn prevents anergy.
We have identified GRAIL (gene related to anergy in
lymphocytes) using differential display. GRAIL contains a highly
conserved zinc binding ring domain and exhibits E3 ligase activity
in vitro. Our studies have shown that constitutive expression of
GRAIL, but not the enzymatically inactive form, H2N2 GRAIL, is
sufficient to induce anergy in naRve CD4+ T cells, suggesting that
GRAIL is an anergy factor. Furthermore, we have shown that
pharmacological inhibition of downstream targets of CD28 signal-
ing such as PI3K and mTOR, as well as blocking IL-2 signaling
using an antagonist antibody, all result in a significant increase in
GRAIL expression, indicating that GRAIL is regulated by CD28.
Our results suggest that GRAIL functions to maintain anergy in T
cells through the ubiquitination pathway to degrade essential
signaling molecules that are involved in T cell immunity. Our
studies also shed light on the signal transduction pathways
downstream of CD28/IL-2 that are involved in GRAIL expression,
thereby elucidating the basis of costimulation blockade. A better
mechanistic understanding of GRAIL and its regulation by
costimulatory molecules could lead to novel treatments for patients
suffering from autoimmune disease or from transplantation
complications.
Su1.70. Immune Monitoring the Effects of hOKT3;1
Ala-Ala in a Patient with New Onset Type 1 Diabetes
Mellitus.
W. H. Liu,1 G. Szot,1 K. E. Earle,1,2 K. C. Herold,3
U. Masharani,1,2 S. E. Gitelman,4 J. A. Bluestone.1,2 1Diabetes
Center, University of California at San Francisco, San Francisco,
CA; 2Department of Medicine, University of California at San
Francisco, San Francisco, CA; 3Department of Medicine, Division
of Endocrinology, and the Naomi Berrie Diabetes, Columbia
University, New York, NY; 4Department of Pediatrics, University of
California at San Francisco, San Francisco, CA.
Background: Type1 diabetes (TID) is an autoimmune disease
caused by the pathogenic action of T lymphocytes which destroy
insulin producing beta cells. An effective immunomodulatory anti-
CD3 antibody, hOKT3g1(Ala-Ala), used to treat new onset TIDM
had direct effects on pathogenic T cells and induced regulatory
cells. Methods: In a Phase II trial sponsored by the Immune
Tolerance Network, we studied the effects of the hOKT3g1(Ala-
Ala) on immune responses in patients with new onset TID. Six
patients were treated with hOKT3g1(Ala-Ala) I.V. daily for 12
days. Immunophenotyping; T cell proliferation by CFSE-based
flow cytometry; and cytokine secretion were performed. Results:
Transient depletion of T cells in patients followed by recovery of
the cells after the 12 day antibody course was observed in all but
one patient who demonstrated a prolonged reduction in the number
of circulating CD4+ T cells. Nine months after therapy, the
patientTs CD4 count was 102106/mL and did not return to normal
levels till 29 months post therapy (512  106/ml). In contrast, the
CD8+ T cell count recovered rapidly and reached 86% of baseline
by 30 days. No obvious difference in either coating or modulation
of CD3 on T cells was observed on the CD4+ T cells as compared
to the other treated individuals. Trough levels of drug were higher
but not exceptionally different than observed in the majority of
AbstractsS212treated individuals. However, there was selective recovery of
CD45RO cells and CD4+CD62L+CD25hi Treg population
increased during the treatment. In spite of the reduced CD4+ T
cell count, the T cells functioned normally on a per cell basis as
demonstrated by CFSE proliferation and IL-2 secretion. Clinically,
the patient had an uneventful clinical course with only a transient
viral syndrome shortly after treatment, with all cultures and
serological studies negative. The patient was maintained on anti-
microbial prophylaxis until her CD4+ count recovered. The
patientTs c-peptide levels remain high at 2 years (77% of baseline)
while maintaining a normal Hemoglobin A1c at 18 months
comparable to that noted in other responders. Discussion: In the
present clinical study of hOKT3g1 (Ala-Ala) one patient experi-
enced a prolonged decrease in CD4+ T cells. The therapy did not
lead to impaired CD4 function ex vivo, or to opportunistic
infections. The unremarkable clinical course may relate to lack
of depletion centrally, and/or failure to cause more generalized
immunosuppression. Since the higher circulating levels did not
result in a better clinical response, the data support dosing at the
previous lower phase I/II levels helping define the window for
safety and efficacy with this agent. [AuthorTs note: one of the
authors of this study holds the patent on the antibody under
investigation.]
Su1.71. Essential Role of the Co-Receptor CD72 in B
Cell Peripheral Tolerance.
Daniel H. Li,1 Albert Chen,1 James Tung,2 Paulo Fontoura,3
Larry Steinman,3 Jane R. Parnes.1 1Department of Medicine,
Stanford University, Stanford, CA, USA; 2Department of Genetics,
Stanford University, Stanford, CA, USA; 3Department of
Neurology & Neurological Sciences, Stanford University, Stanford,
CA, USA.
CD72, a type II transmembrane protein expressed predom-
inantly on B cells, acts as a negative regulator of B cell activation
through the B-cell receptor (BCR). However, whether CD72 plays
a role in autoimmunity is unknown. We found that aged CD72-
deficient mice develop lupus-like autoimmune features such as
anti-nuclear Ab, anti-DNA Ab, and glomerulonephritis. To study
the mechanism of this spontaneous autoimmune disease, we
employed a transgenic mouse model of autoimmunity to elucidate
how CD72-deficient B cells break down tolerance in vitro. B cells
from double-transgenic (dTg) mice expressing an anti-HEL (hen
egg lysozyme)-specific BCR and soluble HEL in the circulation
are anergic (unresponsive) to HEL antigen (Ag) stimulation. We
found that B cells from CD72 HEL dTg mice are hyperprolifer-
ative in response to HEL Ag stimulation, as compared to the
anergic response of B cells from wild-type (WT) HEL dTg mice.
To further understand the signal transduction pathways employed
by CD72, the downstream signaling events such as NF-kB, NF-AT,
ERK, p38, and JNK pathways were examined. The results show
that B cells from CD72 HEL dTg mice have (1) greater NF-kB p65
DNA binding activity, (2) greater NF-ATc1 activation, (3) greater
ERK activity, (4) greater JNK activity, and (5) greater p38 activity,
as compared to those of B cells from WT HEL dTg mice. We next
examined the early events of signaling. We found that the calcium
flux in response to HEL Ag stimulation is greatly enhanced in
CD72 HEL dTg B cell when compared to the WT HEL dTg B
cells. To identify the targets of CD72 signaling immediately
following stimulation, we examined the phosphorylation status of
many early signaling molecules such as Lyn, Syk, Ig-a/b, PLCg-
2, Blnk, Vav, and Cbl etc. Our results show that Cbl-b is a directtarget of CD72 signaling. To determine whether these effects of
CD72 on B cell tolerance have clinical relevance to the
development of autoimmune disease, we induced EAE (exper-
imental autoimmune encephalomyelitis) in both WT and
CD72KO mice. We found that MOG (35-55) peptide induced
an earlier onset and more severe EAE in CD72KO mice as
compared to WT mice. Taken together, these findings indicate
that CD72 plays an essential role in modulating B cell peripheral
tolerance.
Su1.72. Identification of the Target Self-Antigens in
Ischemia/Reperfusion Injury.
M. Zhang,1 E. M. Alicot,5 I. Chiu,1 N. Verna,2 T. Vorup-Jensen,1
B. Kessler,3 M. Shimaoka,1 R. Chan,2 D. Friend,2 L. H. Michael,4
M. L. Entman,4 F. D. Moore,2 M. C. Carroll.1 1CBR Institute of
Biomedical Research, Harvard Medical School, Boston, MA, USA;
2Surgery-Brigham & WomenTs Hospital, Harvard Medical School,
Boston, MA, USA; 3Pathology, Harvard Medical School, Boston,
MA, USA; 4DeBakey Heart Center and Department of Medicine,
Baylor College of Medicine and the Methodist Hospital, Houston,
MA, USA; 5DecImmune Therapeutics, Boston, MA, USA.
Ischemia/reperfusion injury (I/R), a potential life-threatening
disorder, represents an acute inflammatory response following
periods of ischemia resulting from myocardial infarction, stroke,
surgery or trauma. The recent identification of a monoclonal natural
IgM that initiates I/R led to the identification of conserved self-
antigens as the target. Utilizing proteomics and phage-display-
peptide library, we have identified the antigenic epitope of I/R
specific antigen and developed peptide inhibitors for injury in three
different models (intestine, skeletal muscle, and heart). These results
identify a novel pathway in which the innate response to a highly
conserved self-antigen results in tissue destruction through a
generalized autoimmune mechanism.
Su1.73. Shared Epitopes among HLA Class II Molecules
in Common Autoimmune Diseases.
Elissaveta J. Naumova,1 Milena I. Ivanova,1 Snejina M.
Mihaylova,1 Antoaneta P. Nedialkova,1 Anastassia P. Mihaylova.1
1Central Laboratory for Clinical Immunology, University Hospital
Alexandrovska, Sofia, Bulgaria.
Our previous studies revealed common HLA class II haplotypes
that confer predisposition or protection to IDDM, MS, JCA,
pemphigus vulgaris (PV) and SLE in the Bulgarian population. In
order to evaluate further the role of HLA antigens in those
autoimmune diseases we looked for common sequence motifs in
the hipervariable regions of molecules encoded by protective and
predisposing DRB1 and DQB1 alleles. We found that the b-chains
coded by the common predisposing DRB1*0301, 0401, 0402, 0404
alleles have similarities in HVRIII: a motif 57D58A in pocket 9 and
an electric charge of pocket 4, generated by residues 70-74. Similar
characteristics are observed for molecules coded by other predis-
posing DRB1 alleles in our population: 1401 and 1404 (PV); 1501
and 1001 (MS); 0701 (SLE). The protective allele DRB1*1104
codes a molecule with a neutral charge of pocket 4 and absence of
57D58A in pocket 9. Predisposing DQB1*0302 and 02 alleles
encode a common motif 13G, 26L, 57A. Part of this motif (13G,
26L) is shared by other predisposing for our population alleles:
DQB1*0602 (MS), 0604 and 0303 (SLE). The b-chain, encoded by
the common protective DQB1*0301 is characterized by different,
hydrophobic amino acids-13A, 26Y, and has D at position 57 si-
milarly to DQB1*0503-another protective for IDDM allele in Bul-
Abstracts S213garians. In conclusion, based on these results we suggest that more
than one amino acid regions in b-chains of DR and DQ molecules,
predicted to be involved in processed antigen binding and helical
regions, are important for disease predisposition and protection.
Su1.74. In Vivo Blockade of Human IL-2 Receptor
(IL-2R) Induces Expansion of CD56bright Regulatory NK
Cells in Patients with Active Uveitis.
Zhuqing Li,1 Wee Kiak Lim,1,2 Sankaranarayana P. Mahesh,1
Robert B. Nussenblatt.1 1Laboratory of Immunology, National Eye
Institute, NIH, Bethesda, MD, USA; 2Singapore National Eye
Center, Singapore, Singapore.
In vivo blockade of the human IL-2 receptor (IL-2R) by
antibody has been used for immunosuppression in transplantation,
therapy for leukemia and autoimmune diseases. In this study, we
report that administration of a humanized IL-2R blocking antibody
induced a 4- to 20-fold expansion of CD56bright regulatory NK cells
in uveitis patients over time. The induced CD56bright regulatory NK
cells from the treated patients exhibited the same phenotype as those
from normal donors except that they had a lower level expression of
CD161. In addition, patients with active uveitis had a significantly
lower level of CD56bright regulatory NK cells in the periphery as
compared to normal donors (P b 0.01). The induction of the
CD56bright regulatory NK subset occurred prior to the onset of a
clinically therapeutic effect. Our observation may have implications
for the potential role of CD56bright regulatory NK cells in
autoimmune diseases and to IL-2R blockade therapy.
Su1.75. Premature Senescence of the Immune System in
Rheumatoid Arthritis and Multiple Sclerosis Patients.
M. M. Thewissen, L. Linsen, P. Geusens, J. Raus, P. Stinissen.
1Biomedisch Onderzoeksinstituut (BIOMED), Limburgs
Universitair Centrum (LUC)/Transnational University Limburg
(tUL), Diepenbeek, Belgium.
The decline in immunocompetence with age is accompanied by
a steadily increasing incidence of autoimmune diseases. A reduced
thymic output, which is an important aspect of immunosenescence,
will induce compensatory auto-proliferation. This process can lead
to a premature senescence of T cells and contribute to the immune
abnormalities associated with autoimmunity and aging. In this
study we tested whether the immune system of patients with
rheumatoid arthritis (RA), multiple sclerosis (MS) and ankylosing
spondylitis (AS) shows signs of an age-independent aging.
Therefore, we measured two indicators of aging, the number of
T cell receptor excision circles (TRECs) and the percentage of
CD4+CD28null T cells, in peripheral blood mononuclear cells
(PBMC). In addition, characteristics of senescent CD4+CD28null T
cells were analyzed. PBMC were isolated from blood of 60 RA, 30
MS and 20 AS patients as well as 40 healthy controls (HC). The
percentage of CD4+CD28null T cells was measured by flow
cytometry. The number of TRECs in 100 ng of gDNA was
determined by real-time PCR analysis. Intracellular FACS analysis
and CDR3 fragment length analysis were used to determine the
cytokine profile and the clonal origin of the CD4+CD28null T cells,
respectively. In RA and MS patients, TREC numbers were
significantly decreased compared to age-matched HC. TREC
numbers were comparable between AS patients and HC. Fur-
thermore, an increased percentage of CD4+CD28null T cells was
detected in 40% of RA patients, 32% of MS patients and 12% of
AS patients versus 10% of HC. In HC and RA patients, the
presence of the HLA-DR4 haplotype, a genetic risk factor fordeveloping RA, was found to be linked with the percentage of
CD4+CD28null T cells. CD4+CD28null T cells were also detected in
the synovial tissue of RA patients. Analysis of the CD4+CD28null
T cells revealed clonal expansions and pro-inflammatory proper-
ties. This study provides indications for a premature senescence of
the immune system in both RA and MS patients. Premature aging,
associated thymic involution and compensatory auto-proliferation
might play an important role in the pathogenesis of autoimmunity.
CD4+CD28null T cells have tissue damaging properties, are
prematurely increased in both RA and MS patients and might
therefore play an active role in the pathogenesis of these
autoimmune diseases. Further study will be necessary to reveal
the exact role of an aged immune system and more particular the
role of CD4+CD28null T cells in the pathogenesis of autoimmunity.
Su1.76. Histamine Release and Autoantbodies in
Chronic Idiopathic Urticaria and Cough.
Francesca Gibellino,1 Stefania Stella,2 Michele Massimino,2
Manuela Di Stefano,3 Anna M. Longo,1 Costantino Sipione,4
Angelo Messina.1 1Respiratory Pathophisiology Service,
Cannizzaro Hospital, Catania, Italy; 2Biomedical Sciences,
University of Catania, Catania, Italy; 3Endoscopic Service,
Cannizzaro Hospital, Catania, Italy; 4Endocrinology and Diabetes
Unit, Cannizzaro Hospital, Catania, Italy.
It has been shown the presence of autoantibodies in patients
with thyroid immunity disease and IgG, IgA and IgE antibodies in
patients with Helicobacter pylori infection.
Chronic bidiopathicQ urticaria and cough are present in
almost 50% of patients with either diseases. In a subset of chronic
b idiopathicQ urticaria patients, the disease is caused by the presence
of IgG autoantibodies against the high affinity IgE receptor FcqRIa
and anti-IgE autoantibodies. These functional autoantibodies
stimulate normal activation of mast cells and basophils via FcqRIa
causing whealing, angioedema and cough.
The aim of the study is:
to evaluate in patients with chronic idiopathic urticaria and/or
cough:
the presence of Helicobacter pylori antibodies and/or thyroid
autoimmunity the histamine release and the prevalence of IgG
autoantibodies against FceRIa and anti-IgE autoantibodies in
patients positive for thyroid autoimmunity or Helicobacter pylori
infection before and after levothyroxine sodium or HP eradication
therapy
Methods
All patients had chronic urticaria and /or cough, for all of them
the following investigations were performed:
skin prick test for aeroallergens and food allergens, blood test
for antithyroid antibodies (AAT, ATPO), FT3, FT4, TSH.,
Helicobacter pylori antibodies (IgG, IgA), total IgE, autologous
serum skin test (ASPT) in patients with positive anthithyroid and
HP antibodies, histamine- release activity, serum IgG anti-Fca RI e
and anti-IgE in all patientsT sera
Results
Our preliminary data show:
100% of patients were with normal thyrotropin levels
100% of patients with thyroid autoimmunity had cough and
33% of them also had urticaria
100% of patients with HP positive had only urticaria and 41%
of them also had cough
85% of the patients had ASPT and antibodies positive, 80% had
ASPT and histamine release positive
AbstractsS21470 to 100 % remission rate (either partial or complete) of
urticaria and cough in patients treated with levothyroxine.
All patients treated with HP eradication therapy had negative
breath test after treatment; 80% of them had remission of urticaria.
85% of the patients had ASPT and antibodies positive, 80% had
ASPT and histamine release positive
Conclusions
These results suggest that histamine releasing autoantidodies
are important in the pathogenesis of chronic urticaria and cough
by stimulating or facilitating degranulation of basophils and
coutaneous mast cells through cross-linking cell surface IgE
receptors.
Su1.77. A Polymorphism of the Inhibitory Receptor,
Fc;RIIb, Prevents Its Access to Lipid Rafts and Alters
Macrophage Responses to Immune Complexes and
Opsonized Bacteria.
R. A. Floto,1 M. R. Clatworthy,1 P. A. McAry,1 E. U. Walker,1 K. R.
Heilbronn,1 A. Rankin,2 J. M. Allen,3 N. A. Watkins,2 K. G. C.
Smith.1 1Cambridge Institute for Medical Research and
Department of Medicine, University of Cambridge School of
Clinical Medicine, Cambridge, Cambs, United Kingdom;
2Division of Transfusion Medicine, University of Cambridge
School of Clinical Medicine, Cambridge, Cambs, United
Kingdom; 3Discovery Biology, Inpharmatica, London,
United Kingdom.
Receptors for the constant region of IgG (FcgRs) link the
humoral and cellular arms of the immune system. Their dysregu-
lation has been implicated in the development of autoimmune
conditions particularly systemic lupus erythematosus (SLE). A
polymorphism at position 232 in the transmembrane domain of the
inhibitory receptor, FcgRIIb, results in an isoleucine to threonine
substitution is prevalent in SLE patients. Using the FcgRIIb-
negative monocytic cell line, U937, we assessed the consequences
of expression of either wild type (wt) or mutant (232T) FcgRIIb on
activatory Fcg receptor function. Expression of wt but not 232T
prevents lysosomal trafficking of immune complexes and super-
oxide generation, inhibits phagocytosis of opsonised pneumococci
and reduces pro-inflammatory cytokine release. The 232T receptor
is unable to partition into lipid rafts, excluding it from the pro-
inflammatory signalling complex. Primary macrophages from
232T homozygotes show similar defects in FcgR control,
correctable by lentiviral introduction of wt FcgRIIb. Thus, this
receptor polymorphism radically alters the cellular response to
opsonised particles and may predispose to the development of
SLE. This mutation is the first described which could contribute to
disease by excluding a surface receptor from lipid rafts, potentially
representing a novel mechanism underlying human genetic disease.
Su1.78. On the Role of Th1 Cytokines (gIFN, IL18) and
Growth Factor TGFb1 in Autoimmune Thyroid Disease.
Roman Khanferyan,1 Ljudmila Ravovaya.1 1Clinical Immunology
and Allergy, Kuban State Medical Academy, Krasnodar, Russian
Federation.
INTRODUCTION
In a number of previous investigations it has been demonstrated
the crucial role of different immune cells and subsets in the
pathogenesis of autoimmune thyroid disease (AITD). The role of
different T cell cytokines and the growth factors is now appreciated
in development and progression of AITD (Hunt et al, 2000;
Paschke et al., 1994;Ajjan et al., 1997; Hrda et al., 2003 etc.).THE AIM OF INVESTIGATION
The aim of the investigation was the study and compare of in
vitro synthesis and serum concentrations of gIFN, IL18 and TGFb1
in patients with AITG.
THE MATERIALS AND METHODS
25 patients with AITD were studied. The control group
consisted of 12 healthy volunteers with similar to the investigated
patients in sex and age. The serum concentrations of gIFN, IL18
and TGFb1 and MNC supernatant levels (24–48 h culture) of
cytokines were determined using ELISA method.
RESULTS
An increase in the serum concentrations of both cytokines
(gIFN, IL18) and growth factor TGFb1 were noted in the studied
group when compared to the control group. The increase in serum
concentrations of gIFN, IL18 accompanied by their increased
synthesis by peripheral MNC more than 2.5–3.2 times in
comparison to control data. The average serum concentration of
TGFb1 in AITD was 274 pg/ml and in control group-47.4 pg/ml
(P = 0,02). The serum concentrations of gIFN and IL18 were from
3.8 to 4.5 times higher than in control group.
CONCLUSION
The increase of the serum concentrations of gIFN, IL18 and
TGFb1 and increased synthesis by peripheral MNC of gIFN and
IL18 suggest that Th1 cytokines as well as growth factor TGFb1
plays an important role in AITD.
Su1.79. Autoimmunity: Common Origin for Diverse
Diseases.
G. J. Tobon,1,2 P. Vega,1,2 R. Pineda-Tamayo,1,2 J. M. Anaya.1,2
1Rheumatology, Clinica Universitaria Bolivariana, Medellin,
Colombia; 2Cellular Biology and Immunogenetics Unit,
Corporacion para Investigaciones Biologicas, Medellin,
Colombia.
Objective: The current study investigated the presence of
autoimmune diseases (AID) among first degree relatives (FDR) of
primary SjfgrenTs syndrome (pSS) and type 1 diabetes mellitus
(T1DM) patients. Materials and Methods: To this purpose, a
case-control study was undertaken in which individuals were
interviewed personally using a questionnaire that sought informa-
tion about demographic and medical characteristics including AID
family history. Results: In pSS, there were 101 women defined
according to the Revised European Criteria and 124 matched
controls without AID. We found that 38 (38%) families had at least
one FDR having an AID, while in controls there were 27 (22%)
(OR: 2.2, 95%CI = 1.2-3.9, P = 0.01). An AID was registered in 56
(6%) of 980 FDR of patients as compared with 33 (2%) of 1433
FDR in controls (OR: 2.6, 95%CI = 1.66-3.98, P b 0.0001). Sixty-
four AID were observed in the 56 FDR of patients, of whom five
had more than one AID. No FDR among controls had more than
one AID (OR: 2.96, 95%CI = 1.9 4.5, P b 0.0001). In patients
with T1DM, defined according to the Expert Committee Criteria,
there were 107 patients and 113 matched controls without AID. In
patients, there were 25 (26%) FDR with at least one AID while in
controls there were 9 (8%) with the same characteristics (OR: 3.96,
95%CI = 1.74-9, P = 0.0006). Among the T1DM patients, an AID
was registered for 26 (8.3%) of the 312 FDR as compared with 9
(2.4%) of the 362 FDR among controls (OR: 3.56, 95%CI = 1.64-
7.32, P = 0.0008). The most frequents AID registered in FDR of
pSS patients were autoimmune hypothyroidism and rheumatoid
arthritis, and in FDR of T1DM patients were autoimmune
hypothyroidism and T1DM. Conclusion: These results indicate
Abstracts S215that familial autoimmunity is a major trait in AID, thus sustaining
the common variants/multiple disease hypothesis which empha-
sizes that similar immunogenetic mechanisms underlie AID.
Su1.80. Selective Unresponsiveness of TNFR1/
Macrophages to IFN-; Stimulation Is Critical in
Resistance to Experimental Autoimmune Uveoretinitis.
C. J. Calder,1 A. D. Dick,2 L. B. Nicholson.1,2 1Pathology &
Microbiology, University of Bristol; 2Clinical Sciences, University
of Bristol, Bristol, United Kingdom.
In experimental autoimmune uveoretinitis (EAU), an animal
model of autoimmune inflammatory eye disease, activated
macrophages play a critical role in tissue destruction in the
retina, since depletion of macrophages reduces retinal damage
without concomitant reduction in numbers of other infiltrating
cells. Macrophage activation is modulated by signals received in
the local micro-environment from soluble cytokines such as IFN-
g and TNF-a, as well as signals received from cell surface
receptor interactions, for example of CD200 with CD200R. Using
NOS2 mediated production of nitrite (NO) as a measure of
activation in vitro and EAU to study the course of disease in
vivo, we have analysed the activation of wild type or TNFR1-
/-
macrophages.
As in the model of multiple sclerosis, experimental autoimmune
encephalomyelitis, TNFR1-
/- mice are resistant to the induction of
EAU. They have a lower incidence of disease and lower disease
scores. Priming of T cells is only modestly impaired, but by the
time the animals reach peak disease (day18–21), antigen specific
proliferation in the spleen is significantly reduced in the TNFR1-
/-
mice. To investigate this further macrophage function was assessed
in vitro by activation with various stimulators. In response to
stimulation with IFN-g, wild type mice produce substantial
amounts of NO. On the other hand TNFR1-
/- mice cannot be
stimulated to produce NO by IFN-g activation. To test whether this
was due to autocrine stimulation by low levels of TNF-a, we
stimulated wild type macrophages with IFN-g in the presence of
sTNFR-Ig fusion protein, which binds free TNF-a, and showed
that this also blocked NO production. In contrast with this impaired
activation of NO synthesis, MHC class II upregulation was
indistinguishable in wild type and TNFR1-
/- mice stimulated with
IFN-g. We then addressed whether TNFR1 signalling was essential
for NO production, by stimulating macrophages with LPS. Under
these conditions both wild type and TNFR1-
/- mice produced
equivalent amounts of NO.
Together these results show that selected aspects of IFN-g
mediated activation of macrophages are controlled by autocrine
secretion of TNF-a, but that this control is bypassed in the
presence of signals generated by pathogen-associated molecular
pattern recognising receptors. Macrophage activation in a pro-
inflammatory milieu may therefore be modified by the presence of
pathogen derived signals, and may be different in autoimmune
disease where inflammation occurs in the absence of foreign
immune system activators. This implies that in this model,
activation sufficient for priming occurs in the presence of
mycobacterial derived products in draining lymph nodes, but not
when macrophages are exposed to IFN-g alone in the retina.
Su1.81. Suppressor Potency among Regulatory T Cells
Is Discriminated by Functionally Active CD44.
M. Firan,1 P. Estess,1 M. Siegelman.1 1Pathology, University of
Texas Southwestern Medical Center, Dallas, TX, USA.CD4CD25+ regulatory T cells (Tregs), are fundamental to the
maintenance of peripheral tolerance and have great therapeutic
potential. However, efforts have been hampered by limiting cell
numbers in vivo, an anergic phenotype in vitro, and only a
rudimentary understanding of the molecular basis for the functional
state of CD4CD25+ Tregs. We have previously shown that T cell
activation through the TCR results in the activation of CD44 to
bind its ligand hyaluronan (HA), and that the CD44/HA interaction
is used for T cell extravasation at sites of chronic inflammation.
Here we show that CD4CD25+ cells more rapidly and extensively
activate the functionally active, hyaluronan-binding form of CD44
(CD44act) after TCR triggering, with ~85% of cells expressing this
marker compared to ~25% of CD4+CD25- cells after 40 hrs of
activation. Moreover, CD44act expression is strikingly correlated
with suppressor activity in CD4CD25+ T cells, in contrast to other
surface markers or Foxp3 expression. Within 16 hr after in vitro
activation, CD44act can discriminate enhanced suppressive func-
tion in in vitro proliferation assays and in vivo models. After
separation of CD4CD25+ Treg into HA-binding and non-HA-
binding fractions, multiple cytokines, including IL-4, IL-10, and
TGF are preferentially expressed by the HA-binding cells. These
cells also show the preponderance of suppressive function in vitro
and in two in vivo models of allogeneic GVHD. CD44act is
induced on resting CD4CD25+ cells in vivo with antigenic
stimulation, with similar functional consequences. These results
reveal a cell surface marker that delineates functional activity
among CD4CD25+ regulatory T cells, thereby providing a novel
tool to aid in identifying regulatory activity and enriching for
maximal suppressor potency.
Su1.82. Characterization of Immune Response in
B-Tubulin Induced Murine Autoimmune Hearing Loss.
B. Zhou, J. Glickstein, J. Lee, M. H. Kermany, T. J. Yoo.
1Department of Medicine, University of Tennessee, Memphis,
TN, USA.
The main feature of autoimmune disease such as autoimmune
inner ear disease including MeniereTs disease is the development
and persistence of inflammatory processes in the apparent absence
of pathogens, leading to destruction of the target tissues. Western
blot analysis has shown that 59% of MeniereTs disease patients
produce antibodies to a 55 kD inner ear membranous and neural
protein identified to be h-tubulin. Hearing loss in mice can be
induced by immunization with h-tubulin using ABR and DPOAE
recorder and spiral ganglion as well as hair cells damages can be
observed by morphological study of temporal bones. But the precise
immunological mechanism of inner ear disease remains obscure.
In the current study, balb/C mice were subcutaneously injected
with h-tubulin in dosage of 100, 200 and 300 Ag with CFA per
mouse, immunizations were boosted in IFA with varying doses of
tubulin twice at one-week intervals. Control mice underwent
subcutaneous injection of PBS and CFA/IFA as well. After 2 weeks
of last boosting, we have found that the antibodies activity to h-
tubulin increased in dose dependent compared with controls, all
control subjects were relatively unresponsive. Moreover, IFN-
gamma level was markedly increased in both serum and super-
natant of lymphocytes, protein levels of TGF-h, IL-4, IL-5 IL-10
and IL-13 were significantly reduced following h-tubulin immu-
nization. Interestingly, flow cytometric analysis of spleen cells
from h-tubulin induced mice and control mice have been showed
that 2.72% of total splenocytes in control mice were CD25+CD4+
regulatory T cells (Treg cells), the population of Treg cells was
AbstractsS216reduced in h-tubulin induced mice and followed dose dependent
(such as 1.68% in 300Ag, 2.16% in 200 Ag and 2.19% in 100 Ag),
the Treg cells in naRve mice is 2.6%. Moreover, IFN-gamma and
IL-2 level was markedly increased in supernatant of Treg cells
culture, protein levels of TGF-h, IL-4, IL-5, IL-10, IL-12p40
and IL-13 were significantly reduced following h-tubulin
immunization.
Thus, these data indicate an immune reactivity against h-
tubulin, which might be responsible for the autoimmune inner ear
hearing loss. The further study is required to elucidate the role of
CD25+CD4+ T cells in the pathogenesis of this disease, which
would eventually result in better therapy.
Su1.83. Endogenous Expression of IRBP Is Dispensable
for Generation of CD4+CD25+ Regulatory T Cells That
Protect Against IRBP-Induced Retinal Autoimmunity.
R. S. Grajewski,1 P. B. Silver,1 R. K. Agarwal,1 S. B. Su,1 C. C.
Chan,1 G. I. Liou,2 R. R. Caspi.1 1Laboratory of Immunology,
NEI, NIH, Bethesda, MD, USA; 2Department of Ophthalmology,
Medical College of Georgia, Augusta, GA, USA; 3Bethesda, MD,
USA.
bNaturalQ CD4+CD25+ regulatory T cells (T-reg) develop in the
thymus, apparently as a result of interaction with their cognate
antigen. We previously showed that susceptibility to experimental
autoimmune uveitis (EAU), that is elicited in mice with the retinal
autoantigen IRBP and serves as a model for human uveitis, is
controlled by thymus-derived T-reg. In this study we examine
whether endogenous expression of IRBP is necessary to generate
EAU-relevant T-reg, by comparing IRBP knockout (KO) and wild
type (WT) mice. We hypothesized that, if endogenous IRBP is
needed to generate EAU-relevant T-regs, depletion of CD25+ cells
from IRBP KO mice will not alter their responses to IRBP. Mice
were depleted of CD25+ cells with the monoclonal antibody PC61.
To induce EAU, mice were immunized with IRBP in complete
FreundTs adjuvant (CFA), or were infused with T cells from IRBP-
immunized donors. Some mice were immunized with IRBP in
incomplete FreundTs adjuvant (IFA), a non-uveitogenic regimen.
EAU scores and associated immunological responses (delayed
hypersensitivity and proliferation to IRBP) were examined. When
immunized with IRBP/CFA, CD25 depleted WT and KO both had
enhanced immune responses to IRBP. Furthermore, IRBP primed T
cells of CD25 depleted KO donors elicited more severe disease in
WT recipients than did cells from non-depleted KO donors,
suggesting that an EAU-relevant T-reg had been removed.
However, when immunized with IRBP/IFA, only the depleted
WT, but not the depleted KO mice, had enhanced IRBP-specific
immune responses, suggesting that IRBP specific T-regs were
present only in WT. We conclude that, since endogenous
expression of IRBP appears to be needed to generate IRBP-
specific T-regs, the EAU-relevant T-regs in IRBP KO are not
IRBP-specific. We propose that these are T-regs activated by
microbial components present in CFA, that inhibit development of
IRBP-specific effector T cells in a bystander fashion. Thus, the
innate immune stimulation that is needed to elicit EAU also
activates regulatory T cells that help control the disease.
Su1.84. Prevention and Treatment of Experimental
Autoimmune Myocarditis with Altered Peptide Ligand
(APL).
D. Cihakova,1 M. Kimura,1 M. Talor,1 J. Barin,1 E. Talor,2 D.
Zimmerman,2 N. Rose.1 1Pathology, Johns Hopkins MedicalInstitutions, Baltimore, MD, USA; 2Research and Development,
CEL-SCI Corporation, Baltimore, MD, USA.
Background: Current treatment options for autoimmune
conditions are unable to specifically prevent or stop the auto-
immune process. Therefore, there is a need for new antigen specific
therapies for autoimmune diseases. We evaluated the efficiency of
a new APL technology referred to as Ligand Epitope Antigen
Presentation System (L.E.A.P.S.k) to prevent or treat experimen-
tal autoimmune myocarditis (EAM). J-My-1 is a conjugate of My-
1 peptide from the a chain of murine cardiac myosin, which is used
to induce EAM, and J peptide that is a part of the human h-2
microglobulin molecule.
Methods: To evaluate prophylactic or therapeutic vaccination,
6–8 weeks old female A/J mice were injected with J-My-1
emulsified in ISA-51 adjuvant on days-14 and-7 prior to EAM
induction and sacrificed on day 28 (prophylactic), or injected on
days 0, 7, 14, 21 following EAM induction and sacrificed on day
28 (therapeutic). EAM was induced by immunization with My-1,
emulsified in CFA on days 0 and 7 and injection of pertussis toxin
on day 0. Control groups were vaccinated with PBS emulsified in
ISA-51, using the same schedule. Experiments were repeated at
least twice with 8–10 mice per group. Myocarditis severity was
evaluated by histology and by the heart / body weight ratio. My-1
specific antibodies (total, IgG1 and IgG2a) were analyzed by
ELISA. Th1 and Th2 cytokines were evaluated by Linco-
Multiplex (for 22 cytokines) from sera as well as from heart and
spleen homogenates by ELISA. To evaluate whether the mecha-
nism of J-My-1 action was due to general anergy or specific
response towards My-1 peptide, we examined serum antibodies
against mycobacterial antigens (PPD) in the CFA by ELISA and
antigen (My-1) specific lympholiferation in vitro.
Results: J-My-1 administration reduced the incidence and
severity of EAM when given before or after the EAM induction. In
both cases, the J-My-1 treatment significantly lowered the heart/
body weight ratio (prophylactic, P = 0.047; therapeutic, P =
0.006), severity of myocarditis assessed by histology (prophylactic,
P = 0.0187; therapeutic, P = 0.002) and lower levels of anti-My-1
antibodies. The decreased immune response was antigen specific,
as J-My-1 had no effect on antibody responses to mycobacterial
antigens. Spleen lymphocytes from J-My-1 treated mice had
reduced proliferative responses to My-1. The severity of EAM
was not reduced with My-1 and ISA51 in contrast to J-My-1. J-
My-1 resulted in an increased level of IL-13 and decreased levels
of IFN-g in heart homogenate compared to controls.
Discussion and Conclusion: Using the L.E.A.P.S. altered
peptide ligand as a preventive vaccine as well as a treatment, we
were able to significantly reduce incidence and severity of
experimental autoimmune myocarditis. The protective effect of
the vaccine was antigen specific. As a result of such treatment, we
observed increased levels of IL-13 (which we found to be
protective) and levels of proinflammatory IL-1h in sera and IFN-
g in heart decreased. Supported by NIH grants 1R43HL71352-
01A1 and R01 HL67290.
Su1.85. T Cell Responses Induced by Myelin
Oligodendrocyte Glycoprotein Are Suppressed by
CD4+CD25+ FOXP3+ Regulatory T Cells from Thymus
and Cord Blood.
K. Wing,1 P. Larsson,1 K. Sandstrom,2 S. Lundin,3 E. Suri-Payer,4
A. Rudin.1 1Rheumatology and Inflammation Research,
Gothenburg University, Gothenburg, Sweden; 2Paediatric
Abstracts S217Anaesthesia and Intensive Care at, The Queen Silvia ChildrenTs
Hospital, Gothenburg, Sweden; 3Medical Microbiology and
Immunology, Gothenburg University, Gothenburg, Sweden;
4Division of Immunogenetics, German Cancer Research Center,
Heidelberg, Germany.
Activation of self-reactive T cells in healthy adults is prevented
by the presence of autoantigen-specific CD4+CD25+ regulatory T
cells (CD25+ Treg). To better understand where human autoan-
tigen-reactive CD25+ Treg are selected and expanded we inves-
tigated if thymic CD25+ Treg from children and CD25+ Treg from
cord blood are able to suppress proliferation and cytokine
production induced by specific antigens. CD4+CD25- and
CD4+CD25+ cell fractions where purified by magnetic cell
separation and proliferation and cytokine production where
analysed after stimulation with the neural antigen myelin oligo-
dendrocyte glycoprotein (MOG) and the polyconal stimuli staph-
ylococcal enterotoxin B (SEB). CD4+CD25- thymocytes
proliferated in response to MOG but the addition of an equal
number of thymic CD25+ T cells did not significantly suppress this
proliferation. However thymic CD25+ T cells inhibited IFN-g
production induced by MOG, which indicates the presence of
MOG-responsive CD25+ Treg in the thymus. In contrast, cord
blood CD25+ Treg suppressed both proliferation and IFN-g
production induced by MOG. Interestingly, thymic but not cord
blood CD25+ T cells suppressed proliferation and cytokine
production induced by SEB. Both cord blood and thymic CD25+
Treg expressed FOXP3 mRNA, but FOXP3 expression was lower
in cord blood than in thymic CD25+ T cells. This is probably due to
the presence of CD45RA- FOXP3 low cells in addition to
CD45RA+ FOXP3high cells in cord blood. In summary, suppres-
sion of immune responses to MOG where more easily detected in
cord blood than in thymus which, suggests that MOG-reactive
CD25+ Treg are further expanded in the periphery. However, cord
blood derived CD25+ T cells did not suppress SEB induced
responses and expressed lower levels of FOXP3, which indicates
that all CD25+ T cells in cord blood are not regulatory.
Su1.86. Pinocytosis by Human Dendritic Cells Targets
Exogenous Material Selectively to Intracellular
Cathepsin S.
Michael Reich,1 Stella Erfurth,2 Marianne Kraus,1 Herman
Overkleeft,3 Christoph Driessen.1 1Medicine II, University of
Tubingen, Germany; 2Microbiology, University of Tubingen,
Germany; 3Organic Chemistry, University of Leiden, Netherlands.
Antigen processing in the MHC II compartment of human
dendritic cells (DC) is poorly understood, however, strategies that
might interfere with the processing of e.g. autoantigens are
warranted. In particular, information about the nature and the
sequence of proteases, especially cathepsins (cat), attacking a
given exogenous antigen after uptake by live human DC is
lacking. Monitoring the uptake of bead-coupled chemical affinity
probes for cathepsin (cat) activity it has recently been demon-
strated that murine DC selectively route such probes to catS-
containing compartments. Using a similar approach, we have here
followed the uptake and cathepsin-binding of such affinity probes
by live human DC generated from monocytes in vitro. We found
that, in contrast to murine DC, human DC only very poorly
internalize exogenous material by phagozytosis, but are much
more efficient in fluid phase-endocytosis-mediated uptake of the
probe, compared to murine cells. While in cell lysates active catS,
catB, catH, catZ and catL were decorated by the probe, internal-ization of the probe by live human DC revealed only a selective
labelling of catS and catB, but no decoration of catH and catZ by
endocytosis. In a pulse chase analysis, the signal for active catS
selectively increased over a chase period of 60 min, indicating that
exogenously added material was selectively routed to catS-
containg compartments after fluid phase endocytosis in human
DC. Treatment of DC with chloroquine reduced cellular uptake
and cathepsin labelling, as expected, while the H+-ATPase-
inhibitor Concanamycin B selectively abrogated labelling of
CatB, most likely due to the pH-dependent activity of the enzyme.
Treatment of DC with LPS not only reduced the total amount of
catS reached by the probe due to decreased internalization, but
also abrogated the increase in catS labelling that was seen in
untreated DC without a maturation stimulus, while the total
amount of active catS remained unchanged. This suggested that
not only internalization, but also the intracellular transport to catS-
containing compartments is affected by DC maturation. In
summary, catS is liekly to present the functionally dominant
cysteine protease for antigen processing in the MHC class II
compartment of live human DC, because exogenous pan-cathepin-
reactive probes selectively bind to catS after internalization by
fluid-phase endocytosis.
Su1.87. Induction of CD4+CD25+ Treg Suppressive
Activity and IL-10 Production by IL-2.
Susan Brandenburg,1 Maurus De La Rosa,1 Gabriela Karsten,1
Heike Dorninger,1 Sascha Rutz,1 Alexander Scheffold.1
1Immunomodulation, German Rheumatism Research Center,
Berlin, Germany.
Objective of the study: CD4+CD25+ regulatory T cells (Treg)
suppress T cell activation in vitro and regulate multiple immune
reactions in vivo. IL-2 has been shown to be required for Treg
homeostasis. Here, we show that IL-2 is in addition an important
activator of Treg suppressive activity. Moreover, since Treg do not
produce IL-2 by themselves but depend on IL-2 produced by
activated T cells we also provide a new concept for the regulation
of Treg activity by there own target cells via IL-2.
Materials and methods: We used in vitro cultures systems of
purified T cell populations to analyse the specific effect of IL-2 on
Treg. In addition we studied the role of IL-2 for Treg activity in an
in vivo T cell transfer system.
Results: We and others have previously shown, that in vitro
blockade of the IL-2 receptor on Tregs during co-culture with
responder T cells completely blocks their suppressive activity. Here
we demonstrate, that the uptake of IL-2 during priming of Treg is
required to induce the capacity to produce IL-10 upon restim-
ulation. IL-4 which induces significant production of IL-10 in
naRve T cells is not sufficient to induce IL-10 production from Treg
but acts synergistically with IL-2. Furthermore, in vivo application
of IL-2 by gene-gun immunization in normal mice selectively
activates Treg and induces the complete suppression of prolifer-
ation of a transferred population of Ova-specific T cells in response
to vaccination with ovalbumin.
Conclusion: Our results show that IL-2 is a potent inducer of
Treg suppressive activity including the production of IL-10. The
regulation of Treg activity by IL-2 produced from their own
target cells allows to adapt Treg effector function to the strength
of an immune response. Furthermore, the specific activation of
Treg suppressive activity in vivo may represent a new strategy
for the therapeutic intervention in autoimmunity and chronic
inflammation.
AbstractsS218Su1.88. Comparison of Anti- DNA Antibodies for Their
Ability To Restore Mesenteric
Ischemia/Reperfusion-Induced Injury and Remote
Tissue Damage in Rag 1 Deficient Mice.
C. Moratz,1/4 S. Fleming,2 M. Monestier,3 G. Tsokos.1/4
1Department of Medicine, Uniformed Services University of the
Health Sciences, Bethesda, MD, USA; 2Department of Biology,
Kansas State University, Manhattan, KS, USA; 3Department of
Microbiology and Immunology, School of Medicine, Temple
University, Philadelphia, PA, USA; 4Department of Cellular
Injury, Walter Reed Army Institute of Research, Silver Spring,
MD, USA.
Natural antibodies as well as antibodies from an autoimmune
strain of mice (B6.MRL/lpr) have been shown to mediate
mesenteric ischemia/reperfusion (I/R)-induced tissue injury. Intes-
tinal injury is initiated when neoantigens reveled on ischemic or
apoptotic cells are bound by antibody and complement is activated.
In addition to the local (intestinal damage), remote tissue damage
in the lung occurs. In the autoimmune mice it has been reported
that injury in older (five month) animals is accelerated with
increased severity. Mice deficient in Rag1 or deficient in comple-
ment components, such as Cr2, are resistant to I/R-induced tissue
damage. Passive antibody transfer, of either purified natural
antibody or IgG serum from older B6.MRL/lpr mice, into Rag1
deficient mice restores I/R- induced tissue damage. These previous
studies indicate that auto-antibodies contribute to tissue damage
through complement activation after a tissue or organ suffers from
another damaging event such as ischemia. However it is not clear if
a particular neoantigen(s) is dominant in initiating the I/R-induced
tissue damage. Nor is the relationship between local (intestinal)
and remote (lung) tissue damage clear. Subsequently, we have
expanded upon the autoimmune studies to examine if auto-
antibodies with specificities for either dsDNA or ssDNA at varying
concentrations would cause equivalent local and remote I/R-
induced tissue damage. As expected, at high concentrations, the
passive transfer of all anti-DNA antibodies into Rag1 -/- mice
resulted in local intestinal and remote damage. However at lower
concentration the anti-dsDNA antibody was more efficient in
facilitating mesenteric I/R-induced tissue damage. When remote
lung damage was evaluated the transfer of the anti-dsDNA
antibody resulted in increase septal thicken and cellular infiltrate
in the lung compared to the transfer of anti-ssDNA antibodies or
from wild type control mice. Further studies addressing the
recruitment of cellular infiltrate, levels of complement deposition,
and the signals controlling polymorphonuclear neutrophil infiltra-
tion into intestinal or lung tissue are ongoing. These studies may
help clarify the role of circulating auto antibodies in organ damage
in patients and mice with systemic lupus erythematosis.
Su1.89. The Functional Role of CD48-Related Pathways
in Autoimmunity.
A. Tamir,1 C. Arancibia,2 M. Ali,1 A. Sharpe,2 Y. Latchman.1
1Department of Immunology, Puget Sound Blood Center and
Program, Seattle, WA, USA; 2Department of Pathology, Harvard
Medical School, Boston, MA, USA.
CD48 is a member of the CD2 superfamily of costimulatory
molecules and has an important role in regulating the immune
response. CD48 is broadly expressed on B cells, T cells, dendritic
cells, macrophages and NK cells, and may indicate that this
molecule participates in immune regulation via various cell types.
The importance of the interaction between CD48 and its receptors,CD2 and CD244 (2B4), in autoimmunity has not been clearly
addressed. Systemic lupus erythematosus (SLE) is a complex
autoimmune disease characterized by production of autoantibodies,
in particular anti-nuclear antibodies, B cell hyperactivity and
activation of self-reactive T cells. Genetic studies indicated that
three regions on different mouse chromosomes (SLE 1,2 and 3) are
linked with susceptibility to the SLE at different severities. A sub-
region of the SLE 1 locus on mouse chromosome 1 (SLE1b)
includes members of the CD2 superfamily The present study
investigated the role of CD48 in tolerance and autoimmunity by
studying the spontaneous autoimmune disease that occurs in aging
CD48-/- mice. Our data indicates that C57BL/6 CD48-/- mice have
elevated levels of dsDNA antibodies as detected by ELISA. In
CD48-/- mice, anti dsDNA IgG antibodies levels were higher than
IgM but levels of both were at least 2-fold higher in 6-month old
compared to 3-month old mice. Similarly, these antibodies could
be clearly detected in kidney tissue sections of CD48-/- mice but
not in WT mice. Phenotypic analysis of T cells in 6-month old
mice showed that levels of activation markers including CD62L,
but also CD69 and CD25 were increased at least 2-fold on CD4
and CD8 T cells of CD48-/- mice compared to their WT
counterparts. By T cell cloning, we have demonstrated the presence
of anti-nucleosomal T cell responses in CD48-/- mice. The
breakdown in tolerance is not a result of a defect in activation-
induced cell death therefore further studies are required in order to
delineate the mechanism underlining the regulatory effect of the
CD48 pathway. Overall, the present study presents evidence
suggesting that CD48 plays a key role in the control of
autoimmunity.
Su1.90. The Lifecycle of In Vitro Generated
CD4+CD25+FoxP3+ Human TR: Generation,
Expansion, and Persistence.
M. R. Walker,1,3 B. D. Carson,2,3 S. F. Ziegler,2,3 J. H. Buckner.1
1Diabetes, Benaroya Research Institute at Virginia Mason, Seattle,
WA, USA; 2Immunology, Benaroya Research Institute at Virginia
Mason, Seattle, WA, USA; 3Immunology, University of
Washington, Seattle, WA, USA.
A small population of CD4+ T cells present in both humans and
mice has the ability to regulate immune responses. These cells,
known as regulatory T cells (TR) are characterized by the
expression of CD25 and FoxP3. Originally, CD4+CD25+ TR were
thought to be derived from the thymus. Recent data suggests that
adaptive CD4+CD25+ TR can be generated in the periphery. In a
previous report, we have shown that activation of human
CD4+CD25- results in expression of FoxP3 and CD25, as well
as, acquisition of a cell contact dependent, cytokine independent
regulatory activity by a portion of the original CD4+CD25- T cells.
Recently, we have focused on determining the factors involved in
generating this type of TR and their lifecycle. Results from our lab
show that the addition of IL-2 to generation cultures results in an
increased number of resulting regulatory T cells, whereas, blockade
of the cytokines TGF-h and IL-10 by the addition of blocking
antibodies to the generation culture has no effect on the number or
function of the resulting TR. This demonstrates that the generation
of these TR is independent of TGF-h or IL-10 and is enhanced in
the presence of IL-2. Furthermore, results show that the
CD4+CD25+FoxP3+ TR resulting from the generation cultures
will retain their suppressive ability upon restimulation and when
reactivated in the presence of high dose IL-2 can be expanded 50-
fold. Together these results suggest that generated TR may be a
Abstracts S219good candidate for immunotherapy due to their ability to retain
suppressive activity and their capacity to be expanded.
Su1.91. siRNA Targeted Reduction of IL-23 Production
by Human Dendritic Cells Increases IL-10 Production
and Decreases Antigen Presentation Capacity.
A. Vaknin-Dembinsky, H. L. Weiner. 1Neurology, Center for
Neurological Diseases, Boston, MA, USA.
Background: IL-23 is a heterodimeric cytokine that comprises
a p19 subunit that associates with the IL-12/23p40 subunit. Like
IL-12, IL-23 is expressed predominantly by activated dendritic
cells (DCs) and phagocytic cells and both cytokines induce IFN-
secretion by T cells. Unlike IL-12, IL-23 also functions by
stimulating secretion of the pro-inflammatory cytokine IL-17 from
T cells. A central role for IL-23 in autoimmune inflammation is
supported by the observation that induction of experimental
autoimmune encephalitis (EAE) occurred in mice lacking IL-12,
but not in mice with targeted disruption of IL-23 or both IL-12
and IL-23. Thus IL-23 expression in dendritic cells (DC) may play
an important role in the pathogenesis of human autoimmune
diseases. One of the ways to explore the role of IL-23 in DC
function is by down regulating DC gene expression.The aim of
this study was to investigate the role of IL-23 in DC function and
to evaluate the use of IL-23 specific antisense oligonucleotides
(AS-oliges) and small interfering RNAs (siRNA) as a tool to
silence IL-23 expression.
Methods: We transfected human monocyte derived- DCs (mo-
DCs) with specific AS-oligos to IL-23p19, IL-12 /23p40 and IL-
12p35 and small interfering RNAs (siRNA) to IL-23p19. We
compared the surface markers by FACS analysis and the APC
function of mo-DCs that secrete lower amount of IL-23 and /or IL-
12 to mo-DCS transfected with control AS-oligoes and control
siRNA.
Results: We found that mo-DCS are efficiently transfected
with AS-oligos and siRNA (90–60%, respectively). Transfection
of DCs with the AS-oligos and siRNA specific for the IL-23 p19
and IL-12 p35 genes resulted in potent suppression of gene
expression and blockade of bioactive IL-23 and /or IL-12 p70
production without affecting unrelated genes or cellular viability.
Inhibition of IL-23 and IL-12 was associated with increased IL-10
production and decreased TNF alpha production. Furthermore,
transfected mo-DCs were poor allostimulators in a mixed
lymphocyte reaction.
Conclusions: We demonstrate that AS-oligos and siRNA can
be used for immune modulation by targeting human dendritic cell
(DC) gene expression. Targeted reduction in the expression of
either IL-23 and /or IL-12 resulted in DCs that are less potent
APCs and that secrete more IL-10. Knocking down the expression
of IL-23 by AS-oligos or siRNA may be used as an avenue to
develop therapy that target DCs in chronic inflammatory auto-
immune diseases.
Su1.92. Opposite Effect of IL-4 and IL-13 in
Experimental Autoimmune Myocarditis (EAM).
Daniela Cihakova,1 Marina Afanasyeva,1,2 Miho Kimura,1
Monica Talor,1 Jobert Barin,1 Noel R. Rose.1 1Department of
Pathology, The Johns Hopkins Medical Institutions, Baltimore,
MD, USA; 2Department of Medicine, University of Calgary,
Calgary, AB, Canada.
Background: In a previous study, we found that the severe
form of EAM in A/J mice exhibits a Th2-like phenotype. BlockingIL-4 with anti-IL-4 monoclonal antibodies (mAb) reduced the
severity of EAM in A/J mice, showing that IL-4 plays a pathogenic
role in EAM. We therefore speculated that another important Th2
cytokine; IL-13; could have an additive effect to IL-4. Methods:
6–8 weeks old IL-13 knockout mice (KO); IL-4 KO; IL-4/IL-13
double knockout (DKO) on BALB/c background and BALB/c
wild type (WT) were immunized with myosin BALB/c peptide
emulsified in CFA on days 0 and 7, injected with pertussis toxin on
day 0. To confirm our previous results in A/J mice, we also
blocked IL-4 with anti-IL-4 mAb in BALB/c WT. Myocarditis
severity was evaluated by histology and by the heart/body weight
ratio (HW/BW). Myosin peptide specific antibodies were analyzed
by ELISA. Th1 and Th2 cytokines were evaluated from heart and
spleen homogenates by ELISA. Results: Absence of IL-13 in IL-
13 KO mice as well as in IL-4/ IL-13 DKO resulted in a significant
increase in myocarditis incidence and severity assessed by
histology and the HW/BW ratio. IL-13 KO mice had a higher
histology score (P = 0.0000001) as well as HW/BW ratio (P =
0.00008) compared to BALB/c WT. IL-13/IL-4 DKO mice had
still greater EAM severity than BALB/c WT mice; however, their
phenotype was intermediate between IL-13 KO and BALB/c WT.
It was challenging to show clearly that IL-4 is a pathogenic factor
in BALB/c EAM as we observed in A/J EAM. BALB/c are
moderate responders to the EAM induction; therefore we could not
show a statistically significant lowering of myocarditis severity by
histology in absence of IL-4 on BALB/c background. However, the
HW/BW ratio was significantly lower in IL-4 KO mice than in
BALB/c WT (P = 0.025), suggesting that IL-4 promotes disease in
BALB/c mice. Next to increased EAM severity, IL-13 KO mice
showed significantly higher levels of anti-myosin peptide IgG,
IgG1, IgG2a and IgG2b compared to BALB/c WT. IL-13
deficiency resulted in increased levels of IL-1h and IFN-g in heart
homogenates compared to BALB/c WT. Discussion and Con-
clusions: By inducing EAM in IL-13 KO mice, we were able to
significantly increase the incidence and severity of myocarditis,
showing a protective effect of IL-13 in EAM in BALB/c mice. The
protective effect of IL-13 was also observed in IL-4/IL-13 DKO
mice, in which myocarditis severity was intermediate between IL-
13 KO and BALB/c WT mice. This intermediate phenotype,
together with the reduced disease in IL-4 KO and BALB/c with IL-
4 blocked by anti IL-4 mAb, suggests a pathogenic role of IL-4 in
EAM in BALB/c mice. The protective effect of the IL-13 is
associated with increases of two key regulatory cytokines (IL-1 h
and IFN-g) in a heart homogenate from IL-13 KO mice. The two
main Th2 cytokines, IL-4 and IL-13, thus have opposite effects on
EAM, IL-13 being a major protective factor and IL-4 being a
pathogenic factor. Supported by NIH grant R01 HL67290.
Su1.93. CTLA4-Ig Inhibts IL-2 Production and In-Vivo
Expansion of Antigen-Stimulated Memory CD4 T Cells.
M. P. Ndejembi, D. S. Patke, A. W. Bingaman, D. L. Farber.
1Surgery, University of Maryland, Baltimore, MD.
Costimulation via the CD28/B7 pathway is required for
activation of naive T cells; however, the precise role of this
costimulatory pathway in memory T cell function has not been
elucidated. In this study, we directly tested the role of the CD28/B7
costimulation pathway on CD4 memory function, by assessing the
ability of CTLA4-Ig to block memory CD4 T cell function and
expansion in vitro and in vivo. We used antigen specific CD4 T
cells derived from transgenic mice expressing a transgene encoded
T cell receptor specific for Influenza Hemagglutinin (HA) peptide
AbstractsS220(110-119) and I-E d and generated HA- specific memory cells by in
vitro priming with HA and antigen presenting cells followed by
adoptive transfer of HA-activated cells into syngeneic RAG2-/-
hosts. HA-specific memory CD4 T cells were harvested from these
adoptive hosts 8–10 weeks post transfer. In vitro recall of HA-
specific memory CD4 T cells with HA in the presence of CTLA4-
Ig led to a fifty percent reduction in the number of IL-2 producing
cells, while IFN-g production was comparable between CTLA4-Ig
and isotype control (IgG2a) treated cells. To test the effect of
CTLA4-Ig on antigen stimulated HA-specific CD4 memory T cells
in vivo, we transferred CFSE labeled HA-specific memory CD4 T
cells into secondary BALB/c hosts and treated the recipient mice
with CTLA4-Ig or IgG2a as an isotype control, then boosted these
mice with HA peptide or PBS. We observed a reduced expansion
of HA-specific CD4 memory T cells in HA-boosted recipient mice
treated with CTLA4-Ig compared to IgG2a treated mice. The total
antigen-specific memory CD4 T cell recovery of HA-boosted mice
that received CTLA4-Ig versus control IgG2a was 20% of control
in the spleen and 44% of control in the lymph nodes. These results
indicate that the CD28/B7 pathway plays a key role in IL-2
production and in vivo expansion of re-stimulated memory CD4 T
cells. These findings suggest a key role for CD28/B7 in promoting
optimal memory T cell responses.
Su1.94. Both Fc;R and C5a Are Indispensable in
Antibody Dependent Autoimmune Disease.
Varsha Kumar,1 Syed R. Ali,1 Olga Felda,1 Jorg Zwirner,2 Josef S.
Verbeek,3 Reinhold E. Schmidt,1 Johannes E. Gessner.1
1Department of Clinical Immunology, Hannover Medical School,
Hannover, Lower Saxony, Germany; 2Department of Immunology,
Georg-August-University Gottingen, Gottingen, Germany;
3Department of Human Genetics, Leiden University Medical
Center, Al Leiden, Netherlands.
Introduction: Complement C5a is a candidate target molecule
for the treatment of inflammatory diseases such as respiratory
distress syndrome and sepsis.The participation of C5a and C5aR in
the development of autoimmune disease has not been investigated.
The phagocytic responses by the two activating Fc receptors,
FcgRI and FcgRIII, have been directly implicated in the patho-
genesis of antibody-dependent autoimmune diseases, such as
autoimmune vitiligo, immune thrombocytopenic purpura and
autoimmune hemolytic anemia. In contrast, however, C5aR has
not been thought to play a significant role in these diseases. Using
an experimental model of autoimmune hemolytic anemia (AIHA)
in C5aR-deficient mice, we show here that C5aR, although a
nonphagocytic receptor, promotes cellular immune destruction in
antibody-mediated autoimmune disease through a mechanism of
bidirectional interaction between C5a and activating FcgR.
Methods: Lethal AIHA was induced by a single intraperitoneal
(IP) injection of aMRBC autoantibodies 34-3C. Kupffer cells were
isolated by percoll gradient of the liver homogenate followed from
control and anemic mice by sorting from the interphase by Mac-1-
coated magnetic beads. Surface protein was analysed by FACS and
mRNA expression by Taqman RT-PCR. The liver supernatant was
assayed for C5a-dependent chemotactic activity. Results and
Conclusions: In the present study, we identified C5a as a key
mediator of AIHA and showed that mice lacking C5aR are
resistant to this IgG autoantibody-induced disease model. Upon
administration of anti-erythrocyte antibodies, C5aR deficiency
resulted in impaired FcgR-mediated in vivo-erythrophagocytosis.
The upregulation of the activating FcgR on Kupffer cells inducedby the early C5a produced is also absent, in contrast to that
observed in wild-type mice. Surprisingly, in mice deficient for
FcgRI and FcgRIII, anti-erythrocyte antibody induced C5a
production is abolished identifying activating FcgR as dominant
mediators of autoantibody-induced release of C5a. Thus our data
are consistent with a pathogenic mechanism of antibody-depend-
ent hemolytic anemia in which IgG-opsonized erythrocytes trigger
FcgR-mediated C5a release that in turn activates a positive cellular
feedback signal uopn engagement of C5aR, which results in
increased FcgRI and FcgRIII expression required for effective
erythrophagocytosis. This shows that developement of a full
blown antibody-dependent autoimmune disease requires co-oper-
ation of C5a and the activating FcgR in the same activation
pathway and suggest therapeutic benifits of C5a-C5aR blockade in
AIHA and other disease closely related to type II autoimmune
injury.
Work supported by the Deutsche Forschungsgemeinschaft (Ge
892/8-1).
Su1.95. Regulatory T Cells: Differential Requirement
for Innate and Adaptive Immune Cells Inhibition In
Vitro.
S. Zelenay,1 I. Caramalho,1 J. Demengeot.1 1Lymphocyte
Physiology Unit, Instituto Gulbenkian de Ciencia, Oeiras,
Portugal.
CD4+ CD25+ regulatory T cells (TR) have been implicated in the
control of autoimmune diseases, allergy and inflammation. Devel-
opment of in vitro model systems has facilitated the analysis of the
functional properties of these cells. In this regard, inhibition of
conventional T cell proliferation by TR is currently the most used
assay. However, TR suppressor mechanism in these in vitro assays
remains unknown andmore importantly, appears to differ from the in
vivo scenario. Whereas in the latter case, inhibitory cytokines, such
as TGF-beta and IL-10, have been shown to play a role, this is not the
case in vitro. In addition, while competition for IL-2 has been
proposed to be themain suppressor mechanism in vitro, the presence
of saturating amount of IL-2 in culturemedia was shown not to affect
TR ability to suppress IL-2 production by the target cells. In this
work, we first present evidences that Foxp3+ TR consume significant
amounts of IL-2 in standard suppression assays and this consump-
tion positively correlates with their suppressor efficiency. As similar
results were obtained when testing Foxp3-negative suppressor cells,
we conclude that IL-2 consumption by CD25-expressing T cells
participates in a non-specific manner to the overall suppression of
proliferation observed in these cultures. We next describe a
suppression assay that does not rely on IL-2 consumption, as it
monitors the inhibitory function of TR on components of the innate
immune system. We show that Foxp3+ TR specifically suppress
TNF-alpha production by LPS activated peritoneal cells. This
control requires expression of MHC class II molecules, is
independent of the inhibitory cytokines IL-10 or secreted TGF-beta
and appears as cell contact dependent. Moreover, in this assay,
regulatory activity is not abrogated when saturating amounts of IL-2
are added to the cultures. The physiological relevance of these in
vitro assays is currently being tested in vivo.
Su1.96. CCR6 Expression Defines Regulatory
Effector/Memory-Like Cells within the CD25+CD4+ T
Cell Subset.
Markus Kleinewietfeld,1 Fabiola Puentes,1 Giovanna Borsellino,2
Luca Battistini,2 Olaf Rotzschke,1 Kirsten Falk.1 1Cellular
Abstracts S221Immunology of Autoimmune Reactions, Max-Delbruck-Center for
Molecular Medicine (MDC), Berlin, Berlin, Germany;
2Laboratory of Neuroimmunology, IRCCS Santa Lucia, Rome,
Rome, Italy.
Objective: The identification of naive and memory subsets of T
cells has been fundamental for the current understanding of the
immune system. It is now generally accepted that regulatory
CD25+CD4+ T cells are a central element of peripheral tolerance.
Little is known, however, about phenotypic and functional
characteristics of these cells with regard to memory. Aim of this
study was therefore to identify regulatory memory cell subsets and
to determine their markers and specific functions. Methods: T cells
were purified by FACS/MACS-sorting. Phenotypic characteriza-
tion (naive vs. memory, effector vs. suppressor) was carried out by
flow cytometry, expression-levels of transcription factor foxp3 was
determined by real time RT-PCR. Functional studies included in
vitro proliferation and cell migration assays. As experimental in
vivo systems congenic (SJL) and TCR-tg EAE models (TG4) were
used. Induction of memory phenotype was demonstrated in vivo by
adoptive transfer experiments of CFDA labelled cells. Results: In
this study we show that the chemokine receptor CCR6 is expressed
on a distinct subset of mouse Treg cells. Similar to their CD25-
counterparts, CCR6+ Treg cells exhibit markers of activation,
memory and expansion that are indicative for an effector-memory
function. They are memory-like cells, generated in vivo from
CCR6-CD25+ T cells after the encounter of antigen. As conven-
tional CD25- effector-memory T cells, they have a high turn-over
rate and, in contrast to CCR6- Treg cells, they respond rapidly to
restimulation in vitro with up-regulation of IL-10. CCR6+ Treg
cells are enriched in the peripheral blood and accumulate in the
CNS after induction of EAE. Importantly, these cells are also
present in humans. Here the expression of CCR6 fully co-
segregates with CD45RO, an established marker of human
memory T cells. Conclusions: The subset of CCR6+ Treg cells
seems to represent a population of dregulatory effector-memoryT T
cells (TREM), destined to control potentially destructive immune
responses directly in inflamed tissues. TREM cells therefore seem to
be the natural counter-players of effector-memory T cells (TEM),
involved primarily in front-linesuppression.
Su1.97. Small Molecules Trigger Peptide Loading of
HLA-DR by Allele-Specific Induction of a
Peptide-Receptive State.
Heiko Kramer,1 Katharina Dickhaut,1 Maria Hofstaatter,1 Sabine
Hopner,1 Dominik Ruckerl,1 Arvid Soderhall,2 Viviana
Marin-Esteban,1 Ronald Kuhne,2 Christian Freund,2 Gunther
Jung,3 Kirsten Falk,1 Olaf Rotzschke.1 1Celluar Immunology of
Autoimmune Reactions, Max-Delbruck-Center for Molecular
Medicine (MDC), Berlin, Berlin, Germany; 2NMR Supported
Structural Biology, Forschungsinstitut for Molecular Pharmacy
(FMP), Berlin, Berlin, Germany; 3Organic Chemistry, Eberhard
Karls Universitat, Tubingen, Tubingen, Baden Wurtenberg,
Germany.
Objectives: Class II MHC molecules, upon loosing their
peptide ligand, rapidly acquire a non-receptive state that prevents
rebinding of new peptides. Here we show that certain small
molecules are able to reverse this process. We had recently
identified a number of organic compounds that accelerate ligand
exchange reactions of HLA-DR molecules in a similar fashion as
the natural catalyst HLA-DM. In contrast to HLA-DM, however,
these compounds are effective even at neutral pH and can thereforemediate ligand-exchange directly on the surface of living cells.
Aim of this study was to identify the molecular mechanism by
which small molecules mediate ligand exchange and whether these
compounds can exhibit allele specificity. Methods: The experi-
ments were carried out with soluble HLA.DR molecules expressed
in insect cells. The kinetics of binding and release of peptide
ligands was determined by ELISA experiments. The effect was
validated in a cellular in vitro T cell system by using HLA-DR
transfected fibroblasts as APC and by a flow cytometry based
peptide binding assay. Results: The mechanism was found to be
based on the induction/stabilization of the peptide-receptive state
and facilitates loading of class II MHC molecules with both
peptide antigens or with full-length proteins. Importantly, some of
these compounds were active only on a subset of HLA DR
molecules. While they catalyse efficiently the loading of peptide
ligands onto allelic variants such as HLA DR1, they completely
failed to accelerate peptide binding to HLA DR2. Conclusions:
Small molecular compounds can influence the ligand composition
on the surface of antigen-presenting cells in an allele-specific
manner. While they represent a novel class of molecular tools
which can be used in therapeutic settings to facilitate antigen
loading they might also represent environmental risk factors for
allergy and autoimmune diseases. In this respect the strict allele-
specificity of these compounds could even have an influence on the
apparent linkage between incidence of certain diseases and HLA
DR allele.
Su1.98. B Cell Receptor Editing Begins in the Bone
Marrow.
Elahna Paul,1 Thomas J. Schneider,2 Michael C. Carroll.2
1Pediatric Nephrology, Massachusetts General Hospital, Boston,
MA, USA; 2CBR Institute for Biomedical Research, Harvard
Medical School, Boston, MA, USA.
Objective: It has been postulated that the bulk of B cell receptor
(BCR) editing detected in peripheral B cell populations in both
human and murine systems results from a tolerogenic process that
occurs earlier in ontogeny, during B cell maturation. This
possibility is substantiated by studies demonstrating that bone
marrow B cells cultured ex vivo are capable of editing their BCRs
when faced with self antigen. The purpose of the current study is to
determine whether immature B cells isolated directly from murine
bone marrow display evidence of BCR light chain editing.
Methods: Hybridoma studies of IgH56R mice (with the anti-
DNA 56R VHDJH transgene inserted in the IgH locus upstream of
CA) have suggested that IgK editing is reflected in two ways: by
preferential rearrangements to the Jk4 and Jk5 gene segments and
also by skewed distributions of Vk gene usage. The hybridoma
approach, however, is unable to distinguish between events early
and late in B cell ontogeny because only mature splenocytes are
captured via cell fusion. We have looked at IgK gene usage in a
strictly defined immature B cell population from the bone marrow
of IgH56R mice. B220+ CD43- IgD- cells further phenotyped as
IgMa+ IgMb- (expressing the IgH transgene) or IgMa- IgMb+
(expressing an endogenous IgH) were single cell sorted into 96-
well plates. RT-PCR amplification and sequencing of expressed
IgK genes were performed and identities of Jk segments and Vk
gene families were assigned using the NCBI IgBlast website
(www.ncbi.nlm.nih.gov/igblast).
Results: Evidence of in vivo receptor editing in IgH56R bone
marrow is revealed by comparing IgK gene expression in IgMa B
cells (n = 143) to the IgMb control population (n = 184). In the
AbstractsS222potentially autoreactive IgMa population, J segment rearrange-
ments are skewed towards the downstream Jk4 and Jk5 elements
(P = 0.02). Furthermore, the two subsets of immature B cells have
significantly different predilections for Vk family gene usage (P =
0.0007). In particular, expression of anti-DNA generating Vk1 and
Vk4 genes is substantially reduced in the IgH56R expressing cells
versus controls (P = 0.017 and 0.006, respectively).
Summary: This description of IgK gene expression in primary
B cells from the bone marrow of IgH56R transgenic mice
demonstrates that receptor editing begins as early as the immature
B cell stage of development. Nonetheless, comparison of our
observations to other sequence analyses of 56R B cells from a
variety of sources clearly indicates that selective forces continue
shaping the maturing B cell repertoire beyond this stage of
development and probably well after their migration from the
murine bone marrow to peripheral lymphoid tissues.
Su1.99. The Macrophage C5a:C5aR-Gai2-FcgRIIB/
FcgRIII-Axis Defines the Inflammatory Response in
the Arthus Reaction.
S. R. Ali,1 J. Skokowa,1 O. Felda,2 V. Kumar,1 S. Konrad,1 R. E.
Schmidt,1 R. P. Pierkorz,2 B. Nunberg,2 K. Spicher,3 L.
Birnbaumer,4 J. Zwirner,5 N. Rooijen,6 J. E. Gessner.1 1Clinical
Immunology, Hannover Medical School, Hannover, Germany;
2Biochemistry and Molecular Biology, Heinrich-Heine-University,
Dusseldorf, Germany; 3Institute of Pharmacology, Berlin Free
University, Berlin, Germany; 4Laboratory of Signal Transduction,
NIEHS, NIH, USA; 5Department of Immunology, Georg August
University, Gottingen, Germany; 6Department of Molecular Cell
Biology, Vrije University, Amsterdam, Netherlands.
Introduction: IgG immune complex (IC) induced inflammatory
reactions can be triggered by two pathways; the complement
system (especially C5a) or the cellular receptors for IgG, FcgR.
In mice, IC can interact with either of three cellular receptors,
two of which FcgRI and FcgRIII lead to cellular activation,
while FcgRIIB is an inhibitory receptor. A hallmark of the
immune response to IC is its ability to modulate the balance
between these receptors. Recent reports identified C5a depend-
ent inverse regulation of FcgRIII versus FcgRIIB on lung
macrophages in the mouse model of acute alveolitis. Objectives:
This study was carried out to analyze the underlying cellular
and molecular mechanism of their cooperation in immune-
regulation of IC lung pathology. Methods: The methods used in
the study include adaptive cell transfer experiments in which
alveolar macrophages (AM) depleted C5aR and FcgR deficient
mice were reconstituted with ex- vivo modified AM from
CD45.1 congenic mice. C5a:C5aR-dependent modulation of
FcgR expression and its functional consequence was analyzed
in presence of specific pathway inhibitors and quantified by IC
injury, chemotaxis, TaqMan RT-PCR and FACS analysis.
Results and Conclusion: Here we analyzed a novel regulatory
C5aR-FcgR cross-talk on AM as the dominant event in the lung
Arthus reaction, the classical animal model of immune complex
(IC) disease. Strikingly, initial contact between IC and AM
results in cellular regulation leading to plasma complement-
independent C5a production; selective Gai2-dependent C5aR
signaling; and C5aR-Gi-mediated FcgR alterations towards
FcgRIII, the main inducer of TNFa and CXCR2 ligand
production. Distinct inhibitors of this refined inflammatory
cascade are each effective in disease prevention, thus indicating
cellular components of the C5aR-FcgR-axis, like Gai2, aspotential new therapeutic targets in the treatment of inflamma-
tion and autoimmune diseases. In summary, our results imply a
revised multimolecular model of the inflammatory cascade.
Remarkably, our findings showed that macrophages function as
an alternative source of C5a. These data also highlight the
importance of local C5a-induced cellular mechanisms in disease
pathogenesis.
Supported by MD PhD Program, MHH and Deutsche
Forschungsgemeinschaft (GE892/8-1).
Su1.100. T Cells and Autoimmunity: Immunoregulation
by CD40 Expressed on CD4+ T Lymphocytes.
M. E. Munroe,1 G. A. Bishop.1,2 1Departments of Microbiology
and Internal Medicine, University of Iowa, Iowa City, IA, USA;
2VAMC.
CD40 is known to play a significant role in the pathogenesis of
inflammation in autoimmunity. CD40 can stimulate autoreactive B
cells directly, resulting in autoantibody production. However,
recently published data indicate that autoaggressive CD4+ T
lymphocytes also express CD40, including T cells from mice with
collagen induced arthritis (CIA). Our lab has extensively studied
signaling by CD40 in B cells and these reports prompted us to
produce mouse (2B4.11) and human (Jurkat) T cell lines expressing
transfected human (h)CD40. The objective of this study was to
compare CD40 signaling in B vs.T cells, as well as characterize
CD40 as a possible costimulatory molecule on T lymphocytes. As in
B cells, CD40 in Tcells binds to cytoplasmic adaptor proteins called
TNF-R associated factors (TRAFs), including TRAF2 and TRAF3.
However, CD40 mediated TRAF degradation is less efficient in T
cells compared to their B cell counterparts. CD40 stimulation in T
cells leads to JNK and NFnB activation and TNF-a production. Of
particular interest is the ability of CD40 to act as a costimulatory
molecule for T cell receptor signals, just as it does for the B cell
receptor. Stimulating hCD40 transfected 2B4.11 T cells, or T cells
expressing CD40 frommicewith CIA,with anti-CD3, anti-CD28, or
anti-CD40 alone leads to minimal secretion of IL-2 or IFN-g.
However, stimulating via anti-CD3 in conjunction with anti-CD28
and/or anti-CD40 results in significantly increased secretion of these
cytokines. This increase in cytokine production is paralleled by
increased NFnB activation via both classical (NFnB1) and alternate
(NFnB2) pathways, as well as increased activation of JNK. These
findings are particularly exciting and suggest that T cell specific
inhibition of CD40 signaling could be a means for blocking the
autoimmune response without altering general immune function.
Su1.101. Induction of Tolerance by Gene Therapy with
B-Cells Expressing Ig Fusion Proteins: Mechanisms and
Pre-Clinical Success in NaRve and Immune Hemophilia
A Mice.
D. W. Scott,1 T. C. Lei,1 Y. Su,1 N. Soukhareva.1 1Surgery,
University of Maryland School of Medicine, Rockville, MD, USA.
Our lab has demonstrated that B-cell blasts, activated by LPS,
anti-Ig or CD40L and transfected with a retrovirus encoding an
IgG-peptide fusion protein are tolerogenic in both normal and
primed recipients. Success has been achieved with multiple
antigens in different mouse strains and in rats, and in preclinical
models for MS, uveitis and diabetes. We also have demonstrated
that class II MHC on the presenting B cells is necessary for
tolerance and that the Ig carrier enhanced the degree and duration
of tolerance. We have now adapted this system to a murine model
for hemophilia A. Approximately 25% of hemophilia A patients
Abstracts S223make inhibitory antibodies that block clotting and therefore reverse
the potential therapeutic benefit of factor VIII delivery. We know
that most of these inhibitors are directed at epitopes in the C2 and
A2 domains of factor VIII. Thus, for clinical application in
hemophilia, we inserted residues S2173-Y2332 of the factor VIII
C2 domain and S373-R740 of the fVIII A2 domain onto the IgG
heavy chain backbone, respectively, to induce tolerance in
hemophilia A mice. Specific tolerance to each domain was induced
by this protocol. Importantly, a combination of A2-IgG and C2-
IgG expressing B cells induced tolerance to the full length fVIII
molecule, a result which supports the dominance of these domains
in the immune response to fVIII. Tolerance was manifested in
terms of ELISA titers, T-cell proliferation and especially Bethesda
Unit titers (95% reduction). Importantly, similar results were
obtained even when treatment was initiated after mice had pre-
formed anti-fVIII titers, indicating its potential for the treatment of
patients with binhibitorQ titers. Recent data suggest that CD25+ T
regulatory cells are needed for in vivo tolerance induction with
transfected B cells. These studies hold promise for a future clinical
trial in hemophilia A patients. (Supported by NIH grants
HL061883, AI035622 and a Lab Grant from the National
Hemophilia Foundation.)
Su1.102. Increase of Pancreatic NK Cells at Early Onset
of Autoimmune Diabetes in IFNB Transgenic NODMice.
A. Alba,1 R. Planas,1 J. Carrillo,1 M. C. Puertas,1 R. Ampudia,1
X. Pastor,1 M. A. Fernandez,1 R. Pujol-Borrell,1 J. Verdaguer,1 M.
Vives-Pi.1 1Immunobiology for Research and Diagnostic
Applications, Transfusion Centre and Tissue Bank, Fundacio
Institut dTInvestigacio en Ciencies de la Salut Germans Trias i
Pujol, Badalona, Barcelona, Spain.
Genetic and environmental factors are decisive in the etiology
of type 1 diabetes (T1D). Viruses have been proposed as a
triggering environmental event and some evidences have been
reported, i.e. type I IFNs exist in the pancreata of diabetic patients
and transgenic mice expressing these molecules in beta cells
develop diabetes. Our group has generated the first NOD mice
expressing a type I IFN (RIP-IFNbeta) in the islets, a new model of
autoimmune diabetes. These mice develop accelerated diabetes at 3
weeks of age (equivalent to childhood in humans), with a
cumulative incidence reaching 60% at 30 weeks age. This early-
onset diabetes is characterized by selective destruction of beta
cells, MHC class I hyperexpression in the islets, severe insulitis,
and a high number of Natural Killer cells in the pancreas. NK cells
are innate immune cells that control certain virus infections and
tumors, and have been recently associated to destructive forms of
pancreatic islet autoimmunity in NOD mice. A significant increase
of NK cells and NKT cells has been observed in the insulitis of the
NOD RIP-HuIFNbeta and NOR RIP-HuIFNbeta transgenic mice at
the early onset of diabetes when compared to healthy subjects. This
high amount of pancreatic NK cells has not been found in
transgenic mice or NOD wild type developing diabetes after 12
weeks of age. The percentage of NK cells in spleen and pancreatic
regional lymph nodes is not altered in diabetic animals (early or
late) when compared to healthy animals. This subset of NK cells is
not maintained during the disease, decreasing quickly after 24
hours of the clinical onset. An imbalance NK / NKT subsets exists
at the early onset of T1D. Transgenic mice NOD-Scid RIP-
IFNbeta, unable to produce mature T and B lymphocytes although
they have unaffected NK subset, do not develop diabetes thus
suggesting the need of interaction between NK cells and otherlymphocyte subsets (T, B) for autoimmunity. Microarray experi-
ments demonstrate a correlation of the NK cell subset in early onset
diabetes to the islet expression of adhesion molecules, costimula-
tory molecules (CD86), cytokines (IFNgamma, IL6) and NK
attractant chemokines: CCL2 (MCP-1), CCL3 (MIP-1alpha),
CCL5 (RANTES), CXCL10 (IP10) and XCL1 (lymphotactin).
Since type I IFNs production takes place in cells infected mainly
by viruses, our transgenic model could be an interesting tool for
studying how the production of IFNbeta causes cellular stress,
generates danger signals, inflammation and eventually NK cell-
mediated autoimmunity. The characterization of the role of NK
cells at early onset of T1D may help us to understand and to
prevent this autoimmune disease.
Su1.103. Rapid Protocol To Generate Tolerogenic
Dendritic Cells Using Microbial Lipopeptide (BLP).
O. A. Aravena,1 L. Salazar,1 C. Mass,1 A. Aguirre,1 D. Catalan,1
M. Hermoso,1 J. C. Aguillon.1 1Disciplinary Program of
Immunology, ICBM, University of Chile, Santiago, Chile.
Dendritic cells (DCs) are potent antigen presenting cells
capable of antigen uptake and presentation. In the immature
developmental stage DCs are thought to induce T-cell anergy.
Immature DCs have a high rate of endocytosis and low levels of
MHC class II (MHC-II), and CD80 and CD86 co-stimulatory
molecules expression. Upon maturation, DCs down-regulate
mechanism of antigen capture and increase co-stimulatory
molecules expression. In the steady state, meaning in the
absence of acute infection and inflammation, DCs deliver the
antigen to T cells without of essential co-stimulatory molecules
inducing T cell tolerance. The key role of DCs in the induction
of immunity to infectious agents, malignancy and transplanted
allografts, and in the maintenance of T cell tolerance in the
periphery has prompted the interest in their use as immunother-
apeutic agents.
OBJECTIVE: In this study we examine whether bacterial
lipopeptide (BLP) may induce phenotypic and functional changes
associated with DCs maturation through Toll-Like Receptor 2
(TLR2). METHODS: DCs were generated from bone marrow
precursors (BMDCs) by using granulocyte-macrophage colony
stimulating factor (GM-CSF). On the days 3 and 5 appropriated
cytokines were added. We assessed DCs maturation using LPS,
TNF and BLP as stimulators. CD11c, MHC-II, CD80 and CD86
surface molecules expression was determined using murine
monoclonal antibodies conjugated to phycoerithrin (PE) and
isocthiocyanate (FITC) by flow cytometry. The capacity of
BMDCs to endocytose antigen was determined by flow cytometry
using FITC-conjugated dextran. RESULTS: We demonstrated that
BMDCs generated in vitro by using GM-CSF and BLP for two
days show a high MHC-II expression and an increased yield of
differentiated DCs. The expression of CD80 and CD86 molecules
was not affected by the presence of BLP. These phenotypic features
of DCs correspond to a semi-mature (sm-DCs) developmental
stage. In contrast, bone-marrow precursor cultured for five days
under BLP stimulus or alternative standard protocols using TNF or
LPS for over eight days yield the same number of differentiated
DCs and a mature phenotype demonstrated by functional assays.
CONCLUSION: This protocol has shown to be more rapid and
efficient to generate sm-DCs with tolerogenic characteristic and
mature DCs that will be use in immunological therapy.
Financed by Fondecyt-Chile 1040860, Fondef-Chile D03I1055
and Mecesup UCH0115.
AbstractsS224Su1.104. Mucosal Administration of Anti-CD3 Antibody
Suppresses EAE, Collagen Arthritis, Diabetes and
Prolongs Cardiac Allograft Survival.
H. L. Weiner,1 H. Ochi,1 M. Abraham,1 H. Ishikawa,1 H. Wu,1
R. Maron,1 D. Frenkel,1 R. Gandi,1 M. L. Chen,1 A. Izawa,1
I. Guleria,1 M. H. Sayegh.1 1Brigham and WomenTs Hospital,
Harvard Medical School, Boston, MA, USA.
Background and Objectives. Mucosal administration of
antigen is an established method to induce immunologic tolerance
and mucosal administration of auto and alloantigens is effective
in treatment of animal models of autoimmunity, inflammation,
and transplantation. Parenteral administration of anti-CD3 is
efficacious in animal models of autoimmunity and in humans
anti-CD3 is an approved therapy for transplant rejection and
positive results have been reported in patients with new onset
type 1 diabetes treated with parenteral anti-CD3. We investigated
the effect of mucosally administered anti-CD3 in animal models
of autoimmunity and transplantation. Methods. We orally or
nasally administered anti-CD3 or FabT2 fragments of anti-CD3
(or appropriate isotype control antibody) in doses ranging from
0.5ug to 500ug. Results. In the SJL model of PLP induced EAE
anti-CD3 suppressed EAE when given prior to or at the peak of
disease. The PLP specific immune response of anti-CD3 fed
animals immunized with PLP demonstrated a decreased prolifer-
ative response, reduced IL-2 secretion and increased secretion of
IL-10, IL-4 and TGF-b. Oral anti-CD3 was associated with an
increase in the numbers of CD4+ TGF-b latency associated
peptide (CD4+LAP+) in the mesenteric lymph node. CD4+
LAP+ cells suppressed proliferation of CD4+CD25-LAP- T cells
in vitro and adoptive transfer of CD3+LAP+ cells suppressed
EAE in a TGF-b dependent fashion. No modulation of CD3 on
the surface of CD4+ T cells occured after oral anti-CD3. Similar
results were obtained in MOG induced chronic EAE in the NOD
mouse. Pathologically there were less CD4+ cells and macro-
phages in the spinal cord. Suppression also occured with FabT2
fragments of anti-CD3. In the NOD model of diabetes, oral anti-
CD3 given in the neonatal period suppressed the incidence of
diabetes. In streptozocin induced diabetes oral anti-CD3 FabT2
suppressed diabetes in association with CD4+LAP+ cells whose
suppressive function increased after oral anti-CD3. In vivo
neutralization of TGF-b reversed the suppressive effect. In the
DBA2 model of collagen induced arthritis, nasal anti-CD3 FabT2
suppressed the incidence of arthritis, was associated with decreased
levels of TNF in the joints, and was more effective that mucosally
administered collagen. In allogeneic cardiac transplantation (Balb/c
into C57BL/6), oral anti-CD3 was given on day -5 and continued
until day +10 post transplantation. Cardiac transplants in mice
receiving oral anti-CD3 survived an average of 16.2 days vs. 8.4
days for controls (P = 0.0004).Conclusions.Anti-CD3 given orally
or nasally is immunologically active at mucosal surfaces. The Fc
portion of the Ig molecule is not required for the immunologic effect.
Oral anti-CD3 induces regulatory T cells characterized by surface
LAP that function in a TGF-b dependent fashion. These results
identify a novel and physiologic mechanism to induce regulatory T
cells that is clinically applicable to a variety of immune mediated
disorders.
Su1.105. The Role of Ultralarge Complexes (ULC) in
Heparin Induced Thrombocytopenia (HIT).
L. Rauova,1 D. B. Cines,2 B. B. Sachais,2 M. Poncz.1 1Division of
Hematology, ChildrenTs Hospital of Philadelphia, Philadelphia,PA, USA; 2Department of Pathology and Laboratory Medicine,
University of Pennsylvania, Philadelphia, PA, USA.
HIT is a serious complication of heparin therapy caused by
antibodies (Ab) to complexes between high molecular weight
heparin and an endogenous protein, Platelet Factor 4 (PF4),
leading to limb and/or life-threatening thrombosis in ~50% of
affected patients. We are interested in understanding the basis of
an important clinical observation: HIT auto-Ab form in most
heparinized patients, but only a small percentage of these develop
thrombocytopenia and/or thrombosis. In the present work we
show by gel filtration that PF4 and heparin form antigenic ULC
over a very narrow molar ratio (~1:1) of reactants. ULC are
stable and visible by electron microscopy, but can be dissociated
into smaller complexes (SC) upon addition of heparin. Formation
of ULC is inefficient when PF4 is incubated with low molecular
weight heparin, and none form with the pentasaccharide
fondaparinux. Mutation studies show that formation of ULC
depends on the capacity of PF4 to form tetramers, which then
assemble into multimolecular lattices on a heparin scaffold. ULC
are capable of binding N1 HIT-like monoclonal Ab/complex, are
more antigenic than SC and are more capable of causing platelet
activation in an Ab- and FcgRIIA-dependent. Additional of PF4
to human or mouse platelets and other vascular cells leads to the
self-assembly of antigenic complexes presumably nucleated by
membrane glycosaminoglycans (GAG). PF4 evokes binding of
HIT-like monoclonal Ab to cells in a dose-dependent manner
over a narrow range of concentrations and induces FcgRIIA-
dependent platelet activation analogous to ULC. We conclude
that the capacity of PF4 to form ULC composed of multiple PF4
tetramers arrayed in a lattice with several molecules of heparin
and/or GAG may play a fundamental role in autoAb formation.
The capacity of ULC to bind multiple Ab and cross-link/trigger
FcgRIIA promotes platelet activation and explains the propensity
for thrombosis. We are currently testing the hypothesis that the
patients with high steady-state level of surface PF4 based on
genotype and acquired through platelet activation are those most
likely to generate autoAb, form ULC and develop HIT.
Su1.106. Effect of Freezing/Thawing Conditions and
Their Optimization for Quality Control of PBMC
Viability and Functional Assays.
Khadir Raddassi,1,2 Kasia Bourcier,2 Jose Estevam,1,2 David A.
Hafler,1 Vicki Seyfert-Margolis.2 1Neurology, Harvard Medical
School, Boston, MA, USA; 2Immune Tolerance Network,
University California San Francisco, San Francisco, CA, USA.
Objective: To compare and optimize freezing protocols for
PBMCs taken from whole blood for detection of autorective T cells.
Background: To detect the effects of potentially immunomo-
dulatory drugs on autoreactive T cells, clinical trials performed by
the Immune Tolerance Network employ assays that quantify T cell
responses to autoantigens. Centralized assay facilities are used to
reduce the problem of inter-site variability. However, some inter-
site variability can occur during the preparation of PBMC samples
at various geographic locations. These steps require freezing of
PBMCs prior to shipping, as well as thawing of samples prior to
assay. We have therefore examined the effects of our freezing and
thawing procedures to minimize inter-site variability of the results
of T cell assays.
Methods: PBMCs from healthy donors and MS patients were
isolated by ficoll separation. Parts of the samples were exposed to
different doses of tetanus toxoid, myelin antigens, PHA or no
Abstracts S225antigen, while the other part was frozen for 3 weeks using various
freezing media and temperatures prior to stimulation in T cell
assays. Proliferation ([3H]-Thymidine incorporation), cytokine
production (ELISA, flow cytometry (FACS) and elispot) and cell
death/apoptosis (FACS) were assayed in parallel in both fresh and
frozen samples. Subpopulations of PBMCs were phenotyped by
FACS analysis.
Results: Cell viability and recovery decreased after a cycle
of freezing/thawing (2 to 10% and 20 to 60%, respectively).
The viability as well as PBMC response to antigens were
significantly improved when human AB serum (+10% DMSO)
was used to freeze the cells. The viability of PBMCs using fetal
bovine serum (+10% DMSO) resulted in a fair viability (91%)
but high background for proliferation and cytokine production.
Using cold (48C) freezing media decreased both the viability
(by 4%) and the response of T cells to antigens (by 20%).
PBMCs were better preserved (numerically and functionally)
and retained a greater response to antigens when the temper-
ature of freezing medium used was kept at 258C than 48. Using
these optimal conditions we did not find significant differences
in the cell population percentage between the fresh and frozen
regarding CD3, CD4, CD8, CD14, CD19, activated or memory
T cells.
Conclusions: We have found as expected that freezing and
thawing of PBMCs decrease cell viability (2 to 10%) and T cell
response (50%). This decrease in count and viability did not
disproportionately affect a specific cell population among those
examined. The best combination of freezing conditions was
obtained using human AB serum+10% DMSO at 258C. Thus,
we have identified procedures optimal for PBMC viability and T
cell responses to PHA and a panel of nominal and self-antigens.
This protocol has been adopted as standard operating procedure for
all studies conducted by the ITN and therefore expands the ITNTs
capability to evaluate mechanisms of disease and treatment
response in multicenter trials.
Su1.107. MBLA/C Deficienct Mice Display Defective
Apoptotic Cell Clearance but No Autoimmune
Phenotype.
L. M. Stuart,1,2 K. Takahshi,1 L. Shi,1 J. Savill,2 R. A. Ezekowitz.1
1Laboratory of Developmental Immunology, Massachusetts
General Hospital, Boston, MA, USA; 2MRC Center for
Inflammation Research, University of Edinburgh, Edinburgh,
United Kingdom.
MBL is a member of the collectin family with structural
similarities to the lung collectins, SPA and SPD. In addition,
MBL has functional similarities to C1q as they both activate
complement; C1q activates the classical pathway and MBL the
lectin pathway. Like C1q, MBL is a circulating serum protein that
is sequestered to sites of inflammation and infection. Limited
reports of patients deficient in MBL have raised the possibility
that lack of MBL, in a manner similar to C1q deficiency, might be
associated with autoimmunity. Cells dying by apoptosis are an
important target for the autoantibodies that develop in systemic
lupus and failure of removal of dying cells has been implicated in
development of autoimmunity in C1q deficiency. Here we show
that MBL, like the other collectins and C1q, is able to bind
apoptotic cells in vitro. Using mice deficient in both mouse MBL
genes, MBLA and MBLC, we demonstrate that MBL null animals
show a 50% defect in their ability to clear apoptotic cells,
confirming a role for MBL in clearance of apoptotic cells in vivo.Analysis of MBL null animals demonstrated expanded B1 cells
but no spontaneous activation of antigen presenting cells.
Importantly, despite demonstrating a defect in apoptotic cell
clearance comparable to that seen in the C1qA-/- animals, MBL
null animals did not develop spontaneous autoimmunity, lympho-
proliferation or germinal centre expansion. These data demonstrate
an important in vivo role for MBL in clearance of dying cells and
add the MBL null animals to the short list of animals with
demonstrable in vivo apoptotic cell clearance defects. Further-
more, it demonstrates that failure of apoptotic cell clearance can
be dissociated from autoimmunity indicating that other factors
must be required for autoantibody generation and end organ
damage.
Su1.108. Study of the Thymic Function in Patients with
Autoimmune Thyroiditis.
M. P. Armengol,1 M. A. Fernandez,2 L. Sabater,1 M. Juan,1
R. Pujol-Borrell.1 1Laboratory of Immunobiology for Research
and Diagnosis (LIRAD). Centre for Transfusion and Tissue Bank
(CTBT), Institut per a la Recerca Biomedica Germans Trias i
Pujol., Badalona, Barcelona, Spain; 2Cytometry Unit, Institut per
a la Recerca Biomedica Germans Trias i Pujol., Badalona,
Barcelona, Spain.
Autoimmune thyroid disease (AITD) is a term that includes
various clinical entities, among them HashimotoTs thyroiditis (HT)
and GravesT disease (GD). Lymphocytic infiltration by T-, B-
lymphocytes and DC and FDC that is often organized as
functional lymphoid follicles with germinal centers is an almost
constant feature. In order to investigate specific homing of recent
thymic emigrants (RTE) to the thyroid and the distribution of
recent RTEs in the different subsets of PBLs in patients with
AITD, TCR excision circles (TRECs) have been measured in
CD3+ intrathyroidal lymphocytes (ITL) and in peripheral blood
(PBMC) of the same patients. TRECS were measured by real-time
PCR in CD3+ lymphocytes obtained by cell sorting from
dispersed cell preparations of thyroid glands (n = 10) and from
peripheral blood from (n = 15) patients and (n = 12) healthy
controls. The comparison of TREC levels ITLs and PBMCs in
each individual showed two patterns: in one half of patients
TRECs in ITL were higher than in PBMCs whereas in the other
half was higher in PBMCs. On the other hand TREC content in
PBMC from AITD patients was not significantly different from
controls (1.799 F 2.62/104 cells vs. 3.212 F 3.06/104 cells, P =
0.902, t test). To assess the influence of T cell proliferation on
TREC levels, we measured telomere length in B- and T-
lymphocytes in groups of 10 patients with AITDs (ITL and
PBMC) and controls (PBMC). In AITD patients, the relative
telomere length (RTL) in ITL was significantly lower than in
PBMC (11.21 F 1.22 vs. 13.73 F 2.21, P = 0.0266, paired t test)
but in PBMC there was no difference with healthy donors
(13.73AˆF 2.21 vs. 13.02 F 1.06, P = 0.6165, t test). RTLs were
also measured in thyroid infiltrating and peripheral B cells. ITL
CD19+ B infiltrating lymphocytes had longer RTLs than
peripheral B cells (17.69 F 2.70 vs. 15.06 F 1.53; P = 0.0260,
paired t test) in AITD while in PMBCs RTLs from AITD were
similar to those in healthy donors (15.06 F 1.53 vs. 15.13 F 2.13;
P = 0.6669, t test). No correlation was found between the RTL in
T cells and the levels of TRECS. Taken together, these results
suggest the existence of proliferation in ITL CD3+ cells within the
thyroid or regional lymph nodes although selective homing of
memory T cells to the thyroid could not be excluded.
AbstractsS226Su1.109. A Novel Low-Calcemic Vitamin D Analog as a
Potential Therapeutic Treatment for Autoimmune
Diseases.
N. Chouinard,1 A. H. Collop,1 K. A. Ryder,1 S. P. Tabash,1 G. H.
Posner,2 B. Korczak,1 S. S. Chuang.1 1Research and Development,
Cytochroma Inc., Markham, ON, Canada; 2Department of
Chemistry, The Johns Hopkins University, Baltimore, MD, USA.
Several autoimmune diseases such as psoriasis, multiple
sclerosis and CrohnTs disease, are associated with an imbalance
between Th1/Th2 towards Th1 cells. This creates a state of chronic
inflammation with predominance of Th1 cytokines such as IFN-g,
TNF-a and IL-2. In contrast, the Th2 cytokines like IL-4 and IL-10
have shown beneficial effects and manipulation of Th1/Th2 balance
is part of the current strategy developed against Th1-mediated
immune diseases. 1a,25-dihydroxyvitamin D3 (calcitriol) has been
shown to exert several immunomodulatory functions on T cells and
antigen-presenting cells (APC) both in vitro and in vivo. Our goal
was to evaluate the immunomodulatory effects of a new vitamin D
analog, QW1624F2-25SO2-1, for the therapeutic treatment of
autoimmune diseases. Methods: QW1624F2-25SO2-1 was
assessed for its ability to activate the VDR-responsive gene
CYP24 by real-time PCR and to bind to VDR. We also examined,
using ELISA, the effect of our compound on Th1/Th2 cytokines in
human peripheral blood mononuclear cells (PBMC) and on
cytokines secreted by macrophages. The use of vitamin D analogs
is currently limited by the induction of hypercalcemia; therefore, the
effect of QW1624F2-25SO2-1 on serum calcium level was
evaluated in mice. Results: Transcriptional analysis in human
PBMC revealed that calcitriol is a strong inducer of the VDR-
responsive gene CYP24which indicates these cells are responsive to
VDR-mediated gene transcription. In a macrophage cell line, very
low concentrations of QW1624F2-25SO2-1 significantly induced
CYP24 expression. Interestingly, the ability of this analog to bind to
VDR was weaker than calcitriol. Calcitriol has been shown to
repress IFN-g, GM-CSF, IL-2 in T cells and IL-12 in APC, an effect
that is dependent on the presence of VDR. Our results revealed that
QW1624F2-25SO2-1 significantly decreased pro-inflammatory
Th1 cytokine production (IFN-g, TNF-a and IL-2) and increased
the production of the Th2 cytokine IL-4 in human PBMC. This
analog also affected macrophage functions by inducing the secretion
of IL-10 in LPS-stimulated U937 cells. In vivo, this analog did not
induce hypercalcemia even at the highest dose of 40 Ag/kg body
weight. Conclusion: These results demonstrate that QW1624F2-
25SO2-1 is a low-calcemic analog and a strong inducer of vitamin
D-dependent transcription. This novel compound modulates Th1/
Th2 balance in favor of the Th2 and macrophages function
suggesting its potential for the treatment of Th1-mediated auto-
immune diseases.
Su1.110. SP-A May Be a Candidate of bQiQ Molecule
Triggers Some Autoimmune Diseases.
J. Luo,1 Y. Wan.2 1Orthopaedics, Rhode Island Hospital/Brown
Medical School, Providence, RI, USA; 2Biology, Providence
College, Providence, RI, USA.
INTRODUCTION: The IR-SP-A was found in alveolar,
parenchyma, pleura of lung; myelin sheath of brain; epithelia of
BowmanTs capsule, glomerulus and renal tubules of kidney;
epithelia of colon, stomach, duct of salivary gland, pharynx; and
blood vessel wall and connective tissue of extracellular matrix. The
positive signal was blocked by pre-absorbed SP-A antigen from
recombinant or BAL. The regularity of distribution is likelycompatible with the primary injury sites of some autoimmune
diseases. SP-A or like molecules is a candidate of bQiQ (meaning
air) molecule and it may trigger some autoimmune diseases.
IR-SP-A in Lung: In lung, strong signal of IR-SP-A was
detected in alveolar type II cells, the surface of alveoli and
bronchiole, and pulmonary parenchyma. Our results of IR-SP-A in
the sites of pulmonary parenchyma and blood vessel indicate the
primary involvement in the pulmonary autoimmune diseases.
Many clinicians recognized that certain autoimmune diseases are
often associated with the initial pulmonary abnormalities such as
alveolitis, hemorrhage.
IR-SP-A in Extrapulmonary Sites: In Kidney, the strong
positive signals were located in some glomerulus, renal tubules and
vasculature. In glomerulus, positive signal was detectable on some
epithelia of BowmanTs capsule, and glomerular basement mem-
brane. In brain it showed strong IR-SP-A positive signals were
located in myelin sheaths of cerebrum, cerebellum and walls of
blood vessels. In digestive system, IR-SP-A positive signal in
epithelia of stomach and large intestine, and very faint positive
signal in blood vessels of connective tissue. In blood vessel and
connective tissues, IR-SP-Awas also detectable in blood vessel and
connective tissue of lung and some extrapulmonary tissues. The
positive signal in the blood vessel of brain was very strong, and the
signal in other tissues is very faint and barely detectable. The SP-A
or likely molecules is likely compatible with primary injury sites of
some autoimmune diseases. The etiology of those diseases is still
unknown, but the epidemiological investigation showed that non-
specific environment exposure is a high risk factor. Conclusion:
Thus far the mechanisms of bQiQ communication in Traditional
Chinese Medicine have not been well established. In fact, current
technology remains insufficient for the understanding of the
relationship between the local stimulation and whole body response
by acupuncture, Qigong and other Chinese medicine. Herein, we
analyze the molecular structure and regularity of SP-A or SP-A like
proteins sharing common antigenic determinants. Those molecules
may act in dual manner, either enhancing or suppressing inflamma-
tory response. The distribution of SP-A molecule is compatible with
the primary autoimmune injury site, thus is likely a candidate of bQiQ
communication in Traditional Chinese Medicine.
Su1.111. The Inhibition of Autoreactive T-Cell Functions
by a Peptide Based on the Complementarity
Determining Region-1 of an Anti-DNA Autoantibody Is
Via TGFB Mediated Suppression of LFA-1 and CD44
Expression and Function.
Uri Sela,1 Nora Mauermann,1 Rami Hershkoviz,2 Edna Mozes,1
Liora Cahalon,1 Ofer Lider.1 1Immunology Department, The
Weizmann Institute of Science, Rehovot, Israel; 2Internal
Department D, Assaf-Harofeh Medical Center and the Sakler
Faculty of Medicine, Tel-Aviv University, Zerifin, Israel.
We have previously shown that systemic lupus erythematosus
(SLE), which is characterized by the increased production of
autoantibodies and by defective T-cell responses, can be induced in
mice by immunization with a human anti-DNA monoclonal
antibody (mAb) which expresses a major idiotype, designated 16/
6Id. We also showed that a peptide based on the sequence of the
complementarity determining region (CDR) 1 of the 16/6Id
(hCDR1) ameliorated the clinical manifestations of SLE, and
down-regulated ex-vivo, the 16/6Id-induced T-cell proliferation.
Herein, we examined the mechanism responsible for the hCDR1-
induced modification of T-cell functions related to the pathogenesis
Abstracts S227of SLE. We found that hCDR1 treatment of BALB/c mice resulted
in a marked elevation of expression of TGFh in vivo, and in TGFh-
induced suppression of 16/6Id-stimulated T-cell proliferation ex-
vivo. In addition, we provide evidence that one possible mechanism
underlying the hCDR1 and TGFh-induced inhibition of T-cell
proliferation is by down-regulating the expression, and therefore,
the functions, of a pair of key cell adhesion receptors, LFA-1
(aLh2) and CD44, which operate as accessory molecules in
mediating antigen presenting cell (APC)-T-cell interactions. Indeed,
T cells of mice treated with hCDR1 showed a TGFh-induced
suppression of adhesion to the LFA-1 and CD44 ligands, hyaluronic
acid and ICAM-1, respectively, induced by SDF-1a (CXCL12) and
PMA. The latter suppression is through the inhibition of ERK
phosphorylation. Thus, the down-regulation of SLE by hCDR1
treatment may result from the influence of the up-regulated TGFh
on the expression and function of T-cell adhesion receptors, and
consequently, T-cell stimulation, adhesion, and proliferation.
hCDR1 (Edratide) is under a clinical development for the
treatment of SLE by Teva Pharmaceutical Ind.
Su1.112. Fas Ligand (CD95L)-Transduced
Monocyte-Derived Killer-DC Are Protected from
CTL-Induced Cytotoxicity and Delete Antigen-Specific
CD8+ T Cells.
Ch. Schuetz,1 A. Mackensen,2 H. Herfarth,1 D. Halbritter,1
M. Fleck.1 1Department of Internal Medicine I, University of
Regensburg, Regensburg, Bavaria, Germany; 2Division of
Hematology, University of Regensburg, Regensburg, Bavaria,
Germany.
Rationale: Numerous studies have been performed in vitro and
in various animal models to modulate the interaction of DC and T
cells by Fas (CD95/Apo-1) signaling to delete activated T cells via
induction of activation-induced cell death (AICD). However,
similar studies with primary human cells have not been performed.
Recently, we could demonstrate that Fas Ligand (FasL/CD95L)-
expressing bKiller-DCQ can be generated from human monocyte-
derived mature DC using adenoviral gene transfer. To evaluate,
whether these FasL-expressing DC (DC-FasL) could eliminate
human CD8+ T in vitro, coculture experiments were performed.
Methods: Human CD8+ T cells and a CTL clone specific to the
HLA-A2 binding Melan-A26-35 peptide were activated in a first
mixed lymphocyte reaction (MLR) with mature DC pulsed with
Melan-A peptide. Activated T cells were rescued and a second
MLR was established with either DC-FasL, EGFP-transduced
control DC (DC-EGFP) or untreated DC loaded with Melan-A- or
control peptide at different ratios. As a read-out system prolifer-
ation (thymidine incorporation) and apoptosis (Annexin V/PI
staining) of T cells were determined.
Results: FACS-analysis of PKH26 labeled DC revealed that
FasL-transduced DC but not DC or DC-EGFP loaded with Melan-A
peptide were protected from cytotoxicity mediated by Melan-A
specific CD8+ T cells. In addition, no proliferation could be
observed in Melan-A specific CD8+ T cells cocultured with DC,
DC-EGFP or DC-FasL loaded with control peptide. In contrast,
proliferation of activated Melan-A specific CD8+ T cells was
markedly reduced in cocultures with Melan-A peptide-loaded DC-
FasL, whereas a strong secondary proliferative Tcell response could
be observed in cocultures with DC-EGFP or DC. Inhibition of T cell
proliferation was directly related to the numbers of DC-FasL present
in cocultures, and at a ratio of 1:1, T cell proliferation was
completely inhibited by DC-FasL, which was due to induction ofapoptosis in the majority of Melan-A specific CD8+ T cells
(approximately 70%). Spontaneous apoptosis detected in CD8+ T
cells cocultured withMelan-A peptide-loaded DC or DC-EGFP was
low (approximately 25%).
Conclusion: The present results demonstrate for the first time
that human DC-FasL were protected from CTL-mediated cytotox-
icity (counter attack). In addition, Melan-A specific CD8+ T cells
were efficiently eliminated by Melan-A peptide-loaded DC-FasL,
supporting the concept to apply FasL-expressing bKiller-DCQ as a
novel strategy for the treatment of T cell dependent autoimmune
disease.
Inflammatory Bowel Diseases
Su1.113. The Peripheral Cannabinoid Receptor CB2 Is
Required for the Normal Formation of B and T Cell
Subsets.
D. A. Ziring,1 B. Wei,2 P. Velazquez,2 M. Schrage,2 N. Buckley,3
J. Braun.2 1Division of Pediatric Gastroenterology, UCLA David
Geffen School of Medicine, Los Angeles, CA, USA; 2Department of
Pathology and Laboratory Medicine, UCLA David Geffen School
of Medicine, Los Angeles, CA, USA; 3Department of Biological
Sciences, California State Polytechnic University, Pomona, CA,
USA.
Gai2 / mice are deficient in the formation of certain B and
T cell subsets and are susceptible to immune dysregulation, notably
developing inflammatory bowel disease (IBD). A key issue is the
identity of the Gi-coupled receptors mediating this Gai2 require-
ment for lymphocyte development. Here, we test the prediction
that CB2, the Gai2-coupled peripheral endocannabinoid receptor,
is one such receptor. B and T cell subsets, isolated from tissues of
the peripheral, mucosal, and serosal lymphoid compartments of
CB2 null and sufficient mice were quantified by flow cytometry.
Mice bearing the CB2 null phenotype had profound deficiencies in
both B and T cell subsets, particularly splenic marginal zone (MZ)
and peritoneal B1a cells, as well as splenic memory T cells and
intestinal NK and NKT cells. CB2 is required for the formation of
many immunoregulatory B and T cell subsets. These findings
phenocopy and extend the developmental disorder associated with
Gai2 / and suggest that the endocannabinoid system is required
for the formation of T and B cell subsets involved in immune
homeostasis.
Su1.114. The Effect of Bifidobacterium on Murine
Experimental Colitis.
Aiping Bai, Qin Ouyang, Renwei Hu. 1Department of
Gastroenterology, The First Affiliated Hospital, Sun Yat-sen
University, Guangzhou, Guangdong, China; 2Department of
Gastroenterology, Westchina Hospital, Sichuan University,
Chengdu, Sichuan, China; 3Department of Gastroenterology,
Westchina Hospital, Sichuan University, Chengdu, Sichuan,
China.
BACKGROUND AND AIM: The etiology of inflammatory
bowel disease(IBD) is still unknown, but more and more reports
show gut microflora plays some role in pathogenesis of IBD.
Microflora in gut of IBD patients becomes aberrant, with normal
microflora decreased, harmful and potential harmful bacteria
increased. As have been reported, there has close relationship
between gut aberrant microflora and mucosal immune function
disorder, and modification of intestinal microflora may have
therapeutic effect on IBD. In the experiment, we used dextran
sulfate sodium(DSS)-induced colitis in mice which has same
AbstractsS228pathological property as human IBD, and fed mice with
Bifidobacterium before inducing colitis, to study the therapeutic
effect of supplement with bifidobacterium on pathogenesis of
colitis, and explore the possible mechanism.
METHODS: Mice were randomly divided into four groups:
Control,DSS,SASP,and Bifidobacterium(Bif in short). Mice of
groups DSS,SASP,and Bif were fed with 5% DSS(w/v) solution for
7 days to induce colitis, mice of Control just drink distilled
solution, and disease activity index (DAI) was calculated every
day. Mice of SASP were fed with SASP every day during inducing
colitis, and mice of Bif were given Bifidobacterium by oral gavage
from 7 days before the experiment to the end of experiment. The
expression of TNF-a,NF-nB P65,Fas and MPO in inflamed colon
of each group mice was measured at the end of experiment.
RESULTS: Mice of group SASP,Bif showed lower DAI than
those of group DSS since the forth day of experiment. There were
lower expression of TNF-aand MPO in murine inflammatory
colon, lower NF-nB P65 appearance in nuclei of inflammatory
cells, lower Fas expression in colonic epithelia of group SASP,Bif
compared with group DSS at the end of experiment.
CONCLUSION: Treatment with bifidobacterium has benefi-
cial effect on murine experimental colitis, the mechanism may be
involved in such respect: Bifidobacterium inhibits proinflamma-
tory cytokine secretion and NF-nB activation in inflammatory
cells, limits colonic inflammation, downregulates Fas expression in
colonic epithelia of murine inflamed colon, alleviates inflammatory
damage of colonic epithelia and protects the integrity of intestinal
mucosal barrier.
Key words: probiotic experimental colitis
Dextran sulfate sodium inflammation
Su1.115. Anti-Murine TNF-alpha Reverses TNBS Colitis
in Mice but Not Oxazolone Colitis: Potential Role of
Apoptosis Induction.
Chong Shen,1 Philippe Maerten,1 Gert VanAssche,2 Karel
Geboes,3 Paul Rutgeerts,2 Jan L. Ceuppens.1 1Laboratory of
Experimental Immunology, Campus Gasthuisberg, Catholic
University Leuven, Leuven, Vlaams-Brabant, Belgium;
2Department of Gastroenterology, Campus Gasthuisberg, Catholic
University Leuven, Leuven, Vlaams-Brabant, Belgium;
3Department of Pathology, Campus Gasthuisberg, Catholic
University Leuven, Leuven, Vlaams-Brabant, Belgium.
Background: Differences and similarities of cytokine patterns in
CrohnTs disease (CD) and Ulcerative colitis (UC) have been
reported. Proinflammatory cytokines like TNF-alpha, are up-
regulated in the mucosa of CD as well as UC patients. However,
administration of infliximab (a chimeric anti-TNF mAb) has shown
beneficial effect in clinical trials in CD but is less effective in UC.
Aim: 1) to investigate the effect of anti-TNF on trinitrobenzene-
sulphonate (TNBS) and oxazolone (Oxa) colitis in mice as models
for CD and UC respectively; 2) to study the apoptosis-inducing
effect of anti-murine TNF both in vitro and in vivo in mice.
Method: 1) Colitis was induced by rectal administration of 1mg
TNBS or Oxa in 50% ethanol after 2 pre-sensitizations via the skin.
Anti-murine TNF-alpha was given intraperitoneally (i.p.) daily. 2)
Thioglycollate-elicited peritoneal macrophages were treated in
vitro with LPS and anti-murine TNF-alpha or non-specific control
antibody. Annexin V & propidium iodide and 7AAD were used to
study apoptosis on the cell membrane and DNA level respectively.
3) For in vivo analysis of anti-TNF effects on macrophages, anti-
murine TNF-alpha or control antibody was administrated to SCIDmice. Peritoneal macrophages were recovered and apoptotis was
analyzed as described above. Results: 1) In the TNBS colitis
model, mice treated with anti-TNF recovered more rapidly
compared to the control treated mice. Histological analysis
revealed less severe signs of colitis; on the contrary, no beneficial
effect of anti-TNF was found in the Oxa colitis mice. 2) Apoptosis
was induced by anti-murine-TNF in peritoneal macrophages. In
vitro, apoptotic cells in the presence of anti-TNF amount to ~40%
compared to ~20% in the control cultures. In vivo, ~30% less
macrophages could be harvested from the anti-TNF treated group.
A higher percentage of peritoneal macrophages were apoptotic
(~50%) compared to the control group (~25%). Conclusion: Anti-
TNF treatment rescued TNBS colitis mice but had no effect on Oxa
colitis. These results correlate with difference in efficacy of anti-
huamn TNF treatment in UC and CD respectively. The apoptosis
inducing-effect of anti-TNF could be demonstrated in peritoneal
macrophages. The data suggest a different involvement of TNF
expressing cells in the pathogenesis of both disease models.
Su1.116. Evaluation of 5 vs 10 Granulocyteapheresis
Treatments in Patients with Moderate Active Steroid
Dependent Ulcerative Colitis: A Prospective Multicenter
Randomized Trial.
E. Ricart,1 D. Monfort,1 J. Panes,2 M. Esteve,3 R. Lafuente,4 M.
Andreu,5 F. Casellas,6 M. Sans.2 1Gastroenterology, Hospital de
la Santa Creu i Sant Pau, Barcelona, Spain; 2Gastroenterology,
Hospital Clinic i Provincial, Barcelona, Spain; 3Gastroenterology,
Hospital Mutua de Terrassa, Terrassa, Barcelona, Spain;
4Intensive Care Unit, Hospital General de L’Hospitalet, Hospitalet
de Llobregat, Barcelona, Spain; 5Gastroenterology, Hospital Vall
d´Hebron, Barcelona, Spain.
Introduction: Increasing evidence indicates that granulocytea-
pheresis (GCAP) is effective and safe therapeutical strategy in
treatment of the ulcerative colitis (UC). However the ideal
treatment scheme is not established yet.
Objective: This study was carried out to evaluate the efficacy
and safety of 5 as compared to 10 GCAP treatments in patients
with moderate active steroid dependent UC.
Matherials and methods: In this prospective multicenter
randomized clinical trial 20 patients were randomized to 5 or 10
GCAP treatments (1 weekly). Each treatment consisted in a 1hour
apheresis session with AdacolumnR at 30 ml/h with 1,8 l of blood
being processed. The principle efficacy variable was the remission
rate defined by the Rachmilewitz index (CAI) at week 17. Secondary
variables included CAI at all weeks, quality of life questionnaires
(IBDQ and EuroQoL), endoscopic activity index (EAI) at week 17,
as well as steroid consumption and analytical parameters.
Inclusion criteria were: active UC (CAI between 6 and 12),
EAI N4, total colon affected length N25 cm and steroid dependency
defined as at least one unsuccessful attempt to taper down steroids
plus use of N400 mg of prednisone within 4 weeks prior to the study
start. All patients gave written informed consent. Clinical remission
was defined as CAI V4 and clinical response as a drop in CAI z3.
Since some patients are still in the follow-up, efficacy for each
treatment regimen, as well as other secondary variables analysis
will be reported on completing the study.
Results: 12 males and 8 females were included, being the mean
age 41, 7F 15, 2 years and mean disease duration 80, 7 months (6-
528). Two patients had chronic active UC whereas mean number of
flare ups during the year prior to the study entry was 2, 2 F 1 for
remaining patients. All patients were previously treated with 5-ASA
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sporine. 9 patients were randomized to 5 GCAP sessions and 11
patients to 10 GCAP sessions. Global mean CAI was 8 F 1, 2 at
study entry (n = 19); 4, 2 F 2, 5 at week 6 (n = 14); 4, 7 F 3, 5 at
week 11 (n = 11). Global mean prednisone dose was 39, 7F 15, 8 at
baseline, 23, 3F 11, 9 at week 6 and 5, 5F 6, 1 at week 11. Five out
of 11 patients were steroid free at week 11. Mean IBDQ score was
133, 4F 55, 1 at baseline, going up to 175, 5F 40.5 at week 6 and at
188.1 F 47.4 at week 11. Two not serious adverse events, and one
community pneumonia were reported.
Conclusions: Granulocyteapheresis is a safe and effective
treatment for moderate active steroid dependent ulcerative colitis.
In addition, it shows an important steroid sparing effect in a
severely steroid dependant population, even allowing complete
steroid withdrawal.
Su1.117. Cytokine and Chemokine Transcript Profiles in
Acute Pouchitis.
A. Stallmach,1 T. Giese,2 C. Schmidt,3 B. Ludwig,3 S. Meuer.2
1Gastroenterology, Catholic Clinics Essen-Nord, Essen, Germany;
2Immunology, University of Heidelberg, Heidelberg, Germany;
3Internal Medicine II, Saarland University, Homburg, Germany.
Background: After ileo-anal pouch anastomosis (IAP) 10-40% of
patients with ulcerative colitis (UC) but only 5% of patients with
polyposis coli (FAP) develop a pouchitis. Immunoregulatory abor-
malities might be of importance in the pathogenesis of the disease.
Therefore we characterized cytokine and chemokine transcripts in
inflamed and non-inflamed pouches in patients with UC and FAP.
Methods: Mucosal biopsies were taken from 42 patients with
IAP (UC (n = 37) or FAP (n = 5)). Patients with active ileal Crohn´s
disease (CD; n = 14), active UC (n = 8), specific colitis (infectious
colitis, ischemic colitis; n = 15) and patients with non-inflammatory
conditions (n = 13) served as controls. Expression of 30 pro-
inflammatory gene transcripts were quantified using real-time PCR.
Results: Compared to normal ileal mucosa from controls,
biopsies from non-inflamed mucosa from IAP (UC and FAP)
patients expressed elevated transcript levels for MRP-14, IL-8, IL-
1h, IFN-g and MIP-2a. In addition in UC patients expression of
MMP-1 and IL-23 was increased. In UC-IAP patients MRP-14
(2,9-fold), IL-8 (2,6-fold) and IL-1h (3,8-fold) transripts were
elevated in their inflamed mucosa in comparison to their non-
inflamed mucosal biopsies. No differences were found concerning
TNF-a, IP-10, IL-18 and ELC. Levels of TNF-a, IFN-g and IL-23
were elevated in inflamed CU pouch mucosa in comparison to
specific colitis, suggesting a predominantly Th1 mediated inflam-
mation. Transcripts of IL-2, IL-4, IL-6 and IL-12p35 could not be
detected. A good correlation between pouchitis activity (PDAI)
and MMP-1 and MIP-2a transcripts was observed.
Discussion: In acute pouchitis in UC patients after IAP
anastomosis transcript levels of pro-inflammatory cytokines and
chemokines of predominantly Th1 origin were found elevated,
even if these data cannot completely explain the immunolgical
etiology. Quantification of transcript levels allows to estimate the
extent of mucosal inflammation.
Su1.118. Inflammatory Transcript Profiles Reflect Onset
of Clinical Remission in Patients with Steroid Refractory
CrohnTs Disease after Treatment with
Cyclophosphamide or Infliximab.
A. Stallmach,1 T. Giese,2 B. Ludwig,3 M. Zeitz,4 S. Zeuzem,3 S.
Meuer.2 1Gastroenterology, Catholic Clinics Essen-Nord, Essen,Germany; 2Immunology, University of Heidelberg, Heidelberg;
3Internal Medicine II, Saarland University, Homburg, Germany;
4Internal Medicine I, Charite, Berlin, Germany.
Background: Concentrations of proinflammatory cytokines are
increased in the intestinal mucosa of patients with active CD. We
investigated in a prospective study whether cytokine profiles
reflect clinical activity and predict onset of remission in patients
with refractory CD.
Methods: Cytokine transcripts were quantified using Real-time
PCR in mucosal biopsies from 13 patients with active, steroid
refractory CD. Patients were treated with infliximab (n = 7; one
single infusion (5 mg/kg body weight)) or cyclophosphamide (n =
6, 3 cycles of monthly treatment of IV cyclophosphamide (750 mg))
and were followed for up to 8 weeks. Based on a group of 48
patients with active CD and 16 patients without gastrointestinal
disease normal values and pathologic ranges of cytokines/chemo-
kines transcripts were calculated and transfered into a simple
scoring system (Inflammatory Bowel Disease Mucosal Inflamma-
tory Transcript Index (IBD-MITI)) ranging from 0 to 12 points.
Results: 5 of 7 infliximab and 5 of 6 cyclophosphamide treated
patients enter into remission. The IBD-MITI based on MRP-14-,
MIP2a-, IL-8- and MMP-1-transcript levels was strongly elevated
in 12 of 13 patients (median: 9 points). Normalization of increased
values was predictive for onset of remission in these patients.
Discussion: Real-time PCR quantification represents a simple
and objective method for grading inflammation of intestinal
mucosa and has considerable potential in the analysis of clinical
disease activity in CD patients, especially in patients with
immunosuppressive therapies.
Su1.119. Long Term Follow-Up of Ulcerative Colitis
(UC) Treated with a Probiotic Containing the Pingel/BM
Non-Pathogenic Strain of E coli.
M. L. McCann, R. Buck.2 ; 2Microbiology, Kaiser Permanente,
Cleveland, OH, USA.
Patients with UC have different E. coli compared to controls,
including both higher concentrations of specific serotypes, specific
cytotoxic antibodies, higher amounts of adhesive E. coli, and cross-
reactive epitopes on colon mucosa. These putative pathogenic E.
coli, may be normal flora in controls who are not genetically
susceptible to UC. If they could be replaced by antigenically
dissimilar, non-adhesive E. coli, then remissions should occur. The
following cases support this hypothesis in a subgroup of UC.
Beginning in 1972 patients with severe UC were selected for
treatment. The first was a 17 year old boy scheduled for colectomy.
He was anemic from blood loss and growth retarded. Following
temporary sterilization of his bowel with a 2 day course of non-
absorbable antibiotics, a benign E. coli incubated in buttermilk was
administered by mouth. The patient made an unexpected complete
recovery. He remained well for 10 years after which he relapsed.
Based on this case the procedure was refined and additional 27
patients were so treated.
The non-pathogenic E. coli was selected from a donor who had
life-long normal bowel function. It was extensively studied for
cytotoxicity including all known pathogenic serotypes. The non-
absorbable antibiotics vancomycin, cefamandol, gentamycin and
nystatin were selected which regularly rendered the feces tempora-
rily sterile after 36 to 48 hours given P.O. q 4 to 8 hrs with a clear
liquid diet. On day three 60 ml of Pingel/BM E. coli, containing 7-9
billion organisms/ml were administered q 4 h with sterile food. On
day four Lactobacillus acidophilus, DDS-1 strain was added and
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discontinued when remissions occurred, (although we discovered
later that probiotics needed to be continued long-term.).
Results: In patients so treated, with rare exceptions, remissions
regularly occurred, lasting days to months. However most
eventually relapsed. The exceptions were four patients who
sustained complete remissions for over 10 years. In three of these,
by contrast to those who relapsed, the Pingel/BM E. coli replaced
the resident coliform and was consistently cultured from the stool
as the predominant coliform. They also elected to continue to take
prophylactic probiotics. Follow up colonoscopies and biopsies
were normal. In one case, AP, the donor strain disappeared from
feces following prophylactic ceftin therapy for a knee replacement.
He gradually relapsed, the treatment was repeated successfully, and
the Pingel/BM strain was reestablished. He remains well 12 years
after he declined colectomy. A 9 year old girl was treated in 1990.
She remains well and continues to take both E. coli (Mutaflor,
Ardeypharm Co, Germany) and L. acidophilus. Her 20 year old
brother was also treated 10 years later but he did not colonize. He
is improved but unlike his sister, he has not sustained a complete
remission. Other cases with intermediate results will be presented
which suggest that this approach should be pursued with controlled
studies and especially using continued prophylactic probiotics
containing a non-pathogenic E. coli.
Su1.120. Blockade of Interleukin 21 with Soluble
IL21RFc Reduces Inflammatory Cytokines and
Correlates with Suppression of Disease in Mice
Adoptively Transplanted with CD45RBhi CD4+ T Cells.
M. Senices,1 L. Lowe,1 C. Groves,1 S. Benoit,1 X. Li,1 M. Leach,1
C. Nickerson-Nutter,1 M. Collins,1 D. Young.1 1Inflammation,
Wyeth Research, Cambridge, MA, USA.
Interleukin 21 (IL-21), a member of the common gamma-chain
family of cytokines, is secreted by activated T cells and can have a
diverse range of immunomodulatory effects dependent upon the
particular context of the immune response. Interleukin 21 Receptor
(IL-21R) is expressed on many immune system cell types
including activated T cells. Rationale: In situ hybridization studies
have shown that IL-21R is highly expressed in the lymphoid
compartment in the gut, and the human IL-21R gene has been
mapped to chromosome 16 within the CrohnTs Disease suscept-
ibility region, suggesting that the IL-21 pathway may be involved
in regulation of gut homeostasis. We examined the role of IL-21 in
a T cell mediated model of intestinal and skin inflammation.
Methods: CD45RBhi CD4+ naive T cells were transferred into
severe combined immunodeficient (SCID) mice and housed under
different caging conditions so that the mice developed colitis or
colitis with skin lesions resembling psoriasis. Mice were treated
with soluble murine IL-21RFc or an IgG2a control Antibody and
assessed for development of disease. Purified CD45RBhi cells were
also cultured with anti-CD3 and IL-21 or IL-21RFc to determine
the effect on proliferation and cytokine secretion. Results: In
culture, anti-CD3 stimulated CD45RBhi (naive) but not CD45RBlo
(memory) CD4+ T cells proliferated in response to IL-21 and
secreted increased levels of IL-2, IL-4, IL-10, IL-17, IL-18, IFN-g
and TNF-a. Blockade of endogenous IL-21 with neutralizing
soluble IL-21RFc resulted in decreased levels of cytokines in these
cultures. In mice that developed skin inflammation, treatment with
thrice-weekly IL-21RFc seven weeks after CD45RBhi cell transfer,
resulted in reduced erythema, scaling and hair loss when compared
to IgG2a-treated controls. Treatment of CD45RBhi recipient micewith 200 ug IL-21RFc, 3 times per week at the time of cell transfer,
resulted in a significant reduction of clinical signs of colitis as
measured by body weight loss and stool score when compared with
control -treated mice. Macroscopic evaluation of colons from
control treated CD45RBhi recipients showed severe thickening and
swelling which was almost completely suppressed in mice treated
with IL-21RFc. Microscopically, control- treated mice also
exhibited a greater degree of epithelial hyperplasia and leukocyte
infiltration in the lamina propria/submucosa when compared with
IL21RFc-treated mice. Conclusions: Taken together these results
suggest that IL-21 is a potent potential player in the inflammatory
responses in this model and blockade of this pathway may be of
therapeutic benefit in Th1 mediated diseases such as CrohnTs and
psoriasis.
Su1.121. Role of ICOS in Regulating Mucosal Tolerance.
C. V. Arancibia, A. H. Sharpe. 1Department of Pathology, Harvard
Medical School, Boston, MA, USA.
Inducible costimulator (ICOS) is a CD28 homologue that is
induced upon T cell activation. ICOS binds to its ligand ICOSL
which is expressed on fibroblasts, endothelial cells, some epithelial
cells and constitutively at low levels on resting B cells, on some
macrophages and dendritic cells. ICOS ligation enhances T cell
proliferation and the production of several cytokines such as IFN-
g, IL-4 and has a key role in IL-10 production. IL-10 plays an
important role in the induction of regulatory T cells and suppression
of autoimmunity. We have used ICOS deficient (/) mice to
investigate the role of ICOS on 1) the induction and function of
regulatory T cells, and 2) the function of pathogenic effector T cells
using the colitis model developed by Powrie and colleagues. In this
colitis model, the transfer of CD4 + CD25-CD45RBhigh T cells
(Teff) from normal mice to C.B-17 SCID recipients leads to the
development of a Th1-mediated inflammatory bowel disease
similar to IBD in humans. Intestinal inflammation is the result of
the development of a Th1 response driven by enteric bacteria.
Colitis induced by transfer of Teff cells can be prevented by
cotransferring cells contained within the CD4 + CD25 +
CD45RBlow population (Treg).
Surprisingly, we found that ICOS/ regulatory T cells
protected mice from colitis, indicating that ICOS is not required
for the induction of a functional regulatory T cell population.
However, we found that wild type regulatory T cell could not
protect from IBD induced by T effector cells lacking ICOS.
Without ICOS the balance appears to be shifted in the favour of
autopathogenic Th1 cells, such that these effector cells cannot be
controlled by regulatory T cells, thereby resulting in more severe
clinical disease. Thus, these studies suggest that ICOS is a critical
regulator of the balance between regulatory T cells and effector T
cells.
Su1.122. A Critical Regulatory Role of Th2-Like
Transcription Factor c-Maf in Th1-Mediated
Experimental Colitis.
B. Weigmann,1 A. Nemetz,1 C. Becker,1 H.-A. Lehr,2 D. Strand,1
P. R. Galle,1 I.-C. Ho,3 M. Neurath.1 1Laboratory of Immunology,
I. Medical Clinic, Johannes Gutenberg University, Mainz,
Germany; 2Institute of Pathology, Johannes Gutenberg University,
Mainz, Germany; 3Harvard School of Public Health and Harvard
Medical School, Boston, MA.
In this study, we investigated the role of c-Maf, a transcription
factor known to induce IL-4 production, in inflammatory bowel
Abstracts S231diseases. Although CrohnTs disease (CD) is associated with low IL-
4 production by T-bet-expressing Th1 cells in the lamina propria,
surprisingly a higher expression of c-Maf in these cells was found
as compared with control patients. The relevance of this finding
was further evaluated in an animal model of CD induced by
adoptive transfer of CD4 + CD62L+ T cells in RAG-deficient
mice. In this Th1-mediated model, an increase of c-Maf-expressing
T lymphocytes in the lamina propria over time was observed.
Interestingly, adoptive transfer of c-Maf transgenic CD4 + CD62L
+ T cells in RAG-1-deficient mice resulted in an IL-4-dependent
inability to induce colitis and suppressed colitis activity induced by
wild-type CD4+CD62L+ T cells.
In contrast, transfer of CD4+CD62L- T cells from c-Maf
transgenic, but not wild-type mice, induced colitis and augmented
a colitis induced by CD4 + CD62L+ T cells from wild-type mice
in an IL-4-independent pathway, as determined by macroscopic,
histologic, and endoscopic criteria. This was associated with an
accumulation of CD4+ T-bet + CD25 + effector Th1 cells in the
lamina propria of colitic mice. Our results reveal a novel
regulatory role of c-Maf in colitis. Although overexpression of
c-Maf in naive T cells prevents Th1-mediated colitis, over-
expression of c-Maf in memory T-bet+ Th1 cells regulates CD25
expression and augments such colitis. Targeting of c-Maf in
memory T cells in CD appears to be an attractive target for
therapeutic interventions.
Su1.123. Dual Immune Suppressive Activity of
4AZA1378 Alleviates TNBS-Induced Colitis in Mice.
Chong Shen,1 Yuan Lin,2 Gavin Clydesdale,2 Ilse Sienaert,2
Steven De Jonghe,2 Karel Geboes,3 Louis Boon,2 Paul Rutgeerts,4
Jan L. Ceuppens.1 1Laboratory of Experimental Immunology,
Campus Gasthuiberg, Catholic University Leuven, Leuven,
Vlaams-Brabant, Belgium; 24AZA Biosciences, Leuven,
Vlaams-Brabant, Belgium; 3Department of Pathology, Campus
Gasthuiberg, Catholic University Leuven, Leuven,
Vlaams-Brabant, Belgium; 4Department of Gastroenterology,
Campus Gasthuiberg, Catholic University Leuven, Leuven,
Vlaams-Brabant, Belgium.
Introduction: Elevated production of TNF-alpha and activated T
cells play a central role in the pathogenesis of CrohnTs disease
(CD). Recently, 4AZA1378 was identified as a phosphodiesterase-
4 (PDE4) inhibitor (IC50; 31 nM), which explains its inhibitory
effect on LPS-induced TNF-alpha production in vitro (IC50; 245
nM) as well as in vivo. PDE4 inhibition can however not account
for the strong inhibitory effect in the Mixed Lymphocyte Reaction
(MLR) assay (IC50; 4 nM) which suggests another target in this
assay. The latter was confirmed by the inability of Rolipram (a
specific PDE4 inhibitor) up to 50.000 nM to inhibit the MLR. Aim:
To investigate the efficacy of 4AZA1378 in trinitrobenzenesulph-
onate (TNBS) induced colitis in mice, a model of CrohnTs disease.
Methods: Colitis was induced by rectal administration of 1mg
TNBS in 50% ethanol after 2 pre-sensitizations via the skin.
4AZA1378 (20 mg/kg) was given intraperitoneally daily. Results:
Mice treated with 4AZA1378 had less severe signs of colitis and
recovered more rapidly, as evidenced by more rapid weight
recovery, and histologically by a reduction of inflammatory
lesions, less edema, a reduction of goblet cells loss and reduced
wall thickness. Cell infiltration, especially infiltration of neutro-
phils, as shown by myeloperoxidase activity, was reduced in
4AZA1378 treated animals. Conclusion: Our findings show that
4AZA1378 has a strong remission-inducing effect in TNBS colitis.This study supports further pre-clinical and clinical development of
this novel molecule for treatment of Crohn´s disease.
Su1.124. Immunohistochemical Localization of
Interleukin-6 in Pancreatitis and Normal Pancreas.
M. Jablonowska,1 H. Milnerowicz,1 J. Rabczynski,2 S.
Milnerowicz.3 1Departament of Biomedical and Environmental
Analyses, Wroclaw University of Medicine, Wroclaw, Poland;
2Department of Pathological Anatomy, Wroclaw University of
Medicine, Wroclaw, Poland; 3Department and Clinic of
Gastointestinal and General Surgery, Wroclaw University of
Medicine, Wroclaw, Poland.
INTRODUCTION:
Experimental and clinical studies have indicated that cytokines
play an essential role as mediators of inflammatory process
associated with pancreatitis. One of the most important mediators
of inflammation is interleukin-6 (IL-6). Interleukin-6 is a 22–30-
kDa glycoprotein produced by many cell types and has a wide
variety of biologic, differentiation, and growth-promoting effects in
a variety of target cell types.
The importance of IL-6 in the acute phase has been confirmed
by the observation that it stimulates the synthesis of acute phase
proteins, including C reactive protein (CRP), from hepatocytes in
vitro and in vivo. IL-6 levels are raised in patients with acute
pancreatitis (AP) and correlate with disease severity. Serum
concentrations IL-6 of patients during the first 48 hours of
hospitalization is a valuable marker permitting the differentiation
of various types of pancreatitis (AP, CP-chronic pancreatitis, CEP-
chronic exacerbated pancreatitis).
The immunhistochemical detection of IL-6 in pancreas during
pancreatitis, to our knowledge, has not been previously described.
In previous studies, the presence of IL-6 in human pancreatic cells
had only been shown on biopsy material from diabetic patients or
normal gland.
AIMS & METHODS:
The aim of the study was to identify immunohistochemically
the localization of IL-6 and to determine IL-6 expression in CP and
CEP. Samples of tissues of normal pancreas (n = 5) (obtained at
autopsy) and CP (n = 14), CEP (n = 2) were verified
histopathologically and then IL-6 was localized by immunohis-
tochemical staining using the monoclonal anti-human IL-6 anti-
body (R&D Systems USA) and test LSAB2–HRP (DAKO,USA)
to visualize IL-6/Ab complexes.
RESULTS:
We found only scare acinar cells staining positively for IL-6 in
the normal human pancreas (/+); islets cells did not show IL-6
immunoreactivity. In slices of the pancreas, derived from patients
with CP and CEP, a much stronger immunohistochemical reaction
(+ +; + + +; diffused and focal) was noticed as compared to controls.
IL-6 was localized in exocrine and islet cells of the pancreas. The
immunohistochemical reaction of ducts cells was also strong.
Interestingly, this cytokine was detected in cytoplasm and very
close to nucleus. Moreover, in cases of CP and CEP with
inflammatory infiltration, there were a markedly stronger IL-6
expression (+ + + +), than that observed in specimens without
infiltrate.
CONCLUSION:
In conclusion, the results presented herein clearly demonstrated
a moderate and strong expression of IL-6 in exocrine and
endocrine cells of patients with CP and CEP. This suggests that
elevated IL-6 levels of patients with pancreatitis are probably
AbstractsS232owing to leakage of this cytokine in the circulation following
massive pancreatic cells destruction.
Su1.125. Tumor Derived TGF-beta Suppresses
Inflammation Dependent Colon Cancer Development by
Inducing FoxP3 in Tumor Infiltrating CD4+ T Cells.
C. Becker,1 M. C. Fantini,1 C. Schramm,1 A. Nikolaev,1 P. R.
Galle,1 M. F. Neurath.1 1I. Department of Medicine, University of
Mainz, Mainz, Germany.
Recent data suggest that thymus derived CD4+CD25+ regu-
latory T cells play an important role in the tolerance of the immune
system towards tumors. These regulatory cells specifically express
the transcription factor FoxP3 which is believed to be a master
regulator of regulatory T cell development. In contrast to this
thymic development, recent data have demonstrated that
CD4+CD25+ regulatory T cells can also be induced from naRve
cells in the periphery. We and others have further provided evidence
that TGF-beta is critical for this peripheral induction of regulatory
cells by inducing the expression of FoxP3. Here we now
demonstrate that the induction of FoxP3+ regulatory T cells by
TGF-beta is a physiological event in the colon with a potential role
in the pathogenesis of colon cancer.
Accordingly mice were injected with a single dose of the
mutagenic agent azoxymethane followed by three weekly periods
of Dextran sulphate (DSS) in drinking water, interrupted by each
14 days of recovery. Treated animals developed numerous tumors
in the colon. In a recent study we have shown that tumor growth
in this colitis associated colon cancer model was driven by
inflammatory CD4+ T cells infiltrating the tumor. As described
for human colon cancer, we now demonstrate that dysplastic
epithelial cells produced very high amounts of TGF-beta.
Interestingly CD4+ cells isolated from the same tumors expressed
high levels of FoxP3 mRNA while CD4+ cells isolated from
surrounding non-dysplastic colon tissue did not. Our findings
were further confirmed by immunohistochemical staining.
Accordingly, FoxP3 expressing cells were found in high numbers
in the lamina propria of the tumor closely associated to dysplastic
epithelial cells. In contrast only few FoxP3 positive cells were
detectable in the lamina propria of surrounding normal colon
tissue. Based on these data, we speculated that tumor derived
TGF-beta may induce FoxP3 in tumor infiltrating T cells. In order
to functionally analyze whether tumor derived TGF-beta may
play a role in the induction of FoxP3+ regulatory T cells in vivo
we induced colon tumors in mice overexpressing a dominant
negative TGF-beta receptor specifically in T cells. Tumors
collected from these mice showed a similar infiltration with
CD4+ T cells as compared to wildtype mice. However, CD4+ T
cells isolated from tumor tissue of such transgenic mice showed
strongly diminished expression of FoxP3 mRNA as compared to
tumors of wildtype animals. Strikingly, tumors in transgenic mice
were larger that wildtype tumors implicating that in this model of
inflammation dependent colon cancer, tumor induced regulatory
T cells control tumor growth.
Based on our findings we propose a model in which tumor
derived TGF-beta induces FoxP3 expression in infiltrating
CD4+ T cells giving them a regulatory phenotype. Such tumor
induced regulatory T cells in the case of inflammation
dependent cancer can control tumor growth. However, in
spontaneous cancer development tumor induced regulatory T
cells may mediate tolerance towards the tumor by inhibiting
anti-tumor immunity.Su1.126. Cross-Linking of Lipid Rafts on CD4+ T Cells
by an Epithelial Lectin, Galectin-4, Contributes to the
Exacerbation of Intestinal Inflammation.
K. Shirane,1 A. Hokama,1 Y. Shimomura,1 A. Ogawa,1 M.
Yoshida,2 S. T. Rietdijk,3 S. B. Snapper,4 C. Terhorst,3 R. S.
Blumberg,2 A. Mizoguchi.1 1Department of Pathology,
Massachusetts General Hospital, Boston, MA, USA; 2Division of
Gastroenterology, Brigham and WomenTs Hospital, Boston, MA,
USA; 3Department of Immunology, Beth Israel Deaconess Medical
Center, Boston, MA, USA; 4Department of Medicine,
Massachusetts General Hospital, Boston, MA, USA.
Accumulating studies has addressed inflammatory bowel
disease as an autoimmune disease. However, it is not known
whether the intestinal epithelial cell-derived antigens are involved
in generation of mucosal immune responses or are the target of
the pathogenic process. By using a modified Serological Analysis
of Recombinant cDNA Expression Libraries (SEREX) which is
an antigen-screening approach utilizing humoral and cellular
immune responses, we herein identify an epithelial cell-derived
endogenous lectin, galectin-4 (G4), as a pathogenic mediator to
exacerbate intestinal inflammation. G4 specifically stimulated the
production of IL-6 by CD4+ T cells but not other cell types
present in the diseased colon of CD45RBhigh-treansfer and DSS-
induced colitis models and TCRa knockout (KO) mice. In
contrast, G4 was unable to stimulate IL-6 production by CD4+ T
cells present in the normal colon of these colitis models as well
as wild type mice. Confocal microscopic analysis showed that G4
interacts with the immunological synapse on colonic CD4+ T
cells as indicated by specific binding of G4 to the lipid raft-
accumulating regions. Interestingly, the binding intensity of G4
on CD4+ T cells and the G4-mediated IL-6 production were
increased under intestinal inflammatory conditions. G4 has been
recently shown to specifically bind to sulfated (non-sialylated)
core1 O-glycan structure. Indeed, expressions of a member of
sialyltransferases (ST6GalNAc-2, 3, 6 and ST8Sia-1,3) that are
specifically utilized for the modification of O-glycans were
markedly downregulated in the CD4+ T cells only under
inflammatory conditions. In addition, the exposure of core1 O-
glycan without sialylation on the CD4+ T cells was confirmed by
intensified binding of PNA that specifically binds to this
oligosaccharide structure. Mechanistically, the G4-mediated IL-6
production by CD4+ T cells is mediated by protein kinase C
(PKC) u-associated cascade as indicated by a fact that colonic
CD4+ T cells from PKCu KO mice treated with DSS were unable
to respond to G4 to produce IL-6. Functionally, administration of
anti-G4 mAb not only led to the attenuation of chronic colitis in
B cell-deficient TCRa double knockout mice but also effectively
enhanced the recovery from 3.5% DSS-induced acute colitis.
These studies not only indicate the presence of an immunogenic
epithelial lectin that contributes to the exacerbation of intestinal
inflammations but also provide a novel insight into the biological
role of lectin/CD4+ T cell interactions under inflammatory
conditions.
Su1.127. Immunohistochemical Localization of Copper/
Zinc-Containing Superoxide Dismutase in Normal
Pancreas and in Pancreatitis.
H. Milnerowicz,1 M. Jablonowska,1 J. Rabczynski,2 K.
Grabowski.3 1Department of Biomedical and Environmental
Analyses, Wroclaw University of Medicine, Wroclaw, Poland;
2Department of Pathological Anatomy, Wroclaw University of
Abstracts S233Medicine, Wroclaw, Poland; 3Department and Clinic of
Gastointestinal and General Surgery, Wroclaw University of
Medicine, Wroclaw, Poland.
INTRODUCTION:
The role of oxitative stress in the pathogenesis of pancreatitis
and benefits of antioxidants have been suggested in various
studies. Superoxide dismutase (SOD), a primary antioxidant
enzyme, scavenges reactive free radicals by catalyzing the
dismutation of superoxide anion into molecular oxygen and
peroxide. Copper and zinc-containing SOD (Cu/Zn SOD) is the
intracellular eznymes, which activity depends on metals.It has been
shown that metallotionein (MT), also antioxidant protein, in high
concentration in the pancreas- serves a function of exceptionally
sensitive indicator of Zn status. Our recent studies confirm that MT
is present in exocrine and endoxrine cells of patients with chronic
pancreatitis, particularly in acinar cells of pancreas (1).
In the last years, evidence was provided that there appears to be
a decrease in Cu/Zn SOD expression in pancreatic cells from
normal pancreas to chronic pancreatitis (2).
AIMS & METHODS:
The aim of the study was to identify immunohistochemically
the distribution pattern of the Cu/Zn SOD in chronic pancreatitis
(CP) and chronic exacerbated pancreatitis (CEP). Samples of tissues
of normal pancreas (n = 5) (obtained at autopsy) and CP (n = 14),
CEP (n = 2) were verified histopathologically and then Cu/Zn SOD
was localized by immunohistochemical staining using the primary
polyclonal anti-human Cu/Zn SOD antibody (Calbiochem, UK) and
second anti-sheep peroxidase conjugated antibody (Sigma, Ger-
many) to visualize Cu/Zn SOD- Ab complexes.
RESULTS:
We found only scare acinar cells staining positively for Cu/Zn
SOD in the normal human pancreas (the body and tail of pancreas)
(/+; +); islets cells did not show Cu/Zn SOD immunoreactivity.
In slices of the pancreas, derived from patients with CP and CEP, a
much stronger immunohistochemical reaction (+ +; + + +) was
noticed as compared to controls. Cu/Zn SOD was localized in both
acinar and islet cells of the pancreas. Interestingly, immunohisto-
chemical reaction of ducts cells was considerably stronger (+ + + +)
than that of islet and acinar cells (+; ++). We also compared
expression of Cu/Zn SOD and metallothionein (MT), at the same
histological specimens and experimental conditions. Whereas, Cu/
Zn SOD was markedly manifested in ducts cells of pancreas, MT
did not apeared in it.
CONCLUSION:
In conclusion, these studies clearly demonstrate a moderate and
strong expression of Cu/Zn SOD in acinar, islets and duct cells of
patients with CP and CEP. This suggests that pancreatitis induce
expression Cu/Zn SOD in pancreas. The overexpression of this
enzyme in ducts cells may function as an intracellular antioxidant
and can compensate for the lack of MT in the cells of pancreas.
1. Milnerowicz H., Chmarek M., Rabczynski J., et al.: Pancreas
2004, 29: 28-32.
2. Cullen J.J., Mitros F.A., Oberley L.W.: Pancreas 2003, 26:
23-27.
Su1.128. The Response of Blood Monocytes of Coeliac
Patients to Gliadin.
L. Palova-Jelinkova,1 J. Cinova,1 B. Pecharova,1 M. Cerna,2 L.
Tuckova, 1 H. Tlaskalova -Hogenova. 1 1Department of
Immunology, Czech Academy of Sciences, Prague, Czech Republic;
23rd Medical Faculty, Charles University, Prague, Czech Republic.Celiac disease (CoD), an intestinal damage, is induced by
gliadin, an alcohol soluble fraction of gluten. Peptic fragments of
gliadin were shown to activate cells of innate immunity including
macrophages/monocytes to cytokine and chemokine production.
The aim of this study was to examine whether: (i) peripheral blood
monocytes (PBMoC) respond to peptic digest of gliadin by IL-8
and or TNF-a production, (ii) this activity depends on the presence
of IFN-g, (iii) there exist a difference in response of PBMoC
isolated from blood donors, active and treated (GFD) coeliac
patients (including analysis of the causal factors) (iiii) the signal-
ling pathway is mediated via NF-nB molecule activation.
Methods: PBMoC were incubated with various doses of peptic
digest of gliadin alone or together with IFN-g, or pre-incubated
with IFN-g before adding the gliadin. HLA genes were typed using
PCR with sequence-specific primers (SSP-PCR). NF-nB DNA
binding activity was detected by TransAM NF-kB transcription
factor assay kit.
Results: The capacity of monocytes isolated from active CoD
patients and patients on GFD to produce IL-8 was significantly
higher than that of healthy donors. The simultaneous addition of
IFN-g had no enhancing effect on IL-8 production and the
prestimulation of cells with IFN-g for 24 hours resulted in a
significant increase of IL-8 production mainly in cells from
healthy controls. The enhanced TNF-a secretion was detected
mainly in gliadin stimulated monocytes from CoD patients and
was markedly increased by simultaneous addition of IFN-g.
Interestingly, prestimulation of cells with IFN-g for 24 hours
increased gliadin-induced TNF-a production in the group of
healthy donors and patients on a GFD, and slightly in the group
of active CoD patients. This effect reduced the differences in
TNF-a production among tested groups. The signaling pathway
triggered by gliadin was mediated via NF-nB subunits p50 and
p65. Specific inhibitors suppressed DNA binding activity of NF-
nB as well as gliadin induced IL-8 and TNF-a secretion. The
impact of HLA-DQ2/DR3 antigen expression in healthy donors
and the keeping of GFD in treated patients on cell response were
evaluated.
Conclusions: IL-8 and TNF-a produced by the cells of innate
immunity could enhance the effect of gliadin specific lymphocytes
and participate in the cascade leading to the damage of intestinal
mucosa in celiac patients.
Su1.129. Eosinophilic Esophagitis (EE): Improved
Clinical Responses without a Concomitant Reduction in
Esophageal Eosinophilic Infiltration.
F. M. Schaffer, R. B. Pillai, K. A. Hetherington, R. Shannon, T. C.
Hulsey, D. Lewin, S. N. Khubchandani, V. Tolia. 1Pediatric
Pulmonary, Allergy, and Immunology, MUSC, Charleston, SC,
USA; 2Pediatric Gastroenterology, MUSC, Charleston, SC, USA;
3Pediatrics, MUSC, Charleston, SC, USA; 4Pediatric
Gastroenterology, MUSC, Charleston, SC, USA; 5Pediatric
Epidimiology, MUSC, Charleston, SC, USA; 6Pathology, MUSC,
Charleston, SC, USA; 7Gastroenterology, Wayne State School of
Medicine, Detroit, MI, USA; 8Gastroenterology, Wayne State
School of Medicine, Detroit, MI, USA.
Objective: EE is an allergic inflammatory disorder of the
esophagus with a significant recent increase in the number of
reported pediatric cases. The initiation of the esophageal inflam-
matory injury has been theorized to be due to food allergies and
possibly aeroallergen sensitivities. We reviewed the cases of 32
pediatric patients (pts) with EE in order to discern clinical,
AbstractsS234histological, and treatment correlates and to acquire a better
understanding of disease pathogenesis.
Methods: Allergy (food and aeroallergen) testing was com-
pleted on 26/32 pts. Serial Esophageal Biopsies were performed on
23/32 pts and serial clinical scores were determined on 25/32 pts.
Clinical scores (0 to 5) were based upon the presence/absence of
Abd pain, Vomiting, Dysphagia, Wt loss/gain, and Chest pain.
Results: 22/25 pts (88%) demonstrated clinical improvement
based on a comparison of clinical scores from baseline until after 3
to 45 months of treatment. Treatment: 11/22 pts-Elimination Diet
(ED) + Steroids (swallowed Flovent or oral steroid); 8/22 pts- ED
only; 2/22 pts-steroids only; 4/22 pts-noncompliant or PPI only.
While the majority of pts (65%) demonstrated diminished
esophageal eosinophilic infiltration (15/23 pts who underwent
serial biopsies), 8/23 demonstrated clinical improvement with no
evidence of diminished esophageal eosinophilic infiltration. No
differences in treatment regimens existed between these groups.
Further, 2/8 pts had been treated longer than average lengths of
time, respectively for 30 and 34 months.
Conclusions: EE is an allergic inflammatory disorder that in
most cases clinically responds to a treatment regimen of ED and
steroids. A subset of patients demonstrated an improved clinical
outcome without diminished esophageal eosinophilic infiltration.
These results may reflect an incomplete therapeutic response which
requires close follow-up in order to detect an end of disease
remission. Alternatively, these findings may be characteristic of a
unique patient subset that merits further investigation.
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Immunodeficiency: Primary or Acquired
Su2.01. Rheumatic Manifestations in a South Italy
Population HIV Positive: Correlation with CD4 Count.
A. Caliri,1 L. G. De Filippis,1 G. Scibilia,1 C. Romano,1 G. F.
Bagnato.1 1Rheumatology Unit, Policlinico Universitario G
Martino, Messina, ME, Italy.
Infection by human immunodeficiency virus can involve
several clinical manifestations affecting almost every organ or
system in the body. Rheumatic manifestations may develop at any
time of the clinical spectrum, but usually are seen in late stages,
although sometimes they constitute the initial presentation of the
viral illness. 46 patients (43 males, 3 females), with infection by
HIV, from South Italy, were recruited for the study. HIV
positivity was detected by enzyme-linked immunosorbent assay
(ELISA) and confirmed by Western Blot. Patients were asked to
complete a questionnaire containing 10 questions pertaining to
rheumatic diseases. The following data were collected: age, sex,
duration of HIV infection, CD4 count. Rheumatologic manifes-
tations were found on clinical evaluation by questionnaire
administration and physical examination in 11 of 43 patients
(23.9%). RESULTS: Arthralgias were the commonest manifes-
tations, occurring in 9 patients (82%). Pain was usually
intermittent and of moderate intensity and involved 2 or more
joints. One patient had ReiterTs syndrome (9%) with a mild
oligoarthritis of the knees and spondylitis responding promptly to
NSAIDs. Another patient had a mild oligoarthritis (9%) involving
knees and ankles. CD4 count was 481 F 264 (mean F standard
deviation) in the group of patients with HIV without arthralgias
and 385.5 F 170.3 in the group of patients with arthralgia,without significant correlation between CD4 count or viral load
and arthralgias.
Su2.02. Quality Control of siRNA, Optimizing ItTs
Transfection Efficiency and Monitoring CD4 Gene
Silencing Effect with a Microfluidic Chip Device.
T. Preckel,1 C. Buhlmann,1 M. Valer.1 1Liquid Phase Analysis,
Agilent Technologies, Waldbronn, BW, Germany.
Gene silencing with RNA interference (RNAi) is a new
breakthrough technology with high potential for development of
therapeutics. Here, the delivery of small interfering RNA (siRNA)
into cells is of key importance in elucidating gene and protein
function. Differing types of interfering RNAs and several
methods of delivery into cell types exist. All require transfection
optimization, as the efficiency of transfection can be affected by
many factors. Furthermore, the selection of the best silencing
sequence at optimized siRNA transfection conditions is based on
the integrity and purity of siRNA, siRNA uptake and cell
viability. Given the complexity of monitoring and optimizing
these types of experiments a new tool is required that would
allow for minimal sample and reagent consumption in a fast and
easy to use format.
We describe the use of a microfuidic chip-based system to
quickly verify siRNA quality and to determine the optimal
conditions for gene silencing experiments. First, RNA integrity
and purity is assessed. Second, fluorescently labeled siRNA is
used to optimize transfection parameters in mammalian cells. Life
cell staining is performed on-chip reducing the overall analysis
time for 6 samples to less than 50 minutes from harvesting the
cells to final results with actual hands-on-time of less than 10
minutes. Transfection efficiency is measured as the percentage of
cells with a strong siRNA uptake within the live cell population.
Third, gene knockdown is measured with the same system. Here,
staining the protein of interest, e.g. CD4, with fluorescently
labeled antibodies demonstrates the downregulation of proteins
after siRNA transfection. The gene silencing mechanism can also
be verified in a given cell line by using a GFP-tag and co-
transfecting the tagged protein and a Cy5 labeled siRNA against
that protein. Successful silencing can be measured by reduced
GFP expression within Cy5 positive cell population at different
timepoints after transfection.
Su2.03. Cardiac Thrombus in Omenn Syndrome.
S. S. Kilic.1 1Pediatric Immunology, Uludag University School of
Medicine, Bursa, Turkey.
Omenn syndrome is characterized by generalized erythematous
skin rash, lymph node enlargement, hepatosplenomegaly, increased
serum Ig E levels, eosinophilia, and evidence of severe combined
immune deficiency. Patients develop fungal, bacterial, and viral
infections. A-three-month-old girl with Omenn syndrome devel-
oped right ventricular thrombosis. Echocardiographic investigation
revealed a rounded structure filling the apex and corpus of the the
right ventricle. We investigated for hypercoagulation state and
discussed ventricular thrombosis which is uncommon in Omenn
syndrome.
Su2.04. The Frequency and Effects of Vitamin A
Deficiency in Common Variable Immunodeficiency
Patients.
S. S. Kilic.1 1Pediatric Immunology, Uludag University School of
Medicine, Bursa, Turkey.
Abstracts S235Common Variable Immunodeficiency (CVID) is a heterogenous
group of B-cell deficiency syndromes characterized by hypogam-
maglobulinemia, impaired antibody production and recurrent
bacterial infections. Vitamin A (Vit A), a naturally occuring
antioxidant micronutrient, has immunomodulating effect in
patients with immunodeficiency, including an influence on
cytokine production and lymphocyte growth and functions. Vit A
deficiency is associated with a shift from type 2 cytokines to
predominantly type 1 cytokines. The aim of this study was to
investigate vitamin A levels in CVID patients and the effects of Vit
A deficiency on cytokine production.
Nineteen CVID patients and 13 healthy controls who attended
to the Department of Pediatric Immunology in Uludag University
School of Medicine, Turkey, were involved in this study. Serum Vit
A, serum neopterin (indicator of chronic inflammatory state),
serum type 1 (TNF-alpha, IL-2) and type 2 cytokine levels (IL-4,
IL-10) were determined. 9-cis retinal which is Vit A derivative was
added to lymphocyte cultures of CVID patients and controls and the
effects on cytokine production were investigated.
While serum Vit A levels of CVID patients were obviously low
in CVID patients (in 75%), serum neopterin levels were higher than
control group (in 31%). Elevated serum neopterin levels and low Vit
A levels in CVID patients suggests that serum Vit A levels were
lower secondary to recurrent infections seen in these patients. Serum
IL-4 level was found lower in CVID patients than controls. The
results of lymphocyte culture in CVID patients showed that IL-4 was
higher in 9-cis retinal stimulated group than unstimulated group.
However the expected change on other cytokines was not seen.
As a result, our study shows that CVID patients have low serum
Vit A levels and this finding correlates with their chronic
inflammatory condition and supplementation with Vit A may have
role in downregulation of inflammatory responses.
Su2.05. Pulmonary Abscess Due to Aspergillus spp. in
Patients with Chronic Granulomatous Disease.
S. S. Kilic.1 1Pediatric Immunology, Uludag University School of
Medicine, Bursa, Turkey.
Chronic granulomatous disease (CGD) is the most common
phagocytic disorder. Invasive fungal infections are an important
cause of morbidity and mortality in CGD patients, with Aspergillus
spp. being the most frequent fungal pathogens.
A fifteen-month-old boy with a cavitation in the right upper lobe
presented with persistent weight loss, fever, cough and roentgeno-
graphic evidence of right upper lobe abscess resistant to antibiotic
therapy. A lung biopsy led to the diagnosis of pulmonary asper-
gillosis. A respiratory burst assay revealed the diagnosis of CGD.
He was treated with high doses of liposomal amphotericin B (7/
mg/kg) for an invasive pulmonary Aspergillus nidulans infection.
The infection regressed during 12 weeks of treatment to the
addition of interferon-gamma.
Su2.06. HodgkinTs Lymphoma Developing in a
4.5-Year-Old Girl with Hyper-IgE Syndrome.
Mohammad Amin Kashef,1 Sara Kashef,2 Farhad Hanjani,3
Mehran Karimi.4 1Allergy Research Center, Shiraz University of
Medical Sciences, Shiraz, Fars, Islamic Republic of Iran;
2Immunology and Allergy, Shiraz University of Medical Sciences,
Shiraz, Fars, Islamic Republic of Iran; 3Dermatology, Shiraz
University of Medical Sciences, Shiraz, Fars, Islamic Republic of
Iran; 4Pediatric Oncology, Shiraz University of Medical Sciences,
Shiraz, Fars, Islamic Republic of Iran.We report a case of HodgkinTs lymphoma developing in a 4.5-
year-old child with hyper-IgE syndrome. This is one of few cases of
malignancy reported in this syndrome. A white girl with asthma,
recurrent pneumonia, bronchiectasis, atopic dermatitis, recurrent
skin infections and growth retardation. Immunologic evaluation
revealed high level of immunoglobulin E (7000 IU/dl) and
peripheral eosinophilia.
She was found to have normal values for serum IgG, IgM,
IgA, sweat chloride test, WBC chemotaxis and serum comple-
ment function. The occurance in this patient of HodgkinTs
lymphoma suggests that individuals with hyper-IgE syndrome
may also be at increased risk for developing premature
malignancies, although the precise immunologic defect in this
syndrome is still unknown.
Su2.07. The Prognostic Importance of Variants of Allele
Genes HLA DRB1 and IL-4 in HIV-Infection.
Loudmila P. Sizyakina, Julia V. Sokolova. 1Center of Clinical
Immunology, State Medical University, Rostov-on-Don, Russian
Federation; 2Russian Federation.
The purpose of our study is developing of distribution of
variants of allele genes HLA DRB1 and IL-4 (on SNP in a
promotor site-C-590T) in HIV-infected patients for an establish-
ment of immunological and genetic markers of determination and/
or resistance to HIV-infection.
HLA-detecting of HLA DRB1 genes and IL-4 in 30 HIV-
infected patients was made using the method of multiprimer
amplifications sequence-specific primers basis on PCR at a level
of allele groups with the set of reagents: (bDNA-technologyQ,
Moscow). Variants of allele gene IL-4 were defined with the
help of PCR with the subsequent restriction of products of
amplification.
Immunological and genetic analysis revealed, that the most
significant protective effect have the specificities DR B1*01
(RR = 0,46; PF = 0,15), DR B1*04 (Rr = 0,52; PF = 0,175) and
DR B1*13 (Rr = 0,6; PF = 0,108). The strongest positive
associative correlation has been revealed in specificities DR
B1*16 (Rr = 4,3; EF = 0,124) and, probably, DR B1*14 (Rr = 4,76;
PF = 0,051).
Distinction in distribution of variants of allele promotor genes
IL-4 in HIV-infected and healthy European people has been
revealed. Quantity of HIV-infected people with homozygous
variant C/C was lower, than in healthy European people (28,6 %
and 83,3 %, accordingly), while with variants T/T (21,4% and 0%)
and C/T (50,0% and 16,7 %) are essentially higher. Besides
distinctions in formation of the immune response and cytokine
status in HIV-infected patients have been revealed various variants
of promotor allele gene IL-4.
The received results testify that immunological and genetic
factors have essential influence on processes of infecting and
development of disease and can be used for defying of probability
of case of infection, and the individual predicting of disease, and for
the development of the individualized approach for monitoring and
diving adequate immunocorrection therapy of the HIV-infection.
Su2.08. Recurrent Infections and Cytokine Imbalance in
Hyper-IgE Syndrome Are Not Due to a Defect in
Toll-Like Receptor Pathways.
E. D. Renner,1 F. Hoffmann,1 I. Pawlita,1 V. Hornung,2 D. Hartl,1
M. Albert,1 A. Jansson,1 S. Endres,2 G. Hartmann,2 B. H.
Belohradsky,1 S. Rothenfusser.2 1University ChildrenTs Hospital,
AbstractsS236Dr. von Haunersches Kinderspital, Ludwig-Maximilians-University,
Munich, Germany; 2Department of Internal Medicine, Division of
Clinical Pharmacology, Ludwig-Maximilians-University, Munich,
Germany.
Hyper-IgE syndrome is a rare primary immunodeficiency of
unknown etiology characterized chronic eczema, elevated total
serum IgE, recurrent infections of skin and respiratory tract, and
variable associated skeletal symptoms. Recent reports about
pyogenic bacterial infections in patients and animals with defects
in Toll-like receptor (TLR) pathways lead us to search for related
defects in patients with hyper-IgE syndrome.
Cytokine profiles in six patients with hyper-IgE syndrome were
analyzed in serum samples, in T cells after stimulation with PMA/
Ionomycin and in peripheral blood mononuclear cells stimulated
by TLR ligands and bacterial products including LPS (TLR4),
peptidoglycan (TLR2), PolyIC (TLR3), R848 (TLR7/8), CpG-A
and CpG-B (TLR9), zymosan and heat killed listeriae mono-
cytogenes. Results were compared to healthy controls.
Reduced percentage of IFN-gamma, IL-2, and TNF-alpha
producing T cells after PMA stimulation in patients with hyper-
IgE syndrome was found implying an impaired inflammatory T
cell response. Augmented serum levels of IL-5 point to an
associated Th-2 shift. However, normal production of cytokines
(TNF-alpha, IL-6, IL-10, IFN-gamma, IP-10) and upregulation of
CD86 on B cells and monocytes after TLR stimulation ruled out a
defect in TLR signaling pathways.
In conclusion, a dysbalance in T cell responses of patients with
hyper-IgE syndrome was detected as described before, but no
indication for an underlying defect in Toll-like receptor pathways
was observed.
Su2.09. Defective Functioning of Dendritic Cells in
Common Variable Immuno Deficiency (CVID): A
Common Denominator for the Multiple Symptoms
Displayed by CVID Patients.
Jagadeesh Bayry, Olivier Hermine, Eric Oksenhendler, Michel D.
Kazatchkine, Srini V. Kaveri. 1Memory Group, The Edward Jenner
Institute for Vaccine Research; INSERM U681, Compton, Nr
Newbury, Berkshire, United Kingdom; 2CNRS-UMR 8147, Necker
Hospital, Paris, France; 3Department of Clinical
Immunopathology, Saint Louis Hospital, Paris, France; 4INSERM
U681, Institut des Cordeliers, Paris, France; 5INSERM U681,
Institut des Cordeliers, Paris, France.
Objective:
Common variable immunodeficiency (CVID) is a heteroge-
neous immunodeficiency with characteristic recurrent bacterial
infections due to hypogammaglobulinemia and incapacity to
generate memory B cells. In addition to dysfunctional immuno-
globulin production, patientTs T-cell activation is impaired,
resulting in low production of cytokines and decreased T-cell
proliferation. Patients further suffer from gastrointestinal infec-
tions, autoimmune disease, and various B-cell neoplasm. We
addressed whether CVID is associated with impairment in the
dendritic cell (DC) compartment, as DCs play a central role in the
development of adaptive immunity.
Materials and Methods:
Heparinized blood samples were collected from CVID patients
at least 21 days following the last infusion of intravenous
immunoglobulin (IVIg) or from newly diagnosed naive CVID
patients prior to IVIg therapy. As control, blood samples were
obtained from patients with selective antibody deficiencies whoreceived IVIg similar to CVID patients, and healthy controls.
Monocyte-derived DC from patientsT blood and from control
groups were generated after differentiation for six days in the
presence of GM-CSF, IL-4 and10% autologous plasma.
For allogeneic mixed lymphocyte reaction, DCs from CVID
patients and healthy donors were exposed to CD4+ T-cells of third-
party healthy donors.The CD4+ T cells were isolated by magnetic
cell sorter (MACS) cell isolation kit (Miltenyi Biotech, Bergisch
Gladbach, Germany). Cytokines were quantified by Quantikine
ELISA kit (Immunotech, Marseilles, France).
Results:
Dendritic cells (DC) from CVID patients have severely
perturbed diiferentiation and maturation. Although the total
number of DC appears normal as determined by CD11c
expression, they express only nominal levels of CD1a, a hallmark
of LangerhanTs cells, and completely fail to up-regulate CD83,
typically expressed on fully mature DC. Moreover, patientsT DC
express markedly reduced levels of the costimulatory molecules
CD80 and CD86 that are critical for T-cell stimulation; and HLA
class II, the antigen presenting molecule. In turn, patientsT DC
induced weak proliferation of allogeneic T cells and produced
significantly low amounts of interleukin-12 (IL-12) upon CD40
signaling.
Conclusions:
Since DC play a central role in T-cell activation, and in
immunoglobulin synthesis, a failure of DC to mature into fully
stimulatory cells and to present antigens may provide a more
general explanation for the various symptoms of CVID patients.
Multiple defects in the immune system, including malfunctioning
of DC, appear to be prominent features of CVID patients.
Su2.10. Clinical Profile of Primary Immunodeficiencies
Diseases Patientes Followed up at Hospital das Clı´nicas
da Universidade Federal de Minas Gerais.
L. A. O. Cunha,1 D. B. Greco,2 J. A. Pinto.1 1Paediatrics,
Faculdade de Medicina da Universidade Federal de Minas Gerais,
Belo Horizonte, Minas Gerais, Brazil; 2Infectious and Contagious
Diseases, Faculdade de Medicina da Universidade Federal de
Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.
Objective: To describe the clinical and social demographic
profile of patients with Primary Immunodeficiencies Diseases
followed up at HC-UFMG. Methods: The patients followed up at
HC-UFMG, diagnosed as Primary Immunodeficiency Disease
according international consesus criteria, were studied. In these
patients, a questionnaire was applied after informed consent,
obtained from the parents and patients. It was performed nutritional
evaluation by body mass index for age. The statistical analysis was
performed using Epiinfo 6.0 package. Results: We studied 46
patients, 61% male sex. The followed diseases were found:
common variable immunodeficiency, X-linked agammaglobuline-
mia, C1-esterase deficiency, IgA-deficiency, IgG subclass defi-
ciency, specific antibody deficiency, chronic granulomatous
disease and ciclic neutropenia. The median age was 14 years old
and the median age at onset of symptoms was 1 year old. The
diagnosis was made at median age of 9,5 years old. Only familial
history was significant factor in early diagnosis (P = 0,03). The
patients showed high frequency of infectious diseases, hospital-
ization and need of intensive care. They present also allergic,
autoimmune and chronic inflammatory disease. Discussion: The
study shows the need of adequate investigation of patients with
increased susceptibility to infection. The careful investigation
Abstracts S237including familial history and immunological assessment may
contribute to reduce morbidity and mortality.
Su2.11. New Single Nucleotide Polymorphisms in the
Gene Encoding the Phagocyte Oxidase 67 kDa Protein.
L. Gomez-Restrepo,1 M. T. Rugeles,2 P. J. Patino,2 A.
Condino-Neto.1,3 1Pediatrics, State University of Campinas
Medical School, Campinas, SP, Brazil; 2Immunology, University
of Antioquia Medical School, Medellin, Colombia;
3Immunology-Institute of Biomedical Sciences, University of Sao
Paulo, Sao Paulo, Brazil.
The NADPH oxidase of phagocytes produces reactive oxygen
species, necessary for the innate immune response against a variety
of bacteria and fungi. One of its essential components is p67-phox,
a 67-kDa cytosolic protein is encoded by the NCF2 gene located in
the long arm of chromosome 1. Varied mutations involving the
NCF2 gene result in an autosomal recessive form of chronic
granulomatous disease (CGD), a primary immunodeficiency
characterized by severe and recurrent infections. We have
described nucleotide changes in the NCF2 gene of normal subjects
and some p67-phox–deficient patients that apparently were not
responsible for the CGD phenotype, but they potentially modify
the expression of NCF2 gene. In order to determine if one of these
changes corresponds to a non-pathogenic polymorphism, we
analyzed its occurrence in the general population. This nucleotide
change corresponds to an AYG transition in position -21 of the 3V
end of intron 10 (IVS10-21AYG), within the branch acceptor
sequence necessary for RNA splicing. This substitution was
analyzed in 114 subjects: 36% were homozygous for A, 43%
were heterozygous and 21% were homozygous for G. The region
between exons 9 and 13 containing of NCF2 cDNA was analysed
by RT-PCR amplification and sequencing. Complete (452 bp) and
alternative (284 bp, without exon 11) fragments were observed in
G genotypes. Functional analysis included respiratory burst
activity and NCF2 gene expression. The DHR test as assayed by
flow cytometry was 99.6% for G/G individuals, 99.45% for A/G
and 99% for the A/A individuals (P = 0.81, Kruskal-Wallis Test).
The NCF2 gene expression was assayed by real time PCR. The A/
A genotype was used as a reference for comparing the A/G and G/
G genotypes. The NCF2 gene expression was similar among
subjects carrying the 3 genotypes (P = 0.937, Kruskal-Wallis test).
We conclude that the IVS10-21AYG substitution corresponds to a
polymorphism in the NCF2 gene, and its location within a branch
acceptor sequence gives rise to alternative splicing. However it
does not alter NCF2 gene expression or the respiratory burst
activity under certain experimental conditions.
Su2.12. Chronic Granulomatous Disease in Latin
American Patients: Clinical Spectrum and Molecular
Genetics.
P. Agudelo-Florez,1 C. Prando-Andrade,1 J. A. Lopez,1 B. T.
Costa-Carvalho,2 A. Quezada,3 F. J. Espinosa,4 M. A.
Souza-Paiva,5 P. Roxo,6 M. M.S. Carneiro-Sampaio,7 P. E.
Newburger,8 A. Condino-Neto.1,7 1Pediatrics, State University of
Campinas Medical School, Campinas, SP, Brazil;
2Pediatrics-Allergy, Immunology & Rheumatology, Federal
University of Sao Paulo Medical School, Sao Paulo, Brazil;
3Pediatrics, University of Chile Medical School, Santiago, Chile;
4Immunology, National Institute of Pediatrics, Mexico, Mexico;
5Pediatrics, Rio de Janeiro State Employees Hospital, Rio de
Janeiro, Brazil; 6Pediatrics, Ribeirao Preto MedicalSchool-University of Sao Paulo, Ribeirao Preto, SP, Brazil;
7Immunology, Institute of Biomedical Sciences-University of Sao
Paulo, Sao Paulo, Brazil; 8Pediatrics, University of Massachusetts
Medical School, Worcester, MA, USA.
Background: Chronic granulomatous disease (CGD) is a
primary immunodeficiency characterized by early onset of
recurrent and severe infections. The molecular defects causing
CGD are heterogeneous and lead to absence, low expression, or
malfunctioning of one of the phagocyte NADPH oxidase
components. The aim of this work was to analyze the clinical
features and to investigate the molecular genetic defects of Latin
American patients with CGD.
Procedures: The study included 14 patients. The diagnosis was
based on a history of recurrent severe infections, impaired
respiratory burst, and the demonstration of an underlying mutation
by single strand conformation polymorphism (SSCP) or RT-PCR
analysis, followed by genomic DNA or cDNA sequencing.
Results: Seven unrelated patients were found to have the X-
linked form of CGD. Heterogeneous mutations affected the CYBB
gene: 2 insertions, 1 substitution, and 4 splice site defects; two of
them are novel. Seven patients presented with one of the autosomal
recessive forms of CGD (A47-CGD); all had the most common
mutation, a DGT deletion in exon 2 of the NCF1 gene. Pneumonia
was the most frequent clinical feature, followed by pyodermatitis,
sinusitis, otitis, and liver abscess. Patients with X-CGD were more
likely to have initial infections before age 2 years and to have
inflammatory obstructive granulomas later. None of the patients
had severe adverse reactions to BCG immunization.
Conclusions: X-CGD patients from Latin America showed a
high degree of molecular heterogeneity, including two novel
mutations. Their clinical characteristics included early onset of
infections and eventual obstructive granulomas. A47-CGD repre-
sented 50% of the reported cases, a higher prevalence than reported
in other series.
Su2.13. Hereditary Angioedema in Childhood-A
Practice Guideline.
R. J. Boyle,1 M. L.K. Tang.1 1Immunology, Royal ChildrenTs
Hospital, Parkville, Victoria, Australia.
Hereditary angioedema is an uncommon condition which
usually first presents in childhood. In the absence of appropriate
treatment hereditary angioedema has a high mortality. There are a
number of reports of successful short and long-term treatment
with individual agents in those who suffer from hereditary
angioedema, and the availability of these agents varies interna-
tionally. A recently published international consensus statement
provides guidance for the management of such patients in
adulthood, but there remains little guidance in the literature for
the management of children and adolescents with hereditary
angioedema. The needs of this age group are different to those of
adults-in particular their symptomatology differs from adults, and
the adverse effects of androgen treatment are different in children
and adolescents. Here we review the treatment options available
for children and adolescents with hereditary angioedema, and
propose a simple evidence based guideline for the management of
such patients.
Su2.14. Abnormal NeutrophilTs Chemotactic Activity in
Children with Congenital Insensitivity to Pain with
Anhidrosis (CIPA): The Role of Nerve Growth Factor
in Chemotactic Activity.
AbstractsS238A. Beigelman,1 J. Levy,1 N. Hadad,2 V. Pinsk,1 R. Levy.2
1Department of Pediatrics, Soroka Medical Center, Beer Sheva,
Israel; 2Infectious Disease Laboratory, Soroka Medical Center,
Beer Sheva, Israel.
Congenital insensitivity to pain with anhidrosis (CIPA) is a rare
and severe genetic disorder. It comprises absence of sensation to
noxious stimuli and inability to sweat. Loss of pain sensation leads
to skin lacerations followed by deep tissue infections. CIPA has a
relatively high prevalence in the consanguineous Israeli-Bedouin
population, who carry a common mutation in the TrkA gene
encoding the tyrosine kinase receptor for nerve growth factor
(NGF). This defect in the NGF receptor results in complete
absence of nonmyelinated and small myelinated fibers in the dorsal
root ganglia. NGF has been shown to have chemotactic activity on
neutrophils in-vitro and in animal models. We analyzed neutrophil
functions in children diagnosed with CIPA and hypothesized that
neutrophil chemotaxis is impaired as a result of the abnormal
activity of the TrkA receptor.
Twelve children genetically diagnosed with CIPA and carrying
a 1926 ins-T mutation in the gene encoding for TrkA were
recruited for the study. Two independent analyses of neutrophil
functions including: chemotaxis, superoxide generation and
phagocytosis, were performed in each child. Chemotaxis was
assessed toward fMLP on agarose plates. Superoxide production
was measured by reduction of acetyl- ferricytochrome c after
stimulation of PMA, OZ and fMLP. Phagocytosis was assayed
by ingestion of zymosan particles opsonized by pooled human
serum.
Chemotactic migration of CIPA patientsT neutrophils was
significantly suppressed compared to controls (68.9 F 4.7%),
while superoxide production and phagocytosis were normal. NGF
alone did not act as a chemoatractant to neutrophils obtained from
healthy donors. However, in the presence of NGF, neutrophils
migration toward fMLP was elevated.
Our results demonstrate an impaired chemotactic activity of
neutrophils in CIPA patients. The chemotactic defect can account
for the high prevalence of severe staphylococcal skin and bone
infections of these children. Decreased chemotactic migration can
be attributed to the molecular defect in the TrkA receptor as it was
revealed that NGF has a strong adjuvant effect on fMLP-directed
migration of neutrophils.
Su2.15. The IgG 2F5-Like Antibody in Serum of
Mexican Patients with AIDS Progression Prior to and
after the Highly Active Anti-Retroviral Therapy.
Y. Palacios-Rodriguez,1 T. G. Gazarian,2 A. Majluf-Cruz,3 K. G.
Gazarian.1 1Department of Molecular Biology and Biotechnology,
Institute of Biomedical Research, Mexican National
University(UNAM), Mexico-City, DF, Mexico; 2Department of
Public Health, Faculty of Medicine, Mexican National
University(UNAM), Mexico-City, DF, Mexico; 3AIDS Clinic,
Regional Hoospital bGabriel ManceraQ, Mexico-City, DF,
Mexico.
The mAb 2F5 is one of the few cloned human antibodies
with strong neutralizing activity against a broad range of HIV-1
laboratory and primary isolates. The evaluation of its anti-viral
role in the infection and in the disease development usually
meets difficulties because of its law amount or even absence in
HIV-1-infected individuals. Using synthetic peptides containing
the ELDKWA sequence from the gp41 membrane-proximal
region recognized by the mAb 2F5 and mAb 2F5 as a positivecontrol, we assayed in ELISA the reactivity with ELDKWA of
IgG purified from sera of 30 Mexican patients with disease
progression prepared prior to and after the initiation of Highly
Active Antiretroviral Therapy (HAART). We found all sera to
contain different but substantial levels of antibody reacting with
ELDKWA. In addition, initiation of HAART led to elevation of
the seroreactivity, which decreased gradually to the initial level
after 24-hours of therapy. Serum of a patient with highest
reactivity was investigated in a detail and shown the reactivity
level to correlate with the decrease in viral load. The detection
of 2F5-like antibody in all 30 patients, not reported for other
countries, may either be explained by differences in the
infection phases investigated or assigned to the local genetic
variations of HIV-1 found in recent epidemiological survey.
Since the epitope eliciting the antibody is conserved in clade B
population, and the epitope is linear and available in form of
synthetic peptide as antigen, we explore the possibility that the
seroreactivity with ELDKWA peptides may be a diagnostic
marker of the infection and disease progression in this country.
Further studies are in progress to verify the hypothesis that the
observed elevation of ELDKWA-seroreactivity by the therapy is
due to the improved immunological status resulting from a
suppression of the viral load in the critical phase of the disease
progression.
Su2.16. Genetically Determined Deficiency of the Innate
Immune Defence Protein, MBL-Associated Serine
Protease-2 (MASP-2).
S. Thiel,1 J. C. Jensenius,1 L. Truedsson,2 M. Carlsson,2 W. K.
Ip,3 Y. C. Lau.3 1Medical Microbiology and Immunology,
University of Aarhus, Aarhus, Denmark; 2Clinical Microbiology
and Immunology, Lund University Hospital, Lund, Sweden;
3Paediatrics and Adolescent Medicine, The University of Hong
Kong, Hong Kong, China.
The innate immune defence is important for preventing
infections or for eliminating microorganisms, which have
penetrated the mechanical barriers of the body. Cell-bound as
well as humoral molecules participate in recognizing the
microorganisms by their pathogen-associated molecular patterns
(PAMPs). Among the first group (termed pathogen recognizing
receptors, PRRs) are the Toll-like proteins, while collectins and
ficolins represent the latter group, and thus belong to the broader
group of pathogen recognizing molecules, or PRMs. One of the
collectins, mannan-binding lectin (MBL) and two ficolins, H-
and L-ficolin are capable of activating the complement system.
MBL, H-ficolin and L-ficolin each, thanks to their oligomeric
structure provides for 12 or more clustered recognition domains,
which allows for high avidity binding to suitably spaced PAMPs.
MBL, and the mentioned ficolins are all three found in complex
with proenzymes, named MBL-associated serine proteases
(MASPs). Three MASPs, MASP-1, MASP-2 and MASP-3 exist.
After recognition of PAMPS the binding allows for the
activation of the MBL-associated serine proteases. MASP-2 in
turn activates C4 and C2 to generate the C3 convertase,
C4bC2b. The outcome is the direct killing of the invader by
the membrane attack complex or opsonization and killing via
phagocytosis.
When examining about 100 patients with suspect immunode-
ficiency we identified one patient who had normal levels of MBL
but did not have the capacity to activate the complement system
when probed on a carbohydrate surface. The patient was found to
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CUB1 domain) (Steengard-Petersen et al, New Eng J Med,
2003). This mutation, changing an aspartic acid to a glycine,
prevents the association of MASP-2 to MBL and the ficolins. We
have since observed homozygocity in two more patients. The
SNP occurs in Caucasians with a gene frequency of about 1%,
giving rise to deficiency in about 1/10,000. The gene frequency
of 5.5 % stated in the above mentioned paper was based on 100
blood donors and was independently verified; however it appears
to be a statistical aberration. We did not observe this MASP-2
SNP when analyzing samples from 200 healthy Asians from
Hong Kong.
As innate immune system factors may be involved in poor
outcome in cystic fibrosis 112 of such patients (aged 4–45 years),
were screened for MBL and MASP-2 levels and for MBL
genotypes and for the MASP-2 SNP. We observed a higher
frequency of the MASP-2 SNP in this patient population (no
homozygous individuals) but no correlation to lung function was
seen with MASP-2 SNP or with MASP-2 levels.
Theoretically MASP-2 deficiency is a more serious condition
than MBL deficiency, since MASP-2 is also required for comple-
ment activation by the H- and L-ficolin.
Su2.17. Phenotypic Analysis of Peripheral Blood and
Tissue Memory B Cells in Common Variable
Immunodeficiency (CVID).
A. P. Williams,1 C. Stephens,1 L. Hedges,1 A. Mani,1 E. Hodges,1
J. Smith.1 1Department of Clinical Immunology, Southampton
General Hospital, Southampton, United Kingdom.
CVID is a heterogeneous primary immunodeficiency disorder
characterised by hypogammaglobulinaemia and repeated bacterial
infections. Whilst many cellular abnormalities have been described
in such patient, recent interest has focused on subtyping such
patients based upon the presence or absence of peripheral B cell
memory subsets. We have developed a whole blood assay for the
detection of naRve and memory B cells in peripheral blood and
compared this to the previously described PBMC separation
techniques for subtyping peripheral B cells. Additionally, we have
analysed a cohort of CVID patients using this assay and compared
their peripheral blood memory B cell subset distributions to that
seen within their peripheral secondary lymphoid organs.
Four colour flow cytometry was undertaken upon lysed whole
blood and density centrifugation separated peripheral blood
mononuclear cells. A series of 10 healthy controls was used to
compare the 2 methods and a further 30 controls analysed to set up
a reference range using the whole blood assay. 11 CVID patients
were subtyped by this method into MBO (no memory cells), MB1
(no class switched memory cells)and MB2 (normal memory cells)
classifications. Patients within the MB0, MB1 and MB2 classi-
fications that had secondary lymphoid tissue archived, were
analysed by immunohistochemistry for the presence of memory
B cells.
The whole blood assay performed well and correlated with the
density centrifugation separation technique previously described.
For the IgM memory cells the correlation coefficient (R2)
between the two assays was 0.958 and for class switched cells
it was 0.984. A normal reference range was established using
healthy controls. As a percentage of peripheral B cells, naRve B
cells = 64% F 24% (2SD), total memory cells = 32% F 24%,
IgM memory cells = 17% F 16% and class switched memory
cells = 15% F 12%.11 CVID patients were analysed and 5 subtyped as MBO, 4 as
MB1 and 2 as MB2. These subtypes were stable over a 12 month
period. Tissue sections were analysed for a representative patient of
each of the 3 groups. A lymph node from a MB0 patient showed no
evidence of germinal centre CD27 B cells compared to a normal
tonsil. Similarly a lymph node biopsy of a MB1 patient showed no
evidence memory B cells in a lymph node. Finally, a duodenal
biopsy of a MB2 patient did show evidence of CD27 positive
memory B cells within this tissue.
The whole blood assay appears to be as informative as the
previously described assay for assessing B cell memory status.
This assay is more cost effective and convenient to undertake
within a routine laboratory. The reference ranges establish a
minimum level of 12% for total memory B cells (mean F 2SD)
with no individual having less than 14% total memory cells, 4%
IgM memory cells or 9% class switched memory cells. Such B cell
memory subsets are constant over time in adult patients with CVID
and correlate with the B cells identified in their peripheral
lymphoid tissues.
Su2.18. Plasma Interleukin-7 Levels before Highly
Active Antiretroviral Therapy May Predict CD4+
T-Cells Recovery in HIV-Children.
A. Perez,1 S. Resino,1 A.A. Meca,1 M.D. Gurbindo,2 M.A.
Munoz-Fernandez.1 1Laboratorio de Immunobiologia Molecular,
Hospital bGregorio MaranonQ, Madrid, Spain; 2Servicio de
Inmuno-Pediatria, Hospital bGregorio MaranonQ, Madrid, Spain.
Objective: The recovery of CD4+ T cells in children after
HAART supports the existence of some homeostatic mechanism
that detects low levels of CD4+ T-cells and activates the necessary
mechanisms to achieve a T-cell repopulation. In our experience, the
thymus plays a key role in this repopulation, being thus these
homeostatic mechanisms likely to lead to an increase in the thymic
production of new T cells. In order to establish the role of plasma
IL-7 levels before HAART as prognostic marker of CD4+ T-cells
recovery in HIV-infected children, a retrospective longitudinal
study was performed in HIV-children on first-line of highly active
antiretroviral therapy (HAART).
Patients and methods: The inclusion criteria were: a) to begin
HAARTwith protease inhibitor; b) CD4+ T-cells V20% at entry to
the study; c) at least 6 months on follow-up; d) more than one year
of age. From initial 67 HIV-infected children on first-line HAART,
only 27 HIV-children with CD4+ T-cells V20% had biological
samples and they could be selected to be studied. Those HIV-
infected children were divided into two groups according to their
percentile 75 (P75) of plasma IL-7: a) Low IL-7: 21 HIV-children
on HAART with low IL-7 (IL-7 VP75 (11.97 pg/ml)) at baseline;
b) High IL-7: 6 HIV-children on HAART with high IL-7 (IL-7 N
P75 (11.97 pg/ml)) at baseline.
Results: HIV-infected children with plasma IL-7 levels N11.97
pg/ml achieved CD4+ T-cells z25% faster than HIV-children with
plasma IL-7 levels V11.97 pg/ml (P =0.017). This way, HIV-
children with plasma IL-7 levels N11.97 pg/ml achieved CD4+ T-
cells z25% to 10.6 (Confidence interval of 95% (CI95%): 0; 23.1)
months and HIV-children with plasma IL-7 levels V11.97 pg/ml
achieved CD4+ T-cells z25% to 37.1 (CI95%: 4.7; 69.4) months.
The RP of immunological response to HAART were also
calculated, and high IL-7 group had a RP to achieve CD4+ T-
cells z25% of 3.24 (CI95%: 1.16; 9.0).
Conclusion: Our data indicate that IL-7 was a good marker of
CD4+ T-cells recovery in HIV-infected children.
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Children and Adults with HIV-Infection after HAART.
S. Resino,1 E. Seoane,1 A. Perez,1 E. Ruiz-Mateos,2 M. Leal,2
M.A. Munoz-Fernadez.1 1Laboratorio de Inmuno-Biologia
Molecular, Hospital General Universitario bGregorio MaranonQ,
Madrid, Spain; 2Grupo de Estudio Hepatitis Virica y SIDA,
Hospital Universitario bVirgen del RocioQ, Sevilla, Spain.
Objective: To assess the different profile of immune recon-
stitution after HAART in HIV-children and HIV-adults who
recovered normal CD4+ T-cell counts on highly active antiretro-
viral therapy (HAART).
Design: Cross-sectional study.
Patients and methods: We carried out a study in 9 HIV-
Rec-adults and 10 HIV-Rec-children on HAART with viral
load (VL) V400 copies/ml at least during 6 months before
beginning the study, and with CD4+ z500 cells/AL at the start
of immunologic studies and CD4+ V300 cells/AL anytime
before. These patients were compared with 9 HIV-A-adults and
8 HIV-A-children who never had had CD4+ b500 cells/AL;
and 15 Healthy-adults and 20 Healthy-control (HIV seronegative
subjects).
Results: Children had higher values of TRECs and lower IL-7
levels than adults. When we compared Z-score values of HIV-
adults and HIV-children, we observed that HIV-Rec-adults had
lower TRECs levels (P = 0.036) and similar IL-7 levels than HIV-
Rec-children. The HIV-children had higher values of
CD4+CD45RAhi+CD27+ counts than HIV-adults. However, HIV-
children had similar percentage of CD8+CD45RAhi+CD27+ than
HIV-adults, and higher values of CD8+CD45RAhi+CD27+/Al than
HIV-adults. HIV-children had similar values of memory CD4+ T-
cell counts and CD8+CD45RO+ percentages than HIV-adults, but
lower values of CD8+CD45RO+/Al than HIV-adults. Only, HIV-
Rec-children had lower values of CD8+CD45RAhi+CD27+ Z-score
than HIV-Rec-adults (P = 0.055). Also, HIV-A-children had lower
values of CD8+CD45RAhi+CD27+ (P = 0.046) and
CD8+CD45RO+ (P = 0.015) Z-scores than HIV-A-adults.
Conclusion: The restoration of CD4+ and CD8+ T cells after
HAART in HIV-infected adults seems to be mainly the conse-
quence of antigen-independent peripheral expansion of T-cells,
although a role of the thymus in immune reconstitution in adults
cannot be discarded.
Su2.20. Understanding HIV Infection through
Dynamical Modeling: Vaccines WonTt Work, What
Will?
I. Kramer.1 1Physics, University of MD, Catonsville, MD.
Mathematical modeling the transmission and dynamics of HIV
infection can lead to a deeper understanding of the disparate
experimental data and identify therapies most likely to be effective
in controlling the disease. Dynamically modeling the time-
dependent HIV prevalence in the Nairobi Sex Worker cohort lead
to the prediction, subsequently observed, that the observed
resistance or immunity to HIV infection exhibited by some
members of the cohort is not absolute but transient. Thus, whatever
cellular or other type of immunity that is responsible for this
observed resistance to HIV infection is not strong enough to
reliably prevent infection. The dynamics of HIV infection below
the viral density threshold can only be inferred from a dynamical
model extrapolated into this region. A model analysis of viral load
growth during the primary HIV infection leads to the conclusion
that the viral load doubling time immediately following infectionvaries between 0.16 and 0.46 days. Analyzing published modeling
results on the steady-state HIV infection in chronically infected
patients leads to the conclusion that the viral load doubling times
immediately following HAART interruption are virtually identical
to the above results for primary infection patients. Moreover, the
doubling times at threshold for infected patients treated with
vaccine and/or IL-2 therapies before and/or after HAART with-
drawal are virtually identical to those of untreated cohorts. Thus,
neither prolonged familiarity with HIV infection nor vaccine and/or
IL-2 therapies significantly increase the strengths of the immune
systemTs humoral or interferon responses to HIV infection. An
important question to answer is why vaccine and/or IL-2 therapies
all fail to measurably strengthen the immune system response to
HIV infection. Dynamically modeling the rebound of HIV
infection following HAART withdrawal leads to the conclusion
that the immune systemTs inability to reduce the viral load to a
value below threshold is not due a failure in its phagocytic arm but
to the failure of its cellular arm to clear productively infected cells
from the host at a rapidly enough rate. This failure is traceable to
the existence of a pool of productively infected CD4+ cells (T cells,
natural killer cells, etc.) whose half-lives in vivo are uncharacter-
istically long so that their numbers are easily replaced by newly
infected, similarly long-lived, CD4+ cells. One compartment of
this pool consists of CD4+ Natural Killer cells that are HIV-
1infectable, have higher survival half lives than typically infected
CD4+ T cells, and are unaffected by HAART. This pool cannot be
cleared by the immune system, primed by vaccines and/or IL-2 or
not, and is responsible for the observed, characteristic, saturation in
the viral density curve at the viral set-point. Thus, an HIV infected
immune system cannot eliminate all sources of viral production on
its own- outside antiviral intervention is needed. Expanding
HAART to include fusion blockers and overcoming its current
deficiencies is the most promising path to take in seeking an
effective therapy for HIV infection. Moreover, achieving and using
the ideal HAART as a prophylactic would prevent infection in the
uninfected.
Su2.21. Model for the Repopulating Capacity of
Transplanted T Cells.
Sebastian Newrzela,1 Sanaz Taromi,1 Roland Zahn,1 Dorothee
Von Laer.1 1Georg-Speyer-Haus (Chemotherapeutisches
Forschungszentrum), Georg-Speyer-Haus (Chemotherapeutisches
Forschungszentrum), Frankfurt AM Main, Hessen, Germany.
Transfer of gene-modified T cells is a potent option for treatment
of immune deficiencies. A major technical challenge is to preserve
the repopulating capacity of T cells during ex vivo expansion and
culture.A limited survival of transplanted gene-modified Tcells was
observed in several clinical trials. This shows that the transplanted
ex vivo expanded T cells may have a competitive disadvantage to
the non-manipulated cells in the recipient, especially if the
transgene does not confer a strong selective advantage.We
established a transplantation model in the lymphocyte deficient
mouse strain Rag-1/ to analyze the repopulation capacity of
transplanted T cells. Donor T cells were collected from Ly-5.1
C57BL/6 and Ly-5.2 mice. One population was treated with an ex
vivo expansion and transduction protocol, the other population
served as unmanipulated competitor cells. Both populations were
mixed in several variations and transplanted into Rag-1 recipients.
The competitive repopulation between treated and untreated cells
was analyzed by distinguishing surface antigen expression. The
data predict that not only high levels of gene marking, but also the
Abstracts S241dfitnessT of transplanted cells determine the effectiveness of
therapies with gene-modified T cells.
Su2.22. Apoptosis and the Emergence of Clonal Dual
Positive CD4CD8 Cells in a Young Boy with CD4
Lymphopenia.
M. T. Krishna,1 E. Hodges,1 S. Harris,1 S. M. Morgan,1 J. O.
Warner,2 J. Hourihane,2 J. L. Smith.1 1Wessex Immunology
Service, Southampton University Hospitals NHS Trust,
Southampton, Hampshire, United Kingdom; 2Division of Infection,
Inflammation and Repair, School of Medicine, Southampton
University Hospitals NHS Trust, Southampton, Hampshire, United
Kingdom.
BW presented at age 2 yrs with tonsillitis, pneumonia,
lymphadenopathy, oral thrush, anaemia and hepatosplenomegaly.
Investigations revealed lymphopenia wbc- 5.2  109 /L (neut: 4.5,
lymp: 0.5, mono: 0.1). Throat and mouth swabs revealed a h
haemolytic group C strepococcus, pseudomonas aeroginosa and
candida, chest radiography showed right middle lobe pneumonia.
He was treated with a IV erythromycin and cefuroxime and made a
good recovery. Within 3 months he presented with right sided
pneumonia complicated by empyema, treated effectively with
intravenous azlocillin and tobramycin. Four months later he
presented with strepococcal pneumonia treated with intravenous
penicillin and cefotaxime and was commenced on long term
penicillin prophylaxis. At the age of 3 years he presented with a
vasculitic rash on lower limbs and buttocks compatible with
pityriasis lichenoides. At this stage he was assessed immunologi-
cally, this revealed normal serum IgG (13 g/l), IgM (6 g/l) and IgA
(1.7G/L) and a poor response to pneumococcus and HIB vacci-
nations. Immunophenotyping of blood lymphocytes showed
reduced CD3, CD4 and CD8 positive cells (0.16, 0.07 and 0.09 
10 9 /l respectively), normal CD19+ B cells (0.27  10 9 /l) with a
poor response to PHA and anti-CD3. Bonemarrow examination was
unremarkable. EBV serology was positive for IgG consistent with
recently acquired infection. An apoptotic defect of both CD4 and
CD8 cells was shown with excessive surface expression of CD95 on
CD4 and CD8 cells, together with enhanced apoptosis in cell
cultures as judged by propidium iodide and annexin V staining. At
age 5 yrs BW mounted a good antibody response to pneumococcus
and HIB and lymphocyte response to PHA was normal. However,
his CD3, CD4 and CD8 lymphopenia (0.24, 0.11 and 0.11  10 9 /l
respectively) persisted. BW was monitored routinely and at age 10,
his lymphocyte count improved and a population of CD4 CD8 dual
positive cells was found for the first time (lymphocytes 1.210*9/l,
CD3 0.76, CD4 0.24, CD8 0.18, CD4 CD8 dual positives 0.4). A
TCRVB7 clone was identified in association with CD4 CD8 double
positive cells confirmed by cell sorting analysis. This clone was not
identified in earlier populations of cells and there was no evidence
for TCR or IgH clones in earlier cell preparations. BW is currently
well without prophylactic antibiotics. We present a child with an
apoptotic defect and low CD4 count who developed a clonal
CD4CD8 dual positive TCRVB7 T cell population with clinical
improvement. While there is no evident cause for this population,
viral aetiologies remain a possibility.
Su2.23. Hypogammaglobulinemia and
Lymphoproliferation in Two Patients with Heterozygous
Deleterious Mutation of the Caspase-9 Gene.
A. Chiocchetti,1 R. Mesturini,1 T. Bensi,1 A. Biava,1 M. Ferretti,1
C. Santoro,1 C. Pignata,2 F. Rieux-Laucat,3 I. Dianzani,1 U.Ramenghi,4 L. D. Notarangelo,5 U. Dianzani.1 1IRCAD and
Department of Medical Sciences, University of Eastern Piedmont,
Novara, Italy; 2Department of Pediatrics, University of Naples,
Naples, Italy; 3INSERM Unite 429, Hopital Necker-Enfants
Malades, Paris, France; 4Department of Pediatrics, University
of Turin, Turin, Italy; 5Department of Pediatrics, University of
Brescia, Brescia, Italy.
Fas triggering induces apoptosis by activating a caspase cascade
composed of caspase-8, -10, -7, and -3. A second pathway induces
mitochondrial release of cytocrome c that induces assembly of
Apaf-1 and several procaspase-9 molecules, that are then activated,
and activate caspase-3. In lymphocytes, Fas-induced apoptosis is
involved in shutting off the immune response. Inherited deleterious
mutations impairing Fas function cause the autoimmune lympho-
proliferative syndrome (ALPS), characterized by autoimmunities,
lymphoadenopathy/splenomegaly, and expansion of CD4/CD8
double-negative (DN) T-cells. ALPS can be caused by hetero-
zygous mutations of Fas (ALPS-Ia), FasL (ALPS-Ib) or caspase-10
(ALPS-II), whereas the mutated gene is unknown in other patients.
Intriguingly, the parent transmitting the mutation is often healthy,
which suggests a role for other complementary factors.
Looking for genes involved in ALPS, we detected a hetero-
zygous single nucleotide mutation (A/C in position 710 of cDNA)
of the caspase-9 gene in two non-consanguineous patients; one
(patient-1) displayed an ALPS-like pattern associated with severe
hypogammaglobulinemia, the other (patient-2) displayed mild
hypogammaglobulinemia and developed Burkitt lymphoma. The
mutation was not detected in 140 healthy donors and changed
histidine 237 to proline at a site involved in the catalytic activity. In
patient-1, it was inherited from the father and carried also by a
sister, who were both healthy; similarly, it was carried by the
healthy sister of patient-2 (his parents were not available). All
mutated subjects displayed defective lymphocyte response to
mitogens, with decreased proliferation, expression of activation
antigens, and cytokine secretion; all of them displayed defective
mitochondrial-induced apoptosis (induced by etoposide) and
caspase-9 activation. Transient cotransfection of the wild-type
and the mutated caspase-9 into 293T cells showed that the mutated
form has a dominant negative activity. Moreover, stable trans-
fection of the mutated form in Jurkat cells expressing an
endogenous wild-type form showed that the mutated form inhibits
not only etoposide-induced apoptosis, but also cell proliferation
and CD25 expression. Similar results were obtained using the
specific caspase-9 inhibitor Z-LEHD-FMK on PBMC activated
with anti-CD3 mAb; cells treated with Z-LEHD-FMK displayed
lower cell proliferation and CD25 expression than untreated cells.
These data suggest that mutations of the caspase-9 gene may favor
development of immunodeficiency and lymphoproliferation. It is
noteworthy that a similar pattern has been previously described by
other authors in a family carrying mutations of the caspase-8 gene.
Su2.24. Haplotypes, Mutations and Phenotype Genotype
Correlation in Turkish A-T Patients.
O. Sanal,1 B. Behjatnia,2 M. Mitsui,2 F. Ersoy,1 I. Tezcan,1
A. I. Berkel,1 R. A. Gatti.2 1Pediatric Immunology, Hacettepe
University School of Medicine, Ankara, Turkey; 2Pathology and
Laboratory Medicine, UCLA School of Medicine, Los Angeles, CA,
USA.
The ataxia-telangiectasia mutated (ATM) gene was screened for
haplotypes and mutations in 57 unrelated AT families of Turkish
origin. Four microsatellite markers localized to an interval
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haplotypes were observed more than once across the families (47 %
of all cases). Of the 27 probands carrying the recurring haplotypes,
the most common, haplotype [A] carrying 3576GNA, was present
in 11 patients (19% of all cases). Mutation screening was done by
SSCP, PTT, dHPLC, and direct sequencing of cDNA, with
subsequent sequencing of the abnormal regions. Twenty eight
different mutations were identified in 46 patients, 14 of which were
new; most were aberrant splicing. In all, eight founder mutations
were found in the 92 alleles. Phenotypic features of the patients
(presence of ATM protein, ATM kinase activity, CSA, serum AFP
level, serum Ig levels, antibody production against pneumococcal
polysaccharides, frequency of sinopulmonary infections, rate of
progression of ataxia and outcome) were compared to genotypes.
In general, disease outcome did not correlate with genotype;
however,differences in disease progression were noted. Patients
with mutation 3576GNA had milder disease with infrequent
sinopulmonary infections, longer life span, and positive antibody
production against pneumococcal polysaccharides. ATM protein
was undetectable in those tested. Five of the 57 patients developed
lymphoma, two developed leukemia and one developed thyroid
carcinoma. This survey demonstrated that haplotyping is an
efficient initial screening technique to identify mutations in Turkish
AT patients and other ethnic populations.
Su2.25. Mechanisms of Immunotoxicity of Mycotoxins.
Elena Dorofeeva,1 Roman Khanferyan.1 1Immunoregulation,
Institute of Allergy and Asthma, Krasnodar, Russian Federation.
Background. The fungi have been implicated in inflammatory
reactions with immune and non-immune mechanisms, such as
rhinitis, asthma, hypersensitivity pneumonitis, allergic broncho-
pulmonary mycoses, allergic fungal sinusitis, extrintic allergic
alveolitis etc. The exact prevalence of fungal allergies is not
known. Studies based on skin tests suggest that at least 3–10% of
adults and children worldwide are affected by fungal allergy (Bush
RK, Portnoy JM, 2001; Homer WE et al., 1995). Apart from their
direct allergenic effects, fungi may carry mycotoxins in their spores
or produce volatile metabolites (Miller JD et al., 1998). Trichote-
cene mycotoxins are a group of structurally toxins produced
mainly by Fusarium fungi found on many crops. A variety of
Fusarium fungi produce a number of different mycotoxins of the
class of trichothecenes. Three of the better known toxins are T-2,
HT-2 toxin and deoxynivalenol (DON, vomitoxin). Inhalation of
mycotoxins such as aflatoxins, secalonic acid D, zearalenone and
trichothecens produced by Aspergillus, Penicillium and Fusarium
fungi, may affect the immunological response of the lung tissue or
present other hazards to human health.
Aim of investigation. To evaluate the possible mechanisms of
immunosuppressive effects of T-2 toxin and DON on different cells
and mechanisms of immune system.
Results. T-2 toxin and DON dose-dependently increase syn-
thesis of anti-ovalbumin-IgE-Ab and this effect was not genetically
restricted. Both mycotoxins dose-dependently inhibited stem cell
proliferation in mice and PHA-induced MNC proliferation. T-2
toxin and DON suppress the activity of peritoneal, spleen, bone
marrow and alveolar macrophages. The production of IL1 under
the influence of toxins decreased as well as the activity of different
hydrolases. Most sensitive were enzymes in bone marrow macro-
phages. T-2 toxin as well as DON suppressed the activity of all
enzymes, especially thiol proteinases-catepsins B, C and H. Less
sensitive were hydrolases of spleen and peritoneal macrophages.Conclusion. T-2 and DON trichotecenic mycotoxins induce
immunotoxic, mainly immunosuppressive effects on different
immune cells via multiple mechanisms. Bone marrow cells are
most sensitive to immunosuppressive effects of studied mycotoxins.
Su2.26. Immunotherapy by Cytogenes in Patients with
Acquired Neutropenia.
Vardan Sergey Aprikyan, Nata Adolf Otieva. 1Neuroimmunology,
Inst. of Biochemistry, Yerevan, Armenia; 2Pharmacology, State
University, Yerevan, Armenia.
It is known that acquired neutropenia is disorder of neutrophil
production predisposing patients to acute or recurrent bacterial
infections.
The purpose of our study was to examine the effect of new
cytogenes- synthetic short peptides on the base of naturally
originated brain and bone marrow immunoregulatory peptides,
designed in our laboratory on blood count and the development of
infections in patients with acquired neutropenia of different genesis.
It was provided hematological and clinical analysis using standard
methods of patientsT objective investigation. 37 healthy volunteers
with previous cytotoxic chemotherapy or radiotherapy were under
daily observation. Healthy individuals without cytogenes treatment
or with normal blood counts served as controls.
It was found that peptides completely restored quantitative and
qualitative index of blood neutrophil counts, and stimulated their
functional activity. During all time it was not observed any
complications deviation of blood count. Only 2 of 37 patients,
observable during 4 months after immunotherapy had been illness
with the easy form of a simple herpes virus.
The results of the presented study indicate that cytogenes may
to restore differential blood count, avert the development of
infections and to put in complete recovery in patients with acquired
neutropenia of different genesis.
Su2.27. Evaluation of Humoral Immune Responsein
Children with Otitis Media and Control Group.
Farzad Oreizi, Maryam Saleminik, Ahmad GhavamiNejad,
Fereshteh Sahebfosul. 1Immunology, Isfahan University of
Medical Science, Isfahan, Isfahan, Islamic Republic of Iran;
2Flowcytometry, BD Company, San Francisco, CA, USA;
3Immunology, Isfahan University of Medical Sciences, Isfahan,
Isfahan, Islamic Republic of Iran; 4Immunology, Isfahan
University of Medical Sciences, Isfahan, Isfahn, Islamic Republic
of Iran.
Introduction:
Acute otitis media is acute inflammation of middle ear with
signs and symptoms such as fever, otalgia,redness of tympanic
membrane and accumulation of fluid in the middle ear. The most
important bacteria that cause otitis media are streptococcus
pneumonia and hemophilus influenza, both of them have
polysaccharide capsule. Acute otitis media is one of the major
childhood infection and cause temporary hearing losses that may
affect language development of the patient.
We have not any information about level of immunoglobulin
and complement in patient with otitis media in Iran. this along with
frequent complications of otitis media encourage us to evaluate the
level of immunoglobulin and complement in patients and help
them if there is defect in immunity of them.
Materials and Methods:
In our study 75 children with otitis media and 75 healthy
children under age of 6 year were evaluated. Serum gamma
Abstracts S243globulins were determined with serum electrophoresis. IgM, IgG,
IgA, C3,C4 in serum were determined with single radial
immunodiffusion.Level of IgG2 in serum was determined with
Sandwich ELISA through our Homemade ELISA.
Result:
Show that otitis media occurred in male 1.3 times more than
female. The level of gammaglobulins,IgM,IgA have increase in
patient group versus health group in 1–2 year age group
(P b 0.05), but no meaningful increase in 3–4 and 5–6 years age
group was noted (P N 0/05). No statically difference was noted in
the level of IgG,C3 and C4 between patient and health groups in all
age groups (P b 0.05). IgG2 has decreased in group versus health
group in 3–4 year age group (P b 0.05) but no statistical difference
was noted in 1–2 year and 5–6 year age groups (P N 0.05).
Su2.28. New Composition Immunotherapy in Treatment
of Secondary Immunodeficiency Accompanied by Viral
Infectious Syndrome.
Nesterova V. Irina. 1Department of Family Medicine,
Educational-Scientific Centre of Medical Centre of MD of Russian
President, Moscow, Russian Federation.
Among different clinical syndromes accompanied the secon-
dary damage of immune system-the viral syndrome is leading
one. Our studies last years had demonstrated facts: persons
having few recurrent episodes, from 4 till 24, of acute viral
respiratory infections (RAVRI) by the year may have also
persisting viral infections such as CMV, VEB, HSV (I, II
types), VHG-6. Often their clinical manifestations are similar
bsyndrome of chronic fatigue. We had studied 325 patients with
RAVRI (75M, 50 F) in age from 20 till 72 years. All of them
had clinical markers of secondary immunodeficiency accompa-
nied by viral infection syndrome. We detected: the system of
IFN (plasmaTs IFN, IFNa, IFNg); immune system (CD3+,
CD4+, CD8+, CD16+, CD19+, RBTL, IgG, IgA, IgM,
neutrophylic phagocyts); herpes viral infection (HSV I/II types,
CMV, VEB, VHG-6) by means of PCR and there were tested
specific antibodies-IgG and IgM classes against HSV I/II types,
CMV, VEB. 100% patients had have combine defects of IFNTs
system, different deficiencies of T-cellTs immunity, NK cells,
phagocytes. More than 90,0% patients had have suggesting
herpesviral infections. All of this patients were treated following
complex immunotherapy in different combination: 1) local and
systemic IFN therapy (recombinant IFNa-viferon-1, -2, -3, -4,
viferon oil), using high-, middle- and low-dose therapy during
2,5-3,5 month-base therapy; 2) specific and non specific passive
intravenous immunoglobulins (cytotect, pentaglobin, intraglobin,
octagam) only if it was necessary; 3) immunomodulation
therapy thymusTs factors (tactivin, tymogen, imunofan) was
directed to restoration of T-cellTs immunity; 4) synthetic
preparation with polyvalent effects as polyoxidonium and
licopidum (reconstruction of NK and neutrophylic leucocyts).
At present itTs possible to combine immunotherapy and therapy
with synthetic antiviral drugs. This kind of immunoreconstruc-
tion may be accompanied by bsupport therapyQ. Using new
kinds of complex immunotherapy in treatment of secondary
immunodeficiency accompanied viral syndrome we had obtain
positive clinical and immunological effects. Those effects had
shown decreasing frequency of acute episodes of recurrent viral
infections from 4-24 till 1-2 per year, elimination of viral
pathogens (81,5% patients), reconstruction of destroy different
immune mechanisms (88,8%).Su2.29. Therapeutic Efficacy of Gc Protein-Derived
Macrophage Activating Factor for HIV-Infected/AIDS
Patients.
N. Yamamoto,1 M. Ueda.1 1Molecular Immunology, Socrates
Institute for Therapeutic Immunology, Philadelphia, PA, USA.
Although human immunodeficiency virus (HIV) is reported to
be infective to macrophages, the activated macrophages do not
support growth of HIV due to lack of DNA replication. Macro-
phages, when highly activated via inflammation, can recognize
(development of receptors for viruses) and destroy a variety of
viruses and their infected cells. Inflammation-primed macrophage
activation process is the principal macrophage activation cascade
that requires serum vitamin D3-binding protein (known as Gc
protein) and participation of B and T lymphocytes. Stepwise
hydrolysis of Gc protein with the membranous h-galactosidase
(Bgli) of inflammation-primed B cells and the Neu-1 sialidase of T
cells yields a potent macrophage activating factor, the protein with
N-acetylgalactosamine as the remaining sugar (Yamamoto 1996.
Mol Immunol 33: 1157-1164). Thus, Gc protein is the precursor for
the principal macrophage activating factor (MAF). However, the
MAF precursor activity of serum Gc protein of HIV-infected
patients was lost or reduced because Gc protein is deglycosylated
by serum a-N-acetylgalactosaminidase (Nagalase) secreted from
HIV-infected cells (Yamamoto et al. 1995. AIDS Res Hum
Retrovirus 11: 1373-8). Thus, deglycosylated Gc protein cannot
be converted to MAF. Since macrophage-activation for enhanced
phagocytosis and antigen presentation to B and T lymphocytes is
the first indispensable step in both humoral and cellular immunity
development, lack of macrophage activation leads to immunosup-
pression. Exogenously given MAF, however, can bypass the
deglycosylated Gc protein and directly act on macrophages for
activation. Stepwise treatment of highly purified Gc protein with
immobilized h-galactosidase and sialidase generates the most
potent macrophage activating factor (termed GcMAF) ever
discovered but it produces no side effect in humans. Efficacy of
GcMAF for several HIV-infected/AIDS patients was assessed by
HIV-specific serum Nagalase activity because the serum Nagalase
level is proportional to the amount of HIV-infected cells (or virus
load). After approximately 16 weekly administrations of 100 ng
GcMAF (once a week intramuscular injection), these patients
exhibited insignificantly low serum Nagalase levels equivalent to
healthy controls. Eradication of HIV and HIV-infected cells was
confirmed by complete clearance of viral antigens (i.e., 24p and
gp120) in their blood stream. The disease did not relapse four years
after completion of GcMAF therapy.
Su2.30. Pathogenic Significance of
A-N-Acetylgalactosaminidase Activity Found in the
Fusion Protein gp160 of Human Immunodeficiency
Virus Type 1.
N. Yamamoto. 1Molecular Immunology, Socrates Institute for
Therapeutic Immunology, Philadelphia, PA, USA.
Serum vitamin D3-binding protein (known as Gc protein) is the
precursor for the principal macrophage activating factor (MAF).
The precursor activity of serum Gc protein was lost or reduced in
HIV-infected/AIDS patients. These patient sera contained a-N-
acetylgalactosaminidase (Nagalase) that deglycosylates serum Gc
protein (Yamamoto et al. 1995. AIDS Res Hum Retrovirus 11:
1373-8). Deglycosylated Gc protein cannot be converted to MAF,
thus loses the MAF precursor activity. Since macrophage
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and T lymphocytes is the first indispensable step in both humoral
and cellular immunity development, lack of macrophage activation
leads to immunosuppression and opportunistic neoplasm. There-
fore, the Nagalase activity level of HIV-infected/AIDS patient sera
regulates the degree of immunosuppression. Nagalase in HIV-
infected patient blood stream was found to be complexed with
patient immunoglobulin G, suggesting that this enzyme is
immunogenic, seemingly a viral gene product. In fact, Nagalase
was inducible by treatment of HIV-infected patient peripheral
mononuclear cells with a provirus inducing agent, Mitomycin C.
This glycosidase should reside on an outer envelope protein
capable of interacting with cellular O-glycans. Although cloned
gp160 exhibited no Nagalase activity, treatment of gp160 with
0.01% trypsin for 30 min expressed Nagalase activity suggesting
that proteolytic cleavage of gp160 to generate gp120 and gp41 is
required for Nagalase activity. In fact cloned gp120 exhibited
Nagalase activity while cloned gp41 showed no enzyme activity.
Since proteolytic cleavage of the protein gp160 is required for
expression of both fusion capacity and Nagalase activity, Nagalase
seems to be an enzymatic basis promoting fusion for initiation of
infection. When cloned gp120 was treated with 0.001% trypsin for
30 min, Nagalase activity further increased significantly. This
suggests that a proteolytic cleavage site of V3 loop of gp120 may
be required for further enhancement of Nagalase activity for
infectivity. Dipeptidylpeptidase IV (DPPIV) activity of CD26 is
also able to cleave immediately adjacent (2 residues) to the tryptic
site of V3 loop, supporting that CD26 is required for infectivity its
enhancing capacity of Nagalase activity. Therefore, the Nagalase
appears to play dual roles in viral infectivity and immunosuppres-
sion. The Nagalase activity has the pathogenic significance in HIV
infection.
Su2.31. Clinical and Laboratory Findings in Twenty
Eight Patients with a Primary Immunoglobulin
Deficiency Associated with Lymphadenopathy,
Hepatosplenomegaly and Pulmonary Infiltrates.
W. Ding,1 C. R. Weiler.1 1Internal Medicine, Mayo Clinic College
of Medicine, Rochester, MN, USA.
Background: Some patients with common variable immuno-
deficiency (CVID) present with adenopathy and hepatosplenome-
galy. Tissue biopsy shows the presence of sarcoid-like granulomas.
Objective: To evaluate the underlying pathology of the lymph
nodes, liver or lungs in patients with humoral immunodeficiency.
The pathology will be correlated with clinical presentation,
immunoglobulin levels, T and B-cell counts, and microbiology
studies.
Design: Retrospective chart review of patients evaluated at the
Primary Immune Deficiency Clinic, Mayo clinic Rochester
between 1998 and 2004.
Setting: Large tertiary care medical center.
Patients: Patients with an immunoglobulin deficiency includ-
ing CVID, IgG subclass deficiency and selective IgA deficiency
who have adenopathy, pulmonary infiltrates and hepatospleno-
megaly are included. Twenty eight patients were identified out of
a total of one hundred and fifty with a humoral antibody
deficiency. The electronic charts of the 28 patients were
reviewed.
Evaluation: Patients underwent clinical and peripheral blood
laboratory studies. The results presented are based on pathologic
evaluation of lymph node, lung or liver biopsies. Tissues frombiopsies and bronchioalveolar lavage were also cultured for the
presence of bacterial, fungal and mycobacterial infections.
Results: Sixteen of the 28 patients were males. The average age
of the 28 patients was 43 F 14, with a median of 44 and range
from 16-23. Generalized adenopathy affected 89%, splenomegaly
71% and hepatomegaly 50%. 50% had sarcoid-like granulomas
and 40% follicular lymphoid hyperplasia. Two patients developed
lymphoma and one chronic lymphocytic leukemia. One patient had
nocardia lung infection, another atypical mycobacterium, one
osteomyelitis and two sepsis. Twelve (43%) had a significant
autoimmune disease; this includes hemolytic anemia (21%),
idiopathic thrombocytopenic purpura (32%), and inflammatory
arthritis (7%). Other autoimmune disorders included Celiac
disease, systemic lupus, type-1 diabetes, hypothyroidism and
anti-phospholipid syndrome. All patients with autoimmune disease
had adenopathy, 93% splenomegaly, 57% granulomas and 50%
lymphoid hyperplasia. Compared with 75% of those without
autoimmunity having adenopathy, 47% splenomegaly, 40% hep-
atomegaly, 33% lymphoid hyperplasia and 27% granulomas.
Patients with granulomatous disease had significantly higher
hepatomegaly (P = 0.044) and hemolytic anemia (P = 0.035).
Average CD-19 cell count was 217 with a median of 83. Mean
CD4 count was 676 and median 573, and mean CD8 count was
394 and median 278. No subgroup difference in immunoglobulin
levels or T and B-cell counts was noted.
Conclusion: Adenopathy and/or hepatosplenomegaly in
patients with immunoglobulin deficiency are not all granulomatous
in nature but also include nodular lymphoid hyperplasia. Auto-
immune disease is also prevalent among those patients. No
difference in the immunoglobulin levels or the T and B-cell count
between the two groups is noted. Larger number of patients and
genetic mutation analysis might differentiate between the different
subgroups of patients.
Su2.32. Thirteen Years ofM. bovis-BCG Culture-Positive
Infection in an IL-12RB1 Deficient Patient: Treatment
and Outcome.
Sergio D. Rosenzweig,1 Judith Yancoski,1 Andrea Bernasconi,1
Silvia Krasovec,1 Beatriz E. Marciano,1 Lidia Casimir,1 Norberto
Simboli,2 Griselda Berberian,1 Marcela Russeau,1 Graciela
Calle.1 1Hospital Nacional de Pediatria, bJ. P. GarrahanQ, Buenos
Aires, Argentina; 2Servicio de Micobacterias, INEI ANLIS bDr.
C. G. MalbranQ, Buenos Aires, Argentina.
The IFNg/IL-12 pathway plays a critical role in controlling
mycobacterial infections. Patients with mutations in this pathway
show an exquisite susceptibility to these germs. Patient FP was
BCG-vaccinated at birth, and at 6 months of age he developed a
right arm regional/localized BCGitis. Thereafter, and until he was 2
years old, he presented with recurrent lung infections partially
responsive to antibiotics. Pyrazinamide-resistant M. bovis-BCG
was isolated from sputum at age 2. FP received multiple anti-
mycobacterial drug regimes without clearance of mycobacteria or
clinical improvement. At 9 years of age he was referred to our unit.
He presented with a mild pulmonary insufficiency, and mycobac-
terial suppurative cervical adenitis. Traditional primary immuno-
deficiencies and HIV were ruled out. Recombinant (r) IFNg was
added to his treatment (SC, 40Ag/mt2, 3 times a week), with
resolution of the suppurative lesions. His sputum persisted culture-
positive for another 6 years despite combined anti-mycobacterial
treatment (enteral route; according to mycobacterial susceptibility),
plus rIFNg (upon availability). IL-12Rh1 deficiency was con-
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1688; leading to V541V-Q542X). At the age of 15, FP showed a
profound clinical deterioration with severe respiratory insuffi-
ciency and a 1055 cm thoracic mycobacterial mass. The
patientTs sputum and mass grew a multidrug resistant M. bovis-
BCG (resistant to isoniazid, rifampicin, pyrazinamide, rifabutin,
and ethionamide), and his serum showed no mycobactericidal
activity in vitro. Protein-loosing enteropathy and steatorrhea was
also detected at that time. He initiated treatment with streptomycin/
ciprofloxacin/ clarithromycin/ amoxicillin-clavulanic acid/ clofazi-
mine/ linezolid (all sensitive by antibiogram), and rIFNg was
raised to 100Ag/mt2. Two months after this therapeutic scheme was
started, his sputum turned culture-negative and his serum showed a
positive bactericidal activity in vitro. At 8 months of treatment he
presented with a sensitive peripheral neuropathy and optic neuro-
pathy. Because of this complication, streptomycin and linezolid
were withdrawn, and capreomycin was introduced. After 1 year of
anti-mycobacterial treatment, the whole regime was suspended.
Four months later, and under weekly azythromycin prophylaxis,
the patient remains culture-negative (14 months), the thoracic
mass has completely resolved, the peripheral and optic neuro-
pathy show a significant but not complete recovery, and he
leads a normal life. A combination of parenteral and enteral
anti-mycobacterial treatment, including linezolid and rIFNg,
helped to clear a 15 years-long/13 years culture-positive disease
caused by M. bovis-BCG with acquired multidrug-resistance, in
an IL-12Rh1 deficient patient with impaired intestinal
absorption.
Su2.33. Equivalent Performance of VACUTAINERR
CPTk to Ficoll-Hypaque Gradient Separation in
Maintaining the Quality and Function of PBMC from
HIV Seropositive Blood Samples.
J. J. Ruitenberg,1 C. B. Mulder,2 V. C. Maino,1 A. L. Landay,2 S. A.
Ghanekar.1 1R&D, BD Biosciences, San Jose, CA, USA; 2Immu-
nology and Microbiology, RUSH University Medical Center,
Chicago, IL, USA.
For immune monitoring studies during HIV vaccine clinical
trials, whole blood specimens from HIV seropositive patients may
be collected at multiple sites and sent to a central location for
PBMC isolation, cryopreservation and evaluation. Clinical
researchers prefer to use cryopreserved PBMC because they
enable batch analysis of multiple time points, and the samples can
be archived for future evaluation. Typically, investigators have
two sample collection options: (1) whole blood can be collected in
a VACUTAINERR tube and sent to a central location for isolation
of PBMC using Ficoll-Hypaque density gradient separation, or (2)
whole blood can be collected in a VACUTAINERR CPTk (Cell
Preparation Tube), and PBMC isolated by centrifugation at the
collection site, and shipped to a central location in the collection
tube. The CPT option has some advantages over the Ficoll-
Hypaque option such as ease of use, and less hands-on sample
manipulation. For functional studies, it is desirable to know that
PBMC samples are handled in a manner that will not compromise
the ability of the cells to respond to activation stimuli. It is
likewise important that sufficient recovery and viability of PBMC
be retained in cryopreserved preparations. Therefore, it would be
of value to know that PBMC collected and processed by either
method perform in a similar manner. In this study we show a
comparison of both PBMC collection options, using whole blood
specimens from 19 HIV seropositive patients (CD4 N 350, viralload b 50). The performance of samples collected by these two
methods was compared by assessment of antigen-specific CD8+
and CD8- T cell immune responses (using cytokine flow
cytometry), and cellular viability and recovery (using a hemacy-
tometer and Trypan Blue exclusion). Antigen-specific IFNg
expression was measured by stimulating PBMC with CMV
pp65 and HIV p55 peptide mixes for 6 hours in vitro, followed
by fixation, permeabilization, and intracellular staining. For data
comparison, non-parametric paired t-test analysis of the intra-
cellular expression of IFNg, viability, and cellular recovery was
performed. The results indicate that after PBMC had been frozen
and thawed, samples tested for CMV- and HIV- specific IFNg
expression performed comparably to fresh PBMC under both
collection conditions. The viability was significantly different
between fresh and frozen PBMC derived using Ficoll-Hypaque
(p = 0.0005), although it was never less than 90% for PBMC
harvested by either collection method. There were no significant
differences in the post-freezing IFNg response, viability, or
recovery between PBMC derived by Ficoll-Hypaque and by
CPT, suggesting that either collection method would result in
comparable yields of the viable cells needed to perform
equivalently in functional studies. Overall, these data suggest that
CPT is an efficient system for the collection and cryopreservation
of functionally active HIV seropositive PBMC, as well as a viable
alternative to Ficoll-Hypaque.
Su2.34. Binding of the Green Tea Polyphenol,
Epigallocatechin Gallate, to the CD4 Receptor on
Human CD4+T Cells Resulting in Inhibition of
HIV-1-gp120 Binding.
C. L. Nance,1 M. P. Williamson,2 T. G. McCormick,1 W. T.
Shearer.1 1Pediatrics/Allergy and Immunology, Baylor College of
Medicine, Houston, TX, USA; 2Biochemistry, University of
Sheffield, Sheffield, England, United Kingdom.
Background: HIV-1 infection ultimately results in impaired
specific immune function by virtue of the initial binding of the
HIV-1 virion envelope glycoprotein, gp120, to the CD4 receptor.
Epigallocatechin gallate (EGCG), a component of green tea,
binds strongly to many biological molecules and is responsible
for multiple health benefits. EGCG inhibits HIV-1 replication in
human peripheral blood mononuclear cells in vitro by inhibiting
the biochemical activity of HIV-1 reverse transcriptase resulting
in a subsequent decrease in HIV p24 antigen concentration. We
present evidence that EGCG (at physiologically relevant levels)
binds to the CD4 molecule at the gp120 attachment site, thus
establishing the potential use of EGCG as a therapeutic treatment
for HIV infection. Methods: CD4+T cells were positively
selected by immunomagnetic separation from platelet-depleted
human leukopaks to obtain a highly purified CD4+Tcell
population. Nuclear magnetic resonance (NMR) spectroscopy
and saturation transfer difference (STD) experiments examined
the binding of EGCG to CD4. Inhibition binding studies were
assessed by flow cytometry. Results: NMR titration studies
revealed that addition of CD4 to 100 uM EGCG voided the
NMR signal from EGCG but not from the control, (+)-catechin.
Addition of an IgG to EGCG had no effect. In STD experiments,
addition of 21 mM CD4/binding site to 520 mM EGCG showed
strong saturation at rings B and D of EGCG, while catechin or IgG
had little effect. To investigate whether the binding of EGCG to the
CD4 molecule on human lymphocytes is capable of inhibiting the
binding of gp120 to CD4, we analyzed the binding ability of gp120
AbstractsS246to the EGCG-treated and untreated CD4+T cells. EGCG markedly
inhibited the binding of gp120 to CD4+ T cells in a dose-dependent
manner (0% at 20nM, 25% at 200nM P b0.01, and 45% at 2000nM,
P b 0.01). Thus, at physiologically relevant levels of 200nM,
EGCG exerted an inhibitory effect. The control catechin did not
alter the binding capacity of gp120. Molecular modeling studies
suggested a binding site for EGCG (Phe 43, Arg 59, Trp 62) in the
D1 domain of CD4, the pocket that binds gp120. By calculation, we
find that concentrations of EGCG, which are achievable by drinking
green tea (170 nM), could reduce the binding of gp120 to CD4 by
10- to 20-fold. Conclusions: We have demonstrated clear
evidence of high affinity binding of EGCG to the CD4 molecule.
Along with this we, conclude that EGCG at concentrations
equivalent to those obtainable by the consumption of green tea is
able to significantly reduce the attachment of gp120 to CD4. It is
reasonable to suspect that EGCG has potential use as adjunctive
therapy in HIV infection. The potential competitive binding
properties of EGCG for the CD4 binding sites by gp120 may
translate to an HIV-1 preventative strategy. It is possible that
green tea or its extracts may be involved in the future treatment
of HIV-1 infection.
Su2.35. Defect in CRAC Ca2+ Channel Function
Associated with Altered K+ Channel Gating Properties
in T Cells from Immunodeficient Patients.
S. Feske,1 M. Prakriya,2 R. S. Lewis,2 A. Rao.1 1CBR Institute for
Biomedical Research, Harvard Medical School, Boston, MA, USA;
2Dept Molecular and Cellular Physiology, Stanford University,
Stanford, CA, USA.
Activation of the T cell receptor (TCR) triggers a rise in
intracellular Ca2+, essential for a productive immune response.
Influx of Ca2+ occurs through store-operated Ca2+ release
activated Ca2+ (CRAC) channels, the molecular identity of
which remains unknown. We identified a congenital human
immunodeficiency (SCID) characterized by a complete absence
of ion permeation through CRAC channels resulting in virtually
no Ca2+ influx following active or passive depletion of
intracellular Ca2+ stores. While a minimal Ca2+ influx was
seen in the SCID T cells at high extra cellular Ca2+
concentrations, this influx could be blocked by 2-APB, La3+,
Gd3+ and SKF96365, respectively and is therefore likely to be
mediated by CRAC channels. In the absence of CRAC
mediated Ca2+ influx, no other significant sources of Ca2+
influx were detected in the SCID T cells suggesting that CRAC
channels provide the predominant, if not the sole Ca2+ influx
pathway following TCR stimulation in human T cells. Intrigu-
ingly, the voltage-gated K+ channel Kv1.3, instrumental for
setting a negative membrane potential and providing the driving
force for Ca2+ entry, showed altered activation properties in the
SCID T cells which were not secondary to reduced intracellular
Ca2+ levels. Potential candidate genes for the CRAC channel
pore protein, particularly transient receptor potential (TRP)
channel genes, were tested for their involvement in the Ca2+
defect, but no alterations were observed. TRPV6 and TRPV5,
two TRP channels with electrophysiological properties similar to
those of CRAC channels, were able to restore Ca2+ influx in the
CRAC deficient T cells but this influx was not dependent on
prior store depletion indicating that these channels form
constitutively open Ca2+ channels when heterologously
expressed. A comprehensive complementation cloning approach
was initiated to localize genes, which are able to restore Ca2+influx in CRAC deficient T cells. To this end, human
chromosomes derived from a monochromosomal somatic hybrid
panel were introduced into Ca2+ deficient T cells using micro-
cell-mediated chromosome transfer (MMCT). We identified two
chromosomes, which can functionally complement the Ca2+
signaling defect in the CRAC deficient T cells. A subchromoso-
mal fragment (SCF) representing a ~25 Mb region of one of the
chromosomes defined by FISH mapping was sufficient for
complementation of Ca2+ influx in CRAC deficient T cells.
Homozygosity mapping of both chromosomes revealed an
autozygous region within the borders of the SCF defining a
potential candidate gene region of 3 Mb. Genes in this region are
under investigation for their contribution to Ca2+ influx in T
cells. From our studies in the CRAC deficient SCID T cells we
conclude that CRAC currents provide the paramount Ca2+ influx
pathway in human T cells and that the defect in the SCID patients
resides in a channel component itself or a protein involved in its
regulation.
Su2.36. Proposal for Diagnostic Criteria for
Immunodeficiency Associated with DiGeorge Syndrome.
A. Sediva,1 A. Janda.1 1Institute of Immunology, University
Hospital Motol, Prague, Czech Republic.
DiGeorge syndrome is a congenital disorder characterized by
developmental defects usually associated with immunodeficiency
due to the hypoplasia or pathologic migration of the thymus.
ESID/PAGID diagnostic criteria for DiGeorge associated immu-
nodeficiency can be found on www.esid.org. We tested our
cohort of patients with FISH proven del22q11 deletion against
these currently valid and available criteria. As majority of
patients failed the diagnosis despite genetically proven status of
syndrome DiGeorge, we propose revised criteria for this
disorder.
DiGeorge syndrome have genetic (del 22q11.2 or deletion on
chromosome 10p) or non-genetic causes (eg. CHARGE association
or alcoholic embryopathy). For the definition of immunodeficiency
following situations apply:
1. Immunodeficiency associated with del22q11.2
Male or female patient with reduced number of CD3 F Tcells
(less than 1500/mm3) in the first 3 years of life and two of the three
following characteristics:
1.1. Conotruncal cardiac defect (exceptionally other cardiac)
1.2. Laboratory and/or clinical signs of hypoparathyreosis
1.3. Deletion of chromosome 22q11.2
2. Immunodeficiency associated with DiGeorge syndrome
del22q11.2 neg.
No criteria available due to extremely large variation in phenotype.
3. Complete syndrome DiGeorge
3.1. Athymia documented as fewer than 50 recent thymic
emigrants (CD3 F CD45RA F CD62L F cells/cubic mm) and/or
TRECs b100/100 000 T cells
3.2. Hypoparthyreosis
3.3. Heart defects supported by phenotypic features associated
with DiGeorge syndrome.
These criteria represented solid diagnostic base for all our
patients. Immune parameters vary greatly with age in DiGeorge
syndrome, therefore, age-dependent changes must be considered in
the diagnostic procedure.
This proposal of diagnostic criteria is widely open for
discussions and revision.
Abstracts S247Su2.37. Immunological Characterization of Children
with Transient Hypogammaglobulinemia of Infancy
(THI): In Vitro Immunoglobulin Production Is a
Candidate Predictive Marker.
V. Moschese,1 S. Graziani,1 M.A. Avanzini,2 R. Carsetti,3 I.
Quinti,4 A. Plebani,5 A. Soresina,5 S. Di Cesare,1 L. Chini,1 M.
Marconi,2 G. Bossi,6 M. La Rocca,1 R. Maccario,2 P. Rossi,1,3
A.G. Ugazio.3 1Pediatrics, Policlinico Tor Vergata, University of
Tor Vergata, Rome, Italy; 2Laboratorio Area Trapianti, IRCCS,
Policlinico San Matteo, Pavia, Italy; 3Ospedale Pediatrico
Bambino Gesu, Rome, Holy See (Vatican City State); 4University
La Sapienza, Rome, Italy; 5Pediatrics, University of Brescia,
Brescia, Italy; 6Scienze Pediatriche, Policlinico San Matteo,
Pavia, Italy.
Transient hypogammaglobulinemia of infancy (THI) may
represent a self-limited maturational delay of normal immunoglo-
bulin synthesis or an early manifestation of a primary immunode-
ficiency. We evaluated distinct immunological parameters to
predict the natural outcome and highlight their relevance in the
pathogenesis of this disorder. B cells subsets, stimulated in vitro
immunoglobulin production (sIVIP) and specific antibody
response to tetanus toxoid, HiB and Streptococcus pneumoniae
vaccines have been evaluated in 15 patients (mean age 12–36 mo)
with a) IgG values b2DS below the mean for age associated to low
values of IgA and/or IgM; b) intact cellular immunity; c) absence
of clinical and immunological signs of other immunodeficiencies.
No abnormalities in distinct B cell subsets have been documented
except for 1/15 patients with a low expression of B memory
unswitched cells (CD22+/CD27+/IgD-/IgM-) compared to age-
matched normal controls (1.8% versus normal range of 6.9–11.2%).
Stimulated in vitro immunoglobulin production (sIVIP) in baseline
conditions and after addition of IL-10 revealed a normal response to
all isotypes in 8/15 (53%) patients, while low values of sIVIgGP,
sIVIgMP, sIVIgAP were identified respectively in 6/15 (40%), 3/15
(20%) and 3/15 (20%). sIVIP patients didnTt correlate with serum Ig
concentrations. Antibody response to vaccine antigens showed a
low antibody response to Streptococcus pneumoniae in 2 children
with altered sIVIgGP. These preliminary data emphasize the role of
sIVIgGP and sIVIgAP as biological predictive and/or prognostic
markers of this disorder and make us advance the hypothesis that a
defect of class-switching mechanism can contribute to the
pathogenetic scenario of THI. Extensive clinical and immunolog-
ical evaluation is needed to better define this condition.
Acknowledgements: This study is in the contest of the Italian
THI CSS-ID/AIEOP.
Su2.38. Health-Related Quality of Life in Patients with
Primary Immunodeficiencies in North America
Receiving Home-Based Subcutaneous
Immunologlobulin Replacement Therapy.
Uwe Nicolay,1 Peter Kiessling,2 Ann Gardulf,1 Hans D. Ochs.3
1Department of Laboratory Medicine, Section of Clinical
Immunology, Karolinska Institutet at Karolinska University
Hospital, Stockholm, Sweden; 2Clinical Research & Development,
ZLB Behring GmbH, Marburg, Germany; 3Department of
Pediatrics, University of Washington, Seattle, WA, USA.
INTRODUCTION: Intravenous infusions of immunoglobulin
(IVIG) every 2–6 weeks either as hospital- or home-based
therapy are the mainstay treatment for patients with primary
immunodeficiencies diseases (PID) in North America. Weeklyself-administered subcutaneous immunoglobulin (SCIG) infusions
at home have been proven to be a feasible, safe and effective
alternative. However, data regarding health-related quality of life
(HRQL) in PID patients is limited, even though self-administered
infusions at home confront the patient with an array of
challenges. In the present study we assessed the HRQL in
patients switching from hospitalbINS cite=mailto:HS date-
Time=2005-01-13T14:02N-b/INSN or home-based IVIG therapy
to self-infused SCIG at home. METHODS: In a prospective
longitudinal study in the US and Canada, 44 adult PID patients
self-infused weekly SCIG (VivaglobinR, ZLB Behring) at home
for 12 months. HRQL was assessed at baseline, 6-, 9-, and 12-
months using a generic instrument (SF-36), a questionnaire
addressing treatment satisfaction (Life Quality Index), preference
questions and the Health Status (assessed on a visual analogue
scale ranging from 0-100 points). RESULTS: 28 patients had
received hospital- (dpre-hosp groupT) and 16 home-(dpre-home
groupT) based IVIG replacement therapy prior to study entry.
After 12-months, 81% of the patients in the pre-hosp group and
69% in the pre-home group preferred SCIG replacement therapy;
90% and 91%, respectively, of the patients preferred home
therapy. The pre-hosp group reported significant improvements
(p V 0.05; z 10-points difference) with respect to the SF-36
scales Vitality, Role-Physical, General Health and Health
Transition. For patients in the pre-home group the General
Health scale was improved (p V 0.05; 10-points difference).
Treatment satisfaction was significantly (p V 0.05) improved in
13 of 15 items in the pre-hosp group, whilst patients in the pre-
home group did not report notable changes after 12-months.
PatientsT perception of their health status increased from 71-points
at baseline to 85-points at 12-months in the pre-hosp group and
from 73 to 76-points in the pre-home group. CONCLUSIONS:
Subcutaneous, home-based immunoglobulin replacement therapy
significantly improved key parameters of the health-related quality
of life and a wide range of aspects addressing treatment satisfaction
of patients, who had received IVIG replacement therapy at the
hospital. For patients already experienced with IVIG replacement
therapy at home, no great changes were observed.Su2.39. Host MHC Influences Susceptibility to
Hypersensitivity Reactions to Two Drugs Commonly
Used in HIV Therapy.
F. T. Christiansen,1 A. M. Martin,1 D. A. Nolan,1 S. Gaudieri,1
C. A. Almeida,1 E. Phillips,1 P. U. Cameron,1 C. B. Moore,1 I.
James,1 S. A. Mallal.1 1Department of Clinical Immunology &
Biochemical Genetics & Centre for Clinical Immunology &
Biomedical Statistics, Royal Perth Hospital, Perth, Western
Australia, Australia.
Host genetic factors influence the outcome of HIV infection at
multiple levels including susceptibility to infection, rate of decline
of immune function, the adaptation of the virus to the hostTs
immune response and the development of AIDS related illnesses.
Genes within the major histocompatibility complex (MHC)
predispose to the development of an immune mediated hyper-
sensitivity response to two active antiretroviral drugs. Abacavir
hypersensitivity is strongly associated with the 57.1AH charac-
terised by the presence of HLA-B*5701 and a particular HSP70
polymorphism (HSP70-hom M493T). The presence of these
markers is associated with a positive predictive value of N90%
and a negative predictive value of N99%.
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reactions to Nevirapine are associated with the MHC class II
region. HLA-DRB1*0101 was associated with such hyper-sensi-
tivity but specifically in those with more than 25% CD4+ cells (OR
17.7; Pc = 0.0006), suggesting the HLA class II molecules are
likely to be directly involved in the pathogenesis.
Thus immunogenetics laboratories are likely to be involved
increasingly in pharmocogenomic studies, both in providing a
practical clinical application in preventing drug hypersensitivity
reactions and for providing insights into the pathogenesis of
immunologically mediated drug hypersensitivity reactions.
Su2.40. Multisystem Disease in CAEBV Infection.
A. P. Williams,1 J. OTB Hourihane,2 E. Hodges,1 H. B. Gaspar,3 J.
Smith.1 1Department of Clinical Immunology, Southampton
General Hospital, Southampton, United Kingdom; 2Department of
Child Health, Southampton General Hospital, Southampton,
United Kingdom; 3Molecular Immunology Unit, Institute of Child
Health, London, United Kingdom.
We describe a 16 year old Caucasian male with a 7 year history
of chronic active EBV infection. At the age of 5 he developed
uncomplicated glandular fever. He remained well until 9 years of
age, when he represented with a history of headaches, hemiplegic
migraine and splenomegaly. Ultrasound scan confirmed spleno-
megaly without hepatomegaly or lymphadenopathy. A head CT
scan was normal. One year later he developed a left sided BellTs
palsy and abnormal optic disc appearances. Ophthalmic review
diagnosed bilateral pseudooptic disc swelling with retinal periph-
lebitis. Immunoglobulin analysis showed a raised IgG of 24.7g/L.
At the age of 12 his height had fallen from the 10th centile at age 5
to the 0.4th centile and an endocrinology assessment was under-
taken. A bone scan showed a bone age delay of 3 years but no
other abnormalities.
At the age of 15 he was admitted with a 2 week history of
pyrexia, lethargy and hepatosplenomegaly and an immunology
opinion was requested. He had accompanying neutropaenia and
thrombocytopaenia. Investigations revealed 7000 EBV DNA
copies per ml with serology consistent with past infection.
Ultrasound revealed a 20cm spleen of uniform echotexture with
additional large intra-abdominal nodes. Bone marrow examina-
tion was normal. Liver biopsy showed no evidence of
lymphoma but some evidence of acute necrosis and chronic
inflammation.
Immunological testing revealed hypergammaglobulinaemia
with an IgG of 19.3 G/L (normal 6–16) and normal IgA and
IgM. Anti neutrophil antibodies were detected but no other
autoantibodies were identified. Cellular immunophenotyping was
as shown below:CD3=1.91 (0.8–3.5), CD4= 0.75 (0.4–2.1), CD8=
1.14 (0.2–1.2), CD19 = 0.15 (0.2–0.6) and NK = 0.08–1.2).
Currently his immunophenotype shows a CD3 = 1.12, CD4 = 0.6,
CD8 = 0.47, CD19 = 0.02 and NK = 0.05.
TCR h immunophenotyping showed an expansion of Vh17 T
cells, accounting for 40% of the T cells. This population was
mainly CD8 positive (N95%). TCR h clonality studies were
consistent with a clonal population. A protein blot for SAP was
unremarkable. These changes persisted after clearance of EBV
which occurred by day 20, following treatment of the acute illness
with Rituximab (anti CD20 MoAb) and intravenous immunoglo-
bulin. Further testing outside of the acute illness has shown a low
EBV count of 140 copies/ml in blood, a reduction in Vh17 T cells
to 9% and the demonstration of EBV DNA in a liver biopsy.This individual exhibits some of the diverse, multisystem
features that have been previously recognised in chronic active
EBV infection. The underlying immunological defect of such
patients is poorly understood. A clearer understanding of the
underlying defects in such patients will advance our understanding
of how chronic latent viral infections are immunologically
controlled and improve therapeutic approaches to this difficult to
manage condition.
Su2.41. Infants with Recurrent Infections and Low
Immunoglobulins: Analysis of Immunoglobluin
Normalization.
M. A. Whelan,1 S. J. Kung,1 S. J. McGeady.2
1Allergy/Immunology, Thomas Jefferson University Hospital,
Philadelphia, PA, USA; 2Allergy/Immunology, AI duPont Hospital
for Children, Wilmington, DE, USA.
RATIONALE: Infants presenting with recurrent infections and
low immunoglobulins(Igs) lacking evidence of other immune
deficiency disorders are often diagnosed with Transient Hypogam-
maglobulinemia of Infancy(THI). Although THI is considered a
primary immunodeficiency, it is not well defined, and long term
follow-up not reported. The purpose of this study is to: 1)
Characterize infants with recurrent infections and low Igs. 2)
Analyze characteristics to correlate them with time elapsed to Ig
normalization. 3) Provide long term follow-up. METHODS:
Patients evaluated between 1977-2004 were eligible if they:1)Were
term born and b24 months at presentation. 2) Had one or more Ig
class 2 SD below normal. 3) Produced antibody to diphtheria and
tetanus. 4) Had evidence of intact cell mediated immunity. 5)
Lacked features of other immunodeficiency syndromes and 6) Had
at least one follow-up set of Igs. Forty-nine patients had the
following collected: Igs at presentation and follow-up, age at
presentation and Ig normalization, and gender. The data was
analyzed utilizing parametric survival analysis which assumes a
logarithm of time to normalization has a logistic distribution The
time to normalization indicates the time from age at diagnosis.
RESULTS: Of those included, 33/49 were male and 16/49 female.
Mean age of presentation was 9.6 months. When the data was
evaluated by gender, it took longer for the females Igs to normalize
when compared to males. Twenty-five percent of the males had
normalized by time of 0.3 years, while 25% of the females
demonstrated normalization at 4 years. Likewise, 50% of the males
had normalized at 1.1 years post-diagnosis, where it took the
females 10.4 years for 50% to normalize. This difference was
statistically significant (P b 0.001). When the data was evaluated
with respect to gender and age at diagnosis, it was found that the
younger the females at diagnosis the longer time to normalization,
but for males the earlier diagnosis the shorter time to normalization.
This gender by age at diagnosis interaction was a strong trend (P-
value = .083). Overall the course of these patients was benign. None
had serious infections, however 2 female non-identical twins met
criteria for IgA deficiency. Over half (59%) had a history of
wheezing and 26% were atopic. Several have been followed to age
greater than 20 years. CONCLUSIONS: 1) Females presenting with
diminished immunoglobulins during infancy require longer time to
normalization compared to males. 2) Females presenting younger
take a longer time to normalize 3) Males presenting with low Igs
during infancy display a strong trend toward longer time to
normalization the older at presentation. 4) Children with decreased
Igs in infancy are a heterogeneous population. In many, especially
females, the hypogammaglobulinemia is neither transient nor
Abstracts S249limited to infancy and thus diagnosis of THI can only be made
retrospectively. 5) Children with low Igs and demostrated ability to
produce specific antibody have a generally benign course and fewer
infections as they grew older, but excess atopy.
Su2.42. The Role of Wiskott Aldrich Syndrome Protein
in T Helper Cell Function.
J. Aoki,1 A. Konno,2 D. Jankovic,3 J. Cannons,1 F. Candotti,2
P. Schwartzberg.1 1Genetic Disease Research Branch, National
Human Genome Research Institute, Bethesda, MD, USA;
2Genetics and Molecular Biology Branch, National Human
Genome Research Institute, Bethesda, MD, USA; 3Laboratory of
Parasitic Diseases, National Institute of Allergy and Infectious
Diseases, Bethesda, MD, USA.
Wiskott Aldrich Syndrome (WAS) is characterized by immune
deficiency, thrombocytopenia, eczema, and increased incidence of
autoimmune disease. The protein deficient in this syndrome,
WASp, is required for actin-based cytoskeletal rearrangement and
T cell activation. Recent data suggest that the Tec kinase, Itk, is
required for WASp activation and actin polymerization. Addition-
ally, Itk-deficient mice show defective T helper cell differentiation.
Regulation of T helper cell differentiation and cytokine production
is essential for mounting appropriate responses against pathogens,
while dysregulation of these pathways has been implicated as a
possible cause of hypersensitivity and autoimmunity. Given the
increased incidence of eczema and autoimmune disease in WAS
patients, we asked whether WASp might also be involved in T
helper cell differentiation and function.
We have found that murine WAS/ CD4+ T cell cultures
exhibit marked reductions in secretion of both the Th1 cytokine
IFN-gamma and the Th2 cytokine IL-4. Nonetheless, intracellular
staining revealed that WASP-deficient CD4 cells produce normal
to elevated levels of IFN-gamma and IL-4. These data suggest that
WASp may be involved in the secretion, but not production of IL-4
and IFN-gamma in CD4+ T cells.
Surprisingly, following challenge with the Th2 inducing agent,
Schistosoma mansoni eggs, WAS/ mice show heightened
responses including larger pulmonary granulomas and higher
production and secretion of Th2 cytokines. Moreover, 30 days
post- infectious challenge with the Th1 inducing parasite Tox-
oplasma gondii, WAS/ mice show fewer numbers of brain cysts
and increased production and secretion of IFN-gamma. Thus, in
response to parasitic challenge, WASp-deficient mice can mount
both a Th1 and Th2 response in vivo that may be exaggerated.
Together, these findings suggest that WASp-deficiency has
complex effects on T helper cell effector function, which may
provide insight into the development of autoimmunity in patients
with Wiskott Aldrich Syndrome.
Su2.43. Cyclic CD4 Lymphopenia and Absence
Interleukin-2: A Novel Immunodeficiency Presentation.
Ronit Herzog, Joan Berman, Shirley Fung, Arye Rubinstein.
1Allergy and Immunology, Albert Einstein College of Medicine,
Bronx, NY, USA.
Introduction: Immunodeficiency with CD4+ lymphopenia in the
absence of HIV infection has been described and represents a
heterogeneous condition. Interleukin-2 (IL-2) is a potent T cell
growth factor produced primarily by activated CD4+ T cells, and its
synthesis is tightly regulated at the mRNA level. A closely related
cytokine, Inteleukin-15 (IL-15), shared two of the IL-2 receptor
(IL-2R) subunits, but utilizes a unique IL-15 receptor a chain(IL-15Ra) instead of IL-2Ra (CD25). Both cytokines appear to
generate identical intracellular signals; however, they may have
distinct in vivo properties. There are few reports related to altered
regulation of IL-2 in primary immunodeficiency in human, and one
case of human immunodeficiency arising from a mutation in the IL-
2Ra. We report here a novel immunodeficiency accompanied by
cyclic CD4+ lymphopenia, undetectable IL-2 and high IL-15. Case
report: The patient is a 20 year old male, without underlying HIV
infection, with recurrent mucosal candidiasis and cyclic CD4+
lymphopenia (CD4+ b250 cells/ul) since infancy. His mother died
at the age 41 from Pneumocystis pneumonia with no HIV infection.
Immune evaluation shortly before her death showed an IgG level of
440 mg/dl and a low CD4+ T cell count. The patient presented with
recurrent oral and esophageal candidiasis preceded or accompanied
by a low CD4+ T cell count and anergy to candida. His clinical
course has been stable between the episodes of lymphopenia. In a
recent exacerbation the patient presented with dysphagia and oral
thrush that resolved with oral fluconazole, but was followed by
severe diarrhea and weight loss. Colonoscopy revealed severe
descending colon colitis with deep ulcerations. All bacterial, fungal,
and mycobacterial cultures were negative. Total CD3+ T cells count
was low at 630 cells/ul (63%), CD4+ T cells count was low at 200
cells/ul (24%). Immunoglobulin M (IgM) was low at 29 mg/dl
(normal 48–271 mg/dl), IgG subclass 4 was low at 1.3 mg/dl
(normal 13.5–73.9 mg/dl). IgG response to pneumococcal poly-
saccharide antigens was normal. Mitogen induced lymphoprolifer-
ative response was decreased to Pokeweed mitogen. Anti nuclear
antibody was positive. The colitis resolved with intravenous
antifungal and antibiotics. Repeat total CD3+ T cells count doubled
to 1,410 cells/ul, and the CD4+ T cells count increased to 296 cells/
ul. Lymphocyte phenotyping revealed low CD4+CD45RA+ naive
T cells at 3%, and proportionally increased CD45RO+CD4+
memory T cells to 17%. The percentage of CD4+CD25+ T cells
was constantly low at 3% and 6%, and CD19+CD25+ were
undetectable (0%). IL-2 and mRNA for IL-2 were undetectable
while IL-15 levels were markedly increased. Conclusions: We
present a familial immunodeficiency in a patient with cyclic CD4+
lymphopenia, recurrent mucosal candidiasis and ulcerative colitis.
The finding of IL-2 deficiency with a concomitant increase of IL-15
may suggest a compensatory mechanism by which IL-15 mounts
incomplete adaptive immune responses through an IL-2-independ-
ent pathway with a persistent susceptibility to fungal infections.
Su2.44. Novel Severe T-Cell Immunodeficiency
Syndrome Involving Absent Thymus, Coloboma,
Bullous Dermatitis, Eosinophilia, and Elevated IgE.
K. P. Shanks,1 L. M. Noroski,1 C. Langston,2 E. M. McKay,2 M. L.
Levy,3 S. L. Abramson.1 1Department of Pediatrics, Baylor
College of Medicine, Houston, TX, USA; 2Department of
Pathology, USA; 3Department of Dermatology, USA.
Objective: To report a novel severe immunodeficiency of absent
thymus, coloboma, bullous dermatitis (BD), eosinophilia, elevated
IgE, and monoclonal T cell expansion with a CD4+ defect.
Methods: 10wk WM with hx of coloboma, eczema and otitis
presented with BD and Pseudomonas superinfection involving
trunk and eyes. Due to the unusual skin findings and ocular
pathogen, an immune assessment was done as delineated in results
section. Clinical course included skin improvement on antibiotics
and 6d of immunosuppressants. Based on immunofluorescence
studies, immunosuppressants were stopped. He then developed
eczema herpeticum and recurrent BD, hypertension, HSM, and
AbstractsS250lymphadenopathy. Despite IVIG and aggressive antibiotic therapy,
he deteriorated clinically with HSV-1 viremia, Parainfluenza
infection, Pseudomonas bacteremia, respiratory failure, and died
with Enterococcus and CONS bacteremia at age16wk. Results:
Skin cultures grew Pseudomonas and CONS. While skin biopsy
initially showed nonspecific dermatitis, classic features of pemphi-
gus vulgaris were seen on 2 later biopsies. Direct and indirect
immunofluorescence studies for pemphigus were not conclusive
and serum was negative for desmoglian Ab. Initial CBC showed
ANC 8960, ALC 1344, AEC 1991. Eosinophilia persisted(8–18%).
Serum Ig levels prior to IVIG were IgG 1070mg/dL, IgA 16.1, IgM
120, IgE 39,900 IU/ml. HIVAb and DNA PCR were negative. NBT
and complement screens were normal. Isohemagglutinins were
negative with blood type O. Lymphocyte phenotyping showed
CD3+CD4+ 8.4%(#538/mm^3), CD3+CD8+ 61.9%(#3963), CD3-
CD19+ 20.4%(#1024), CD56+ 4% (#256), CD45RA+ 0%(#0),
CD29+ 5.6%(#359), and a CD4:CD8 ratio of 0.14. Mitogen studies
10d off immunosuppressants showed very poor response to PHA,
ConA and PWM. Karyotype was 46 XY, indicating neither maternal
engraftment nor aneuploidy. Echocardiogram and abdominal ultra-
sound at age 11wk were normal. EBV PCR and CMVantigenemia
were negative. No deletions were found by FISH at 22q11 and
10p13. RAG-1 and -2 mutational analysis is pending. Two mono-
clonal T cell expansions were detected by PCR of TCR gamma
locus. HSV IgM was present and HSV IgG was not detected until
after IVIG was given. Tracheal aspirate silver stain was negative.
Autopsy revealed an absent thymus, HSM, and diffuse massive
lymphadenopathy with lack of normal architecture. Interfollicular
zones were depleted with scattered dendritic cells and plasma
cells, few T lymphocytes, rare primary follicles, and increased
stromal elements without increase in histiocytes. No evidence of
GVHD was found. Conclusion: We describe a severe immuno-
deficiency syndrome consisting of CD8+ T cell predominance,
CD4+ and nave T cell deficiency, absence of thymic tissue, poor
mitogen responses, 2 distinct monoclonal T cell expansions,
eosinophilia, and elevated IgE. Although possibly representing a
new form of combined immunodeficiency, this group of findings
is most consistent with a novel presentation of atypical DiGeorge
syndrome.
Su2.45. Isolated PCP Infection in Children-A Systemic
or Specific Immunodeficiency?
A. P. Williams,1 J. OTB Hourihane,2 E. Hodges,1 G. Davies,3
J. Smith.1 1Department of Clinical Immunology, Southampton
General Hospital, Southampton, United Kingdom; 2Department of
Child Health, Southampton General Hospital, Southampton,
United Kingdom; 3Molecular Immunology Unit, Institute of Child
Health, London, United Kingdom.
We report 3 cases of pneumocystis cainii (PCP) pneumonia
occurring in Caucasian male infants in the absence of other typical
clinical or laboratory features of immune incompetence.
Case 1
A 5 month old male infant presented with a short history of
poor feeding and respiratory distress. Following a CXR which was
characteristic of PCP a brochoalveolar lavage (BAL) was under-
taken which confirmed the presence of PCP. The child responded
to high dose steroids, Septrin and IVIG and was discharged on day
24. Immunological investigations on admission were as follows:
CD3 = 0.23 (2.3–6.5), CD4 = 0.19 (1.5–5), CD8 = 0.05 (0.5–1.6)
CD19 = 0.69 (0.6–3) and NK = 0.07 (0.1–3). Currently these are;
CD3 = 0.27, CD4 = 0.20, CD8 = 0.07, CD19 = 0.99 and NK = 0.29.The stimulation index following PHA was 156. Lymphocytes
were low on admission at 1.7 (Normal = 6–9). HIV testing was
negative. CD40 ligand was expressed upon activated T cells and
CD132 (common g chain) was demonstrated by protein blotting.
TCR ah immunophenotyping was normal. He is currently well on
prophylactic Septrin and SCIG.
Case 2
A 4 month old infant was admitted with a 3 day history of poor
feeding and respiratory distress. A CXR was consistent with PCP
and a subsequent BAL confirmed the presence of PCP. He was
treated and discharged home on day14. Immunological inves-
tigations on admission were as follows: CD3–2.18, CD4 = 1.5,
CD8 = 0.44, CD19 0.99 and NK = 0.24
The stimulation index following PHA was 2 on admission and
50 at his most recent review. Immunoglobulins were normal. HIV
testing was negative. CD40 ligand was expressed upon activated T
cells and protein blotting confirmed the presence of CD132. TCR
ah immunophenotyping was normal. Interestingly, this childTs
mother had been previously diagnosed with hyper IgE syndrome
but he has not yet been shown to have a raised IgE or other typical
features of his motherTs condition. The child has had no further
clinical episodes associated with immune incompetence and
remains well on Septrin and SCIG.
Case 3
A 3 month old infant presented with a respiratory distress,
weight loss and an enterocolitis. A CXR showed a bilateral hilar
infiltrate and a BAL sample confirmed PCP. Immunological
investigations on admission were as follows: CD3 = 4.79, CD4 =
4.07, CD8 = 0.61, CD19 = 0.39 and NK = 0.22.
The stimulation index following PHA was normal. Immuno-
globulins were normal. HIV testing was negative. TCR ah
immunophenotyping was normal. CD40 ligand was expressed
upon activated T cells.
All 3 children demonstrated a susceptibility to PCP without
other typical features of immunodeficiency that usually accompany
such a presentation in children with SCID or HIGM syndromes.
The long term management of such children with apparent single
pathogen sensitivity is of interest with regard to the use of a watch
and wait approach with imperfect prophylactic treatments or bone
marrow transplantation (BMT).
Su2.46. Combined Immunodeficiency with Defective
Expression in MHC Class II Genes.
Anastassia P. Mihaylova,1 Kalina L. Penkova,1 Danilela N.
Baltadzhieva,1 Milena I. Ivanova,1 Elissaveta J. Naumova.1
1Central Laboratory for Clinical Immunology, University Hospital
Alexandrovska, Sofia, Bulgaria.
The bare lymphocyte syndrome is a member of the relatively
heterogeneous class of severe combined immunodeficiency and is
associated with lack of expression of HLA antigens on some cells
of hematopoietic origin. We report cases with BLS who had
protracted pneumonia, repeated sever infections of the upper and
lower respiratory tract, persistent diarrhea, candidiasis for several
months. Laboratory tests revealed hypogammaglobulinemia, mild
anaemic syndrome and leucocytosis. Peripheral blood immuno-
phenotyping showed prominent decrease of CD4+ T-cells with
inverted CD4/CD8 ratio. Antigen-induced lymphocyte prolifer-
ation and cell-mediated lymphocytotoxicity were absent in vitro.
The detection of MHC molecules expression by flowcytometry
using monoclonal antibodies to HLA-DR, DQ and DP antigens as
well as to HLA class I antigens revealed lack of MHC class II
Abstracts S251molecules expression on non-stimulated and IFNg stimulated
PBMC. In contrast the expression of MHC class I molecules was
conserved. SBT typing did not show any unknown polymor-
phisms in HLA-DRB1, DQB1 and DPB1 loci. Since the genes
coding for class II polypeptides seemed to be unaffected, the
genetic defect in these patients must have concerned the
regulation of the expression of the HLA-DR genes. By studding
mutations in transacting genes MHC2TA, RFX5, RFXAP we
were able to detect genetic defects responsible for a failure to
express class II genes in our patients.
Su2.47. Efficacy and Safety of Subcutaneous
Immunologlobulin Replacement Therapy at Home in
Patients with Primary Immunodeficiency Diseases:
Combined Analysis of Two Clinical Studies, One in
North America and One in Europe.
Hans D. Ochs & Clinical Investigators,1 Ann Gardulf,2 Michaela
Praus,3 Peter Kiessling.4 1Department of Pediatrics, University of
Washington, Seattle, WA, USA; 2Department of Laboratory
Medicine, Section of Clinical Immunology, Karolinska Intitutet at
Karolinska University Hospital, Stockholm, Sweden; 3Biostatistics,
Accovion GmbH, Marburg, Germany; 4ZLB Behring GmbH,
Marburg, Germany.
INTRODUCTION: Intravenous infusions of immunoglobulin
(IVIG) every 2–6 weeks have been the standard therapy for
patients with primary immunodeficiency diseases (PID). Compli-
cations of IVIG therapy limit the use of IGIV at home. Weekly
self-administered subcutaneous immunoglobulin (SCIG) infusions
at home are becoming an alternative therapy regime. We
evaluated a 16% pasteurized, preservative free, liquid, human
IgG preparation intended for subcutaneous use with regard to
safety and efficacy.
METHODS: In two prospective studies, one in the US and
Canada (NA study) and one in Europe and Brazil (EU study), 125
PID patients between 3 and 74 years of age self-infused SCIG
(VivaglobinR, ZLB Behring) on a weekly basis at home. The
patients began the SCIG therapy one week after their last IVIG
infusions, and entered a 3-month wash in/wash out period followed
by a 12-months efficacy period in the NA study and a 6-months
efficacy period in the EU study. Clinical endpoints included the
rate of serious bacterial infections (SBI), rates of all types of
infections, as well as serum (S) IgG levels observed during the
study. Safety variables comprised local and systemic reactions,
laboratory investigations and vital signs.
RESULTS: A total of 5,953 infusions were administered to
125 patients in the course of the two studies. The patients received
a weekly man dose of 158 mg/kg in the NA study and 89 mg/kg in
the EU study during the efficacy phase of the studies. Only three
SBIs (pneumonias) were reported during the efficacy phase in the
two studies; two in the NA study and one in the EU study, resulting
in an identical annualized rate of 0.04 SBI per patient. The
annualized rate for any kind of infection was similar in both studies
with 4.4 episodes / patient year in the NA study and 4.3 episodes/
patient year in the EU study. Upper respirator infections were the
most frequently reported types of infection. Mean S-IgG levels
increased from 837 mg/dL to 922 mg/dL at 101% of the previous
IVIG dose in the EU study and from 786 mg/dL at start of SCIG to
1040 mg/dL at 136% of the previous IVIG dose in the NA study.
No study drug related serious adverse events were reported in any
of the studies. Local injection site reactions, of mostly mild or
moderate intensity, dropped rapidly in both studies from initially85% to about 40% during the course of the NA study and from
65% to about 20% in the EU study.
CONCLUSIONS: Two major clinical trials have demonstrated
that weekly self-administration of SCIG with a 16% IgG
preparation is safe and effective in patients with PID, resulting in
normalized stable S-IgG levels and providing satisfactory protec-
tion against severe bacterial infections.
Su2.48. Abstract Withdrawn.
Su2.49. Association of IgA Deficiency and Ciliary
Dyskinesia: Report of a Familiar Case.
D. Strozzi,1,3 M. Toledo-Barros,1,3 L. V. Rizzo,1,3 P. H.N. Saldiva,2
E. G. Caldini,2 J. Kalil,1,3 C. M. Kokron.1,3 1Division of Clinical
Immunology and Allergy, Department of Medicine, University of
Sao Paulo Medical School, Sao Paulo, Sa˜o Paulo, Brazil;
2Department of Pathology, University of Sao Paulo Medical
School, Sao Paulo, Sa˜o Paulo, Brazil; 3Institute for Investigation
in Immunology (iii), Sao Paulo, Sa˜o Paulo, Brazil.
Rationale: Selective IgA deficiency is the most common form of
primary immunodeficiency. However, there is a difference in
frequency between the Caucasian and Asian populations (approx-
imately 1 in 700 Caucasians and 1 in 18500 Japanese being affected).
In addition some IgA deficiency individuals have increased
susceptibility to upper respiratory tract or gastrointestinal infections.
Primary ciliary dyskinesia is a phenotypically and genetically
heterogeneous condition in which the primary defect is in the
ultrastructure or function of cilia, highly complex organelles that are
structurally related to the flagella of sperm and protozoa. Its clinical
features include recurrent sinopulmonary infections, subfertility and
laterality defects; the latter due to ciliary dysfunction at the
embryological node. Then here we describe for the first time a
familiar case of association of IgADeficiency andCiliaryDyskinesia.
Methods: Clinical and Laboratory evaluation of two siblings
who presented to our division with a history of bronchiectasis and
recurrent infections.
Results: We describe 2 male siblings, 35 and 39 years old,
which started to present recurrent infections in childhood, mainly
sinus and lung infections. They evoluted with progressive loss of
pulmonary function, and one of them had already been submitted
to pulmonary transplantation. Family history included a father and
older brother with similar symptoms who died because of
disseminated bronchiectasis. Laboratory findings showed IgA
deficiency with normal IgG and IgG subclasses and normal
response to polyssacharide antigens. Pulmonary CT scans con-
firmed bronchiectasis. Further evaluation showed oligospermia
with reduction of sperm motility. Electronic microscopy of
respiratory mucosa was compatible with ciliary dyskinesia.
Conclusion: This is the first report of the association of IgA
Deficiency and Ciliary Dyskinesia which reinforces the importance
of a complete laboratory evaluation of patients with recurrent
infections.
Su2.50. Atypical Mycobacterial Infection and Chronic
Granulomatous Disease: Experience of One Center.
G. Uzel,1 H. L. Malech,2 S. M. Holland.1 1NIAID, Laboratory of
Clinical Infectious Diseases, NIH, Bethesda, MD, USA; 2NIAID,
Laboratory of Host Defenses, NIH, Bethesda, MD.
Increased incidence of tuberculosis has been reported in CGD
patients who live in endemic countries. There are multiple reports
of complications following Bacillus Calmette-Guerin (BCG)
AbstractsS252vaccination in affected patients, manifesting with axillary lympha-
denitis and local ulceration. Also known are several cases of
disseminated BCG infection in the setting of CGD. Less
commonly, atypical mycobacteria other than the vaccine strain,
have been recognized as causes of pulmonary infection in CGD.
We describe and discuss three CGD patients from one center
followed between 1975 and 2004, who have been diagnosed with
atypical mycobacterial infection.
Patient 1: A 27 year old man with a family history of autosomal
recessive CGD, was diagnosed with CGD following Myobacte-
rium fortuitum pneumonia (previously reported). Patient 2: A 7
year old boy, one of three affected siblings with p47phox
deficiency, was referred for Myobacterium avium pneumonia and
bronchiectasis, but had had numerous bacterial pneumonias
previously. Patient 3: A p22phox deficient 7 year old boy was
diagnosed with CGD shortly before presentation with disseminated
Myobacterium chelonae infection. All three patients responded to
anti-mycobacterial antibiotics and have not had recurrent myco-
bacterial disease to date.
In our series, atypical mycobacterial infection either roughly
coincided with or preceded the diagnosis of CGD. Surprisingly, all
of our patients had recessive forms of CGD, 2 with p47phox
deficiency, and one with the rarer p22phox deficiency, despite the
fact that recessive CGD is less common and generally thought to
be less severe than X-linked gp91phox deficiency. None of the
patients had been on interferon gamma (IFNg) or antibacterial
prophylaxis at the time of development of their nontuberculous
infection. Unlike patients with severe defects in the interferon
gamma receptor, none of these patients had recurrences of
mycobacterial disease. Although limited in-vitro data have
demonstrated no difference in the inhibition of intracellular
mycobacterial growth within PMNs and monocytes derived from
either patients with CGD or normal volunteers, there appears to be
a predisposition to infection with atypical mycobacteria based on
our experience. We suggest ruling out CGD in patients with
pulmonary or disseminated atypical mycobacterial disease and
considering mycobacteria as possible pathogens in infections in
CGD patients
Su2.51. Use of Subcutaneous Immunoglobulin for
Treatment of Chronic Warts in Patient with Common
Variable Immunodeficiency.
J. H. Lin,1 R. L. Roberts.1 1Department of Pediatric Allergy,
Immunology, Rheumatology, University of California Los Angeles,
Los Angeles, CA, USA.
We describe a 19 year old man with a diagnosis of common
variable immunodeficiency (CVID) and a two year history of
chronic warts. At eighteen years of age, he was diagnosed with
CVID following a history of chronic sinusitis, chronic otitis
media, and persistent cervical lymphadenopathy. His serum IgG
levels were very low (37 mg/dL) although B and T cell subsets
were within normal limits. Monthly infusions of intravenous
immunoglobulin and continuous oral antibiotics led to improve-
ment of infectious episodes and decreased lymphadenopathy, but
warts on all his fingers and elbows persisted and became very
disfiguring. He attempted laser therapy, cryotherapy, and imiqui-
mod for removal of warts but met with little success. Difficult-to-
treat warts are common in patients with immune deficiencies.
Most cases are described in patients with cell-mediated immu-
nodeficiencies, and immunomodulatory treatment is often focused
on enhancing lymphocyte function. This patient had normaldelayed hypersensitivity responses but topical immunotherapy
using dinitrochlorobenzene (DNCB) was also not effective. One
syndrome, called WHIM (Warts, Hypogammaglobulinemia,
recurrent bacterial Infections, Myelokathexis) is characterized by
low serum gammaglobulins, failure of leukocytes to leave the
bone marrow, and chronic neutropenia. Treatment of warts with
intravenous immunoglobulin for these patients have been met
with poor success. Our patient did not suffer from chronic
neutropenia. His therapy for CVID changed from monthly
infusions of immunoglobulin to weekly subcutaneous immuno-
globulin infusions. Two months into subcutaneous immunoglo-
bulin therapy, his warts resolved completely with no scarring,
even though the patient did not receive any specific therapy for
the warts while on subcutaneous immunoglobulin. The successful
resolution of cutaneous warts with subcutaneous immunoglobulin
treatment suggests subcutaneous immunoglobulin may provide a
more steady-state level of IgG to allow for an enhanced ability to
combat human papillomavirus in hypogammaglobulinemic
patients.
Su2.52. Distribution and Clinical Aspects of Pediactir
Primary Immunodeficiencies in Taiwan.
Wen-I. Lee,1 Jing-Long Huang,1 Ming-Ling Kuo,2 Syh-Jae Lin,1
Cheng-Jang Wu.2 1Department of Pediatric Allergy, Immunology
and Rheumatology, Chang Gung University and ChildrenTs
Hospital, Kwei-Shan, Taoyuan, Taiwan; 2Department of
Microbiology and Immunology, Graduate Institute of Basic
Medical Sciences, Chang Gung University, Kwei-Shan, Taoyuan,
Taiwan.
Recent advances in immunologic techniques have lead to
increased recognition of primary immunodeficiencies (PID). A
review of pediatric patients with suspected immunodeficiencies in
Taiwan from Jan. 1985 to Jan. 2005 and molecular/genetic analyses
done on some patients were investigated. Based on the International
Classification of Disease, Ninth Revision (ICD-9) and published
articles, 99 patients with PID (22 females and 77 males) were
identified: 59 (60%) with antibody production deficiencies, 15
(15%) with defective phagocyte function, 8 (8%) with combined B
and T cell immunodeficiencies, 16 (16%) with T cell deficiencies,
and one (1%) with primary complement deficiencies. Those with
secondary immunodeficiencies were excluded from the study.
Recurrent sinopulmonary infections (62%) were the most common
clinical manifestation, followed by sepsis (57%), severe skin
infection (40%), splenomagaly/hepatomegaly (27%), central nerv-
ous system dysfunction (22%), chronic diarrhea (22%), and failure
to thrive (19%). Ten (10%) patients died, seven of infections, one of
disseminated intravascular coagulopathy, one of hepatocellular
carcinoma and one of lymphoma. Six novel mutations were found
from 22 selected patients. This is the first report on PID in Taiwan,
based on Chineses population.
Su2.53. Experimental Study of the Complex
Bi-Directional Interactions between Human
Immunodeficiency Virus Type 1 (HIV-1) and the
Protozoan Parasite Leishmania.
Chenqi Zhao,1 Michel J. Tremblay.2 1Microbiology-Immunology,
Centre de Recherche en Infectiologie, Ste-Foy, QC, Canada;
2Microbiology-Immunology, Centre de Recherche en Infectiologie,
Ste-Foy, QC, Canada.
As a result of overlapping geographical distribution, co-
infection with human immunodeficiency virus type 1 (HIV-1)
Abstracts S253and protozoan parasite Leishmania is becoming a common event
and presents an extremely serious clinical problem. The two
diseases produce cumulative deficiencies of the immune response
as both pathogens destroy the same immune cells, exponentially
increasing disease severity and consequences. On one hand,
Leishmania increases the risk of progression to acquired immu-
nodeficiency syndrome (AIDS) and AIDS-related deaths. On the
other hand, HIV-1 accelerates the dissemination of Leishmania
infection and quickens the natural course of the parasitic diseases.
The optimal therapeutic approach to HIV/Leishmania co-infected
patients is still uncertain, due to the complex pathogenesis of the
co-infection and the lack of literature and information. This study
was aimed at exploring (1) the putative effect of Leishmania on the
process of HIV-1 replication and transmission, and (2) the potential
role played by HIV-1 in Leishmania infection. The experiments
were performed with physiological experimental models, namely a
human lymphoid tissue ex vivo culture system, human primary
monocyte-derived macrophages (MDMs), as well as dendritic cells
that include human primary monocyte-derived dendritic cells
(MDDCs) and a DC-SIGN transfected cell line. The results show
that (1) Leishmania enhances HIV-1 replication in both primary
human macrophages and in human lymphoid tissues, (2) the
Leishmania-directed increase in HIV-1 production is associated
with a complex network of proinflammatory cytokines, such as
TNF-a, IL-1a, and IL-6, (3) Leishmania also modulates the process
of HIV-1 transmission through competition binding to DC-SIGN in
dendritic cells, and (4) HIV-1, on the other hand, is also able to
promote the intracellular growth of Leishmania in human primary
macrophages through an enhanced uptake of the parasite. These
findings help to unravel the molecular cellular mechanisms through
which the two microorganisms interact, provide novel insight into
the complex relationships between both human pathogens, and,
most importantly, offer information that may be useful for the
design of effective therapeutic strategies to control disease
progression in persons dually infected with HIV-1 and Leishmania.
Su2.54. Hereditary Angioedema: A New Mutation and a
Search of Gravity Factor?
Kamel Djenouhat, Veronique Fremeaux-Bacchi, Jacques Blouin,
Marie Therese Guinnepin, Jerome Laurent, Mario Tosi, Mohamed
Cherif Abbadi. 1Immunology, Institut Pasteur dTAlger, ElHamma,
Alger, Algeria; 2Immunology, Hopital Europeen Georges
Pompidou, Paris, Paris, France; 3Immunology, Hopital Europeen
Georges Pompidou, Paris, Paris, France; 4Allergy, Institut
Pasteur de Paris, Paris, Paris, France; 5Allergy, Institut Pasteur
de Paris, Paris, Paris, France; 6Immunogenetic, Faculte de
Medecine et de Pharmacie, Rouen, Rouen, France;
7Immynology, I.P.ALGER, Alger, Alger, France.
Hereditary angioedema (HAE) is an autosomal dominant
disease, it manifests as recurrent attaks of intense, massive,
localized edema without concomitant pruritus. In case of laryngeal
edema, the attack can be life-threatening with the risk of
asphyxiation if not treated adequately.
AIMS: Our objectives are to study the place of a new intronic
mutation (640 GN A) as a molecular basis of HEA typeI, and to
investigate the effect of sequence variation within the coding
region of C1 inhibitor gene (polymorphism 566 T N G) on disease
expression as it has been reported recently (S-A Cumming al, J
Med Genet 2003, 40: e114).
METHODS: The studies were performed on 15 members of an
Algerian family, five patients with HAE type I and the others arehealthy. PCR products were purified using a QIA quick PCR
purification kit (QIAGEN, CRAWLEY, UK) and the fragments
were then sequenced by direct sequencing of PCR amplified DNA
according to the ABI Prism 3700 DNA-Analyser (Biosystems).
Fonctionnel tests were perfomed in HepG2 and Hep3B transfected
cells by C1inhibitor minigene (all exonic regions and only inton 2
and 3) fellowed by reverse transcription of RNA and agarose
electrophoresis of cDNA.
RESULTS AND DISCUSSION: Five members of our family
have HAE typeI and all of them present a 640 GN A mutation
within the intron2 in position+3 (IVS2+3) which isnTt a canonic
splice-site region. Fonctionnel tests reveal a presence of 02
different bands, the first one migrates in position 186pb (as W.T
band which includes exon2) and the second one in 107pb(as 638
GN A mutation which causes total splicing defect of exon 2). We
conclued that our new mutation 640 GN A, never descibed right
now, causes a partial splicing defect of exon2. Neverthless, only 02
patients with HAE have a 566 T N G mutation (inherited from the
mother whoTs healthy and already described as a polymorphism).
Fonctionnel tests have shown no difference in C1 inhibitor
synthesis dependig of the presence or no of 566 T N G mutation,
and the severe clinical expression of the disease was observed in
one patient without that mutation.
CONCLUSION: We describe a new intronic mutation in C1
inhibitor gene associated with HAE: 640 GN A that will cause a
partial splicing defect of exon2, and we conclude that clinical
severity of HAE in our family cannot be explained by the presence
or the absence of a 566 T N G polymorphism.
Immuno-dermatology
Su2.55. Bexarotene Gel 1% vs. Vehicle Gel in
Combination with Narrow-Band Ultraviolet B
Phototherapy for Moderate to Severe Psoriasis Vulgaris.
M. A. Magliocco,1 K. Pandya,1 V. Dombrovskiy,1 Y. Wong,1 L.
Christiansen,1 A. B. Gottlieb.1 1Clinical Research Center,
UMDNJ-Robert Wood Johnson Medical School, New Brunswick,
NJ, USA.
Background: Psoriasis is a chronic, autoimmune dermatolog-
ical disorder characterized by erythematous, hyperkeratotic plaques.
Ultraviolet B (UVB) phototherapy is FDA-approved for psoriasis
and acts by inducing apoptosis in lesional T-cells. However,
phototherapy is often inconvenient and less effective for thick
plaques. Oral retinoids are teratogenic and rarely clear psoriasis as
monotherapy. Retinoids thin the epidermis in thick plaques,
allowing for better penetration of UVB; since limited UVB
penetration through thick plaques inhibits efficacy, combining
retinoids with UVB would be expected to yield synergistic
improvement of efficacy. Bexarotene is a topical retinoid that is
FDA-approved for the treatment of cutaneous T-cell lymphoma and
is being clinically evaluated in the treatment of psoriasis.Objective:
To determine whether bexarotene gel 1% plus narrow-band UVB
(NBUVB) phototherapy is more effective for moderate to severe
psoriasis than NBUVB plus vehicle gel. Materials and Methods:
This was a single-center, double-blind, vehicle-controlled, bilateral
comparison of bexarotene gel 1% vs. placebo, in combination with
NBUVB, for moderate to severe psoriasis. Nine subjects were
randomly assigned gels to be applied to target lesions on the right
and left sides of the body. For 10 weeks, subjects applied bexarotene
and placebo to the assigned sides. Subjects receivedNBUVB3 times
weekly for 8 weeks, beginning 2 weeks after the start of topical
AbstractsS254treatment. Evaluations were done at week 0 (baseline), then weekly
for 8 weeks, starting at the initiation of NBUVB. Efficacy was
assessed using target lesion scoring and photography. Results:
Bexarotene gel 1% plus NBUVB was significantly more effective
than placebo plus NBUVB for moderate to severe psoriasis. The
changes in target lesion scores were compared for active drug- and
placebo-treated sides. The mean decrease in score from baseline for
drug-treated lesions was 67.6% (95% CI 50.9%–84.3%), while that
of placebo-treated lesions was 48.2% (95% CI 24.0%–72.5%).
Because of the small sample size, the nonparametric Wilcoxon rank-
sum test was used to analyze differences in score changes between
two groups. The score improvement with drug was significantly
greater compared to placebo (P = 0.04). Scaling, erythema, and
induration were reduced to a greater extent with drug. Adverse
events were mild and included rash and skin irritation.Conclusions:
Compared to placebo, bexarotene gel 1% appeared to increase the
efficacy of NBUVB phototherapy with minimal toxicity. Further
studies are warranted which include a larger number of subjects.
Su2.56. The Higher pH Level Present in the Skin of
Patients with Atopic Eczema Stimulates the Release of
Malassezia sympodialis Allergens.
Annika Scheynius,1 Christine Selander,1 Omid Rasool,1 Reto
Crameri,2 Arezou Zargari.1 1Department of Medicine, Clinical
Allergy Research Unit, Karolinska Institutet and University
Hospital, Stockholm, Sweden; 2Swiss Institute of Allergy and
Asthma Research (SIAF), Davos, Switzerland.
Atopic eczema (AE) is a chronic inflammatory skin disorder. The
pathogenesis of AE is not fully understood, but defects in the
immune system and the ruptured skin barrier are of importance. The
pH of both lesional and non-lesional skin in patients with AE is
higher (pH 6) as compared to healthy skin (pH 5.5). The yeast
Malassezia belongs to the normal human skin micro flora and can
induce IgE and T cell reactivity in patients with AE. Previously, we
have identified several IgE-binding components, including a 67-kDa
protein, in M. sympodialis extract. Furthermore, based on amino
acid sequencing and screening of IgE-binding clones from a M.
sympodialis phage display cDNA library, we could isolate a clone
with partial sequence of the above mentioned 67-kDa allergen. We
have also shown that the 67-kDa allergen is exposed on the cell
surface of M. sympodialis. The aim of this study was to investigate
whether the 67-kDa allergen can be released under different pH
conditions mimicking those of AE skin and healthy skin. M.
sympodialis was cultured in Dixon broth pH 5.5 or 6.1 at 32 8C.
Culture supernatants were analysed for the presence of IgE-binding
components by immunoblotting using serum from an AE patient
with specific IgE to M. sympodialis. The result showed that the
release of the 67-kDa allergen was substantially enhanced in the
culture supernatants with the higher pH. RACE-PCR, cloning and
sequencing were used to find the complete coding sequence of the
67-kDa protein which showed similarity to the glucose oxidase
family. This sequence was expressed in Escherichia coli as a 6-
histidine tagged recombinant protein. The IgE-binding frequency of
the recombinant allergen was 59%, to 22 sera from AE patients with
serum IgE-antibodies to M. sympodialis, indicating that the 67-
kDa protein is a major M. sympodialis allergen. In conclusion, we
have cloned a major M. sympodialis allergen which is released to
a higher extent at pH 6. The data suggest that the skin barrier in
AE patients provides an environment that can enhance the release
of allergens from M. sympodialis, which can contribute to the
inflammation.Su2.57. Tuberculin Skin Testing Widely Used as a
Diagnostic Aid for Tuberculosis, False Negative
Outcome Has Questioned Its Specificity & Sensitivity
Inspite of Tuberculous Infection.
M. Ishaq, I. M. Sameera, K. M. Miraj. 1Allergy/Pulmonology,
Al-Junaid Hospital, Nowshera, NWFP, Pakistan.
Purpose: Skin test to exclude/include infection by Mycobacte-
rium tubercle bacillus had been popular in the good olden days, but
now has limited its wide spread significance.
Methods: Tuberculin skin testing an evidence of tuberculous
infection had been in practice since years as diagnostic tool for
epidemiological study of the whole/random population, to judge
the degree of control of tuberculosis & exclude/include indications
for BCG vaccination. Problems had arisen for its limiting value in
patients having imminent tuberculous infection as confirmed by
isolation of organisms in the sputum smear/culture, a conclusive
chemotherapeutic response or clinical evidence of tuberculous
infection. Since 1998 to early2002 tuberculous conditions as under
with false negative outcome had been documented.
Infection by atypical Mycobacterial infection.
Advanced age with tuberculosis.
False techniques of testing/ improper storage of tuberculin
solution.
Overwhelming tuberculosis.
Early stages of sarcoidosis.
*Miliary tuberculosis.
Hodgkins diseases.
Malnutrition.
Aids/Immunodeficiency.
Tuberculosis with hyperpyrexia.
Tuberculosis with generalized skin xanthoma.
In some cases no induration had been observed even to
100TU,despite the active tuberculous infection.
Results: In face of its limitations as an ideal diagnostic aid in
the detection of tuberculosis, its role had been now a supporting
test in the absence of BCG with conclusive evidence on
radiological & clinical grounds.
Conclusions: The cellular mechanisms responsible for skin test
reactivity are related mainly to previously sensitizedCD4+
population of lymphocytes that are attracted to the site of skin test.
*Tuberculin test had been negative, reactivity restored during
the continuation of chemotherapy.
Clinical Implications: Tuberculin test despite short of ideal to
conclude the diagnosis of tuberculosis still had been an important
place in the diagnostic tool list.
MIM khan et.al.alj.h.nsr.nwfp pk.
Su2.58. Absence of Draining Lymph Nodes Results in
Th2 Immune Deviation and Loss of Resistance to
Leishmania major Infection.
T. W. Spahn,1,2 W. Domschke,1 J. Roth,3 C. Sorg,3 T. Kucharzik,1
J. M. Ehrchen.3 1Department of Medicine B, Muenster University
Hospital, Muenster, NRW, Germany; 2Department of Internal
Medicine and Gastroenterology, Marienhospital Osnabrueck,
Osnabrueck, Niedersachsen, Germany; 3Department of
Experimental Dermatology, Muenster University Hospital,
Muenster, NRW, Germany.
Lymph nodes (LNs) are important sentinel organs which
harbour circulating lymphocytes and APCs. Antigen specific
cellular and humoral immune responses are induced in LNs.
Abstracts S255Objective: We investigated if LNs are required for the induction
of protective immunity against Leishmania (L.) major infection.
Materials and Methods: We utilized mice lacking peripheral
LNs due to in utero blockade of membrane lymphotoxin
(LT)(peripheral (p)LN null). Mesenteric LNs were present in
pLN null mice. In utero antagonism of membrane LT is transient
and the organogenic defects in LN development are irreversible.
The secondary lymphoid architecture in the adult progeny of mice
undergoing gestational treatment is intact.
We also investigated the course of leishmaniasis in mice with
genetic deletion of LT ligands (LT-h/) or of the LT-h
receptor(R) which lack skin draining LNs (LT-h/) or all LNs
(LT-h-R/). To distinguish between the role of LT and LNs in
anti-L. major immunity, we also infected wild typeY LT-h-R/
bone marrow chimera which express the LT-h receptor on
hematopoetic cells. In addition, C57BL/6 wild type mice were
treated with neutralizing LT-h-R-IgG during L. major infection.
Splenectomy experiments were performed in order to investigate
the role of the spleen in resistance against L. major.
Results: pLN null mice of the resistant C57BL/6 strain
developed systemic infection with increased IL-4 and reduced g-
interferon secretion in the presence of mesenteric LNs. Similarly, in
gene deficient mice without local draining LNs (LT-h/) or
lacking all LNs (LT-h-receptor/) leishmaniasis was dissemi-
nated and accompanied by increased secretion of IL-4 in CD4+ T
cells. The clinical course of infection was similar in LT-h-
receptor/ mice and wild type Y LT-h-R/ bone marrow
chimera, which similarly secreted more IL-4. Treatment of wild
type mice with LT-h-R-IgG during L. major infection did not
abrogate resistance against L. major. Splenectomized C57BL/6
mice cleared the infection at the same rate as sham operated mice.
Conclusions: Peripheral LNs are critical for immunity against
L. major in a genetically resistant mouse strain. These LNs provide
a milieu which stimulates the induction of a Th1-anti-Leishmania
response and prevents Th2 immunity. In the absence of pLNs
mesenteric LNs and/or the spleen prime for a Th2 response. The
spleen is dispensable for the induction of resistance against L.
major in the presence of pLNs. Interaction between LT ligands and
the LT-R is not required for control of L. major in C57BL/6 mice.
Su2.59. Dissociation of Transactivation from
Transrepression Activity by a Selective Glucocorticoid
Receptor Agonist (SEGRA) Leads to Separation of
Therapeutic Effects from Side Effects.
H. Schaecke,1 A. Schottelius,1 W.D. Doecke,1 P. Strehlke,2 S.
Jaroch,2 N. Schmees,2 H. Rehwinkel,2 H. Hennekes,3 K.
Asadullah.1 1RBA Dermatology, Schering AG, Berlin, Germany;
2Medicinal Chemistry, Schering AG, Berlin, Germany; 3Corporate
Project Management SBU Specialized Therapeutics, Schering AG,
Berlin, Germany.
Glucocorticoids (GCs) are the most commonly used anti-
inflammatory and immunosuppressive drugs. Their outstanding
therapeutic effects, however, are often accompanied by severe
and sometimes irreversible side effects. Thus, the goal of GC
pharmacological research is the development of new drugs which
show a reduced side effect profile while maintaining the anti-
inflammatory and immunosuppressive properties of classical
GCs. GCs affect gene expression either by transactivation or
transrepression mechanisms. The anti-inflammatory effects are
mediated to a major extent via transrepression while many side
effects are induced by a transactivation mechanism. Therefore, weaimed to identify ligands of the glucocorticoid receptor (GR) that
preferentially induce transrepression while avoiding or at least
strongly reducing transactivation. Here we describe a selected
non-steroidal selective GR-agonist (SEGRA), ZK 216348, which
shows a significant dissociation of transrepression and trans-
activation activities both in vitro and in vivo. In a murine model
of skin inflammation ZK 216348 is anti-inflammatorily active
comparable to prednisolone after both systemic and topical
application. A remarkable superior side effect profile was found
with regard to blood glucose induction, spleen involution and to a
lesser extend skin atrophy but not to ACTH suppression.
Accordingly ZK 216348 should have a lower risk e.g. for
induction of diabetes mellitus. Thus, the SEGRAs represent a
promising new class of drug candidates with an improved effect/
side effect profile in comparison to classical GCs. Moreover, they
are attractive tool compounds for further investigating the
mechanisms of GR-action.
Su2.60. The Effect of Burn Trauma in Rats on
Neutrophil Recruitment and Antioxidant Enzymes
Activity in Epidermis.
E. V. MikhalTchik,1 S. M. Titkova,2 M. V. Anurov,2 A. P. Oettinger,2
L. G. Korkina.1 1Department of Molecular Biology, Russian State
Medical University, Moscow, Russia, Russian Federation;
2Department of Physiology, Russian State Medical University,
Moscow, Russia, Russian Federation; 3Deparment of Physiology,
Russian State Medical University, Moscow, Russia, Russian
Federation; 4Department of Physiology, Russian State Medical
University, Moscow, Russia, Russian Federation; 5Department of
Molecular Biology, Russian State Medical University, Moscow,
Russia, Russian Federation.
The results of autodermoplasty after severe burns may depend
on inflammatory changes of epidermis in donor sites.This study
was aimed at evaluation of myeloperoxidase (MPO) and
antioxidant enzymes activity in unburned epidermis after burn
trauma as well as after burn trauma complicated by endotoxemia
in rats.
Rats were scald burned (20% of total body area) and E.coli
liposaccharide was administered at the 4th day postburn
(p.b.).Probes of unburned epidermis were cut at days 1,4,5
p.b.Activity of MPO, catalase(Cat), superoxide dismutase(SOD),-
glutathione peroxidase(GPx)were assessed. Results: MPO was
elevated from the1st day p.b. SOD and Cat were lowered at the
1st day and returned to normal by the 4th day. GPx was slightly
activated at the 1st day. Endotoxin (ET) injection gave 2-fold
increase in MPO activity from the 4th to 5th day wich was
accomponied by significant increase of GPx and SOD activity.
Conclusions: burn trauma is followed by raise of MPO activity in
unburned epidermis (especially at endotoxemia) and by early (at the
1st day) decrease of SOD and Cat activity. Further growth of MPO
activity is accomponied by activation of antioxidant enzymes.
Su2.61. Quantitative Changes of Mast Cells Following
Topical Application of Honey on Third Degree Burns in
Rats.
Mohammad Bayat,1 Mojtaba Karimipour,1 Mohammadali
Almasieh.1 1Anatomy, Shaheed Beheshti University of Medical
Sciences, Tehran, Tehran, Islamic Republic of Iran.
Objectives: Hypertrophy scar and keloid may be ocurred after
burning. Mast cells have important roles in pathogensis of them.
The purpose of present study was determination of number
AbstractsS256changes of mast cells in a experimental model of third degree
burn.
Methods: A third degree burn was made in 24 rats by direct
contact of skin with boiling water for 8 seconds. Rats were divided
randomly into four groups. Group1-Burns of control, 2, 3- Burns of
these groups were received topical application of unboiled
commercial honey one-time per day and twice daily. Group 4-
Burns of this group were received topical application of nitro-
furazone cream daily. Samples were extracted from 3 rats at day 15
and of another 3 rats at day 30, for light microscopical study were
stained with toluidine blue. Numbers of mast cells were counted
and Data were analyzed by non- parametric tests.
Results: Group 4 had highest number of mast cells at day 15
(30.43 F 41.1) and of at day 30 (31.52 F 41.1). Control group had
lowest number of mast cells at day 15 (11.9 F 15.43). Group 2 had
lowest number of mast cells at day 30(17.19 F 22.85).
Conclusions: It is concluded that topical applications of honey
on 3 degree burns, didnTt have significant effect on the number of
mast cells in comparison with control and routine treatment groups.
Su2.62. Anti-IFN-gamma as a Universal Treatment for
Th1 Mediated Skin Diseases.
S. Skurkovich,1 B. Skurkovich,2 N. Korotky,3 N. Sharova,3 G.
Lukina,4 Y. Sigidin.4 1R&D, Adv Biotherapy, Inc., Rockville, MD,
USA; 2Brown Med School, Providence, RI, USA; 3Department of
Skin Dis, Russian St Med U, Moscow, Russian Federation; 4Clinic,
Rheumatol Institute, Moscow, Russian Federation.
We pioneered anticytokine therapy (AT), proposing removal of
hyperproduced IFN (Skurkovich,Nature, 1974) and TNF-a together
with certain IFNs (Skurkovich, J IFN Research, 1989) to treat
various autoimmune diseases (AD). Cytokines induced by IFN-
gamma (IFN-g), such as TNF-a, IL-1 and their receptors, often work
similarly. We conducted the 1st AT in 1975. We had good results
treating Th-1 AD, e.g., RA, MS, and corneal transplant rejection
with anti-IFN-g. Here we treated Th-1 skin diseases having Th1
cytokines or autoreactive T cells that induce IFN-g and other Th1
cytokines in the lesions.Objective: To test removing IFN-g in these
diseases. Method: Anti-IFN-g was given topically or IM for 3–5
days. Results: Acne vulgaris. Propionibacteria and estrogen in
adolescence, pregnancy and premenstrual period are IFN-g
inducers. By day 2 after treatment, most pustular elements had
dried. By day 4, infiltrated elements remained but had paled.
Psoriasis vulgaris. Group A strep. antigen-reactive T cells and IFN-
g are found in skin lesions of psoriasis. Patients (pts.) had a rapid
reduction of the erythema leading to disappearance of papular
infiltrates and after 2–3 weeks, clearing of plaques and complete
remission in most pts. Some with small infiltrates on the legs were
given UV treatments, after which they went into remission or
completed therapy with 80% plaque reduction. Psoriatic arthritis.
Th-1 cytokines are found in the synovial fluid. Pts. responded as in
psoriasis vulgaris. Seborrheic dermatitis. Expression of IFN-g
mRNA has been detected in skin biopsies. After treatment, itchiness
and peeling of skin decreased, and the skin turned paler. Herpes
simplex virus type 1 (HSV1). Autoreactive T cells in lesional skin
induce IFN-g. 3 to 3.5 hours after treatment, pts. noted rapid
reduction of burning and pain in the lesion. After 2 days, scabs
formed, which faded in 5 days. Dystrophic epidermolysis bullosa
(a genetic disease but with some AD features). After the 2nd
injection of anti-IFN-g, temperature normalized. On day 2, pain,
swelling and hyperemia of the ulcerative lesions at the neck
disappeared as did signs of infectious damage to the skin on theback. By day 5, erosive lesions on the mouth epithelialized. By day
7, active epithelialization of the ulcerative skin lesions was
observed. HSV2 genital lesions. Dysregulated production of IFN-
g may exert a pathological effect by increasing virus replication.
Within hours after the 1st topical application, itching and pain
disappeared. By day 3–4, the eroded area epithelialized.
Conclusions: These diseases are connected with immune dis-
turbances in which IFN-g plays a key role and could also be treated,
besides with anti-IFN-g, with anti-TNF-a and anti-IL-1 alone or
together and soluble receptors to IFN-g, TNF-a, or IL-1, an IL-1
receptor antagonist or anti-CD20. Anti-IFN-g may have fewer
complications than anti-TNF-a, such as infection, SLE, demyeli-
nation, and others. Rosacea may also be treated with anti-IFN-g.
Su2.63. BuschkeTs Scleredema: Atypical Onset and
Evolution. Case Report.
Victor Cristea,1 Monica Crisan,1 Claudia Magurici,1 Ramona
Bologa,1 Nicolae Miron.1 1Immunology, Iuliu Hatieganu
University of Medicine and Pharmacy, Cluj Napoca, Cluj,
Romania.
In August 2004, a 58-year-old female patient presented to the
Emergency Department of the Clinic for significant facial edema
and erythema, generalized pruritus, dyspnea, altered general
condition. The manifestations appeared after a diet rich in fats
and spices. The patient reported that she had had two previous
similar episodes for which she had received antihistamine and
cortisone treatment on an outpatient basis. The case was interpreted
as QuinckeTs edema and the patient was administered intravenous
and oral cortisone and antihistamine preparations. During hospital-
ization, laboratory investigations were performed, which showed an
extremely low ESR (2-5), along with leukocytosis that reached
shortly 48,500/mm3. The patient developed during this interval
BuschkeTs scleredema located in the cephalic extremity and upper
thorax, which was confirmed by both histopathological examina-
tion and antitopoisomerase I antibodies. Blood examination
excluded the possibility of malignant hemopathy. Ten days after
admission, the patient became confused, presented severe headache,
impaired vision and temporospatial disorientation. CT examination
showed no changes. The patient was transferred to the Clinic of
Dermatology with the suspicion of tertiary syphilis (in spite of a
negative VDRL test), and penicillin treatment was initiated. After 3
weeks, the patient was discharged in an improved condition, but
with manifestations of spastic paraparesis. The case is unusual in
terms of onset and evolution and no direct causal connection can be
established between QuinckeTs edema, BuschkeTs scleredema and
spastic paraparesis manifestations.
Su2.64. The Characteristics of Mucosal Immunity in
Chronic Adult Periodontitis Patients.
I. Kaidashev,1 V. Shinkevich,1 L. M. DuBuske.2 1Ukrainian
Medical Stomatological Academy, Poltava, Ukraine; 2Immunology
Research Institute of New England, Gardner, MA, USA.
Background. Chronic periodontitis is the result of the immune
response to specific bacterial infections in relation to oral flora. The
present study investigates the quantitative and qualitative aspects
of immune cells in the oral mucosa with correlation to disease
progression.
Methods. We investigated 30 patients (23–58 years) with
chronic adult periodontitis. The diagnosis was verified by tradi-
tional clinical and radiologic examinations. The control group was
6 healthy individuals without symptoms of periodontal disease.
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were taken after approval from the Ethics committee. Serial frozen
sections of gingival mucosa were assessed using the avidin-biotine-
peroxidase technique with monoclonal antibodies against HLA-
DR, CD3, CD4, CD8, TCR gy-chains and CD20. All data were
assessed using non-parametric statistics.
Results. This investigation demonstrated an interaction
between antigens and immune cells which moved from the
epithelium to the lamina propria related to the severity of the
periodontitis. This process paralleled the loss of the protective
potential of the epithelium.
Specific immunological features for the early stage of perio-
dontitis include an increase in antigen pressure related to an
increase in antigen-uptake by dendritic cells and subsequent
persistent inflammation in the epithelium. Further immunological
events occur in the lamina propria, with cytotoxic response
reduced. The intensity of inflammation in this site was promoted
by autoantigens inducing T cell sensitization. CD3+ and CD8+ T
cells were the major cell populations associated with tissue
damage, while B cells (CD20+) were the most significant cells
in the progression of chronic adult periodontitis.
Conclusion. Chronic adult periodontitis caused by pathogenic
microorganisms may in part be related to host response in an
immune-mediated event. Therapy of severe chronic periodontitis
should target not only microorganisms which should be eradicated
but also the immune response in oral mucosa which may enhance
disease progression.
Su2.65. Acquired Angioedema and Coagulopathy
Several Years after Syphilis.
Soheil F. Chegini, Michael J. Davies, Timothy J. Craig. 1Medicine,
Division of Pulmonary, Allergy & Critical Care, Penn State
College of Medicine, Hershey, PA, USA.
Angioedema (AE) is a rare condition, which is characterized
by recurrent, episodic, nonpruritic, subcutaneous or submucosal
swelling that primarily affects the face, extremities, upper
airways and gastrointestinal tract. AE results from unrestrained
activation of the complement system due to an inherited or
acquired deficiency of C1 inhibitor (C1-Inh). Acquired AE
(AAE) manifests in the adulthood, usually after the forth decade
with low serum levels of C1, C1q, C2, C4 and C1-INH activity
and can exists in two forms. Type I AAE is mostly associated
with lymphoproliferative or neoplastic disorders that result in
exuberant complement activation, which overwhelms normal C1-
Inh reserves by accelerated consumption. Type II AAE is defined
by the presence of autoantibodies against the C1-Inh, which
interfere with its function, thus allowing unopposed complement
activation.
We report the case of a 67-year old man with a distant
history of syphilis treated with penicillin, who experienced his
first episode of facial edema in 4/02 after ingestion of sweet
myrrh root that subsided spontaneously. In 11/02 he developed
diffuse swelling of his upper extremities and tongue. No triggers
could be identified and a minimal work-up at that time was
unrevealing. He remained asymptomatic until 1/04 when he
experienced two episodes of tongue swelling that were preceded
by minor trauma from poorly fitting dentures. He was treated in
a local emergency department with diphenhydramine, predni-
sone, and epinephrine on both occasions with gradual resolution
of edema over several days. He was not taking any medications
that could cause angioedema, and did not experience concom-itant urticaria or pruritus. Subsequently, his primary care
physician discovered a suppressed CH50, and referred him to
our clinic for further evaluation and management of recurrent
angioedema.
On presentation to our office, he was asymptomatic, and had
a normal physical exam. He had not had any swelling until
after age 65 and no family history of angioedema. He has never
had any bleeding tendency or thrombotic events. His laboratory
evaluation revealed markedly decreased complement levels,
CH50, C1q, C2, C4 (all below range of detection), depressed
C1-Inh level and function, reactive RPR at 1:2 and T. pallidum
particle agglutination, elevated lupus anticoagulant, anti-cardio-
lipin IgA and IgM but not IgG. His PT and PTT were
significantly elevated, which did not correct even at 1:9 mixing
with pooled normal serum. Factor XI and XII were 19% and
45%, respectively (50–150%). Fibrin split product was 320 (0-
10) and D-dimer was beyond the assay range, even after serial
dilutions.
Our case demonstrates interconnection between the comple-
ment and coagulation cascades at several levels. It also indicates
that multiple autoantibodies can coexist in the same individual and
suggests that syphilis might have been the inciting culprit, which
resulted in AAE. This case exemplifies the diagnostic and
therapeutic challenges associated with AAE, which will be
presented along with a review of the literature.
Su2.66. Expression of the Costimulatory Molecules on
Antigen-Presenting Cells in Atopic Dermatitis.
G. N. Drannik,1 A. I. Kurchenko,1 L. M. DuBuske.2 1Department
Clinical Immunology and Allergology, National Medical
University, Kiev, Ukraine; 2Immunology Research Institute of New
England, Gardner, MA, USA.
Background. Atopic dermatitis (AD) is a common dermato-
logic condition that is characterized by pruritic and eczematous
lesions which can be chronic and persistent. Skin lesions are
histologically characterized by infiltrating activated T-cells, but the
mechanism of this activation remains unclear. IgE-mediated
facilitated antigen presentation by IgE-bearing dendritic cells
(DC) to T-cells may be a key event in the pathogenesis of AD.
Methods. Punch biopsies were obtained from 9 patients with
chronic AD after obtaining signed informed consent with the
approval of the local ethics committee. AD was diagnosed
according to the criteria defined by Hanifin and Rajka. Human
skin biopsies taken from patients undergoing cosmetic surgery (n =
9) served as normal controls. The expression of CD80 (B7-1) and
CD86 (D7-2) was demonstrated on CD1a+ epidermal dendritic
cells (DC) in AD lesions by immunohistological analysis.
Results. Cryosections of inflammatory skin were immunos-
tained to localize the CD80+ and CD86+ cells. CD80+ as well as
CD86+ cells were identified in the lesional epidermis and dermis.
In the epidermis, cells expressing CD80 and CD86 were found at
the suprabasal as well as the basal level, scattered throughout the
epidermis in an LC-like distribution pattern, being dendritically
shaped and exhibiting a membranous staining pattern, suggestive
of DC. In this study, we were able to demonstrate that DC are the
major epidermal cell population expressing the costimulatory
molecules CD80 and CD86 in situ, with AD patients showing
the greatest expression.
Conclusion. Costimulatory molecules are an essential factor in
the generation of an effective immune response, as failure to
deliver costimulatory signals during antigen presentation leads to
AbstractsS258T-cell anergy. The in situ enhanced expression of CD80 and CD86
molecules on epidermal DC may be relevant to the pathogenesis of
inflammatory skin lesions in AD.
Su2.67. Differential Distribution of Lymphocyte
Subpopulations in Peripheral Blood and Muscle Biopsies
in Untreated Juvenile Dermatomyositis (JDM).
C. Chuu,1 M. OTGorman,1 L. M. Pachman.1 1Pediatrics, Feinberg
College of Medicine, Northwestern University, Chicago, IL, USA.
Rationale: Juvenile Dermatomyositis (JDM) is a chronic
inflammatory disease that is characterized by a distinctive
pattern of skin rash and muscle weakness. Untreated children
with JDM have significantly lower total lymphocytes and CD8
cells in their peripheral blood than healthy age-matched
controls (OTGorman & Pachman, Clin Diag Lab Immunol,
1995, 2000). The current study used immunohistochemistry to
examine the distribution of infiltrating lymphocyte subsets in
muscle biopsies from untreated JDM patients and flow
cytometry to examine the concurrent distribution of circulating
lymphocyte subsets. The purpose of this study was to
demonstrate a redistribution of lymphocyte subsets between
blood and muscle, which may support the conjecture that these
immune cells are activated and migrate from circulation to the
affected tissue in untreated JDM.
Methods: Five children aged from 3 to 10 with untreated JDM
were enrolled with IRB-approved consent signed. Fresh frozen
muscle biopsies were sectioned and tissue sections were immu-
nostained with McAb against CD3, CD4, CD8, CD14, CD19 and
CD56. Vectastain ABC kit (Vector Laboratories, Burlingame, CA)
and DAB substrate (Biogenix) were used in combination to detect
the target antigens. Positively stained cells were examined under
the microscope and counted within the measured area defined by
the computer software. Peripheral blood samples of these children
were analyzed on a Becton Dickinson FACScan flow cytometry
(Mountain View, Calif.) using a scheme of four-color (FITC, PE,
ACP and PerCP) three panel reagent system.
Results: Immunohistological studies of JDM muscle biopsies
demonstrate a pattern of focal lymphocyte infiltration. For each
mm2 of muscle tissue, subsets of lymphocytes ranged in
number from 36–87 for CD4, 10-28 for CD8, 40-52 for CD14,
10–40 for CD56 and 2–12 for B cells. Corresponding flow
cytometry absolute counts were 474–1629 for CD4, 308–850
for CD8, 61– 258 for CD56 and 339–992 for B cells. The
relationship between flow cytometry and immunohistological
results were evaluated by regression analysis using correlation
coefficiences. NK cells (CD 56) in blood is inversely correlated
with the number of NK cells in the muscle biopsy from the
same patient (r2 = 0.5848, P b 0.045). Both CD4 and CD8
also showed an inverse association (r2 = 0.3593 and r2 =
0.2063 respectively), but not as statistically significant
(P N 0.05).
Conclusion: JDM is the most common pediatric inflammatory
myopathy involving the immunological activation of several lines
of immune cells. The current study indicates that while CD4, CD8,
CD14 and CD19 positive cells are present in the muscle biopsies,
there is a decrease of NK cells in the blood and increased cells in
the same patientTs muscle. The inverse relationship between NK
cells in blood and muscle suggests their influx, trafficking from the
circulation to the inflamed site which implies that they may play an
important role in the pathogenesis of the target damage seen in
JDM.Supported by R01 AR48289, The Arthritis Foundation and The
Myositis Association (to LMP).
Su2.68. Thalidomide, an Anti-Inflammatory Medication,
Inhibits the Induction of Tumor Necrosis Factor-A
(TNFA) in Ultraviolet B (UVB)-Irradiated Human
Keratinocytes by Destabilizing the TNFA mRNA.
J. H. Lin,1 M. M. Bashir,1 W. Zhang,1 V. P. Werth.1,2
1Dermatology, University of Pennsylvania, Philadelphia, PA,
USA; 2Dermatology, Philadelphia VA Medical Center,
Philadelphia, PA, USA.
UVB induces TNFa, a cytokine that contributes to UV-induced
apoptosis of keratinocytes (KCs). Exposure of apoptotic antigens
may then trigger an immune response in photosensitive disorders,
such as subacute cutaneous LE (SCLE). Thalidomide (Thal) is
beneficial in TNFa associated diseases, and our prior studies
demonstrate that it inhibits UVB-induced TNFa mRNA and
protein. The goal of the current study was to understand the
mechanism of this inhibition and to define the role of IL-1a in the
induction of TNF-a.
All experiments were conducted with neonatal KCs. Cells were
pre-treated for 2h with 50 Ag of Thal/ml and irradiated with 30 mJ
UVB/cm2 F IL-1a. TNF-a protein in culture medium was
quantified by ELISA. Real-time PCR (RT-PCR) was used to
quantify KCs TNF-a mRNA.
As previously reported, TNFa gene expression 3 h post-UVB
was 7.6 (range 7.4–7.9) times the level in sham-irradiated controls.
Thal reduced this induction by 54% (P b 0.001). TNFa gene
expression 3h after treatment with UVB + IL-1a increased to 116
(range 112–120) times the level in the no-IL-1a, sham-irradiated
controls. Thal treatment of KCs + IL-1a reduced this induction by
70% (P b 0.005).
By RNA protection assay, we found that Thal selectively
inhibits TNF-a mRNA relative to other human cytokines (TNFh,
LTh, IFNh, IFNg and TGFh) studied in a multi-probe set. We
showed that Thal inhibited UVB+IL-1a-induced TNFa mRNA by
61% similar to the results seen with RT-PCR.
To examine the mechanism of Thal inhibition of UV-induction
of TNFa, we assessed the TNFa mRNA half-life by using
actinomycin D, an inhibitor of RNA synthesis. KCs were pre-tx
with Thal and irradiated with UVB, IL-1a was added immediately
after irradiation. In two separate experiments, we found that the
degradation of TNFa mRNA was increased at least three-fold in
the presence of Thal + Il-1a.
Thus, Thal inhibits UV-induced TNFa protein secretion by
enhancing the degradation of TNFa mRNA. This action may
contribute to the drugTs therapeutic effects in photosensitive
disease.
Su2.69. Gene Transcripts as Potential Diagnostic
Markers for Allergic Contact Dermatitis.
M. B. Hansen,1 L. Skov,1 T. Menne,1 J. Olsen.2 1Department of
Dermatology, Gentofte Hospital, Hellerup, Denmark;
2Department of Medical Biochemistry and Genetics, University of
Copenhagen, Copenhagen, Denmark.
The standard procedure for diagnosing allergic contact derma-
titis is to perform a patch test. Since this has several disadvantages,
the development of a new in vitro test system would be of immense
value. Gene transcripts that distinguish allergics from non-allergics
may have the potential to serve as the molecular basis for such a
diagnostic tool.
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the identification of differentially expressed genes in allergen-
stimulated peripheral blood mononuclear cells (PBMC) from
chromium-allergic patients versus healthy controls.
To qualify for the gene expression study, chromium-allergic
patients should show a positive patch test to both CrCl3 and
K2Cr2O7 and mononuclear cell cultures established from the
patients should have a strong in vitro proliferative response to
CrCl3 assessed with the
3H-thymidine assay. Non-allergic controls
would only be accepted for the study if they had no clinical
reactions to both chromium compounds and no cellular in vitro
response to CrCl3. Using these criteria, 3 out of 6 patients and 3 out
of 6 controls were selected for the study.
Using an Affymetrix GeneChipR, the gene expression was
analysed in PBMC cultures grown with 100 m g/ul CrCl3 or in
media alone for 24 h.
A total of 26 genes were differentially expressed by more than 2
fold (P b 0.01) in allergen-activated PBMC from patients compared
to controls. 18 of these were upregulated whereas 8 were down-
regulated. Using real-time PCR, the differential expression was
confirmed for three selected genes: CISH, ETS2, CASP8. This was
statistically significant (P b 0.01) for CISH and ETS2.
The 26 differentially expressed genes identified in this studymay
potentially function as diagnostic markers for contact sensitivity.
Su2.70. Potent Anti-Inflammatory Effect of Topical
Nuclear Factor kappa B Decoy in Skin Inflammation.
B. Schryver,1 T. Muchamuel,1 A. Oo,1 J. Alleman,1 M. Dajee,1
L. M. McEvoy,1 R. Ehrhardt.1 1Research, Corgentech. Inc, South
San Francisco, CA, USA.
Rational: Treating chronic skin inflammation is an ongoing
challenge in children and adults. The long-term use of topical
calcineurin inhibitors and corticosteroids raises concerns about
immunosuppression and malignancy. Nuclear Factor kappa B
(NFkB) transcription factor plays a central role in the progression
and maintenance of chronic skin inflammation. This study explores
the possibility of using topical NFkB decoy (NFkBD) as a safer
therapeutic alternative for skin inflammation. Methods: Efficacy
and skin penetration of a high affinity, specific NFkBD was
examined in nonclinical animal models. Since pig skin is similar to
human skin, topical NFkBD penetration was tested in porcine skin.
A dustmite antigen induced atopic dermatitis (AD) Nc/Nga mouse
model, was employed to further evaluate the potency of NFkBD
with approved drugs including corticosteroids, tacrolimus and
pimecrolimus. Results: 0.5% topical NFkBD application to pig
skin resulted in efficient nuclear localization. Nuclear localization
of the NFKBD was evident throughout the epidermis as well as the
dermal layers. In a dustmite antigen induced AD mouse model,
topical NFkBD (0.1–1.0%) produced a dose-dependent reduction
of ear swelling (up to 80%), similar to betamethasone treatment.
Topical NFKBD was more efficacious at both doses (0.25% and
1.0%) compared to topical calcineurin inhibitors, tacrolimus and
pimecrolimus. NFkBD therapy, resembling betamethasone,
decreased expression of the pro-inflammatory cytokines IL-1beta,
IL-6, TNF-alpha and TSLP in inflamed ears. In addition, topical
application of NFKBD decreased inflammation, epidermal hyper-
proliferation and cellular infiltration. Cessation of 0.1% topical
betamethasone resulted in a severe rebound of inflammation,
whereas NFkBD efficacy was maintained for at least 15 days after
treatment termination. Notably, unlike betamethasone that induces
skin atrophy within 4 days, prolonged NFkBD application fails toshow any such side effect. Conclusion: These results show anti-
inflammatory steroid-like efficacy of topical NFkBD in skin
inflammation without the side effects of topical steroids. Hence,
these observations illustrate the potential of topical NFkBD as a
novel effective and safe therapeutic agent of inflammatory skin
diseases.
Su2.71. Dual Diagnosis of Pemphigus Vulgaris and
Connective Tissue Disease.
Mohsin Malik,1 A. Razzaque Ahmed.1 1Oral Medicine, Infection
and Immunity, Harvard School of Dental Medicine, Boston, MA,
USA.
Background: Patients with a dual diagnosis of pemphigus
vulgaris (PV) and autoimmune connective tissue disease (CTD)
have previously been reported. These few reports lack long-term
follow-up and clinical details on the relationship of the two
diseases.
Objective: We report thirteen patients diagnosed with PV who
had an additional CTD diagnosis of systemic lupus erythematosus
(SLE), mixed connective tissue disease (MCTD), or both.
Methods: We conducted a retrospective analysis of the clinical
profile, serological data, treatment, and follow-up of patients seen
at one tertiary academic referral center.
Results: The thirteen patients were Caucasian with a mean age
of onset of PV of 47 years (range 23–71). Ten were female and
three were male. In three patients both diseases occurred
simultaneously and in the remaining ten PV preceded SLE/MCTD.
PV was severe and difficult to treat in twelve patients, though it
eventually responded to therapy and these patients were in
remission or stable and controlled on tapering therapy. Long-term
follow-up, mean 8 years (range 3–18 years), revealed that in six
patients the CTD was stable and under control, with periodic need
for symptomatic therapy. In seven patients the CTD was controlled
but required corticosteroids or other systemic agents. Life-threat-
ening systemic involvement observed in SLE or MCTD, such as
renal, cardiac, and neurological manifestations, were absent.
Conclusion: The thirteen patients reported here may have a
genetic predisposition to develop autoantibodies. Unknown trig-
gering factors are likely to influence the levels of autoantiobodies
in such susceptible individuals and result in clinical disease
presentation. The differences in response to therapy of the two
diseases, PV and CTD, would suggest that both similar and
different mechanisms influence autoimmunity, define the extent of
disease, and regulate the immune response.
Su2.72. Production and Characterization of Human
Monoclonal Antibody Against Desmoglein 3 from
Pemphigus Vulgaris Patient.
Shih Wei Yeh,1 Kailash C. Bhol,1 Mukesh Kumar,2 Lisa A.
Cavacini,2 Marshall Posner,2 A. Razzaque Ahmed.1 1Oral
Medicine, Infection and Immunity, Harvard School of Dental
Medicine, Boston, MA, USA; 2Beth Israel Deaconess Medical
Center, Boston, MA, USA.
Pemphigus vulgaris is a potentially fatal autoimmune mucocu-
taneous disease associated with production of IgG autoantibodies
to desmoglein 3, a 130 kDa epidermal protein. To further
characterize the epitope(s) of pemphigus vulgaris antigen we
established a human-human hybridoma by fusion of the peripheral
blood mononuclear cells with a human and mouse heterohybri-
doma. This hybridoma designated as PVMAB706 and stable in
culture and demonstrated yield of monoclonal antibodies specific
AbstractsS260for pemphigus vulgaris. Immunofluorescence, immunoblot, ELISA
assays demonstrated that the monoclonal antibody bind to the
intercellular cement substance and to 130 kDa protein present in
the skin and specifically binds to recombinant desmoglein 3
protein, but no to desmoglein 1 protein. The IgG subclass
distribution study demonstrated that the antibody is of IgG4
subclass in nature. The antibody was pathogenic as demonstrated
in vitro by their ability to produce acantholysis in normal human
skin and mucous membranes in organ culture or in vivo by the
induction of disease in neonatal BALB/c mice. The relevance and
value of these monoclonal antibodies in the pathogenesis fo
pemphigus vulgaris is discussed.
Su2.73. Identification of Epitope for Autoantibody and
Its Role in Basement Membrane Separation in Oral
Pemphigoid.
Khwaja Aftab Rashid,1 Adnan Q. Usman,1 Shih Wei Yeh,1 Joel
N.H. Stern,1 Kailash C. Bhol,1 A. Razzaque Ahmed.1 1Oral
Medicine, Infection and Immunity, Harvard School of Dental
Medicine, Boston, MA, USA.
Oral pemphigoid (OP) is a chronic autoimmune disease
characterized by blisters and erosive lesions in the oral mucosa.
We identified an epitope for OP Abs within the integrin alpha (a)6
subunit, and designated four subunit fragments (A,B,C,D).
Immunofluorescence studies demonstrated that all the fragments
were present in the oral mucosa. Sera of 20 patients with active OP
bound only to fragment A and its subfragment A2. The peptide
A2.1, within fragment A2, accounted for the binding of all the test
sera. Controls were sera samples from 10 healthy volunteers and 30
patients with other pemphigoid diseases. The OP patient sera and
immunoaffinity-purified OP sera, rabbit antisera for fragments A
and A2, and mAb GoH3 produced basement membrane separation
of oral mucosa. Biopsies of oral lesions from OP patients showed
that Ab to integrin a6 binds to the roof of the blister and that
laminin 5 binds to the base. This in vitro study identifies a peptide
in the integrin a6 molecule to which Abs in the sera of OP patients
bind, and which may play an important role in the pathogenesis of
OP.
Su2.74. Effects of Electrical Microcurrent on Open Skin
Wound Healing in Rabbit.
Mohammad Bayat,1 Zahra Asgari-Moghadam,1 Mohammad
Rakhshan,1 Fateme-sadat Rezai,1 Mohammadali Almasieh.1
1Anatomy, Shaheed Beheshti University of Medical Sciences,
Tehran, Tehran, Islamic Republic of Iran.
Objective: With regarding acceleration of fractures healing by
application of microcurrent electrical stimulation, in this study the
effects of microcurrent (microampere) on the full thickness
incisional wound healing of rabbits were studied.
Methods: 30 male adult rabbits were randomly divided into
control and experimental groups. Each group divided into 3
subgroups, based on duration of study (4, 7, 15 days). Under
general anesthesia and sterile conditions, one full thickness
incision on skin of each rabbit was made. From day of surgery
experimental group received electrotherapy daily for 2 hours
(current intensity: 200 A/cm2, current density: 66 A/cm2,
frequency 0.5 Hz). Polarity was negative at first 3 days and
was positive at following days. At the end, rabbits were killed
by choloroform and 2 samples were obtained from wound tissue
and adjacent normal skin for histological and tensiometerical
studies. Number of neurtrophils and fibroblasts and crosssections of vessels were counted. Data were analyzed by student
T test.
Results: Number of fibroblasts of experimental group at
seventh day (862.6 + 70.1were higher significantly (P b 0.01)
than relevant control group (468.2 + 59). Tensile strength of
experimental group at fifteenth day (2138.2 + 212) was higher
significantly than relevant control group (1443.1 + 218.8).
Discussion: It seems the administration of microcurrent serves
to boost the electromotive force behind the moving ions and
radicals sufficient to allow entery into injured region so that
favorable metabolism and repair can take place. Microcurrent by
increasing ATP production could accelerate wound healing process.
Key words: electrical microcurrent stimulation, wound healing,
histology, tensiometery, rabbit.
Su2.75. Morphometric Assessment of Nitrofurazone
Ointment on Healing of Infectous Second Degree Burns
of Rat.
Mohammad Bayat,1 Hasan Bagheri-Yazdi,1 Mohammadali
Almasieh.1 1Anatomy, Shaheed Beheshti University of Medical
Sciences, Tehran, Tehran, Islamic Republic of Iran.
Objectives: The therapeutic effects of Nitrofurazone ointment
on healing of infectous and non-infectous second degree burns of
rats were studied from morphometric and tensiometric and micro-
biological examinations point of views.
Methods: The type of investigation was experimental. 40 adult
males and females rats distributed into infectous and non infectous
groups. Each group divided into control and Nitrofurazone
subgroups. Rats burned according to the standard method and
10% of total body surface of them contacted with boiling water
(958C) or 6 seconds. The day of burning was day zero. Half of burns
were contaminated by a standard sample of pseudomonas aerugi-
nosa. The burns of Nitrofurazone groups received Nitrofurazone
ointment topically one time per day. At 15th and 30th day morpho-
metric and microbiological examination and at 30 the day tensio-
metrical test performed. Data were analyzed by student test method.
Results: Results of the Nitrofurazone groups were significantly
better than control groups. With regard of the results of present
investigation it is concluded that topical application of Nitro-
furazone had positive and significant effect on second degree burn
wound healing of rats and in non-infectous burns itTs effect was
better that in infectous burns.
Key words: Nitrofurazone. Burn. Morphometry. Rat.
Su2.76. Effect of Low-Power Gallium Aluminum
Arsenide Laser Radiation on Mast Cells of Open Skin
Wound Bed of Rats.
Mohammad Bayat,1 Mohammadghasem Golmohammadi,1
Mohammadali Almasieh.1 1Anatomy, Shaheed Beheshti University
of Medical Sciences, Tehran, Tehran, Islamic Republic of Iran.
Objectives: The effect of low power Gallium Aluminum
Arsenide Laser (Ga. Al. Ar. Laser) radiation on numbers and
degranulation of mast cells of open skin wound bed of rats from
quantitative histological point of view were studied.
Methods: 46 male rats were randomly divided into exper-
imental and control groups. Each group divided in to 3 subgroups.
Under general anesthesia and sterile conditions one full thickness
skin circular wound were made on the dorsum of neck of each rat.
The wounding day was day zero. From day one 1/2 doses of
anesthetized drugs were injected to all rats and also experimental
rats were received Ga. Al. Ar. laser which its energy density was
Abstracts S2611.2 J/cm2. At the day 4, day 7, and day 15 after doing daily
treatments, several rats were killed by ether and one sample was
obtained from wound bed and normal adjacent skin from each rat.
Samples were fixed in formalin saline and were prepared for
routine histological study and sections were stained by % 1 watery
solution of toulidine blue. Total number of mast cells and its grades
(No. one, No. two, and No. three) were counted. In grade one, mast
cell was intact and in grade two some granules have been extruded
from the cell and in mast cells of grade 3, degranulation is more
extensive and wide spread. Data were analyzed by Mann Whitney
U test method.
Results: Total number of mast cells and its grades of control
group at the day 4 was higher than experimental group, and
difference of grade one mast cell with experimental group was
significant (P b 0.01). Total number of mast cells and its grades of
experimental group at the day 7 and day 15 were higher than
control groups respectively (P b 0.05).Low power Gallium
Aluminum Arsenide Laser radiation on open skin wound of rats
were reduced significantly intact mast cells at inflammatory phase
and increased total of them at proliferation and remodeling phases
of wound healing process.
KEY WORDS: Laser, Mast cell, Wound Healing, Skin,
Histology, Rat.
Laboratory Immunology
Su2.77. Influence of Atopic History on Cord Blood IgE.
Mohammad Amin Kashef,1 Sara Kashef,2 Narjes Pishva,3
Mozhgan Afshari, Zahra Amirgofran,4 Hamed Jalaeian.1 1Allergy
Research Center, Shiraz University of Medical Sciences, Shiraz,
Fars, Islamic Republic of Iran; 2Immunology and Allergy, Shiraz
University of Medical Sciences, Shiraz, Fars, Islamic Republic of
Iran; 3Neonatalogy, Shiraz University of Medical Sciences, Shiraz,
Fars, Islamic Republic of Iran; 4Immunology, Shiraz University of
Medical Sciences, Shiraz, Fars, Islamic Republic of Iran.
Background: Although the value of cord blood IgE in
predicting the development of allergic diseases is unclear but it is
widely used as a screening parameter for atopy. Therefore it is
necessary to define factors affecting cord blood IgE values.
Objectives: To determine the influence of atopic history in relatives
on cord blood IgE. Methods: Cord blood obtained immediately
after birth from a total of 201 newborns, including 100 high risk
infants (with history of atopy in relatives) and 101 newborns
without family history of atopic disease. Mothers were recruited
prenatally from the Obstetric ward of Hafez Hospital, Shiraz,
Iran.Total IgE levels were determined by use of ELISA system.
Results: Family atopic history does not correlate with elevated cord
blood IgE levels as 51% of newborns in case group (with family
atopic history) and 64.3% of newborns in control group had values
of cord blood IgE higher than 0.5 IU/ml (P = 0.158). No significant
association could be shown between cord blood IgE distribution
and gestational age, birth weight, and age of mother. Conclusion:
Family history of atopy does not play a significant role in
determining the level of IgE in cord blood.
Su2.78. Lymphocyte Adenosine Deaminase Activity in
Children with Idiopathic Nephrotic Syndrome.
Om P. Mishra, Jayant K. Ghosh, Ziledar Ali, Malay R. Sen, Rajniti
Prasad. 1Department of Pediatrics, Institute of Medical Sciences,
Varanasi, Uttar Pradesh, India; 2Department of Pediatrics,
Institute of Medical Sciences, Varanasi, Uttar Pradesh, India;3Department of Biochemistry, Institute of Medical Sciences,
Varanasi, Uttar Pradesh, India; 4Department of Microbiology,
Institute of Medical Sciences, Varanasi, Uttar Pradesh, India;
5Department of Pediatrics, Institute of Medical Sciences, Varanasi,
Uttar Pradesh, India.
Adenosine deaminase (ADA) activity, as a marker of cell-
mediated immunity, was evaluated in the serum (S-ADA) and
lymphocyte (L-ADA) of 47 children with idiopathic nephrotic
syndrome and 23 healthy controls. The mean S-ADA and L-ADA
levels were significantly raised in active nephrotic syndrome (ANS)
and in its sub-groups in comparison to controls. The ADA activity
was significantly more elevated in relapsers than the first attack of
nephrotic patients and the frequent relapsers had the highest
enzymatic levels both in serum as well as lymphocytes. A
significant positive correlation was found between serum and
lymphocyte ADA levels (r = 0.736, P b 0.01). In remission, the S-
ADA showed significant fall in comparison to their corresponding
ANS value (P b 0.001) and reached the level of controls. The mean
L-ADA also showed reduction but the difference was statistically
insignificant and the value was significantly raised, when compared
with controls. The enzyme activity in serum and lymphocytes
normalized in long-term remission group. Thus, ADA activity was
abnormal in ANS cases and L-ADA demonstrated change both in
active as well as remission stage of the disease.
Key words: Nephrotic syndrome, cell mediated immunity,
adenosine deaminase activity.
Su2.79. ESN: A Potent Natural Inhibitor of
Proliferating and Inducer of Apoptosis on K562 Cells.
Yang Ping Niu. 1School of Pharmacology, Zhejiang Univerisity of
Technology, Hangzhou, Zhejiang, China.
Objective: To study the effects of ESN on inhibition of
proliferation and induction of apoptosis of K562 cells, ESN is a
natural extraction isolated from Chinese Herb. Methods: The
inhibitory rates of the proliferation were detected by colony
formation method and cell growth curves. The apoptosis was
analyzed by morphology, flow cytometry (DNA contents), agarose
gel electrophoresis (DNA Ladder) and Annexin V-FITC /PI
staining (the percent of apoptosis cells). Results: After cells were
treated with ESN at the concentration of 30 mg.L1for 24, 48 and
72h, the inhibitory rate were 26.6%, 45.4% and 60.3%, respec-
tively. After cells were treated with ESN at the concentration of 50
mg.L1for 24, 48 and 72h, The inhibitory rate were 41.5%, 71.2%
and 89.6%, respectively. The inhibitory rate of cell growth were
significantly increased compared with the control group
(P b 0.05).The inhibitory effects are dose- and time-dependent.
After the cell cultured with ESN at the concentration of 10,30,50
and 70 mg.L1 for 24 h, The percent of apoptosis cells were 7.8%,
21.5%,48.7% and 32.1% respectively, itTs peak at 48.7%. By
methods of flow cytometry, agarose gel electrophoresis and
morphology, the apoptosis peaks, DNA ladder and the body of
apoptosis were found. Conclusion: ESN can strongly inhibit the
proliferation and induce apoptosis of K562 cells with a time and
dose related manner. It is suggest that ESN might be applied in
leukemia treatment.
Su2.80. An Automatic System for the Image Analysis
and Interpretation of HEp-2 Image Pattern.
Petra Perner,1 Horst Perner.1 1Research Department,
ImageInterpret GmbH, Leipzig, Germany.
The kinds of cells that are considered are Hep-2 cells, which are
used for the identification of antinuclear autoantibodies (ANA).
AbstractsS262ANA testing for the assessment of systemic and organ specific
autoimmune disease has increased progressively since immuno-
fluorescence techniques were first used to demonstrate antinuclear
antibodies in 1957. Hep-2 cells allow for recognition of over 30
different nuclear and cytoplasmic patterns, which are given by
upwards of 100 different autoantibodies. The identification of the
patterns has up to now been done manually by a human inspecting
the slides with the help of a microscope. The lacking automation of
this technique has resulted in the development of alternative
techniques based on chemical reactions, which have not the
discrimination power of the ANA testing. We present a decision
support system that can automatically inspect and classify the cell
patterns [1][2]. We describe the image acquisition unit, the image
analysis and the feature extraction unit as well as the classification
unit. The system was evaluated on a data set of 600 cell image
samples. Finally, we give result on the classification accuracy and
describe the final system.
1. P. Perner, H. Perner, and B. Mqller, Mining Knowledge for
Hep-2 Cell Image Classification, Journal Artificial Intelligence in
Medicine, 26 (2002), pp. 161-173.
2. P. Perner, Classification of HEp-2 Cells Using Fluorescent
Image Analysis and Data Mining, J. Crespo, V. Maojo, and F.
Martin (Eds.), Medical Data Analysis, Springer Verlag, lnai 2199,
p. 219-225.
Su2.81. Determination of ANA Autoantibodies with
Multiplexed Immunoassays.
J. L. Hadley,1 D. O. Onley,1 G. J. Harradence,1 N. F. Cahir,1
C. Garey,1 P. A. Swarbrick.1 1R&D, SmartBead Technologies,
Cambridge, United Kingdom.
The diagnosis and monitoring of autoimmune disease has
traditionally been done by a three-stage process: starting with
immunofluorescence, followed by further testing of positive
samples by immunoassays. This approach is labour intensive,
requiring trained specialists, multiple testing systems and large
reagent and sample volumes, and frequently results in false
positives. A multiplexed immunoassay system was developed that
allows these steps to be combined in one automated assay, thus
reducing time to result, labour and sample requirements. Nine key
antigens for detection of anti-nuclear antibodies (ANA) were each
tagged with unique barcoded microparticles, enabling tracking of
each antigen and therefore allowing mixing of all ANA reagents
and controls. Antigens included Jo-1, Scl-70, Sm, SmRNP, Ro
(SSA), La (SSB), U1snRNP, Centromere B, dsDNA and internal
controls. Recombinant antigens were used, resulting in better
clinical sensitivity and specificity, a necessary feature for accurate
rheumatic disease autoantibody testing. All reagents were lyophi-
lised in a 96-well plate for assay stability and convenience. Using
automated liquid handling robotics, serum samples were added to
each well, followed by a fluorescently tagged detection antibody.
Analysis was performed on the UltraPlexk Automated Plate
Reader. This fully automated multiplexed ANA immunoassay was
used to screen hundreds of patient samples for ANA autoanti-
bodies. In one day, 160 patients plus controls can be screened
simultaneously for 9 autoantibodies, requiring 66% less labour and
90% less sample and reagents, with an overall 2–3 fold improve-
ment in turnaround time of sample to result over traditional
immunoassays. Furthermore, this approach can eliminate the need
for the labour intensive front-end immunofluorescence test, which
can have a high degree of false positives.With validation and
testing done on large panels of patient samples, resulting inspecificity and sensitivity over 90% and 80% respectively, this
multiplexed ANA assay is recommended for the screening,
diagnosis and monitoring of autoimmune diseases. The assay,
called UltraPlexk ANA, provides a fast, flexible and cost-
effective means for measuring multiple disease markers from a
single sample.
Su2.82. Distribution of Killer Cell Immunoglogulin-Like
Receptors Genes in Chinese Han Population.
K. Jiang, F. M. Zhu, Q. F. Lv, L. X. Yan. 1HLA Typing Laboratory,
Blood Center of Zhejiang Province, Hangzhou, Zhejiang, China.
Objective To design a series of primers to detect the diversity
of killer Ig-like receptor(KIR) gene content and the haplotypes in
Chinese Han population in Zhejiang. Methods DNA were
extracted, and samples were genotyped with PCR-SSP method.
Result (1)All 17 known KIR genes were observed in the
population. All individuals contain 3DL3, 2DL4 and 3DL2;
2DL3, 2DL1, 2DP1, 3DP1 * 3, 3DL1, 2DS4 * 1/2 are also very
common; the frequencies of 2DS4 * 3, 2DL5, 2DS1, 3DS1, 2DS5,
2DS2, 2DL2, 2DS3 and 3DP1 * 1/2 were 0.23, 0.19, 0.18, 0.16,
0.11, 0.1, 0.1, 0.08 and 0.07, respectively. (2)13 haplotypes were
detected, and the most frequent one is haplotyoeA2, followed by
A1. (3)34 kinds of genotypes were detected, AJ(A2,A2) and
AF(A1,A2) show higher frequencies. Among them, 20 have not
been found in Caucasians so far, and 8 can not been divided into
haplotypes. (4) Linkage disequilibrium analysis indicated that
some pairs of KIR genes show remarkable linkage disequilibrium.
Conlusion There are distinctive frequencies of KIR gene content,
haplotype, and genotype in Chinese Han population in Zhejiang,
and new KIR haplotype might exist.
Su2.83. Problems of Immunodiagnostics of Hepatitis C
in Senior Patients.
A. A. Potapova, P. G. Bogush, E. B. Redchenko. 1Laboratory of
HIV-Detection, Urban Sexually Transmitted Diseases Clinic N 1 of
Moscow Health Care Department, Moscow, Russian Federation.
Antibodies to hepatitis C virus (HCV) are found in 5% of
Moscow population seeking medical aid through the city health
care system. Significant part of the patients are senior citizens
(18.5%) for whom some difficulties in lab diagnostics are
encountered. Due to these difficulties, there is an urgent need to
improve the immunodiagnostics of HCV infection C in this
population. It is well established fact that among people over 60-
years old, anti-HCV antibodies are found 2.6 times less frequently
than in the younger patients by use anti-HCV ELISA (2.72% and
7.03% respectively, P b 0.001). Among positive sera samples of
senior patients, there are more samples with low optical density
(signal-to-cutoff ratio is less than 3.0) compared to the group of
samples of the younger patients (15.21% and 8.66%, respectively,
P b 0.05). When low-positive sera were tested using other
systems in addition to the required (screen test and confirming
test) some samples showed controversial results. These
bproblematicQ sera samples from senior patients tested with strip
immunoblot assay were negative, and no viral RNA were found
using PCR. Trying to find out the reason for nonspecific positive
reaction with ELISA, we could not detect elevated concentrations
of circulating immune complexes, or monoclonal gamma-glob-
ulinopathy in any of these sera samples. The rheumatoid factor
did not have any effect on ELISA results. When protein fraction
was analysed, it has been found the increase in alpha1–globulins
in the sera of senior patients with nonspecific positive reaction,
Abstracts S263compared to the negative or anti-HCV antibodies positive
samples.
Su2.84. The Novel Docosatriene, Protectin D1, Produced
by TH2-Polarization Promotes Human T Cell Apoptosis
Via Lipid-Raft Clustering.
Amiram Ariel,1 Pin-Lan Li,1,2 Wei Wang,1 Wang-Xian Tang,1,2
Song Hong,1 Katherine H. Gotlinger,1 Charles N. Serhan.1
1Center for Experimental Therapeutics and Reperfusion Injury,
Department of Anesthesiology, Perioperative and Pain Medicine,
Brigham and WomenTs Hospital and Harvard Medical School,
Boston, MA, USA; 2Department of Pharmacology and Toxicology,
Medical College of Wisconsin, Milwaukee, WI, USA.
Docosahexaenoic acid (DHA), a major N-3 fatty acid in human
brain, synapses, retina, and other neural tissues, displays beneficial
actions in neuronal development, cancer, and inflammatory
diseases by unknown mechanisms. In this study, using lipidomic
analysis, we found that the novel 10,17S-docosatriene termed
protectin D1 (PD1) is generated from DHA by T helper type 2
(TH2)-polarized peripheral blood mononuclear cells (PBMC) in a
lipoxygenase-dependent manner. PD1 (100 ng/mouse) blocked T
cell migration in vivo. It also potently (1–10 nM) inhibited TNFa
and IFNg secretion by activated T cells, and promoted their
apoptosis through lipid raft clustering. These results demonstrate
novel anti-inflammatory roles for PD1 in regulating events
associated with inflammation and resolution.
Su2.85. FACS-Based Method To Evaluate Inhibitory
Antibodies in Patients Receiving Enzyme Replacement
Therapy.
K. Seiger,1 L. Cherry,1 V. Theobald,1 S. Richards.1 1Clinical
Laboratory Science, Genzyme Corporation, Framingham, MA, USA.
Lysosomal storage disorders are genetic diseases characterized
by the deficiency of an active enzyme, resulting in the accumu-
lation of macromolecular substrates in the lysosome. This
accumulation disrupts cellular and organ function, ultimately
leading to disease pathology. Enzyme replacement therapy, where
a patient is infused with a recombinant enzyme, has been shown to
be an effective treatment for these disorders. The development of
an antibody response to the therapy is a key safety factor and can
also impact product efficacy. A cell based assay using flow
cytometry has been developed to evaluate whether patient anti-
bodies interfere with cellular uptake of the replacement enzyme,
which is mediated by the mannose 6-phosphate receptor. This
assay is a novel method to determine whether antibodies inhibit
enzyme uptake without relying on enzyme activity and without
interference from endogenous enzyme. Results suggest that this
assay is a specific and reproducible way to detect inhibitory
antibodies in patients receiving enzyme replacement therapy.
Su2.86. Experimental (war) Type System of
Hemaimmune Reaction Road Map.
Guo Feng. 1Department of Blood Transfusion, Chang Hai
Hospital Second Military Medical University, Shanghai, China.
Objective: To establish a detection method of IL-8, which is
applicated in the study of hemaimmune reaction road map.
Methods: 0.2ml suspension of cancer cells (S180, 5I´106/
ml)or yeast cells (5I´108/ml) (or 0.2ml NS as control) were added
into 0.2ml fresh anticoagulant whole blood (or 0.2ml blood cells
or 0.2ml white blood cells and 0.3ml plasma) treated by citric
acid, and incubated for 1 h at 378. Using ELISA method of IL-8, we detected experimental system of hemaimmune reaction
road map.
Results: It was found that cancer cells or yeast cells can
activate hemaimmune reaction: in whole blood group with cancer
cells and yeast cells added, level (138–126.3 pg/ml) of IL-8 was
higher than that (3.906pg/ml) of whole blood group with NS
added. And on the cancer cells or yeast cells activation time, level
(138–126.3pg/ml) of IL-8 in white blood cell group with plasma
added was significantly higher than that (55.99–3.90pg/ml)in white
blood cell group without plasma added. Level (59.99–52.19pg/ml)
of IL-8 in white blood cell group with red blood cell and plasma
added was significantly higher than that (27.35–20.83pg/ml) in
white blood cell group without red blood cell.
Conclusion: These results indicate that: there is a road map of
blood immune reaction. And in the hemaimmune reaction, plasma
and red blood cells is requisite.The complement (in plasma) and
red blood cell plays a vital role (like white blood cells) in blood
hemaimmune reaction road map.
Su2.87. Activation of Red Blood Cell Innate Immune
Reaction Main Road by Antigen.
Guo Feng. 1Department of Blood Tansfusion, Changhai Hospital
Second Military Medical University, Shanghai, China.
Objective: To determine the activation of antigen in red blood
cell innate immune reaction main road.
Methods: Cancer cells (5  106/ml) and/or Bacillus calmette-
Guerin(BCG 0.1mg) or yeast cells(5  108/ml) were added in
whole blood cells 0.2ml (or white blood cells 0.2ml) and fresh
plasma 0.3ml (or NS 0.3ml) treated by citric acid, and incubated
for 1h at 378 to see results. Main aut- come index: IL-8 (ELASA
method).
Results: It was found cancer cells. BCG and yeast cells can
activate hemaimmune reaction, but these antigen not can activate
white blood cells immune reaction in not adding plasma group,
activation Index (2.124 F 0.860) of IL-8 in antigen adding whole
blood cells and plasma group was significantly higher than that
(0.390 F 0.080) in antigen adding white blood cells and plasma
group (P b 0.01).
Conclusion: These results indicate that there is red blood cells
main road map of hemaimmune reaction, The red blood cell and
complement plays a vital role in hemaimmune reaction road map.
Su2.88. Evaluation of the Effects of Different Freezing
Procedures on the Function and Composition of
Lymphocyte Subpopulations from Blood and Synovial
Fluid.
Mona Widhe,1 Nimrod Kiss,1 Therese Wallerskog,1 Andreas
Fasth,1 Vivianne Malmstrom,1 Christina Trollmo.1 1Rheumatology
Research Unit, Dep of Medicine at Solna, Karolinska Institutet,
Stockholm, Sweden.
Background: With the development of biological drugs it is
important to perform immunological studies on patient samples,
both to monitor the treatment, but also to increase our under-
standing of the mechanism of the drug. Thus, both for
comparative analyses between samples from different laboratory
sites but also for practical reasons in the laboratory, analyses of
frozen cells is an option that should be more used. However, the
freezing of cells is known to affect their survival and function,
and selective loss of certain populations is at risk. This could
significantly affect the outcome of various analyses, as compared
to the usage of fresh cells. Objectives: To evaluate the effect of
AbstractsS264different freezing media and different freezing and thawing
procedures on the proliferative capacity and the composition of
the lymphocyte populations. Material and methods: Mononu-
clear cells were prepared from blood or synovial fluid from
patients with rheumatic diseases and from healthy control blood.
Proliferation in response to B and T cell stimulation (PwM, PHA
and anti-CD3) was measured by incorporation of 3H-thymidine.
Subpopulations of B cells (naive, memory, activated and plasma
cells) and T cells (helper T cells, CTL, activated T cells,
regulatory T cells and CD28null T cells) were analysed by four
colour flow cytometry. We also studied yield and viability.
Results: Our first results indicate that both the yield and viability
seem to differ markedly depending on the freezing and thawing
procedure used. An increased background proliferation level was
observed in frozen/thawed mononuclear cells as compared to
freshly prepared, with a decreased stimulatory index as a
consequence. It was also evident that the different freezing/
thawing protocols affected the B and T cell subpopulations
differently. Conclusion: Different freezing protocols affects the
properties of mononuclear cells differently, stressing the impor-
tance of testing different protocols in order to get the best
possible yield and to retain the specific properties of the
subpopulations of interest.
Su2.89. Does the CD203c Basophil Marker Improve the
Flow-Cytometry Diagnosis of Immediate Allergy?
A. Ocmant,1 A. Michils,2 Y. Peignois,1 L. Schandene.1 1Department
of Immunology, Erasme Hospital, Brussels, Belgium; 2Department
of Chest Medecine, Erasme Hospital, Brussels, Belgium.
Background: Flow cytometry tests based either on the
detection of the induced-expression of CD63 or the upregulation
of CD203c by activated basophils in response to allergens has been
developed as alternative methods for in vitro diagnosis of IgE-
mediated reactions. The CD63 test is now currently used and has
been proved to be effective in the diagnosis of allergy to various
allergens. However there is no consensus about the diagnostic
reliability of the CD203c test. The goal of our study was to
compare the two assays using whole blood in the diagnosis of
immediate-type allergy to cat.
Methods: 22 patients characterized by positive skin test and
positive specific IgE to cat dander as well as 26 non allergic
individuals were examined. Heparinized whole blood, primed or
not with IL3, was incubated at 378C with optimal concentrations of
the major purified cat dander allergen of Felis domesticus (Feld I).
Anti-IgE and anti-FceRI Abs or washing solution were used as
positive and negative controls respectively. After defined incuba-
tion times, suspensions were stained either with an anti-IgE PE and
an anti-CD63 FITC provided by Basotest KitR (Orpegen Pharma,
Germany) or an anti-CD203c PE (Coulter Immunotech, France)
and an anti-IgE FITC. In both techniques, an optimal gating of the
basophils (CD45low) was obtained with the addition of an anti-
CD45 PerCP. Analysis was performed on a FACSCalibur flow
cytometer. Results were given as the percentages of IgE+ basophils
expressing CD63 or CD203c above the threshold defined by the
negative control. Alternatively, induced upregulation of CD203c
was calculated as stimulation index (SI) of MFIs (mean fluo-
rescence intensities) obtained with stimulated and unstimulated
cells.
Results: When performed on IL-3 primed whole blood,
exposure to Feld I resulted in marked expression of CD63 by
basophils in 96 % of the patients. By comparison, using similarexperimental conditions (IL-3 priming, multiple staining strategy)
the sensitivity obtained with the CD203c protocol only reached 86
%. Of the non-allergic individuals, only one showed a positive
CD63 test but none demonstrated a positive CD203c test leading to
a specificity of 96 % and 100 % respectively. On the other hand,
none of the five patients tested exhibited basophil activation in
response to an irrelevant allergen (birch allergen) reflecting a 100
% antigenic specificity in both protocols. Interestingly, the CD203c
test was clearly improved in terms of sensitivity (92 % vs 86 %) in
absence of IL-3 priming of whole blood in response to Feld I
allergen.
Conclusion: Taken together our results indicate that, when
using well defined analytical conditions (whole blood, no IL-3,
gating strategy, expression of results. . .), the measurement of the
CD203c as well as the CD63 markers on allergen-activated
basophils constitute reliable in vitro flow-cytometry tests for the
diagnosis of immediate allergy. However, the CD203c test remains
to be investigated in other types of allergy (drug, food.) using
similar approaches before drawing definitive conclusions.
Su2.90. Prospective Comparison of ELISA and
Immunodiffusion for Detection of Antibodies to
Extractable Nuclear Antigens.
J. L. Schmitz,1 K. Freeman,1 S. Orton,1 J. D. Folds.1 1McLendon
Clinical Laboratories, UNC Hospitals, Chapel Hill, NC, USA.
We recently performed an evaluation of 3 ELISA based assay
systems for detection of antibodies to extractable nuclear antigens
(ENATs; Orton, et al. CDLI. 2004). The ELISA systems consisted
of a single well screening ELISA, using pooled ENATs (Sm, RNP,
SSA, SSB, Scl-70 and Jo-1) followed by the use of a multiwell
specificity ELISA employing individual ENATs to determine the
identity of the ENA antibodies in screen positive samples. We
identified the system with the best overall sensitivity and
specificity in our selected test sample population and implemented
it in our laboratory. After implementation, we noted a significant
number of weakly positive samples, the clinical significance of
which, was not clear. The current study reports the results of a
prospective comparison of the ELISA ID assays, the objective of
which, was to determine if we could predict the likelihood of a
positive ID assay based upon ELISA results. Over a 3 month
period we tested 399 consecutive sera with the ENA ELISA screen
assay. All samples that demonstrated z20 ENA units were then
tested with the specificity ELISA and an ID assay that identified
antibodies to the same group of ENATs. Thirty-two of 399 samples
were borderline positive (range 20– 25 ENA units) and 97 were
positive (range 26–z422 ENA units). Only 1 of the 32 screen ENA
borderline positive samples had a positive specificity ELISA
antibody detected (Scl-70) and none had positive ID results.
Twenty three samples had borderline (20–30 ENA Units)
specificity ELISA results (1 RNP, 4 SSA, 2 SSB, 4 Scl-70 and
12 Jo-1). None of these had a positive ID result. Positive results for
Sm, RNP, SSA, SSB, Scl-70 and Jo-1 by specificity ELISA was
found in 7, 13, 38, 17, 13 and 2 sera, respectively while ID was
positive with 4, 7, 20, 8, 4 and 0 sera, respectively. Seventy Five
percent of specificity ELISA positive/ID positive samples had N100
specificity ENA Units (one sample was ID positive for SSA and
borderline specificity SSA ELISA positive). Eighty five percent of
47 specificity ELISA positive/ID negative samples had b100
specificity ENA units. The results of this prospective evaluation
confirm our previous results showing the increased sensitivity of
ELISA compared to ID for ENA antibody detection. Additionally,
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increased and that we could eliminate specificity ELISA testing of
borderline positive samples without missing a significant number of
specificity ELISA positive samples. In our laboratory, specificity
ELISA positive samples with b100 ENA Units were less likely to
demonstrate ID reactivity than were samples with N100 ENA Units
indicating that only relatively strong ELISA reactivity predicts
positive ID results. This analysis has provided a link between
ELISA and ID results facilitating interpretation of ENA ELISA
results, particularly for weakly positive samples.
Su2.91. A Novel Proteomics Assay Employing
Amplification of Oligonucleotide Tags from Monoclonal
Antibodies.
M. G. Kattah,1 J. Coller,2 P. J. Utz.1 1Division of Immunology and
Rheumatology, Stanford University, Stanford, CA, USA; 2Stanford
Functional Genomics Facility (SFGF), Stanford University,
Stanford, CA, USA.
Protein microarray technology represents a rapidly evolving
branch of proteomics research. Antibody arrays, in which anti-
bodies are attached to a surface, are potentially useful tools for a
variety of experimental questions. Inherent difficulties in this
approach, however, have limited their efficacy. To address this
problem, we are developing an assay to detect multiple specific
protein analytes in a complex mixture without attaching antibodies
to a solid support. The assay is based on linear amplification of
unique oligonucleotide tags from antibodies that are indirectly
coupled to an oligonucleotide template. The oligonucleotide tag is
a distinctive 30-mer sequence downstream of a common T7
promoter. The antibody binds the protein of interest and indirectly
indicates the concentration of analyte. After unbound material is
washed away, T7 RNA polymerase amplifies labeled RNA
transcripts from the template. In order to interpret the profile, the
labeled probe is then hybridized to an oligonucleotide microarray
that contains the complementary 30-mer sequences. There are
several advantages to this approach, including a greater degree of
multiplexing capability than is possible with fluorescent tags, linear
amplification of signal, and sensitive and specific detection of
protein analytes. Further, this approach is potentially compatible
with many experimental designs, including multiplexed analysis of
cell-surface markers or lysate preparations of rare cell populations.
Su2.92. Identification of Major Histocompatibility
Complex (MHC) Class I-Realted Genes in Cattle.
C. De Juan Sanjuan,1 S. A. Ellis.1 1Immunopathology, Institute for
Animal Health, Compton, Berkshire, United Kingdom.
Non-classical MHC class I and class I-related molecules do not
generally present antigenic peptides but may have other important
immunological roles. A number of functional class I-related genes
have been identified in or near the human MHC region. These
include the MHC class I chain-related (MIC) genes and HFE.
MICA/B encode molecules important for the regulation of immune
responses by functioning as ligands for a natural killer (NK) cell
receptor, NKG2D, and a subset of gy T cell receptors. HFE is
involved in the regulation of iron metabolism. Studies of class I-
related MHC molecules in species other than human and mouse
could shed light on their evolution. The project aims to identify and
characterise the MIC and HFE genes in cattle.
A small number of partial cDNA sequences from cattle,
homologous to human MICA and MICB were identified in public
databases, and used to amplify MIC cDNA from three cattleepithelial cell lines. DNA thus generated was used as a probe on
Southern blots of restriction enzyme-digested genomic (g) and
bacterial artificial chromosome (BAC) DNA. RNA was extracted
from five tissues from a calf and used for reverse transcription
experiments with MIC and HFE primers. Human HFE cDNA was
used as a probe on cattle gDNA Southern blots. Primers for PCR
were designed based on published HFE sequences from human,
mouse, rat and rhinoceros and Rapid Amplification of cDNA Ends
(RACE) was performed on cattle epithelial cDNA.
Southern blotting and sequencing analysis provide evidence for
the presence of at least two MIC genes. At least four different
cDNA sequences have been found in total, and each cell line
contains at least three different sequences. Sequences fall into two
groups that differ by a 21 nucleotide indel in the a2 domain. Both
long and short sequences are approximately 60% similar to human
MICA and MICB. The positions of polymorphic residues differ
bewteen cattle and human MIC sequences. MIC mRNA can be
detected at low levels in cattle lung and heart, and at very low
levels in the stomach, intestine and liver. A single putative HFE
gene was revealed by Southern blotting and the full lenght cDNA
sequence has been determined. In contrast to human HFE, cattle
HFE has an extra 24 nucleotides in the a1/a2 boundary, as in
mouse and rat. Tissue expression studies in cattle demonstrate the
presence of HFE in heart, liver, lung, stomach and intestine with
the highest mRNA expression in the heart and liver.
Cattle orthologues of the human MIC and HFE genes have been
identified in this study. MIC a1-a3 sequence data demonstrate the
presence of at least two expressed genes in cattle. Southern
hybridisation of cattle gDNA and BAC DNA from MHC
homozygous animals suggests the presence of four or more MIC
genes in cattle. MIC genes are known to be highly polymorphic in
human but the significance of these polymorphisms to ligand
interactions remains unknown. Cattle HFE cDNA is 80% similar to
the human HFE suggesting a role in iron metabolism in cattle.
Molecular modelling of the cattle molecule predicts that the extra
eight amino acids in the a1/a2 boundary form a loop, although its
function has not yet been established.
Su2.93. Pathogenic Significance of
A-N-Acetylgalactosaminidase Activity Found in the
Hemagglutinin of Influenza Virus.
N. Yamamoto,1 M. Urade,2 M. Ueda.1 1Molecular Immunology,
Socrates Institute for Therapeutic Immunology, Philadelphia, PA,
USA; 2Oral Surgery, Hyogo College of Medicine, Hyogo, Japan.
Serum vitamin D3-binding protein (known as Gc protein) is the
precursor for the principal macrophage activating factor (MAF). The
precursor activity of serum Gc protein was reduced in all influenza
virus-infected patients. These patient sera were found to contain a-
N-acetylgalactosaminidase (Nagalase) that deglycosylates serumGc
protein. Deglycosylated Gc protein cannot be converted to MAF,
thus loses the MAF precursor activity. Since macrophage activation
for enhanced phagocytosis and antigen presentation to B and T
lymphocytes is the first indispensable step in both humoral and
cellular immunity development, lack of macrophage activation leads
to immunosuppression and secondary infection. Therefore, the
Nagalase activity level of influenza patient sera regulates the degree
of immunosuppression. An influenza virus stock grown on
embryonated eggs contained a large amount of Nagalase activity.
A sucrose gradient centrifugation analysis of the virus stock revealed
that the profile of the Nagalase activity corresponds to that of the
hemagglutinating activity. When these gradient fractions were
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fraction increased significantly, suggesting that the Nagalase activity
resides on an outer structural envelope protein of the influenza virion
and is expressed by a proteolytic process. After disruption of
influenza virions with sodium deoxycholate, fractionation of the
envelope proteins with mannose specific lectin affinity column
along with electrophoretic analysis of the Nagalase peak fraction
revealed that Nagalase is the intrinsic component of the hemag-
glutinin (HA). Since both the fusion capacity and the Nagalase
activity of the HA protein are expressed by proteolytic cleavage, the
Nagalase activity appears to be an enzymatic basis promoting
fusion for initiation of infection. Thus, Nagalase has pathogenic
significance in regulating infectivity and immnosuppression.
Similar results were also found in HIV (Yamamoto et al. 1995.
AIDS Res Hum Retrovirus 11: 1373-8) and other enveloped viruses
(e.g., Sendai, rubella and measles viruses).
Su2.94. Role of L-Arginine Transporter, Solute Carrier
7A2 (SLC7A2), in the Immune System.
R. M. Sanchez-Munoz,1 J. Kleeman,1 C. L. MacLeod,1 L. G.
Ellies.1 1Cancer Center, University of California San Diego, San
Diego, CA, USA.
INTRODUCTION Although nitric oxide (NO) is a major
regulator of inflammation, little attention has been focused on
upstream regulators of NO such as the solute carrier (SLC) family
of molecules. SLC7A2 supplies L-arginine to the inducible NO
synthase (iNOS) and is required for sustained NO production by
macrophages. Bacterial lipopolysaccaharide (LPS) and the cyto-
kine interferon-g (IFN-g) are strong inducers of iNOS in macro-
phages. OBJECTIVES Identify immune cytokines modulated in
LPS and IFN-g stimulated SLC7A2-/- macrophages and examine
T-dependent immune responses in SLC7A2 deficient mice.
MATERIAL AND METHODS Adult wild type, iNOS deficient
and SLC7A2 deficient mice of both sexes in the C57Bl/6 strain
were stimulated with thioglycolate for 72 h. Peritoneal macro-
phages (PM) were primed with 20 units/ml IFN-g in culture media
for 2 h, and then 100 ng/ml LPS were added for an additional 17 h.
Total RNA was isolated and after reverse transcription, cDNA
products were used for amplification of SLC7A2, iNOS and
several cytokines by real time PCR. In other studies, mice of the
three genotypes were inoculated intraperitoneally with 100 Ag
DNP-KLH in FreundTs complete adjuvant on day (d) 0 and boosted
on d21 using 100 Ag DNP-KLH in FreundTs incomplete adjuvant.
Serum was collected at d0, d7, d14, d21, d28 and d35 and tested by
ELISA for immunoglobulin production. RESULTS Loss of iNOS
did not significantly affect SLC7A2 expression nor did loss of
SLC7A2 affect iNOS expression. IFN-g, IL-10 and IL-4 expres-
sion were all significantly increased in iNOS and SLC7A2
deficient PM compared with wild type control PM. IL-6 and
TGFg-2 expression was significantly decreased in iNOS-/- and
SLC7A2-/- PM compared with wild type controls and TGFg-1,
TNF-a and phospholipase A2 were unchanged. Arginase-I, but not
arginase-II, was upregulated specifically in iNOS-/- PM, suggesting
that arginase-I activity may be increased in the absence of substrate
usage by iNOS. Serum IgG2a levels were dramatically reduced in
iNOS and SLC7A2 deficient mice during the primary immune
response, but returned to wild type levels after the boost. Serum
IgM, IgG1 and IgG3 levels were normal in both genotypes.
CONCLUSIONS Overall, SLC7A2 deficiency in macrophages
results in a similar phenotype to iNOS deficiency. Interestingly,
when L-arginine metabolism by iNOS is absent, there is anupregulation of arginase-I expression, presumably to utilize the
excess L-arginine. Whether this effect is dependent on SLC7A2
remains to be determined. Despite increased INF-g expression by
iNOS and SLC7A2 deficient PM, IgG2a production is reduced
following immunization, suggesting that the increase in Th2
cytokines IL-4 and IL-10 dominate this response; so the absence
of SLC7A2 and iNOS genes can modulate cytokines levels
expression. Thus, in PM it appears that a major function of
SLC7A2 is to supply L-arginine for use in the NO pathway. And
defining this function in inflammation; that is, understanding
molecular pathways controlling NO production in macrophages,
is an important step towards developing improved therapies for
inflammatory diseases and primary immunodeficiencies.
Su2.95. Improved Immunological Methods Using
Peptides: Western Blots, Peptide Arrays, Kinase Assays
and ELISAs.
I. Ghosh,1 L. Sun,1 M.-Q. Xu.1 1Research and Development, New
England Biolabs, Beverly, MA, USA.
Peptides have become an instrumental tool in immunological
research. Their use, however, in protein arrays is hampered by
ineffective and variable binding efficiency of peptides that could
result in low sensitivity, false positives and inconsistent signals; in
Western blots and ELISAs their use is limited due to their small
molecular mass. To overcome these hurdles, we apply intein-
mediated protein ligation (IPL) in which a peptide possessing a N-
terminal cysteine is linked to the carboxyl terminus of a reactive
carrier protein via a peptide bond. The ligation products are then
arrayed on to a membrane or used in Western blot analysis. In this
poster, we demonstrate multiple applications of intein technology in
immunological methods:
a) Easy generation of carrier-peptide substrates suitable for
Western
blot analysis (1).
b) Production of peptide arrays with improved sensitivity,
including
defining antibody epitopes (2).
c) Generation of tailored substrates for kinase and phosphatase
assays (3).
d) Production of antigens for improved sensitivity in ELISA
assays.
1) Ghosh, I, Sun, L., Evans, T.C. Jr., and Xu, M.-Q. (2004) J. of
Imm. Methods. 293:85–95.
2) Sun, L., Rush, J., Ghosh, I., Maunus, J.R. and Xu, M.-Q.
(2004) Biotechniques. 37:430–443.
3) Xu, J., Sun, L., Ghosh, I., and Xu, M.-Q. (2004)
Biotechniques. 36:976–981.
Su2.96. Characterization of Assay Variability in
Real-Time and Batch Assays of Sequential Samples from
the Same Donors.
J. L. Lathey,1 K. Martinez,1 S. Gregory,1 P. DTSouza,2 W.
Lopaczynski.1 1Virology/Immunology, BBI Biotech, a Division of
SeraCare Life Sciences, Gaithersburg, MD, USA; 2Vaccine,
NIAID, Bethesda, MD, USA.
Background: The enzyme-linked immunospot (ELISpot)
assay is useful in measuring responses to vaccination and
changes following immunotherapy. We have developed, opti-
mized, and validated a customized BBI ELISpot kit for
immunogenicity assessments in NIAID-sponsored HIV clinical
trials, and compared its precision in fresh and frozen samples
Abstracts S267collected at one month intervals, while measuring biological
variability.
Methods: The capture antibody, detection antibody, Streptavi-
din-HRP, and substrate were titrated for optimal performance of the
BBI kit and used according to kit instructions. Repeatability was
characterized using PHA and CEF pool (CMV, EBV and Flu
peptides) in a minimum of triplicate wells. The within donor
variability was determined using 3 different donors with 5 time
points collected one month apart. Samples were assayed by
ELISpot using fresh cells in real time and by batch assay using
frozen cells at the end of 6 months from the first time point. Within
donor variability was presented as mean SFC per 200,000 PBMCF
SD (%CV) for CEF for each of the 3 donors. PHA SFC were given
per 100,000 cells.
Results: Repeatability within assay was similar whether CEF or
PHA was assayed fresh (13% vs. 16%) or frozen (16% vs. 11%).
For within donor measurements, CEF was 283 F 58 (20%), 419 F
99 (24%), and 19F 3 (18%) for fresh; and 172F 60 (35%), 416F
169 (40%), and 16 F 10 (62%) for frozen. For PHA, the
measurements were 136 F 27 (20%), 184 F 75 (41%), 211 F
18 (9%) for fresh, and 252 F 72 (28%), 351 F 136 (38%), and
329 F 117 (36%) for frozen. The CEF SFC values were higher for
donor 1 in fresh vs. frozen; however there was no difference in the
other 2 donors. The variability among samples from the same
donor was higher in the batched frozen samples than in the
individually run fresh samples. PHA showed opposite results, with
all fresh samples having lower SFC values than frozen, and the
variabilities were similar except for donor 3, which was higher in
the frozen samples.
Conclusion: Both fresh individual and frozen batch assays
demonstrated similar intra-assay repeatability. For CEF the mean
values for 2 of 3 donors over 5 time points were essentially the
same for fresh and frozen samples. Interestingly, the variability
within a donor was greater in the batched frozen samples than the
fresh samples. This suggests that day to day variations in freezing
procedures may result in greater variability than testing real time
on different days with donor samples drawn at different times.
Supported by NIAID- Contract # N01-AI-85341.
Su2.97. HLA-Typed PBMC Samples with Established
Antigen/Peptide Reactivity for Accelerating and
Standardizing Human Immunological Research.
P. V. Lehmann,1 S. Gregory,2 M. Ewell,2 W. Lopaczynski,2 T.
Watts,2 C. Shive,1 N. Sigmund,1 O. Targoni,1 J. Lathey,2 W.J.
Zhang.1 1R&D, Cellular Technology Ltd, Cleveland, OH, USA;
2BBI Biotech Research Laboratories, A Division of SeraCare Life
Sciences, Gaithersburg, MD, USA.
We have developed a protocol to cryopreserve human peripheral
blood mononuclear cells (PBMC) while maintaining full function-
ality. The thawed PBMC display N 80% viability, and when tested
for peptide or protein antigen-induced T cell recall responses in
cytokine ELISPOT assays, the frequencies and per-cell cytokine
productivities of the thawed cells approximate 100% of the fresh
PBMC. Since serum is a highly variable breagentQ that affects the
results, we developed serum free freezing and testing media towards
standardization. We have started to build a PBMC library of HLA-
typed healthy human donors. The PBMC of each donor has been
characterized for reactivity to a panel of 23 individual peptides
(common viral Class I-restricted determinants) and 5 protein recall
antigens, recognized by CD8 and CD4 cells, respectively. Up to
1,500 vials of each of the characterized samples have beencryopreserved and made available as positive and negative
controls for T cell monitoring in ELISPOT, ELISA, cytokine
bead array, tetramer/pentamer, and cytokine capture assays. Ready
access to such highly characterized PBMC should facilitate
human immunological research and offers reference samples for
assay standardization within laboratories, and between different
laboratories.
Su2.98. Cell Proliferation Index. A Reliable and
Validated Method That Quantifies Cell Proliferation
According to CFSE Dilution.
J. C. Crispin,1 M. I. Vargas-Rojas,1 J. Alcocer-Varela.1
1Department of Immunology and Rheumatology, Instituto
Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,
Mexico City, Mexico.
Cell proliferation is a mechanism intimately linked to the
immune response. Several cellular activation-induced pathways
converge in it, and it takes place synchronously to the acquisition
of effector functions and phenotype. Thus, its measurement is
essential because it is an important marker of response against a
variety of stimuli. Several methods for the quantification of cell
proliferation are available. The measurement of [3H]-thymidine
uptake is probably the most widely used. However, it requires the
handling of carcinogenic and radioactive materials. Moreover,
when more than one cell population is being cultured, the method
does not distinguish between them. An alternative approach is
based on labeling T cells with carboxyfluorescein diacetate
succinimidyl ester (CFSE). CFSE is membrane-permeable fluo-
rescent dye that binds covalently intracellular molecules. When a
cell divides, the fluorescence intensity halves in each of the two
resultant cells. Thus, each round of cell division produces a
population of cells that have one half of the fluorescence intensity
than the cells they arose from. Using a FACS, cells that have not
proliferated can be easily distinguished from cells that have
proliferated, and according to the dilution of the dye, one can
assume how many division rounds each cell has gone through. Its
principal drawback is that results are semi-quantitative and, when
differences are subtle, comparison is difficult. In the present work
we present an algorithm that translates the semi-quantitative data
obtained from the FACs and yields a numerical result. Materials
and Methods. PBMC (from healthy donors) and Jurkat cells
were used. Cells were cultured during 72 hours and stimulated
with either plate bound aCD3 plus soluble aCD28, or PHA. Cell
proliferation was quantified by: a) manual count of live and dead
cells (according to trypan blue exclusion); b) [3H]-thymidine
uptake; c) Cell Proliferation Index (CPI). For the FACS studies, a
histogram (FL1 [CFSE intensity] vs. cell number) was drawn
with the target population. A first marker (M1) was set according
to a negative control (non-stimulated cells). Its geometric mean
was recorded. Next, markers (M2, M3, etc) were set progres-
sively, each one including a daughter population (considering the
geometric mean must halve in each population). Hence, the cells
accounted within the M1 have not proliferated, the cells in M2
have undergone one round of proliferation, the cells in M3 three
rounds, and so on. The data was incorporated into this
algorithm: CPI = A Mn  2n-1. The results obtained with each
method were compared. Results. Cell proliferation was detected
by the three methods. The results obtained with the CPI
correlated closely to the measurement of cell proliferation with
[3H]-thymidine uptake (R = 0.92, P b 0.0001). At low mitogen
concentrations, CPI was more sensitive than [3H]-thymidine
AbstractsS268uptake. Conclusion. CPI is a sensitive and reliable means of
quantifying cell proliferation.
Su2.99. Evaluation of CellPrep, an Automated Cell
Washing Instrument for Analysis of Surface Markers
on Leukocyte Subpopulations Via Flow Cytometry.
J. G. Wilkinson,1 C. Aparicio,1 C. Smith,1 E. Rabellino,1 S.
DTCosta.1 1Biomedical Research Division, Beckman Coulter Inc.,
Miami, FL, USA.
The use of flow cytometry-based assays in leukocyte subset
analysis is a routine practice in basic research and clinical research
settings. There have been significant improvements in reagents,
procedures, and instrumentation that have allowed for the
introduction of automated techniques for the preparation of cell
samples prior to flow cytometric analysis. An invaluable advantage
to automation is the standardization and reduced bhands-on timeQ
as compared to manual techniques.
The current and most commonly used technique of centrifuga-
tion to wash cells by removing contaminating materials prior to
flow cytometric analysis, does not lend itself well to automation.
Additionally, subjecting cell populations to both g-force and
intense cell-to-cell contact through centrifugation may alter
sensitive activation and signal transduction expression. To simplify
and automate cell washing in tubes, the non-centrifugal CellPrep
instrument was designed and developed to wash cells using
polysulfone hollow fibers.
The present study was carried out to compare scatter profiles,
surface antigen expression, and recoveries of rare and non-rare
events in unwashed, centrifuge-washed, and CellPrep-washed cell
samples. It has been shown that the CellPrep instrument can be used
successfully to wash peripheral blood cell suspensions with no
adverse effects on the phenotypic and scatter profiles, as well as cell
recoveries.
Su2.100. Optimization of the Aspiration Dose of IL-1ra
Preparation To Stop an Inflammation in the Mouse
Respiratory Tract.
A. M. Ischenko,1 B. P. Nikolaev,2 E. V. Vorobeychikov,2 L. Yu
Yakovleva,2 T. V. Kotova,2 L. Ya Soloviova,1 V. G. Konusova.3
1Protein Biochemistry, Institute of Highly Pure Biopreparations,
Saint-Petersburg, Russian Federation; 2New Drug Formulations,
Institute of Highly Pure Biopreparations, Saint-Petersburg, Rus-
sian Federation; 3Immunopharmacology, Institute of Highly Pure
Biopreparations, Saint-Petersburg, Russian Federation.
Hyperproduction of interleukin-1 (IL-1) is a main factor to
provoke inflammation. The interleukin-1 receptor antagonist (IL-
1ra) may serve as a promising therapeutic and prophylactic agent
for stopping inflammatory processes, including the infectious
ones. In this study the prophylactic efficacy of IL-1ra was
assessed after aerosol application to mice, in which inflammation
was induced by instranasal instillations of LPS. The efficacy of
IL-1ra was studied after two routes of application- the aerosol and
the injection one. Based on a theory of multifactor analysis, the
aspiration dose of IL-1ra and the particle size distribution in
aerosol were optimized.
It was demonstrated that IL-1ra applied in a form of aerosol
caused the decrease of inflammation in the respiratory tract of a
mouse. The efficacy of this decrease depended on the aspiration
dose of IL-1ra inhaled and on size of particles. 50% decrease of
inflammation was registered for the aspiration dose of IL-1ra 150
mcg/mouse. The same effect for the injection IL-1ra was registeredat a dose of 270 mcg/mouse of IL-1ra. The anti-inflammatory
effect of the fine-dispersed fraction of IL-1ra (particles of 2 mcm in
size) was 30% higher than that of the coarse-dispersed fraction
(particles of 10 mcm in size). The resultant data demonstrated the
advantage of aerosol route of administration of IL-1ra over the
injection one.
Su2.101. The Use of Arginine-Rich Peptide Conjugated
Antisense Oligomers To Alter Immune Function.
N. B. Marshall,1 D. V. Mourich,1 H. M. Moulton,1 P. L. Iversen.1
1Biology, AVI BioPharma Inc., Corvallis, OR, USA.
Phosphorodiamidate Morpholino Oligomers (PMOs) are effec-
tive antisense agents for inhibiting gene expression; however limited
uptake into populations of immune cells without the use of
mechanical and chemical procedures often detrimental to cellular
functions, restricts their usefulness. A strategy shown to enhance
cellular uptake of PMOs into fibroblasts is the conjugation of an
arginine-rich peptide to the oligomer. To examine uptake of these
peptide-conjugated PMOs into lineages of primary T cells, B cells,
and NK cells, as well as bone-marrow derived macrophages, and
dendritic cells, we used flow cytometry to measure the presence of a
fluorescein-linked PMO in treated cells. Uptake of the oligomer into
these cell types is greatly enhanced by the addition of the arginine-
rich peptides compared to unmodified PMO. Furthermore, differ-
ential uptake into different cell types was observed and found to be
dependent on the amino acid composition of the peptide and the
activation status of the cell. Demonstration of an antisense-specific
effect is shown by targeting the expression of CD45 in cells treated
with the PMO peptide conjugate CD45-(RxR)4. Antisense efficacy
was also demonstrated by forcing alternative splicing of the CD45
mRNA using antisense PMO conjugates targeting the splice
junctions of exons 4, 5, & 6. Successful uptake of PMO peptide
conjugates into immune cells and target inhibition of gene
expression suggests that PMO modified with arginine-rich peptides
could potentially be used as an immune modulating therapeutic
strategy.
Su2.102. A Multi-Level Approach to Analyzing Immune
Responses in Targeted Cells by Combining Cytomic and
Proteomic Techniques of Cell Sorting and Protein
Fractionation.
S. DTCosta,1 E. Betgovargez,1 C. Snow,1 M. Simonian.1
1Biomedical Research Division, Beckman Coulter Inc., Miami, FL,
USA.
In order to simplify the study of bSystems BiologyQ and
facilitate the transition to bCytomicsQ i.e. linking of genomics
and proteomics to functionality of the cell, a multi-level and
multi-pronged approach needs to be pursued. This requires that
cell-based events that have so far been interrogated in isolation,
for e.g. gene expression, protein synthesis, phenotype and
function, signal transduction etc. now need to be integrated to
better understand the bcomplexQ cellular response. This con-
tinuum can to some extent be achieved by integrating cellular
analysis techniques (for e.g., flow cytometry, imaging, multiplex
assays) with genomics and proteomics techniques to understand
the various aspects of such a response, thus accomplishing the
unified evaluation of the cell. In the current study, the authors
have attempted such an evaluation by integrating well-known
techniques of flow cytometry-based phenotypic analysis and cell
sorting with protein fractionation and analysis to better under-
stand the complex nature of an immune response.
Abstracts S269Peripheral blood mononuclear cells or T cell lines were
subjected to brestricted polyclonalQ or btrue polyclonalQ activation
for 24hrs. Cells were then fluorescently labeled with antibodies to
distinguish activated and non-activated cells and isolated using
flow-based sorting techniques. Lysates of sorted-activated and
sorted-non-activated cells were fractionated by two-dimensional
liquid chromatography. The first dimension separation was
achieved by chromatofocusing wherein intact proteins were
separated by their isoelectric points and fractions collected by
pH. These fractions were further separated by hydrophobicity on a
second-dimension with high resolution, reversed-phase chroma-
tography. The net result was the generation of high-resolution
protein profile of the complex mixture. Qualitative and quantitative
differences in protein profiles in activated and non-activated cells
could be easily identified. The gel- free and intact nature of the
fractions of interest allows for further interrogation and identi-
fication of the differentially expressed proteins in activated and
non-activated cells to accomplish a thorough analysis of an
activation profile.
The combination of flow-cytometry-based cell sorting and
protein fractionation enables a more refined and targeted profiling
and analysis of complex events associated with an immune
response. Further combinations of genomic, proteomic and
cytomic profiling will accomplish the unified evaluation of such
a response.
Su2.103. Notch Modulation of Peripheral Immunity: A
Novel Approach to Antigen-Specific Immunotherapy.
B. R. Champion,1 S. Ballantyne,1 A. Rust,1 L. Perry,1 H.
Beacock-Sharp,1 C. Howard,1 L. Green,1 A. Watkins,1 R.
Bartram,1 G. Martin,1 E. Briend,1 H. Harper,1 T. Tugal,1 S.
Ragno,1 L. L. Young.1 1Discovery Research, Lorantis Ltd,
Cambridge, United Kingdom.
Notch signalling plays an important role in the fate decisions
made by multiple cell types during development. Using recombi-
nant human Notch ligands, we have been evaluating the effects of
Notch signalling on peripheral T-cell function both in vitro and in
vivo. With murine CD4+ T-cells in vitro, we have shown that Notch
signalling mediated via the ligand Delta1 promotes a dose-
dependent inhibition of effector cytokine production, along with
an up-regulation of IL-4 and IL-10 synthesis. Similar modulation
could be seen with Jagged1 and Delta4 ligands, and the balance
between cytokine up-regulation and down-regulation was depend-
ent upon both TCR and Notch signal strengths. Similar cytokine
modulatory effects are also observed with human peripheral blood
CD4+ T-cells. Using the g-secretase inhibitor DAPT to block
cleavage of Notch, which is required for prototypic CBF1-
dependent Notch signalling, we show that Delta-induced IL-4
and IL-10 upregulation involves this well-described pathway. By
contrast, the Delta-mediated inhibition of effector cytokine
production occurs more rapidly and involves a different, cleav-
age-independent signalling mechanism. Together, these activities
are associated with a Delta1-modified differentiation of the cells:
inhibited development of a Th1 phenotype and enhanced acquis-
ition of a shared Th2/Treg profile. These effects are operative even
under conditions for promoting Th1 or Th2 effector differentiation
in vitro. Using both DNA gene-delivery and recombinant protein
based treatments, we have also been able to down-modulate
immune responses to antigens in vivo. Notch signalling may,
therefore, provide a unique therapeutic approach to the treatment of
immune disorders.Su2.104. Serum Heat-Inactivation and Granulocyte
Presence Exerts a Differential Effect on the
Antigen-Induced Proliferation of Lymphoid Subsets.
N. J. Andersen,1 D. A. Lawrence.1 1Wadsworth Center, New York
State Dept of Health, Albany, NY, USA.
The results from an in vitro lymphocyte proliferation assay
(LPA) can provide valuable information on the functional
capabilities of an individualTs immune system. However, the assay
lacks standardization and the procedure and outcome can vary
dependent on the laboratoryTs protocol. Here, we assessed via
BrdU uptake and lymphocyte surface marker staining how heat-
inactivation of autologous serum affects the in vitro lymphocyte
proliferative response to Candida albicans antigen (CA) in the
presence and absence of granulocytes. Method: Peripheral blood
mononuclear cells (PBMC) F granulocytes (PBMC+) were
cultured for 6 days with either fresh (FS) or heat-inactivated
(HIS) autologous serum. BrdU was then added for an additional
24h to assess cell proliferation. The cells were harvested and
stained on day 7 to determine the extent and phenotype of the
proliferating cells. Results: A comparison of cultures containing
FS vs. HIS revealed a significant difference in the degree of BrdU
incorporation for the PBMC+ cultures only, with the FS group
containing a greater number of BrdU+ cells (CD3+, P b 0.05;
CD3-4+, P = 0.03). Serum treatment did not significantly affect the
PBMC cultures. Comparing PBMC vs. PBMC+ cultures, PBMC
cultures overall incorporated more BrdU compared to the PBMC+
cultures. The presence of granulocytes significantly reduced the
percentage of BrdU+ cells in FS (CD3+, P = 0.027; CD3+4+, P =
0.016; CD3-4-, P = 0.029) or HIS (CD3+, P = 0.005; CD3-4-, P =
0.013). Interestingly, the subset most affected by the presence of the
granulocytes was the CD3- subset, independent of serum treat-
ment (for PBMC vs. PBMC+: FS, 34% vs. 3% BrdU+ cells; HIS,
45% vs. 0.5% BrdU+ cells). Conclusion: In vitro assays are used
as a measure of the in vivo state. Both complement and
granulocytes are present in the in vivo situation, but they are
often missing in in vitro assay protocols. While our initial interest
was in determining whether heat-inactivation could significantly
affect the in vitro immune response, the most interesting results
were obtained with cultures containing granulocytes. Our results
demonstrate that the selective removal of in vivo immune
response components significantly affected the outcome of an in
vitro assay. The outcome of assay variables such as those
explored here should be further evaluated to improve the
predictive scope of the in vitro proliferation assay and to determine
the protective role of heat-sensitive serum protein against gran-
ulocyte suppression.
Su2.105. Provision and Integration of HLA Alleles into
Scientific Research.
S. J. Cate,1 R. Tian,1 M. Jones,1 S. Chandrasekaran,1 W. H.
Hildebrand.1 1Microbiology, University of Oklahoma, Oklahoma
City, OK, USA.
The class I and class II human leukocyte antigens (HLA)
mediate most adaptive immune responses. Disease susceptibility,
disease resistance, vaccine development, autoimmunity, and
clinical transplantation all represent immune responses in which
HLA molecules play a vital role. A new generation of assays,
including tetramers, ELIspots, cytokine-based flow cytometry
(CFC), and more traditional assays such as chromium release
and 3H-thymidine incorporation, are poised to reveal the con-
tribution of HLA molecules to various immune responses.
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immune response or lack thereof is complicated by the fact that
most individuals have different HLA alleles and haplotypes.
Furthermore, the many HLA alleles in the population tend to
differ functionally. One must realize an HLA type in order to
determine which class I or class II MHC molecule presented a
particular peptide epitope in a positive ELIspot experiment. There
are now 349 HLA-A, 627 HLA-B, 182 HLA-C, 394 DRB1, 80
DRB2-9, 28 DQA1, and 61 DQB1 alleles at the respective loci.
The goal of our laboratory is to provide immunologists with a two-
pronged HLA resource. Our first HLA resource is to provide
researchers with a definitive class I and class II HLA type using
DNA sequence-based typing. We have typed samples from
populations throughout the world, identifying new and rare HLA
alleles and haplotypes in a racially unbiased and precision manner.
Of the MHC Class I and Class II linkage disequilibrium haplotype
determining loci, we have typed 100 HLA-B and 55 HLA-DRB1
alleles. Our HLA typing laboratory is ASHI/CLIA accredited and
is directed by ABHI certified laboratory director. Our second
HLA resource is the HLA Ligand Database (http://hlaligand.
ouhsc.edu) through which we provide an online resource whereby
all known HLA class I and class II peptide ligands and motifs are
catalogued. The HLA Ligand Database provides a resource
whereby scientists can find or predict peptide epitopes that bind
to particular HLA molecules. The database now contains 3724
peptide epitopes including those from A-C pathogens. In summary,
our laboratory provides precision HLA typing and a catalogue of
peptide ligands/motifs such that the functional role of human MHC
molecules can be more easily elucidated.
Su2.106. Potassium Channels IR, Kv1.5, and Kv1.3 Are
Expressed on Human Dendritic Cells and Have a
Functional Role in Maturation.
K. M. Mullen,1 M. Rozycka,2 L. Hu,1 H. Rus,2 J. Graber,1 M. W.
Pennington,3 D. C. Johns,4 S. I. Judge,2 P. A. Calabresi.1
1Neurology, Johns Hopkins University, Baltimore, MD, USA;
2Neurology, University of Maryland, Baltimore, MD, USA;
3Bachem Bioscience, Inc, King of Prussia, PA, USA;
4Neurosurgery, Johns Hopkins Hospital, Baltimore, MD, USA.
Potassium channels on immune cells have gained attention
recently as promising targets of immunotherapy. We therefore
turned our attention to potassium channels on antigen-presenting
cells, specifically human dendritic cells, whose K+ channel profile
has not yet been described in the literature. We generated a
population of immature dendritic cells by culturing monocytes
from the blood of healthy human donors in vitro with GM-CSF
and IL-4, as previously described, and then stimulated these cells
with LPS or TNF-a to induce maturation. Whole-cell patch clamp
analysis of these cells revealed an inward-rectifying K+ current at
early timepoints after stimulation, replaced by a mix of voltage-
gated Kv1.3 and Kv1.5 channels at later stages of maturation. The
identity of these channels was established by characteristic
inactivation curves and pharmacological blockade. Further, immu-
nofluorescent staining confirmed the presence of Kv1.3 and Kv1.5
on the surface of stimulated cells, colocalizing with HLA-DR. In
order to determine whether these channels have a functional role in
DC maturation, we then analyzed DCs stimulated in the presence
of pharmacological Kv1.3 blockers, and found that both CD83 and
CD80 upregulation and production of IL12 and IL6 were
significantly impaired (28% decrease in CD83, 46% in CD80,
16% in IL6, 32% in IL12). To validate these results with a morestable means of blocking Kv1.3 and Kv1.5 function, we turned to a
dominant-negative Kv1 adenovirus construct, an ecdysone-indu-
cible and GFP-tagged virus coding for a Kv1.3 molecule with a
mutation in the pore-forming region. When induced, this mutant
protein associates with other Kv1 family members in membrane
tetramers and blocks channel function. We compared DCs infected
with this Kv1 dominant-negative construct to DCs infected with a
control virus coding for luciferase, and found that maturation of
DCs expressing the Kv1.x viral product was highly reduced (53%
less CD83 expression than control). Overall, our data are the first
to report Kv1.5 and Kv1.3 expression on mature human DCs, and
further indicate that these channels have a functional role in DC
maturation. Our results therefore bolster the argument for K+
channel blockade as an immunotherapeutic strategy targeting
mature antigen presenting cells, which has implications for the
treatment of a wide range of immune-mediated diseases. The
therapeutic mechanism of Kv1.3 blockade in EAE, for example,
has not yet been fully explored, and may include an effect on
antigen presentation and priming of T-cells in conjunction with a
direct suppression of T-cell function. Indeed, immunohistochem-
ical staining of plaques in the brains of MS patients reveals Kv1.3
and Kv1.5 on microglia, offering a first piece of evidence that
targeting these channels may affect antigen presentation to T-cell
infiltrates within the brain.
Su2.107. Monitoring the Effects of Immuno-Modulating
Therapies.
J. B. Woodcock, J. A. Britz, D. R. Post, R. J. Kowalski.1 1Product
Development, Cylex Incorporated, Columbia, MD, USA.
As immune modifying therapies continue to be employed,
developed and expanded to treat diseases such as rheumatoid
arthritis, inflammatory bowel disease, HIV, HCVand cancer, a need
exists to assess their effects on the immune system. CylexR has
developed several cell-based assays to measure the functional
activity of lymphocytes from a small amount of whole blood. These
assays utilize in vitro stimulation of a patientTs blood sample,
followed by magnetic isolation of specific sub-sets of lymphocytes.
ImmuKnowTM, an FDA-cleared assay, measures the global immu-
nological response of CD4+ cells and the T-cell Memory assay is a
research test that measures antigen-specific responses of CD3+ cells.
By examining both global and antigen-specific cell mediated
immunity, the Cylex platform is useful for monitoring the immune
status of patients receiving immune modifying therapies. In this
study, immune responses of apparently healthy individuals and
drug-induced immunosuppressed transplant recipients to foreign
antigens including Influenza, CMV, Tetanus and EBV as well as
global immune responses to PHA were measured. Transplant
recipients undergoing lymphocyte depleting therapies showed a
marked decrease in global and antigen- specific responses. Recovery
of these immunological responses occurred gradually over the next
6–12 months and was largely independent of the absolute
lymphocyte count. Healthy volunteers with known natural exposure
or vaccination showed significant responses to vaccine antigens
whereas those not exposed or unvaccinated showed no response. In a
study of response to tetanus, 90% of apparently healthy adults had an
in vitro response to tetanus toxoid, but only 18% of transplant
recipients and 28% of HIV+ individuals had positive antigen
responses. By examining both global and antigen-specific immune
responses, the Cylex platform is useful for monitoring the effects of
immuno- modulating therapies, whether they are designed to
enhance or suppress the patientTs immune response.
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Expander Bead: Combining Quality with Practicality.
E. Leung,1 A. Aas-Eng,2 G. Okern,2 A. M. Rasmussen,2 O.
Amellem,2 A. Simonsen,2 O. A. Garden.1 1Molecular
Immunoregulation Team, Department of Immunology, Imperial
College London, London, United Kingdom; 2Immunosystems,
Dynal Biotech ASA, Oslo, Norway.
Murine models of human disease are established immunolog-
ical tools, prompting the need for a product to expand murine T
cells ex vivo. The antigen CD28 provides an important T cell
costimulatory signal. DynabeadsR coated with anti-CD3 and anti-
CD28 monoclonal antibodies (mAbs) were used in short-term (b14
day) cultures of BALB/c CD4+ or CD8+ T cells in vitro, in order
to define ratios of the mAbs and of beads:cells allowing optimal
upregulation of activation markers, increase in cell volume, and
expansion of T cell numbers. The performance of the beads in both
short and long-term cultures of various lymphocyte populations
was then evaluated. Over 35-fold expansion of BALB/c CD4+ T
cells was observed over 18 days; robust proliferation of CD8+ T
cells, mononuclear cells and antigen-specific T cell clones could
also be achieved, without loss of function. CD4+ T cells could be
expanded for periods of z6 weeks; CD8+ T cells could not be
expanded for N3 weeks. Following initiation of the cultures, re-
stimulation was necessary at 7–12 day intervals. In summary, we
have thus developed and rigorously validated a product allowing
the expansion of diverse populations of murine T cells in vitro.
Su2.109. Characterization of Endogenously Loaded
Rhesus Macaque MHC Class I Peptides.
A. R. Gilb,1 H. D. Hickman-Miller,1 W. Bardet,1 A. D. Luis,1 D. I.
Watkins,2 K. Jackson,1 W. H. Hildebrand.1 1Microbiology and
Immunology, University of Oklahoma Health Sciences Center,
Oklahoma City, OK, USA; 2Wisconsin Regional Primate Center,
University of Wisconsin, Madison, WI, USA.
The SIV-infected Indian Rhesus Macaque (Macacca mulatta)
is an often used animal model for the study of HIV infections in
humans. SIV, a retrovirus, is closely related to HIV-1 in
nucleotide sequence and causes an AIDS like syndrome in the
Rhesus Macaque. In terms of anti-viral immune responses, both
macaques and humans mount strong cytotoxic T lymphocyte
(CTL) driven anti-SIV and anti-HIV immune responses, respec-
tively. In order to compare human and macaque anti-viral
immune responses, to test SIV vaccine strategies, and to interpret
viral escape mutants, human and macaque class I major
histocompatibility complex (MHC) peptide binding properties
must be elucidated. Our laboratory is focused upon the amino
acid sequencing of pooled motifs and of individual peptide
epitopes that are endogenously generated, trafficked, loaded, and
class I MHC presented. In this study we transfected 4 macaque
class I molecules (Mamu A*02, A*11, B*01, and B*12) into a
human cell line and harvested 10–20 milligrams of each macaque
class I molecule. Eluted peptides were initially subjected to 14
cycles of Edman degradation and the resulting data shows that
macaque class I molecules are endogenously loaded with
nonamers demonstrating P2, P9, and other ancillary anchors. At
least 10 individual ligands were sequenced by MS/MS for each of
the macaque class I, demonstrating variability in length as well as
variability in sequence as compared to the pooled motifs. Finally,
anchors and motifs not detected by other methods are apparent
through the characterization of endogenous ligands. In summary,
the characterization of endogenous macaque class I peptideepitopes provide a more thorough understanding of immune
responses in this animal model.
Su2.110. NUSE and RLE: Quality Assessment of
Oligonucleotide Microarray Data To Quantify Systemic
Variation.
F. Collin,1 A. L. Asare,1 S. A. Kolchinsky,1 T. P. Speed,2 V. L.
Seyfert-Margolis.1 1Immune Tolerance Network, University of
California, San Francisco, Bethesda, MD, USA; 2Department of
Statistics, University of California, Berkeley, CA, USA.
Introduction: Measurement of differential RNA expression in
multicenter clinical trials requires special attention to the quality in
sample preparation. Sample collection and handling can adversely
affect results; therefore, quality metrics are required to detect and
assess the potential errors induced by these factors. We compared
the reliability of newly devised quality metrics derived from fitted
statistical models of probe level data from high-density oligonu-
cleotide microarrays and compared them to standard GeneChipn
microarray quality metrics. Method: We devised metrics using the
Robust Multichip Analysis (RMA) process for deriving probe set
summaries from GeneChipn microarrays. The first metric,
Normalized Unscaled Standard Error (NUSE), provides a measure
of relative chip quality derived from the residuals from the RMA
model. The second metric, the Relative Log Expression (RLE), is
an absolute metric that gauges variability of expression measures
by summarizing the distribution of relative log expressions within
a set of microarrays against a reference set. The RLE summaries
are sensitive to technical sources of variability that are large
compared to biological variation. These metrics were compared to
standard quality metrics: Percent Present calls, GAPDH 3V/5V,
Background, and Scaling Factor. Two clinical trial sample sets
were assessed: 368 microarrays from a Type I diabetes trial and
350 arrays from a ragweed allergy trial. A set of standard normal
human control samples were sent blinded within patient sets during
the course of ITN clinical trials and were used as the reference set
against which RLE assessments were made. Result: NUSE and
RLE metrics detected systematic variation within certain partic-
ipant sets that were not detectable using the standard Affymetrix
quality metrics. Elevated GAPDH 3V/5V ratios typically cited as an
indicator of poor quality RNA showed no relationship to quality
when applying the NUSE and RLE (cor, 0.09). Hybridization/
washing artifacts were easily visualized by plotting NUSE
residuals. While not always true, Percent Present calls provided
the closest approximation to NUSE and RLE; in cases of
extremely low Percent Present, NUSE and RLE are adversely
affected (cor, -0.50). In both trials in which these metrics were
applied, we identified chips within a participant time series that
required exclusion from the analysis that would not have been
discovered otherwise. Conclusion: In differentiating NUSE from
RLE, NUSE values have no units and can only be used to assess the
relative quality of arrays within an analysis set; RLE summaries
provide a measure of reproducibility of gene expression data that
can be compared across batches, experiments, or trials. Reflecting
variability in expression measures, these proposed metrics provide a
better basis for judging quality compared to standard metrics.
Su2.111. High Resolution HLA Typing for Vaccine and
Autoimmune Studies.
R.Y. Tian,1 S. J. Cate,1 M. M. Jones,1 W. H. Hildebrand.1
1Microbiology and Immunology, University of Oklahoma Health
Science Center, Oklahoma City, OK, USA.
AbstractsS272The class I and class II Human leukocyte antigens (HLA)
mediate most, if not all, adaptive immune responses. Since each
individual has a different combination of class I and class II HLA
molecules inherited from her/his parents, the immune response to
infection and vaccination differs respectfully from person to person.
In addition, many autoimmune diseases, such as arthritis and
diabetes, are associated with particular class I and/or class II
molecules. Knowledge of a patients/populations HLA molecules
therefore becomes a key element in vaccine design and uncovering
autoimmune triggering mechanisms. HLA DNA sequence-based
typing (SBT) represents a method that identifies all polymorphisms
in a racially independent manner. Our laboratory pioneered and
continues to employ a precision HLA SBT method for studies of
bone marrow transplantation, vaccine development, and auto-
immunity. The class I and II HLA SBT process is split into three
steps- PCR, DNA sequencing, & data processing-and here we report
on the evolution of these 3 steps during the high resolution SBT of
more than 20,000 individuals in the last 8 years. We describe the
migration of our method from a solid phase sequencing chemistry to
a capillary DNA sequencer, we discuss the location of PCR and
DNA sequencing primers, we compare SSP and RSCA methods for
the resolution of ambiguities, we discuss the software packages
available for data processing, and we describe the costs now
associated with HLA SBT. The robust nature and cost-efficiency of
HLA SBT supports the continued application for studies of disease
resistance, vaccine design, and autoimmunity.
Organ Transplantation
Su2.112. On the Possibility of Oral Tolerance To Be Used
in Graft Transplantation.
Xiao-Bin Zheng. 1Research and Development, Beijing
Zhongbangyumin Sci-trade Company Co. Ltd., Beijing, China.
Oral tolerance has been studied for many decades. Some of its
immunological mechanisms have been revealed. And oral toler-
ance has been used to treat autoimmune diseases, such as
rheumatoid arthritis, uveitis, EAE, as well as some others,
experimentally and/or clinically. Many of these seemed have
obtained beneficial effects. Interestingly, oral tolerance has also
been used in reproductive immunology, i.e. pregnant immunology.
It has been used to induce maternal tolerance to paternal antigens,
in order to establish an immune tolerance to the semi-allograft fetus
by the mother to treat the abortions. But, as a way of being possible
to establish an antigen-specific immune tolerance, why should not
we use it to the transplantation immunology, trying to use this way
to induce an immune tolerance to the transplant graft antigens, for
the purpose to establish an immune tolerance to avoid the graft
rejection. And this is what I would like to suggest strongly, and
hope to draw some special attentions.
Su2.113. Evidence for Naturally Occurring and Induced
Regulatory T-Cells in Non-Human Primates.
K. G. Haanstra,1 J. A.M. Wubben,1 M. Jonker.1 1Immunobiology,
Biomedical Primate Research Centre, Rijswijk, ZH, Netherlands.
Non-human primates (NHP) are often used as preclinical model
for the evaluation of tolerance inducing therapies. Regulatory T-
cells (Treg) may be crucial for the maintenance of tolerance. Here
we describe the identification and characterisation of Treg in NHP.
CD4+CD25+ cells were isolated from peripheral blood mono-
nuclear cells (PBMC) of healthy monkeys and from PBMC of 3
long-term drug free kidney transplant recipients (long-term trans-plant survivors, LTS). One LTS monkey is 23 years post
transplantation after treatment with pre-transplant bloodtransfu-
sions and CsA for 1 year and two monkeys are 3 years after
cessation of treatment with costimulation blockade and CsA.
Several characteristics known to be specific for CD4+CD25+ Treg
in humans and rodents were investigated.
Naturally occurring CD4+CD25+ cells were present in healthy
monkeys as well as in the LTS monkeys. Similar to CD4+CD25+
T-cells in humans, CD4+CD25+ T-cells in NHP do not proliferate
upon polyclonal or allogeneic stimulation. However, in contrast to
humans, proliferation is only slightly increased upon addition of
IL-2.
When CD4+CD25- cells are activated by a polyclonal (ConA) or
allogeneic stimulus, CD4+CD25+ cells can suppress this prolifer-
ation and, although not proliferating themselves, the CD4+CD25+
cells cannot inhibit proliferation when they are irradiated. Inhibition
cannot be blocked by anti-IL-10 or anti-TGF-beta.
CD25+ cells have, in accordance with human CD25+ cells
more intracellular CD152 than CD25- cells.
CD4+CD25+ cells are present in the LTS monkeys in the same
numbers as can be found in healthy NHP and they also do not
proliferate upon ConA or allogeneic (donor specific and 3rd party)
stimulation. To evaluate possible donor specific regulation in other
subsets, anti-TGF-beta and anti-IL-10 were added to whole PBMC
cultures. In the LTS monkey 23 years post transplantation,
regulation seems to be TGF-beta mediated, which correlates with
the presence of large amounts of latent TGF-beta in the kidney. In
the other two LTS monkeys, neither anti-TGF-beta nor anti-IL10
seems to uncover proliferation, but the combination of both
antibodies induces increased proliferation against the donor.
Naturally occurring Tregs, with similar characteristics as
described in humans are present in NHP and can suppress
CD4+CD25- cells. Although CD4+CD25+ cells in LTS monkeys
are immunosuppressive, this is not donor specific, and therefore,
donor specific regulation may be confined to another T-cell subset.
Su2.114. Phenotypically and Functionally Distinct CD8+
Lymphocyte Populations in Long-Term Drug-Free
Tolerance in Human Kidney Graft Recipients.
D. Baeten,1 S. Louis,1 C. Braud,1 C. Braudeau,1 A. Pallier,1 M.
Giral,1 S. Brouard,1 J.P. Soulillou.1 1INSERM U643, ITERT,
Nantes, France.
Objectives: Kidney graft recipients with stable renal function in
absence of immunosuppressive therapy are characterized by a
skewed TCR Vbeta chain usage, essentially in the CD8+ subset.
Therefore, the present study analyzes in more detail phenotypical
and functional alterations of CD8+ lymphocytes in these drug-free
tolerant patients (DF-Tol).
Methods: Peripheral blood CD8+ lymphocytes from DF-Tol,
chronic rejection (CR), healthy controls (HC), and patients with
stable kidney function under immunosuppression (StA) were
analysed by flow cytometry for phenotypic and cytotoxic markers.
Apoptosis was measured by annexin-V staining and proliferation
by CFSE.
Results: Phenotyping revealed an increase of CD45RA-CCR7+
central memory and a decrease of CD45RA+CCR7-effector CD8+
lymphocytes in DF-Tol versus CR. The expression of CD28+ and
CD27+ on effector and effector memory CD8+ lymphocytes was
decreased in CR, with a high correlation between both markers.
These profiles were stable over time and independent of treatment.
The cytotoxic nature of CD8+ CD28- cells was indicated by the
Abstracts S273higher expression of perforin and granzyme A in CR versus DF-
Tol, the inverse correlation of these markers with CD28 and CD27
expression, and the increased expession of the cytotoxic marker
CD57 on the CD8+ CD28- subset. The CD8+ CD28- lymphocytes
expressed lower levels of Fas and were less sensitive to apoptosis
than their CD8+ CD28+ counterparts. HC displayed the same
profile as DF-Tol, indicating an increase of CD8+ CD28- effector
lymphocytes in CR rather than a decrease in DF-Tol. Sta displayed
a mixed profile, with some patients resembling DF-Tol and others
mimicking CR.
Conclusion: A strong cytotoxic CD8+ CD28- signature differ-
entiates CR from DF-Tol and HC, suggesting a suppression of
pathological cytotoxicity in DF-Tol. Further investigation of the
targets of these cytotoxic cells and evaluation of these profiles to
identify patients at risk for CR are warranted.
Su2.115. Could Early Posttransplant Allosensitivity
Predict Patients at High Risk for Rejection and Graft
Loss in Kidney Transplantation.
Petia P. Boneva,1 Anastassia P. Mihaylova,1
Daniela N. Baltadzhieva,1 Kalina L. Penkova,1 Daniela L.
Jordanova,1 Pepi K. Angelova,1 Elissaveta J. Naumova.1 1Central
Laboratory for Clinical Immunology, University Hospital
Alexandrovska, Sofia, Bulgaria.
While the relevance of pre-formed anti-HLA antibodies is well
determined, less known is the role of alloantibodies produced after
cadaveric kidney transplantation on graft outcome. The aim of this
study was to evaluate the incidence, dynamics and profiles of
developed post-transplant anti-HLA antibodies and their impact on
graft outcome in kidney recipients. We retrospectively investigated
72 patients with no detectable alloantibodies prior to their first
cadaveric kidney transplantation for the period October 1998-
January 2004. All patients received triple immunosuppressive
therapy. Biopsy-proven acute rejection was observed in 11.1%
and chronic rejection-in 15.3% of the recipients. The alloantibody
profile was determined with Flow-PRA Screening and Specific
Tests (One Lambda, USA). Anti-HLA antibodies after trans-
plantation were detected in 22.2% of the studied patients. Of them
56.25% had HLA class I-reactive only alloantibodies, 18.75%-class
II-reactive only, and 25% both HLA class I and class II reactive.
Donor-specific reactivity was determined in 75% of the alloanti-
body positive patients. A correlation between triplet mismatches
and alloantibody production was observed. Most of the recipients
(81.25%) produce alloantibodies in the early post-transplant period.
Nine of 16 alloantibody-positive patients (56.2%) lost their graft
due to immunologic cause compared to those with no detectable
antibodies (7.1%). Alloantibody titre evaluation demonstrated that
patients with high titers experienced acute rejections and early graft
loss, while in those with low and stable titers chronic rejections
were more common. In conclusion our data suggest that recipients
with post-transplant HLA-reactive antibodies were more likely to
develop allograft rejection that might be predicted early following
transplantation. Algorithms, on the basis of our approach, could be
tested for influence of post-transplant allosensitization on graft
survival.
Su2.116. Humoral and Cellular Response to Influenza
Vaccination in Human Recipients Naturally Tolerant to
a Kidney Allograft.
G. Roussey-Kesler,1 C. Ballet,1 J. T. Aubin,2 S. Brouard,1 J. P.
Soulillou.1 1ITERT, INSERM U643, Nantes, France; 2CentreNational de Reference du Virus Influenza, Institut Pasteur, Paris,
France.
Background: A rare cohort of kidney recipients continue to
enjoy a normal renal function years after interruption of their
immunosuppressive treatment and are considered as btolerantQ. To
assess wether this state of tolerance is specific to their graft and
not the result of a state of immunodeficiency, we studied the
immune response of these patients following influenza vaccina-
tion. We compared this response to that of kidney recipients under
conventional maintenance immunosuppression and to healthy
volunteeers.
Patients and Methods: 4 tolerant recipients (TOL), 5 immu-
nosuppressed-recipients (IS) and 9 healthy volunteers (HV) received
a trivalent influenza vaccine (A/Moscow/10/99; A/NewCaledonia/
20/99; B/HongKong/330/01) during the period of 2003–2004. The 3
groups were matched for age and renal function (mean age: 49F 22,
48F 14 and 48F 14 years for TOL, IS and HV respectively; mean
creatininemia: 104F 7.2Amol/l for TOL, 108F 16,8Amol/l for IS).
All IS recipients received a conventional immunosuppressive
treatment, associating a calcineurin inhibitor with mycophenolate
mofetil. The humoral response was measured by hemagglutination
inhibition (HI) titers before vaccination and after 1 and 3 months. A
positive response was defined as a 4 fold increase in HI titers. During
the period of 2004–2005, 4 TOL, 8 IS and 9 HV received a trivalent
influenza vaccine (A/Fujian/411/2002, A/Newcaledonia/20/99, B/
Shanghai/361/2002). The cellular immune response was analyzed
before and 1 month after vaccination. The frequency of specific T
cells was determined by IFNg-secreting T cells detected with an
Enzyme-Linked-Immunosorbent Spot (ELISPOT) assay after a 24
hour in vitro stimulation with the vaccine.
Results: According to the viral strain, a positive humoral
response was observed in 25 to 75% of TOL, in 0 to 40% of IS and
in 33 to 89% of HV. Thus, IS recipients presented a poor humoral
response as compared to HV, reaching a significant difference for
the A/NewCaledonia strain (P b 0.05), whereas the humoral
response for TOL was not statistically different from HV. However,
1 month after vaccination, 87% of IS presented a strong cellular
response to the influenza vaccination, whereas a comparable
positive response was observed only in 50% of TOL and 55% of
HV (not statistically different). Taken together, these data suggest
that the patients who are tolerant to their kidney respond to the
vaccination. In addition we show that the frequency of cells
producing IFNg following vaccination is unusually high, possibly
due to repetitive stimulations.
Conclusion: TOL recipients present a humoral and cellular
response to influenza vaccination similar to HV, suggesting that the
tolerance state of this small cohort of patients is not related to a
global immunodeficiency.
Su2.117. Pharmacodynamic Monitoring of Calcineurin
Inhibitors by Quantitative Analysis of NFAT-Regulated
Gene Expression.
T. Giese,1 M. Schoels,1 T. Dengler,2 M. Zeier,3 S. Meuer.1
1Immunology, University of Heidelberg, Heidelberg, Germany;
2Cardiology, University of Heidelberg, Heidelberg, Germany;
3Nephrology, University of Heidelberg, Heidelberg, Germany.
With the introduction of calcineurin inhibitors (CNI) long-term
allograft function has significantly improved. The problem of
limited therapeutic margins and the toxicity of CNI remain
unsolved. The quantitative assessment of inhibition of NFAT-
regulated gene expression 2 hr after Cyclosporine A (CsA) intake
AbstractsS274represents a novel approach to evaluate the biological effectiveness
of CsA therapy and provides means to enable individualized
immunosuppressive regimens.
In 55 patients carrying heart allografts we compared the
degree of inhibition of IL-2, IFN-g and GM-CSF gene expression
with the peak blood concentration of CsA. Functional immuno-
suppression as assessed by RT-PCR varies considerably among
CsA treated individuals with stable graft function. Given the
relatively constant level of inhibition over a broad range of drug
concentrations, we felt that a considerable group of patients with
unnecessarily high CsA doses might benefit from a reduced
dosing of the drug without compromising the efficacy of the
immunosuppressive therapy. Therefore, we started a clinical study
reducing the dosage of CsA with close pharmacodynamic
monitoring of the patients. Six patients after kidney trans-
plantation enrolled in this study were monitored over the period
of more than one year so far. In all patients the doses of CsA
could be safely reduced without significantly changing the level
of immunosuppression.
In conclusion, patients treated with calcineurin inhibitors might
benefit from a reduced dosage of the drug, if they respond to CNI
with a strong inhibition of NFAT-regulated gene expression.
Su2.118. Profiling of bOperationally TolerantQ Kidney
Recipients Using SELDI-TOF Mass Spectroscopy.
Christophe Braud,1 Alexandre DuPont,1 Magali Giral,1
Jean-Paul Soulillou,1 Sophie Brouard.1 1INSERM U643,
ITERT-CHU Hotel Dieu Nantes, Nantes, France.
Despite the discovery of potent immunosuppressive agents,
chronic rejection remains the main cause of graft loss after solid
organ transplantation. In addition, exposure to immunosuppres-
sion may cause infections and malignancies which contribute to
the high level of post-transplant morbidity. Achieving clinical
tolerance would represent a major progress in transplantation.
Operationally tolerant patients, accepting their graft in an
imunosuppressive free environnement after clinical organ trans-
plantation, are still extremely rare but represent a unique
opportunity of identifying tolerance fingerprints. Surface
Enhanced Laser Desorption Ionization Time-of-Flight (SELDI-
TOF) mass spectroscopy analysis was used here to profile sera
from drug-free tolerant kidney recipients (n = 7) compared to
recipients undergoing chronic rejection (n = 8) and control non-
grafted patients with renal failure related to bnon-immunologicQ
kidney diseases (uropathy, diabetis, n = 8) and whose renal
function match that of recipients with chronic rejection Sera
were fractionated into 6 fractions and each fraction was loaded
on 2 different chromatographic surfaces (metal affinity
IMAC30-Cu2+ and cation exchange CM10). Results were cross
validated by analysing serum samples from each individual in
two independent experiments. Four protein peaks of interest
were selected in 3 out of 6 fractions on the 2 chemistries. The
3 first protein peaks were found significantly increased in sera
from patients with chronic rejection and renal failure controls
compared to operationally tolerant patients (P b 0.05) suggest-
ing that these protein peaks may be related to renal failure.
However, interestingly, the fourth protein peak was increased
specifically in sera from operationally tolerant patients (P b
0.05) but neither found in sera from patients with chronic
rejections nor in renal failure controls. Considering the absence
of specific tolerance markers, the identification of a non
invasive and specific biological signature of tolerance wouldopen new perspectives for managing immunosuppressive drugs
in long term recipients.
Su2.119. Mega Dose Allogeneic Hematopoietic Stem Cell
Transplantation, Natural Suppressor Cell Chimerism
and Tolerance in Clinic- Ahmedabad Experience.
H. L. Trivedi, A. V. Vanikar, P. R. Modi, V. R. Shah, J. M. Vakil, S. I.
Khemchandani, V. B. Trivedi. 1Department of Transplantation
Medicine, Institute of Transplantaion Sciences and Institute of
Kidney Diseases & Research Centre, Ahmedabad, Gujarat, India;
2Department of Pathology, Lab Medicine and Transfusion Services
and Department of Immunohematology, Institute of Transplantaion
Sciences and Institute of Kidney Diseases & Research Centre,
Ahmedabad, Gujarat, India; 3Department of Urology, Institute of
Transplantaion Sciences and Institute of Kidney Diseases &
Research Centre, Ahmedabad, Gujarat, India; 4Department of
Anesthesia, Institute of Transplantaion Sciences and Institute of
Kidney Diseases & Research Centre, Ahmedabad, Gujarat, India;
5Department of Transplantation Medicine, Institute of Trans-
plantaion Sciences and Institute of Kidney Diseases & Research
Centre, Ahmedabad, Gujarat, India; 6Department of Urology,
Institute of Transplantaion Sciences and Institute of Kidney
Diseases & Research Centre, Ahmedabad, Gujarat, India;
7Department of Pathology, Lab Medicine and Transfusion Services
and Department of Immunohematology, Institute of Transplantaion
Sciences and Institute of Kidney Diseases & Research Centre,
Ahmedabad, Gujarat, India.
Aims:
Mega dose hematopoietic stem cell transplantation (HSCT)
was performed in 150 living-related donor (LRD) renal allograft
recipients under different conditioning protocol treated group(Tn)
with equal number of controls(Cn), for chimerism associated
tolerance.
Methods:
Unmodified HSCT (mean: 20108 cells/kgBW recipient) were
administered in recipientsT thymus, bone marrow(BM), portal,
peripheral circulation with non-myeloablative conditioning. Trans-
plantation was performed following negative lymphocytotoxicity
cross matching. Immunosuppression regime in Tn included low
dose cyclosporine(CsA), Prednisolone. Tn received standard triple
drug immunosuppression. CsA doses in both groups were adjusted
to maintain trough levels around 110 ng/ml. Immunologic
monitoring included donor BM lineage subset chimerism measure-
ment with CD epitope markers using flow cytometry at different
time intervals in peripheral blood(PB) and BM.
Results:
Tnwithmean follow up of 54.4months, had adequate stable graft
function with mean serum creatinine(SCr), 1.1 mg %. Chimerism
was stabilized in PB, measured in terms of CD3 dimCD4- CD8-
(mean: 3.44%-PB, 5.82%-BM) and CD34+ cells (mean: 1.49% -PB,
2.84 % BM). Tn had 100 % graft + patient survival with 8 rejection
episodes on low dose CsA monotherapy; 11 patients are without
immunosuppression for N3 years. Cn with mean follow up of 52
months, hadmean SCr, 2.75mg%. Chimerismwas absent in PB and
BM measured with same parameters. There was 68 graft, 72 patient
survival and 105 rejection episodes on standard triple drug
immunosuppression.
Conclusion:
This is the first report of reproducible cytoanalytic method
identifying subset of donor chimeric cells in LRD recipients
correlating with clinical tolerance.
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the Sera of Sensitized Patients on Hemodialisis.
Minoo K. Adib,1 Edna Abkarshahnazar.2 1Immunology, Medical
School, Isfahan, Isfahan, Islamic Republic of Iran; 2Immunology,
Medical School., Isfahan, Isfahan, Islamic Republic of Iran.
Introduction: The specificity of HLA class one (HLA-A and
B) alloantibodies was studied in 30 serum samples from antibody
positive,potential kidney transplant recipients who had percent
panel reactive antibody values (%PRA) of more than 5%.
Methods: Antibody detection was performed using the
microlymphocytotoxicity technique.In this study,the specificity
of antibodies was categorized as either private epitopes or cross
reactive group (CREG) epitope clusters.A P value of less than
0.05 and R values greater than 3.841 indicated a significant
association between a known antigen and an unknown serum
sample.
Results: No specific antibody was defined in seven (23.33%)
serum samples with %PRA values of less than 20%. At 88% to
100% PRA values(Seven patients = 23.33%),most of the serum
reactions were positive because the patients had developed
multiple antibodies against a large array of HLA antigens.
Identifiable antibodies were found in 16 (53.3%) serum samples
with % PRA values between 20% to 87%. Anti-CREG antibodies
with or without antiprivates were identified in nine of the 16
samples (59.25%),whereas only six (37.5%) of these 16 samples
(6.25%).
Contained two different private antibodies.
Conclusion: Antibody reactivity against CREG clusters was
more common among patients with defineable antibodies.Knowing
the specificity of HLA antibodies in patients sera, helps to define a
suitable kidney with negative cross-matching for sensitized
patients,among previously HLA typed donor banks.The records
of these banks are maintained in computer programs at the Isfahan
Transplantation Laboratory.
Su2.121. IgG Monitoring Can Predict the Development
of Infection in Heart Transplantation.
E. Sarmiento,1 J.J. Rodriguez-Molina,1 J. Fernandez-Yanez,2
J. Palomo,2 P. Munoz,3 E. Fernandez-Cruz,4 E. Bouza,1
J. Carbone.1 1Immunology Department, University Hospital
Gregorio Maranon, Madrid, Spain; 2Cardiology Department,
University Hospital Gregorio Maranon, Madrid, Spain;
3Microbiology Department, University Hospital Gregorio
Maranon, Madrid, Spain.
Introduction. Infectious complication continue to represent a
significant source of morbidity and mortality in heart trans-
plantation. Among risk factors for 5 year mortality conditional on
survival to 1 year, treatment for infection during the first year has
been associated with a 28% increase in the risk of mortality.
Objective. To assess humoral immunity markers that can provide
prognostic value for the development of infection in heart
transplant recipients. Patients and methods. Between October
2002 and December 2004, we prospectively studied the clinical
outcome of 32 consecutive heart transplanted recipients per-
formed at a single center (84,4% men, aged 54 F 9 years).
Patients received induction therapy with daclizumab. Mainte-
nance immunosupression included mycophenolate mofetil, pre-
dnisone and either cyclosporine or tacrolimus based on side-effect
profile. Humoral immunity studies included: Immunoglobulin
(IgG, IgA, IgM) and IgG subclasses determined by nephelometry
in serum samples obtained before transplantation, 7 days post-transplantation and 1-month after transplantation. Potential
clinical risk factors were evaluated, including recipientTs age,
pretransplant CMV serological status of donor (D) and recipient
(R), and occurrence of treated rejection episodes before infection.
Outcome measure. Infection requiring intravenous (IV) drug
therapy during the first year. Cox regression analysis was used to
determine whether immunological parameters were associated
with infectious events. Immunoglobulin levels were split into
two groups using the median value [m.v.] observed as the cut-
off. Results. During a mean follow-up of 12.6 months 12
patients had at least one episode of infection (37.5%); 9 of these
were CMV infections treated with IV gancyclovir, 2 were
episodes of bacterial pneumonia and one patient had pulmonary
nocardiosis. Pretransplant IgG (below m.v. = 1160 mg/dl)
(Relative Risk [RR] 6.31; 95% confidence interval [CI] 1.38-
28.9; P = 0.018) and post-transplant IgG levels at day 7 (below
m.v. = 676 mg/dl) (RR 8.84; CI 107-72.54; P = 0.042) were
associated with an increase in the risk of developing infections.
The decreased risk of development of infection associated with
an increase of 100 mg/dl in the level of pre-transplant IgG was
27% (RH 0.71; CI 0.52-0.97; P = 0.036). D+/R- CMV serostatus
was identified as significant risk factor of infection (RR 3.54; CI
1.11-11.26, P = 0.032). In the analysis that included clinical
predictive variables, decreased values of pre-transplant IgG and
post-transplant IgG levels at day 7 showed independent
significant predictive values (RR 6.30; CI 1.38-28.9, P =
0.018 and RR 8.83; CI 1.07-72.54, p = 0.043, respectively).
Conclusions. IgG level monitoring, a rapid and well stand-
ardized nephelometric determination, at baseline (pre-transplant)
and 7 days post-transplant might help to identify the risk of
developing infection in heart transplantation.
Su2.122. New Insights in Mechanisms of Action of
Different Immunosuppressive Drug Therapies by
Assessing the Pharmacodynamics in Heart Transplant
Recipients.
M. J. Barten,1 A. Rahmel,1 M. Richter,1 J. Garbade,1 H. B. Bittner,1
S. Dhein,1 F. W. Mohr,1 J. F. Gummert.1 1Cardiac Surgery,
University Leipzig, Heart Center Leipzig, Leipzig, Germany.
Objective: Therapeutic drug monitoring (TDM) in heart
transplanted (HTx) recipients for the calcineurin-inhibitors (CNI)
cyclosporin (CsA)and tacrolimus (TRL) and the mTOR-inhibitors
sirolimus (SRL) and everolimus (ERL) relies on the daily
measurements of blood concentrations (pharmacokinetic, PK) to
maintain drug concentrations within their respective target ranges.
However, the unknown absolute bioavailability, the inter-individ-
ual variability regarding the biological effect and drug interactions
are the limitations of TDM based on PK alone. Therefore, in this
study we used our established T lymphocyte function assays to
monitor the pharmacodynamics (PD) of a CNI based immunosup-
pression with a SRL based immunosuppression and compared both
therapy regimes after conversion with a ERL based immunosup-
pression in HTx recipients.
Methods: 10 HTx recipients were converted from CNI to ERL,
because of severe renal dysfunction (5 patients), and from SRL to
ERL, because of the approval of ERL for HTx (5 patients). 24 or
48 hours after the last CNI or SRL dose, respectively, patients were
treated with a fixed dosing regime: of 0,75 mg / BID ERL on days-
1 to-3. PK measurements of CNI were done by EMIT and for SRL
and ERL by LC-MS/MS. PD effects on adhesion molecules (e.g.
CD11a, CD11b, CD54, CD62) and cytokines (e.g. IFN-g, TNF-a,
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FACS.
Results: For all patients Ctrough blood concentrations were
within their respective target levels ( F SEM): CsA: 115.67 F
4.67ng/ml; TRL: 10.52 F 1.52ng/ml; SRL:4.38 F 0.17ng/ml and
ERL:4.13 F 0.63mg/L. PD effects at trough (%expression F
SEM) under CNI therapy compared to PD effects under SRL
therapy were significant different for the following parameters
(P b 0,05): CNI: CD11a: 45,56 F 5,67; CD62: 5,6 F 1,24;
IFN-g: 32,40 F 4,23; TNF-a: 13,60 F 4,05; 28,78 F 8,11.
SRL: CD11a: 34,38 F 7,03; CD62: 16,88 F 7,89, IFN-g:
51,63 F 9,07, TNF-a: 47,43 F 10,56. PD effects at trough
(%expression F SEM) in patients under CNI or SRL therapy
before and after conversion to ERL (day-3) were significant
different for the following parameters(P b0,05): TNF-a: CNI:
13,60 F 4,05, ERL: 28,34 F 6,03; IL-2: CNI: 25,25 F 3,94,
ERL: 47,78 F 5,05; CD11a: SRL: 34,38 F 7,03, ERL:
51,48 F 3,37; CD62: SRL: 16,88 F 7,89, ERL: 4,18 F 0,62.
Conclusion: For the first time, the assessment of PD effects
on T cell functions showed new insights of mechanisms of
action of different immunosuppressive therapies in HTx
recipients. Furthermore, the results indicate that assessing PD
effects on T lymphocyte functions may enhance the value of
PK monitoring to avoid drug toxicity and to enhance drug
efficacy.
Su2.123. Assessment of Peripheral Blood Dendritic Cell
Subsets and Their Functions To Monitor
Immunosuppression after Heart Transplantation.
M. J. Barten,1 A. Rahmel,1 M. Richter,1 J. Garbade,1 H. B.
Bittner,1 S. Dhein,1 F. W. Mohr,1 J. F. Gummert.1 1Cardiac
Surgery, University Leipzig, Heart Center Leipzig, Leipzig,
Germany.
Objective: Everolimus (ERL), the derivate of the mTOR
inhibitor sirolimus (SRL) with a shorter half life, was recently
approved for immunosuppressive therapy after heart transplantion
(HTx). Dendritic cells (DCs) are potent antigen presenting cells
that posses the ability to activate naRve T cells. Earlier studies
revealed an inhibitory effect of SRL on antigen expression in
isolated DCs. However, nothing is known but the effects of either
SRL or ERL on DCs in peripheral blood in vivo (pharmacody-
namics, PD). Therefore, in this study we used DCs assays to
monitor the conversion of a SRL based immunosuppression to a
ERL based immunosuppression in HTx patients.
Methods: We assessed PD effects and the pharmacokinetics
(PK) in 6 HTx patients before and after conversion of SRL to
ERL. 48 hours after the last SRL dose (0,5 or 1 mg QD / day)
patients were treated with a fixed dosing regime of 0,75 mg of
ERL BID on days 1 to 3. All patients received mycophenolate
mofetil / BID co-therapy with a dose range of 500-2000 mg /
day. PK measurements of SRL and ERL were measured by LC-
MS / MS. FACS analysis was used to characterized myeloid and
plasmacytoid DCs by expression of CD11c+ and CD123+,
respectively, and to assess DCs cytokine production (IL-1g,
TNF-a, IL-6 and IL-12).
Results: For all patients Ctrough-values of SRL and of ERL on
day 3 were within their respective target levels: SRL:4.38 F
0.17ng/ml and ERL:4.13 F 0.63mg/L. PD effects (%expression F
SEM) on day-3 under ERL therapy were compared with PD effects
under SRL at trough levels: CD11c+: ERL: 51,26 F 6,34, SRL:
48,90 F 3,41; CD123+: ERL: 22,08 F 2,83, SRL: 16,18 F 2,65(P b 0,05); IL-1g: ERL: 25,14 F 7,38, SRL:10,50 F 5,86
(P b 0,05); IL-12: ERL: 9,72F 4,52, SRL: 5,45F 1,88 (P b 0,05);
TNF-a: ERL: 24,44 F 7,21, SRL: 28,68 F 9,55; IL-8: ERL:
27,62 F 10,49, SRL: 25,48 F 8,13.
Conclusion: For the first time, the effects of SRL and ERL
on DC subsets and cytokine production in peripheral blood were
assessed in HTx patients. The results show that the mTOR-
inhibitors SRL and its derivative ERL have different effects on
DCs subsets and functions. Peripheral blood DCs monitoring
(PD) may provide a new insight of mechanisms of immunosup-
pressants to improve the safety and efficacy of immunosuppres-
sive therapy after HTx.
Su2.124. T Helper Cells Produced Increased IL-6 and
TNF-A Levels in Human Heart Transplant Recipients.
M. J. Barten,1 A. Rahmel,1 M. Richter,1 J. Garbade,1 H. B.
Bittner,1 S. Dhein,1 F. W. Mohr,1 J. F. Gummert.1 1Cardiac
Surgery, University Leipzig, Heart Center Leipzig, Leipzig,
Germany.
Objective: Differential expression of cytokine production of T
helper 1 (Th1) and 2 (Th2) cells is known to play a major role in
allograft rejection. Furthermore, in earlier studies we show the
importance to measure the pharmacodynamics (PD) of immuno-
suppressive drug therapy after heart transplantation (HTx) to
enhance pharmacokinetic (PK) drug monitoring. Therefore, in this
study we assessed the PD effects of the combination cyclosporin
(CsA) plus mycophenolate mofetil (MMF) on the cytokine
production of Th1 and 2 cells in human HTx recipients at different
time points and compared these with the cytokine expression in
untreated control groups.
Methods: Blood from 50 HTx recipients was drawn before
(C0) and 2h after dosing (C2) with CsA and MMF. Untreated
control groups consisted of 47 patients with dilated cardiomyop-
athy (DCM) and 20 healthy volunteers (HV). CsA and mycophe-
nolic acid (MPA) concentrations were measured by EMIT.
Cytometric bead array (CBA) assay was used to asses cytokine
production of Th1 cells (INF-g, IL-2, TNF-a) and Th2 cells (IL-4,
IL-10, IL-6) in serum with FACS.
Results: Evening doses of CsA (25 / 50 / 75 or 100 mg) and
MMF (250 / 500 or 1000 mg) produced C0-levels: CsA: 160 F 11
ng/ml and MPA: 1.7 F 0.2 mg/L. Morning doses of CsA (50 / 75
or 100 mg) and MMF (250 / 500 / 1000 or 1500 mg) produced C2-
levels: CsA: 533 F 53 ng/ml and MPA: 7.5 F 1.2 mg/L. Cytokine
production (pg/ml F SEM) in HTx recipients was significant
different at C0 compared to C2 for TNF-a and IL-6 (P b 0,05): C0:
TNF-a: 9 F 2; IL-6: 75 F 11; C2: TNF-a: 5 F 1; IL-6: 51 F 12:
Production for both TNF-a and IL-6 was significant increased at
C0 andC2 compared toDCMandHV (P b 0,05): TNF-a: DCM: 2F
0,5; HV: 1 F 0,1 IL-6: DCM: 30 F 7; HV:32 F 6.
Conclusion: For the first time, the CBA assay was used to
assess differences in cytokine production of Th1 and 2 cells at
different time points of CsA and MMF treated human HTx
recipients and untreated control groups. Future studies in HTx
recipients have to show if a PD monitoring of IL-6 and TNF-a
production could be biomarkers for clinical outcome like rejection
or infection.
Su2.125. The Expression of Survivin in T Cells and Its
Possible Significance.
Ning Zeng, Bicheng Chen, Zhonghua Klause Chen, Li Tang, Shang
Chang, Dunfeng Du. 1Key Laboratory of Organ Transplantation
Abstracts S277Ministry of Education, Key Laboratory of Organ Transplantation
Ministry of Health, Institute of Organ Transplantation Tongji
Hospital, Wuhan, Hu Bei, China.
AIM: To investigate the expression of survivin in T cells
in vitro and in vivo. METHODS: Expression of survivin in
splenocytes stimulated with ConA or alloantigen was detected
by immunohistochemical straining. Anti-IL2 receptor antibodies
were added to inhibit T cells proliferation. Flow cytometry
was used to analyze CD3, CD25 and survivin expressions.
Splenocytes from C57BL/6(H-2b) mice were infused into F1
mice (Balb/cC57BL/6)to develop GVHR model, and expres-
sion of the survivin was observed by immunohistochemical
strain in vivo after alloantigen stimulation. RESULTS:
Expression of survivin was detected in stimulated cells.
Survivin+ cells were CD3+ T cells, and lymphoblasts could
simultaneously express CD3, CD25 and survivin. Anti-IL2
receptor antibodies inhibited the survivin expression, and the
percentage of M phase cells decreased. From day 4 to 12 after
infusion, the alloantigen–activated T cell infiltrating in livers of
F1 mice expressed survivin. CONCLUSIONS: As a marker of
activated T cells, survivin can be detected in T cells after in
vivo and in vitro stimulation and divided the procedure of T
cells response to alloantigen into activation and effect phase.
Keywords: T cells; survivin; CD25
Su2.126. Anti-CD132 Monoclonal Antibodies Inducing
Activated T Cells Apoptosis after Alloantigen
Stimulation.
Fu-li Xiang,1 Chang Sheng,1 Bicheng Chen,1 Dunfeng Du,1
Zhonghua Clause Chen.1 1Organ Transplantation, Tongji
Hospital, Tongji Medical College, HUST, Wuhan, Hubei, China.
Aim: To investigate the mechanism of anti-CD132 monoclonal
antibodies (mAbs)inhibiting T cells proliferation in vitro.
Methods: Balb/c and C57BL/6 mice splenocytes were
harvested for two-way mixed lymphocyte culture (MLC)(con-
trol group). Anti-CD132 mAbs (final concentration
100mgd L1) were added in MLC on day 0 (group 1) or
day 3 (group 2). Fluorescence activated cell sorting (FACS)
was used to measure the proliferation(CFSE), the apoptosis of
T cells (PE-CD3, FITC-Annexin-v) and cell cycle (propidium
iodide stain). The expression of survivin(a kind of protein
highly expressed in the G2/M phase) in T cells was detected
by immunochemical stain.
Results: Multi-generation of CFSE-labeled splenocytes were
found dividing and their fluorescent strength decreased in MLC
in the control group while there was no obvious change in
fluorescent intensity in group 1 and group 2 implying no sign of
division. On day 3, apoptosis induced by anti-CD132 mAbs was
detected in partial T cells, but not in the former two days in group
1. In group 2, the number of cells in M phase (activated T cells)
decreased and apoptotic cells increased on the fourth day. The
phenomena were not observed in control group (P b 0.01).
Exression of survivin in T cells was detected in control group but
not in group 1 and 2.
Conclusions: Our study shows that blockade of CD132
signaling pathway can inhibit T cells proliferation in vitro by
means of inducing activated alloreactive T cells apoptosis but not
affecting the resting T cells. Anti-CD132 mAbs may be valuable
candidates for clinical applications.
Key Words: CD132, apoptosis, two-ways MLCSu2.127. Cytomegalovirus-Specific CD4 T-Cell
Immunity Is Associated with Protection from Human
Cardiac Allograft Rejection and Negative
Coronary-Artery Remodeling.
W. Tu,1 L. Potena,2 P. Stepick-Biek,1 L. Liu,1 K. Y. Dionis,1
L. Bashyam,3 W. Fearon,2 H. A. Valantine,2 E. S. Mocarski,3 D. B.
Lewis.1 1Department of Pediatrics, Stanford University School of
Medicine, Stanford, CA, USA; 2Department of Medicine, Stanford
University School of Medicine, Stanford, CA, USA; 3Department
of Microbiology and Immunology, Stanford University School of
Medicine, Stanford, CA, USA.
Cytomegalovirus (CMV) infection in cardiac allograft recip-
ients, particularly symptomatic disease with high levels of viral
replication, has been associated with a greater risk of graft
rejection and negative coronary-artery remodeling, a likely
precursor of frank transplant arteriopathy (TA). The role of
CMV-specific T-cell responses in modifying these risks in
patients with asymptomatic CMV replication after transplant is
unknown. Methods. We longitudinally studied post-transplant
CMV-specific T-cell immunity by intracellular cytokine staining
for IFN-g+ cells using flow cytometry in 30 consecutive cardiac
transplant recipients during the first year after transplant. All
patients had pre-transplant acquisition of CMV based on antibody
seropositivity, and received initial post-transplant CMV prophy-
lactic therapy with ganciclovir/valganciclovir and a 3-drug
immunosuppression that included cyclosporine, mycophenolate
mofetil and prednisone. None of the patients had symptomatic
CMV disease. CMV load in circulating PMNs was determined by
real-time PCR. Allograft rejection was assessed by endomyocar-
dial biopsy, and TA was evaluated by intravascular ultrasound
(IVUS) of the left anterior descending coronary artery at baseline
(within 6 weeks) and at 1 year after transplantation, by measuring
the changes in intimal (plaque), lumen and whole vessel area.
Results. Recipients with a detectable CMV-specific CD4 T-cell
response by 3 months post-transplantation (early response group)
were significantly protected from acute rejection and had
significantly lower viral load compared to those who lacked
detectable an early CMV-specific CD4 T-cell response (late
response group). Despite intimal hyperplasia did not differ
between groups, patients with a late CD4 response had a
significant reduction of vessel area (P = 0.039), and consequently
loss in coronary lumen (P = 0.052). This process suggests
important variability in coronary geometry according to CD4 T-
cell specific immunity. In contrast, an early CD8 T-cell response
was not significantly associated with freedom from rejection,
negative remodeling, or low viral load. Conclusions. The control
of CMV replication by T-cell immunity, particularly by CD4 T
cells, is important in limiting allograft immune rejection and the
evolution of transplant vascular disease. This is demonstrable in a
patient population with relatively low levels of post-transplant
CMV viral load because of pre-transplant CMV immunity and
early post-transplant ganciclovir/valganciclovir prophylaxis. Inter-
ventions to increase CMV T-cell immunity might provide a
clinically useful adjunct for limiting the deleterious post-trans-
plant effects of CMV.
Su2.128. Immunological Evaluation of Lymphocyte
Activation, Cytokines and Apoptosis on
Tacrolimus-Sirolimus-Induced Long-Term Allograft
Survival in Nonhuman Primates.
AbstractsS278MA/Anlun,1 Qi/Shijie,1 Xu/Dasheng,1 Daloze/Pierre,1
Chen/Huifang.1 1Laboratory of Experimental Surgery, Research
Centre Hospitilier de lTUniversity de Montreal (CHUM), Hopital
Notre-Dame, Universite de Montreal, Montreal, QC, Canada.
Background: We reported previously that a 60-day course of
combined tacrolimus (FK506) and sirolimus (RAPA) therapy
induced long-term survival of renal allografts after withdrawal of
immunosuppressants in Vervet monkeys. The mechanism of drug-
induced allograft survival was evaluated via Th1/Th2 cytokines,
apoptosis and mixed lymphocyte reaction (MLR) activity in
primates in the present study.
Methods: Phenotypes were analyzed by flow cytometric
analysis (FACS). Cytokines were quantified by enzyme linked
immunosorbent assay (ELISA). MLR and cytotoxin T lymphocyte
assays were performed by incorporation of 72-h 3H- thymidine and
4-h 51Cr release.
Results: A 60-day course of combined FK506 and RAPA
treatment resulted in long-term survival of kidney allografts (67%
N100 days) without intermittent acute rejection. Low sensitivity to
MLRwas seen in long-term renal allograft survival among monkeys
treated with FK506 and RAPA. Increased levels of CD3+CD8+,
CD3+/CD56+ natural killer (NK) T and CD86+CD8-CD11+ den-
dritic cells were observed. High expression of CD4+FasL+ was
detected. In addition, Interleukin (IL)-2 and interferon (IFN)-g
concentrations with long-term allograft survival were not increased
significantly. Late-phase dominance of Th2, IL-4, IL-10 and
transforming growth factor (TGF)-b was found to result in long-
term survival by combined FK506 and RAPA treatment of.
Conclusions: FK506 and RAPA-induced long-term allograft
survival in primates is related to up-regulation of FasL expression,
NKT cells and dendritic cells with down-regulation of MLR
sensitivity. It is also associated with late-dominant expression of
Th2 cytokines.
Su2.129. Baohuoside-1, a Novel Immunosuppressive
Molecule, Inhibits Lymphocyte Activation In Vitro and
In Vivo.
MA/Anlun,1 Qi/Shijie,1 Xu/Dasheng,1 Daloze/Pierre,1
Chen/Huifang.1 1CHUM, Notre-Dame Hospital, University of
Montreal, Montreal, QC, Canada.
Background. Immunosuppressive effect of Baohuoside-1, a
novel flavonoid isolated from Epimedium davidii, was evaluated in
vitro and in vivo in this study.
Methods. The antiproliferative properties of B1 were evaluated
by proliferation assay. Western blotting and fluorescence activated
cell sorting were employed to investigate the expression of cyclins
and cyclin-dependent kinase proteins.
Results. The major findings were: (1) B1 effectively inhibited
the cell proliferation activated by interleukin 2 and mitogenic
antigen, with a 50% inhibitory concentration in low mM and in a
dose- and time-dependent manner. (2) B1 resulted in G1-S phase
cell arrest. (3) It down-regulated the expression of cyclin A, D and
p33 cyclin-dependent kinase-2 (p33cdk2) proteins. (4) B1 sup-
pressed the growth of several tumour cell lines. (5) The synergistic
immunosuppression between B1 and FK506 was observed a heart
transplantation model in vivo.
Conclusions. B1 immunosuppression of IL-2-activated T cell
proliferation occurs in G1-S transition. It may be associated with
the expression of cyclin A, D and p33cdk2 proteins. B1 prolongs
effectively heart allograft survival in rats. The mechanism of B1 is
different from tacrolimus and sirolimus.Su2.130. Cellular Reactivity to Human Hsp60 in Murine
Skin and Heart Transplantation.
Veronica Coelho,1,2,3 Ernesto Luna,1,2 Luiz A. Benvenuti,1 Luiz R.
Mundel,1 Valquiria Bueno,4 Leo K. Iwai,1 Cristina Caldas,1 Jorge
Kalil.1,2,3 1Heart Institute (Incor), University of Sao Paulo, Sao
Paulo, Sao Paulo, Brazil; 2Division of Allergy and Clinical
Immunology, Internal Medicine Department, University of Sao
Paulo, Sao Paulo, Sao Paulo, Brazil; 3Institute for Investigation in
Immunology-Millenium Institute, CNPq, Brazil; 4Nephrology
Division, Department of Medicine, Paulista School of Medicine,
Paulista School of Medicine UNIFESP, Sao Paulo, Sao Paulo,
Brazil.
Introduction: The increased expression of Hsp60 in different
kinds of graft tissues has been associated with rejection and suggests
a proinflammatory role for Hsp60. On the other hand, there are
reports in which treatment with Hsp60 delayed rejection of skin
allograft. Our group has reported an association between Hsp60-
induced T cell proliferation and rejection and Hsp60-induced IL-4
production and no rejection, in human kidney allotransplantation,
suggesting the existence of both proinflammatory and potentially
regulatory autoreactive T cells directed to Hsp60. The aim of this
work was to functionally analyze the cellular response to human
Hsp60, in different murine transplantation models.Method: Briefly,
we studied T cell proliferative response and antigen-induced
cytokine production by ELISA. Antigens used: 11 Hsp60 synthetic
peptides, I-Hsp60 (intermediate region), C-Hsp60 (C-terminal
region) and Hsp60 protein in different transplantation groups: (i)
syngenic skin, (ii) allogenic skin, and (iii) vascularized heart
transplantation. Results In the syngenic group, we observed a
predominant IL-4 and IL-10 production induced by Hsp60 peptides
in both BALB/c and C57BL/6models. In the skin allogeneic groups,
(BALB/c (H-2d) as recipients of C57BL6 (H-2b), (n = 4) and
C57BL6 mice as recipients of BALB/c, (n = 5), we observed IFNg
and IL-10 production induced by Hsp60 and different Hsp60
peptides, but IL-4 was not detected. In the heart allografting model,
using BALB/c as recipients of C57BL6 mice, (n = 4), all animals
showed proliferative response to Hsp60. This group displayed IFNg
production induced by recombinant Hsp60 in 4 out of 4 animals. IL-
10 production was induced by Hsp60 in 2 out of 4 animals.
Conclusion: These results show a predominant Th2 profile in T cell
reactivity to Hsp60 in syngenic skin transplantation. In contrast, we
observed predominantly Th1 proinflammatory cytokine production,
induced by Hsp60, in both skin and heart allograft rejection, with a
low frequency of IL-10 production and no IL-4 production. Further
analysis of Hsp60 peptides and regions may allow the identification
of potentially regulatory epitopes, which may be used for the
induction of immune tolerance. Supported by FAPESP and
CNPq.
Su2.131. Evaluation of Skin Graft Survival Using the
Encapsulated Hsp60 Peptide (p277) in a Murine Model
of Minor Antigen Disparities.
Ernesto Luna,1,2 Edilberto Postol,1 Luiz A. Benvenuti,1 Jose M.
Rodrigues,4 Karla M. Lima,4 Cristina Caldas,1 Jorge Kalil,1,2,3
Veronica Coelho.1,2,3 1Heart Institute (Incor), University of Sao
Paulo, Sao Paulo, Sao Paulo, Brazil; 2Division of Allergy and
Clinical Immunology, Department Internal Medicine, University of
Sao Paulo, Sao Paulo, Sao Paulo, Brazil; 3Institute for Inves-
tigation in Immunology, Millenium-Institute, Brazil; 4Center for
Tuberculosis Research, School of Medicine of Ribeirao Preto,
Ribeirao Preto, Sao Paulo, Brazil.
Abstracts S279Introduction: T cell reactivity induced by Hsp60 has been
frequently implicated in the inflammatory process in autoimmune
diseases and graft rejection. Our group has reported an association
between Hsp60-T induced cell proliferation and rejection in human
kidney allotransplantation and Hsp60-induced IL-4 production and
no rejection, suggesting the existence of both proinflammatory and
potentially regulatory autoreactive T cells directed to Hsp60. We
evaluated the capacity of a human Hsp60-derived peptide (p277) to
induce tolerance in a murine model of skin grafting with minor
antigen disparities. Methods: Briefly, BALB/c (H-2d, CD51) mice
were used as recipients of skin graft from DBA2 mice (H-2d,
CD52) mice. Six recipients received five intranasal inoculation of
p277 peptide encapsulated in poly-lactic/glycolic-acid micro-
spheres (50m g). As control group, animals immunized with
empty microspheres (n = 6) and non-immunized animals (n = 9)
were used. Results We obtained a slight increase in graft survival,
with median survival time (MST) 15,5 days in p277 treated
animals, in comparison with controls groups (15 days, P = 0.17),
but 2 animals from this group had a graft survival over 20 days. We
did not observe proliferative response against p277 or Hsp60. We
observed a predominant IFNg production induced by Hsp60 and
recombinant fragment corresponding to the intermediary region of
the Hsp60 (I-Hsp60), in animals from different experimental
groups. In contrast, IL-4 production was induced predominantly by
the C-terminal fragment of the Hsp60 (C-Hsp60) in 3 out of 6 mice
from p277 treated group. Finally, IL-10 production induced by
p277 peptide was observed in 4 out of 6 mice from p277 treated
group. Conclusion: These results show that reactivity to Hsp60
may be used to prolong graft survival in a model of minor antigen
disparities. The combination of the tolerogenic potential of the
mucosal route and the capacity of different Hsp60 regions to
induce regulatory cytokines may be further explored for down
modulating inflammatory processes. Supported by FAPESP and
CNPq.
Su2.132. The Role of Indoleamine 2,3-Dioxygenase
(IDO) in a Murine CTLA4Ig-Based Mixed Chimerism
Model.
I. Pree,1 S. Bigenzahn,1 P. Nierlich,1 Z. Koporc,1 P. Blaha,1
F. Langer,1 E. Selzer,2 D. Fuchs,3 C. Winkler,3 G. Brandacher,4
M. Sykes,5 F. Muehlbacher,1 T. Wekerle.1 1Department of Surgery,
Division of Transplantation, Medical University of Vienna;
2Department of Radiotherapy and Radiobiology, Vienna Gernal
Hospital; 3Institute of Medical Chemistry and Biochemistry;
4Department of General and Transplant Surgery, University of
Innsbruck, Austria; 5Transplantation Biology Research Center,
MGH/Harvard Medical School, Boston, USA.
Background: Apart from indirectly blocking the CD28
costimulation pathway by competing for ligation with B7
molecules, recent data suggest that the dimeric fusion protein
CTLA4Ig can initiate a negative signaling pathway in APCs by
inducing the tryptophan catabolizing enzyme IDO. Decreasing
availability of tryptophan and the accumulation of catabolic
byproducts such as kynurenine result in impaired T cell prolifer-
ation and apoptotic death. We therefore investigated whether IDO
played a role in our allogeneic mixed chimerism protocol involving
the use of CTLA4Ig.
Materials and Methods: C57BL/6 mice received non-myeloa-
blative total body irradiation (TBI, 3 Gy, d-1), approx. 20106
fully allogeneic Balb/c bone marrow cells (d0) and costimulation
blockade consisting of anti-CD154 mAb (1mg, d0) and CTLA4Ig(0.5mg, d2). Additional groups were either treated with the same
regimen without CTLA4Ig or were implanted with 7-day-release 1-
methyltryptophan pellets on d-1 (1-MT, which is a competitive
inhibitor of IDO, 200mg/pellet) or placebo pellets. Macrochimer-
ism and deletion of donor-reactive T cells were followed by flow
cytometry. Serum levels of tryptophan and kynurenine (trp, kyn)
were measured at several time-points by high performance liquid
chromatography (HPLC). Kyn to trp ratios were calculated,
indicative of IDO activity.
Results: 15/18 mice which received bone marrow trans-
plantation (BMT), TBI, anti-CD154 plus CTLA4Ig, but only 6/
18 mice without CTLA4Ig treatment developed lasting (20 weeks)
mixed chimerism (pooled data from two independent experiments,
P b 0.01). 10/17 mice with CTLA4Ig treatment accepted donor
skin grafts for more than 100 days, whereas only 2/17 mice without
CTLA4Ig accepted donor skin long-term (P b 0.01). 3rd party
grafts were promptly rejected in all groups. Thus, CTLA4Ig is
critically important for chimerism and tolerance induction in this
protocol. Serum kyn/trp ratios were similar in groups treated with
and without CTLA4Ig at several time points post-BMT (e.g. on d3:
11.8F 2.7 vs. 12.1F 3.3, d4: 10.4F 3.4 vs. 13.9F 4.6, d11: 16.2F
4.3 vs. 17.4F 6,3, d14: 37.7F 14.5 vs. 40.8F .20.7; P = n.s. for all
time-points). 10 weeks after BMT 6/8 mice treated with 1-MT
pellets showed multilineage chimerism, which was not significantly
different from the group implanted with placebo pellets (4/4
chimeras; 70.1 F 33.9 vs. 61.1 F 38.2% myeloid chimerism,
34.0F 19.51 vs. 33.0F 21.2% B cell chimerism, P = n.s). Deletion
of donor-reactive CD4 cells was not significantly affected by
treatment with 1-MT.
Conclusion: CTLA4Ig is critically required for reliable chimer-
ism induction in this model of fully allogeneic BMT. Its effect was
not reversed by inhibition of the tryptophan depleting enzyme IDO.
Su2.133. Evaluation of Immuknow-Immune Cell
Function Assay as a New Parameter of Net State of
Immunosuppresion in Monitoring Renal Transplant
Recipients.
Alex Yussim,1 Moshe Israeli,2 Eytan Mor,1 Dan Krest,2 Tirza
Klein.2 1Department of Transplantation, Research Unit, Rabin
Medical Centre, Affiliation to Tel Aviv University School of
Medicine, Petach Tikva, Israel; 2Tissue Typing Laboratory.
Background: The survival of transplanted organ is dependent
on maintenance of continuous immunosuppression. However, even
strictest adherence to the recommended drug levels does not
prevent numerous complications associated with immunosuppres-
sion. The Immuknow assay measures cell-mediated immunity and
is reportedly able to discern between profiles of over and under-
immunosuppression. The aim of this pilot study was to evaluate
this assay in characterization of immune status of renal transplant
recipient in correlation with patientTs clinical condition. Method:
13 kidney recipients were monitored for a period of first six post-
transplantation weeks. The immune function was determined by
quantitative measurement of intracellular ATP level in CD4+
lymphocytes after PHA stimulation. FK or CSA blood levels and
parameters of rejection, graft function and infection, were
correlated with the assay results.
Results: ATP release and FK/CSA blood level values were
evaluated at baseline (n 13), during quiescence (n 26), acute
rejection (n 4) and infection (n 4). Rejection was positively
correlated with ATP 25–100% elevation from baseline in 3/4
instances. Such correlation with CNI levels (20% decrease) could
AbstractsS280be found in only 1/4 instances. Likewise, infection was
correlated with 50–60% decrease in ATP release in 2/4 instances
but not by CNI levels (0/4). In stable patients, the ATP deviation
from the preoperative baseline, indicative of quiescence, was
much smaller than that of CNI levels (means of deviations 0.4 F
36 % vs. 18 F 56 %).
Conclusion: Immuknow is better correlated with the clinical
status than CNI level and therefore could be recommended for
post-transplant monitoring.
Su2.134. CD80 but Not CD86 Costimulatory Molecules
Suppresses Xenogeneic Humoral Rejection by
Regulation of Complement C3dg Generation.
K. A. Hosiawa,1,2 H. Wang,3 B. Garcia,3 R. Zhong,2,3 D. J.
Kelvin.1,2,4 1Division of Experimental Therapeutics, University
Health Network-Toronto General Research Institute, Toronto, ON,
Canada; 2Microbiology and Immunology, University of Western
Ontario, London, ON, Canada; 3Surgery, University of Western
Ontario, London, ON, Canada; 4Immunology, University of
Toronto, Toronto, ON, Canada.
OBJECTIVE: Acute vascular rejection (AVR) and cell-
mediated rejection (CMR) remain the primary immunological
barriers to successful xenotransplantation. While the CD86, but not
CD80, costimulatory pathway has been shown to play a critical
role in allotransplantation heart allograft rejection, the immunor-
egulatory roles of CD80 and CD86 have not been fully dissected in
xenotransplantation.
METHODS: Using a concordant Lewis rat-to-mouse hetero-
topic heart xenotransplantation model we characterized the role of
CD80 and CD86 in xenotransplantation using CD80 and CD86
knockout mice on the C57BL/6 background (Jackson Labs). Graft
function was monitored by abdominal palpation. Xenoantibody
levels were measured by flow cytometry by incubating sera from
transplant recipients with Lewis rat lymph node cells, followed by
staining with anti-mouse IgM, IgG1 or IgG2a -FITC or -PE
conjugated antibodies. C3dg intragraft deposition was characterized
by western blotting with a goat-anti-mouse C3 polyclonal antibody.
RESULTS: C57BL/6 recipients reject xenograft hearts on
POD17-21 and show CMR/AVR histopathology. We now report
that CD80/ recipients reject xenograft hearts on POD5 and show
AVR histopathology (an antibody driven process). In contrast,
CD86/ recipients reject xenograft hearts on POD17 but show
predominantly CMR pathology (T cell driven process). We show
that CD80/ recipients have significantly increased serum levels
of IgG1/2a xenoantibodies, as well as intragraft IgG deposition,
than CD86/ or C57BL/6 recipients at POD5-6. Furthermore,
C57BL/6 but not CD86/ recipients show an increase in IgG1/2a
xenoantibodies on POD17-21. Furthermore, CD80/ recipients
showed deposition of complement C3dg protein in the graft on
POD5, whereas CD86/ and C57BL/6 recipients on POD6 or
POD17-21 did not show any C3dg deposition.
CONCLUSIONS: This data demonstrates that CD80 sup-
presses xenogeneic antibody-driven AVR, while CD86 promotes
CMR. Furthermore, this data suggests that CD80 costimulatory
molecule suppresses xenogeneic humoral responses by inhibiting
the generation of C3dg, a result of C3 activation. We contend that
CD80 and CD86 play distinct roles in regulation of xenogeneic
rejection by differentially regulating B cell responses and comple-
ment activation/degradation. These results highlight the importance
of different mechanisms regulating xenogeneic and allogeneic graft
rejection.This work was supported by grants from CIHR, MOTS,
ORDCF, and CANVAC.
Su2.135. Lack of Correlation between the Presence of
Anti-Human Panel Reactive Antibodies (PRA) and
Anti-Swine Non-Galactose-A1,3-Galactose (NonGal)
Cytotoxic Antibodies in Patients Awaiting Life-Saving
Organ Transplantation.
B. S. Wong,1 P. E. OTMalley,1 Y.-L. Tseng,1 F. J.M.F. Dor,1 S. L.
Saidman,2 K. Yamada,1 D. H. Sachs.1 1Transplantation Biology
Research Center, Massachusetts General Hospital/Harvard
Medical School, Boston, MA, USA; 2Department of Pathology,
Massachusetts General Hospital/Harvard Medical School, Boston,
MA, USA.
Background: Until recently, hyperacute xenograft rejection
(HXR) mediated by preformed xenoreactive natural antibodies
against the Gal epitope, produced by the a1,3-galactosyltransferase
(GalT) enzyme, appeared an insurmountable obstacle to clinical
xenotransplantation. Recent studies demonstrate that use of organs
from GalT-knockout (KO) miniature swine prevents HXR. It was
not known whether highly-allosensitized patients unlikely to
receive crossmatch-negative human organs are also xenosensitized
against nonGal swine antigens.
Aim: To determine if correlation exists between PRA levels and
anti-swine nonGal reactivity in patients awaiting renal allotrans-
plantation.
Methods: Serum samples were obtained from 15 highly-
allosensitized patients (bhigh PRAQ denotes PRA z 80%) and
45 non-allosensitized patients (blow PRAQ denotes PRA V
10%) on the waiting list for cadaveric renal transplantation.
The %PRA was determined using a standard anti-human
globulin-augmented cytotoxicity assay. GalT-KO PBMC were
obtained from a GalT/ miniature swine using standard
density gradient centrifugation. Assays included FACS for
serum IgM and IgG binding and complement-dependent
cytotoxicity (CDC), in which reactions containing no test
serum, normal human serum, and known sensitized serum
were included as controls.
Results: Comparisons between high and low PRA sera for
FACS and CDC results against GalT-KO PBMC are expressed as
average % antibody binding F 95% CI and average %
cytotoxicity F 95% CI. No statistically significant difference
was found in: 1) serum IgM binding between high PRA (25.2 F
6.9) and low PRA (30.1 F 6.0) patients, nor in 2) serum IgG
binding between high PRA (10.9 F 5.3) and low PRA (8.2 F
2.0) patients, nor in 3) serum cytotoxicity at 1:4 dilution between
high PRA (21.5 F 5.7) and low PRA (22.2 F 5.9) samples. Of
the 15 highly-allosensitized sera tested, only 1 patientTs serum
showed high IgM binding (N50%) and high cytotoxicity (N50% at
1:4 serum dilution) against GalT-KO targets. None of the 15
highly-sensitized sera showed high IgG binding (b50%) against
GalT-KO PBMC. Cytotoxicity levels showed a positive correla-
tion with IgM binding (r = 0.657), but not with IgG binding (r =
0.046). Studies on target cells from additional GalT-KO animals
are in progress.
Conclusion: No correlation was found between anti-human and
anti-GalT-KO swine reactivity in patients awaiting life-saving renal
transplantation. Xenosensitization against nonGal antigens is
uncommon in highly-allosensitized patients, who may therefore
be candidates for xenotransplantation of GalT-KO porcine organs
in a future clinical trial.
Abstracts S281Su2.136. TIRC7 Is Expressed upon Immune Activation
Early in Peripheral Blood Lymphocytes and Remains
Induced in Inflammatory Cells during Rejection after
Kidney Transplantation as Well as in Joints from
Patients with Established Rheumatoid Arthritis.
S. G. Tullius,1 H. D. Volk,2 A. Tamura,2,3 M. Winter,2 P. Fraser,5
R. S. Blumberg,5 N. Utku.2,4 1Department of General and
Transplantation Surgery, Charite-Campus Virchow Clinic,
Humboldt-University, Berlin, Germany; 2Institute of Medical
Immunology, Humboldt-University of Berlin, Berlin, Germany;
3School of Medicine, Keio University, Tokyo, Japan; 4GenPat77
Pharmacogenetics AG, Berlin, Germany; 5Department of
Medicine, Rheumatology and Gastroenterology, Brigham and
WomenTs Hospital, Harvard Medical School, Boston, MA, USA.
Aims: TIRC7 is an activation induced cell surface molecule on
T and B cells that negatively regulates their function. To analyze
the potential role of TIRC7 expression associated with the early
immune response, several human tissues including transplanted
kidneys, joint samples and peripheral blood lymphocytes (PBL)
were analyzed for TIRC7 expression.
Methods: Expression of TIRC7 was tested in clinical biopsies of
renal allograft recipients treated with a calcineurin inhibitor-based
immunosuppression by immunohistology using a FITC labelled
anti-TIRC7 mAb following the biopsy-confirmed diagnosis of acute
rejections. Joint tissues isolated from patients with Rheumatoid
Arthritis (RA) were subjected to immunohistology using a directly
FITC labelled anti-TIRC7 mAb. Flow cytometric analysis was
performed using an anti-TIRC7 mAb on PBL activated with
alloantigen. TIRC7 protein expression was determined on CD4+
and CD8+ Tcells using a polyclonal TIRC7-specific antibody. Cells
were stained with conjugated mAb (CD28, CD45RO) and the
samples were analyzed by a FACScalibur flow cytometer.
Results: Immune fluorescent microscopy revealed that lympho-
cytes of human tissues obtained from patients with acute rejection
under immunosuppressive combination therapy with various
agents Calcineurin inhibitors; FK 506/Cylosporin A (CyA), methyl
prednisolone (MP), and mycophenolate mofetil (CC) strongly
expressed TIRC7 (n = 5) whereas normal kidneys did not show
any TIRC7 expression. TIRC7 mAb staining revealed strong
upregulation of TIRC7 protein expression in tissues obtained from
knee joint samples as well as in mononuclear cells from joint fluid
obtained from patients with established RA. No staining was
observed in all experiments using control antibody for staining. On
human PBLTIRC7 was predominantly induced within the first hour
of activation on CD4+45RO+28+ and CD8+45RO+28+ but less on
CD28-negative T cells suggesting primary expression on resting
memory T cells but less on naRve and effector/memory T cells.
Conclusions: TIRC7 is strongly upregulated following in vitro
activation of resting memory T cells but less on naRve (CD45RO-)
and effector/memory (CD28-) T cells and also in vivo in patients
with Rheumatoid Arthritis (RA) and in rejected kidney tissues. In
summary, these studies suggest TIRC7 might be suitable for
targeting of memory T cells and as a diagnostic marker of immune
activation.
Su2.137. Peripheral and Graft Infiltrating T Cell
Responses to Self Heat Shock Protein 60 in Renal
Transplant Patients.
C. Caldas,1 M. Spadafora-Ferreira,1 S. E. Oshiro,1 J. A.
Fonseca,2 E. Luna,1,5 P. L. Ho,3 J. Kalil,1,4,5 V. Coelho.1,4,51Heart Institute (InCor), University of Sao Paulo Medical School;
2Renal Transplantation Unit, University of Sao Paulo Medical
School; 3Butantan Institute; 4Institute for Investigation in
Immunology-Millenium Institute; 5Clinical Immunology and
Allergy, Departament of Clinical Medicine, University of Sao
Paulo Medical School, Sao Paulo, SP, Brazil.
Heat Shock Proteins (HSP) are highly conserved molecules
with a wide range of functions including activation of B and T cell
responses. The expression of these proteins is elevated in stress
conditions, such as inflammation and tissue damage. In trans-
plantation (Tx), it has been shown that T cells reactive to
mycobacteria Hsp65 and to human Hsp70 infiltrate the graft and
may have a role in pro-inflammatory activities. However, other
findings suggest that self-Hsp60 T-cell reactivity is also part of a
normal regulatory response that down-regulates inflammatory
processes. Previous data from our group suggested that in the
early period post-Tx the anti-Hsp60 peripheral T cell repertoires in
renal transplanted patients were predominantly pro-inflammatory
while later they were predominantly regulatory. In this context, our
objective was to analyze the potentially regulatory response to
Hsp60 in renal transplant patients in different clinical stages, and
also to analyze whether human graft infiltrating lymphocytes
recognize self Hsp60. PBMC from 17 long-term (LT) renal
transplant patients (mean time post-Tx = 29 years, stable renal
function) and from 12 renal transplant patients with recently
diagnosed chronic rejection (CR) (mean time post-Tx = 4 years)
were stimulated with Hsp60 or PHA as control. We analyzed
cytokine production by ELISA. The production of IL-10 induced
by Hsp60 was detected in 12% (2/17) of the stable LT patients and
in 73% (8/11) of the patients with CR. IFN-g was induced by
Hsp60 in 17% (3/17) of the stable LT and in 50% (6/12) of the CR
patients. In contrast, TGF-h was induced in 60% and 28% of the
LT and CR patients, respectively. The production of IL-4 was
uniformly low in all patients. To study the response to Hsp60 in
graft infiltrating lymphocytes (GIL), we established GIL T cell
lines from five renal transplant patients. The immunophenotype of
T cell lines was characterized by FACS and proliferation and
cytokine production induced by Hsp60 or PHA were measured.
Our results showed a predominance of CD8+ T cells in four of the
five T cell lines analyzed, with only one pure CD4+ T cell line.
Only one T cell line proliferated in response to Hsp60. We
observed IL-10 production induced by Hsp60 in four out of the
five T cell lines studied. IFN-g was induced by Hsp60 in only one
of the five T cell lines. These results show that autoreactive T cells
to Hsp60 infiltrate the graft and suggest that these T cells may also
have immunoregulatory functions. The analyses of the peripheral
repertoire suggest that the putative regulatory IL-10 response to
Hsp60 is present in a high frequency in CR patients, and that LT
patients may have a regulatory mechanism induced by reactivity
to Hsp60 mediated by TGF-h. Supported by FAPESP/CNPq.
Su2.138. MHC Class I Restricted EBV-Peptides
Pulsed-DC1 Boost In Vitro IFN-g (Type-1) and IL-10
(Treg) CD8+ T Cells in Solid Organ Transplant Patients.
I. Popescu,1 R. Shapiro,1 K. Abu-Elmagd,1 B. Eghtesad,1
W. Storkus,1 D. Metes.1 1Surgery, University of Pittsburgh,
Pittsburgh, PA, USA.
Introduction: Post-transplantation lymphoproliferative disor-
ders (PTLDs) are potentially life-threatening complications of
solid organ transplantation (SOTx), triggered by EBV infection in
AbstractsS282chronically immunosuppressed (IS) recipients. Our goal is to
establish dendritic cell (DC)-based protocols for vaccination and
adoptive immunotherapy for refractory PTLD encountered in IS
SOTx patients. In this study we analyzed the comparative ability
of EBV-peptide pulsed Type-1 polarized DCs (i.e. DC1)
generated from IS SOTx patients and healthy donors to boost
Type-1 (IFN-g) EBV-specific CD8+ T cells ex vivo. Methods:
EBV+/HLA-A02+ IS SOTx patients receiving chronic 2 drugs
maintenance therapy (n = 9) or healthy controls (n = 10) were
recruited for this study. The EBV-specific CTLs were generated
ex vivo by co-culturing autologous T cells with DC1 loaded with
a mixture of three peptides derived from EBV Ags. To assess
the incidence and the functional polarization of CD8+ T cell
responses to EBV epitopes, ELISPOT assays for IFN-g and
IL-5, and ELISA assays for TGF-b and IL-10 were performed
on PBMC, or on ex vivo generated EBV-specific CTLs. Results:
PatientsT peripheral blood circulating CD8+ T lymphocytes
preserved their functional Type-1 polarization against EBV
Ags, as compared to healthy donors. After 10 days of ex vivo
stimulation with EBV peptide-pulsed DC1, the patientsT co-
cultures contained lower numbers of CTLs, as compared tohealthy controls, suggesting a defect in patientsT T cell
proliferative potential. However, IFN-g producing EBV-specific
CD8+ T cells were successfully boosted in both IS SOTx patients
and normal controls, at comparable frequencies, and this appeared
to reflect an expansion of pre-existing EBV bmemoryQ T cells. In
addition, the patientsCTLs produced significantly higher levels of
IL-10 (but no TGFb) as compared to healthy donors, suggesting that
some regulatory T cells may have been expanded in vitro.
Conclusion: Our results show that IS stable SOTx patients display
Type-1 immune (IFN-g) responses against EBV Ags in their
peripheral blood, to a degree comparable to that observed in
normal controls. These T cells can be further boosted ex vivo using
EBVAg-loaded Type-1 polarized DCs. However, only the patientsT
expanded co-cultures contained EBV-specific CD8+ T cells
producing IL-10. These data suggest that patientsT (but not normal
donor) DCs might be partially impaired in their ability to become
fully matured, since they elicited both IFN-g and IL-10 production
from EBV-specific CD8+ T cells. We are currently investigating
approaches to expand Type-1 biased T cells in DC-based co-culture
conditions, for the optimization of adoptive immunotherapy of
PTLD in SOTx patients.
